<SEC-DOCUMENT>0000318154-21-000010.txt : 20210209
<SEC-HEADER>0000318154-21-000010.hdr.sgml : 20210209
<ACCEPTANCE-DATETIME>20210208192456
ACCESSION NUMBER:		0000318154-21-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		147
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210209
DATE AS OF CHANGE:		20210208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		21603152

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>amgn-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e0ca318f-3884-42e6-a64c-8779d462d73a,g:75807743-642d-4c80-8d38-07220e8d8bcd,d:f8d0740b43d148a5ba67e4dd5b38ce46--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:amgn="http://www.amgen.com/20201231" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8wLTEtMS0xLTA_0e5c16e2-32da-4a9d-9502-081dcba8e5ba">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8xLTEtMS0xLTA_2fdb560c-c334-478e-ab0c-833c1c6dbe77">false</ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8yLTEtMS0xLTA_bf379578-320d-4432-b266-003f4dbe28f9">2020</ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8zLTEtMS0xLTA_63a0bd8b-c45c-4f3a-8b70-b3458f939137">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9617e3716fd343959fb610e4be443616_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iff105cdfcde045cbb7f837fd8890833f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia1073bcf953749a699413c12f9ead93c_I20210203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0a9e21adce47979f7e38ab4025e6ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25a2862d79c42ba91f97b4241baa3f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62e077713b1f432fb30f0a3751b4bdf4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia802888bb7a6406592ff586c244944e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b90fa0f4424779a6c9281cad32ba28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe76d84d24b74fe19c507ca3db178e07_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9879d3c7b9a4deaaa7e74de73561d9c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae5629c343b34f27808360cb92a2f04a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie781bbd2a4b948e48767b11ee16f2352_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6087f9de751b4b1a9a41839e6521a886_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide99a054d6604b4c891c408659ba5c67_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d7388f79e144b99235c416c99550db_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86190fe874cb49e198e5942201bb77cf_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43beae92bfce49bc8cbb9c9c6cf4c99f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia658e307c35b4f75920a20f604851e24_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i606f729d14154f1bbee6cd17cade6bc7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b885f0f1534e088ba923195043b35c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda2fa41bf7b4d32acb584d26141eb44_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14141fd9eb484f7ba4154b56ad24b478_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514f593334634486be45550fb53d0771_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2336bd3c48ac47339665832c8ac91be4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cfd04cd281a41f9b3cf4f0a483ab314_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f039062c98414ea66e3d16a12dea4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff5e78fe2444f869a1054445d876292_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f92a1519afd4ee790c4f7f9669bc32b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59b48b26e6d439d9a321fdb3fda477d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i127c87cb43eb488dbd0f2e72bc977df7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i180132b4355d4e00b34bceb464b6e2bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298fcb4aef42470c9b276ca00abf854c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae63d786325d4ba28cd18ab21ff84b6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4afec46242043c98ea5b32c79a3dadc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b0fccf031241ce995839be6adc2e18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>amgn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3e0600ada49541efa4f790040e4c766b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500dae5a099d445bb1e35d1af32c7bce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f66cb73cc34c1f99ee0486a92779e4_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27362feb5854496997daf71cceac6d2c_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>amgn:market</xbrli:measure></xbrli:unit><xbrli:context id="i5551c96cc50149c1880f899738b3a80d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77f9d1e3b77e4676870c5f350d1ef04a_I20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4762422d6345f488ba0c0ce5c4df0e_I20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c2747ebad4402e9ac07aae03462e78_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8c902e15924dd683695464fe7097de_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">amgn:AssembledWorkforceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3c1c1c0a9b4e5eab8231f9ac287d8b_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2e62d8eeb048f38ca8736344e50d1d_D20190715-20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-15</xbrli:startDate><xbrli:endDate>2019-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20538b33ec0455ea0039c1984301d31_D20190715-20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-15</xbrli:startDate><xbrli:endDate>2019-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b9b3333490457493d595249f49eea6_I20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047674f49e494a17949b2b546351ed81_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94c75a285ca4a36b1982968d4172401_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4940f97696f6461f9e3e54bffb7828bf_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f9e4779ad6d4c519da3afeb8a9750dd_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926aaf96c0584bbdad52c9ef18251ea8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c90fddb2bc49aca05ba3690ecb0e12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb99da9fcc0c4198a6a265c212af7ab1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01555b26feb044308b7e206b9dccd0f5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic204c7f26f03488aab5ee3f10cb8e502_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2bf2bacd2b2492bb28ef69a40f8ec26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f527e1b66d49af9406611b9596ff22_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974741dcb1524051a7646fedb5f2c5ab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8afc5561327f469a8133f9d02a2cb093_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2d439e1e6f409bba4a3347af4696d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ccac04c7f24f92b788839f717d6523_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2728b90e4d4b7aa0313586de0029cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5483364e0744c68922713f01e91c7a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief15e22862ba4cf39454d38e1cbdcd80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0fa621683b24ffdac5458723dae9a1e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac24acf4d93f495ab9d6b3536f41e0ed_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cda4e685d04ba792d0adfb5f0a1437_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7459c244aa8e43f79da3a9ea0637ec62_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480fcce9b28440b8b0224b6be301e101_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92377c788f944386a84ed9e862d6a789_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d93219c901f4d2993fd42b15214c20b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01a0ca8cf65419c8aec6edf5d45bba2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda0fe0d08b14312b1ce2f95d9af1d9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66f6e020a4a4abd9de549021d7c3700_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b462b363df4e43ac25594c6bc680ac_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54b6d4d4a4f740d9bf97809cb4f715de_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c93f72881be41c283567c566484b6ba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba5aa16ed3e64d8187270f007bf3bef9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b09f7a19b84d2bb41e108ff3322951_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785509d5031b4d25817f65f949f65892_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b3a114ec374c5c97599ab0369d2720_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948008cca6de4273bad98a9766aaba9d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f37efa18d214f73a67190daafe053dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954f15f923f241b18df02db5dbb43dc5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b55b920060459e9114165eaf8c36bb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc6b87796b943d7934bab2b49c79114_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e053e17a9c8401b9e7ebd23b33490dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00a07432ae44f0e9d1fe5c284da0bf8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0738e434f843b586e64e732d02c689_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e04b7c055e466cad54c342d9bbc9ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6539a6cf160e487581559eeb0031769e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie608b9d0be364ba0ba1110fcb2c0fc98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8758e51a2d4092bcb71092363b47a0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e790b9674254ba09f653c813982f56e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i565f06fae6c54af084a236838566deec_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2f55bcc30a4cfca648fe698fc70f10_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4de803606b49cf808e39411da4f3fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8b822803f747429f4e453f30a1f8c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ae041643bb42a9bd46624d883f023f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ac4fa9d33b4a7b953dcfb37f07cb31_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82550ed044ae48fcad2e75453e121d7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7283e03d6b247e5b00618781810a864_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba12b5c33af41909da76cfd32eb41b6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5881997bfdf454b806bb4e23f90b0f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if858ed80d6524471b48fe73e181c069b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837af2fa08e640ef82a438132d76de4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aade48bbe8e4569b0b5690c45eaa909_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c55591acd534a2bbf75ee8ff1c0fc2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b00f3f0c5064b28bcf5ecd0be53d820_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8fccaf64c14f8eb120b3b7d5ba9bd0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c300e2b07004083841461728c0799c5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9064c0fd8a47349673fd7361fe5c17_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4ed7c0dd1f403dbb6a02eae47b79e1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8c8a3331fe4b2cbcbfac819fa802e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4a40aa83a243ddb4bd0747024f97c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f35c7cec9fe40ec8747a982642437ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4954236e263c4019bc3eeeca23e8ba96_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70f8bc85eb544149a219b33c04fdc84_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64ae6d964234f3e967e327673f9b5fb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ee66a0043a4f228b82c153cef85490_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf63a10013548d8817d20a261bd0901_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3484149e2df04c2685210fde93380a2c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ed027ed29142ed9606f57e5869839d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2835d9ca084e8fb4795aa78b07d43a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1186b599c8874028bb81519ce6bb2c59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d438d374ae4f78b599ce6bf7a19bab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72bee99f05d48eea6c4eb1bf4db9e82_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4092f5882c8142d39834b7722d6d303f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f466fc09cd44386b87d1c42d0cee056_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5caf3504dcd64ab2ac04090326aa57b2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b6988cfabf40cd958ae6cf44c7f9d3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b14be4183743e4b46f705ac6239e47_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedcb63d22b9249af85cc7ca7293e287d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630a0351e5c24898bfb45b915cc63356_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9811f73a8446e4b074fdb187aa7238_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b360a237fa4db9b2adfe8a31418cb1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i116be71a0f84428099ebff205742ed3c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i965bb3051c3c43e5a0bfa194108e71ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9bc46f725a420caa5d9c001fe229ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67042c7baef94c1e889169924cf1d15d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672733c420164f04985cc409f649c152_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39bda5bc42554606892f0ef083ebb8ef_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e4fc03ab19f4f3399d8c1f71e1a4ea5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d5a2a803f5d48dcb8f85fdb926cdeee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ebf38a5dda46d0af6058ec22408dd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf240dc750624161beefc465d5d2520f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02193c66855b4a3d9d3f81f4d4d0aa3e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6193cdb49341959aaf15728de81f9e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dcdd28acc6e4387a9bb47e6478a91ee_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>amgn:customer</xbrli:measure></xbrli:unit><xbrli:context id="ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14301973b9e04d95bee6bcdcae7c842d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c07a4b5b5b4cdd80a13653f61ff54b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic744474389a6477387cf4ff42d717bae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd7acc9830e47eea1f588c56bdee6ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271dc91e748b4ddea09ef131d4fd6b38_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d15f91e0634082b728d72dc4737601_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad54f16489e40c38fdd8b424bd6f702_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4eb4dc90c94e328e1dbe4584b6099a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866165e293d6482ca7b4135f27841405_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ce8a336da14fa284511392f12999d3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie818cfed00624ad480f081b1918b959a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce4ceb699bb403ca25d48176261113a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143d4186981e48d49d7be92adfcc173f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4cd73575da4db0ba421cc3362a29bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id433645fbf594175aab48fd4faf64790_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f742d812e548f1805b409e3b3b3abb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9f45734b1443d9bf7b7850cb8ebccf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f8bbadab1f4527a14acd4c6c81cac8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5dfd09c3d064b5981a2ddae65d2710a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b0a52267d94c948c70743bd7a58fb1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9549cf1daa744587b04c3442d532545e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f91811a9c8c47ab955099101550454c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:ExpirationInTaxYearsBetween2023And2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9c7cf9064143caa206e3b78960b8ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316f6795382a4358b0d4048594444996_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2021And2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9455afa2b91e45d18c2d587bfa989d67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2021And2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e22a47202d49c79c39aaafff5c59a5_I20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c3de7ba47e48ddbb6721ed2b6093e0_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08caf3a57bd45d9a187961c49e97c9a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9eb1e8041bf4e8b93d86d4c965d1bcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb08466e4c94fc284de233b8b27d515_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64588391e1684a749dec8deb14c630d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018453dd7c3743639ceacf5473e7c62d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6aa7777cdbf4d8ba13b5dcf14c0d732_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0041c53471f04a019348539dd1051757_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d26623d3f34500a3be4c9287eaf130_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147ff41e3aad46019e4652e564939eeb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c99bb199b504bc5813a6070a2c0f7a2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>amgn:country</xbrli:measure></xbrli:unit><xbrli:context id="i5aae7473918a4b2fbd03dbe169ce9681_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26fb37cd13a747f1b39eabafba709ded_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:NonUsExcludingJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e670e37529947c6a6e43ad60cc1072e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac446a3f5b049498d97d5cdc40e8884_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib720207eae304b4db4149e5ba761b733_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc295629ce08431a87b6af7ac665aa1c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6accd8c04bc64375b6db9a710bfd1a7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4923b31ebb413985529cfbbf320c70_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abab397f36846d2963dacabb469a08b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia314c059b63d4452a382baae50386fbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1043550a1f84782876ef562e9149716_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2783b98e50e847a19205180e25cee168_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6cfcba5921d484abc0c737229312fef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25670902a03f4a9dbaa51f18d7ece454_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11aafa3aec9e4f27a262448b9328cb31_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe13998c78a94509a6a1caa4150f8b85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i211dbe0e1d8346459bff435cfdf00a61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43ed126e7434f0eb4b8c08281ec7bae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i747e8d251292449b9dcf1d1f95265375_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7050eead3da44efb7f96c0d139c398b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504ebb212b0e4de29bade641d2b4fb63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9255d5d6fe481fad09edd63beb52e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78fbd934d2344ce09137ff8acd872830_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3acbfa95e2d42d59a15e70c74debd7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8005c102cf76487dae26362888d802fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6cc35d1d07485d8a62dae2b89a8859_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcbc99707a942a3b9412cca58536799_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if984bbfefa824630ad0be7898a756667_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2cdef4357c64e9cb34661796f119661_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d4a84d1d744c3196a3054655ba8dc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4746bb368e19427abd5d968255881278_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf2f91f1812e4b6985813bd5ad956751_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de40ffd50114a4b85de7a66f9fe7476_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f8655d04b041f4ad4b564443d75726_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895c1063378b4068a891fd1e71fb3589_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8a60c530804890ab62b6e0d832989f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3dc8e131e74b639d5fa9747c30f69f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:FixedEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i396cde7c35a94e749b408f43a2826d8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4defc84603e845d1abe667bb41b2c371_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71cd1836df64fa297d00f961c9878db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd99c6d5f7e14c2b9fb17834726169ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380c4519a6324acb9471d6b0846ff47a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7412d430651b4c3aa09e75a732689d3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib25925681a284e8a8cc4bc5abf1a3047_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf95f14d878c44b7bd718c95c6943ab4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9275605c200a4299bbfa5428560e8a03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ea8f1bac6a4be3807a3e1482036184_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb8f56cf7cb441696514975a5535ece_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d4fa50eb91422a8dde19c58f864d75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2f82635b7e4140849137d3c5812d24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795833ab718e4229838a54da0009fbc2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05bcdb11924b427696274755e057121c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058ba3d94d2c43168ff6130531a4ace6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8242170454444bd1ad4819726216ab26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96ddc98bc504632bed269fd22978fdc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87ff255d0fe407c8d140590358ce557_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:AbandonedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief37ee91742248e0885bab6c4ed8ddde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc37b0f57f9e459ab9249c3fd0808c48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i115359deafc44691979f165eb053cdfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c11ed6245e4fa0a369c9f3aec56f9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib58dc479cd3d42319169a103d07a7574_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba619c4c18fc45ddb3aa9c5914a043e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72dd6be73064790892c440bdd065b6e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f0c45930bf446597ffdba0232d3d0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie507cdb44629455bb7c6aa2c3247d935_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a25ca8db8794930a6444001d3c53561_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7223a974c3e04bcba5c39ed1c654173e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic46c172c9e0a45198c8c6c17804b44f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766f4994093f4740852f0817f605b8ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65782159d9f447c1a8360410b35c8b0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c3bbee60b53406ba6799bf10576c70a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9ad1274914495687f1554666e681b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321d29cee0af4ec499ff94a4d005e9d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i857fefc9adb94c98b9b9329678b7db36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d3ad6c912a4480fa33aa0d7eaac3019_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1366b31913416482ed05d65527ce09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5601f95c84ff45209305a7ba1d0ed21f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2022e1a82ecc471c9bb13d27e09c51fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86fea773d394279b54bf0ad27439680_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e302b2d804443b3b3a819a6e695f03a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce43115364e4f88a797d0e9e1224e77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i6eb195b8085e465b9c73e9a2403f0ca3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2a2479b69b4482a8047db796a1bb33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4292b26906463fba3b1c0f23beb71b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd6d09277ed4900bbac50776efa7a38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35327bb737e64d47a0eec71b3f1a920e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955823ca905943e2bd3d94ca46061a7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35651b0d044d46cc9af068d473bf549b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89c330f27314741941344d0b54c18ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf087f04fa3b433688c1f56ee1145222_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6894d534af44c5c9113bb8bb4838cfd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab8ddb0cf45940228df2b710f4b10a4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ib2a0aa4ebe0f4b39820910ec59611fc8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4cf58147d464ca393871d4bdabefa52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9d8f452a50403f85e95d6a431bb569_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6de40b43c344b3680010e784e3163c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fd52a87555424a9429b2446e6b20cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a6377397b24b53a373e7137cbd06b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a255f173843436c994520d12b5046cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25a4a0e3fad546309834f83971cde048_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9f0f7677c04b97bdc7ecf0cfe1bf34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8c556faa66a4640add9a389585dcb8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26bb56750156451db1cace7c4f21e6bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33bc0e6a798a4daa94404d7e959a5646_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6f035a7cd84be5bea195a303cdeeb3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc950c75ba04c2f88fd9c7425c305e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e8c0425a564da7849ac5fe7b5db51c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47bb60d0f1944a82bf76a4a9c8335c42_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37ba0818a4249c3a031f0454e3aed09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e029c89be1a4c2aab1ec7352a2738da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dcacc53791a4df7b253b539b0644b8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84255d0cb47445195c3652626198334_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cd436bd1f242d4bd92a582319d9cd9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98459dd3f7df4a9da1f0e4d9bfaf76c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22a6012e30946cbaa82df3fa40dddb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c28235c53c439eb0926746169e1187_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7539fdd6385f4c38b6c106d6250118b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c4338c09d6451da39a441444432847_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ffc8374c7ee4daba236297c1ca19559_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia60bd30780674b5e8423eae04786b160_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab35f913d01401c9cec4c3e1e26676e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d6a61884124f82bfbd04c56c2051d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b51bd6ee36d4eaaa9fad68470af51f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id13b5ae91c924275a407d360294f8076_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5ec697f57d429aa10a96bcc66005bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3741539a3da4406cb0892abdf6eb315d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425c9514aedb4868a2ebec2a29ba5de7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1649580135964fee8432cd12950a049f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ff7bfe32094c3b987aaaceb3014b9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a772dcf3d84f278093296bdf9e1ce1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec571ed5581a4732ae9ee4817e228b10_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec6c7c7b81b48d8a20694d3b57b6b70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d34c35332374923becedb1eee1b52cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60960cf4128a4427b534a20b852e2475_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e99d32a99b3493ba14074d4564ee157_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e69a6358c564547a5eca8d5fbe70622_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b9a5668fbc41e6b4d63640b91febe6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie045a042bc9343f1a35b00097a53456a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9776aef7fdb48c8a1734dec44ec2dd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea83a41a94354282ac825a30792e7bd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if621495ed0e44e7f8c27f9d541876077_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfac5674c6443a598611b253a645a0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9165ad7e95445d9b3372c1c0f63c245_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3396b8f489aa45d9a88f6c5fbf1dcd70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5d1ff18dbb4fe5bc76abb5d4d5b3c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa733d1395a445ba18de686112112bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia054a1ac7a0c4c5a84daf3e02d258cd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2173cb44ec942b0b5e652729f5aedad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b731805304467297b2b3b116999268_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6382073fcb1d4883b6219e6dc102e745_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ace2901bf0040e2a96399efee4d66aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cea61b7422240dcbf72d21fa3477501_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec3c2bdd29840c1b5cdb46000fb3552_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4925dc03736d47f9ae8d2a690a4103f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9936d965b2ba462d8b3888f904a7ae96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f84b1e89726471186203024e416a4a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7759f579c524eab8b6b4da9a496f1e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368a178ea7354ca9b710ce74b30bcfce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie14c8cade2044c48a2677b8b57df8403_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb33bcf941a4a40b8e393ef62e8026d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea19f674a134cfaa06e00ebe4983f41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d73c382070d4582bf5468d1be4dc656_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517838d7aad1452d98142cd5be6f49a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45e9dc787514755b7bc52c6e863a740_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3699b330b1b42a9bfd233ae168532eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a00aa8b5524778b4c286af30fb3fd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e8ff43661f4d5f912595d1b30d72ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb46aca57e78435db45dee35d03b5ff1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcd5a1c6a104b778997f6496ca15582_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef7ddaa81cf4000b87b570d84cd9ed9_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53845265cb94d07851b1fe0a47a9756_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc614e1370249759a9ccfd03593d582_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2bdf148e7042b9a29c5b3af1301bb6_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9023f496d24d308cf4d1c092fc6f42_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53985fa4c39e414b9da42cd3aab030a4_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e01b4d5cfb74268ae6c81e2e50ade30_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia51aff5886bd45d0924ffffa26acaf1e_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3994865e1ce04255bf33546e570e6feb_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515b38364a38405fb4bcf56004a5d984_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8430beaafbd43bfacdaa980eb0137df_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if188b1207e144488bc49e6f9af13f349_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc092c6728d4fd490eda91a340a32ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea4835b2dc040188992a34180538c3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ced667ce35e445b84fea4f94ea73857_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4179a6ea77a3452ea924a970e6862138_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725941cbca38484e85e015486a9604dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963c8d3dfffb425ab800f22538a80972_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdeec3400fe43809c845700b9250d21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d664e75d7a74f7491af9306d427a5c5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96e075bdda244694a4469e256df31166_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35730380319944e3910f345b948c0df9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358bdc0bde924dd6a9e6f8e2d53a4fda_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6c0363be7c499eb126c69c7c63a409_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointOneFivePercentNotesDue2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8daf767f6e14e758523360043a12636_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointOneFivePercentNotesDue2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6268acd3d2a46dba0b2e730840ecee5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointThreeSevenFivePercentEuroNotesDue2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce07b37db1a4118b69a6f7fd3709440_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointThreeSevenFivePercentEuroNotesDue2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8fd749026d9457e843e73baf3eedd7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a91bd5c90e8492fa703ad1a89545d34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c9cfe81f3e4917a0b8ebe47bd9a715_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8f6352b8834211af6d0c68477f85f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90978c11283437c9156f060d82208ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a7501d33a3a455691d18c20b0223337_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eb21bbc622f4765b1b17b9e42cffcc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90e46dcb35e465890654a17ea25721b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce2131b83c543178a1ff35a8a9f7b29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb51cf3560f44fd82a1ed3524aba9e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4f018bc432431ba9e3ebae45b475b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7249a2eb8741476eac1bbed378060085_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6a942464df49888f5da90fa7d3079f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f92b19c4e34a72af65be5f26e24641_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib22110db36464336ba83d0caaaae87ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief290ad7941b442fab79e88967534cd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2335a1cb123c499e80a1aa39baa5fda5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7351dc6225e40e5b3d4da990aaafd0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54306a521a5410e83f206562df048e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec5e5f1709434645a4f86bee8db7c5c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d46bf88a054fb0abd4b6f021382f5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icda7d092fb704dcca96b59957bd2a0dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97abdf954cf14e22986f9fb69d4e08cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i959c8054e99b4ba4a601a0f7b2e68fb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22d72d2f9754767b787702ea64e3553_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief48420564f04693bfa31f3606365235_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f44fcba83d42e1a232fd794b15ec7d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86bd689abf77408fa7438dcaea1c9165_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968c11eef2e44b85b73c09287db49afd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee91c42bda54e20b6e7adf10ee4a30c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25258a7ecd234572bf5dbcbe63e9334c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9adb74cd7d004de18ef5c0ff3957a722_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd511439740c4be9a99104d33dcbf8bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362b746ef24043558b07c52bd684d25b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c809f8f67643efa3a6bb558412f991_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ddee0d2991140ffa22fd07e6d2467be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39652c0a62c5481095ff480fce17ca6c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd497f181c14d5ab36c9202a891b09d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ba1158d5c74f23be9c43c581ee22e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913aa3eb20c44b64967ed53a9ab6af9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a160e4cefe420d887e332af50138c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib951b96e66134344b87919e6a15e9627_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>amgn:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f832aa086b4bd39c60c6c87db97472_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d59abe384541c89aa4311f241834bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473af25953c84328a062db4c39eed37c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65105b8f350547a9afe51cf16587594c_D20210308-20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-08</xbrli:startDate><xbrli:endDate>2021-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60869bc47af9405383d397dfe67b7ce8_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15cba6363e694ebfbb2115df9607f890_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec98fde84dd7443daf65e4d48bd33cae_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e51d8ec78e482f981fd6bf9a9ca60c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i508432a61553416fbdccf7e432d4e8bd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8870a99dcef48e5aa17b95e8de89a23_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a72f83ff6643498ddd2ad2b28672d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab14641cde404512b613907261773c1b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2cdd35e2524c0c8b0dca79a961b38d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f71e0b4ef646179cff4ca0c5bb2784_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff02eb33259b4098afad9b87c2f8f6f1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab46e3e374ed4320a79dc7f501ca2a0f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ef7d0edff34c2eb74bbbcb8615f89d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe63279db194377849f0b40c57d4391_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84262de6ad99499488051396e0055031_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae7fdb0b6a64177be82f0c59a390de8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie382593a89bb40f88cbb7baae6848d85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834e68b1d71c4cf88092899abf36f0bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36dd4baf66a496999b27ea628bd7365_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e1359200bb485e82a279c005e655f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a567dae4771464c8ac036044fce4ba5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38568b10d86a4316bf7376de6e8728d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445ee927bb9f4ec6a1e136928e6720e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06b327237f54c16b3d3e03f5d5e7398_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946ba1f102a249339cc475cc38dbff62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe6d63071dc4400d8c5203ab02d542d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe17c4200c54926b08b32de808d1607_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e10debea2943bfa038e3e584b92196_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48a4f1daf6e423eb316bae15e9e3e54_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f81c16e1ff44269b3e2017ea6eef9b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d4dd2242a604708a35885bb2742cbd6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9682afd0b98a49479f04e9a056ac6cf9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9644e2219642dfb8b959deb45d2db9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9f08921cf64e6b95d1f81c11c62ab9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625fa9d4a306409181259806d10464fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6101c783a3084635bdf9cd570e9f1282_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac001eaacc55452bae4119e1a7b27c9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a3f5fa8487f48658b63af871c8fe2c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b4a2b455184822b0f1116160cc18e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b7da5c12534b3981691aba7cb821cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia986bf30e56b467ca51da380a21cfe6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5983e886096845e08a0cc96ad73632ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6edf08d2463042549609c2d138554631_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b1be9e0be7e44b886c4bba9044e55c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3220d9002c542069391fbf17f94d1ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91de10fa99174e29b365d56c9f6d3d48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33a9c55953194cd3a01eabe3994fd206_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ce59970e704a549cf6e24fdbc6115d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809345b5da314af5a55dfa6cc31e9467_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dbf334d697f42bcb8a2ab7042237c55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7054c920374f98b6f1c0fb02b93de9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie386d2bd778d480f836e2fa1df624708_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ddbd84bf09413aa009b1a257b36e6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1609b78f64499fb1992720d032da1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib182df74839648c99a69305123764d98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4888dd7b32ab43db957c063fe6af1b4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cf4219cf3644d3396775ef8d389195a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5e3f8152754918ab5eda6f40636b7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30b3769d1f54f7aa9a0ad91a5b2b2a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab820ea663b142d683c134deffedff4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f8425a23694b76902e702c9427cd89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i064fcfcd92604a3c88418ad109a62465_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9db18cb51ff42eaa1fdf223be2cef55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb077631c2943a386f31198be2b482a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52081e4ae094d09bfb8afeef0d34a19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86eb7a229bd452995503e7a79b231f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649ca6b917ff4847aefd1d96a215f411_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id401fea1268645f08278ada72856ed9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i272140d66a7c4798aed64a4683f7f5c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b21ba0b68054fb980abeb4ece605ae6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e5faa80b5b4b10adeecf22f66b3581_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d5adbe89e6449698d66ec80b68a414_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8c6115d404415db720dd2a742d8eb4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef1d913febf4a47abb4d2d49554d87e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d55a7ee2cd4a33a48689caa2dcf916_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286a3763387b42bc9a3cb41202817a79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadfd2fc877304237a30a42e164d32f71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie900b0b41bfb46fb953391112402fcb4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e5d44ae1e344489c69734a0bc2cc50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib246c8ea900c4139925b4277352eb5e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d01e59834f4139b4e0c85a155b259b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a87e19790014e689ae6a75f01a9d82e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd56a68a7ae47358902b75f24b8098e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c5c8997cac420db031456c5bd0c5a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id815d1f62e17488f819d1554819ccb75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515615df7d0649f19fcd37f592c7ece9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic879f5b36d054ed9a76eb771bfb892b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae474e4eb1174434902da312c3116aea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe3539b33168456ba7b264fa95739a21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b75e88402c841058a01fea422a2d5e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a943209d2bc469ca0bc93bd11d07f9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32090b1bcda448d0b03e44dc48a112e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4671a4128224590847baa4d91f4f23c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id243dd82ed464c5782fba60066763a4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb15475cbd6497f8125ba218618f3bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2e56aa52234a9295f48ee3eb721a25_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeeedafe9493400eaaf0bafdb1cc9eec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf5136a442245e5983ef4b4dd9fe1a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f07dda96ee49b7b10ec42bfd9ee318_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a356ae88a6f494eb208b656cfb3d39b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d3d663147d4671afc5b78a2cd03fd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ffb83e4ee44f928713cdb0b9355245_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae4c13d4f1a4e789c5111bdd1953619_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc54bfdcf154b1c99478e3369c649f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80341c6920be4b8f83233fdbad6decc2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f39dc9f49db4cdb801668e25f02b78a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f0734c1cfd345e9b84e6222bec110fb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07aff99eff5e43eab44bd82f5c93ad1c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87ed81df5cd4df18bf1c76cedc6ff15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3094f6fc9cc8496c8f65948eaea987c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide1f0bd164be4ab48c682b4349325400_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78e562fe4a247969552202afc671b7d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0694e7fc221e482c91e8838576738184_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ba2d75207254328aa10efe32c1d7d92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec4c95044a6412abcc5d68913628085_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39bb9a5237948c1b1665fb28924169c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7cab6ff6f34e259c4a6ca09c02afd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60cd5ec752de4c98b0157f82d6b72e5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7343472b32c748d99b7140235bb94b4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f07f28ce2a46cbbc068409addaea19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89094b01572546878b2ff1d75b3818ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if028ba21936c4586893e5c30ab36bbac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05187f24dca245f89aba477135b8f57a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db5b4699b5c43b1bcd765fc6632aa11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7d28914099a4db4a141ed2fbb2afc50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8a2e81c4d541849a664d3e8219f829_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca9160fcbd645a58623671457697045_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8781f9dbe8224717b48a58ba39d8e44a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f84184b50a44f7b23e2915f0e16c7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie75450fb332b47589035297dd2cbfef4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab3fe75d88d4a25a823aa9d5bb0fa1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c26149bf9bc4af9b601bdee1ab9cef3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9313578881564713bd51c45434307224_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ae6fbb6ad64fb9b9ae8eee82d8664d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471e2bff63624e0e81a47854f415cf1e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7fa60265134785b2cab0462930cf52_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5991882c8d74449db1e6b1214ea17429_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f7642813ee4758a8d46ddcc6037f64_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79e5b12752f45cf9a8cdcc982b21b92_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2961200acffa4d0c935574bdd8f22f7d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a30d28949ff465693152dab8f329ef6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic198d94557414ab3b4fc50e9ddb159f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:InterestRateSwapAtThenCurrentInterestRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d904f96dd854c81b5c1105b3760f9e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fe46af694c14b4098014e42d59a4512_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643b333982544519816452a792886641_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dbf0c2d81894f1f9732052b9877a70b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4fc6eaae654eff9e476549ca95692a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if807e88d6a89408d9d6c6adb4b5eea3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c35c83ea16240faabb17b7cad3444a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ec37ac4b3fa42bc95ed748f124e3eec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9833b553be6144e3aaf934620c21e9ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ef5371ae064ef6b77eead6de300e3f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b72e30920c84ae2a3d1e0e9a36c0610_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa717f16dfa641f381206fe8143aa927_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea320fbc2a944611a7e2a4627a50e4a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForeignCurrencyAndCrossCurrencySwapsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88cfe8096cf349ad9c97224ff1238178_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182cce935cf94552ba35327c4614152f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e8455f1edd4114b88fb3f5d1776535_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7516b524eadf4fe7bb058ffbd7cea637_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f64a6e311384121b9c8e278f3e7e78e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e546c55c6f64762bd48841a65da24d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148fcee1a48b44a09d68649c316ae387_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ee7f80e77b4cf38ef1e80f188af7ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b25825f647249218c055b6f57195f14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f76be3dfb864f1bba5b05a191f9d797_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a25b66b469d4c179aa132a6977ec4a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f104f0b1c7a4beb8c5cab4258107bee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5405ba26a454429daeaeb5a6346566fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcadd8bcd0564f47a4fcfdd5ac5f886a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1df008b78a4d38ace56a2668c9f0bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7dde35b44684174afdf5dbfa0f9fd26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f16286ba82544188ba31ea248441fb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27613a286f447649231bc7761e21a43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9926a2533e5347f6998a569828670148_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824e358512984891ac64732ce456bf70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7232598b5dd4cbf8628dca2b745de71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadbc19c30e2d4747861f30ae61174fb5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3a8d84d7a143f08a25619be5bb364b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>amgn:patent</xbrli:measure></xbrli:unit><xbrli:context id="i0bfce81b8b324711af659a7858516c9b_D20161001-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:KYPROLIScarfilzomibPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809cbf0f95194f08903685ccb680427e_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>amgn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i3adccb2cee77458681e77740f4995ece_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:AmnealPharmaceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="affiliate"><xbrli:measure>amgn:affiliate</xbrli:measure></xbrli:unit><xbrli:context id="ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ImmunexAndSandozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0906f0e464443487073d2cfd195558_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ImmunexAndSamsungBioepisCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e8f31ce26e4873a861d070ec4bab78_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1117b8cfa8440a9fe7743afd265be3_D20160201-20160228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fad48569ed547d6bda68c928f79c3aa_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amgn:claim</xbrli:measure></xbrli:unit><xbrli:context id="i4ae1970a90b64a67af70b4ac4a36cab8_I20190520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>amgn:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i80dd2b5d6a6741578cd8c92ca187c67d_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiffs"><xbrli:measure>amgn:plaintiffs</xbrli:measure></xbrli:unit><xbrli:context id="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4745ee7d51c48f38ab56aea1953d9eb_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="complaints"><xbrli:measure>amgn:complaints</xbrli:measure></xbrli:unit><xbrli:context id="i4c336ecb8a8a4d67a7a3bd87243f7b8d_D20190301-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if453a7e1fbf04c769fde5a4f2ed3c28b_I20190604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>amgn:installment</xbrli:measure></xbrli:unit><xbrli:context id="i61225a3c72514f859602e544d725ab0e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bf1db2cec2744fe9cf8a8abb012ff11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d59301d26594c2ba4ab4f364829aa82_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b74954f05984826a98fa8d1de70b8ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43febb6cb9d3444caa73da4c92560180_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09079b5a58e246b5947144cbde795c44_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4254e372a9cd437fa13067b22cd6fc34_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8404b3b31ac149eca5db19a64dd46da4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc3_599ad375-b3ed-4c09-80ba-04236b1f3c5b">10-K</ix:nonNumeric> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:5.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6M2FkNGU4OGQ5YTRlNDIwMGFjODlkMDQ1NzAwOWFhNDAvdGFibGVyYW5nZTozYWQ0ZTg4ZDlhNGU0MjAwYWM4OWQwNDU3MDA5YWE0MF8wLTAtMS0xLTA_f9c3428f-2c1e-4fbc-9ddf-48c53ea63430">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMjc_44b7b4c6-1972-4c8b-b53b-73ddf0dbff20"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMjc_2efa904a-d37c-4aae-984e-a69e944ec6fe">December 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:5.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODJlMjlhYmQ2NjZmNGExMzgyOTgzZTEyZjgxNWU2N2QvdGFibGVyYW5nZTo4MmUyOWFiZDY2NmY0YTEzODI5ODNlMTJmODE1ZTY3ZF8wLTAtMS0xLTA_f89f8c07-e2e3-45ee-993f-0be1536a4042">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcz_a8e79d6b-c7d5-4a3c-9610-92bbfd2c8c5c">001-37702</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcy_53248507-e48d-4f34-9db3-437ece765d7c">Amgen Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8wLTAtMS0xLTA_1b95d869-34c1-4e0c-819e-f29da9d58fe5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8wLTItMS0xLTA_e9bdb400-cd65-4235-923e-32aa763eb81d">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8yLTAtMS0xLTA_02f1b579-22e5-4e2d-92d0-3443f9b1b0e9">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8yLTItMS0xLTA_f5176428-862b-4f93-9d90-4c5d63f5e220">91320-1799</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8zLTAtMS0xLTA_0067850c-a8d0-4ba9-b607-a87062b7f582">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF80LTAtMS0xLTA_ec0ced36-077e-40c7-a392-bded06708bc5">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc0_b7a3370a-d946-4d9d-b46d-bca4d0789dab">805</ix:nonNumeric>) <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDY3_432183bd-68c1-45fe-943a-c2d6f1e64893">447-1000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol (s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9617e3716fd343959fb610e4be443616_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8xLTAtMS0xLTA_8ba43c56-c40d-4d83-bcbb-bfda2fe7d6f8">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9617e3716fd343959fb610e4be443616_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8xLTEtMS0xLTA_6f8aa053-aa7a-47a2-b95d-2f2f4be4e33e">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9617e3716fd343959fb610e4be443616_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8xLTItMS0xLTA_734957be-40eb-444a-96b9-09c8e808567f">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8yLTAtMS0xLTA_eea90414-449b-4ae0-953c-27bccceacd9a">1.250% Senior Notes Due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8yLTEtMS0xLTA_36b0b6ba-e316-48bc-b11f-3b96c9acd63c">AMGN22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8yLTItMS0xLTA_3bd0e286-65bc-4da9-bd2a-5a69813b3cd3">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8zLTAtMS0xLTA_196071a1-f56a-404d-8dec-c5c62c18306c">2.00% Senior Notes Due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8zLTEtMS0xLTA_4763f4c2-0f52-4503-8f69-c418bb57e1e5">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8zLTItMS0xLTA_f8252c91-2469-4a78-95f0-8b6cc16e5737">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> None</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc1_9a75b6b6-16e7-4887-98f2-ddc33507f5aa">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDY4_f2edc272-97fa-4174-8be9-5ed72df78bf9">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or Section&#160;15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDY5_61bf328c-1702-4659-8b62-99666ca621e2">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcw_0c82ff31-13d1-41ea-98d4-7e90de5c4dce">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODg0YmNiYTYzNTU4NGY5NzljNTBjODI5ZjM1MjAyNTgvdGFibGVyYW5nZTo4ODRiY2JhNjM1NTg0Zjk3OWM1MGM4MjlmMzUyMDI1OF8wLTAtMS0xLTA_75d8faf7-e013-4dd4-aee3-e873d46ad1ca">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODg0YmNiYTYzNTU4NGY5NzljNTBjODI5ZjM1MjAyNTgvdGFibGVyYW5nZTo4ODRiY2JhNjM1NTg0Zjk3OWM1MGM4MjlmMzUyMDI1OF8xLTMtMS0xLTA_7ed7db2c-d1cc-4a68-82b9-92a2d7eac2bc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODg0YmNiYTYzNTU4NGY5NzljNTBjODI5ZjM1MjAyNTgvdGFibGVyYW5nZTo4ODRiY2JhNjM1NTg0Zjk3OWM1MGM4MjlmMzUyMDI1OF8xLTQtMS0xLTA_6b552458-afa3-4349-960a-35161cc6b786">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.     </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMDk5NTExNjMxMzA3_d9cf223d-40c4-4fe4-a9d2-b88ef5cd8546">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcx_19d56f58-98b3-46b1-b600-7dffe85096c5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approximate aggregate market value of voting and non-voting stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="iff105cdfcde045cbb7f837fd8890833f_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMDk5NTExNjMwODYx_c16dccb3-33d1-4349-8a2d-6fd0c0490555">138,056,968,288</ix:nonFraction> as of June&#160;30, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(A)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.41pt">Excludes 1,045,777 shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding, at June&#160;30, 2020. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia1073bcf953749a699413c12f9ead93c_I20210203" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8yNzY4_000f2731-bcce-4bd9-90bf-bc79528f8c95">577,566,383</ix:nonFraction></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Number of shares of common stock outstanding as of February 3, 2021)</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc2_580608e0-d662-4159-8ac6-98b8599e626a" escape="true"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s Proxy Statement with respect to the 2021 Annual Meeting of Stockholders to be held May 18, 2021, are incorporated by reference into Part&#160;III of this annual report.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_13">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_16">Significant Developments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_19">Marketing, Distribution and Selected Marketed Products</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_22">Reimbursement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_22">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_25">Manufacturing, Distribution and Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_25">12</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_28">Government Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_28">13</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_31">Research and Development and Selected Product Candidates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_31">17</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_34">Business Relationships</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_34">23</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_37">Human </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_37">Capital </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_37">Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_37">24</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_40">Information about our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_40">26</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_43">Geographic Area Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_43">27</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_46">Investor Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_46">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_2411">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_2411">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_52">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_52">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_55">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_55">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_58">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_58">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_61">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_61">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_64">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_67">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_67">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_70">SELECTED FINANCIAL DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_70">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_73">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_73">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_109">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_109">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_112">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_112">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_115">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_115">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_118">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_118">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_127">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_127">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_130">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_130">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_133">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_133">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_139">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_139">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_142">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_142">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_151">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_151">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_154">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_154">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_157">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_157">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_160">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_160">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_163">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_163">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_166">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_166">93</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_13"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BUSINESS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#8217;s lives. A biotechnology pioneer, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. We have a presence in approximately 100 countries worldwide. Amgen operates in one business segment: human therapeutics.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_16"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Developments </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of significant developments affecting our business that have occurred and that we have reported since the filing of our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A novel strain of coronavirus (SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2, causing coronavirus disease 19, or COVID-19) was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. Since the first quarter of 2020 and continuing into 2021, we have seen some impact of the pandemic to our operations. We continue to monitor and respond as the pandemic evolves to ensure the continued development, manufacture and distribution of our medicines. For further discussion, see Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Overview, Selected Financial Information and Results of Operations. For a discussion of the risks presented by the COVID-19 pandemic to our results, see Risk Factors in Item 1A. Also see the remainder of Item 1. Business for discussion of pandemic-related impacts to our overall business.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products/Pipeline </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology/Hematology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(carfilzomib)</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In August 2020, we announced that the U.S. Food and Drug Administration (FDA) had approved the expansion of the KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. prescribing information to include its use in combination with DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) plus dexamethasone in two dosing regimens&#8212;once weekly and twice weekly&#8212;for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sotorasib (formerly AMG 510)</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In September 2020, we announced updated phase 1 data evaluating sotorasib in 129 patients across multiple advanced solid tumors with Kirsten rat sarcoma viral oncogene homolog (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS) G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutation, which were published in the New England Journal of Medicine. Data from 59 patients with advanced non-small cell lung cancer (NSCLC) were also featured in an oral presentation at a September 2020 medical conference. In the patients with advanced NSCLC who were treated with the 960 mg daily dose, the confirmed objective response rate (ORR) was 35.3%. Across all dose levels, the confirmed ORR was 32.2%, with median duration of response of 10.9 months and median progression-free survival (PFS) of 6.3 months; 10 of 19 responders were still in response as of the data cutoff.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In October 2020, we announced top-line phase 2 results in 126 patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutant advanced NSCLC. Sotorasib demonstrated an ORR (primary endpoint) consistent with previously reported phase 1 data in patients taking the 960 mg daily dose. Other measures of efficacy, including duration of response, were promising, and more than half of the responders were still on treatment and continuing to respond as of the data cutoff date. The results of this phase 2 study are potentially registrational, and a phase 3 confirmatory study comparing sotorasib to docetaxel is currently recruiting patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutant advanced NSCLC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2020, we announced that the FDA had granted Breakthrough Therapy designation for our investigational KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor, sotorasib, for the treatment of patients with locally advanced or metastatic NSCLC with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutation, as determined by an FDA-approved test, following at least one prior systemic therapy. Following this announcement, we submitted a New Drug Application (NDA) to the FDA. The sotorasib NDA is being reviewed by the FDA&#8217;s Real-Time Oncology Review (RTOR) pilot program, which aims to explore a more efficient review process that ensures safe and effective treatments are made available to patients as early as possible. Later in December, we also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In January 2021, we announced results from the phase 2 cohort of the clinical study evaluating sotorasib in 126 patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutant advanced NSCLC. Sotorasib demonstrated a confirmed ORR and disease control rate of 37.1% and 80.6%, respectively, a median duration of response of 10 months and median progression-free survival of 6.8 months. In addition, sotorasib was granted Breakthrough Therapy designation by the Center for Drug Evaluation of the National Medical Products Administration in China. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (rituximab-arrx) (formerly ABP 798)</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2020, we announced that the FDA had approved RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to Rituxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rituximab), for the treatment of adult patients with non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s granulomatosis) and microscopic polyangiitis. RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> launched in the United States in January 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflammation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (apremilast)</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In May 2020, we announced positive top-line results from a phase 3 study to assess the efficacy of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in adults with mild-to-moderate plaque psoriasis. The study showed that oral Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30 mg twice daily achieved a statistically significant improvement, compared with placebo, in the primary endpoint of the static Physician&#8217;s Global Assessment (sPGA) response (defined as an sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(etanercept)</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In July 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the judgment by the U.S. District Court for the District of New Jersey upholding the validity of the two patents that describe and claim ENBREL and methods for making it. See Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tezepelumab</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In November 2020, we and AstraZeneca plc (AstraZeneca) announced positive top-line results from the registrational phase 3 NAVIGATOR trial in adults and adolescents with severe uncontrolled asthma. The trial met the primary endpoint with tezepelumab added to standard of care (SoC), demonstrating a statistically significant and clinically meaningful reduction compared with placebo plus SoC in the annualized asthma exacerbation rate (AAER) over 52 weeks in the overall patient population. SoC consisted of medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controller medication with or without oral corticosteroids (OCS). We expect to submit results of this study to regulators in 2021.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2020, we and AstraZeneca announced that the SOURCE trial had not met the primary endpoint of a statistically significant reduction in the daily OCS dose, without loss of asthma control, with tezepelumab compared to placebo. The results of this trial have no impact on our submission plans.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omecamtiv mecarbil</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In November 2020, based on results of the omecamtiv mecarbil phase 3 trial, we provided notice to Cytokinetics, Incorporated (Cytokinetics) of termination of our collaboration and our intention to transition to them the development and commercialization rights for omecamtiv mecarbil and AMG 594.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Establishment of wholly owned affiliate in Japan </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In April 2020, we completed our purchase from Astellas of the remaining shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, now a wholly owned Amgen affiliate in Japan and renamed Amgen K.K., has enabled us to build a strong presence in Japan as we continue to advance treatments for serious illnesses. The purchase did not have a material impact to our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_19"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing, Distribution and Selected Marketed Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest concentration of our sales and marketing forces is based in the United States and Europe. In addition, we continue to expand the commercialization and marketing of our products into other geographic territories, including parts of Asia, the Middle East, Canada and Latin America. This expansion is occurring by establishing our own affiliates, by acquiring existing third-party businesses or product rights or by collaborating with third parties. See Business Relationships for our significant alliances. Whether we use our own sales and marketing forces or a third party&#8217;s varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, substantially all of our sales are to pharmaceutical wholesale distributors, which are the principal means of distributing our products to healthcare providers. We also market certain products through direct-to-consumer channels, including print, television and online media. For further discussion, see Government Regulation&#8212;Regulation in the United States&#8212;Regulation of Product Marketing and Promotion. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product sales to three large wholesalers, AmerisourceBergen Corporation, McKesson Corporation and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2020, 2019 and 2018. On a combined basis, these wholesalers accounted for 83%, 81% and 84% of worldwide gross revenues for 2020, 2019 and 2018, respectively. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are marketed around the world, with the United States being our largest market. The following chart shows our product sales by principal product, and the table below (dollar amounts in millions) shows product sales by geography for the years 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;text-align:center"><img src="amgn-20201231_g1.jpg" alt="amgn-20201231_g1.jpg" style="height:550px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Sales by Geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market ENBREL, a tumor necrosis factor blocker, primarily in the United States. ENBREL was launched in 1998 and is used primarily in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (denosumab)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily in the United States, Europe and the Asia Pacific region. Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contains the same active ingredient as XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (denosumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but is approved for different indications, patient populations, doses and frequencies of administration. Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the United States and Europe in 2010. In the United States, it is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk of fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy. In Europe, Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (pegfilgrastim)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in 2002 and is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count in patients with certain types of cancer (nonmyeloid) who receive anticancer medicines (chemotherapy) that can cause fever and a low blood cell count. In 2015, the Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit became available in the United States. The Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit provides physicians the opportunity to initiate the administration of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the same day as chemotherapy, with drug delivery of the recommended dose of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at home the day after chemotherapy, thereby saving patients a trip back to the doctor.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a small molecule that inhibits phosphodiesterase 4 (PDE4), primarily in the United States and Europe. Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was acquired from Bristol-Myers Squibb Company (BMS) in November 2019, post their acquisition of Celgene Corporation (Celgene). Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral therapy approved for the treatment of adult patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate, patients with active psoriatic arthritis and patients with oral ulcers associated with Beh&#231;et&#8217;s disease. In Europe, Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved for second-line use in the treatment of psoriatic arthritis and psoriasis.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily in the United States and Europe. XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in 2010 and is used primarily in the indication for prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in patients with bone metastases from solid tumors and multiple myeloma.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(darbepoetin alfa)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily in the United States and Europe. It was launched in 2001 and is indicated to treat a lower-than-normal number of red blood cells (anemia) caused by chronic kidney disease (CKD) in both patients on dialysis and patients not on dialysis. Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in certain patients with nonmyeloid malignancies and when chemotherapy will be used for at least two months after starting Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily in the United States and Europe. KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was launched in 2012 and is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. It is also approved as a single agent for patients with relapsed or refractory multiple myeloma who have received one or more previous therapies. In September 2019, the CANDOR phase 3 study of KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with dexamethasone and DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) met its primary endpoint of PFS in patients with relapsed or refractory multiple myeloma. In August 2020, the FDA approved the expansion of the KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. prescribing information to include its use in combination with dexamethasone and DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(evolocumab)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprotein convertase subtilisin/kexin type 9 (PCSK9), primarily in the United States and Europe. Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in 2015 and is indicated to reduce the risks of myocardial infarction, stroke and coronary revascularization in adults with established cardiovascular (CV) disease.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Marketed Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also market a number of other products in various markets worldwide, including Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (romiplostim), Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (panitumumab), MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bevacizumab-awwb), Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(etelcalcetide), EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (epoetin alfa), KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(trastuzumab-anns), BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (blinatumomab), Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (erenumab-aooe), EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (romosozumab-aqqg), AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(adalimumab), Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (cinacalcet), NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(filgrastim), IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(talimogene laherparepvec), Corlanor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ivabradine) and AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab-axxq).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists our outstanding material patents for the indicated product by territory, general subject matter and latest expiry date. Certain of the European patents are the subjects of&#160;supplemental protection certificates that provide additional protection for the products in certain European countries beyond the dates listed in the table. See footnotes to the patent table below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(etanercept)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment using aqueous formulations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/8/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/19/2037</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fusion protein and pharmaceutical compositions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/22/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNA encoding fusion protein and methods of making fusion protein</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/24/2029</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(denosumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/17/2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/25/2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nucleic acids encoding RANKL antibodies and methods of producing RANKL antibodies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/30/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including sequences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/19/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including epitope binding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/23/2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including sequences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/25/2022</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(apremilast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and compounds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/16/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystalline form</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/9/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/29/2034</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions, compounds and methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/20/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/26/2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (darbepoetin alfa)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Glycosylation analogs of erythropoietin proteins</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2024</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (carfilzomib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and compounds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2027</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of making</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/8/2033</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions, compounds and methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(evolocumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/25/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/8/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/22/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/10/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/3/2033</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(romiplostim)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thrombopoietic compounds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/19/2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/12/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thrombopoietic compounds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/20/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(panitumumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Human monoclonal antibodies to epidermal growth factor receptor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/5/2018</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(etelcalcetide)</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compound and pharmaceutical composition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/7/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/27/2034</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of making</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2035</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compound and pharmaceutical composition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/29/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/27/2034</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical compositions and bifunctional polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/6/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/28/2027</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bifunctional polypeptides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/26/2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/6/2029</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (erenumab-aooe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CGRP receptor antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/9/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/22/2036</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CGRP receptor antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/10/2035</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(romosozumab-aqqg)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/25/2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/11/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation and methods of using formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/28/2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/18/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation and methods of using formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2031</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(talimogene laherparepvec)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/23/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/27/2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Composition and uses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/27/2022</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CGRP = calcitonin gene-related peptide, RANKL = receptor activator of nuclear factor kappa-B ligand</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A European patent with this subject matter may also be entitled to supplemental protection in one or more countries in Europe, and the length of any such extension will vary by country. For example, supplementary protection certificates have been issued related to the indicated products for patents in at least the following countries:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">denosumab &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2025</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">carfilzomib &#8212; France, Germany, Italy and Spain, expiring in 2030</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">romiplostim &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2024</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">panitumumab &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2022</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">evolocumab &#8212; France and Spain, expiring in 2030</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">etelcalcetide &#8212; France and Italy, expiring in 2031</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">blinatumomab &#8212; France, Italy and Spain, expiring in 2029</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">erenumab &#8212; France, Italy and Spain, expiring in 2033</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">talimogene laherparepvec &#8212; Spain, expiring in 2026; France, Germany, Italy and the United Kingdom, expiring in 2027</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">romosozumab &#8212; Italy, expiring in 2031</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">apremilast &#8212; Italy and Spain, expiring in 2028</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A patent with this subject matter may be entitled to patent term extension in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. A number of our marketed products are indicated for disease areas in which other products or treatments are currently available or are being pursued by our competitors through research and development (R&amp;D) activities. Additionally, some competitor-marketed products target the same genetic pathways as our recently launched marketed products or are currently in development. This competition could impact the pricing and market share of our products. We continue to pursue ways of increasing the value of our medicines through innovations during their life cycles, which can include expanding the disease areas for which our products are indicated and finding new methods to make the delivery of our medicines easier and less costly. Such activities can offer important opportunities for differentiation. For example, we market the Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit, which provides physicians the opportunity to initiate the administration of the recommended dose of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the same day as chemotherapy, with drug delivery at home the day after chemotherapy, thereby saving patients a trip back to the doctor. We plan to continue pursuing innovation efforts to strengthen our competitive position. Such position may be based on, among other things, safety, efficacy, reliability, availability, patient convenience, delivery devices, price, reimbursement, access to and timing of market entry and patent position and expiration.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the existing patents on our principal products have expired, and we face new and increasing competition, including from biosimilars and generics. A biosimilar is another version of a biological product for which marketing approval is sought or has been obtained based on a demonstration that it is &#8220;highly similar&#8221; to the original reference product. We expect that the adverse impact on our originator-product sales from biosimilar competition will reflect current trends and actual results given similar conditions. We also believe that when multiple biosimilar versions of one of our originator products get approved and launched, competition could intensify more rapidly, leading to net price declines for both reference and biosimilar products, resulting in a greater impact on our products&#8217; sales. In the United States, companies have now launched biosimilar versions of EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have approved biosimilars for ENBREL. See also Government Regulation&#8212;Regulation in the United States&#8212;Approval of Biosimilars. Although we expect competitor biosimilars to compete on price, we believe many patients, providers and payers will continue to place high value on the reputation, reliability and safety of our products. As additional biosimilar competitors come to market, we will leverage our global experience versus both branded and biosimilar competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have our own biosimilar products both in the United States and outside of U.S. markets that are competing against branded and biosimilar versions of our competitors&#8217; products. In 2019, Amgen launched MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bevacizumab), and KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trastuzumab), in the United States; and AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (adalimumab) in Europe. We have also received FDA approval for AMJEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (adalimumab-atto), a biosimilar to Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2020, we launched AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (infliximab),</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in January 2021, we launched RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar for Rituxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(rituximab). We expect additional biosimilar competition against both our branded and biosimilar products in the future across all markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although most of our products are biologics, some are small molecule products. Because the FDA approval process permits generic manufacturers to rely on the safety and efficacy data of the innovator product rather than having to conduct their own costly and time-consuming clinical trials, generic manufacturers can often develop and market their competing versions of our small molecule products at much lower prices. For example, following loss of exclusivity of patents directed to cinacalcet, the active ingredient in our small molecule calcimimetic Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we lost a significant share of the market and corresponding revenues in a very short period of time. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result (i) in increased competition for our marketed products, even for those protected by patents and/or (ii) in reductions in the prices we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. (As used in this document, the term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may include prospective clinical trials, observational studies, registries and other studies.) See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products face substantial competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and expect to face increasing competition from biosimilars and generics in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our significant competitors and is not exhaustive.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitor-marketed product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitors</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Inc. (AbbVie)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xeljanz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RINVOQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alendronate, raloxifene and zoledronate generics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UDENYCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coherus BioSciences, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fulphila</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mylan Institutional Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filgrastim biosimilars</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(3)&#8224;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cosentyx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Pharma AG (Novartis)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Lilly)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tremfya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skyrizi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methotrexate generics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoledronate generics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epoetin alfa biosimilars</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Millennium Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POMALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc.<br/>Sanofi</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Approved biosimilars available.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224; Approved biosimilars available in Europe.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of Johnson &amp; Johnson (J&amp;J).</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Other biosimilars under regulatory review in the United States and Europe.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Dermatology only.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> competes with Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in supportive cancer care and predialysis settings.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is facing increased competition from several recently approved products.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of Takeda Pharmaceutical Company Limited.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of BMS.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:4.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_22"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our principal products are dependent on the availability and extent of coverage and reimbursement from third-party payers. In many markets around the world, these payers, including government health systems, private health insurers and other organizations, remain focused on reducing the cost of healthcare; and their efforts have intensified as a result of rising healthcare costs, economic pressures and broader challenges generated by the COVID-19 pandemic. Drugs remain heavily scrutinized for cost containment. As a result, payers are becoming more restrictive regarding the use of biopharmaceutical products and are scrutinizing the prices of these products while requiring a higher level of clinical evidence to support the benefits such products bring to patients and the broader healthcare system.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pressures are intensified when our products are subject to competition, including from biosimilars.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, healthcare providers and other entities such as pharmacies and pharmacy benefit managers (PBMs) are reimbursed for covered services and products they deliver through both private-payer and government healthcare programs such as Medicare and Medicaid. We provide negotiated rebates to healthcare providers, private payers, government payers and PBMs. In addition, we are required to (i) provide rebates or discounts on our products that are reimbursed through certain government programs, including Medicare and Medicaid, and (ii) provide discounts to qualifying healthcare providers under the federal 340B Drug Pricing Program. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both private and government payers use formularies to manage access and utilization of drugs. A drug&#8217;s inclusion and favorable positioning on a formulary are essential to ensure patients have access to a particular drug. Even when access is available, some patients abandon their prescriptions for economic reasons. Payers continue to institute cost reduction and containment measures that lower drug utilization and/or spending altogether and/or shift a greater portion of the costs to patients. Such measures include, but are not limited to, more-limited benefit plan designs, higher patient co-pays or coinsurance obligations, limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs), stricter utilization management criteria before a patient may get access to a drug, higher-tier formulary placement that increases the level of patient out-of-pocket costs and formulary exclusion, which effectively encourages patients and providers to seek alternative treatments or pay 100% of the cost of a drug. The use of such measures by PBMs and insurers has continued to intensify and has thereby limited Amgen product usage and sales. Furthermore, during the past few years, many PBMs and insurers have consolidated, resulting in a smaller number of PBMs and insurers overseeing a large portion of total covered lives in the United States. As a result, PBMs and insurers have greater market power and negotiating leverage to mandate stricter utilization criteria and/or exclude drugs from their formularies in favor of competitor drugs or alternative treatments. In highly competitive treatment markets such as the markets for ENBREL, Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PBMs are also able to exert negotiating leverage by requiring incremental rebates from manufacturers in order for them to gain and/or maintain their formulary position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to market actions taken by private and government payers in the United States, policy makers from both of the major U.S. political parties are pursuing policies to lower drug costs. Potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; instituting international reference pricing (IRP) schemes, which would set the prices of certain drugs based on those available in other countries; establishing caps on price increases based on inflation metrics; increasing transparency on drug pricing; and using third-party value assessments to determine drug prices. Examples of such policies include the previous Administration&#8217;s November 2020 interim final rule, which attempts to institute most favored nation (MFN) IRP in Medicare Part B and final rule instituting rebate reform in Medicare Part D. Both of these rules are being challenged in court and therefore have not yet been implemented. The direction of drug pricing policy reforms remains unclear at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries outside the United States, government-sponsored healthcare systems are the primary payers for drugs and biologics. With increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in mandates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many countries have health technology assessment organizations that use formal economic metrics such as cost-effectiveness to determine prices, coverage and reimbursement of new therapies; and these organizations are expanding in both established and emerging markets. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that countries will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dynamics and developments discussed above serve to create pressure on the pricing and potential usage of our products and the industry. Given the diverse interests in play between payers, biopharmaceutical manufacturers, policy makers, healthcare providers and independent organizations, if and whether the parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">investing billions of dollars annually in R&amp;D;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">pricing our medicines to reflect the value they provide;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">partnering with payers to share risk and accountability for health outcomes;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">providing patient support and education programs; </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">helping patients in financial need access our medicines; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and where patients and their healthcare professionals are the primary decision makers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures may affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_25"></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing, Distribution and Raw Materials</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are a leader in the manufacture of biologics and that our manufacturing capabilities represent a competitive advantage. The products we manufacture consist of both biologics and small molecule drugs. The majority of our products are biologics that are produced in living cells and that are inherently complex due to naturally occurring molecular variations. Highly specialized knowledge and extensive process and product characterization are required to transform laboratory-scale processes into reproducible commercial manufacturing processes. Further, our expertise in the manufacture of biologics positions us well for leadership in the global biosimilars market. For additional information regarding manufacturing facilities, see Item&#160;2. Properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal manufacturing network has commercial production capabilities for bulk manufacturing, formulation, fill, finish, tableting and device assembly. These activities are performed within the United States and its territories in our Puerto Rico, Rhode Island and California facilities as well as internationally in our Ireland, Netherlands and Singapore facilities. In addition, we use third-party contract manufacturers to supplement the capacity or capability of our commercial manufacturing network.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support our clinical trials, we manufacture product candidates primarily at our California facilities. We also use third-party contract manufacturers to supplement the capacity or capability of our overall clinical manufacturing network.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate distribution centers in Puerto Rico, Kentucky, California and the Netherlands for worldwide distribution of the majority of our commercial and clinical products. We also use third-party distributors to supplement distribution of our products worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the manufacturing and distribution activities noted above, each of our manufacturing locations includes key manufacturing support functions such as quality control, process development, engineering, procurement, production scheduling and warehousing. Certain of those manufacturing and distribution activities are highly regulated by the FDA as well as international regulatory agencies. See Government Regulation&#8212;Regulation in the United States&#8212;Regulation of Manufacturing Standards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Initiatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple ongoing initiatives that are designed to extend our manufacturing advantage by optimizing our manufacturing network and/or by mitigating risks while continuing to ensure adequate supply of our products. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, our licensed next-generation biomanufacturing plant operating in Singapore incorporates multiple innovative technologies into a single facility and was built in half the construction time and at approximately half the operating cost of a traditional plant. Next-generation biomanufacturing plants require smaller manufacturing footprints and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions. Within such plants, the equipment is portable and smaller, and some components are disposable, which provides greater flexibility and speed when manufacturing different medicines simultaneously. This eliminates the otherwise costly and complex retrofitting inherent in standard plants and enables Amgen to respond to changing demands for its medicines with increased agility, ultimately increasing the speed at which a medicine can become available for patients. The Singapore site also has a plant that has been approved to produce small molecule drugs for commercial manufacturing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we broke ground for our newest next-generation biomanufacturing plant at our West Greenwich, Rhode Island, campus. Construction on this new plant, the first of its kind in the United States, is complete. Upon approval by the FDA and global regulatory authorities, this plant will expand our capacity to manufacture certain products for U.S. and global markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we initiated projects to expand our manufacturing capabilities in Thousand Oaks, California, as well as at contract manufacturers. These investments will initially support clinical manufacturing but in the future may also be leveraged for commercial manufacturing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an arrangement with Lilly to manufacture Lilly&#8217;s potential COVID-19 therapies. For 2021&#8212;and, potentially, through 2022&#8212;we expect to allocate a portion of our manufacturing capacity to support this production. Additionally, starting in 2021, we will initiate projects that will expand our manufacturing capacity to enable supply of products and product candidates. These projects will employ new technologies that are being developed by Amgen that are anticipated to allow further optimization of our manufacturing network and processes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Raw Materials and Medical Devices</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain raw materials, medical devices (including companion diagnostics) and components necessary for the commercial and/or clinical manufacturing of our products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be our only sources for such materials. We currently attempt to manage the risk associated with such suppliers by means of inventory management, relationship management and evaluation of alternative sources when feasible. We also monitor the financial condition of certain suppliers and their ability to supply our needs. See Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform various procedures to help authenticate the sources of raw materials, including intermediary materials used in the manufacture of our products, which include verification of the country of origin. The procedures are incorporated into the manufacturing processes we and our third-party contract manufacturers perform.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To better ensure supply, Amgen has a risk mitigation strategy that uses a combination of methods, including multiple sources or backup inventory of critical raw materials. In response to COVID-19, we continue to closely monitor our inventory levels and have taken additional measures to mitigate against raw material supply interruption as part of our ongoing business continuity efforts. See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_28"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation by government authorities in the United States and other countries is a significant factor in the production and marketing of our products and our ongoing R&amp;D activities. To clinically test, manufacture and market products for therapeutic use, we must satisfy mandatory procedures and safety and effectiveness standards established by various regulatory bodies. Compliance with these standards is complex, and failure to comply with any of these standards can result in significant implications. See Item 1A. Risk Factors for a discussion of factors, including global regulatory implications, that can adversely impact our development and marketing of commercial products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation in the United States</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Public Health Service Act; the Federal Food, Drug, and Cosmetic Act (FDCA); and the regulations promulgated thereunder as well as other federal and state statutes and regulations govern, among other things, the production, research, development, testing, manufacture, quality control, labeling, storage, record keeping, approval, advertising, promotion and distribution of our products in addition to the reporting of certain payments and other transfers of value to healthcare professionals and teaching hospitals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development and Product Approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug development in our industry is complex, challenging and risky, and failure rates are high. Product development cycles are typically very long&#8212;approximately 10 to 15 years from discovery to market. A potential new medicine must undergo many years of preclinical and clinical testing to establish its safety and efficacy for use in humans at appropriate dosing levels and with an acceptable risk&#8211;benefit profile. We continue to work toward reducing cycle times by applying our expertise in human genetics and innovation in technology, clinical trials and real-world evidence.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After laboratory analysis and preclinical testing in animals, we file an Investigational New Drug Application (IND) with the FDA to begin human testing. Typically, we undertake an FDA-designated three-phase human clinical testing program.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase 1, we conduct small clinical trials to investigate the safety and proper dose ranges of our product candidates in a small number of human subjects.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase 2, we conduct clinical trials to investigate side-effect profiles and the efficacy of our product candidates in a patient population larger than phase 1 but still relatively small, who have the disease or condition under study.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase&#160;3, we conduct clinical trials to investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA monitors the progress of each trial conducted under an IND and may, at its discretion, reevaluate, alter, suspend or terminate the testing based on the data accumulated to that point and the FDA&#8217;s risk&#8211;benefit assessment with regard to the patients enrolled in the trial. The results of preclinical and clinical trials are submitted to the FDA in the form of either a Biologics License Application for biologic products or a NDA for small molecule products. We are not permitted to market or promote a new product until the FDA has approved our marketing application.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act (ACA) authorized the FDA to approve biosimilars via a separate, abbreviated pathway. The pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on the nonclinical-trial and clinical-trial data of an originator product to which the biosimilar has been demonstrated to be &#8220;highly similar&#8221; and to have no clinically meaningful differences in terms of safety, purity and potency. The relevance of demonstrating &#8220;similarity&#8221; is that in many cases, biosimilars can be brought to market without conducting the full suite of clinical trials typically required of originators, because risk&#8211;benefit has previously been established. To preserve incentives for future innovation, the law establishes a period of exclusivity for originators&#8217; products, which in general prohibits biosimilars from gaining FDA approval based in part on reliance on or reference to the originator&#8217;s data in their application to the FDA for 12 years after initial FDA approval of the originator product. The law does not change the duration of patents granted on biologic products. As part of the implementation of the abbreviated approval pathway for biosimilars, the FDA released a number of guidance documents, some of which remain in draft form.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Product Marketing and Promotion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA regulates the marketing and promotion of drug products. Our product promotions for approved product indications must comply with the statutory standards of the FDCA and the FDA&#8217;s implemented regulations and guidance. The FDA&#8217;s review of marketing and promotional activities encompasses but is not limited to direct-to-consumer advertising, healthcare-provider-directed advertising and promotion, sales representative communications to healthcare professionals, promotional programming and promotional activities involving electronic media. The FDA may also review industry-sponsored scientific and educational activities that make representations regarding product safety or efficacy in a promotional context. The FDA may take enforcement action against a company for promoting unapproved uses of a product or for other violations of the FDA&#8217;s advertising and labeling laws and regulations. Enforcement action may include product seizures, injunctions, civil or criminal penalties or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals. Failure to comply with the FDA&#8217;s regulations also can result in adverse publicity or increased scrutiny of company activities by the U.S. Congress or other legislators. Additionally, as described below, such failure may lead to additional liability under U.S. healthcare fraud and abuse laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Manufacturing Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA regulates and inspects the equipment, facilities, laboratories and processes used in the manufacturing and testing of products prior to granting approval to market products. If after receiving approval from the FDA we make a material change in manufacturing equipment, location or process, additional regulatory review may be required. We also must adhere to current Good Manufacturing Practice regulations and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA conducts regular, periodic visits to reinspect our equipment, facilities, laboratories and processes following an initial approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Combination Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Combination products are defined by the FDA as products composed of two or more regulated components (e.g., a biologic and/or drug and a device). Biologics/drugs and devices each have their own regulatory requirements, and combination products may have additional requirements. A number of our marketed products meet this definition and are regulated under this framework, and we expect that a number of our pipeline product candidates will be evaluated for regulatory approval under this framework as well.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation outside the United States</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In European Union (EU) countries as well as in Switzerland, Canada, Australia and Japan, regulatory requirements and approval processes are similar in principle to those in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, there are currently two potential tracks for seeking marketing approval for a product not authorized in any EU member state: a decentralized procedure and a centralized procedure. In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">decentralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, identical applications for marketing authorization are submitted simultaneously to the national regulatory agencies. Regulatory review is led by one member state (the reference-member state), and its assessment&#8212;based on safety, quality and efficacy&#8212;is reviewed and approved (assuming there are no concerns that the product poses a serious risk to public health) by the other member states from which the applicant is seeking approval (the concerned-member states). The decentralized procedure leads to a series of single national approvals in all relevant countries. In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">centralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is required of all products derived from biotechnology, a company submits a single MAA to the EMA, which conducts an evaluation of the dossier, drawing upon its scientific resources across Europe. If the drug product is proven to fulfill requirements for quality, safety and efficacy, the EMA&#8217;s Committee for Medicinal Products of Human Use (CHMP) adopts a positive opinion, which is transmitted to the European Commission (EC) for final decision on granting of the marketing authorization. Even though the EC generally follows the CHMP&#8217;s opinion, it is not bound to do so. Subsequent commercialization is enabled by country-by-country reimbursement approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biosimilars are approved under a specialized pathway of the centralized procedure. As with the U.S. pathway, an applicant seeks and obtains regulatory approval for a biosimilar once the data exclusivity period for the original reference product has expired, relying in part on the data submitted for the originator product together with data evidencing that the biosimilar is &#8220;highly similar&#8221; in terms of quality, safety and efficacy to the original reference product authorized in the European Economic Area.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the United Kingdom&#8217;s decision to leave the EU, the EMA in March 2019 relocated to Amsterdam. The United Kingdom officially left the EU in January 2020, and in December 2020, a new trade deal was agreed that starts to clarify how U.K. medicines will be independently supervised and where continued collaborations and recognitions can be expected. Amgen continues to monitor future negotiations to ensure no interruption in the supervision, regulation or supply of medicines in the United Kingdom and Europe.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other countries such as Russia, Turkey and those in Latin America and the Middle East have review processes and data requirements similar to those of the EU and in some cases can rely on prior marketing approval from U.S. or EU regulatory authorities. The regulatory process in these countries may include manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Asia Pacific, a number of countries such as China, Japan, South Korea and Taiwan may require local clinical-trial data for bridging purposes as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. In most of the Asian markets, registration timelines depend on marketing approval in the United States or the EU. In some markets in Asia, such as China, Indonesia and Thailand, the regulatory timelines can be less predictable. The regulatory process may also include manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements. Countries such as Australia and Japan have more-mature systems that would allow for submissions under more-competitive time frames. Regarding biosimilars, several of these countries have pathways to register biosimilars (e.g., Australia, India, Singapore, South Korea and Taiwan), and biosimilar products are already present on the markets (e.g., Australia and South Korea).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, such as Japan and those in the EU, medical devices may be subject to regulatory regimes whereby manufacturers must establish that their medical devices conform to essential requirements set out in the law for the particular device category. For example, in the EU, with limited exceptions, medical devices placed on the market must bear the Conformit&#233; Europ&#233;enne marking to indicate their conformity with legal requirements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Postapproval Phase</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, we continue to monitor adverse events and product complaints reported following the use of our products through routine postmarketing surveillance and studies when applicable. We report such events to the appropriate regulatory agencies as required by local regulations for individual cases and aggregate reports. We proactively monitor (according to good pharmacovigilance practices) and ensure the implementation of signal detection, assessment and the communication of adverse events that may be associated with the use of our products. We also proactively monitor product complaints through our quality systems, which includes assessing our drug delivery devices for device complaints, adverse events and malfunctions. We may also be required by regulatory agencies to conduct further clinical trials on our marketed products as a condition of their approval or to provide additional information on safety and efficacy. Health regulators, including the FDA, have authority to mandate labeling changes to products at any point in a product&#8217;s life cycle based on new safety information or as part of an evolving label change to a particular class of products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health regulators, including the FDA, also have authority, before or after approval, to require a company to implement a risk management program for a product to ensure that the benefits of the drug outweigh the risks. Each risk management program is unique and varies depending on the specific factors required. In the United States, a risk management program is known as a risk evaluation and mitigation strategy (REMS), and we currently have REMSs for Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various laws pertaining to healthcare fraud and abuse, including antikickback laws and false-claims laws. Antikickback laws make it illegal to solicit, offer, receive or pay any remuneration in exchange for or to induce the referral of business, including the purchase or prescribing of a particular drug that is reimbursed by a state or federal program. False-claims laws prohibit knowingly and willingly presenting or causing to be presented for payment to third-party payers (including Medicare and Medicaid) any claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). Liability under the false-claims laws may also arise when a violation of certain laws or regulations related to the underlying product (e.g., violations regarding improper promotional activity or unlawful payments) contributes to the submission of a false claim.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, Amgen entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the U.S. Department of Health &amp; Human Services (HHS), which was formally closed out in August 2018. On April 25, 2019, we entered into a settlement agreement with the U.S. Department of Justice (DOJ) and the OIG of the HHS to settle certain allegations related to our support of independent charitable organizations that provide patients with financial assistance to access their medicines. Additionally, we entered into a corporate integrity agreement that requires us to maintain a corporate compliance program and to undertake a set of defined corporate integrity obligations for a period of five years. Due to the breadth of the statutory provisions and the absence of guidance in the form of regulations or court decisions addressing some of our practices, it is possible that in the future, our practices might be further challenged under antikickback or similar laws. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S.&#160;Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA arguably includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anticorruption laws and/or regulations. Failure by our employees, agents, contractors, vendors, licensees, partners or collaborators to comply with the FCPA and other anticorruption laws and/or regulations could result in significant civil or criminal penalties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations globally regarding privacy and data protection. These laws and regulations involve the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environments regarding privacy and data protection are continually evolving and developing, as these issues are the subjects of increasing amounts of attention in countries globally. For example, we are subject to the EU&#8217;s General Data Protection Regulation (GDPR), which became effective on May 25, 2018, and the California Consumer Privacy Act of 2018, which became effective on January 1, 2020. Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations. Failure to comply with these laws could result in significant penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been and will continue to be subject to various other U.S. and foreign laws, rules and regulations. See Reimbursement section above.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_31"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development and Selected Product Candidates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our R&amp;D on novel human therapeutics for the treatment of serious illness. We capitalize on our strengths in human genetics, novel biology and protein engineering. We leverage our biologic expertise and take a modality-independent approach to R&amp;D. And we use cutting-edge science and technology to study subtle biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery research programs may therefore yield targets that lead to the development of human therapeutics delivered as large molecules, small molecules, other combination modalities or new modalities. We have reshaped our portfolio and have increasingly focused our efforts on human genetics when possible to enhance the likelihood of success.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we managed our clinical development on a case-by-case basis. Patients who were already enrolled in studies continued to receive study drug, including through direct-to-patient shipments. For studies that had the potential for significant benefit in a serious or life-threatening condition and when site resources enabled new patients to be enrolled safely and monitored closely, we continued enrollment. For clinical trials experiencing uncertainty with regard to the trial sites&#8217; ability to ensure subject safety or data integrity at that time, we temporarily paused enrollment. We remain focused on supporting our active clinical sites in providing care for these patients and providing investigational drug supply. To date, the majority of clinical trials that were paused at the onset of the pandemic to ensure subject safety or data integrity have resumed. Study enrollments were affected the most in the second quarter of 2020 and by the end of the year resumed to prepandemic levels, although COVID-19 infection rates and related vaccination activities may impact future patient enrollment. We continuously monitor and reevaluate the status of studies, pausing when uncertainty arises with regard to the trial sites&#8217; ability to ensure safety or data integrity. We remain focused on supporting our active clinical sites in providing care for these patients and in providing investigational drug supply. In addition, our R&amp;D organization is supporting efforts to combat the COVID-19 pandemic in a number of ways, including by (i) working to support production of therapeutic antibodies that could diminish the impact of COVID-19 on patients, (ii) joining a public&#8211;private partnership between leading companies in our industry and U.S. government health agencies to develop a strategy for a coordinated research response and (iii) participating in platform studies to investigate treatments in adult patients hospitalized with severe COVID-19 infections.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2020, 2019 and 2018, our R&amp;D expenses were $4.2 billion, $4.1 billion and $3.7 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have major R&amp;D centers in Thousand Oaks and San Francisco, California; Iceland; and the United Kingdom, as well as smaller research centers and development facilities globally. See Item&#160;2. Properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial activities are conducted by both our internal staff and third-party contract clinical trial service providers. To increase the number of patients available for enrollment in our clinical trials, we have opened clinical sites and will continue opening clinical sites and enrolling patients in a number of geographic locations. See Government Regulation&#8212;Regulation in the United States&#8212;Clinical Development and Product Approval for a discussion of government regulation over clinical development. Also see Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors are actively engaged in R&amp;D in areas in which we have products or in which we are developing product candidates or new indications for existing products. For example, we compete with other clinical trials for eligible patients, which may limit the number of available patients who meet the criteria for certain clinical trials. The competitive marketplace for our product candidates is greatly dependent on the timing of entry into the market. Early entry may have important advantages in gaining product acceptance, thereby contributing to a product&#8217;s eventual success and profitability. Accordingly, we expect that in some cases, the relative speed with which we can develop products, complete clinical testing, receive regulatory approval and supply commercial quantities of a product to the market will be important to our competitive position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to product candidates and marketed products generated from our internal R&amp;D efforts, we acquire companies, acquire and license certain product and R&amp;D technology rights and establish R&amp;D arrangements with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D capabilities, product pipeline and marketed product base. In pursuing these R&amp;D arrangements and licensing or acquisition activities, we face competition from other pharmaceutical and biotechnology companies that also seek to license or acquire technologies, product candidates or marketed products from those entities performing the R&amp;D.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a selection of certain of our product candidates by phase of development in our therapeutic areas of focus as of February&#160;2, 2021, unless otherwise indicated. Additional product candidate information can be found on our website at www.amgen.com. (The website address is not intended to function as a hyperlink, and the information contained on our website is not intended to be a part of this filing.) The information in this section does not include other, nonregistrational clinical trials that we may conduct for purposes other than for submission to regulatory agencies for their approval of a new product indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may conduct nonregistrational clinical trials for various reasons, including to evaluate real-world outcomes or to collect additional safety information with regard to the use of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 13.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Disease/condition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Male osteoporosis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weekly dosing for relapsed multiple myeloma</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chemotherapy-induced thrombocytopenia</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">COVID-19</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genital psoriasis</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mild-to-moderate psoriasis</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sotorasib</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSCLC with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">KRAS G12C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">mutations</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tezepelumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severe asthma</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 654</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psoriasis, psoriatic arthritis and Crohn&#8217;s disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 938</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 959</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paroxysmal nocturnal hemoglobinuria (PNH)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 2 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran (formerly AMG 890)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cardiovascular disease</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa (formerly AMG 570)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sotorasib</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Advanced colorectal cancer</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other solid tumors with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">KRAS G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> mutations</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tezepelumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 714/PRV-015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Celiac disease</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa (formerly AMG 592)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inflammatory diseases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small-cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obesity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 160</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 171</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obesity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 176</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematologic malignancies</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 199</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic gastric and gastroesophageal junction cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 256</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 330</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 397</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematologic malignancies</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 427</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 506</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 509</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMG 594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 673</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 701</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multiple myeloma</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 757</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small-cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 910</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gastric and gastroesophageal junction cancer</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">In November 2020, we provided notice to Cytokinetics of termination of our collaboration effective May 20, 2021 and of our intention to transition to them the development and commercialization rights for omecamtiv mecarbil and AMG 594.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate side-effect profiles and efficacy of product candidates in a larger patient population than phase 1, but still relatively small, who have the disease or condition under study.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate the safety and proper dose ranges of product candidates in a small number of human subjects.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Product Candidate Program Changes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 12, 2020, we had 14 phase 3 programs. As of February 2, 2021, we had 13 phase 3 programs, as regulatory approvals were received for three programs, two programs initiated phase 3 studies, two programs initiated biosimilarity studies, one concluded and one termination and transition of program to Cytokinetics. These changes are set forth in the following table.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Disease/condition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Multiple myeloma</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved by the FDA</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beh&#231;et&#8217;s disease</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved by the FDA</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-Hodgkin&#8217;s lymphoma</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved by the FDA</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sotorasib</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 654</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Psoriasis, psoriatic arthritis and Crohn&#8217;s disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated biosimilarity study</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 938</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated biosimilarity study</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic melanoma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concluded</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omecamtiv mecarbil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic heart failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concluded; no longer pursuing our marketing application with the FDA and EC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:4pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">In November 2020, we provided notice to Cytokinetics of termination of our collaboration effective May 20, 2021 and of our intention to transition to them the development and commercialization rights for omecamtiv mecarbil and AMG 594.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our approval pathway that did not require phase 3 study, in January 2021, Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the FDA for treatment of hematopoietic syndrome of acute radiation syndrome.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Product Candidate Patent Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes our composition-of-matter patents that have been issued thus far for our product candidates in phase 3 development that have yet to be approved for any indication in the United States or the EU. Patents for products already approved for one or more indications in the United States or the EU but that are currently undergoing phase 3 clinical trials for additional indications have been previously described. See Marketing, Distribution and Selected Marketed Products&#8212;Patents.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;expiration*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sotorasib</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tezepelumab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Patent expiration estimates are based on issued patents, which may be challenged, invalidated or circumvented by competitors. The patent expiration estimates do not include any term adjustments, extensions or supplemental protection certificates that may be obtained in the future and thereby extend these dates. Corresponding patent applications are pending in other jurisdictions. Additional patents may be filed or issued and may provide additional exclusivity for the product candidate or its use.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phases 3 and 2 Program Descriptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides additional information about selected product candidates that have advanced into human clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being evaluated as a treatment for male osteoporo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sis. EVENITY</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is being developed in collaboration with UCB.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). A Phase 3 study evaluating IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with pembrolizumab (KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) versus pembrolizumab alone for treatment of unresectable stage IIIB to IVM1c melanoma was stopped for futility after an interim analysis by the Data Monitoring Committee. No new safety signals were observed.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a small molecule proteasome inhibitor. It is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for relapsed multiple myeloma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FDA approved the expansion of the KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. prescribing information to include its use in combination with DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus dexamethasone in two dosing regimens&#8212;once weekly and twice weekly&#8212;for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a thrombopoietin receptor agonist. It is being investigated in phase 3 studies for chemotherapy-induced thrombocytopenia.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December, the European Commission approved an expanded indication for use in adult patients who have had immune thrombocytopenia for 12 months or less and who have had an insufficient response to corticosteroids or immunoglobulins. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the FDA has approved Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of hematopoietic syndrome of acute radiation syndrome.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OLPASIRAN</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated in phase 2 for the treatment of atherosclerotic CV disease.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a small molecule that inhibits PDE4. It is being investigated in phase 3 studies for the treatment of patients with mild-to-moderate plaque psoriasis, patients with moderate-to-severe genital psoriasis and, in collaboration with some of the members of the COVID R&amp;D Alliance, adult patients hospitalized with COVID-19.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we announced positive results from the ADVANCE trial, a phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in adults with mild-to-moderate plaque psoriasis. The study showed that oral Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30 mg twice daily achieved a statistically significant improvement, compared with placebo, in the primary endpoint of the sPGA response at week 16. In addition, the week 16 secondary endpoints of achieving at least 75% improvement from baseline in the percent of affected body surface area (BSA), change in BSA total score from baseline and change in Psoriasis Area and Severity Index (PASI) total score from baseline were each also statistically significant for the treatment effect of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared with placebo.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a human monoclonal antibody that inhibits PCSK9. It is being investigated as a treatment for atherosclerotic CV disease in high-risk patients with high low-density lipoprotein cholesterol (LDL-C) without prior heart attack or stroke.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we announced positive results from the BEIJERINCK study evaluating the efficacy and safety of Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients who are human immunodeficiency virus-positive (HIV+) and have high LDL-C despite stable background lipid-lowering therapy. The study demonstrated that treatment with Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> significantly reduced LDL-C.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar candidate to Rituxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MabThera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(rituximab), is an anti-CD20 monoclonal antibody. It is being investigated in a phase 3 study for treatment of rheumatoid arthritis. The reference-product primary conditions are non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Funding and execution of the pivotal study was provided by the National Institute of Allergy and Infectious Diseases (NIAID) and the Priority Review regulatory submission was conducted in partnership with the Biomedical Advanced Research and Development Authority (BARDA).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that the FDA had approved RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of adult patients with non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s granulomatosis), and microscopic polyangiitis. RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> launched in the United States in January 2021.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rozibafusp alfa </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rozibafusp alfa is a novel bispecific antibody-peptide conjugate that simultaneously blocks the B lymphocyte stimulator (BAFF) and inducible costimulatory ligand (ICOSL)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity. It is being investigated as a treatment for systemic lupus erythematosus.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sotorasib</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sotorasib is a KRAS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> small molecule inhibitor. It is being investigated as a treatment for a variety of solid tumors, including NSCLC, colorectal cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other solid tumor cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that the FDA had granted Breakthrough Therapy designation for sotorasib for the treatment of patients with locally advanced or metastatic NSCLC with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutation as determined by an FDA-approved test, following at least one prior systemic therapy. The sotorasib application is being reviewed under the FDA&#8217;s RTOR pilot program, which aims to explore a more efficient review process that ensures safe and effective treatments are made available to patients as early as possible.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C-mutant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> advanced NSCLC, who had failed a median of two prior lines of anticancer therapies (immunotherapy and/or chemotherapy). Sotorasib demonstrated a confirmed ORR (primary end point) and disease control rate of 37.1% and 80.6%, respectively, a median duration of response of 10 months and median progression-free survival of 6.8 months. Patients were treated with sotorasib 960 mg once daily orally.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tezepelumab </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tezepelumab is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin. It is being evaluated in phase 3 as a treatment for severe asthma. It is also being investigated in phase 2 for chronic obstructive pulmonary disease. Tezepelumab is being developed jointly in collaboration with AstraZeneca.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we announced positive results from the registrational phase 3 NAVIGATOR trial, in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma. The NAVIGATOR trial met the primary endpoint with tezepelumab added to SoC, demonstrating a statistically significant and clinically meaningful reduction compared to placebo plus SoC in the AAER over 52 weeks in the overall patient population. SoC consisted of medium- or high-dose ICS plus at least one additional controller medication with or without OCS.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that the SOURCE trial had not met the primary endpoint of a statistically significant reduction in the daily OCS dose, without loss of asthma control, with tezepelumab compared to placebo. The results of this trial have no impact on our submission plans.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG 714/PRV-015</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG 714/PRV-015 is a human monoclonal antibody that binds to interleukin-15. It is being investigated for the treatment of celiac disease and is being developed in collaboration with Provention Bio.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 654</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 654, a biosimilar candidate to STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ustekinumab), is a monoclonal antibody that inhibits interleukin-12 and interleukin-23. It is being investigated in a phase 3 study for biosimilarity to STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The reference-product primary conditions are psoriasis, psoriatic arthritis and Crohn&#8217;s disease.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 938</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 938, a biosimilar candidate to EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (aflibercept), is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein. It is being investigated in a phase 3 study for neovascular (wet) age-related macular degeneration (AMD). The reference-product primary conditions are wet AMD, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 959</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 959, a biosimilar candidate to SOLIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(eculizumab), is a monoclonal antibody that specifically binds to the complement protein C5. It is being investigated in a phase 3 study for PNH. The reference-product primary conditions are PNH and atypical hemolytic uremic syndrome (aHUS).</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_34"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Relationships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D capabilities, product pipeline and marketed-product base. These arrangements generally provide for nonrefundable, upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we generally require counterparties to execute confidentiality agreements upon commencement of a business relationship with us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% stake in BeiGene, Ltd. (BeiGene) for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene commenced selling XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will commercialize KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global R&amp;D costs by providing cash and development services up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis to jointly develop and commercialize Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the United States, Amgen and Novartis jointly develop and collaborate on the commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen, as the principal, recognizes product sales of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, shares U.S. commercialization costs with Novartis and pays Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Novartis pays Amgen double-digit royalties on net sales of the product in the Novartis-exclusive territories and funds a portion of global R&amp;D expenses. In addition, Novartis will make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds are achieved with respect to Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Amgen manufactures and supplies Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in litigation with Novartis over our collaboration agreements for the development and commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer HealthCare LLC</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a licensing arrangement with Bayer HealthCare LLC (Bayer) for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2020, we amended the terms of our agreement with Bayer, which transferred all of our operational responsibilities outside the United States to Bayer, including commercial and medical affairs activities. Prior to the amendment of the agreement, we shared equally in the profits outside the United States, excluding Japan. In lieu of this profit share, Bayer now pays us a royalty on sales of Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at a percentage rate in the low 30s. The rights to develop and market Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan are reserved to Bayer. In the United States, Bayer pays us a royalty on sales of Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at a percentage rate in the high 30s.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a six-year supply agreement with DaVita Inc. (DaVita), which superseded the previously existing, seven-year supply agreement that commenced in 2012. Pursuant to the 2017 agreement, we supply EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in amounts necessary to meet specified annual percentages of DaVita&#8217;s and its affiliates&#8217; requirements for erythropoiesis-stimulating agents (ESAs) used in providing dialysis services in the United States and Puerto Rico. Such percentages vary during the term of the agreement, but in each year are at least 90%. The agreement expires in 2022. The agreement may be terminated by either party before expiration of its term in the event of certain breaches of the agreement by the other party.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information concerning our significant collaborative arrangements, see Part IV&#8212;Note 8, Collaborations, to the Consolidated Financial Statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s approach to human capital resource management starts with our mission to serve patients. Our industry exists in a complex regulatory and reimbursement environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, require talent that is highly educated and/or has significant industry experience. Additionally, for certain key functions, we require specific scientific expertise to oversee and conduct R&amp;D activities and the complex manufacturing requirements for biopharmaceutical products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, Amgen had approximately 24,300 staff members, and we have had relatively low global turnover rates. We consider our staff relations to be good; supported by our regular staff engagement assessments, with surveys on a wide range of topics (including engagement in the COVID-19 environment, diversity, inclusion and belonging and ethics). We discuss the results of these surveys with our Board of Directors. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation, Benefits and Development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to employee compensation and benefits is designed to deliver cash, equity and benefit programs that are competitive with those offered by leading companies in the biotechnology and pharmaceutical industries to attract, motivate and retain talent with a focus on encouraging performance, promoting accountability and adherence to Company values and alignment with the interests of the Company&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our base pay program aims to compensate staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also provide annual incentive programs to reward our staff in alignment with achievement of Company-wide goals that are established annually and designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. The majority of our staff members are also eligible for the grant of equity awards under our long-term incentive program that are designed to align the experience of these staff with that of our shareholders. All staff also participate in a regular performance measurement process that aligns pay to performance and through which staff receive performance and development feedback. To support the development of our staff, we provide a variety of programs, including leadership development programs, virtual instructor-led courses and self-paced learning options.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit programs are also generally broad-based, promote health and overall well-being and emphasize saving for retirement. All regular U.S. staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other U.S. employee benefits include medical plans, dental plans, access to childcare, employee assistance programs, employee stock purchase plan, flexible spending accounts, life, long-term care and business travel accident insurance, short and long-term disability benefits, wellness benefits and work-life resources and referrals. Comparable programs and benefits are available globally, with the same health and well-being intent, consistent with statutory requirements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation and Management Development Committee provides oversight of our compensation plans, policies and programs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety and Wellness and Our Response to COVID-19</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Creating a safe and healthy workplace for our staff is a priority at Amgen. Our goal is to have a world class safety record through safety leadership, risk management practices and integrating safety throughout our business processes. To foster our safety culture, we implement a comprehensive safety program, driving to understand and mitigate the root cause of safety incidents and manage and control variability. We use leading indicators to assess the effectiveness of our safety programs and make course corrections as needed. Additionally, we perform formal executive management review of functional safety performance for Operations, Global Commercial Operations and R&amp;D on a quarterly basis with a focus on identifying early signals and taking action to drive continuous improvement. Based on our 2019 performance, compared to a benchmark of twelve companies in the pharmaceutical industry, Amgen was in the quartile with the lowest injury rate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic and as part of our commitment to work to ensure the safety and well-being of our employees, we have activated our applicable business continuity plans, including having those of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees who are able to work from home to do so since mid-March 2020. For employees returning to the workplace and the field, we have also taken additional safety measures, including implementing occupancy limits, restricting business travel, providing and requiring the use of personal protective equipment, temperature screening and COVID-19 testing to access our workplaces.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate Responsibility and Compliance Committee provides general oversight of our safety programs and initiatives, while our Board of Directors, as a whole, has overseen our specific responses to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Inclusion and Belonging</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. Further, we also believe our global presence is strengthened by having a workforce that reflects the diversity of the patients we serve. It is with these beliefs in mind that we have continued to strengthen and grow our culture of diversity, inclusion and belonging. Our internal efforts include, in 2019, establishing a Diversity, Inclusion and Belonging Council chaired by our Chief Executive Officer. In 2020, we implemented a global unconscious bias training program, and launched a portal devoted to diversity, inclusion and belonging that includes learning and resources. Further, we are leveraging our Employee Resource Groups (listed below) to represent and support the diversity of Amgen staff: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.643%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#0063c3;border-left:1pt solid #0063c3;border-right:1pt solid #0063c3;border-top:1pt solid #0063c3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Employee Resource Groups</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Asian Association (AAA)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Black Employee Network (ABEN)</span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-left:1pt solid #0063c3;border-right:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ability Bettered through Leadership and Education (ABLE), a resource group for the physically or cognitively disabled</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Early Career Professionals (AECP)</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-right:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Indian Subcontinent Network (AISN)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Latin Employee Network (ALEN)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen LGBTQ and Allies Network (PRIDE)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Veterans Employees Network (AVEN)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women Empowered to be Exceptional (WE2)</span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #0063c3;border-left:1pt solid #0063c3;border-right:1pt solid #0063c3;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women in Information Systems Enrichment (WISE)</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In areas of underrepresentation, we develop plans with a goal of bringing our representation in line with availability, and we also engage in outreach efforts to attract, retain and advance more women and minorities in our workforce. For example, we have worked to enhance our diverse candidate recruiting pool by developing relationships with organizations that can serve as a source of diverse candidates, such as the National Black MBA Association and National Sales Network, as well as historically black colleges and universities. Additionally, at the end of 2020, we became a founding member of OneTen, a coalition of 35 of the world&#8217;s largest, best-known companies, that aims to hire one million Black Americans (with a specific focus on those without four-year college degrees) into good-paying, family-sustaining jobs over the next ten years. Other examples of actions that we are taking in this area include investment and participation in Healthcare Businesswomen&#8217;s Association (a global organization focused on development and business networking for women in healthcare) and the University of California, Los Angeles (UCLA) Anderson School of Management women&#8217;s leadership program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to provide additional transparency into the makeup of our workforce, we intend to disclose our 2020 Consolidated EEO-1 Report after our submission of the report to the U.S. Equal Employment Opportunity Commission.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate Responsibility and Compliance Committee provides oversight of our policies, programs and initiatives focusing on workforce diversity and inclusion.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_40"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Our Executive Officers</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The executive officers of the Company as of February 8, 2021, are set forth below. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Robert A. Bradway, age 58, has served as a director of the Company since 2011 and Chairman of the Board of Directors since 2013. Mr. Bradway has been the Company&#8217;s President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as the Company&#8217;s President and Chief Operating Officer. Mr. Bradway joined the Company in 2006 as Vice President, Operations Strategy, and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining the Company, Mr. Bradway was a Managing Director at Morgan Stanley in London, where, beginning in 2001, he had responsibility for the firm&#8217;s banking department and corporate finance activities in Europe. Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes, defense, space and securities systems, since 2016. He has served on the board of trustees of the University of Southern California since 2014. From 2011 to 2017, Mr. Bradway was a director of Norfolk Southern Corporation, a transportation company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Murdo Gordon, age 54, became Executive Vice President, Global Commercial Operations, in 2018. Prior to joining the Company, Mr. Gordon was Chief Commercial Officer at BMS from 2016 to 2018. Mr. Gordon served as Head of Worldwide Markets at BMS from 2015 to 2016. Prior to this, Mr. Gordon served in a variety of leadership roles at BMS for more than 25 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Jonathan P. Graham, age 60, became Executive Vice President, General Counsel and Secretary in 2019. Mr. Graham joined the Company in 2015. From 2015 to 2019, Mr. Graham was Senior Vice President, General Counsel and Secretary. Prior to joining Amgen, from 2006 to 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporation. From 2004 to 2006, Mr. Graham was Vice President, Litigation and Legal Policy, at General Electric Company (GE). Prior to GE, Mr. Graham was a partner at Williams &amp; Connolly LLP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Peter H. Griffith, age 62, became Executive Vice President and Chief Financial Officer in 2020. Mr. Griffith joined the Company in 2019 as Executive Vice President, Finance. Prior to joining Amgen, Mr. Griffith was President of Sherwood Canyon Group, LLC. From 1997 to 2019, Mr. Griffith was a partner at EY and served in a variety of senior leadership roles, with his last position being Global Vice Chair, Corporate Development. Prior to EY, Mr. Griffith was a Managing Director and head of the investment banking division of Wedbush Securities Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Nancy A. Grygiel, age 53, became Senior Vice President and Chief Compliance Officer in 2020. Ms. Grygiel joined the Company in 2015. From 2016 to 2020, Ms. Grygiel was Vice President, Compliance. Prior to joining Amgen, from 2011 to 2015, Ms. Grygiel served as Vice President, Compliance, Corporate &amp; International, at Allergan, Inc. (Allergan). Prior to Allergan, Ms. Grygiel held several management positions at Mylan Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Lori A. Johnston, age 56, became Executive Vice President, Human Resources, in 2019. From 2016 to 2019, Ms. Johnston served as the Company&#8217;s Senior Vice President, Human Resources. From 2012 to 2016, Ms. Johnston was Executive Vice President and Chief Administrative Officer of Celanese Corporation (Celanese). Prior to Celanese, Ms. Johnston served in a series of progressive leadership roles at Amgen from 2001 to 2012, with her last position being Vice President, Human Resources. Prior to joining the Company, Ms. Johnston held human resources and other positions at Dell Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. David A. Piacquad, age 64, became Senior Vice President, Business Development, in 2014. Mr. Piacquad joined the Company in 2010 and served as Vice President, Strategy and Corporate Development, until his appointment to the role of Vice President, Business Development, in 2014. Prior to joining the Company, from 2009 to 2010, Mr. Piacquad was Principal of David A. Piacquad Consulting LLC. From 2006 to 2009, Mr. Piacquad served as Senior Vice President, Business Development and Licensing, at Schering-Plough Corporation (Schering-Plough). Prior to Schering-Plough, Mr. Piacquad served in a series of leadership roles in finance and business development at J&amp;J, with his last position being Vice President, Ventures and Business Development.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. David M. Reese, age 58, became Executive Vice President, R&amp;D, in 2018. Dr. Reese joined the Company in 2005 and has held leadership roles in development, medical sciences and discovery research. Dr. Reese was Senior Vice President, Translational Sciences and Oncology, from 2017 to 2018 and Senior Vice President, Translational Sciences, from 2015 to 2017. Prior to joining Amgen, Dr. Reese was director of Clinical Research at the Breast Cancer International Research Group from 2001 to 2003 and a cofounder, president and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, from 2003 to 2005. Dr. Reese previously served on the faculty at UCLA and the University of California, San Francisco.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Esteban Santos, age 53, became Executive Vice President, Operations, in 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From 2008 to 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. From 2013 to 2016, Mr. Santos was Senior Vice President, Manufacturing. Prior to joining the Company, Mr. Santos served as Site General Manager of J&amp;J&#8217;s Cordis operation in Puerto Rico. Prior to J&amp;J, Mr. Santos held several management positions in GE&#8217;s industrial and transportation businesses.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_43"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Area Financial Information</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information concerning the geographic areas in which we operate, see Part IV&#8212;Note 3, Revenues and Note 11, Property, plant and equipment, to the Consolidated Financial Statements.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_46"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.amgen.com. We make available on our website, free of charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or furnish it to the U.S. Securities and Exchange Commission (SEC). In addition, we have previously filed registration statements and other documents with the SEC. Any document we file may be inspected without charge at the SEC&#8217;s website at www.sec.gov. (These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing.)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_2411"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Economic Conditions and Operating a Global Business, Including During the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Government Regulations and Third-Party Policies</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be affected by litigation and government investigations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Competition</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products face substantial competition and our product candidates are also likely to face substantial competition.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Research and Development</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to develop commercial products despite significant investments in R&amp;D.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our current products and products in development cannot be sold without regulatory approval.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sale of our products.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Operations</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is volatile</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS, INCLUDING DURING THE COVID-19 PANDEMIC</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus identified in late 2019, SARS-CoV-2, which causes the disease known as COVID-19, is an ongoing global pandemic that has resulted in public and governmental efforts to contain or slow the spread of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns. The COVID-19 pandemic and the resulting measures implemented in response to the pandemic are adversely affecting, and is expected to continue to adversely affect, our business (including our R&amp;D, clinical trials, operations, supply chains, distribution systems, product development and sales activities), the business activities of our suppliers, customers, third-party payers and our patients. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and see also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Due to the pandemic and these measures and their effects, we have experienced, and expect to continue to experience, unpredictable reductions in demand for certain of our products, and in some cases, have experienced, and could continue to experience, unpredictable increases in demand for certain of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials have been, and are expected to continue to be, adversely affected by the COVID-19 pandemic. We have clinical work ongoing at investigational sites across the globe. A number of clinical trial sites, including those in regions experiencing new or resurgent outbreaks of COVID-19, have restricted site visits and imposed restrictions on the initiation of new clinical trials and/or patient visits to protect both site staff and patients from possible COVID-19 exposure that has stopped or slowed clinical trial activities. In response to the safety concerns related to COVID-19, we have suspended, and will continue to suspend, enrollment and screening in clinical trials where sites are unable to perform clinical trial work due to COVID-19 or there is uncertainty around the ability of sites to ensure subject safety or data integrity. Further, the COVID-19 pandemic has adversely affected, and may continue to adversely affect, our ability to enroll or to continue to enroll certain required post-marketing studies, including pediatric studies. While many of our clinical trial activities have recommenced over the course of 2020, the initial disruption caused by the COVID-19 pandemic to our clinical trials and our clinical trial plans and timelines, and any similar future disruptions (including as a result of the current surge and lockdowns in numerous regions), may have a significant adverse effect on our product development and launches, and, in turn, on future product sales, business and results of operations. For example, to ensure patient safety we initially paused enrollment of our sotorasib Phase 1 combination cohort with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Phase 3 lung cancer study, and such interruptions in enrollment may ultimately affect the timeline of these or other studies. Additionally, while we are investing in research, collaborations and operational support to potentially develop and/or produce treatments for COVID-19, such activities may not result in therapeutic candidates, product approvals, successful production and/or significant commercial value being derived from potential COVID-19-related medicines.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, we have experienced, and expect to continue to experience, regulatory delays, including delays in receiving regulatory advice, reviews of applications, or performance of inspections required for approvals. The pandemic may also result in greater regulatory uncertainty. For example, the FDA and the EMA have issued guidance to provide biopharmaceutical manufacturers greater flexibility in certain regulatory areas, including protocol deviations and adverse event reporting. However, such flexibility may result in greater uncertainty regarding the expectations of such health authorities in relation to this guidance. Additionally, there may be delays in ongoing or new patent office or patent proceedings in the United States or internationally that may delay the outcome of such proceedings. Such delays and disruptions could have a significant adverse effect on our product development and launches, product sales, business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to COVID-19, we have activated our applicable business continuity plans, including suspending U.S. in-person meetings and interactions with the healthcare community and professionals in a substantial number of states, suspending, as a general matter, all international business travel and the majority of domestic travel within the United States, and U.S. employees who are able to work from home have been doing so since mid-March 2020. Our ability to perform critical functions and maintain operations have been adversely affected and could continue to be adversely affected as a result of such workforce restrictions, and the COVID-19-related support programs we have put into place for our staff, suppliers and customers have increased, and are expected to continue to increase, our operating expenses and reduce the efficiency of our operations. Notwithstanding such support programs, the COVID-19 pandemic&#8217;s effects on the health and availability of our workforce, as well as those of the third parties on which we rely, could have an adverse effect on our business. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and our operations may be adversely affected. Additionally, disruptions in public and private infrastructure, including transportation and supply chains, have adversely affected, and continue to adversely affect, the efficiency of our business operations. Also, the transition of the majority of our workforce to a remote work environment in response to COVID-19, as well as that of our third-party service providers, have exacerbated certain risks to our business, including, but not limited to, those associated with an increased demand for information technology resources, increased risk of cybersecurity attacks (including social engineering attacks), and increased risk of unauthorized dissemination of sensitive personal information or our proprietary or confidential information. As the pandemic continues to progress, we have observed an increase in cybersecurity incidents, predominantly ransomware and social engineering attacks, experienced by our third-party service providers. Further, government entities have also been the subject of cyberattacks. The EMA disclosed in December 2020 that it had been the subject of a cyberattack that targeted and accessed third-party documents relating to regulatory submissions, and that such documents were published on the internet (some of which were manipulated prior to publication). Such third-party and governmental incidents have created the risk of the loss of availability and/or control of information (including information related to our clinical trials) important to the operation of our business. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the future, as the pandemic progresses and afterwards, we may experience significant adverse effects on our commercial and clinical manufacturing activities, our operations, and our cybersecurity, and our suppliers and vendors may also experience significant disruptions to their activities and operations on which we depend, as a result of these cybersecurity incidents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and local, and international governmental policies and initiatives designed to reduce the transmission of COVID-19 also have resulted in the cancellation or delay of diagnostic, elective, specialty and other procedures and appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. These measures and challenges will likely continue to varying degrees for the duration of the pandemic and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a product requiring administration by a healthcare provider in doctors&#8217; offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> instructs healthcare professionals who discontinue Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to transition the patient to an alternative antiresorptive, including oral treatments that do not require administration by a healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting less immunosuppressive therapies or therapies that do not require administration in a hospital setting, potentially adversely affecting certain of our products. Also, new patients are less likely to be diagnosed and/or to start therapeutics during the pandemic. Once the pandemic subsides, we anticipate there will be a substantial backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate limited provider capacity, and this limited provider capacity could have a continued adverse effect on our sales following the opening up of various geographies and/or the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences among healthcare professionals and patients toward treatments that do not require administration by healthcare professionals or visits to medical facilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory environment governing our businesses is dynamic and changing frequently in response to COVID-19. For example, the COVID-19 pandemic has resulted in increased interest in compulsory licenses, march-in rights or other governmental interventions, both in the United States and internationally, related to the procurement of drugs, such as the WHO&#8217;s COVID-19 Technology Access Pool initiative, which provides an approach for sharing all intellectual property, information and clinical trial data necessary to enable generic drug manufacturing. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, the challenges of the pandemic have resulted in the exploration of signification legislation to address the need to supply medicines to address COVID-19. Pursuant to the declaration of a national emergency in the United States in March 2020 under the Stafford Act, state and local governments may request access to discounted pricing for certain items related to the COVID-19 response. The Coronavirus Aid, Relief and Economic Security (CARES) Act implements initiatives to provide advanced payments from Medicare to healthcare providers, clinics and physicians and to require Medicare plans to provide up to a 90-day supply of Part D drugs. However, despite such initiatives and government support, there may be adverse effects on the timing and collectability of our customer receivables as a result of the COVID-19 pandemic. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The COVID-19 pandemic has also resulted in a significant increase in unemployment and underemployment which may continue after the pandemic. Such a significant increase in unemployment or other disruptions in the labor market have led to a substantial reduction in disposable income and, in the U.S., access to healthcare insurance, including reductions in the commercially insured population that has led to growth (and is expected to continue to lead to growth) in Medicaid enrollment, which has adversely affected our product sales. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Such reduction in healthcare insurance could be compounded by any full or partial repeal of the ACA by the U.S. Supreme Court. Further, globally, the substantial pressures placed on governmental and payor budgets as a result of the COVID-19 pandemic and the projected governmental budget shortfalls caused by significantly reduced economic activity during and potentially after the COVID-19 pandemic, together with the long-term impact from the pressures on healthcare systems, may result in greater and continued downward price pressure on biopharmaceutical products and increased intensity of stakeholder negotiations across the biopharmaceutical value chain. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from third-party payers, and pricing and reimbursement pressures may affect our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the pandemic continues, and if conditions worsen or if the duration of the pandemic extends significantly, we expect to experience additional adverse effects on our operational and commercial activities, customer purchases and our collections of accounts receivable. It is unclear which adverse effects may be material, and it remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections even if conditions begin to improve. There was a resurgence in COVID-19 infections in numerous jurisdictions in the autumn of 2020 and winter of 2020-2021, resulting in the reinstatement of stricter restrictions and shutdowns in a number of jurisdictions. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. In addition to existing travel restrictions, jurisdictions may continue or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travel and business activity, which could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain, and prevent or discourage patients from seeking healthcare services and the administration of certain of our products. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the U.S., on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19, including the production of COVID-19 vaccinations or related therapies, such as our agreement to contribute to the production of one of Lilly&#8217;s potential COVID-19 antibody therapies, could also result in increased competition for, or reduced availability of, materials used in the manufacturing or distribution of our products. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described in this &#8220;Risk Factors&#8221; section, which could materially adversely affect our business, operations and financial conditions and results. For example, if a natural disaster or other potentially disruptive event occurs concurrently with the COVID-19 pandemic, such disaster or event could deplete our inventory levels and we could experience a disruption to our manufacturing or ability to supply our products. Further, the global pandemic has exacerbated geopolitical tensions, and some countries, such as China, may be especially vulnerable to such dynamics. If relations between the United States and China or other governments deteriorates, our business and investments in China or other such markets may also be adversely affected. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid development and fluidity of the pandemic preclude any prediction as to the ultimate effect of COVID-19 on us. The duration of the measures being taken by the authorities to mitigate against the spread of COVID-19 (including the distribution of vaccines), and the extent to which such measures are effective, if at all, remain highly uncertain. The magnitude and degree of COVID-19&#8217;s adverse effect on our business (including our product development, product sales, operating results, and resulting cash flows) and financial condition will be driven by the severity and duration of the pandemic, the pandemic&#8217;s effect on the United States and global economies and the timing, scope and effectiveness of federal, state, local and international governmental responses to the pandemic. If the spread continues at or near its current trajectory or mitigation continues to require similar levels of shelter-in-place and shut-down orders, any adverse effects of COVID-19 will likely grow and could be enduring and our business and financial position could be materially adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve our business objectives, we rely on sophisticated information technology systems, including software, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems are highly integrated into our business, including our R&amp;D efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as the majority of our employees are working remotely, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. The complexity and interconnected nature of our systems makes them potentially vulnerable to breakdown or other service interruptions. Our systems are also subject to frequent cyberattacks. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity and are becoming increasingly difficult to detect. Such attacks could include the use of harmful and virulent malware, including ransomware or other denials of service, that can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering. Attacks such as those experienced by governmental entities (including those that approve and/or regulate our products, such as the EMA) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data, and could have a material adverse effect on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattack involving virulent malware that significantly disrupted its operations, including its research and sales operations and the production of some of its medicines and vaccines. As a result of the cyberattack, its orders and sales for certain products in certain markets were negatively affected. In December 2020, SolarWinds Corporation, a leading provider of software for monitoring and managing information technology infrastructure, disclosed that it had suffered a cybersecurity incident whereby attackers had inserted malicious code into legitimate software updates for its products that were installed by myriad private and government customers, enabling the attackers to access a backdoor to such systems. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the cyberattack on the EMA.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems also contain and utilize a high volume of sensitive data, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal information belonging to us, our staff, our patients, customers and/or other parties. In some cases, we utilize third-party service providers to process, store, manage or transmit such data, which may increase our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) or lapses by employees, service providers (including providers of information technology-specific services), nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, &#8220;hacktivists&#8221; or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors, or the public. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and global government regulators, our business partners, suppliers with whom we do business, companies that provide us or our partners with business services and companies we may acquire may face similar risks, and security breaches of their systems could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information or expose our confidential data. For example, in 2019, two vendors that perform testing and analytical services that we use in developing and manufacturing our products have experienced cyberattacks, and in April and September of 2020, vendors that provide us with information technology services and clinical data services, respectively, each experienced ransomware attacks. Each of these incidents required us to disconnect our systems from those vendors&#8217; systems. While we were able to reconnect our systems following restoration of these vendor&#8217;s capabilities without significantly affecting product availability, a more extended service outage affecting these or other vendors, particularly where such vendor is the single source from which we obtain the services, could have a material adverse effect on our business or results of operations. In addition, we distribute our products in the United States primarily through three pharmaceutical wholesalers, and a security breach that impairs the distribution operations of our wholesalers could significantly impair our ability to deliver our products to healthcare providers and patients.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have experienced system breakdowns, attacks and information security breaches, we do not believe such breakdowns, attacks and breaches have had a material adverse effect on our business or results of operations. We continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems. However, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks, and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal, business or reputational harm to us or negatively affect our stock price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover us against all losses that could potentially result from a service interruption, breach of our systems or loss of our critical or sensitive data.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, we are subject to the EU&#8217;s GDPR, which became effective in May 2018, and the California Consumer Privacy Act of 2018, which became effective in January 2020, both of which provide for substantial penalties for non-compliance. Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations. Failure to comply with these current and future laws could result in significant penalties and could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue our expansion efforts in emerging markets around the world, through acquisitions and licensing transactions as well as through the development and introduction, both independently and through collaborations such as our collaboration with BeiGene, of our products in new markets, we face numerous risks to our business. There is no guarantee that our efforts and strategies to expand sales in emerging markets will succeed. Our international business, including in China and emerging market countries, may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements including those previously utilized by companies we partner with or acquire in emerging markets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our expansion efforts in China and emerging markets around the world is dependent upon the establishment of an environment that is predictable, navigable and supportive of biopharmaceutical innovation, sustained access for our products and limited pricing controls. For example, China continues to strengthen regulations on the collection, use and transmission of Chinese human genetic resources, and has expanded regulations on the conduct of biotechnology R&amp;D activities in China. Our applications to the Human Genetic Resources Administration of China (HGRAC) seeking approval to conduct clinical trials in China are delayed pending further guidance from HGRAC. Our international operations and business may also be subject to less protective intellectual property or other applicable laws, diverse data privacy and protection requirements, changing tax laws and tariffs, trade restrictions or other barriers designed to protect industry in the home country against foreign competition, far-reaching antibribery and anticorruption laws and regulations and/or evolving legal and regulatory environments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand internationally, we are subject to fluctuations in foreign currency exchange rates relative to the U.S. dollar. While we have a program in place that is designed to reduce our exposure to foreign currency exchange rate fluctuations through foreign currency hedging arrangements, our hedging efforts do not completely offset the effect of these fluctuations on our revenues and earnings. In addition, we have a number of financial instruments referencing the London Interbank Offered Rate (LIBOR). On July 27, 2017, the U.K Financial Conduct Authority, which regulates LIBOR, announced that it will no longer require banks to submit rates for the calculation of LIBOR to the LIBOR administrator after 2021, and it is anticipated that LIBOR will be phased out and replaced by 2023. In March 2020, the Financial Accounting Standards Board issued a new accounting standard to ease the financial burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. While various replacement reference rates have been proposed, an alternative reference rate to LIBOR has not yet been widely adopted, and the specific mechanisms to replace LIBOR in our existing LIBOR-linked financial instruments have not been finalized. As such, the replacement of LIBOR could have an adverse effect on the market for, or value of, our LIBOR-linked financial instruments. See Part IV, Note 1, Summary of significant accounting policies&#8212;Recent accounting pronouncements. We are also subject to the economic and political uncertainties stemming from the United Kingdom&#8217;s exit from the EU, commonly referred to as &#8220;Brexit,&#8221; which occurred on January 31, 2020. While our manufacturing and packaging activities take place largely outside the United Kingdom, minimizing the need to make costly and significant changes to those operations, we have nevertheless been working to put in place contingency plans to attempt to mitigate the effects of Brexit on us. Overall, the legal and operational challenges of our international business operations, along with government controls, the challenges of attracting and retaining qualified personnel and obtaining and/or maintaining necessary regulatory or pricing approvals of our products, may result in material adverse effects on our international product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. These payers are increasingly focused on the effectiveness, benefits and costs of similar treatments, which could result in lower reimbursement rates for our products or narrower populations for whom payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which could have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced in an attempt to lower drug prices. These include proposals that would allow the U.S. government to negotiate drug price directly, limit drug reimbursement based on prices abroad or permit importation of drugs from Canada. Proposals focused on drug pricing are likely to continue to be proposed and may be adopted and implemented in some form.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing U.S. federal coverage and reimbursement policies and practices have affected and may continue to affect access to, pricing and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See Item 1. Business&#8212;Reimbursement. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. Since late 2018, Congressional focus on drug pricing has increased, placing our industry under greater Congressional scrutiny. For example, in early 2019, the chair of the House Oversight and Reform Committee sent letters to twelve different biopharmaceutical manufacturers, including Amgen, seeking documents and detailed information about such companies&#8217; drug pricing practices. Subsequently, in the fall of 2020, the House Oversight and Reform Committee released staff reports and held hearings with executives from six biopharmaceutical manufacturers, including Amgen, about their companies&#8217; drug pricing practices. Also, between 2019 and 2020, a number of other Congressional committees held hearings and evaluated proposed legislation on drug-pricing and payment policy. For example, in 2019, the Senate Finance Committee advanced a bill that would, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts B and/or D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries, and require higher/additional manufacturer discounts in Medicare Part D. Additionally, in late 2019, a drug-pricing bill, H.R. 3, passed the House of Representatives, which would, among other things, enable direct price negotiations by the federal government on certain drugs (with the maximum price paid by Medicare capped by prices derived from an international index), includes a penalty for failing to reach agreement with the government, and requires that manufacturers offer these negotiated prices to other payers. We expect H.R. 3, or some similar proposed legislation, to be debated by Congress this year. Additional legislative or regulatory proposals have been introduced by members of Congress and the prior Administration that, if enacted and implemented in whole or in part, could also affect access to and sales of our products, including, but not limited to, proposals to allow importation of prescription medications from Canada or other countries and to set Medicare payment rates using international price referencing. Further, in mid-2020, the prior Administration announced a number of Executive Orders intended to reduce the cost of biopharmaceuticals for patients, including a MFN policy for Medicare Parts B and D, under which the HHS was directed to take steps to implement payment models that set Medicare purchase prices based on the lowest price available in economically comparable countries for certain Part B and Part D medicines. In September 2020, in response to the corresponding Executive Order, HHS released a final rule to allow states (or other nonfederal government entities) to submit proposals to the FDA allowing for the importation of certain nonbiologic prescription drugs from Canada. Currently, the rule is being challenged by litigation, however, should such litigation be unsuccessful and should the Secretary of HHS authorize state proposals for importation, this rule could allow the importation of Canadian versions of certain of Amgen&#8217;s products (including Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), that could have a material adverse effect on Amgen&#8217;s business. Further, in November 2020, also in response to the corresponding Executive Order, HHS released an interim final rule to implement the MFN pricing approach. If implemented, the MFN rule would set the reimbursement rate for 50 Medicare Part B drugs (including our products, such as Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) equal to the lowest adjusted price for such products of the 22 Organization for Economic Co-operation and Development (OECD) nations. Lawsuits have been filed by certain trade groups challenging the implementation of this MFN rule based on, among other things, procedural defects. Late in 2020, in the case filed by the Biotechnology Industry Organization and others, the U.S. District Court for the Northern District of California issued a preliminary injunction preventing the rule from taking effect nationwide, pending the government&#8217;s completion of required administrative procedures. The case was subsequently stayed by the court and the parties were ordered to file a joint status report by April 23, 2021. Another case, filed by the Pharmaceutical Research and Manufacturers of America and others in the U.S. District Court for the District of Maryland, was also stayed. Notwithstanding these stays, the MFN rule&#8217;s approach to drug pricing and other similar approaches, remain of interest. Further, despite the change in Administration, we expect continued significant focus on healthcare and similar drug pricing proposals, including proposals similar to the MFN rule, for the foreseeable future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been, and is expected to continue to be, affected by changes in U.S. federal reimbursement policy resulting from federal regulations and federal demonstration projects. For example, the previous Administration released a drug pricing blueprint in 2018 which introduced an array of policy ideas intended to increase competition, improve the negotiating power of the federal government, reduce drug prices and lower patient out-of-pocket costs with the potential to significantly affect, whether individually or collectively, our industry. Such policy ideas included, but were not limited to, moving coverage and reimbursement for Medicare Part B drugs into Medicare Part D and instituting a competitive acquisition program for Part B drugs in which competing third-party vendors take on the financial risk of acquiring drugs and billing Medicare.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, over the past three years, federal agencies, including the Centers for Medicare &amp; Medicaid Services (CMS), announced a number of recommendations, policies, proposals and demonstration projects to implement various elements of the drug pricing blueprint. CMS is the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces and has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. CMS issued guidance to allow certain Medicare plans offered by private insurance companies to require that patients receiving Medicare Part B drugs first try a drug preferred by the plan before covering another therapy (Step Therapy) and lowered reimbursement rates for new Medicare Part B drugs. Further, HHS issued a final rule under Medicare Part D revising the regulations under the federal antikickback statute to encourage PBMs to use rebates received from biopharmaceutical manufacturers to reduce patient cost-sharing at the point of sale. Changes to the regulations will be phased-in beginning on March 22, 2021, with all changes effective as of January 1, 2023. However, there are numerous logistical hurdles to overcome before such rule can be effectively implemented and it is unclear how PBMs will change their business practices in response. Furthermore, a trade association representing PBMs recently filed litigation challenging this HHS final rule. Given these uncertainties, it remains unclear when any anticipated benefits to patients will materialize. The incoming Administration also could develop and seek to advance a range of policy proposals that could impact U.S. federal reimbursement policy for drugs and biologics. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS policy changes and demonstration projects to test new care, delivery and payment models can significantly affect how drugs, including our products, are covered and reimbursed. In end-stage renal disease (ESRD), CMS uses bundled payment rates. Between 2018 and 2020, Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our calcimimetics that are used in dialysis clinics, were eligible for temporary drug add-on payment adjustments (TDAPA) to the bundled rate. In November 2020, CMS released its final rule ending the TDAPA for calcimimetics and adjusting ESRD Prospective Payment System bundled rates on January 1, 2021 by $9.93 per dialysis treatment for calcimimetics, and we expect the sales of our calcimimetics to be materially adversely affected by this rule change. Additionally, CMS created a new mandatory payment model effective January 1, 2021 focused on encouraging greater use of home dialysis and kidney transplants for ESRD patients that could result in changes to treatment of dialysis patients, including reduction of the use of our ESAs. Further, back in November 2019, CMS announced additional voluntary payment models for nephrologists and dialysis facility partners that also seek to encourage home dialysis and preemptive transplantation through increased risk sharing, but due to COVID-19, the start date of such programs has been pushed back to April 1, 2021. CMS has also solicited suggestions regarding other potential care models. In 2016, CMS initiated the Oncology Care Model demonstration, which provides participating physician practices with performance-based financial incentives that aim to manage or reduce Medicare costs without negatively affecting the efficacy of care, that has been extended by one year (to 2022) due to COVID-19. We believe the Oncology Care Model has reduced utilization of certain of our oncology products by participating physician practices and expect it to continue to do so in the future. Additionally, in late 2019, CMS announced a request for information on the Oncology Care First model, a new voluntary model that builds on the Oncology Care Model. CMS recently finalized a rule that, starting January 1, 2023, unless a manufacturer can ensure that the full amount of manufacturer patient assistance programs is passed on to the patient, such amount will be treated as a price reduction that will be taken into account when reporting our Best Price and/or Average Manufacturer Price (AMP). Given the use by PBMs and insurers of copay accumulator adjustment programs to apply such patient assistance for the benefit of such companies and not to defray costs to patients, it could be difficult to impossible for manufacturers to ensure that the full value of such amounts is being passed on to the patient. This new policy, if implemented, would have significant implications for our ability to offer copay assistance programs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this dynamic environment, we are unable to predict which or how many federal policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our U.S. products, or limit our ability to offer co-pay payment assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require a biopharmaceutical manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing reimbursement and pricing actions in various states have negatively affected, and may continue to negatively affect, access to, and have affected, and may continue to affect, sales of our products</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, government actions or ballot initiatives can also affect how our products are covered and reimbursed and/or create additional pressure on our pricing decisions. A number of states have adopted, and many other states are considering, drug importation programs or other new pricing actions, including proposals designed to require biopharmaceutical manufacturers publicly to report proprietary pricing information, limit price increases or place a maximum price ceiling or cap on biopharmaceutical products. Existing and proposed state pricing laws have added complexity to the pricing of drugs and may already be affecting industry pricing decisions. For example, a California law, the constitutionality of which is currently being challenged, purports to require biopharmaceutical manufacturers to notify health insurers and government health plans at least 60 days before scheduled prescription drug price increases that exceed certain thresholds. Similar laws exist in Oregon and Washington. States are also seeking to change the way they pay for drugs for patients covered by state programs. California adopted a 2020-21 budget that incorporates international pricing into Medicaid supplemental rebate negotiations and allows its Medicaid program to seek federal approval to extend supplemental rebates to non-Medicaid populations. New York, Massachusetts and Ohio have established Medicaid drug spending caps, and additional states may consider doing so as they face budget deficits from the effects of COVID-19. Additionally, Colorado, Florida, Maine, New Hampshire, New Mexico and Vermont have enacted laws, and several other states have proposed laws, to facilitate the importation of drugs from Canada. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs. Ultimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;U.S. commercial payer actions have affected and may continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from the consolidation of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant limitations on patients&#8217; use of manufacturer commercial copay assistance programs. Further, government regulation of payers may affect these trends. For example, CMS recently finalized a policy that could cause commercial payers to adopt copay accumulator adjustment programs more widely. Payers have sought, and will likely continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, particularly in treatment areas where the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer&#8217;s prior authorization before covering the product or that patients use a mail-order pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers may also choose to exclude certain indications for which our products are approved or even choose to exclude coverage entirely. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been prescribed meet payer utilization management criteria, and these requirements have limited, and may continue to limit, patient access to Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by providing greater discounts and rebates to payers, including PBMs that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescriptions rather than pay their co-pay payment, we introduced a set of new National Drug Codes to make Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available at a lower list price to attempt to address affordability for patients, particularly those on Medicare and on December 31, 2019, we discontinued the higher list price option for Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Despite these net and list price reductions, some payers have restricted, and may continue to restrict, patient access and may change formulary coverage for Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, seek further discounts or rebates or take other actions that could reduce our sales of Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These factors have limited, and may continue to limit, patient affordability and use, and negatively affect Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in the United States, in 2020, the top five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019 and 2020, CVS and Express Scripts created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage or plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse effect on our product sales, business and results of operations. Policy reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or consequences for our business and how we interact with these entities.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Item 1. Business&#8212;Reimbursement. IRP has been widely used by many countries outside the United States to control costs based on an external benchmark of a product&#8217;s price in other countries. IRP policies can change quickly and frequently and may not reflect differences in the burden of disease, indications, market structures, or affordability differences across countries or regions. In addition, countries may refuse to reimburse or may restrict the reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA&#8217;s approval of Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in France is limited to a narrower patient population (such as those with homozygous familial hypercholesterolemia) following a national health technology assessment. While the pricing and reimbursement process in that country remains ongoing, the assessment currently limits our efforts in France to expand Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and reimbursement, or a decline in the timeliness or certainty of payment by payers to physicians and other providers has negatively affected, and may further negatively affect, the ability or willingness of healthcare providers to prescribe our products for their patients and otherwise negatively affect the use of our products or the prices we realize for them. Such changes have had, and could in the future have, a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies promulgate regulations and guidelines directly applicable to us and to our products. Professional societies, practice management groups, insurance carriers, physicians&#8217; groups, private health and science foundations and organizations involved in various diseases also publish guidelines and recommendations to healthcare providers, administrators and payers, as well as patient communities. Recommendations by government agencies or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapies. In addition, a growing number of organizations are providing assessments of the value and pricing of biopharmaceutical products, and even organizations whose guidelines have historically been focused on clinical matters have begun to incorporate analyses of the cost effectiveness of various treatments into their treatment guidelines and recommendations. Value assessments may come from private organizations that publish their findings and offer recommendations relating to the products&#8217; reimbursement by government and private payers. Some companies and payers have announced pricing and payment decisions based in part on the assessments of private organizations. In addition, government health technology assessment organizations in many countries make reimbursement recommendations to payers in their jurisdictions based on the clinical effectiveness, cost-effectiveness and service effects of new, emerging and existing medicines and treatments. Such health technology assessment organizations have recommended, and may in the future recommend, reimbursement for certain of our products for a narrower indication than was approved by applicable regulatory agencies or may recommend against reimbursement entirely. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such recommendations or guidelines may affect our reputation, and any recommendations or guidelines that result in decreased use, dosage or reimbursement of our products could have a material adverse effect on our product sales, business and results of operations. In addition, the perception by the investment community or stockholders that such recommendations or guidelines will result in decreased use and dosage of our products could adversely affect the market price of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax returns are routinely examined by tax authorities in the United States and other jurisdictions in which we do business, and a number of audits are currently underway. Tax authorities, including the Internal Revenue Service (IRS), are becoming more aggressive in their audits and are particularly focused on the allocations of income and expense among tax jurisdictions. In 2017, we received a Revenue Agent Report (RAR) and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and have been pursuing resolution with the IRS administrative appeals office. However, we have been unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a Notice of Deficiency which we would expect to vigorously contest through the judicial process. In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office. The IRS audit for years 2016, 2017 and 2018 is expected to start in the near term. We are also currently under examination by a number of other state and foreign tax jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The Tax Cuts and Jobs Act (the 2017 Tax Act) is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. The new Administration and Congress could make changes to existing tax law, including an increase in the corporate tax rate and the tax rate on foreign earnings. Changes to existing tax law in the U.S., the U.S. territory of Puerto Rico, or other jurisdictions, including efforts by the OECD to align countries on corporate tax matters that would likely result in tax increases where we do business could have a material adverse effect on the results of our operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are involved in legal proceedings. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. Civil and criminal litigation is inherently unpredictable, and the outcome can result in costly verdicts, fines and penalties, exclusion from federal healthcare programs and/or injunctive relief that affect how we operate our business. Defense of litigation claims can be expensive, time consuming and distracting, and it is possible that we could incur judgments or enter into settlements of claims for monetary damages or change the way we operate our business, which could have a material adverse effect on our product sales, business and results of operations. In addition, product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products we sell after regulatory approval. Product liability claims, regardless of their merits, could be costly and divert management&#8217;s attention and could adversely affect our reputation and the demand for our products. We and certain of our subsidiaries have previously been named as defendants in product liability actions for certain of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in government investigations that arise in the ordinary course of our business. In recent years, there has been a trend of increasing government investigations and litigations against companies operating in our industry, both in the United States and around the world. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from third-party payers, and pricing and reimbursement pressures may affect our profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business activities outside of the United States are subject to the FCPA and similar antibribery or anticorruption laws, regulations or rules of other countries in which we operate, including the UK Bribery Act. We cannot ensure that all our employees, agents, contractors, vendors, licensees, partners or collaborators will comply with all applicable laws and regulations. On April 25, 2019, we entered into a settlement agreement with the DOJ and the OIG of the HHS to settle certain allegations relating to our support of independent charitable organizations that provide patients with financial assistance to access their medicines. As a result, we entered into a corporate integrity agreement with the OIG that requires us to maintain a corporate compliance program and to undertake a set of defined corporate integrity obligations for a period of five years. While we expect to fully comply with all of our obligations under the corporate integrity agreement, failure to do so could result in substantial penalties and potential exclusion from government healthcare programs. We may also see new government investigations of or actions against us citing novel theories of recovery. For example, prosecutors are placing greater scrutiny on patient support programs, including commercial copay assistance programs, and further enforcement actions and investigations regarding such programs could limit our ability to provide co-pay assistance to commercial patients. Greater scrutiny has also been placed on sponsorships, speaker programs and other arrangements where healthcare professionals receive remuneration, travel or other value to participate in certain events, and further enforcement actions could limit our ability to participate in such arrangements. Any of these results could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO COMPETITION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products face substantial competition and our product candidates are also likely to face substantial competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. We expect that our products and product candidates will compete with existing drugs, new drugs currently in development, drugs currently approved for other indications that may later be approved for the same indications as those of our products and drugs approved for other indications that are used off-label. Large pharmaceutical companies and generics manufacturers of pharmaceutical products are expanding into the biotechnology field, and some pharmaceutical companies and generics manufacturers have formed partnerships to pursue biosimilars. With the proliferation of companies pursuing biopharmaceuticals, a number of our product candidates may enter markets with one or more competitors or with competitors soon to arrive. In addition, some of our competitors may have technical, competitive or other advantages over us for the development of technologies and processes or greater experience in particular therapeutic areas, and consolidation among pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or new product indications they may bring to market. As a result, our products have been competing and may continue to compete, and our product candidates may compete, against products or product candidates that offer higher rebates or discounts, lower prices, equivalent or superior efficacy, better safety profiles, easier administration, earlier market availability or other competitive features. If we are unable to compete effectively, this could reduce sales, which could have a material adverse effect on our business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific and factual questions. Driven by cost pressures, efforts to limit or weaken patent protection for our industry are increasing. For example, the COVID-19 pandemic has resulted in increased interest in compulsory licenses, march-in rights or other governmental interventions, both in the United States and internationally, related to the procurement of drugs. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties have challenged and may continue to challenge, invalidate or circumvent our patents and patent applications relating to our products, product candidates and technologies. Challenges to patents may come from potential competitors or from parties other than those who seek to market a potentially-infringing product. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not infringe our patents. For certain of our product candidates, there are third parties who have patents or pending patent applications that they may claim necessitate payment of a royalty or prevent us from commercializing these product candidates in certain territories. Patent disputes are frequent, costly and can preclude, delay or increase the cost of commercialization of products. We have been in the past, are currently and expect to be in the future, involved in patent litigation. These matters have included, and may in the future include, litigation with manufacturers of products that purport to be biosimilars of certain of our products for patent infringement and for failure to comply with certain provisions of the Biologics Price Competition and Innovation Act of 2009 (BPCIA). A determination made by a court, agency or tribunal concerning infringement, validity, enforceability, injunctive or economic remedy, or the right to patent protection, for example, are typically subject to appellate or administrative review. Upon review, such initial determinations may be afforded little or no deference by the reviewing tribunal and may be affirmed, reversed or made the subject of reconsideration through further proceedings. A patent dispute or litigation has not discouraged, and may not in the future discourage, a potential violator from bringing the allegedly-infringing product to market prior to a final resolution of the dispute or litigation. The period from inception until resolution of a patent dispute or litigation is subject to the availability and schedule of the court, agency or tribunal before which the dispute or litigation is pending. We have been, and may in the future be, subject to competition during this period and may not be able to recover fully from the losses, damages and harms we incur from infringement by the competitor product even if we prevail. Moreover, if we lose or settle current or future litigations at certain stages or entirely, we could be subject to competition and/or significant liabilities, be required to enter into third-party licenses for the infringed product or technology or be required to cease using the technology or product in dispute. In addition, we cannot guarantee that such licenses will be available on terms acceptable to us, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the Hatch-Waxman Act, our products approved by the FDA under the FDCA have been, and may in the future be, the subject of patent litigation with generics competitors before expiry of the five-year period of data exclusivity provided for under the Hatch-Waxman Act and prior to the expiration of the patents listed for the product. Likewise, our innovative biologic products have been, and may in the future be, the subject of patent litigation prior to the expiration of our patents and, with respect to competitors seeking approval as a biosimilar or interchangeable version of our products, prior to the 12-year exclusivity period provided under the BPCIA. In addition, we may face patent litigation involving claims that the biosimilar product candidates we are working to develop infringe the patents of other companies, including those that manufacture, market or sell the applicable reference products or who are developing or have developed other biosimilar versions of such products. Due to the COVID-19 pandemic, there may be delays in ongoing or new patent office or court proceedings in the U.S. or abroad that may delay the outcome of such proceedings. While we have attempted, and expect to continue to attempt, to challenge the patents held by other companies, our efforts may be unsuccessful. Alternatively, such patents have contributed, and may in the future contribute, to a decision by us to not pursue all of the same labeled indications as are held by these companies. For examples of and information related to our patent litigation, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the existing patents on our products have expired. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Patents. As our patents expire, competitors are able to legally produce and market similar products or technologies, including biosimilars, which has had, and may continue to have, a material adverse effect on our product sales, business and results of operations. In addition, competitors have been, and may continue to be, able to invalidate, design around or otherwise circumvent our patents and sell competing products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics in most of the territories in which we operate, including Europe and the United States, and we expect to face increasing biosimilar and/or generics competition this year and beyond. Expiration or successful challenge of applicable patent rights or expiration of an applicable exclusivity period has accelerated such competition, and we expect to face more litigation regarding the validity and/or scope of our patents. Our products have also experienced greater competition from lower cost biosimilars or generics that come to market when branded products that compete with our products lose their own patent protection. To the extent that governments adopt more permissive regulatory approval standards and competitors are able to obtain broader or expedited marketing approval for biosimilars and generics, the rate of increased competition for our products could accelerate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biosimilars are evaluated for marketing authorization pursuant to a set of general and product class-specific guidelines. In addition, in an effort to spur biosimilar utilization and/or increase potential healthcare savings, some EU countries and some Canadian provinces have adopted or are considering the adoption of biosimilar uptake measures such as physician prescribing quotas or automatic pharmacy substitution of biosimilars for the corresponding reference products. Some EU countries impose automatic price reductions upon market entry of one or more biosimilar competitors. While the degree of competitive effects of biosimilar competition differs between EU countries and between products, in the EU the overall use of biosimilars and the rate at which product sales of innovative products are being affected by biosimilar competition is increasing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the BPCIA authorizes the FDA to approve biosimilars via a separate, abbreviated pathway. See Item 1. Business&#8212;Government Regulation&#8212;Regulation in the United States&#8212;Approval of Biosimilars. The first biosimilar entrant into the U.S. market was Sandoz&#8217;s Zarxio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(filgrastim-sndz), a biosimilar version of NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in 2015. Since then, the FDA has approved additional biosimilars, including biosimilar versions of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ENBREL, and a growing number of companies have announced that they are also developing biosimilar versions of our products. Four biosimilar versions of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are now marketed in the United States, and we expect other biosimilar versions of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to receive approval in 2021 and beyond. Impact to our Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales has accelerated as additional competitors have launched. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. An approved biosimilar version of EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has also launched in the United States, and we are currently involved in patent litigations with the manufacturers of the approved biosimilar versions of ENBREL. Manufacturers of biosimilars have attempted, and may in the future attempt, to compete with our products by offering lower list prices, greater discounts or rebates, or contracts that offer longer-term pricing or a broader portfolio of other products. Companies pursuing development of biosimilar versions of our products have challenged and may continue to challenge our patents well in advance of the expiration of our material patents. For example, we recently successfully defended our ENBREL patents against a litigation challenge. For examples of and information related to our biosimilars and generics patent litigation, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. pathway includes the option for biosimilar products that meet certain criteria to be approved as interchangeable with their reference products. Some companies currently developing or already marketing biosimilars may seek to obtain interchangeable status from the FDA, which could potentially allow pharmacists to substitute those biosimilars for our reference products without prior approval from the prescriber in most states. In November 2019, the FDA issued draft guidance that provides that comparative immunogenicity studies will not generally be expected for biosimilar and interchangeable insulin products. This may open the door for other product-specific guidance development and the removal of the expectation for certain studies, which may contribute to increased biosimilar competition for our innovative products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, critics of the 12-year exclusivity period in the biosimilar pathway law will likely continue to seek to shorten the data exclusivity period and/or to encourage the FDA to interpret narrowly the law&#8217;s provisions regarding which new products receive data exclusivity. In late 2019, the previous Administration agreed to remove from the United States-Mexico-Canada Agreement a requirement for at least 10 years of data exclusivity for biologic products. Also, the FDA is considering whether subsequent changes to a licensed biologic would be protected by the remainder of the reference product&#8217;s original 12-year exclusivity period (a concept known in the generic drug context as &#8220;umbrella exclusivity&#8221;). If the FDA were to decide that umbrella exclusivity does not apply to biological reference products or were to make other changes to the exclusivity period, this could expose us to biosimilar competition at an earlier time. There also have been, and may continue to be, legislative and regulatory efforts to promote competition through policies enabling easier generic and biosimilar approval and commercialization, including efforts to lower standards for demonstrating biosimilarity or interchangeability, limit patents that may be litigated and/or patent settlements, implement preferential reimbursement policies for biosimilars and passage of new laws requiring more disclosure in the FDA&#8217;s Orange and Purple Books.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the expiration or loss of patent protection and/or applicable exclusivity for one of our small molecule products, we can lose the majority of revenues for that product in a very short period of time. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. Additionally, if one of our small molecule products is the subject of an FDA Written Request for pediatric studies and we are unable to adequately complete these studies, we may not obtain the pediatric exclusivity award that extends existing patents for the product by an additional six months. For example, as a result of the product already introduced and/or that could further be introduced into the U.S. market, our product sales for Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been adversely affected and could be further materially and adversely affected by competing generics.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California is the first state to have passed legislation, effective on January 1, 2020, against &#8220;pay for delay&#8221; settlements of patent infringement claims filed by manufacturers of generics or biosimilars where anything of value is given in exchange for settlement. Under this law, such settlement agreements are presumptively anticompetitive. The law may result in prolonged litigation and fewer settlements. Other states, including Connecticut, New York, Illinois, and Minnesota, may adopt similar laws or a similar law could be adopted at the federal level.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are unable to predict the precise effects of biosimilars and generics on our products, we are currently facing and expect to face greater competition in the United States, Europe and elsewhere in 2021 and beyond as a result of biosimilar and generic competition and, in turn, downward pressure on our product prices and sales. This competition has had and could increasingly have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our distributors, customers and payers have substantial purchasing leverage, due to the volume of our products they purchase or the number of patient lives for which they provide coverage. The substantial majority of our U.S. product sales is made to three pharmaceutical product wholesaler distributors: AmerisourceBergen, McKesson and Cardinal Health. These distributors, in turn, sell our products to their customers, which include physicians or their clinics, dialysis centers, hospitals and pharmacies. One of our products, EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is sold primarily to free-standing dialysis clinics. DaVita owns or manages a large number of the outpatient dialysis facilities located in the United States and accounts for approximately 90% of all EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales. Similarly, as discussed above, there has been significant consolidation in the health insurance industry, including that a small number of PBMs now oversee a substantial percentage of total covered lives in the United States. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from third-party payers, and pricing and reimbursement pressures may affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The three largest PBMs in the United States are now part of major health insurance providers. The growing concentration of purchasing and negotiating power by these entities may put pressure on our pricing due to their ability to extract price discounts on our products, fees for other services or rebates, negatively affecting our bargaining position, sales and/or profit margins. In addition, decisions by these entities to purchase or cover less or none of our products in favor of competitive products could have a material adverse effect on our product sales, business and results of operations due to their purchasing volume. Further, if one of our significant wholesale distributors encounters financial or other difficulties and becomes unable or unwilling to pay us all amounts that such distributor owes us on a timely basis, or at all, it could negatively affect our business and results of operations. In addition, if one of our significant wholesale distributors becomes insolvent or otherwise unable to continue its commercial relationship with us in its present form, it could significantly disrupt our business and adversely affect our product sales, our business and results of operations unless suitable alternatives are timely found or lost sales are absorbed by another distributor.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RESEARCH AND DEVELOPMENT</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to develop commercial products despite significant investments in R&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen invests heavily in R&amp;D. Successful product development in the biotechnology industry is highly uncertain, and very few R&amp;D projects produce commercial products. Product candidates, including biosimilar product candidates, or new indications for existing products (collectively, product candidates) that appear promising in the early phases of development may fail to reach the market for a number of reasons, such as:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate did not demonstrate acceptable clinical trial results even though it achieved its primary endpoints and/or demonstrated positive preclinical or early clinical trial results, for reasons that could include changes in the standard of care of medicine or expectations of health authorities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate was not effective or not more effective than currently available therapies in treating a specified condition or illness;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate was not cost effective in light of existing therapeutics;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate had harmful side effects in animals or humans;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the necessary regulatory bodies, such as the FDA or EMA, did not approve the product candidate for an intended use;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate was not economical for us to manufacture and commercialize;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other parties had or may have had proprietary rights relating to our product candidate, such as patent rights, and did not let us sell it on reasonable terms, or at all;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we and certain of our licensees, partners, contracted organizations or independent investigators may have failed to effectively conduct clinical development or clinical manufacturing activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pathway to regulatory approval or reimbursement for product candidates was uncertain or not well-defined;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the biosimilar product candidate failed to demonstrate the requisite biosimilarity to the applicable reference product, or was otherwise determined by a regulatory authority to not meet applicable standards for approval; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a companion diagnostic device that is required with the use of a product candidate is not approved by the necessary regulatory authority.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have spent considerable time, energy and resources developing our expertise in human genetics and acquiring access to libraries of genetic information with the belief that genetics could meaningfully aid our search for new medicines and help guide our R&amp;D decisions and investments. We have focused our R&amp;D strategy on drug targets validated by genetic or other compelling human evidence. However, product candidates based on genetically validated targets remain subject to the uncertainties of the drug development process and may not reach the market for a number of reasons, including the factors listed above.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our product candidates have failed or been discontinued at various stages in the product development process. For example, in 2015, we terminated our participation in the co-development and commercialization of brodalumab, a product candidate that was in phase 3, with AstraZeneca. The decision was based on events of suicidal ideation and behavior in the brodalumab program that occurred late in the development program, which we believed likely would necessitate restrictive labeling that would limit the appropriate patient population. Inability to bring a product to market or a significant delay in the expected approval and related launch date of a new product for any of the reasons discussed could potentially have a negative effect on our product sales and earnings and could result in a significant impairment of in-process research and development (IPR&amp;D) or other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we sell any products, we must conduct clinical trials to demonstrate that our product candidates are safe and effective for use in humans. The results of those clinical trials are used as the basis to obtain approval from regulatory authorities such as the FDA and EMA. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to conduct clinical trials using an appropriate number of trial sites and patients to support the product label claims. The length of time, number of trial sites and number of patients required for clinical trials vary substantially, and we may spend several years and incur substantial expense in completing certain clinical trials. In addition, we may have difficulty finding a sufficient number of clinical trial sites and patients to participate in our clinical trials, particularly if competitors are conducting clinical trials in similar patient populations. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients may withdraw from clinical trials at any time, and privacy laws and/or other restrictions in certain countries may restrict the ability of clinical trial investigators to conduct further follow-up on such patients, which may adversely affect the interpretation of study results. Delays and complications in planned clinical trials can result in increased development costs, associated delays in regulatory approvals and in product candidates reaching the market and revisions to existing product labels.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to increase the number of patients available for enrollment in our clinical trials, we have opened, and will continue to open, clinical sites and enroll patients in a number of locations where our experience conducting clinical trials is more limited, including Russia, India, China, South Korea, the Philippines, Singapore and some Central and South American countries, either through utilization of third-party contract clinical trial providers entirely or in combination with local staff. Conducting clinical trials in locations where we have limited experience requires substantial time and resources to understand the unique regulatory environments of individual countries. For other examples of the risks of conducting clinical trials in China, see also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we must ensure the timely production, distribution and delivery of the clinical supply of our product candidates to numerous and varied clinical trial sites. Additionally, regional disruptions, including natural and man-made disasters or health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19), could significantly disrupt the timing of clinical trials. If we fail to adequately manage the design, execution and diverse regulatory aspects of our large and/or complex clinical trials or to manage the production or distribution of our clinical supply, or such sites experience disruptions as a result of a natural/man-made disaster or health emergency, corresponding regulatory approvals may be delayed or we may fail to gain approval for our product candidates or could lose our ability to market existing products in certain therapeutic areas or altogether. For example, our clinical trials have been adversely affected by the COVID-19 pandemic. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to market and sell our products or product candidates or to obtain approvals in the timeframe needed to execute our product strategies, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on independent third-party clinical investigators to recruit patients and conduct clinical trials on our behalf in accordance with applicable study protocols, laws and regulations. Further, we rely on unaffiliated third-party vendors to perform certain aspects of our clinical trial operations. In some circumstances, we enter into co-development arrangements with other pharmaceutical and medical devices companies that provide for the other company to conduct certain clinical trials for the product we are co-developing or to develop a diagnostic test used in screening or monitoring patients in our clinical trials. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our pharmaceutical pipeline and of our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sale of our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may acquire companies that have past or ongoing clinical trials or rights to products or product candidates for which clinical trials have been or are being conducted. These trials may not have been conducted to the same standards as ours; however, once an acquisition has been completed we assume responsibility for the conduct of these trials, including any potential risks and liabilities associated with the past and prospective conduct of those trials. If regulatory authorities determine that we or others, including our licensees or co-development partners, or the independent investigators or vendors selected by us, our co-development partners or by a company we have acquired or from which we have acquired rights to a product or product candidate, have not complied with regulations applicable to the clinical trials, those authorities may refuse or reject some or all of the clinical trial data or take other actions that could delay or otherwise negatively affect our ability to obtain or maintain marketing approval of the product or indication. In addition, delays or failures to develop diagnostic tests for our clinical trials can affect the timely enrollment of such trials and lead to delays or inability to obtain marketing approval. If we were unable to market and sell our products or product candidates, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our clinical trials utilize drugs manufactured and marketed by other pharmaceutical companies. These drugs may be administered in clinical trials in combination with one of our products or product candidates or in a head-to-head study comparing the products&#8217; or product candidates&#8217; relative efficacy and safety. In the event that any of these vendors or pharmaceutical companies have unforeseen issues that negatively affect the quality of their work product or create a shortage of supply, or if we are otherwise unable to obtain an adequate supply of these other drugs, our ability to complete our applicable clinical trials and/or evaluate clinical results may also be negatively affected. As a result, such quality or supply problems could adversely affect our ability to timely file for, gain or maintain regulatory approvals worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must generally be designed based on the current standard of medical care. However, in certain diseases, such as cancer, the standard of care is evolving rapidly. In some cases, we may design a clinical trial based on the standard of care we anticipate will exist at the time our study is completed. The duration of time needed to complete certain clinical trials may result in the design of such clinical trials being based on standards of medical care that are no longer or that have not become the current standards by the time such trials are completed, limiting the utility and application of such trials. Additionally, the views of regulatory agencies relating to the requirements for accelerated approval may change over time, and trial designs that were sufficient to support accelerated approvals for some oncology products may not be considered sufficient for later candidates. We may not obtain favorable clinical trial results and therefore may not be able to obtain regulatory approval for new product candidates or new indications for existing products and/or maintain our current product labels. Participants in clinical trials of our products and product candidates may also suffer adverse medical events or side effects that could, among other factors, delay or terminate clinical trial programs and/or require additional or longer trials to gain approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product is on the market, safety concerns may require additional or more extensive clinical trials as part of a risk management plan for our product or for approval of a new indication. For example, in connection with the June 2011 ESA label changes, we agreed to and conducted additional clinical trials examining the use of ESAs in CKD. Additional clinical trials we initiate, including those required by the FDA, could result in substantial additional expense, and the outcomes could result in further label restrictions or the loss of regulatory approval for an approved indication, each of which could have a material adverse effect on our product sales, business and results of operations. Additionally, any negative results from such trials could materially affect the extent of approvals, the use, reimbursement and sales of our products, our business and results of operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to extensive regulation by numerous state and federal government authorities in the United States, including the FDA, and by foreign regulatory authorities, including the EMA. We are required in the United States and in foreign countries to obtain approval from regulatory authorities before we manufacture, market and sell our products. Once our products are approved, the FDA and other U.S. and foreign regulatory agencies have substantial authority to require additional testing and reporting, perform inspections, change product labeling or mandate withdrawals of our products. Failure to comply with applicable regulatory requirements may subject us to administrative and/or judicially imposed sanctions or monetary penalties as well as reputational and other harms. The sanctions could include the FDA&#8217;s or foreign regulatory authorities&#8217; refusals to approve pending applications, delays in obtaining or withdrawals of approvals, delays or suspensions of clinical trials, warning letters, product recalls or seizures, total or partial suspensions of our operations, injunctions, fines, civil penalties and/or criminal prosecutions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approvals have been, and will continue to be, increasingly difficult, time-consuming and costly. Legislative bodies or regulatory agencies could enact new laws or regulations, change existing laws or regulations or change their interpretations of laws or regulations at any time, which could affect our ability to obtain or maintain approval of our products or product candidates. The rate and degree of change in existing laws and regulations and regulatory expectations have accelerated in established markets, and regulatory expectations continue to evolve in emerging markets.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict whether and when any further changes to laws or regulatory policies affecting our business could occur, such as changes to laws or regulations governing manufacturer communications concerning drug products and drug product candidates and whether such changes could have a material adverse effect on our product sales, business and results of operations. In the United States, a partial federal government shutdown halted the work of many federal agencies and their employees from late December 2018 through late January 2019. A subsequent extended shutdown could result in reductions or delays of FDA&#8217;s activities, including with respect to our ongoing clinical programs, our manufacturing of our products and product candidates and our product approvals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have questioned, and may in the future question, the sufficiency for approval of the endpoints we select for our clinical trials. A number of our products and product candidates have been evaluated in clinical trials using surrogate endpoints that measure an effect that is known to correlate with an ultimate clinical benefit. For example, a therapeutic oncology product candidate may be evaluated for its ability to reduce or eliminate minimal residual disease (MRD), or to extend the length of time during and after the treatment that a patient lives without the disease worsening, measured by PFS. Demonstrating that the product candidate induces MRD-negative responses or produces a statistically significant improvement in PFS does not necessarily mean that the product candidate will show a statistically significant improvement in overall survival or the time that the patients remain alive. In the CV setting, a heart disease therapeutic candidate may be evaluated for its ability to reduce LDL-C levels, as an elevated LDL-C level has been a surrogate endpoint for CV events such as death, heart attack and stroke. The use of surrogate endpoints such as PFS and LDL-C reduction, in the absence of other measures of clinical benefit, may not be sufficient for broad usage or approval even when such results are statistically significant. Regulatory authorities could also add new requirements, such as the completion of enrollment in a confirmatory study or the completion of an outcomes study or a meaningful portion of an outcomes study, as conditions for obtaining approval or obtaining an indication. For example, despite demonstrating that Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reduced LDL-C levels in a broad patient population, only after our large phase 3 outcomes study evaluating the ability of Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to prevent CV events met certain of its primary composite endpoint and key secondary composite endpoint did the FDA grant a broader approval of Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reduce the risk of certain CV events, and also to be used, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia to reduce LDL-C. There may also be situations in which demonstrating the efficacy and safety of a product candidate may not be sufficient to gain regulatory approval unless superiority to other existing treatment options can be shown. The imposition of additional requirements or our inability to meet them in a timely fashion, or at all, has delayed, and may in the future delay, our clinical development and regulatory filing efforts, delay or prevent us from obtaining regulatory approval for new product candidates or new indications for existing products, or prevent us from maintaining our current product labels.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our products have been approved by U.S. and foreign regulatory authorities on an accelerated or conditional basis with full approval conditioned upon fulfilling the requirements of regulators. For example, in March 2018, we announced that the FDA approved BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under accelerated approval for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with MRD greater than or equal to 0.1 percent. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Regulatory authorities are placing greater focus on monitoring products originally approved on an accelerated or conditional basis and on whether the sponsors of such products have met the conditions of the accelerated or conditional approvals. If we are unable to fulfill the regulators&#8217; requirements that were conditions of a product&#8217;s accelerated or conditional approval and/or if regulators reevaluate the data or risk-benefit profile of our product, the conditional approval may not result in full approval or may be revoked or not renewed. Alternatively, we may be required to change the product&#8217;s labeled indications or even withdraw the product from the market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities can also impose post-marketing pediatric study requirements. Failure to fulfill such requirements may result in regulatory or enforcement action, including financial penalties or the invalidation of a product&#8217;s marketing authorization.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety problems or signals can arise as our products and product candidates are evaluated in clinical trials, including investigator sponsored studies, or as our marketed products are used in clinical practice. We are required continuously to collect and assess adverse events reported to us and to communicate to regulatory agencies these adverse events and safety signals regarding our products. Regulatory agencies periodically perform inspections of our pharmacovigilance processes, including our adverse event reporting. In the United States, for our products with approved REMS (see Item 1. Business&#8212;Government Regulation&#8212;Postapproval Phase), we are required to submit periodic assessment reports to the FDA to demonstrate that the goals of the REMS are being met. REMS and other risk management programs are designed to ensure that a drug&#8217;s benefits outweigh the risks and vary in the elements they contain. If the FDA is not satisfied with the results of the periodic assessment reports we submit for any of our REMS, the FDA may also modify our REMS or take other regulatory actions, such as implementing revised or restrictive labeling. The drug delivery devices approved for use in combination with our products are also subject to regulatory oversight and review for safety and malfunctions. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory agencies determine that we or other parties (including our clinical trial investigators, those operating our patient support programs or licensees of our products) have not complied with the applicable reporting, other pharmacovigilance or other safety or quality assessment requirements, we may become subject to additional inspections, warning letters or other enforcement actions, including fines, marketing authorization withdrawal and other penalties. Our product candidates and marketed products can also be affected by safety problems or signals occurring with respect to products that are similar to ours or that implicate an entire class of products. Further, as a result of clinical trials, including sub-analyses or meta-analyses of earlier clinical trials (a meta-analysis involves the use of various statistical methods to combine results from previous separate but related studies) performed by us or others, concerns may arise about the sufficiency of the data or studies underlying a product&#8217;s approved label. Such actual or perceived safety problems or concerns can lead to:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revised or restrictive labeling for our products, or the potential for restrictive labeling that has resulted, and may in the future result, in our decision not to commercialize a product candidate;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement of risk management or minimization activities or other regulatory agency compliance actions related to the promotion and sale of our products;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing commitments, mandated post-marketing requirements or pharmacovigilance programs for our approved products;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls of our approved products;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required changes to the processes used in the manufacture of our products, which could increase our manufacturing costs and affect the availability of contract manufacturers we may utilize to assist in such manufacturing;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revocation of approval for our products from the market completely, or within particular therapeutic areas or patient types;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased timelines or delays in being approved by the FDA or other regulatory bodies; and/or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">treatments or product candidates not being approved by regulatory bodies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, after an imbalance in positively adjudicated CV serious adverse events was observed in one of the phase 3 clinical trials for EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but not in another, larger phase 3 study, in April 2019 the FDA approved EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of osteoporosis in postmenopausal women at high risk for fracture, along with a post-marketing requirement. The requirement includes a five-year observational feasibility study that could be followed by a comparative safety study or trial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our innovative products, we are working to develop and commercialize biosimilar versions of a number of products currently manufactured, marketed and sold by other pharmaceutical companies. In some markets, there is not yet a legislative or regulatory pathway for the approval of biosimilars. In the United States, the BPCIA provided for such a pathway; while the FDA continues to implement it, discussions continue as to the evidence needed to demonstrate biosimilarity or interchangeability for specific products. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Delays or uncertainties in the development or implementation of such pathways could result in delays or difficulties in getting our biosimilar products approved by regulatory authorities, subject us to unanticipated development costs or otherwise reduce the value of the investments we have made in the biosimilars area. Further, we cannot predict whether any repeal or reform of the ACA or other legislation or policy initiatives would affect the biosimilar pathway or have a material adverse effect on our development of biosimilars or on our marketed biosimilars. In addition, if we are unable to bring our biosimilar products to market on a timely basis and secure &#8220;first-to-market&#8221; or other advantageous positions, our future biosimilar sales, business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates may be used in combination with a drug delivery device, such as an injector or other delivery system. For example, Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available as part of the Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit, and our AutoTouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reusable autoinjector is used with ENBREL Mini</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> single-dose prefilled cartridges. In addition, some of our products or product candidates, including many of our oncology product candidates, including sotorasib, may also require the use of a companion or other diagnostic device such as a device that determines whether the patient is eligible to use our drug or that helps ensure its safe and effective use. In some regions, including the United States, regulatory authorities may require contemporaneous approval of the companion diagnostic device and the therapeutic product; in others the regulatory authorities may require a separate study of the companion diagnostic device. Our product candidates or expanded indications of our products used with such devices may not be approved or may be substantially delayed in receiving regulatory approval if development or approval of such devices is delayed, such devices do not also gain or maintain regulatory approval or clearance, or if such devices do not remain commercially available. When approval of the product and device is sought under a single marketing drug application, the increased complexity of the review process may delay receipt of regulatory approval. In addition, some of these devices may be provided by single-source unaffiliated third-party companies. We are dependent on the sustained cooperation and effort of those third-party companies to supply and/or market the devices and, in some cases, to conduct the studies required for approval or clearance by the applicable regulatory agencies. We are also dependent on those third-party companies continuing to meet applicable regulatory or other requirements. Failure to successfully develop, modify, or supply the devices, delays in or failures of the Amgen or third-party studies, or failure of us or the third-party companies to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs; delays in, or failure to obtain or maintain, regulatory approval; and/or associated delays in a product candidate reaching the market or in the addition of new indications for existing products. We are also required to collect and assess user complaints, adverse events and malfunctions regarding our devices, and actual or perceived safety problems or concerns with a device used with our product can lead to regulatory actions and adverse effects on our products. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, regulatory agencies conduct routine monitoring and inspections to identify and evaluate potential issues with our devices. For example, in 2017, the FDA reported on its adverse event reporting system that it was evaluating our Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kit. Subsequently, we implemented device and labeling enhancements to address product complaints received on this device. We continuously monitor complaints and adverse events and implement additional enhancements as needed. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop, supply, or gain or maintain approval for these devices could adversely affect sales of the related approved products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sale of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on alliances with other companies, including pharmaceutical and biotechnology companies, vendors and service providers, for the development of a portion of the products in our pharmaceutical pipeline and for the commercialization and sales of certain of our commercial products. For example, we have collaborations with third parties under which we share development rights, obligations and costs and/or commercial rights and obligations. See Item 1. Business&#8212;Business Relationships.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failures by these parties to meet their contractual, regulatory, or other obligations to us or any disruption in the relationships between us and these third parties, could have a material adverse effect on our pharmaceutical pipeline and business. In addition, our collaborative relationships for R&amp;D and/or commercialization and sales often extend for many years and have given, and may in the future give, rise to disputes regarding the relative rights, obligations and revenues of us and our collaboration partners, including the ownership or prosecution of intellectual property and associated rights and obligations. This could result in the loss of intellectual property rights or protection, delay the development and sale of potential pharmaceutical products, affect the effective sale and delivery of our commercialized products and lead to lengthy and expensive litigation, administrative proceedings or arbitration. For example, we are currently involved in litigation with Novartis over our collaboration agreements for the development and commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. While our collaboration remains in place until the litigation is resolved and we remain committed to continuing to work with Novartis to sell and deliver Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it is possible that the dispute may nevertheless affect the efficiency of operation and future growth of the collaboration. The litigation may also affect or delay, or lead to a termination of, other projects with Novartis.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek innovation through significant investment in both internal R&amp;D and external transactions, including collaborations, partnering, alliances, licenses, joint ventures, mergers and acquisitions (collectively, acquisition activity). Acquisition activities may be subject to regulatory approvals or other requirements that are not within our control. There can be no assurance that such regulatory or other approvals will be obtained or that all closing conditions required in connection with our acquisition activities will be satisfied or waived, which could result in us being unable to complete the planned acquisition activities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition activities are complex, time consuming and expensive and may result in unanticipated costs, delays or other operational or financial problems related to integrating the acquired company and business with our company, which may divert our management&#8217;s attention from other business issues and opportunities and restrict the full realization of the anticipated benefits of such transactions within the expected timeframe or at all. We may pay substantial amounts of cash, incur debt or issue equity securities to pay for acquisition activities, which could adversely affect our liquidity or result in dilution to our stockholders, respectively. Further, failures or difficulties in integrating or retaining new personnel or in integrating the operations of the businesses, products or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing, distribution and general business operations and procedures) may affect our ability to realize the benefits of the transaction and grow our business and may result in us incurring asset impairment or restructuring charges. These and other challenges may arise in connection with our recent acquisition of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and/or collaboration with BeiGene, or with other acquisition activities, which could have a material adverse effect on our business, results of operations and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global supply of our products and product candidates for commercial sales and for use in our clinical trials is significantly dependent on the uninterrupted and efficient operation of our manufacturing facilities, in particular those in the U.S. territory of Puerto Rico and Thousand Oaks, California. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform a substantial majority of our clinical manufacturing that supports our product candidates at our facility in Thousand Oaks, California. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply our product candidates for use in our clinical trials, leading to delays in development of our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico. In recent years, Puerto Rico has been affected by natural disasters, including droughts in mid-2020, earthquakes in early 2020 and Hurricane Maria in 2017. These natural disasters have affected, and may continue to affect, public and private properties and Puerto Rico&#8217;s electric grid and communications networks in the future. While the critical manufacturing areas of our commercial manufacturing facility were not significantly affected by these natural disasters, the restoration of electrical service on the island after Hurricane Maria was a slow process, and our facility operated with electrical power from backup diesel powered generators for some time. We also operated on backup generators for a few weeks after the early 2020 earthquakes in Puerto Rico. Further instability of the electric grid could require us to increase the use of our generators or to continue using them exclusively. In addition, future storms, earthquakes or other natural disasters or events could cause a more significant effect on our manufacturing operations. Puerto Rico and the rest of the world are facing the effects of the COVID-19 pandemic and the associated health and economic implications. Since March2020, the Governor of Puerto Rico issued Executive Orders requiring the lockdown of businesses and government facilities, imposing restrictions on business operations and a curfew on residents. Our operations and employees have been exempted from the lockdown and curfew, but we cannot predict how long these orders will continue in effect and what impact these orders and the COVID-19 pandemic will have on our future operations, and whether the Governor will issue future Executive Orders imposing stricter lockdown and curfew measures should COVID-19 cases rise in Puerto Rico. Although our ability to manufacture and supply our products has not, to date, been significantly affected by these natural disasters or the COVID-19 pandemic, a combination of these challenges or other issues that could give rise to any substantial disruption to our ability to operate our Puerto Rico manufacturing facility or get supplies and manufactured products transported to and from that location could materially and adversely affect our ability to supply our products and affect our product sales. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hurricane Maria, the earthquakes of early 2020 and the COVID-19 pandemic have placed greater stress on the island&#8217;s already challenged economy. Beginning in 2016, the government of Puerto Rico defaulted on its roughly $72 billion in debt. In response, the U.S. Congress passed the Puerto Rico Oversight, Management, and Economic Stability Act (PROMESA), which established a Financial Oversight and Management Board (Oversight Board) to provide fiscal oversight. Title III of PROMESA provides Puerto Rico with a judicial process for restructuring its debt similar to, but not identical to, Chapter 9 of the U.S. Bankruptcy Code, including a stay of debtholder litigation. In 2017, the Oversight Board approved and certified the filing in the U.S. District Court for the District of Puerto Rico of a voluntary petition under Title III of PROMESA for the government of Puerto Rico and certain of its governmental entities, including the Puerto Rico Electric Power Authority, which is currently undergoing a privatization process of its transmission and distribution infrastructure. Under PROMESA, other Title III filings for additional government entities may occur, further complicating Puerto Rico&#8217;s already uncertain fiscal stability. In June 2019, in response to legal challenges, the U.S. Supreme Court ruled in favor of PROMESA and confirmed the constitutionality of the appointment process.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year since 2017, the Oversight Board has updated Puerto Rico&#8217;s fiscal plans imposing significant expense reductions. Each plan has stressed the need for fiscal and structural reforms to address Puerto Rico&#8217;s challenging economic and demographic trends. There is pending litigation between the Government of Puerto Rico and the Oversight Board with regards to the Oversight Board&#8217;s powers under PROMESA and authority to review and prevent the enforcement of government-approved legislation. This litigation, currently underway in the Title III Court, may impact how and when Puerto Rico will eventually restructure its debt and achieve fiscal and economic stability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the government and the Oversight Board have authorized emergency relief packages due to the COVID-19 pandemic, it is uncertain how, or the degree to which, the pandemic will impact Puerto Rico&#8217;s fiscal and structural reforms and its economy. In addition, the 2017 Tax Act no longer permits deferral of U.S. taxation on Puerto Rico earnings, although these earnings generally will be taxed in the United States at a reduced rate. Given Puerto Rico&#8217;s challenged economy, disaster recovery needs and impact from the COVID-19 pandemic, it may be difficult for Puerto Rico to sustain or grow its manufacturing base, which contributes significantly to Puerto Rico&#8217;s economy, due to competition from other locations subject to similar levels of taxation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While PROMESA and the actions above continue to be important factors in moving Puerto Rico toward economic stability, Puerto Rico&#8217;s ongoing economic and demographic trend challenges and political situation, the effects of natural disasters, the COVID-19 pandemic, and the effects of the 2017 Tax Act or other potential tax law changes have negatively affected, and may in the future negatively affect, the territorial government&#8217;s provision of utilities or other services in Puerto Rico that we use in the operation of our business and could create the potential for increased taxes or fees to operate in Puerto Rico, result in a migration of workers from Puerto Rico to the mainland United States, or make it more expensive or difficult for us to operate in Puerto Rico. These factors could have a material adverse effect on our ability to supply our products, on our business and on our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on unaffiliated third-party suppliers for certain raw materials, medical devices and components necessary for the manufacturing of our commercial and clinical products. Certain of those raw materials, medical devices and components are proprietary products of those unaffiliated third-party suppliers and are specifically cited in our drug applications with regulatory agencies so that they must be obtained from that specific sole source or sources and could not be obtained from another supplier unless and until the regulatory agency approved such supplier. For example, Scandinavian Health Limited Group is our single source of SureClick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">autoinjectors for Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ENBREL, Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Also, certain of the raw materials required in the commercial and clinical manufacturing of our products are sourced from other countries and/or derived from biological sources, including mammalian tissues, bovine serum and human serum albumin.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the reasons we may be unable to obtain these raw materials, medical devices and components include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements or action by regulatory agencies or others;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse financial or other strategic developments at or affecting the supplier, including bankruptcy;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected demand for or shortage of raw materials, medical devices or components;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with our quality standards which results in quality and product failures, product contamination and/or recall;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a material shortage, contamination, recall and/or restrictions on the use of certain biologically derived substances or other raw materials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery of previously unknown or undetected imperfections in raw materials, medical devices or components;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cyberattacks on supplier systems; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labor disputes or shortages, including from the effects of health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19) and natural disasters.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in prior years we have experienced shortages in certain components necessary for the formulation, fill and finish of certain of our products in our Puerto Rico facility. Further quality issues that result in unexpected additional demand for certain components may lead to shortages of required raw materials or components (such as we have experienced with EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> glass vials). We may experience similar or other shortages in the future resulting in delayed shipments, supply constraints, clinical trial delays, contract disputes and/or stock-outs of our products. These or other similar events could negatively affect our ability to satisfy demand for our products or conduct clinical trials, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biologic and small molecule human therapeutic products is difficult, complex and highly regulated. We manufacture many of our commercial products and product candidates internally. In addition, we currently use third-party contract manufacturers to produce, or assist in the production of, a number of our products, and we currently use contract manufacturers to produce, or assist in the production of, a number of our late-stage product candidates and drug delivery devices. See Item 1. Business&#8212;Manufacturing, Distribution and Raw Materials&#8212;Manufacturing. Our ability to adequately and timely manufacture and supply our products (and product candidates to support our clinical trials) is dependent on the uninterrupted and efficient operation of our facilities and those of our third-party contract manufacturers, which may be affected by:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capacity of manufacturing facilities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contamination by microorganisms or viruses, or foreign particles from the manufacturing process;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural or other disasters, including hurricanes, earthquakes, volcanoes or fires;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labor disputes or shortages, including the effects of health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19) or natural disasters;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with regulatory requirements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in forecasts of future demand;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing and actual number of production runs and production success rates and yields;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">updates of manufacturing specifications;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual disputes with our suppliers and contract manufacturers;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing and outcome of product quality testing;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">power failures and/or other utility failures;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cyberattacks on supplier systems;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breakdown, failure, substandard performance or improper installation or operation of equipment (including our information technology systems and network-connected control systems or those of our contract manufacturers or third-party service providers); and/or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the ability of the FDA or foreign regulatory agencies to provide us necessary reviews, inspections and approvals, including as a result of a subsequent extended U.S. federal or other government shutdowns. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other problems affect production in one or more of our facilities or those of our third-party contract manufacturers, or if we do not accurately forecast demand for our products or the amount of our product candidates required in clinical trials, we may be unable to start or increase production in our unaffected facilities to meet demand. If the efficient manufacture and supply of our products or product candidates is interrupted, we may experience delayed shipments, delays in our clinical trials, supply constraints, stock-outs, adverse event trends, contract disputes and/or recalls of our products. From time to time we have initiated recalls of certain lots of our products. For example, in July 2014 we initiated a voluntary recall of an Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lot distributed in the EU after particles were detected in a quality control sample following distribution of that lot, and in April 2018 we initiated a precautionary recall of two batches of Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> distributed in Switzerland after potential crimping defects were discovered in the metal seals on some product vials. If we are at any time unable to provide an uninterrupted supply of our products to patients, we may lose patients and physicians may elect to prescribe competing therapeutics instead of our products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing processes, those of our third-party contract manufacturers and those of certain of our third-party service providers must undergo regulatory approval processes and are subject to continued review by the FDA and other regulatory authorities. It can take longer than five years to build, validate and license another manufacturing plant, and it can take longer than three years to qualify and license a new contract manufacturer or service provider. If we elect or are required to make changes to our manufacturing processes because of new regulatory requirements, new interpretations of existing requirements or other reasons, this could increase our manufacturing costs and result in delayed shipments, delays in our clinical trials, supply constraints, stock-outs, adverse event trends or contract negotiations or disputes. Such manufacturing challenges may also occur if our existing contract manufacturers are unable or unwilling to timely implement such changes, or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulatory agencies conduct routine monitoring and conduct inspections of our manufacturing facilities and processes as well as those of our third-party contract manufacturers and service providers. If regulatory authorities determine that we or our third-party contract manufacturers or certain of our third-party service providers have violated regulations, they may mandate corrective actions and/or issue warning letters, or even restrict, suspend or revoke our prior approvals, prohibiting us from manufacturing our products or conducting clinical trials or selling our marketed products until we or the affected third-party contract manufacturers or third-party service providers comply, or indefinitely. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such issues may also delay the approval of product candidates we have submitted for regulatory review, even if such product candidates are not directly related to the products, devices or processes at issue with regulators. Because our third-party contract manufacturers and certain of our third-party service providers are subject to the FDA and foreign regulatory authorities, alternative qualified third-party contract manufacturers and third-party service providers may not be available on a timely basis, or at all. If we or our third-party contract manufacturers or third-party service providers cease or interrupt production or if our third-party contract manufacturers and third-party service providers fail to supply materials, products or services to us, we may experience delayed shipments, delays in our clinical trials, supply constraints, contract disputes, stock-outs and/or recalls of our products. Additionally, we distribute a substantial volume of our commercial products through our primary distribution centers in Louisville, Kentucky for the United States and in Breda, Netherlands for Europe and much of the rest of the world. We also conduct most of the labeling and packaging of our products distributed in Europe and much of the rest of the world in Breda. Our ability to timely supply products is dependent on the uninterrupted and efficient operations of our distribution and logistics centers, our third-party logistics providers and our labeling and packaging facility in Breda. Further, we rely on commercial transportation, including air and sea freight, for the distribution of our products to our customers, which may be negatively affected by natural disasters, security threats and/or the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been legislative and administrative proposals seeking to incentivize greater drug manufacturing in the United States with the stated goal of improving supply reliability in the United States. For example, on August 6, 2020, the previous Administration issued an Executive Order aimed at boosting domestic production of essential medicines, medical countermeasures, and critical inputs titled &#8220;Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States.&#8221; Additionally, one legislative proposal would prohibit the U.S. Department of Veterans Affairs from purchasing certain drugs that have active pharmaceutical ingredients manufactured outside the United States. While we perform a substantial majority of our commercial manufacturing activities in the United States, including in the U.S. territory of Puerto Rico, and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California, the passage of such legislation could result in foreign governments enacting retaliatory legislation or regulatory actions, which may have an adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions. The economic downturn resulting from the COVID-19 pandemic has precipitated a global recession which may be of an extended duration. Additionally, financial pressures may cause government or other third-party payers to more aggressively seek cost containment measures. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from third-party payers, and pricing and reimbursement pressures may affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford health care as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our products, which could have a material adverse effect on our product sales, business and results of operations. Economic conditions may also adversely affect the ability of our distributors, customers and suppliers to obtain the liquidity required to buy inventory or raw materials and to perform their obligations under agreements with us, which could disrupt our operations. Although we monitor our distributors&#8217;, customers&#8217; and suppliers&#8217; financial condition and their liquidity to mitigate our business risks, some of our distributors, customers and suppliers may become insolvent, which could have a material adverse effect on our product sales, business and results of operations. A significant worsening of global economic conditions could materially increase these risks facing us.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a significant portfolio of investments disclosed as cash equivalents and marketable securities on our Consolidated Balance Sheets. The global spread of COVID-19 has also led to disruption and volatility in the global capital markets. We have certain assets, including equity investments, that are exposed to market fluctuations that could, in a sustained or recurrent series of market disruptions, result in impairments. The value of our investments may also be adversely affected by interest rate fluctuations, downgrades in credit ratings, illiquidity in the capital markets and other factors that may result in other-than-temporary declines in the value of our investments. Any of those events could cause us to record impairment charges with respect to our investment portfolio or to realize losses on sales of investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price, like that of our peers in the biotechnology and pharmaceutical industries, is volatile. Our revenues and operating results may fluctuate from period to period for a number of reasons. Events such as a delay in product development, changes to our expectations or strategy or even a relatively small revenue shortfall may cause financial results for a period to be below our expectations or projections. As a result, our revenues and operating results and, in turn, our stock price may be subject to significant fluctuations. Announcements or discussions, including via social media channels, of possible restrictive actions by government or private payers that would negatively affect our business or industry if ultimately enacted or adopted may also cause our stock price to fluctuate, whether or not such restrictive actions ever actually occur. Similarly, actual or perceived safety issues with our products or similar products or unexpected clinical trial results can have an immediate and rapid effect on our stock price, whether or not our operating results are materially affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The capital and credit markets may experience extreme volatility and disruption, which may lead to uncertainty and liquidity issues for both borrowers and investors. For example, early in 2020, there were significant disruptions in the commercial paper market and several borrowers were unable to obtain funding at normal rates or maturities, which resulted in a significant increase in draws of corporate credit lines with banks. Similarly, the bond markets experienced extreme volatility in terms of interest rates and credit spreads, with several days without new issuances of corporate bonds. We expect to access the capital markets, from time to time, to supplement our existing funds and cash generated from operations in satisfying our needs for working capital; capital expenditure and debt service requirements; our plans to pay dividends and repurchase stock; and other business initiatives we strategically plan to pursue, including acquisitions and licensing activities. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on similar favorable terms, or at all, which could have a material adverse effect on our business and results of operations. Changes in credit ratings issued by nationally recognized credit-rating agencies could adversely affect our ability to obtain capital market financing and the cost of such financing and have an adverse effect on the market price of our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_52"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNRESOLVED STAFF COMMENTS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTIES</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we owned or leased approximately 180 properties. The locations and primary functions of significant properties are summarized in the following tables:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales &amp; marketing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warehouse</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution center</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thousand Oaks, CA*</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Francisco, CA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisville, KY</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge, MA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woburn, MA</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Juncos, Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Greenwich, RI</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tampa, FL</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other U.S. cities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate headquarters</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ex-U.S. Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales &amp; marketing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warehouse</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution center</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China </span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iceland</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. There are no material encumbrances on our owned properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1. Business&#8212;Manufacturing, Distribution and Raw Materials.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_58"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the legal proceedings in which we are involved are discussed in Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements and are hereby incorporated by reference.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_61"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MINE SAFETY DISCLOSURES</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_67"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the NASDAQ Global Select Market under the symbol AMGN. As of February 3, 2021, there were approximately 5,336 holders of record of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance graph</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the value of an investment of $100 on December&#160;31, 2015, in each of Amgen common stock, the Amex Biotech Index, the Amex Pharmaceutical Index and Standard&#160;&amp; Poor&#8217;s 500 Index (S&amp;P 500). All values assume reinvestment of the pretax value of dividends and are calculated as of December&#160;31 of each year. The historical stock price performance of the Company&#8217;s common stock shown in the performance graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:6pt;text-align:justify"><img src="amgn-20201231_g2.jpg" alt="amgn-20201231_g2.jpg" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen (AMGN)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$92.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$113.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$166.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$162.76</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amex Biotech (BTK)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.85</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$111.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$111.72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$134.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$152.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amex Pharmaceutical (DRG)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$91.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$106.90</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$114.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$135.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$147.86</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 (SPX)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$111.95</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$136.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$171.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$203.12</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material in this performance graph is not soliciting material, is not deemed filed with the SEC and is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made on, before or after the date of this filing and irrespective of any general incorporation language in such filing.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months and year ended December 31, 2020, we had one outstanding stock repurchase program, under which the repurchasing activity was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>number of<br/>shares<br/>purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">price&#160;paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;number<br/>of&#160;shares<br/>purchased as<br/>part&#160;of<br/>publicly<br/>announced<br/>program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum dollar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">value that may</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">yet be purchased</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">under the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,230,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400,688,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,579,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1 - December&#160;31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,190,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,190,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:15pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Average price paid per share includes related expenses.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">In December 2019, our Board of Directors increased the amount authorized under the stock repurchase program by an additional $4.0 billion.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2020 and 2019, we paid quarterly dividends. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to approval by our Board of Directors. Additional information required by this item is incorporated herein by reference to Part IV&#8212;Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Authorized for Issuance Under Existing Equity Compensation Plans</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about securities authorized for issuance under existing equity compensation plans is incorporated by reference from Item 12&#8212;Securities Authorized for Issuance Under Existing Equity Compensation Plans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELECTED FINANCIAL DATA</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Consolidated Statements of Income Data:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Consolidated Balance Sheets Data:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2017, we recorded a net charge of $6.1 billion as a result of the 2017 Tax Act.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Part IV&#8212;Note 15, Financing arrangements, to the Consolidated Financial Statements, for discussion of our financing arrangements in 2020, 2019 and 2018. In 2017, we issued $4.5 billion of debt and repaid $4.4 billion of debt. In 2016, we issued $7.3 billion of debt and repaid $3.7 billion of debt. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Throughout the five years ended December 31, 2020, we had a stock repurchase program authorized by the Board of Directors, through which we repurchased $3.5 billion, $7.6 billion, $17.9 billion, $3.1 billion and $3.0 billion, respectively, of Amgen common stock.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above notes, see Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, Part IV&#8212;Consolidated Financial Statements and accompanying notes as well as previously filed Annual Reports on Form 10-K for further information regarding our consolidated results of operations and financial position for periods reported therein and for known factors that will affect the comparability of future results. Also see Part IV&#8212;Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements, for information regarding cash dividends declared per share of common stock for each of the four quarters of 2020, 2019 and 2018. In addition, our Board of Directors declared dividends per share of $1.15 and $1.00, which were paid in each of the four quarters of 2017 and 2016, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following management&#8217;s discussion and analysis (MD&amp;A) is intended to assist the reader in understanding Amgen&#8217;s business. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and accompanying notes. Our results of operations discussed in MD&amp;A are presented in conformity with U.S. generally accepted accounting principles (GAAP). Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;assume&#8221; and &#8220;continue&#8221; as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Part I, Item 1A. Risk Factors. We have based our forward-looking statements on our management&#8217;s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, earnings per share (EPS), liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. In 2020, we celebrated our 40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> anniversary, continuing our history of focusing on innovative medicines that have the potential to be first-in-class molecules and that have a large-effect size on serious diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal products&#8212;those with the most significant annual commercial sales&#8212;are ENBREL, Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also market a number of other products, including Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Corlanor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For additional information about our products, see Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy includes integrated activities intended to maintain and strengthen our competitive position in the industry. We focus on six commercial areas: inflammation, oncology/hematology, bone health, CV disease, nephrology and neuroscience, and we conduct discovery research primarily in three therapeutic areas: inflammation, oncology/hematology and CV/metabolic diseases. In 2020, we advanced our innovative pipeline, successfully integrated Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, acquired in November 2019, into our inflammation portfolio, advanced our international expansion and continued to provide uninterrupted supply of our medicines globally through the COVID-19 pandemic. We accomplished these objectives while maintaining a strategic and disciplined approach to capital allocation, and advancing our environmental, social and governance efforts. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year, while meeting the challenges of a global pandemic and facing increased competition from biosimilars and generics, total product sales increased 9%, driven by volume growth primarily from Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower net selling prices. Product sales increased 9% and 10% in the United States and rest of the world, respectively. Total operating expenses increased 19%, driven by expenses related to Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to advance our pipeline, including sotorasib and tezepelumab&#8212;two molecules with respect to which we have achieved positive registration enabling data from our clinical trial activities. We also continued to advance our biosimilar program with the launch of AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the approval of RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Our biosimilars are expected to launch in new markets throughout 2021. Lastly, we broadened our international reach, particularly in the Asia Pacific region with our investment in and strategic collaboration with BeiGene to expand our oncology presence in China, as well as the establishment of our wholly owned affiliate in Japan.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities totaled $10.5 billion, enabling us to invest in our business while returning capital to shareholders through the payment of cash dividends and stock repurchases. For 2020, we increased our quarterly cash dividend by 10% to $1.60 per share of common stock. In December 2020, we declared a cash dividend of $1.76 per share of common stock for the first quarter of 2021, an increase of 10% for this period, to be paid in March 2021. We also repurchased 15.2 million shares of our common stock throughout 2020, at an aggregate cost of $3.5 billion. During the year, we had proceeds from the issuance of debt of $8.9 billion and repayments of debt of $6.5 billion. In addition, we exchanged some of our higher interest rate debt for newly issued debt with a lower interest rate and a later maturity date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s approach to, and investment in, human capital resource management is directed at attracting, motivating and retaining talent to tackle the challenges of running an enterprise focused on the discovery, development, and commercialization of innovative medicines. Our compensation, benefits and development programs are designed to encourage performance, promote accountability and adherence to Company values, and in alignment with the interests of the Company&#8217;s shareholders. Further, we believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. We also believe our global presence is strengthened by having a workforce that reflects the diversity of the patients we serve. It is with these beliefs in mind that we have continued to strengthen and grow our culture of diversity, inclusion and belonging. Our internal efforts include, in 2019, establishing a Diversity, Inclusion and Belonging Council. We are engaging in activities and setting goals to improve our focus on diversity, inclusion and belonging. For further information on these and other efforts, see Part I, Item 1. Business&#8212;Human Capital Resources.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-standing ambition to be environmentally responsible, and we regularly set targets to challenge ourselves to deliver further improvements. In 2020, we met or exceeded our environmental sustainability targets set out in 2013 that called for reducing fleet carbon output by up to 20%, facility carbon output by 10%, water consumption by 10% and waste disposal by 35%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We achieved our 2020 targets while growing revenues, increasing production capacity, and expanding to more than 100 countries over the same 2013 to 2020 period. To continue on our path to greater environmental sustainability, in January 2021 we announced a new set of long-term environmental targets to achieve by 2027, including achieving carbon neutrality, reducing water consumption by 40% and reducing waste disposed by 75%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends to a great extent on our ability to continue to discover, develop and commercialize innovative products and acquire or collaborate on therapies currently in development by other companies. We must develop new products to achieve revenue growth and to offset revenue losses when products lose their exclusivity or when competing products are launched. Certain of our products face increasing pressure from competition, including biosimilars and generics. For additional information, including information on the expirations of patents for various products, see Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Patents, and Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. We devote considerable resources to R&amp;D activities, but successful product development in the biotechnology industry is highly uncertain. We also face increasing regulatory scrutiny of safety and efficacy both before and after products launch.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rising healthcare costs and uncertain economic conditions continue to pose challenges to our business, including increasing pressure by third-party payers, such as governments and private payers, to reduce healthcare expenditures. As a result of public and private healthcare-provider focus, the industry continues to experience significant pricing pressures and other cost containment measures. Finally, wholesale and end-user buying patterns can affect our product sales. These effects can cause fluctuations in quarterly product sales and have generally not been significant when comparing full-year product performance to the prior year. See Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products and Part I, Item 1A. Risk Factors for further discussion of certain factors that could impact our future product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had a moderate impact to our business in 2020. Since the onset of the pandemic in early 2020, we have been carefully monitoring its impact on our global operations. We have taken appropriate steps to minimize the risk to our employees. A significant number of our employees have been working remotely, with the exception of certain staff that require access to our manufacturing and laboratory research facilities, in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions or shortages of our supply of medicines.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the COVID-19 pandemic, we have seen changes in demand trends for some of our products, including lower demand for certain products as continuing patient access to those products has been affected by COVID-19, particularly in the early phases of the pandemic. For example, near the end of March, we began to observe a decline in sales of Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as elderly patients, who are relatively more vulnerable to COVID-19, avoided doctors&#8217; offices. Demand has since recovered to varying degrees by product as local conditions improved in certain geographies that opened after an initial improvement in COVID-19 infection rates, allowing patients to resume receiving their treatments. During the second half of the year, our own efforts remain focused on assisting patients with improving their continuity of care to increase product access as compared to what they experienced during the earlier stages of the pandemic. Recently, higher rates of infection have been observed in certain geographies, including the United States and Europe, which may further restrict demand, similar to early phases of the pandemic. As a result, we expect to see continued volatility through at least the duration of the pandemic as governments respond to current local conditions.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents reductions against established baselines, taking into account only verified reduction projects, and does not take into account changes associated with contraction or expansion of the company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of clinical trials that were paused at the onset of the pandemic to ensure subject safety or data integrity have resumed. Study enrollment was affected negatively the most in the second quarter of the year and by the end of 2020 resumed to around pre-pandemic levels. However, going forward COVID-19 infection rates and related vaccination activities may impact future study enrollment. We continuously monitor our ability for study enrollment on an institution by institution basis and reevaluate the status of studies, pausing when uncertainty arises with regard to the trial sites&#8217; ability to ensure safety or data integrity. We remain focused on supporting our active clinical sites in providing care for these patients and in providing investigational drug supply. In addition, our R&amp;D organization is supporting efforts to combat the COVID-19 pandemic in a number of ways, including by (i) working to support production of therapeutic antibodies that could diminish the impact of COVID-19 on patients, (ii) joining a public&#8211;private partnership between leading companies in our industry and U.S. government health agencies to develop a strategy for a coordinated research response and (iii) participating in platform studies to investigate treatments in adult patients hospitalized with severe COVID-19 infections.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in the capital-return and other business initiatives that we plan to strategically pursue. For a discussion of the risks presented by the COVID-19 pandemic to our results, see Part I, Item 1A. Risk Factors of this Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_79"></div><div style="margin-bottom:8pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Financial Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an overview of our results of operations (in millions, except percentages and per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest-of-world (ROW)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,362&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased for 2020, primarily driven by unit demand increases from newer brands including Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, acquired in November 2019, MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These unit demand increases were partially offset by declines in net selling prices for certain products, unit demand declines for mature brands that face biosimilar or generic competition and the effects of the COVID-19 pandemic. For 2021, we expect that net selling prices will continue to decline. We also expect increasing competition against our biosimilar products.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Further, the first quarter historically represents the lowest product sales quarter for the year, in part, due to plan changes, insurance reverifications and higher co-pay expenses as U.S. patients work through deductibles, particularly for our pharmacy benefit products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the initial stages of the COVID-19 pandemic, we experienced changes in demand trends for some of our products. The pandemic interrupted many physician&#8211;patient interactions, which led to delays in diagnosis and treatment, with varying degrees of impact across our portfolio. In general, sales of negatively affected products fell the most in the early part of the second quarter, with product demand beginning to show some recovery in the second half of the year but still below pre-pandemic levels. Nevertheless, given the increased intensity exiting 2020 and the unpredictable nature of the pandemic, we expect there could be intermittent disruptions in physician&#8211;patient interactions going forward, and thus we continue to expect quarter-to-quarter variability. See Part I, Item 1A. Risk Factors of this Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other changes in the healthcare ecosystem introduce variability into product sales trends. For example, changes in U.S. employment could lead to changes to the insured population, with growth in Medicaid enrollees and uninsured individuals having a negative impact on revenues. Overall, uncertainty has increased around the timing and magnitude of our sales during the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues increased for 2020, primarily driven by higher royalties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses increased for 2020, primarily driven by acquisition- and commercial-related expenses for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is partially offset by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Our hedging activities seek to offset the impacts, both positive and negative, that foreign currency exchange rate changes may have on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material in 2020, 2019 or 2018.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_82"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide product sales were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S.</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products&#8217; significant competitors, see Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total ENBREL sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL&#160;&#8212;&#160;Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ENBREL</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in ENBREL sales for 2020 was driven by lower unit demand and net selling price, partially offset by favorable changes to estimated sales deductions and inventory. Consistent with prior periods, ENBREL has continued to lose market share, and this decline has been compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. For 2021, we expect ENBREL to follow the historic pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increase co-pay expenses as U.S. patients work through deductibles. In addition, for 2021, we expect volume and net selling price declines to continue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in ENBREL sales for 2019 was primarily driven by favorable changes to estimated sales deductions and an increase in net selling price, partially offset by lower unit demand.</span></div><div style="margin-bottom:7.7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the FDA approved a second biosimilar version of ENBREL, and we are involved in patent litigations with the two companies seeking to market their FDA-approved biosimilar versions of ENBREL. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. Companies with approved biosimilar versions of ENBREL may seek to enter the U.S. market if we are not successful in our litigations, or even earlier. Other companies are also developing proposed biosimilar versions of ENBREL.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions in patient visits as a result of the COVID-19 pandemic affected demand during 2020 by altering the timing of patients receiving their semiannual doses and by lowering the diagnosis of osteoporosis in new patients. This deceleration of demand has softened the historical growth rates and altered demand patterns of Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experienced in years prior to the pandemic. For 2021, historical demand patterns may continue to be impacted by the pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2020 was driven by higher unit demand and net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for 2019 was driven by higher unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in global Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2020 and 2019 were driven by the impact of biosimilar competition on net selling price and unit demand. Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales included a $98 million order from the U.S. government in the first quarter of 2019.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have increased competition in the United States and Europe as a result of biosimilar versions of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which has had and will continue to have a material adverse impact on sales. We also expect other biosimilar versions to be approved in the future. For a discussion of ongoing patent litigations related to these and other biosimilars, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#8212;&#160;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#8212;&#160;&#160;ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was acquired on November 21, 2019, and generated $2.2 billion and $178 million in global sales for the years ended December 31, 2020 and 2019, respectively. For 2021, we expect Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to follow the historic pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increase co-pay expenses as U.S. patients work through deductibles. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for 2020 was driven by lower unit demand as a result of the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2019 was primarily driven by higher unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for 2020 was driven by declines in net selling price and unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for 2019 was primarily driven by the impact of competition on unit demand in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> faces competition from a long-acting ESA. Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also faces competition from a biosimilar version of EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For 2021, we expect that sales will continue to decline due to short- and long-acting competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for 2020 was primarily driven by an increase in net selling price and favorable changes in inventory, partially offset by lower unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2019 was primarily driven by higher unit demand. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in litigation with two companies that are challenging certain of our patents related to KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that are seeking to market generic carfilzomib products.&#160;Separately, we have entered into confidential settlement agreements with other companies developing generic carfilzomib products, and the court has entered consent judgments enjoining those companies from infringing certain of our patents, subject to terms of the confidential settlement agreements.&#160;See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. The FDA reported that it has granted tentative or final approval to Abbreviated New Drug Applications (ANDAs) for generic carfilzomib products filed by a number of companies for generic carfilzomib products. The date of approval of those ANDAs for generic carfilzomib products is governed by the Hatch-Waxman Act and any applicable settlement agreements between the parties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in global Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for 2020 and 2019 were driven by higher unit demand, partially offset by lower net selling price. The decrease to the Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net selling price in 2020 was the result of contracting changes to improve Medicare Part D patient access.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; U.S.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8212; ROW</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other &#8212; ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. &#8212; other products</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,511&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW &#8212; other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased to 24.2% of total revenues for 2020, primarily driven by the amortization of expenses related to our acquisition of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and higher royalty expenses and profit share, partially offset by lower manufacturing costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased to 18.6% of total revenues for 2019, primarily driven by unfavorable product mix and amortization of intangible assets as a result of our acquisition of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower royalties and lower manufacturing costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups all of its R&amp;D activities and related expenditures into three categories: (i)&#160;research and early pipeline, (ii)&#160;later-stage clinical programs and (iii)&#160;marketed products. These categories are described below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and early pipeline </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism, and process development</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later-stage clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in support of the Company&#8217;s marketed products that are authorized to be sold primarily in the United States or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regulatory approval of a product in a new market after approval in either the United States or the EU has been obtained</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense by category was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and early pipeline</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later-stage clinical programs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&amp;D expense for 2020 was driven by higher spend for later-stage clinical programs, including sotorasib, biosimilar programs and Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and higher spend for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in marketed-product support. These increases were partially offset by recoveries from our collaboration with BeiGene that reduced expenses in later-stage clinical programs and in research and early pipeline, and lower spend in certain oncology programs included in research and early pipeline.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&amp;D expense for 2019 was primarily driven by higher spend in research and early pipeline in support of our oncology programs, partially offset by lower marketed-product support.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Selling, general and administrative (SG&amp;A) expense for 2020 was driven by investments in certain marketed products, primarily Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and preparation for product launches, partially offset by a reduction in conference-related expenses due to the impact of COVID-19.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in SG&amp;A expense for 2019 was primarily driven by lower general and administrative expenses, the end of certain amortization charges in 2018 and lower spend for launched and marketed products, partially offset by spending for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> commercial-related expenses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2020 primarily consisted of legal settlement expenses.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2019 included $47 million in restructuring costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2018 included a $330 million impairment charge associated with an IPR&amp;D asset and a $42 million favorable net change in the fair values of contingent consideration liabilities. See Part IV&#8212;Note 17, Fair value measurement, to the Consolidated Financial Statements.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_88"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonoperating expenses/income and income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Interest expense, net, for 2020 was primarily due to lower LIBOR rates on debt for which we effectively pay a variable rate of interest, partially offset by net costs associated with the early retirement of debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Interest expense, net, for 2019 was primarily due to a reduction in outstanding long-term debt as a result of maturities in 2019.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Interest and other income, net, for 2020 was primarily due to reduced interest income as a result of lower average cash balances and a decline in interest yields and losses incurred in connection with our BeiGene investment, partially offset by gains recognized on our investments in publicly traded equity securities and limited partnerships. We may continue to recognize losses in connection with our BeiGene investment in 2021. See Part IV&#8212;Note 9, Investments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Interest and other income, net, for 2019 was primarily due to net gains on sales of investments in interest-bearing securities liquidated to fund our acquisition of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our investment in BeiGene compared with losses in the prior year, partially offset by reduced interest income as a result of lower average cash balances and a gain recognized in connection with our acquisition of Kirin-Amgen, Inc. (K-A), in the first quarter of 2018. See Part IV&#8212;Note 2, Acquisitions, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for 2020 compared with 2019 was primarily driven by favorable items, including audit settlements, adjustments to prior year tax liabilities, lower interest expense on uncertain tax positions and amortization related to the Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acquisition, partially offset by changes in valuation allowance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our effective tax rate for 2019 compared with 2018 was primarily driven by a prior-year tax benefit associated with intercompany sales under U.S. corporate tax reform.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021, were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. We do not expect any significant benefit to our income tax provision as a result of this legislation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primar</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and have been pursuing resolution with the IRS administrative appeals office. However, we have been unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a Notice of Deficiency which we would expect to vigorously contest through the judicial process. In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office. The IRS audit for years 2016, 2017 and 2018 is expected to start in the near term. We are also currently under examination by a number of other state and foreign tax jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Summary of Critical Accounting Policies&#8212;Income taxes, and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_94"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial data was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have global access to our $10.6 billion balance of cash, cash equivalents and marketable securities. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital allocation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), repayment of debt, payment of dividends and stock repurchases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to invest in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and periodic determinations by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company&#8217;s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include private block purchases, tender offers and market transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors declared quarterly cash dividends of $1.60, $1.45 and $1.32 per share of common stock paid in 2020, 2019 and 2018, respectively, an increase of 10% over the prior year in both 2020 and 2019. In December 2020, the Board of Directors declared a cash dividend of $1.76 per share of common stock for the first quarter of 2021, an increase of 10% for this period, to be paid in March 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also returned capital to stockholders through our stock repurchase program. During 2020, we repurchased $3.5 billion of common stock and had cash settlements of $3.5 billion. In 2019, we repurchased $7.6 billion of common stock and had cash settlements of $7.7 billion. In 2018, we repurchased $17.9 billion of common stock and had cash settlements of $17.8 billion, which included 52.1 million shares of common stock repurchased through a $10.0 billion tender offer. In May 2019 and December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $5.0 billion and $4.0 billion, respectively. As of December 31, 2020, $3.0 billion remained available under the stock repurchase program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of December 31, 2020 and 2019. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our expected continued profitability and strong financial position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, our plans to pay dividends and repurchase stock and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current and noncurrent portions of our long-term borrowings as of December 31, 2020, were $0.1 billion and $32.9 billion, respectively. The current and noncurrent portions of our long-term borrowings as of December 31, 2019, were $3.0 billion and $27.0 billion, respectively. The carrying values of our long-term borrowings are net of fair value adjustments for interest rate swaps and unamortized discounts, premiums and offering costs. As of December 31, 2020, Standard &amp; Poor&#8217;s Financial Services LLC (S&amp;P), Moody&#8217;s Investors Service, Inc. (Moody&#8217;s) and Fitch Ratings, Inc. (Fitch), assigned credit ratings to our outstanding senior notes of A&#8211; with a stable outlook, Baa1 with a stable outlook and BBB+ with a stable outlook, respectively, which are considered investment grade. Unfavorable changes to these ratings may have an adverse impact on future financings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we issued debt with an aggregate principal amount of $9.0 billion. During 2019 and 2018, we did not issue any debt or debt securities. During 2020, 2019 and 2018, we repaid debt of $6.5&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.5 billion and $1.1 billion, respectively. In addition, during 2020, we exchanged $0.7 billion of certain of our outstanding note issuances with $0.9 billion of newly issued notes with a lower interest rate and later maturity date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted a fixed-rate interest coupon for certain of our debt issuances to a floating LIBOR-based coupon over the lives of the respective notes. These interest rate swap contracts qualify and are designated as fair value hedges. As of December 31, 2020 and 2019, we had interest rate swap contracts with aggregate notional amounts of $5.9 billion and $9.6 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts, which effectively convert the interest payments and principal repayment of the respective notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts qualify and are designated as cash flow hedges. As of both December 31, 2020 and 2019, we had cross-currency swap contracts with aggregate notional amounts of $4.8 billion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. During 2020, 2019 and 2018, we did not issue any commercial paper. No commercial paper was outstanding as of December 31, 2020 and 2019.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions related to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2020 and 2019, no amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is anticipated that LIBOR will be phased out and replaced by 2023. While various replacement reference rates have been discussed, an alternative reference rate to LIBOR has not yet been widely adopted. Therefore, the mechanics to modify existing contracts that reference LIBOR have not been finalized. We are currently evaluating the impact that the change in the reference rate will have on our financial condition. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This shelf registration statement expires in February 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2020. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 15, Financing arrangements, and Note 18, Derivative instruments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our summarized cash flow activity was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities increased during 2020 primarily due to higher Net income after adding back the noncash amortization related to the acquisition of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the monetization of interest rate swap contracts and working capital adjustments. Cash provided by operating activities decreased during 2019 primarily due to changes in working capital, an increase in payments to the IRS related to an advance deposit and lower Net income.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during 2020 was primarily due to our $3.2 billion of purchases of equity method investments, primarily BeiGene, and net cash outflows related to marketable securities of $1.5 billion. Cash provided by investing activities during 2019 and 2018 was primarily due to net cash inflows related to marketable securities of $20.0 billion and $15.0 billion, respectively. The liquidation of portions of our marketable securities portfolio in 2019 was primarily the result of funding the acquisition of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our investment in BeiGene and, in 2018, to fund our tender offer to repurchase our common stock. Capital expenditures were $608 million, $618 million and $738 million in 2020, 2019 and 2018, respectively. We currently estimate 2021 spending on capital projects to be approximately $900 million. A majority of the increase in expenditures relates to expansion of manufacturing capacity to enable supply of products and product candidates.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during 2020 was primarily due to repayments of debt of $6.5 billion, the payment of dividends of $3.8 billion and payments to repurchase our common stock of $3.5 billion, partially offset by proceeds from issuance of debt of $8.9 billion. Cash used in financing activities during 2019 was primarily due to repurchases of our common stock of $7.7 billion, repayments of debt of $4.5 billion and payments of dividends of $3.5 billion. Cash used in financing activities during 2018 was primarily due to repurchases of common stock of $17.8 billion, payments of dividends of $3.5 billion and repayments of debt of $1.1 billion. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 9, Investments, Note 15, Financing arrangements, and Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_97"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements that are material or reasonably likely to become material to our consolidated financial position or consolidated results of operations.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_100"></div><div style="margin-bottom:8pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude contingent liabilities for which we cannot reasonably predict future payment. Additionally, the expected timing of payment of the obligations presented below is estimated based on current information. Timing of payments and actual amounts paid may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our contractual obligations aggregated by type (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due by period as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years 2 and 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years 4 and 5</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years 6<br/>&#160;and&#160;beyond</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. repatriation tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (UTBs)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,187&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Long-term debt obligations includes future interest payments on our fixed-rate obligations at the contractual coupon rates. To achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that effectively convert a fixed-rate interest coupon for certain of our debt issuances to a floating LIBOR-based coupon over the terms of the related hedge contracts. We used an interest rate forward curve as of December 31, 2020, in computing net amounts to be paid or received under our interest rate swap contracts, which resulted in an aggregate net decrease in future interest payments of $67 million. See Part IV&#8212;Note 15, Financing arrangements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Long-term debt obligations includes contractual interest payments and principal repayments of our foreign-denominated debt obligations. In order to hedge our exposure to foreign currency exchange rate risk associated with our euro-, pound-sterling- and Swiss-franc-denominated long-term debt, we entered into cross-currency swap contracts that effectively converted interest payments and principal repayments on this debt from euros, pounds sterling and Swiss francs to U.S. dollars. For purposes of this table, we used the contracted exchange rates in the cross-currency swap contracts to compute the net amounts of future interest payments and principal repayments on this debt. See Part IV&#8212;Note 18, Derivative instruments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Operating lease obligations includes payments for leases that have not yet commenced, net of lease incentives, and excludes $107 million of future receipts under noncancelable subleases of abandoned facilities.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Purchase obligations relates primarily to (i)&#160;R&amp;D commitments (including those related to clinical trials) for new and existing products, (ii)&#160;capital expenditures and (iii)&#160;open purchase orders for the acquisition of goods and services in the ordinary course of business. Our obligation to pay certain of these amounts may be reduced based on certain future events.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to our prior indefinitely invested earnings of our foreign operations. See Part IV&#8212;Note 19, Contingencies and commitments&#8212;Commitments&#8211;U.S. repatriation tax, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Liabilities for UTBs are not included in the table above because due to their nature there is a high degree of uncertainty regarding the timing of future cash outflows and other events that extinguish these liabilities. See Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to amounts in the table above, we are contractually obligated to pay additional amounts that in the aggregate are significant, upon the achievement of various development, regulatory and commercial milestones for agreements we have entered into with third parties, including contingent consideration incurred in the acquisitions of K-A and BioVex Group Inc. (BioVex). These payments are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring. These contingent payments have not been included in the table above, and except with respect to the fair value of the contingent consideration obligations, are not recorded on our Consolidated Balance Sheets. As of December 31, 2020, the maximum amount that may be payable in the future for agreements we have entered into with third parties is $5.4 billion, including $250 million of contingent consideration payments in connection with the acquisition of BioVex.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Critical Accounting Policies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate. Accruals are also adjusted to reflect actual results. Amounts recorded in Accrued liabilities in the Consolidated Balance Sheets for sales deductions were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2020, 2019 and 2018, total sales deductions were 44%, 41% and 39% of gross product sales, respectively. The increase in the total sales deductions balance as of December 31, 2020, compared to December 31, 2019, was primarily driven by the increase in gross sales and the impact of higher U.S. commercial rebate rates. Included in the amounts are immaterial net adjustments related to prior-year sales due to changes in estimates. Such amounts represent less than 1% of the aggregate sales deductions charged against product sales in the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we utilize wholesalers as the principal means of distributing our products to healthcare providers such as physicians or their clinics, dialysis centers, hospitals and pharmacies. Products we sell in Europe are distributed principally to hospitals and/or wholesalers depending on the distribution practice in each country where the products are sold. We monitor the inventory levels of our products at our wholesalers by using data from our wholesalers and other third parties, and we believe wholesaler inventories have been maintained at appropriate levels (generally two to three weeks) given end-user demand. Accordingly, historical fluctuations in wholesaler inventory levels have not significantly affected our method of estimating sales deductions and returns.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given year, can be affected by the mix of products sold.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates include primarily amounts paid to payers and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements that vary by product, by payer and by individual payer plans. As we sell products, we estimate the amount of rebate we will pay based on the product sold, contractual terms, estimated patient population, historical experience and wholesaler inventory levels; and we accrue these rebates in the period the related sales are recorded. We then adjust the rebate accruals as more information becomes available and to reflect actual claims experience. Estimating such rebates is complicated, in part because of the time delay between the date of sale and the actual settlement of the liability. We believe the methodology we use to accrue for rebates is reasonable and appropriate given current facts and circumstances, but actual results may differ. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wholesaler chargebacks relate to our contractual agreements to sell products to healthcare providers in the United States at fixed prices that are lower than the prices we charge wholesalers. When healthcare providers purchase our products through wholesalers at these reduced prices, wholesalers charge us for the difference between their purchase prices and the contractual prices between Amgen and the healthcare providers. The provision for chargebacks is based on the expected sales by our wholesaler customers to healthcare providers. Accruals for wholesaler chargebacks are less difficult to estimate than rebates are, and they closely approximate actual results because chargeback amounts are fixed at the date of purchase by the healthcare providers and because we generally settle the liability for these deductions within a few weeks.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated by comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. In each of the past three years, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-year sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is measured based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We believe our estimates for uncertain tax positions are appropriate and sufficient for any assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are included in our tax return at different times than they are reflected in the financial statements, and they cause temporary differences between the tax bases of assets and liabilities and their reported amounts. Such temporary differences create deferred tax assets and liabilities. Deferred tax assets are generally items that can be used as a tax deduction or credit in the tax return in future years but for which we have already recorded the tax benefit in the consolidated financial statements. We establish valuation allowances against our deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities are either (i)&#160;tax expenses recognized in the consolidated financial statements for which payment has been deferred, (ii)&#160;expenses for which we have already taken a deduction on the tax return but have not yet recognized in the consolidated financial statements or (iii) liabilities for the difference between the book basis and tax basis of the intangible assets acquired in many business combinations, as future expenses associated with these assets most often will not be tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a vertically integrated enterprise with operations in the United States and various foreign jurisdictions. We are subject to income tax in the jurisdictions where we conduct operations based on the tax laws and principles of such jurisdictions and the functions, risks and activities performed therein. Our pretax income is therefore attributed to domestic or foreign sources based on the operations performed and risks assumed in each location and the tax laws and principles of the respective taxing jurisdictions. For example, we conduct significant operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes, pertaining to manufacturing, distribution and other related functions to meet our worldwide product demand. Income from our operations in Puerto Rico is subject to tax incentive grants through 2035.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in 2017 we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and have been pursuing resolution with the IRS administrative appeals office. However, we have been unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a Notice of Deficiency which we would expect to vigorously contest through the judicial process. In addition, in 2020 we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appeals office. The IRS audit for years 2016, 2017 and 2018 is expected to start in the near term. We are also currently under examination by a number of other state and foreign tax jurisdictions. Final resolution of these complex matters is not li</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">kely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. See Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to the tax laws, regulations and administrative practices of the United States, the U.S. territory of Puerto Rico, U.S. state jurisdictions and other countries in which we do business. Significant changes in these rules could have a material adverse effect on our results of operations. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters such as intellectual property disputes, contractual disputes and class action suits that are complex in nature and have outcomes that are difficult to predict. We describe our legal proceedings and other matters that are significant or that we believe could become significant in Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of assets and liabilities in connection with acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired and continue to acquire intangible assets in connection with business combinations and asset acquisitions. These intangible assets consist primarily of technology associated with currently marketed human therapeutic products and IPR&amp;D product candidates. Discounted cash flow models are typically used to determine the fair values of these intangible assets for purposes of allocating consideration paid to the net assets acquired in an acquisition. See Part IV&#8212;Note 2, Acquisitions, to the Consolidated Financial Statements. These models require the use of significant estimates and assumptions, including but not limited to:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">determining the timing and expected costs to complete in-process projects, taking into account the stage of completion at the acquisition date;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">projecting the probability and timing of obtaining marketing approval from the FDA and other regulatory agencies for product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">estimating the timing of and future net cash flows from product sales resulting from completed products and in-process projects; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing appropriate discount rates to calculate the present values of the cash flows. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the fair values used to record intangible assets acquired in connection with business combinations and asset acquisitions are based on reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of our property, plant and equipment and our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such circumstances exist, an estimate of undiscounted future cash flows to be generated by the long-lived asset is compared to the carrying value to determine whether an impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our estimations of future cash flows used for assessing impairment of long-lived assets are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of our equity method investments whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time and the extent to which the fair value is below the carrying value, volatility of the security price, the financial condition of the issuer, changes in technology that may impair the earnings potential of the investment and our intent and ability to retain the investment to allow for a recovery in fair value. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our judgments used in assessing impairment of equity method investments are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_106"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 1, Summary of significant accounting policies, to the Consolidated Financial Statements for a discussion of recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of December 31, 2020.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_109"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in interest rates, foreign currency exchange rates and prices of equity instruments as well as changes in general economic conditions in the countries where we conduct business. To reduce certain of these risks, we enter into various types of foreign currency and interest rate derivative hedging transactions as part of our risk management program. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we have assumed a hypothetical change in interest rates of 100 basis points from those as of December 31, 2020 and 2019. Except as noted below, we have also assumed a hypothetical 20% change in foreign currency exchange rates against the U.S. dollar based on its position relative to other currencies as of December 31, 2020 and 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-rate-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of available-for-sale investments as of December 31, 2020 and 2019, was composed of U.S. Treasury securities and money market mutual funds, and with respect to investments as of December 31, 2019, corporate debt securities and other short-term interest-bearing securities. The fair values of our available-for-sale investments were $9.8 billion and $8.2 billion as of December 31, 2020 and 2019, respectively. Duration is a sensitivity measure that can be used to approximate the change in the value of a security that will result from a 100 basis point change in interest rates. Applying a duration model, a hypothetical 100 basis point increase in interest rates as of December 31, 2020 and 2019, would not have resulted in a material reduction in the fair values of these securities. In addition, a hypothetical 100 basis point decrease in interest rates as of December 31, 2020 and 2019, would not result in a material effect on income in the respective ensuing year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had outstanding debt with a carrying value of $33.0 billion and a fair value of $39.4 billion. As of December 31, 2019, we had outstanding debt with a carrying value of $29.9 billion and a fair value of $33.7 billion. Our outstanding debt was composed almost entirely of debt with fixed interest rates. Changes in interest rates do not affect interest expense on fixed-rate debt. Changes in interest rates would, however, affect the fair values of fixed-rate debt. A hypothetical 100 basis point decrease in interest rates relative to interest rates as of December 31, 2020 and 2019, would have resulted in increases of $4.5 billion and $3.0 billion, respectively, in the aggregate fair value of our outstanding debt on each of these dates. Analysis of the debt does not consider the impact that hypothetical changes in interest rates would have on the related interest rate swap contracts and cross-currency swap contracts, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified and were designated for accounting purposes as fair value hedges for certain of our fixed-rate debt. These interest rate swap contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective notes. Interest rate swap contracts with aggregate notional amounts of $5.9 billion and $9.6 billion were outstanding as of December 31, 2020 and 2019, respectively. A hypothetical 100 basis point increase in interest rates relative to interest rates as of December 31, 2020 and 2019, would have resulted in reductions in fair values of approximately $230 million and $380 million, respectively, on our interest rate swap contracts on these dates. Analysis of the interest rate swap contracts does not consider the impact that hypothetical changes in interest rates would have on the related fair values of debt that these interest-rate-sensitive instruments were designed to offset. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, we had outstanding cross-currency swap contracts with aggregate notional amounts of $4.8 billion that hedge our foreign-currency-denominated debt and related interest payments. These contracts effectively convert interest payments and principal repayment of this debt to U.S. dollars from euros, pounds sterling and Swiss francs and are designated for accounting purposes as cash flow hedges. A hypothetical 100 basis point adverse movement in interest rates relative to interest rates as of December 31, 2020 and 2019, would have resulted in reductions in the fair values of our cross-currency swap contracts of approximately $250 million and $280 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign-currency-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations are affected by fluctuations in the value of the U.S. dollar as compared to foreign currencies, predominantly the euro. Increases and decreases in our international product sales from movements in foreign currency exchange rates are partially offset by the corresponding increases or decreases in our international operating expenses. Increases and decreases in our foreign-currency-denominated assets from movements in foreign currency exchange rates are partially offset by the corresponding increases or decreases in our foreign-currency-denominated liabilities. To further reduce our net exposure to foreign currency exchange rate fluctuations on our results of operations, we enter into foreign currency forward, option and cross-currency swap contracts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had outstanding euro-, pound-sterling- and Swiss-franc-denominated debt with a principal carrying value and a fair value of $4.8 billion and $5.4 billion, respectively. As of December 31, 2019, we had outstanding euro-, pound-sterling- and Swiss-franc-denominated debt with a principal carrying value and a fair value of $4.5 billion and $5.0 billion, respectively. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2020, would have resulted in an increase in fair value of this debt of $1.1 billion on this date and a reduction in income in the ensuing year of $1.0 billion. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2019, would have resulted in an increase in fair value of this debt of $1.0 billion on this date and a reduction in income in the ensuing year of $900 million. The impact on income from these hypothetical changes in foreign currency exchange rates would be substantially offset by the impact such changes would have on related cross-currency swap contracts, which are in place for the related foreign-currency-denominated debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have cross-currency swap contracts that are designated as cash flow hedges of our debt denominated in euros, pounds sterling and Swiss francs with aggregate notional amounts of $4.8 billion as of both December 31, 2020 and 2019. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates on these dates would have resulted in reductions in the fair values of these contracts of $1.1 billion and $1.0 billion on these dates, respectively. The impact of this hypothetical adverse movement in foreign currency exchange rates on ensuing years&#8217; income from these contracts would be fully offset by the corresponding hypothetical changes in the carrying amounts of the related hedged debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward and options contracts that are designated for accounting purposes as cash flow hedges of certain anticipated foreign currency transactions. As of December 31, 2020, the fair values of these contracts were a $28 million asset and a $237 million liability. As of December 31, 2019, the fair values of these contracts were a $223 million asset and a $31 million liability. As of December 31, 2020, we had primarily euro based open foreign currency forward contracts with notional amounts of $5.1 billion. As of December 31, 2019, we had primarily euro based open foreign currency forward contracts with notional amounts of $5.0 billion. With regard to foreign currency forward and option contracts that were open as of December 31, 2020, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2020, would have resulted in a reduction in fair value of these contracts of approximately $1.1 billion on this date and in the ensuing year, a reduction in income of approximately $420 million. With regard to contracts that were open as of December 31, 2019, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2019, would have resulted in a reduction in fair value of these contracts of $930 million on this date and in the ensuing year, a reduction in income of $400 million. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign-currency-sensitive instruments were designed to offset.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, we had open short-duration foreign currency forward contracts that mature in less than one month, with notional amounts of $1.0 billion and $1.2 billion, respectively, that hedged fluctuations of certain assets and liabilities denominated in foreign currencies but were not designated as hedges for accounting purposes. These contracts had no material net unrealized gains or losses as of December 31, 2020 and 2019. With regard to these foreign currency forward contracts that were open as of December 31, 2020 and 2019, a hypothetical 5% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates on these dates would not have a material effect on the fair values of these contracts or related income in the respective ensuing years. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on assets and liabilities that these foreign-currency-sensitive instruments were designed to offset.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-price-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, we were exposed to price risk on equity securities included in our portfolio of investments, which were acquired primarily for the promotion of business and strategic objectives. These investments are generally in small-capitalization stocks in the biotechnology industry. Price risk relative to our equity investment portfolio as of December 31, 2020 and 2019, was not material.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Counterparty credit risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments, including derivatives, are subject to counterparty credit risk, which we consider as part of the overall fair value measurement. Our financial risk management policy limits derivative transactions by requiring that transactions be made only with institutions with minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch; and it places exposure limits on the amount with any individual counterparty. In addition, we have an investment policy that limits investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_112"></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to the financial statements and schedule listed in Item&#160;15(a)1 and (a)2 of Part IV and included in this Annual Report on Form 10-K.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_115"></div><div style="margin-bottom:2pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td></tr></table></div><div style="margin-bottom:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under the Securities Exchange Act Rule&#160;13a-15(e), that are designed to ensure that information required to be disclosed in Amgen&#8217;s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to Amgen&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen&#8217;s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen&#8217;s management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation under the supervision and with the participation of our management, including Amgen&#8217;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen&#8217;s disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2020.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determined that as of December 31, 2020, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_121"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP in the United States. However, all internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on our assessment, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report appearing below, which expresses an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Amgen Inc. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amgen Inc.&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Amgen Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and the financial statement schedule listed in the Index at Item 15(a)2  and our report dated February 8, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:right;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ernst &amp; Young LLP</span></div><div style="text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Los Angeles, California</span></div><div style="text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 8, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.3pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_127"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER INFORMATION</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_130"></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_133"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our Directors is incorporated by reference from the section entitled ITEM&#160;1&#8212;ELECTION OF DIRECTORS in our Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2020 (the Proxy Statement). Information about the procedures by which stockholders may recommend nominees for the Board of Directors is incorporated by reference from APPENDIX A&#8212;AMGEN INC. BOARD OF DIRECTORS GUIDELINES FOR DIRECTOR QUALIFICATIONS AND EVALUATIONS and OTHER MATTERS&#8212;Stockholder Proposals for the 2022 Annual Meeting in our Proxy Statement. Information about our Audit Committee, members of the committee and our Audit Committee financial experts is incorporated by reference from the section entitled CORPORATE GOVERNANCE&#8212;Audit Committee in our Proxy Statement. Information about our executive officers is contained in the discussion entitled Part I&#8212;Item&#160;1. Business&#8212;Information about our Executive Officers.</span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_136"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Code of Ethics for the Chief Executive Officer and Senior Financial Officers applicable to our principal executive officer, principal financial officer, principal accounting officer or controller and other persons performing similar functions. To view this code of ethics free of charge, please visit our website at www.amgen.com. (This website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing.) We intend to satisfy the disclosure requirements under Item&#160;5.05 of Form 8-K regarding an amendment to or a waiver from a provision of this code of ethics, if any, by posting such information on our website as set forth above.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_139"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTIVE COMPENSATION</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about director and executive compensation is incorporated by reference from the section entitled EXECUTIVE COMPENSATION in our Proxy Statement. Information about compensation committee matters is incorporated by reference from the sections entitled CORPORATE GOVERNANCE&#8212;Compensation and Management Development Committee and CORPORATE GOVERNANCE&#8212;Compensation Committee Report in our Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td></tr></table></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_145"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Existing Equity Compensation Plans</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information as of December 31, 2020, concerning the shares of our common stock that may be issued under any form of award granted under our equity compensation plans in effect as of December 31, 2020 (including upon the exercise of options, upon the vesting of awards of restricted stock units (RSUs) or when performance units are earned and related dividend equivalents have been granted).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:54.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price of outstanding options and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity compensation plans approved by Amgen security holders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2009 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,108,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 1991 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,393,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total approved plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,896,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,502,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity compensation plan not approved by Amgen security holders:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Profit Sharing Plan for Employees in Ireland</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total unapproved plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total all plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,896,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,562,249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:12pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. In accordance with this formula, each option or stock appreciation right counts as one share, while each RSU, performance unit or dividend equivalent counts as 1.9 shares. The number under column (a) represents the actual number of shares issuable under our outstanding awards without giving effect to the fungible share-counting formula. The number under column (c) represents the number of shares available for issuance under this plan based on each such available share counting as one share. Commencing with the grants made in April 2012, RSUs and performance units accrue dividend equivalents that are payable in shares only to the extent and when the underlying RSUs vest or underlying performance units have been earned and the related shares are issued to the grantee. The performance units granted under this plan are earned based on the accomplishment of specified performance goals at the end of their respective three-year performance periods; the number of performance units granted represent target performance, and the maximum number of units that could be earned based on our performance is 200% of the performance units granted in 2018, 2019 and 2020. </span></div><div style="margin-bottom:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the number of outstanding awards under column (a) includes (i) 4,721,305 shares issuable upon the exercise of outstanding options with a weighted-average exercise price of $179.92; (ii) 3,256,390 shares issuable upon the vesting of outstanding RSUs (including 199,676 related dividend equivalents); and (iii)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1,913,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares subject to outstanding 2018, 2019 and 2020 performance units (including 93,738 related dividend equivalents). The weighted-average exercise price shown in column (b) is for the outstanding options only. The number of available shares under column (c) represents the number of shares that remain available for future issuance under this plan as of December 31, 2020, employing the fungible share formula and presumes the issuance of target shares under the performance units granted in 2018, 2019 and 2020 and related dividend equivalents. The numbers under columns (a) and (c) do not give effect to the additional shares that could be issuable in the event above target performance on the performance goals under these outstanding performance units is achieved. Maximum performance under these goals could result in 200% of target shares being awarded for performance units granted in 2018, 2019 and 2020.</span></div><div style="margin-bottom:5pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">This plan has terminated as to future grants. The number under column (a) with respect to this plan includes 5,913 shares issuable upon the settlement of deferred RSUs (including 1,160 related dividend equivalents).</span></div><div style="margin-bottom:5pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">The Amgen Profit Sharing Plan for Employees in Ireland (the Profit Sharing Plan) was approved by the Board of Directors on July 28, 2011. The Profit Sharing Plan permits eligible employees of the Company&#8217;s subsidiaries located in Ireland who participate in the Profit Sharing Plan to apply a portion of their qualifying bonus and salary to the purchase of the Company&#8217;s common stock on the open market at the market price by a third-party trustee as described in the Profit Sharing Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Directors and Executive Officers and Certain Beneficial Owners</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about security ownership of certain beneficial owners and management is incorporated by reference from the sections entitled SECURITY OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS and SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS in our Proxy Statement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_151"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about certain relationships and related transactions and director independence is incorporated by reference from the sections entitled CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS and CORPORATE GOVERNANCE&#8212;Director Independence in our Proxy Statement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_154"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the fees for professional services rendered by our independent registered public accountants is incorporated by reference from the section entitled AUDIT MATTERS&#8212;Independent Registered Public Accountants in our Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_160"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></td></tr></table></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Index to Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Consolidated Financial Statements are included herein:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page<br/>number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_175">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_175">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income for each of the three years in the period ended December&#160;31,&#160;2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_178">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_178">4</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December&#160;31,&#160;2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_181">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_181">5</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_184">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_184">6</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December&#160;31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_190">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_190">7</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for each of the three years in the period ended December&#160;31,&#160;2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_196">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_196">8</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_199">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_199">9</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:15pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Index to Financial Statement Schedules</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Schedule is filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page<br/>number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II. Valuation and Qualifying Accounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_286">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if8d0740b43d148a5ba67e4dd5b38ce46_286">60</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable, not required or because the required information is included in the consolidated financial statements or notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Exhibits</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex21.htm">Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519270139/d655928dex101.htm">Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a23amendmentno2toapa.htm">Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a24letteragreementv3.htm">Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgen&#8217;s acquisition of Otezla&#174;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex22.htm">Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000144530513001107/amgn-exh31_2013331xq1.htm">Restated Certificate of Incorporation of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516466178/d46204dex31.htm">Amended and Restated Bylaws of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-97-000008.txt">Form of stock certificate for the common stock, par value $.0001 of the Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508040431/dex43.htm">Agreement of Resignation, Appointment and Acceptance dated February 15, 2008.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001006.txt">First Supplemental Indenture, dated February 26, 1997.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">8-1/8% Debentures due April 1, 2097.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">Officer&#8217;s Certificate of Amgen Inc., dated April 8, 1997, establishing a series of securities entitled &#8220;8 1/8% Debentures due April 1, 2097.&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000104746903026118/a2115639zex-4_1.htm">Indenture, dated August 4, 2003.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-98-000005.txt">Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede &amp; Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March&#160;31, 1998 on May&#160;13, 1998 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312507126045/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 30, 2007, including form of the Company&#8217;s 6.375% Senior Notes due 2037.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508121768/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 23, 2008, including form of the Company&#8217;s 6.90% Senior Notes due 2038.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509007552/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated January 16, 2009, including form of the Company&#8217;s 6.40% Senior Notes due 2039.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510055545/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated March 12, 2010, including form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510055545/dex42.htm"> of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510055545/dex42.htm">5.75% Senior Notes due 2040.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510211595/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 16, 2010, including form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510211595/dex42.htm"> of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510211595/dex42.htm">4.95% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511178620/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated June 30, 2011, including form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511178620/dex42.htm"> of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511178620/dex42.htm">5.65% Senior Notes due 2042.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511306300/d254287dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated November 10, 2011, including form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511306300/d254287dex42.htm"> of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511306300/d254287dex42.htm">5.15% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511329468/d265264dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated December 5, 2011, including form of the Company&#8217;s 5.50% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512234621/d352967dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 15, 2012, including forms of the Company&#8217;s 3.625% Senior Notes due 2022 and 5.375% Senior Notes due 2043.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512390074/d410209dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 13, 2012, including form of the Company&#8217;s 4.000% Senior Notes due 2029.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex41.htm">Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 22, 2014, including form of the Company&#8217;s 3.625% Senior Notes due 2024.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312515165541/d919213dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated May 1, 2015, including forms of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312515165541/d919213dex42.htm">2.700% Senior Notes due 2022, 3.125% Senior Notes due 2025 and 4.400% Senior Notes due 2045.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516476783/d129782dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 25, 2016, including forms of the Company&#8217;s 1.250% Senior Notes due 2022 and 2.000% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex41.htm">Form of Permanent Global Certificate for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex42.htm">Terms of the Bonds for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516621372/d203675dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Company&#8217;s 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 14, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516686451/d187158dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 19, 2016, including forms of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516686451/d187158dex43.htm">2.250% Senior Notes due 2023 and 2.600% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 19, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517167330/d389370dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of May 11, 2017 including form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517167330/d389370dex42.htm"> of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517167330/d389370dex42.htm">2.650% Senior Notes due 2022.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 11, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517331065/d472956dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Company&#8217;s 3.200% Senior Notes due 2027.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520044757/d894000dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 21, 2020, including forms of the Company&#8217;s 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes due 2030, 3.150% Senior Notes due 2040 and 3.375% Senior Notes due 2050.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on February 21, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520134934/d925911dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Company&#8217;s 2.300% Senior Notes due 2031.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Company&#8217;s 2.770% Senior Notes due 2053.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex43.htm">Registration Rights Agreement, dated as of August 17, 2020, by and among Amgen Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, Blaylock Van, LLC and Siebert Williams Shank &amp; Co., LLC, as co-dealer managers </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex433_20201231xq4.htm">Description of Amgen Inc.&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513145924/d475543ddef14a.htm#toc475543_21">Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 8, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000010/amgn-ex102_2015331xq1.htm">First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000035/amgn-ex103_2016331xq1.htm">Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20201231xq4.htm">Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20201231xq4.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20201231xq4.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20201231xq4.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20201231xq4.htm">.)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20201231xq4.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20201231xq4.htm">15,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20201231xq4.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20201231xq4.htm">2020.)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815418000004/exhibit106performanceaward.htm">Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20201231xq4.htm">Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20201231xq4.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20201231xq4.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20201231xq4.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20201231xq4.htm">.)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">Amgen Inc. 2009 Director Equity Incentive Program. (As Amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">Octo</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">ber </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">1, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex108_20201231xq4.htm">.)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509105621/dex107.htm">Form of Grant of Non-Qualified Stock Option Agreement for the Amgen Inc. 2009 Director Equity Incentive Program.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1011-amgenxdirectorca.htm">Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex109_20131231x10k.htm">Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1012_2016930xq3.htm">First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1014-secondamendmento.htm">Second Amendment to the Amgen Inc. Supplemental Retirement Plan (As Amended and Restated effective October 23, 2019).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000095012311048073/v58996exv10w9.htm">Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508228861/dex1019.htm">Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January&#160;1, 2009.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September&#160;30, 2008 on November&#160;7, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000144530513000364/amgn-ex1017_2012123110k.htm">First Amendment to the Amgen Inc. Executive Incentive Plan, effective December 13, 2012.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2012 on February 27, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000009/amgn-ex1016_2017033110q.htm">Second Amendment to the Amgen Inc. Executive Incentive Plan, effective January 1, 2017.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex1015_20131231x10k.htm">Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1017_2016930xq3.htm">First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1021-secondamendmentt.htm">Second Amendment to the Amgen Nonqualified Deferred Compensation Plan (As Amended and Restated effective January 1, 2020).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815418000022/exhibit1023agmtamgenincand.htm">Agreement between Amgen Inc. and Murdo Gordon, dated July 25, 2018.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2018 on October 31, 2018 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/petergriffith-signedof.htm">Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519312129/d834361dex101.htm">Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513312834/d573775dex1054.htm">Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited dated May 10, 2002 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K/A for the year ended December 31, 2012 on July 31, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000004/amgn-ex1032_20161231x10k.htm">Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2016 on February 14, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815419000037/amgn-ex282019630xq2.htm">Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012311047784/f58570exv10w1wi.htm">Collaboration Agreement, dated April 22, 1994, by and between Bayer Corporation (formerly Miles, Inc.) and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 by Onyx Pharmaceuticals, Inc. on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095014906000261/f20295exv10w1xiy.htm">Amendment to Collaboration Agreement, dated April 24, 1996, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095014906000261/f20295exv10w12.htm">Amendment to Collaboration Agreement, dated February 1, 1999, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000119312512081975/d265452dex101v.htm">Settlement Agreement and Release, dated October 11, 2011, by and between Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Pharma AG and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000119312512081975/d265452dex101iv.htm">Fourth Amendment to Collaboration Agreement, dated October 11, 2011, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000022/amgn-ex1043_2015630xq2.htm">Side Letter Regarding Collaboration Agreement, dated May 29, 2015, by and between Bayer HealthCare LLC and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 on August 5, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/sideletterregardingcol.htm">Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000009/amgn-exhibit1040_2017033110q.htm">Sourcing and Supply Agreement, dated January 6, 2017, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1041amgenxnovartism.htm">Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1042amend1tolicense.htm">Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1043amend2tonovarti.htm">Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1044collaborationag.htm">Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815418000008/exhibit1038amendtocollabor.htm">Amendment No. 1 to the Collaboration Agreement, dated March 20, 2018, by and between Novartis Pharma AG and Amgen Inc</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2018 on April 25, 2018 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/a1041amendmentno2tocol.htm">Amendment No. 2 to the Collaboration Agreement, dated August 19, 2020, by and between Amgen Inc. and Novartis Pharma AG </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1041bridgecollaborati.htm">Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1042guaranteeagreement.htm">Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex991.htm">Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex992.htm">Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/a1046restatedamendment.htm">Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/d312223dex1055.htm">Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2012 on May 8, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/amgn-ex1037_20141231x10k.htm">Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-K for the year ended December 31, 2014 on February 19, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/amgn-ex10492020630xq2.htm">Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex1050_20201231xq4.htm">Amendment No. 7 to the Collaboration Agreement, dated December 18, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex21_20201231xq4.htm">Subsidiaries of the Company.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of the Independent Registered Public Accounting Firm. The consent is set forth on page 94 of this Annual Report on the 10-K.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney. The Power of Attorney is set forth on page 95 of this Annual Report on Form 10-K.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex31_20201231xq4.htm">Rule 13a-14(a) Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex32_20201231xq4.htm">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*  = filed herewith)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(** = furnished herewith and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+  = management contract or compensatory plan or arrangement)</span></div><div style="text-align:justify"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_163"></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K SUMMARY</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;PETER H. GRIFFITH</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23</span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-3 No. 333-236351) of Amgen Inc., </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No.&#160;333-159377) pertaining to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, </span></div><div style="padding-left:40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No.&#160;33-39183) pertaining to the Amgen Inc. Amended and Restated Employee Stock Purchase Plan, </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 No.&#160;33-39104, as amended by Form S-8 Nos.&#160;333-144581 and 333-216719) pertaining to the Amgen Retirement and Savings Plan, </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 Nos.&#160;33-47605, 333-144580 and 333-216715) pertaining to The Retirement and Savings Plan for Amgen Manufacturing, Limited (formerly known as the Retirement and Savings Plan for Amgen Manufacturing, Inc.), </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 Nos.&#160;333-81284, 333-177868 and 333-216723) pertaining to the Amgen Nonqualified Deferred Compensation Plan, and</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No.&#160;333-176240) pertaining to the Amgen Profit Sharing Plan for Employees in Ireland;</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February 8, 2021, with respect to the consolidated financial statements of Amgen Inc. and the effectiveness of internal control over financial reporting of Amgen Inc. included in this Annual Report (Form 10-K) of Amgen Inc. for the year ended December 31, 2020.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young LLP</span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 24</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert A. Bradway, Peter H. Griffith and Jonathan P. Graham, or any of them, his or her attorney-in-fact, each with the power of substitution and re-substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT A. BRADWAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board, Chief Executive Officer<br/>and President, and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert A. Bradway</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;PETER H. GRIFFITH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;LINDA H. LOUIE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance and<br/>Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Linda H. Louie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;WANDA M. AUSTIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wanda M. Austin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;BRIAN J. DRUKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Brian J. Druker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT A. ECKERT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert A. Eckert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;GREG C. GARLAND</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greg C. Garland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;FRED HASSAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fred Hassan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;CHARLES M. HOLLEY, JR.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charles M. Holley, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;TYLER JACKS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tyler Jacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ELLEN J. KULLMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ellen J. Kullman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;AMY E. MILES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amy E. Miles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;RONALD D. SUGAR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ronald D. Sugar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;R. SANDERS WILLIAMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R. Sanders Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">To the Stockholders and the Board of Directors of Amgen Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Amgen Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and the financial statement schedule listed in the Index at Item 15(a)2 (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 8, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:14.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales deductions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company recorded accrued sales deductions of $4.8 billion. As described in Note 1 to the financial statements under the caption &#8220;Product sales and sales deductions,&#8221; revenues from product sales are recognized net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively sales deductions), which are established at the time of sale. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the estimation of sales deductions, which are netted against product sales, is complex, requires significant judgment, and the amounts involved are material to the financial statements taken as a whole.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, and is based on an amount that reflects the consideration to which the Company expects to be entitled, which represents an amount that is net of accruals for estimated sales deductions. The estimated sales deductions are based on current contractual and statutory requirements, market events and trends, internal and external historical data, and forecasted customer buying patterns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the sales deduction processes. This included testing controls over management&#8217;s review of significant assumptions and inputs used in the estimate of sales deductions, including actual sales, contractual terms, historical experience, wholesaler inventory levels, demand data and estimated patient population.  We also tested management&#8217;s controls over the accuracy of forecasting demand activity as well as the completeness and accuracy of the significant components included in the final sales deduction estimates. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimated sales deductions, we obtained management&#8217;s calculations for the respective estimates and performed the following procedures, among others. We tested management&#8217;s estimation process over the determination of sales discount accruals by developing an independent expectation of the estimated accrual balances, including comparing accrual balances recorded by management to those implied by historical payment trends, performing a lookback analysis using actual historical data to evaluate the forecasted amounts, assessing subsequent events to determine whether there was any new information that would require adjustment to the initial accruals, evaluating trends in actual sales and discount accrual balances, comparing cash receipts to product sales, confirming terms and conditions for a sample of contracts with the Company&#8217;s customers, testing a sample of credits issued and payments made throughout the year, and agreeing rates to underlying contract terms.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 6 to the consolidated financial statements, the Company operates in various jurisdictions in which differing interpretations of complex tax laws and regulations create uncertainty and necessitate the use of significant judgment in the determination of the Company&#8217;s unrecognized tax benefits related to allocation of profits among various jurisdictions (&#8220;transfer pricing&#8221;), particularly in the U.S. federal tax jurisdiction where the Company has significant assets and operations. In this regard, the Company uses significant judgment in (1) determining whether a tax position&#8217;s technical merits are more-likely-than-not to be sustained and (2) measuring the amount of tax benefit that qualifies for recognition. As of December 31, 2020, the Company accrued $3.4 billion of gross unrecognized tax benefits including transfer pricing. Auditing the assessment of the technical merits and measurement of the Company&#8217;s unrecognized tax benefits is challenging because they can be complex, highly judgmental, and based on interpretations of tax laws and regulations and application of those interpretations to the Company&#8217;s facts and circumstances.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company&#8217;s process to assess the technical merits of its tax positions, as well as management&#8217;s process to measure the unrecognized tax benefits of those tax positions, particularly in regard to transfer pricing. This included testing controls over management&#8217;s review of the inputs, calculations, assumptions and methods selected to measure the amount of tax benefits that qualify for recognition. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We involved tax and transfer pricing professionals to assist in assessing the technical merits and measurement of certain of the Company&#8217;s unrecognized tax benefits. Depending on the nature of the specific tax position and, as applicable, developments with the relevant tax authorities, our procedures included obtaining and reviewing the Company&#8217;s correspondence with such tax authorities and evaluating certain third-party advice to support the Company&#8217;s evaluations and recorded positions. We used our knowledge of and experience with how the income tax laws and regulations related to transfer pricing are applied by the relevant tax authorities to evaluate the Company&#8217;s accounting for its unrecognized tax benefits. We evaluated developments in the applicable regulatory environments to assess potential effects on the Company&#8217;s recorded positions. We analyzed the assumptions and data used by the Company when it determined the amount of tax benefits to recognize, including applicable interest and penalties, and we tested the accuracy of those underlying calculations. We have also evaluated the Company&#8217;s income tax disclosures included in Note 6 in relation to these matters.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ernst &amp; Young LLP</span></div></td></tr></table></div><div style="padding-right:13.5pt;text-align:right"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 1980.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Los Angeles, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 8, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzItMS0xLTEtMA_30a38ba8-aa57-4011-9dea-39c25284821d">24,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzItMy0xLTEtMA_a74a1eab-cc1a-4782-b95c-0aa8c0460d8d">22,204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzItNS0xLTEtMA_75bf9f38-70de-43dc-9436-da61457c189f">22,533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0a9e21adce47979f7e38ab4025e6ca_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMtMS0xLTEtMA_857b3be8-1f5e-499f-997f-73f6fded74ba">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25a2862d79c42ba91f97b4241baa3f9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMtMy0xLTEtMA_59188e86-0672-4297-b6f7-2e7c6e797f24">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e077713b1f432fb30f0a3751b4bdf4_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMtNS0xLTEtMA_26e94618-5e77-4a5d-a63b-b431e93027e2">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzQtMS0xLTEtMA_142d85ab-168e-46cb-a8f2-f21be5880fc0">25,424</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzQtMy0xLTEtMA_53e6f216-3fac-4762-b7ec-278c4f7d87c3">23,362</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzQtNS0xLTEtMA_51c1d242-4bcc-49b9-ab13-c23e3d00072a">23,747</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzctMS0xLTEtMA_b94d87f7-b4ac-43ca-8c76-6247c1874558">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzctMy0xLTEtMA_48a6627b-b867-4f1d-880c-e94d1ba98982">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzctNS0xLTEtMA_5bb27cd1-80c9-4529-8f7b-928f5f6dd2b4">4,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzgtMS0xLTEtMA_b42fc5b4-a7ce-40d0-a4e7-cdb9cb9dea4a">4,207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzgtMy0xLTEtMA_238afe1a-99f5-46cc-b7f4-3f39d62a2692">4,116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzgtNS0xLTEtMA_fcd263f7-1bd1-4446-894e-fd66824324c5">3,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzktMS0xLTEtMA_6b493609-6314-448d-8515-d5216dccdcbc">5,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzktMy0xLTEtMA_1f2ee039-d810-4b83-b759-a3eb77cb48fc">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzktNS0xLTEtMA_1e9aa7fd-455e-43ce-adee-079a93d15069">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzExLTEtMS0xLTA_6ad0e4e3-2b31-4df7-a4ad-24fdfe8840bb">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzExLTMtMS0xLTA_6aeed021-810d-4f27-bdfe-3e98634053a6">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzExLTUtMS0xLTA_31a61443-c602-449d-bbec-bf3e574045a2">314</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzEyLTEtMS0xLTA_edefd3bd-baf5-46bd-8f01-09cb3e4e905a">16,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzEyLTMtMS0xLTA_df077847-0720-4e64-a856-d0bfdd205341">13,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzEyLTUtMS0xLTA_5a2703f3-0619-46c0-a547-4d51b31853f2">13,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE0LTEtMS0xLTA_a2b7324a-c8ed-4934-b825-05e1584d6d82">9,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE0LTMtMS0xLTA_4b51558f-e49f-4eaf-a506-6325661d9bf1">9,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE0LTUtMS0xLTA_4d885f88-de66-4a37-ae04-cc64277200bc">10,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE2LTEtMS0xLTA_26fd0b66-a390-4398-b357-7ace2d70ed16">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE2LTMtMS0xLTA_02401e47-b2cd-420d-a8bc-9ad4ed4f0a5c">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE2LTUtMS0xLTA_f4afa613-5647-4478-a8b3-cee096a4af2a">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE3LTEtMS0xLTA_6484aae4-e468-48ac-806f-12115bac5b9f">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE3LTMtMS0xLTA_8cc447c8-7b5b-41ff-8edf-0b47c61e0a9b">753</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE3LTUtMS0xLTA_e244e3af-a3f9-49f3-b640-b0095bd5db55">674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE5LTEtMS0xLTA_c21e7a00-b73c-47dc-b863-d6569ba7f69f">8,133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE5LTMtMS0xLTA_87f5ca2d-8a7a-4b1a-8ba9-c4249d9b5362">9,138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE5LTUtMS0xLTA_60a5c629-b976-4917-bbcd-f0e37a20eea6">9,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIxLTEtMS0xLTA_f5ad3b17-aaa9-41ad-91c4-c3ee19e141c3">869</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIxLTMtMS0xLTA_5236cf2a-335d-42fc-aa21-280f058b0a8b">1,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIxLTUtMS0xLTA_1ec5d8bf-a7ff-419a-bb86-11b60ea19871">1,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIzLTEtMS0xLTA_dac79fd7-cb52-4a5a-8439-851eef96f654">7,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIzLTMtMS0xLTA_aa407ebe-a5f1-4434-b400-56c8bbb2cf23">7,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIzLTUtMS0xLTA_b98a1d23-7b64-4e1a-9d6b-6f4ca0d26bf5">8,394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI2LTEtMS0xLTA_1e5b00a7-9e37-4cea-9aaa-5587cb1f459d">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI2LTMtMS0xLTA_bf223a85-6910-4055-b66f-c34a2d573fab">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI2LTUtMS0xLTA_2121072b-dc6a-4d1e-863b-610f3805370f">12.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI3LTEtMS0xLTA_4b55a643-ae67-4fdf-9bd8-114472541310">12.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI3LTMtMS0xLTA_fec266c0-2adc-4230-8281-8ac4a8251de0">12.88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI3LTUtMS0xLTA_e91aca47-4c2d-4ace-b6c1-717530da4960">12.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in the calculation of earnings per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMwLTEtMS0xLTA_917e16ab-684f-410f-b1c3-3da58ca1dddc">586</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMwLTMtMS0xLTA_a9b81ca9-1881-4d39-8c4d-464287925ca3">605</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMwLTUtMS0xLTA_a18a15f4-cbd0-40aa-b6d4-45d5da1d9c7c">661</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMxLTEtMS0xLTA_171c5b2b-6013-4d1a-a9ee-0a626105b2b4">590</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMxLTMtMS0xLTA_bd5e48d5-6402-48e6-a94c-ff7532690dad">609</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMxLTUtMS0xLTA_2b03f26f-18a7-451f-8ee1-e749abe87a62">665</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzEtMS0xLTEtMA_c9bca7ee-1300-4928-b70f-82a351304365">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzEtMy0xLTEtMA_655fea8a-2575-4ccc-b0ee-8a2b01870b06">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzEtNS0xLTEtMA_b051651e-8507-4269-bab0-2f0f37b6a2b3">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of reclassification adjustments and taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzMtMS0xLTEtMA_f86fc041-1e3a-4949-9cb6-e47cee67c881">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzMtMy0xLTEtMA_66c9b7fc-d5a2-47a5-b526-5d6d10f0638d">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzMtNS0xLTEtMA_fc4b49d4-d436-4d7c-abee-df949517edd3">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on cash flow hedges</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzQtMS0xLTEtMA_d600f63c-1b71-4040-99b2-0448a396f029">438</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzQtMy0xLTEtMA_5fa996d3-24dc-4287-90b2-2eae66694407">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzQtNS0xLTEtMA_db0c70e9-f278-42d6-b26a-91b7ec291bbe">247</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzUtMS0xLTEtMA_7710a675-4438-4251-8b41-802003c4b33b">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzUtMy0xLTEtMA_562ad561-2c70-4071-a7c1-03c089c5198c">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzUtNS0xLTEtMA_e1557d6c-452d-49e8-a2f2-65a0f56a0312">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzYtMS0xLTEtMA_a23c196c-a390-4a4c-a9d2-1764f29bf650">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzYtMy0xLTEtMA_795dc8f0-7da5-48a3-9c40-b2b9481b3ffd">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzYtNS0xLTEtMA_e90e8934-45c2-4792-96e8-65f3ba95705e">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzctMS0xLTEtMA_fea8cf72-d10d-494e-a710-88eabaf853c0">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzctMy0xLTEtMA_68e00212-75b2-44c5-9769-ef073cae4581">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzctNS0xLTEtMA_7a801f51-0eed-4aa7-a601-6ce92e366457">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzgtMS0xLTEtMA_b1830ecf-fe39-46d7-adc0-e0a654297d54">6,807</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzgtMy0xLTEtMA_bfdb7c64-170b-4460-a9f0-6bdd60bd5102">8,083</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzgtNS0xLTEtMA_ee0685b8-4898-4a7f-826e-1bce6256ad47">8,313</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMtMS0xLTEtMA_5f352e41-af4f-46be-9389-aaa9b920a502">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMtMy0xLTEtMA_395ea0a1-c5ff-42b9-af29-22eba5256191">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzQtMS0xLTEtMA_660391e1-768a-4d28-b358-a7425b2e7b8c">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzQtMy0xLTEtMA_7907e893-d9a1-46e1-b94c-02c7f15d169e">2,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzUtMS0xLTEtMA_78af5912-a89a-4189-b7f9-53035a78cdf6">4,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzUtMy0xLTEtMA_5d1b3a85-75d6-4094-8dc3-8caf7c733092">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzYtMS0xLTEtMA_8243cf85-190e-40d1-8561-b5861640f39b">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzYtMy0xLTEtMA_8c9c132f-0805-462d-9baa-64780f482074">3,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzctMS0xLTEtMA_411d35b9-bcd4-4d1a-970f-aee026177a36">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzctMy0xLTEtMA_9b577e70-b0c9-4ea8-9538-c30b98e9ba56">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzgtMS0xLTEtMA_9a52d2d0-5aee-4d1b-9525-591263528515">21,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzgtMy0xLTEtMA_94a9edb1-4d82-4970-9716-a586c576fd79">18,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEwLTEtMS0xLTA_4ca60e49-3fff-45d4-b060-b2aa365f4e81">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEwLTMtMS0xLTA_59a70c46-d449-478a-8021-cc74d16f405b">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzExLTEtMS0xLTA_b2ba520e-860f-41d2-92c1-bd42fc68a6cb">16,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzExLTMtMS0xLTA_e6925b82-8dca-47d2-95cc-70cfa462989a">19,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEyLTEtMS0xLTA_89e862e9-d92d-4550-a8af-940de771f91f">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEyLTMtMS0xLTA_dd20a4bb-a598-4f81-9c4e-acd898f4335e">14,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEzLTEtMS0xLTA_0933e518-364c-4841-8b02-6430d6fbe96b">5,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEzLTMtMS0xLTA_4141b67f-f28f-4dff-b27f-a8e011a6e05e">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE0LTEtMS0xLTA_f010fa21-4424-4aff-82ed-495b94cddb93">62,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE0LTMtMS0xLTA_9a6e5750-b2c9-40c5-a8b0-b5dd85733467">59,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE4LTEtMS0xLTA_9aa03d42-694e-4ce2-80a0-ec767d751044">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE4LTMtMS0xLTA_306319a6-c609-4880-838d-2384644a6501">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE5LTEtMS0xLTA_f1d8416f-247c-4a50-adb3-964e87b15985">10,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE5LTMtMS0xLTA_465ef01d-e2bd-40d6-8c21-30d1dee120d3">8,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIwLTEtMS0xLTA_d3d014c7-2bd5-4265-9404-aa0d76c57c90">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIwLTMtMS0xLTA_291973c4-fb6b-405c-b508-f6a73d6ef9fc">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIxLTEtMS0xLTA_d7800381-d384-4b5a-b0fd-e4be2deec27d">11,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIxLTMtMS0xLTA_6a1d2ecc-0c43-451b-8d45-a7783868ee3f">12,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIzLTEtMS0xLTA_01a68903-92a9-435f-8952-e4c661ef8498">32,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIzLTMtMS0xLTA_bfd5e048-85b2-495d-a016-f160855f39dd">26,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI1LTEtMS0xLTA_cf9c0553-8200-4287-87ac-bc29fb9b01ff">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI1LTMtMS0xLTA_37d07d73-cc28-49d4-97bb-81ca94ef1c0e">8,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI2LTEtMS0xLTA_4c71ffa5-02cc-46f5-828f-19e989558e98">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI2LTMtMS0xLTA_7f1d3aba-aa4a-4f56-9114-4df117fe3a1a">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingencies and commitments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI4LTEtMS0xLTA_6d6d1a63-7371-4c54-a089-094736ad29df"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI4LTMtMS0xLTA_9d64c592-e914-4c4d-924f-383d54e4078b"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital; $<ix:nonFraction unitRef="usdPerShare" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMDk5NTExNjI3OTQ1_1ceb9758-585b-43d3-a811-63d30f307af7"><ix:nonFraction unitRef="usdPerShare" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMDk5NTExNjI3OTQ1_b8311494-1efb-43f0-9c86-137c4a29dbf6">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg2OQ_2e9a1b7e-0773-40d0-8c2c-67290f3546e0"><ix:nonFraction unitRef="shares" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg2OQ_708c5b03-2ca5-4826-8349-26dac4e3d1e7">2,750.0</ix:nonFraction></ix:nonFraction> shares authorized; outstanding&#8212; <ix:nonFraction unitRef="shares" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg3Ng_4ee0d94f-d698-4a59-9dea-304df3e69bc2">578.3</ix:nonFraction> shares in 2020 and <ix:nonFraction unitRef="shares" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg4Mw_a56d2ecb-980d-4b5c-ab6e-0780cfa58f19">591.4</ix:nonFraction> shares in 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTEtMS0xLTA_59094a32-1603-42be-9786-967ec4a64672">31,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTMtMS0xLTA_ede11230-487c-439b-97df-51864b2f0a6b">31,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMyLTEtMS0xLTA_d5805e63-bbaf-4089-8be7-919c1dce5729">21,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMyLTMtMS0xLTA_2259557f-dae1-4518-aa5e-b718efda905c">21,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMzLTEtMS0xLTA_04f99aca-024f-46c1-b37a-c818df03f07b">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMzLTMtMS0xLTA_2b5fbe89-a3f6-45f8-9ff7-165098ba1fbe">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM0LTEtMS0xLTA_f0d5dcad-a9eb-45b6-bfd9-ddfa45868f33">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM0LTMtMS0xLTA_6ff9ce17-fb3a-48e7-a726-9ba77835bab4">9,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM1LTEtMS0xLTA_56e3174d-2af2-4b00-bd5a-f34dd3799873">62,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM1LTMtMS0xLTA_68c60252-0eeb-491b-8277-e33d4f32ae12">59,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares<br/>of&#160;common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock and<br/>additional<br/>paid-in&#160;capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>(loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe76d84d24b74fe19c507ca3db178e07_I20171231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtMS0xLTEtNjQ4MQ_e1481fbe-5717-4b29-9b29-005aeee36c23">722.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9879d3c7b9a4deaaa7e74de73561d9c_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtMy0xLTEtNjQ4MQ_04099f2b-3982-4367-8ff3-dca43ec5b071">30,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae5629c343b34f27808360cb92a2f04a_I20171231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtNS0xLTEtNjQ4MQ_1f867c28-37d3-454e-b047-33a0f541879e">5,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie781bbd2a4b948e48767b11ee16f2352_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtNy0xLTEtNjQ4MQ_6247ce47-12ec-4cdf-93b2-3b7f0f474eec">679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtOS0xLTEtMA_3565705e-035a-4edd-b865-f85a58d41a71">25,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of changes in accounting principles, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide99a054d6604b4c891c408659ba5c67_I20171231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItNS0xLTEtNjQ4Mw_0f673ae9-cc03-448d-a50d-6105b4c0c724">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36d7388f79e144b99235c416c99550db_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItNy0xLTEtNjQ4Nw_0625e6db-ca89-4f89-88b5-92343383f564">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86190fe874cb49e198e5942201bb77cf_I20171231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItOS0xLTEtNjQ4NQ_23a80439-0509-4ec8-a32e-d9898cb2d6d0">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzMtNS0xLTEtNjQ3OQ_d026f2dd-44a9-4888-bc75-81fa62b6ab05">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItOS0xLTEtMA_d3087363-950c-41ae-a1cc-4a0ce2b52bed">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzQtNy0xLTEtNjQ3OQ_056baaf6-ad53-4b65-acb7-4d68fc49b994">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzMtOS0xLTEtMA_6326100f-b1ec-4032-9edc-3660d3ab22a4">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE3YTliMzkyODQzNTRiYTZiZDdkNzQ5MDFhYjg0OTU5XzEwOTk1MTE2Mjc4NDI_45d1a244-f07d-4370-a324-1a818588c94e">5.41</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzUtNS0xLTEtNjQ3OQ_fb1eb8ec-abd5-402c-827f-59fdb494c159">3,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzQtOS0xLTEtMA_e211471d-f600-440e-99b9-b83fb407edd8">3,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43beae92bfce49bc8cbb9c9c6cf4c99f_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzYtMS0xLTEtNjQ3OQ_673fe8de-cf48-445d-ac45-7a6f95fc8a1b">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzYtMy0xLTEtNjQ3OQ_e6e27a41-82bb-409d-b931-f8a626a3c53d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzUtOS0xLTEtMA_ae9af7cb-ae66-4d0d-9e77-c92425f7b89f">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzctMy0xLTEtNjQ3OQ_323d2f92-35c1-4bc8-bd96-0a5f67dd2c15">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzYtOS0xLTEtMA_97460920-4019-44bf-aed2-c2a6288bdf25">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzgtMy0xLTEtNjQ3OQ_d640d52c-3d8f-494d-94f3-561f6e4e6db8">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzctOS0xLTEtMA_07420b33-c889-4822-b044-e190f34d0802">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i43beae92bfce49bc8cbb9c9c6cf4c99f_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktMS0xLTEtNjQ3OQ_68f19653-316d-4689-bf62-6b72e147c266">94.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktNS0xLTEtNjQ3OQ_82a95602-6643-4a96-ac47-1d6181ccca79">17,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzgtOS0xLTEtMA_403cebf8-397b-4702-8f9c-f60247b04eab">17,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia658e307c35b4f75920a20f604851e24_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktMS0xLTEtMA_501d9572-f029-4f8c-993a-9f34afb90b83">629.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606f729d14154f1bbee6cd17cade6bc7_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktMy0xLTEtMA_06408295-2bb2-4093-a813-a319d298cb5c">31,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46b885f0f1534e088ba923195043b35c_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktNS0xLTEtMA_d585b3e4-bc1c-4359-b7f4-2339742d6afb">17,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idda2fa41bf7b4d32acb584d26141eb44_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktNy0xLTEtMA_2b30c3f3-a3ad-4b4b-8b3f-c4f5dba5feb4">769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktOS0xLTEtMA_f47c6267-0141-4247-9fd5-d51aa0324347">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514f593334634486be45550fb53d0771_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEyLTUtMS0xLTY0Nzc_48406c71-94b7-4fce-99ef-17658d05b993">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzExLTktMS0xLTA_8419f8ea-a9fb-41c8-b177-9ac188113ebe">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEzLTctMS0xLTY0Nzc_f33ebf18-3872-4007-a6f1-bc3449e1ae16">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEyLTktMS0xLTA_32b47ded-f456-4c93-bb60-763d924619c6">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MmFmZjY2OWUxZTk0NjhhYWM0YmY0OTExOTQyMjZlN18xMDk5NTExNjI3ODQy_7711c68f-346b-4b3b-871e-ca3cffaf45d6">5.95</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i514f593334634486be45550fb53d0771_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE0LTUtMS0xLTY0Nzc_c98d8731-6dae-46e5-89e9-1c6f895e5208">3,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEzLTktMS0xLTA_71a2fc27-9b8b-4a9d-bbc7-33c2ab3e23bd">3,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2336bd3c48ac47339665832c8ac91be4_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE1LTEtMS0xLTY0Nzc_93edf0ea-8026-4854-b7bc-34e3e3dc55d8">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE1LTMtMS0xLTY0Nzc_56644932-1549-4a36-8d50-e64105395489">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE0LTktMS0xLTA_877a00f7-151b-45f0-8b0c-bc892743c683">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE2LTMtMS0xLTY0Nzc_d51f48c9-b281-4336-a9ad-8dc6603063f4">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE1LTktMS0xLTA_1a2b6d6e-0185-4659-bd8e-6fe4f3fbbce4">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE3LTMtMS0xLTY0Nzc_bbb03c49-5659-4da9-b944-6e48dac05930">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE2LTktMS0xLTA_b463ddae-3d79-40ad-aaca-91b97630eee1">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2336bd3c48ac47339665832c8ac91be4_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTEtMS0xLTY0Nzc_5344cbe7-a903-492f-851e-7756ea5a0c57">40.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i514f593334634486be45550fb53d0771_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTUtMS0xLTY0Nzc_2b36d974-8f7d-4f49-8925-f72ddf131996">7,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE3LTktMS0xLTA_080258fd-805b-471b-a99d-c6f3640aad91">7,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cfd04cd281a41f9b3cf4f0a483ab314_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTEtMS0xLTA_8fbe2506-ffd2-45d6-b923-a360c28666ed">591.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f039062c98414ea66e3d16a12dea4d_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTMtMS0xLTA_3f564b69-f769-4326-959f-6db710e063ef">31,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ff5e78fe2444f869a1054445d876292_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTUtMS0xLTA_0f146c48-0c61-48c2-a0b7-f8a8ba6dc24c">21,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f92a1519afd4ee790c4f7f9669bc32b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTctMS0xLTA_c394391c-4ba7-4a15-9a0e-1aceee8d9dd9">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTktMS0xLTA_bee500b7-b604-4c87-922c-ca7c5106135f">9,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of changes in accounting principles, net of taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib59b48b26e6d439d9a321fdb3fda477d_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE5LTUtMS0xLTA_9dc54155-238b-41ad-960d-14a4608f4c47">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i127c87cb43eb488dbd0f2e72bc977df7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIwLTktMS0xLTE2Njg2_e343a325-265d-40cb-9d16-11962485ce45">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIwLTUtMS0xLTA_e50ba7b8-750e-4052-a57a-be4280f1f10e">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIwLTktMS0xLTA_113aeaff-d50b-4b2d-b2d1-a84f4f6adf0c">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIxLTctMS0xLTA_32db2e38-a947-4ff1-8cdf-c0dd4d58e089">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIxLTktMS0xLTA_fa9b9b8d-2684-4b36-b13c-d85dd8c82842">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NTVlYzg5MDg3ZjE0NWVjYTM4M2NkYTE2NDE5MDBkMV8xMDk5NTExNjI3ODM3_c6d88d2a-20bc-4690-82e0-cdccb96aa77d">6.56</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIyLTUtMS0xLTA_04ca1623-2fa6-4f26-83e9-a575cca9a1e9">3,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIyLTktMS0xLTA_fb6e1060-684a-4ad5-8545-2e11278d04ad">3,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i180132b4355d4e00b34bceb464b6e2bd_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIzLTEtMS0xLTA_4a419c42-54c7-4970-b0d2-2b3d8ce8ea79">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIzLTMtMS0xLTA_3ad5d2ca-c0e7-4f65-911b-59430a4a887d">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIzLTktMS0xLTA_16a883c1-4c46-4928-af22-429495cccc07">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI0LTMtMS0xLTA_2b0e4b38-8939-4531-a114-17a83f09c8c1">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI0LTktMS0xLTA_b07911b5-ce7e-4a93-aa04-c0baa0687d1f">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI1LTMtMS0xLTA_9d59fe83-c94f-4ce4-823c-26204f66b085">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI1LTktMS0xLTA_9e99aa7e-de8a-4502-b583-9cfae46de324">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i180132b4355d4e00b34bceb464b6e2bd_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI2LTEtMS0xLTA_03f68c6d-7f7c-43e2-87b8-67d4f55e36e6">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI2LTUtMS0xLTA_40195be1-3b6a-4a9e-8c39-0ea1dabe6319">3,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI2LTktMS0xLTA_ceb8a551-1270-44b1-8013-4410fae58431">3,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i298fcb4aef42470c9b276ca00abf854c_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTEtMS0xLTA_32f866e6-5475-43ec-a6cf-26b0aefc81e0">578.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae63d786325d4ba28cd18ab21ff84b6c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTMtMS0xLTA_7cfb5d30-5ce6-445f-818f-74f79a74f06a">31,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4afec46242043c98ea5b32c79a3dadc_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTUtMS0xLTA_635cba52-f89c-43ae-8324-6f7a692eede6">21,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42b0fccf031241ce995839be6adc2e18_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTctMS0xLTA_59bfc40f-bc38-4224-81c2-3d5b2bb30fd3">985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTktMS0xLTA_4e0e9ad5-ad43-4193-9b1a-0a56e27363c2">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzItMS0xLTEtMA_d322fc4a-f167-4361-94b7-2caefe90e9cf">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzItMy0xLTEtMA_d3a4f672-0c82-48f6-b3c1-baa2610d749d">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzItNS0xLTEtMA_a8682b46-c994-4156-a877-8b84535f2a3d">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMtMS0xLTEtMA_dc814103-a2d9-4e5f-bd4c-940228f14e64">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMtMy0xLTEtMA_a859a671-9e9c-4128-bf6f-685ecbeee8b9">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMtNS0xLTEtMA_30b778e5-b305-4ec9-aa3c-ff2b4ae31a55">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQtMS0xLTEtMA_b95135a1-b806-4002-9145-50c6d9726264">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQtMy0xLTEtMA_c0462ad2-d22f-4e90-8bb9-39c367a47b20">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQtNS0xLTEtMA_0fc52057-ca6b-41eb-a759-77a2044d9f7f">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzUtMS0xLTEtMA_d02c94d6-751f-46f9-95b7-d82447df07e6">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzUtMy0xLTEtMA_47667dfc-a1df-48b4-9eea-39d1b587cc21">289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzUtNS0xLTEtMA_fa160a1c-a089-4ca6-81e7-5ad1d1b07291">363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzYtMS0xLTEtMA_064d39d0-2bfc-41c6-896e-9d9e951c16fd">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzYtMy0xLTEtMA_784c06ca-78a3-4298-b498-538c99a39951">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzYtNS0xLTEtMA_f34e3274-744e-46f2-8922-8c5148faad02">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzgtMS0xLTEtMA_43a8fa9f-8e77-4bce-b031-0a4441dc2d39">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzgtMy0xLTEtMA_40e58a91-7ab4-4141-908f-0fd7c020b723">504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzgtNS0xLTEtMA_b58b12b8-c613-402b-a26e-3bbaae0873a8">378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzktMS0xLTEtMA_a911ba54-8bf8-4054-8540-0f9004098799">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzktMy0xLTEtMA_809f808b-5d88-4dc7-b163-9eefd0c1c9a6">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzktNS0xLTEtMA_70a48afe-8c58-43b5-b8c7-6753c67b8f5b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEwLTEtMS0xLTA_9b770e65-4e82-4097-b03f-1c3cf8293d3a">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEwLTMtMS0xLTA_decaf1f1-d60f-4a19-8922-6fc369c41017">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEwLTUtMS0xLTA_b366ef6e-4462-4221-b142-9663dab36339">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzExLTEtMS0xLTA_2991ee3a-0fe0-427a-be12-e4977b26cfbe">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzExLTMtMS0xLTA_48e97326-dbaa-4263-8523-4c7075d54a7f">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzExLTUtMS0xLTA_1a9b2b36-3ead-4c86-ada3-82da61a8e95e">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEyLTEtMS0xLTA_3e1f4cc9-da70-4ad4-ac2a-1adcf790844b">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEyLTMtMS0xLTA_69c32e31-5541-4e6b-a39e-bde903d31a34">585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEyLTUtMS0xLTA_0a89cc63-3ccb-4b05-ae67-a381f175f456">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEzLTEtMS0xLTA_5dc4e123-884a-4685-bba6-9c64f1802160">482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEzLTMtMS0xLTA_a670735b-b1f4-4d18-a98c-cc4636450e40">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEzLTUtMS0xLTA_92eec083-9cf5-4e9e-973d-1b4e5ece3a0f">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE0LTEtMS0xLTA_4f892d44-abc9-4113-aab0-e634d53803d9">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE0LTMtMS0xLTA_cdb97134-3988-435b-aaeb-d486d02b339b">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE0LTUtMS0xLTA_3adf4943-ec43-4daa-a1a6-be9ede8d455b">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE1LTEtMS0xLTA_5935c32c-a14c-432f-8663-ec2371caabe5">10,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE1LTMtMS0xLTA_1979fde2-919f-43db-a6bb-5246e79a2cca">9,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE1LTUtMS0xLTA_c64d35d8-590f-41e8-9301-7a0e0c9b188c">11,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE4LTEtMS0xLTA_134c2752-60c9-4def-a6cc-ea3c0f90cbcd">8,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE4LTMtMS0xLTA_20d24e43-7d28-45c8-83e7-c96b05b41f07">9,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE4LTUtMS0xLTA_a567c588-2133-423c-89c1-05a84f8176ac">18,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE5LTEtMS0xLTA_e4c6ef26-3d0a-4b27-a472-1208b31936d0">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE5LTMtMS0xLTA_84aedec5-13ff-495f-b03d-e5c4665bae86">8,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE5LTUtMS0xLTA_2d01faf3-9169-44fe-b1d0-be0620759321">28,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIwLTEtMS0xLTA_33c078ab-1b02-4c6b-8116-4e030e4c8d38">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIwLTMtMS0xLTA_788d735a-1472-4384-8faa-99e99eb88cba">20,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIwLTUtMS0xLTA_39d63db7-8f47-4e0f-81f7-e075b835d286">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIxLTEtMS0xLTA_f69287d2-bb49-4fe6-830b-3ff966bb7143">608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIxLTMtMS0xLTA_ac0a618c-c474-41c1-9ad8-853fef610134">618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIxLTUtMS0xLTA_c16e0583-b6c3-4850-9603-a2e2910beaf9">738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTEtMS0xLTA_fee16d33-1cdb-46d7-9e58-6b1ccca4f000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTMtMS0xLTA_bd564866-0b5f-4896-88a6-4863192c5a60">13,617</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTUtMS0xLTA_95f2dc58-162d-45ae-981b-a834632c44b3">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTEtMS0xLTEwNTE0_ea8ff11c-5464-4e82-bc0b-4446258a5d00">3,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTMtMS0xLTEwNTE4_4568b41d-2abe-436d-b0ac-8342a19bdff9">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTUtMS0xLTEwNTIy_17c9930a-31b3-4e66-86fa-526668727ecb">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI1LTEtMS0xLTA_c6d46310-3ae9-4efd-a2c3-af11d5bb5eff">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI1LTMtMS0xLTA_743458a3-8cef-4ce3-9a8b-001e2a831f32">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI1LTUtMS0xLTA_98327575-5f98-43ad-b39b-2cd577f9e363">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTEtMS0xLTA_0e091706-55f0-4f0a-93aa-3508b12268f1">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTMtMS0xLTA_d8afd8d5-f366-451f-a08b-743864bdef89">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTUtMS0xLTA_8080a23f-5d32-498c-938a-c1a2076f05b6">14,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTEtMS0xLTE3MTg_3374bd14-7d9e-4131-aab6-d9a7ce0a9108">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTMtMS0xLTE3MjE_566ffa2f-0f0c-4f96-9666-279166626f0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTUtMS0xLTE3MjQ_3f70ade8-779a-47e8-bf94-e96722a282a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI5LTEtMS0xLTA_22d644a3-2aff-40fd-abe3-21991530df87">6,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI5LTMtMS0xLTA_8d189b14-af32-4752-b652-8378017435c5">4,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI5LTUtMS0xLTA_ad70c368-6748-4484-afac-db176c00d577">1,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMwLTEtMS0xLTA_45402ba3-52e2-47ff-814e-54f85b99fef6">3,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMwLTMtMS0xLTA_3ae55498-fcb2-445b-ae33-44b27eee56e1">7,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMwLTUtMS0xLTA_4b197ef6-d7c8-4840-a88f-7aa73c9ac88e">17,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMxLTEtMS0xLTA_50aa47d1-9713-48c8-aef6-99b639af5ae1">3,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMxLTMtMS0xLTA_fbc6f534-cbaf-4f9a-9b65-109df322d67f">3,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMxLTUtMS0xLTA_cb5e7c34-03a7-4eae-8c99-548a11b1c063">3,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM2LTEtMS0xLTA_31eabee8-41e8-4985-ba2d-80ec7fe1d979">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM2LTMtMS0xLTA_18e00df1-3493-46e6-88ed-633524648a81">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM2LTUtMS0xLTA_07f5112e-84ef-405c-b30c-71fd30ad4602">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM3LTEtMS0xLTA_6d38f7f7-295d-4063-b876-743df66cd88e">4,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM3LTMtMS0xLTA_654bcad2-0a3e-45bc-be33-0fb69a3ddb6e">15,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM3LTUtMS0xLTA_f2f6c9f5-d1d3-441f-b781-30a4d619c05c">22,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM4LTEtMS0xLTA_cb8404c4-3f70-462d-9770-c7fc527b5ee9">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM4LTMtMS0xLTA_ca4e5e3a-1767-4cbc-aad0-80a19d3ff5d6">908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM4LTUtMS0xLTA_cd4ab9a4-9004-4c91-b30a-2eab2897d800">3,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM5LTEtMS0xLTA_19cc9f86-d9be-411b-ab2e-916dc64db1f6">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM5LTMtMS0xLTA_1124ae2f-cca3-4fb8-9bd1-15b57426f5ff">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM5LTUtMS0xLTA_0ca53325-e53c-4b8c-893b-4c33e2f5c018">3,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQwLTEtMS0xLTA_5915a6cd-71e8-42e0-9674-bcd1437a66c0">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQwLTMtMS0xLTA_8072f08a-16ef-4e73-80f1-2fb8c9de9dcb">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQwLTUtMS0xLTA_3238df67-205a-4cb9-94b5-0bfebfa7f566">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020 </span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_202"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMjg0_cdb12497-49a0-4827-8c70-3324c911bdfd" continuedAt="i26f1e4fb453e4885b9955c0a180030a8" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i26f1e4fb453e4885b9955c0a180030a8" continuedAt="ic71cf84b175e42c2b9f222d2f0b1984a"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:NatureOfOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDQ0_7aef9cce-f839-4075-b9af-0a895f332605" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in <ix:nonFraction unitRef="segment" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzI5MQ_edf2aedd-49a0-4858-8875-49340096c781">one</ix:nonFraction> business segment: human therapeutics.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzM1_a68299e2-1565-4d5b-92b9-49414da30298" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzEx_03a47182-6e1a-45f2-a103-9d522f1c780e" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDA1_8fd8a8d6-7b8f-4d08-8217-9e5c975c78ca" continuedAt="ia353d45a539a46c3a8fd2f4c8ff8921f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than <ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="amgn:SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyOTY_ff4302c1-6819-4002-bf38-df53bf0acaa6">1</ix:nonFraction>% of the aggregate sales deductions charged against product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than <ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="amgn:SalesReturnProvisionsAsPercentageOfProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzI3MTU_8d398b29-874f-4fc7-9f40-a4e4bb26ed37">1</ix:nonFraction>% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from <ix:nonNumeric contextRef="i3e0600ada49541efa4f790040e4c766b_D20200101-20201231" format="ixt-sec:durday" name="amgn:RevenuePaymentArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzMwNDQ_bc222c0e-dd35-4902-b8e0-868c924c005d">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i500dae5a099d445bb1e35d1af32c7bce_D20200101-20201231" format="ixt-sec:durday" name="amgn:RevenuePaymentArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzMwNTA_083bafde-4a07-4ae5-8b87-24dd27cfaec5">120</ix:nonNumeric> days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative (SG&amp;A) expense in the Consolidated Statements of Income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic71cf84b175e42c2b9f222d2f0b1984a" continuedAt="ic73e930bd24d486cbd0bfa3464393981"><ix:continuation id="ia353d45a539a46c3a8fd2f4c8ff8921f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the research and development (R&amp;D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div></ix:continuation><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDEw_0456f550-375d-44a1-832d-47e75bdb2ddb" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDE3_8171b911-3ecc-4d74-8bf4-5a3fc8aa1932" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2Xzc3NjM_b45ee439-0659-47c5-9ab6-6b51b2a382e3">962</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2Xzc3Njc_d621b14d-9cb5-47a9-91f6-9d23e4f36219">789</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2Xzc3NzQ_d288abc1-c2e7-4229-a666-87c9b2b8a498">674</ix:nonFraction> million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic73e930bd24d486cbd0bfa3464393981" continuedAt="ia2b3d17740ec409884eb062d610ff6e0"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzI5_58cdcda5-e55c-493b-a061-b1bf63b14d41" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of new lease standard</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new standard resulted in total lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ie4f66cb73cc34c1f99ee0486a92779e4_I20190101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzkzNDU_5747abcd-8f34-4817-b52b-a00ddc01aa86">510</ix:nonFraction> million and right-of-use (ROU) assets of $<ix:nonFraction unitRef="usd" contextRef="ie4f66cb73cc34c1f99ee0486a92779e4_I20190101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzkzODE_09a5ff82-791a-4f30-94b9-567aa92d767d">439</ix:nonFraction> million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDM0_79aa46ec-1a0e-4f2f-822f-645d196f3112" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDA2_e3d96fec-3659-4020-b64e-722f3845e22a" continuedAt="i64191a6bbff34f8ea92d614e1bf6ffa7" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia2b3d17740ec409884eb062d610ff6e0" continuedAt="i697ec72ead354a29b5582d44a8ead4c9"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i64191a6bbff34f8ea92d614e1bf6ffa7">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzQ5_12ddfaa8-b6cf-402b-b05c-7b03445dfe6c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&amp;D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDQw_f1cec887-0d18-4cdd-9544-7268efe41b4a" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzUy_1aebae7b-84aa-4d53-bae2-8792b6232b9f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDI5_7737c317-f660-4f2d-a28d-fc2c5f5b47cd" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDAy_d21244b3-0e6f-4b6b-a43e-e3fa7a98a94f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDM3_b78fdbfc-9538-451a-b429-52d62854ca24" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i697ec72ead354a29b5582d44a8ead4c9" continuedAt="i96532757b6fe479c92f9177fb4702e66"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzc1_c3a3eecd-3536-4dbb-b1a6-e55845dd6380" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&amp;D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDQ2_8f207bc4-872d-473e-900f-9e7e8a1614ef" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzky_04ce12e6-28f5-4798-a917-fe6d22f84e46" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars using average exchange rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzU0OTc1NTgxODg3NDA_5326b4c8-15c9-4c58-9c3e-dd95a79f94f3" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i96532757b6fe479c92f9177fb4702e66"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzE3_0094860f-f666-4f6a-95e1-975e2ffeeb61" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets are now presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the former other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand on the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impact that both standards will have on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="if8d0740b43d148a5ba67e4dd5b38ce46_205"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzcwODM_376ae1ec-f9fe-4d56-ae0e-19d2240e3606" continuedAt="i0e84af5c304c44b3845073f7ffe4f793" escape="true">Acquisitions </ix:nonNumeric></span></div><ix:continuation id="i0e84af5c304c44b3845073f7ffe4f793" continuedAt="iacae2d901f8c4b9789323dd6edb65603"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(apremilast)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2019, we acquired worldwide rights to Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene Corporation (Celgene). Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than <ix:nonFraction unitRef="market" contextRef="i5551c96cc50149c1880f899738b3a80d_I20201231" decimals="INF" name="amgn:ApprovedMarkets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQ1Mw_285eee24-d767-49e7-b34f-233eb605609c">50</ix:nonFraction> markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The operations of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been included in our consolidated financial statements commencing on the acquisition date.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzcwOTg_8e669f9b-8d59-4c02-be43-9dda191fd3fc" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzEtMi0xLTEtMA_04a3ca79-66ec-4147-9286-59cc159b86e8">13,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121" decimals="-6" name="amgn:Transactioncostsassetacquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzItMi0xLTEtMA_7ff0c9d2-495c-4a63-8d38-ec6915c3705d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated cost (consideration transferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121" decimals="-6" format="ixt:numdotdecimal" name="amgn:Businessassetacquisitionconsiderationtransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzMtMi0xLTEtMA_424ea156-09ec-4742-9484-11fe9ef09ca1">13,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77f9d1e3b77e4676870c5f350d1ef04a_I20191121" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzYtMi0xLTEtMA_6754789b-1b2d-4134-849d-cb3c555d6ee1">13,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4762422d6345f488ba0c0ce5c4df0e_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzctMi0xLTEtMA_56a2b2e8-c7c7-48c8-bad4-730e8c575401">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionInventoryacquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzgtMi0xLTEtMA_71be2d16-05dd-4f70-b1c7-f3e7005e3fe6">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzktMi0xLTEtMA_7af0eb08-b2dd-4018-a650-af15e08bab3a">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionDeferredCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzEwLTItMS0xLTA_4b7db508-72be-4b93-9884-b64de9dd67bf">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzExLTItMS0xLTA_9c8bb0ec-5cf4-45d3-b0e5-39dbb91d62d1">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzEyLTItMS0xLTA_4b200e22-1896-4dde-a343-50909082654f">13,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iacae2d901f8c4b9789323dd6edb65603" continuedAt="i5e9a1d0360954bc2bffb5a55cc94e920"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed-product-technology rights acquired relate to Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i33c2747ebad4402e9ac07aae03462e78_D20191121-20191121" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzE4NjQ_64f3b4a2-eeb9-44b3-ab2b-ba0e0c14cde9">8.5</ix:nonNumeric> years by using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce will be amortized over a period of <ix:nonNumeric contextRef="ibc8c902e15924dd683695464fe7097de_D20191121-20191121" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzIyNTE_27c35a74-34c3-4601-8237-201f18f249cf">5</ix:nonNumeric> years by using the straight-line method. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#8217;s effort are applied. Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate <ix:nonNumeric contextRef="idc3c1c1c0a9b4e5eab8231f9ac287d8b_D20191121-20191121" format="ixt-sec:duryear" name="amgn:AcquiredFinitelivedAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzI2NjY_03c3eb0c-fde5-41c5-a2d9-43650169f514">2.5</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzg1_7389b0a3-829a-4fb1-92b0-23821ed452d3">119</ix:nonFraction>&#160;million, a net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzU5_11351e9d-cd27-450d-adf6-eba6016c518d">24</ix:nonFraction>&#160;million and a deferred credit of $<ix:nonFraction unitRef="usd" contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzcy_b6a7de30-8ad9-44e5-b69e-dd48ab8f5d91">96</ix:nonFraction>&#160;million. The tax effects of the acquisition are based on Amgen&#8217;s estimated blended statutory tax rate of <ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzk5_9bb276d8-e545-44eb-b0a6-b7411c0891a9">20</ix:nonFraction>%. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuevolution AB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i8a2e62d8eeb048f38ca8736344e50d1d_D20190715-20190715" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzI5MTU_703fc49a-58d9-499e-873a-4bead3bb816b">183</ix:nonFraction> million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution&#8217;s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ic20538b33ec0455ea0039c1984301d31_D20190715-20190715" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzMzNTk_5a71ad74-28a8-4121-89b2-c6c932a4f891">150</ix:nonFraction> million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of <ix:nonNumeric contextRef="ic20538b33ec0455ea0039c1984301d31_D20190715-20190715" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM0Njc_a04ac9f8-5c61-49ab-bee4-3dba2557af1e">10</ix:nonNumeric> years; goodwill of $<ix:nonFraction unitRef="usd" contextRef="i36b9b3333490457493d595249f49eea6_I20190715" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM0ODM_ec0dd8c2-e773-43fe-852a-0f95d3ca76cf">26</ix:nonFraction> million, which is not tax deductible; deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i36b9b3333490457493d595249f49eea6_I20190715" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM1NDQ_c2ce95ff-212b-45d8-8552-68792a24df45">22</ix:nonFraction> million; and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i36b9b3333490457493d595249f49eea6_I20190715" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM1NzI_bc69c03b-904d-4f16-bfbc-671045e56bf0">29</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kirin-Amgen, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018, we acquired the remaining <ix:nonFraction unitRef="number" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQxOTc_5ba5132b-97bd-4424-b7f2-4efe96830bd1">50</ix:nonFraction>% ownership of Kirin-Amgen, Inc. (K-A), from Kirin Holdings Company, Limited (Kirin), making K-A a wholly owned subsidiary of Amgen. Upon the acquisition, K-A&#8217;s operations have been included in our consolidated financial statements commencing on the share acquisition date. The acquisition relieved Amgen of future royalty obligations to K-A. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the share acquisition date, we owned <ix:nonFraction unitRef="number" contextRef="ie94c75a285ca4a36b1982968d4172401_I20180331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQ1ODg_7e16f83e-8ed9-4c7a-bd27-53da124d6765">50</ix:nonFraction>% of K-A and accounted for our interest in K-A by using the equity method of accounting.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing <ix:nonFraction unitRef="number" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="INF" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQ4MDA_d5f3f185-76e5-422f-8a47-a53ca61d4c37">50</ix:nonFraction>% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K-A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $<ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzUxMTk_987ea437-de91-47b1-b11a-770dd93cb5c1">80</ix:nonFraction> million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5e9a1d0360954bc2bffb5a55cc94e920"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary means of consideration for this transaction was a payment of $<ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzUyOTI_14c77be0-f764-4e47-b9f7-6bbdf525597e">780</ix:nonFraction> million in cash. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzcwNzg_04864e70-5c2c-4272-af01-cf4966e96003" continuedAt="i9456cdef4320454289cfde43cc2b9948" escape="true">The aggregate share acquisition date consideration to acquire the remaining <ix:nonFraction unitRef="number" contextRef="ie94c75a285ca4a36b1982968d4172401_I20180331" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzUzODA_f4dbce0c-6192-4d3e-9e57-aaa6a6568bd2">50</ix:nonFraction>% ownership in K-A and the fair value of Amgen&#8217;s preacquisition investment consisted of the following (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i9456cdef4320454289cfde43cc2b9948"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash paid to Kirin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzEtMi0xLTEtMA_a2767a2c-2580-42af-9fdf-d86e6d444aeb">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzItMi0xLTEtMA_baff41fb-2113-4db8-9747-1c5b5e62f826">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on settlement of preexisting relationship</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzMtMi0xLTEtMA_9d8c49e3-5443-46ad-92a1-b180c58bb882">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred to acquire K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzQtMi0xLTEtMA_f74c8195-4260-4602-9a02-acbc156c0603">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Amgen&#8217;s investment in K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzYtMi0xLTEtMA_642b1659-3d87-4d1c-b07c-ff317f060f15">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzctMi0xLTEtMA_d4adb474-84c4-4e8b-a1ee-d093bf2cdc8d">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. The estimated fair value of this contingent consideration obligation was $<ix:nonFraction unitRef="usd" contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU3MTE_baff41fb-2113-4db8-9747-1c5b5e62f826">45</ix:nonFraction> million as of the share acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of assets acquired and liabilities assumed consisted of cash of $<ix:nonFraction unitRef="usd" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU4Mjg_1e2aa4df-f4f0-4373-81f6-7da3a27e7978">977</ix:nonFraction> million, licensing rights of $<ix:nonFraction unitRef="usd" contextRef="i4940f97696f6461f9e3e54bffb7828bf_I20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU4NTI_66d6936e-49df-4c07-a47f-f2a5cf14b9dc">470</ix:nonFraction> million, deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU4ODQ_b1fc2636-408d-4f82-bc84-bc7f480b25d9">102</ix:nonFraction> million, other assets and liabilities of $<ix:nonFraction unitRef="usd" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU5MjA_6cff050c-264a-4b93-8b4c-01f0c86d8eec">131</ix:nonFraction> million and goodwill of $<ix:nonFraction unitRef="usd" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU5Mzk_ba9bbaf1-e84c-4796-a6d4-d550a8976da3">6</ix:nonFraction> million. The estimated fair value of acquired licensing rights was determined by using a probability-related-income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i5f9e4779ad6d4c519da3afeb8a9750dd_D20180101-20180331" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzY0NDg_b32eec5a-46e8-4bc5-af7b-78ade40f724e">four years</ix:nonNumeric> by using the straight-line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzY2MjU_3eda34a7-2e82-45e0-b5f4-b6ebf193a4a8">6</ix:nonFraction> million was recorded as goodwill, which is not deductible for tax purposes. The $<ix:nonFraction unitRef="usd" contextRef="i047674f49e494a17949b2b546351ed81_I20180331" decimals="-6" format="ixt:numdotdecimal" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzY3MDA_048e332d-8e2f-406c-a8e0-ff8ea811c140">131</ix:nonFraction> million in other assets and liabilities primarily represents receivables for royalties earned by K-A but not yet received, partially offset by payables representing R&amp;D expenses incurred but not yet reimbursed by K-A. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results of operations for this acquisition have not been presented because this acquisition was not material to our consolidated results of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE5NDg_ae02e1b9-1492-46fe-bd43-f8456b9fa80f" continuedAt="i3f8cd1856e8d4773b298cdc642eaa439" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="i3f8cd1856e8d4773b298cdc642eaa439" continuedAt="i3b1d1bee2122468d928e31a88f54e414"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzMx_84255a21-02d1-4423-a0ed-bfe9314b05e2">one</ix:nonFraction> business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of rest-of-world (ROW) revenues relates to products sold in Europe. </span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE5NDk_b2bb9102-c0a0-4e7f-b039-3b15aa7e039d" continuedAt="i82ada896043245628cd90c5adb86a120" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(etanercept)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926aaf96c0584bbdad52c9ef18251ea8_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMi0xLTEtMA_6b4af797-1da7-4742-bff9-d95b943050e5">4,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c90fddb2bc49aca05ba3690ecb0e12_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItNC0xLTEtMA_d64ffba3-d91a-49fb-b4e9-6a24a6e19ada">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb99da9fcc0c4198a6a265c212af7ab1_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItNi0xLTEtMA_fe24e670-4ae6-42ad-9c77-ce2a2652c4a6">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01555b26feb044308b7e206b9dccd0f5_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItOC0xLTEtODc4Mg_38a2b492-2c87-468f-90b5-6a0a89b405fc">5,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic204c7f26f03488aab5ee3f10cb8e502_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTAtMS0xLTg3ODI_a692c165-c392-4a4d-8e85-6d611766a822">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bf2bacd2b2492bb28ef69a40f8ec26_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTItMS0xLTg3ODI_91a35ea0-c61f-4b2c-9619-a4dbf7ab5309">5,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f527e1b66d49af9406611b9596ff22_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTQtMS0xLTg4ODE_f0a3c98b-25a9-4384-944b-624c8460673f">4,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974741dcb1524051a7646fedb5f2c5ab_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTYtMS0xLTg4ODE_e9ec3e6e-d2e3-497d-a917-8706c8604689">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afc5561327f469a8133f9d02a2cb093_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTgtMS0xLTg5MTI_f57cacf9-6800-46c1-8988-c758ef506ef2">5,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2d439e1e6f409bba4a3347af4696d6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMi0xLTEtMTc2MA_847c73c6-a24d-4b50-9d31-79a0061fb36e">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ccac04c7f24f92b788839f717d6523_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNC0xLTEtMTc2Mw_ee5d87d6-adb3-444c-a850-64182cc4363c">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2728b90e4d4b7aa0313586de0029cb_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNi0xLTEtMTc2Ng_800b4fe7-5104-41fc-a8aa-feea458f84ae">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5483364e0744c68922713f01e91c7a3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtOC0xLTEtODc4Nw_8fe178b8-e2f7-4030-82c1-2d7ed1168c34">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief15e22862ba4cf39454d38e1cbdcd80_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTAtMS0xLTg3ODc_3a229ed4-96f6-4384-8cc8-b31bcabb7c4b">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fa621683b24ffdac5458723dae9a1e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTItMS0xLTg3ODc_62b22a0e-039e-4d9d-97fa-45ee5cb19af1">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac24acf4d93f495ab9d6b3536f41e0ed_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTQtMS0xLTg4ODM_4e8c4d40-f1b1-4833-bdc2-37bebd87f4cd">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10cda4e685d04ba792d0adfb5f0a1437_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTYtMS0xLTg4ODM_b648a947-0854-4dd0-a9c9-40bb77c99968">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7459c244aa8e43f79da3a9ea0637ec62_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTgtMS0xLTg5MTI_e21ca065-0d96-45d5-8278-188c433ba920">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(pegfilgrastim)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480fcce9b28440b8b0224b6be301e101_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMi0xLTEtMA_70e57a5d-c35a-40c5-8699-c18f6a819444">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92377c788f944386a84ed9e862d6a789_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNC0xLTEtMA_2a6ad296-5466-4511-b389-ca78af720c1d">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d93219c901f4d2993fd42b15214c20b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNi0xLTEtMA_54036485-1432-4eef-a501-9a17d3240bab">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01a0ca8cf65419c8aec6edf5d45bba2_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtOC0xLTEtODc5Mg_76205860-2f0c-434c-a163-4dd096f79269">2,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda0fe0d08b14312b1ce2f95d9af1d9b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTAtMS0xLTg3OTI_217ef721-bc6d-495a-a4c8-9c500bede593">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66f6e020a4a4abd9de549021d7c3700_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTItMS0xLTg3OTI_2537ecc1-4e24-4800-928b-bf8373519c18">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b462b363df4e43ac25594c6bc680ac_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTQtMS0xLTg4ODU_e5bd7689-782c-4cf0-9c48-423a63f7bca8">3,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b6d4d4a4f740d9bf97809cb4f715de_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTYtMS0xLTg4ODU_bcb4ecf1-3e4c-47bf-9bad-896e5cedc7ef">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c93f72881be41c283567c566484b6ba_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTgtMS0xLTg5MTI_c03e751a-8d49-42de-a7a4-af88738ee047">4,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5aa16ed3e64d8187270f007bf3bef9_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMi0xLTEtMA_565c832d-0db5-4aa0-9eee-1efa3e26eb3a">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5b09f7a19b84d2bb41e108ff3322951_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtNC0xLTEtMA_45e6c812-0834-4034-b00e-c77630f082f1">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785509d5031b4d25817f65f949f65892_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtNi0xLTEtMA_e51be870-f6cf-49af-b45a-3c1116b06d49">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b3a114ec374c5c97599ab0369d2720_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtOC0xLTEtODgyMA_00dba7bd-e8d0-4a2d-9aa4-1c95804eb49f">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948008cca6de4273bad98a9766aaba9d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTAtMS0xLTg4MjA_d24f3433-8ea0-4a9c-9885-01e838ab9e56">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f37efa18d214f73a67190daafe053dc_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTItMS0xLTg5MTA_41117f1d-2f4c-4d0e-adcd-1df8c9d1ea65">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i954f15f923f241b18df02db5dbb43dc5_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTQtMS0xLTg4ODc_15acb080-bcb2-477d-8289-df292fd017ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b55b920060459e9114165eaf8c36bb_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTYtMS0xLTg4ODc_1c11e1b7-6d04-47ac-944f-a0be7d39e020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc6b87796b943d7934bab2b49c79114_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTgtMS0xLTg5MTI_7842b71f-87a3-4ab3-af0a-af3c30de5843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e053e17a9c8401b9e7ebd23b33490dd_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMi0xLTEtMA_74cf75c3-476d-4392-8b4d-b847dba61c16">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00a07432ae44f0e9d1fe5c284da0bf8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtNC0xLTEtMA_43bb71de-005d-4dc2-bc0f-d241d81ae814">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0738e434f843b586e64e732d02c689_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtNi0xLTEtMA_9b5c941e-9dd8-4589-902f-e20a3762d22b">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e04b7c055e466cad54c342d9bbc9ae_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtOC0xLTEtODgyMg_edd4165b-7c8d-4f76-9d70-476bfa1c98e2">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6539a6cf160e487581559eeb0031769e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTAtMS0xLTg4MjI_fe14f9a1-ddf8-4b97-84ca-ce2fbfa52ab4">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie608b9d0be364ba0ba1110fcb2c0fc98_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTItMS0xLTg5MTA_2dbfc323-0106-4371-a81a-c0b1e2e83e6e">1,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8758e51a2d4092bcb71092363b47a0_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTQtMS0xLTg4ODk_1f5fe874-6aaa-4630-ab50-d336259e0016">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e790b9674254ba09f653c813982f56e_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTYtMS0xLTg4ODk_c76c34d6-ce53-41ec-80b0-51795732be18">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565f06fae6c54af084a236838566deec_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTgtMS0xLTg5MTI_1aace9de-2206-495c-9d6f-7decd1a8a827">1,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(darbepoetin alfa)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2f55bcc30a4cfca648fe698fc70f10_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMi0xLTEtMA_77485db9-4962-4fea-8ff3-064f4613ce39">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4de803606b49cf808e39411da4f3fb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtNC0xLTEtMA_7d2ef952-5841-4df7-a8c7-58daab8965bc">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8b822803f747429f4e453f30a1f8c3_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtNi0xLTEtMA_ea37e1a2-3816-4d63-8b32-ddfa53107054">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae041643bb42a9bd46624d883f023f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctOC0xLTEtODgyNA_92c96122-cb82-4c5b-8df7-2bbc73a9ec62">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ac4fa9d33b4a7b953dcfb37f07cb31_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTAtMS0xLTg4MjQ_8df07125-6a16-4139-b301-090cb4f15bf6">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82550ed044ae48fcad2e75453e121d7d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTItMS0xLTg5MTA_39f409cb-0452-44e4-a009-a9f52b1fbc4d">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7283e03d6b247e5b00618781810a864_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTQtMS0xLTg4OTE_9c2c7536-f4a6-4099-bf72-e8bef3550cf1">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba12b5c33af41909da76cfd32eb41b6_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTYtMS0xLTg4OTE_9d507c19-7d15-4317-92c0-c822036271d9">935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5881997bfdf454b806bb4e23f90b0f9_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTgtMS0xLTg5MTI_c82504b2-be07-4a44-a1c6-4df5cfa50453">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(carfilzomib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if858ed80d6524471b48fe73e181c069b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMi0xLTEtMA_db01cf5d-2ab6-46e4-bc7b-c9704d805fb2">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837af2fa08e640ef82a438132d76de4c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctNC0xLTEtMA_39d6fa4a-9654-4aab-9d2d-aba8b621f217">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aade48bbe8e4569b0b5690c45eaa909_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctNi0xLTEtMA_a9393415-f785-43eb-801f-168da567d9f1">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c55591acd534a2bbf75ee8ff1c0fc2c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtOC0xLTEtODgyNg_6d9c27d6-925b-4140-ba46-9dc0b7453df3">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b00f3f0c5064b28bcf5ecd0be53d820_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTAtMS0xLTg4MjY_598fae20-06ad-4955-9f6a-3f3b450cace1">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8fccaf64c14f8eb120b3b7d5ba9bd0_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTItMS0xLTg5MTA_eacfecb1-cba8-48d7-a365-f19fdb5d188f">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c300e2b07004083841461728c0799c5_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTQtMS0xLTg4OTM_3093ff69-73b4-49db-8d72-c9750c2d6e1d">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9064c0fd8a47349673fd7361fe5c17_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTYtMS0xLTg4OTM_28f74902-8882-42d3-beca-5ac539e7398e">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4ed7c0dd1f403dbb6a02eae47b79e1_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTgtMS0xLTg5MTI_724df929-c9c7-4dd6-a5d1-fe9baba595ea">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8c8a3331fe4b2cbcbfac819fa802e6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMi0xLTEtMTc4OQ_1cd6e150-9aeb-4add-beab-636a828d2316">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4a40aa83a243ddb4bd0747024f97c6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtNC0xLTEtMA_52a66559-0fc0-442b-bb8e-13d8f6c3e127">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f35c7cec9fe40ec8747a982642437ea_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtNi0xLTEtMA_8b7e0cf7-562a-410e-ba41-060b879be01f">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4954236e263c4019bc3eeeca23e8ba96_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktOC0xLTEtODgyOA_d334309e-ee0e-432f-bdcb-8f7d28906a20">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70f8bc85eb544149a219b33c04fdc84_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTAtMS0xLTg4Mjg_04df7a5e-7f9f-41b4-a79a-8287488c53a4">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64ae6d964234f3e967e327673f9b5fb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTItMS0xLTg5MTA_86b9c308-e1d1-4bed-a403-3e41b4586846">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ee66a0043a4f228b82c153cef85490_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTQtMS0xLTg4OTU_0ec31984-a8b0-42e6-aaba-f4fa363ec7b3">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf63a10013548d8817d20a261bd0901_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTYtMS0xLTg4OTU_61613603-3a1f-4e5f-b4ff-410d9d2e63db">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3484149e2df04c2685210fde93380a2c_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTgtMS0xLTg5MTI_6f6a1d57-20a3-49b0-be82-5c41d7dec7f3">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ed027ed29142ed9606f57e5869839d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTItMS0xLTA_972650fb-a1af-4600-8fdd-c60c1134ee0e">4,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2835d9ca084e8fb4795aa78b07d43a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTQtMS0xLTA_d47e2a15-240c-4135-8f0e-99448fa2846a">2,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1186b599c8874028bb81519ce6bb2c59_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTYtMS0xLTA_7f7da72f-f4f7-45d9-b02c-53aed951312f">6,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d438d374ae4f78b599ce6bf7a19bab_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTgtMS0xLTg4MzA_3d53bfce-f036-42c2-a91f-4f22e7a72259">3,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72bee99f05d48eea6c4eb1bf4db9e82_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTEwLTEtMS04ODMw_f7631152-70e2-4c50-bad7-14b6c7b9f0c0">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4092f5882c8142d39834b7722d6d303f_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTEyLTEtMS04OTEw_ed264d88-4361-46db-971a-54b670100354">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f466fc09cd44386b87d1c42d0cee056_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTE0LTEtMS04ODk3_223d4dcd-2117-41af-8e04-4a606c039349">4,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5caf3504dcd64ab2ac04090326aa57b2_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTE2LTEtMS04ODk3_d0a22e99-372c-41a4-9bdd-769078c57005">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b6988cfabf40cd958ae6cf44c7f9d3_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTE4LTEtMS04OTEy_78d21d46-72f2-4c50-85e3-30a6e68a3a01">5,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b14be4183743e4b46f705ac6239e47_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTItMS0xLTA_f71fead0-173e-4d59-a3d5-e7f671b3acfc">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcb63d22b9249af85cc7ca7293e287d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTQtMS0xLTA_3c944f9b-6496-41df-ab36-dfadb1d0629f">6,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTYtMS0xLTA_3bbb8010-d237-461a-923f-96633cc5c99c">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630a0351e5c24898bfb45b915cc63356_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTgtMS0xLTg4MzI_eae5253a-e163-48cd-83c4-41e65022acdf">16,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9811f73a8446e4b074fdb187aa7238_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTEwLTEtMS04ODM5_969baa3f-786f-47e3-b5a0-8b827096f46f">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTEyLTEtMS04OTIy_f5229778-8db6-48bf-95ed-b6e28c59c081">22,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b360a237fa4db9b2adfe8a31418cb1_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTE0LTEtMS04OTE2_21f3fc76-678d-4320-a293-d908e3e1e9d1">17,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116be71a0f84428099ebff205742ed3c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTE2LTEtMS04OTIw_2283b9cc-26db-413e-b0f4-ba3d385db143">5,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTE4LTEtMS04OTI0_55314b70-8300-48b5-8d0d-53c9c658d937">22,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965bb3051c3c43e5a0bfa194108e71ae_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTItMS0xLTA_5ebd8c3b-3fe0-423b-a4af-5efcda9113c9">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9bc46f725a420caa5d9c001fe229ec_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTQtMS0xLTA_0b36c85c-ce57-46bd-a013-5c852fb68149">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0a9e21adce47979f7e38ab4025e6ca_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTYtMS0xLTA_1baeee2c-5490-4118-891b-abf735bf8e85">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67042c7baef94c1e889169924cf1d15d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTgtMS0xLTg4Nzk_e685919d-ddfa-4754-b6f0-53584569ee5d">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672733c420164f04985cc409f649c152_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTEwLTEtMS04ODc5_5c1ef18c-5085-4a6c-8622-23867a50e9e8">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25a2862d79c42ba91f97b4241baa3f9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTEyLTEtMS04OTAx_699273a6-0b84-46a5-bf61-e121e121684c">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bda5bc42554606892f0ef083ebb8ef_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTE0LTEtMS04ODk5_38d2e292-01f0-431a-be0b-712e03794cd9">929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4fc03ab19f4f3399d8c1f71e1a4ea5_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTE2LTEtMS04ODk5_19853c60-a5a6-4d6a-b0f5-c6967c8236cd">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e077713b1f432fb30f0a3751b4bdf4_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTE4LTEtMS04OTI4_c8e359ef-4aef-4449-9dd7-f94426d662aa">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5a2a803f5d48dcb8f85fdb926cdeee_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTItMS0xLTA_221de37a-3b0c-4101-936c-0d216bf05f9b">18,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ebf38a5dda46d0af6058ec22408dd7_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTQtMS0xLTA_0b64302c-aadb-405a-9c18-141307511788">6,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTYtMS0xLTA_23d6d476-e2fa-435a-831c-646b58521d3c">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf240dc750624161beefc465d5d2520f_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTgtMS0xLTg5MzA_bdc1d80c-f393-4e4e-9057-ee98a1e7abd4">17,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02193c66855b4a3d9d3f81f4d4d0aa3e_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTEwLTEtMS04OTMy_4261c56a-d584-4bd1-be47-3f382d1afce6">6,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTEyLTEtMS04OTM0_3dabb74f-f026-4220-97a7-eea730e20fa0">23,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb6193cdb49341959aaf15728de81f9e_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTE0LTEtMS04OTMw_11c74a8c-269e-49a8-9f57-20fb8533ed9a">18,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dcdd28acc6e4387a9bb47e6478a91ee_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTE2LTEtMS04OTMy_700a0890-54a1-49d6-a1ec-7a8355cc4f7d">5,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTE4LTEtMS04OTM0_363abbc5-f9a4-4047-bb5d-83596bd0e160">23,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was acquired on November 21, 2019.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i82ada896043245628cd90c5adb86a120" continuedAt="ibccbde24c31549e1b9df478f90e0bb2d">(2)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibccbde24c31549e1b9df478f90e0bb2d">Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3b1d1bee2122468d928e31a88f54e414"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had product sales to <ix:nonFraction unitRef="customer" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzExNjk_3f1fc236-c30b-40a2-a6cf-9c27b211e047"><ix:nonFraction unitRef="customer" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzExNjk_7cbff791-ae9b-40ac-9fa3-62514f083221"><ix:nonFraction unitRef="customer" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzExNjk_9478b9f0-a240-4cce-b64e-2c7f7aa036fa">three</ix:nonFraction></ix:nonFraction></ix:nonFraction> customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for <ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzEzNTk_82d6e374-7d54-47ef-a08a-e268bec90188">83</ix:nonFraction>% of total gross revenues as shown in the following table. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE5NTI_0efc3230-1c2d-4d98-a3db-caf33518797c" continuedAt="ib13fa5186b2b464fa61e67258ae269f0" escape="true">Certain information with respect to these customers was as follows (dollar amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="ib13fa5186b2b464fa61e67258ae269f0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzMtMS0xLTEtMA_35c5d3fa-4b83-4b9d-a5bc-657dc3690d9b">14,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14301973b9e04d95bee6bcdcae7c842d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzMtMy0xLTEtMA_ccbbce34-cbb1-457e-81ac-bae02be1b2f7">12,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c07a4b5b5b4cdd80a13653f61ff54b_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzMtNS0xLTEtMA_74b69678-8ab1-45c4-9288-a58c7736a8ce">12,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzQtMS0xLTEtMA_393f9d86-f958-48a0-b1cd-b27c21e86eec">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14301973b9e04d95bee6bcdcae7c842d_D20190101-20191231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzQtMy0xLTEtMA_77f105c8-ba2a-4629-aa29-15eb4ad90603">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40c07a4b5b5b4cdd80a13653f61ff54b_D20180101-20181231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzQtNS0xLTEtMA_59f9fac8-c942-4803-a23a-c7e963d687ec">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic744474389a6477387cf4ff42d717bae_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzYtMS0xLTEtMA_acac64df-fdff-484b-8d4b-3418eb00ee30">13,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd7acc9830e47eea1f588c56bdee6ed_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzYtMy0xLTEtMA_4b28034a-9630-44c5-a046-fe69fbdf9cd9">11,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271dc91e748b4ddea09ef131d4fd6b38_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzYtNS0xLTEtMA_efa924d7-b36c-4b1b-9625-13fcd6023c5e">11,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic744474389a6477387cf4ff42d717bae_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzctMS0xLTEtMA_73b546a3-cec4-43d4-a110-a07a6ea084b3">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4bd7acc9830e47eea1f588c56bdee6ed_D20190101-20191231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzctMy0xLTEtMA_4eb5bcf6-3c89-4448-962b-9edae2388e57">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i271dc91e748b4ddea09ef131d4fd6b38_D20180101-20181231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzctNS0xLTEtMA_7e61cb3c-9c49-4b73-be39-cfd90d096595">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d15f91e0634082b728d72dc4737601_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzktMS0xLTEtMA_8221e23c-1ef6-4d0b-ac10-4a7b5c87c47e">7,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ad54f16489e40c38fdd8b424bd6f702_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzktMy0xLTEtMA_1c583e5c-b996-468e-b611-3d973d6baff0">6,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4eb4dc90c94e328e1dbe4584b6099a_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzktNS0xLTEtMA_ebca5694-dda5-4dcd-ac0a-380b49451436">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77d15f91e0634082b728d72dc4737601_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzEwLTEtMS0xLTA_9cba3d81-1da1-41de-b484-dc7bd6181669">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ad54f16489e40c38fdd8b424bd6f702_D20190101-20191231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzEwLTMtMS0xLTA_f2682b43-d8cb-4add-883f-96be805c751b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b4eb4dc90c94e328e1dbe4584b6099a_D20180101-20181231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzEwLTUtMS0xLTA_1f516b9f-cfe3-401e-a4f0-1108b884a31e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, amounts due from these <ix:nonFraction unitRef="customer" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE1NTg_6b6c03ed-d6b0-4343-b71b-b97fe2eb218d"><ix:nonFraction unitRef="customer" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE1NTg_9afc0d0c-bbef-4d42-a551-30ccbab4e2bb">three</ix:nonFraction></ix:nonFraction> customers each exceeded 10% of gross trade receivables and accounted for <ix:nonFraction unitRef="number" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="2" name="amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE2MzM_12b38e55-0ef7-4333-ad65-7badbd38574f">74</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="2" name="amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE2NDA_6d72358d-ea84-437c-847d-4d72fbb1c2f5">73</ix:nonFraction>%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, <ix:nonFraction unitRef="number" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="2" name="amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE3MjE_fb7695ac-51cf-4d03-b2c0-4addc19cc4c0">28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="2" name="amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE3Mjg_1a85100c-2d32-4474-bd2b-a1f3279a98aa">27</ix:nonFraction>%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.</span></div></ix:continuation><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_214"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0MjI_8c11c1f0-0d09-4c1d-94fa-0ffb3230c320" continuedAt="i889eb9b5942a423db4c80fd4338d3ee5" escape="true">Stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="i889eb9b5942a423db4c80fd4338d3ee5" continuedAt="i7764ef0e285e45dd8193bfc2038e1ae4"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated 2009 Equity Incentive Plan (the Amended 2009 Plan) authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by <ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQzMg_c7d55b04-b7c5-4d15-8dcf-84b373e95dbd">one</ix:nonFraction> share for each stock option granted and by <ix:nonFraction unitRef="shares" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQ3OA_cc17e3f2-954c-4e08-96c0-c85ce61af93f"><ix:nonFraction unitRef="shares" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQ3OA_cc7c594f-7cb1-4c7a-9fd8-2f839140e6d3">1.9</ix:nonFraction></ix:nonFraction> shares for other types of awards granted, including RSUs and performance units (full-value awards). In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of <ix:nonFraction unitRef="shares" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="INF" name="amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzEwNTU_b636fdb0-6625-4602-ae3f-7977d47767f4"><ix:nonFraction unitRef="shares" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="INF" name="amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzEwNTU_dfcf0ca4-7dd8-4d01-8819-c0f57bbae1be">1.9</ix:nonFraction></ix:nonFraction> shares. As of December 31, 2020, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately <ix:nonFraction unitRef="shares" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzExNTE_1ab2df71-c000-4e65-8d33-2b9c0d877c87">23</ix:nonFraction> million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0Mjg_fb57f8ac-4571-43c7-820b-22f3b0bd0661" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzItMS0xLTEtMA_f29b5a20-338e-4bfa-aa24-ecc97d7e8b2a">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzItMy0xLTEtMA_62a70ee4-f6ba-46e7-9c55-2fbe88df82ee">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ce8a336da14fa284511392f12999d3_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzItNS0xLTEtMA_eaa128d9-5367-475b-b4bf-401a04a3e0a3">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzMtMS0xLTEtMA_acbede0c-318f-4815-b58a-237a2728d678">118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzMtMy0xLTEtMA_192a7282-b325-47f8-b5ce-ce15a6cfbd5e">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzMtNS0xLTEtMA_102adee4-f4b0-4a54-9dd9-6961a653c455">117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzQtMS0xLTEtMA_fcdec163-e0ac-41b7-bdc3-86d08712eee5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzQtMy0xLTEtMA_f66101b9-167d-41ee-af6f-f00a76189f70">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzQtNS0xLTEtMA_d2430de9-e10a-483a-85a1-19ac63549359">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzUtMS0xLTEtMA_f6008377-d32b-42d3-bae0-5fca67e77c5a">330</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzUtMy0xLTEtMA_4bc29d3c-d3db-4c57-8662-23f965a3a278">308</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzUtNS0xLTEtMA_5587d1c3-d736-405d-acfe-f769ef4be924">311</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzYtMS0xLTEtMA_8dfa379a-9ec8-4ca0-9bb7-23ae130b0fc9">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzYtMy0xLTEtMA_8c321bbf-4b2d-4205-8c0b-5147c699854b">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzYtNS0xLTEtMA_60cf9920-6305-4176-be17-57847574d85a">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzctMS0xLTEtMA_09d5f447-0d6d-4a43-bf71-02360e214624">258</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzctMy0xLTEtMA_cbf92909-e9ce-4919-9241-2598483b1827">241</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzctNS0xLTEtMA_efc3c875-71b7-430e-8918-63d69c5e13e1">244</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units and stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#8217;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7764ef0e285e45dd8193bfc2038e1ae4" continuedAt="id338f2e6a4f24b74b6f7422e80494b1b"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0MzA_5b926492-6437-43da-ba57-f408ebb480e5">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.</ix:nonNumeric> RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usdPerShare" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzI4MjE_c9c07145-7a82-4465-94fe-5685241afe96">235.63</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzI4MjU_6a8379c3-d074-47d5-8f24-70d62c297225">182.12</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i97ce8a336da14fa284511392f12999d3_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzI4MzI_7599545b-c126-4aa8-8ea1-fc01e8526a60">179.18</ix:nonFraction>, respectively. </span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0MzE_8a50a70b-6d5e-46ab-a22e-6289a3d59682" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie818cfed00624ad480f081b1918b959a_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzItMS0xLTEtMA_eecd7b63-031d-474f-9050-c075acfb87ab">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie818cfed00624ad480f081b1918b959a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzItMy0xLTEtMA_1a717963-77ef-439a-b0a6-1fd8bc3888a8">174.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzMtMS0xLTEtMA_7a7e2960-80a5-4cfc-b494-9556af677e53">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzMtMy0xLTEtMA_9b33ce3a-af1b-4bcd-80f1-23a74190ce81">235.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzQtMS0xLTEtMA_2da24aed-a0e1-4e8b-9e56-29f32398ff2d">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzQtMy0xLTEtMA_349a6f88-b1b1-4ec8-9f9b-a022a81a89c3">167.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzUtMS0xLTEtMA_6283c7dc-e5fe-40f5-a600-241b1d26b640">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzUtMy0xLTEtMA_668c8a56-9dde-42c6-8d1b-d672c04f5a67">190.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce4ceb699bb403ca25d48176261113a_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzYtMS0xLTEtMA_bc1ae1b4-d5b3-43eb-9096-1e1b5ca7aa1f">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ce4ceb699bb403ca25d48176261113a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzYtMy0xLTEtMA_d98443de-117c-4128-9373-74cd9366c647">198.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair values of RSUs that vested during the years ended December 31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMwMjU_939d8785-6751-4f8e-a119-da12c1820c5e">161</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMwMjk_193c54ac-5fb0-4ee5-b257-b260e0b0b355">160</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i97ce8a336da14fa284511392f12999d3_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMwMzY_5884b9cc-a2d0-40e9-a25f-ba7b1c3a8a47">167</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire <ix:nonNumeric contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMyNTg_06a3933a-a368-4ee4-a38d-449f7ebf03a8">10</ix:nonNumeric> years from the date of grant. We use the Black&#8211;Scholes option valuation model to estimate the grant date fair value of stock options. </span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzczOTY_c5829ab1-3e82-4950-8e0c-1d38ff3c5e06" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzItMS0xLTEtMA_7d6d51b5-02e8-4447-bb97-b494dfca0038">236.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzItMy0xLTEtMA_9c4162cf-d67e-44d3-b69e-a1766fa58999">177.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzItNS0xLTEtMA_14f49736-e195-4696-bd8a-abd60d0386c0">177.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzMtMS0xLTEtMA_71cdefea-a76c-45c5-a8e3-93b5ccdf4135">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzMtMy0xLTEtMA_454e7647-218a-473d-a154-fc9aca36f69b">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzMtNS0xLTEtMA_28e24a51-b1a2-413b-98b0-3b01f49ea80f">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzQtMS0xLTEtMA_de0d8748-5fed-4891-8b28-6d5f77b5e7e3">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzQtMy0xLTEtMA_45764b29-33c2-4e3c-97af-d9264f9980bf">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzQtNS0xLTEtMA_ca7fd66b-0ba4-461a-ba60-9b75cac6e6d1">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzUtMS0xLTEtMA_5d279dfd-d65b-4257-8db1-84639a98218d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzUtMy0xLTEtMA_894f3d9f-0cf0-4a9c-8096-4f1ee83fa90b">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzUtNS0xLTEtMA_cc38f96c-4fb3-4b7c-9efc-3b5e1947b96d">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzYtMS0xLTEtMA_3ed191de-7476-44a6-afad-5ec24812f430">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzYtMy0xLTEtMA_5238fe85-12d9-41d9-9548-798957cf89d8">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzYtNS0xLTEtMA_24c503f0-904f-4d5a-8cb5-c2523036169e">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzctMS0xLTEtMA_a4262764-6fc1-4e6c-9471-63719eff3d6a">42.34</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzctMy0xLTEtMA_fd21a8c1-13d1-4522-a71a-947dd31ac009">30.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzctNS0xLTEtMA_e34273ff-1165-4f39-9ac7-221a76835aa2">34.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id338f2e6a4f24b74b6f7422e80494b1b" continuedAt="iff054fe0d85c46f4bdae078411f48519"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0Mzk_6e85d365-f719-4436-9077-f45f0b285e20" escape="true"><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i143d4186981e48d49d7be92adfcc173f_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzItMS0xLTEtMA_6a6f6ee4-5d76-4bdd-be79-895e6009c7fe">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i143d4186981e48d49d7be92adfcc173f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzItMy0xLTEtMA_de643b7b-f44b-40fa-bb87-e25b792ade73">157.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzMtMS0xLTEtMA_53186532-6e35-4383-92fa-5412786cceeb">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzMtMy0xLTEtMA_3961b116-f6ca-4281-9673-27d355a0041a">236.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzQtMS0xLTEtMA_78c39f3a-fc3c-4324-97e1-153be7f1345a">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzQtMy0xLTEtMA_e405cc5e-5999-44eb-8dbf-bc84f7565ed3">117.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzUtMS0xLTEtMA_6b423e09-e4a0-4283-801b-ca3e1325eea5">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzUtMy0xLTEtMA_013cf294-55d9-4ef8-89ff-58eec44aaa88">178.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtMS0xLTEtMA_c61f2bb4-99f5-44ed-ad11-2776b9ec7354">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtMy0xLTEtMA_1b21d025-c031-405e-874f-9cf85b5eea29">179.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtNS0xLTEtMA_2cbdf055-2cc6-4ea3-bd25-3f5b9b7baad7">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtNy0xLTEtMA_0f2ab287-3fe9-4572-979a-4b92c8211a37">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctMS0xLTEtMA_2d9bb554-8300-4608-9a23-8325250897df">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctMy0xLTEtMA_13450a2f-98ed-4ece-9644-6740bd09f339">178.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctNS0xLTEtMA_270e5a46-6ac7-4ec8-8241-abfe10470701">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctNy0xLTEtMA_c10c4928-1190-4488-bc35-ae28c022d3c7">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtMS0xLTEtMA_13df4308-3359-4276-9257-900138562ee1">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtMy0xLTEtMA_6ab98260-30ed-452c-9dfc-efaee8266ff9">150.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtNS0xLTEtMA_f3e2f0eb-3e80-41a9-a8da-08bddb720a75">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtNy0xLTEtMA_316ba1f9-f99f-4a06-b706-009a35760078">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised during the years ended December 31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM3MjU_38934783-1e68-4f26-a760-92bcdf198ec6">98</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM3Mjk_64568d85-654b-4b82-a1a6-989a604542bc">68</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM3MzY_9a066dd4-52b7-4c06-a95c-9653b4a93b5e">53</ix:nonFraction> million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM4NzI_6720a31e-c93e-4925-a29c-edb6c31113e0">21</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM4NzY_ef616026-0fab-4cce-936e-d5d1c5b2ab47">15</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM4ODM_606c6864-8788-4c93-b3a6-d48e1935d0de">12</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM5MTE_142e4c52-ce05-4a28-8ca2-016bcc551616">345</ix:nonFraction> million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQwOTM_245ae269-eefa-4fea-a3f9-f745e5c27d6f">1.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQzODI_c8f6cb62-202c-437d-be16-b775bba92ae4">three years</ix:nonNumeric>. The performance goals for the units granted during the years ended December 31, 2020, 2019 and 2018, which are accounted for as equity awards, are based on (i) Amgen&#8217;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#8217;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a <ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzYwNDczMTM5NjAyMTM_43d6d82c-65e7-4852-b28a-e481f37e6810"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzYwNDczMTM5NjAyMTM_8e0db10a-850f-4cde-b205-bb6e3c9f9281"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzYwNDczMTM5NjAyMTM_e17d2d85-6f8d-47e7-a563-0622bfe515f2">one</ix:nonFraction></ix:nonFraction></ix:nonFraction>-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a payout simulation model to estimate the grant date fair value of performance units. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0NDA_6f6d6d93-bc08-40bf-83d0-732e8db28ece" continuedAt="ie9168fee9b644f408fd25965e7dcf06f" escape="true">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="ie9168fee9b644f408fd25965e7dcf06f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzItMS0xLTEtMA_838f683f-7395-4e20-8d7a-3f58f72eee8b">236.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzItMy0xLTEtMA_87eb8fac-f74f-42dc-8d3c-c7117939b57e">177.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzItNS0xLTEtMA_47d013bd-358e-4637-9fe8-608b8cdab5d5">177.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzMtMS0xLTEtMA_bdf53e54-fec8-4b35-86bb-97e06a1334cc">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzMtMy0xLTEtMA_1534af2c-c7ca-47fc-a5cd-b51ccb8cc2cd">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzMtNS0xLTEtMA_3d17734e-7158-4563-ac41-c527329f94a0">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzQtMS0xLTEtMA_880009d6-5159-46a4-9442-11dcc40ffbb4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzQtMy0xLTEtMA_72a79048-3d07-47a5-b65e-f7f6013b0550">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzQtNS0xLTEtMA_8d4c38dd-36c5-441e-9809-1344fd618f1e">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzUtMS0xLTEtMA_5534e5f4-a4f4-4f79-962d-ccc8c7aa0560">249.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzUtMy0xLTEtMA_43759ad0-91ad-4468-9eb6-1da746630b76">188.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzUtNS0xLTEtMA_8463ac66-09c7-4e16-af1c-da3594122c76">189.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iff054fe0d85c46f4bdae078411f48519" continuedAt="id88d2495abb14c459ae1dca18ab99df6"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY2MTI_3163413e-25cb-4529-a6b5-ef63960d0708">1.8</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ide4cd73575da4db0ba421cc3362a29bb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY2MTk_5dff4c3f-c2bd-45e2-a030-62db54463830">2.0</ix:nonFraction> million performance units were outstanding with weighted-average grant date fair values per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY3MDU_fa0a2615-3274-448b-9678-a233a0dade0b">207.52</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ide4cd73575da4db0ba421cc3362a29bb_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY3MTI_6b0bc18f-f87e-4e59-8f6e-2471a700a4d8">185.64</ix:nonFraction> per unit, respectively. During the year ended December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY3NjU_0d9097b2-3c2b-4578-9e4d-69da0636794a">0.6</ix:nonFraction> million performance units with a weighted-average grant date fair value per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY4MzU_e1fdc544-3f49-4ab4-9221-b04da86004e8">249.07</ix:nonFraction> were granted, and <ix:nonFraction unitRef="shares" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY4NTY_de9e318b-faf7-4d4e-90c4-5c215eb97711">0.1</ix:nonFraction> million performance units with a weighted-average grant date fair value per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY5MjY_6fb0c21c-3e7b-499f-9176-6339a49a2589">199.86</ix:nonFraction> were forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair values of performance units paid during the years ended December 31, 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usd" contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcwNDg_96eb67c8-da11-456c-a2fc-6937aa9eb6fe">230</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcwNTI_2c2ef15b-357b-4d41-9aee-b13e4b99d2be">176</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcwNTk_9555cb45-9e92-43c5-bac5-bf8d4e4640f0">133</ix:nonFraction> million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id88d2495abb14c459ae1dca18ab99df6">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcyMzY_20090935-97f3-4c9b-91fa-f4c58ada630c">127</ix:nonFraction> million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzczODY_c511d648-344e-4dd8-8391-7f77da798d10">one year</ix:nonNumeric>.</ix:continuation> </span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_220"></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzQzNQ_c4332333-4127-48fb-b4b3-6afc36962677" continuedAt="i00cad6dbe2e84338bc521c5c75225de9" escape="true">Defined contribution plan</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00cad6dbe2e84338bc521c5c75225de9">The Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzM3Mg_0fa742cf-9fa6-4e42-843c-b9adf1cbe4ae">231</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzM3Ng_6a1e8699-5010-49d1-9518-a42e23c57135">220</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzM4Mw_5ec3c4d6-05f8-43dc-ac52-408bd8faf282">173</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</ix:continuation></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_223"></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0MjA_fd53c7a7-2f14-4d77-8a36-128e884fc068" continuedAt="i25f32edc3da3482390d4852e37c18a0c" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="i25f32edc3da3482390d4852e37c18a0c" continuedAt="i43886622ac9a43f18c8406483ab072d3"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0MjI_73bd484e-6d05-4738-979e-d31fabc4d009" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id433645fbf594175aab48fd4faf64790_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzItMS0xLTEtMA_f58bb6fa-0fd8-4593-840c-2934aeb59818">4,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f742d812e548f1805b409e3b3b3abb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzItMy0xLTEtMA_5dd8b418-2a9f-4025-8414-8fe9e3fb0d4d">4,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f45734b1443d9bf7b7850cb8ebccf_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzItNS0xLTEtMA_8bfc8ee4-c7d5-45b5-9fbe-32eca3d0eb6f">4,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f8bbadab1f4527a14acd4c6c81cac8_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzMtMS0xLTEtMA_d8d40c9b-bdd5-40de-b2ed-d535742733a5">4,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5dfd09c3d064b5981a2ddae65d2710a_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzMtMy0xLTEtMA_725d565e-d032-495c-bfea-d376049da3c7">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b0a52267d94c948c70743bd7a58fb1_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzMtNS0xLTEtMA_30f82d69-504d-4589-88e3-a0f7a86ebc78">4,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzQtMS0xLTEtMA_846fefe3-fbd9-47c2-8372-6e86b359b511">8,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzQtMy0xLTEtMA_93cee81c-e87f-41f6-b4d0-cfa1bb7b07f1">9,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzQtNS0xLTEtMA_f58739bc-5ddc-4ebb-839c-4b6b14346769">9,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0NDc_0d1b3b47-597e-40b7-9f99-f6100fbad613" escape="true"><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzMtMS0xLTEtMA_bc400aa7-47cb-46b1-968f-3ce299f1a667">921</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzMtMy0xLTEtMA_2f396b87-2566-4af7-94eb-300561eda192">1,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzMtNS0xLTEtMA_91ea055b-4fac-4c31-9c6b-2fc2074a2beb">1,270</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzQtMS0xLTEtMA_2e10adaa-b256-4edb-8491-77fbabb32f07">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzQtMy0xLTEtMA_7b8fd221-5e22-4892-99f8-8bc600735984">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzQtNS0xLTEtMA_d68d498e-8a4e-456a-a0df-860bacea3bdf">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzUtMS0xLTEtMA_2dab93be-4183-4e7f-8f86-0c7b15a2e530">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzUtMy0xLTEtMA_ab2abdb0-3423-4911-a009-56af3ed34ebb">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzUtNS0xLTEtMA_b906003c-01e8-4d06-82f0-917e1e9537ef">227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzYtMS0xLTEtMA_3d7750bf-805d-4657-beb8-a71822849c9c">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzYtMy0xLTEtMA_f0b2497b-c82c-4136-8777-120a7f2d612b">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzYtNS0xLTEtMA_55441319-83bc-4db7-ac6d-797036403c0c">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) provision:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzgtMS0xLTEtMA_1114ac2e-c9c8-4a59-8150-765924c37230">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzgtMy0xLTEtMA_effbffdc-4ea7-488f-9a41-1731f4de9170">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzgtNS0xLTEtMA_ad0dae7f-ffc5-49da-a1b6-7e961f53157f">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzktMS0xLTEtMA_84cd7836-700f-478f-ae78-bdce56d2bded">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzktMy0xLTEtMA_eb483f3b-e355-4a79-9c76-0a3710eb56d4">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzktNS0xLTEtMA_90af050e-9f62-45e1-bdac-7eb4bb9478e3">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEwLTEtMS0xLTA_266e4d51-5816-4094-b6b2-e4039bd78309">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEwLTMtMS0xLTA_eeb580b9-b7bd-4b87-8ce6-170e2aaa5ff2">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEwLTUtMS0xLTA_18bec500-272b-4c73-9dfb-d80c52b359fd">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzExLTEtMS0xLTA_b9a93cd0-c465-4fd3-9ca5-751648e43e6f">363</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzExLTMtMS0xLTA_af2e9c6d-51f3-4c97-827f-2f988906109c">304</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzExLTUtMS0xLTA_f80ba00c-ea4d-450c-9391-075622f71f81">363</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEyLTEtMS0xLTA_3f200725-4a35-4819-acd9-c8ea048af6b5">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEyLTMtMS0xLTA_10c1c742-77dc-4cdd-b09e-fea2313f4ec9">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEyLTUtMS0xLTA_8ee38904-fe53-4fb9-a19e-82d47e482259">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i43886622ac9a43f18c8406483ab072d3" continuedAt="i956de32aaaf54eaeb4cfe2d4f2ab1b06"><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss (NOL) carryforwards. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0NTA_bdd9e146-b5e6-4d61-bcec-44c22edf5c45" continuedAt="if1f0654c599c47b9ada860671ccc43aa" escape="true">Significant components of our deferred tax assets and liabilities were as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="if1f0654c599c47b9ada860671ccc43aa"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzMtMS0xLTEtMA_cd40ed15-4d48-47ae-a87f-14364c6297fd">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzMtMy0xLTEtMA_785770d3-45d7-4337-8f56-658f7778b586">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzQtMS0xLTEtMA_c4d8f0eb-e0a7-403c-bdc1-b4ad5d2771d9">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzQtMy0xLTEtMA_779b0a5a-4db5-4da1-a828-55ebbef11c5b">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzUtMS0xLTEtMA_70f8a415-25ab-4a7a-9589-e1603d828c1d">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzUtMy0xLTEtMA_a7917845-97f0-4149-9d2a-20a35902ed8a">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzYtMS0xLTEtMA_e97bcfba-560b-4be7-8d70-9e3685fb0fd0">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzYtMy0xLTEtMA_26b4c3f4-6cd0-4726-9823-a45115447bb3">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzgtMS0xLTEtMA_c5695dd6-e364-48a3-828d-8c1749df07a5">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzgtMy0xLTEtMA_e2169f8e-a738-4e68-a356-9b45631e1878">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzktMS0xLTEtMA_15035145-5da3-488a-a374-dc2ba30cfc95">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzktMy0xLTEtMA_0b6bd57f-7f9e-419c-8115-37ad0ce93056">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzEwLTEtMS0xLTA_6007c3e8-ab0d-4981-bfc8-c8cb7ee4ef21">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzEwLTMtMS0xLTA_8827a657-4f24-4641-b35a-515ba7f0f41e">517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzExLTEtMS0xLTA_faa6f97e-f69f-4162-8f9f-fff40397bd12">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzExLTMtMS0xLTA_b6966c22-2d16-4b37-9420-b94bd636923f">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE0LTEtMS0xLTA_e20026ff-4137-4fdb-8eaf-da06b3f0fd10">903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE0LTMtMS0xLTA_ee7fa2fd-8e93-46e7-9a26-f11de91f685b">1,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE1LTEtMS0xLTA_6c4ce4b8-1e86-4676-8c3c-4cfeda74fe68">282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE1LTMtMS0xLTA_bd1d0f20-0870-4c91-b71d-e66b22696ff6">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTEtMS0xLTExNTY4_5ccd5bc6-e6cb-4dde-883b-fac06aa7c3ff">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTMtMS0xLTExNTc3_fd814813-e4d7-41f8-8d0a-261a29e41d62">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTEtMS0xLTA_eed07070-3cb7-4780-a758-b29345043c0f">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTMtMS0xLTA_9cbbb2e3-65df-4bf3-87a3-175d308cef53">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE3LTEtMS0xLTA_07f2478e-c6d5-49e8-9fb1-1ad5b7310eb4">1,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE3LTMtMS0xLTA_48255c85-a4e7-4fd1-a2f6-4f1c9eecf7d0">1,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE4LTEtMS0xLTA_467d90f3-abe3-4bfc-8e9e-23b8b98f4a7f">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE4LTMtMS0xLTA_9df2b8ff-3388-4a2d-97a6-a989426d74c6">514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased in 2020, primarily driven by the Company&#8217;s expectation that some state R&amp;D credits will not be utilized and that certain foreign net operating losses will expire unused.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i9549cf1daa744587b04c3442d532545e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1Xzk5NQ_31c719ef-8260-4f26-9e3a-16459da076c0">20</ix:nonFraction> million of federal tax credit carryforwards available to reduce future federal income taxes and have provided <ix:nonFraction unitRef="usd" contextRef="i1f91811a9c8c47ab955099101550454c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzExMDA_583269c2-b425-4aa6-8d1b-5fcf0e62f565">no</ix:nonFraction> valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2035. We had $<ix:nonFraction unitRef="usd" contextRef="i8b9c7cf9064143caa206e3b78960b8ee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzEyNDE_c47c4685-8636-4036-bbb1-abbc989a344c">681</ix:nonFraction> million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i8b9c7cf9064143caa206e3b78960b8ee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzEzNjg_5366953f-dc11-4c37-99e3-4a75c00c14df">585</ix:nonFraction> million of those state tax credit carryforwards.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i9549cf1daa744587b04c3442d532545e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE1NDY_95e372b8-8092-4f69-a6e7-be952be6bb62">143</ix:nonFraction> million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i9549cf1daa744587b04c3442d532545e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE2NzA_1a70c9ec-ea6f-4cf0-b3cf-b2326bb12139">6</ix:nonFraction> million of those federal NOL carryforwards. The federal NOL carryforwards, for which <ix:nonFraction unitRef="usd" contextRef="i316f6795382a4358b0d4048594444996_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE3NTA_f6ed4f02-f501-4dff-b32d-2400712ed96a">no</ix:nonFraction> valuation allowance has been provided, expire between 2021 and 2035. We had $<ix:nonFraction unitRef="usd" contextRef="i8b9c7cf9064143caa206e3b78960b8ee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE4Mjk_ed3eb888-aabb-4b82-981d-1d94a6655f51">167</ix:nonFraction> million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for all of the state NOL carryforwards. We had $<ix:nonFraction unitRef="usd" contextRef="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE5OTM_71e1117e-fccc-48e5-8a23-8e965ebed854">1.9</ix:nonFraction> billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzIxMTc_26c3a52c-b282-4d55-9374-1deb603326a7">754</ix:nonFraction> million of those foreign NOL carryforwards. For the foreign NOLs with <ix:nonFraction unitRef="usd" contextRef="i9455afa2b91e45d18c2d587bfa989d67_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzIxODI_8be27d13-e472-4207-8ce8-39fd2db3950f">no</ix:nonFraction> valuation allowance provided, $<ix:nonFraction unitRef="usd" contextRef="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzIyMTU_014e8387-a4ef-41bc-a7d1-df47732ca552">861</ix:nonFraction> million has no expiry; and the remainder will expire between 2021 and 2030.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i956de32aaaf54eaeb4cfe2d4f2ab1b06" continuedAt="i6b4f0433dc464a7e8ca7d3d3e4b1b3be"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0MTQ_35b538af-c35a-4a8e-9110-4430b8f68c0e" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzItMS0xLTEtMA_6342d74d-5910-4c34-8ca1-d10ef96d60a2">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzItMy0xLTEtMA_bdc66ab4-48c6-47e1-8169-3fa41ea38f4a">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzItNS0xLTEtMA_f6a09f9e-eee2-4064-928c-c60b9963ca6f">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzMtMS0xLTEtMA_4f67ccca-3787-4963-b8f0-1dce6ffb7f90">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzMtMy0xLTEtMA_c0aebaa9-7e52-475b-baff-a1d23d6afcd5">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzMtNS0xLTEtMA_cf4e6544-f5a4-4ba0-a4ea-4a73e1ab4f6d">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzQtMS0xLTEtMA_65120094-192d-4cd3-b912-6cc525158361">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzQtMy0xLTEtMA_26614834-4708-4c93-8f3f-ccda67263dc6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzQtNS0xLTEtMA_dd0606b3-b6d0-4615-bba4-33f8adec526d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzUtMS0xLTEtMA_c085d44a-ba75-4f40-9c1a-3f9953943df1">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzUtMy0xLTEtMA_84c5829d-59e4-4962-a0f0-089d23c3cc7e">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzUtNS0xLTEtMA_14e00aaf-ec6e-4e91-9c8f-c22eff80064f">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzctMS0xLTEtMA_5357041e-f0f2-47af-8ca5-308fcd66c68f">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzctMy0xLTEtMA_1a576fd3-91cb-4dde-895f-0a4456bddee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzctNS0xLTEtMA_d6e4c956-2ddb-4a8c-a4da-603469b05d0d">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzgtMS0xLTEtMA_ba5bd05a-7b0d-4572-a030-1ac861cb6636">3,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzgtMy0xLTEtMA_3ad89e38-5352-41fa-82f9-d58462d7d3fb">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzgtNS0xLTEtMA_d6cea23c-debc-4258-b305-05c3cd101975">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the UTBs as of December 31, 2020, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2020, 2019 and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI2MTk_1e010e60-740e-430c-a25b-2ce9f1a54f79">116</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI2MjM_c3743df1-8f3a-4bfe-bb2f-7fe65248ab81">198</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI2MzA_f7a36964-9a84-4dc9-b280-27c9e1a208ac">137</ix:nonFraction> million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2020 was primarily due to lower interest rates during 2020. As of December 31, 2020 and 2019, accrued interest and penalties associated with UTBs were $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI4MjM_1cddc125-1152-40d5-ae52-13ab75f41192">783</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI4MzA_ea1c1733-4aae-4bed-844c-75ee84c0845f">667</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0NTQ_54b5f846-494c-4b33-b396-f75b5e872b01" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzItMS0xLTEtMA_2857899a-b26c-4ec4-a97b-cf3f03099818">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzItMy0xLTEtMA_2467c386-9d9a-4f02-b6b4-848f9aa834b3">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzItNS0xLTEtMA_cefb9d1e-a306-40b2-b642-8304199c9697">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMS0xLTEtMA_a218b452-3163-4735-bd98-5901e6a80aee">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMy0xLTEtMA_95052da1-5c50-426d-b2fd-d53a80901daa">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtNS0xLTEtMA_2d5d712d-ebf0-4d6a-be07-8e71d01d0c5c">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMS0xLTEtMTIyNjc_c74c2c75-36ce-47ee-bcc8-f5aec0f365b0">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMy0xLTEtMTIyNjk_02bda4b5-0312-4b90-a781-8a153322dfc9">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtNS0xLTEtMTIyNzE_8f936516-805c-4258-a80c-a74c565d94e3">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico Excise Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzYtMS0xLTEtMA_4c7964cf-46ff-42ff-86a2-9854ae52a4fb">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzYtMy0xLTEtMA_f28a16eb-0b7c-4dcc-8599-84a9aa75b40b">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzYtNS0xLTEtMA_970056f6-1158-4275-9c26-9c7ee8e5a316">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act, net impact on intercompany sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" format="ixt:zerodash" name="amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzctMS0xLTEtMA_baec2865-878a-40a1-8a69-62f2b55b2ba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" format="ixt:zerodash" name="amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzctMy0xLTEtMA_da42633d-83ea-4fa7-9ec4-f7cb94df1bb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzctNS0xLTEtMA_80b6d45f-737a-4e79-b8de-d8370b2d5c03">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzgtMS0xLTEtMA_8921384d-0c51-4099-a6ca-59adc8cd0fcf">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzgtMy0xLTEtMA_da2766e6-0e24-42bf-a38d-3b350d543096">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzgtNS0xLTEtMA_f8728d39-7490-4e69-9f8f-bdd165e8973e">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzktMS0xLTEtMA_a93c32e0-45b6-430d-97ce-0de2cd7dffc6">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzktMy0xLTEtMA_0e9b5d9e-6b35-49f7-8af0-401ab29a431b">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzktNS0xLTEtMA_22e33993-d2e8-467e-baa8-16ad9216eb72">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTEtMS0xLTA_a59d0b3b-3cca-468f-9931-a3ffc029597d">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTMtMS0xLTA_ce514ac9-633d-402a-8ea7-29365a39fc4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTUtMS0xLTA_d7d0f565-621f-407c-933a-8036708648c6">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTEtMS0xLTEyNDE4_ab83e438-d50f-4fba-ba95-cde54e3edbe0">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTMtMS0xLTEyNDIw_02782802-1ee5-4226-a786-4f62b50c6ceb">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTUtMS0xLTEyNDIy_7d0f48af-c306-4c67-a95d-0b873d88848f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzExLTEtMS0xLTE2ODkx_59a3d18d-938c-488a-969f-e88f51636f02">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzExLTMtMS0xLTE2ODkz_835f52ef-e2e2-4208-864a-ff1a7b301004">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzExLTUtMS0xLTE2ODk1_8d971a5a-c8f3-4698-a3fc-fbdc03ba3b4b">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the years ended December 31, 2020, 2019 and 2018 differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#8217;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid during the years ended December 31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzQzNzk_aae2423a-8de3-47ca-adf8-8c5ca0662455">1.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzQzODM_9fc8429a-8ed3-4252-ae5c-01f00cf00720">1.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzQzOTA_a07ba9f1-29c3-4a0c-be3e-3c5787bee98b">1.9</ix:nonFraction> billion, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6b4f0433dc464a7e8ca7d3d3e4b1b3be"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. In 2017, we received a Revenue Agent Report (RAR) and a modified RAR from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and have been pursuing resolution with the IRS administrative appeals office. However, we have been unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a Notice of Deficiency, which we would expect to vigorously contest through the judicial process. In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office. The IRS audit for years 2016, 2017 and 2018 is expected to start in the near term. We are also currently under examinat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion by a number of other state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div></ix:continuation><div id="if8d0740b43d148a5ba67e4dd5b38ce46_226"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90ZXh0cmVnaW9uOjQ1ODIxNDk3ZDcxOTRhYTY5YWI2YmQzNmFkMmY5MmY5Xzc3Mw_146608ac-8d5c-4553-8f7a-0c2251c2d7be" continuedAt="i2f276228340d4334823d32791a351508" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:continuation id="i2f276228340d4334823d32791a351508"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90ZXh0cmVnaW9uOjQ1ODIxNDk3ZDcxOTRhYTY5YWI2YmQzNmFkMmY5MmY5Xzc3MA_72a30a2f-7404-4914-bfd6-cc7017a2d295" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzMtMS0xLTEtMA_c9bca7ee-1300-4928-b70f-82a351304365">7,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzMtMy0xLTEtMA_655fea8a-2575-4ccc-b0ee-8a2b01870b06">7,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzMtNS0xLTEtMA_b051651e-8507-4269-bab0-2f0f37b6a2b3">8,394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzYtMS0xLTEtMA_917e16ab-684f-410f-b1c3-3da58ca1dddc">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzYtMy0xLTEtMA_a9b81ca9-1881-4d39-8c4d-464287925ca3">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzYtNS0xLTEtMA_a18a15f4-cbd0-40aa-b6d4-45d5da1d9c7c">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzctMS0xLTEtMA_0f193dc8-134f-4ccd-b427-af7e77c64368">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzctMy0xLTEtMA_2601530e-c474-4e4b-8ae4-f62294a4a6ee">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzctNS0xLTEtMA_3c13753e-1961-484d-957c-d873eacd46e5">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzgtMS0xLTEtMA_18e74bb5-4f09-41c8-a37e-e1f69e23e480">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzgtMy0xLTEtMA_7ddba103-c611-49db-9f0a-7aa8035d5c97">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzgtNS0xLTEtMA_2e0d790e-ecab-45ad-8954-679af6b9e558">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzEwLTEtMS0xLTA_aeb33b9f-78c0-4bb8-8608-65f331f73ebb">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzEwLTMtMS0xLTA_9c0920bc-56e8-49ea-bd19-8ad45c2b293b">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzEwLTUtMS0xLTA_485923b7-2a72-4773-bb0b-cd0f6f4642e8">12.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzExLTEtMS0xLTA_786e3d78-88e6-4f20-8096-f3ef5687d7e3">12.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzExLTMtMS0xLTA_3c44914a-df73-4965-a7a0-53768053f3ce">12.88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzExLTUtMS0xLTA_2570656c-d38d-411c-9907-c39d51bdcbc2">12.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three years ended December 31, 2020, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzEwOTk1MTE2NDIyNTY_103e1b2c-cc9a-460d-8009-7aa71236a7a2" continuedAt="i046d7c3934eb447abdef4c29d00594fa" escape="true">Collaborations</ix:nonNumeric></span></div><ix:continuation id="i046d7c3934eb447abdef4c29d00594fa" continuedAt="ibe28cb51a4d8421499d3cbfbe8630463"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized for these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a <ix:nonFraction unitRef="number" contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzExNTQ0ODcyMTEzOTg1_109f394b-d8cf-4179-ac6d-9c1e1361cd32">20.5</ix:nonFraction>% stake in BeiGene, Ltd. (BeiGene), for approximately $<ix:nonFraction unitRef="usd" contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzExNTQ0ODcyMTEzOTcx_682f7e9b-794a-4fd0-af62-caaf6a103a78">2.8</ix:nonFraction>&#160;billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene commenced selling XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will commercialize KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global R&amp;D costs by providing cash and development services up to $<ix:nonFraction unitRef="usd" contextRef="id4c3de7ba47e48ddbb6721ed2b6093e0_D20200102-20200102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE2NDkyNjc0NTI1OTE_adbb65c3-bdc0-43fd-bc27-d6d65a74c662">1.25</ix:nonFraction>&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, net costs recovered from BeiGene for oncology product candidates were $<ix:nonFraction unitRef="usd" contextRef="if08caf3a57bd45d9a187961c49e97c9a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RecoveryOfDirectCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjUwMTE2_f27766ad-9822-4fc1-8774-fab3cdd4ff89">225</ix:nonFraction>&#160;million and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. Profit share payments and product sales between Amgen and BeiGene were not material for the year ended December 31, 2020. As of December 31, 2020, the amount owed from BeiGene for net costs recovered was $<ix:nonFraction unitRef="usd" contextRef="ic9eb1e8041bf4e8b93d86d4c965d1bcf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:RecoveryOfDirectCostsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjUwNTI4_26e692f1-b004-4b1e-b4cb-f76ef7c9bf27">113</ix:nonFraction>&#160;million, which is included in Other current assets in the Consolidated Balance Sheets. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 9, Investments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis Pharma AG (Novartis) to jointly develop and commercialize Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(erenumab-aooe). In the United States, Amgen and Novartis jointly develop and collaborate on the commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen, as the principal, recognizes product sales of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, shares U.S. commercialization costs with Novartis and pays Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Novartis pays Amgen double-digit royalties on net sales of the product in the Novartis exclusive territories and funds a portion of global R&amp;D expenses. In addition, Novartis will make a payment to Amgen of up to $<ix:nonFraction unitRef="usd" contextRef="i7cb08466e4c94fc284de233b8b27d515_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzIxNjg_60546b6f-66eb-4768-88dd-7f52a5206593">100</ix:nonFraction> million if certain commercial and expenditure thresholds are achieved with respect to Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Amgen manufactures and supplies Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> worldwide. The migraine collaboration will continue for the commercial life of the product unless terminated in accordance with its terms.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in litigation with Novartis over our collaboration agreements for the development and commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 19, Contingencies and commitments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, net costs recovered from Novartis for migraine products were $<ix:nonFraction unitRef="usd" contextRef="i64588391e1684a749dec8deb14c630d1_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RecoveryOfDirectCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzI3MzY_f1e509f1-e46b-41c2-8ed2-1edc80b3ca0a">192</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i018453dd7c3743639ceacf5473e7c62d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RecoveryOfDirectCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzExNTQ0ODcyMTEzOTY4_7900a9f6-eaaf-4b83-a38a-6df630389a8c">187</ix:nonFraction> million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the year ended December&#160;31, 2018, net costs paid to Novartis for migraine products were $<ix:nonFraction unitRef="usd" contextRef="ia6aa7777cdbf4d8ba13b5dcf14c0d732_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DirectOperatingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzMxNTY_acbff8b0-07a7-4736-83bd-acba3428a4b7">44</ix:nonFraction> million and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2020, 2019, and 2018, royalties due to Novartis for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $<ix:nonFraction unitRef="usd" contextRef="i0041c53471f04a019348539dd1051757_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjQ2Mzg2_51b8a187-2df9-4c5c-a6bf-8f2a4c228652">139</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i43d26623d3f34500a3be4c9287eaf130_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzMzMzc_49ee7f0e-2ff7-4543-a282-53ef762633ef">115</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i147ff41e3aad46019e4652e564939eeb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzMzNDQ_af1b2b7f-b422-47a3-b66f-26348afca521">43</ix:nonFraction> million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2020, 2019 and 2018, royalties due from Novartis for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were not material. As a result of certain regulatory and commercial events, we received milestone payments from Novartis of $<ix:nonFraction unitRef="usd" contextRef="i5c99bb199b504bc5813a6070a2c0f7a2_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzM2NTM_3804d79f-b5c0-44ae-bee9-a76c014a0f9d">295</ix:nonFraction> million during the year ended December 31, 2018, which was recorded in Other revenues in the Consolidated Statements of Income. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibe28cb51a4d8421499d3cbfbe8630463"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer HealthCare LLC</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a licensing arrangement with Bayer HealthCare LLC (Bayer) for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently marketed and sold in more than <ix:nonFraction unitRef="country" contextRef="i5aae7473918a4b2fbd03dbe169ce9681_D20200101-20201231" decimals="INF" name="amgn:NumberofCountriesProductsisMarketedandSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzQwNTY_692fcf5e-b8e3-4e74-9c29-93603dc4f763">100</ix:nonFraction> countries around the world for the treatment of unresectable liver cancer and advanced kidney cancer. In the United States, Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we amended the terms of our agreement with Bayer, which transferred all our operational responsibilities outside the United States to Bayer, including commercial and medical affairs activities. Prior to the amendment of the agreement, we shared equally in the profits outside the United States, excluding Japan. In lieu of this profit share, Bayer now pays us a royalty on sales of Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at a percentage rate in the low <ix:nonFraction unitRef="number" contextRef="i26fb37cd13a747f1b39eabafba709ded_D20200101-20201231" decimals="2" name="amgn:CollaborativeArrangementRoyaltyIncomePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU0OTc1NTgxNjEyMzE_2adba96c-98c1-4a14-af18-23de958fa2c7">30</ix:nonFraction>s. The rights to develop and market Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan are reserved to Bayer. In the United States, Bayer pays us a royalty on sales of Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at a percentage rate in the high <ix:nonFraction unitRef="number" contextRef="i6e670e37529947c6a6e43ad60cc1072e_D20200101-20201231" decimals="2" name="amgn:CollaborativeArrangementRoyaltyIncomePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU0OTc1NTgxNjEyMzk_aa0996bd-ec54-4548-bbfb-3da712e2ed32">30</ix:nonFraction>s.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with Bayer will terminate at the later of the date when patents expire that were issued in connection with product candidates discovered under the agreement or on the last day that we or Bayer market or sell products commercialized under the agreement anywhere in the world. Patents related to Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> began to expire in 2020.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2020 amendment to the collaboration agreement, royalties due from Bayer for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $<ix:nonFraction unitRef="usd" contextRef="i9ac446a3f5b049498d97d5cdc40e8884_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzI3NDg3NzkwOTE0Mzc_1aabf36d-f990-4005-9dae-e51848235739">217</ix:nonFraction>&#160;million and net profits were not material for the year ended December 31, 2020. During the years ended December 31, 2019 and 2018, royalties due from Bayer for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were $<ix:nonFraction unitRef="usd" contextRef="ib720207eae304b4db4149e5ba761b733_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjQ5NjU3_c1d41023-db8f-4e0d-9c2a-ecc5d509d67c">79</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc295629ce08431a87b6af7ac665aa1c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjQ5NjY1_991a82e4-4a48-4d48-a6d1-aadc5e893a51">91</ix:nonFraction> million, respectively. During the years ended December 31, 2019 and 2018, Amgen recorded Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net profits of $<ix:nonFraction unitRef="usd" contextRef="i6accd8c04bc64375b6db9a710bfd1a7a_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:CollaborativeArrangementNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU5MjY_5b0f6bfb-a17d-4e4d-901a-bead5fa1155e">210</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icd4923b31ebb413985529cfbbf320c70_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="amgn:CollaborativeArrangementNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU5MzM_44e42a1e-37a1-4785-8c5a-b7bfcb5b04de">164</ix:nonFraction> million, respectively. Royalties and profit share due from Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were recorded in Other revenues in the Consolidated Statements of Income. Net R&amp;D expenses related to the agreement were not material for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones, which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDI1Nzk_f45b17ac-98a5-4c3d-9602-f22e1f05b6da" continuedAt="i1ac70eea36774af79dca844d13412047" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i1ac70eea36774af79dca844d13412047" continuedAt="ia93ad65916b14393844b496ff0ed9824"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzQyODA_49bf78c1-05dc-48db-9ab8-06e3ac9420cb" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abab397f36846d2963dacabb469a08b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtMi0xLTEtMA_6eaf915b-9fea-4c73-9449-7fdaadfda096">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abab397f36846d2963dacabb469a08b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtNC0xLTEtMA_d71bbab0-e172-42f5-b804-c0abde68ef0b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abab397f36846d2963dacabb469a08b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtNi0xLTEtMA_20ad443d-3f7c-4e4a-981f-d840b682fb82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abab397f36846d2963dacabb469a08b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtOC0xLTEtMA_9354d54f-5ade-4cbd-9ea2-12d03bb361a4">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia314c059b63d4452a382baae50386fbd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItMi0xLTEtMA_5ecbafdb-eef8-41ad-8e51-438ebec99e24">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia314c059b63d4452a382baae50386fbd_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItNC0xLTEtMA_1a47db3b-2fdf-42a9-baf2-470820d25cd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia314c059b63d4452a382baae50386fbd_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItNi0xLTEtMA_02841f4c-c12b-4679-823c-3307258303d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia314c059b63d4452a382baae50386fbd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItOC0xLTEtMA_ed6dc9b7-05a7-44fd-88e8-3be93b92701d">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctMi0xLTEtMA_796cfaa6-1feb-428b-a4f6-9506d9cd553f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctNC0xLTEtMA_3249e532-d20f-4faa-baa3-81c28ca78aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctNi0xLTEtMA_28cc51d2-fc92-4cd9-8b41-1cdefddb3dcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctOC0xLTEtMA_a169a4f2-a12b-4c96-8f5d-ff6f7f781bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1043550a1f84782876ef562e9149716_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtMi0xLTEtMA_feca299c-dab8-4ee6-b09e-7f5433035337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1043550a1f84782876ef562e9149716_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtNC0xLTEtMA_3e21ec6d-e933-4f59-88e5-73d9297f428e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1043550a1f84782876ef562e9149716_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtNi0xLTEtMA_44dc9a40-0226-4477-b9d9-ab51b5e36296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1043550a1f84782876ef562e9149716_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtOC0xLTEtMA_e4ca395e-8a39-40db-b356-80e0908bc036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktMi0xLTEtMA_a3ba77bd-ff99-4fbb-b722-96bda46128a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktNC0xLTEtMA_d3c8dd92-ea1b-4020-aae3-85d6cfcd86dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktNi0xLTEtMA_b2806ee6-35ed-4993-b084-d2cc409b8eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktOC0xLTEtMA_6492bb18-d4a5-490c-a6c3-e2053dc201c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTItMS0xLTA_3c9f5973-5574-4311-8173-f6e5409ed63f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTQtMS0xLTA_fa11aae1-2928-4544-96ec-0cc67ca54723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTYtMS0xLTA_13c6649f-8799-4204-95fb-9bf7f799a976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTgtMS0xLTA_9b3ca34c-829e-47c1-a5cb-f5f0ff95c567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783b98e50e847a19205180e25cee168_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTItMS0xLTA_a4590dc5-4041-4e07-a49b-6e8358e10bee">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783b98e50e847a19205180e25cee168_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTQtMS0xLTA_935ae129-3b6c-45ab-9239-1d210ca184ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783b98e50e847a19205180e25cee168_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTYtMS0xLTA_3d2707f8-0e52-41f8-b56c-8f3a8e8e1c59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783b98e50e847a19205180e25cee168_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTgtMS0xLTA_1377f42b-d587-4117-a26b-f6356c300627">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTItMS0xLTA_e8ba2d88-d01c-43f0-8374-517b5e8b66a1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTQtMS0xLTA_9a024a3d-6447-4fbe-9393-8a5eb058b134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTYtMS0xLTA_9fc4c460-f735-47a6-aa1e-93a9174f837b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTgtMS0xLTA_db480a34-4e79-4f42-91bb-e0257914327b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTItMS0xLTA_bf22bff2-eda1-4686-a6f2-6a395eb01ecb">9,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTQtMS0xLTA_b6922224-2a81-404c-b17a-c460558aa388">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTYtMS0xLTA_f29eb048-80d3-4eba-882f-da596e529f47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTgtMS0xLTA_e2090d7c-7baa-404d-ae03-c819c9cbb927">9,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtMi0xLTEtMA_724f3728-f9fa-45f0-bdb9-5da298fad395">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtNC0xLTEtMA_dc8821f6-b79e-4c25-a5f1-af7ee55593d8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtNi0xLTEtMA_5da3c7cd-bd94-4197-bfaf-a405f78dd501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtOC0xLTEtMA_b719db84-f88e-474c-af54-f0d494abbf3a">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItMi0xLTEtMA_05346ff9-0165-464d-86a2-fc041e1b1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItNC0xLTEtMA_4d2d05d0-f701-4551-9755-12e780cfc82a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItNi0xLTEtMA_c892251d-a902-4c23-9ae5-a83df6c31d1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItOC0xLTEtMA_f56601cf-ccce-49f5-b491-30e31792c87f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctMi0xLTEtMA_359781f5-8dc4-4190-a593-52f246df1b75">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctNC0xLTEtMA_e60c6cd9-348c-4ccb-a10f-a678cdb4984b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctNi0xLTEtMA_86975278-6b13-4213-b3b8-9a88102a5881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctOC0xLTEtMA_a85aad6c-bc50-47f0-8b6e-e1cdf30b0c20">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtMi0xLTEtMA_d607bb10-2ae5-4bc0-8b66-27c4b10c35b3">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtNC0xLTEtMA_6314e3c6-90b3-480a-9387-06d7acb95572">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtNi0xLTEtMA_a1d7d406-20ab-4fb7-8568-8472bc45bc14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtOC0xLTEtMA_676ec692-1a5e-4f88-9440-bcb94cfce034">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktMi0xLTEtMA_289354ef-be0e-4b7f-a363-8076138c6831">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktNC0xLTEtMA_c6d7db09-6fcf-4671-8cd7-9e7d045bcd89">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktNi0xLTEtMA_73b179d6-2d9f-44fc-8023-72422fdf5a99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktOC0xLTEtMA_238b057d-5c79-45bf-a03c-0d80caffdcbb">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTItMS0xLTA_1e5b369f-31ca-45ca-8b74-675187d5ffd0">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTQtMS0xLTA_0f95eff8-0358-41a8-ba4d-721bdd0fddb0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTYtMS0xLTA_f4120b82-3abf-4ecc-b515-5286fa30d898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTgtMS0xLTA_33d248a3-8293-4ae0-a86f-fe3babccc92e">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTItMS0xLTA_59f5978c-9554-4b84-928c-038b2dd4374a">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTQtMS0xLTA_97ef5bec-d089-4bdd-bdc5-2e33a12f1ed6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTYtMS0xLTA_be8c62bd-1bda-42c3-9561-90792bc92486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTgtMS0xLTA_8ba15bdd-8f5f-43e4-9aef-7095d1e93ca4">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTItMS0xLTA_97a4ab37-4959-4b96-b5ad-40500afb98d1">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTQtMS0xLTA_ae7a68ab-5c9a-41c6-8a9f-4bfe068da41f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTYtMS0xLTA_12c04100-585a-4520-babe-13cac5d461c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTgtMS0xLTA_aa30c7c0-0de6-40fb-9112-93c64225d773">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTItMS0xLTA_efd1d7b9-98fd-4ae2-96b8-fa8866691661">8,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTQtMS0xLTA_e9e00410-9c0c-45d0-ac0f-64ede380ee08">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTYtMS0xLTA_d8221152-acd0-49cf-b693-6830164fa5d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTgtMS0xLTA_9809f383-87a0-419b-88bb-f0e040857546">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzQyODg_0520f94f-b0dc-4f32-b1d1-fc9dbffeb6a3" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9255d5d6fe481fad09edd63beb52e7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzItMi0xLTEtMA_971c16cb-3aea-41d3-8593-742955dd32e1">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fbd934d2344ce09137ff8acd872830_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzItNC0xLTEtMA_b8ba7a5d-471f-489c-b25d-39298d77047f">5,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9255d5d6fe481fad09edd63beb52e7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzMtMi0xLTEtMA_b89dceb6-4d8b-48ac-b851-9ea6194a90bc">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fbd934d2344ce09137ff8acd872830_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzMtNC0xLTEtMA_a07b272c-10ad-4744-823d-3d984672de52">2,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9255d5d6fe481fad09edd63beb52e7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzUtMi0xLTEtMA_b9a13638-f744-4b48-8bc8-8893a688061b">9,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fbd934d2344ce09137ff8acd872830_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzUtNC0xLTEtMA_c0007556-9201-43bb-833e-790926637041">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzIxMTE_c32ce812-74ba-4f46-8da9-2fdd02b8fd7a">802</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzIxMDc_2d00e5a6-86e6-437d-bf63-5ea426f591f5">677</ix:nonFraction> million as of December 31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia93ad65916b14393844b496ff0ed9824" continuedAt="ib0678e0f973e48888927eb1c37db7767"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzQzMDg_75959010-5c9f-4186-82b4-087010503cd0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual maturities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzItMi0xLTEtMA_7ca73891-30e4-45cb-8953-4c83ac6e80cc">9,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzItNC0xLTEtMA_8f7dd26d-60e3-4665-9b80-12ef6b404cf2">5,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through three years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzMtMi0xLTEtMA_7ac70d62-646b-46d6-9cfc-335ee9f3a5ae">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzMtNC0xLTEtMA_2f8245bc-7a61-49f7-8e9b-90d26e42180d">2,304</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after three years through five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:zerodash" name="amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzQtMi0xLTEtMA_00b857bf-b984-4305-8299-fad4c734576e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzQtNC0xLTEtMA_9502c33e-d395-4677-beb9-8b25bd21252c">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzctMi0xLTEtMA_947b01e5-161a-44d6-aafa-1d6b9cd6730a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzctNC0xLTEtMA_b483a49d-4e4c-463e-b5c0-ab819c002c71">182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzgtMi0xLTEtMA_d14febe6-9f3d-4822-b8df-ee8d25d5e0bc">9,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzgtNC0xLTEtMA_d958f7d8-265d-4d31-984f-50a5bca1bec1">8,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2020, 2019 and 2018, realized gains on interest-bearing securities were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzgwMg_81b2fe58-6654-428b-b767-8261d6805dba">37</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzgwNg_be4da055-9c9d-4b85-a9f5-24c5a4155f2b">92</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzgxMw_060a1eb1-5dfa-4029-849d-4122ab0ae1b5">29</ix:nonFraction> million, respectively, and realized losses on interest-bearing securities were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzg4Nw_cb7f2863-2b12-46a5-8b29-bdd021956f3a">4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzg5MQ_7594b226-9565-485b-938d-e13fc77a0c11">36</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzg5OA_b118e9d5-5a5b-45d2-bf84-0fb02939bb19">394</ix:nonFraction> million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review our available-for-sale investments for declines in fair value below our cost basis each quarter or whenever circumstances indicate that the cost basis of an asset may not be recoverable and assess whether the decline was due to credit-related factors or other factors. Our evaluation is based on a number of factors, including the extent to which the fair value is below our cost basis as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is impaired could change in the future based on new developments or changes in assumptions related to that particular security. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values of $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMwMDg_48c1c8d4-c8da-4ab3-b753-655f2bd269f3">477</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMwMTU_5b1763e2-41bb-4427-8068-4501b0d3acc5">303</ix:nonFraction> million as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. For the years ended December 31, 2020, 2019 and 2018, net unrealized gains on publicly traded securities were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDI1ODY_1509a25a-dd8b-4d44-9ee2-dbef2268e3cb">174</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzExNTQ0ODcyMTA2MzA4_fafc980d-bc3d-43e6-a841-4756062f4280">112</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzExNTQ0ODcyMTA2MzIy_e2726f50-a636-4e87-8fe3-10166d7c0cbd">24</ix:nonFraction>&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2020, 2019 and 2018, were not material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMzMzI_cc8bd9ae-ee1a-4b72-bc90-df070096d475">203</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMzMzk_928157e4-c6a0-4b10-8368-0893578ee7a3">176</ix:nonFraction> million in equity securities without readily determinable fair values as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. Gains and losses recognized on these securities, including adjustments to the carrying values of these securities, were not material for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnership investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $<ix:nonFraction unitRef="usd" contextRef="ib3acbfa95e2d42d59a15e70c74debd7d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AlternativeInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzM2ODk_c4827ecc-5995-4d36-b6ab-0f91d5cdeea0">496</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8005c102cf76487dae26362888d802fc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AlternativeInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzM2OTY_fc58dd98-a67f-4ca5-b1e7-d6b062eea26b">320</ix:nonFraction> million as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2020, unfunded additional commitments to be made for these investments during the next several years were not material. For the years ended December 31, 2020, 2019 and 2018 net gains recognized from our limited partnership investments were $<ix:nonFraction unitRef="usd" contextRef="i9f6cc35d1d07485d8a62dae2b89a8859_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AlternativeInvestmentNetGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDI2MTQ_9bed3911-537c-447e-bfa3-4c7f9193710c">241</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i1bcbc99707a942a3b9412cca58536799_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AlternativeInvestmentNetGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzY5OTc_c8bee449-a5e1-4477-afce-99e57e8df57b">27</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if984bbfefa824630ad0be7898a756667_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AlternativeInvestmentNetGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzcwMDI_ff22c156-452d-4574-9237-756f18d1f92c">91</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib0678e0f973e48888927eb1c37db7767"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a <ix:nonFraction unitRef="number" contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNTI_0df06163-a1b1-43ea-8c11-96c093fae20f">20.5</ix:nonFraction>% ownership interest in BeiGene for $<ix:nonFraction unitRef="usd" contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwMDU_25e0c009-0b1c-487b-8d6f-64986050a2cd">2.8</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwMTk_db6f8ff0-cc69-443b-84ab-5ae90ed94353">2.6</ix:nonFraction>&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other assets in the Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $<ix:nonFraction unitRef="usd" contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDMzNzM_6a196eaf-1b22-4ed7-ae20-a3b3d4f7b69d">2.4</ix:nonFraction>&#160;billion. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Interest and other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from <ix:nonNumeric contextRef="ic2cdef4357c64e9cb34661796f119661_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNTk_68a67454-7717-41a7-aa6d-a040eaf47a45">8</ix:nonNumeric> to <ix:nonNumeric contextRef="i96d4a84d1d744c3196a3054655ba8dc9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNjI_0fd8ccf1-2684-4efa-bc14-7a921a0b5d8a">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recognized an increase in the carrying value of our investment by purchasing additional shares to maintain our ownership interest for an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:EquityMethodInvestmentChangeInCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNzg_779d02b5-f62d-42ae-b946-5886303d8626">569</ix:nonFraction> million and recognized $<ix:nonFraction unitRef="usd" contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:EquityMethodInvestmentChangeInCarryingValueOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIxNDY_e12795fd-0e6b-48e1-860a-12a09eebe764">34</ix:nonFraction> million for the impact of other BeiGene ownership transactions. The carrying value of the investment during the year ended December 31, 2020, was reduced for our share of BeiGene&#8217;s net losses of $<ix:nonFraction unitRef="usd" contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIyMzc_29230eb4-ce55-4223-846e-f17b77c39627">229</ix:nonFraction> million and amortization of the basis difference of $<ix:nonFraction unitRef="usd" contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIyNjc_69c12cf7-6791-4011-9078-5b5a1a8395f8">109</ix:nonFraction> million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the carrying value and fair value of our approximately <ix:nonFraction unitRef="number" contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIzMTg_663b8568-8a58-45f2-afa1-1ff4df6e234b">20.5</ix:nonFraction>% ownership interest in BeiGene totaled $<ix:nonFraction unitRef="usd" contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIzMzM_9e3742be-41f4-497d-b72d-71b662bdded9">2.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIzNTI_0c312e8b-c30c-4cd7-a8d4-adb892e29821">4.9</ix:nonFraction> billion, respectively. We believe that as of December 31, 2020, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_235"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90ZXh0cmVnaW9uOmE1ZmQzNDNlNTFkYzRiZjVhZjcyNzkxOGYxOTQwNWEyXzkw_3c588be0-187f-4e34-8db5-4ad16a3593b7" continuedAt="i08b34ce58a624a9a96559841afc74116" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i08b34ce58a624a9a96559841afc74116"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90ZXh0cmVnaW9uOmE1ZmQzNDNlNTFkYzRiZjVhZjcyNzkxOGYxOTQwNWEyXzg0_9319dd09-9ce3-4a47-a8c8-103925088573" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzItMS0xLTEtMA_bf8b2708-4153-4cd4-9495-43e4019c5be1">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzItMy0xLTEtMA_d763ee66-bc2e-48f9-a683-459a3c91b2c5">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzMtMS0xLTEtMA_dd018593-360b-4bab-b4e0-52e1b392c8ba">2,437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzMtMy0xLTEtMA_a460ac72-0674-435b-aef2-1f954f743068">2,227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzQtMS0xLTEtMA_20789795-d842-46eb-a5b1-7e1165625b65">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzQtMy0xLTEtMA_72e7c18a-5b83-45f7-9762-b8b752399dc6">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzUtMS0xLTEtMA_be91908f-d638-4a42-b12f-8a981282dda7">3,893</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzUtMy0xLTEtMA_8562d545-f221-4e5d-8b71-853acfcda903">3,584</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_238"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzQ2NQ_00269458-29bb-4f11-8a69-f53659be3eb5" continuedAt="ibcd4840979fb4678bdb26e82a5d4b977" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="ibcd4840979fb4678bdb26e82a5d4b977" continuedAt="ib44c563edea1422b9e2914402c0369df"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzQ2MQ_92b8731f-21a2-43d6-aac5-37996d96bcce" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzItMy0xLTEtMA_e12b9d49-9700-47a7-98ee-f9e5d55f0806">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzItNS0xLTEtMA_299e06af-f5fa-40e8-8da9-888039f2b67e">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4746bb368e19427abd5d968255881278_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjY2NzM3ZDgzZTQyMjQxZTg4MDI2OTg1NzVjN2U1ZmQ5XzEwOTk1MTE2Mjc3ODc_8130dd4b-b963-4784-920f-56ea5dc490f0">10</ix:nonNumeric>-<ix:nonNumeric contextRef="icf2f91f1812e4b6985813bd5ad956751_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjY2NzM3ZDgzZTQyMjQxZTg4MDI2OTg1NzVjN2U1ZmQ5XzEwOTk1MTE2Mjc3OTI_ad40719e-960c-457a-8541-82f85e2cfd15">40</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtMy0xLTEtMA_7cc7daaf-c9c3-4f8b-a295-9473177d36d7">3,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtNS0xLTEtMA_5b9eb619-eeb1-4eb4-ba73-973314da31e4">3,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8de40ffd50114a4b85de7a66f9fe7476_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjVjNWQzNGU0ODA1YTQ5YzQ5NGEzODFhZDk4N2RlMDAzXzEwOTk1MTE2Mjc3ODU_97aa69a8-32e6-41e0-8b73-243dfcdf39e1">8</ix:nonNumeric>-<ix:nonNumeric contextRef="if6f8655d04b041f4ad4b564443d75726_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjVjNWQzNGU0ODA1YTQ5YzQ5NGEzODFhZDk4N2RlMDAzXzEwOTk1MTE2Mjc3OTA_005b2b5c-10a2-4c95-b911-9803735c9bc5">12</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtMy0xLTEtMA_f6b64077-c05b-46b5-8286-629f453e86e2">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtNS0xLTEtMA_4b1c6750-7064-4f49-b88e-d320770e39c8">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i895c1063378b4068a891fd1e71fb3589_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjMxYjc4ZDBlYWFlMDRhYjQ4ZGUwNmY1Zjg0NjU3Y2M1XzEwOTk1MTE2Mjc3ODU_efe65445-522a-46cc-8dc2-18f76d0c07b9">8</ix:nonNumeric>-<ix:nonNumeric contextRef="i1d8a60c530804890ab62b6e0d832989f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjMxYjc4ZDBlYWFlMDRhYjQ4ZGUwNmY1Zjg0NjU3Y2M1XzEwOTk1MTE2Mjc3OTA_93715969-f691-4aa7-aea1-1e1006baeb28">12</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:LaboratoryEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtMy0xLTEtMA_f1c663a8-2c11-4b5a-9389-871ab5ecf222">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:LaboratoryEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtNS0xLTEtMA_15bd5b1b-9d4f-4d98-b9f4-082fef1ada2d">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e3dc8e131e74b639d5fa9747c30f69f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMS0xLTEtMTEwNDc_1b5b2d52-cfb1-46f8-9d38-a45398cbaeb5">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:FixedEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMy0xLTEtMTEwNDc_d4190f9d-a9eb-4928-98c9-33f76fb6cfe3">2,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:FixedEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtNS0xLTEtMTEwNDc_13489259-b0cc-4c2d-9e16-242d725c42e8">2,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i396cde7c35a94e749b408f43a2826d8b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMS0xLTEtMC90ZXh0cmVnaW9uOjRlZmRhODhiYjg5YzQxM2FhNTQzNjk5NzI3N2I1YWRhXzEwOTk1MTE2Mjc3ODQ_ace13850-4ca0-45e0-ad8f-782c4e369b44">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i4defc84603e845d1abe667bb41b2c371_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMS0xLTEtMC90ZXh0cmVnaW9uOjRlZmRhODhiYjg5YzQxM2FhNTQzNjk5NzI3N2I1YWRhXzEwOTk1MTE2Mjc3ODg_3e9cba8a-706c-4af4-b633-8cc89bf7f954">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMy0xLTEtMA_3ab18d62-7da7-4659-bcf7-8bfd5246ae31">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtNS0xLTEtMA_396ca00a-5712-4172-a7ca-cbb55741f0dc">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if71cd1836df64fa297d00f961c9878db_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctMS0xLTEtMC90ZXh0cmVnaW9uOjVkMjNkZWJmNTlmMjQwN2U5ODQ2YTdkYmRkM2ViMzNjXzEwOTk1MTE2Mjc3ODU_9cdf522b-6252-429a-88a6-68d9cf567950">5</ix:nonNumeric>-<ix:nonNumeric contextRef="idd99c6d5f7e14c2b9fb17834726169ed_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctMS0xLTEtMC90ZXh0cmVnaW9uOjVkMjNkZWJmNTlmMjQwN2U5ODQ2YTdkYmRkM2ViMzNjXzEwOTk1MTE2Mjc3OTA_ebfc1a19-b414-4e42-8570-e02893253c58">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctMy0xLTEtMA_09d1b096-a744-4e36-a1d6-7b8e4f2745c8">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctNS0xLTEtMA_d69f7587-1589-45bb-b9b9-dc273390ad71">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzgtMy0xLTEtMA_b02beb37-a39d-4533-a159-68facef8dcea">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzgtNS0xLTEtMA_ebb8aeb8-be14-4125-a2a1-2e86bd929868">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzktMy0xLTEtMA_7ba602d3-4a23-4e71-9c08-1b048aa9d7c7">13,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzktNS0xLTEtMA_fedeb1c6-cbbf-4c53-ae29-26b88be3b8e2">13,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzEwLTMtMS0xLTA_6df3f1b2-b09e-4610-a4bf-3f175eeae19d">8,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzEwLTUtMS0xLTA_87290a40-963f-4ed3-9d98-e99cd5b1d21c">8,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzExLTMtMS0xLTA_527895ab-8970-4885-9c56-98faef83ad44">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzExLTUtMS0xLTA_e070c6d1-ccdf-4143-b0b7-c12e2c085213">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib44c563edea1422b9e2914402c0369df"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020, 2019 and 2018, we recognized depreciation and amortization expense associated with our property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzI3Mg_f05c9a8e-5da4-4c3d-9bf3-0be1ae1eb182">640</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzI3Ng_db208f11-2e27-4f53-a9cb-8f1ee29b8725">635</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzI4Mw_2f0ada78-166a-4f20-a039-78c7d98d6f1e">630</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic information</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzQ2Mw_5dac49df-c84a-4eea-9da3-f68ced921a86" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380c4519a6324acb9471d6b0846ff47a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzItMS0xLTEtMA_9333fee1-a9ff-4226-88d7-ce9e2b57a979">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7412d430651b4c3aa09e75a732689d3e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzItMy0xLTEtMA_fa2993e4-0a4c-479d-b1fb-2663b4f3700c">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25925681a284e8a8cc4bc5abf1a3047_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzMtMS0xLTEtMA_64e8adb6-82b7-4846-82b3-5a36663383e6">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95f14d878c44b7bd718c95c6943ab4_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzMtMy0xLTEtMA_2814f5c6-f486-49e7-95bb-031c7c72c2ba">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9275605c200a4299bbfa5428560e8a03_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzQtMS0xLTEtMA_f81c064a-bc21-4e2c-8e63-f91fcb78e375">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ea8f1bac6a4be3807a3e1482036184_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzQtMy0xLTEtMA_1865d1b6-2459-4b51-8752-3bcd8c108e1b">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzUtMS0xLTEtMA_c828dc7f-c173-4956-99f4-23ebbd0ea675">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzUtMy0xLTEtMA_cfbbef58-8d22-41c2-b7e4-c6ef10cdf9b3">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_244"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5ODE_3f038e0b-fa0e-4a94-8565-ada6a1914b89" continuedAt="i9561213a49cb44adbd7cb28e7e79c280" escape="true">Goodwill and other intangible assets</ix:nonNumeric></span></div><ix:continuation id="i9561213a49cb44adbd7cb28e7e79c280" continuedAt="i38553b68fc0f4b11a0cba9a3e9666c5e"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5ODI_c61404df-30eb-40f8-8562-f14316935dc2" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzItMS0xLTEtMA_888cbd69-e88a-4479-9eba-8b8d704610c8">14,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzItMy0xLTEtMjI4MQ_a6dbed78-f7ac-4de7-b383-7d3a86af839b">14,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition from acquisitions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzMtMS0xLTEtMA_d8a98352-0d00-4264-b2bb-c204c8352659">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzMtMy0xLTEtMjI4MQ_ab8fc5d9-aa96-42e4-955b-f2a261668a3a">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzQtMS0xLTEtMA_c40691b2-598f-4389-a7e1-4a58ad1fa9ca">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzQtMy0xLTEtMjI4MQ_05bf43e1-8313-444f-be37-258948fb98bb">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzUtMS0xLTEtMA_446e706a-2b5b-4c96-bf2f-7e2bc93f1b5d">14,689</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzUtMy0xLTEtMA_2944c92a-e832-4941-9788-e6429a4ff7c4">14,703</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:ScheduleOfIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5ODk_2c3ab157-a0c7-4aa4-9945-a86b84b26d32" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb8f56cf7cb441696514975a5535ece_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtMS0xLTEtMA_8e9b5cd0-7f18-4d46-a8a2-068fa671cd54">25,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddb8f56cf7cb441696514975a5535ece_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtMy0xLTEtMA_8399619c-7c41-4589-aef0-456f68fe58c9">10,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb8f56cf7cb441696514975a5535ece_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtNS0xLTEtMA_165507c2-42b3-4c28-9ab0-0c0ca3103906">15,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d4fa50eb91422a8dde19c58f864d75_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtNy0xLTEtMA_ade9bd5b-441f-45fe-9495-798981973e1f">25,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d4fa50eb91422a8dde19c58f864d75_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtOS0xLTEtMA_a20d09dc-af8f-4383-b33c-b0c8e3898f9f">8,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d4fa50eb91422a8dde19c58f864d75_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtMTEtMS0xLTA_9696075c-c4f4-4cec-bdc4-86d4ec2545b4">17,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2f82635b7e4140849137d3c5812d24_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtMS0xLTEtMA_ba4b1fa0-ef71-4b99-bfaa-c551e9823240">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd2f82635b7e4140849137d3c5812d24_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtMy0xLTEtMA_f030cb2f-2042-4221-a807-f516f6860e15">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2f82635b7e4140849137d3c5812d24_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtNS0xLTEtMA_d57aab99-48e1-48a2-bb07-a9c3e7e3c886">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795833ab718e4229838a54da0009fbc2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtNy0xLTEtMA_cabc147d-e282-4138-9c1f-a34f2b97a749">3,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i795833ab718e4229838a54da0009fbc2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtOS0xLTEtMA_e9fc8a94-ce42-4ceb-9f54-131429accc3a">2,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795833ab718e4229838a54da0009fbc2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtMTEtMS0xLTA_0bcac85f-e38e-48c9-9b51-fa6ff7aa0689">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtMS0xLTEtMA_55217b0c-593f-46c0-96b7-044f8d1feeb7">1,367</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtMy0xLTEtMA_ea5ce533-8507-464a-bf8a-b82c59bc6d69">1,041</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtNS0xLTEtMA_6b97c96c-ae43-4058-b045-84d53167e607">326</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bcdb11924b427696274755e057121c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtNy0xLTEtMA_397af5cc-7120-464c-bbad-250ae7a01108">1,382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05bcdb11924b427696274755e057121c_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtOS0xLTEtMA_c16dbf9b-0370-45d8-ab45-1102e31ca87a">965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bcdb11924b427696274755e057121c_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtMTEtMS0xLTA_a2daf894-61dd-4b85-8c95-f42c0117afc7">417</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058ba3d94d2c43168ff6130531a4ace6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctMS0xLTEtMA_8f8ca67a-bbb9-40a4-a834-8b10688df69f">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i058ba3d94d2c43168ff6130531a4ace6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctMy0xLTEtMA_1c0083a7-6029-45bb-9cc0-d7ded1c09c71">1,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058ba3d94d2c43168ff6130531a4ace6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctNS0xLTEtMA_99589602-0e9c-42b0-9ce7-1d5d6c604873">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctNy0xLTEtMA_fb4fb08a-ad7c-4d15-b07b-11b0527bb2dc">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctOS0xLTEtMA_195f7e69-f0bd-4d1a-9678-c86f32aa96cf">947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctMTEtMS0xLTA_e8ab9462-2c2d-4b9d-8fb6-edd48366d2da">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtMS0xLTEtMA_70c83c07-5c9a-4a8a-b5e7-eba2a719acd7">32,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtMy0xLTEtMA_33107f05-df19-4055-abcf-7a1e8d36273e">15,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtNS0xLTEtMA_09e8b6ea-ad1d-4765-b827-78619b255f6b">16,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtNy0xLTEtMA_6b7e9222-ff07-4436-beb2-2c2f192454a1">31,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtOS0xLTEtMA_5116ef06-0143-4e7b-bcef-f0a385e58219">12,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtMTEtMS0xLTA_93b4f055-e37c-42b5-a46e-4d03be195eb0">19,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8242170454444bd1ad4819726216ab26_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTEtMS0xLTA_74a978ad-4d29-473c-aff6-8f55ff865a56">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8242170454444bd1ad4819726216ab26_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTUtMS0xLTA_48dcb53a-0e81-4079-a94c-875d74221a94">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96ddc98bc504632bed269fd22978fdc_I20191231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTctMS0xLTA_978f3fac-187d-4d49-88a2-cdf400c1f6ea">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96ddc98bc504632bed269fd22978fdc_I20191231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTExLTEtMS0w_dba6d5d5-bcfb-4fd8-9d4b-d04dd57e2a56">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:IdentifiableIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTEtMS0xLTA_ba9441a9-640a-48a4-9894-2b8929441ba2">32,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTMtMS0xLTA_9b926c3d-56b9-4c32-a0b8-9a4c53f675d8">15,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTUtMS0xLTA_1d70b6af-ae12-4842-b669-dbcc50a129df">16,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:IdentifiableIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTctMS0xLTA_12d75470-d864-4592-bac7-054df0778b0c">32,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTktMS0xLTA_d3ad3777-44a5-4093-9fb7-3eace2c9e11a">12,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTExLTEtMS0w_6b476728-cb18-4d91-a0dc-07f99363ff70">19,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i38553b68fc0f4b11a0cba9a3e9666c5e" continuedAt="i1cfec17dd6204f88a6f091c1f7a06264">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1cfec17dd6204f88a6f091c1f7a06264">During the years ended December 31, 2020, 2019 and 2018, we recognized amortization associated with our finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzE2NDkyNjc0NDQ2Njg_b69fab0e-c967-4c5d-a1e9-823937ab49a7">2.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI2NTY_a7960f43-ed69-4042-a1ab-491f4fbe4fcd">1.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI2NjM_57fe2c08-25c6-4922-83b4-bd15dac55aff">1.3</ix:nonFraction> billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2021, 2022, 2023, 2024 and 2025, are $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5Mzk_60524bbe-9fc9-4a77-9a41-fad68877dbe4">2.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NDM_086a4b7c-504f-4607-b2e8-6baf055b0025">2.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NDc_7a38cc41-58b5-4ad1-b6c9-b898d2eee284">2.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NTE_73b35243-7042-4079-b0cb-6cd356fed15e">2.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NTg_1de716d4-4fad-4152-856a-ffa60f502e84">2.2</ix:nonFraction> billion, respectively.</ix:continuation> </span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_247"></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzU0OTc1NTgxNDMxMDI_f1c92bf7-2548-4f79-a0d7-4ab27023ff28" continuedAt="i28cfafc307604b2980764d418203129b" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i28cfafc307604b2980764d418203129b" continuedAt="i8816b844cc244836a0f6db1de82ecde0"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. Certain required disclosures have been made on a prospective basis in accordance with the standard&#8217;s guidance. See Note 1, Summary of significant accounting policies. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and equipment related primarily to administrative, R&amp;D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most leases include one or more options to renew, with renewal terms that may extend the lease term up to <ix:nonNumeric contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzY4Mw_4b14265e-347f-4cd6-acec-c46c888c6fa1">seven years</ix:nonNumeric>. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;D and administrative space.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzI2Nzk_bc245150-ff3e-4230-93d9-63638082cb2f" continuedAt="i009a2feb7a36414789402d7b742bb23f" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzItMi0xLTEtMA_a1bc1fc3-e055-4678-9f46-643c64238c55">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzMtNC0xLTEtNTkwMw_8ca2e572-12c7-4e94-bfbf-f93cebf8c6b9">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzQtMi0xLTEtMA_bd61e59a-6955-43a4-b6aa-9c908712d6d8">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtNC0xLTEtNTkwNw_904e9b8c-91df-4d39-b4da-7c0bc2e0005e">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMi0xLTEtMA_54d6da1c-3438-4b72-b7c2-6b88e36c8175">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtNC0xLTEtNTkxMQ_1c430393-2667-46f2-b0f9-6697c322ad5c">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMi0xLTEtMA_ef60759d-b4f3-455f-9429-a49a04eea184">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzctNC0xLTEtNjg2MA_a45cc84b-581d-4a60-a56e-dd7488f227e7">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzEtNC0xLTEtMA_1998a9c1-d564-4820-86e3-d891823d06a0">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzItNi0xLTEtNTk0Nw_9f8dca36-2221-4dc1-9b3b-618982fe6ead">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzgtNC0xLTEtMA_428911db-56ef-4181-9512-e264bbdbf51e">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzktNi0xLTEtNTk1MQ_8613df51-9e1f-4ef8-b6b7-adfa1859fa3e">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzktNC0xLTEtMA_0b25ffe4-af88-4850-9034-ae45c7dc9b9f">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzEwLTYtMS0xLTY4NjI_636a2b77-544e-47a8-bd4e-b3ceb68b8051">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2020 and 2019.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8816b844cc244836a0f6db1de82ecde0"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzI2ODA_2d7d22cb-214e-4adc-96e4-cdd00520ccc5" continuedAt="i2bbe0b26524942ddb37df82b9a31a5f0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020, were as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzEtMi0xLTEtMA_455f65ee-4188-4f63-979b-71776eae4fee">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzItMi0xLTEtMA_17bd5c1d-8dd9-4ef8-87fa-268a94eaa7d3">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzMtMi0xLTEtMA_7e84093e-3c10-408f-846d-088b88cd79f3">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzQtMi0xLTEtMA_a2d2bda4-086e-4313-b0e5-74527ed8f84f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzUtMi0xLTEtMA_5bb124b4-1ffe-49dc-8d75-e3c15d27b677">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzYtMi0xLTEtMA_0820cc3d-00ac-4a17-8086-0ab9f94055f0">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzctMi0xLTEtMA_6dd90e65-f6cf-42e0-bae3-a0f411ba4c8f">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzgtMi0xLTEtMA_f9ddcef7-3fe3-4195-8fd7-7a4d4fcb6eee">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzktMi0xLTEtMA_c7e080af-20c1-4567-aa08-0bd668c8c8ea">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i2bbe0b26524942ddb37df82b9a31a5f0" continuedAt="i6c8fc19c8af54ceeb4bec1571692cd10">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6c8fc19c8af54ceeb4bec1571692cd10">Includes future rental commitments for abandoned leases of $<ix:nonFraction unitRef="usd" contextRef="ib87ff255d0fe407c8d140590358ce557_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODI3_58b01215-7bc8-4050-aa2a-b2fa3de1a8d7">133</ix:nonFraction>&#160;million. We expect to receive total future rental income of $<ix:nonFraction unitRef="usd" contextRef="ib87ff255d0fe407c8d140590358ce557_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODU1_4e679be8-2bbd-4f03-b4a5-bbb8a2516719">107</ix:nonFraction>&#160;million related to noncancelable subleases for abandoned facilities.</ix:continuation> </span></div><ix:continuation id="i009a2feb7a36414789402d7b742bb23f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzItNC0xLTEtMTM2MzA_349d69b8-d220-465d-b1e0-fc798679605d">3.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzItNi0xLTEtMTcxODA_d4ee2c08-c2f9-472c-be18-4099069020cc">4.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzMtNC0xLTEtMTM2Mzg_0b24536d-7b03-4a75-affc-3d7fed18db2a">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzMtNi0xLTEtMTcxODA_7331aa51-c49e-487b-9b31-74f8194df7e2">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzItNC0xLTEtMA_855b54be-898e-4639-af1c-bf7587041c3a">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzMtNS0xLTEtNTk4MA_49c07d82-9629-4d14-b35e-6f4c78faa5ca">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzYtNC0xLTEtMA_6a8ac0b9-5cd2-479d-967f-35dc403b0549">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzctNS0xLTEtNTk4NA_d9b52da9-d0d3-4e1d-9a08-a1a2310b99b9">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODQx_da9bb4cc-817d-4d47-89ec-6b2ba3628638">339</ix:nonFraction>&#160;million. These leases will commence in 2021 with lease terms from <ix:nonNumeric contextRef="ief37ee91742248e0885bab6c4ed8ddde_I20201231" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODI1_65a3ac21-b6a4-4b2d-8cd5-015ab886d8af">30</ix:nonNumeric> months to <ix:nonNumeric contextRef="icc37b0f57f9e459ab9249c3fd0808c48_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzIxNTg_5b116af1-1264-49a1-be4c-60ea8e3c42f0">15</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental expense on operating leases under the prior lease guidance for the year ended December 31, 2018, was $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzU0OTc1NTgxNDMxMjg_a4e34f64-b182-4593-b46d-83366258d31e">166</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_250"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:AccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90ZXh0cmVnaW9uOmNmODYwY2EwMGNhNzQyZmI5NDQ3MjI2OWY2MmYyNTQ3XzIwMA_e5bcce46-0ccd-401b-8b53-8253c2900382" continuedAt="if328b5aee03c465a82a7259fd5e8194b" escape="true">Other current assets and accrued liabilities</ix:nonNumeric></span></div><ix:continuation id="if328b5aee03c465a82a7259fd5e8194b"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90ZXh0cmVnaW9uOmNmODYwY2EwMGNhNzQyZmI5NDQ3MjI2OWY2MmYyNTQ3XzE5Nw_6fcf80a5-d1e6-4c4f-92b3-8724a5d19822" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzItMS0xLTEtMA_8e66debd-1fb5-4d6e-a2fb-79b55a222097">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzItMy0xLTEtMA_d0351954-12d4-43c7-9016-a1c8f064312e">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzMtMS0xLTEtMA_4883bd74-56cb-4959-8514-1fa09a3a36db">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzMtMy0xLTEtMA_d9e56e77-847b-4588-ac5c-beb88a3bb191">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzQtMS0xLTEtMA_6ed3ef23-713e-49f8-a57b-f84075eecce4">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzQtMy0xLTEtMA_fe49df6e-678c-41bd-8bac-249023704dd3">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzUtMS0xLTEtMA_5cd5db33-fac9-4219-8b0f-8569370ffed2">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzUtMy0xLTEtMA_124bed58-2897-487a-84cb-71f2bedfbdf7">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzYtMS0xLTEtMA_59c30597-5e9e-41b8-b821-6d8ae508177c">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzYtMy0xLTEtMA_eedb587a-f12d-4cb5-8d5e-5d82979336af">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90ZXh0cmVnaW9uOmNmODYwY2EwMGNhNzQyZmI5NDQ3MjI2OWY2MmYyNTQ3XzE5MA_72788861-c1aa-45c9-a1b3-d19e8670f1bb" escape="true"><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AccruedSalesDeductionsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzItMS0xLTEtMA_c03b1b30-319d-4c2d-9394-cc1447937c02">4,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AccruedSalesDeductionsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzItMy0xLTEtMA_73127b17-9ac5-43d4-9411-c6c2bbbdc1a4">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzMtMS0xLTEtMA_5bffed93-86b0-453f-bada-1694bb9e3d1c">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzMtMy0xLTEtMA_d6acdb83-811d-4dad-ab33-d7f03b92a925">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzQtMS0xLTEtMA_c512c8e2-adea-41d4-8157-e4a35bf4db35">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzQtMy0xLTEtMA_d3fa81b9-70bf-41c5-ba4f-b4e619e0cf31">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzUtMS0xLTEtMA_1b5c997f-93a8-4e82-bd82-cc317e6158bc">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzUtMy0xLTEtMA_91cf4fb8-1f7c-4193-90c5-dd49d1eac2bc">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="amgn:AccruedSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMS0xLTEtMTI2NTY_fe526579-8cd2-4fb4-878a-ab25e479eb6f">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="amgn:AccruedSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMy0xLTEtMTI2NjA_ef5f96b2-28c9-40bd-9481-d5bcf4bb8766">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMS0xLTEtMA_db007d3d-eee1-4fee-9798-567a0755c199">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMy0xLTEtMA_f6549c70-9593-4ee2-a7df-f2e74bc07a56">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzctMS0xLTEtMA_67fd943b-c28b-4343-bce4-f2d5d07b9d6a">10,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzctMy0xLTEtMA_ef08ea0c-718f-4102-9184-7415b3dfb530">8,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNDU_b3b825e4-d3a9-486c-a85e-9ce35328eff9" continuedAt="ic9dd0007812d43948c3c59f9c64a6faa" escape="true">Financing arrangements</ix:nonNumeric></span></div><ix:continuation id="ic9dd0007812d43948c3c59f9c64a6faa" continuedAt="i1fe8ed2d828e4a818f44b3733795e809"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNTQ_4a5d4f41-e9cb-4c65-b094-3c905876dc82" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i115359deafc44691979f165eb053cdfc_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmY5NzQ1ZjRhYmYzNjRkNjE5NWQ0MzZjMmRiZWIyNDA5XzEwOTk1MTE2Mjc4MjQ_65456f7d-5296-4241-bfb2-91fced90f1a8">4.50</ix:nonFraction>% notes due 2020 (4.50% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c11ed6245e4fa0a369c9f3aec56f9c_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEtMy0xLTEtMA_2dfd21e7-4dcf-4a53-b463-a12e1c5d35b9">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzItMC0xLTEtMC90ZXh0cmVnaW9uOjE2ZjRmYmQ5ZTQyZDQyNDk5M2FjN2ZkMzE4MzM2MGM3XzEwOTk1MTE2Mjc4Mjc_a3b100d2-3253-4893-9e55-c68f737fa6aa">2.125</ix:nonFraction>% notes due 2020 (2.125% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzItMS0xLTEtMA_69b8f4bc-2739-43be-ad3f-9bc3304426cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58dc479cd3d42319169a103d07a7574_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzItMy0xLTEtMA_22c99999-11a9-4a63-aaf2-fc8f5508dec4">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating Rate Notes due 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba619c4c18fc45ddb3aa9c5914a043e6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMtMS0xLTEtMA_4cc643fe-2e24-42a3-9fad-3badbbb6c9d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72dd6be73064790892c440bdd065b6e_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMtMy0xLTEtMA_5bf1979f-dcc4-46b4-8038-9141e2ba0217">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81f0c45930bf446597ffdba0232d3d0a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzUtMC0xLTEtNzA1NC90ZXh0cmVnaW9uOjEwZjAwMWZiYzg0ODQ2ODViN2I4N2ZiNjkxZDYyYjQ5XzEwOTk1MTE2Mjc4MjQ_92e0dc40-3198-4720-acb6-e2a971e19e3b">2.20</ix:nonFraction>% notes due 2020 (2.20% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f0c45930bf446597ffdba0232d3d0a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQtMS0xLTEtMA_739db8de-1e27-4a3d-981a-32f146b3e329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie507cdb44629455bb7c6aa2c3247d935_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQtMy0xLTEtMA_08768468-b132-40e2-9d02-b7e642ba54eb">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a25ca8db8794930a6444001d3c53561_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFjNzNiODQyNGY4ZDQ4OTA5YzU2MDUzMjdiNjAxYmI0XzEwOTk1MTE2Mjc4MjQ_fadc2d72-758e-4299-bda7-56109c3f0245">3.45</ix:nonFraction>% notes due 2020 (3.45% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7223a974c3e04bcba5c39ed1c654173e_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzUtMy0xLTEtMA_e68c8e69-793e-4bc5-af39-e69aa713ba9d">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic46c172c9e0a45198c8c6c17804b44f9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmNjMDE4NWFkYmIxYjQ5Y2E5YzllNGExYjExNjE2N2M1XzEwOTk1MTE2Mjc4MjQ_711e1339-2d17-4a37-9d82-3ed54b7309db">4.10</ix:nonFraction>% notes due 2021 (4.10% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766f4994093f4740852f0817f605b8ad_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzYtMy0xLTEtMA_d8d6023f-c600-445a-9466-2cc8b806fe7d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjA4MThiZWQ3NjQzYjdhMDUxNDZjMTkyMjI3NjI2XzEwOTk1MTE2Mjc4MjQ_54efd4ac-8109-484b-b345-6e63a20952b2">1.85</ix:nonFraction>% notes due 2021 (1.85% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzctMS0xLTEtMA_e8cae819-43d8-4c08-a2b4-dd7939ca77ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65782159d9f447c1a8360410b35c8b0f_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzctMy0xLTEtMA_a1b9fbec-5a1b-4f21-b56f-2a474b9bc40c">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c3bbee60b53406ba6799bf10576c70a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzgtMC0xLTEtMC90ZXh0cmVnaW9uOmQzZGRiMjE4ZDE5MzQyMjU4MmQyYTk2NGQ5NWUwYzhiXzEwOTk1MTE2Mjc4Mjc_436bfa1e-53ad-4957-a71e-7a64502ad2dd">3.875</ix:nonFraction>% notes due 2021 (3.875% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9ad1274914495687f1554666e681b7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzgtMy0xLTEtMA_2da38eb8-df7f-40a6-8214-ce088b38db23">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i321d29cee0af4ec499ff94a4d005e9d0_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMC0xLTEtMC90ZXh0cmVnaW9uOjc5YTk3MjQ2MjU4ODRiMjhiOGYyNzRhODAwYzkyMWM3XzEwOTk1MTE2Mjc4NDQ_3754f242-f40a-4059-97d0-e24ff186194a">1.25</ix:nonFraction>% &#8364;<ix:nonFraction unitRef="eur" contextRef="i321d29cee0af4ec499ff94a4d005e9d0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMC0xLTEtMC90ZXh0cmVnaW9uOjc5YTk3MjQ2MjU4ODRiMjhiOGYyNzRhODAwYzkyMWM3XzEwOTk1MTE2Mjc4NjE_d311dac7-c103-49b8-9509-c30c81d8ff63">1,250</ix:nonFraction> million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i321d29cee0af4ec499ff94a4d005e9d0_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMS0xLTEtMA_9ddd38f1-6134-4976-b8b9-133a9e15a019">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857fefc9adb94c98b9b9329678b7db36_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMy0xLTEtMA_dc38473b-acbb-41e2-ba86-4cdfa6a27232">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d3ad6c912a4480fa33aa0d7eaac3019_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNTY4YzkwNDQxNjk0MjhkYWU2Y2FhMjA5ZmI1ZWI0MF8xMDk5NTExNjI3ODI0_d472a9d9-15e2-4026-abb2-d5383b30a71b">2.70</ix:nonFraction>% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3ad6c912a4480fa33aa0d7eaac3019_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEwLTEtMS0xLTA_c27445ea-3fb7-4f6e-8e90-e34a671a9e86">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1366b31913416482ed05d65527ce09_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEwLTMtMS0xLTA_fb5a3d54-2569-481c-a8db-ea16f91d9b40">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5601f95c84ff45209305a7ba1d0ed21f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjpjZWU1MDRhNjIxMmQ0NDQ4OGRhM2I1ODQ3MDUyZGExY18xMDk5NTExNjI3ODI0_ae1e0062-ee4f-47ef-830b-912caf32ff84">2.65</ix:nonFraction>% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5601f95c84ff45209305a7ba1d0ed21f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzExLTEtMS0xLTA_cb963e46-41cb-4288-a043-1066ff207663">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2022e1a82ecc471c9bb13d27e09c51fe_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzExLTMtMS0xLTA_1f6ae8e5-0e20-48d0-9f88-cf21fa9f12c3">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib86fea773d394279b54bf0ad27439680_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjoxNjFiNzYxNjQ5MTc0ZDk4ODZlYzIyOGZiOTIzZDJjMl8xMDk5NTExNjI3ODI3_30762426-da9b-4ced-be6d-22b5d4045fb4">3.625</ix:nonFraction>% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86fea773d394279b54bf0ad27439680_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTEtMS0xLTA_e8ff762b-7a8e-446c-9f04-02c3181c3697">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e302b2d804443b3b3a819a6e695f03a_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTMtMS0xLTA_eff4a654-096e-44d4-8006-67c3877069e4">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ce43115364e4f88a797d0e9e1224e77_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4MDBmZTIwOWFjYjQ0NjhiYmVkMWRmNzUwMWRhZjgyZF8xMDk5NTExNjI3ODUx_183763bd-3c2c-48ea-bc4d-f5dd6ea86b85">0.41</ix:nonFraction>% CHF<ix:nonFraction unitRef="chf" contextRef="i8ce43115364e4f88a797d0e9e1224e77_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4MDBmZTIwOWFjYjQ0NjhiYmVkMWRmNzUwMWRhZjgyZF8xMDk5NTExNjI3ODY4_61178b70-0be5-4ac6-9e02-02d245991148">700</ix:nonFraction> million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce43115364e4f88a797d0e9e1224e77_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTEtMS0xLTA_13b6da9e-8056-41a0-9312-01534e7066fd">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb195b8085e465b9c73e9a2403f0ca3_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTMtMS0xLTA_632782cd-574d-4678-ba00-82fa6934b2e7">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d2a2479b69b4482a8047db796a1bb33_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMTdmNDBmYThhZTg0MWQxOTVkNzkxMWI5ZjRhMTU5M18xMDk5NTExNjI3ODI0_3fd5db2f-0fb6-47af-99c0-60a0f65070f0">2.25</ix:nonFraction>% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2a2479b69b4482a8047db796a1bb33_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE0LTEtMS0xLTA_d9178226-5a56-49b5-900a-5c87c7ae6e88">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4292b26906463fba3b1c0f23beb71b_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE0LTMtMS0xLTA_ed7c46d4-1229-4b5c-9a64-03b4efc00377">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcd6d09277ed4900bbac50776efa7a38_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjphM2NlMTVkM2VjMzI0YjE3YmFlMWJiZTE5ZDQ1MmNmMF8xMDk5NTExNjI3ODI3_9617fae6-b38c-4fd6-876f-d5db02ac6b38">3.625</ix:nonFraction>% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd6d09277ed4900bbac50776efa7a38_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE1LTEtMS0xLTA_28b80a86-42d3-4958-ab31-a9b9d19864a8">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35327bb737e64d47a0eec71b3f1a920e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE1LTMtMS0xLTA_f38e384e-f8d7-4399-8836-f4b9dd0283fd">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i955823ca905943e2bd3d94ca46061a7b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDI0YjQ1YWZiN2I0ZTg1YTgwN2JlNzZjODY3NGZjZF8xMDk5NTExNjI3ODI0_baecb7b0-5dc5-45a5-8c22-22c7cf95f0dd">1.90</ix:nonFraction>% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955823ca905943e2bd3d94ca46061a7b_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE2LTEtMS0xLTA_bb237196-2e4d-4350-89bc-654b25e02fee">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjo4YTIxNjUyNzk1NDM0NTdiOGEwN2VmMjM5ZDRiZDJjMl8xMDk5NTExNjI3ODI3_df4a1c23-a02e-4508-8d22-fb28c966a812">3.125</ix:nonFraction>% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE3LTEtMS0xLTA_8938d7a7-5426-4c65-9358-a12ce1288c17">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35651b0d044d46cc9af068d473bf549b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE3LTMtMS0xLTA_f6db8547-ed01-487d-9de6-e455555c2853">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NDg3NTgxMWJiNzU0YzBjODYwMDE4NDRiMTJjZTA5Ml8xMDk5NTExNjI3ODQy_84bc3165-a385-4b41-8c66-178af08ec400">2.00</ix:nonFraction>% &#8364;<ix:nonFraction unitRef="eur" contextRef="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NDg3NTgxMWJiNzU0YzBjODYwMDE4NDRiMTJjZTA5Ml8xMDk5NTExNjI3ODU3_1a61c12c-5b87-4ea9-8e19-5e5b90d78162">750</ix:nonFraction> million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTEtMS0xLTA_b79c0edc-0bb6-479b-8a2e-3a042262904d">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89c330f27314741941344d0b54c18ab_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTMtMS0xLTA_e934609f-6f4c-4bcb-b0d4-55293e9a84d3">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf087f04fa3b433688c1f56ee1145222_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZGYwOTMyY2Q3ZjY0OWYwYjllNDY5MTZkYzEwOGQwN18xMDk5NTExNjI3ODI0_3257039e-c8c8-4d3b-b318-2c981a9c5d19">2.60</ix:nonFraction>% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf087f04fa3b433688c1f56ee1145222_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE5LTEtMS0xLTA_21f808b2-54f8-4df7-835b-10c7b5c23baa">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6894d534af44c5c9113bb8bb4838cfd_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE5LTMtMS0xLTA_b58aa32a-42ac-44d2-96fc-222df3f61272">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZTYyYTc0ZTVkNjU0NzAyYTgwMTgzNGRlNzlmNmExOF8xMDk5NTExNjI3ODUy_23c9498a-b687-4707-b4b9-143d8ae40c5a">5.50</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZTYyYTc0ZTVkNjU0NzAyYTgwMTgzNGRlNzlmNmExOF8xMDk5NTExNjI3ODY3_4bff0223-2993-4c8f-b827-fd5f2e8b2e1f">475</ix:nonFraction> million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTEtMS0xLTA_12997fa4-4337-419c-a436-99d31986df45">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a0aa4ebe0f4b39820910ec59611fc8_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTMtMS0xLTA_601c1fca-def0-4011-8621-b31aa65501e6">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4cf58147d464ca393871d4bdabefa52_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjphYzNkNmY4ZWE4ZDM0NjA5ODkzZDNiZTA4YmM0NjQzM18xMDk5NTExNjI3ODI0_63c91fbb-a86e-4671-85e0-a318419b9347">2.20</ix:nonFraction>% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4cf58147d464ca393871d4bdabefa52_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIxLTEtMS0xLTA_03e0f266-a3d6-4328-94b7-907b43b91a1a">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d9d8f452a50403f85e95d6a431bb569_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo5NzQ5MzU5ZDU5YmE0MTJmYWE4MjA1NzEyMTdkM2Y2YV8xMDk5NTExNjI3ODI0_4e712a56-7a48-4a08-a930-cd5ef0fcd281">3.20</ix:nonFraction>% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9d8f452a50403f85e95d6a431bb569_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIyLTEtMS0xLTA_adc05211-40bc-4c32-a867-89f9412cad69">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6de40b43c344b3680010e784e3163c2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIyLTMtMS0xLTA_f57b786b-7ee5-4ab4-9462-6d69147563d5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNWE0YmIzOGJiOGE0MTM4YmE4NDY3YmE1MWUwYWNkY18xMDk5NTExNjI3ODUy_9d75dd37-b128-47e3-98ec-6bba83cc2da2">4.00</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNWE0YmIzOGJiOGE0MTM4YmE4NDY3YmE1MWUwYWNkY18xMDk5NTExNjI3ODY3_8216452f-18d5-488f-a362-463039ba0011">700</ix:nonFraction> million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTEtMS0xLTA_5765e651-445e-47c5-9b42-3acbd65184dc">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a6377397b24b53a373e7137cbd06b1_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTMtMS0xLTA_2bd90ec2-4bb8-4158-9314-952d6c37efdf">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a255f173843436c994520d12b5046cb_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjpiMzRhY2I4MzVhNTk0ZmVkOTdjZmFmMjMxOWM3NDc0NV8xMDk5NTExNjI3ODI0_2d17a557-ee3c-4b46-8406-1e51d14ded39">2.45</ix:nonFraction>% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a255f173843436c994520d12b5046cb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI0LTEtMS0xLTA_6fda2ce8-2592-43b7-897b-96e3f5538949">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25a4a0e3fad546309834f83971cde048_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo4YzczZmVkNjdkZGM0MGY4YmNhNGMyMDBmYjkwMDc4OF8xMDk5NTExNjI3ODI0_231f83ab-ad05-4f9c-89d7-9fbbb7cdf6d2">2.30</ix:nonFraction>% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a4a0e3fad546309834f83971cde048_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTEtMS0xLTI3NzQ_d92d8c0f-0e1e-448f-a036-4fe4aa3a9932">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjpmM2MyNTBkOTNlOTE0ZWE5YWQxNzE0ZmU0ZmYxMGRhN18xMDk5NTExNjI3ODI3_b9a0dc12-3866-42e1-9d2d-1a56b619afb8">6.375</ix:nonFraction>% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTEtMS0xLTA_eaae123a-a71b-418f-a4da-2c8bd5b51a14">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9f0f7677c04b97bdc7ecf0cfe1bf34_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTMtMS0xLTA_8684cd27-4f01-406f-bd25-6550834a0895">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c556faa66a4640add9a389585dcb8d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpiYThiNzg3YTVmZjg0MWU5OGNhZjBhMWRlNzFiZTRlZF8xMDk5NTExNjI3ODI0_778b6ade-2fc6-4026-9a1c-2f26df1a2588">6.90</ix:nonFraction>% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c556faa66a4640add9a389585dcb8d_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTEtMS0xLTA_ee486e18-b538-4cef-a83c-7ed4148172df">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26bb56750156451db1cace7c4f21e6bc_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTMtMS0xLTA_359b083c-73c4-45b7-b8dd-2d34b3e37348">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33bc0e6a798a4daa94404d7e959a5646_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMjQ0YzJjMDUyMWQ0NzdhOTY4YTk3MDQ0MjQ5MDhjOF8xMDk5NTExNjI3ODI0_f55ea364-3c6b-4b7b-b4ec-6344deaed42a">6.40</ix:nonFraction>% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33bc0e6a798a4daa94404d7e959a5646_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI3LTEtMS0xLTA_64b0e9a1-de87-46a3-b290-7fa4c4bfe254">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6f035a7cd84be5bea195a303cdeeb3_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI3LTMtMS0xLTA_8d82179d-a5ad-4789-8791-a9d7d4b63118">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4bc950c75ba04c2f88fd9c7425c305e6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo3ZTlkYzRlNjVjNDQ0ZDZiODQ3ZTYxZDkyMWRhNDY2M18xMDk5NTExNjI3ODI0_64d98708-de3f-4041-9e1f-cb0e6ba138b9">3.15</ix:nonFraction>% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc950c75ba04c2f88fd9c7425c305e6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI4LTEtMS0xLTA_df605e4b-30ec-4297-bcf6-37966901b130">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86e8c0425a564da7849ac5fe7b5db51c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjozYWZiMTY0NWIxMjc0Y2VkODgwZmQxNmIwMTdkZTMzOF8xMDk5NTExNjI3ODI0_aa661097-3646-4b3e-be9e-85bad1c7da53">5.75</ix:nonFraction>% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e8c0425a564da7849ac5fe7b5db51c_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI5LTEtMS0xLTA_2f208375-9e65-4353-ad24-e331e7895063">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bb60d0f1944a82bf76a4a9c8335c42_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI5LTMtMS0xLTA_60944628-76a1-4d81-ac77-ff6394772ca2">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic37ba0818a4249c3a031f0454e3aed09_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo3N2U5ZjE0ZjljZDQ0YWYyOGVhZDU5NDNmNWViZjAyMl8xMDk5NTExNjI3ODI1_46605f1c-5568-4d65-84a8-28f30789f39a">4.95</ix:nonFraction>% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ba0818a4249c3a031f0454e3aed09_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTEtMS0xLTA_90fc2c31-f211-48ff-bd14-c01dbe616247">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e029c89be1a4c2aab1ec7352a2738da_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTMtMS0xLTA_b8259177-2eef-4cb0-83b7-987555a639b7">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dcacc53791a4df7b253b539b0644b8f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxNzc3MDkxNmE5MmI0ZGZiOTljODM5ZjI3MDJlNmMzY18xMDk5NTExNjI3ODI0_3eb636f9-d211-4f68-a250-b336ebda9617">5.15</ix:nonFraction>% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcacc53791a4df7b253b539b0644b8f_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMxLTEtMS0xLTA_efdbd92b-b18a-4588-a1e0-daa1726988d7">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84255d0cb47445195c3652626198334_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMxLTMtMS0xLTA_4c1f88e5-3ef5-4e01-9b8e-dbfc4d7b7916">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76cd436bd1f242d4bd92a582319d9cd9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYjk4MjMxODk5MTc0OTgzOTRlZWY1MzhmYzA1ZWQyOF8xMDk5NTExNjI3ODI0_cdc7c9a7-74f4-45fa-8cb6-beb90aebee09">5.65</ix:nonFraction>% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cd436bd1f242d4bd92a582319d9cd9_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMyLTEtMS0xLTA_27c1270b-28d6-4ff9-a3df-fc5b95f8ee3e">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98459dd3f7df4a9da1f0e4d9bfaf76c5_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMyLTMtMS0xLTA_1f93241a-bb42-4cc0-8cd5-51982ee66f1b">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie22a6012e30946cbaa82df3fa40dddb3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpmOGY2MDc1NjVjYWU0ZWNjODU5MzM5MjQzN2U3OTRlMl8xMDk5NTExNjI3ODI3_2cc5bf80-44ed-4860-9929-77e6c63cf80a">5.375</ix:nonFraction>% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22a6012e30946cbaa82df3fa40dddb3_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMzLTEtMS0xLTA_74742292-54af-4347-9f19-c885cae312ff">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c28235c53c439eb0926746169e1187_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMzLTMtMS0xLTA_eec8c5c3-0d2c-461b-991b-c636d28e4e58">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7539fdd6385f4c38b6c106d6250118b3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZTYxMDllNDFmZWI0Yzg2YTlhMTBjZDEyOTdlODU1OV8xMDk5NTExNjI3ODI0_873b1aa3-f549-476e-a5a8-a6fcde03b948">4.40</ix:nonFraction>% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7539fdd6385f4c38b6c106d6250118b3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM0LTEtMS0xLTA_368c6336-e163-490b-afd7-240c688fb842">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c4338c09d6451da39a441444432847_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM0LTMtMS0xLTA_8c4d4ed3-6922-4d24-a3b4-06074a93b143">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjc2NzA5Njc4MTA0MTFlOGE5MjI4MzBjOTRmNGIzZV8xMDk5NTExNjI3ODI3_52bde1d2-52f6-4f0b-b4dd-3f84907b4fef">4.563</ix:nonFraction>% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM1LTEtMS0xLTA_6111b8ab-7881-4e6e-9b0e-acd00215256a">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60bd30780674b5e8423eae04786b160_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM1LTMtMS0xLTA_31a327bc-999b-46b9-9b15-9f0be163994d">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ab35f913d01401c9cec4c3e1e26676e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM4LTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjplYzAxZTliZjliZjk0NDhhOTNhYmIwNjJhYTM4NzAwYV8xMDk5NTExNjI3ODI3_4102c8ef-4869-495f-9a3b-b4eb500c38e4">3.375</ix:nonFraction>% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab35f913d01401c9cec4c3e1e26676e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM2LTEtMS0xLTA_2dca6af1-e9d7-404a-8fac-79efca441ced">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NzhlNWNmZDk1NTQ0OTgzODViZmY3Njg2NjE0MjNiY18xMDk5NTExNjI3ODI3_8e8bfaf2-47cf-4f01-87be-a85af2628eba">4.663</ix:nonFraction>% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM3LTEtMS0xLTA_c22ebc81-79d7-45f3-bd06-7716b55df1ba">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b51bd6ee36d4eaaa9fad68470af51f7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM3LTMtMS0xLTA_9a0cdf40-b594-4062-874e-72f2da746834">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo3YWU0YzgwMmM5OWI0NGU3YWUyM2EzYzcxN2YwNjY0NV8xMDk5NTExNjI3ODI0_72fff9f3-656d-47cf-9910-84510a1baa41">2.77</ix:nonFraction>% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTEtMS0xLTI3NzE_ea002d59-67d9-430c-bc52-2f45490bbde9">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5ec697f57d429aa10a96bcc66005bd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTMtMS0xLTI3Njg_250b7f09-8f98-4c92-b69b-2a07660a6462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3741539a3da4406cb0892abdf6eb315d_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM4LTEtMS0xLTA_42f684e9-55d2-4655-a50e-82d66e9c6c5f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425c9514aedb4868a2ebec2a29ba5de7_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM4LTMtMS0xLTA_10a551d2-5f97-4cba-8d8f-c5efeba427ac">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM5LTEtMS0xLTA_c6518b2b-59a3-491c-a536-9749094d7c46">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM5LTMtMS0xLTA_6baed0f8-06e2-4ec5-b6c6-bc4cf9eb389c">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTEtMS0xLTA_00d9dddc-b595-4182-ab5e-fc8173043f38">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTMtMS0xLTA_7cb6036b-9440-4dd1-8bc9-41da03935fb0">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQ0LTEtMS0xLTI4MDY_e69357bc-32a1-4a87-a7e2-d5628e8f008b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQ0LTMtMS0xLTI4MDk_9c174f09-f302-4736-8111-f4d0f4a12264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQxLTEtMS0xLTA_22ed7c77-04de-4262-a684-7534d79fa28b">32,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQxLTMtMS0xLTA_92f4cca9-5945-42eb-be41-95325a1aefad">29,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQyLTEtMS0xLTA_bd0d6b93-685d-4e06-808e-9d6d15dc9c47">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQyLTMtMS0xLTA_df02a8ad-c424-4f6e-a74e-05e6c185b3a0">2,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQzLTEtMS0xLTA_97af5160-fb3a-4ee1-a697-dfe39c786c70">32,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQzLTMtMS0xLTA_aaadd993-44a9-4589-bc78-9a3f8844c529">26,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the <ix:nonFraction unitRef="number" contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIyNA_16132e2f-8ae5-4555-ae96-fc593724c904">4.563</ix:nonFraction>% 2048 Notes, the <ix:nonFraction unitRef="number" contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI0Ng_c5d5def9-7df8-4b1d-8b8c-748772d50642">4.663</ix:nonFraction>% 2051 Notes and the <ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTEyMTgy_efcc420b-40ee-4465-938c-65d4544d4743">2.77</ix:nonFraction>% 2053 Notes, which have effective interest rates of <ix:nonFraction unitRef="number" contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzMwMA_c075ddf0-7b02-43ab-841c-8fe76914fd32">6.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzMwNw_b128e177-bfae-4f6d-bd6f-5f745265b8ac">5.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTEyMTg5_38e03fda-0f48-4949-b810-4112c3fa62d4">5.2</ix:nonFraction>%, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1fe8ed2d828e4a818f44b3733795e809" continuedAt="i492fa951e78f4fcc8fcb0df0904722e4"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to <ix:nonFraction unitRef="number" contextRef="i1649580135964fee8432cd12950a049f_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_01e7530d-8a38-47a1-9514-36acc092f99d"><ix:nonFraction unitRef="number" contextRef="i13ff7bfe32094c3b987aaaceb3014b9f_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_0bc64288-dfde-472c-8756-0dff2eb0d862"><ix:nonFraction unitRef="number" contextRef="i39a772dcf3d84f278093296bdf9e1ce1_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_0c9ee806-cc6e-4f52-8d7b-02543a762150"><ix:nonFraction unitRef="number" contextRef="iec571ed5581a4732ae9ee4817e228b10_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_14127acb-b6e6-463b-9292-8f176fe095a0"><ix:nonFraction unitRef="number" contextRef="i1ec6c7c7b81b48d8a20694d3b57b6b70_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_17469e0d-d89b-4fdd-871e-21f1d4142ba7"><ix:nonFraction unitRef="number" contextRef="i1d34c35332374923becedb1eee1b52cb_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_1a9171b3-1144-477a-a46e-48dfe2ee75ca"><ix:nonFraction unitRef="number" contextRef="i60960cf4128a4427b534a20b852e2475_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_25665fca-7762-467c-bf9b-0648ae4ce79d"><ix:nonFraction unitRef="number" contextRef="i2e99d32a99b3493ba14074d4564ee157_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_2bf96af5-55d6-4f0e-b560-3e05d380652e"><ix:nonFraction unitRef="number" contextRef="i0e69a6358c564547a5eca8d5fbe70622_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_364cb473-67be-4528-9afd-7720646fe64c"><ix:nonFraction unitRef="number" contextRef="i92b9a5668fbc41e6b4d63640b91febe6_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_38df0ddd-61cc-42f9-8873-789d6a4756b5"><ix:nonFraction unitRef="number" contextRef="ie045a042bc9343f1a35b00097a53456a_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_44344ca5-63da-4457-bc5a-3e5df2af54f7"><ix:nonFraction unitRef="number" contextRef="id9776aef7fdb48c8a1734dec44ec2dd2_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_466be4de-f6dd-45d8-a3c0-945181057ff6"><ix:nonFraction unitRef="number" contextRef="iea83a41a94354282ac825a30792e7bd6_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4a1d0b6d-6ed8-43af-b0ad-007194ccff62"><ix:nonFraction unitRef="number" contextRef="if621495ed0e44e7f8c27f9d541876077_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4b049ee8-210f-4368-85b1-264ab322666b"><ix:nonFraction unitRef="number" contextRef="i8cfac5674c6443a598611b253a645a0e_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4e3a62e8-508c-41d5-9060-48f8f1e9be5f"><ix:nonFraction unitRef="number" contextRef="ib9165ad7e95445d9b3372c1c0f63c245_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4fef81e7-dc5a-4133-be99-996cdf725bb4"><ix:nonFraction unitRef="number" contextRef="i3396b8f489aa45d9a88f6c5fbf1dcd70_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_575f61f4-bc77-45f9-b549-63285aa47962"><ix:nonFraction unitRef="number" contextRef="iec5d1ff18dbb4fe5bc76abb5d4d5b3c0_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_5781e02f-a24c-448f-bf20-d69f63917b51"><ix:nonFraction unitRef="number" contextRef="iafa733d1395a445ba18de686112112bb_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_58eaf9b1-5ac5-492d-8d45-7897c2cc2e22"><ix:nonFraction unitRef="number" contextRef="ia054a1ac7a0c4c5a84daf3e02d258cd5_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_59563fb5-243a-48d2-bd36-1d34e3588f0e"><ix:nonFraction unitRef="number" contextRef="ie2173cb44ec942b0b5e652729f5aedad_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_5b5598a5-dd39-4de5-bc49-c0cd4ae47277"><ix:nonFraction unitRef="number" contextRef="i85b731805304467297b2b3b116999268_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_5e3a409a-8b21-4dc4-a9a2-2c2438d9c74b"><ix:nonFraction unitRef="number" contextRef="i6382073fcb1d4883b6219e6dc102e745_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_651cd7ea-e5c1-4a1b-9933-a87d247459d5"><ix:nonFraction unitRef="number" contextRef="i9ace2901bf0040e2a96399efee4d66aa_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_6e3d2bf1-7214-4773-8280-34aa37cbf3f6"><ix:nonFraction unitRef="number" contextRef="i9cea61b7422240dcbf72d21fa3477501_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_70096666-cda3-4822-90a4-d744ac05eee1"><ix:nonFraction unitRef="number" contextRef="i0ec3c2bdd29840c1b5cdb46000fb3552_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_74c94845-66eb-4033-91d3-1a9ed810f9ce"><ix:nonFraction unitRef="number" contextRef="i4925dc03736d47f9ae8d2a690a4103f8_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_792fbd8f-8ead-44f8-bed9-e86b3d347bb8"><ix:nonFraction unitRef="number" contextRef="i9936d965b2ba462d8b3888f904a7ae96_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_81ec30ee-922f-4a0c-b0e4-7a90e6b897cb"><ix:nonFraction unitRef="number" contextRef="i1f84b1e89726471186203024e416a4a8_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_8f0b4882-6f0c-4bcd-bdbe-a766da9e968d"><ix:nonFraction unitRef="number" contextRef="ic7759f579c524eab8b6b4da9a496f1e7_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_a43d0f65-529a-4c85-9900-d6430239566a"><ix:nonFraction unitRef="number" contextRef="i368a178ea7354ca9b710ce74b30bcfce_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_a96fec0d-84ba-43d6-a63d-1dd84ea1d391"><ix:nonFraction unitRef="number" contextRef="ie14c8cade2044c48a2677b8b57df8403_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_c8f12a04-329d-488b-bfd7-9e2c97782fc3"><ix:nonFraction unitRef="number" contextRef="ibdb33bcf941a4a40b8e393ef62e8026d_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_d39fc6c5-2b8b-4f18-9206-4fa36108c3fd"><ix:nonFraction unitRef="number" contextRef="i5ea19f674a134cfaa06e00ebe4983f41_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_da164d4f-9b21-4c4e-a8fe-f71ff388da0d"><ix:nonFraction unitRef="number" contextRef="i2d73c382070d4582bf5468d1be4dc656_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_dbb2e023-bf87-4dd6-8d84-5f2dfa78ad5b"><ix:nonFraction unitRef="number" contextRef="i517838d7aad1452d98142cd5be6f49a0_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_ddf3357c-9860-4f13-aa36-c34b6ba4cded"><ix:nonFraction unitRef="number" contextRef="ib45e9dc787514755b7bc52c6e863a740_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_e97b6074-b2a6-4d19-aa39-a1cd83a2f521"><ix:nonFraction unitRef="number" contextRef="ia3699b330b1b42a9bfd233ae168532eb_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_ecef5ab8-4018-47ff-9e2c-6c9a30eab0b0"><ix:nonFraction unitRef="number" contextRef="i01a00aa8b5524778b4c286af30fb3fd3_D20200101-20201231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_fdac08b0-42aa-475d-b86b-124ee0e05dfa">101</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#8212;except our <ix:nonFraction unitRef="number" contextRef="i49e8ff43661f4d5f912595d1b30d72ff_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcwMQ_dfdc149c-ecb0-4bdf-a232-0bb01e2246ec">0.41</ix:nonFraction>% 2023 Swiss franc Bonds and Other notes due 2097&#8212;may be redeemed at any time at our option&#8212;in whole or in part&#8212;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from <ix:nonNumeric contextRef="ifb46aca57e78435db45dee35d03b5ff1_D20200101-20201231" format="ixt-sec:durwordsen" name="amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNzM_9d5f9f42-ea62-410b-ad05-b079e7a4c0f4">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="i1bcd5a1c6a104b778997f6496ca15582_D20200101-20201231" format="ixt-sec:durwordsen" name="amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNzk_ebfedb68-47ed-42d4-82df-2a875d50c4a4">six months</ix:nonNumeric> prior to maturity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt issuances</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we issued debt securities in the following offerings:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In February 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="ibef7ddaa81cf4000b87b570d84cd9ed9_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MTgz_4965e4ea-4c65-4488-996c-be49d3b6f22d">5.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="ib53845265cb94d07851b1fe0a47a9756_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MTk3_0aa54cfd-0b52-4d9d-ac0f-a6e8166d578f">500</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="ib53845265cb94d07851b1fe0a47a9756_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjEx_dbd90532-81ec-467f-babc-8e3deb147032">1.90</ix:nonFraction>% 2025 Notes, $<ix:nonFraction unitRef="usd" contextRef="i7cc614e1370249759a9ccfd03593d582_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjE4_94af0880-5190-417f-98e2-cbf6ca67dfa5">750</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="i7cc614e1370249759a9ccfd03593d582_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjMy_2cd7870f-9eae-432a-8ae9-0cc1136c542e">2.20</ix:nonFraction>% 2027 Notes, $<ix:nonFraction unitRef="usd" contextRef="ifa2bdf148e7042b9a29c5b3af1301bb6_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjM5_f610e3a9-07df-46ac-8d36-76ef1afc6ea6">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ifa2bdf148e7042b9a29c5b3af1301bb6_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjU0_6d908019-863b-4f2b-a741-50daf8a43cfa">2.45</ix:nonFraction>% 2030 Notes, $<ix:nonFraction unitRef="usd" contextRef="icc9023f496d24d308cf4d1c092fc6f42_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjYx_5973817c-2173-415b-a798-a1bc41d92668">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="icc9023f496d24d308cf4d1c092fc6f42_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mjc2_b38a1890-9ad8-41f8-b435-b76e87a059ed">3.15</ix:nonFraction>% 2040 Notes and $<ix:nonFraction unitRef="usd" contextRef="i53985fa4c39e414b9da42cd3aab030a4_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mjgz_37571075-c3b6-4785-bba2-cfd39d258653">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i53985fa4c39e414b9da42cd3aab030a4_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mjk4_e0f9d141-2e18-427d-ab40-1321074fe7d1">3.375</ix:nonFraction>% 2050 Notes.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In May 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i7e01b4d5cfb74268ae6c81e2e50ade30_I20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzA2_c237e030-442c-4475-959d-e13104889c01">4.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="ia51aff5886bd45d0924ffffa26acaf1e_I20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzIw_8d6ab9d8-b9f0-40e5-84d7-068e227e5141">1.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ia51aff5886bd45d0924ffffa26acaf1e_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzM0_8b1a2760-8e01-4921-a90c-f00f956af1fa">2.20</ix:nonFraction>% 2027 Notes, $<ix:nonFraction unitRef="usd" contextRef="i3994865e1ce04255bf33546e570e6feb_I20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzQx_014cc985-1933-4685-8f74-cb798c4de03b">750</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="i3994865e1ce04255bf33546e570e6feb_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzU1_b4e10809-3a16-48fb-96f9-f79363a58ff4">3.15</ix:nonFraction>% 2040 Notes and $<ix:nonFraction unitRef="usd" contextRef="i515b38364a38405fb4bcf56004a5d984_I20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzYy_3e031e00-c176-42f2-b1c0-fc2d35b97a1f">1.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i515b38364a38405fb4bcf56004a5d984_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mzc2_98a87bfb-25c5-4658-b95d-8573ebbd98a4">3.375</ix:nonFraction>% 2050 Notes, which represents a further issuance of, and which forms a single series with, each of the corresponding series of notes issued in February 2020, and $<ix:nonFraction unitRef="usd" contextRef="ie8430beaafbd43bfacdaa980eb0137df_I20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mzg0_d6e32fc1-6214-4d0f-a7a1-f97ddbbfc54c">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ie8430beaafbd43bfacdaa980eb0137df_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mzk5_9e9c874d-b8f8-4587-b381-9be630b04cfe">2.30</ix:nonFraction>% 2031 Notes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any debt or debt securities during the years ended December 31, 2019 and 2018. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt repayments/redemptions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made debt repayments/redemptions during the years ended December 31, 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we repaid/redeemed $<ix:nonFraction unitRef="usd" contextRef="if188b1207e144488bc49e6f9af13f349_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MzAz_57c02b65-68e7-4857-90b1-6f3aa4ceb62c">6.5</ix:nonFraction>&#160;billion of debt, including the repayment at maturity of the $<ix:nonFraction unitRef="usd" contextRef="if621495ed0e44e7f8c27f9d541876077_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTEw_ffde69c4-6076-456b-b488-d3229fc94452">300</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i115359deafc44691979f165eb053cdfc_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDM2_d110a717-9f5e-4e35-a8b0-a0ce92ebfc13">4.50</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="iec571ed5581a4732ae9ee4817e228b10_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTM4_5038c1c4-be6e-42b0-97fc-56e6799c83cf">750</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDQz_8e96d998-7172-4cfe-8cf1-051e999de789">2.125</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="id9776aef7fdb48c8a1734dec44ec2dd2_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU0OTc1NTgxNjU4OTA_cd728289-f4e4-4ff6-bf93-d27c816b35a5">300</ix:nonFraction>&#160;million Floating Rate Notes due 2020 and the $<ix:nonFraction unitRef="usd" contextRef="ie2173cb44ec942b0b5e652729f5aedad_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTUy_698978aa-05c7-4455-a627-edd303557435">700</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i81f0c45930bf446597ffdba0232d3d0a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDUx_61644446-0cd2-4b9b-9067-0a847e8826df">2.20</ix:nonFraction>% 2020 Notes. In connection with the redemption of the $<ix:nonFraction unitRef="usd" contextRef="i8cfac5674c6443a598611b253a645a0e_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTY2_f92594e0-aa7e-4cca-9511-a24e4a38c6f4">900</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i7a25ca8db8794930a6444001d3c53561_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDU4_af7857b9-988e-47ae-97ca-5c3d52484f38">3.45</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="ia3699b330b1b42a9bfd233ae168532eb_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MDk1_947b9cb8-3e29-4505-b3db-16da0a8d4260">1.0</ix:nonFraction>&#160;billion aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="ic46c172c9e0a45198c8c6c17804b44f9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDY1_531383a8-df94-40ae-8483-c3a67f9ec5a3">4.10</ix:nonFraction>% 2021 Notes, the $<ix:nonFraction unitRef="usd" contextRef="i39a772dcf3d84f278093296bdf9e1ce1_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MzE5_b76a28a0-3631-48f0-ae97-e04d6283c43f">750</ix:nonFraction>&#160;million aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDcy_8ed6242e-57e4-4bc3-bd3c-93aea6450287">1.85</ix:nonFraction>% 2021 Notes and the $<ix:nonFraction unitRef="usd" contextRef="i60960cf4128a4427b534a20b852e2475_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTk2_95139b2f-fe6c-4b57-ab21-3ea728af37f9">1.75</ix:nonFraction>&#160;billion aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i8c3bbee60b53406ba6799bf10576c70a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDkz_adc43568-f361-488e-9a95-c0216beac67d">3.875</ix:nonFraction>% 2021 Notes, we paid a total of $<ix:nonFraction unitRef="usd" contextRef="if188b1207e144488bc49e6f9af13f349_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY0ODkx_041457e9-f8f5-4a5c-b215-d0a922b72b3c">96</ix:nonFraction>&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2019, we repaid $<ix:nonFraction unitRef="usd" contextRef="i2bc092c6728d4fd490eda91a340a32ae_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NTE2ODc_ea8471f9-6b1e-4e05-8f25-fc65b362ef09">4.5</ix:nonFraction> billion of debt, including the $<ix:nonFraction unitRef="usd" contextRef="i0ea4835b2dc040188992a34180538c3d_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIwODc_bf4bc8ca-91f7-44ab-8c53-b8009a417e2c">1.4</ix:nonFraction> billion aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i0ced667ce35e445b84fea4f94ea73857_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxMjQ_4a0a264e-f47a-4395-ad75-3bf9ca5dc4ac">2.20</ix:nonFraction>% 2019 Notes, the $<ix:nonFraction unitRef="usd" contextRef="i4179a6ea77a3452ea924a970e6862138_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxNDM_6cc0ab0e-8fdf-48ca-a633-ab53473b3f0d">1.0</ix:nonFraction> billion aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i725941cbca38484e85e015486a9604dd_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxODA_2823c650-ca90-4a73-a9e1-5adbe675c2ee">5.70</ix:nonFraction>% 2019 Notes, the &#8364;<ix:nonFraction unitRef="eur" contextRef="i963c8d3dfffb425ab800f22538a80972_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxOTk_8aaf70b6-b900-4e94-be63-e5ac0a857319">675</ix:nonFraction> million aggregate principal amount ($<ix:nonFraction unitRef="usd" contextRef="i963c8d3dfffb425ab800f22538a80972_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIyMzA_622320e8-bd40-4b5c-9f66-a829491cfdf4">864</ix:nonFraction> million upon settlement of the related cross-currency swap) of the <ix:nonFraction unitRef="number" contextRef="icfdeec3400fe43809c845700b9250d21_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIyOTI_ff18f7a8-5455-4cd7-8a13-6f4d6cf39247">2.125</ix:nonFraction>% 2019 euro Notes, the $<ix:nonFraction unitRef="usd" contextRef="i2d664e75d7a74f7491af9306d427a5c5_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIzMTY_e23977af-03ed-487d-b2f1-52eac178cb80">700</ix:nonFraction> million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i96e075bdda244694a4469e256df31166_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIzNTM_fd56b8a8-ca1c-4160-a9f0-78b9b484d7d3">1.90</ix:nonFraction>% 2019 Notes and the $<ix:nonFraction unitRef="usd" contextRef="i35730380319944e3910f345b948c0df9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIzNzU_6b8a1022-a7a2-4167-8ec6-5bb4d273793f">550</ix:nonFraction> million Floating Rate Notes due 2019.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2018, we repaid $<ix:nonFraction unitRef="usd" contextRef="i358bdc0bde924dd6a9e6f8e2d53a4fda_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NTE2Nzg_0514a766-8754-4499-8db4-37794abeec6a">1.1</ix:nonFraction> billion of debt, including the $<ix:nonFraction unitRef="usd" contextRef="idd6c0363be7c499eb126c69c7c63a409_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI0NTQ_cb123c06-eebe-4b96-9443-4abbe4be48f7">500</ix:nonFraction> million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="ie8daf767f6e14e758523360043a12636_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI0OTE_98c8868e-3c96-42ba-bfcf-98edd229cf9f">6.15</ix:nonFraction>% 2018 Notes and the &#8364;<ix:nonFraction unitRef="eur" contextRef="ic6268acd3d2a46dba0b2e730840ecee5_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1MTM_4218a77c-3e3a-4708-be8b-adfe4903c4fe">550</ix:nonFraction> million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i6ce07b37db1a4118b69a6f7fd3709440_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1NTA_f9d8605c-b62d-4b21-b88a-0364cff84290">4.375</ix:nonFraction>% 2018 Notes revalued at $<ix:nonFraction unitRef="usd" contextRef="ic6268acd3d2a46dba0b2e730840ecee5_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1NzY_d1443e51-f241-4170-84db-9f923aad5346">621</ix:nonFraction> million upon maturity. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $<ix:nonFraction unitRef="usd" contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231" decimals="-7" format="ixt:numdotdecimal" name="amgn:DerivativeNotionalAmountAmountTerminated" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1NjEy_c869c62f-c4dd-4430-9cd9-67a082a9c3c8">3.65</ix:nonFraction>&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="id8fd749026d9457e843e73baf3eedd7a_I20201231" decimals="-8" format="ixt:numdotdecimal" name="amgn:DerivativeNotionalAmountAmountTerminated" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDA2_4c95d1b8-2d2b-4d01-9630-11b656386380">5.2</ix:nonFraction>&#160;billion that hedged the <ix:nonFraction unitRef="number" contextRef="ifcd6d09277ed4900bbac50776efa7a38_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDUx_d163a1c5-37c4-47c6-a715-5653a3aa47eb">3.625</ix:nonFraction>% 2024 Notes, the <ix:nonFraction unitRef="number" contextRef="idf087f04fa3b433688c1f56ee1145222_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDQ0_5a6651bd-85bb-4d68-8ce8-3ea3e80d155b">2.60</ix:nonFraction>% 2026 Notes, the <ix:nonFraction unitRef="number" contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDM2_b9f4ae95-e9b7-49b0-8ba9-10b33e5c82a0">4.663</ix:nonFraction>% 2051 Notes and portions of the <ix:nonFraction unitRef="number" contextRef="ib86fea773d394279b54bf0ad27439680_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDIw_f173f4b2-5f8d-48a2-8409-7a01e6c4a08b">3.625</ix:nonFraction>% 2022 Notes and the <ix:nonFraction unitRef="number" contextRef="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDI4_12805f23-fb04-4667-81df-26b61a3339e2">3.125</ix:nonFraction>% 2025 Notes, which resulted in the receipt of $<ix:nonFraction unitRef="usd" contextRef="i3a91bd5c90e8492fa703ad1a89545d34_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDE3ODg_f2183d8e-69b5-4b30-ba15-5241381278a9">576</ix:nonFraction> million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $<ix:nonFraction unitRef="usd" contextRef="ic5c9cfe81f3e4917a0b8ebe47bd9a715_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDE3OTQ_372825c4-562e-45dc-8d83-5eb2e957361f">5.2</ix:nonFraction> billion principal amount of notes. See Note 18, Derivative instruments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i492fa951e78f4fcc8fcb0df0904722e4" continuedAt="iec18d1bff5f3453dad29f6f7961ccf0f"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNDI_4286a225-e57d-4ce2-a1e2-b41cd84a622b" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb8f6352b8834211af6d0c68477f85f1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjk4M2JlYTdhZTFiMjRkY2JiOTYyYTVjMGJmZmU4NmIwXzEwOTk1MTE2Mjc4MDE_e8e0734f-ee38-4fbc-8bee-cf0aa10a0739">3.45</ix:nonFraction>% 2020 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8f6352b8834211af6d0c68477f85f1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItMi0xLTEtMjk0Nw_94f3f447-9c70-4a20-bb49-e6d16cf838f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="if90978c11283437c9156f060d82208ee_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjllZDVkNDhhMmMxOTQyYjY5MTNhMzIxNDA1OGU0NmI3XzEwOTk1MTE2Mjc3OTY_42b62240-7da3-42be-aef9-f332a5750ef7">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a7501d33a3a455691d18c20b0223337_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItNS0xLTEtMjk1NA_19dedace-9f26-4185-a3b0-584fa9092411">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i2eb21bbc622f4765b1b17b9e42cffcc1_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItNi0xLTEtMjkzNC90ZXh0cmVnaW9uOmM4Y2YyYTllM2EwYTRhYTJhYThhZjQ0ZTA2MTY2Mjk3XzEwOTk1MTE2Mjc3OTY_c4a5e660-4a2c-4ca6-a8a5-a62790b4198b">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia90e46dcb35e465890654a17ea25721b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjBjOGQyYzkwYTE5MDQ0NGM4NWJkMTVlZWU0ZjljMmY2XzEwOTk1MTE2Mjc4MDE_c752f750-f1d9-40d0-bdc7-c2a2ac40cb9c">4.10</ix:nonFraction>% 2021 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e46dcb35e465890654a17ea25721b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtMi0xLTEtMjk0Nw_c4dcefbf-1195-4eab-80f2-a729fa94e039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i9ce2131b83c543178a1ff35a8a9f7b29_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjU4OTI0YTI5Y2NlNTQxNThiN2U3OWQxODYwNjNmZDIzXzEwOTk1MTE2Mjc3OTY_630cb50b-391b-45e2-856e-84a252a1c3cd">1.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb51cf3560f44fd82a1ed3524aba9e2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtNS0xLTEtMjk1NA_3817f383-75ef-4671-966d-653f88fee25a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i8b4f018bc432431ba9e3ebae45b475b9_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjVmNmY3YzAxYzk3YTRjZDU4Y2M0NWM3ZTVjODc0NTZlXzEwOTk1MTE2Mjc3OTY_6d455556-5988-4340-9438-06a7b1f559d9">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7249a2eb8741476eac1bbed378060085_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjMzMTcwYjc2NTQ4YjQyNTA4ZGJiYjgxNDM2MzBiOTkwXzEwOTk1MTE2Mjc4MDM_a9257be8-7791-460c-9a62-7086c97d86c2">3.875</ix:nonFraction>% 2021 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7249a2eb8741476eac1bbed378060085_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtMi0xLTEtMjk0Nw_3ccc6a74-6da9-4973-841d-0ddc66638c5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i6e6a942464df49888f5da90fa7d3079f_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjNlZmZhNmVhMmJkMzQzODE4YWZjY2EwOWYwYmFhOTM2XzEwOTk1MTE2Mjc3OTY_e4dadb8d-7933-4c68-91ca-639cfc45e036">2.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f92b19c4e34a72af65be5f26e24641_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtNS0xLTEtMjk1NA_d18ae809-4cc8-4ec4-894e-9e6c30b5c7cd">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ib22110db36464336ba83d0caaaae87ce_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjc0OGIxNmFmMGFlMjQ4ZTU4NTIyYzUyMTgwMjExZTU3XzEwOTk1MTE2Mjc3OTY_60185a31-9d49-4498-aacd-eb3d8420a3d9">2.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief290ad7941b442fab79e88967534cd6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjhhZTllYjczZmJlZDQxZGQ4YTI0Y2Y3MzQwODhlYWNmXzEwOTk1MTE2Mjc4MDM_e27d160f-4ae4-4ad6-ba44-637ddf86c468">3.625</ix:nonFraction>% 2022 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief290ad7941b442fab79e88967534cd6_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtMi0xLTEtMjk0Nw_112e25cf-e26e-4c92-8600-2f9ce1aee61b">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i2335a1cb123c499e80a1aa39baa5fda5_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmQ3ZWZmOTMwOTViNTRjOGZiMDdjNmUyMGE2NDU1NzYxXzEwOTk1MTE2Mjc3OTY_4ee848f2-72eb-4584-9748-72d16147f770">2.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7351dc6225e40e5b3d4da990aaafd0d_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtNS0xLTEtMjk1NA_f7203449-ca0e-44c5-8817-869da7c8160f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ic54306a521a5410e83f206562df048e7_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjc0YjgyMjk0NzQ2ZTQxOTk5YTMwYWU5NjJhMjJkNTA3XzEwOTk1MTE2Mjc3OTY_a7639bec-830c-4ff6-a2f2-5d660a8277af">1.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec5e5f1709434645a4f86bee8db7c5c4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjc5OGYxMjE2ODYxYjQxZjdhNGQ1MWNiYmQzMDBhNWVjXzEwOTk1MTE2Mjc4MDM_4fd71c8d-18eb-415c-996b-4eff52aa7756">3.625</ix:nonFraction>% 2024 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5e5f1709434645a4f86bee8db7c5c4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtMi0xLTEtMjk0Nw_e20e183d-4ba4-436b-a98b-755bc758bb06">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i69d46bf88a054fb0abd4b6f021382f5c_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmMwZjkyNjVjNWYyZjRjZmE5MDdiMGRkMjA1ODczMTYzXzEwOTk1MTE2Mjc3OTY_375b4c54-b6f1-441a-aaeb-40be92e168df">3.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda7d092fb704dcca96b59957bd2a0dd_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtNS0xLTEtMjk1NA_b5322cf6-5d65-473a-a90a-52442d33c704">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i97abdf954cf14e22986f9fb69d4e08cf_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjE2NGVjZTQyMWFiZTQ4NGM5YWU4NWRkOTc2NDU4OTNmXzEwOTk1MTE2Mjc3OTY_6fd7351c-8b99-4c14-a7be-a06a9218fff9">1.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i959c8054e99b4ba4a601a0f7b2e68fb9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjk1OTUyZmVmMWEyYjQ0MTlhNTE5ZmMwYWExMWMwYjU1XzEwOTk1MTE2Mjc4MDM_b7631846-ee5b-4ab1-820f-61b148a91bb2">3.125</ix:nonFraction>% 2025 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959c8054e99b4ba4a601a0f7b2e68fb9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctMi0xLTEtMjk0Nw_d0ec4ec2-3a51-4d56-a25b-6ab5c0c83018">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="if22d72d2f9754767b787702ea64e3553_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjlhMGI2ODNlOWU3MTRhNTlhZWJkZDM4ZDUxNjUzMjkyXzEwOTk1MTE2Mjc3OTY_df83de48-26a1-4f87-8768-0d5b0c684d9b">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief48420564f04693bfa31f3606365235_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctNS0xLTEtMjk1NA_370e2ef6-8f54-4220-acfa-e4412582d380">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i37f44fcba83d42e1a232fd794b15ec7d_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjgyMDQzMmFiYWU5MTQ4ZDM4OGIyNDI0MDhkYTAxYWI1XzEwOTk1MTE2Mjc3OTY_d8d77e02-a044-43b4-a33e-cacd9aecc6d0">0.9</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86bd689abf77408fa7438dcaea1c9165_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjg2NzhhYjNjMzBhMzQ2MWJhODJhZTBhZmViZjhiODIwXzEwOTk1MTE2Mjc4MDE_a58dd08d-e8cf-4fd7-a543-bcb9e9aef584">2.60</ix:nonFraction>% 2026 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bd689abf77408fa7438dcaea1c9165_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtMi0xLTEtMjk0Nw_d7d8985a-a507-4faa-8771-f058104072b8">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i968c11eef2e44b85b73c09287db49afd_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmRlNzQ1OWFmYWY5MTQ5ZjI4MTQwMjAwZDMzZDQzMDg5XzEwOTk1MTE2Mjc3OTY_daad87c8-a4a8-4610-903b-d79db8967da9">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee91c42bda54e20b6e7adf10ee4a30c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtNS0xLTEtMjk1NA_5948e3dd-eecb-4233-8a46-892f4b9f6ec1">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i25258a7ecd234572bf5dbcbe63e9334c_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOmJiMDJhNjllN2UxNjRjM2I5ZjI0Nzg4MGQzMGRkMzJiXzEwOTk1MTE2Mjc3OTY_62ae08c5-79ac-40b1-a5af-3e2fd73a9ebd">0.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9adb74cd7d004de18ef5c0ff3957a722_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjBmYmQwMWU3ZGYyZDRhNjY4Zjg4NTRlMzAzNTVlMTQwXzEwOTk1MTE2Mjc4MDk_6eac0cd8-3665-41ca-9f66-0d7b06212cb8">4.663</ix:nonFraction>% 2051 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adb74cd7d004de18ef5c0ff3957a722_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktMi0xLTEtMjk0Nw_e1817719-02fa-4a85-b12c-e7cc8da8b518">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="idd511439740c4be9a99104d33dcbf8bb_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmUyMjUyNGQwMjI5MjRkYmY4MTVhYjQ0MmRhZTU2YmM4XzEwOTk1MTE2Mjc3OTY_72704264-49b7-4aeb-9b0e-31ead82fbe97">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362b746ef24043558b07c52bd684d25b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktNS0xLTEtMjk1NA_6ec5507f-d2b7-4ca2-b357-3290577c5ba2">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ib6c809f8f67643efa3a6bb558412f991_I20191231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktNi0xLTEtMjkzNC90ZXh0cmVnaW9uOmQzNWMxNjkwY2JjNjRkZGNhNDRiZjUwMGI1OGNlMzg2XzEwOTk1MTE2Mjc3OTc_b8518fb6-7f75-45b5-9f41-1f27205a4f59">0.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ddee0d2991140ffa22fd07e6d2467be_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzEwLTItMS0xLTc0MTU_aa7e1fdd-7b91-4a99-b285-fbd384d7d846">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39652c0a62c5481095ff480fce17ca6c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzEwLTUtMS0xLTc0MTc_927ff75e-bfee-47f8-8de6-483d9da24ce0">9,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Excludes an additional <ix:nonFraction unitRef="number" contextRef="ibdd497f181c14d5ab36c9202a891b09d_D20200101-20201231" decimals="3" name="amgn:Ratedifferenceinaninterestrateswaprelationship" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDE5MDk_cbdcd2f1-88e7-41c5-a34e-9d68922d2050">1.5</ix:nonFraction>% of interest for the difference between the coupon rate paid to noteholders and the fixed rate received under the interest rate swap contracts.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt exchange</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $<ix:nonFraction unitRef="usd" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIzNTM_c5e0e91c-dd8c-4ee4-b350-da685f400d22">940</ix:nonFraction>&#160;million principal amount of the newly issued <ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIzOTQ_b2684ae6-60e7-46e6-80ff-5a2109f24e20">2.77</ix:nonFraction>% 2053 Notes (the Exchange Offer).</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NjA3_422386df-9355-49b4-81c8-b1574f031bb2" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently cancelled in connection with the Exchange Offer (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzEtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOmE3ZGZiN2E4MDMzMTQwNTliYjFjNmQ3M2ZjOWY0N2FlXzE2NDkyNjc0NDE2OTE_6ede4705-6ee7-4019-8a7d-f013e3c43fcf">6.375</ix:nonFraction>% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b9a5668fbc41e6b4d63640b91febe6_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzEtMS0xLTEtMzAwOA_cd9ce0c1-02f1-4851-9ea3-a273345039ee">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c556faa66a4640add9a389585dcb8d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzItMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjU5N2NlMzk3MWRmYzQ5NWU5MDNhMzJhMTc4Y2ViMDYxXzE2NDkyNjc0NDE2ODk_7d23008b-1e9a-414a-beab-9d0c6b7a3119">6.90</ix:nonFraction>% 2038 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b731805304467297b2b3b116999268_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzItMS0xLTEtMzAwOA_dec4f277-8079-41c3-af38-ab2b5d436be3">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33bc0e6a798a4daa94404d7e959a5646_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzMtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjg1YTA0NDUwOGJlNzQ0MGVhZjg0MGNiNWU1MmMzNWRiXzE2NDkyNjc0NDE2ODk_92b588eb-bd6e-4847-9f93-3c84c172a576">6.40</ix:nonFraction>% 2039 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382073fcb1d4883b6219e6dc102e745_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzMtMS0xLTEtMzAwOA_9542d2c5-3926-4768-b878-975d3b379594">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86e8c0425a564da7849ac5fe7b5db51c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzQtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjgzMTUxOWE0MjI2MTRmODE4YTEyOWU2ZmUwODk1M2NmXzE2NDkyNjc0NDE2ODk_50b56909-6275-4c9e-96a6-57c5188a08c9">5.75</ix:nonFraction>% 2040 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7759f579c524eab8b6b4da9a496f1e7_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzQtMS0xLTEtMzAwOA_4e0372ef-4f4c-496b-822a-9f81b08f8ff4">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dcacc53791a4df7b253b539b0644b8f_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzUtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOmViNWQ3ZTFhZmRkYzQxNjQ4YzExYmFiOTcyZGM4NGJmXzE2NDkyNjc0NDE2ODk_0935d900-995f-4fd6-a9c5-3ef67181771a">5.15</ix:nonFraction>% 2041 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d73c382070d4582bf5468d1be4dc656_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzUtMS0xLTEtMzAwOA_c3bb066e-a798-4934-b749-ee7acb0cce81">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76cd436bd1f242d4bd92a582319d9cd9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzYtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOmE5MTlkZjlmZjk5YzRjODBhZmNlMWMwZWVkZTJjM2NkXzE2NDkyNjc0NDE2ODk_2a816a8c-4872-4dae-beee-84b397f92956">5.65</ix:nonFraction>% 2042 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d34c35332374923becedb1eee1b52cb_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzYtMS0xLTEtMzAwOA_59fc5aad-ed58-43c7-9038-da5a9fee2403">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie22a6012e30946cbaa82df3fa40dddb3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzctMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjViZDFlNWE3NTM4MjQ0NTg5M2JkMTM2NGZhMjU1NDdhXzE2NDkyNjc0NDE2OTE_929b7c7b-8124-4e72-9266-ee442f99a582">5.375</ix:nonFraction>% 2043 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec6c7c7b81b48d8a20694d3b57b6b70_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzctMS0xLTEtMzAwOA_1a1fa900-2584-4f65-abb3-d68a0c2a54f6">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0MTc_c1c02054-3265-47b5-b6b0-7a7ecec37db0">2.77</ix:nonFraction>% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the <ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0MzA_b64a0041-b58d-4e23-9101-2364ab97f061">2.77</ix:nonFraction>% 2053 Notes. In connection with the Exchange Offer, $<ix:nonFraction unitRef="usd" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:DebtExchangeAdditionalCashConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0NDk_29150a7e-635c-4958-90f9-b55bf82c6218">85</ix:nonFraction> million was paid to holders of the Old Notes (the cash consideration).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $<ix:nonFraction unitRef="usd" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0Nzg_d09a7984-c544-4357-abc8-12b4250b3eec">264</ix:nonFraction> million discount associated with the <ix:nonFraction unitRef="number" contextRef="id13b5ae91c924275a407d360294f8076_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0ODY_baa5552c-5834-489f-882c-580f56af7373">2.77</ix:nonFraction>% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec18d1bff5f3453dad29f6f7961ccf0f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our <ix:nonFraction unitRef="number" contextRef="i70ba1158d5c74f23be9c43c581ee22e6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzM4NDY_2c3784a6-ab2c-4821-96d3-ac3e8dce4476">1.25</ix:nonFraction>% 2022 euro Notes, <ix:nonFraction unitRef="number" contextRef="i913aa3eb20c44b64967ed53a9ab6af9a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzM4NjY_146d5252-b6e8-463e-93eb-6fa47fcdc137">0.41</ix:nonFraction>% 2023 Swiss franc Bonds, <ix:nonFraction unitRef="number" contextRef="i09a160e4cefe420d887e332af50138c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzM4OTM_f3f48745-2d5e-4526-9a93-9dcc6085ab07">2.00</ix:nonFraction>% 2026 euro Notes, <ix:nonFraction unitRef="number" contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIwNzI_a73ca271-1cc9-4852-96fc-163cdf9686a5">5.50</ix:nonFraction>% 2026 pound sterling Notes and <ix:nonFraction unitRef="number" contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIwOTE_cf0955dc-c615-417e-8778-65cb6530f7c9">4.00</ix:nonFraction>% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement and other facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have a commercial paper program that allows us to issue up to $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="amgn:MaximumBorrowingCapacityUnderCommercialPaper" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTExODU0_f124ec69-d32a-44ff-8b49-0d09fd10097c">2.5</ix:nonFraction> billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2020 and 2019, we had no amounts outstanding under our commercial paper program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $<ix:nonFraction unitRef="usd" contextRef="ib951b96e66134344b87919e6a15e9627_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM2ODg_21c2fab9-f58a-428e-a8c4-7048dc99489d">2.5</ix:nonFraction> billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $<ix:nonFraction unitRef="usd" contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM2OTU_333028f0-bf18-4d2e-912a-ef8fd484e16e">750</ix:nonFraction> million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of <ix:nonNumeric contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231" format="ixt-sec:durwordsen" name="amgn:LineOfCreditFacilityInitialCommitmentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzQ2NTI_e29c2701-525e-48e9-9446-6d995fd9a952">five years</ix:nonNumeric>. This term may be extended for up to <ix:nonFraction unitRef="renewal_option" contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:LineofCreditFacilityNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzQ2OTI_531cc180-3a05-40ae-b85b-49dea9f8e05e">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231" format="ixt-sec:durwordsen" name="amgn:LineOfCreditFacilityExtensionOfCommitmentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU0OTc1NTgxNjI4OTQ_37ede041-faea-492a-ae46-6c5a7875ed82">one-year</ix:nonNumeric> periods with the agreement of the banks. Annual commitment fees for this agreement are <ix:nonFraction unitRef="number" contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM3MDE_676d6a69-5d52-4736-84d7-ef64df4d952a">0.09</ix:nonFraction>% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus <ix:nonFraction unitRef="number" contextRef="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM3MDg_36cc51b9-d5c6-4995-8e55-31a1511ad18e">1</ix:nonFraction>% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus <ix:nonFraction unitRef="number" contextRef="ia1f832aa086b4bd39c60c6c87db97472_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUxNDc_58380fd6-383e-46eb-9732-b03c448e0c90">0.50</ix:nonFraction>% or (C) <ix:nonNumeric contextRef="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyMzE_49365dbc-b984-42aa-a338-8a41815c7e9e">one-month LIBOR</ix:nonNumeric> plus <ix:nonFraction unitRef="number" contextRef="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUxNzg_d6f82f0b-91bb-4f25-bde6-e64766b5940c">1</ix:nonFraction>%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2020 and 2019, <ix:nonFraction unitRef="usd" contextRef="id3d59abe384541c89aa4311f241834bc_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUzNjU_78e9ea71-c41a-4ffc-bc29-23f7733ddac0"><ix:nonFraction unitRef="usd" contextRef="ib951b96e66134344b87919e6a15e9627_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUzNjU_c36a3815-ac3e-48e3-85bc-4a615242d1e8">no</ix:nonFraction></ix:nonFraction> amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the U.S. Securities and Exchange Commission that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual maturities of debt obligations</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNDA_ac7f32b7-d4ef-4fd2-90b4-f40f8bc5494c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2020, are as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzEtMi0xLTEtMA_66f6bb4d-0dfe-4537-9bb0-bfd1cde981f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzItMi0xLTEtMA_d01ff550-944a-461b-939c-4a5ddb32e774">4,277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzMtMi0xLTEtMA_c9e04941-fda4-4359-aeb4-f63beea9429c">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzQtMi0xLTEtMA_ae5965b1-749f-499e-aabe-23ac30ac4a1c">1,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzUtMi0xLTEtMA_f9759e98-b7c2-4427-9b7f-06673b2f730c">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzYtMi0xLTEtMA_94c27ebc-7b85-493f-9a13-2b551ad78bc3">24,890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzctMi0xLTEtMA_a68823f8-75cd-442c-97b3-2aef8b81ad8c">33,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2020, 2019 and 2018, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcxODk_2a8cd629-49b7-4169-80ca-74be7f8b72d8">1.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcxOTM_52474d66-3de1-4c8c-80ba-2eb46e236bb3">1.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyMDA_5152ca51-8ebf-4fab-9a86-91371036da5f">1.5</ix:nonFraction> billion, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_259"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwOTA_97df7707-f234-4815-8f64-f4cd31df24f7" continuedAt="i70cc4eb1554d416c8c2e52e7585e645a" escape="true">Stockholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="i70cc4eb1554d416c8c2e52e7585e645a" continuedAt="i23c1251450cb4586a22abc376286423a"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:StockRepurchaseProgramTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwNjU_74a714ed-481d-4c6c-8de1-5dd7b9e5e3e7" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtMS0xLTEtMA_ef1d4119-6933-4902-ad67-3dee7c4283e0">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtMy0xLTEtMA_aae036ae-23aa-43c7-be8a-d6edc6df54af">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtNS0xLTEtMA_6ce4b802-9711-48a3-9f1b-afecccde4b2f">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtNy0xLTEtMA_3a5eafcc-ec68-46e2-8a6b-d2768a8b80c7">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtOS0xLTEtMA_2f63d56f-aa8a-4e3d-a131-db32edf77c4d">56.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtMTEtMS0xLTA_ed8d0b24-aa53-45b6-9ed0-d7d0aba05e34">10,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtMS0xLTEtMA_cd3e8c4c-dfc1-4189-b63b-33bc4c530eff">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtMy0xLTEtMA_bcf3d03d-3012-45f0-b9f2-0f85fcc4fe64">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtNS0xLTEtMA_804365d4-a5e4-464d-92bf-abd94db8552d">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtNy0xLTEtMA_bd9f8305-0b86-4f3c-9d39-25be3d6a09e5">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtOS0xLTEtMA_c255af36-cb0e-4f0c-a96c-c389b7a0eac6">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtMTEtMS0xLTA_1b12e195-2743-41a8-a804-b2e9d649e8ce">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtMS0xLTEtMA_665330d5-a755-499a-8c7e-ecfc879bfed5">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtMy0xLTEtMA_97c6b643-384d-4585-9617-3ab8bcd787a7">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtNS0xLTEtMA_290f713d-368e-46ae-8f72-f898cad2c2e6">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtNy0xLTEtMA_fc336c4d-ba83-44d2-90b2-3b385897437f">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtOS0xLTEtMA_6c72c8b7-9de9-4882-afdc-f7fa830eb233">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtMTEtMS0xLTA_f456e659-d8c2-419c-8931-02795cea6806">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtMS0xLTEtMA_3d9493f2-e1a1-488c-8df6-17db6d68ef42">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtMy0xLTEtMA_5f32f677-e3fd-4c1e-8642-32c7c3b1b3ad">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtNS0xLTEtMA_3845575a-c763-4e56-b7e9-60dfa8d32cb6">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtNy0xLTEtMA_2076b042-50df-461c-9a50-8f26b102db09">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtOS0xLTEtMA_77a5d3b5-b0f7-4785-9f8a-cb091169b7ba">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtMTEtMS0xLTA_37ce8e82-b120-4f94-a86a-a8d3cd3e46cf">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctMS0xLTEtMA_92f55724-2522-443c-812e-88dc0739bb97">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctMy0xLTEtMA_a3d531c8-e8a2-498f-8b3f-c2c8726160be">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctNS0xLTEtMA_085eb9d3-363b-4fd3-bc30-55e1bf00134a">40.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctNy0xLTEtMA_c29b77a1-f553-4f08-82c1-005913741fa1">7,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctOS0xLTEtMA_6134e881-af9b-43f5-9728-5669e89bc959">94.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctMTEtMS0xLTA_bdb19737-b3dd-450d-ad3c-d28ef3efb3fd">17,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Total shares do not add due to rounding.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzM0MQ_fcc59ff2-7317-4095-b49d-d95d5e86b1e8">4.0</ix:nonFraction> billion. As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzM2OQ_fc547d70-1394-4c54-bde8-ab7164c618da">3.0</ix:nonFraction> billion remained available under our stock repurchase program. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors declared quarterly dividends per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_47d76540-c76c-4647-b366-933fb14602f3"><ix:nonFraction unitRef="usdPerShare" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_8116adba-270f-4d7c-b768-ca1c46d300ed"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_beabf666-ce91-4e1d-9814-377717ec1d0f"><ix:nonFraction unitRef="usdPerShare" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_e7cf8fcf-6ed6-49eb-a031-9729b60d70f6">1.60</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_09aea56f-d27e-401a-b33e-1ba2b2e39964"><ix:nonFraction unitRef="usdPerShare" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_3aa916ef-9c13-454b-8502-3f8693d2fa22"><ix:nonFraction unitRef="usdPerShare" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_ac09a7b7-47e2-4823-8c6d-afc76a8e92b4"><ix:nonFraction unitRef="usdPerShare" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_ad111ff8-23fc-4e20-91ef-374e686bd248">1.45</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_13d86021-a73a-4330-b466-09edaca30078"><ix:nonFraction unitRef="usdPerShare" contextRef="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_213b8f6a-2a3d-4832-8fc7-fc8068c16e02"><ix:nonFraction unitRef="usdPerShare" contextRef="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_cf7f7d0b-3551-45df-aac0-63e346f7b2f9"><ix:nonFraction unitRef="usdPerShare" contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_d0d211e0-8196-4939-8120-17150229afea">1.32</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, which were paid in each of the four quarters of 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 16, 2020, the Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i65105b8f350547a9afe51cf16587594c_D20210308-20210308" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5Xzk1Mw_60a179cd-8e4a-43a2-843d-5569c63c6cdd"><ix:nonFraction unitRef="usdPerShare" contextRef="i60869bc47af9405383d397dfe67b7ce8_D20201216-20201216" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5Xzk1Mw_bf2f6f99-32a8-4b6d-b80d-f104f8f7e486">1.76</ix:nonFraction></ix:nonFraction> per share of common stock, which will be paid on March 8, 2021, to all stockholders of record as of the close of business on February 15, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i23c1251450cb4586a22abc376286423a" continuedAt="id6d0da293d424ea88c95e36edb8ce69d"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwODk_0a0ef37d-d11b-4470-aec4-792acaec9fab" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15cba6363e694ebfbb2115df9607f890_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctMS0xLTEtMA_f630aeae-3d62-4dfa-b4eb-217fcfef8b99">529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec98fde84dd7443daf65e4d48bd33cae_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctMy0xLTEtMA_a3cb7a4d-1c6a-4d6c-a6d8-f55bd27aecdb">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3e51d8ec78e482f981fd6bf9a9ca60c_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctNS0xLTEtMA_3d2ebad6-130e-438c-bd04-d29130e80eb4">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i508432a61553416fbdccf7e432d4e8bd_I20171231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctNy0xLTEtMA_3707aa6a-56d1-4f48-9881-04bd2d582bee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie781bbd2a4b948e48767b11ee16f2352_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctOS0xLTEtMA_72eca268-df05-4509-b66f-20bf5c1cf06d">679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of change in accounting principle, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8870a99dcef48e5aa17b95e8de89a23_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzgtNS0xLTEtMA_41324b14-3ea1-4161-b14c-82987bad271d">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36d7388f79e144b99235c416c99550db_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzgtOS0xLTEtMA_85378a7c-696a-431d-83cb-d3da72d158fd">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a72f83ff6643498ddd2ad2b28672d0_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzktMS0xLTEtMA_9f24ff4a-91e0-4ab3-9673-d5c3a8f80ba8">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzktOS0xLTEtMA_24092006-1059-4833-a5b2-b300aa22bc7a">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab14641cde404512b613907261773c1b_D20180101-20181231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEwLTMtMS0xLTA_23cc80a0-4c6b-414a-8b22-533f317f1807">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEwLTUtMS0xLTA_52057118-dac3-4420-9bc6-ddfe99a11319">556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEwLTktMS0xLTA_e27be00a-88c8-4766-9638-ea3849a441d2">495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab14641cde404512b613907261773c1b_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzExLTMtMS0xLTA_abc76020-2b51-4571-9549-016debcefc35">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzExLTUtMS0xLTA_55d82fd1-0073-4271-a650-4e6710f0c86f">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzExLTktMS0xLTA_46932323-06d3-403f-a15c-e8828b65abea">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c2cdd35e2524c0c8b0dca79a961b38d_D20180101-20181231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEyLTctMS0xLTA_92e55796-ed7f-40d8-8207-2b5f1b449c98">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEyLTktMS0xLTA_31a6e758-b7ee-4d20-9791-c6f1cb64b48c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a72f83ff6643498ddd2ad2b28672d0_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTEtMS0xLTA_62d72744-f6f1-420b-8fa5-e2c9a4d4e7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab14641cde404512b613907261773c1b_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTMtMS0xLTA_6e02680f-28a7-449e-afd3-5c712f5d5f63">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTUtMS0xLTA_c9f32ae0-8cf2-4c27-b677-c2eda1a81f04">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTktMS0xLTA_e4a1e739-11d0-41fa-b40c-2ee92ddd81ee">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88f71e0b4ef646179cff4ca0c5bb2784_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTEtMS0xLTA_598c2038-c88b-4468-b24b-4894f2c584fa">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff02eb33259b4098afad9b87c2f8f6f1_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTMtMS0xLTA_06510dc1-47d8-4a78-aa6f-b773cf4a8ae9">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab46e3e374ed4320a79dc7f501ca2a0f_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTUtMS0xLTA_94f1be24-3625-4abd-b0e4-b1c7a1bf739d">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4ef7d0edff34c2eb74bbbcb8615f89d_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTctMS0xLTA_b2bf0dcb-3931-43ab-8578-9df0cdcf0594">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idda2fa41bf7b4d32acb584d26141eb44_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTktMS0xLTA_3581705a-f7b2-4a16-a92f-366f814e6880">769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebe63279db194377849f0b40c57d4391_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE2LTEtMS0xLTA_fbe36a79-ee50-4236-9ced-e76ccba8aec7">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE2LTktMS0xLTA_9894d690-5139-490a-a92a-c48427f0d475">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84262de6ad99499488051396e0055031_D20190101-20191231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTMtMS0xLTA_0ae9a5cf-8302-4cfa-b48a-daa0d23749fc">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTUtMS0xLTA_04e182ef-4e76-41ad-a469-c97e12e8330d">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTktMS0xLTA_92e0ea7a-1222-45dc-9550-256988834796">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84262de6ad99499488051396e0055031_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTMtMS0xLTA_a37aa309-c104-4536-8070-e29e2d6b9f58">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTUtMS0xLTA_17ce6cdd-26a3-4550-9e29-0cede3ecbfed">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTktMS0xLTA_27b45fdc-21f5-46a6-b36a-796dc136d7ae">267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieae7fdb0b6a64177be82f0c59a390de8_D20190101-20191231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTctMS0xLTA_617185d0-692c-403f-b709-8910c2e9d102">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTktMS0xLTA_255f7e1b-ea85-42bb-b7c1-0ddf7648dcc5">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe63279db194377849f0b40c57d4391_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTEtMS0xLTA_9cdff90b-af11-42a2-9f66-899524a48edb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84262de6ad99499488051396e0055031_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTMtMS0xLTA_adb5f04b-14d0-47d4-8f3b-60ad721e6cb8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTUtMS0xLTA_a0a03846-73cb-4f7b-9aad-610001b48045">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTktMS0xLTA_39ef9894-409a-4230-bbe0-a9366d9a1851">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie382593a89bb40f88cbb7baae6848d85_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTEtMS0xLTA_180b67f4-936c-4390-9bf8-675f1ccdec16">718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i834e68b1d71c4cf88092899abf36f0bb_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTMtMS0xLTA_c74c8a99-742a-43cd-a774-f5ef62fd8999">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36dd4baf66a496999b27ea628bd7365_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTUtMS0xLTA_10a1dd5d-72c7-4214-b416-8d43d4707766">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59e1359200bb485e82a279c005e655f0_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTctMS0xLTA_ccb4e8e7-2e51-460f-936e-468a79294483">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f92a1519afd4ee790c4f7f9669bc32b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTktMS0xLTA_106dca83-ccdd-42ae-a8c1-eddeed4cb1c8">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a567dae4771464c8ac036044fce4ba5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTEtMS0xLTMyNjM_d3d0b3fe-bdb2-4c61-972a-932c3aa3a878">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTktMS0xLTY4MTE_0ed48055-d4f5-4e2b-8931-de5cb53a473a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTMtMS0xLTMyMzk_3edd27c0-a359-436d-94a8-d486ee4ac3ba">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTUtMS0xLTMyNDM_33f46ce7-39b1-4ef1-a2e6-10a4d5e8dafd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTktMS0xLTY4MTE_2b23ef9e-1bf7-49d7-b09a-5450cafbc19b">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTMtMS0xLTMyMzk_07b66c5d-b2b6-481f-8b11-5227c35c093d">501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTUtMS0xLTMyNDM_701065f5-4968-4a06-b18b-73df6bd6e709">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTktMS0xLTY4MTE_4fbbd70e-c04c-41c4-8a10-75f2c5a41aa1">534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38568b10d86a4316bf7376de6e8728d7_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTctMS0xLTMyNDc_170f3606-3c5e-4d52-beb1-a261bd660978">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTktMS0xLTY4MTE_11ebb18a-7a96-4c04-aed4-7ecefd189310">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a567dae4771464c8ac036044fce4ba5_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTEtMS0xLTMyNjM_bf4bc374-ff97-444e-9c0e-03f9759973ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTMtMS0xLTMyMzk_2f6d94fe-7bfb-4f28-8512-62a1bf21a398">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTUtMS0xLTMyNDM_09c1c967-f9dc-471f-b002-b08fc0177c8b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTktMS0xLTY4MTE_ad52d822-824b-46f9-bbc5-9f0caa333bc0">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i445ee927bb9f4ec6a1e136928e6720e2_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTEtMS0xLTY4MTE_5f0d93d5-61ac-49d8-9050-699e06b2d7f0">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie06b327237f54c16b3d3e03f5d5e7398_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTMtMS0xLTY4MTE_6ae83a95-fb04-4c88-8a98-665531e3d0d3">263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946ba1f102a249339cc475cc38dbff62_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTUtMS0xLTY4MTE_611b510f-cde0-494e-a241-71aba541b0b2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe6d63071dc4400d8c5203ab02d542d4_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTctMS0xLTY4MTE_40296766-8eb2-4438-95cf-5f070cf00ed3">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42b0fccf031241ce995839be6adc2e18_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTktMS0xLTY4MTE_7269f3aa-716c-4489-93a2-440b39bb14f3">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzEzODI_fff6dafc-832c-42e7-9c13-7ff340511160">14</ix:nonFraction> million benefit and a $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzEzOTk_64e5a7fe-aa22-443e-8c7c-960b3af0198c">110</ix:nonFraction> million benefit in 2020, a $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0MTk_0a4dc0b7-8c7b-4e71-9b53-c9181c363e1d">28</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0MzY_1117ecb2-10e4-4db6-bda0-319d19cee239">46</ix:nonFraction> million benefit in 2019 and a $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0NTk_42dc3578-79ba-4cef-87c7-0d2a29165292">21</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0NzY_a24018be-e01d-428b-aa65-74d03b924d7f">55</ix:nonFraction> million expense in 2018, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE2Njg_7367ff3c-1d1b-4a61-acc3-47aca174e1e2">1</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE2ODU_71c61662-fed2-47f6-8bc9-30701748f70b">7</ix:nonFraction> million benefit in 2020, a $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3MDU_01b889a5-3fd2-4abf-a0e0-59140be8dd49">22</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3MjI_1736be78-691f-4fdd-bfc4-39e120c141b5">14</ix:nonFraction> million benefit in 2019 and a $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3NDU_4fb8c9b5-2349-45c4-aeff-c072e71d54d4">9</ix:nonFraction> million benefit and a $<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3NjM_0c5b1c4c-bab0-4ef3-b553-d080c918358e">3</ix:nonFraction> million expense in 2018, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id6d0da293d424ea88c95e36edb8ce69d"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwNjY_fdedf5cb-17b4-432e-ad13-71d15969e90c" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe17c4200c54926b08b32de808d1607_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzMtMi0xLTEtMA_b08e2dfc-2aa5-44a4-9e44-bfa197ea8858">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e10debea2943bfa038e3e584b92196_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzMtNC0xLTEtMA_d7e6f985-1d36-4c02-8e4a-2c15851234de">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a4f1daf6e423eb316bae15e9e3e54_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzMtNi0xLTEtMA_1737d46a-f982-4d74-a6c1-73d99bb1842f">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f81c16e1ff44269b3e2017ea6eef9b_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzQtMi0xLTEtMA_d66e0adc-6790-4e77-8438-682c20744cd9">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4dd2242a604708a35885bb2742cbd6_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzQtNC0xLTEtMA_3a0cebd5-9e44-4add-acd6-381d7f61f1ad">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9682afd0b98a49479f04e9a056ac6cf9_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzQtNi0xLTEtMA_91bc8ddc-99a3-400d-803e-d1b8ba0a141b">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzYtMi0xLTEtMA_532a65c0-9368-4b50-ada1-c630b977b28c">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzYtNC0xLTEtMA_aef0deb8-3bff-4be7-99fb-fda94f83db1f">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzYtNi0xLTEtMA_ec63ca96-196e-40cd-966d-6474bece6098">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzctMi0xLTEtMA_33df52f2-ab5c-4042-85c0-e2afce6e935d">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzctNC0xLTEtMA_53ca61b8-6b85-424c-bdad-774911d09927">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzctNi0xLTEtMA_6c3ab326-0fbb-4099-8656-3710f5f15f05">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzgtMi0xLTEtMA_1ccb62d4-8b54-4bbf-a0a8-c7eca9d76110">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzgtNC0xLTEtMA_8c1122e5-4c42-4cb9-ae13-b4e280c317cd">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzgtNi0xLTEtMA_2fe7c69b-9625-4add-b084-858bda3d9f74">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEwLTItMS0xLTA_367f155a-770c-42be-b58c-134efe41d294">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEwLTQtMS0xLTA_a56e6cb9-097f-4c6e-b343-4e077bb9f994">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEwLTYtMS0xLTA_39a2636a-048b-4157-92b1-1097213f2073">365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzExLTItMS0xLTA_1b6ad844-90ac-41bc-9e27-f01abc9e142b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzExLTQtMS0xLTA_cc4e5fed-b4ff-4c45-825e-ea4e45cbbaeb">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzExLTYtMS0xLTA_adf6dc2e-1606-4f45-a0ee-f4215a91bb44">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEyLTItMS0xLTA_cae73f83-623d-4cd4-80d7-fb08ad2f77da">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEyLTQtMS0xLTA_33f959de-376a-469a-adea-38bdd10a2299">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEyLTYtMS0xLTA_2b44f8af-942f-419c-9a10-8ceb5c68a5b4">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to common stock, our authorized capital includes <ix:nonFraction unitRef="shares" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE5NDM_eaff4940-1724-4400-9045-d09de95c40a7">5</ix:nonFraction> million shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE5NzM_e07f66b1-ee58-488b-acc2-6e56471c7ca8">0.0001</ix:nonFraction> par value. As of December 31, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_06c4875f-8795-46be-8d24-1e957ffbe2a7"><ix:nonFraction unitRef="shares" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_7d7eeec5-18c7-4347-bdf7-f4349528ac18"><ix:nonFraction unitRef="shares" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_9e956017-8907-441c-9076-b918ce8eb888"><ix:nonFraction unitRef="shares" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_add55591-e95e-497a-a474-c2dbcc56705f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div></ix:continuation><div id="if8d0740b43d148a5ba67e4dd5b38ce46_265"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5MzI_71ec76f4-4279-41b5-b29d-3c27284015ee" continuedAt="i35251c3a0f0a4850be56b3176f42eb10" escape="true">Fair value measurement</ix:nonNumeric></span></div><ix:continuation id="i35251c3a0f0a4850be56b3176f42eb10" continuedAt="i93b21f30cd23480382c71c78b72733bc"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i93b21f30cd23480382c71c78b72733bc" continuedAt="ibcb321734f0f42b58ebfd3609757ddf3"><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5NDI_795b3065-3a5f-445d-b048-69d99f6dd289" continuedAt="i343ac9cf1c7a4504b3fd5dbca6b16903" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9644e2219642dfb8b959deb45d2db9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtMi0xLTEtMA_4cbd02cb-473e-4673-925f-a61a1b5b49f1">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb9f08921cf64e6b95d1f81c11c62ab9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtNC0xLTEtMA_58e7c021-7e0d-4903-aaa1-039478066391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625fa9d4a306409181259806d10464fc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtNi0xLTEtMA_e3b7283e-27bd-4dbd-95e0-3ece08e88a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abab397f36846d2963dacabb469a08b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtOC0xLTEtMA_211a3b75-701a-4bbe-9d81-ed6659d4df1c">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6101c783a3084635bdf9cd570e9f1282_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtMi0xLTEtMA_de2f9586-d9f9-4e1d-a1f4-936cb838be7b">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac001eaacc55452bae4119e1a7b27c9e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtNC0xLTEtMA_308be263-bab0-4151-ba5e-3428d946117c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3f5fa8487f48658b63af871c8fe2c9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtNi0xLTEtMA_9d47fb6b-f568-49b9-80bd-f628a23b1dbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia314c059b63d4452a382baae50386fbd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtOC0xLTEtMA_ef7fa163-72f4-4d18-9329-5c29003c8e85">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b4a2b455184822b0f1116160cc18e3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktMi0xLTEtMA_0f455cd4-616e-45de-9a1b-b755fc77ec06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b7da5c12534b3981691aba7cb821cf_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktNC0xLTEtMA_aaf0c8dd-edfc-4f39-b634-5ad4fdc80772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia986bf30e56b467ca51da380a21cfe6b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktNi0xLTEtMA_2a32d2c9-dd93-45cc-8787-c381fc283657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktOC0xLTEtMA_ed9a52cb-67e4-4393-a6a4-1df304055d5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5983e886096845e08a0cc96ad73632ac_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTItMS0xLTA_978028d7-dec5-425e-b4f9-c19ae3473cd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edf08d2463042549609c2d138554631_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTQtMS0xLTA_98871ff8-a284-4543-bf77-2481888f8efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1be9e0be7e44b886c4bba9044e55c8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTYtMS0xLTA_d8ede855-eede-4405-bc53-4e235eb17a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1043550a1f84782876ef562e9149716_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTgtMS0xLTA_056f390f-5cc3-4ba2-9482-ae6e8194e022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3220d9002c542069391fbf17f94d1ce_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTItMS0xLTA_12d84b9f-f8e7-4af1-b8e3-cf363515a684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91de10fa99174e29b365d56c9f6d3d48_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTQtMS0xLTA_600fb2e9-107b-4d0a-a4b7-9e29acf11aee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a9c55953194cd3a01eabe3994fd206_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTYtMS0xLTA_d061baeb-d4da-455f-8816-6da5d301be27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTgtMS0xLTA_7a3a7a0a-884f-4ebb-a233-03d2761a812a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ce59970e704a549cf6e24fdbc6115d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTItMS0xLTA_63b24324-c3bb-4067-af75-667f4f284be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809345b5da314af5a55dfa6cc31e9467_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTQtMS0xLTA_933b29e9-d69d-4158-aa2d-372899ceaff6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dbf334d697f42bcb8a2ab7042237c55_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTYtMS0xLTA_8cd77632-7bf3-4384-9a87-6423cf2cdf50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTgtMS0xLTA_03d8fa24-edba-4705-b172-67abf77b4a21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7054c920374f98b6f1c0fb02b93de9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTItMS0xLTA_b43502c6-0144-45e6-a915-63b2be66bea5">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie386d2bd778d480f836e2fa1df624708_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTQtMS0xLTA_ba70c6c1-e1f7-4525-9f18-61f5a606850e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ddbd84bf09413aa009b1a257b36e6d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTYtMS0xLTA_a12e9f17-fc92-4091-bd7f-644ca2d24bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2783b98e50e847a19205180e25cee168_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTgtMS0xLTA_6826d0f4-43c8-499e-b1a5-6d5fa5e69405">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1609b78f64499fb1992720d032da1d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTItMS0xLTA_5d13ddc6-17e1-43e3-9ebe-e10c80572801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib182df74839648c99a69305123764d98_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTQtMS0xLTA_5b086809-161b-4957-be6d-4d6abc8de2e7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4888dd7b32ab43db957c063fe6af1b4b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTYtMS0xLTA_33393dbb-52ab-4ca2-92ed-592f979870dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTgtMS0xLTA_6f84dfe7-c6e5-4baa-8173-85ee750bc37b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTItMS0xLTA_49063eb2-8986-4918-9e7f-ad14fa052f73">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTQtMS0xLTA_41c15d72-2c42-4bfa-8c48-bc976cab2fc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTYtMS0xLTA_c5a1c289-6883-4dfd-8fa9-4647bbbc5fab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTgtMS0xLTA_20371f02-28fb-44fb-a9d2-a9efc730b9ee">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b3769d1f54f7aa9a0ad91a5b2b2a8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTItMS0xLTA_0dc4f4b6-6640-40bf-afbd-818472d97887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab820ea663b142d683c134deffedff4d_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTQtMS0xLTA_56129b67-04b5-41fe-b783-dd5a33e0a6fa">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f8425a23694b76902e702c9427cd89_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTYtMS0xLTA_351536a0-4d15-4d97-865a-3a2f34fddd30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064fcfcd92604a3c88418ad109a62465_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTgtMS0xLTA_e80e1dca-2e4c-40c4-8f71-f61f95fce20e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9db18cb51ff42eaa1fdf223be2cef55_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTItMS0xLTA_b63aea2b-2a64-45d4-86e4-d36e6549abb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb077631c2943a386f31198be2b482a_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTQtMS0xLTA_da07707e-89ba-43f8-b240-4a31348070d1">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52081e4ae094d09bfb8afeef0d34a19_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTYtMS0xLTA_5517c4b1-3156-4d79-81c9-727a25dc9104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86eb7a229bd452995503e7a79b231f0_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTgtMS0xLTA_b0347c00-96ce-4180-832b-69be2d1300ae">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649ca6b917ff4847aefd1d96a215f411_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTItMS0xLTA_8902cbe0-fa89-4a78-b0ce-d23c39c9e67d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id401fea1268645f08278ada72856ed9b_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTQtMS0xLTA_9d362c15-f1af-4b8c-b1b2-ab0cee96bf41">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272140d66a7c4798aed64a4683f7f5c9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTYtMS0xLTA_c08afff4-3cdc-4f36-b25d-847aa370c4b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b21ba0b68054fb980abeb4ece605ae6_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTgtMS0xLTA_dfbf9f98-ffb7-47e3-9d8e-8551524e00d2">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIxLTItMS0xLTA_84966f7f-926f-4d4f-a2eb-89cd27522b1b">10,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIxLTQtMS0xLTA_893d55e4-1fa3-4776-b907-0fc6e05a0f1a">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIxLTgtMS0xLTA_5fd19e7d-97fc-427d-bcf9-5048a1c5e3fd">10,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b3769d1f54f7aa9a0ad91a5b2b2a8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTItMS0xLTA_1c39ec55-e6ed-4d2f-b613-dd90534f16dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab820ea663b142d683c134deffedff4d_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTQtMS0xLTA_00671d6a-830e-4719-902a-217e45cde60d">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f8425a23694b76902e702c9427cd89_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTYtMS0xLTA_40c10ce2-07aa-4ca3-9f96-635a6b57ccaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064fcfcd92604a3c88418ad109a62465_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTgtMS0xLTA_8339e216-f7e1-45ab-8e6b-ed754916ffb5">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9db18cb51ff42eaa1fdf223be2cef55_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTItMS0xLTA_daa651c3-1e2b-4f7e-a3cb-510df001d451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb077631c2943a386f31198be2b482a_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTQtMS0xLTA_d878683f-60ce-4209-8c1e-8051974eebd5">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52081e4ae094d09bfb8afeef0d34a19_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTYtMS0xLTA_0d8d171e-4da5-4af5-b15f-3a60c3901bab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86eb7a229bd452995503e7a79b231f0_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTgtMS0xLTA_b4c1c214-8d42-49d4-81ff-449ac771a3f9">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649ca6b917ff4847aefd1d96a215f411_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTItMS0xLTA_f95afd06-a7e9-464c-ae62-9e7326de8de1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id401fea1268645f08278ada72856ed9b_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTQtMS0xLTA_45d33633-65eb-4c08-9529-4d9487439a64">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272140d66a7c4798aed64a4683f7f5c9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTYtMS0xLTA_49503af2-ef86-461a-82b0-6faca38cc451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b21ba0b68054fb980abeb4ece605ae6_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTgtMS0xLTA_40a838d2-bafc-4f2b-914a-943249322960">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTItMS0xLTA_f3954ee2-4318-4cfb-a8ee-bf518c065b94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTQtMS0xLTA_206647da-f937-408c-ae21-f702bdbc9e5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTYtMS0xLTA_cb0f5a3d-e2e8-4a83-99cb-d616d0e9cf9f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTgtMS0xLTA_2080b09c-ef4a-424d-a58b-76dbbf8cc471">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTItMS0xLTA_dcdbbbc7-921b-45dd-83ab-8f9f3c7f7ca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTQtMS0xLTA_e2e7a946-a1c2-434e-a238-17b2b99c5226">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTYtMS0xLTA_241d4aec-47f9-4110-8395-03ccc6eea928">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTgtMS0xLTA_530354df-e44f-4113-ade2-aa39121161da">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibcb321734f0f42b58ebfd3609757ddf3" continuedAt="i2dee586c25b14e35a593a77037f07e00"><div style="margin-bottom:6pt"><ix:continuation id="i343ac9cf1c7a4504b3fd5dbca6b16903"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2019, using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5faa80b5b4b10adeecf22f66b3581_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtMi0xLTEtMA_6fe150d5-ecc5-4a1b-9a51-3fe845b5ae1a">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d5adbe89e6449698d66ec80b68a414_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtNC0xLTEtMA_0daa4859-6b38-4a7c-a580-e24bd54a10db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8c6115d404415db720dd2a742d8eb4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtNi0xLTEtMA_b4ce1ea8-28fe-42b7-ab5e-f884503f1e86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtOC0xLTEtMA_953b4da7-88d3-44f2-8c1d-f74ada14e84b">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef1d913febf4a47abb4d2d49554d87e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtMi0xLTEtMA_bbc7d724-b604-4774-9734-528ba9cef3c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d55a7ee2cd4a33a48689caa2dcf916_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtNC0xLTEtMA_02bf386c-a661-4a82-9a7a-f0c841d98d19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286a3763387b42bc9a3cb41202817a79_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtNi0xLTEtMA_364749c5-9b3c-4f9d-a1e6-53f5ae1ca499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtOC0xLTEtMA_c9cc67ad-4214-42b5-a8f8-0dca9fd8f2f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfd2fc877304237a30a42e164d32f71_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktMi0xLTEtMA_456f73ff-688f-4dc6-bfca-70dca4335d71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie900b0b41bfb46fb953391112402fcb4_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktNC0xLTEtMA_cf969c49-be42-43c0-8cca-655233e49a37">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e5d44ae1e344489c69734a0bc2cc50_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktNi0xLTEtMA_99a6f0c6-1ad4-4893-859b-568e098defcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktOC0xLTEtMA_d3105788-96b4-4659-b43a-aea04c717d20">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib246c8ea900c4139925b4277352eb5e4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTItMS0xLTA_8ec6e294-2737-470b-b8c5-e21e9ef1c42a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d01e59834f4139b4e0c85a155b259b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTQtMS0xLTA_e711aca4-eca0-4bdc-81cc-0e05551cbf7d">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a87e19790014e689ae6a75f01a9d82e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTYtMS0xLTA_14609b34-92d5-4125-a887-39b9d5022eb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTgtMS0xLTA_49cb219a-d96c-4394-a2a1-531847e8587d">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd56a68a7ae47358902b75f24b8098e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTItMS0xLTA_5a7e6e7f-2c62-4d03-83c8-a03a39f36d25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c5c8997cac420db031456c5bd0c5a1_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTQtMS0xLTA_640ad4d2-87cc-4cca-9362-dd57aee7c947">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id815d1f62e17488f819d1554819ccb75_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTYtMS0xLTA_7923f38d-eca5-40fd-b7e3-f1f154cac5f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTgtMS0xLTA_cffbc330-135b-44da-8c32-46a55763375e">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515615df7d0649f19fcd37f592c7ece9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTItMS0xLTA_40dba74e-4a93-489b-8a2a-cc43d958d4a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic879f5b36d054ed9a76eb771bfb892b0_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTQtMS0xLTA_b24de2bb-be35-4d71-848e-a50bdaf3b6d7">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae474e4eb1174434902da312c3116aea_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTYtMS0xLTA_31a15bfc-64fb-4346-aca1-1d75018a8105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTgtMS0xLTA_868a1003-8718-4d52-9bb4-64196437574d">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3539b33168456ba7b264fa95739a21_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTItMS0xLTA_eaf0be59-9a59-4e67-b16d-ff40abc27565">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b75e88402c841058a01fea422a2d5e2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTQtMS0xLTA_cb5772c8-eff6-4888-b59f-5b1236c202e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a943209d2bc469ca0bc93bd11d07f9c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTYtMS0xLTA_e39e0813-1858-42dc-bed8-2644fe6844fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTgtMS0xLTA_38041550-b8f8-4a25-b621-fa659f66c637">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32090b1bcda448d0b03e44dc48a112e1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTItMS0xLTA_c536e89e-fe2c-4012-a455-98eb542624b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4671a4128224590847baa4d91f4f23c_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTQtMS0xLTA_4fb06021-1a66-44f1-89f6-f131d12bad40">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id243dd82ed464c5782fba60066763a4d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTYtMS0xLTA_7c16ec24-430c-40ba-bb0f-bef4c37456ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTgtMS0xLTA_e22d80ab-111b-4007-83e6-55c47430903c">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTItMS0xLTA_bb5e55c8-aa64-4928-bc98-1fc588459075">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTQtMS0xLTA_30bfb084-a2f3-4ad1-a5b8-7c2c381f31b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTYtMS0xLTA_9ee76e3d-7eb0-4ffd-a9ba-66bd8e84a71e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTgtMS0xLTA_459572d0-5322-4cef-83cf-bd800c5a7e63">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2e56aa52234a9295f48ee3eb721a25_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTItMS0xLTA_f280c919-f24c-419b-b8f7-d09eea006d75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeeedafe9493400eaaf0bafdb1cc9eec_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTQtMS0xLTA_15167f66-5b14-4b2e-941b-180939fd264f">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf5136a442245e5983ef4b4dd9fe1a0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTYtMS0xLTA_507c11ba-8147-4454-af23-7f261d811417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f07dda96ee49b7b10ec42bfd9ee318_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTgtMS0xLTA_b416c72b-76a8-4c71-93f2-aa71ac099596">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a356ae88a6f494eb208b656cfb3d39b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTItMS0xLTA_1c433dab-5836-4205-a2b9-3b3dde7b5373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d3d663147d4671afc5b78a2cd03fd3_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTQtMS0xLTA_37daedc8-0c02-48b8-9717-acab73d6a7c2">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ffb83e4ee44f928713cdb0b9355245_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTYtMS0xLTA_b3a9bd34-327b-45a6-b100-0aad9b12fd14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae4c13d4f1a4e789c5111bdd1953619_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTgtMS0xLTA_27fcda8a-645d-4074-8379-8d7bd8ed551c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc54bfdcf154b1c99478e3369c649f0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTItMS0xLTA_8aec4785-2f76-4f69-9194-4771bc4e3052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80341c6920be4b8f83233fdbad6decc2_I20191231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTQtMS0xLTA_a3ba7b48-39b7-40c2-86c5-3fc22f3bfd7c">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f39dc9f49db4cdb801668e25f02b78a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTYtMS0xLTA_8d0c7a8e-1b18-4db6-bfab-0634487e71a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0734c1cfd345e9b84e6222bec110fb_I20191231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTgtMS0xLTA_c709dc6e-e555-4d40-bd25-2561f71727ba">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTItMS0xLTA_277244ea-1ed8-41b3-bc16-6354602ae503">5,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTQtMS0xLTA_7c773315-f5f6-4f0b-93e2-40ae3cbcb122">3,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTYtMS0xLTA_79e83b80-bc78-4f2b-9580-038c2885dee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTgtMS0xLTA_6b9a7864-2e31-4de3-be6f-bc6140d56385">9,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2e56aa52234a9295f48ee3eb721a25_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTItMS0xLTA_042a609d-6f20-4f0d-97e1-ad4d16e6f743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeeedafe9493400eaaf0bafdb1cc9eec_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTQtMS0xLTA_f3969826-6244-4f80-9691-e4c909986133">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf5136a442245e5983ef4b4dd9fe1a0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTYtMS0xLTA_d138ed4d-9251-4d70-a1ab-abdcdd0b8d48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f07dda96ee49b7b10ec42bfd9ee318_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTgtMS0xLTA_bed59344-001c-474d-85cd-020333c54c7a">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a356ae88a6f494eb208b656cfb3d39b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTItMS0xLTA_7fba42d8-c7c3-42f5-a74a-e7595e363964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d3d663147d4671afc5b78a2cd03fd3_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTQtMS0xLTA_ae3384d9-8636-4f9b-bed1-4ff24ef46986">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ffb83e4ee44f928713cdb0b9355245_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTYtMS0xLTA_b76a8c5a-1a0f-4164-8e5f-1d1b6154b597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae4c13d4f1a4e789c5111bdd1953619_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTgtMS0xLTA_64717076-2515-41ab-b4d0-5293b217d6d6">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc54bfdcf154b1c99478e3369c649f0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTItMS0xLTA_371cf34c-f824-48c5-9b68-0502e62a41ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80341c6920be4b8f83233fdbad6decc2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTQtMS0xLTA_d18482b1-bc4c-49c1-a636-5186bb67fe6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f39dc9f49db4cdb801668e25f02b78a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTYtMS0xLTA_fedb437e-4f10-4421-8e95-7f12dd3180e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0734c1cfd345e9b84e6222bec110fb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTgtMS0xLTA_be55f7a7-9584-45e5-ae97-7d3c1079ed18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTItMS0xLTA_e4ea1eb0-1d57-4690-ab01-b002638423ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTQtMS0xLTA_896d210f-9111-40e8-8e87-bcccc72e9cf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTYtMS0xLTA_d0f8aab4-46fd-443d-9525-e2618ae6adb9">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTgtMS0xLTA_1123027c-fe99-4e28-892f-605e8cf09e86">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTItMS0xLTA_65f09c0d-de33-4b0d-9f8b-8fe881327e74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTQtMS0xLTA_e3980901-4c48-44ff-9abd-50992a3e6eb3">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTYtMS0xLTA_0ebd78d6-a405-4739-bc1d-6fd98cf9bbea">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTgtMS0xLTA_a2609855-08d7-4782-8395-2a3fdb3db8f9">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of our corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of our residential-mortgage-backed securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2dee586c25b14e35a593a77037f07e00"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward and option derivative contracts have maturities of <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzM3MDA_a94c3c41-d296-436f-ac6a-e5fb81858de8">three years</ix:nonNumeric> or less, and all are with counterparties that have minimum credit ratings of A&#8211; or equivalent by Standard &amp; Poor&#8217;s Financial Services (S&amp;P), Moody&#8217;s Investors Service, Inc. (Moody&#8217;s) or Fitch Ratings, Inc. (Fitch). We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. During the year ended December 31, 2018, we discontinued the internal development of a program that resulted in an impairment of an IPR&amp;D asset of $<ix:nonFraction unitRef="usd" contextRef="i07aff99eff5e43eab44bd82f5c93ad1c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzgzMjY_c7ee7619-2a5b-481a-9850-88271f6355f6">330</ix:nonFraction> million, which was recognized in Other operating expenses in the Consolidated Statements of Income and included in Other items, net, in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2020 and 2019, the aggregate fair values of our borrowings were $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg4NTU_a911dbef-ad80-4898-9a56-fbefdf530aba">39.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg4NjI_992831fc-11fd-495f-b031-04622ab3a8a4">33.7</ix:nonFraction> billion, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5MDk_86449209-f400-4bf3-9ce9-892038b82643">33.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5MTY_5446e7e5-4e89-4d9c-92cb-3cc616bc2659">29.9</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2020, the fair value and carrying value were $<ix:nonFraction unitRef="usd" contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzExNTQ0ODcyMTA1MTE3_16a7d50c-a481-4198-b8bf-d1eb228bf835">4.9</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzExNTQ0ODcyMTA1MTMx_0e59b253-8b3a-4681-9875-c5ec7057660c">2.9</ix:nonFraction>&#160;billion, respectively.</span></div></ix:continuation><div id="if8d0740b43d148a5ba67e4dd5b38ce46_268"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1ODY_25d3f3b9-7669-407a-9f0f-d3a48ccd1d2a" continuedAt="i10767a6998394472a8f4c6ac0ff4cdb1" escape="true">Derivative instruments</ix:nonNumeric></span></div><ix:continuation id="i10767a6998394472a8f4c6ac0ff4cdb1" continuedAt="ic92862fe55e14bd484caa20c6f66618a"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic92862fe55e14bd484caa20c6f66618a" continuedAt="icbf1145431cd4bd8beb684df0ce569fb"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, 2019 and 2018, we had outstanding foreign currency forward contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ia87ed81df5cd4df18bf1c76cedc6ff15_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE1NjA_c7773042-a295-4a99-bee6-33f6ca16fcee">5.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i3094f6fc9cc8496c8f65948eaea987c1_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE1NjQ_1d740c8d-6bd2-4a39-aa7b-bbc6b914ba4f">5.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ide1f0bd164be4ab48c682b4349325400_I20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE1NzE_2c871fc7-d9ce-4540-8bbb-91e96f9f328a">4.5</ix:nonFraction> billion, respectively. As of December 31, 2018 we had outstanding foreign currency option contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="id78e562fe4a247969552202afc671b7d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE3MTc_71e881b8-1de9-4b59-a707-e1ca093ce3e1">21</ix:nonFraction> million, and no such outstanding contracts as of December 31, 2020 and 2019. We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1ODc_b7db4ce8-7a2a-4602-a6c3-82a573c42de9" continuedAt="i8f32e2d4b2c94b628ae7892ee6d119bb" escape="true">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2020, were as follows (notional amounts in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i8f32e2d4b2c94b628ae7892ee6d119bb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% 2022 euro Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i0694e7fc221e482c91e8838576738184_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtMi0xLTEtMA_f83fb9c0-bbe2-41b4-99fb-a6d7348bf634">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ba2d75207254328aa10efe32c1d7d92_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtNC0xLTEtMA_1141092d-cde1-4c9b-a37f-9e22c2eae20e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0694e7fc221e482c91e8838576738184_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtNi0xLTEtMA_35501b57-78ac-4333-bd7f-b18a48cfddeb">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idec4c95044a6412abcc5d68913628085_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtOC0xLTEtMA_75e637bd-bc8b-4096-bc9c-2ad2dd714fec">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="chf" contextRef="id39bb9a5237948c1b1665fb28924169c_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtMi0xLTEtMA_369ef6c2-1c05-412c-a326-fe9a7119abd6">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7cab6ff6f34e259c4a6ca09c02afd1_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtNC0xLTEtMA_b103370f-28c0-411e-a314-5ca4e5f05829">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39bb9a5237948c1b1665fb28924169c_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtNi0xLTEtMA_de9488fb-dd47-4ad8-b4f7-0f0b245d8eef">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60cd5ec752de4c98b0157f82d6b72e5a_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtOC0xLTEtMA_c6df3f55-b0d7-40b4-bef5-5e21fbfa1986">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i7343472b32c748d99b7140235bb94b4d_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtMi0xLTEtMA_4973afb6-83d2-4f46-846b-42fb5466960e">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23f07f28ce2a46cbbc068409addaea19_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtNC0xLTEtMA_cbfb9120-09a1-435d-ae39-3e685adcda86">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7343472b32c748d99b7140235bb94b4d_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtNi0xLTEtMA_6a907216-14fd-4ba5-aa2b-57d7d5b68e9e">833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89094b01572546878b2ff1d75b3818ef_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtOC0xLTEtMA_d749b8a8-06f4-4fc3-84fd-99c0affacb4c">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="if028ba21936c4586893e5c30ab36bbac_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtMi0xLTEtMA_b0dbcf32-5a06-408c-95f4-2b0ad1555f27">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05187f24dca245f89aba477135b8f57a_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtNC0xLTEtMA_ca022368-a691-4819-980b-03d6a91585ce">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if028ba21936c4586893e5c30ab36bbac_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtNi0xLTEtMA_e9aff562-aab6-44f7-af71-1ecd6620f472">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7db5b4699b5c43b1bcd765fc6632aa11_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtOC0xLTEtMA_718f2ef0-f866-40cf-827e-e06ecb933b8c">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="ie7d28914099a4db4a141ed2fbb2afc50_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctMi0xLTEtMA_908c8425-29e2-4fcd-a127-57e62b575e3b">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd8a2e81c4d541849a664d3e8219f829_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctNC0xLTEtMA_89bd4ca0-ae4d-42df-b3c1-b1503f58925b">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d28914099a4db4a141ed2fbb2afc50_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctNi0xLTEtMA_48b09cee-c113-4db1-8016-cc4e9bcf5432">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ca9160fcbd645a58623671457697045_I20201231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctOC0xLTEtMA_a0d41086-863e-45f5-a1fc-82a9206d9426">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, our <ix:nonFraction unitRef="number" contextRef="icfdeec3400fe43809c845700b9250d21_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzM2OTE_37f37449-5545-4f93-ab20-c6661ffcb1d9">2.125</ix:nonFraction>% 2019 euro Notes matured, and the related cross-currency swaps were settled. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2020, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1OTM_dde088f8-bed6-4037-8118-d9f815a07be6" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and gains recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8781f9dbe8224717b48a58ba39d8e44a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzItNC0xLTEtMA_c0aec4e7-88ef-4067-ab32-2f8e0fafcef8">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f84184b50a44f7b23e2915f0e16c7b_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzItNi0xLTEtMA_b89154c8-2a18-4dad-9489-f0bb1e835bf3">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie75450fb332b47589035297dd2cbfef4_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzItOC0xLTEtMA_3a8eabf2-82b1-4595-a472-722d7804313e">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab3fe75d88d4a25a823aa9d5bb0fa1d_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzMtNC0xLTEtMA_f839a78b-82ac-4b69-ab4a-405b2103ecd2">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c26149bf9bc4af9b601bdee1ab9cef3_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzMtNi0xLTEtMA_eed5aad3-14e1-41be-a407-8999f647db78">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9313578881564713bd51c45434307224_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzMtOC0xLTEtMA_58b61f46-a1b3-436d-a693-40271fd087af">287</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ae6fbb6ad64fb9b9ae8eee82d8664d_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzQtNC0xLTEtMA_6062c4b5-8ee3-40af-ab48-47d8c5b8b6cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471e2bff63624e0e81a47854f415cf1e_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzQtNi0xLTEtMA_ae7f8091-44e3-44ff-8096-7f7e8381f120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7fa60265134785b2cab0462930cf52_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzQtOC0xLTEtMA_559ec0bb-113a-449c-a09f-a8ed30142b01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized (losses) gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5991882c8d74449db1e6b1214ea17429_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzUtNC0xLTEtMA_9ca899be-2083-483f-8746-d1fdd16ccbfd">61</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f7642813ee4758a8d46ddcc6037f64_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzUtNi0xLTEtMA_8f31774a-1cab-4ad7-925a-f4e4365b13b2">127</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79e5b12752f45cf9a8cdcc982b21b92_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzUtOC0xLTEtMA_014e6596-3df2-4bac-9d39-e3aee27d4c43">61</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icbf1145431cd4bd8beb684df0ce569fb" continuedAt="if61064c57dac4360839484917014eaf2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2020 and 2019, we had interest rate swap contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzUxNDA_010249fa-56a9-4393-a5f1-87935e5730ac">5.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i2961200acffa4d0c935574bdd8f22f7d_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzUxNDc_3f7c1940-4627-488d-b9f5-174812bb8fbb">9.6</ix:nonFraction> billion, respectively, that hedge certain portions of our long-term debt issuances.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps with an aggregate notional value of $<ix:nonFraction unitRef="usd" contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231" decimals="-8" format="ixt:numdotdecimal" name="amgn:DerivativeNotionalAmountAmountTerminated" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODMw_c0d5bf97-c6e9-421d-9eef-cfbc9f07d613">3.7</ix:nonFraction>&#160;billion were terminated during the year ended December 31, 2020, in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $<ix:nonFraction unitRef="usd" contextRef="i1a30d28949ff465693152dab8f329ef6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainOnDerivative" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODU4_aa157320-0cc2-47fb-979c-44d9ce541928">40</ix:nonFraction>&#160;million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $<ix:nonFraction unitRef="usd" contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231" decimals="-8" format="ixt:numdotdecimal" name="amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODQ0_cd9dda8d-6583-4754-94b0-058679fba84c">5.2</ix:nonFraction>&#160;billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $<ix:nonFraction unitRef="usd" contextRef="i3a91bd5c90e8492fa703ad1a89545d34_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODcx_fe175605-8eb8-40fc-a40e-2e199973528b">576</ix:nonFraction>&#160;million from the counterparties that was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount will be recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $<ix:nonFraction unitRef="usd" contextRef="ic198d94557414ab3b4fc50e9ddb159f9_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0OTMw_cfbcc177-670c-45a2-ad2b-a9d11184a9b4">5.2</ix:nonFraction>&#160;billion principal amount of notes. See Note 15, Financing arrangements, for information on our interest rate swaps.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1NTQ_e0608925-4596-44f8-acf8-4f3fe5d00a23" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtMi0xLTEtMA_56553694-0349-4a5b-82f1-a65dde3e053a">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe46af694c14b4098014e42d59a4512_I20191231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtNC0xLTEtMA_23cd7bf0-cabb-4025-8e6a-f610b27fa81e">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtNi0xLTEtMA_b60b8347-aed6-46a1-81af-4c4fbe5e777d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe46af694c14b4098014e42d59a4512_I20191231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtOC0xLTEtMA_a055de6b-be1d-4d81-81ca-c4294947da17">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643b333982544519816452a792886641_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtMi0xLTEtMA_1ac43b67-ffc4-4ef0-a2f0-bec0579cc5d2">6,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtNC0xLTEtMA_8a05c3ca-ab6c-4f43-931f-37dd2737dd32">8,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643b333982544519816452a792886641_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtNi0xLTEtMA_24f42496-ecfc-4892-85d1-932b6093931c">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtOC0xLTEtMA_5fce96c0-82c6-4734-b541-49f1bfd002b0">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODI4MzE_bfd5eba0-1c07-43a1-bda3-a25ba6834cb9">89</ix:nonFraction> million of carrying value with discontinued hedging relationships as of December 31, 2020. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i643b333982544519816452a792886641_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODI5NDI_1ffe25ff-79ff-43bc-be03-3a914f837050">525</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODI5NTA_0b3d2b2b-9501-4661-b192-095c62d2f56d">136</ix:nonFraction> million of carrying value with discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODMzNzE_c020263d-8b53-4614-bb9d-ed20d473bd6e">89</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of December 31, 2020. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i643b333982544519816452a792886641_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODM0ODU_39186d06-ae0c-47ba-b626-6a09bf415398">425</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODM0OTM_3df48559-6195-4a27-909a-77f96b11083a">36</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if61064c57dac4360839484917014eaf2" continuedAt="i3ba766bf3df44b4c8b8826c34ebdf2f8"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1NTU_df3ca58e-b3d5-4941-b7e3-58a15b9c1e9c" continuedAt="ic2881d7109e44c8e830400be6c4cd93b" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzItMi0xLTEtMzM4Mg_03da4bf8-5744-4e04-9413-5e96584f8345">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzItNC0xLTEtMzM4NQ_7156e0b9-caf6-4147-8da3-fb002331c7e3">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzItNi0xLTEtMzM4OQ_7a7806ad-7aa9-464a-870c-0efe212603f0">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4fc6eaae654eff9e476549ca95692a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzUtMi0xLTEtMzM5Mw_d45e962c-fe32-4be7-b6ae-7ec44005ecc7">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if807e88d6a89408d9d6c6adb4b5eea3e_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzYtNC0xLTEtMzM5Ng_e123fb2c-7e9b-4305-9533-bc7ec596efa5">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzgtNi0xLTEtMzQwNA_b17406d7-f156-4776-a301-2674776b00ab">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzktNi0xLTEtMzQwNA_396f807b-1e45-45ed-96f5-7a9642b92fbd">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzItMi0xLTEtMzQwNg_59d46d29-f4ce-4d38-ac1c-3c335dab88de">22,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzItNC0xLTEtMzQxMA_d7a49d2b-b814-45e5-88ce-65c0aeb69403">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzItNi0xLTEtMzQxMw_25568d28-5e54-492f-9628-b22b39482971">1,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c35c83ea16240faabb17b7cad3444a1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzUtMi0xLTEtMzQxNg_dc0149bf-9dff-4d1a-8b76-d7fc96e19317">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec37ac4b3fa42bc95ed748f124e3eec_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzYtNC0xLTEtMzQxOA_59f2a08d-4e09-4d0d-a706-9883eac67cc0">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9833b553be6144e3aaf934620c21e9ef_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzgtNi0xLTEtMzQyNg_97f5ffa3-1af1-41e3-a1b4-bee616d4e05b">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9833b553be6144e3aaf934620c21e9ef_D20190101-20191231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzktNi0xLTEtMzQyNg_8922e702-26d0-4267-8802-187336feb9ff">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income (expense), net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzItMi0xLTEtMzQyOA_734a7d1a-f3a7-4819-8f79-a8e993204f61">22,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzItNC0xLTEtMzQzMg_245ad335-0159-4322-97e3-8f072f278941">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzItNi0xLTEtMzQzNg_88b024e2-e8e7-441a-a883-ddf6c7a9dfbe">1,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8ef5371ae064ef6b77eead6de300e3f_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzUtMi0xLTEtMzQzOQ_85c55444-3009-48cf-bef6-cbfbfac1be19">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b72e30920c84ae2a3d1e0e9a36c0610_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzYtNC0xLTEtMzQ0Mg_9add617e-91d1-4869-94e3-3e57e7acc4ae">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa717f16dfa641f381206fe8143aa927_D20180101-20181231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzktNi0xLTEtMzQ1NQ_bf9c551b-1d52-411c-ba93-b67f8a7ed9a7">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa717f16dfa641f381206fe8143aa927_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzEwLTYtMS0xLTM0NTU_1546449b-f638-4166-91d4-f87ae3da736a">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ic2881d7109e44c8e830400be6c4cd93b" continuedAt="if1f8af3debd845ce9043e6d838e91a6c">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if1f8af3debd845ce9043e6d838e91a6c">&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2020, we expected to reclassify $<ix:nonFraction unitRef="usd" contextRef="iea320fbc2a944611a7e2a4627a50e4a8_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzczNDU_8b17d18f-2f1b-4d36-8861-01b436203a2f">136</ix:nonFraction> million of net losses on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3ba766bf3df44b4c8b8826c34ebdf2f8" continuedAt="i23414c5b42244a5e952574a203952c6b"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2020, 2019 and 2018, the total notional amounts of these foreign currency forward contracts were $<ix:nonFraction unitRef="usd" contextRef="i88cfe8096cf349ad9c97224ff1238178_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzc4OTY_b0c51cac-5789-42a2-a9d4-36477b3a5efb">1.0</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i182cce935cf94552ba35327c4614152f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzc5MDA_061414dd-ebf7-43e2-83de-e1491968a3a7">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie4e8455f1edd4114b88fb3f5d1776535_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzc5MDc_341ca9bb-b1e3-445c-ae56-86d1e0846bd0">737</ix:nonFraction> million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2020, 2019 and 2018. </span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1ODQ_79873b91-802c-42d1-8d33-87af1e887f41" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7516b524eadf4fe7bb058ffbd7cea637_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzMtNC0xLTEtMA_04c7ff1b-e71d-488e-b588-526d00ab4f3b">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f64a6e311384121b9c8e278f3e7e78e_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzMtOC0xLTEtMA_7c1013b0-35e0-4dc2-86b3-9377859ebbf1">237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e546c55c6f64762bd48841a65da24d0_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzQtNC0xLTEtMA_da0b6a09-cca9-43ac-8dfa-9eae81e5ac3c">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148fcee1a48b44a09d68649c316ae387_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzQtOC0xLTEtMA_e1cdb7fa-524e-4029-9ead-95ef74e6f60c">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ee7f80e77b4cf38ef1e80f188af7ac_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzUtNC0xLTEtMA_f38d0e98-bc20-49fe-9607-af976ef6eb1d">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b25825f647249218c055b6f57195f14_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzUtOC0xLTEtMA_bc645742-3d2b-430a-9312-9fe7b5b14bcb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f76be3dfb864f1bba5b05a191f9d797_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzYtNC0xLTEtMA_17bd00e1-2fb0-43b2-8356-95807c63db39">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f76be3dfb864f1bba5b05a191f9d797_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzYtOC0xLTEtMA_5cf50790-f98d-4414-b99d-c820ee5cbe32">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25b66b469d4c179aa132a6977ec4a5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzgtNC0xLTEtMA_90e2ecc4-d8f3-49f7-a72f-5ab407990e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f104f0b1c7a4beb8c5cab4258107bee_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzgtOC0xLTEtMA_6f367a0c-32c6-49e8-b0d0-523faa32d032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5405ba26a454429daeaeb5a6346566fb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzktNC0xLTEtMA_365e4833-3310-4706-99b4-ffbe99a33404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5405ba26a454429daeaeb5a6346566fb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzktOC0xLTEtMA_bab232ad-8505-4017-b951-f103fba473d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzEwLTQtMS0xLTA_9ff7ce46-27b6-46cb-8a7d-a76a729e8363">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzEwLTgtMS0xLTA_6638d09f-861c-4728-8655-e3f370fcb644">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcadd8bcd0564f47a4fcfdd5ac5f886a_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE1LTQtMS0xLTA_7eff8c67-9f7a-46f4-8489-6f3285afe5de">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1df008b78a4d38ace56a2668c9f0bd_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE1LTgtMS0xLTA_79cecba2-f1a3-426e-a131-7ff8991163d1">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7dde35b44684174afdf5dbfa0f9fd26_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE2LTQtMS0xLTA_2db85b42-9f3c-4ef4-b6bf-5b0eb8aabd27">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f16286ba82544188ba31ea248441fb8_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE2LTgtMS0xLTA_99a408aa-5a29-43fe-aaec-e250b73acb01">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27613a286f447649231bc7761e21a43_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE3LTQtMS0xLTA_712c181f-a11b-428b-8d17-3d45c9eace44">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9926a2533e5347f6998a569828670148_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE3LTgtMS0xLTA_ef1ce455-fe0d-4b98-a164-cc7713f49754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e358512984891ac64732ce456bf70_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE4LTQtMS0xLTA_077acb9b-efbf-4934-9b28-f77e45c72221">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824e358512984891ac64732ce456bf70_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE4LTgtMS0xLTA_2d004d36-8b8d-4766-869c-72853a2174a2">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7232598b5dd4cbf8628dca2b745de71_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIwLTQtMS0xLTA_c5a52c8f-813b-47e4-9468-689e61045b53">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadbc19c30e2d4747861f30ae61174fb5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIwLTgtMS0xLTA_eaa05fbd-7232-4853-a22e-62ede58996e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3a8d84d7a143f08a25619be5bb364b_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIxLTQtMS0xLTA_0d965fd3-3e81-41e2-b7a8-564ed5c5b08f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3a8d84d7a143f08a25619be5bb364b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIxLTgtMS0xLTA_cb5b9117-efb5-4470-a767-cbe867ea3b13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIyLTQtMS0xLTA_0256da1c-02b6-4272-9226-e91ee656cf0f">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIyLTgtMS0xLTA_c16439d9-cbc1-493c-a3de-5cddf03aff62">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i23414c5b42244a5e952574a203952c6b" continuedAt="if8e5752f23d04739b0cf5d1f1c0a7c9d">Our derivative contracts that were in liability positions as of December 31, 2020, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our, or the surviving entity&#8217;s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if8e5752f23d04739b0cf5d1f1c0a7c9d">The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</ix:continuation> </span></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_271"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzYzNzAw_0eaadfd2-c61c-49f6-9a2c-be7c6f77cee0" continuedAt="i50adb3ce44044059bdfead0e1729d5f2" escape="true">Contingencies and commitments </ix:nonNumeric></span></div><ix:continuation id="i50adb3ce44044059bdfead0e1729d5f2" continuedAt="i50456bd194004b298e945c3c6465aef9"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i50456bd194004b298e945c3c6465aef9" continuedAt="i6d1fb407e21d4223b42b4e638f2f4e26"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated New Drug Application (ANDA) Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 2016 and April 2018, Onyx Therapeutics, Inc. (Onyx Therapeutics, a wholly-owned subsidiary of Amgen), filed separate lawsuits in the U.S. District Court for the District of Delaware (the Delaware District Court) against: (1) Cipla Limited and Cipla USA, Inc. (collectively, Cipla); (2) Sagent Pharmaceuticals, Inc. (Sagent); (3) Breckenridge Pharmaceutical, Inc. (Breckenridge); and (4) Fresenius Kabi, USA LLC, Fresenius Kabi USA, Inc., Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited; (5) Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.; (6) MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN); (7) Dr. Reddy&#8217;s Laboratories, Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL); (8) Qilu Pharma, Inc. and Qilu Pharmaceutical Co. Ltd. (collectively, Qilu); (9) Apotex Inc. and Apotex Corp. (Apotex); (10) InnoPharma, Inc. (InnoPharma); and (11) Aurobindo Pharma USA, Inc., each for infringement of <ix:nonFraction unitRef="patent" contextRef="i0bfce81b8b324711af659a7858516c9b_D20161001-20180430" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA2NjE_1ca2e2f9-851f-4e4c-9cf4-fd5c7b2bf7d8">one</ix:nonFraction> or more of our following patents, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) for KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: U.S. Patent Nos. 7,232,818 (the &#8217;818 Patent), 7,417,042 (the &#8217;042 Patent), 7,491,704 (the &#8217;704 Patent), 7,737,112 (the &#8217;112 Patent), 8,129,346 (the &#8217;346 Patent), 8,207,125 (the &#8217;125 Patent), 8,207,126 (the &#8217;126 Patent), 8,207,127 (the &#8217;127 Patent) and 8,207,297 (the &#8217;297 Patent). Each of these lawsuits was based on each defendant&#8217;s submission of an ANDA seeking U.S. Food and Drug Administration (FDA) approval to market a generic version of KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In each lawsuit, Onyx Therapeutics sought an order of the Delaware District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents. The Delaware District Court consolidated these lawsuits for purposes of discovery into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, by stipulation with Onyx Therapeutics, Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited were dismissed from the lawsuit, leaving Fresenius Kabi, USA LLC and Fresenius Kabi USA, Inc. (collectively, Fresenius) as the remaining Fresenius defendants. In September 2017 and February 2018, respectively, by joint stipulation with Onyx Therapeutics, Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. were each dismissed from the lawsuit, and in February 2018, Qilu was dismissed from the lawsuit by joint stipulation between Onyx Therapeutics and Qilu. Between April and July of 2018, the Delaware District Court entered orders on stipulations between Onyx Therapeutics and each of Apotex, DRL, Sagent, Fresenius, Breckenridge, Aurobindo Pharma USA, Inc., Cipla and InnoPharma, respectively, that each defendant infringes the &#8217;042, &#8217;112, &#8217;125, &#8217;126 and &#8217;127 Patents. Onyx Therapeutics provided those defendants, either through a stipulated order or other agreement, a covenant that it would not assert patent infringement of the &#8217;818,&#8217;704,&#8217;346 and &#8217;297 Patents against certain of the respective defendants&#8217; ANDA applications and products. In June 2018, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and MSN that MSN infringes the &#8217;112 Patent. In December 2018, Apotex, DRL, Fresenius, InnoPharma, Sagent, Breckenridge, Aurobindo Pharma USA, Inc. and Cipla amended their responses to the complaints to add the defense of unclean hands and to seek declarations of unenforceability of the asserted patents based on allegations of inequitable conduct. In January 2019, MSN amended its responses to the complaints to add the defense of unclean hands.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2019, Onyx Therapeutics filed a separate lawsuit in the Delaware District Court against Breckenridge for infringement of the &#8217;042, &#8217;112 and &#8217;125 Patents in connection with its ANDA that seeks approval to market generic versions of KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On March 4, 2019, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and Breckenridge, providing that Breckenridge infringes the asserted claims of the &#8217;042, &#8217;112 and &#8217;125 Patents, and consolidated this lawsuit against Breckenridge into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for all purposes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2019, the Delaware District Court commenced trial in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. consolidated case. During trial, the Delaware District Court signed consent judgments filed by Onyx Therapeutics and each of Aurobindo Pharma USA, Inc., InnoPharma, Sagent, Apotex, Fresenius, DRL and Breckenridge, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties&#8217; claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the &#8217;042, &#8217;112 and &#8217;125 Patents by the manufacture, use, sale, offer to sell or importation into the United States of the applicable defendant&#8217;s carfilzomib product unless specifically authorized pursuant to the applicable confidential settlement agreement. During trial, the Delaware District Court also entered a consent judgment between Onyx Therapeutics and MSN, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties&#8217; claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the &#8217;112 Patent by the manufacture, use, sale, offer to sell or importation into the United States of MSN&#8217;s carfilzomib product unless specifically authorized pursuant to the confidential settlement agreement. On May 16, 2019, trial concluded between Onyx Therapeutics and the lone remaining defendant, Cipla. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6d1fb407e21d4223b42b4e638f2f4e26" continuedAt="i740d9916d9cd41e8983aeee5202e05ad"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020, consistent with its May 4, 2020 decision and order, the Delaware District Court entered final judgment in favor of Onyx Therapeutics and against Cipla on infringement, validity and enforceability of claims 23 and 24 of the &#8217;042 Patent, claim 1 of the &#8217;125 Patent and claim 31 of the &#8217;112 Patent. The Delaware District Court entered judgment in favor of Cipla and against Onyx Therapeutics on Cipla&#8217;s counterclaim for invalidity of claim 32 of the &#8217;112 Patent and ordered that the effective date of any final approval by the FDA of Cipla&#8217;s ANDA must be after expiration of the <ix:nonFraction unitRef="patent" contextRef="i809cbf0f95194f08903685ccb680427e_D20200508-20200508" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfAssertedPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA2NzA_4501b17e-76cb-4077-9da0-a3e71d96d1f6">three</ix:nonFraction> asserted patents (the &#8217;042, &#8217;125 and &#8217;112 Patents) and any regulatory exclusivity to which Onyx Therapeutics may become entitled. The final judgment includes an injunction prohibiting Cipla from making, using, offering to sell, selling or importing into the United States Cipla&#8217;s carfilzomib product during the term of the <ix:nonFraction unitRef="patent" contextRef="i809cbf0f95194f08903685ccb680427e_D20200508-20200508" decimals="INF" format="ixt-sec:numwordsen" name="amgn:NumberOfAssertedPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA2ODE_ca53ec2c-24aa-445b-abb3-31e6b7c37720">three</ix:nonFraction> asserted patents. On May 29, 2020, Cipla filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). The Federal Circuit Court has set the hearing date on Cipla&#8217;s appeal for March 5, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2018, Celgene filed <ix:nonFraction unitRef="lawsuit" contextRef="i3adccb2cee77458681e77740f4995ece_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MDM_7b2ea974-5685-47a0-a727-e1f8ac1f327a">19</ix:nonFraction> separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC; Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited; Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc.; Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc., each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#8217;940 Patent), 7,208,516 (the &#8217;516 Patent), 7,427,638 (the &#8217;638 Patent), 7,659,302 (the &#8217;302 Patent), 7,893,101 (the &#8217;101 Patent), 8,455,536 (the &#8217;536 Patent), 8,802,717 (the &#8217;717 Patent), 9,018,243 (the &#8217;243 Patent) and 9,872,854 (the &#8217;854 Patent), which are listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of the defendants is seeking to market a generic version of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before expiration of the asserted patents. The New Jersey District Court consolidated these <ix:nonFraction unitRef="lawsuit" contextRef="i3adccb2cee77458681e77740f4995ece_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MDc_fdb4e76d-6922-49e4-8498-1a4292dae07d">19</ix:nonFraction> lawsuits for discovery and case management purposes into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz Inc., Actavis, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 9,724,330 (the &#8217;330 Patent), which is listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN Laboratories Private Limited, Pharmascience, Prinston, Sandoz Inc., Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 10,092,541 (the &#8217;541 Patent), which is listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN Laboratories Private Limited and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#8217;940, &#8217;302, &#8217;536, &#8217;243 and &#8217;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus Pharmaceuticals (USA) Inc. in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#8217;283 Patent) and 8,629,173 (the &#8217;173 Patent), which are not listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz Inc., Shilpa, Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Amgen&#8217;s acquisition of the patents-in-suit and the new drug application for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i740d9916d9cd41e8983aeee5202e05ad" continuedAt="i7ddb9bee65d04799bdf1f7c6e635ded7"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;854 and &#8217;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz Inc. with respect to the &#8217;717, &#8217;516 and &#8217;854 Patents, leaving the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents asserted by Amgen against Sandoz Inc. in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#8217;s apremilast product during the term of the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#8217; apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal Pharmaceuticals LLC, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal Pharmaceuticals LLC&#8217;s apremilast product during the term of the &#8217;101, &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#8217;s apremilast product during the term of the &#8217;638, &#8217;101 and &#8217;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#8217; apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;536, &#8217;717, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial in the consolidated action against the remaining defendants is scheduled to commence on June 14, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(cinacalcet) ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2016, Amgen filed <ix:nonFraction unitRef="lawsuit" contextRef="icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MTE_0985cb67-8b25-43ab-9202-10b101e3f6e4">14</ix:nonFraction> separate lawsuits in the Delaware District Court for infringement of our U.S. Patent No. 9,375,405 (the &#8217;405 Patent) against a number of manufacturers of purported generic versions of our Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. In February 2017, the Delaware District Court consolidated these <ix:nonFraction unitRef="lawsuit" contextRef="icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930" decimals="INF" name="amgn:GainContingencyNumberOfLawsuitsConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MTU_11072fa2-a741-47eb-9369-b7efbfbd4e01">14</ix:nonFraction> lawsuits into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2017, Amgen filed an additional lawsuit in the Delaware District Court for infringement of the &#8217;405 Patent which was consolidated into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. in August 2017. The &#8217;405 Patent is entitled &#8220;Rapid Dissolution Formulation of a Calcium Receptor-Active Compound&#8221; and expires in 2026. All defendants responding to the complaint denied infringement and sought judgment that the &#8217;405 Patent is invalid and/or not infringed.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between September and November of 2017, Amgen filed, and the Delaware District Court signed, stipulated dismissals of the lawsuit against Micro Labs Ltd. and Micro Labs USA, Inc., and the lawsuit against Apotex, as well as consent judgments filed by Amgen and each of (1) Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, Sun); (2) Ajanta Pharma Limited and Ajanta Pharma USA, Inc.; (3) Hetero USA Inc., Hetero Labs Ltd. and Hetero Labs Ltd. Unit V; and (4) Breckenridge. Each consent judgment stipulated to an entry of judgment of infringement and validity of the &#8217;405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the respective defendant&#8217;s cinacalcet product during the term of the &#8217;405 Patent, unless specifically authorized pursuant to the confidential settlement agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ddb9bee65d04799bdf1f7c6e635ded7" continuedAt="i599a39c4fd004806919c182e4ad959d1"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Delaware District Court commenced trial on the infringement claims and defenses in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated lawsuit against the defendants that remained in the lawsuit, collectively consisting of (1) Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson); (2) Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); (3) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus); and (4) Piramal Healthcare UK Limited (Piramal). Just prior to trial, the Delaware District Court signed consent judgments filed by Amgen and each of Cipla, and Strides Pharma Global Pte Limited and Strides Pharma, Inc. (collectively, Strides), and a consent judgment filed by Amgen and Aurobindo. In each consent judgment, the parties stipulated to an entry of judgment of infringement and validity of the &#8217;405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the applicable defendant&#8217;s cinacalcet product during the term of the &#8217;405 Patent, unless specifically authorized pursuant to the applicable confidential settlement agreement. Just prior to trial, the Delaware District Court also entered orders dismissing each of DRL and Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan), on stipulations between Amgen and such parties, respectively, subject to the terms of confidential settlement agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Delaware District Court issued a trial order finding on the infringement claims and defenses in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated lawsuit that Zydus infringes the &#8217;405 Patent and that Amneal, Piramal and Watson do not infringe the &#8217;405 Patent. In August 2018, the Delaware District Court issued an order dismissing, without prejudice, the invalidity counterclaims of Amneal, Piramal and Watson and entered judgment of noninfringement of the &#8217;405 Patent in favor of Amneal, Piramal and Watson. In September 2018, Amgen filed a notice of appeal to the Federal Circuit Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Delaware District Court dismissed, without prejudice, the invalidity counterclaims of Zydus and entered judgment of infringement of the &#8217;405 Patent by Zydus in favor of Amgen, including an order that the effective date of the FDA approval of Zydus&#8217; generic version of Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be no earlier than the expiry date of our &#8217;405 Patent. Also in October 2018, Zydus filed a notice of appeal to the Federal Circuit Court, and the Federal Circuit Court consolidated the appeals of Zydus and Amgen.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the FDA approved Watson&#8217;s generic version of Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Watson&#8217;s parent company, Teva Pharmaceutical Industries Ltd. (Teva), began selling its product at-risk notwithstanding that the appeals were pending at the Federal Circuit Court. On January 2, 2019, Amgen, Watson and Teva entered into a settlement agreement in which Teva agreed to stop selling its generic product until the mid-year 2021 (or earlier under certain circumstances) and to pay Amgen an undisclosed amount. On January 9, 2019, Watson and Amgen filed a motion asking the Delaware District Court to vacate its final judgment of noninfringement as to Watson and to enter a proposed consent judgment of infringement and validity of the &#8217;405 Patent and an injunction prohibiting the making, having made, using, selling, offering to sell, or distributing Watson&#8217;s cinacalcet product in the United States or importing Watson&#8217;s cinacalcet product into the United States, consistent with the confidential settlement agreement. On January 11, 2019, the Federal Circuit Court stayed the pending appeal by Amgen of the judgment of noninfringement as to Watson in order for the Delaware District Court to rule on the motion of Watson and Amgen. On March 26, 2019, the Delaware District Court denied the joint motion for indicative ruling of Watson and Amgen. On April 10, 2019, Amgen filed an appeal to the Federal Circuit Court and the Federal Circuit Court lifted the stay of Amgen&#8217;s appeal of the judgment of noninfringement as to Watson and consolidated it with Amgen&#8217;s appeal of the Delaware District Court&#8217;s denial of the joint motion for indicative ruling. On September 13, 2019, the Federal Circuit Court denied Amgen&#8217;s motion and lifted the stay of the briefing schedule which had been stayed pending disposition of Amgen&#8217;s motion to vacate. On July 9, 2020, the Federal Circuit Court granted a motion filed by Amgen and Watson to dismiss Amgen&#8217;s appeals of the Delaware District Court&#8217;s judgment of noninfringement as to Watson and denial of the joint motion for indicative ruling.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2019, Amgen filed an emergency motion for an injunction pending appeal, seeking an order from the Delaware District Court enjoining defendant Piramal from making, using, selling, offering for sale or importing its generic cinacalcet product. Amgen&#8217;s motion follows an announcement that Slate Run Pharmaceuticals LLC (Slate Run), in partnership with Piramal, had begun selling Piramal&#8217;s generic cinacalcet product at-risk notwithstanding the appeals pending at the Federal Circuit Court. On April 15, 2019, the Delaware District Court signed an order enjoining Piramal and Slate Run from selling their generic cinacalcet product until certain events occur related to a decision by the Federal Circuit Court on the parties&#8217; appeal. The order has no effect on the product that Piramal and Slate Run had already sold to third parties. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2020, the Federal Circuit Court issued an opinion affirming the judgment of noninfringement with respect to Piramal, affirming the judgment of infringement with respect to Zydus and vacating and remanding to the Delaware District Court for further consideration the judgment of noninfringement with respect to Amneal. On April 22, 2020, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court. On September 8, 2020, the Delaware District Court entered judgment of validity and infringement of the &#8217;405 Patent in the lawsuit filed against Amneal and, except to the extent specifically authorized in a confidential settlement agreement, enjoined Amneal from infringing the &#8217;405 Patent by making, using, selling, offering to sell or importing Amneal&#8217;s cinacalcet product during the term of the patent. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i599a39c4fd004806919c182e4ad959d1" continuedAt="i194f055ab48b4ef59168504f7ec9b67c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A hearing before the Delaware District Court on the request of Piramal to recover damages for being enjoined during the pendency of Amgen&#8217;s appeal has been rescheduled for March 24, 2021. On October 14, 2020, the Delaware District Court issued an order permitting Slate Run, Piramal&#8217;s business partner, to intervene in the pending action. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunex Corporation, et al. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, <ix:nonFraction unitRef="affiliate" contextRef="ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228" decimals="INF" format="ixt-sec:numwordsen" name="amgn:GainContingencyNumberofAffiliates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MTg_d2c45417-bb81-48e5-be7e-40fc537b0f3c">two</ix:nonFraction> affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (collectively, Sandoz). This lawsuit stems from Sandoz&#8217;s submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#8217;s ENBREL. Amgen and Roche have asserted infringement of <ix:nonFraction unitRef="patent" contextRef="ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Mjc_08a1d007-671d-4e56-94c1-28cbb9b2e6ba">five</ix:nonFraction> patents: U.S. Patent Nos. 8,063,182 (the &#8217;182 Patent), 8,163,522 (the &#8217;522 Patent), 7,915,225 (the &#8217;225 Patent), 8,119,605 (the &#8217;605 Patent) and 8,722,631 (the &#8217;631 Patent). By their complaint, Amgen and Roche seek an injunction to prohibit Sandoz from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. All Sandoz defendants responded by denying infringement and/or asserting that the patents at issue are invalid. In August 2016, and subject to the terms of a confidential stipulation, the New Jersey District Court entered a preliminary injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz&#8217;s etanercept product. Sandoz&#8217;s Erelzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to ENBREL, was approved by the FDA in August 2016.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the New Jersey District Court entered an order that the making, using, offering to sell or selling in the United States or the importation into the United States by Sandoz of Sandoz&#8217;s biosimilar etanercept product infringes the &#8217;182 and &#8217;522 Patents and held a bench trial, focusing on Sandoz&#8217;s challenges to the validity of these patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2019, the New Jersey District Court issued its decision upholding the validity of the &#8217;182 and &#8217;522 Patents. On October 8, 2019, by stipulation of Amgen and Sandoz, the New Jersey District Court entered final judgment and a permanent injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz&#8217;s etanercept product, and, on the same day, Sandoz appealed the final judgment to the Federal Circuit Court. Following a motion by Sandoz, the Federal Circuit Court ordered an expedited briefing schedule for the appeal.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2020, the Federal Circuit Court heard oral argument on the appeal. On July 1, 2020, the Federal Circuit Court affirmed the judgment of the New Jersey District Court upholding the validity of the &#8217;182 and &#8217;522 Patents. On September 29, 2020, the Federal Circuit Court denied the petition for rehearing of Sandoz filed on July 31, 2020. On January 29, 2021, Sandoz filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s affirmance of the validity of the &#8217;182 and &#8217;522 Patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2019, <ix:nonFraction unitRef="affiliate" contextRef="ifc0906f0e464443487073d2cfd195558_D20190401-20190430" decimals="INF" format="ixt-sec:numwordsen" name="amgn:GainContingencyNumberofAffiliates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Mzc_6a417990-3198-47f6-a12b-616c23e7699c">two</ix:nonFraction> affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Roche, filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis&#8217; submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#8217;s ENBREL. Amgen and Roche have asserted infringement of five patents: the &#8217;182, &#8217;522, &#8217;225, &#8217;605 and &#8217;631 Patents. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis&#8217; etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court&#8217;s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i194f055ab48b4ef59168504f7ec9b67c" continuedAt="i0d51f00568544f03a397f2a6f6936174"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Amgen initiated a series of lawsuits that were consolidated by the Delaware District Court in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing <ix:nonFraction unitRef="patent" contextRef="ia0e8f31ce26e4873a861d070ec4bab78_D20141001-20141031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3NDY_6d35106d-85eb-4564-8adb-a1461bc09567">seven</ix:nonFraction> of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#8217;165 Patent); 8,859,741 (the &#8217;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#8217;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#8217;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#8217;s infringement of Amgen&#8217;s patents is willful.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringe certain of Amgen&#8217;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a <ix:nonNumeric contextRef="i0c1117b8cfa8440a9fe7743afd265be3_D20160201-20160228" format="ixt-sec:durwordsen" name="amgn:LitigationSettlementLengthofTrial" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4Nzc_04c63e19-a648-4880-a260-73c48f5a8326">five-day</ix:nonNumeric> jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#8217;s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#8217;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#8217;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on <ix:nonFraction unitRef="patent" contextRef="i9fad48569ed547d6bda68c928f79c3aa_D20180301-20180331" decimals="INF" format="ixt-sec:numwordsen" name="amgn:GainContingencyNumberOfChallenges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Njg_3811a437-25dc-45fa-89ee-29fc2ff42ce6">two</ix:nonFraction> of Sanofi and Regeneron&#8217;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s conclusion that the judgment affirming the validity of Amgen&#8217;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#8217;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#8217;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#8217;s claim of willful infringement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, a jury of the Delaware District Court unanimously upheld the validity of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. The jury also found that claims 7 and 15 of the &#8217;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse judgment as a matter of law or for a new trial with respect to claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent, and Amgen filed a motion for a permanent injunction. On June 6, 13 and 21, 2019, the Delaware District Court held evidentiary hearings on Amgen&#8217;s motion for a permanent injunction against PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron&#8217;s request for a new trial and their request to reverse the jury verdict that the &#8217;165 Patent and the &#8217;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court. On December 9, 2020, the Federal Circuit Court heard oral argument on the appeal.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in the United Kingdom, Germany, France, the Netherlands, Italy, Spain and Japan. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0d51f00568544f03a397f2a6f6936174" continuedAt="i016825b5c31c41468a08464ac942ff1b"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#8217;s patent, and each of Eli Lilly and Company, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#8217;s patent. In November 2018, the EPO confirmed the validity of Amgen&#8217;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but ruled that broader claims encompassing PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were invalid. As a result of the TBA&#8217;s decision, national litigations regarding PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe are in the process of being resolved. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#8217;s appeals making final the Japanese High Court&#8217;s decisions that PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes Amgen&#8217;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#8217;s Japanese patents that were previously held infringed by PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and valid over challenges filed by Sanofi K.K. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (filgrastim)/Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Pfizer Inc. et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Pfizer Inc. and Hospira Inc. (collectively, Pfizer). This lawsuit stems from Pfizer&#8217;s submission of an application for FDA licensure of a filgrastim product as biosimilar to Amgen&#8217;s NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen has asserted infringement of U.S. Patent No. 9,643,997 (the &#8217;997 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#8217;997 Patent. In July 2018, the FDA approved Pfizer&#8217;s NIVESTYM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was subsequently launched in October 2018. In August 2018, Pfizer answered the complaint and counterclaimed seeking a declaration that Pfizer does not infringe Amgen&#8217;s &#8217;997 Patent and that the patent is invalid. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, Amgen filed an amended complaint against Pfizer in the Delaware District Court narrowing the patent claims at issue in the infringement dispute and adding a request for damages. On April 11, 2019, Pfizer answered Amgen&#8217;s amended complaint including counterclaims seeking declaratory judgments of noninfringement and invalidity. On February 18, 2020, the Delaware District Court entered an amended scheduling order moving the trial on the infringement of our &#8217;997 Patent to May 17, 2021, to enable Amgen to seek additional discovery into Pfizer&#8217;s invalidity defenses. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, Amgen filed a separate lawsuit in the Delaware District Court against Pfizer for infringement of U.S. Patent No. 10,577,392 (the &#8217;392 Patent) and seeks, among other remedies, damages and injunctive relief to prohibit Pfizer from infringing the &#8217;392 Patent by the manufacture, import and sale of Pfizer&#8217;s NIVESTYM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On January 7, 2021, the Delaware District Court granted Pfizer&#8217;s request to stay the patent infringement lawsuit on the &#8217;392 Patent until the co-pending patent infringement lawsuit on the &#8217;997 Patent is resolved.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Hospira Inc. et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Pfizer. This lawsuit stems from Pfizer&#8217;s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen&#8217;s Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the &#8217;707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#8217;707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the &#8217;707 Patent. In June 2020, the FDA approved Pfizer&#8217;s NYVEPRIA&#8482;, a biosimilar to Amgen&#8217;s Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Trial and Appeal Board (PTAB) Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lupin PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, Lupin Limited (Lupin) filed a petition to institute inter parties review (IPR) proceeding at the U.S. Patent and Trademark Office (USPTO) of U.S. Patent No. 9,856,287 (the &#8217;287 Patent) challenging claims of the &#8217;287 Patent as unpatentable. Amgen&#8217; s preliminary response is due on April 14, 2021 and the PTAB will then have no more than three months to decide whether to institute a proceeding.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i016825b5c31c41468a08464ac942ff1b" continuedAt="i8d270d682f18412c9b1c152582b2919f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Apotex PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the PTAB of the USPTO granted Apotex&#8217;s petition to institute IPR proceeding of U.S. Patent No. 8,952,138 (the &#8217;138 Patent), challenging claims of the &#8217;138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but <ix:nonFraction unitRef="claim" contextRef="i4ae1970a90b64a67af70b4ac4a36cab8_I20190520" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Nzc_1f1d8129-8312-4a56-a23e-4c66e925af7d">one</ix:nonFraction> claim of the &#8217;138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2019, the PTAB issued a decision denying Apotex&#8217;s request for rehearing on the PTAB&#8217;s finding and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">sua sponte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amending the final decision with a finding that the <ix:nonFraction unitRef="claim" contextRef="i4ae1970a90b64a67af70b4ac4a36cab8_I20190520" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3ODY_01c40759-6555-4ab2-b839-a40a32818315">one</ix:nonFraction> remaining claim in Amgen&#8217;s &#8217;138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court&#8217;s decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc. v. Smith &amp; Nephew, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., 941 F.3d 1320 (Fed. Cir. 2019). </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the &#8217;138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the &#8217;138 Patent, for proceedings consistent with its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex Inc. v. Smith &amp; Nephew, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 941 F.3d 1320 (Fed. Cir. 2019), requesting that such remanded cases be held pending the U.S. Supreme Court&#8217;s disposition of the petition for writ of certiorari in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Arthrex, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government&#8217;s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breach of Contract Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG v. Amgen Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis Pharma AG (Novartis) seeking a declaratory judgment that Novartis materially breached <ix:nonFraction unitRef="agreement" contextRef="i80dd2b5d6a6741578cd8c92ca187c67d_D20190401-20190430" decimals="INF" format="ixt-sec:numwordsen" name="amgn:GainContingencyNumberOfAgreementsBreached" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3OTU_da3e6954-e56e-4f2a-9ce6-b0cbbf9037e6">two</ix:nonFraction> collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to Novartis&#8217; affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and entrant in the calcitonin gene-related peptide (CGRP)-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis&#8217; complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis&#8217; first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Amgen&#8217;s second amended counterclaims. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, the New York Southern District Court entered an order granting Novartis&#8217; motion for judgment on the pleadings that Novartis did not breach the 2017 Agreement, and denying Amgen&#8217;s motions for judgment on the pleadings seeking dismissal of Novartis&#8217; amended complaint that Novartis did not breach the 2015 Agreement or the 2017 Agreement, and Novartis timely cured any breach. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the June 9, 2020 order, which was denied on September 14, 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8d270d682f18412c9b1c152582b2919f" continuedAt="i13fa83b90edc4f51963507df6c506f0d"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.46pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Class Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From February to April 2019, <ix:nonFraction unitRef="plaintiffs" contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MDQ_4b8da9a9-6c10-445d-b83c-221cc32c0b98">four</ix:nonFraction> plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. <ix:nonFraction unitRef="claim" contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MTQ_be183ce9-7569-4c2a-bdd9-fdbcd6109897">Two</ix:nonFraction> of those actions were brought in the Delaware District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 21, 2019) (Local 1500) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cesar Castillo, Inc. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and alleges that the plaintiffs have overpaid for Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of Amgen&#8217;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson and Teva of the parties&#8217; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#8217; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the <ix:nonFraction unitRef="lawsuit" contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430" decimals="INF" format="ixt-sec:numwordsen" name="amgn:LossContingencyNumberOfLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MjQ_ebce46ac-b927-420e-b5a3-959f13f20a5d">four</ix:nonFraction> lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the <ix:nonFraction unitRef="lawsuit" contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430" decimals="INF" format="ixt-sec:numwordsen" name="amgn:LossContingencyNumberOfLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MzQ_c7091d83-6eb0-48f2-99d2-d91f3112bb75">four</ix:nonFraction> lawsuits, along with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla Ltd. v. Amgen Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated and designated as a MDL in the Delaware District Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#8217; consolidated class action complaint and the indirect purchaser end payor plaintiffs&#8217; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#8217;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Delaware District Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#8217;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#8217; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#8217;s recommendation in part and denied it in part, denying Amgen&#8217;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#8217;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#8217; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#8217;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Biosimilar Antitrust Class Actions </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March to May 2019, <ix:nonFraction unitRef="claim" contextRef="ia4745ee7d51c48f38ab56aea1953d9eb_I20200531" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4NDQ_3320d680-a887-4ec3-a858-6538407ebf07">twelve</ix:nonFraction> purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). The cases are captioned: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 18, 2019) (Local 1500); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 20, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mayor and City Council of Baltimore v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 22, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pipe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trades Services MN Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">St. Paul Electrical Workers&#8217; Health Plan v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C and 137R v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 1, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 9, 2019) (Law Enforcement); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 16, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sheet Metal Workers&#8217; Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 19, 2019) (Sheet Metal Workers&#8217;); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Locals 302 &amp; 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 25, 2019) (Construction Industry); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Louisiana Health Service &amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 30, 2019) (Louisiana Health); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (May 10, 2019) (Cleveland Bakers) (collectively, Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions).</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i13fa83b90edc4f51963507df6c506f0d"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and biosimilars of Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including by creating an allegedly unlawful so-called patent thicket around Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the Local 1500, Sheet Metal Workers&#8217; and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilars, including Bioepis, Mylan, Sandoz, Inc., Fresenius Kabi USA, LLC, Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whereby Amgen and the other defendants that have developed Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(adalimumab), its Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilar in that market for five months, beginning in January 2023. In each of the Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney&#8217;s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Defendants&#8217; responses to the first <ix:nonFraction unitRef="complaints" contextRef="i4c336ecb8a8a4d67a7a3bd87243f7b8d_D20190301-20190531" decimals="INF" format="ixt-sec:numwordsen" name="amgn:LossContingencyNumberOfComplaintsStayedByTheCourt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4NTY_3179ccca-01ba-4e38-903c-59b9cd45cc19">six</ix:nonFraction> complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the <ix:nonFraction unitRef="claim" contextRef="if453a7e1fbf04c769fde5a4f2ed3c28b_I20190604" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4NjU_013eabd5-86fc-4602-a595-bc362a4b8a3e">twelve</ix:nonFraction> purported class action cases for pre-trial purposes. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz, Inc. and Fresenius Kabi USA LLC. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs&#8217; allegations to state any claim for relief under the law. On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support of the motion to dismiss. On June 8, 2020, the Illinois Northern District Court issued an order granting the motion by the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the Federal Trade Commission and one on behalf of 20 states, each filed on October 13, 2020. On December 21, 2020, the defendants-appellees filed their opposition brief. Defendants-appellees amicus briefs, including one by the Department of Justice, were filed on December 28, 2020. The plaintiffs-appellants&#8217; reply brief was filed on February 1, 2021, and oral argument has been scheduled for February 25, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments &#8211; U.S. repatriation tax</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in <ix:nonFraction unitRef="installment" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzYzNDI5_5c40b67e-855f-4242-989d-7d128071e288">eight</ix:nonFraction> annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="amgn:ScheduleOfU.S.RepatriationTaxCommitments" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzYzNjk4_8e7193e3-246f-4399-a1d6-d2d1697bec4c" continuedAt="i6ef039e9f56a421f8bf88267687471cb" escape="true">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2020 (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i6ef039e9f56a421f8bf88267687471cb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzEtMS0xLTEtMA_2a8a1fd3-024f-49af-91fc-4dfb19f09a05">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzItMS0xLTEtMA_c75709f3-853c-49d6-ab47-7bca9496df0a">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzMtMS0xLTEtMA_6c0829ad-2c19-4aac-9527-c552fe5293c2">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzQtMS0xLTEtMA_6538e12e-50f9-4922-b4d0-f9efb1ef7181">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzUtMS0xLTEtMA_bce56fc8-d88e-4773-b3a7-a34c6c248f87">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzctMS0xLTEtMA_a1c47f9d-8a3b-40c4-80e7-adea4f9ebdcf">5,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90ZXh0cmVnaW9uOmU5YjFkODE4ZGI3NDRiNDQ5YWZmOWU5ZDlkZWI4ODU5XzUxNQ_8b00981e-fbe2-48e7-9bb8-c0c259649d79" continuedAt="id69209507660400591936276cef09a1c" escape="true">Quarterly financial data (unaudited)</ix:nonNumeric></span></div><ix:continuation id="id69209507660400591936276cef09a1c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s unaudited financial data on a quarterly basis. The sum of the quarterly earnings per-share amounts may not equal the amount reported for the full year because per-share amounts are computed independently for each quarter and for the full year based on respective weighted-average shares outstanding and dilutive securities.</span></div><ix:nonNumeric contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90ZXh0cmVnaW9uOmU5YjFkODE4ZGI3NDRiNDQ5YWZmOWU5ZDlkZWI4ODU5XzUxMQ_e390c6b4-640e-4204-ad57-e22f70c1ef09" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly financial data is summarized as follows (in millions, except per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Quarters ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61225a3c72514f859602e544d725ab0e_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItMS0xLTEtMA_6438aa53-46ed-4c35-93a0-55d13a530553">6,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf1db2cec2744fe9cf8a8abb012ff11_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItMy0xLTEtMA_12646a33-2042-447f-8eb8-cc30533ea8f9">6,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d59301d26594c2ba4ab4f364829aa82_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItNS0xLTEtMA_5075f5f6-de07-4155-9fec-4d8d12ef399e">5,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b74954f05984826a98fa8d1de70b8ad_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItNy0xLTEtMA_d36d3fda-841c-4d0b-ba44-d424dfc3fcb3">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit from product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtMS0xLTEtMA_40402f54-9d01-4bae-a588-e6b404b15c15">4,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtMy0xLTEtMA_3cfc9277-2241-4152-a86b-9c946a7d3779">4,543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtNS0xLTEtMA_989ae5e1-764b-423b-9dc5-567a9756327a">4,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtNy0xLTEtMA_97956d9c-fea3-4fe9-91e6-1e49644d4696">4,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtMS0xLTEtMA_668d08b5-458e-4db8-be15-40a8126f39c4">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtMy0xLTEtMA_1d966ab5-e4aa-4ad5-81c3-1dff76472758">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtNS0xLTEtMA_dd9584da-7822-411e-8b1d-719b8ab3842a">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtNy0xLTEtMA_d51f9793-079f-47a2-8133-068bd6f25b90">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtMS0xLTEtMA_efa7a47a-784d-43c9-83f5-626b798691d9">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtMy0xLTEtMA_02462aa5-6ba9-4e5b-83a2-b341de99d765">3.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtNS0xLTEtMA_03146820-52dc-4b1b-b908-08f160f849cf">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtNy0xLTEtMA_fcfbcbdb-bdb0-4743-b042-9c9285fba1d7">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctMS0xLTEtMA_58057737-883f-4661-b18d-3399f8435f4d">2.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctMy0xLTEtMA_85a72d08-c557-4b14-991f-e5ced98940c4">3.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctNS0xLTEtMA_96ada069-10a3-48e7-a583-c67c26d91418">3.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctNy0xLTEtMA_7c3e570a-1c95-4561-bdcb-aff4c1ec3c90">3.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 Quarters ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43febb6cb9d3444caa73da4c92560180_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTEtMS0xLTA_289674fa-413c-474f-ae4d-0caec570a6a6">5,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09079b5a58e246b5947144cbde795c44_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTMtMS0xLTA_0485b718-1983-4c64-aa10-48675248c96c">5,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4254e372a9cd437fa13067b22cd6fc34_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTUtMS0xLTA_e55b6017-657c-46c0-92ae-5302b31aafff">5,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8404b3b31ac149eca5db19a64dd46da4_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTctMS0xLTA_77458eff-05c0-4490-9d7a-311ff8ddd4b5">5,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit from product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTEtMS0xLTA_dad0e978-ad6a-46b6-894d-622f701ac14d">4,628</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTMtMS0xLTA_b53737ea-a1a9-442d-a781-cb153dc1a399">4,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTUtMS0xLTA_1de88344-eb14-40ef-b720-c0f551899451">4,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTctMS0xLTA_b4b0ff7b-b299-4548-a5d9-b45b61bdb5d9">4,231</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTEtMS0xLTA_f5b0b0a2-0820-4ca3-b716-dff57c1df4e2">1,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTMtMS0xLTA_0b61acbb-4399-4b14-a059-6f1ca360a238">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTUtMS0xLTA_b6580c5d-4982-4d5d-9369-3021126c3c33">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTctMS0xLTA_2e788e98-5a0e-4f42-8df7-68b93584fc31">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTEtMS0xLTA_501a6ed4-cbd1-4754-a74f-d89915adcc74">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTMtMS0xLTA_55a0f887-6d79-4346-9436-247db435575a">3.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTUtMS0xLTA_394551b7-bccf-4461-9444-29a1fa08b441">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTctMS0xLTA_b452044e-a61d-4cae-98c2-3b4179c34e92">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTEtMS0xLTA_d86e150b-baae-4b2c-8349-59e6aabe4473">2.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTMtMS0xLTA_d1440379-0d6d-412a-b53f-ba193fe42aa2">3.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTUtMS0xLTA_76b941ca-9d48-46b7-8024-04ee0b786f92">3.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTctMS0xLTA_739d3031-616c-4ac9-b4c5-5fc45d63f0d3">3.18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><div id="if8d0740b43d148a5ba67e4dd5b38ce46_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90ZXh0cmVnaW9uOmZkY2Y2YzQwZjc2MTRkNDI4YjEzZDFhZGI0NThhYTgzXzEwOA_723e6f73-7d40-4858-99e3-a3203f19c174" escape="true"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at beginning<br/>of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>charged&#160;to<br/>costs and<br/>expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end<br/>of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtMi0xLTEtMA_2538b951-020e-4e90-9bd4-716d964a14b8">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtNC0xLTEtMA_4211f53e-9f1d-4005-ad75-bb98dbcd6c95">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtNi0xLTEtMA_4ff29030-3d61-4a14-a69c-e114d084f114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtOC0xLTEtMA_fa9d829f-1132-4122-b934-3b8a1a0c608a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia802888bb7a6406592ff586c244944e8_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtMTAtMS0xLTA_4339edc7-98d4-4dca-abac-995903bfeb62">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItMi0xLTEtMA_ca141574-58ea-4032-bea5-33789a741969">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItNC0xLTEtMA_8979f2cf-1224-40ae-98a9-9433a6482ede">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItNi0xLTEtMA_aa47352a-c21c-46e5-9b66-271ff5544cb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItOC0xLTEtMA_7db377c7-05e3-49c3-b0e8-ad9b2d35cc57">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItMTAtMS0xLTA_32f5feb7-51e6-48b5-9290-7384bcaa7e17">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtMi0xLTEtMA_34abded9-c571-482a-9f6d-e6ca08b5b865">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtNC0xLTEtMA_3ee78cd9-0b19-42a7-b9b6-55dce513ed59">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtNi0xLTEtMA_43cf0171-0b51-4493-a658-fd38110b4459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtOC0xLTEtMA_24928c09-2386-432d-a76a-a895181b3a7d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtMTAtMS0xLTA_77d84198-f25b-484e-9a93-f185d8cf5d67">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.33
<SEQUENCE>2
<FILENAME>amgn-ex433_20201231xq4.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7e6e877dd03c4a9d9669bec4af942e74_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 4.33 </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF AMGEN INC.&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 5, 2021, Amgen Inc. has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#58; (1) our common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;)&#59; (2) our 1.250% Senior Notes due 2022 (the &#8220;2022 Notes&#8221;)&#59; and (3) our 2.000% Senior Notes due 2026 (the &#8220;2026 Notes&#8221; and, together with the 2022 Notes, the &#8220;Notes&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our capital stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our restated certificate of incorporation, as amended (&#8220;certificate of incorporation&#8221;) and our amended and restated bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K (&#8220;Annual Report&#8221;). The terms &#8220;Amgen&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer solely to Amgen Inc. and not its subsidiaries.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock includes 2,750,000,000 shares of Common Stock.  Each holder of our Common Stock is entitled to one vote per share on all matters to be voted upon by our stockholders. Upon any liquidation, dissolution or winding up of our business, the holders of our Common Stock are entitled to share equally in all assets available for distribution after payment of all liabilities, subject to the liquidation preference of shares of preferred stock, if any, then outstanding. Our Common Stock has no preemptive or conversion rights. All outstanding shares of common stock are fully paid and non-assessable. Our outstanding shares of common stock are quoted on the Nasdaq Global Select Market under the symbol &#8220;AMGN.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable to any preferred stock (if any such stock be issued and outstanding), the holders of Common Stock are entitled ratably to receive dividends, if any, declared by our board of directors out of funds legally available for the payment of dividends. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Delaware Law</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prior to such time, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;203, a &#8220;business combination&#8221; includes&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any transaction which results in the issuance or transfer by the corporation or by any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder, subject to limited exceptions&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation which has the effect, directly or indirectly, of increasing the proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the corporation or of any such subsidiary which is owned by the interested stockholder&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or any direct or indirect majority-owned subsidiary of the corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section&#160;203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our Common Stock is the American Stock Transfer&#160;&#38; Trust Company.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF THE NOTES</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our 2022 Notes and the&#160;2026 Notes is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the indenture, dated as of May&#160;22, 2014 (the &#8220;Indenture&#8221;), between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;Trustee&#8221;), which are incorporated by reference as exhibits to the Annual Report of which this Exhibit 4.33 is a part. The 2022 Notes, and the 2026 Notes are each traded on The Nasdaq Stock Market LLC under the trading symbols of &#8220;AMGN22,&#8221; and &#8220;AMGN26,&#8221; respectively. We encourage you to read the above referenced Indenture for additional information. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes&#58;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued &#8364;1,250,000,000 in aggregate principal amount of 1.250% Senior Notes, maturing February 25, 2022 and bearing interest at a rate of 1.250% per annum, payable annually on February&#160;25 of each year. As of February 5, 2021, &#8364;1,250,000,000 aggregate principal amount of the 2022 Notes was outstanding.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2026 Notes&#58;</font></div><div style="text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We issued &#8364;750,000,000 in aggregate principal amount of 2.000% Senior Notes, maturing February 25, 2026 and bearing interest at a rate of 2.000% per annum, payable annually on February&#160;25 of each year. As of February 5, 2021, &#8364;750,000,000 aggregate principal amount of the 2026 Notes was outstanding.</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;We may, without notice to or the consent of the holders or beneficial owners of the Notes of any series, create and issue additional Notes and&#47;or notes having the same ranking, interest rate, maturity and other terms as the Notes of that series. Any additional debt securities having such similar terms, together with that series of Notes, could be considered part of the same series of Notes under the Indenture&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, in the case of any notes represented by global notes, for so long as may be required by the United States Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the procedures of the common depositary, the Euroclear System (&#8220;Euroclear&#8221;) or Clearstream Banking, S.A. (&#8220;Clearstream&#8221;) (or a successor or clearing system), such additional Notes will be represented by one or more separate global notes in accordance with the terms of the Indenture and subject to applicable transfer or other restrictions. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are redeemable prior to maturity as described below under the headings &#8220;&#8212;Optional Redemption&#8221; and &#8220;&#8212;Redemption Upon Changes in Withholding Taxes.&#8221; The Notes do not have the benefit of any sinking funds. The Notes of each series are issued only in registered form without coupons attached in minimum denominations of &#8364;100,000 and any integral multiple of &#8364;1,000 in excess thereof. Each series of Notes are represented by one or more global securities deposited with, or on behalf of, a common depositary for Euroclear and Clearstream (the &#8220;global notes&#8221;).  </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Definitions </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used herein, the following terms have the meanings set forth below. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attributable Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means in connection with a sale and lease-back transaction the lesser of&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the fair market value of the assets subject to such transaction&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the present value (discounted at a rate per annum equal to the average interest borne by all outstanding debt securities issued under the Indenture (which may include debt securities in addition to the Notes) determined on a weighted average basis and compounded semi-annually) of the obligations of the lessee for rental payments during the term of the related lease.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any day on which commercial banks and foreign exchange markets are open for business in New York and London and which is a day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer System (TARGET2) is operating. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Calculation Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an independent financial institution appointed by Amgen, which may include the paying agent, any of the managers or their respective affiliates who agree to serve in such capacity. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Indebtedness represented by a lease obligation of a Person incurred with respect to real property or equipment acquired or leased by such Person and used in its business that is required to be recorded as a capital lease in accordance with GAAP. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Net Worth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, the Stockholders&#8217; Equity of us and our Consolidated Subsidiaries on that date. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination and with respect to any Person, any Subsidiary of that Person whose financial data is, in accordance with GAAP, reflected in that Person&#8217;s consolidated financial statements. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, one or more debt facilities (including, without limitation, the revolving credit agreement and the term loan credit agreement, as applicable) or commercial paper facilities, in each case, with banks or other institutional lenders providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to borrow from such lenders against such receivables) or letters of credit, in each case, as amended, restated, modified, renewed, refunded, replaced (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities to institutional investors) in whole or in part from time to time. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exempted Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the sum of the following as of the date of determination&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">our Indebtedness incurred after the first issue date of the Notes and secured by Liens not permitted by the first sentence under &#8220;&#8212;Limitation on Liens&#8221; below&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">our and our Subsidiaries&#8217; Attributable Liens in respect of sale and lease-back transactions entered into after the first issue date of the Notes pursuant to the second paragraph of &#8220;&#8212;Limitation on Sale and Lease-Back Transactions&#8221; below.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means accounting principles generally accepted in the United States set forth in the Accounting Standards Codification of the Financial Accounting Standards Board or in such other documents by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governmental Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any foreign, federal, state, county or municipal government, or political subdivision thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any governmental or quasi-governmental agency, authority, board, bureau, commission, department, instrumentality or public body&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any court or administrative tribunal&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">with respect to any Person, any arbitration tribunal or other nongovernmental authority to whose jurisdiction that Person has consented.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any specified Person, the obligations of such Person under&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">other agreements or arrangements designed to manage interest rates or interest rate risk&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">other agreements or arrangements designed to protect such Person against fluctuations in currency exchange rates or commodity prices.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of any Person means, without duplication, any indebtedness, whether or not contingent, in respect of borrowed money or evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements with respect thereto) or representing the balance deferred and unpaid of the purchase price of any Property (including pursuant to Capital Leases), except any such balance that constitutes an accrued expense or trade payable, if and to the extent any of the foregoing indebtedness would appear as a liability upon a balance sheet of such Person prepared on a consolidated basis in accordance with GAAP (but does not include contingent liabilities which appear only in a footnote to a balance sheet), and shall also include, to the extent not otherwise included, the guaranty of items which would be included within this definition. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, all foreign, federal, state and local statutes, treaties, rules, regulations, ordinances, codes and administrative or controlling precedents of any Governmental Agency. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any lien, security interest, charge or encumbrance of any kind (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any agreement to give any security interest). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Make-Whole Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the excess of (1)&#160;the net present value, on the redemption date, of the principal being redeemed or paid and the amount of interest (exclusive of interest accrued to the date of redemption) that would have been payable if such redemption had not been made, over (2)&#160;the aggregate principal amount of the Notes being redeemed or paid. Net present value shall be determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate (as defined below and as determined on the third Business Day preceding the date such notice of redemption is given) from the respective dates on which such principal and interest would have been payable if such redemption had not been made. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens securing Indebtedness under Credit Facilities&#59;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on accounts receivable, merchandise inventory, equipment, and patents, trademarks, trade names and other intangibles, securing our Indebtedness&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on any of our assets, any of our Subsidiaries&#8217; assets, or the assets of any joint venture to which we or any of our Subsidiaries is a party, created solely to secure obligations incurred to finance the refurbishment, improvement or construction of such asset, which obligations are incurred no later than 24 months after completion of such refurbishment, improvement or construction, and all renewals, extensions, refinancings, replacements or refundings of such obligations&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a) Liens given to secure the payment of the purchase price incurred in connection with the acquisition (including acquisition through merger or consolidation) of Property (including shares of stock), including Capital Lease transactions in connection with any such acquisition, and (b)&#160;Liens existing on Property at the time of acquisition thereof or at the time of acquisition by us or one of our Subsidiaries of any Person then owning such Property whether or not such existing Liens were given to secure the payment of the purchase price of the Property to which they attach&#59; provided that, with respect to clause (a), the Liens shall be given within 24 months after such acquisition and shall attach solely to the Property acquired or purchased and any improvements then or thereafter placed thereon&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens securing reimbursement obligations with respect to letters of credit that encumber documents and other Property relating to such letters of credit and the products and proceeds thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on key-man life insurance policies granted to secure our Indebtedness against the cash surrender value thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(9)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens encumbering customary initial deposits and margin deposits and other Liens in the ordinary course of business, in each case securing Hedging Obligations and forward contract, option, futures contracts, futures options or similar agreements or arrangements designed to protect us or any of our Subsidiaries from fluctuations in interest rates, currencies or the price of commodities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by us or any of our Subsidiaries in the ordinary course of business&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(11)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">pre-existing Liens on assets acquired by us or any of our Subsidiaries after the first issue date of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(12)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens in our favor or the favor of any of our Subsidiaries&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(13)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">inchoate Liens incident to construction or maintenance of real property, or Liens incident to construction or maintenance of real property, now or hereafter filed of record for sums not yet delinquent or being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made therefor&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">statutory Liens arising in the ordinary course of business with respect to obligations which are not delinquent or are being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made therefor&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of pledges or deposits to secure obligations under workers&#8217; compensation laws or similar legislation, including Liens of judgments thereunder which are not currently dischargeable&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of pledges or deposits of Property to secure performance in connection with operating leases made in the ordinary course of business to which we or any of our Subsidiaries is a party as lessee, provided the aggregate value of all such pledges and deposits in connection with any such lease does not at any time exceed 16&#160;2&#8260;3% of the annual fixed rentals payable under such lease&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of deposits of Property to secure our statutory obligations or statutory obligations of any of our Subsidiaries in the ordinary course of its business&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of deposits of Property to secure (or in lieu of) surety, appeal or customs bonds in proceedings to which we or any of our Subsidiaries is a party in the ordinary course of its business, but not in excess of $75,000,000&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">purchase money Liens or purchase money security interests upon or in any Property acquired or held by us or any of our Subsidiaries in the ordinary course of business to secure the purchase price of such Property or to secure indebtedness incurred solely for the purpose of financing the acquisition of such Property&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on an asset created in connection with the acquisition, construction or development of additions, extensions or improvements to such asset which shall be financed by obligations described in Sections 142, 144(a) or 144(c) of the Code, or by obligations entitled to substantially similar tax benefits under other legislation or regulations in effect from time to time&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(21)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on Property subject to escrow or similar arrangements established in connection with litigation settlements.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any property or asset, whether real, personal or mixed, or tangible or intangible. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Bund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for the 2022 Notes , the Federal Government Bond of Bundesrepublik Deutschland due January 4, 2022, with ISIN 0001135465, and for the 2026 Notes , the Federal Government Bond of Bundesrepublik Deutschland due&#160;February 15, 2026, with ISIN 0001102390. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Dealers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means each of the four banks selected by a Calculation Agent which are primary European government security dealers, and their respective successors, or market makers in pricing corporate bond issues. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinvestment Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for the 2022 Notes , 0.250%, and for the 2026 Notes , 0.300%, in each case plus the average of the four quotations given by the Reference Dealers of the mid-market annual yield to maturity of the Reference Bund at 11&#58; 00 a.m. (Central European time (&#8220;CET&#8221;)) on the fourth Business Day preceding such redemption date and if the Reference Bund is no longer outstanding, a Similar Security will be chosen by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculation Agent at 11&#58; 00 a.m. (CET) on the third Business Day in London preceding such redemption date, quoted in writing by the Calculation Agent to us. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Similar Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a reference bond or reference bonds issued by the German Federal Government having an actual or interpolated maturity comparable with the remaining term of the Notes that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, stockholders&#8217; equity as of that date determined in accordance with GAAP&#59; provided that there shall be excluded from Stockholders&#8217; Equity any amount attributable to capital stock that is, directly or indirectly, required to be redeemed or repurchased by the issuer thereof at a specified date or upon the occurrence of specified events or at the election of the holder thereof. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paying Agent and Registrar </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bank of New York Mellon, London Branch, is the principal paying agent for the Notes (the &#8220;principal paying agent&#8221;). The Bank of New York Mellon Trust Company, N.A., is the security registrar for the Notes. Upon notice to the Trustee, we may change any paying agent or security registrar, and we or any of our subsidiaries may act as paying agent or registrar. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes accrue interest at a rate of 1.250% per annum and the 2026 Notes accrue interest at a rate of 2.000% per annum. The Notes accrue interest on their stated principal amounts from the most recent interest payment date on which interest has been paid or duly provided for. Accrued and unpaid interest on the Notes are payable annually in arrears on February&#160;25 of each year. In each case, interest is paid to the holder in whose name a note is registered at the close of business on the day that is one Business Day prior to the relevant interest payment date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the Notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the Notes, to but excluding the next scheduled interest payment date. This payment convention is referred to as Actual&#47;Actual (ICMA) as defined in the rulebook of the International Capital Market Association. If any date on which interest, principal or premium is payable on the Notes is not a Business Day, then payment of such amounts payable on such date will be made on the next succeeding day that is a Business Day (and, except as provided under &#8220;&#8212;Payment of Additional Amounts,&#8221; without any interest or other payment in respect of any such delay) with the same force and effect as if made on such interest payment date or maturity date, as the case may be. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts payable on any Notes that are not punctually paid on any payment date will cease to be payable to the person in whose name such Notes are registered on the relevant record date, and such defaulted payment will instead be payable to the person in whose name such Notes are registered on the special record date or other specified date determined in accordance with the Indenture. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ranking </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of Amgen. The Notes rank&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">equal in right of payment to all of our other existing and future senior unsecured indebtedness&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">senior in right of payment to all of our existing and future subordinated indebtedness&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">effectively subordinated in right of payment to all of our subsidiaries&#8217; obligations (including secured and unsecured obligations) and subordinated in right of payment to our secured obligations, to the extent of the assets securing such obligations.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes and the Indenture do not limit our ability to incur additional indebtedness. We may incur substantial additional amounts of indebtedness in the future. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Optional Redemption </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes may be redeemed prior to maturity at our option, at any time in whole or from time to time in part. If the 2022 Notes are redeemed before November&#160;25, 2021 (three months prior to the maturity date of the 2022 Notes ), the redemption price will equal the sum of (1)&#160;100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date, and (2)&#160;the Make-Whole Amount (as defined below), if any. If the 2022 Notes are redeemed on or after November&#160;25, 2021 (three months prior to the maturity date of the 2022 Notes), the redemption price will equal 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2026 Notes may be redeemed prior to maturity at our option, at any time in whole or from time to time in part. If the 2026 Notes are redeemed before November&#160;25, 2025 (three months prior to the maturity date of the 2026 Notes), the redemption price will equal the sum of (1)&#160;100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date, and (2)&#160;the Make-Whole Amount, if any. If the 2026 Notes are redeemed on or after November&#160;25, 2025 (three months prior to the maturity date of the 2026 Notes), the redemption price will equal 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we give notice as provided in the Indenture and funds for the redemption of any Notes called for redemption sufficient to pay the redemption price have been deposited with the principal paying agent on or before 10&#58;00 a.m., London time, on the redemption date, such Notes will cease to bear interest on the date fixed for redemption. Thereafter, the only right of the holders of such Notes will be to receive payment of the redemption price. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon surrender of a note that is redeemed in part, we shall execute and the Trustee shall authenticate for the holder a new note of the same series and the same maturity equal in principal amount to the unredeemed portion of the note surrendered. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are redeemable prior to maturity as described below under the headings &#8220;&#8212;Optional Redemption&#8221; and &#8220;&#8212;Redemption Upon Changes in Withholding Taxes.&#8221; The Notes do not have the benefit of any sinking funds. The Notes of each series are issued only in registered form without coupons attached in minimum denominations of &#8364;100,000 and any integral multiple of &#8364;1,000 in excess thereof. Each series of Notes are represented by one or more global securities deposited with, or on behalf of, a common depositary for Euroclear and Clearstream (the &#8220;global notes&#8221;). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on the global notes are made through the principal paying agent (as defined herein under the heading &#8220;&#8212;Paying Agent and Registrar&#8221;). Payments on the Notes are made at the specified office or agency of the principal paying agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that all such payments with respect to Notes represented by one or more global notes registered in the name of or held by a nominee of Euroclear or Clearstream, as applicable, will be by wire transfer of immediately available funds to the account specified by the holder or holders thereof. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, at our option, if certificated notes are issued, we may make payments by check mailed to the holder&#8217;s registered address or by wire transfer to the account shown on the register for the certificated notes. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certificated notes are issued, they will be issued only in minimum denominations of &#8364;100,000 principal amount and integral multiples of &#8364;1,000 in excess thereof upon receipt by the applicable registrar of instructions relating thereto and any certificates and other documentation required under the Indenture. It is expected that such instructions will be based upon directions received by Euroclear or Clearstream, as applicable, from the participant which owns the relevant book-entry interests. Certificated notes issued in exchange for book-entry interests will, except as provided in the Indenture, be subject to, and will have a legend with respect to the restrictions on transfer summarized below. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the restrictions on transfer referred to above, Notes issued as certificated notes may be transferred or exchanged, in whole or in part, in minimum denominations of &#8364;100,000 principal amount and integral multiples of &#8364;1,000 in excess thereof to persons who take delivery thereof in the form of certificated notes. In connection with any such transfer or exchange, the Indenture requires the transferring or exchanging holder to, among other things, furnish appropriate endorsements and transfer documents, to furnish information regarding the account of the transferee at Euroclear or Clearstream, where appropriate, to furnish certain certificates and opinions, and to pay any tax or other governmental charge in connection with such transfer or exchange. Any such transfer or exchange will otherwise be made without charge to the holder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we are not required to register the transfer or exchange of any Notes&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a period of 15 days prior to any date fixed for the redemption of the Notes&#59; </font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">for a period of 15 days immediately prior to the date fixed for selection of Notes to be redeemed in part&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">for a period of 15 days prior to the record date with respect to any interest payment date&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">which the holder has tendered (and not withdrawn) for repurchase in connection with a change of control offer.</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redemption Upon Changes in Withholding Taxes </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If (a)&#160;as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated thereunder) of the United States (or any political subdivision or taxing authority thereof or therein having power to tax) (a &#8220;Relevant Taxing Jurisdiction&#8221;), or any change in, or amendment to, the official position regarding the application or interpretation of such laws, regulations or rulings (including by virtue of a holding, judgment or order by a court of competent jurisdiction or a change in published administrative practice), which change or amendment is announced on or after the date of the applicable prospectus supplement, we become or will become obligated to pay additional amounts as described herein under the heading &#8220;&#8212;Payment of Additional Amounts&#8221; or (b)&#160;any act is taken by a Relevant Taxing Jurisdiction on or after the date of the applicable prospectus supplement, whether or not such act is taken with respect to us or any affiliate, that results in a substantial probability that we will or may be required to pay such additional amounts, then we may, at our option, redeem the Notes of any affected series, as a whole but not in part, upon not less than 15 days&#8217; nor more than 60 days&#8217; published notice in accordance with the applicable notice requirement, at 100% of their principal amount, together with interest accrued thereon to the date fixed for redemption&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that we determine, in our business judgment, that the obligation to pay such additional amounts cannot be avoided by the use of reasonable measures available to us (which does not include substitution of the obligor under the Notes). No redemption pursuant to (a)&#160;or (b)&#160;above may be made unless we have received an opinion of independent counsel to the effect that as a result of such change or amendment we will, or that an act taken by a Relevant Taxing Jurisdiction has resulted in a substantial probability that we will, or may, be required to pay the additional amounts described herein under the heading &#8220;&#8212;Payment of Additional Amounts,&#8221; and we shall have delivered to the Trustee a certificate, signed by a duly authorized officer, stating that based on such opinion we are entitled to redeem the Notes pursuant to their terms. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font><br></font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notice of Redemption </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will publish a notice of any redemption of any affected series of Notes described above in accordance with the applicable notice provisions. If fewer than all of the Notes are to be redeemed at any time, the principal paying agent will select the Notes to be redeemed in accordance with the rules of the principal securities exchange, if any, on which the Notes are listed at such time or, if the not Notes are not listed on a securities exchange, in accordance with the rules of Euroclear or Clearstream, or absent any such rules, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, by lot&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that no such partial redemption shall reduce the portion of the principal amount of a note not redeemed to less than &#8364;100,000. The principal paying agent shall not be liable for any selections made by it in accordance with this paragraph. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will give notice of any optional redemption to the registered holders of Notes at least 15 but not more than 60 days before a redemption date. The notice shall identify the Notes to be redeemed and shall state&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the redemption date&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the redemption price&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the name and address of the paying agent&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">if any Notes are being redeemed in part, the portion of the principal amount of such notes to be redeemed and that, after the redemption date and upon surrender of such Notes, a new note or notes in principal amount equal to the unredeemed portion of the original note shall be issued in the name of the holder of the Notes thereof upon cancellation of the original note&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">that the notes called for redemption must be surrendered to the paying agent to collect the redemption price&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">that interest on the Notes called for redemption ceases to accrue on and after the redemption date unless we default in the deposit of the redemption price&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the CUSIP and&#47;or ISIN number of the Notes.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our request, the Trustee shall give the notice of redemption in our name and at our expense. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment of Additional Amounts </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments of principal and interest on the Notes will be made free and clear of and without withholding or deduction for or on account of any present or future tax, assessment or other governmental charge (collectively, &#8220;Taxes&#8221;) imposed by any Relevant Taxing Jurisdiction, unless the withholding of such Taxes is required by law or the official interpretation or administration thereof. We will, subject to the exceptions and limitations set forth below, pay such additional amounts as are necessary in order that the net payment of the principal of and interest on the applicable series of Notes to a holder who is not a U.S. person for U.S. federal income tax purposes, after deduction for any present or future Taxes of any Relevant Taxing Jurisdiction, imposed by withholding with respect to the payment, will not be less than the amount provided in such Notes to be then due and payable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#59; provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the foregoing obligation to pay additional amounts shall not apply&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of the holder or beneficial owner, or a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;being or having been present or engaged in a trade or business in the United States or having or having had a permanent establishment in the United States&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;having a current or former relationship with the United States, including a relationship as a citizen or resident thereof&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;being or having been a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation with respect to the United States or a corporation that has accumulated earnings to avoid U.S. federal income tax&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;being or having been a &#8220;10-percent shareholder&#8221; of the obligor under the Notes within the meaning of section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or any successor provision&#59; or </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) &#160;&#160;&#160;&#160;being or having been a bank receiving interest described in section 881(c)(3)(A) of the Code or any successor provision&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;to any holder that is not the sole beneficial owner of the note, or a portion thereof, or that is a fiduciary or partnership, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or member of the partnership would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of the failure to (a)&#160;comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with a Relevant Taxing Jurisdiction of the holder or beneficial owner of such note, if compliance is required by statute or by regulation of the Relevant Taxing Jurisdiction as a precondition to relief or exemption from such Taxes (including the submission of an applicable U.S. Internal Revenue Service (&#8220;IRS&#8221;) Form W-8 (with any required attachments)) or (b)&#160;comply with any informational gathering and reporting requirements or to take any similar action (including entering into any agreement with the IRS), in each case, that are required to obtain the maximum available exemption from withholding by a Relevant Taxing Jurisdiction that is available to payments received by or on behalf of the holder&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) &#160;&#160;&#160;&#160;to any Taxes that are imposed otherwise than by withholding from the payment&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) &#160;&#160;&#160;&#160;to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or a similar tax, assessment or governmental charge&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) &#160;&#160;&#160;&#160;to any Taxes required to be withheld by any paying agent from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) &#160;&#160;&#160;&#160;to any Taxes that are imposed or levied by reason of the presentation (where presentation is required in order to receive payment) of such notes for payment on a date more than 30 days after the date on which such payment became due and payable, except to the extent that the holder or beneficial owner thereof would have been entitled to additional amounts had the notes been presented for payment on any date during such 30 day period&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld pursuant to Sections 1471 through 1474 of the Code, as of the issue date (or any amended or successor version of such sections), any U.S. Treasury Regulations </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promulgated thereunder, any official interpretations thereof, any similar law or regulation adopted pursuant to an intergovernmental agreement between a non-U.S. jurisdiction and the United States with respect to the foregoing or any agreements entered into pursuant to Section&#160;1471(b)(1) of the Code&#59; or </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) &#160;&#160;&#160;&#160;in the case of any combination of any items (1)&#160;through (9). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable thereto. Except as specifically provided under this heading &#8220;&#8212;Payment of Additional Amounts,&#8221; we are not required to make any payment with respect to any tax, assessment or governmental charge imposed by any government or a political subdivision or taxing authority thereof or therein. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change of Control Offer </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change of control triggering event occurs, unless we have exercised our option to redeem the notes as described above, we will be required to make an offer (the &#8220;change of control offer&#8221;) to each holder of the notes to repurchase all or any part (equal to &#8364;100,000 or integral multiples of &#8364;1,000 in excess thereof) of that holder&#8217;s notes on the terms set forth in such notes. In the change of control offer, we will be required to offer payment in cash equal to 101&#160;% of the aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase (the &#8220;change of control payment&#8221;). Within 30 days following any change of control triggering event, a notice will be provided to holders of the notes describing the transaction that constitutes the change of control triggering event and offering to repurchase the notes on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is provided (the &#8220;change of control payment date&#8221;)&#59; provided, however, that in no event will the change of control payment date occur prior to the date 90 days following the first issue date of the notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the change of control payment date, we will, to the extent lawful&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">accept for payment all notes or portions of notes properly tendered pursuant to the change of control offer&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">by 10&#58;00 a.m., London time, deposit with the principal paying agent an amount equal to the change of control payment in respect of all notes or portions of notes properly tendered&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">deliver or cause to be delivered to the Trustee the notes properly accepted together with an officer&#8217;s certificate stating the aggregate principal amount of notes or portions of notes being repurchased.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not repurchase any notes if there has occurred and is continuing on the change of control payment date an event of default under the Indenture, other than a default in the payment of the change of control payment upon a change of control triggering event. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will comply with the requirements of Rule 14e-1 under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a change of control triggering event. To the extent that the provisions of any such securities laws or regulations conflict with the change of control offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the change of control offer provisions of the notes by virtue of any such conflict. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the change of control offer provisions of the notes, the following terms will be applicable&#58; </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beneficial owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be determined in accordance with Rules 13d-3 and 13d-5 under the Exchange Act or any successor provisions, except that a person will be deemed to have beneficial ownership of all shares that person has the right to acquire irrespective of whether that right is exercisable immediately or only after the passage of time. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change of control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following&#58; (1)&#160;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any person or group (other than our company or one of our subsidiaries) becomes the beneficial owner, directly or indirectly, of more than 50% of our voting stock or other voting stock into which our voting stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares&#59; provided, however, that a person shall not be deemed beneficial owner of, or to own beneficially, (A)&#160;any securities tendered pursuant to a tender or exchange offer made by or on behalf of such person or any of such person&#8217;s affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (B)&#160;any securities if such beneficial ownership (i)&#160;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&#160;is not also then reportable on Schedule 13D (or any successor </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">schedule) under the Exchange Act&#59; (2)&#160;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our subsidiaries, taken as a whole, to one or more persons or groups (other than our company or one of our subsidiaries), provided that none of the circumstances in this clause (2)&#160;will be a change of control if the persons that beneficially own our voting stock immediately prior to the transaction own, directly or indirectly, shares with a majority of the total voting power of all outstanding voting securities of the surviving or transferee person that are entitled to vote generally in the election of that person&#8217;s board of directors, managers or trustees immediately after the transaction&#59; (3)&#160;we consolidate with, or merge with or into any person, or any person consolidates with, or merges with or into, us, in any such event pursuant to a transaction in which any of our outstanding voting stock or the voting stock of such other person is converted into or exchanged for cash, securities or other property, other than such transaction where the shares of our voting stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the voting stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction&#59; or (4)&#160;the adoption of a plan relating to our liquidation or dissolution. Notwithstanding the foregoing, a transaction will not be deemed to involve a change of control under clause (1)&#160;above if (i)&#160;we become a direct or indirect wholly-owned subsidiary of a holding company and (ii)&#160;(A)&#160;the direct or indirect holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders of our voting stock immediately prior to that transaction or (B)&#160;immediately following that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the voting stock of such holding company. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change of control triggering event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the occurrence of both a change of control and a rating event. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fitch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Fitch, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning given by Section&#160;13(d) and 14(d) of the Exchange Act or any successor provisions and includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the Exchange Act or any successor provision. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment grade rating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s, BBB&#8212;(or the equivalent) by S&#38;P and BBB&#8212;(or the equivalent) by Fitch, and the equivalent investment grade credit rating from any additional rating agency or rating agencies selected by us. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Moody&#8217;s Investors Service, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning given by Section&#160;13(d) and 14(d) of the Exchange Act or any successor provisions. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rating agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (1)&#160;each of Fitch, Moody&#8217;s and S&#38;P&#59; and (2)&#160;if any of Fitch, Moody&#8217;s or S&#38;P ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Section&#160;3(a)(62) of the Exchange Act selected by us (as certified by a resolution of our Board of Directors) as a replacement agency for Fitch, Moody&#8217;s or S&#38;P, or all of them, as the case may be. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rating event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the rating on the applicable series of notes is lowered by at least two of the three rating agencies and the notes are rated below an investment grade rating by at least two of the three rating agencies on any day during the period commencing 60 days prior to the first public notice of the occurrence of a change of control or our intention to effect a change of control and ending 60 days following consummation of such change of control (which period will be extended so long as the rating of the applicable series of notes is under publicly announced consideration for a possible downgrade by any of the rating agencies). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Standard&#160;&#38; Poor&#8217;s Rating Services, a division of The McGraw-Hill Companies, Inc., and its successors. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as applied to stock of any person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence of a contingency. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Covenants </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitation on Liens </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not, nor will we permit any of our Subsidiaries to, create or incur any Lien on any of our or their respective Properties, whether now owned or hereafter acquired, or upon any income or profits therefrom, in order to secure any of our Indebtedness, without effectively providing that each series of notes shall be equally and ratably secured until such time as such Indebtedness is no longer secured by such Lien, except&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Liens existing as of the first issue date of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Liens granted after the first issue date of the notes on any of our or our Subsidiaries&#8217; Properties securing our Indebtedness created in favor of the holders of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Liens securing our Indebtedness which are incurred to extend, renew or refinance Indebtedness which is secured by Liens permitted to be incurred under the Indenture&#59; provided that those Liens do not extend to or cover any of our or our Subsidiaries&#8217; Property other than the Property securing the Indebtedness being refinanced and that the principal amount of such Indebtedness does not exceed the principal amount of the Indebtedness being refinanced&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Liens created in substitution of or as replacements for any Liens permitted by the clauses directly above, provided that, based on a good faith determination of one of our officers, the Property encumbered under any such substitute or replacement Lien is substantially similar in nature to the Property encumbered by the otherwise permitted Lien which is being replaced&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Permitted Liens. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we and any of our Subsidiaries may, without securing any series of notes, create or incur Liens which would otherwise be subject to the restrictions set forth in the preceding paragraph, if after giving effect thereto, Exempted Debt does not exceed the greater of (a)&#160;35% of Consolidated Net Worth calculated as of the date of the creation or incurrence of the Lien or (b)&#160;35% of Consolidated Net Worth calculated as of the first issue date of the notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitation on Sale and Lease-Back Transactions </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not, nor will we permit any of our Subsidiaries to, enter into any sale and lease-back transaction for the sale and leasing back of any Property, whether now owned or hereafter acquired, of ours or any of our Subsidiaries, unless&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) such transaction was entered into prior to the first issue date of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) such transaction was for the sale and leasing back to us of any Property by one of our Subsidiaries&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) such transaction involves a lease for less than three years&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) we would be entitled to incur Indebtedness secured by a mortgage on the property to be leased in an amount equal to the Attributable Liens with respect to such sale and lease-back transaction without equally and ratably securing the notes pursuant to the first paragraph of &#8220;&#8212;Limitation on Liens&#8221; above&#59; or </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) we apply an amount equal to the fair value of the Property sold to the purchase of Property or to the retirement of our or any of our Subsidiaries&#8217; long-term Indebtedness within 120 days of the effective date of any such sale and lease-back transaction. In lieu of applying such amount to such retirement, we may, or may cause any of our Subsidiaries to, deliver debt securities to the Trustee therefor for cancellation, such debt securities to be credited at the cost thereof to us. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we and any of our Subsidiaries may enter into any sale lease-back transaction which would otherwise be subject to the foregoing restrictions if after giving effect thereto and at the time of determination, Exempted Debt does not exceed the greater of (a)&#160;35% of Consolidated Net Worth calculated as of the closing date of the sale-leaseback transaction or (b)&#160;35% of Consolidated Net Worth calculated as of the first issue date of the notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Event of default means, with respect to each series of notes, any of the following&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">default in the payment of any interest on the notes of that series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the Trustee or with the principal paying agent prior to the expiration of the 30-day period)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">default in the payment of principal of the notes of that series at their maturity&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">default in the performance or breach of any other covenant or warranty by us in the Indenture (other than defaults pursuant to the previous two bullet points above or pursuant to a covenant or warranty that has been included in the Indenture solely for the benefit of a series of debt securities other than that series of notes), which default continues uncured for a period of 90 days after we receive written notice from the Trustee or we and the Trustee receive written notice from the holders of not less than a majority in principal amount of the outstanding Notes of the affected series as provided in the Indenture&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of our company.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No event of default with respect to the Notes (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under our bank credit agreements in existence from time to time. In addition, the occurrence of certain events of default or an acceleration under the Indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide the Trustee written notice of any default or event of default within 30 days of becoming aware of the occurrence of such default or event of default, which notice will describe in reasonable detail the status of such default or event of default and what action we are taking or propose to take in respect thereof. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default with respect to a series of Notes occurs and is continuing (other than an event of default regarding certain events of bankruptcy, insolvency or reorganization of our company), then the Trustee or the holders of not less than a majority in principal amount of the outstanding Notes of that series may, by a notice in writing to us (and to the Trustee if given by the holders), declare to be due and payable immediately the principal of, and accrued and unpaid interest, if any, on all Notes of that series. In the case of an event of default resulting from certain events of bankruptcy, insolvency or reorganization, the principal of and accrued and unpaid interest, if any, on all outstanding debt securities issued under the Indenture will become and be immediately due and payable without any declaration or other act on the part of the Trustee or any holder of outstanding debt securities, including the Notes. At any time after a declaration of acceleration with respect to a series of Notes has been made, and before a judgment or decree for payment of the money due has been obtained by the Trustee, the holders of a majority in principal amount of the outstanding Notes of that series may, by written notice to us and the Trustee, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal and interest, if any, with respect to the Notes of that series, have been cured or waived as provided in the Indenture. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture provides that the Trustee will be under no obligation to exercise any of its rights or powers under the Indenture at the request of any holder of notes, unless the Trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in exercising such right or power. Subject to certain rights of the Trustee, the holders of a majority in principal amount of the outstanding Notes of the affected series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes of that series. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No holder of any Note of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the Indenture, or for the appointment of a receiver or Trustee, or for any remedy under the Indenture unless, among other things&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">that holder has previously given to the Trustee written notice of a continuing event of default with respect to the Notes of that series&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the holders of at least a majority in principal amount of the outstanding Notes of that series have made written request, and offered reasonable indemnity or security, to the Trustee to institute the proceeding as Trustee, and the Trustee has not received from the holders of a majority in principal amount of the outstanding Notes of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days.</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provision in the Indenture, the holder of any Note will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on that Note on or after the due dates expressed in that Note and to institute suit for the enforcement of any such payment. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any securities are outstanding under the Indenture, the Indenture requires us, within 120 days after the end of each fiscal year, to furnish to the Trustee a statement as to our compliance with the indenture. If a default or event of default occurs and is continuing with respect to notes of any series and if it is known to a responsible officer of the Trustee, the Trustee shall deliver to each holder of the Notes of that series notice of a default or event of default within 90 days after it occurs. The Indenture provides that the Trustee may withhold notice to the holders of the Notes of any default or event of default (except in the case of a default or event of default in payment of principal of or interest on any Note of that series) with respect to Notes of that series if it in good faith determines that withholding notice is in the interest of the holders of those Notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification and Waiver </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the Trustee may modify and amend the Indenture or Notes of any series without the consent of any holder of Notes&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to cure any ambiguity, defect or inconsistency&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to comply with the covenant described below under the heading &#8220;&#8212;Consolidation, Merger and Sale of Assets&#59;&#8221;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to provide for uncertificated notes in addition to or in place of certificated notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to add guarantees with respect to Notes of any series or secure notes of any series&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to surrender any of our rights or powers under the Indenture&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to add covenants or events of default for the benefit of the holders of Notes of any series&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to comply with the applicable procedures of the applicable depositary&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to make any change that would not adversely affect the rights of any holder of Notes in any material respect&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to provide for the issuance of and establish the form and terms and conditions of additional Notes of any series as permitted by the Indenture&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to effect the appointment of a successor trustee with respect to the Notes and to add to or change any of the provisions of the Indenture to provide for or facilitate administration by more than one trustee&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to comply with requirements of the U.S. Securities and Exchange Commission in order to effect or maintain the qualification of the Indenture under the U.S. Trust Indenture Act of 1939.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also modify and amend the Indenture with the consent of the holders of at least a majority in principal amount of the outstanding Notes of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected Note then outstanding if that amendment will&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reduce the amount of Notes whose holders must consent to an amendment, supplement or waiver&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reduce the rate of or extend the time for payment of interest (including any additional amounts) on the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reduce the principal of or premium on or change the fixed maturity of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">waive a default in the payment of the principal of, premium or interest on the notes (except a rescission of acceleration of the notes by the holders of at least a majority in aggregate principal amount of the then outstanding Notes of that series and a waiver of the payment default that resulted from such acceleration)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">make the principal of or interest on the Notes payable in currency other than that stated in the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">make any change to certain provisions of the Indenture relating to, among other things, the right of holders of the Notes to receive payment of the principal of, premium and interest on the Notes and to institute suit for the enforcement of any such payment and to waivers or amendments&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">waive a redemption payment with respect to the Notes.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding Notes of the affected series may, on behalf of the holders of all the Notes of that series, waive our compliance with provisions of the Indenture. The holders of a majority in principal amount of the outstanding Notes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the affected series may, on behalf of the holders of all the Notes of such series, waive any past default under the Indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any Note of that series&#59; provided, however, that the holders of a majority in principal amount of the outstanding Notes of the affected series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amendment to cure any ambiguity, defect or inconsistency in the Indenture made solely to conform the Indenture to the description of notes contained in the applicable prospectus supplement will be deemed to adversely affect the interests of the holders of the Notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation, Merger and Sale of Assets </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to, any person, which we refer to as a &#8220;successor person,&#8221; unless&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">we are the surviving corporation or the successor person (if other than Amgen) is organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes, pursuant to a supplemental Indenture, our obligations on the notes and under the Indenture&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing under the Indenture.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, any of our Subsidiaries may consolidate with, merge into or transfer all or part of its properties and assets to us. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance and Covenant Defeasance </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Defeasance </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture provides that we may be discharged from any and all obligations in respect of the Notes (subject to certain exceptions). We will be so discharged upon the deposit with the Trustee, in trust, of money, U.S. government obligations and&#47;or foreign government obligations that, through the payment of interest and principal in accordance with their terms, will provide money, U.S. government obligations or foreign government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on the Notes on the stated maturity of those payments in accordance with the terms of the Indenture and the Notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discharge may occur only if, among other things, we have delivered to the Trustee an opinion of counsel stating that we have received from, or there has been published by, the IRS a ruling or, since the date of execution of the Indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defeasance of Certain Covenants </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture provides that upon compliance with certain conditions&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">we may omit to comply with the covenant described under the heading &#8220;&#8212;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the Indenture, as well as any additional covenants set forth in the applicable prospectus supplement&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any omission to comply with those covenants will not constitute a default or an event of default with respect to the Notes, which we refer to as a &#8220;covenant defeasance.&#8221;</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conditions include&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">depositing with the Trustee money, U.S. government obligations and&#47;or foreign government obligations that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on the notes on the stated maturity of those payments in accordance with the terms of the Indenture and the Notes&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">delivering to the Trustee an opinion of counsel to the effect that the holders of the Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred.</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covenant Defeasance and Events of Default </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we exercise our option to effect covenant defeasance with respect to any series of the Notes and the Notes of that series are declared due and payable because of the occurrence of any event of default, the amount of money, U.S. government obligations and&#47;or foreign government obligations on deposit with the Trustee will be sufficient to pay amounts due on the Notes of that series at the time of their stated maturity but may not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient to pay amounts due on the notes of that series at the time of the acceleration resulting from the event of default. In such a case, we would remain liable for those payments. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concerning the Trustee</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Bank of New York Mellon Trust Company, N.A. is Trustee under the Indenture.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture and the Notes, including any claim or controversy arising out of or relating to the Indenture or the Notes, are governed by the laws of the State of New York. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>amgn-ex104_20201231xq4.htm
<DESCRIPTION>FORM OF GRANT OF STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iaa5cb74be75a41e3905a125cb74121fb_37"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GRANT OF STOCK OPTION AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE SPECIFIC TERMS OF YOUR STOCK OPTION ARE FOUND IN THE PAGES RELATING TO THE GRANT OF STOCK OPTIONS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS GRANT OF STOCK OPTIONS.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On the Grant Date, specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), has granted to you, the grantee named in the Award Notice, under the plan specified in the Award Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to purchase the number of shares of the $0.0001 par value common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) specified in the Award Notice, pursuant to the terms set forth in this Stock Option Agreement, any additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Award Notice (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Option is not intended to qualify and will not be treated as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, as amended (together with the regulations and other official guidance promulgated thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The terms and conditions of your Option are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions of the Plan and this Agreement, on each Vesting Date the Option shall vest with respect to the number of Shares indicated on the Vesting Schedule, provided that you have remained continuously and actively employed with the Company or an Affiliate (as defined in the Plan) through each applicable Vesting Date, unless &#91;(i) your employment has terminated due to your Voluntary Termination (as defined in Section IV(A)(5)) or (ii)&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> you experience a Qualified Termination (as defined in Section IV(B)(4)), or as otherwise determined by the Company in the exercise of its discretion as provided in Section IV(A)(7).  This Option may only be exercised for whole shares of the Common Stock, and the Company shall be under no obligation to issue any fractional Shares to you.  Subject to the limitations contained herein, this Option shall be exercisable with respect to each installment on or after the applicable Vesting Date.  Notwithstanding anything herein to the contrary, the Vesting Schedule may be accelerated (by notice in writing) by the Company in its sole discretion at any time during the term of this Option.  In addition, if not prohibited by local law, vesting may be suspended by the Company in its sole discretion during a leave of absence as provided from time to time according to Company policies and practices&#59; provided, that, in no event shall </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Section IV(A)(5) of this Agreement is not applicable to awards identified by the Administrator as new hire, retention or promotion grants and the provisions of such section shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any such suspension extend the term of this Option beyond the Expiration Date set forth on the Award Notice and in this Agreement.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;The per share exercise price of this Option is the Grant Price as defined in the Award Notice, being not less than the Fair Market Value of the Common Stock on the date of grant of this Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;To the extent permitted by applicable statutes and regulations, payment of the exercise price per share is due in full upon exercise of all or any part of each installment which has become exercisable by you by means of (i) cash or a check, (ii) any cashless exercise procedure through the use of a brokerage arrangement approved by the Company, or (iii) any other form of legal consideration that may be acceptable to the Board or the Committee in their discretion. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">(3)&#160;&#160;&#160;&#160;To the extent permitted by applicable statutes and regulations, if, at the time of exercise, the Company&#8217;s Common Stock is publicly traded and quoted regularly in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%;text-decoration:underline">Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">, payment of the exercise price may be made by delivery of already-owned Shares of a value equal to the exercise price of the Shares for which this Option is being exercised.  The already-owned Shares must have been owned by you for the period required to avoid adverse accounting treatment and owned free and clear of any liens, claims, encumbrances or security interests.  Payment may also be made by a combination of cash and already-owned Shares.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Company reserves the right to restrict the methods of payment of the exercise price if necessary or advisable to comply with applicable law or regulation, as determined by the Company in its sole discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21.03pt">Notwithstanding anything to the contrary contain herein, the Company shall not take any actions that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange. The Company, in its sole discretion, may impose any timing or other restrictions with respect to the exercise of this Option arising from compliance with any securities or tax laws or other rules or regulations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding anything to the contrary contained herein, this Option may not be exercised and no Shares underlying the Option will be issued unless such Shares are then registered under the Securities Act, or, if such Shares are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act, and that the issuance satisfies all other applicable legal requirements.  If the Option cannot be exercised and expires during this period, you will forfeit the Option and no Shares or value will be transferred to you.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IV.&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;The term of this Option commences on the Grant Date and, unless sooner terminated as set forth below or in the Plan, terminates on the &#91;_______ (__th)&#93; anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Option shall terminate prior to the Expiration Date as follows&#58;  three (3) months after the termination of your employment with the Company or an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Affiliate (as defined in the Plan) for any reason or for no reason, including if your employment is terminated by the Company or an Affiliate without Cause (as defined below), or in the event of any other termination of your employment caused directly or indirectly by the Company or an Affiliate, unless&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;such termination of your employment is due to your Permanent and Total Disability (as defined below), in which case the Option shall terminate on the earlier of the Expiration Date or five (5) years after termination of your employment and the vesting of the Option shall be accelerated and the Option shall be fully exercisable, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), as of the day immediately preceding such termination of your employment with respect to the Option, except that if the Option was granted in the calendar year in which such termination occurs, the Option shall be accelerated to vest with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Permanent and Total Disability without consideration therefor&#59;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;such termination of your employment is due to your death, in which case the Option shall terminate on the earlier of the Expiration Date or five (5) years after your death and the vesting of the Option shall be accelerated and the Option shall be fully exercisable as of the day immediately preceding your death with respect to the Option, except that if the Option was granted in the calendar year in which your death occurs the Option shall be accelerated to vest with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of termination of your active employment due to your death without consideration therefor&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;during any part of such three (3) month period, this Option is not exercisable solely because of the condition set forth in Section III above, in which event this Option shall not terminate until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your employment&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;exercise of this Option within three (3) months after termination of your employment with the Company or with an Affiliate would result in liability under Section 16(b) of the Exchange Act, in which case this Option will terminate on the earliest of&#58;  (a) the tenth (10th) day after the last date upon which exercise would result in such liability&#59; (b) six (6) months and ten (10) days after the termination of your employment with the Company or an Affiliate&#59; or (c) the Expiration Date&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;&#91;such termination of your employment is due to your voluntary termination (and such voluntary termination is not the result of Permanent and Total Disability (as defined below)) after you are at least sixty five (65) years of age, or after you are at least fifty-five (55) years of age and have been an employee of the Company and&#47;or an Affiliate for at least ten (10) years in the aggregate as determined by the Company in its sole discretion according to Company policies and practices as in effect from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%;text-decoration:underline">Voluntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;), in which case this Option shall terminate on the earlier of the Expiration Date or five (5) years after termination of your employment and the unvested portions of this Option will become exercisable pursuant to the Vesting Schedule without regard to your Voluntary Termination of your employment prior to the Vesting Date, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), with respect to the Option&#59; if the Option was granted in the calendar year in which your Voluntary Termination occurs, the Option will become exercisable pursuant to the Vesting Schedule only with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Voluntary Termination without consideration therefor&#59; notwithstanding the definition of Voluntary Termination set forth above, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in your jurisdiction that would likely result in the favorable treatment upon Voluntary Termination described above being deemed unlawful and&#47;or discriminatory, then the Committee will not apply the favorable treatment described above&#59;&#93;&#91;Reserved&#93;*</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:9.1pt;font-weight:400;line-height:111%;position:relative;top:-4.89pt;vertical-align:baseline"> 2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6)&#160;&#160;&#160;&#160;such termination of your employment is due to a Qualified Termination, in which case, the Option shall terminate on the earlier of (a) the date that is three (3) months following the date of such Qualified Termination or (b) the Expiration Date, and, to the extent permitted by applicable law, the vesting of the Option shall be accelerated and the Option shall be fully exercisable as of the day immediately prior to the Qualified Termination&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7)&#160;&#160;&#160;&#160;the Company determines, in its sole discretion at any time during the term of this Option, in writing, to otherwise extend the period of time during which this Option will vest and may be exercised after termination of your employment&#59; provided, that, in no event shall any such extension extend the term of this Option beyond the Expiration Date set forth on the Award Notice and in this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;However, in any and all circumstances and except to the extent the Vesting Schedule has been accelerated by the Company in its sole discretion during the term of this Option or as a result of your Permanent and Total Disability or death as provided in Sections IV(A)(1) or </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Section IV(A)(5) of this Agreement is not applicable to awards identified by the Administrator as new hire, retention or promotion grants and the provisions of such section shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IV(A)(2) above, respectively, &#91;as a result of your Voluntary Termination as provided in Section IV(A)(5) above,&#93;* as a result of a Qualified Termination as provided in Section IV(A)(6) above or as otherwise determined by the Company in the exercise of its discretion as provided in Section IV(A)(7) above, this Option may be exercised following termination of your employment only as to that number of Shares as to which it was exercisable on the date of termination of your employment under the provisions of Section I of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;For purposes of this Option&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as a Director to the Company or an Affiliate&#59; in the event of termination of your employment (whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive options and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, active employment would not include any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).  Your right, if any, to exercise the Option after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law.  The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of this Agreement (including whether you may still be considered to be providing services while on a leave of absence)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) your conviction of a felony (or similar crime under applicable law, as determined by the Company), or (ii) your engaging in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out your duties, resulting, in either case, in material economic harm to the Company or any Affiliate, unless you believed in good faith that such conduct was in, or not contrary to, the best interests of the Company or any Affiliate.  For purposes of clause (ii) above, no act, or failure to act, on your part shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by you not in good faith&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term under Section 22(e)(3) of the Code and with such permanent and total disability being certified prior to termination of your employment by (a) the U.S. Social Security Administration, (b) the comparable governmental authority applicable to an Affiliate, (c) such other body having the relevant decision-making power applicable to an Affiliate, or (d) an independent medical advisor appointed by the Company in its sole discretion, as applicable, in any such case&#59; </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;if you are an employee who participates in the Change of Control Plan (as defined below), your termination of employment within two (2) years following a Change of Control (i) by the Company other than for Cause, Disability (as defined below) or as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a result of your death, or (ii) by you for Good Reason (as defined in the Change of Control Plan)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;if you are an employee who does not participate in the Change of Control Plan or the Change of Control Plan is no longer in effect, your termination of employment within two (2) years following a Change of Control by the Company other than for Cause, Disability (as defined below) or as a result of your death&#59; </font></div><div><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">(5) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; shall mean the occurrence of any of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group,&#8221; within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or any of its Affiliates, or any employee benefit plan of the Company or any of its Affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then outstanding Shares or the combined voting power of the Company&#8217;s then outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company&#8217;s then outstanding voting securities) or a liquidation or dissolution of the Company or of the sale of all or substantially all of the assets of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein or in any Award Agreement to the contrary, if a Change of Control constitutes a payment event with respect to any Award that is subject to United States income tax and which provides for a deferral of compensation that is subject to Section 409A of the Code, the transaction or event described in subsection (a) or (b), (c) above must also constitute a &#8220;change in control event,&#8221; as defined in U.S. Treasury Regulation &#167;1.409A-3(i)(5), in order to constitute a Change of Control for purposes of payment of such Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Company&#8217;s change of control and severance plan, including the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto), or any equivalent plan governing the provision of benefits to eligible employees upon the occurrence of a Change of Control (including resulting from a termination of employment that occurs within a specified time period following a Change of Control), as in effect immediately prior to a Change of Control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be determined in accordance with the Company&#8217;s long-term disability plan as in effect immediately prior to a Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;To the extent specified above, this Option may be exercised by delivering a notice of exercise in person, by mail, via electronic mail or facsimile or by other authorized method designated by the Company, together with the exercise price to the Company Stock Administrator, or to such other person as the Company Stock Administrator may designate, during regular business hours, together with such additional documents as the Company may then require pursuant to Section 7.2(b) of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer&#58; (a) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Option grant or the underlying Shares, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends&#59; and (b) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax Obligations or achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(C)&#160;&#160;&#160;&#160;Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements satisfactory to the Company and&#47;or your Employer to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47;or your Employer, or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares acquired upon exercise of the Option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;withholding in Shares to be issued or cash to be paid upon exercise of the Option, provided that, if Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value equal to the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates. If the Tax Obligations are satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">number of Shares subject to the exercised Option, notwithstanding that a number of the Shares is held back solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(D)&#160;&#160;&#160;&#160;Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.  You agree to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Section V.  Notwithstanding anything to the contrary contained herein, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VI.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option is not transferable, except by will or the laws of descent and distribution, and is exercisable during your life only by you except if you have named a trust created for the benefit of you, your spouse, or members of your immediate family (a &#8220;Trust&#8221;) as beneficiary of this Option, this Option may be exercised by the Trust after your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VII.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any notices provided for in this Option or the Plan shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VIII.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option is subject to all the provisions of the Plan and its provisions are hereby made a part of this Option, including without limitation the provisions of Articles 6 and 7 of the Plan relating to Options, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Option and those of the Plan, the provisions of the Plan shall control.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In order for the Company to facilitate your participation in the Plan, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan (&#8220;personal data&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received upon exercise of this Option may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Options or other equity awards and administer or maintain such awards.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;X.&#160;&#160;&#160;&#160;The terms of this Option shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Option is made and&#47;or to be performed.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.85pt">Notwithstanding any provision of this Option to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Option granted hereunder shall be subject to any additional terms and conditions for your country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the following additional terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;the terms and conditions of this Option, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration to the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;if applicable, the effectiveness of this Option is conditioned upon its compliance with any applicable foreign laws, regulations, rules or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59; and</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">the Company may take any other action before or after the date of this Option that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt"> (A)&#160;&#160;&#160;&#160;In accepting this Option, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;the grant of this Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of options, or benefits in lieu of options even if options have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;your participation in the Plan is voluntary&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;the grant of Options, the underlying Shares, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;neither the grant of options nor any provision of this Option, the Plan or the policies adopted pursuant to the Plan confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Option shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;if the underlying Shares do not increase in value, this Option will have no value&#59; if you exercise this Option and obtain Shares, the value of those Shares acquired upon exercise may increase or decrease in value, even below the Grant Price per Share&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;in consideration of the grant of this Option, no claim or entitlement to compensation or damages arises from forfeiture of options resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">where you are employed or the terms of your employment agreement, if any), and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Options, the underlying Shares, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(12) &#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Options and the benefits evidenced by this Agreement do not create any entitlement to have the Options or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;for employment law purposes outside the United States, the Option, underlying Shares, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to the exercise of the Option or the subsequent sale of any Shares acquired upon exercise of the Option.</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt">If one or more of the provisions of this Option shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">retroactively to permit this Option to be construed so as to foster the intent of this Option and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.37pt">By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Furthermore, if you have received this Option or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt">This Option is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Code Section 409A, but rather is intended to be exempt from the application of Code Section 409A.  To the extent that this Option is nevertheless deemed to be subject to Code Section 409A for any reason, this Option shall be interpreted in accordance with Code Section 409A and U.S. Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date.  Notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee (as defined in the Plan) determines that this Option may be or become subject to Code Section 409A, the Committee may adopt such amendments to the Plan and&#47;or this Option or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan and&#47;or this Option from the application of Code Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Option, or (b) comply with the requirements of Code Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.68pt">By electing to accept this Option, you acknowledge receipt of this Option and hereby confirm your understanding that the terms set forth in this Option constitute, subject to the terms of the Plan, which terms shall control in the event of any conflict between the Plan and this Option, the entire agreement and understanding of the parties with respect to the matters contained herein and supersede any and all prior agreements, arrangements and understandings, both oral and written, between the parties concerning the subject matter of this Option.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt">The Company reserves the right to impose other requirements on your participation in the Plan, on this Option and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.7pt">This Option and all compensation payable with respect to it shall be subject to recovery by the Company pursuant to&#160;any and all of the Company&#8217;s policies with respect to the recovery of compensation, as they shall be in effect and may be amended from time to time, to the maximum extent permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.71pt">You acknowledge that a waiver by the Company of breach of any provision of this Option shall not operate or be construed as a waiver of any other provision of this Option, or of any subsequent breach by you or any other grantee.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Very truly yours,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMGEN INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Duly authorized on behalf</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  of the Board of Directors</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="iaa5cb74be75a41e3905a125cb74121fb_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GRANT OF STOCK OPTION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(BY COUNTRY)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Appendix includes additional terms and conditions that govern any Options granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern any Options granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2020.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you exercise the Options and acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision replaces Section II(3)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent permitted by applicable statutes and regulations, payment of the exercise price per Share is due in full in cash or check upon exercise of all or any part of this Option which has become exercisable by you.  Due to legal restrictions outside the U.S., you are not permitted to pay the exercise price by delivery of already-owned Shares of a value equal to the exercise price of the Shares for which this Option is being exercised.  Furthermore, payment may not be made by a combination of cash and already-owned Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision supplements Section V(C) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may be subject to insider trading restrictions and&#47;or market abuse laws</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., Options) or rights linked to the value of Shares during such times as you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). &#160;Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Asset&#47;Account, Tax Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision replaces Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to staffing-hrconnect&#64;amgen.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;personal data&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received upon exercise of this Option may be deposited.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Due to legal restrictions in Argentina, you may be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; The following provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Option, you acknowledge, understand and agree that the grant of the Option is made by the Company (not your Employer) in its sole discretion and that the value of the Option or any Shares acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information. &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither the Option nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; Provided you are not required to purchase foreign currency and remit funds out of Argentina to acquire Shares under the Plan, local exchange control restrictions would not apply.  However, if so required, you personally are responsible for complying with any and all Argentine currency exchange regulations, approvals and reporting requirements.  Exchange control requirements in Argentina are subject to change&#59; you should consult with your personal advisor regarding any obligations you have under the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you acquire Shares under the Plan and offer the Shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law.  You should consult with your own legal advisor before making any such offer in Australia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Options granted under the Plan, such that the Options are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; If you are an Austrian resident and you hold Shares acquired under the Plapn outside of Austria, you may be subject to reporting obligations to the Austrian National Bank.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A separate reporting requirement applies when you sell Shares acquired under the Plan or receive a cash dividend paid on such Shares.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Taxation of the Option.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Your tax consequences will vary depending on when you accept the Option.  If you accept the Option in writing within 60 days of the offer date, you will be subject to taxation on the 60th day after the offer date.  If you accept the Option more than 60 days after the offer date, you will be subject to taxation at exercise.  Please refer to the additional materials that will be delivered to you for a more detailed description of the tax consequences of accepting the Option.  You should consult your personal tax advisor prior to accepting the Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are a Belgian resident, you are required to report any taxable income attributable to the Option granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares acquired under the Plan) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  By accepting the Option, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the exercise of the Option, the sale of Shares acquired under the Plan and the payment of dividends on such Shares.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Option, you acknowledge (i) that you are making an investment decision, (ii) that the Options will be exercisable by you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$100,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv) leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$100,000 are not required to submit a declaration. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If funds are remitted to purchase Shares abroad, a declaration of the purpose of the remittance must be provided to the local bank that is transferring the funds.  If the funds are remitted to a bank outside the European Union and the amount exceeds a specified amount, documentation evidencing the underlying transaction (for instance a copy of the option agreement) must be provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds a specified amount as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Section IV(B)(1) of the Agreement is amended to read as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as Director to the Company or an Affiliate&#59; in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive the Option and vest under the Plan, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to the Option after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Options, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Language Consent.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention (&#171;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#187;), ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section IX of the Agreement&#58;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Nasdaq Global Select Market).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specified foreign property, including Shares, Options and other rights to receive Shares of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such Options must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The following terms apply only to nationals of the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;) residing in the PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Due to legal restrictions in the PRC, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To comply with requirements imposed by the State Administration of Foreign Exchange, to the extent that, under Section IV of the Agreement, you may exercise any Option after termination of your employment, you will be permitted to exercise such Option for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">shorter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the period set forth in Section IV of the Agreement and six (6) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">months from the date of termination of your employment&#59; any unexercised Option shall immediately lapse six (6) months following the termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company reserves the right to impose such further restrictions or conditions as may be necessary to comply with changes in applicable local laws in the PRC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please note that the above provisions will apply to all Options granted to you under the Plan, as well as to any Options granted to you in the past under the Plan.    </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You understand and agree that, pursuant to PRC exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued upon the exercise of the Option to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds from the sale of the Shares may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the date the Option is exercised and the time that (i) the Tax Obligations are converted to local currency and remitted to the tax authorities, and (ii) net proceeds are converted to local currency and distributed to you. You acknowledge that neither the Company nor any Affiliate will be held liable for any delay in delivering the proceeds to you.  You agree to sign any agreements, forms and&#47;or consents that may be requested by the Company or the Company&#8217;s designated broker to effectuate any of the remittances, transfers, conversions or other processes affecting the proceeds. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The following provision supplements Section XII of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan and related benefits do not constitute a component of &#8220;salary&#8221; for any purpose. Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefits, vacations, indemnities</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Investment in assets located abroad (such as Shares acquired under the Plan) does not require prior approval from the Central Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Banco de la Rep&#250;blica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at exercise (every year as long as you keep them). This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US$22.000)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CROATIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Option, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If you transfer funds into or out of Egypt in connection with the exercise of the Option or the receipt of sale proceeds, you are required to transfer the funds through a registered bank in Egypt.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> There are no specific reporting requirements with respect to foreign assets&#47;accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Terms and Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Language Consent.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By accepting the grant, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise.  Vous acceptez les termes de ces documents en connaissance de cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notifications</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained if (i) the value of the Shares acquired exceeds &#8364;150,000 or (ii) in the unlikely event you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of dividends), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) can be accessed via the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bundesbank&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> website (www.bundesbank.de) and is available in both German and English.  You are responsible for satisfying any applicable reporting obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you exercise the Option through a cash exercise, withdraw funds from a bank in Greece and remit those funds out of Greece (in an amount exceeding a specified threshold), you may be required to submit a written application to the bank.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you exercise the Option by way of a cashless method of exercise as described in Section&#160;II(2)(ii) of the Agreement, this application will not be required because no funds will be remitted out of Greece. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Shares received at exercise are accepted as a personal investment.  In the event that Shares are issued in respect of the Options within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of the Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SECURITIES WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Option and any Shares issued in respect of the Option do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Option and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Due to legal restrictions in Iceland, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notifications</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan, regardless of the value of the Shares acquired under the Plan.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Due to legal restrictions in India, you will not be permitted to pay the exercise price for Shares subject to the Option granted hereunder by a cashless &#8220;sell-to-cover&#8221; procedure, under which method a number of Shares with a value sufficient to cover the exercise price, brokerage fees and any applicable Tax Obligations would be sold upon exercise and you would receive only the remaining Shares subject to the exercised Option.  The Company reserves the right to permit this procedure for payment of the exercise price in the future, depending on the development of local law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;If you remit funds out of India to purchase Shares at exercise of the Option granted hereunder, you are responsible for complying with applicable exchange control regulations.  In particular, it will be your obligation to determine whether approval from the Reserve Bank of India is required prior to exercise or whether you have exhausted the investment limit of US$250,000 for the relevant fiscal year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You must repatriate any cash dividends paid on Shares acquired under the Plan to India, as well as any proceeds from the sale of Shares acquired under the Plan within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash dividends, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Option, you acknowledge that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Due to legal restrictions in Italy, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In accepting this Option, you acknowledge that (1)&#160;you have received a copy of the Plan, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the Option granted, you further acknowledge that you have read and specifically and explicitly approve, without limitation, the following Sections of the Option Agreement&#58; Section I, Section IV, Section V, Section X, Section XII, Section XIII, Section XIV, Section XVII and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is subject to a foreign assets tax at a flat rate.  The fair market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you acquire Shares valued at more than &#165;100,000,000 in a single transaction, you must file a Securities Acquisition Report with the Ministry of Finance through the Bank of Japan within 20 days of the purchase of the Shares.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you pay more than &#165;30,000,000 in a single transaction for the purchase of Shares when you exercise the Option, you must file a Payment Report with the Ministry of Finance through the Bank of Japan by the 20th day of the month following the month in which the payment was made.  The precise reporting requirements vary depending on whether or not the relevant payment is made through a bank in Japan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Payment Report is required independently from a Securities Acquisition Report.  Therefore, if the total amount that you pay upon a one-time transaction for exercising the Option and purchasing Shares exceeds &#165;100,000,000, then you must file both a Payment Report and a Securities Acquisition Report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any outstanding Options, Shares or cash that you hold.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold on any month-end date during a calendar year.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of your Employer, the Company or an Affiliate.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares).  If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement of the Agreement.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the Option granted hereunder, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Option Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section XII of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of the Option granted and&#47;or Shares issued under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;In accepting the Option granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Spanish Translation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Al aceptar cualquier Opci&#243;n bajo el presente documento, usted reconoce que ha recibido una copia del Plan, que ha revisado el mismo en su totalidad, as&#237; como tambi&#233;n el Acuerdo de Opci&#243;n, incluyendo este Ap&#233;ndice, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan y del Opci&#243;n, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n XII del Acuerdo de Opci&#243;n, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el mismo son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de la opci&#243;n otorgada y&#47;o de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Al aceptar cualquier Opci&#243;n bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amgen-M&#233;xico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Asimismo, usted entiende que su participaci&#243;n en el Plan es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Options and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Options may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="ex105image1b.jpg" src="ex105image1b.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return. Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration. Such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information may then be pre-completed in a Norwegian resident&#8217;s tax return. However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Options will be considered assets and are, therefore, subject to wealth tax. An exemption from wealth tax may be available for non-transferrable awards. However, because the wealth tax regulations and the practice of the tax authorities are not well developed, Norwegian residents should provide the tax authorities with information concerning the Options in the annual tax return even if the Norwegian resident maintains that no wealth tax is payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Conhecimento da Lingua.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of dividends in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RUSSIA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Due to legal restrictions in Russia, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You may be required to repatriate cash proceeds from participation in the Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, cash dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment. If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia. After the funds are initially received in Russia, they may be further remitted to other accounts, including ones at foreign banks, in accordance with Russian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of April 17, 2020, the repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You should consult with your personal legal advisor to determine the applicability of the repatriation requirement to any cash received in connection with your participation in the Plan and to ensure compliance with any applicable exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;The Option granted hereunder, the Agreement, including this Appendix, the Plan and all other materials you may receive regarding your participation in the Plan or the Option granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares under the Plan has not and will not be registered in Russia&#59; therefore, Shares may not be offered or placed in public circulation in Russia.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event will Shares acquired under the Plan be delivered to you in Russia&#59; any and all Shares will be maintained on your behalf in the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are not permitted to sell any Shares acquired under the Plan directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Option.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Russian residents are required to notify Russian tax authorities within one (1) month of opening, closing or changing the details of&#160;a foreign account.  Russian residents also are required to submit an annual transaction report for any such foreign brokerage account, including cash flow and financial asset (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Share) transactions, on or before June 1 of the following year.  The tax authorities can require you to provide appropriate supporting documents related to transactions in a foreign bank account.  You are encouraged to contact your personal advisor before remitting your proceeds from participation in the Plan to Russia as exchange control requirements may change. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restriction on Sale and Transferability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You hereby agree that any Shares acquired pursuant to the Option will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The grant of the Option is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Option being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Director Notification Requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act, regardless of whether they are resident or employed in Singapore. Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Options, Shares, etc.) in the Company or any related company within two (2) business days of (i)&#160;its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> when the Shares are sold), or (iii) becoming a director. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;The following provision supplements Section XII of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Option, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant the Option under the Plan to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision, which is entered into upon the express assumption and condition that the Option granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the Agreement, including this Appendix.  Consequently, you understand that the Option granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of the Option since the future value of the Option and the underlying Shares is unknown and unpredictable.  In addition, you understand that the Option granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of an Option or right to an Option shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further, the vesting of the Option is expressly conditioned on your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Option may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section IV of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, subject to a &#8220;despido improcedente&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Options that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that you have read and specifically accept the conditions referred to in Section IV of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;offer of securities to the public,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.&#160;&#160;After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of any previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorization to Withhold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section V of the Agreement&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Options, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon exercise to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Neither this document nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of dividends) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you receive funds in connection with the Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, dividends or sale proceeds) with a value equal to or greater than US$1,000,000 per transaction, you are required to immediately repatriate such funds to Thailand.  Any foreign currency repatriated to Thailand must be converted to Thai Baht or deposited into a foreign currency deposit account opened with any commercial bank in Thailand acting as the authorized agent within 360 days from the date the funds are repatriated to Thailand.  You are also required to inform the authorized agent of the details of the foreign currency transaction, including your identification information and the purpose of the transaction. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you do not comply with the above obligations, you may be subject to penalties assessed by the Bank of Thailand.  Because exchange control regulations change frequently and without notice, you should consult your legal advisor before selling any Shares (or receiving any other funds in connection with the Plan) to ensure compliance with current regulations.  It is your responsibility to comply with exchange control laws in Thailand, and neither the Company nor your Employer will be liable for any fines or penalties resulting from failure to comply with applicable laws.&#160;&#160;&#160;&#160;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Option is made available only to Employees of the Company and its Affiliates, and the offer of participation in the Plan is a private offering.  The grant of the Option and the issuance of Shares at exercise takes place outside of Turkey. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any activity related to investments in foreign securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the sale of Shares under the Plan or the receipt of cash dividends) must be conducted through a bank or financial intermediary institution licensed by the Turkish Capital Markets Board and should be reported to the Turkish Capital Markets Board by the bank or intermediary assisting with the transaction.  You should contact a personal legal advisor for further information regarding these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Options under the Plan are granted only to select Board members and Employees of the Company and its Affiliates and are for the purpose of providing equity </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">incentives.  The Plan and the Agreement are intended for distribution only to such Board members and Employees and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Options offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This provision supplements Section V of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limitation to Section V of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if you are an executive officer or director within the meaning of Section 13(k) of the Exchange Act, as amended from time to time, you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the value of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section V of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Option, as a condition of the Option granted hereunder, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which may be payable by the Company or your Employer with respect to the exercise of the Option and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">issuance of Shares subject to the Option, the assignment or release of the Option for consideration, or the receipt of any other benefit in connection with the Option.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Option, without any liability to the Company or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED STATES</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">TERMS AND CONDITIONS</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The following provision replaces Section IV(B)(1) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not in breach of local labor laws), your right to exercise the Option and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed&#59; provided, however, that such right will be extended by any notice period mandated by law (e.g. the Worker Adjustment and Retraining Notification Act (&#8220;WARN Act&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  Your right, if any, to exercise the Option after termination of employment will be measured by the date of termination of your active employment&#59; provided, however, that such right will be extended by any notice period mandated by law (e.g. the Worker Adjustment and Retraining Notification Act (&#8220;WARN Act&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave, unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  Notwithstanding anything to the contrary herein, in no event shall the term of this Option extend beyond the Expiration Date set forth on the Award Notice and in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Price&#58; &#160;&#160;&#160;&#160;$________</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of Shares</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Covered by Option&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Expiration Date&#58;&#160;&#160;&#160;&#160;The &#91;______ (__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#93; anniversary of the Grant Date</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) carefully.&#160; If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.1pt;font-weight:400;line-height:120%;position:relative;top:-4.89pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">case the Award will be cancelled.&#160; For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">If you do not open a brokerage account by this deadline, your grant will be cancelled.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-30</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>amgn-ex105_20201231xq4.htm
<DESCRIPTION>FORM OF RESTRICTED STOCK UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6f92bc45120443948d8ed12d8c3ff90e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE SPECIFIC TERMS OF YOUR GRANT OF RESTRICTED STOCK UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF RESTRICTED STOCK UNITS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS RESTRICTED STOCK UNIT AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), has granted to you, the grantee named in the Award Notice, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Number of Units with respect to the number of shares of the $0.0001 par value common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) specified in the Award Notice, on the terms and conditions set forth in this Restricted Stock Unit Agreement, any additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Award Notice (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Units shall constitute Restricted Stock Units under Section 9.5 of the Plan, which is incorporated herein by reference.  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;text-decoration:underline">Vesting Schedule and Termination of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.68pt">General.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Agreement, on each Vesting Date, the Number of Units indicated on the Vesting Schedule shall vest, provided that you have remained continuously and actively employed with the Company or an Affiliate (as defined in the Plan) through each applicable Vesting Date, unless (i) &#91;your employment has terminated due to your Voluntary Termination (as defined in paragraph (d) of this Section I below) &#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#91;(ii)&#93; you experience a Qualified Termination (as defined below), or (iii)&#91;(ii)&#93; as otherwise determined by the Company in the exercise of its discretion as provided in paragraph (f) of this Section I.  The Units represent an unfunded, unsecured promise by the Company to deliver Shares.  Only whole Shares shall be issued upon vesting of the Units, and the Company shall be under no obligation to issue any fractional Shares to you.  If your employment with the Company or an Affiliate is terminated for any reason or for no reason, including if your active employment is terminated by the Company or an Affiliate without Cause (as defined below), or in the event of any other termination of your active employment caused directly or indirectly by the Company or an Affiliate, except as otherwise provided in paragraphs (b), (c), &#91;(d), &#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (e) or (f) of this Section I below, your unvested Units shall automatically expire and terminate on the date of </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph (d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">termination of your active employment.  Notwithstanding anything herein to the contrary, the Vesting Schedule may be accelerated (by notice in writing) by the Company in its sole discretion at any time that the Units remain outstanding and unvested (in whole or in part).  In addition, if not prohibited by local law, vesting may be suspended by the Company in its sole discretion during a leave of absence as provided from time to time according to Company policies and practices.  </font></div><div><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Permanent and Total Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding the provisions in paragraph (a) above, if your employment with the Company or an Affiliate terminates due to your Permanent and Total Disability (as defined below), then the vesting of Units granted under this Agreement shall be accelerated, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), to vest as of the day immediately preceding such termination of your employment with respect to all Units granted hereunder, except that if the Units were granted in the calendar year in which such termination occurs, the Units shall be accelerated to vest with respect to a number of Units equal to the number of Units subject to this Agreement multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Permanent and Total Disability without consideration therefor.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.68pt">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the provisions in paragraph (a) above, if your employment with the Company or an Affiliate terminates due to your death, then the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately preceding your death with respect to all Units granted hereunder, except that if the Units were granted in the calendar year in which your death occurs the Units shall be accelerated to vest with respect to a number of Units equal to the number of Units subject to this Agreement multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested shall automatically expire and terminate on the date of the termination of your active employment due to your death without consideration therefor.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">&#91;Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the provisions in paragraph (a) above, if you terminate your employment with the Company or an Affiliate due to your voluntary termination (and such voluntary termination is not the result of Permanent and Total Disability (as defined below)) after you are at least sixty-five (65) years of age, or after you are at least fifty-five (55) years of age and have been an employee of the Company and&#47;or an Affiliate for at least ten (10) years in the aggregate as determined by the Company in its sole discretion according to Company policies and practices as in effect from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voluntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the Units will vest pursuant to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Schedule without regard to the termination of employment prior to the Vesting Date, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), with respect to all Units granted hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if the Units were granted in the calendar year in which the Voluntary Termination occurs, the Units will vest pursuant to the Vesting Schedule provided in the Award Notice, provided, that each tranche of Units scheduled to vest upon each remaining Vesting Date in the Vesting Schedule will vest only with respect to the number of Units in such tranche multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested in excess of such number of Units shall automatically expire and terminate on the date of termination of your active employment due to your Voluntary Termination without consideration therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in the event of your death following your Voluntary Termination, any Units that remain outstanding as of the date of your death will become vested (and the Vesting Date with respect to such Units will occur) as of the day immediately preceding your death.  Notwithstanding the definition of Voluntary Termination set forth above, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in your jurisdiction that would likely result in the favorable treatment upon Voluntary Termination described above being deemed unlawful and&#47;or discriminatory, then the Committee will not apply the favorable treatment described above.&#93;&#91;Reserved&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.68pt">Qualified Termination after a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the provisions in paragraph (a) above, in the event of a Qualified Termination (as defined below), then, to the extent permitted by applicable law, the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately prior to the Qualified Termination.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.01pt">Continued Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the provisions in paragraph (a) above, the Company may in its sole discretion at any time during the term of this Agreement, in writing, otherwise provide that the Units will vest pursuant to the Vesting Schedule without regard to the termination of employment prior to the Vesting Date, subject to any terms and conditions that the Company may determine.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Agreement&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph(d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company or an Affiliate&#59; in the event of termination of your employment (whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are working or the terms of your employment agreement, if any), your right to receive Units and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively providing services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, active employment would not include any period of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">garden leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).  The Company shall have exclusive discretion to determine when you are no longer actively providing services for purposes of this Agreement (including whether you may still be considered to be providing services while on a leave of absence)&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) your conviction of a felony (or similar crime under applicable law, as determined by the Company), or (ii) your engaging in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out your duties, resulting, in either case, in material economic harm to the Company or any Affiliate, unless you believed in good faith that such conduct was in, or not contrary to, the best interests of the Company or any Affiliate.  For purposes of clause (ii) above, no act, or failure to act, on your part shall be deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">willful</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; unless done, or omitted to be done, by you not in good faith&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term under Section 22(e)(3) of the Code and with such permanent and total disability being certified prior to termination of your employment by (i) the U.S. Social Security Administration, (ii) the comparable governmental authority applicable to an Affiliate, (iii) such other body having the relevant decision-making power applicable to an Affiliate, or (iv) an independent medical advisor appointed by the Company in its sole discretion, as applicable, in any such case&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;if you are an employee who participates in the Change of Control Plan (as defined below), your termination of employment within two (2) years following a Change of Control (i) by the Company other than for Cause, Disability (as defined below), or as a result of your death or (ii) by you for Good Reason (as defined in the Change of Control Plan)&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;if you are an employee who does not participate in the Change of Control Plan or the Change of Control Plan is no longer in effect, your termination of employment within two (2) years following a Change of Control by the Company other than for Cause, Disability (as defined below), or as a result of your death&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160; the acquisition (other than from the Company) by any person, entity or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or any of its Affiliates, or any employee benefit plan of the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or any of its Affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then-outstanding Shares or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160; the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company&#8217;s then-outstanding voting securities) or a liquidation or dissolution of the Company or of the sale of all or substantially all of the assets of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein or in the Agreement to the contrary, if a Change of Control constitutes a payment event with respect to any Unit that is subject to United States income tax and which provides for a deferral of compensation that is subject to Section 409A of the Code, the transaction or event described in subsection (A) or (B) above must also constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">change in control event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; as defined in U.S. Treasury Regulation &#167;&#160;1.409A-3(i)(5), in order to constitute a Change of Control for purposes of payment of such Unit.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Company&#8217;s change of control and severance plan, including the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto), or equivalent plan governing the provision of benefits to eligible employees upon the occurrence of a Change of Control (including resulting from a termination of employment that occurs within a specified time period following a Change of Control), as in effect immediately prior to a Change of Control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be determined in accordance with the Company&#8217;s long-term disability plan as in effect immediately prior to a Change of Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to satisfaction of tax or similar obligations as provided for in Section III, any vested Units shall be settled by the Company delivering to you a number of Shares equal to the number of such vested Units or in a lump sum in cash with a value equal to the Fair Market Value of the number of Shares subject to the vested Units as of the applicable Vesting Date (without interest thereon), or in a combination of Shares and cash, as determined by the Administrator at any time prior to settlement and in its discretion, as soon as practicable, and in any event within 90 days, after the applicable Vesting Date, which for purposes of this Section II, includes the date of any accelerated vesting, if any (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  &#91;(For the avoidance of doubt, in the event that any Units continue to vest following a Voluntary Termination in accordance with Section 1(d) above, the Vesting Date(s) for purposes of settlement pursuant to this Section II shall be the regularly scheduled Vesting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dates following such termination.)&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding anything to the contrary in the foregoing, in the event that (i) the vesting and settlement of Units is conditioned on your execution and delivery of a release and (ii) the Settlement Period commences in one calendar year and ends in the next calendar year, the Units will be settled in the second calendar year.  Shares issued in respect of a Unit shall be deemed to be issued in consideration of past services actually rendered by you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.03pt;text-decoration:underline">Tax Withholding&#59; Issuance of Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Obligations&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Units or the underlying Shares, including the grant of the Units, the vesting of Units, the conversion of the Units into Shares or the receipt of an equivalent cash payment, the subsequent sale of any Shares acquired at vesting and the receipt of any Dividends (as defined in Section IV, below) or Dividend Equivalents, and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate your liability for Tax Obligations or achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior to any relevant taxable or tax withholding event, as applicable, you shall pay, or make adequate arrangements satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47;or your Employer or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares acquired upon vesting or payment of the Units either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph (d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;withholding in Shares to be issued or cash to be paid upon vesting or payment of the Units, provided that, if Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value equal to the Tax Obligations.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full number of Shares subject to the vested Units, notwithstanding that a number of the Shares is held back solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any Shares withheld by the Company hereunder shall not be deemed to have been issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.&#160; You agree to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Section III.  Notwithstanding Section II above, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Dividend Equivalents</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Crediting and Payment of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to this Section IV, Dividend Equivalents shall be credited on each Unit granted to you under this Agreement in the manner set forth in the remainder of this Section IV.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the shares of Common Stock subject to the Units are issued to you, whether in the form of cash, Common Stock or other property, then on the date such Dividend is paid to the Company&#8217;s stockholders you shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to you if you held a number of shares of Common Stock equal to the number of your Units as of the record date for such Dividend, unless the Units have been forfeited between the record date and payment date for such Dividend.  Any such Dividend Equivalents shall be credited and deemed reinvested in the Common Stock as of the Dividend payment date.  Dividend Equivalents shall be payable in full shares of Common Stock, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash.  Dividend Equivalents payable with respect to fractional shares of Common Stock shall be paid in cash.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as otherwise expressly provided in this Section IV, any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Unit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">becomes payable.  Dividend Equivalents shall not be payable on any Units that do not vest, or are forfeited, pursuant to the terms of this Agreement.  Dividend Equivalent rights and any amounts that may become distributable in respect thereof shall be treated separately from the Units and the rights arising in connection therewith for purposes of the designation of time and form of payments required by Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No benefit payable under, or interest in, this Agreement or in the Shares that are scheduled to be issued to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, your or your beneficiary&#8217;s debts, contracts, liabilities or torts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, nothing in this Section V shall prevent transfer (i) by will or (ii) by applicable laws of descent and distribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notices provided for in this Agreement or the Plan shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or settlement of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement is subject to all the provisions of the Plan, which provisions are hereby made a part of this Agreement, including without limitation the provisions of Section 9.5 of the Plan relating to Restricted Stock Units, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.37pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The terms of this Agreement shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The time and form of payment of the Units is intended to comply with the requirements of Section 409A and this Agreement shall be interpreted in accordance with Section 409A.  Accordingly, no acceleration or deferral of any payment shall be permitted if it would cause the payment of the Units to violate Section 409A.  In addition, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee (as defined in the Plan) determines that it may be necessary or appropriate to do so, the Committee may adopt such amendments to the Plan and&#47;or this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan and&#47;or the Units from the application of Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Award, or (b) comply with the requirements of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.  For purposes of Section 409A, the right to receive payment of Units at each Vesting Date shall be treated as a right to receive separate and distinct payments. No payment hereunder shall be made to you during the six (6)-month period following your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (within the meaning of Section 409A) to the extent that the Company determines that paying such amount at the time set forth herein would be a prohibited distribution under Section 409A(a)(2)(B)(i). If the payment of any such amounts is delayed as a result of the previous sentence, then within thirty (30) days following the end of such six (6)-month period (or, if earlier, your death), the Company shall pay to you (or to your estate) the cumulative amounts that would have otherwise been payable to you during such period, without interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By electing to accept this Agreement, you acknowledge receipt of this Agreement and hereby confirm your understanding that the terms set forth in this Agreement constitute, subject to the terms of the Plan, which terms shall control in the event of any conflict between the Plan and this Agreement, the entire agreement and understanding of the parties with respect to the matters contained herein and supersede any and all prior agreements, arrangements and understandings, both oral and written, between the parties concerning the subject matter of this Agreement.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Acknowledgement of Nature of Plan and Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting this Agreement, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of Units, or benefits in lieu of Units even if Units have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;your participation in the Plan is voluntary&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the grant of Units, the Shares subject to the Units, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;neither the grant of Units nor any provision of this Agreement, the Plan or the policies adopted pursuant to the Plan confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Units shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;in consideration of the grant of Units hereunder, no claim or entitlement to compensation or damages arises from termination of Units, and no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Units, the Shares subject to the Units, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k) &#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Units and the benefits evidenced by this Agreement do not create any entitlement to have the Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)  for employment law purposes outside the United States, the Units, Shares subject to the Units, and the income from and value of same, are not part of normal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)  neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Units or of any amounts due to you pursuant to the settlement of the Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt;text-decoration:underline">No Advice Regarding Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.37pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provision of this Agreement to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Units granted hereunder shall be subject to any additional terms and conditions for your country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and to the following additional terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;the terms and conditions of this Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration of the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;if applicable, the effectiveness of your award of Units is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;to the extent necessary to comply with applicable foreign laws, the payment of any earned Units shall be made in cash or Common Stock, at the Company&#8217;s election&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;the Company may take any other action, before or after an award of Units is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained herein, the Company shall not take any actions hereunder that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange.  Notwithstanding anything to the contrary contained herein, the Shares issuable upon vesting of the Unit shall not be issued unless such Shares are then registered under the Securities Act, or, if such Shares are not then so registered, the Company has determined that such vesting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and issuance would be exempt from the registration requirements of the Securities Act, and that the issuance satisfied all other applicable legal requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.69pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  In order for the Company to facilitate your participation in the Plan, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Units may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Units or other equity awards and administer or maintain such awards.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.68pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Further, if you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.7pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on your participation in the Plan, on the Units and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.71pt;text-decoration:underline">Compensation Subject to Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160; The Units subject to this Award and all compensation payable with respect to them shall be subject to recovery by the Company pursuant to&#160;any and all of the Company&#8217;s policies with respect to the recovery of compensation, as they shall be in effect and may be amended from time to time, to the maximum extent permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.68pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement&#8217;s section headings are for convenience only and shall not constitute a part of this Agreement or affect this Agreement&#8217;s meaning.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMGEN INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i6f92bc45120443948d8ed12d8c3ff90e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GRANT OF RESTRICTED STOCK UNITS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(BY COUNTRY)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Appendix includes additional terms and conditions that govern any Units granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern any Units granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2020.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you vest in the Units and acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding&#59; Issuance of Certificates.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., Units) or rights linked to the value of Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Dividend Equivalents) during such times as you are considered to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">inside information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).&#160; Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information.  Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">need to know</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; basis) and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account, Tax Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any Dividends or Dividend Equivalents received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter. </font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision replaces Section XIV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to staffing-hrconnect&#64;amgen.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Units may be deposited.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ARGENTINA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; The following provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Agreement, you acknowledge, understand and agree that the grant of the Units is made by the Company (not your Employer) in its sole discretion and that the value of the Units or any Shares acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;Neither the Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; Exchange control regulations in Argentina are subject to frequent change.&#160; You should consult with your personal legal advisor regarding any exchange control obligations that you may have prior to receiving proceeds from Dividend Equivalents, the sale of Shares or dividends.&#160; You must comply with any and all Argentine currency exchange restrictions, approvals and reporting requirements in connection with your participation in the Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Australia Offer Document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The offer of the Award is intended to comply with the provisions of the Corporations Act 2001, ASIC Regulatory Guide 49 and ASIC Class Order CO 14&#47;1000.  Additional details are set forth in the Offer Document for the Offer of Restricted Stock Units to Australian Resident Employees.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Units granted under the Plan, such that the Units are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160; If you are an Austrian resident and you hold Shares acquired under the Plan outside of Austria, you may be subject to reporting obligations to the Austrian National Bank.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; A separate reporting requirement applies when you sell Shares acquired under the Plan, receive a cash Dividend paid on such Shares or Dividend Equivalents paid in cash.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;If you are a Belgian resident, you are required to report any taxable income attributable to the Units granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares acquired under the Plan) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the vesting of the Units, the sale of Shares acquired under the Plan, the payment of Dividends on such Shares and the receipt of any Dividend Equivalents paid in cash.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement of Nature of Plan and Units.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Agreement, you acknowledge (i) that you are making an investment decision, (ii) that the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$100,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv) leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$100,000 are not required to submit a declaration. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds BGN 50,000 as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Section I(i) of the Agreement is amended to read as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive any Units and vest under the Plan, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to the Units after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law.  You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">nor will you be entitled to any compensation for lost vesting.  Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Settlement &#8211; Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any discretion in Section&#160;9.5 of the Plan or anything to the contrary in the Agreement, the Units do not provide any right for you, as a resident of Canada, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Language Consent.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention (&#171;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#187;), ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section XIV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Nasdaq Global Select Market). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specified foreign property, including Shares, stock options and other rights to receive Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Units) of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such stock options and Units must be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The following terms apply only to individuals who are subject to exchange control restrictions in the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;), as determined by the Company in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting of the Units. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;Notwithstanding anything to the contrary in Section I(d) of the Agreement, if your employment with the Company or an Affiliate terminates due to your Voluntary Termination, as defined in Section I(d), then the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately preceding such Voluntary Termination with respect to all Units granted hereunder.&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sale Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Agreement, due to exchange control laws in the PRC, you agree that the Company reserves the right to require the immediate sale of any Shares issued upon settlement of the Units.  You understand and agree that any such immediate sale of Shares will occur as soon as is practical following settlement of the Units.  Alternatively, if the Shares are not immediately sold upon settlement of the Units, the Company will require the sale of any Shares you may then hold within six (6) months (or such other period as may be required under applicable legal or exchange control requirements) following the termination of your employment with the Company including its Affiliates.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You agree that the Company is authorized to instruct Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company to assist with the sale of the Shares on your behalf pursuant to this authorization, and you expressly authorize such broker to complete the sale of such Shares.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company (or the Company&#8217;s designated broker) to effectuate the sale of the Shares (including, without limitation, as to the transfers of the proceeds and other exchange control matters noted below) and to otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur.  Upon the sale of the Shares, you will receive the cash proceeds from the sale, less any applicable Tax Obligations, brokerage fees or commissions, in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph (d) of Section I of the Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company is under no obligation to arrange for the sale of the Shares at any particular price.  Due to fluctuations in the Share price and&#47;or applicable exchange rates between the settlement date and (if later) the date on which the Shares are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the Shares on the settlement date (which is the amount relevant to determining your liability for Tax Obligations).  You understand and agree that the Company is not responsible for the amount of any loss that you may incur and that the Company assumes no liability for any fluctuations in the Share price and&#47;or any applicable exchange rate.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Designated Broker Account.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Shares issued upon the settlement of the Units are not immediately sold, you acknowledge that you are required to maintain the Shares in an account with Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company until the Shares are sold through such Company-designated broker.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You understand and agree that, pursuant to local exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued to you upon settlement of the Units and from the receipt of any Dividends or Dividend Equivalents to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; The following provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan and related benefits do not constitute a component of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; for any purpose.  Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefits, vacations, indemnities,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Investment in assets located abroad (such as Shares acquired under the Plan) does not require prior approval from the Central Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Banco de la Rep&#250;blica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at vesting (every year as long as you keep them).  This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US$22.000).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CROATIA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DENMARK</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the Units, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you transfer funds into Egypt in connection with the Units, you are required to transfer the funds through a registered bank in Egypt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  There are no specific reporting requirements with respect to foreign assets&#47;accounts.  However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported.  If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">terms and Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Language Consent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  By accepting the grant, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained if (i) the value of the Shares acquired exceeds &#8364;150,000 or (ii) in the unlikely event you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of Dividends or Dividend Equivalents), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) can be accessed via the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bundesbank&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> website (www.bundesbank.de) and is available in both German and English.  You are responsible for satisfying any applicable reporting obligation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Settlement &#8211; Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any discretion in Section&#160;9.5 of the Plan or anything to the contrary in the Agreement, the Units do not provide any right for you to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Shares received at vesting are accepted as a personal investment.  In the event that Shares are issued in respect of the Units within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of the Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SECURITIES WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Units and any Shares issued in respect of the Units do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Units and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notifications</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan, regardless of the value of the Shares acquired under the Plan.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;You understand that you must repatriate any cash Dividends paid on Shares acquired under the Plan to India or any Dividend Equivalents paid in cash, as well as any proceeds from the sale of Shares acquired under the Plan within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash Dividends or Dividend Equivalents, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from the bank where you deposit the foreign currency, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement of Nature of Plan and Units.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this Agreement, you understand and agree that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement of Nature of Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In accepting this Agreement, you acknowledge that (1)&#160;you have received a copy of the Plan, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For any Units granted, you further acknowledge that you have read and specifically and explicitly approve, without limitation, the following sections of the Agreement&#58; Section&#160;I&#59; Section&#160;II&#59; Section&#160;III&#59; Section VIII&#59; Section X&#59; Section XI&#59; Section XVI&#59; Section XVII&#59; and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is subject to a foreign assets tax at a flat rate.  The fair market value is considered to be the value of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any Shares or cash that you hold.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold on any month-end date during a calendar year.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible Employees of your Employer, the Company or an Affiliate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares).  If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement of the Agreement.&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section XI of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of the Units granted and&#47;or Shares issued under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;In accepting any Award granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Spanish Translation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Al aceptar cualquier Otorgamiento bajo el presente documento, usted reconoce que ha recibido una copia del Plan, que ha revisado el mismo en su totalidad, as&#237; como tambi&#233;n el Acuerdo de Opci&#243;n, el Acuerdo, incluyendo este Ap&#233;ndice, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan y del Otorgamiento, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n XI del Acuerdo, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el mismo son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de Unidades o de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Al aceptar cualquier Otorgamiento de Acciones bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amgen-M&#233;xico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Asimismo, usted entiende que su participaci&#243;n en el Plan es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Units and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of AmgenMexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="ex105image1a.jpg" src="ex105image1a.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return.  Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration.  Such information may then be pre-completed in a Norwegian resident&#8217;s tax return.  However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry.  If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conhecimento da Lingua.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may be required to repatriate cash proceeds from participation in the Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, cash Dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment.  If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia.  After the funds are initially received in Russia, they may be further remitted to other accounts, including ones at foreign banks, in accordance with Russian exchange control laws.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of April 17, 2020, the repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank.  Statutory exceptions to the repatriation requirement also may apply.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You should consult with your personal legal advisor to determine the applicability of the repatriation requirement to any cash received in connection with your participation in the Plan and to ensure compliance with any applicable exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Any Units granted hereunder, the Agreement, including this Appendix, the Plan and all other materials you may receive regarding your participation in the Plan or any Units granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares under the Plan has not and will not be registered in Russia&#59; therefore, Shares may not be offered or placed in public circulation in Russia.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event will Shares acquired under the Plan be delivered to you in Russia&#59; all Shares will be maintained on your behalf in the United States.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are not permitted to sell any Shares acquired under the Plan directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You acknowledge that if you continue to hold Shares acquired under the Plan after an involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision supplements Section XIV of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Units.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Russian residents are required to notify Russian tax authorities within one (1) month of opening, closing or changing the details of&#160;a foreign account.  Russian residents also are required to submit an annual transaction report for any such foreign brokerage account, including cash flow and financial asset (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Share) transactions, on or before June 1 of the following year.  The tax authorities can require you to provide appropriate supporting documents related to transactions in a foreign bank account.  You are encouraged to contact your personal advisor before remitting your proceeds from participation in the Plan to Russia as exchange control requirements may change.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restriction on Sale and Transferability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You hereby agree that any Shares acquired pursuant to the Units will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The grant of the Units is being made pursuant to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualifying Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Units being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Director Notification Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act, regardless of whether they are resident or employed in Singapore.  Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Units, Shares, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> when the Shares are sold), or (iii) becoming a director.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;The following provision supplements Section XI of the Agreement&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By accepting the Units granted hereunder, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant any Units under the Plan to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision, which is entered into upon the express assumption and condition that any Units granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the Agreement, including this Appendix.  Consequently, you understand that the Units granted hereunder are given on the assumption and condition that they shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of Units since the future value of the Units and the underlying Shares is unknown and unpredictable.  In addition, you understand that any Units granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of Units or right to Units shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further, the vesting of the Units is expressly conditioned on your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Units may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section I of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, subject to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">despido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Units that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that you have read and specifically accept the conditions referred to in Section I of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">offer of securities to the public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.&#160;&#160;After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorization to Withhold.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Units, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vesting or settlement to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Neither this document nor any other materials relating to the Awards (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TAIWAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">THAILAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If proceeds from the sale of Shares or the receipt of any Dividends or Dividend Equivalents exceed US$50,000, you must (i) immediately repatriate such funds to Thailand and (ii) report the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form.  In addition, within three hundred and sixty (360) days of repatriation, you must either convert any funds repatriated to Thailand to Thai Baht or deposit the funds in a foreign exchange account with a Thai commercial bank.    Any such commercial bank must be duly authorized by the Bank of Thailand to engage in the purchase, exchange and withdrawal of foreign currency.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Units are made available only to employees of the Company and its Affiliates, and the offer of participation in the Plan is a private offering.  The grant of the Award and the issuance of Shares at vesting takes place outside of Turkey. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any activity related to investments in foreign securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the sale of Shares under the Plan, the receipt of cash Dividends or Dividend Equivalents) must be conducted through a bank or financial intermediary institution licensed by the Turkish Capital Markets Board and should be reported to the Turkish Capital Markets Board by the bank or intermediary assisting with the transaction.  You should contact a personal legal advisor for further information regarding these requirements.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Units under the Plan are granted only to select Board members and Employees of the Company and its Affiliates and are for the purpose of providing equity incentives.  The Plan and the Agreement are intended for distribution only to such Board members and Employees and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Units offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limitation to Section III of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act, as amended from time to time), you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the value of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section III of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Units, as a condition of the Units granted hereunder, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which may be payable by the Company or your Employer with respect to the Units and&#47;or payment of the Units and issuance of Shares pursuant to the Units, the assignment or release of the Units for consideration, or the receipt of any other benefit in connection with the Units.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section III of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Units, without any liability to the Company or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED STATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The following provision replaces Section I(i) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Units and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such right will be extended by any notice period mandated by law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Worker </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Adjustment and Retraining Notification Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that notwithstanding the effect of any such extension, in no event will the Units be paid later than the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day following your termination of employment&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#93; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Price&#58; &#160;&#160;&#160;&#160;$________</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of Shares&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of Units</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;&#160; Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) carefully.&#160; If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.&#160; For the purpose of determining the forty-five calendar days, </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  If you do not open a brokerage account by this deadline, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">your grant will be cancelled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>amgn-ex107_20201231xq4.htm
<DESCRIPTION>FORM OF PERFORMANCE UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic5ef1dc8183543ed8ab67246cab0e0a7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PERFORMANCE UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE SPECIFIC TERMS OF YOUR GRANT OF PERFORMANCE UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF PERFORMANCE UNITS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS PERFORMANCE UNIT AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), has granted to you, the grantee named in the Award Notice, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Number of Performance Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) specified in the Award Notice on the terms and conditions set forth in this Performance Unit Agreement (and any applicable additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as described in greater detail in Section XIV below)) (collectively, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Plan, the Amgen Inc. 2009 Performance Award Program, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Resolutions (as defined in the Award Notice).  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Performance Period shall have the meaning set forth in the Award Notice.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Value of Performance Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The value of each Performance Unit is equal to a share of Common Stock.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.03pt;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  An amount of the Performance Units up to the maximum amount specified in the Resolutions shall be earned, depending on the extent to which the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">achieves</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> objectively determinable performance goals established by the Committee pursuant to the Resolutions.  The Performance Units earned shall be calculated in accordance with the Resolutions and the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section XIII and except as set forth in the Program, any Performance Units earned pursuant to Section III above shall be settled by the Company delivering to you a number of Shares equal to the number of Shares covered by the earned Performance Units or in a lump sum in cash with a value equal to the Fair Market Value of the number of Shares subject to the earned Performance Units as of the last day of the Performance Period (without interest thereon), or in a combination of Shares and cash, as determined by the Administrator at any time prior to settlement and in its discretion, as soon as practicable, and in any event within 90 days, after the last day of the Performance Period, in each case, subject to the terms of the Program (including Section 4.2 thereof).  Shares issued in respect of a Performance Unit shall be deemed to be issued in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consideration of past services actually rendered by you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period by reason of your Voluntary Retirement and you are Retirement-Eligible on the date of such termination, the full or prorated amount of your Award, if any, applicable to the Performance Period shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which your Voluntary Retirement occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which your Voluntary Retirement occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (b) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (b) shall supersede Section 7.1(a) of the Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.7pt;text-decoration:underline">Death and Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period by reason of your death or Permanent and Total Disability, the full or prorated amount of your Award, if any, applicable to such Performance Period shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which such termination occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which such termination occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, if your employment is terminated due to your Permanent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Total Disability, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (c) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (c) shall supersede Section 7.1(b) of the Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt;text-decoration:underline">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period for any reason other than as specified in paragraphs (b) and (c) above, all of your rights to an Award for the Performance Period shall be forfeited, unless, prior to the payment date described in Article VI of the Program, the Company, in its sole discretion, makes a written determination to otherwise pay the full or prorated amount of your Award, if any, applicable to the Performance Period, which full or prorated amount shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, if the payment of your Award is prorated, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which such termination occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which such termination occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (d) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (d) shall supersede Section 7.1(c) of the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Issuance of Certificates&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and the Program and legally applicable to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company and&#47;or your Employer (i) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Performance Units or the underlying Shares, including the grant of the Performance Units, the vesting of the Performance Units, the conversion of the Performance Units into shares or the receipt of an equivalent cash payment, the subsequent sale of any shares acquired at settlement and the receipt of any Dividends (as defined in Section VI, below) or Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Performance Units to reduce or eliminate your liability for Tax Obligations or to achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47; or your Employer, or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a) &#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares issued upon settlement of the Performance Units, either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;withholding in Shares to be issued or cash to be paid upon settlement of the Performance Units provided that, if Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value equal to the Tax Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full number of shares subject to the earned Performance Units, notwithstanding that a number of Shares is held back solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any Shares withheld by the Company hereunder shall not be deemed to have been issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder).</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan and the Program that cannot be satisfied by the means previously described.  You agree to take any further actions and to execute any additional documents as may be necessary to effectuate the provisions of this Section V.  Notwithstanding Section IV above, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Dividend Equivalents</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Crediting of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to this Section VI, Dividend Equivalents shall be credited on each Performance Unit granted to you under this Agreement in the manner set forth in the remainder of this Section VI.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the Shares subject to the Performance Units are issued to you, whether in the form of cash, Common Stock or other property, then, on the date such  Dividend is paid to the Company&#8217;s stockholders, you shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to you if you held a number of Shares equal to the number of Performance Units granted to you on the Grant Date (including any previously credited Dividends which have been deemed to have been reinvested in Common Stock as provided by the next succeeding sentence), as of each such record date for each such Dividend (not including on any Performance Units which were previously paid or forfeited) as if each such amount had been reinvested in Common Stock as of the date of the payment of such Dividend (such accumulated dividends, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Accumulated Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each such Dividend Equivalent shall be deemed to have been reinvested in Common Stock as of the Dividend payment date.  Dividend Equivalents shall be payable in full Shares, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash.  Dividend Equivalents payable with respect to fractional Shares shall be paid in cash.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as otherwise expressly provided in this Section VI any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Performance Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Performance Unit becomes payable.  Dividend Equivalents shall not be payable on any Performance Units that do not vest, or are forfeited, pursuant to the terms of this Agreement.  Dividend Equivalent rights and any amounts that may become distributable in respect thereof shall be treated separately from the Performance Units and the rights arising in connection therewith for purposes of the designation of time and form of payments required by Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No benefit payable under, or interest in, this Agreement or in the Shares that may become issuable to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, your or your beneficiary&#8217;s debts, contracts, liabilities or torts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, nothing in this Section VII shall prevent transfer (i) by will or (ii) by applicable laws of descent and distribution. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.37pt;text-decoration:underline">No Contract for Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement is not an employment or service contract with the Company or an Affiliate and nothing in this Agreement shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment or service with the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the grant of Performance Units, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Plan and the Program are established voluntarily by the Company, are discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan and in the Program&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the grant of the Performance Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of Performance Units, or benefits in lieu of Performance Units, even if Performance Units have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;your participation in the Plan and the Program is voluntary&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the grant of Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;neither the grant of Performance Units nor any provision of this Agreement, the Plan, the Program or the policies adopted pursuant to the Plan or Program confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g) &#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Performance Units shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;the future value of the Shares that may be earned upon the end of the Performance Period is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160; in consideration of the grant of Performance Units hereunder, no claim or entitlement to compensation or damages arises from termination of Performance Units, and no claim or entitlement to compensation or damages shall arise from forfeiture of the Performance Units resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;in the event of termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive Performance Units and receive shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, active employment would not include a period of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">garden leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Performance Units and the benefits evidenced by this Agreement do not create any entitlement to have the Performance Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;for employment law purposes outside the United States, the Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Performance Units or of any amounts due to you pursuant to the settlement of the Performance Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan and the Program, or your acquisition or sale of the underlying Shares.  You should </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consult with your personal tax, legal and financial advisors regarding your participation in the Plan and the Program before taking any action related thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.35pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notices provided for in this Agreement, the Plan or the Program shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or settlement of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.36pt;text-decoration:underline">Resolutions, Plan and Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement is subject to all of the provisions of the Resolutions, the Plan and the Program and their provisions are hereby made a part of this Agreement and incorporated herein by reference, including, without limitation, the provisions of Articles 5 and 9 of the Plan (relating to Performance-Based Compensation and Performance Awards, respectively) and Section 13.2 of the Plan (relating to adjustments upon changes in the Common Stock), and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Agreement and those of the Resolutions, the Plan and the Program, the provisions of the Plan shall control.  Notwithstanding any provision of this Agreement or the Program to the contrary, any earned Performance Units paid in cash rather than Shares shall not be deemed to have been issued by the Company for any purpose under the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.37pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The time and form of payment of the Performance Units is intended to comply with the requirements of Section 409A and this Agreement shall be interpreted in accordance with Section 409A. Accordingly, no acceleration or deferral of any payment shall be permitted if it would cause the payment of the Performance Units to violate Section 409A.  In addition, notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee determines that it may be necessary or appropriate to do so, the Committee may adopt such amendments to the Plan, Program and&#47;or this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan, Program and&#47;or the Performance Units from the application of Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Award, or (b) comply with the requirements of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.  No payment hereunder shall be made to you during the six (6)-month period following your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (within the meaning of Section 409A) to the extent that the Company determines that paying such amount at the time set forth herein would be a prohibited distribution under Section 409A(a)(2)(B)(i). If the payment of any such amounts is delayed as a result of the previous sentence, then within thirty (30) days following the end of such six (6)-month period (or, if earlier, your death), the Company shall pay to you (or to your estate) the cumulative amounts that would have otherwise been payable to you during such period, without interest.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt;text-decoration:underline">Provisions Applicable to Participants in Foreign Jurisdictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provision of this Agreement or the Program to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, your award of Performance Units shall be subject to any additional terms and conditions for such country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and to the following additional terms and conditions&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the terms and conditions of this Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration of the Plan and the Program&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;if applicable, the effectiveness of your Award is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;to the extent necessary to comply with applicable foreign laws, the payment of any earned Performance Units shall be made in cash or Common Stock, at the Company&#8217;s election&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Committee may take any other action, before or after an award of Performance Units is made, that it deems necessary or advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained herein, the Company shall not take any actions hereunder, and no Award of Performance Units shall be granted, and no Shares payable with respect to an Award shall be issued, that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange. Notwithstanding anything to the contrary contained herein, no Shares issuable with respect to an Award shall be issued unless such shares are then registered under the Securities Act, or, if such shares are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act and that the issuance satisfied all other applicable legal requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:15.68pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. In order for the Company to facilitate your participation in the Plan and the Program, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan and the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8221;).  </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Performance Units may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Performance Units or other equity awards and administer or maintain such awards.   </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Furthermore, if you have received this Agreement or any other document related to the Plan and&#47;or the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.7pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The terms of this Agreement shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.71pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to&#160;deliver any documents related to current or future participation in the Plan and&#47;or the Program (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.68pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on your participation in the Plan and the Program, on the Performance Units and on any Shares acquired under the Plan and the Program, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XXI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XXII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.7pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement&#8217;s section headings are for convenience only and shall not constitute a part of this Agreement or affect this Agreement&#8217;s meaning.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMGEN INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;___________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="ic5ef1dc8183543ed8ab67246cab0e0a7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD OF PERFORMANCE UNITS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(BY COUNTRY)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Appendix includes additional terms and conditions that govern any Performance Units granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern the Performance Units granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2020.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan and the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the notifications are gen eral in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance of Certificates&#59; Tax Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision supplements Section V. of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., Performance Units) or rights linked to the value of Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Dividend Equivalents) during such times as you are considered to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">inside information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).&#160; Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information.  Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">need to know</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; basis) and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account, Tax Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any Dividends or Dividend Equivalents received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter.  </font></div><div style="margin-bottom:12pt;text-indent:31.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision replaces Section XV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan and the Program.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to staffing-hrconnect&#64;amgen.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8221;).  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Performance Units may be deposited.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ARGENTINA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the grant of Performance Units, you acknowledge, understand and agree that the grant of the Performance Units is made by the Company (not your Employer) in its sole discretion and that the value of the Performance Units or any Shares acquired under the Plan and the Program shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;Neither the Performance Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; Exchange control regulations in Argentina are subject to frequent change.&#160; You should consult with your personal legal advisor regarding any exchange control obligations that you may have prior to receiving proceeds from Dividend Equivalents, the sale of Shares or dividends.&#160; You must comply with any and all Argentine currency exchange restrictions, approvals and reporting requirements in connection with your participation in the Plan and the Program. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Australia Offer Document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The offer of the Award is intended to comply with the provisions of the Corporations Act 2001, ASIC Regulatory Guide 49 and ASIC Class Order CO 14&#47;1000.  Additional details are set forth in the Offer Document for the Offer of Performance Units to Australian Resident Employees.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Performance Units granted under the Plan, such that the Performance Units are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; If you are an Austrian resident and you hold Shares acquired under the Plan and the Program outside of Austria, you may be subject to reporting obligations to the Austrian National Bank. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  A separate reporting requirement applies when you sell Shares acquired under the Plan and the Program, receive a cash Dividend paid on such Shares or Dividend Equivalents paid in cash.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;If you are a Belgian resident, you are required to report any taxable income attributable to the Award granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares acquired under the Plan and the Program) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  By accepting the Performance Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the vesting of the Performance Units, the sale of Shares acquired under the Plan and the Program, the payment of Dividends on such Shares and the receipt of any Dividend Equivalents paid in cash.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the grant of Performance Units, you acknowledge (i) that you are making an investment decision, (ii) that the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$100,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv)&#160;leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan and the Program&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$100,000 are not required to submit a declaration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds BGN 50,000 as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This provision supplements Section IX(j) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive an Award and vest in such Award under the Plan and the Program, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to an Award after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. Notwithstanding the foregoing, if applicable employment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Performance Units, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Settlement - Performance Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any discretion in Section 9.5 of the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Canada, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Language Consent.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention (&#171;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#187;), ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section XV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan and the Program.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Nasdaq Global Select Market).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specified foreign property, including Shares, stock options and other rights to receive Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Performance Units) of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such stock options and Performance Units must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The following terms apply only to individuals who are subject to exchange control restrictions in the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;), as determined by the Company in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting of the Performance Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding anything to the contrary in Article 7.1 of the Program, if your employment with the Company or an Affiliate terminates at any time during the Performance Period, you shall forfeit all Performance Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sale Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Agreement, due to exchange control laws in the PRC, you agree that the Company reserves the right to require the immediate sale of any Shares acquired upon settlement of the Performance Units.  You understand and agree that any such immediate sale of Shares will occur as soon as is practical following settlement of the Performance Units.  Alternatively, if the Shares are not immediately sold upon settlement of the Performance Units, the Company will require the sale of any Shares you may then hold within six (6) months (or such other period as may be required under applicable legal or exchange control requirements) following the termination of your employment with the Company, including its Affiliates.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You agree that the Company is authorized to instruct Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company to assist with the sale of the Shares on your behalf pursuant to this authorization, and you expressly authorize such broker to complete the sale of such Shares.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company (or the Company&#8217;s designated broker) to effectuate the sale of the Shares (including, without limitation, as to the transfers of the proceeds and other exchange control matters noted below) and to otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur.  Upon the sale of the Shares, you will receive the cash proceeds from the sale, less any applicable Tax Obligations, brokerage fees or commissions, in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company is under no obligation to arrange for the sale of the Shares at any particular price.  Due to fluctuations in the Share price and&#47;or applicable exchange rates between the settlement date and (if later) the date on which the Shares are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the Shares on the settlement date (which is the amount relevant to determining your liability for Tax </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligations).  You understand and agree that the Company is not responsible for the amount of any loss that you may incur and that the Company assumes no liability for any fluctuations in the Share price and&#47;or any applicable exchange rate.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Designated Broker Account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If Shares issued upon the settlement of the Performance Units are not immediately sold, you acknowledge that you are required to maintain the Shares in an account with Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company until the Shares are sold through such Company-designated broker.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You understand and agree that, pursuant to local exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued upon settlement of the Performance Units and from the receipt of any Dividends or Dividend Equivalents to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan, the Program and related benefits do not constitute a component of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; for any purpose. Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and therefore the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Investment in assets located abroad (such as Shares acquired under the Plan and the Program) does not require prior approval from the Central Bank (Banco de la Rep&#250;blica).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at vesting (every year as long as you keep them).  This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US $22.000).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CROATIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan and the Program) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the Performance Units, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you transfer funds into Egypt in connection with the Performance Units, you are required to transfer the funds through a registered bank in Egypt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no specific reporting requirements with respect to foreign assets&#47;accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">terms and Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Language Consent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  By accepting the Award, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Consentement Relatif &#224; la Langue Utilis&#233;e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  En acceptant l&#8217;prix, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained if (i) the value of the Shares acquired exceeds &#8364;150,000 or (ii) in the unlikely event you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of Dividends or Dividend Equivalents), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) can be accessed via the Bundesbank&#8217;s website (www.bundesbank.de) and is available in both German and English. You are responsible for satisfying any applicable reporting obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Settlement - Performance Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any discretion in Section 9.5 of the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Hong Kong, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Shares received at vesting are accepted as a personal investment.  In the event that Shares are issued in respect of Performance Units within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of such Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SECURITIES WARNING&#58;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Performance Units and any Shares issued in respect of the Performance Units do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Performance Units and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notifications</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan and the Program, regardless of the value of the Shares acquired under the Plan and the Program.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;You understand that you must repatriate any cash Dividends paid on Shares acquired under the Plan and the Program to India or any Dividend Equivalents paid in cash, as well as any proceeds from the sale of Shares within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash Dividends or Dividend Equivalents, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the grant of Performance Units, you acknowledge that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In accepting the grant of Performance Units, you acknowledge that (1)&#160;you have received a copy of the Plan, the Program, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Program, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You further acknowledge that you have read and specifically and explicitly approve, without limitation, the following sections of the Agreement&#58; Section III, Section IV, Section V, Section IX, Section IV, Section XVI, Section XX and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is subject to a foreign assets tax at a flat rate.  The market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan and the Program) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any Shares or cash that you hold.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold on any month-end date during a calendar year.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible Employees of your Employer, the Company or an Affiliate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares). If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement of the Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan and the Program, have reviewed the Plan and the Program and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan, the Program and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section IX of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan and the Program do not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan and the Program are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan and the Program is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of any Shares issued with respect to the Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;In accepting any Award granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the Program and the benefits that you may derive from participation in the Plan and the Program do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You further understand that your participation in the Plan and the Program is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen&#160;Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Spanish Translation </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Al aceptar cualquier Otorgamiento de Acciones bajo el presente documento, usted reconoce que ha recibido una copia del Plan y del Programa, que ha revisado el Plan y el Programa, as&#237; como tambi&#233;n el Ap&#233;ndice en su totalidad, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan, del Programa y del Otorgamiento, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n IX del Acuerdo del Otorgamiento, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan y en el Programa de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Su participaci&#243;n en Plan y en el Programa son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan y en el Programa es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Al aceptar cualquier Otorgamiento bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y el Programa y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Asimismo, usted entiende que su participaci&#243;n en el Plan y en el Programa es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Performance Units and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Performance Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="ex105image1c.jpg" src="ex105image1c.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return. Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration. Such information may then be pre-completed in a Norwegian resident&#8217;s tax return. However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If any transfer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan, the Program and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conhecimento da Lingua.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano, no Programa e no Acordo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may be required to repatriate cash proceeds from participation in the Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, cash Dividends, sale proceeds ) as soon as you intend to use those cash amounts for any purpose, including reinvestment. If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia. After the funds are initially received in Russia, they may be further remitted to other accounts, including ones at foreign banks, in accordance with Russian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of April 17, 2020, the repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You should consult with your personal legal advisor to determine the applicability of the repatriation requirement to any cash received in connection with your participation in the Plan and to ensure compliance with any applicable exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;The Award granted hereunder, the Agreement, including this Appendix, the Program, the Plan and all other materials you may receive regarding your participation in the Plan and the Program or the Award granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares in respect of the Award has not and will not be registered in Russia&#59; therefore, such Shares may not be offered or placed in public circulation in Russia.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event will Shares acquired under the Plan and the Program be delivered to you in Russia&#59; all Shares will be maintained on your behalf in the United States.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are not permitted to sell any Shares acquired under the Plan and the Program directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You acknowledge that if you continue to hold Shares acquired under the Plan and the Program after an involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The following provision supplements Section XV of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or maintain the Performance Units.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Russian residents are required to notify Russian tax authorities within one (1) month of opening, closing or changing the details of&#160;a foreign account.  Russian residents also are required to submit an annual transaction report for any such foreign brokerage account, including cash flow and financial asset (e.g., Share) transactions, on or before June 1 of the following year.  The tax authorities can require you to provide appropriate supporting documents related to transactions in a foreign bank account.  You are encouraged to contact your personal advisor before remitting your proceeds from participation in the Plan to Russia as exchange control requirements may change.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan and the Program).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restriction on Sale and Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You hereby agree that any Shares acquired pursuant to the Performance Units will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; ), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The grant of the Performance Units is being made pursuant to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualifying Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Performance Units being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Director Notification Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, regardless of whether they are resident or employed in Singapore. Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Performance Units, Shares, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> when the Shares are sold), or (iii) becoming a director.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;The following provision supplements Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By accepting the Award granted hereunder, you consent to participation in the Plan and the Program and acknowledge that you have received a copy of the Plan and the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant the Award under the Plan and the Program to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that the Awards granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the applicable Agreement, including this Appendix.  Consequently, you understand that the Award granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of the Award since the future value of the Award and any Shares that may be issued in respect of such Award is unknown and unpredictable.  In addition, you understand that the Award granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then the grant of the Award or right to the Award shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further, the vesting of the Performance Units is expressly conditioned your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Performance Units may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section I of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, subject to a &#8220;d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">espido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Performance Units that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that you have read and specifically accept the conditions referred to in Section I of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">offer of securities to the public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.  After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorization to Withhold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Performance Units, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon vesting or settlement to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160; Neither this document nor any other materials relating to the Performance Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available to any person other than an employee of the Company or one of its Subsidiaries in Switzerland or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If proceeds from the sale of Shares or the receipt of any Dividends or Dividend Equivalents exceed US$50,000, you must (i) immediately repatriate such funds to Thailand and (ii) report the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form.  In addition, within three hundred and sixty (360) days of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">repatriation, you must either convert any funds repatriated to Thailand to Thai Baht or deposit the funds in a foreign exchange account with a Thai commercial bank.  Any such commercial bank must be duly authorized by the Bank of Thailand to engage in the purchase, exchange and withdrawal of foreign currency.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Performance Units are made available only to employees of the Company and its Affiliates, and the offer of participation in the Plan is a private offering.  The grant of the Award and the issuance of Shares at vesting takes place outside of Turkey. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any activity related to investments in foreign securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the sale of Shares under the Plan, the receipt of cash Dividends or Dividend Equivalents) must be conducted through a bank or financial intermediary institution licensed by the Turkish Capital Markets Board and should be reported to the Turkish Capital Markets Board by the bank or intermediary assisting with the transaction.  You should contact a personal legal advisor for further information regarding these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Performance Units under the Plan are available only to Participants under the Program and are for the purpose of providing equity incentives.  The Plan, the Program and the Agreement are intended for distribution only to such Participants and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Performance Units offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This provision supplements Section V of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limitation to Section V of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (or any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act, as amended, from time to time), you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the value of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section V of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Performance Units, as a condition of the Award, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) which may be payable by the Company or your Employer with respect to the earning and&#47;or payment of the Performance Units and issuance of Shares in respect of the Performance Units, the assignment or release of the Performance Units for consideration or the receipt of any other benefit in connection with the Performance Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law.  You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer.  You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement.</font></div><div id="ic5ef1dc8183543ed8ab67246cab0e0a7_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Performance Units, without any liability to the Company or your Employer.   </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED STATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The following provision replaces Section IX(j) of the Award Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Performance Units and receive Shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such right will be extended by any notice period mandated by law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., the Worker Adjustment and Retraining Notification Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  In such event, payment of the Performance Units shall be made in accordance with Section IV&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that notwithstanding the effect of any such extension, subject to Section 4.2 of the Program, in no event will the Performance Units be paid later than the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day following the last day of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#93; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Program&#160;&#160;&#160;&#160;Amgen Inc. 2009 Performance Award Program, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of Shares&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Units&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Period&#58;&#160;&#160;&#160;&#160;The Performance Period beginning on                           and ending on                           .</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Resolutions&#58;&#160;&#160;&#160;&#160;The Resolutions of the Compensation and Management Development Committee of the Board of Directors of Amgen Inc. establishing the performance goals and Performance Period applicable to this Award.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) carefully.  If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.  For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">If you do not open a brokerage account by this deadline, your grant will be cancelled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX A-29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>6
<FILENAME>amgn-ex108_20201231xq4.htm
<DESCRIPTION>DIRECTOR EQUITY INCENTIVE PROGRAM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9d9a172939994ea294cfb1b315c87e79_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Effective January 1, 2021 (the &#8220;Effective Date&#8221;))</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As Amended and Restated October 21, 2020</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE I</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PURPOSE</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The purpose of this document is to set forth the general terms and conditions of the Amgen Inc. 2009 Director Equity Incentive Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) established by the Board of Directors of Amgen Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) including, with respect to certain awards granted to Non-Employee Directors of the Company hereunder, pursuant to the Company&#8217;s 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2009 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Program is intended to provide a means to reinforce and motivate the Non-Employee Directors of the Company to focus on sustained long-term performance and value creation by awarding each such Non-Employee Director (alternatively, each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) stock or stock-based awards, subject to the restrictions and other provisions of the Program and, as applicable, the 2009 Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE II</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unless otherwise defined herein, capitalized terms used herein shall have the meanings assigned to such terms in the 2009 Plan. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alternate Payee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the spouse, former spouse or child of an Eligible Director.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a Restricted Stock Unit granted to an Eligible Director pursuant to the Program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Board of Directors of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Compensation Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each date that the Company makes an Eligible Periodic Cash Compensation payment to Eligible Directors who have not elected to defer such compensation pursuant to Section 3.2 of this Program or the Deferred Compensation Program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Internal Revenue Code of 1986, as amended from time to time, together with the regulations and official guidance promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the common stock, par value $0.0001 per share, of the Company.&#160;&#160;&#160;&#160;</font></div><div id="i9d9a172939994ea294cfb1b315c87e79_4"></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Compensation Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Amgen Nonqualified Deferred Compensation Plan, as amended and&#47;or restated from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a member of the Board who is not an employee of the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Periodic Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Board retainer, committee meeting fees and&#47;or, if applicable, chair, lead independent director or other fees payable periodically to an Eligible Director by the Company for services performed as a member of the Board in respect of the applicable period to which such retainer and&#47;or fees relate, in each case, with respect to which no valid deferral election has been made under the Deferred Compensation Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Final Eligible Periodic Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last Eligible Periodic Cash Compensation amount earned by a Participating Eligible Director (but not paid by the Company) prior to the date that such director retires from, or otherwise ceases to serve as a member of, the Board.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participating Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an Eligible Director who, pursuant to Sections 3.2(e) or (f), has elected to receive deferred Restricted Stock Units in lieu of all or a portion of his or her Eligible Periodic Cash Compensation for a given calendar year or any remainder thereof, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">QDRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act of 1974, as amended from time to time, or the rules thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a restricted right to receive, on the applicable settlement date, a share of Common Stock or an amount in cash equal to the Fair Market Value of a share of Common Stock as of such settlement date, granted pursuant to Article III.  For the avoidance of doubt, Restricted Stock Units may, but need not be, granted pursuant to the 2009 Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RESTRICTED STOCK UNITS</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.1&#160;&#160;&#160;&#160;(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On the date of each annual meeting of stockholders of the Company, beginning with the 2021 annual meeting of stockholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each person who is at that time elected to serve as an Eligible Director shall automatically be granted, without further action by the Company, the Board, or the Company&#8217;s stockholders, Restricted Stock Units to acquire a number of shares of Common </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Stock (rounded down to the nearest whole number) equal to the quotient obtained by dividing (x) $210,000, by (y) the closing market price of a share of Common Stock on the Annual Grant Date (rounded to two decimal places) (such Restricted Stock Units, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, each person who becomes an Eligible Director during the period following the Annual Grant Date with respect to any year and the date of the next annual meeting of stockholders (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall automatically be granted, on the date which is two business days after the release of the Company's quarterly or annual earnings for the Initial Period next following such person becoming an Eligible Director, and without further action by the Company, the Board, or the Company&#8217;s stockholders, a prorated Annual RSU Award (rounded down to the nearest whole number) for the Initial Period based on the number of months during which such person would serve as an Eligible Director during the Initial Period if the Eligible Director were to serve through the end of the Initial Period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly Grants in Lieu of Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Participating Eligible Director shall automatically be granted, on the date which is two business days after the release of the Company&#8217;s quarterly earnings for the fiscal quarter most recently ending after the occurrence of each applicable Cash Compensation Payment Date (each such date of grant, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Restricted Stock Unit awards as follows&#58; (i) with respect to each such Eligible Periodic Cash Compensation amount other than Final Eligible Periodic Cash Compensation, deferred Restricted Stock Units to acquire a number of shares of Common Stock (rounded to four decimal places) equal to the quotient obtained by dividing (x) the dollar value of such Eligible Periodic Cash Compensation amount by (y) the closing market price of a share of Common Stock on such Quarterly Grant Date (rounded to two decimal places), and (ii) with respect to Final Eligible Periodic Cash Compensation, a number of cash-settled deferred Restricted Stock Units equal to the quotient obtained by dividing (x) the dollar value of such Final Eligible Periodic Cash Compensation by (y) the closing market price of a share of Common Stock on such Quarterly Grant Date (rounded to two decimal places) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cash-Settled RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the Restricted Stock Units described in (i), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly RSU Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Cash-Settled RSU granted pursuant to Section 3.1(b)(ii) shall represent a restricted right to receive, on the applicable Deferred Payment Date (as defined in Section 3.2(d) below), an amount in cash per Restricted Stock Unit equal to the Fair Market Value of a share of Common Stock as of such Deferred Payment Date.  For the avoidance of doubt, no portion of the Board retainer, committee meeting fees or, if applicable, chair, lead independent director or other fees payable to an Eligible Director by the Company for services performed as a member of the Board with respect to which a valid deferral election has been made by such Eligible Director pursuant to the Deferred Compensation Plan shall constitute &#8220;Eligible Periodic Cash Compensation&#8221; hereunder.  In the event of any conflict between the deferral elections made by an Eligible Director pursuant to the Deferred Compensation Plan and this Program, the deferral election made under the Deferred Compensation Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any fractional Restricted Stock Units that remain outstanding as of the Deferred Payment Date shall represent a restricted right to receive, on the applicable Deferred Payment Date, an amount in cash per fractional Restricted Stock Unit equal to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">corresponding fraction of the Fair Market Value of a share of Common Stock as of such Deferred Payment Date, and any such fractional Restricted Stock Units shall be settled in cash.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Restricted Stock Units, other than Cash-Settled RSUs, shall constitute Restricted Stock Units under Section 9.5 of the 2009 Plan. Cash-Settled RSUs granted pursuant to Section 3.1(b)(ii) hereof shall not be granted under, or subject to the terms of, the 2009 Plan. Each Restricted Stock Unit granted pursuant to this Program shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate.  The provisions of separate Restricted Stock Units need not be identical, but each Restricted Stock Unit shall include (through incorporation of provisions hereof by reference in the Restricted Stock Unit agreement or otherwise) the substance of each of the following provisions as set forth in this Section 3.2 and Section 9.5 of the 2009 Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;Each grant of Restricted Stock Units made to an Eligible Director shall be fully vested as of the date of grant of such Restricted Stock Units (such date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).    </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;A holder&#8217;s vested Restricted Stock Units shall be paid by the Company in shares of Common Stock (on a one-to-one basis) on, or as soon as practicable after, the Vesting Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), but in any event by the fifteenth day of the third month following the end of the tax year in which such Restricted Stock Units vest, unless the payment of such Restricted Stock Units has been properly deferred pursuant to this Section 3.2.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)&#160;&#160;&#160;&#160;With respect to an Eligible Director&#8217;s Annual RSU Award, such Eligible Director may irrevocably elect in writing by December 31 of the year preceding the grant of such Annual RSU Award to defer the payment of such Annual RSU Award, and any dividends paid thereon, to another date under one of the following options (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which payment form or forms shall be specified at the time of the deferral election&#58; (i) full payment of the vested Restricted Stock Units in January of a year specified by the Eligible Director which shall be no earlier than the third calendar year following the calendar year in which the date of grant occurs and no later than the tenth calendar year following such year&#59; (ii) full payment of the vested Restricted Stock Units in January of the calendar year following the year in which the Eligible Director with respect to whom the Restricted Stock Units were granted ceases to be an Eligible Director and ceases to otherwise provide services to the Company in a manner that constitutes a &#8220;separation from service&#8221; (within the meaning of Code Section 409A) for any reason&#59; (iii) payment of the vested Restricted Stock Units in five substantially equal annual installments, commencing in January of the calendar year following the year in which the Eligible Director with respect to whom the Restricted Stock Units were granted ceases to be an Eligible Director and ceases to otherwise provide services to the Company in a manner that constitutes a &#8220;separation from service&#8221; (within the meaning of Code Section 409A) for any reason&#59; or (iv) payment of the vested Restricted Stock Units in ten substantially equal annual installments, commencing in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">January of the calendar year following the year in which the Eligible Director with respect to whom the Restricted Stock Units were granted ceases to be an Eligible Director and ceases to otherwise provide services to the Company in a manner that constitutes a &#8220;separation from service&#8221; (within the meaning of Code Section 409A) for any reason.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(e)&#160;&#160;&#160;&#160;On or before December 31 of any year, an Eligible Director may irrevocably elect in writing to receive deferred Restricted Stock Units in lieu of all or a portion of his or her Eligible Periodic Cash Compensation earned during the year following the year of such election. In the event of such election, such Eligible Director shall be granted Quarterly RSU Awards pursuant to Section 3.1(b) hereof and, at the time of any such election, such Eligible Director shall further irrevocably elect in writing to defer the payment of such Quarterly RSU Award, and any dividends paid thereon, to a Deferred Payment Date in accordance with Section 3.2(d) hereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(f)&#160;&#160;&#160;&#160;Notwithstanding anything in Sections 3.2(d) or 3.2(e) to the contrary, any person who shall become an Eligible Director during any year, and who was not an Eligible Director on the preceding December 31, may elect within thirty (30) days after such person first becomes an Eligible Director to (i) defer payment of the portion of such Eligible Director&#8217;s Annual RSU Award earned during the remainder of such year and any dividends paid thereon, to a Deferred Payment Date, and (ii) receive Restricted Stock Units in lieu of all or a portion of his or her Eligible Periodic Cash Compensation earned during the remainder of such year and granted as deferred Quarterly RSU Awards pursuant to Section 3.1(b) hereof, the payment of which (and any dividends paid thereon) shall be deferred to a Deferred Payment Date.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(g)&#160;&#160;&#160;&#160;In each case, any shares of Common Stock issued in respect of a Restricted Stock Unit shall be deemed to be issued in consideration for future services to be rendered or past services actually rendered to the Company or for its benefit, by the Eligible Director, which the Board deems to have a value not less than the par value of a share of Common Stock.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Crediting and Payment of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to this Section 3.3, Dividend Equivalents shall be credited on each Restricted Stock Unit (including fractional Restricted Stock Units) granted to an Eligible Director under the Program in the manner set forth in the remainder of this Section 3.3.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the date of grant through and including the day immediately preceding the day the shares of Common Stock and&#47;or the cash amount subject to the Restricted Stock Units are issued or paid to the Eligible Director, whether in the form of cash, Common Stock or other property, then on the date such Dividend is paid to the Company&#8217;s stockholders the Eligible Director shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to the Eligible Director if the Eligible Director held a number of shares of Common Stock (including fractional shares) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">equal to the number of the Eligible Director&#8217;s Restricted Stock Units (including fractional Restricted Stock Units) as of the record date for such Dividend.  Any such Dividend Equivalents, including Dividend Equivalents with respect to Cash-Settled RSUs, shall be credited and deemed reinvested in the Common Stock as of the Dividend payment date.  Dividend Equivalents with respect to Quarterly RSU Awards other than Cash-Settled RSUs shall be payable in full shares of Common Stock, unless the Board determines, at any time prior to payment and in its discretion, that they shall be payable in cash, and Dividend Equivalents with respect to Cash-Settled RSUs granted pursuant to Section 3.1(b)(ii) hereof shall be payable in cash. Dividend Equivalents payable with respect to fractional shares of Common Stock shall be paid in cash.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except as otherwise expressly provided in this Section 3.3, any Dividend Equivalents credited to an Eligible Director shall be subject to all of the provisions of the Program and the Restricted Stock Unit Agreement which apply to the Restricted Stock Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Restricted Stock Unit becomes payable.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IV</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Administration of the Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Program shall be administered by the Board and, to the extent permitted by applicable law or the rules of any Securities Exchange, the Board may delegate to a committee of one or more members of the Board the authority to administer the Program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of 2009 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Program is subject to all of the provisions of the 2009 Plan, including Section 13.2 thereof (relating to adjustments upon changes in the Common Stock), and its provisions are hereby made a part of the Program, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the 2009 Plan.  In the event of any conflict between the provisions of this Program and those of the 2009 Plan, the provisions of the 2009 Plan shall control.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything herein to the contrary, the Board may, at any time, terminate, modify or suspend the Program&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, without the prior consent of the Eligible Directors affected, no such action may adversely affect any rights or obligations with respect to any Awards theretofore earned but unpaid, whether or not the amounts of such Awards have been computed and whether or not such Awards are then payable.  Any amendment of this Program may, in the sole discretion of the Board, be accomplished in a manner calculated to cause such amendment not to constitute an &#8220;extension,&#8221; &#8220;renewal&#8221; or &#8220;modification&#8221; (each within the meaning of Code Section 409A) of any Restricted Stock Units that would cause such Restricted Stock Units to be considered &#8220;nonqualified deferred compensation&#8221; (within the meaning of Code Section 409A).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Contract for Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing contained in the Program or in any document related to the Program or to any Award shall confer upon any Eligible Director any right to continue as a director or in the service of the Company or an Affiliate or constitute any contract or agreement of service for a specific term or interfere in any way with the right of the Company or an Affiliate to reduce such person&#8217;s compensation or to remove, disqualify or otherwise terminate the service of such person, with or without cause. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;No benefit payable under, or interest in, this Program shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, debts, contracts, liabilities or torts of any Eligible Director or beneficiary&#59; provided, however, that, nothing in this Section 4.5 shall prevent transfer (i) by will, (ii) by applicable laws of descent and distribution or (iii) to an Alternate Payee to the extent that a QDRO so provides. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;The transfer to an Alternate Payee of an Award pursuant to a QDRO shall not be treated as having caused a new grant.  If an Award is so transferred, the Alternate Payee generally has the same rights as the Eligible Director under the terms of the Program&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) the Award shall be subject to the same terms and conditions, including the vesting terms and termination provisions, as if the Award were still held by the Eligible Director, and (ii) such Alternate Payee may not transfer an Award, except transfer (1) by will or (2) by applicable laws of descent and distribution.  In the event of the Company Stock Administrator&#8217;s receipt of a domestic relations order or other notice of adverse claim by an Alternate Payee of an Eligible Director of an Award, transfer of the proceeds of such Award, whether in the form of cash, stock or other property, may be suspended.  Such proceeds shall thereafter be transferred pursuant to the terms of a QDRO or other agreement between the Eligible Director and Alternate Payee.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Eligible Director, beneficiary or other person shall have any right, title or interest in any fund or in any specific asset of the Company or any Affiliate by reason of any award hereunder.  There shall be no funding of any benefits which may become payable hereunder.  Nothing contained in this Program (or in any document related thereto), nor the creation or adoption of this Program, nor any action taken pursuant to the provisions of this Program shall create, or be construed to create, a trust of any kind or a fiduciary relationship between the Company or an Affiliate and any Eligible Director, beneficiary or other person.  To the extent that an Eligible Director, beneficiary or other person acquires a right to receive payment with respect to an award hereunder, such right shall be no greater than the right of any unsecured general creditor of the Company or other employing entity, as applicable.  All amounts payable under this Program shall be paid from the general assets of the Company or employing entity, as applicable, and no special or separate fund or deposit shall be established and no segregation of assets shall be made to assure payment of such amounts.  Nothing in this Program shall be deemed to give any person any right to participate in this Program except in accordance herewith.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Program shall be construed in accordance with the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;To the extent that this Program constitutes a &#8220;non-qualified deferred compensation plan&#8221; within the meaning of Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date, this Program shall be interpreted and operated in accordance with Code Section 409A.  Notwithstanding any provision of this Program to the contrary, in the event that following the grant of any Restricted Stock Units, the Board determines that any Award does or may violate any of the requirements of Code Section 409A, the Board may adopt such amendments to the Program and any affected Award or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Board determines are necessary or appropriate to (a) exempt the Program and any such Award from the application of Code Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to the Award, or (b) comply with the requirements of Code Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this paragraph shall not create an obligation on the part of the Board to adopt any such amendment, policy or procedure or take any such other action.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>7
<FILENAME>amgn-ex1050_20201231xq4.htm
<DESCRIPTION>AMENDMENT NO. 7 TO THE COLLABORATION AGREEMENT BETWEEN AMGEN AND ASTRAZENECA
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i63b31f0419da433ea8c41dc7d4b023b6_1"></div><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &#8220;&#91;***&#93;&#8221;.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 7</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">COLLABORATION AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment No. 7 to the Collaboration Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of the 17th day of December, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AstraZeneca Collaboration Ventures, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AstraZeneca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Amgen and AstraZeneca are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Amgen and AstraZeneca entered into that certain Collaboration Agreement, dated as of March 30, 2012, as amended by Amendment No.1 to the Collaboration Agreement, dated October 1, 2014, as further amended by Amendment No.2 to the Collaboration Agreement and Release, dated May 2, 2016, as further amended by Amendment No.3 to the Collaboration Agreement, dated May 27, 2016, as further amended by Amendment No.4 to the Collaboration Agreement, dated October 2, 2016, and as further amended by Amendment No.5 to the Collaboration Agreement, dated January 31, 2018, and as further amended by Amendment No. 6 to the Collaboration Agreement, dated May 15, 2020 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Amgen and AstraZeneca wish to amend certain terms of the Agreement&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the mutual promises and covenants hereinafter set forth, the Parties agree to amend the Agreement as follows.  Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PART 1 - AMENDMENTS TO CERTAIN TERMS</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Amendment to Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">From and after the Amendment Effective Date, the Parties hereby agree that the following definitions in the Agreement are hereby deleted in their entirety and replaced with the following&#58;</font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means both internal and external costs and expenses (including the cost of allocated FTEs at the applicable FTE Rate).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a person (other than an employee that Details a Product), the equivalent of the work of one (1) employee full time for one (1) year (consisting of at least &#91;***&#93; or &#91;***&#93; hours per year (excluding vacations and holidays)). Overtime, and work on weekends, holidays and the like &#91;***&#93; be counted &#91;***&#93; toward the number of hours that are used to calculate the FTE contribution. For an employee that Details a Product, FTEs will be calculated as set forth in Section 7.2.11 (Calculation of Sales Force Costs). The budget for commercial employees (other than &#91;***&#93; will be approved as part of the annual budget planning process&#59; those projected to contribute less than &#91;***&#93; of such employee&#8217;s time on an annual basis to the applicable activities will be &#91;***&#93;. For invoicing purposes, actuals for commercial employees will be invoiced on a &#91;***&#93; basis, </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the parties will use reasonable efforts to ensure that commercial employees contributing less than &#91;***&#93; of such employee&#8217;s time in an applicable quarter not be counted as contributing toward an FTE.  </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;FTE Rate&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, until such time as the Parties agree otherwise, (A) for activities in the U.S (other than activities covered under Sales Force FTE Rate), &#91;***&#93; and (B) (i) for activities in other geographic locations (other than activities covered under Sales Force FTE Rate and other than activities performed by Other Commercial Personnel) $&#91;***&#93;  and (ii) for activities performed by Other Commercial Personnel outside the US, the applicable Blended Rate. The FTE Rate (other than the Blended Rates) will be increased by &#91;***&#93;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The FTE Rate (other than the Blended Rates) shall include costs of salaries, benefits, supplies, other employee costs, facility costs, depreciation and supporting general and administration allocations. The Blended Rate will include the categories set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  From and after the Amendment Effective Date, the Parties hereby agree that the following definitions are hereby added to the Agreement in appropriate alphabetical order&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Blended Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the rates set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and including the categories set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Blended Rates shall be reviewed and adjusted annually pursuant to the principles set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Global Commercial Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any person performing global above-market commercial activities, including global marketing, insights, market access, and other functions contributing to global and regional commercial efforts and who are not specifically allocated to commercial activities within a marketing company. </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Other Commercial Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any personnel other than Global Commercial Personnel and sales representatives, performing commercialization activities, as well as medical liaisons and access and pricing and field based marketing personnel in or for the Collaboration Territory in accordance with this Agreement. For clarity, Other Commercial Personnel includes first line sales managers, regional and national sales leaders and other sales force support roles that do not specifically Detail a Product. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Sales Force FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) for sales representatives in the U.S&#91;***&#93; and (ii) for sales representatives in other geographic locations, the applicable Blended Rate. The Sales Force FTE Rate includes the categories set forth on Schedule B.  The Sales Force FTE Rate shall be reviewed and adjusted annually pursuant to the principles set forth on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Schedule B.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;FTE Rate Territory&#8221; or &#8220;FTE Rate Territories&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means US, Canada, Japan, EU and International respectively, with International including all countries outside US, Canada, Japan and EU.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment to Section 7.2.3 (FTE Rate)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  From and after the Amendment Effective Date, Section 7.2.3 (FTE Rate) is hereby amended as follows, with any added or changed language indicated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">underline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The FTE Rate used for calculation of Costs pursuant to this Article 7 (Profit&#47;Expense Sharing) with respect to any activity will be the relevant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> FTE Rate for the calendar year in which such activity was undertaken.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment to Section 7.2.11 (Calculation of Sales Force Costs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  From and after the Amendment Effective Date, Section 7.2.11 (Calculation of Sales Force Costs) is hereby amended as follows, with any added or changed language indicated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">underline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Calculation of Sales Force Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Sales force FTE costs for each of the Parties will be determined by including in Partner Costs or Amgen Costs, as the case may be, a pro rata portion of each Party&#8217;s sales representative&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Sales Force</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> FTE Rate as follows&#58; (i) &#91;***&#93; if such sales representative Details only a single Product (and no other products) with the approval of the CRC&#59; (ii)&#160;&#91;***&#93; if such sales representative Details two (2) products with a Product as the First Position Detail or Details only a Product without the approval of the CRC&#59; (iii) &#91;***&#93; if such sales representative Details three (3) or more products with a Product as the First Position Detail&#59; (iv)&#160;&#91;***&#93; if such sales representative Details two (2) products with a Product as the Second Position Detail&#59; (v) &#91;***&#93; if such sales representative Details three (3) or more products with a Product as the Second Position Detail&#59; and (vi) &#91;***&#93; if such sales representative Details three (3) or more products with a Product as the Other Detail.  If a sales representative Details more than one (1) Product, then the foregoing percentages will be aggregated for each such Product.  For the avoidance of doubt, if a sales representative Details a Product in more than one (1) position, then a pro rata share of the foregoing percentages, to be calculated based on the time spent by such sales representative on Detailing such Product in each such position, will be included in Partner Costs or Amgen Costs, as the case may be.  For periods in which sales representatives are performing activities in support of the collaboration but are not Detailing Products (e.g., during launch preparation or training), FTE costs will be calculated based upon percent of effort, resource utilization or other reasonable measure, in each case calculated and allocated in accordance with the applicable Party&#8217;s accounting procedures, consistently applied.).&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Addition of Section 7.2.13 (Adjustments to Sales Force FTE Rate and Blended Rates)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; From and after the Amendment Effective Date, a new Section 7.2.13 (Adjustments to FTE Rates) is hereby added to the Agreement immediately following the end of Section 7.2.12 and provides as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;7.2.13&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to Sales Force FTE Rate. and Blended Rates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything herein to the contrary, on &#91;***&#93; basis (and no later than &#91;***&#93;), the Parties shall meet to discuss potential adjustment of the Sales Force FTE Rate and Blended Rates in the FTE Rate Territories. The Parties agree to share reasonable supporting documents and materials in connection with an assessment of the applicable Sales Force FTE Rate and Blended Rates and to determine in good faith whether to adjust the rate(s). In the event the Parties are unable to agree upon an applicable Sales Force FTE Rate or Blended Rate, such rate shall be adjusted by increasing such rate by &#91;***&#93;.&#8221;</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PART 2 &#8211; REFERENCE TO AND EFFECT ON THE AGREEMENT</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Reference to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Upon and after the effectiveness of this Amendment, each reference in the Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221; or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Effectiveness of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Upon execution and delivery of this Amendment by the Parties, the amendments set forth above shall be effective as of the Amendment Effective Date.  Except as specifically amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PART 3 &#8211; MISCELLANEOUS</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Choice of Law&#59; Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Amendment will be governed by, and enforced and construed in accordance with, the laws of the State of New York without regard to its conflicts of law provisions. Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the state and federal courts of the State of New York for any matter arising out of or relating to this Amendment and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Amendment or the transactions contemplated hereby in the state and federal courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum. The Parties agree that a final judgment in any such matter will be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. Any proceeding brought by either Party under this Amendment will be exclusively conducted in the English language. The United Nations Convention for the International Sale of Goods will not apply to the transactions contemplated herein.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The heading for each article and section in this Amendment has been inserted for convenience of reference only and is not intended to limit or expand on the meaning of the language contained in the particular article or section.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Amendment may be executed via electronic and pdf format signatures in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Signature page follows&#93;</font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i63b31f0419da433ea8c41dc7d4b023b6_4"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment as of the date first set forth above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:38.541%"><tr><td style="width:1.0%"></td><td style="width:18.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ASTRAZENECA COLLABORATION VENTURES, LLC</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Miriam Koohdary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miriam Koohdary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deputy General Counsel</font></td></tr><tr style="height:18pt"><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:38.541%"><tr><td style="width:1.0%"></td><td style="width:17.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">AMGEN INC.</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Murdo Gordon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Murdo Gordon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP Global Commercial Operations</font></td></tr><tr style="height:21pt"><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule A Omitted from Amendment No. 7 to the Collaboration Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Regulation S-K, Item 601(a)(5), Schedule A to Amendment No. 7 to the Collaboration Agreement, as listed below, has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule A</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">List of Blended Rates</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule B</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Sales Force FTE Rate will be adjusted &#91;***&#93;, no later than &#91;***&#93; of each year, pursuant to Section 7.2.13 of the Agreement and the following principles&#58; the Sales Force FTE Rate in the U.S. will be based on actual recorded expenses without &#91;***&#93;&#59; the Sales Force FTE Rate outside the U.S. (i.e., the Blended Rates) will be based on actual recorded expenses&#91;***&#93;. For the avoidance of doubt, (i) the Sales Force FTE Rate in the U.S. will include salaries, payroll taxes, bonuses, benefits, recruiting, relocation, employee stock option programs or stock grants, retirement programs, travel, training and telecommunications and shall not include &#91;***&#93; and (ii) the Sales Force FTE Rate outside the U.S. (i.e. the Blended Rates) will include salaries, payroll taxes, bonuses, benefits, recruiting, relocation, employee stock option programs or stock grants, retirement programs, travel, training and telecommunications plus &#91;***&#93;. By way of example of (ii) of the foregoing sentence, if the actual recorded expenses for Canada is &#91;***&#93;, the Blended Rate for Canada would be &#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Blended Rates are &#91;***&#93;. and will be adjusted &#91;***&#93;, no later than &#91;***&#93; of each year, pursuant to Section 7.2.13 of the Agreement and the following principles&#58; the Blended Rates will include salaries, payroll taxes, bonuses, benefits, recruiting, relocation, employee stock option programs or stock grants, retirement programs, travel, training and telecommunications plus &#91;***&#93;. The parties will consider in good faith pursuant to the annual adjustment process whether (i) the Blended Rate for International shall be further categorized into regions during the annual adjustment process consistent with the principle that such Blended Rate shall reflect actual costs and (ii) whether sales force costs in certain ex-U.S. markets should be treated seperately than all other ex-U.S. commercial functions (as is done in the U.S).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For the annual adjustment, the Parties agree to the principle that Sales Force FTE Rate and Blended Rates shall reflect actual cost, provided that the Blended Rates shall be inclusive of &#91;***&#93;. The Sales Force FTE Rate and Blended Rates shall be reviewed and adjusted &#91;***&#93; (no later than &#91;***&#93; of each year) and calculated as the average of the applicable FTE rates provided by each party (such rates to be calculated consistent with the Agreement and this Schedule B). An illustrative calculation of the Sales Force FTE Rate in the U.S. for 2021 (i.e., &#91;***&#93;) is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit A to Schedule B Omitted from Amendment No. 7 to the Collaboration Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Regulation S-K, Item 601(a)(5), Exhibit A to Schedule B to Amendment No. 7 to the Collaboration Agreement, as listed below, has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Exhibit A</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">An illustrative calculation of the Sales Force FTE Rate in the U.S. for 2021.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>8
<FILENAME>amgn-ex21_20201231xq4.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9133d5311e59446883fca1314a5b1662_1"></div><div style="min-height:43pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AMGEN INC.</font></div><div><font><br></font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following is a list of subsidiaries of the Company as of December 31, 2020, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.758%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATE OR OTHER JURISDICTION OF</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Name under which subsidiary does business)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION OR ORGANIZATION</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen (Europe) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Fremont Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Global Finance B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen GmbH Germany</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Ila&#231; Ticaret Limited &#350;irketi</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Manufacturing, Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Research (Munich) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Rockville, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen S.A.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen SF, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Singapore Manufacturing Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Technology (Ireland) Unlimited Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Technology, Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen USA Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Worldwide Holdings B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioVex, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunex Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunex Rhode Island Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gensenta &#304;la&#231; Sanayi ve Ticaret Anonim &#350;irketi</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onyx Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onyx Therapeutics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>9
<FILENAME>amgn-ex31_20201231xq4.htm
<DESCRIPTION>RULE 13A-14(A) CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7acf0eb6488e43d3a088e44cfb495980_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i7acf0eb6488e43d3a088e44cfb495980_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>amgn-ex32_20201231xq4.htm
<DESCRIPTION>SECTION 1350 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9a45639139ce4185b0416feea5fe4915_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i9a45639139ce4185b0416feea5fe4915_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 8, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>amgn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e0ca318f-3884-42e6-a64c-8779d462d73a,g:75807743-642d-4c80-8d38-07220e8d8bcd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.amgen.com/role/Coverpage">
        <link:definition>000010001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome">
        <link:definition>100010002 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>100020003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets">
        <link:definition>100030004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>100050006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>100060007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100070008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>210011001 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>220022001 - Disclosure - Summary of significant accounting policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails">
        <link:definition>240034001 - Disclosure - Summary of significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.amgen.com/role/Acquisitions">
        <link:definition>210041002 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.amgen.com/role/AcquisitionsTables">
        <link:definition>230053001 - Disclosure - Acquisitions - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails">
        <link:definition>240064002 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsOtezlaDetails" roleURI="http://www.amgen.com/role/AcquisitionsOtezlaDetails">
        <link:definition>240074003 - Disclosure - Acquisitions - Otezla (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAggregateConsiderationPaidDetails" roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails">
        <link:definition>240084004 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.amgen.com/role/Revenues">
        <link:definition>210091003 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.amgen.com/role/RevenuesTables">
        <link:definition>230103002 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails">
        <link:definition>240114005 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesCustomerConcentrationProductSalesDetails" roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails">
        <link:definition>240124006 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.amgen.com/role/Stockbasedcompensation">
        <link:definition>210131004 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTables" roleURI="http://www.amgen.com/role/StockbasedcompensationTables">
        <link:definition>230143003 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTextualDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails">
        <link:definition>240154007 - Disclosure - Stock-based compensation (Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails">
        <link:definition>240164008 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationSummaryofRSUsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails">
        <link:definition>240174009 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails">
        <link:definition>240184010 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationSummaryofStockOptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails">
        <link:definition>240194011 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails">
        <link:definition>240204012 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedcontributionplan" roleURI="http://www.amgen.com/role/Definedcontributionplan">
        <link:definition>210211005 - Disclosure - Defined contribution plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedcontributionplanDetails" roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails">
        <link:definition>240224013 - Disclosure - Defined contribution plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.amgen.com/role/Incometaxes">
        <link:definition>210231006 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.amgen.com/role/IncometaxesTables">
        <link:definition>230243004 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesIncomeBeforeIncomeTaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails">
        <link:definition>240254014 - Disclosure - Income taxes (Income Before Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesProvisionforIncomeTaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails">
        <link:definition>240264015 - Disclosure - Income taxes (Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>240274016 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTextualDetails" roleURI="http://www.amgen.com/role/IncometaxesTextualDetails">
        <link:definition>240284017 - Disclosure - Income taxes (Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails">
        <link:definition>240294018 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationofFederalStatutoryTaxRateDetails" roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails">
        <link:definition>240304019 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.amgen.com/role/Earningspershare">
        <link:definition>210311007 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.amgen.com/role/EarningspershareTables">
        <link:definition>230323005 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareDetails" roleURI="http://www.amgen.com/role/EarningspershareDetails">
        <link:definition>240334020 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborations" roleURI="http://www.amgen.com/role/Collaborations">
        <link:definition>210341008 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsNovartisAGDetails" roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails">
        <link:definition>240354021 - Disclosure - Collaborations - Novartis AG (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsBayerHealthCarePharmaceuticalsIncDetails" roleURI="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails">
        <link:definition>240364022 - Disclosure - Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsBeiGeneDetails" roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails">
        <link:definition>240374023 - Disclosure - Collaborations - BeiGene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.amgen.com/role/Investments">
        <link:definition>210381009 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.amgen.com/role/InvestmentsTables">
        <link:definition>230393006 - Disclosure - Investments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleDetails" roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails">
        <link:definition>240404024 - Disclosure - Investments - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyClassificationDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails">
        <link:definition>240414025 - Disclosure - Investments - Fair Values by Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleDetails" roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails">
        <link:definition>240424026 - Disclosure - Investments - Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyContractualMaturityDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails">
        <link:definition>240434027 - Disclosure - Investments - Fair Values by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquitySecuritiesDetails" roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails">
        <link:definition>240444028 - Disclosure - Investments - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsLimitedPartnershipInvestmentsDetails" roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails">
        <link:definition>240454029 - Disclosure - Investments - Limited Partnership Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBeiGeneDetails" roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails">
        <link:definition>240464030 - Disclosure - Investments - BeiGene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amgen.com/role/Inventories">
        <link:definition>210471010 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amgen.com/role/InventoriesTables">
        <link:definition>230483007 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amgen.com/role/InventoriesDetails">
        <link:definition>240494031 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.amgen.com/role/Propertyplantandequipment">
        <link:definition>210501011 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables">
        <link:definition>230513008 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentScheduleDetails" roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails">
        <link:definition>240524032 - Disclosure - Property, plant and equipment (Schedule) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentGeographicInformationDetails" roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails">
        <link:definition>240534033 - Disclosure - Property, plant and equipment (Geographic Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandintangibleassets" roleURI="http://www.amgen.com/role/Goodwillandintangibleassets">
        <link:definition>210541012 - Disclosure - Goodwill and intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsTables" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables">
        <link:definition>230553009 - Disclosure - Goodwill and other intangible assets - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsGoodwillRollForwardDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails">
        <link:definition>240564034 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
        <link:definition>240574035 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsNarrativeDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails">
        <link:definition>240584036 - Disclosure - Goodwill and other intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.amgen.com/role/Leases">
        <link:definition>210591013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amgen.com/role/LeasesTables">
        <link:definition>230603010 - Disclosure - Leases - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.amgen.com/role/LeasesNarrativeDetails">
        <link:definition>240614037 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeasesDetails" roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails">
        <link:definition>240624038 - Disclosure - Leases - Summary of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostsDetails" roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails">
        <link:definition>240634039 - Disclosure - Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCashandNoncashInformationofLeasesDetails" roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails">
        <link:definition>240654041 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othercurrentassetsandaccruedliabilities" roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities">
        <link:definition>210661014 - Disclosure - Other current assets and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesTables" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables">
        <link:definition>230673011 - Disclosure - Other current assets and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails">
        <link:definition>240684042 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails">
        <link:definition>240694043 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financingarrangements" roleURI="http://www.amgen.com/role/Financingarrangements">
        <link:definition>210701015 - Disclosure - Financing arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsTables" roleURI="http://www.amgen.com/role/FinancingarrangementsTables">
        <link:definition>230713012 - Disclosure - Financing arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
        <link:definition>240724044 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDebtIssuancesDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails">
        <link:definition>240734045 - Disclosure - Financing arrangements (Debt Issuances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDebtRepaymentsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails">
        <link:definition>240744046 - Disclosure - Financing arrangements (Debt Repayments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails">
        <link:definition>240754047 - Disclosure - Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails">
        <link:definition>240764048 - Disclosure - Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails">
        <link:definition>240774049 - Disclosure - Financing arrangements (Contractual Maturities of Long-term Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsInterestCostsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails">
        <link:definition>240784050 - Disclosure - Financing arrangements (Interest Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.amgen.com/role/Stockholdersequity">
        <link:definition>210791016 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.amgen.com/role/StockholdersequityTables">
        <link:definition>230803013 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityStockRepurchaseProgramDetails" roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails">
        <link:definition>240814051 - Disclosure - Stockholders' equity (Stock Repurchase Program) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityDividendsDetails" roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails">
        <link:definition>240824052 - Disclosure - Stockholders' equity (Dividends) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityComponentsofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails">
        <link:definition>240834053 - Disclosure - Stockholders' equity (Components of AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails">
        <link:definition>240844054 - Disclosure - Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityReclassificationsoutofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails">
        <link:definition>240854055 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityOtherDetails" roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails">
        <link:definition>240864056 - Disclosure - Stockholders' equity (Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurement" roleURI="http://www.amgen.com/role/Fairvaluemeasurement">
        <link:definition>210871017 - Disclosure - Fair value measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementTables" roleURI="http://www.amgen.com/role/FairvaluemeasurementTables">
        <link:definition>230883014 - Disclosure - Fair value measurement - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>240894057 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementNarrativeDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails">
        <link:definition>240904058 - Disclosure - Fair value measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstruments" roleURI="http://www.amgen.com/role/Derivativeinstruments">
        <link:definition>210911018 - Disclosure - Derivative instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsTables" roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables">
        <link:definition>230923015 - Disclosure - Derivative instruments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsNarrativeDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails">
        <link:definition>240934059 - Disclosure - Derivative instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails">
        <link:definition>240944060 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
        <link:definition>240954061 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails">
        <link:definition>240964062 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
        <link:definition>240974063 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsFairValueofDerivativesDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails">
        <link:definition>240984064 - Disclosure - Derivative instruments - (Fair Value of Derivatives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://www.amgen.com/role/Contingenciesandcommitments">
        <link:definition>210991019 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsTables" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables">
        <link:definition>231003016 - Disclosure - Contingencies and commitments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails">
        <link:definition>241014065 - Disclosure - Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsSandozPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails">
        <link:definition>241024066 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails">
        <link:definition>241034067 - Disclosure - Contingencies and commitments (Amneal Pharmaceuticals LLC Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsImmunexandSandozLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails">
        <link:definition>241044068 - Disclosure - Contingencies and commitments (Immunex and Sandoz Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsRepathaPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails">
        <link:definition>241054069 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsAdditionalInformationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails">
        <link:definition>241064070 - Disclosure - Contingencies and commitments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails">
        <link:definition>241074071 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Quarterlyfinancialdataunaudited" roleURI="http://www.amgen.com/role/Quarterlyfinancialdataunaudited">
        <link:definition>211081020 - Disclosure - Quarterly financial data (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyfinancialdataunauditedTables" roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables">
        <link:definition>231093017 - Disclosure - Quarterly financial data (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyfinancialdataunauditedDetails" roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails">
        <link:definition>241104072 - Disclosure - Quarterly financial data (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS">
        <link:definition>211111021 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
        <link:definition>241124073 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_AvailableForSalesInvestmentsMember" abstract="true" name="AvailableForSalesInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" abstract="false" name="ComponentsOfStockBasedCompensationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_AssetsByDescriptionAxis" abstract="true" name="AssetsByDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_OperatingLossesThatExpireBetween2021And2030Member" abstract="true" name="OperatingLossesThatExpireBetween2021And2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FloatingRateNotesDue2019Member" abstract="true" name="FloatingRateNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_Transactioncostsassetacquisition" abstract="false" name="Transactioncostsassetacquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CustomerOneMember" abstract="false" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" abstract="false" name="NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_ManufacturingEquipmentMember" abstract="false" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OtherCurrentNoncurrentAssetsMember" abstract="true" name="OtherCurrentNoncurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OtherNotesDue2097Member" abstract="true" name="OtherNotesDue2097Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" abstract="true" name="TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NumberOfAssertedPatents" abstract="false" name="NumberOfAssertedPatents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" abstract="false" name="DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" abstract="false" name="LongTermDebtMaturitiesRepaymentsOfPrincipalNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" abstract="false" name="LossContingencyNumberOfComplaintsStayedByTheCourt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_GainContingencyNumberOfAgreementsBreached" abstract="false" name="GainContingencyNumberOfAgreementsBreached" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_SalesReturnProvisionsAsPercentageOfProductSales" abstract="false" name="SalesReturnProvisionsAsPercentageOfProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_ImmunexAndSamsungBioepisCoMember" abstract="true" name="ImmunexAndSamsungBioepisCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" abstract="true" name="ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ExpirationInTaxYearsBetween2023And2035Member" abstract="true" name="ExpirationInTaxYearsBetween2023And2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AccruedSalesDeductionsCurrent" abstract="false" name="AccruedSalesDeductionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsGross" abstract="false" name="IdentifiableIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CollaborativeArrangementwithNovartisPharmaAGMember" abstract="true" name="CollaborativeArrangementwithNovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_MaximumBorrowingCapacityUnderCommercialPaper" abstract="false" name="MaximumBorrowingCapacityUnderCommercialPaper" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" abstract="true" name="OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_LitigationSettlementLengthofTrial" abstract="false" name="LitigationSettlementLengthofTrial" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroPercentNotesDue2019Member" abstract="true" name="TwoPointTwoZeroPercentNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" abstract="true" name="OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" abstract="true" name="TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_SandozIncMember" abstract="true" name="SandozIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionInventoryacquired" abstract="false" name="BusinessacquiredassetacquisitionInventoryacquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_SixPointNineZeroPercentNotesDue2038Member" abstract="true" name="SixPointNineZeroPercentNotesDue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_SensiparAntitrustClassActionsMember" abstract="true" name="SensiparAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" abstract="false" name="PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" abstract="false" name="BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_HedgedLiabilityDiscontinuedFairValueHedge" abstract="false" name="HedgedLiabilityDiscontinuedFairValueHedge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FloatingRateNotesDue2020Member" abstract="true" name="FloatingRateNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_GainContingencyNumberofLawsuitsFiled" abstract="false" name="GainContingencyNumberofLawsuitsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" abstract="false" name="PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_ScheduleOfIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_ThreePointTwoZeroNotesDue2027Member" abstract="true" name="ThreePointTwoZeroNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FivePointThreeSevenFivePercentNotesDue2043Member" abstract="true" name="FivePointThreeSevenFivePercentNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ApprovedMarkets" abstract="false" name="ApprovedMarkets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_OtezlaMember" abstract="true" name="OtezlaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RepathaevolocumabMember" abstract="true" name="RepathaevolocumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" abstract="false" name="IdentifiableIntangibleAssetsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_InterestRateSwapAxis" abstract="true" name="InterestRateSwapAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ThreePointFourFivePercentNotesDue2020Member" abstract="true" name="ThreePointFourFivePercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NatureOfOperationsPolicyTextBlock" abstract="false" name="NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" abstract="false" name="LineOfCreditFacilityExtensionOfCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" abstract="false" name="AcquiredFinitelivedAssetsWeightedAverageUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroNotesDue2020Member" abstract="true" name="TwoPointTwoZeroNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" abstract="false" name="SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_EnbrelMember" abstract="false" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_MarketingRelatedRightsMember" abstract="true" name="MarketingRelatedRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" abstract="false" name="BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FourPointNineFivePercentNotesDue2041Member" abstract="true" name="FourPointNineFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionDeferredCredit" abstract="false" name="BusinessacquiredassetacquisitionDeferredCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_PerformanceUnitsMember" abstract="false" name="PerformanceUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TwoPointThreeZeroPercentNotesDue2031Member" abstract="true" name="TwoPointThreeZeroPercentNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_GainContingencyNumberofAffiliates" abstract="false" name="GainContingencyNumberofAffiliates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_DerivativeAssetsFairValueDisclosureAbstract" abstract="true" name="DerivativeAssetsFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ThreePointOneFivePercentNotesDue2040Member" abstract="true" name="ThreePointOneFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_CorporateDebtSecuritiesOtherMember" abstract="true" name="CorporateDebtSecuritiesOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" abstract="true" name="FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" abstract="false" name="EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" abstract="true" name="CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapOneMember" abstract="true" name="InterestRateSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FourPointOneZeroPercentNotesDue2021Member" abstract="true" name="FourPointOneZeroPercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesDisclosureTextBlock" abstract="false" name="AccruedLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AmnealPharmaceuticalsLLCMember" abstract="true" name="AmnealPharmaceuticalsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_CrossCurrencySwapContractsMember" abstract="true" name="CrossCurrencySwapContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" abstract="false" name="NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_LineOfCreditFacilityInitialCommitmentTerm" abstract="false" name="LineOfCreditFacilityInitialCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_GainContingencyNumberOfChallenges" abstract="false" name="GainContingencyNumberOfChallenges" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_InterestRateSwapAtThenCurrentInterestRatesMember" abstract="true" name="InterestRateSwapAtThenCurrentInterestRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" abstract="true" name="DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" abstract="true" name="FourPointThreeSevenFivePercentEuroNotesDue2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ForwardInterestRateContractMember" abstract="true" name="ForwardInterestRateContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_CustomerTwoMember" abstract="false" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AranespMember" abstract="false" name="AranespMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AssetsByDescriptionDomain" abstract="false" name="AssetsByDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_SixPointOneFivePercentNotesDue2018Member" abstract="true" name="SixPointOneFivePercentNotesDue2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NexavarMember" abstract="true" name="NexavarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OtherShortTermInterestBearingSecuritiesMember" abstract="true" name="OtherShortTermInterestBearingSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OnePointNineZeroNotesDue2019Member" abstract="true" name="OnePointNineZeroNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValue" abstract="false" name="EquityMethodInvestmentChangeInCarryingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" abstract="false" name="NumberOfCommonSharesToBeReducedForEachStockOptionGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_CorporateDebtSecuritiesIndustrialMember" abstract="true" name="CorporateDebtSecuritiesIndustrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_XgevaMember" abstract="false" name="XgevaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" abstract="false" name="BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfLawsuitsFiled" abstract="false" name="LossContingencyNumberOfLawsuitsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_RDTechnologyrightsMember" abstract="true" name="RDTechnologyrightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" abstract="true" name="OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" abstract="false" name="NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_BeiGeneMember" abstract="true" name="BeiGeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" abstract="false" name="BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_CustomerThreeMember" abstract="false" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValueOther" abstract="false" name="EquityMethodInvestmentChangeInCarryingValueOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointSixFivePercentNotesDue2042Member" abstract="true" name="FivePointSixFivePercentNotesDue2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" abstract="false" name="DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_DerivativeNotionalAmountAmountTerminated" abstract="false" name="DerivativeNotionalAmountAmountTerminated" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_NeulastaMember" abstract="false" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" abstract="false" name="ThresholdForDisclosureOfProductSalesToMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" abstract="true" name="TwoPercentEuroNotesDueTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_KirinAmgenInc.KAMember" abstract="true" name="KirinAmgenInc.KAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" abstract="false" name="AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" abstract="true" name="AccumulatedOtherAdjustmentAttributabletoParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ImmunexAndSandozMember" abstract="true" name="ImmunexAndSandozMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" abstract="false" name="BusinessacquiredassetacquisitionDeferredTaxLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CollaborativeArrangementNetIncome" abstract="false" name="CollaborativeArrangementNetIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2024Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AbandonedLeasesMember" abstract="true" name="AbandonedLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" abstract="true" name="TwoPointSixZeroNotesDueTwoZeroTwoSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" abstract="false" name="BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_StockRepurchaseProgramTableTextBlock" abstract="false" name="StockRepurchaseProgramTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" abstract="true" name="AcquiredResearchAndDevelopmentTechnologyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_SanofiRegeneronPatentLitigationMember" abstract="true" name="SanofiRegeneronPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" abstract="false" name="OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ScheduleOfU.S.RepatriationTaxCommitments" abstract="false" name="ScheduleOfU.S.RepatriationTaxCommitments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_InterestRateSwapThreeMember" abstract="true" name="InterestRateSwapThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" abstract="true" name="FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_IncreaseDecreaseInNoncurrentTaxLiability" abstract="false" name="IncreaseDecreaseInNoncurrentTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" abstract="false" name="AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_BasicAndDilutedEarningPerShareAbstract" abstract="true" name="BasicAndDilutedEarningPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" abstract="true" name="OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" abstract="false" name="NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_FivePointSevenZeroPercentNotesDue2019Member" abstract="true" name="FivePointSevenZeroPercentNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AlternativeInvestmentNetGainLoss" abstract="false" name="AlternativeInvestmentNetGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LaboratoryEquipment" abstract="false" name="LaboratoryEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RecoveryOfDirectCostsReceivable" abstract="false" name="RecoveryOfDirectCostsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" abstract="true" name="ThreePointThreeSevenFivePercentNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NovartisBreachOfContractActionMember" abstract="true" name="NovartisBreachOfContractActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OperatingLossesThatExpireBetween2021And2035Member" abstract="true" name="OperatingLossesThatExpireBetween2021And2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FourPointFiveZeroPercentNotesDue2020Member" abstract="true" name="FourPointFiveZeroPercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" abstract="false" name="ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_KyprolisMember" abstract="true" name="KyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_Ratedifferenceinaninterestrateswaprelationship" abstract="false" name="Ratedifferenceinaninterestrateswaprelationship" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" abstract="true" name="FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_DebtExchangeAdditionalCashConsideration" abstract="false" name="DebtExchangeAdditionalCashConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LineofCreditFacilityNumberOfRenewalOptions" abstract="false" name="LineofCreditFacilityNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_Businessassetacquisitionconsiderationtransferred" abstract="false" name="Businessassetacquisitionconsiderationtransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FixedEquipment" abstract="false" name="FixedEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_InterestRateSwapTwoMember" abstract="true" name="InterestRateSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" abstract="true" name="TwoPointOneTwoFivePercentEuroNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_GainContingencyNumberOfLawsuitsConsolidated" abstract="false" name="GainContingencyNumberOfLawsuitsConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" abstract="false" name="EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_NonUsExcludingJapanMember" abstract="true" name="NonUsExcludingJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_KYPROLIScarfilzomibPatentLitigationMember" abstract="true" name="KYPROLIScarfilzomibPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_CollaborativeArrangementRoyaltyIncomePercentage" abstract="false" name="CollaborativeArrangementRoyaltyIncomePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_A1.250SeniorNotesDue2022Member" abstract="true" name="A1.250SeniorNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ThreePointEightSevenFivePercentNotesDue2021Member" abstract="true" name="ThreePointEightSevenFivePercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_CorporateDebtSecuritiesFinancialMember" abstract="true" name="CorporateDebtSecuritiesFinancialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FivePointOneFivePercentNotesDue2041Member" abstract="true" name="FivePointOneFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" abstract="true" name="AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" abstract="false" name="NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" abstract="true" name="TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" abstract="false" name="DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_SixPointFourZeroPercentNotesDue2039Member" abstract="true" name="SixPointFourZeroPercentNotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_SixPointThreeSevenFivePercentNotesDue2037Member" abstract="true" name="SixPointThreeSevenFivePercentNotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" abstract="true" name="TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_CommonStockFairValue" abstract="false" name="CommonStockFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="amgn_FixedEquipmentMember" abstract="true" name="FixedEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NuevolutionMember" abstract="true" name="NuevolutionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AssembledWorkforceMember" abstract="true" name="AssembledWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2022Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_NumberofCountriesProductsisMarketedandSold" abstract="false" name="NumberofCountriesProductsisMarketedandSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_ForeignCurrencyAndCrossCurrencySwapsMember" abstract="true" name="ForeignCurrencyAndCrossCurrencySwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_HumiraBiosimilarAntitrustClassActionsMember" abstract="true" name="HumiraBiosimilarAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapDomain" abstract="true" name="InterestRateSwapDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FourPercentPoundSterlingNotesDue2029Member" abstract="true" name="FourPercentPoundSterlingNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" abstract="false" name="PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_StockBasedCompensationExpenseNetOfTax" abstract="false" name="StockBasedCompensationExpenseNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" abstract="false" name="ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amgn_TwoPointFourFivePercentNotesDue2030Member" abstract="true" name="TwoPointFourFivePercentNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_PercentageOfGrossRevenues" abstract="false" name="PercentageOfGrossRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_TwoPointSixFiveNotesDue2022Member" abstract="true" name="TwoPointSixFiveNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_AccruedSalesReturnReserveCurrent" abstract="false" name="AccruedSalesReturnReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RevenuePaymentArrangementTerm" abstract="false" name="RevenuePaymentArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" abstract="false" name="PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amgn_ProliaMember" abstract="false" name="ProliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" abstract="true" name="FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" abstract="true" name="ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amgn_FivePointSevenFivePercentNotesDue2040Member" abstract="true" name="FivePointSevenFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>amgn-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e0ca318f-3884-42e6-a64c-8779d462d73a,g:75807743-642d-4c80-8d38-07220e8d8bcd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20201231.xsd#Coverpage"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a009f01a-e6a9-4406-808a-e5ff18b6d11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8756e01a-ab92-4aed-aedc-de3ab13b6cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a009f01a-e6a9-4406-808a-e5ff18b6d11a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8756e01a-ab92-4aed-aedc-de3ab13b6cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_80d2a265-f4e5-46c0-96db-ca952f336bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a009f01a-e6a9-4406-808a-e5ff18b6d11a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_80d2a265-f4e5-46c0-96db-ca952f336bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_71770904-5c74-4182-9fdb-3d767aaebc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b30321d1-e353-4001-97ed-342bdb6a0251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_71770904-5c74-4182-9fdb-3d767aaebc00" xlink:to="loc_us-gaap_OperatingIncomeLoss_b30321d1-e353-4001-97ed-342bdb6a0251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ea48f577-f10f-4256-8630-e95ff184d9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_71770904-5c74-4182-9fdb-3d767aaebc00" xlink:to="loc_us-gaap_InterestExpenseDebt_ea48f577-f10f-4256-8630-e95ff184d9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4bf70752-0e0b-42f4-9696-bb0896050ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_71770904-5c74-4182-9fdb-3d767aaebc00" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4bf70752-0e0b-42f4-9696-bb0896050ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74919bb9-7934-46be-8f00-d4b84353a9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7e4fe4cc-2477-4130-beda-e8213fb834a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_74919bb9-7934-46be-8f00-d4b84353a9a5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7e4fe4cc-2477-4130-beda-e8213fb834a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d790267d-7398-4010-95b2-a9ed6e5c6f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_74919bb9-7934-46be-8f00-d4b84353a9a5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d790267d-7398-4010-95b2-a9ed6e5c6f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3e271bc6-889a-4c93-89c3-f620ba573a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a0b4ae90-6ace-449b-b246-8f8b01c6a331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3e271bc6-889a-4c93-89c3-f620ba573a10" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a0b4ae90-6ace-449b-b246-8f8b01c6a331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_786356f7-7dd9-41f3-8f6d-1d7d6631f83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3e271bc6-889a-4c93-89c3-f620ba573a10" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_786356f7-7dd9-41f3-8f6d-1d7d6631f83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_50be2d23-bacb-42f4-95d3-01471e3ebbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3e271bc6-889a-4c93-89c3-f620ba573a10" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_50be2d23-bacb-42f4-95d3-01471e3ebbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_adb04b67-ba7a-409f-ae83-5d2b8596e0ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3e271bc6-889a-4c93-89c3-f620ba573a10" xlink:to="loc_us-gaap_OtherGeneralExpense_adb04b67-ba7a-409f-ae83-5d2b8596e0ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b869f877-9563-434c-b252-d4ef745c3a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_758cba3a-5b4f-4c17-9a8d-5c9e372f7110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b869f877-9563-434c-b252-d4ef745c3a70" xlink:to="loc_us-gaap_Revenues_758cba3a-5b4f-4c17-9a8d-5c9e372f7110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9c47d3d3-2cd6-4621-b31c-1eeb5494333e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b869f877-9563-434c-b252-d4ef745c3a70" xlink:to="loc_us-gaap_CostsAndExpenses_9c47d3d3-2cd6-4621-b31c-1eeb5494333e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_52c47fbd-68c3-4aa5-aad2-74d1b99f465f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_154ae858-22ba-4e56-9da3-cf7624da3d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_52c47fbd-68c3-4aa5-aad2-74d1b99f465f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_154ae858-22ba-4e56-9da3-cf7624da3d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_4392f079-d103-4dd7-ab2c-bda7a3de4540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_52c47fbd-68c3-4aa5-aad2-74d1b99f465f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_4392f079-d103-4dd7-ab2c-bda7a3de4540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6940376c-44b7-4382-9025-731ac64fbb46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_52c47fbd-68c3-4aa5-aad2-74d1b99f465f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6940376c-44b7-4382-9025-731ac64fbb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_a16840ba-eac6-4e69-94d8-d0ff5b6dca31" xlink:href="amgn-20201231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_52c47fbd-68c3-4aa5-aad2-74d1b99f465f" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_a16840ba-eac6-4e69-94d8-d0ff5b6dca31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3fe53a6-9d1e-4789-91db-28f26dd2b21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e73bc882-2b99-4e78-a485-6331dd149d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3fe53a6-9d1e-4789-91db-28f26dd2b21c" xlink:to="loc_us-gaap_NetIncomeLoss_e73bc882-2b99-4e78-a485-6331dd149d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fa0e7e08-4a99-40a1-993f-8c117e77b580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3fe53a6-9d1e-4789-91db-28f26dd2b21c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fa0e7e08-4a99-40a1-993f-8c117e77b580" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40e0f315-0998-4428-9d68-40f9a6451811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c3a32757-c9eb-4753-92a2-2f550692600c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40e0f315-0998-4428-9d68-40f9a6451811" xlink:to="loc_us-gaap_AssetsCurrent_c3a32757-c9eb-4753-92a2-2f550692600c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13cec2c7-30de-4012-a407-dd8ff3bd6dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40e0f315-0998-4428-9d68-40f9a6451811" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13cec2c7-30de-4012-a407-dd8ff3bd6dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f82e4501-1fac-468f-9b79-3979043e0539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40e0f315-0998-4428-9d68-40f9a6451811" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f82e4501-1fac-468f-9b79-3979043e0539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_087f1120-89a4-48cb-bb90-7961e3adae7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40e0f315-0998-4428-9d68-40f9a6451811" xlink:to="loc_us-gaap_Goodwill_087f1120-89a4-48cb-bb90-7961e3adae7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1c42e0d6-b12b-4f78-969f-cea1c0dc6e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40e0f315-0998-4428-9d68-40f9a6451811" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1c42e0d6-b12b-4f78-969f-cea1c0dc6e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c0a106ef-a144-4df7-aced-43f734f88faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:to="loc_us-gaap_LiabilitiesCurrent_c0a106ef-a144-4df7-aced-43f734f88faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f6522f57-3c40-41d2-9628-42bb8c6de439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f6522f57-3c40-41d2-9628-42bb8c6de439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_48ae64b4-5684-457f-9861-a1364575a8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_48ae64b4-5684-457f-9861-a1364575a8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e72d0a15-8a81-4813-8fab-4064f074004a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e72d0a15-8a81-4813-8fab-4064f074004a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5b7e1537-1655-4b65-adc7-cfd9392dd7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5b7e1537-1655-4b65-adc7-cfd9392dd7b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b9232595-1901-46b6-8a22-c3282296d98c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9837a564-6015-4b9d-b1db-358e3c316a06" xlink:to="loc_us-gaap_StockholdersEquity_b9232595-1901-46b6-8a22-c3282296d98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fdab0cd7-8038-48c4-9bde-934e65093d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_28e3178c-3912-4757-bbc6-bb57f70c43aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fdab0cd7-8038-48c4-9bde-934e65093d2c" xlink:to="loc_us-gaap_AccountsPayableCurrent_28e3178c-3912-4757-bbc6-bb57f70c43aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5dae850e-3792-4663-8dc6-11c9ca9e85cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fdab0cd7-8038-48c4-9bde-934e65093d2c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5dae850e-3792-4663-8dc6-11c9ca9e85cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f6e516ae-5d5c-494f-a41c-b693546b682d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fdab0cd7-8038-48c4-9bde-934e65093d2c" xlink:to="loc_us-gaap_LongTermDebtCurrent_f6e516ae-5d5c-494f-a41c-b693546b682d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e75dd65e-9c50-42cb-94d3-9a36a511c5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ffb3870-ed6a-4824-9795-60c620c5494b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e75dd65e-9c50-42cb-94d3-9a36a511c5bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ffb3870-ed6a-4824-9795-60c620c5494b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_68d28f05-2914-4e1e-98dd-8ab877bfeb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e75dd65e-9c50-42cb-94d3-9a36a511c5bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_68d28f05-2914-4e1e-98dd-8ab877bfeb0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_deff29ed-478f-4e66-adc9-0c970c11a2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e75dd65e-9c50-42cb-94d3-9a36a511c5bc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_deff29ed-478f-4e66-adc9-0c970c11a2b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2caac547-f771-4984-81ef-f79f27103f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e75dd65e-9c50-42cb-94d3-9a36a511c5bc" xlink:to="loc_us-gaap_InventoryNet_2caac547-f771-4984-81ef-f79f27103f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d3158058-4c3c-49ef-9494-0d703e0071dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e75dd65e-9c50-42cb-94d3-9a36a511c5bc" xlink:to="loc_us-gaap_OtherAssetsCurrent_d3158058-4c3c-49ef-9494-0d703e0071dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d028c9c2-aa0d-45bd-9596-9699f4344ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_22308664-70fb-4991-8b06-13f7b872550d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d028c9c2-aa0d-45bd-9596-9699f4344ca8" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_22308664-70fb-4991-8b06-13f7b872550d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cc69845a-1f0b-4113-aa74-d78154d70d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d028c9c2-aa0d-45bd-9596-9699f4344ca8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cc69845a-1f0b-4113-aa74-d78154d70d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be43c745-ed4d-4f87-9b46-ba1b459d990a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d028c9c2-aa0d-45bd-9596-9699f4344ca8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be43c745-ed4d-4f87-9b46-ba1b459d990a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7ee683b-86b0-490e-a9f1-f4537b0b2dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7ee683b-86b0-490e-a9f1-f4537b0b2dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_491766f9-7097-48ba-9876-1f6affbda75b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_491766f9-7097-48ba-9876-1f6affbda75b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7b8336cd-c159-4b21-aa7d-2d8e10cd850a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7b8336cd-c159-4b21-aa7d-2d8e10cd850a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_0c024165-c8a3-49c1-9055-ad28b61a5cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_0c024165-c8a3-49c1-9055-ad28b61a5cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_be47b78b-9776-4276-a68e-9aa8ccb3c583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_be47b78b-9776-4276-a68e-9aa8ccb3c583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1f3d76f9-50a8-4eb7-bd09-f9adfcb55e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fefe2cd-bf23-4dd9-a3cc-6e660c6806a9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1f3d76f9-50a8-4eb7-bd09-f9adfcb55e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5a51cd30-996b-4edc-a957-bae1f1616aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_NetIncomeLoss_5a51cd30-996b-4edc-a957-bae1f1616aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f7bad848-b013-4d14-bd50-0da44c8010e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f7bad848-b013-4d14-bd50-0da44c8010e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_78484b6e-b4e9-41fd-883f-805cb3552f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_ShareBasedCompensation_78484b6e-b4e9-41fd-883f-805cb3552f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_17c24d40-c497-478c-a0c2-0bacfa215fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_17c24d40-c497-478c-a0c2-0bacfa215fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9dd36516-d617-48bf-a2db-4d271ae50470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9dd36516-d617-48bf-a2db-4d271ae50470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_856660f7-f754-40b5-afa8-4f5534284d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_856660f7-f754-40b5-afa8-4f5534284d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4e824739-0f34-4312-95e7-bcdc52721ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4e824739-0f34-4312-95e7-bcdc52721ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_26a63820-2c2f-423d-a6d3-3f6291c4cc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_26a63820-2c2f-423d-a6d3-3f6291c4cc06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ec38fb0b-54c2-47a6-b769-f99948681b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ec38fb0b-54c2-47a6-b769-f99948681b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_47138feb-13db-427b-bd9b-d93e17c33d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_47138feb-13db-427b-bd9b-d93e17c33d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_815d2e02-5808-4d14-85f0-26df311a792a" xlink:href="amgn-20201231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_815d2e02-5808-4d14-85f0-26df311a792a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c017957d-ce0e-4382-9726-728699924e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347e8b27-2d04-46a7-8ea6-14bc8f82d163" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c017957d-ce0e-4382-9726-728699924e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5d11a195-79de-4e3b-9e5d-da9595a074ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5d11a195-79de-4e3b-9e5d-da9595a074ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_18f50f1b-9bdd-43b5-a744-f82a9bf05d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_18f50f1b-9bdd-43b5-a744-f82a9bf05d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fac6361a-5bc3-49d0-b396-cdc75613181f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fac6361a-5bc3-49d0-b396-cdc75613181f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_eddbcefd-6793-4e1a-a7c9-82f56147d844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_eddbcefd-6793-4e1a-a7c9-82f56147d844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_93582117-e210-456b-8068-a35a8120953e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_93582117-e210-456b-8068-a35a8120953e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7fce80b0-a3f9-4999-97a7-4e5c65578084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7fce80b0-a3f9-4999-97a7-4e5c65578084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_697c4d64-5ba5-48fa-95ab-10038b310913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57a1aca-2c74-460a-bd55-9153e548edc8" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_697c4d64-5ba5-48fa-95ab-10038b310913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10154664-5971-4ab8-81fb-decf22909f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a56ac40d-3b61-46f6-9036-f37ff755f094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10154664-5971-4ab8-81fb-decf22909f17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a56ac40d-3b61-46f6-9036-f37ff755f094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d692ef58-312a-4ab6-a01c-3ad25e056a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10154664-5971-4ab8-81fb-decf22909f17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d692ef58-312a-4ab6-a01c-3ad25e056a1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c7a1ff4-7a04-4579-aead-377c4137d29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10154664-5971-4ab8-81fb-decf22909f17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c7a1ff4-7a04-4579-aead-377c4137d29e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="amgn-20201231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="amgn-20201231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Acquisitions" xlink:type="simple" xlink:href="amgn-20201231.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsOtezlaDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsOtezlaDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsOtezlaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_18cbacc5-320b-4885-96e0-92cee4764cd0" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_074e49f7-6c0d-4ddb-be0b-3603d404d9ce" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_18cbacc5-320b-4885-96e0-92cee4764cd0" xlink:to="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_074e49f7-6c0d-4ddb-be0b-3603d404d9ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_63d7739f-79c0-406e-be82-f910647c9d73" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_18cbacc5-320b-4885-96e0-92cee4764cd0" xlink:to="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_63d7739f-79c0-406e-be82-f910647c9d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_9b713448-efa9-4033-965b-fab2df94a31c" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_18cbacc5-320b-4885-96e0-92cee4764cd0" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_9b713448-efa9-4033-965b-fab2df94a31c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_7e45133a-8abd-4c6d-9fae-955d39729f5a" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_18cbacc5-320b-4885-96e0-92cee4764cd0" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_7e45133a-8abd-4c6d-9fae-955d39729f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_3f3f6ac5-1772-435e-bd76-4ce7fc490635" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_18cbacc5-320b-4885-96e0-92cee4764cd0" xlink:to="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_3f3f6ac5-1772-435e-bd76-4ce7fc490635" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8b9cd521-4331-43a3-a420-553c820907a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_87aa2495-defd-4138-835b-7b106626e6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8b9cd521-4331-43a3-a420-553c820907a4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_87aa2495-defd-4138-835b-7b106626e6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_ec4e496f-2e17-44f2-be48-c3d11c235191" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8b9cd521-4331-43a3-a420-553c820907a4" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_ec4e496f-2e17-44f2-be48-c3d11c235191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_ee3d241b-101a-4ea3-9af8-6dda0e957b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8b9cd521-4331-43a3-a420-553c820907a4" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_ee3d241b-101a-4ea3-9af8-6dda0e957b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d27e141a-4114-47b5-b344-5219f485a6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7239773e-00e8-4f02-a37e-bb7d21e5951f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d27e141a-4114-47b5-b344-5219f485a6a4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7239773e-00e8-4f02-a37e-bb7d21e5951f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a126385e-60f0-485a-8fcb-7da742009fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d27e141a-4114-47b5-b344-5219f485a6a4" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a126385e-60f0-485a-8fcb-7da742009fdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Revenues" xlink:type="simple" xlink:href="amgn-20201231.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="amgn-20201231.xsd#Stockbasedcompensation"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationTextualDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_e9369acd-4d5a-42b3-b4e2-5a070b838ef7" xlink:href="amgn-20201231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a1ff56fe-871e-4058-851d-b1d3232e7925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax_e9369acd-4d5a-42b3-b4e2-5a070b838ef7" xlink:to="loc_us-gaap_ShareBasedCompensation_a1ff56fe-871e-4058-851d-b1d3232e7925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6dc14e67-e379-47c6-8a1e-d4f2dc33de47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax_e9369acd-4d5a-42b3-b4e2-5a070b838ef7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6dc14e67-e379-47c6-8a1e-d4f2dc33de47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Definedcontributionplan" xlink:type="simple" xlink:href="amgn-20201231.xsd#Definedcontributionplan"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Definedcontributionplan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DefinedcontributionplanDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Incometaxes" xlink:type="simple" xlink:href="amgn-20201231.xsd#Incometaxes"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Incometaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_df539439-a279-4191-bcc7-530d7361b295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d12173ee-a5c8-4bb5-9614-a55cf9c25a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_df539439-a279-4191-bcc7-530d7361b295" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d12173ee-a5c8-4bb5-9614-a55cf9c25a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be802769-7ac2-4289-9b06-48734b9adee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_df539439-a279-4191-bcc7-530d7361b295" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be802769-7ac2-4289-9b06-48734b9adee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de7f4763-bdcb-4a1c-832d-b45fe1505bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5f467d42-1048-49f9-8f7f-ba75571fd6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de7f4763-bdcb-4a1c-832d-b45fe1505bf5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5f467d42-1048-49f9-8f7f-ba75571fd6ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_68b2a188-27eb-4ef7-9973-9699e334453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de7f4763-bdcb-4a1c-832d-b45fe1505bf5" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_68b2a188-27eb-4ef7-9973-9699e334453f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_df53acf2-f78d-445f-b2ff-17de9a06f69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de7f4763-bdcb-4a1c-832d-b45fe1505bf5" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_df53acf2-f78d-445f-b2ff-17de9a06f69b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1e0699e8-71ed-4a04-aea6-ab5c09591c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2424b9fe-930b-4a40-a935-5afde503090b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1e0699e8-71ed-4a04-aea6-ab5c09591c4a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2424b9fe-930b-4a40-a935-5afde503090b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_da7acca9-c051-479c-9153-b685dd7e24cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1e0699e8-71ed-4a04-aea6-ab5c09591c4a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_da7acca9-c051-479c-9153-b685dd7e24cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4aaf2ff4-1039-4824-8d95-6c765e7eab7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1e0699e8-71ed-4a04-aea6-ab5c09591c4a" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4aaf2ff4-1039-4824-8d95-6c765e7eab7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_563743b0-d8a6-453f-b136-d37b347c2bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a72ed082-383e-45cf-83fe-a4b92f73580d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_563743b0-d8a6-453f-b136-d37b347c2bb7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a72ed082-383e-45cf-83fe-a4b92f73580d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_c9fedddf-0633-47c2-8e9a-b2008cfb584c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_563743b0-d8a6-453f-b136-d37b347c2bb7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_c9fedddf-0633-47c2-8e9a-b2008cfb584c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ae93e14a-eb3b-403b-9777-b220a8111342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_563743b0-d8a6-453f-b136-d37b347c2bb7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ae93e14a-eb3b-403b-9777-b220a8111342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_771dff0e-c553-4b1f-a9e6-77758118ad62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_563743b0-d8a6-453f-b136-d37b347c2bb7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_771dff0e-c553-4b1f-a9e6-77758118ad62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_74fcbc79-9915-4d82-8ea1-5787b272b59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5842ad01-7f64-430a-b000-ebdf82279c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_74fcbc79-9915-4d82-8ea1-5787b272b59c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5842ad01-7f64-430a-b000-ebdf82279c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_25d474e3-caa0-4e0e-9e7f-85929a0c06fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_74fcbc79-9915-4d82-8ea1-5787b272b59c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_25d474e3-caa0-4e0e-9e7f-85929a0c06fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_56e97ac5-de3c-4871-b674-1a7ae5d3407e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_14888066-cf94-4748-90a2-10a580b13215" xlink:href="amgn-20201231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_56e97ac5-de3c-4871-b674-1a7ae5d3407e" xlink:to="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_14888066-cf94-4748-90a2-10a580b13215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_31ba21d7-255f-447e-adc2-a3beebb98d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_56e97ac5-de3c-4871-b674-1a7ae5d3407e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_31ba21d7-255f-447e-adc2-a3beebb98d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_75000c18-10e2-4439-8dd4-ff937794acf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_56e97ac5-de3c-4871-b674-1a7ae5d3407e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_75000c18-10e2-4439-8dd4-ff937794acf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bb9a3f8a-77bd-403e-8520-712c423c6169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_56e97ac5-de3c-4871-b674-1a7ae5d3407e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bb9a3f8a-77bd-403e-8520-712c423c6169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b44de325-ed40-451d-bf2e-5bdf673820eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_56e97ac5-de3c-4871-b674-1a7ae5d3407e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b44de325-ed40-451d-bf2e-5bdf673820eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_91c7d4e4-718e-4db7-a719-ecd7cf574757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1568de51-6080-4728-9897-b6a7e2d39217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_91c7d4e4-718e-4db7-a719-ecd7cf574757" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1568de51-6080-4728-9897-b6a7e2d39217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_814082ed-42ab-4b59-b25b-443d3c577fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_91c7d4e4-718e-4db7-a719-ecd7cf574757" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_814082ed-42ab-4b59-b25b-443d3c577fbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesTextualDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16eca346-01fb-4b25-a144-443e21b0b075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16eca346-01fb-4b25-a144-443e21b0b075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f90cdad3-c84d-4aae-96d0-f86c62a7b767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f90cdad3-c84d-4aae-96d0-f86c62a7b767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_cca90571-6dc0-4ae2-8385-69eb4ff9fae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_cca90571-6dc0-4ae2-8385-69eb4ff9fae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_1884edab-b756-4939-8071-fa5a6b1e5a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_1884edab-b756-4939-8071-fa5a6b1e5a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_93e15669-0fb7-4582-a706-b57d6cfa9b1c" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_93e15669-0fb7-4582-a706-b57d6cfa9b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_f9d208f3-ddde-4f59-b835-6c423acea14a" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_f9d208f3-ddde-4f59-b835-6c423acea14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_730c490d-3fa4-4c02-92f6-b39d32c8b7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_730c490d-3fa4-4c02-92f6-b39d32c8b7d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_b33c9614-33a4-4a07-8c74-d2eeacf6a66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_b33c9614-33a4-4a07-8c74-d2eeacf6a66e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_013b0e0e-502c-41b8-b15a-c12957c5138f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9167f1bd-bdcb-4f1a-b3d4-0113b833cc21" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_013b0e0e-502c-41b8-b15a-c12957c5138f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Earningspershare" xlink:type="simple" xlink:href="amgn-20201231.xsd#Earningspershare"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Earningspershare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#EarningspershareTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/EarningspershareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#EarningspershareDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3edd7e46-20a9-461b-87e8-942508f0c9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dbc39633-0f20-4e30-8473-5b9bc5702181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3edd7e46-20a9-461b-87e8-942508f0c9fa" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dbc39633-0f20-4e30-8473-5b9bc5702181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_beec23e9-dd88-4da4-82ea-564e4de27353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3edd7e46-20a9-461b-87e8-942508f0c9fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_beec23e9-dd88-4da4-82ea-564e4de27353" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Collaborations" xlink:type="simple" xlink:href="amgn-20201231.xsd#Collaborations"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Collaborations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsNovartisAGDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsBayerHealthCarePharmaceuticalsIncDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsBeiGeneDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Investments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Investments"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_801b50f7-19a9-426e-a951-4339589eb3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42120d51-4fbf-45ff-9b06-d19deca75c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_801b50f7-19a9-426e-a951-4339589eb3bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_42120d51-4fbf-45ff-9b06-d19deca75c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_201a3617-12e7-442c-b7f0-b969a12d79c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_801b50f7-19a9-426e-a951-4339589eb3bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_201a3617-12e7-442c-b7f0-b969a12d79c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4487e7ae-6e19-4674-a537-ef000aa3145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_801b50f7-19a9-426e-a951-4339589eb3bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4487e7ae-6e19-4674-a537-ef000aa3145d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5d24e92-61e6-4322-83d5-2d98216bdedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4e22be6b-7504-4c00-b818-49e013f8ea90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5d24e92-61e6-4322-83d5-2d98216bdedd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4e22be6b-7504-4c00-b818-49e013f8ea90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2fefdfa6-f4fa-4ba0-95e0-2eac6924b412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5d24e92-61e6-4322-83d5-2d98216bdedd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2fefdfa6-f4fa-4ba0-95e0-2eac6924b412" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsAvailableforsaleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ea1660c-9204-44c9-9b8b-581a95181784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_685b4079-fe13-4b71-8ff2-a9ef4651a084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ea1660c-9204-44c9-9b8b-581a95181784" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_685b4079-fe13-4b71-8ff2-a9ef4651a084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_867e5285-a900-48aa-94ba-b9805c737f41" xlink:href="amgn-20201231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ea1660c-9204-44c9-9b8b-581a95181784" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_867e5285-a900-48aa-94ba-b9805c737f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_e78d581b-7d86-4c9d-8c7c-3dfcc6b9f9a0" xlink:href="amgn-20201231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ea1660c-9204-44c9-9b8b-581a95181784" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_e78d581b-7d86-4c9d-8c7c-3dfcc6b9f9a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ee1b087c-7601-4b61-bb4b-0d3e756d19fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ea1660c-9204-44c9-9b8b-581a95181784" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ee1b087c-7601-4b61-bb4b-0d3e756d19fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_18de01dd-4b94-4c6f-afcd-91bdfd2e55bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ea1660c-9204-44c9-9b8b-581a95181784" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_18de01dd-4b94-4c6f-afcd-91bdfd2e55bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsBeiGeneDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Inventories" xlink:type="simple" xlink:href="amgn-20201231.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3c8569c7-c46f-4dcc-a0b8-f61f7c51a46d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0c3272d2-eb23-4cdd-a658-c332e72e7ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3c8569c7-c46f-4dcc-a0b8-f61f7c51a46d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0c3272d2-eb23-4cdd-a658-c332e72e7ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3745d619-8f3d-4004-8edc-25f1872a8d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3c8569c7-c46f-4dcc-a0b8-f61f7c51a46d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3745d619-8f3d-4004-8edc-25f1872a8d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_65989154-90cd-42c1-9625-0a9518e7f476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3c8569c7-c46f-4dcc-a0b8-f61f7c51a46d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_65989154-90cd-42c1-9625-0a9518e7f476" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="amgn-20201231.xsd#Propertyplantandequipment"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cb4b6ca3-45d8-428e-99a3-d53cf8dce636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_119e2da0-aaab-41ff-8ab1-2829e0226932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cb4b6ca3-45d8-428e-99a3-d53cf8dce636" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_119e2da0-aaab-41ff-8ab1-2829e0226932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_68e6fd38-2234-443d-8a34-df7694d16915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cb4b6ca3-45d8-428e-99a3-d53cf8dce636" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_68e6fd38-2234-443d-8a34-df7694d16915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_cb795f9b-2c14-49cb-be4e-2ba6cfaebe80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_us-gaap_Land_cb795f9b-2c14-49cb-be4e-2ba6cfaebe80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_8a5bed58-1263-4d0f-ad3d-c9c12fc9c9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_8a5bed58-1263-4d0f-ad3d-c9c12fc9c9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_08211312-ed6a-46ce-95e5-19a3dffa5315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_08211312-ed6a-46ce-95e5-19a3dffa5315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_a6cd3c5b-1ed9-400c-81ef-27563ed999b7" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_amgn_LaboratoryEquipment_a6cd3c5b-1ed9-400c-81ef-27563ed999b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_a47f8d12-e11d-4553-87ad-09179d8b6024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_a47f8d12-e11d-4553-87ad-09179d8b6024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_dd429775-f363-4bae-a0a0-1f024f353b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_us-gaap_ConstructionInProgressGross_dd429775-f363-4bae-a0a0-1f024f353b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_ba61be6e-4d16-4d32-9114-c16e0f635681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_ba61be6e-4d16-4d32-9114-c16e0f635681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_520a966e-e0c3-4cbd-b031-d7adc8856645" xlink:href="amgn-20201231.xsd#amgn_FixedEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_be2498d6-3d2b-4f66-9603-5be22569e3db" xlink:to="loc_amgn_FixedEquipment_520a966e-e0c3-4cbd-b031-d7adc8856645" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="simple" xlink:href="amgn-20201231.xsd#Goodwillandintangibleassets"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_841ef312-8f9f-4eab-a4ee-5be2115bf643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_06b8fbe2-0941-4068-a216-32f8e68899fb" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_841ef312-8f9f-4eab-a4ee-5be2115bf643" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_06b8fbe2-0941-4068-a216-32f8e68899fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_4a6b284f-d2d6-4693-b4d6-77049233a3a2" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_841ef312-8f9f-4eab-a4ee-5be2115bf643" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_4a6b284f-d2d6-4693-b4d6-77049233a3a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e3bd6dfc-29f9-42c3-a122-3c34a2deabd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bc8a9d94-4188-453a-8b9e-7bd4a154ad6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e3bd6dfc-29f9-42c3-a122-3c34a2deabd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bc8a9d94-4188-453a-8b9e-7bd4a154ad6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2cc902d2-4543-4137-8f53-88240a1c2670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e3bd6dfc-29f9-42c3-a122-3c34a2deabd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2cc902d2-4543-4137-8f53-88240a1c2670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_2f571663-0624-4cd1-86fb-b0e809a2e40a" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_047258d4-2dae-49ea-97dc-2253dca055dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross_2f571663-0624-4cd1-86fb-b0e809a2e40a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_047258d4-2dae-49ea-97dc-2253dca055dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_140b1ca6-61c0-4b2c-bcc0-d8a0da98dd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross_2f571663-0624-4cd1-86fb-b0e809a2e40a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_140b1ca6-61c0-4b2c-bcc0-d8a0da98dd78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Leases" xlink:type="simple" xlink:href="amgn-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_89fb3056-8878-4b49-9daa-76a8389f30c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f07f436e-1de9-4349-a6d8-c3e37bc8b075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_89fb3056-8878-4b49-9daa-76a8389f30c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f07f436e-1de9-4349-a6d8-c3e37bc8b075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7ad47a53-a2a9-4cac-936d-1db09d79bfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_89fb3056-8878-4b49-9daa-76a8389f30c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7ad47a53-a2a9-4cac-936d-1db09d79bfb7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4ba30923-f307-46ef-9294-a787a9df2662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_14e1701c-e8ea-4a59-bea7-2e9cfd8300d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4ba30923-f307-46ef-9294-a787a9df2662" xlink:to="loc_us-gaap_OperatingLeaseCost_14e1701c-e8ea-4a59-bea7-2e9cfd8300d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_f1c1d6ac-4a0f-4c01-994b-8a1cccea4c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4ba30923-f307-46ef-9294-a787a9df2662" xlink:to="loc_us-gaap_SubleaseIncome_f1c1d6ac-4a0f-4c01-994b-8a1cccea4c95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_70761bae-8b16-4320-ae65-412269f3382a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_70761bae-8b16-4320-ae65-412269f3382a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b0de4faf-e37f-4281-8f88-f4169324b5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b0de4faf-e37f-4281-8f88-f4169324b5bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_83077b12-ad46-4546-945c-5dd09cbacccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_83077b12-ad46-4546-945c-5dd09cbacccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5af1152a-6a2f-4e0e-b02f-fc1a554f3d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5af1152a-6a2f-4e0e-b02f-fc1a554f3d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_12cce98c-8e75-40dc-a0e4-fcf226754bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_12cce98c-8e75-40dc-a0e4-fcf226754bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e3bd4bc8-6a78-4a0d-a0d3-af151e4ebf26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b42caa3-1465-4e93-97eb-1b6c27f97ae7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e3bd4bc8-6a78-4a0d-a0d3-af151e4ebf26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e986f8f2-e250-439c-9f5d-2c87aae50292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_68c2291c-2b37-4dbf-b96a-a9e3b9a36626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e986f8f2-e250-439c-9f5d-2c87aae50292" xlink:to="loc_us-gaap_OperatingLeaseLiability_68c2291c-2b37-4dbf-b96a-a9e3b9a36626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e5a4f05-503a-4a49-9df5-a24ef3ed0ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e986f8f2-e250-439c-9f5d-2c87aae50292" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e5a4f05-503a-4a49-9df5-a24ef3ed0ebc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesCashandNoncashInformationofLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="simple" xlink:href="amgn-20201231.xsd#Othercurrentassetsandaccruedliabilities"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_72aff17a-f130-45fd-9384-8760e21d5c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_49d42ada-b1f8-4e54-9414-7a9c96389985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_72aff17a-f130-45fd-9384-8760e21d5c1f" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_49d42ada-b1f8-4e54-9414-7a9c96389985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_235469c6-afe6-4c4b-8a86-df1f4395f99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_72aff17a-f130-45fd-9384-8760e21d5c1f" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_235469c6-afe6-4c4b-8a86-df1f4395f99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_c1597523-2de9-4377-98fa-b04a3cded622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_72aff17a-f130-45fd-9384-8760e21d5c1f" xlink:to="loc_us-gaap_InterestReceivableCurrent_c1597523-2de9-4377-98fa-b04a3cded622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_47a67366-dc53-4a45-82be-8e30f9ad6fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_72aff17a-f130-45fd-9384-8760e21d5c1f" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_47a67366-dc53-4a45-82be-8e30f9ad6fc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent_a7e42f28-8d63-4d9f-ae59-f7a7cfeec3ee" xlink:href="amgn-20201231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:to="loc_amgn_AccruedSalesDeductionsCurrent_a7e42f28-8d63-4d9f-ae59-f7a7cfeec3ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5454360-e224-43ca-8bf7-eb3b78949cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5454360-e224-43ca-8bf7-eb3b78949cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_73710e4f-cad6-41a8-a8b2-2e2981015e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:to="loc_us-gaap_DividendsPayableCurrent_73710e4f-cad6-41a8-a8b2-2e2981015e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent_30db7564-cb83-47a1-bb72-b06afd9a8b1b" xlink:href="amgn-20201231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:to="loc_amgn_AccruedSalesReturnReserveCurrent_30db7564-cb83-47a1-bb72-b06afd9a8b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d1214f01-538f-47af-a92a-beadba9ca941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d1214f01-538f-47af-a92a-beadba9ca941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_29aa56e7-fa95-4f20-aa45-db19692b1b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03365ddf-739e-46f4-b34d-a4640c25c2f5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_29aa56e7-fa95-4f20-aa45-db19692b1b31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Financingarrangements" xlink:type="simple" xlink:href="amgn-20201231.xsd#Financingarrangements"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Financingarrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bbcfc91d-2653-4f83-8796-c02425df310a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3b901e80-20ab-4af6-ad49-71fee18cf95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bbcfc91d-2653-4f83-8796-c02425df310a" xlink:to="loc_us-gaap_LongTermDebtCurrent_3b901e80-20ab-4af6-ad49-71fee18cf95a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d2db5405-911d-4b7c-9a2e-8b22757686bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bbcfc91d-2653-4f83-8796-c02425df310a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d2db5405-911d-4b7c-9a2e-8b22757686bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:href="amgn-20201231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6c677d2b-7d84-40be-bc7e-845cd8240ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6c677d2b-7d84-40be-bc7e-845cd8240ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4a89b93e-7100-44b8-afc2-612ab706ffbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4a89b93e-7100-44b8-afc2-612ab706ffbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_34cdc525-57db-4149-a55c-e7aadbd8d6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_34cdc525-57db-4149-a55c-e7aadbd8d6f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cd4f25d5-8eaf-4d68-96de-079274a67ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cd4f25d5-8eaf-4d68-96de-079274a67ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_78d732b4-9345-434e-95d1-6fe4ce22d129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_78d732b4-9345-434e-95d1-6fe4ce22d129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_8902411e-f707-4d5f-9413-3198170388b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_44e45e13-32da-4fb8-a5d8-83559a689867" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_8902411e-f707-4d5f-9413-3198170388b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsInterestCostsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockholdersequity" xlink:type="simple" xlink:href="amgn-20201231.xsd#Stockholdersequity"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Stockholdersequity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityStockRepurchaseProgramDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityDividendsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityOtherDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="simple" xlink:href="amgn-20201231.xsd#Fairvaluemeasurement"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e30e615f-b6d4-4fea-94df-4fe392727fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f864ec30-d7d6-4adc-a64a-c3de0a956cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e30e615f-b6d4-4fea-94df-4fe392727fca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f864ec30-d7d6-4adc-a64a-c3de0a956cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_912f2a33-4b62-4cb0-9cfb-926b12edc674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e30e615f-b6d4-4fea-94df-4fe392727fca" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_912f2a33-4b62-4cb0-9cfb-926b12edc674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_4114e655-0e96-4437-88cc-4efe8daea393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e30e615f-b6d4-4fea-94df-4fe392727fca" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_4114e655-0e96-4437-88cc-4efe8daea393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_23c6e6f0-0c0e-45c4-b7b4-13fa12ce1dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e30e615f-b6d4-4fea-94df-4fe392727fca" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_23c6e6f0-0c0e-45c4-b7b4-13fa12ce1dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_dbdbd512-a9ed-4e63-9e62-b8204a27ed87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2be8c160-0301-4776-a681-ba081cf03d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_dbdbd512-a9ed-4e63-9e62-b8204a27ed87" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2be8c160-0301-4776-a681-ba081cf03d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_063e1c0d-322e-4138-a4e9-134953df95e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_dbdbd512-a9ed-4e63-9e62-b8204a27ed87" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_063e1c0d-322e-4138-a4e9-134953df95e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1419f815-ff77-4ecb-93c9-00925eb52523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_dbdbd512-a9ed-4e63-9e62-b8204a27ed87" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1419f815-ff77-4ecb-93c9-00925eb52523" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Derivativeinstruments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Derivativeinstruments"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Derivativeinstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Contingenciesandcommitments"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsImmunexandSandozLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_032dc767-3491-4716-924a-0ab6045649e2" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_9a6a7635-90ea-4844-b4b7-872edbf27402" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_032dc767-3491-4716-924a-0ab6045649e2" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_9a6a7635-90ea-4844-b4b7-872edbf27402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_dbd9bc0a-2f67-4ea4-bbad-a0f4ba9419a7" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_032dc767-3491-4716-924a-0ab6045649e2" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_dbd9bc0a-2f67-4ea4-bbad-a0f4ba9419a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_107adf88-54cc-40ca-aff7-f80a3934e3e2" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_032dc767-3491-4716-924a-0ab6045649e2" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_107adf88-54cc-40ca-aff7-f80a3934e3e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_3d9caa0f-552e-4ef5-8eea-91725305927b" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_032dc767-3491-4716-924a-0ab6045649e2" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_3d9caa0f-552e-4ef5-8eea-91725305927b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_a8a6e61e-fa48-412e-9652-c3b2779d6e0f" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_032dc767-3491-4716-924a-0ab6045649e2" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_a8a6e61e-fa48-412e-9652-c3b2779d6e0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Quarterlyfinancialdataunaudited" xlink:type="simple" xlink:href="amgn-20201231.xsd#Quarterlyfinancialdataunaudited"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/Quarterlyfinancialdataunaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#QuarterlyfinancialdataunauditedTables"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#QuarterlyfinancialdataunauditedDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amgn-20201231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>amgn-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e0ca318f-3884-42e6-a64c-8779d462d73a,g:75807743-642d-4c80-8d38-07220e8d8bcd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20201231.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended" id="i3cf690233cc948f4b8f442ae48eef617_Coverpage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c68be916-580b-43cd-84c5-eaf96a2e423c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentType_c68be916-580b-43cd-84c5-eaf96a2e423c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6e3c80db-9557-4a4c-8b2e-78af588f7688" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentAnnualReport_6e3c80db-9557-4a4c-8b2e-78af588f7688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6874bc64-572a-4c7e-8ae0-310fd5a63672" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentPeriodEndDate_6874bc64-572a-4c7e-8ae0-310fd5a63672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bb20a3b5-7aae-4ea4-aed9-9fd73fa91c58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentTransitionReport_bb20a3b5-7aae-4ea4-aed9-9fd73fa91c58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ca3d82e4-3842-44f0-9fc0-3daa9ed82f38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityFileNumber_ca3d82e4-3842-44f0-9fc0-3daa9ed82f38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bbd3543e-6345-418b-a9d0-65ab41265958" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityRegistrantName_bbd3543e-6345-418b-a9d0-65ab41265958" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_037c3888-7196-421f-bd24-85784f9636e0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityIncorporationStateCountryCode_037c3888-7196-421f-bd24-85784f9636e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3acc66a6-c50b-45b0-8598-60a608993a8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityTaxIdentificationNumber_3acc66a6-c50b-45b0-8598-60a608993a8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_73b57b2a-a511-4cf3-ad69-56214a3d09f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressAddressLine1_73b57b2a-a511-4cf3-ad69-56214a3d09f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_323586b2-9579-4964-a1e7-3c111b35ed21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressCityOrTown_323586b2-9579-4964-a1e7-3c111b35ed21" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_35317354-b2b7-48fa-b5eb-794e312137ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressStateOrProvince_35317354-b2b7-48fa-b5eb-794e312137ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_89d98085-9e73-40ba-af78-437eef9abd61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressPostalZipCode_89d98085-9e73-40ba-af78-437eef9abd61" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec47f718-e48c-4281-a60e-516d4b53af12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_CityAreaCode_ec47f718-e48c-4281-a60e-516d4b53af12" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_12496e55-d068-4dbf-af93-921729d2677a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_LocalPhoneNumber_12496e55-d068-4dbf-af93-921729d2677a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d996fa65-6ede-4277-aa90-4d1a37d38311" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_Security12bTitle_d996fa65-6ede-4277-aa90-4d1a37d38311" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fd9b758a-4ea1-4e68-a125-be3e15b3a8e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_TradingSymbol_fd9b758a-4ea1-4e68-a125-be3e15b3a8e9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8f705f45-3295-4c8d-9ac7-32536090567d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_SecurityExchangeName_8f705f45-3295-4c8d-9ac7-32536090567d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9aba663e-2480-44bc-a51b-c316c3281708" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9aba663e-2480-44bc-a51b-c316c3281708" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ac4974a1-f64a-4df2-8834-601f48bd7b02" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityVoluntaryFilers_ac4974a1-f64a-4df2-8834-601f48bd7b02" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0bc04c6f-7c87-40d5-9d7a-d4d08a545b14" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityCurrentReportingStatus_0bc04c6f-7c87-40d5-9d7a-d4d08a545b14" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e7d60b5a-4c81-4901-abdd-b96289f7b1de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityInteractiveDataCurrent_e7d60b5a-4c81-4901-abdd-b96289f7b1de" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eee5b9f1-26f5-4d38-96c6-08ecc998e015" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityFilerCategory_eee5b9f1-26f5-4d38-96c6-08ecc998e015" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1b065504-0a34-4f6e-bfea-df82f6d6cdec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntitySmallBusiness_1b065504-0a34-4f6e-bfea-df82f6d6cdec" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c9b45a98-5e45-4ddb-a8bd-57adf8b50ce2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityEmergingGrowthCompany_c9b45a98-5e45-4ddb-a8bd-57adf8b50ce2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9fe32019-df76-499f-83fe-90bace5552a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9fe32019-df76-499f-83fe-90bace5552a2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4bb0421e-4c9e-44e3-8e46-c8ddb762e23a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityShellCompany_4bb0421e-4c9e-44e3-8e46-c8ddb762e23a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e85578ef-7c1d-4bb4-998b-16590db0c668" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityPublicFloat_e85578ef-7c1d-4bb4-998b-16590db0c668" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_094434fe-fea7-48cc-bca4-c2e78990296c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_094434fe-fea7-48cc-bca4-c2e78990296c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ab80ff66-7fb8-4926-a478-e985135c558e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ab80ff66-7fb8-4926-a478-e985135c558e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1d32706c-9599-4580-a58c-03b6ca152086" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityCentralIndexKey_1d32706c-9599-4580-a58c-03b6ca152086" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5157d6c5-8e11-488a-8c9e-996bf8afd991" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_AmendmentFlag_5157d6c5-8e11-488a-8c9e-996bf8afd991" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_80e91f33-aa34-4cf2-8cb5-b220a0064e66" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentFiscalYearFocus_80e91f33-aa34-4cf2-8cb5-b220a0064e66" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_29291f5b-b357-44cb-8151-ce524a053958" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentFiscalPeriodFocus_29291f5b-b357-44cb-8151-ce524a053958" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a047e07b-6349-4c00-85e9-10de3a652250" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_CurrentFiscalYearEndDate_a047e07b-6349-4c00-85e9-10de3a652250" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:to="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_53a390ff-a435-4fc3-9721-a51397be1658_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:to="loc_us-gaap_ClassOfStockDomain_53a390ff-a435-4fc3-9721-a51397be1658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:to="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a370f04e-4d65-4791-9f49-837adf038c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:to="loc_us-gaap_CommonStockMember_a370f04e-4d65-4791-9f49-837adf038c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A1.250SeniorNotesDue2022Member_bed0d9d2-bb7d-4379-878e-62e5345f09bb" xlink:href="amgn-20201231.xsd#amgn_A1.250SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:to="loc_amgn_A1.250SeniorNotesDue2022Member_bed0d9d2-bb7d-4379-878e-62e5345f09bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_7da707b9-8fa1-4178-ac20-c447c4fe42f7" xlink:href="amgn-20201231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_7da707b9-8fa1-4178-ac20-c447c4fe42f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:to="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_1f1b6c82-805f-4b48-b048-b4f61a6b78e3_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:to="loc_dei_ExchangeDomain_1f1b6c82-805f-4b48-b048-b4f61a6b78e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:to="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_b06f0057-1282-4c44-b12b-5f24bfd4c74e" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:to="loc_exch_XNGS_b06f0057-1282-4c44-b12b-5f24bfd4c74e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_aa7ea2dc-d206-43d2-9415-54c8117e5e33" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:to="loc_exch_XNYS_aa7ea2dc-d206-43d2-9415-54c8117e5e33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i578d27e08684475a95db2e1763cfef52_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5f9b0195-cd81-417f-9e77-d6ffb022bcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5f9b0195-cd81-417f-9e77-d6ffb022bcac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36596d40-6a65-4edc-9c42-165534b230f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36596d40-6a65-4edc-9c42-165534b230f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8d916f5e-ae7f-400c-a5be-320273be9fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:to="loc_us-gaap_Revenues_8d916f5e-ae7f-400c-a5be-320273be9fa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3c6a8ff-fd6d-4ca0-a3cc-22306a15beed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3c6a8ff-fd6d-4ca0-a3cc-22306a15beed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_589ac90b-3a6a-4bc1-98e8-44e355bbf986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_589ac90b-3a6a-4bc1-98e8-44e355bbf986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_40f7a2e8-b8c3-4e25-8231-edb66a55dae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_40f7a2e8-b8c3-4e25-8231-edb66a55dae5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_4899cb2b-029d-49b9-89b6-98b0633dbe3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_OtherGeneralExpense_4899cb2b-029d-49b9-89b6-98b0633dbe3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8e917e78-abd5-4a44-9e5e-5cbcdbcd59a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_CostsAndExpenses_8e917e78-abd5-4a44-9e5e-5cbcdbcd59a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d21b7c32-ff72-494c-8d2a-698b0003c1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_d21b7c32-ff72-494c-8d2a-698b0003c1db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_55daeaff-ce57-4d92-aae5-79ffaecaaba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_InterestExpenseDebt_55daeaff-ce57-4d92-aae5-79ffaecaaba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed9fb0cb-f578-44a8-b9dd-2242dc084d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ed9fb0cb-f578-44a8-b9dd-2242dc084d83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f790091d-c965-4634-910b-79e0de603f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f790091d-c965-4634-910b-79e0de603f0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad5d8e93-39b6-457a-9bba-8e1d830d9546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad5d8e93-39b6-457a-9bba-8e1d830d9546" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9c1db38-0615-4125-90cf-161c6deb665f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_NetIncomeLoss_a9c1db38-0615-4125-90cf-161c6deb665f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fce6bb92-1404-4d49-adae-1a51a91a9d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:to="loc_us-gaap_EarningsPerShareBasic_fce6bb92-1404-4d49-adae-1a51a91a9d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_62f38dd8-4e19-460e-8c2f-02e051ffc0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:to="loc_us-gaap_EarningsPerShareDiluted_62f38dd8-4e19-460e-8c2f-02e051ffc0e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e1d72e1-a0ce-47e5-b9e2-0c69496f4323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e1d72e1-a0ce-47e5-b9e2-0c69496f4323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9dfd8f3-1139-49db-bf4f-c55a15fa0c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9dfd8f3-1139-49db-bf4f-c55a15fa0c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:to="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e16937d0-4fe3-49df-b365-69f4b151cdb6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:to="loc_srt_ProductsAndServicesDomain_e16937d0-4fe3-49df-b365-69f4b151cdb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:to="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d5a746ba-2914-462f-9056-4b517e25a14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:to="loc_us-gaap_ProductMember_d5a746ba-2914-462f-9056-4b517e25a14a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6a6d9c16-e363-45b9-8c21-e187f9be10f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6a6d9c16-e363-45b9-8c21-e187f9be10f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="ifda708d2c8ba4de5b5bacbcae448876b_ConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="id5757d0df5ac47fb933dc23422a95f65_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i239f1260751b4059a92aaee947699331_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i5925335242154998a638d0bd6203df0a_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f4dc3b3c-cc9d-4ba2-8764-7099155bd116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f4dc3b3c-cc9d-4ba2-8764-7099155bd116" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4bb823a2-b437-4f89-9b6b-569e14c67903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4bb823a2-b437-4f89-9b6b-569e14c67903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b495d77-b429-4dfe-b300-c05f31912fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockholdersEquity_3b495d77-b429-4dfe-b300-c05f31912fac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4ed0f28e-5c53-40e6-9170-f833ed62db0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_NetIncomeLoss_4ed0f28e-5c53-40e6-9170-f833ed62db0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_64c63667-4620-4b85-a671-5f74968c88a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_64c63667-4620-4b85-a671-5f74968c88a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_b98806ed-e27f-4de8-ad4a-3d96267c803a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_DividendsCommonStockCash_b98806ed-e27f-4de8-ad4a-3d96267c803a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_315f879a-e9ef-4187-9e37-e2617cac33cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_315f879a-e9ef-4187-9e37-e2617cac33cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1904cfeb-f1b3-4ec1-9a53-87d73e4decdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1904cfeb-f1b3-4ec1-9a53-87d73e4decdc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec5847b7-b68d-4937-9a45-bb7c35a9fb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec5847b7-b68d-4937-9a45-bb7c35a9fb26" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_384d3327-c824-4e89-be2f-37ff5d799f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_384d3327-c824-4e89-be2f-37ff5d799f40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ef1b30f3-b338-4718-842c-b4c39a25297e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ef1b30f3-b338-4718-842c-b4c39a25297e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_7d97461a-bcd7-4a47-95d2-45c7f7839689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_7d97461a-bcd7-4a47-95d2-45c7f7839689" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_592bb46a-cfd4-4439-9151-d98cd6c087dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac484624-d61d-4277-8a90-187411357c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f4dc3b3c-cc9d-4ba2-8764-7099155bd116" xlink:to="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6971ca3e-200d-4c8c-9172-3ce3fc677482_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:to="loc_us-gaap_EquityComponentDomain_6971ca3e-200d-4c8c-9172-3ce3fc677482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:to="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_59c00041-7ae9-4a93-90e1-6488006442af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_CommonStockMember_59c00041-7ae9-4a93-90e1-6488006442af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_579f5cb8-93a5-4bd7-a944-29e378e5ab02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_579f5cb8-93a5-4bd7-a944-29e378e5ab02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5de87f72-6792-4fa5-878d-d396c73dd5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_RetainedEarningsMember_5de87f72-6792-4fa5-878d-d396c73dd5d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dd4bba00-154a-43eb-9d44-ab8fe38fe69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dd4bba00-154a-43eb-9d44-ab8fe38fe69c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5230d4bf-a81d-4f2a-a5a3-586ebd999ce7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5230d4bf-a81d-4f2a-a5a3-586ebd999ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac7478fe-c5fa-4918-985a-b425a41b269a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5230d4bf-a81d-4f2a-a5a3-586ebd999ce7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac7478fe-c5fa-4918-985a-b425a41b269a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i582bbb34f204466fa0c794c383f44bae_ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="id6bf6e1e29d242b28a1645cea6a32aa5_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="amgn-20201231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended" id="ic5bc1da1caf14d39af98d89d7cfae8ad_Summaryofsignificantaccountingpolicies"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="amgn-20201231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended" id="i07ab0ed563af4386be7fe6c99bc925e2_SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended" id="idaa41467da414fb48606c40e985109f3_SummaryofsignificantaccountingpoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_880ef71a-db84-40ee-90a0-9b971815912b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_880ef71a-db84-40ee-90a0-9b971815912b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_a84a7838-ccc9-4e1b-9b06-2cf0a6ae74f1" xlink:href="amgn-20201231.xsd#amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_a84a7838-ccc9-4e1b-9b06-2cf0a6ae74f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_a1fcbef6-ec07-46dd-9c0a-7b78e9f01ab0" xlink:href="amgn-20201231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_a1fcbef6-ec07-46dd-9c0a-7b78e9f01ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_8e1ab004-9178-4a60-9667-145dfdacd7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_AdvertisingExpense_8e1ab004-9178-4a60-9667-145dfdacd7e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm_a2fa4b7f-edcc-49e5-8d3d-23e0f3f7c9a5" xlink:href="amgn-20201231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_amgn_RevenuePaymentArrangementTerm_a2fa4b7f-edcc-49e5-8d3d-23e0f3f7c9a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5895ad53-48f5-41ef-910c-3615ef5e15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_OperatingLeaseLiability_5895ad53-48f5-41ef-910c-3615ef5e15e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_04647a3b-3fec-43c5-b7d8-58c05954539b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_04647a3b-3fec-43c5-b7d8-58c05954539b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:to="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:to="loc_srt_RangeMember_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:to="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7df731dc-7aa0-443d-a7b3-4b7e933081a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:to="loc_srt_MinimumMember_7df731dc-7aa0-443d-a7b3-4b7e933081a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b80dcd7-e9a3-45b3-b3a5-f5f4e7bfe5e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:to="loc_srt_MaximumMember_7b80dcd7-e9a3-45b3-b3a5-f5f4e7bfe5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3ff20c82-651b-4fa5-8579-0f473b85dc08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3ff20c82-651b-4fa5-8579-0f473b85dc08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_9a1fa110-23d6-497b-8b1f-b6cff20a3b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:to="loc_us-gaap_TypeOfAdoptionMember_9a1fa110-23d6-497b-8b1f-b6cff20a3b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_009b2164-5bc4-45e2-b3c7-140091a7f5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_9a1fa110-23d6-497b-8b1f-b6cff20a3b11" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_009b2164-5bc4-45e2-b3c7-140091a7f5d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Acquisitions" xlink:type="simple" xlink:href="amgn-20201231.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Acquisitions" xlink:type="extended" id="i179bbc78cb854e149627ce785f4b9962_Acquisitions"/>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsTables" xlink:type="extended" id="i2f373b807798428484ea1c8c4216c43b_AcquisitionsTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="id42349b62efc4714a7a749ed91412b03_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedMarkets_b71ff025-29bb-4c55-a9de-04c15e81101b" xlink:href="amgn-20201231.xsd#amgn_ApprovedMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_ApprovedMarkets_b71ff025-29bb-4c55-a9de-04c15e81101b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05de375d-ea2a-4f76-a37a-d8c425370e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05de375d-ea2a-4f76-a37a-d8c425370e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_cde3ccf6-2ad2-4f49-8f3a-5d735d7c4949" xlink:href="amgn-20201231.xsd#amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_cde3ccf6-2ad2-4f49-8f3a-5d735d7c4949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_819088ee-f536-46c1-8cca-caa526a39132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_819088ee-f536-46c1-8cca-caa526a39132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_ac69f1f5-2f2d-4536-896d-e917370f7031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_ac69f1f5-2f2d-4536-896d-e917370f7031" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9323c861-75db-4c0c-83ce-b4a4ddeff5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9323c861-75db-4c0c-83ce-b4a4ddeff5a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a80fd174-15b1-4168-97b9-990a1cdf1697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a80fd174-15b1-4168-97b9-990a1cdf1697" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_2a52a68b-4703-4db9-8dad-28892999cdc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_2a52a68b-4703-4db9-8dad-28892999cdc2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss_82e748bc-4b2a-44d3-9f69-3af291d65cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss_82e748bc-4b2a-44d3-9f69-3af291d65cf6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_24431ee9-35cf-4372-b7f0-04a84dc7ef47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_24431ee9-35cf-4372-b7f0-04a84dc7ef47" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_7738d7cf-aa9f-4684-bbac-e5d16dd50a3d" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_7738d7cf-aa9f-4684-bbac-e5d16dd50a3d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4132395-0d4b-4a3e-a74b-f3a1e233b2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4132395-0d4b-4a3e-a74b-f3a1e233b2a2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a09539ea-c558-49a8-bcab-9c343870ab06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a09539ea-c558-49a8-bcab-9c343870ab06" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_5eeba287-354f-4a55-acf2-59ac8fb616b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_5eeba287-354f-4a55-acf2-59ac8fb616b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_11efac7a-3f5b-4f8a-9a08-7ba95b186603" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_11efac7a-3f5b-4f8a-9a08-7ba95b186603" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8002f569-376a-488a-870d-ad62b7820fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_Goodwill_8002f569-376a-488a-870d-ad62b7820fd4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2c9c6f7b-b1a8-43e9-b87f-d78357ae19fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2c9c6f7b-b1a8-43e9-b87f-d78357ae19fa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_3da764de-091f-4035-b3da-210a6134073e" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_3da764de-091f-4035-b3da-210a6134073e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_e34234e7-00ae-45fa-aa37-d6166c55bb44" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_e34234e7-00ae-45fa-aa37-d6166c55bb44" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_b9547234-0f3a-4ef7-8c77-528122511324" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_b9547234-0f3a-4ef7-8c77-528122511324" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_9ac1531b-5494-4268-8a3d-ef0fab11d266_default" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:to="loc_amgn_AssetsByDescriptionDomain_9ac1531b-5494-4268-8a3d-ef0fab11d266_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:to="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember_d6110ec2-ae65-4b6d-8067-6439fdd68497" xlink:href="amgn-20201231.xsd#amgn_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:to="loc_amgn_AssembledWorkforceMember_d6110ec2-ae65-4b6d-8067-6439fdd68497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_7cfd05fa-b0d2-4e97-87f4-21994bfffc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:to="loc_us-gaap_InventoriesMember_7cfd05fa-b0d2-4e97-87f4-21994bfffc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22db6ddb-7ccb-4986-ae9f-05e7095ca360_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22db6ddb-7ccb-4986-ae9f-05e7095ca360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_88fa7d04-97ae-4907-a1a6-b724de785f82" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:to="loc_amgn_OtezlaMember_88fa7d04-97ae-4907-a1a6-b724de785f82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember_ccac54d1-414c-4cf8-a823-118c58171680" xlink:href="amgn-20201231.xsd#amgn_NuevolutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:to="loc_amgn_NuevolutionMember_ccac54d1-414c-4cf8-a823-118c58171680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember_4aac8d17-5e15-4b7c-92ed-9159f62b27ad" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:to="loc_amgn_KirinAmgenInc.KAMember_4aac8d17-5e15-4b7c-92ed-9159f62b27ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0da5c341-1aed-4c60-bc36-5d3a331e6bf4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0da5c341-1aed-4c60-bc36-5d3a331e6bf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6019ea28-70c6-404f-88dd-d331dda9af49" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6019ea28-70c6-404f-88dd-d331dda9af49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember_f7cc8cfa-3a37-4062-9345-7f92384e2314" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6019ea28-70c6-404f-88dd-d331dda9af49" xlink:to="loc_amgn_KirinAmgenInc.KAMember_f7cc8cfa-3a37-4062-9345-7f92384e2314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd1f993-ff6f-4896-a9dd-106b4f476665_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dcd1f993-ff6f-4896-a9dd-106b4f476665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_62763784-2df4-42ef-a4e7-c5f2fcd870e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_62763784-2df4-42ef-a4e7-c5f2fcd870e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_b86a05d5-9325-4f4c-84df-f3d285d60be3" xlink:href="amgn-20201231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_amgn_MarketingRelatedRightsMember_b86a05d5-9325-4f4c-84df-f3d285d60be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_2fbec864-43be-440c-8719-49d8949f2295" xlink:href="amgn-20201231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_amgn_RDTechnologyrightsMember_2fbec864-43be-440c-8719-49d8949f2295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5bb61160-f374-4fc0-89ce-2d36ceb10e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_us-gaap_LicensingAgreementsMember_5bb61160-f374-4fc0-89ce-2d36ceb10e99" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsOtezlaDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsOtezlaDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsOtezlaDetails" xlink:type="extended" id="i38c6ff2693e74d60b0a88c18e2c2101c_AcquisitionsOtezlaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6d012ae7-facf-4f24-8ac5-5ffc321871a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6d012ae7-facf-4f24-8ac5-5ffc321871a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition_54edf5a7-af25-415a-861d-d94b3bd14859" xlink:href="amgn-20201231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_Transactioncostsassetacquisition_54edf5a7-af25-415a-861d-d94b3bd14859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_460930ed-3e1d-4a08-999d-2b60350b57ff" xlink:href="amgn-20201231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_460930ed-3e1d-4a08-999d-2b60350b57ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_55c34802-76f9-4b1d-9c93-f29690c3923d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_55c34802-76f9-4b1d-9c93-f29690c3923d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_8bbccf44-a115-4a50-9c0c-89bf03f8efe6" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_55c34802-76f9-4b1d-9c93-f29690c3923d" xlink:to="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_8bbccf44-a115-4a50-9c0c-89bf03f8efe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_ee082c5a-b74a-43c9-bb42-a89f8ffb0dbb" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_ee082c5a-b74a-43c9-bb42-a89f8ffb0dbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_764cb0c9-dc94-4bee-af26-237bbe265898" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_764cb0c9-dc94-4bee-af26-237bbe265898" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_fa48b97d-0a1c-449b-a087-1f5cb1c27bdb" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_fa48b97d-0a1c-449b-a087-1f5cb1c27bdb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_00217fc4-f23a-452d-8660-f6820db6971a" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_00217fc4-f23a-452d-8660-f6820db6971a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_dea9e596-c22e-4488-a6d8-f65fff423244" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_dea9e596-c22e-4488-a6d8-f65fff423244" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_993db19c-f52c-4786-9959-a15ffca62a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_993db19c-f52c-4786-9959-a15ffca62a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_dd8848fd-dc75-4f43-8c90-54551ee3c4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_dd8848fd-dc75-4f43-8c90-54551ee3c4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_3b88b77a-d38a-4dbc-b3f3-8a07f35f6167" xlink:href="amgn-20201231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:to="loc_amgn_MarketingRelatedRightsMember_3b88b77a-d38a-4dbc-b3f3-8a07f35f6167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3525730-b8eb-4cbc-abb0-64faef1d340f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3525730-b8eb-4cbc-abb0-64faef1d340f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104415e5-1933-4d0c-b615-be4836c9d4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104415e5-1933-4d0c-b615-be4836c9d4fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_5b65c153-3847-4b2c-937b-d4f5378ac940" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104415e5-1933-4d0c-b615-be4836c9d4fb" xlink:to="loc_amgn_OtezlaMember_5b65c153-3847-4b2c-937b-d4f5378ac940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_f0828877-d987-47e9-86ab-32fd2cc3f9c3_default" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:to="loc_amgn_AssetsByDescriptionDomain_f0828877-d987-47e9-86ab-32fd2cc3f9c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_50bd6e2e-81eb-4631-bc2e-bdc599e468bd" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:to="loc_amgn_AssetsByDescriptionDomain_50bd6e2e-81eb-4631-bc2e-bdc599e468bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember_aec988de-741f-48e4-b7c2-bd7d33fd45fb" xlink:href="amgn-20201231.xsd#amgn_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_AssetsByDescriptionDomain_50bd6e2e-81eb-4631-bc2e-bdc599e468bd" xlink:to="loc_amgn_AssembledWorkforceMember_aec988de-741f-48e4-b7c2-bd7d33fd45fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended" id="i0af9d5e5aab142c58eeb982b44269908_AcquisitionsAggregateConsiderationPaidDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c67ab3cb-35c9-4ec4-99e6-b51593141ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c67ab3cb-35c9-4ec4-99e6-b51593141ee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4bea891e-7cc2-48e8-bdd4-d1edf92ae33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4bea891e-7cc2-48e8-bdd4-d1edf92ae33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_52a05792-ebd7-4ed4-80fd-1a24b3e74b0c" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_52a05792-ebd7-4ed4-80fd-1a24b3e74b0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_13d76e1e-747e-43dc-bbc5-92c5d72a208d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_13d76e1e-747e-43dc-bbc5-92c5d72a208d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ac58e78-d16f-4247-b9b4-91b4d6785905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ac58e78-d16f-4247-b9b4-91b4d6785905" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2d2e3ac8-0bb6-476f-b5ac-bd334187c346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2d2e3ac8-0bb6-476f-b5ac-bd334187c346" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_ea1691ee-a9d2-4587-b6e1-5908a3f3c793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_ea1691ee-a9d2-4587-b6e1-5908a3f3c793" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb056059-28b8-4e3e-a18a-049193e5f65d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb056059-28b8-4e3e-a18a-049193e5f65d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1edb71c7-e18e-4d4f-bc52-f00f0436e976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1edb71c7-e18e-4d4f-bc52-f00f0436e976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_06a920b8-f431-4b78-91a4-590ff52c76dd" xlink:href="amgn-20201231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1edb71c7-e18e-4d4f-bc52-f00f0436e976" xlink:to="loc_amgn_RDTechnologyrightsMember_06a920b8-f431-4b78-91a4-590ff52c76dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_031e2392-5f94-4693-b70c-7712d3a8ac34_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_031e2392-5f94-4693-b70c-7712d3a8ac34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember_99283526-f2ea-4175-ac36-59c1d236225e" xlink:href="amgn-20201231.xsd#amgn_NuevolutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:to="loc_amgn_NuevolutionMember_99283526-f2ea-4175-ac36-59c1d236225e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember_eef8743b-ca25-47d9-994a-a47d285092b9" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:to="loc_amgn_KirinAmgenInc.KAMember_eef8743b-ca25-47d9-994a-a47d285092b9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Revenues" xlink:type="simple" xlink:href="amgn-20201231.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Revenues" xlink:type="extended" id="i85183f9eadf941319752af9609ee6eda_Revenues"/>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesTables" xlink:type="extended" id="iaf5a72ce178f42308d93882354a83a09_RevenuesTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i7d43ed1784bd4cd98d76e40dfbada9ba_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_f1366e1f-9e6b-4ed8-be30-a91681985ba6" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_f1366e1f-9e6b-4ed8-be30-a91681985ba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_7cb3d92a-2755-45c8-a4cd-0451ca96f6b8" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_7cb3d92a-2755-45c8-a4cd-0451ca96f6b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_92a696af-66c0-4668-9c39-4bedda40b51f" xlink:href="amgn-20201231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_92a696af-66c0-4668-9c39-4bedda40b51f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_fc5b3e6a-9d56-47a0-bf9d-fb8ce1d7140b" xlink:href="amgn-20201231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_fc5b3e6a-9d56-47a0-bf9d-fb8ce1d7140b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd8523b9-4700-4e72-8ab7-fc6352d8f1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd8523b9-4700-4e72-8ab7-fc6352d8f1f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_0b467fce-7dc6-4075-a5db-f7ea282fd0d5" xlink:href="amgn-20201231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_0b467fce-7dc6-4075-a5db-f7ea282fd0d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e7ca0748-f91f-41f1-8cb5-cee7271d760d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:to="loc_srt_NameOfMajorCustomerDomain_e7ca0748-f91f-41f1-8cb5-cee7271d760d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:to="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_66fbfa2a-5fcd-4ce3-97c9-7acffc0b9051" xlink:href="amgn-20201231.xsd#amgn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:to="loc_amgn_CustomerOneMember_66fbfa2a-5fcd-4ce3-97c9-7acffc0b9051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_d07896d2-6e11-4053-9f91-4c6dd55bc2fb" xlink:href="amgn-20201231.xsd#amgn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:to="loc_amgn_CustomerTwoMember_d07896d2-6e11-4053-9f91-4c6dd55bc2fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_1d53f557-8dcb-445e-9d62-13191dc1f26b" xlink:href="amgn-20201231.xsd#amgn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:to="loc_amgn_CustomerThreeMember_1d53f557-8dcb-445e-9d62-13191dc1f26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63263355-3551-4227-a5d1-34d1e136fd64_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:to="loc_srt_ProductsAndServicesDomain_63263355-3551-4227-a5d1-34d1e136fd64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:to="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:to="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_6c6d311a-87b0-4019-a229-e410ec99f257" xlink:href="amgn-20201231.xsd#amgn_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_EnbrelMember_6c6d311a-87b0-4019-a229-e410ec99f257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_9303a672-3059-46fe-bb08-86c2930b0bce" xlink:href="amgn-20201231.xsd#amgn_ProliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_ProliaMember_9303a672-3059-46fe-bb08-86c2930b0bce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_b2746457-03c6-4803-8369-b7c25677ffeb" xlink:href="amgn-20201231.xsd#amgn_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_NeulastaMember_b2746457-03c6-4803-8369-b7c25677ffeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_57c1e4b1-ef0e-475c-b1b7-e0919fb6202f" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_OtezlaMember_57c1e4b1-ef0e-475c-b1b7-e0919fb6202f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_7dd87efa-5827-4a5e-9c24-5cf238b4c332" xlink:href="amgn-20201231.xsd#amgn_XgevaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_XgevaMember_7dd87efa-5827-4a5e-9c24-5cf238b4c332" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_4d5804f2-48ac-462e-81bf-f8a40c9d621f" xlink:href="amgn-20201231.xsd#amgn_AranespMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_AranespMember_4d5804f2-48ac-462e-81bf-f8a40c9d621f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_fff3a940-8734-4136-b0fa-9bdb4324e6ec" xlink:href="amgn-20201231.xsd#amgn_KyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_KyprolisMember_fff3a940-8734-4136-b0fa-9bdb4324e6ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_2b0273d6-9a94-43e4-a4c6-50e7b4fbca4f" xlink:href="amgn-20201231.xsd#amgn_RepathaevolocumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_RepathaevolocumabMember_2b0273d6-9a94-43e4-a4c6-50e7b4fbca4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_7da03712-ab0a-4986-b769-ae20bd4c8772" xlink:href="amgn-20201231.xsd#amgn_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_OtherProductsMember_7da03712-ab0a-4986-b769-ae20bd4c8772" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e0de3948-5f46-4430-be09-1396fc684187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e0de3948-5f46-4430-be09-1396fc684187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1039bb53-bf75-4737-aee3-1e9f6a089924_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:to="loc_srt_SegmentGeographicalDomain_1039bb53-bf75-4737-aee3-1e9f6a089924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:to="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6c0cef20-9075-4e7e-92f9-41aee08bec1a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:to="loc_country_US_6c0cef20-9075-4e7e-92f9-41aee08bec1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f0c86b04-5956-48ac-a64f-6cf2eb057cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:to="loc_us-gaap_NonUsMember_f0c86b04-5956-48ac-a64f-6cf2eb057cd9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended" id="i1517940c799e42d8be3a230c158406cf_RevenuesCustomerConcentrationProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_28a65cfe-8a67-4f53-93bc-96f04481115e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_28a65cfe-8a67-4f53-93bc-96f04481115e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues_2b997e9d-3fd6-4bba-a1db-16fff6fa45b7" xlink:href="amgn-20201231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_PercentageOfGrossRevenues_2b997e9d-3fd6-4bba-a1db-16fff6fa45b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_77afc4ec-4434-4d13-aa59-ad6d7414f40d" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_77afc4ec-4434-4d13-aa59-ad6d7414f40d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_ca762970-c771-412d-8e1c-db0ab708c809" xlink:href="amgn-20201231.xsd#amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_ca762970-c771-412d-8e1c-db0ab708c809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_02e4ab7d-eccc-4d0c-8383-034a3247fb11" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_02e4ab7d-eccc-4d0c-8383-034a3247fb11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:to="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_787b4774-6a38-4606-9687-a66f2562aa36_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:to="loc_srt_ProductsAndServicesDomain_787b4774-6a38-4606-9687-a66f2562aa36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52ed99a1-43a5-4484-b913-e164477a42f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:to="loc_srt_ProductsAndServicesDomain_52ed99a1-43a5-4484-b913-e164477a42f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_384d8a89-3283-406d-9e90-77f2cd00db69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52ed99a1-43a5-4484-b913-e164477a42f6" xlink:to="loc_us-gaap_ProductMember_384d8a89-3283-406d-9e90-77f2cd00db69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:to="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:to="loc_srt_NameOfMajorCustomerDomain_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:to="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_c07e72a8-5f11-4a66-a015-ca277f22c3fa" xlink:href="amgn-20201231.xsd#amgn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:to="loc_amgn_CustomerOneMember_c07e72a8-5f11-4a66-a015-ca277f22c3fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_2996d45c-effe-4322-8187-603be3f36912" xlink:href="amgn-20201231.xsd#amgn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:to="loc_amgn_CustomerTwoMember_2996d45c-effe-4322-8187-603be3f36912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_59a4af3a-7912-43a1-a6f5-7b930a652d0c" xlink:href="amgn-20201231.xsd#amgn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:to="loc_amgn_CustomerThreeMember_59a4af3a-7912-43a1-a6f5-7b930a652d0c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="amgn-20201231.xsd#Stockbasedcompensation"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="extended" id="icb84e49dcf3141c5a40dbdf33f546811_Stockbasedcompensation"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="extended" id="i9093196ec42f4386bef1f0412df26848_StockbasedcompensationTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended" id="i58f1c26972f1431b85fba78e870b8d5f_StockbasedcompensationTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_0abce899-c92a-4b83-bc5b-6f8363b1adfa" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_0abce899-c92a-4b83-bc5b-6f8363b1adfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_c389febb-0692-43e2-8c27-a49217a07f8b" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_c389febb-0692-43e2-8c27-a49217a07f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d2a802e7-327f-4236-b54f-c918d8f05bd9" xlink:href="amgn-20201231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d2a802e7-327f-4236-b54f-c918d8f05bd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_f3873952-9848-401e-b009-2def0f187bce" xlink:href="amgn-20201231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_f3873952-9848-401e-b009-2def0f187bce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2b601d50-f145-4113-bce2-1b4d9b931a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2b601d50-f145-4113-bce2-1b4d9b931a39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe1bf2fd-f6ec-421a-ab6c-6dc9fd3e6232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe1bf2fd-f6ec-421a-ab6c-6dc9fd3e6232" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_204d12b2-f03b-412f-a379-71a56828b0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_204d12b2-f03b-412f-a379-71a56828b0e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2587fb26-6a51-4acb-a787-aa8f295eebc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2587fb26-6a51-4acb-a787-aa8f295eebc1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_399eaf7e-6ffe-47af-8334-1fa72c1b26b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_399eaf7e-6ffe-47af-8334-1fa72c1b26b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5570d8b8-777d-4048-934c-fccc1d8b1014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5570d8b8-777d-4048-934c-fccc1d8b1014" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e797be22-977a-424d-9c73-00f87e96b440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e797be22-977a-424d-9c73-00f87e96b440" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f56025a3-9dce-40b1-8c4a-0bb73a9605a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f56025a3-9dce-40b1-8c4a-0bb73a9605a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c87c700e-8b2e-466d-9b1a-910baad7f08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c87c700e-8b2e-466d-9b1a-910baad7f08e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_14800bf3-caa8-4b48-bf22-47d2acf52d58" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_14800bf3-caa8-4b48-bf22-47d2acf52d58" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_008cd951-0d3e-4b78-ada4-174d12484add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_008cd951-0d3e-4b78-ada4-174d12484add" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73b97b08-5fb9-453d-b976-7da5ff4e0a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73b97b08-5fb9-453d-b976-7da5ff4e0a44" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6be01a81-f3b2-4800-ad44-941a0a346c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6be01a81-f3b2-4800-ad44-941a0a346c33" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4835a08a-8aa5-41ad-afd4-c5c4046a7e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4835a08a-8aa5-41ad-afd4-c5c4046a7e9f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ddaa7f29-a0ee-45d1-82b6-869dda28c009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ddaa7f29-a0ee-45d1-82b6-869dda28c009" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:to="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2571cef2-bef3-456c-9fdf-ebdd246cdd1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2571cef2-bef3-456c-9fdf-ebdd246cdd1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_87af8e33-0a9b-4c3a-b4dd-15b813ec9fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_87af8e33-0a9b-4c3a-b4dd-15b813ec9fff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b6efaded-add8-4276-9a23-c8647ddf937a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b6efaded-add8-4276-9a23-c8647ddf937a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_2082f823-e2e6-4aa1-a102-2314f0c09400" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:to="loc_amgn_PerformanceUnitsMember_2082f823-e2e6-4aa1-a102-2314f0c09400" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i264cb25d2b614c36ac745660413f48e3_StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c97892e8-568c-481c-9a58-ad83e0f7a089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c97892e8-568c-481c-9a58-ad83e0f7a089" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_70414939-0dcc-44b8-9085-f098c3f08dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:to="loc_us-gaap_ShareBasedCompensation_70414939-0dcc-44b8-9085-f098c3f08dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_522eace6-1822-4028-8db3-5717c76fd39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_522eace6-1822-4028-8db3-5717c76fd39b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_c7b0bd70-9f8f-4d5a-9c07-98c33d6723d7" xlink:href="amgn-20201231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:to="loc_amgn_StockBasedCompensationExpenseNetOfTax_c7b0bd70-9f8f-4d5a-9c07-98c33d6723d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c97892e8-568c-481c-9a58-ad83e0f7a089" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:to="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1819a46e-6000-4ed8-a758-bb8bc36d7964_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1819a46e-6000-4ed8-a758-bb8bc36d7964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0677b7-9f2b-4131-b21b-16a0de863f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0677b7-9f2b-4131-b21b-16a0de863f02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_17271fac-f118-464b-9bf7-8e914306787f" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:to="loc_amgn_PerformanceUnitsMember_17271fac-f118-464b-9bf7-8e914306787f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53473345-4dd6-44c2-8a88-0a3b8cd85174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53473345-4dd6-44c2-8a88-0a3b8cd85174" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended" id="i01a55af15d734310a1eacad1c29516bf_StockbasedcompensationSummaryofRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ac3dce8b-16e6-44c6-9b6f-c6a829c8af33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ac3dce8b-16e6-44c6-9b6f-c6a829c8af33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b515185e-096a-4bc6-9d37-2052402b35c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b515185e-096a-4bc6-9d37-2052402b35c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_312d2521-0c84-4617-a13b-a60aedbf395c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_312d2521-0c84-4617-a13b-a60aedbf395c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_343359bb-dea7-4c87-a79e-347f4b36fda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_343359bb-dea7-4c87-a79e-347f4b36fda7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_37abe796-7644-4da8-a0c9-bb735b203829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_190c4d43-a339-492b-846c-b2c7366fd51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_190c4d43-a339-492b-846c-b2c7366fd51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b290859-d079-45ff-b9d5-32d18601f7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b290859-d079-45ff-b9d5-32d18601f7b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4b0472cb-0a0c-4b91-b207-5d5a1cb152b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4b0472cb-0a0c-4b91-b207-5d5a1cb152b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12c30f88-0116-483c-a8a5-61f865b4c709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12c30f88-0116-483c-a8a5-61f865b4c709" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bca62222-0cc7-4f6e-a5c2-a0b070e6154d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:to="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a495d144-4267-443d-8518-60582f8f59ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a495d144-4267-443d-8518-60582f8f59ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f602f95d-f265-4ec9-97dc-8092e825fe2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f602f95d-f265-4ec9-97dc-8092e825fe2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_823212e6-b919-4d82-ae9c-0400e053c172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f602f95d-f265-4ec9-97dc-8092e825fe2e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_823212e6-b919-4d82-ae9c-0400e053c172" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended" id="i7fee4ff42669448595b98d2337e66866_StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_1417b907-ab50-48ee-a83b-d061a3769750" xlink:href="amgn-20201231.xsd#amgn_CommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_amgn_CommonStockFairValue_1417b907-ab50-48ee-a83b-d061a3769750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81efa34a-0ca8-4851-bd9b-399a4a68d986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81efa34a-0ca8-4851-bd9b-399a4a68d986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e4c7c92a-17d4-422d-bd02-0e5c1b75c21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e4c7c92a-17d4-422d-bd02-0e5c1b75c21d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_907f4172-6944-4551-bed7-4f9ad2c80624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_907f4172-6944-4551-bed7-4f9ad2c80624" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4727d44f-dd93-4e31-a6a1-4f4a38aced94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4727d44f-dd93-4e31-a6a1-4f4a38aced94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fefda351-69f4-420b-9d87-d59b8227fd27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fefda351-69f4-420b-9d87-d59b8227fd27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:to="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec54c481-55e7-4a10-9da9-32dbb9647cca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec54c481-55e7-4a10-9da9-32dbb9647cca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98a12d0-2c24-4b1d-89d8-c518439c5c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98a12d0-2c24-4b1d-89d8-c518439c5c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a0c47649-4d65-4f41-9040-d148061e78be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98a12d0-2c24-4b1d-89d8-c518439c5c9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a0c47649-4d65-4f41-9040-d148061e78be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended" id="ib0a959bc0ef940c7a73c96317e414557_StockbasedcompensationSummaryofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2abd9492-d0ac-49ae-99c8-a897746b4a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2abd9492-d0ac-49ae-99c8-a897746b4a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1b819552-4154-478c-a5af-1293deec3716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1b819552-4154-478c-a5af-1293deec3716" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d6ec8e97-0a99-42fd-84b3-8ef3c18838ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d6ec8e97-0a99-42fd-84b3-8ef3c18838ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ae558ad8-25a5-498d-b452-265435310f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ae558ad8-25a5-498d-b452-265435310f16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff1ce46f-6643-4093-b393-dc3222321362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d2f12f9-2e24-44e5-aa4c-28fcdec8dc8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d2f12f9-2e24-44e5-aa4c-28fcdec8dc8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3dac17d9-d62a-4960-b6e7-edfa46b08c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3dac17d9-d62a-4960-b6e7-edfa46b08c3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f306901f-293c-4aa8-bafb-72a7b089b46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f306901f-293c-4aa8-bafb-72a7b089b46c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8d36475-555d-417c-a507-8b6413e669c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8d36475-555d-417c-a507-8b6413e669c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee2684ee-3f2c-4f85-9310-8a534467a65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee2684ee-3f2c-4f85-9310-8a534467a65a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_97b692d1-482f-4453-85f3-b6f0b0d603b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_97b692d1-482f-4453-85f3-b6f0b0d603b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4553b7f-2975-434a-a02a-d2dcb36e813a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b6ce52a7-8efd-458a-aaec-a88f0ad59924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b6ce52a7-8efd-458a-aaec-a88f0ad59924" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30227a3f-982f-42f2-be9c-803f0a9f7ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30227a3f-982f-42f2-be9c-803f0a9f7ada" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eccb9021-653d-4fcb-aa3d-4115abbae538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eccb9021-653d-4fcb-aa3d-4115abbae538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d6b125be-f216-4c66-b082-f5341b818809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d6b125be-f216-4c66-b082-f5341b818809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f2021d9b-676a-4163-b661-082b589936f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f2021d9b-676a-4163-b661-082b589936f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6584f16f-ff8c-406e-a509-eaa42c2066c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6584f16f-ff8c-406e-a509-eaa42c2066c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c5b3bb38-b3c9-4c05-99b2-2a8dd400d70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c5b3bb38-b3c9-4c05-99b2-2a8dd400d70f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15f1fa3a-5ae4-49f7-bede-87228dd293f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15f1fa3a-5ae4-49f7-bede-87228dd293f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:to="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1309c57-c663-4328-90c9-122594cf98fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1309c57-c663-4328-90c9-122594cf98fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd30ca8-ded8-47e7-95aa-c182908f608d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd30ca8-ded8-47e7-95aa-c182908f608d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8bd225c-b349-4838-999c-0f0a7acf1e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd30ca8-ded8-47e7-95aa-c182908f608d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8bd225c-b349-4838-999c-0f0a7acf1e2b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="i1ec894b47c454033913d0225f630ce16_StockbasedcompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f281a66b-c049-466c-9a3c-8e0c38c3860d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f281a66b-c049-466c-9a3c-8e0c38c3860d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_5cd96715-d30c-4ec9-bbdc-5ed85479f379" xlink:href="amgn-20201231.xsd#amgn_CommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_amgn_CommonStockFairValue_5cd96715-d30c-4ec9-bbdc-5ed85479f379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aa818743-cb65-44bc-8cd9-262d831249b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aa818743-cb65-44bc-8cd9-262d831249b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13ecacf6-3565-49e3-a81e-0e2a7dbb81c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13ecacf6-3565-49e3-a81e-0e2a7dbb81c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da724ab0-e7f9-4248-9cf8-7191c5b25748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da724ab0-e7f9-4248-9cf8-7191c5b25748" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f281a66b-c049-466c-9a3c-8e0c38c3860d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:to="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f65612f-2b1a-435a-9e04-971ed4668dec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f65612f-2b1a-435a-9e04-971ed4668dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f62c7b-0f03-429f-bd47-69e8558c8474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f62c7b-0f03-429f-bd47-69e8558c8474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_06efd60f-8904-4808-98be-4f9307568cbe" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f62c7b-0f03-429f-bd47-69e8558c8474" xlink:to="loc_amgn_PerformanceUnitsMember_06efd60f-8904-4808-98be-4f9307568cbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Definedcontributionplan" xlink:type="simple" xlink:href="amgn-20201231.xsd#Definedcontributionplan"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Definedcontributionplan" xlink:type="extended" id="i8c5beaa35c8740dd8bd362cb5924b136_Definedcontributionplan"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DefinedcontributionplanDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="extended" id="ia9596117090f4ab496918656d3f7f677_DefinedcontributionplanDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Incometaxes" xlink:type="simple" xlink:href="amgn-20201231.xsd#Incometaxes"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Incometaxes" xlink:type="extended" id="i600815db33ea40698942f24783c3ad9c_Incometaxes"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesTables" xlink:type="extended" id="ica45f84c08c140b2968b50e6829c883e_IncometaxesTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended" id="ic46d814bbf824a45a7258bd8be7fb6d8_IncometaxesIncomeBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_6b6f32ee-3f3a-4be5-a97a-682771383c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fd414b69-abf8-43fe-8954-531256db6887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6b6f32ee-3f3a-4be5-a97a-682771383c9a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fd414b69-abf8-43fe-8954-531256db6887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6b6f32ee-3f3a-4be5-a97a-682771383c9a" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d956eaf8-06d1-4fcb-9f2b-4c456600f32c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d956eaf8-06d1-4fcb-9f2b-4c456600f32c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_aa5626e5-f47e-40a8-85f4-8e8dd1ec2e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:to="loc_us-gaap_DomesticCountryMember_aa5626e5-f47e-40a8-85f4-8e8dd1ec2e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0390c886-48d2-4c46-b6da-b57db846407a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:to="loc_us-gaap_ForeignCountryMember_0390c886-48d2-4c46-b6da-b57db846407a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended" id="i363e3286614b40c885386e16be22712c_IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="ifc87963e128249e9aa3223d38deebf65_IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended" id="i7958a94f8a5a4095a27770fd49b65aef_IncometaxesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_134996dc-7560-4a30-9574-629a3077e4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_134996dc-7560-4a30-9574-629a3077e4e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_61dec333-ba3e-4e51-aeee-f3c6f3349168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_61dec333-ba3e-4e51-aeee-f3c6f3349168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_835d532e-87f7-4d40-b654-0187813cc546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_OperatingLossCarryforwards_835d532e-87f7-4d40-b654-0187813cc546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_30972823-136b-4ae3-b7f3-1fffddca290b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_30972823-136b-4ae3-b7f3-1fffddca290b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_750e3157-3ba2-4490-8dba-28be48cc2dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_750e3157-3ba2-4490-8dba-28be48cc2dab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c8b724b1-fe58-4e5d-b3a7-e917d4d277cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c8b724b1-fe58-4e5d-b3a7-e917d4d277cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6950710c-c462-46a3-bffc-ac071fed33a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6950710c-c462-46a3-bffc-ac071fed33a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_53133ae5-1a72-4d13-b002-2a54aad67ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_IncomeTaxesPaid_53133ae5-1a72-4d13-b002-2a54aad67ffe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e71a1314-cc7f-4714-aa13-b4cf3aa4add3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e71a1314-cc7f-4714-aa13-b4cf3aa4add3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4ab1b363-9c5b-4ad9-9cba-75369285ade1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:to="loc_us-gaap_DomesticCountryMember_4ab1b363-9c5b-4ad9-9cba-75369285ade1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_089e7c09-0903-4642-ad28-0a3bcc273231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_089e7c09-0903-4642-ad28-0a3bcc273231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_565ae4a7-fe59-4b55-a5c8-f26941603f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:to="loc_us-gaap_ForeignCountryMember_565ae4a7-fe59-4b55-a5c8-f26941603f01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:to="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_32082435-0f91-40f4-878c-5321d60bef8b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:to="loc_us-gaap_TaxPeriodDomain_32082435-0f91-40f4-878c-5321d60bef8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:to="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2021And2035Member_02cb72d7-991b-4533-894e-49165489aaeb" xlink:href="amgn-20201231.xsd#amgn_OperatingLossesThatExpireBetween2021And2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2021And2035Member_02cb72d7-991b-4533-894e-49165489aaeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2021And2030Member_c8c2e6e7-298f-4fc5-840b-19b661dd04bf" xlink:href="amgn-20201231.xsd#amgn_OperatingLossesThatExpireBetween2021And2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2021And2030Member_c8c2e6e7-298f-4fc5-840b-19b661dd04bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2035Member_c9ca9261-5d71-4f54-bde6-cfc6fef787ef" xlink:href="amgn-20201231.xsd#amgn_ExpirationInTaxYearsBetween2023And2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:to="loc_amgn_ExpirationInTaxYearsBetween2023And2035Member_c9ca9261-5d71-4f54-bde6-cfc6fef787ef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="extended" id="ia10480c2552f4419857b490db1d4f853_IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended" id="i85fef8b7745949d99eeece19b1c91be1_IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Earningspershare" xlink:type="simple" xlink:href="amgn-20201231.xsd#Earningspershare"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Earningspershare" xlink:type="extended" id="i960f32a944c24b798715dc598ff10cdf_Earningspershare"/>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#EarningspershareTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/EarningspershareTables" xlink:type="extended" id="if23179283df44068856e111037531938_EarningspershareTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#EarningspershareDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended" id="i4452cb5612d84a7680f9d75c71eb9378_EarningspershareDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Collaborations" xlink:type="simple" xlink:href="amgn-20201231.xsd#Collaborations"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Collaborations" xlink:type="extended" id="i502ae20768dd43c4b921bdea962073c5_Collaborations"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsNovartisAGDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended" id="i25e30d94adc24c719f18d4a6a17fce10_CollaborationsNovartisAGDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_77169837-7eb0-4bf1-b7a0-19c6e91c23df" xlink:href="amgn-20201231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_77169837-7eb0-4bf1-b7a0-19c6e91c23df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_0b637e5b-04fd-4822-8d84-7e2aa1b9e3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectOperatingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_DirectOperatingCosts_0b637e5b-04fd-4822-8d84-7e2aa1b9e3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_09372c16-19cb-4e02-9947-7843880171ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_09372c16-19cb-4e02-9947-7843880171ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_b47c9985-e9e5-4901-b9f7-f21af0b676a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_RoyaltyExpense_b47c9985-e9e5-4901-b9f7-f21af0b676a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f4ddad75-2c12-4208-b5a5-b827e258b4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_Revenues_f4ddad75-2c12-4208-b5a5-b827e258b4cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c738a416-d298-4289-ab8b-6e6bf40c2b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c738a416-d298-4289-ab8b-6e6bf40c2b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f2b1023e-e1da-4f23-b89d-33ec0864b4e5" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementwithNovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c738a416-d298-4289-ab8b-6e6bf40c2b22" xlink:to="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f2b1023e-e1da-4f23-b89d-33ec0864b4e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bf0253ab-7fdc-468c-9818-487c8acc7b8f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bf0253ab-7fdc-468c-9818-487c8acc7b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_af99b493-aa08-48fa-8f83-e6f99e0fb923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_af99b493-aa08-48fa-8f83-e6f99e0fb923" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_4d3ea7a9-80b6-4cd1-beeb-8484b9e6a451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:to="loc_us-gaap_CostOfSalesMember_4d3ea7a9-80b6-4cd1-beeb-8484b9e6a451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c02b83ca-d4d1-40a0-94b5-b7acef601d7f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:to="loc_srt_ProductsAndServicesDomain_c02b83ca-d4d1-40a0-94b5-b7acef601d7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22b07714-7e82-40f4-a0ce-caaff9e9bd24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:to="loc_srt_ProductsAndServicesDomain_22b07714-7e82-40f4-a0ce-caaff9e9bd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9aa7d0f6-e5e3-4ccf-b3bf-4c377cf31738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22b07714-7e82-40f4-a0ce-caaff9e9bd24" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9aa7d0f6-e5e3-4ccf-b3bf-4c377cf31738" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsBayerHealthCarePharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails" xlink:type="extended" id="i80111a73dbc547488869d38caf87d18e_CollaborationsBayerHealthCarePharmaceuticalsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofCountriesProductsisMarketedandSold_5e69e012-67c1-4098-be09-97c482d4fad9" xlink:href="amgn-20201231.xsd#amgn_NumberofCountriesProductsisMarketedandSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_amgn_NumberofCountriesProductsisMarketedandSold_5e69e012-67c1-4098-be09-97c482d4fad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementRoyaltyIncomePercentage_ca2b8f05-3f90-463d-9def-66162a9b929e" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementRoyaltyIncomePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_amgn_CollaborativeArrangementRoyaltyIncomePercentage_ca2b8f05-3f90-463d-9def-66162a9b929e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementNetIncome_ff1e5405-11ea-4488-9f04-e2f67df09a3e" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_amgn_CollaborativeArrangementNetIncome_ff1e5405-11ea-4488-9f04-e2f67df09a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2f2f44f8-d415-43a1-9761-512ce1148249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2f2f44f8-d415-43a1-9761-512ce1148249" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87c7292f-0a5e-4f43-94de-591add61f0a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87c7292f-0a5e-4f43-94de-591add61f0a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_def072b9-899f-4ebd-971a-3c508e8e4db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_def072b9-899f-4ebd-971a-3c508e8e4db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_3510caff-3872-474b-bd40-10ed7bdfebca" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_def072b9-899f-4ebd-971a-3c508e8e4db7" xlink:to="loc_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_3510caff-3872-474b-bd40-10ed7bdfebca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:to="loc_srt_ProductsAndServicesDomain_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:to="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NexavarMember_57a4314a-5371-4420-a5b7-b4f050836f7e" xlink:href="amgn-20201231.xsd#amgn_NexavarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:to="loc_amgn_NexavarMember_57a4314a-5371-4420-a5b7-b4f050836f7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_97c15cec-dcb5-43b9-a096-a5eebf8dec48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:to="loc_us-gaap_RoyaltyMember_97c15cec-dcb5-43b9-a096-a5eebf8dec48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca17b1f4-6ad3-482c-b3ac-28d717ca170d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca17b1f4-6ad3-482c-b3ac-28d717ca170d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherRevenuesMember_8aa02890-2137-472a-96fb-60e1b604c5ae" xlink:href="amgn-20201231.xsd#amgn_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca17b1f4-6ad3-482c-b3ac-28d717ca170d" xlink:to="loc_amgn_OtherRevenuesMember_8aa02890-2137-472a-96fb-60e1b604c5ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_be198243-dca9-479d-951d-ea87d4162bd2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:to="loc_srt_SegmentGeographicalDomain_be198243-dca9-479d-951d-ea87d4162bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:to="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_216bc4d5-bec8-4061-ae3b-12acdd88718d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:to="loc_country_US_216bc4d5-bec8-4061-ae3b-12acdd88718d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NonUsExcludingJapanMember_a28111fe-59ba-4551-9cc1-479432db09ef" xlink:href="amgn-20201231.xsd#amgn_NonUsExcludingJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:to="loc_amgn_NonUsExcludingJapanMember_a28111fe-59ba-4551-9cc1-479432db09ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended" id="i9ade6cdb14714531a010cd2fdb3eaa0d_CollaborationsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b947b285-41d9-4503-9b29-7f4caa9da17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b947b285-41d9-4503-9b29-7f4caa9da17c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_40d66528-b527-44d7-a3d2-fae8bfe5ab98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_40d66528-b527-44d7-a3d2-fae8bfe5ab98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RecoveryOfDirectCostsReceivable_ce5fb0b6-528e-4029-a85f-06f33058c2da" xlink:href="amgn-20201231.xsd#amgn_RecoveryOfDirectCostsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_amgn_RecoveryOfDirectCostsReceivable_ce5fb0b6-528e-4029-a85f-06f33058c2da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d6254788-23ab-422a-ac83-d259030f2fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d6254788-23ab-422a-ac83-d259030f2fe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_9204bc4a-7868-43f7-b029-5be544794477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_9204bc4a-7868-43f7-b029-5be544794477" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d055969-ec92-4dc4-8c50-6f4bdc8d8586_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d055969-ec92-4dc4-8c50-6f4bdc8d8586_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbaef52c-d2ad-4c2a-a8c5-e4c6e9bc9a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbaef52c-d2ad-4c2a-a8c5-e4c6e9bc9a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_e5804253-da47-4bc3-afac-ff9bd02a4219" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbaef52c-d2ad-4c2a-a8c5-e4c6e9bc9a68" xlink:to="loc_amgn_BeiGeneMember_e5804253-da47-4bc3-afac-ff9bd02a4219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_658845d3-670a-4115-a3c3-61cb8470633f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_658845d3-670a-4115-a3c3-61cb8470633f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_018e593c-a5fd-4097-a5bf-33eaf3796c91_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:to="loc_srt_ProductsAndServicesDomain_018e593c-a5fd-4097-a5bf-33eaf3796c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2be1f29a-a324-41de-ba7e-2896f2afa7fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:to="loc_srt_ProductsAndServicesDomain_2be1f29a-a324-41de-ba7e-2896f2afa7fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d70f2af-10c5-4725-99c4-221e43c88f4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d70f2af-10c5-4725-99c4-221e43c88f4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e293d1b-8d4a-4bdc-8ec8-ace44fbc30a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e293d1b-8d4a-4bdc-8ec8-ace44fbc30a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85ca80f7-f816-4ff9-afd4-ee91093076db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e293d1b-8d4a-4bdc-8ec8-ace44fbc30a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85ca80f7-f816-4ff9-afd4-ee91093076db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07bd719c-2fe7-417c-9ce1-39b70d236be2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07bd719c-2fe7-417c-9ce1-39b70d236be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_da4ab916-dc5c-47be-b201-1bd0c7bbed78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_da4ab916-dc5c-47be-b201-1bd0c7bbed78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_d3ef7f00-9531-4cca-9759-ae1c5d5407d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_da4ab916-dc5c-47be-b201-1bd0c7bbed78" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_d3ef7f00-9531-4cca-9759-ae1c5d5407d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4225364e-e747-4b5f-9c06-71b5e3ba8b80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4225364e-e747-4b5f-9c06-71b5e3ba8b80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34888e2-1815-41e5-9183-47dd1f791938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34888e2-1815-41e5-9183-47dd1f791938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_059cc2d6-11e3-45cc-88bd-f39f2a517898" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34888e2-1815-41e5-9183-47dd1f791938" xlink:to="loc_amgn_BeiGeneMember_059cc2d6-11e3-45cc-88bd-f39f2a517898" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Investments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Investments"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Investments" xlink:type="extended" id="iabc4f02856b84d64b503dba43d31351f_Investments"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsTables" xlink:type="extended" id="iff01ee13b02e41eca412e4a2c002d72e_InvestmentsTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended" id="i0c77a49c60a64fbe8c03fbba8b62e5d5_InvestmentsScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6c6a1a6-3077-41f3-80f8-4828e2b9d7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6c6a1a6-3077-41f3-80f8-4828e2b9d7b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_febf10dc-790a-4766-a176-b2eb274ecef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_febf10dc-790a-4766-a176-b2eb274ecef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23c50fb4-8cd9-4b1b-9758-8e6e2f5a0ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23c50fb4-8cd9-4b1b-9758-8e6e2f5a0ee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d17e9d7a-48d4-419c-87c0-b37f11558c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d17e9d7a-48d4-419c-87c0-b37f11558c51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5160b5b1-fd17-4f34-8ce6-8a1af87ae0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5160b5b1-fd17-4f34-8ce6-8a1af87ae0f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6c6a1a6-3077-41f3-80f8-4828e2b9d7b0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_44006225-b1c6-4501-91bc-ee3a2f2f7fb4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_44006225-b1c6-4501-91bc-ee3a2f2f7fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d1f7e154-e982-46d0-bf08-c6840c87b90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d1f7e154-e982-46d0-bf08-c6840c87b90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_60f599d2-a0a8-4605-b7fb-6c5c237fc7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_60f599d2-a0a8-4605-b7fb-6c5c237fc7fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_5f13d6eb-9aac-4e95-bb20-4eaa089ab4d3" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_5f13d6eb-9aac-4e95-bb20-4eaa089ab4d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_11ec3c7b-cb48-4d59-ab65-798dbb169502" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_11ec3c7b-cb48-4d59-ab65-798dbb169502" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_ecd050f0-fe38-4c34-86b9-4590f8cafd3d" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_ecd050f0-fe38-4c34-86b9-4590f8cafd3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5c5223d1-387a-464b-8997-2cd5d06d4263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5c5223d1-387a-464b-8997-2cd5d06d4263" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f2c5cd19-95dd-4407-9b06-3a9fb32e465a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f2c5cd19-95dd-4407-9b06-3a9fb32e465a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_43afbbf8-f779-49ad-a82d-e0d54e7f456c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_MoneyMarketFundsMember_43afbbf8-f779-49ad-a82d-e0d54e7f456c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_a4b1ec79-e567-4875-b6f0-f77bdb845a88" xlink:href="amgn-20201231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_a4b1ec79-e567-4875-b6f0-f77bdb845a88" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended" id="i55bce9aa31da4958b46c5e44b2e5f8c6_InvestmentsFairValuesbyClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e40fa892-ff8f-4845-8bb0-64bd47b16177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e40fa892-ff8f-4845-8bb0-64bd47b16177" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1e65d2ae-2f01-49df-aef6-1286b2f6f961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1e65d2ae-2f01-49df-aef6-1286b2f6f961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4352a495-0423-453d-89c5-215505c2b1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4352a495-0423-453d-89c5-215505c2b1a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6cd9c3cd-0b56-4e1c-8e9c-2ee5e3653bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6cd9c3cd-0b56-4e1c-8e9c-2ee5e3653bae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e40fa892-ff8f-4845-8bb0-64bd47b16177" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b894d7f1-8c6f-405c-b3d7-0192f77898c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b894d7f1-8c6f-405c-b3d7-0192f77898c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bd2987a-04f1-4893-856a-f985c85666c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bd2987a-04f1-4893-856a-f985c85666c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_e8b2003a-23c9-4d43-8e60-630f0b10caea" xlink:href="amgn-20201231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bd2987a-04f1-4893-856a-f985c85666c2" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_e8b2003a-23c9-4d43-8e60-630f0b10caea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="extended" id="i77356938f9cd44eba9abed4e7c1cb840_InvestmentsAvailableforsaleDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended" id="ia3b40aa3ef5b43be8857cf26712a4f5d_InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended" id="i80d1f4edc8a043e8a8bc2e963d88de8b_InvestmentsEquitySecuritiesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended" id="i6615e9f633ec4ddb8b238fda78d9c4ea_InvestmentsLimitedPartnershipInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_d333bf7a-4387-4c8d-877f-d60a6a3022ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:to="loc_us-gaap_AlternativeInvestment_d333bf7a-4387-4c8d-877f-d60a6a3022ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_ff259424-9111-47dd-a41c-c04b13b5ad40" xlink:href="amgn-20201231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_ff259424-9111-47dd-a41c-c04b13b5ad40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:to="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f327ce10-d715-480b-9705-9b45505f5ecf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f327ce10-d715-480b-9705-9b45505f5ecf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_028dc097-28e4-4e3b-9ac5-5cca6b558cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_028dc097-28e4-4e3b-9ac5-5cca6b558cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_98a241d8-a77c-4473-bb47-8c83a2225f61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_028dc097-28e4-4e3b-9ac5-5cca6b558cde" xlink:to="loc_srt_PartnershipInterestMember_98a241d8-a77c-4473-bb47-8c83a2225f61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_086f9e3f-61f3-45db-90cf-b05d4003b9d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_086f9e3f-61f3-45db-90cf-b05d4003b9d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce015675-db79-45a6-94fb-615c3d2ce934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce015675-db79-45a6-94fb-615c3d2ce934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_dc946008-74df-45e6-bf93-aaac70c305c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce015675-db79-45a6-94fb-615c3d2ce934" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_dc946008-74df-45e6-bf93-aaac70c305c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended" id="ib44540ff4415432c8c5079ec912f1196_InvestmentsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef16c02c-03fc-479b-9143-919ea1a371ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef16c02c-03fc-479b-9143-919ea1a371ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b749749-11bc-4925-a375-79fca290ead3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b749749-11bc-4925-a375-79fca290ead3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_793e0d8d-09b2-4e45-8df0-669fff00e8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_793e0d8d-09b2-4e45-8df0-669fff00e8cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_860d2d7a-ddbd-447e-a7d9-ab05d8ad57ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_860d2d7a-ddbd-447e-a7d9-ab05d8ad57ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c94dd54-4e15-405a-8e0d-f3e92dce194a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c94dd54-4e15-405a-8e0d-f3e92dce194a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_8f19655e-cd75-4e69-80ed-d82db554c2a0" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_8f19655e-cd75-4e69-80ed-d82db554c2a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_49b709ad-06ab-44e6-94ca-5a21c4314713" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_49b709ad-06ab-44e6-94ca-5a21c4314713" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0de030a2-c9e9-46b0-8ebb-e23f9ac8076e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0de030a2-c9e9-46b0-8ebb-e23f9ac8076e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_20e97515-3bc0-4ce2-9157-727c15163541" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_20e97515-3bc0-4ce2-9157-727c15163541" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e98ef61b-3e43-4b91-8e37-2ca96e8e6669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestments_e98ef61b-3e43-4b91-8e37-2ca96e8e6669" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2bde0bb-85cc-4ec3-a128-5dac1c198b30_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2bde0bb-85cc-4ec3-a128-5dac1c198b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1e99871-7c0b-4ef9-9a5d-a67f6f04e731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1e99871-7c0b-4ef9-9a5d-a67f6f04e731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_5b3e0375-9279-4285-9380-b620314bd715" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1e99871-7c0b-4ef9-9a5d-a67f6f04e731" xlink:to="loc_amgn_BeiGeneMember_5b3e0375-9279-4285-9380-b620314bd715" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:to="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2255c03e-b8e3-4628-861d-a18efce0a9bb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:to="loc_srt_RangeMember_2255c03e-b8e3-4628-861d-a18efce0a9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:to="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d58123f-322c-4f85-9c52-f2ac00fb2298" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:to="loc_srt_MinimumMember_6d58123f-322c-4f85-9c52-f2ac00fb2298" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab7d1f7f-9442-46c8-994f-e7fd45ad3890" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:to="loc_srt_MaximumMember_ab7d1f7f-9442-46c8-994f-e7fd45ad3890" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Inventories" xlink:type="simple" xlink:href="amgn-20201231.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Inventories" xlink:type="extended" id="i8b05311e0d304d23943c455e8c484a5b_Inventories"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InventoriesTables" xlink:type="extended" id="ieb08815d52b14809b9745efd2b9b2f45_InventoriesTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended" id="i156a58e84a1540bdba1cfe739666d3a7_InventoriesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="amgn-20201231.xsd#Propertyplantandequipment"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="extended" id="ie772cfa98d7e41aaa31a115e489bfb46_Propertyplantandequipment"/>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="extended" id="i4b736e63295944b7b775110dc4c8811c_PropertyplantandequipmentTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended" id="ibfae6855c3c042a28dc4445a07833232_PropertyplantandequipmentScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_14767723-5b4f-4d14-a837-5936e50f4ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_14767723-5b4f-4d14-a837-5936e50f4ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_edfacf05-0b87-4c0f-a826-c6768fdc3f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_Land_edfacf05-0b87-4c0f-a826-c6768fdc3f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_a8b3658b-b842-4de4-b788-cc9ea4570169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_a8b3658b-b842-4de4-b788-cc9ea4570169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_6d907f36-8ea4-4bef-8b97-d487c7b0a76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_6d907f36-8ea4-4bef-8b97-d487c7b0a76b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_b3979e00-e4d5-4916-a188-22e6ccd3e2db" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_amgn_LaboratoryEquipment_b3979e00-e4d5-4916-a188-22e6ccd3e2db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_8fe80ede-f687-42f6-8b22-5ee264357024" xlink:href="amgn-20201231.xsd#amgn_FixedEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_amgn_FixedEquipment_8fe80ede-f687-42f6-8b22-5ee264357024" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_be78e76c-3b3c-452c-b01a-a062046e4f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_be78e76c-3b3c-452c-b01a-a062046e4f83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_61db1c81-e138-4ba3-91f6-570543f03ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_61db1c81-e138-4ba3-91f6-570543f03ba6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a0738437-08b8-4049-afe6-b7922ab1abc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_ConstructionInProgressGross_a0738437-08b8-4049-afe6-b7922ab1abc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_44f927fe-9f1f-4ba5-a65c-3e475d129e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_44f927fe-9f1f-4ba5-a65c-3e475d129e35" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a081d631-c803-4325-9c6a-a96765bb7ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a081d631-c803-4325-9c6a-a96765bb7ef9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_86707a22-4fcd-44ac-b735-6fc789f38be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_86707a22-4fcd-44ac-b735-6fc789f38be0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c9eb0dbb-b27f-4e96-8d31-cde702878d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_Depreciation_c9eb0dbb-b27f-4e96-8d31-cde702878d31" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39eab571-604e-48d5-97a5-24ca4518e2df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_39eab571-604e-48d5-97a5-24ca4518e2df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a1f37396-9506-462d-a743-45f60e29c37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a1f37396-9506-462d-a743-45f60e29c37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember_093853c5-385e-45a7-b01e-2d5abc68b9ba" xlink:href="amgn-20201231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_amgn_ManufacturingEquipmentMember_093853c5-385e-45a7-b01e-2d5abc68b9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember_af4984dd-42db-4faf-8609-a205db26ebba" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_amgn_LaboratoryEquipmentMember_af4984dd-42db-4faf-8609-a205db26ebba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember_4d72c92c-fae3-4f71-bb75-a52bcc56054f" xlink:href="amgn-20201231.xsd#amgn_FixedEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_amgn_FixedEquipmentMember_4d72c92c-fae3-4f71-bb75-a52bcc56054f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_be21adf9-a1a6-4819-a1d6-649d24a0a86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_be21adf9-a1a6-4819-a1d6-649d24a0a86f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_a3acbef9-9e74-45a7-8e8f-ab92400ced85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_a3acbef9-9e74-45a7-8e8f-ab92400ced85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:to="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37115a26-2dea-4959-9c41-a0185c457d17_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:to="loc_srt_RangeMember_37115a26-2dea-4959-9c41-a0185c457d17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:to="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b7e3a51-1bd7-4661-a07f-0c90ee72870d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:to="loc_srt_MinimumMember_9b7e3a51-1bd7-4661-a07f-0c90ee72870d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a1c9a56-b9c5-4b76-a3e7-3f5b57acfd48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:to="loc_srt_MaximumMember_4a1c9a56-b9c5-4b76-a3e7-3f5b57acfd48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended" id="i7065c45cd4e94d4d98bc3288aa989498_PropertyplantandequipmentGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ffffe148-b26b-4ad6-86ec-39863377f344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca11ab24-9d22-4471-a9e7-00095a3f0a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ffffe148-b26b-4ad6-86ec-39863377f344" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ca11ab24-9d22-4471-a9e7-00095a3f0a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ffffe148-b26b-4ad6-86ec-39863377f344" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:to="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ddc619a8-3f4d-4641-8d73-3e416c142fed_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:to="loc_srt_SegmentGeographicalDomain_ddc619a8-3f4d-4641-8d73-3e416c142fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:to="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_cf761a2c-8ddb-42d0-8018-0c88f3a60259" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:to="loc_country_US_cf761a2c-8ddb-42d0-8018-0c88f3a60259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_7c3c4d11-4eb4-4cb6-b295-50694361a57f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:to="loc_country_PR_7c3c4d11-4eb4-4cb6-b295-50694361a57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember_7b024ac1-7583-4bd5-b68a-fdb026cfeb3f" xlink:href="amgn-20201231.xsd#amgn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:to="loc_amgn_RestOfWorldMember_7b024ac1-7583-4bd5-b68a-fdb026cfeb3f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="simple" xlink:href="amgn-20201231.xsd#Goodwillandintangibleassets"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="extended" id="i908235ae42104d37a0f1c34873d562c5_Goodwillandintangibleassets"/>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended" id="i44ad239c9e854daebe91467291e82130_GoodwillandotherintangibleassetsTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="extended" id="i27461f0a7c87467a848393d99d3d1f53_GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="ic16e4223a9074942b094657ed1645234_GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b631fd9-e047-4146-8d49-30f25d63e31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b631fd9-e047-4146-8d49-30f25d63e31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc7214c7-5fc9-4e60-a835-4f389db0efdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc7214c7-5fc9-4e60-a835-4f389db0efdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bb63774-26bf-4030-b103-1a641b6615ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bb63774-26bf-4030-b103-1a641b6615ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_72d6beb5-538a-4db3-8dff-799578dc55d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_72d6beb5-538a-4db3-8dff-799578dc55d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_11b9b9e6-2c05-4505-9932-15e73c4f9fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_72d6beb5-538a-4db3-8dff-799578dc55d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_11b9b9e6-2c05-4505-9932-15e73c4f9fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_98acdcf5-6598-4102-8786-118138cad4a8" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_98acdcf5-6598-4102-8786-118138cad4a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_ca5376f6-1407-4069-abbc-c997953d1ee7" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_ca5376f6-1407-4069-abbc-c997953d1ee7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d8d2dac-45a9-4e96-ba34-309872fb5503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d8d2dac-45a9-4e96-ba34-309872fb5503" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_665c7464-2bbe-40f1-b8ee-f2209b0706ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_665c7464-2bbe-40f1-b8ee-f2209b0706ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_27936118-01d9-4d1e-bec1-b8cf682b693c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_27936118-01d9-4d1e-bec1-b8cf682b693c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_63871ae6-b9c5-420b-9679-26e76bb502c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_us-gaap_LicensingAgreementsMember_63871ae6-b9c5-420b-9679-26e76bb502c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_094c4034-a3cc-4c40-8545-b579b5fc414f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_094c4034-a3cc-4c40-8545-b579b5fc414f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_f46070e4-7178-4dc8-8319-6cde52618c74" xlink:href="amgn-20201231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_f46070e4-7178-4dc8-8319-6cde52618c74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5b24dfd4-087e-49dc-baf4-fe5a977f4532_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5b24dfd4-087e-49dc-baf4-fe5a977f4532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01e5b7e2-5f63-4d9e-a101-4e8eeb2bc61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01e5b7e2-5f63-4d9e-a101-4e8eeb2bc61a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_02eb1a83-422e-4aab-9587-beae7574c961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01e5b7e2-5f63-4d9e-a101-4e8eeb2bc61a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_02eb1a83-422e-4aab-9587-beae7574c961" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="extended" id="i8784e59081374d9c88cd1ae99f1bd468_GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Leases" xlink:type="simple" xlink:href="amgn-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Leases" xlink:type="extended" id="ic0c5a3b49ce04a278160a58e8388cfc2_Leases"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesTables" xlink:type="extended" id="i2a3834d62e2547aeb5e4bc75bcae4f14_LeasesTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i7c69aa32a0864693901b9318418f1ce8_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_67804408-368a-48a3-b181-8aa2af989949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_67804408-368a-48a3-b181-8aa2af989949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6bfcd98d-a992-4cf7-a1c7-9e6dbedd1a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6bfcd98d-a992-4cf7-a1c7-9e6dbedd1a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_28186cb2-20e1-4a79-a1c2-fbc06f666a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_28186cb2-20e1-4a79-a1c2-fbc06f666a06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_14854e15-d879-4c83-9c03-82e480230d9c" xlink:href="amgn-20201231.xsd#amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_14854e15-d879-4c83-9c03-82e480230d9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0a197de8-ebb8-4a2e-bbbe-4785c046f3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0a197de8-ebb8-4a2e-bbbe-4785c046f3dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0186fa2-fae6-471f-812b-bd953b4d9b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0186fa2-fae6-471f-812b-bd953b4d9b13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_88e02445-e46d-4df8-980f-a26c255dec37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LeaseAndRentalExpense_88e02445-e46d-4df8-980f-a26c255dec37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:to="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1447df4f-e137-439c-bbbe-618fd63b158d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:to="loc_srt_RangeMember_1447df4f-e137-439c-bbbe-618fd63b158d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:to="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca060fb9-9265-432d-8c9a-c0af3a6e0068" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:to="loc_srt_MinimumMember_ca060fb9-9265-432d-8c9a-c0af3a6e0068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_25b8a388-0a88-4177-93aa-34a01f31be30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:to="loc_srt_MaximumMember_25b8a388-0a88-4177-93aa-34a01f31be30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended" id="i067cd807e9f84c9c94131f87c5874b7e_LeasesSummaryofLeasesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended" id="if331b491c0f4476eaf236781969ebe61_LeasesComponentsofLeaseCostsDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="i4779fbe4d55e4e97b52e918791ee4391_LeasesMaturitiesofLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fad7b76d-0671-4814-b587-b4f417b71a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fad7b76d-0671-4814-b587-b4f417b71a91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7a9b38c9-8a86-4fcd-9e5d-cf5ea6a61fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7a9b38c9-8a86-4fcd-9e5d-cf5ea6a61fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4bbc9c0d-7edc-4262-8770-4e3edb804cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4bbc9c0d-7edc-4262-8770-4e3edb804cc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e8a60bd-300a-40fa-ae85-9d1e49756726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e8a60bd-300a-40fa-ae85-9d1e49756726" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a26e33c2-fcdc-4760-bf9c-0b0ae66cc963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a26e33c2-fcdc-4760-bf9c-0b0ae66cc963" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4582d90a-c6a2-48e7-9786-1f8e9e2c1700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4582d90a-c6a2-48e7-9786-1f8e9e2c1700" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e96c0f4-7dbd-4496-aad1-e40a7a49926e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e96c0f4-7dbd-4496-aad1-e40a7a49926e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e747933-f079-405b-a85b-776587100c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e747933-f079-405b-a85b-776587100c9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_88e03ecb-f2ce-4ecc-9b81-09c8b755ca55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_OperatingLeaseLiability_88e03ecb-f2ce-4ecc-9b81-09c8b755ca55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_fded7b46-6047-44bd-8f51-3351fa088976" xlink:href="amgn-20201231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_fded7b46-6047-44bd-8f51-3351fa088976" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_220e5018-a4d7-4cd7-acfa-1613bf3bf387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_220e5018-a4d7-4cd7-acfa-1613bf3bf387" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c7e18a03-8c9d-41d6-8de4-1eb195d3b165_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c7e18a03-8c9d-41d6-8de4-1eb195d3b165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1c73973-6ad1-406d-a7dc-133e180f96af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1c73973-6ad1-406d-a7dc-133e180f96af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember_cebdb7af-1a4f-4a8d-bdc2-e3de86c23037" xlink:href="amgn-20201231.xsd#amgn_AbandonedLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1c73973-6ad1-406d-a7dc-133e180f96af" xlink:to="loc_amgn_AbandonedLeasesMember_cebdb7af-1a4f-4a8d-bdc2-e3de86c23037" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesCashandNoncashInformationofLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="extended" id="i32806f08219a493bb424c210ab1903d5_LeasesCashandNoncashInformationofLeasesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="simple" xlink:href="amgn-20201231.xsd#Othercurrentassetsandaccruedliabilities"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="extended" id="ied0039feb83d4be6b7a01edaf0908b44_Othercurrentassetsandaccruedliabilities"/>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="extended" id="ia39bf9738a8a48e5bf61deff2127d7e0_OthercurrentassetsandaccruedliabilitiesTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended" id="iddaec3249b7548bea1ec4b967bea8190_OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended" id="i3157afb923f44f08a46856241e10a87d_OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Financingarrangements" xlink:type="simple" xlink:href="amgn-20201231.xsd#Financingarrangements"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Financingarrangements" xlink:type="extended" id="i0734a85cf4174658bca53dbf52b20fe1_Financingarrangements"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="extended" id="i4d90fd7d51a04282ac16b63be8f6ec86_FinancingarrangementsTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended" id="i35000b458d61490e902807a5e53e068a_FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_129505db-9fef-4334-a5a5-94f0b0bdc414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_129505db-9fef-4334-a5a5-94f0b0bdc414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8dd022d5-1f21-4d18-a2b2-b62544d8ebdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8dd022d5-1f21-4d18-a2b2-b62544d8ebdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7456ef78-a2be-4e30-8e78-6ca32d6b85d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7456ef78-a2be-4e30-8e78-6ca32d6b85d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_ee619333-0725-47b0-ae54-09fe5c5aed6d" xlink:href="amgn-20201231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_ee619333-0725-47b0-ae54-09fe5c5aed6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_cdd8b4c6-067d-47f3-9e64-a52ad19e165f" xlink:href="amgn-20201231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_cdd8b4c6-067d-47f3-9e64-a52ad19e165f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_76bb419e-2ec0-4f00-a0d5-3ea9a0e69765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_76bb419e-2ec0-4f00-a0d5-3ea9a0e69765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d1a357e-1e42-4f17-9cd2-a7e3dbc3233b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d1a357e-1e42-4f17-9cd2-a7e3dbc3233b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_591ac7bd-debf-41f5-b0dc-0ba80a8fbd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_591ac7bd-debf-41f5-b0dc-0ba80a8fbd11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_cdeddad0-c5d7-4ffb-adf1-425a61a4eaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_OtherLongTermDebt_cdeddad0-c5d7-4ffb-adf1-425a61a4eaaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_29d94c3c-8c0f-43fe-986e-a77fe416f09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_LongTermDebt_29d94c3c-8c0f-43fe-986e-a77fe416f09a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1705d3a8-13b7-482c-aba8-6931bde85fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_LongTermDebtCurrent_1705d3a8-13b7-482c-aba8-6931bde85fd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0d11fa0f-2fd0-4427-9e8b-fd01906bf1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0d11fa0f-2fd0-4427-9e8b-fd01906bf1a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ca4d0b16-5e2c-4a8a-a279-78cebbade161_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ca4d0b16-5e2c-4a8a-a279-78cebbade161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_744d2ad8-4eaf-44c4-a20f-6e561a167d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:to="loc_us-gaap_NotesPayableToBanksMember_744d2ad8-4eaf-44c4-a20f-6e561a167d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_5520e2c3-1898-43dc-ad67-624df70e4035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_5520e2c3-1898-43dc-ad67-624df70e4035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d778eb6d-17c3-4410-875a-5e6fd0a6d209_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d778eb6d-17c3-4410-875a-5e6fd0a6d209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_6ae3111e-bc8a-4f7d-9f56-9276889b77c9" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_6ae3111e-bc8a-4f7d-9f56-9276889b77c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_a264a1c0-3115-4d81-8e8f-82cd0fb528a5" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_a264a1c0-3115-4d81-8e8f-82cd0fb528a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_571380db-7692-447e-b6cb-518d858ba00e" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_571380db-7692-447e-b6cb-518d858ba00e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_6622fdd7-b533-4c80-897a-2a3b49f46ff3" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_6622fdd7-b533-4c80-897a-2a3b49f46ff3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_d9c0b288-4370-4dcd-ac1d-c94a0cd9a577" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_d9c0b288-4370-4dcd-ac1d-c94a0cd9a577" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b3e959d6-c8c8-47b2-aba5-242996da242e" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b3e959d6-c8c8-47b2-aba5-242996da242e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_49aadc88-c0a9-4d62-bbc4-55b5ca352651" xlink:href="amgn-20201231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_49aadc88-c0a9-4d62-bbc4-55b5ca352651" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_b8cccb40-ca15-4a16-a57a-73e54460f5f5" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_b8cccb40-ca15-4a16-a57a-73e54460f5f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_365f0df7-1dd6-4f46-bae0-03daa5b69ac1" xlink:href="amgn-20201231.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_365f0df7-1dd6-4f46-bae0-03daa5b69ac1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5d3a605c-9e2a-48cb-b762-0b60fd5ef2cd" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5d3a605c-9e2a-48cb-b762-0b60fd5ef2cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member_52a28796-5f2b-414e-a304-63733430f9da" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSixFiveNotesDue2022Member_52a28796-5f2b-414e-a304-63733430f9da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_0a9d1e07-aadd-4827-8106-765a1888fa9c" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_0a9d1e07-aadd-4827-8106-765a1888fa9c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_fb825b1e-c4c1-4709-8e3c-6920b8dd1284" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_fb825b1e-c4c1-4709-8e3c-6920b8dd1284" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_1a9544fd-e06b-46b9-8f3a-f75ace4b3295" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_1a9544fd-e06b-46b9-8f3a-f75ace4b3295" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_37879d66-3d08-416a-a4f7-bc77b30c9bf7" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_37879d66-3d08-416a-a4f7-bc77b30c9bf7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_d0adfbc5-f8e1-40c2-a98c-b72078c261fc" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_d0adfbc5-f8e1-40c2-a98c-b72078c261fc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_2cf0ec25-afd2-4b64-be7f-904a6e6c4554" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_2cf0ec25-afd2-4b64-be7f-904a6e6c4554" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_993683f9-8f05-4a8d-9fa8-13324f06af05" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_993683f9-8f05-4a8d-9fa8-13324f06af05" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_7d696b75-7b8d-49ce-9577-4759183691f9" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_7d696b75-7b8d-49ce-9577-4759183691f9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_8413cf73-828b-4b4e-97f7-7037a970e631" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_8413cf73-828b-4b4e-97f7-7037a970e631" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_6e7520cc-7861-4180-99aa-7f4b3d3a23f5" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_6e7520cc-7861-4180-99aa-7f4b3d3a23f5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b830c557-f639-458f-8e62-2c504dad8182" xlink:href="amgn-20201231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b830c557-f639-458f-8e62-2c504dad8182" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_f1aa36ed-ffb5-4cad-a9fd-66d306c952a0" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_f1aa36ed-ffb5-4cad-a9fd-66d306c952a0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_e50ae0c5-5717-4334-a15f-50053c377ae7" xlink:href="amgn-20201231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_e50ae0c5-5717-4334-a15f-50053c377ae7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7b8053c-8403-4cbc-9e6f-ba976fc18039" xlink:href="amgn-20201231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7b8053c-8403-4cbc-9e6f-ba976fc18039" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_a80e2d32-01ad-4892-b094-8a0883b800e4" xlink:href="amgn-20201231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_a80e2d32-01ad-4892-b094-8a0883b800e4" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_e2ab152a-0c0e-4d8a-b62d-0f37c22ef027" xlink:href="amgn-20201231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_e2ab152a-0c0e-4d8a-b62d-0f37c22ef027" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_04b9f98d-23b8-46a2-bfb3-f546b52bbdf8" xlink:href="amgn-20201231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_04b9f98d-23b8-46a2-bfb3-f546b52bbdf8" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_7cbc9b01-541a-4095-b1e2-0e663c1d6b3c" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_7cbc9b01-541a-4095-b1e2-0e663c1d6b3c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_80e34ce9-c70a-45b4-b8b7-5fc5757920b8" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_80e34ce9-c70a-45b4-b8b7-5fc5757920b8" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_b18d122a-a288-4b55-9479-484ae5eda19e" xlink:href="amgn-20201231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_b18d122a-a288-4b55-9479-484ae5eda19e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_22accdc2-4f49-4eb0-a425-5a785d6e0894" xlink:href="amgn-20201231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_22accdc2-4f49-4eb0-a425-5a785d6e0894" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_c1fac421-ff6e-4797-8734-85d41a5fab21" xlink:href="amgn-20201231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_c1fac421-ff6e-4797-8734-85d41a5fab21" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_f28de94d-64da-413d-8a8b-623d132e1b16" xlink:href="amgn-20201231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_f28de94d-64da-413d-8a8b-623d132e1b16" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_1df2b531-3532-44a4-8270-6bda71be1ee9" xlink:href="amgn-20201231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_1df2b531-3532-44a4-8270-6bda71be1ee9" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_60d40717-818a-4aba-98c4-4ff4f4235540" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_60d40717-818a-4aba-98c4-4ff4f4235540" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_d114519a-c079-443e-b443-2de07947f031" xlink:href="amgn-20201231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_d114519a-c079-443e-b443-2de07947f031" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_a909165e-303e-44d5-a468-41da440af8f4" xlink:href="amgn-20201231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_a909165e-303e-44d5-a468-41da440af8f4" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_3c7578fc-0a93-476b-a8c8-06fe5178e48a" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_3c7578fc-0a93-476b-a8c8-06fe5178e48a" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_053b62de-973e-4d6c-a1ae-a5bc761f0318" xlink:href="amgn-20201231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OtherNotesDue2097Member_053b62de-973e-4d6c-a1ae-a5bc761f0318" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1bcef9d-8a5a-4009-a278-bc35c80ea555_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:to="loc_srt_RangeMember_e1bcef9d-8a5a-4009-a278-bc35c80ea555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:to="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4ff281a-1935-4460-b3bb-696893819d4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:to="loc_srt_MinimumMember_c4ff281a-1935-4460-b3bb-696893819d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b61a8812-cdc8-41d8-9906-1d7e2d4b2f49" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:to="loc_srt_MaximumMember_b61a8812-cdc8-41d8-9906-1d7e2d4b2f49" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended" id="i7f340df1940d4c478fbc3d8d770c3c08_FinancingarrangementsDebtIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d11811e7-c1c4-4d14-af61-0c04a316f986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d11811e7-c1c4-4d14-af61-0c04a316f986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e31dbfa4-9646-41b1-bab3-95b449d6b7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e31dbfa4-9646-41b1-bab3-95b449d6b7ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_bde57b04-9a99-41e7-8630-ee660c3a2c17" xlink:href="amgn-20201231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_bde57b04-9a99-41e7-8630-ee660c3a2c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c92c74de-69de-468f-86e6-4277337b0c64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c92c74de-69de-468f-86e6-4277337b0c64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0a95b286-ab16-4455-a857-e3ae85f6ab2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0a95b286-ab16-4455-a857-e3ae85f6ab2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_25ec19bc-6451-49d9-90d2-c8d3b514535b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0a95b286-ab16-4455-a857-e3ae85f6ab2f" xlink:to="loc_us-gaap_NotesPayableToBanksMember_25ec19bc-6451-49d9-90d2-c8d3b514535b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:to="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_119e4a3a-c474-4a37-a7d6-123cd571b4f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_119e4a3a-c474-4a37-a7d6-123cd571b4f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_5a52850b-fb6d-4c15-81a9-531fd2dcf761" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_5a52850b-fb6d-4c15-81a9-531fd2dcf761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_8d6b2df0-3214-497d-a248-0277c41a1499" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_8d6b2df0-3214-497d-a248-0277c41a1499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_ab5b332d-05e4-4957-9d2a-e83afb9b4eb2" xlink:href="amgn-20201231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_ab5b332d-05e4-4957-9d2a-e83afb9b4eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_4722970d-53bc-4e02-9680-a2f0960f3b2d" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_4722970d-53bc-4e02-9680-a2f0960f3b2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_5f04ed14-28ac-462f-9203-9c973e0792c1" xlink:href="amgn-20201231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_5f04ed14-28ac-462f-9203-9c973e0792c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_14d56945-7177-4483-bdaa-6abe5c82a9e2" xlink:href="amgn-20201231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_14d56945-7177-4483-bdaa-6abe5c82a9e2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended" id="i5ec394c048e247a1a6c733087a0b5a9f_FinancingarrangementsDebtRepaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c95b9ab8-9cec-4c33-adff-0669a4df586b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c95b9ab8-9cec-4c33-adff-0669a4df586b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8105ba25-0ea3-4781-9d0b-da4a1d383613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8105ba25-0ea3-4781-9d0b-da4a1d383613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_24f0bdfa-8cbe-4a1c-915c-f7e00d32dc50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_InterestExpenseDebt_24f0bdfa-8cbe-4a1c-915c-f7e00d32dc50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_547cf410-e39c-4bfe-8c2f-5bc714926d47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_547cf410-e39c-4bfe-8c2f-5bc714926d47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9e13f41c-f267-41ae-9b6f-9f52af57918c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9e13f41c-f267-41ae-9b6f-9f52af57918c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_f3d629a0-8ac3-4c37-a628-dddde7bdedb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9e13f41c-f267-41ae-9b6f-9f52af57918c" xlink:to="loc_us-gaap_NotesPayableToBanksMember_f3d629a0-8ac3-4c37-a628-dddde7bdedb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:to="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4483a9a6-f9af-4dbe-9349-b563bd907119_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4483a9a6-f9af-4dbe-9349-b563bd907119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_ff0b21db-634c-41e1-afff-82769dd48f5b" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_ff0b21db-634c-41e1-afff-82769dd48f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_7caf90cf-f427-42ea-98ca-7688ceea19fc" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenZeroPercentNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_7caf90cf-f427-42ea-98ca-7688ceea19fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_d14e3ba7-d10f-4d6f-afe1-6cfda169f8a5" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_d14e3ba7-d10f-4d6f-afe1-6cfda169f8a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroNotesDue2019Member_01f44286-da46-4eeb-83f9-152542a33fad" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_OnePointNineZeroNotesDue2019Member_01f44286-da46-4eeb-83f9-152542a33fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2019Member_7470ff02-2ac3-433e-b81c-44d4a1608116" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FloatingRateNotesDue2019Member_7470ff02-2ac3-433e-b81c-44d4a1608116" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointOneFivePercentNotesDue2018Member_1fff0c5e-7dc5-45a1-9b22-240b75a17cb1" xlink:href="amgn-20201231.xsd#amgn_SixPointOneFivePercentNotesDue2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_SixPointOneFivePercentNotesDue2018Member_1fff0c5e-7dc5-45a1-9b22-240b75a17cb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_28d35a1a-8763-43c1-aca0-279c44541e50" xlink:href="amgn-20201231.xsd#amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_28d35a1a-8763-43c1-aca0-279c44541e50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_f0c3630f-ccc6-42e4-aefb-a2c81db881da" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_f0c3630f-ccc6-42e4-aefb-a2c81db881da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_00f983fd-8f3a-43ff-aaa2-20bca9be7aa4" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_00f983fd-8f3a-43ff-aaa2-20bca9be7aa4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_869ef4cb-e81d-4c54-8a83-9c1bbba340e9" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_869ef4cb-e81d-4c54-8a83-9c1bbba340e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_fd26c5d9-bbc3-48dc-bdb5-9b8c3ded9b55" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_fd26c5d9-bbc3-48dc-bdb5-9b8c3ded9b55" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_7b211aa8-4cb6-448c-9a8e-221c18eebf6d" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_7b211aa8-4cb6-448c-9a8e-221c18eebf6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_a766336c-9352-4d96-ab4b-76ea23a009e2" xlink:href="amgn-20201231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_a766336c-9352-4d96-ab4b-76ea23a009e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3a8411ba-3bc2-4fd3-a916-9b8d5bd88381" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3a8411ba-3bc2-4fd3-a916-9b8d5bd88381" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_3ac3a31a-6f2c-41ea-8b4f-f050fea4cc51" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_3ac3a31a-6f2c-41ea-8b4f-f050fea4cc51" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended" id="iab12e016af634cfcacf9886a16e0f65c_FinancingarrangementsInterestRateandCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_672bed2b-847e-4d61-8fc5-6efcab2da394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_672bed2b-847e-4d61-8fc5-6efcab2da394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_2cf6f9e8-ef45-4e37-aee5-ade863230eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_2cf6f9e8-ef45-4e37-aee5-ade863230eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_adb66a7f-cd50-4a72-8a21-cfca41a3138a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DerivativeNotionalAmount_adb66a7f-cd50-4a72-8a21-cfca41a3138a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_0c228e2f-cff3-4e7d-b4a7-306049f068d3" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_0c228e2f-cff3-4e7d-b4a7-306049f068d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0d7456c-5dd1-4597-8025-a89ea76ab622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0d7456c-5dd1-4597-8025-a89ea76ab622" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Ratedifferenceinaninterestrateswaprelationship_4e8a3fc7-ca51-4737-95c6-c33918eed3b8" xlink:href="amgn-20201231.xsd#amgn_Ratedifferenceinaninterestrateswaprelationship"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_amgn_Ratedifferenceinaninterestrateswaprelationship_4e8a3fc7-ca51-4737-95c6-c33918eed3b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e1223600-7d4d-4dd6-a9f9-1ea1d58ed44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e1223600-7d4d-4dd6-a9f9-1ea1d58ed44e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32814185-8b84-4eb7-a41c-49e126670946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32814185-8b84-4eb7-a41c-49e126670946" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_6b86dc45-fda8-4200-b10d-1fdf519e7f19" xlink:href="amgn-20201231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_6b86dc45-fda8-4200-b10d-1fdf519e7f19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e21c1862-5ff9-49f0-99fb-b8e5ae4e6c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e21c1862-5ff9-49f0-99fb-b8e5ae4e6c04" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4925be2-8c02-47f3-9b87-e0d1e5b098ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4925be2-8c02-47f3-9b87-e0d1e5b098ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_25cf9777-04b5-4cef-978a-233701bb7564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_25cf9777-04b5-4cef-978a-233701bb7564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_1682a4e8-43f3-4659-95df-588db8be8b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:to="loc_us-gaap_NotesPayableToBanksMember_1682a4e8-43f3-4659-95df-588db8be8b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30b386da-d231-411a-8768-7994d189fb30_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30b386da-d231-411a-8768-7994d189fb30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_f4d736cf-4e0b-4d4f-8409-ac6ff6afad7f" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_f4d736cf-4e0b-4d4f-8409-ac6ff6afad7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e25309aa-6b59-42cf-aafa-6c455fa766e7" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e25309aa-6b59-42cf-aafa-6c455fa766e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_3d3ac13c-a2fa-42b9-bc90-d2ed60ae850a" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_3d3ac13c-a2fa-42b9-bc90-d2ed60ae850a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_c04dcda4-123e-4599-aeb1-73318f43413e" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_c04dcda4-123e-4599-aeb1-73318f43413e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_62fac120-3072-4bab-a635-39a35235cd89" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_62fac120-3072-4bab-a635-39a35235cd89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_cfafd3e1-ccb1-49d1-a996-783b78a34d0f" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_cfafd3e1-ccb1-49d1-a996-783b78a34d0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b35abaf3-9e3e-4826-819a-7052f4607256" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b35abaf3-9e3e-4826-819a-7052f4607256" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_a72bc91a-3678-4875-8368-4392d2ed3b34" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_a72bc91a-3678-4875-8368-4392d2ed3b34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_d1361ac4-1577-4a08-8932-2bc2c53d8869" xlink:href="amgn-20201231.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_d1361ac4-1577-4a08-8932-2bc2c53d8869" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_7dfd8d76-81af-4ef6-9206-58677dbd750b" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_7dfd8d76-81af-4ef6-9206-58677dbd750b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_06215934-7184-4bef-b65b-9976bbfc9f7f" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_06215934-7184-4bef-b65b-9976bbfc9f7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_0140a8f7-001e-4f0f-ad4e-c80e2f8a9015" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_0140a8f7-001e-4f0f-ad4e-c80e2f8a9015" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_facf3224-7b39-4598-a6f3-386a978b42eb" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_facf3224-7b39-4598-a6f3-386a978b42eb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_3d70cef5-ef43-4a91-b122-074de5454b13" xlink:href="amgn-20201231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_3d70cef5-ef43-4a91-b122-074de5454b13" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dde10b53-26bb-4b4d-84ea-ae002f938b46" xlink:href="amgn-20201231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dde10b53-26bb-4b4d-84ea-ae002f938b46" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_f2c2d23e-040d-4716-844e-4a686bd051ef" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_f2c2d23e-040d-4716-844e-4a686bd051ef" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_00a3dd17-61d1-4977-80ae-83fb9ccc0dd8" xlink:href="amgn-20201231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_00a3dd17-61d1-4977-80ae-83fb9ccc0dd8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_ba0c622b-5ab9-49d1-8c6d-d9652b6273ea" xlink:href="amgn-20201231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_ba0c622b-5ab9-49d1-8c6d-d9652b6273ea" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ac381713-7544-4ca1-a88f-f2fd3f4fa2af" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ac381713-7544-4ca1-a88f-f2fd3f4fa2af" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b9538959-4af5-4fbe-8094-9109650fb081" xlink:href="amgn-20201231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b9538959-4af5-4fbe-8094-9109650fb081" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8f6b84b8-27ad-4b31-9c60-e57de1857b23" xlink:href="amgn-20201231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8f6b84b8-27ad-4b31-9c60-e57de1857b23" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_1e31a48e-6535-4d98-9d36-e04efc48c993" xlink:href="amgn-20201231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_1e31a48e-6535-4d98-9d36-e04efc48c993" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bd09bc4e-2c61-416b-a638-3a40c82461bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:to="loc_us-gaap_VariableRateDomain_bd09bc4e-2c61-416b-a638-3a40c82461bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e42f3456-bc3e-45a7-8c88-cbb95cc45129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:to="loc_us-gaap_VariableRateDomain_e42f3456-bc3e-45a7-8c88-cbb95cc45129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_cf6b57d4-7b34-4aea-9f64-af4449b11146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e42f3456-bc3e-45a7-8c88-cbb95cc45129" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_cf6b57d4-7b34-4aea-9f64-af4449b11146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_1d09ff48-0cfe-404e-ada1-e51ca053db4c_default" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:to="loc_amgn_InterestRateSwapDomain_1d09ff48-0cfe-404e-ada1-e51ca053db4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:to="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember_7dfb10e3-bcbf-4a6f-9ff9-2f7a2abbe6c8" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:to="loc_amgn_InterestRateSwapOneMember_7dfb10e3-bcbf-4a6f-9ff9-2f7a2abbe6c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_5ca429c1-4f72-4a64-91dd-71da35c00be9" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:to="loc_amgn_InterestRateSwapTwoMember_5ca429c1-4f72-4a64-91dd-71da35c00be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapThreeMember_56a663ca-3874-4a0f-985c-0e1732785ecb" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:to="loc_amgn_InterestRateSwapThreeMember_56a663ca-3874-4a0f-985c-0e1732785ecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_643eb017-f834-4c5b-865f-6d981ae6a632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_643eb017-f834-4c5b-865f-6d981ae6a632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8b869c97-3bbb-43f6-975f-f42cf0bb9df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_643eb017-f834-4c5b-865f-6d981ae6a632" xlink:to="loc_us-gaap_InterestRateSwapMember_8b869c97-3bbb-43f6-975f-f42cf0bb9df4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_89674f38-ca2f-4dc1-adcc-2009b8fc7caa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:to="loc_us-gaap_HedgingDesignationDomain_89674f38-ca2f-4dc1-adcc-2009b8fc7caa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_109efc7b-ac42-4a02-9c61-d66cb3d21af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:to="loc_us-gaap_HedgingDesignationDomain_109efc7b-ac42-4a02-9c61-d66cb3d21af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7e1b3b2b-ed61-4cb9-8ed9-01fdfdd92e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_109efc7b-ac42-4a02-9c61-d66cb3d21af9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7e1b3b2b-ed61-4cb9-8ed9-01fdfdd92e7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended" id="i8f89aab99b7846709d01eea20dff9276_FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6f15526d-0f06-4b35-8ede-28e2a9257fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6f15526d-0f06-4b35-8ede-28e2a9257fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_6e2c7495-cb48-442b-b726-3fa4a2b7ded3" xlink:href="amgn-20201231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_6e2c7495-cb48-442b-b726-3fa4a2b7ded3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_c45c685d-0dba-450e-9cdf-6f9f5010e7d7" xlink:href="amgn-20201231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_c45c685d-0dba-450e-9cdf-6f9f5010e7d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_99332b12-5bfd-4d04-bbc6-678053b11868" xlink:href="amgn-20201231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_99332b12-5bfd-4d04-bbc6-678053b11868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_1a40b349-7cd1-4c8e-9bc3-434592f83621" xlink:href="amgn-20201231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_1a40b349-7cd1-4c8e-9bc3-434592f83621" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f9ec6555-09a5-4ba9-91ba-84933687405a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f9ec6555-09a5-4ba9-91ba-84933687405a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a6e89d13-a83a-4843-9838-94fde715f03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a6e89d13-a83a-4843-9838-94fde715f03e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_925986e7-83e3-4540-9d68-15861229d55a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_925986e7-83e3-4540-9d68-15861229d55a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_7f224415-3aaa-4cb0-88a5-a0db04d82f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_LineOfCredit_7f224415-3aaa-4cb0-88a5-a0db04d82f71" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1873d351-fae2-47ae-a135-0400e7171349_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1873d351-fae2-47ae-a135-0400e7171349_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68cc0c2f-10f5-436d-9739-80773b9d4b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68cc0c2f-10f5-436d-9739-80773b9d4b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8fcd5822-2ac4-4673-a6df-a0aa6045f84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68cc0c2f-10f5-436d-9739-80773b9d4b9e" xlink:to="loc_us-gaap_LineOfCreditMember_8fcd5822-2ac4-4673-a6df-a0aa6045f84f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:to="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_77a03e09-be1d-4c99-9060-7e45d2596afb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:to="loc_us-gaap_VariableRateDomain_77a03e09-be1d-4c99-9060-7e45d2596afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:to="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_4bf5494d-8055-4e7f-8556-39fcaf53a614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_4bf5494d-8055-4e7f-8556-39fcaf53a614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_da07869b-099f-474b-a11c-28f44c5ab463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_da07869b-099f-474b-a11c-28f44c5ab463" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended" id="i76f7b7c979884c6cb30c4f07f56bfe4b_FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsInterestCostsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="extended" id="i9e70edeaecf94d179e7ec4bb0815c2cb_FinancingarrangementsInterestCostsDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockholdersequity" xlink:type="simple" xlink:href="amgn-20201231.xsd#Stockholdersequity"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Stockholdersequity" xlink:type="extended" id="ifa957657e5ca4c9398c8dcc2a5c96a72_Stockholdersequity"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityTables" xlink:type="extended" id="ie5128c1cbf0149c7a686f81506336901_StockholdersequityTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityStockRepurchaseProgramDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="extended" id="i8e517afbce8d4acc98da663b9357b8cd_StockholdersequityStockRepurchaseProgramDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended" id="ic55d8b8a8fcc4bbc9a75233e5aec58be_StockholdersequityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_52665624-0591-4d24-a620-74b04d944629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_52665624-0591-4d24-a620-74b04d944629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_86308a94-f8ff-410f-80e5-85890a85c6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_86308a94-f8ff-410f-80e5-85890a85c6bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:to="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fa3a5212-fb54-4380-b85a-caf505a32e3a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fa3a5212-fb54-4380-b85a-caf505a32e3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ca69937f-d3b9-4b0d-bc36-75f8bf88ac34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ca69937f-d3b9-4b0d-bc36-75f8bf88ac34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1259fc3f-690d-4b6d-bc49-ec0f09c2b4cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ca69937f-d3b9-4b0d-bc36-75f8bf88ac34" xlink:to="loc_srt_ScenarioForecastMember_1259fc3f-690d-4b6d-bc49-ec0f09c2b4cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended" id="i1cef94e3fd6742fe9bfcdc70e93d5cd3_StockholdersequityComponentsofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14a89e73-376c-4972-95ec-6e4a969e37ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14a89e73-376c-4972-95ec-6e4a969e37ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7979b9d9-21aa-4e0d-b6b7-b42c56c15b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_StockholdersEquity_7979b9d9-21aa-4e0d-b6b7-b42c56c15b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8105f1cd-00e9-49f3-888e-740b04bd84e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8105f1cd-00e9-49f3-888e-740b04bd84e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_bb667587-a2c8-41fd-8324-44b5216fdd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_bb667587-a2c8-41fd-8324-44b5216fdd58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_9a3fdef0-464c-46a4-bd11-56517c530b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_9a3fdef0-464c-46a4-bd11-56517c530b61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_d4338aff-47ee-46aa-9083-84b594952d17" xlink:href="amgn-20201231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_d4338aff-47ee-46aa-9083-84b594952d17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_258eb415-aecf-404d-9c97-310434848405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_258eb415-aecf-404d-9c97-310434848405" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_396ba300-59ee-430b-bdb7-eacff8f4b22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14a89e73-376c-4972-95ec-6e4a969e37ae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8681696-c35b-45c1-b372-677a0fac15e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:to="loc_us-gaap_EquityComponentDomain_d8681696-c35b-45c1-b372-677a0fac15e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:to="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe96a858-281a-4f41-b003-87b4bb1fc625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe96a858-281a-4f41-b003-87b4bb1fc625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_ec572665-a4e8-4692-8f9c-6352d5197da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_ec572665-a4e8-4692-8f9c-6352d5197da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c4df6ddd-48b2-4d19-8229-5c0c22b4c480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c4df6ddd-48b2-4d19-8229-5c0c22b4c480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_09a32e81-4419-453b-9202-9aa6456f0ee9" xlink:href="amgn-20201231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_09a32e81-4419-453b-9202-9aa6456f0ee9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d416f9d2-80f5-452c-928b-adea3111ff42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d416f9d2-80f5-452c-928b-adea3111ff42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_140052ea-6763-474f-a430-25bbef8bad5d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_140052ea-6763-474f-a430-25bbef8bad5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f18fb4bd-3a5c-4c72-88d6-c5b17fcfb8db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f18fb4bd-3a5c-4c72-88d6-c5b17fcfb8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7fba6a9d-7fc0-43c8-b552-fb8ca1b8318d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f18fb4bd-3a5c-4c72-88d6-c5b17fcfb8db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7fba6a9d-7fc0-43c8-b552-fb8ca1b8318d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="extended" id="ie817923a04954f5c9f8b9e1483bb84ec_StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended" id="i74946431775e4e93828ba880036dbab7_StockholdersequityReclassificationsoutofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7d53c4f7-f060-46a2-8d66-5528a34cc5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7d53c4f7-f060-46a2-8d66-5528a34cc5a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4952c378-9260-4b6b-ad7a-5129649847e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4952c378-9260-4b6b-ad7a-5129649847e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8e17fedd-f57b-4964-89ed-c5c3c32e8828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_InterestExpenseDebt_8e17fedd-f57b-4964-89ed-c5c3c32e8828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f992d7b2-68e0-4763-8747-cb8a4e3f745a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f992d7b2-68e0-4763-8747-cb8a4e3f745a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1031d01c-a997-4fb3-bee6-58c9edd07d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1031d01c-a997-4fb3-bee6-58c9edd07d71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f693644f-bf18-41a0-af78-e96c62ac6959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_NetIncomeLoss_f693644f-bf18-41a0-af78-e96c62ac6959" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8144d5af-8012-4e2a-8dd3-46fe08a3b45e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_8144d5af-8012-4e2a-8dd3-46fe08a3b45e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0699f699-1297-4448-b420-409815a083d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0699f699-1297-4448-b420-409815a083d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_54338ad3-650c-46aa-b49d-c0d20f4bf998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0699f699-1297-4448-b420-409815a083d6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_54338ad3-650c-46aa-b49d-c0d20f4bf998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4f0c6562-1fab-4b98-afbe-53be607764c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4f0c6562-1fab-4b98-afbe-53be607764c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0956d98f-1a79-4899-b1a4-16eb8ab061f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0956d98f-1a79-4899-b1a4-16eb8ab061f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_f75eb8fa-d0b3-4590-8180-be410333277b" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_f75eb8fa-d0b3-4590-8180-be410333277b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_8ee41b7a-dc14-4214-b450-0e43ee926dc2" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:to="loc_amgn_ForwardInterestRateContractMember_8ee41b7a-dc14-4214-b450-0e43ee926dc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2247dc76-0444-444a-822c-b372dc13b161_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2247dc76-0444-444a-822c-b372dc13b161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9827bf66-c858-4416-9387-f581a4fa87ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9827bf66-c858-4416-9387-f581a4fa87ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_18242cd5-4dd5-46d7-96a2-5f64da4125f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9827bf66-c858-4416-9387-f581a4fa87ca" xlink:to="loc_us-gaap_CashFlowHedgingMember_18242cd5-4dd5-46d7-96a2-5f64da4125f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:to="loc_srt_ProductsAndServicesDomain_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce6f3094-7633-49fd-abd1-6de0311dc8a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:to="loc_srt_ProductsAndServicesDomain_ce6f3094-7633-49fd-abd1-6de0311dc8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0f8f1528-b72e-4688-a72e-eb7f5fb110da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ce6f3094-7633-49fd-abd1-6de0311dc8a1" xlink:to="loc_us-gaap_ProductMember_0f8f1528-b72e-4688-a72e-eb7f5fb110da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d93e214-b051-49b6-9eb7-5ee5ff192feb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:to="loc_us-gaap_EquityComponentDomain_6d93e214-b051-49b6-9eb7-5ee5ff192feb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:to="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c7252605-c27f-4eb7-be6c-296274695336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c7252605-c27f-4eb7-be6c-296274695336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_162ecfe5-7db6-4f5b-a6d9-8538c17213c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_162ecfe5-7db6-4f5b-a6d9-8538c17213c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityOtherDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="extended" id="i730972b1ce1e4f3899bc1b10cfdf026d_StockholdersequityOtherDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="simple" xlink:href="amgn-20201231.xsd#Fairvaluemeasurement"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="extended" id="i20dfb8f599f94f9c8e6da2f1e2f12a44_Fairvaluemeasurement"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="extended" id="i3390a51a6bd0440197051e7e96633459_FairvaluemeasurementTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="id4744eba16404bcc87d847c10085d7af_FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16c13bf-b304-44b9-89dd-7f0cbe9b0d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16c13bf-b304-44b9-89dd-7f0cbe9b0d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0b2ce186-c155-4d5e-bfa9-027824787381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0b2ce186-c155-4d5e-bfa9-027824787381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:href="amgn-20201231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_8db87b38-431c-49a9-b58c-64ee176f8f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_8db87b38-431c-49a9-b58c-64ee176f8f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_bd69f29c-14b1-42f1-93c0-fb6fdc64ab94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_bd69f29c-14b1-42f1-93c0-fb6fdc64ab94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1e62135c-f9ac-4c9e-9ffc-e826f937b8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1e62135c-f9ac-4c9e-9ffc-e826f937b8cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:href="amgn-20201231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_77d8ebbd-562c-42aa-907a-ee27235fff46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_77d8ebbd-562c-42aa-907a-ee27235fff46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_12b59f37-a7e4-49a4-82a8-b8187b35889b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_12b59f37-a7e4-49a4-82a8-b8187b35889b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6dbc2935-1380-4d9a-aaa3-34f343997148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6dbc2935-1380-4d9a-aaa3-34f343997148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_811fa216-738d-410e-81b9-e88215f19cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_811fa216-738d-410e-81b9-e88215f19cbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10c46529-fd43-4a95-bfbf-56d67f32cac7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10c46529-fd43-4a95-bfbf-56d67f32cac7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4978f21-9cb7-4ba1-b38b-328bf3f79d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4978f21-9cb7-4ba1-b38b-328bf3f79d1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_226f3c64-9abc-4aef-a225-0441c426292e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_226f3c64-9abc-4aef-a225-0441c426292e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2f212606-87cb-4cde-b20c-d1f88f7429f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2f212606-87cb-4cde-b20c-d1f88f7429f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_15f24ad3-1509-4e4b-8953-96e5ca7d9570_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_15f24ad3-1509-4e4b-8953-96e5ca7d9570_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b20bec62-e31c-46e1-ae0c-97bdcb17e69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b20bec62-e31c-46e1-ae0c-97bdcb17e69e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_72dd3005-3d22-4a7e-9e74-f070ea435010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_72dd3005-3d22-4a7e-9e74-f070ea435010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_8cfabb71-9d43-4093-bc72-faa5a986f094" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_8cfabb71-9d43-4093-bc72-faa5a986f094" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_226339f4-1ed8-4e8c-b162-bcbd7cf15247" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_226339f4-1ed8-4e8c-b162-bcbd7cf15247" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_6002c581-457e-414d-804b-4e0bf2f8d0d5" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_6002c581-457e-414d-804b-4e0bf2f8d0d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_d5c30c6e-34d5-441b-81fb-65bf02be799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_d5c30c6e-34d5-441b-81fb-65bf02be799d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_229377de-443a-43b5-9c28-d517039bb9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_229377de-443a-43b5-9c28-d517039bb9e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_126f5c56-2ad7-4f55-bd48-122d1174f54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_126f5c56-2ad7-4f55-bd48-122d1174f54b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_7cabaee8-97a1-41e7-a0ca-ff3202c8c9d4" xlink:href="amgn-20201231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_7cabaee8-97a1-41e7-a0ca-ff3202c8c9d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_78da90b6-8c9a-4aa5-8e65-1c342fbc25da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_78da90b6-8c9a-4aa5-8e65-1c342fbc25da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_10cacb78-ce32-4443-bf2e-1f2a50e3e48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:to="loc_us-gaap_ForeignExchangeContractMember_10cacb78-ce32-4443-bf2e-1f2a50e3e48a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_96f459ac-871b-4662-b7d1-cc49e1816616" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_96f459ac-871b-4662-b7d1-cc49e1816616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_820a6906-effe-4f49-9dc1-e8821d35edff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:to="loc_us-gaap_InterestRateSwapMember_820a6906-effe-4f49-9dc1-e8821d35edff" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended" id="i0e36488ed5c54ba6a67ac98b059cfb29_FairvaluemeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_bbcaa7d7-36a5-4123-a18a-9b62e8cdbef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_bbcaa7d7-36a5-4123-a18a-9b62e8cdbef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1588eb75-d60f-4b6f-9efe-869300d90147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1588eb75-d60f-4b6f-9efe-869300d90147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_1f89c9d2-8579-43c0-bbf7-7e5d1d1476cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_1f89c9d2-8579-43c0-bbf7-7e5d1d1476cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d716c265-396f-4d39-94d9-ff5dfce19a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_LongTermDebt_d716c265-396f-4d39-94d9-ff5dfce19a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6df9f6dc-45ba-4b66-be0b-b04fab22b3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6df9f6dc-45ba-4b66-be0b-b04fab22b3ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_35713cd1-1601-4fba-91b9-75b62efc7e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_EquityMethodInvestments_35713cd1-1601-4fba-91b9-75b62efc7e39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40b0b622-3c3b-426c-9f89-9b0b4fae48d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40b0b622-3c3b-426c-9f89-9b0b4fae48d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c85cba-cbcb-4f64-a926-eb96d4e2eebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c85cba-cbcb-4f64-a926-eb96d4e2eebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_3f89c960-f275-4332-a898-e3d8992ba03f" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c85cba-cbcb-4f64-a926-eb96d4e2eebd" xlink:to="loc_amgn_BeiGeneMember_3f89c960-f275-4332-a898-e3d8992ba03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e00696ae-e646-4d6e-8feb-750e25f04cb1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e00696ae-e646-4d6e-8feb-750e25f04cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4e4f141f-2c92-4208-91da-b744f6a6cf18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4e4f141f-2c92-4208-91da-b744f6a6cf18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_7c38b022-bd36-4d4b-92d2-565e2f1561f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4e4f141f-2c92-4208-91da-b744f6a6cf18" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_7c38b022-bd36-4d4b-92d2-565e2f1561f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0c0c9568-21d8-4149-b549-9fd73afdb9cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0c0c9568-21d8-4149-b549-9fd73afdb9cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b3ee3d15-9f8a-4895-8418-3c52b0b70d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b3ee3d15-9f8a-4895-8418-3c52b0b70d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6b40991-7ae8-4c28-bbce-414b7f43cdfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b3ee3d15-9f8a-4895-8418-3c52b0b70d6e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6b40991-7ae8-4c28-bbce-414b7f43cdfb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Derivativeinstruments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Derivativeinstruments"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Derivativeinstruments" xlink:type="extended" id="i42a3bd612cae4eed82855d574121e751_Derivativeinstruments"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="extended" id="i245545e32f924aea97d645c97c7cd91a_DerivativeinstrumentsTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended" id="i20dee2bcc38043c8873295b4a355cf69_DerivativeinstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_efabe922-4d5e-440c-bb85-53b63bf9b37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_efabe922-4d5e-440c-bb85-53b63bf9b37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1807b58-2c79-4fdc-beb1-f7bf63721056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1807b58-2c79-4fdc-beb1-f7bf63721056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_f71440e6-6dee-41b1-9c59-9821a05606f3" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_f71440e6-6dee-41b1-9c59-9821a05606f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6976cf1a-9eb4-4a5b-9ede-b640a8ff55b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6976cf1a-9eb4-4a5b-9ede-b640a8ff55b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_eefb5416-9f1f-4b7a-8bd5-d401ad8bbac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_eefb5416-9f1f-4b7a-8bd5-d401ad8bbac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_28e44bc0-169f-431a-9663-10d5a3ac9e16" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_28e44bc0-169f-431a-9663-10d5a3ac9e16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_14ffd8f1-6efc-4a5d-a3e1-34b7cdd6d199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_14ffd8f1-6efc-4a5d-a3e1-34b7cdd6d199" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e3be4ea4-5435-4706-aaec-399c9364a0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e3be4ea4-5435-4706-aaec-399c9364a0a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_431824cc-2147-4d29-aa7c-80565620037b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_431824cc-2147-4d29-aa7c-80565620037b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a8ba0d8-1b82-45d5-847c-58f899dfcb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a8ba0d8-1b82-45d5-847c-58f899dfcb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_1ba64535-da34-4055-b2a6-cc2f11371ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1a8ba0d8-1b82-45d5-847c-58f899dfcb9b" xlink:to="loc_us-gaap_NotesPayableToBanksMember_1ba64535-da34-4055-b2a6-cc2f11371ea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7d2a1e1-d019-4d43-9c89-a782dcbab918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7d2a1e1-d019-4d43-9c89-a782dcbab918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_da66e5e9-4520-4725-a327-63bf46453ecb" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7d2a1e1-d019-4d43-9c89-a782dcbab918" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_da66e5e9-4520-4725-a327-63bf46453ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:to="loc_us-gaap_HedgingDesignationDomain_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:to="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_40de7323-726b-41b5-be13-302ec7121ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_40de7323-726b-41b5-be13-302ec7121ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f226973a-86b6-4f9c-81e4-b22c900f9864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:to="loc_us-gaap_NondesignatedMember_f226973a-86b6-4f9c-81e4-b22c900f9864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1bf44161-8dd5-4d4e-85aa-846a96c62b5f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1bf44161-8dd5-4d4e-85aa-846a96c62b5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_db0f7810-7ca0-427f-9a2e-4fec645f9d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_us-gaap_ForwardContractsMember_db0f7810-7ca0-427f-9a2e-4fec645f9d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_3cbf0f85-2195-4856-b537-5fe1eab07fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_us-gaap_OptionMember_3cbf0f85-2195-4856-b537-5fe1eab07fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_a6306c02-468b-42e3-b336-610c35bb3cec" xlink:href="amgn-20201231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_a6306c02-468b-42e3-b336-610c35bb3cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_3ece5595-5d4c-4d06-973a-ed0388b34369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_us-gaap_InterestRateSwapMember_3ece5595-5d4c-4d06-973a-ed0388b34369" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_c6c82309-d1a1-4da1-8250-7c78d9816926" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAtThenCurrentInterestRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_c6c82309-d1a1-4da1-8250-7c78d9816926" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_52d02d05-bed7-4edd-a683-e2062e25e51f_default" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:to="loc_amgn_InterestRateSwapDomain_52d02d05-bed7-4edd-a683-e2062e25e51f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_681d2a65-dc60-4c8a-b038-3a4687d47d21" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:to="loc_amgn_InterestRateSwapDomain_681d2a65-dc60-4c8a-b038-3a4687d47d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_70452a64-9655-4046-8767-6d57de7001a6" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_681d2a65-dc60-4c8a-b038-3a4687d47d21" xlink:to="loc_amgn_InterestRateSwapTwoMember_70452a64-9655-4046-8767-6d57de7001a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_056039a5-3d8b-4ded-9b78-4e467a978bd2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_056039a5-3d8b-4ded-9b78-4e467a978bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a60bd776-f05c-4663-81df-e8a00a7d7e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a60bd776-f05c-4663-81df-e8a00a7d7e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_60f8d77e-4505-42a0-8dc8-eb5029fa8769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60bd776-f05c-4663-81df-e8a00a7d7e7d" xlink:to="loc_us-gaap_InterestExpenseMember_60f8d77e-4505-42a0-8dc8-eb5029fa8769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_25b8af99-f939-47b4-9032-40ca36106160_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_25b8af99-f939-47b4-9032-40ca36106160_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7ccb6400-d8fa-4b4f-837f-c60fc40e0197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7ccb6400-d8fa-4b4f-837f-c60fc40e0197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_3704f89c-697a-4c28-be9b-a063ca37beae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7ccb6400-d8fa-4b4f-837f-c60fc40e0197" xlink:to="loc_us-gaap_LongTermDebtMember_3704f89c-697a-4c28-be9b-a063ca37beae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended" id="i398a6cbf2dba4533bfb741258ce1b8b0_DerivativeinstrumentsCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_20fae692-800c-4d91-bdb3-d7f7a6ce4a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:to="loc_us-gaap_DerivativeNotionalAmount_20fae692-800c-4d91-bdb3-d7f7a6ce4a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_2a585601-2261-4a92-b1cb-7e616beb116c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_2a585601-2261-4a92-b1cb-7e616beb116c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:to="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bc7659ed-ec0b-47c5-a472-b2e34db21106_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bc7659ed-ec0b-47c5-a472-b2e34db21106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9256fa86-c9ce-47f5-89c3-54984bdacbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9256fa86-c9ce-47f5-89c3-54984bdacbd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_5d4ae16e-6e0e-4d8d-8ca7-acfd1f8d28b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9256fa86-c9ce-47f5-89c3-54984bdacbd0" xlink:to="loc_us-gaap_CashFlowHedgingMember_5d4ae16e-6e0e-4d8d-8ca7-acfd1f8d28b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_41819d06-b06b-4f32-95d3-874640a01988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_41819d06-b06b-4f32-95d3-874640a01988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_db85d4c7-5ea7-4772-be0f-1d0bde5b06fd" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41819d06-b06b-4f32-95d3-874640a01988" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_db85d4c7-5ea7-4772-be0f-1d0bde5b06fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_108e6710-753b-4bdc-93f6-65a0d6857ad0_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:to="loc_currency_AllCurrenciesDomain_108e6710-753b-4bdc-93f6-65a0d6857ad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:to="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_26e0fc49-2000-4df5-9078-5afdf3c6d97b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_EUR_26e0fc49-2000-4df5-9078-5afdf3c6d97b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_8ceb6f5f-36dc-4fcb-bd9f-42e296860c2f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_CHF_8ceb6f5f-36dc-4fcb-bd9f-42e296860c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_4046fc36-ac96-4d0b-a917-161c94b5688f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_GBP_4046fc36-ac96-4d0b-a917-161c94b5688f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_d42e15fa-9e5b-46fb-8d09-c821bb540842" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_USD_d42e15fa-9e5b-46fb-8d09-c821bb540842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ddac7831-341c-4876-864a-ab987f6aca94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ddac7831-341c-4876-864a-ab987f6aca94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_8d3d189f-37e2-4534-b7c3-eb70b8fdf411" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_8d3d189f-37e2-4534-b7c3-eb70b8fdf411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ac779fbd-5964-41c2-821d-dd7d1eafa99f" xlink:href="amgn-20201231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ac779fbd-5964-41c2-821d-dd7d1eafa99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_6ebe90b3-1a98-4b7e-ab52-98041f08045e" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_6ebe90b3-1a98-4b7e-ab52-98041f08045e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_83183661-00ef-456f-a78b-7dae300c5f27" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_83183661-00ef-456f-a78b-7dae300c5f27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_db73a217-eab3-4fd5-80f5-81183a9b91c1" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_db73a217-eab3-4fd5-80f5-81183a9b91c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_6f0715cd-5f43-438b-b452-8730a4e6d6f0" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_6f0715cd-5f43-438b-b452-8730a4e6d6f0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended" id="i6ee19948b8c24261b38cabd8cc3cd155_DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9768fd1d-3b69-43bc-8635-85ea68a6f4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_9a7235c8-1211-4f32-8dc6-937d3ede91eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9768fd1d-3b69-43bc-8635-85ea68a6f4a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_9a7235c8-1211-4f32-8dc6-937d3ede91eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9768fd1d-3b69-43bc-8635-85ea68a6f4a2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_353f4f60-a2b3-456b-9c17-9ad8a848ff92_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:to="loc_us-gaap_HedgingRelationshipDomain_353f4f60-a2b3-456b-9c17-9ad8a848ff92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_dfded723-7323-48b2-91de-7f4a62bc7369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:to="loc_us-gaap_HedgingRelationshipDomain_dfded723-7323-48b2-91de-7f4a62bc7369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1cf12b15-3c68-417e-8174-edf488aa93cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_dfded723-7323-48b2-91de-7f4a62bc7369" xlink:to="loc_us-gaap_CashFlowHedgingMember_1cf12b15-3c68-417e-8174-edf488aa93cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_67c2b7de-e3d4-491c-be05-dc0924f226b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_67c2b7de-e3d4-491c-be05-dc0924f226b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d6ece120-e5ff-48be-a562-237f72fc4ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d6ece120-e5ff-48be-a562-237f72fc4ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_a957a2bf-f1de-4d25-bbba-448a1dda3cca" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_a957a2bf-f1de-4d25-bbba-448a1dda3cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_50ce46dc-ff76-4852-bbbc-c067e213f9c2" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:to="loc_amgn_ForwardInterestRateContractMember_50ce46dc-ff76-4852-bbbc-c067e213f9c2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended" id="i8dc9291041d24ded816500077f57ce5b_DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_dfedaef4-b3fe-4b66-b9b5-9b4a9c586f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_dfedaef4-b3fe-4b66-b9b5-9b4a9c586f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_33ebaa0f-eb8b-449b-af27-89fdaa8d78ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_33ebaa0f-eb8b-449b-af27-89fdaa8d78ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_e1af43cf-bf48-4f98-82b7-8711fb710b40" xlink:href="amgn-20201231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_e1af43cf-bf48-4f98-82b7-8711fb710b40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_8ecd1a9e-f1fe-45c6-910a-d143727b2e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_8ecd1a9e-f1fe-45c6-910a-d143727b2e7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b339ca4d-994d-4327-910c-23c3badd98be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b339ca4d-994d-4327-910c-23c3badd98be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_e0b44485-78f4-44fb-a75b-302d5bc1abf5" xlink:href="amgn-20201231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_e0b44485-78f4-44fb-a75b-302d5bc1abf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_2a61c8c2-8c7b-4d0e-bf9b-058e165d610a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:to="loc_us-gaap_LongTermDebtMember_2a61c8c2-8c7b-4d0e-bf9b-058e165d610a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended" id="i79ae9348298b465faf272113c040325f_DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0f8c5396-6bda-4814-bd8e-523bd37fb479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0f8c5396-6bda-4814-bd8e-523bd37fb479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_85001156-b3d8-4e9d-8704-061ab9498e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_85001156-b3d8-4e9d-8704-061ab9498e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_dffdd79c-db7a-4523-8194-995a78f436b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_InterestExpenseDebt_dffdd79c-db7a-4523-8194-995a78f436b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bcf12f61-53ff-4363-a471-a612d219f94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bcf12f61-53ff-4363-a471-a612d219f94e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_0d7fabe0-b926-4a78-a250-94e8dd32c688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_0d7fabe0-b926-4a78-a250-94e8dd32c688" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05d464ce-84f2-4178-8511-8d853b48bc16_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:to="loc_srt_ProductsAndServicesDomain_05d464ce-84f2-4178-8511-8d853b48bc16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_291ab721-825c-442a-98ab-3cbd4a31f240" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:to="loc_srt_ProductsAndServicesDomain_291ab721-825c-442a-98ab-3cbd4a31f240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_85753043-ff38-4f01-bb1d-92ec0e4f689f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_291ab721-825c-442a-98ab-3cbd4a31f240" xlink:to="loc_us-gaap_ProductMember_85753043-ff38-4f01-bb1d-92ec0e4f689f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eb240656-a084-47cd-a858-45afe58faacb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eb240656-a084-47cd-a858-45afe58faacb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d09e0772-85f8-403a-b55c-7ef8c26fc104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d09e0772-85f8-403a-b55c-7ef8c26fc104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b045c3-e54d-4ca8-98c5-d7442efdf3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d09e0772-85f8-403a-b55c-7ef8c26fc104" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b045c3-e54d-4ca8-98c5-d7442efdf3ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c2877098-d8c4-49f3-9900-fe3e1e4a12de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:to="loc_us-gaap_EquityComponentDomain_c2877098-d8c4-49f3-9900-fe3e1e4a12de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21b6ea80-1346-4b86-8f62-9266cc3a4429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:to="loc_us-gaap_EquityComponentDomain_21b6ea80-1346-4b86-8f62-9266cc3a4429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_110e580e-5ec5-4668-9b1b-67b8d1b21d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b6ea80-1346-4b86-8f62-9266cc3a4429" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_110e580e-5ec5-4668-9b1b-67b8d1b21d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1709e447-ebf0-42e0-b5b5-dc2387136cad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1709e447-ebf0-42e0-b5b5-dc2387136cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5e49ca8d-21a7-4146-829e-5c5bb4290534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5e49ca8d-21a7-4146-829e-5c5bb4290534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_dd06870c-5d70-4dfc-babe-8ce749b11184" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_dd06870c-5d70-4dfc-babe-8ce749b11184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_32e55c39-469d-49d1-bee1-d7e810138f6a" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_amgn_ForwardInterestRateContractMember_32e55c39-469d-49d1-bee1-d7e810138f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_af1f1bf5-f4a5-43ca-808e-da1f6e2f6e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_us-gaap_InterestRateSwapMember_af1f1bf5-f4a5-43ca-808e-da1f6e2f6e52" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended" id="i716e21d3d37a427eb49145509644fb2a_DerivativeinstrumentsFairValueofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_507725c2-a530-464c-8981-f0bae7a243a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_507725c2-a530-464c-8981-f0bae7a243a5" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_800fb38e-0a19-4f74-8d38-26f40fb7fdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_800fb38e-0a19-4f74-8d38-26f40fb7fdec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ee4634b9-9d72-4a0c-aab6-a4cbe9de3828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_800fb38e-0a19-4f74-8d38-26f40fb7fdec" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ee4634b9-9d72-4a0c-aab6-a4cbe9de3828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_8274a909-64d6-444f-971e-8395f3aec672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_8274a909-64d6-444f-971e-8395f3aec672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a773f6f4-12c3-4229-b7e8-a9d7325f89a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_8274a909-64d6-444f-971e-8395f3aec672" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a773f6f4-12c3-4229-b7e8-a9d7325f89a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_507725c2-a530-464c-8981-f0bae7a243a5" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_30a04b9b-be5b-4916-aa59-243b1af3357e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:to="loc_us-gaap_HedgingDesignationDomain_30a04b9b-be5b-4916-aa59-243b1af3357e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:to="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5dba2127-449b-4d02-8dc6-d74901e1a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5dba2127-449b-4d02-8dc6-d74901e1a481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_eb57eb0c-c781-4396-bef6-dfd160c0e39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:to="loc_us-gaap_NondesignatedMember_eb57eb0c-c781-4396-bef6-dfd160c0e39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9bf33905-2770-4114-9371-78a5cb699254_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9bf33905-2770-4114-9371-78a5cb699254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_90165edd-50cc-4203-8c83-e73288859700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:to="loc_us-gaap_ForeignExchangeContractMember_90165edd-50cc-4203-8c83-e73288859700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_52e6cf80-269e-4a4a-934b-e5264966e6e0" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_52e6cf80-269e-4a4a-934b-e5264966e6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b7b67c04-64d4-448d-9f9e-1b4fcf944d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:to="loc_us-gaap_InterestRateSwapMember_b7b67c04-64d4-448d-9f9e-1b4fcf944d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e6d1f6d5-8d33-4021-9026-3dce3708b852_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e6d1f6d5-8d33-4021-9026-3dce3708b852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_0166a078-c013-4c72-a961-c9165e5061dc" xlink:href="amgn-20201231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_0166a078-c013-4c72-a961-c9165e5061dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_7da7f5dc-e33a-48f5-a829-46e8d258ffe4" xlink:href="amgn-20201231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_7da7f5dc-e33a-48f5-a829-46e8d258ffe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_29c7e983-5c86-4c58-b569-44e353f6046c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_29c7e983-5c86-4c58-b569-44e353f6046c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e2d28088-56db-4237-9654-4286c48a9f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e2d28088-56db-4237-9654-4286c48a9f3c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Contingenciesandcommitments"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="extended" id="i936138c335b64eb5809c564515dcec0a_Contingenciesandcommitments"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="extended" id="i17b597ff97d743759c7d19e313c86b62_ContingenciesandcommitmentsTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" xlink:type="extended" id="i7a553599cff242bda6c57ac479f5c9c5_ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_886751de-873e-4d16-ba77-a431d14db92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_886751de-873e-4d16-ba77-a431d14db92b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfAssertedPatents_bb3a4e6e-b7e1-407a-95d6-c1e955c27d60" xlink:href="amgn-20201231.xsd#amgn_NumberOfAssertedPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:to="loc_amgn_NumberOfAssertedPatents_bb3a4e6e-b7e1-407a-95d6-c1e955c27d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:to="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4eb7ec8a-61f4-4092-bb39-96b984f3294c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4eb7ec8a-61f4-4092-bb39-96b984f3294c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_cdc9cdc9-70c8-4a55-b37c-b50a15b8dbb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_cdc9cdc9-70c8-4a55-b37c-b50a15b8dbb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_eab05206-5298-4fd5-8036-019f6094c116" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_cdc9cdc9-70c8-4a55-b37c-b50a15b8dbb7" xlink:to="loc_srt_SubsidiariesMember_eab05206-5298-4fd5-8036-019f6094c116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:to="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_59a1ef7b-7546-43e6-a19f-9a4743d9904a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:to="loc_srt_LitigationCaseTypeDomain_59a1ef7b-7546-43e6-a19f-9a4743d9904a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d45ffc38-706e-4f87-9de5-5d2653ee916c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:to="loc_srt_LitigationCaseTypeDomain_d45ffc38-706e-4f87-9de5-5d2653ee916c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KYPROLIScarfilzomibPatentLitigationMember_628177a9-f9f0-4ec9-b2dc-14c7bc07bdcc" xlink:href="amgn-20201231.xsd#amgn_KYPROLIScarfilzomibPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d45ffc38-706e-4f87-9de5-5d2653ee916c" xlink:to="loc_amgn_KYPROLIScarfilzomibPatentLitigationMember_628177a9-f9f0-4ec9-b2dc-14c7bc07bdcc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended" id="i6bf43a590ca74ffd9c9e59c4ad43267e_ContingenciesandcommitmentsSandozPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_07f5896e-f619-4bc0-ba7b-1fe2e1b12d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_ecb945b9-279a-4b3e-8b52-9439518f6c5d" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_07f5896e-f619-4bc0-ba7b-1fe2e1b12d25" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_ecb945b9-279a-4b3e-8b52-9439518f6c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_07f5896e-f619-4bc0-ba7b-1fe2e1b12d25" xlink:to="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:to="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6f362153-32cb-4b40-8f74-ac359c295b62_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:to="loc_srt_LitigationCaseTypeDomain_6f362153-32cb-4b40-8f74-ac359c295b62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ecfb8132-3f41-4a05-a13e-016ecfdfd2e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:to="loc_srt_LitigationCaseTypeDomain_ecfb8132-3f41-4a05-a13e-016ecfdfd2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember_8d88b9dd-1a48-49dd-a6bf-db68357dc45e" xlink:href="amgn-20201231.xsd#amgn_SandozIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ecfb8132-3f41-4a05-a13e-016ecfdfd2e7" xlink:to="loc_amgn_SandozIncMember_8d88b9dd-1a48-49dd-a6bf-db68357dc45e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" xlink:type="extended" id="i609a00ef2f3543fabd41b57d6cb96d9b_ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_05c423d7-4b66-4838-af97-bc9ccc95cb35" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_05c423d7-4b66-4838-af97-bc9ccc95cb35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfLawsuitsConsolidated_ac46a36e-1865-42dc-9b9a-95490903350c" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfLawsuitsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:to="loc_amgn_GainContingencyNumberOfLawsuitsConsolidated_ac46a36e-1865-42dc-9b9a-95490903350c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:to="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:to="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5611bb38-8667-482f-87a2-2f89907f6b9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:to="loc_srt_LitigationCaseTypeDomain_5611bb38-8667-482f-87a2-2f89907f6b9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bfeee6bb-0460-496e-82af-7622a89cedff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:to="loc_srt_LitigationCaseTypeDomain_bfeee6bb-0460-496e-82af-7622a89cedff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmnealPharmaceuticalsLLCMember_d58b281d-f4cd-4af9-a3b8-9fa9feee48b7" xlink:href="amgn-20201231.xsd#amgn_AmnealPharmaceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bfeee6bb-0460-496e-82af-7622a89cedff" xlink:to="loc_amgn_AmnealPharmaceuticalsLLCMember_d58b281d-f4cd-4af9-a3b8-9fa9feee48b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsImmunexandSandozLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="extended" id="ieda5c2af0aed4a4fb70e6b9a8480fa60_ContingenciesandcommitmentsImmunexandSandozLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofAffiliates_d2cdcc32-53f4-4acd-bc75-700f5bb6931e" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:to="loc_amgn_GainContingencyNumberofAffiliates_d2cdcc32-53f4-4acd-bc75-700f5bb6931e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7c57e8e9-5363-4b22-aae2-412167e59c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7c57e8e9-5363-4b22-aae2-412167e59c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:to="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:to="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d3e2f93-03db-4ee5-a8aa-59a5701022dc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:to="loc_srt_LitigationCaseTypeDomain_2d3e2f93-03db-4ee5-a8aa-59a5701022dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:to="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSandozMember_be37ea8b-1f64-4b59-87a3-7bde6c2bce2f" xlink:href="amgn-20201231.xsd#amgn_ImmunexAndSandozMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:to="loc_amgn_ImmunexAndSandozMember_be37ea8b-1f64-4b59-87a3-7bde6c2bce2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSamsungBioepisCoMember_c0e9d24a-ec9c-4527-b95a-8329a18812f7" xlink:href="amgn-20201231.xsd#amgn_ImmunexAndSamsungBioepisCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:to="loc_amgn_ImmunexAndSamsungBioepisCoMember_c0e9d24a-ec9c-4527-b95a-8329a18812f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended" id="i09a2789d75394e45950870219fbbf6d9_ContingenciesandcommitmentsRepathaPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1f54155f-184b-4e42-994c-186920fd59a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1f54155f-184b-4e42-994c-186920fd59a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial_972ef52c-49fd-4a6e-b3ee-82d5c9b816b6" xlink:href="amgn-20201231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_amgn_LitigationSettlementLengthofTrial_972ef52c-49fd-4a6e-b3ee-82d5c9b816b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges_bb0edd5d-6ee6-4e07-afa8-71867a416a2f" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_amgn_GainContingencyNumberOfChallenges_bb0edd5d-6ee6-4e07-afa8-71867a416a2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:to="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cdcbee85-04ba-4520-b40d-102a6c3b6daf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:to="loc_srt_LitigationCaseTypeDomain_cdcbee85-04ba-4520-b40d-102a6c3b6daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aac7fc0d-31a3-45ff-8d37-8b4c22e87138" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:to="loc_srt_LitigationCaseTypeDomain_aac7fc0d-31a3-45ff-8d37-8b4c22e87138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_c0bd8407-afb3-4457-abf7-24d8a9704d17" xlink:href="amgn-20201231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aac7fc0d-31a3-45ff-8d37-8b4c22e87138" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_c0bd8407-afb3-4457-abf7-24d8a9704d17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended" id="ia3138473a1e3484b8116cd88ecff811a_ContingenciesandcommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9ca05a76-caf7-4378-a54e-89191dc4a338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9ca05a76-caf7-4378-a54e-89191dc4a338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfAgreementsBreached_9cf93d3f-44e7-4f82-9ebd-17336250d38e" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfAgreementsBreached"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_amgn_GainContingencyNumberOfAgreementsBreached_9cf93d3f-44e7-4f82-9ebd-17336250d38e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cea26143-3c74-4eb3-a89f-c258402deee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cea26143-3c74-4eb3-a89f-c258402deee7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_28046b53-c825-4e51-8e57-0f47697644a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_28046b53-c825-4e51-8e57-0f47697644a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled_eb8c15a2-54d1-45d9-8e5f-78a454bdf922" xlink:href="amgn-20201231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_amgn_LossContingencyNumberOfLawsuitsFiled_eb8c15a2-54d1-45d9-8e5f-78a454bdf922" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_09c4e1f4-414d-4284-b0d4-0317244db29e" xlink:href="amgn-20201231.xsd#amgn_LossContingencyNumberOfComplaintsStayedByTheCourt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_09c4e1f4-414d-4284-b0d4-0317244db29e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:to="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_54cbf776-b158-44d9-95c0-bdc732dabb75_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:to="loc_srt_LitigationCaseTypeDomain_54cbf776-b158-44d9-95c0-bdc732dabb75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:to="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisBreachOfContractActionMember_f08a5215-d78b-4ec3-ab3c-14f28f298001" xlink:href="amgn-20201231.xsd#amgn_NovartisBreachOfContractActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:to="loc_amgn_NovartisBreachOfContractActionMember_f08a5215-d78b-4ec3-ab3c-14f28f298001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_1c181a89-df83-4e9f-b038-262b06b92d0f" xlink:href="amgn-20201231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_1c181a89-df83-4e9f-b038-262b06b92d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_23ed992f-6119-4044-bb75-07f5a85579ec" xlink:href="amgn-20201231.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:to="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_23ed992f-6119-4044-bb75-07f5a85579ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended" id="i7c3ae1caaa5a4c2a94a87efd8ebc10da_ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Quarterlyfinancialdataunaudited" xlink:type="simple" xlink:href="amgn-20201231.xsd#Quarterlyfinancialdataunaudited"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Quarterlyfinancialdataunaudited" xlink:type="extended" id="id02df6e8209d4b458261b15648e29ebc_Quarterlyfinancialdataunaudited"/>
  <link:roleRef roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#QuarterlyfinancialdataunauditedTables"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables" xlink:type="extended" id="i00f0241d705343b080dc262b3ad0a2dd_QuarterlyfinancialdataunauditedTables"/>
  <link:roleRef roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#QuarterlyfinancialdataunauditedDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails" xlink:type="extended" id="icf879be21b634780902949a8c0397863_QuarterlyfinancialdataunauditedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfFourthQuarterEventsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3f36866f-069b-4356-9080-6e98af45eec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3f36866f-069b-4356-9080-6e98af45eec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e1205270-74c7-46ce-9909-7244872f65ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_GrossProfit_e1205270-74c7-46ce-9909-7244872f65ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e01bc67-bc56-4475-bf22-7c9ee1a68aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_NetIncomeLoss_0e01bc67-bc56-4475-bf22-7c9ee1a68aa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_16511a96-7d21-4dae-a9a4-c028fec62549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:to="loc_us-gaap_EarningsPerShareBasic_16511a96-7d21-4dae-a9a4-c028fec62549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7fdcea0c-e532-4867-8d8b-a1251590ce53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7fdcea0c-e532-4867-8d8b-a1251590ce53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:to="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e359c029-363e-474e-af5c-27abf06bb92a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:to="loc_srt_ProductsAndServicesDomain_e359c029-363e-474e-af5c-27abf06bb92a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06155f25-c3dc-484a-a238-956fa731e39a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:to="loc_srt_ProductsAndServicesDomain_06155f25-c3dc-484a-a238-956fa731e39a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8aa9ad11-f889-461d-8f18-9e161e5c4f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06155f25-c3dc-484a-a238-956fa731e39a" xlink:to="loc_us-gaap_ProductMember_8aa9ad11-f889-461d-8f18-9e161e5c4f5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amgn-20201231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended" id="ie5da74540eaf4068bb00d0669062e8bb_SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended" id="ib75ca75bb23c484a86d51e1065fcbd76_SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>amgn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e0ca318f-3884-42e6-a64c-8779d462d73a,g:75807743-642d-4c80-8d38-07220e8d8bcd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a397f45a-8183-488d-8157-c0561e5135b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a31c425d-5c82-48f4-9489-dd2806dbf573_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1ff657ff-b073-444a-a434-e0b7405e46b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ce6388f7-acc7-468c-b45c-dd6453b647e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, unexercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_86700bc4-3cea-4a38-bc04-5aa963d0c383_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3da5c169-7d4c-43a3-91c3-c82ce66e5438_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed, deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_509e6a3c-1ac9-48fb-ab12-33983cce8c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_eaa4026e-fd24-41f7-9269-72892e5bba27_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_31498d8c-8a70-4223-ad55-6756420ae5ba_terseLabel_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:href="amgn-20201231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_fe7a78e8-c135-4e01-a5d6-2315e5ed2240_terseLabel_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_label_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_documentation_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:to="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_5918774c-8888-4fb1-a112-7baa0757dae8_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_54478626-b0c3-4a30-bef2-be369125e686_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_698c1412-1434-47f5-9f1a-390dfb1a5b0d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b480e7de-3c87-4c0a-ad22-da1ee47fe5a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_13d275fa-f787-4d3b-834d-4a7bad6d290f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dcf293f3-e866-4223-9ddf-61f15c731a7f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_640a3fdf-8962-44d3-be57-c27d5da6f0bc_terseLabel_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value with discontinued hedging relationships</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_label_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_documentation_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:href="amgn-20201231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:to="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_eb32fb3c-bcd4-4f25-8a6c-ee191a7efa20_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to deferred credit</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_label_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:to="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_59893469-bd3d-4d53-b4c6-206b59861be5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_927848d6-a69e-4831-8c3f-6785cd2fe69e_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment by geographic information</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d3ddb4ea-4123-442e-93c0-56d274a51daf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_f22b3059-1f47-4868-a165-6b02673b5556_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_c3bb285a-be05-41d0-951a-9904fbee144e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4e00f4f1-a1d8-45c3-a396-3e2ca4ea88a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e9af0e9b-bb09-40ac-bd44-0217e6a080ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_65a3dd32-48bb-4384-8fb3-9000721a79a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f112ea4c-f694-474a-9186-09dabefb83b6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_a68067de-19f3-412b-bccb-a0037d28e2f5_totalLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Gross</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:to="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_b38cc641-948d-4123-a6a5-fed14980f1ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b167a3a4-cf81-4dc7-a08e-1cd79a4857be_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_b6abf457-73c9-4afb-bcd2-edadd5bc3cad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0a4c4a1c-3c40-4b54-a8c7-38f5dd81a473_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fef07b80-f42f-4b0b-a0df-d4882b7384d9_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_dd7615e4-c2c2-48cb-8b61-e7bc88f3557f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_072f26e7-0bb6-4579-9bf3-f52d03e544e7_terseLabel_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% notes due 2042 (5.65% 2042 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_label_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_documentation_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:href="amgn-20201231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:to="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_7d5458d3-91f3-4eea-935a-8d608a8df674_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Onyx Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_b542c546-7224-4e9e-9fe4-9f1889a28476_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f54f81f6-64ce-44ef-8893-4c375656e67c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_fd69c013-71f9-4069-a669-6da4f3a0cea0_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2025</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Five Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c9856f04-7870-4387-8d18-8295d0220c8e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_3d082eed-3581-4243-b09a-0500619ee006_verboseLabel_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% notes due 2041 (4.95% 2041 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:href="amgn-20201231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:to="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ac9a8c27-02cb-43fe-8c60-fdeb46fe0ea4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_2caf58f6-569d-4109-956e-61860a5aa4c1_terseLabel_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% notes due 2020 (3.45% 2020 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:to="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e84cb33-3252-4657-b442-b5e6f049f69d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_73c63131-e680-47cb-b892-fea3d1c77278_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of amortization</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_0f3d6f90-be87-42ba-b07e-e5290a731abc_terseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_8a02862a-a9a3-41a5-9a7a-8f54c23ede2a_verboseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% 2026 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_label_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:to="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_4bc3d2f6-6e2c-46b8-bc1f-c2a52193a4db_terseLabel_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.90% notes due 2038 (6.90% 2038 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_label_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_documentation_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:href="amgn-20201231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:to="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_21a0ba9a-de94-42fa-94f7-df70aca1f928_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef6e764d-00cf-4ca9-8510-667b9cf4f6d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8e54eff0-f568-49c1-99b8-5e56c63d5739_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_04aa0d92-3bfd-4f73-9cd9-e4731d1c4c6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on settlement of preexisting relationship</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aec21e1e-dfd3-4250-891a-dfb8ff9316eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_XgevaMember_bb6306fb-0c44-43eb-9da4-41b512d7df37_terseLabel_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_label_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_documentation_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember" xlink:href="amgn-20201231.xsd#amgn_XgevaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_XgevaMember" xlink:to="lab_amgn_XgevaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NovartisBreachOfContractActionMember_fd6af3da-57f5-417f-b79f-1e61df282519_terseLabel_en-US" xlink:label="lab_amgn_NovartisBreachOfContractActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Breach Of Contract Action</link:label>
    <link:label id="lab_amgn_NovartisBreachOfContractActionMember_label_en-US" xlink:label="lab_amgn_NovartisBreachOfContractActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Breach Of Contract Action [Member]</link:label>
    <link:label id="lab_amgn_NovartisBreachOfContractActionMember_documentation_en-US" xlink:label="lab_amgn_NovartisBreachOfContractActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Breach Of Contract Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisBreachOfContractActionMember" xlink:href="amgn-20201231.xsd#amgn_NovartisBreachOfContractActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NovartisBreachOfContractActionMember" xlink:to="lab_amgn_NovartisBreachOfContractActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8b3a3132-6759-40b6-b969-91c9290be7ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d977fcef-5e44-4cda-a4eb-5b666ccb5a81_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to nonvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionMember_20c0902a-c06a-4c6d-91d1-aff42cffa353_verboseLabel_en-US" xlink:label="lab_us-gaap_OptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency option contracts [Member]</link:label>
    <link:label id="lab_us-gaap_OptionMember_label_en-US" xlink:label="lab_us-gaap_OptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Held [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionMember" xlink:to="lab_us-gaap_OptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_698cbb6e-002d-46f6-9e10-79f505388da3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_71fa8ce5-005e-448e-8881-3fe88c8da0ee_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_ef148786-262a-496b-8e99-1f51e575aa74_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards available to reduce income taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_38320afb-42ca-4f49-84e0-df67eba3d79b_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_682c223f-7dde-44f4-accf-52fb19ee513e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d7c5c884-e20f-44ad-a453-2940312d630c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NuevolutionMember_91f516d3-1785-44e4-a3f2-8a893b848d78_terseLabel_en-US" xlink:label="lab_amgn_NuevolutionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuevolution</link:label>
    <link:label id="lab_amgn_NuevolutionMember_label_en-US" xlink:label="lab_amgn_NuevolutionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuevolution [Member]</link:label>
    <link:label id="lab_amgn_NuevolutionMember_documentation_en-US" xlink:label="lab_amgn_NuevolutionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuevolution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember" xlink:href="amgn-20201231.xsd#amgn_NuevolutionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NuevolutionMember" xlink:to="lab_amgn_NuevolutionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_302702d4-d033-40b7-98fa-f84f072e71c8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1e182d07-ea74-4526-85d9-4a99b8ae363d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of reclassification adjustments and taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e098a90a-3b7a-4cc9-bc46-48f257417cbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_6aa2c05f-eda1-414c-85ed-21dc5356010e_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestment_5a070ea1-9d11-46ef-9305-e82ee9f8aa9d_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestment_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestment" xlink:to="lab_us-gaap_AlternativeInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_13b53455-ba3b-4c31-aa6b-f405cea4cf58_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_40c85414-30f8-4ff4-840d-66fd20c0e0e9_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:to="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_839f265b-1173-4664-8aaf-5e7e628c414d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_bde70f8c-1707-4557-94e7-21e384b451e7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_f3396bcd-20fd-45db-ac7b-9217a62b6608_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_cadd1881-75e6-4442-afd4-d96a66d2cb55_terseLabel_en-US" xlink:label="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Novartis AG [Member]</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_label_en-US" xlink:label="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_documentation_en-US" xlink:label="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Novartis Pharma AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementwithNovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:to="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2424afce-7dbd-48b2-b1a1-93c45fd6e089_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e3e02939-d273-4ff5-8dbe-c04e3cd64054_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of stock options from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_66236819-1ce9-44be-9dd4-6a8b5b47e46f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SandozIncMember_1947a052-dcd2-4b6e-bf54-eda7e8e14ed4_terseLabel_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:label id="lab_amgn_SandozIncMember_label_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc. [Member]</link:label>
    <link:label id="lab_amgn_SandozIncMember_documentation_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember" xlink:href="amgn-20201231.xsd#amgn_SandozIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SandozIncMember" xlink:to="lab_amgn_SandozIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6e480a4a-3fcd-46e2-b6c2-6b2aa5196842_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_6d7e36ad-ced0-4017-80db-d3576830b4ee_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_a97c807c-07b9-4dfb-b163-93c102bfac6e_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.70% notes due 2022 (2.70% 2022 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_26adfca1-826e-44de-9507-69a6644015a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_6650f235-b08d-48c5-a62d-79fb25a23ac2_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20201231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_959cd9fc-b54e-47e6-a8e5-67211c080480_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_85307824-1c58-4128-920f-f95fea8543bc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_6415990f-c82d-43c4-bff9-81b5d644f810_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ImmunexAndSandozMember_d18d4dda-1823-4c83-a6d4-c1fba6bfc7ab_terseLabel_en-US" xlink:label="lab_amgn_ImmunexAndSandozMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex/Sandoz</link:label>
    <link:label id="lab_amgn_ImmunexAndSandozMember_label_en-US" xlink:label="lab_amgn_ImmunexAndSandozMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex And Sandoz [Member]</link:label>
    <link:label id="lab_amgn_ImmunexAndSandozMember_documentation_en-US" xlink:label="lab_amgn_ImmunexAndSandozMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex And Sandoz</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSandozMember" xlink:href="amgn-20201231.xsd#amgn_ImmunexAndSandozMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ImmunexAndSandozMember" xlink:to="lab_amgn_ImmunexAndSandozMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_a8ebf16e-ac59-4c74-b632-4fe9e4665753_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits, Puerto Rico Excise Tax</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_bd162617-029b-42f7-b271-ae2f9b0d8ec7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts of hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepathaevolocumabMember_c06d5875-2071-40de-a13c-bfe1fcb4ac40_terseLabel_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_label_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_documentation_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember" xlink:href="amgn-20201231.xsd#amgn_RepathaevolocumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepathaevolocumabMember" xlink:to="lab_amgn_RepathaevolocumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3f703cf4-9d3b-4a35-856c-ddcadd650d5c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a4962431-56e5-412e-a3ce-4e16ac58bc2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ImmunexAndSamsungBioepisCoMember_b7cc2c34-b985-45ea-b67f-13b4ba8f57d6_terseLabel_en-US" xlink:label="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex/Samsung Bioepis Co.</link:label>
    <link:label id="lab_amgn_ImmunexAndSamsungBioepisCoMember_label_en-US" xlink:label="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex And Samsung Bioepis Co. [Member]</link:label>
    <link:label id="lab_amgn_ImmunexAndSamsungBioepisCoMember_documentation_en-US" xlink:label="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex And Samsung Bioepis Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSamsungBioepisCoMember" xlink:href="amgn-20201231.xsd#amgn_ImmunexAndSamsungBioepisCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ImmunexAndSamsungBioepisCoMember" xlink:to="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_89c1378d-8ca0-4d35-93fd-dc7ce7d60879_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7dfbd65f-f63a-4ce1-9a05-4981c6c32082_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesGrossCurrent_91d982b4-de04-4339-8ee2-6941c5220446_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate partner receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesGrossCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Gross, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:to="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ApprovedMarkets_1ac4e477-74a1-47fb-80fc-88f4569ff9be_terseLabel_en-US" xlink:label="lab_amgn_ApprovedMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved markets</link:label>
    <link:label id="lab_amgn_ApprovedMarkets_label_en-US" xlink:label="lab_amgn_ApprovedMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved Markets</link:label>
    <link:label id="lab_amgn_ApprovedMarkets_documentation_en-US" xlink:label="lab_amgn_ApprovedMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedMarkets" xlink:href="amgn-20201231.xsd#amgn_ApprovedMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ApprovedMarkets" xlink:to="lab_amgn_ApprovedMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1d1db8d5-74f3-46cf-b225-097fa458c1e3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3faa345b-bc9a-489f-a72a-65e0f48dcfc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_94ecaf42-100e-48a9-a86a-174f5cd232a6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in the calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e484e755-0e73-49d3-949b-7d6e7e6db285_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (Denominator):</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e4d48b5-ab1d-4a5c-b143-f8c48dba94b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f76c2de9-11a1-4964-8a57-56aa8b760abc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties associated with unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e2a54d65-8bc0-4bc8-bc2f-5a5032575016_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_e68dee9f-8c7d-47a8-a398-8a0599479c4a_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Stock Exchange</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_bdbaa2c8-4942-4d86-82d2-f24147583a05_verboseLabel_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_label_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sales Investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_documentation_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sales investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember" xlink:href="amgn-20201231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSalesInvestmentsMember" xlink:to="lab_amgn_AvailableForSalesInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d128e32a-a874-4758-aff6-1169d6cbb102_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_96ebfb17-ab35-451f-80a6-021b474f761a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_73fa21ca-620b-49e4-8139-a84781a1a474_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_23bd97f4-22d5-45d8-b11c-4f665c37518d_verboseLabel_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_label_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:href="amgn-20201231.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:to="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_8b560755-2440-47d0-821a-8cd505d98148_terseLabel_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward interest rate contract [Member]</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_a4dca47b-b9fd-4736-8f39-a957be49220c_verboseLabel_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward interest rate contracts [Member]</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_label_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Interest Rate Contract [Member]</link:label>
    <link:label id="lab_amgn_ForwardInterestRateContractMember_documentation_en-US" xlink:label="lab_amgn_ForwardInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForwardInterestRateContractMember" xlink:to="lab_amgn_ForwardInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointNineZeroNotesDue2019Member_3fe16efc-91d4-4c4a-9291-f2db4344cb76_terseLabel_en-US" xlink:label="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2019 (1.90% 2019 Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroNotesDue2019Member_label_en-US" xlink:label="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroNotesDue2019Member" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointNineZeroNotesDue2019Member" xlink:to="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_b55e8f2f-2c2b-4e11-8d92-45232f910d02_terseLabel_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2021 (3.875% 2021 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:to="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0d420d30-447c-45d4-abe2-4b81dfc1e629_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapOneMember_c0926276-4192-43f1-924b-c641b9d02828_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapOneMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapOneMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapOneMember" xlink:to="lab_amgn_InterestRateSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_ae1d2a24-aacd-46c0-a4d0-d0962d7fa877_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5225231c-ad83-4484-9b41-be8351beb28f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_932bbcde-62f7-45b9-922c-a4929b29c582_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6db499e3-547d-4854-8798-ef63e6c0eaac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_88a5e78b-f88f-4c94-96f0-4c2b48b6d6f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c549ca22-34c9-4044-bfb8-58e98e4627b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_c51d538a-c868-4938-84ec-8334967802ae_terseLabel_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions as a percentage of gross product sales (less than)</link:label>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_label_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Provisions As Percentage Of Product Sales</link:label>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_documentation_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Provisions As Percentage Of Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:href="amgn-20201231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:to="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52520e10-8ca2-4da2-afa1-cadd9820a172_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_04a2ffe8-8c5a-4300-b555-619ae12bbadf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_f9e5cbff-083d-4049-a896-d130c4fd91c0_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9de73235-0bed-49ee-91b6-02634a7a2dbd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_2dd0d857-9966-4c35-b6d1-e701831bd0de_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2023</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_91dbaf8c-271b-40b1-a953-52b9644f7f1b_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_a69a41fe-b644-49d8-8692-5095ee9557c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_2725946b-4800-4fd1-ae16-7cbcdbce36c0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_cbd25661-b5f8-4b7a-9d87-e247c2dc2cd2_terseLabel_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2045 (4.40% 2045 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_label_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_documentation_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:href="amgn-20201231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:to="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_af34f0d7-8476-478a-9a3d-7606b38c887b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary information, components of lease costs, cash and noncash information on leases and other lease information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_1b3c201b-5a60-4b87-93c9-00073d268f05_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ee46d872-b247-4038-bb9d-5df365ce40fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6e39b08e-2d88-450f-b87c-8b16c3f1a52f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_68dd92f5-e37a-4657-8718-c70a0227bc0e_totalLabel_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_label_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal Net</link:label>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_documentation_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:href="amgn-20201231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:to="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_e8ad0533-324a-4076-8bd3-3f68b188095a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_703f4303-1586-49f5-b099-f9bf745e998d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e53b5b0f-1375-4ba2-9300-87806e14deac_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c0baa184-34dc-43c3-a2d2-678413a3a5c1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_ce4b8d6b-391b-4141-990e-1db57723cbec_terseLabel_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment [Member]</link:label>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember" xlink:href="amgn-20201231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ManufacturingEquipmentMember" xlink:to="lab_amgn_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_3ef16370-e22c-4f24-a9b2-f4abde4180e4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_0329e20c-bfef-4846-b43f-c45fa518cb41_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make-whole payments recognized in interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_90e153c9-1e90-4e11-b2c9-63cc2a93f15c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b07d31e-5734-4a40-a7d6-65077b76b307_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16d17006-f310-4314-a67e-da1a67eeebde_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55212eae-9114-4b79-b56f-239c7b0ab1fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_3fc93414-3055-4cbf-9e43-91f15789d385_totalLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:to="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64cebbad-c648-444b-b226-fabfac484b1c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f160d066-8008-4a08-99c4-01acc08b87fe_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_e5b0f75c-2279-4ca8-a146-6b6ed9e5e36a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_8d0685b4-a842-4c37-8a6d-2f2cb6f6ed00_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, by Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_275d4a6c-cb49-42a1-a76d-a34800aeff80_totalLabel_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation Expense Net of Tax</link:label>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_documentation_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, net of tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax" xlink:href="amgn-20201231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax" xlink:to="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_a2e23631-d59d-41fe-ad7d-e982ac6c41cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses capitalized for tax</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_15e8a012-3fae-4695-8938-2f0f3a71eec6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ebf17c43-9c57-4b7e-b459-221f96c10695_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired, cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_721521c0-ab03-4fb8-834a-f25b696ed7ab_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_1e6488e1-0369-47af-b368-77d6b46bd302_terseLabel_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% notes due 2039 (6.40% 2039 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_label_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_documentation_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:href="amgn-20201231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:to="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f28dcb8c-bb4d-480f-abfd-b33a745a7a3d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f6f68e15-cb30-4291-a362-681727d57cf5_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b8ca7e87-d35e-4491-aabe-0a850a4de3c1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), vested or expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberOfAgreementsBreached_a826b80a-c440-4275-845d-7498a2e2206a_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements breached</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfAgreementsBreached_label_en-US" xlink:label="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Agreements Breached</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfAgreementsBreached_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Agreements Breached</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfAgreementsBreached" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfAgreementsBreached"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberOfAgreementsBreached" xlink:to="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b3c1bfad-9dc1-4fa7-b6e2-dae48018f6c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ad2f86fa-1b65-4265-a5e7-2f2791256c83_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_a0ccbcbc-1c27-4a8d-9ba8-ea46d5948555_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties related to unrecognized tax benefits recognized in income tax provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c8e95688-0c7c-484d-9904-84acec6454c1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_e8c42be8-8375-4e36-a86d-7052a2cf90d9_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.77% notes due 2053 (2.77% 2053 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:to="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_b6d95235-b375-40c8-aec3-175c188cd06e_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets locations</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cf70649f-5a5f-4f0c-b1a0-5b2883c4e11e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_54690164-6165-42f8-ace3-8f2b7cb2dd53_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RecoveryOfDirectCostsReceivable_e034fe77-09f3-4505-8319-5908c2d745cf_terseLabel_en-US" xlink:label="lab_amgn_RecoveryOfDirectCostsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Of Direct Costs, Receivable</link:label>
    <link:label id="lab_amgn_RecoveryOfDirectCostsReceivable_label_en-US" xlink:label="lab_amgn_RecoveryOfDirectCostsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Of Direct Costs, Receivable</link:label>
    <link:label id="lab_amgn_RecoveryOfDirectCostsReceivable_documentation_en-US" xlink:label="lab_amgn_RecoveryOfDirectCostsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Of Direct Costs, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RecoveryOfDirectCostsReceivable" xlink:href="amgn-20201231.xsd#amgn_RecoveryOfDirectCostsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RecoveryOfDirectCostsReceivable" xlink:to="lab_amgn_RecoveryOfDirectCostsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2d368b9b-a503-4ca6-838b-8f0c2f13bc07_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross-currency swap contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_66936a29-7818-49c7-b0e3-b04cee5bfee3_terseLabel_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation</link:label>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_label_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember" xlink:href="amgn-20201231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SanofiRegeneronPatentLitigationMember" xlink:to="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfAssertedPatents_c032736b-5077-45d6-b864-a0438dc74d0d_terseLabel_en-US" xlink:label="lab_amgn_NumberOfAssertedPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of asserted patents</link:label>
    <link:label id="lab_amgn_NumberOfAssertedPatents_label_en-US" xlink:label="lab_amgn_NumberOfAssertedPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asserted Patents</link:label>
    <link:label id="lab_amgn_NumberOfAssertedPatents_documentation_en-US" xlink:label="lab_amgn_NumberOfAssertedPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asserted Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfAssertedPatents" xlink:href="amgn-20201231.xsd#amgn_NumberOfAssertedPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfAssertedPatents" xlink:to="lab_amgn_NumberOfAssertedPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_f4b914f2-e69b-4ddf-88d4-75f1dba86f00_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate carrying value of the company's equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_59ef42af-513e-40ec-a7c7-3cb332783768_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f901b455-9784-434b-9cee-b13116d6a82f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_575cd902-fc06-434a-ab01-1ff116ba8177_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_901ca539-b5aa-4578-9ea4-44693102085c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_55c0ea43-ccea-44fc-96be-ce3b2a0bc091_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_713be916-02ae-460e-9db6-1e994587cce3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_8e67c56a-4684-4c46-935d-108c691d97ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FloatingRateNotesDue2019Member_a3bb446e-1edc-4858-80ec-5214377f9a7c_terseLabel_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2019Member_label_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2019Member" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FloatingRateNotesDue2019Member" xlink:to="lab_amgn_FloatingRateNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_57f58df6-a654-4095-9019-b4644b2afe73_terseLabel_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL and credit carryforwards</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_label_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_documentation_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:href="amgn-20201231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:to="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6c7ad979-4b69-4464-9097-88e25223fcca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db3fbee1-34a3-459c-86a8-da691cfcae44_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17fcbc0f-1048-43c9-abb0-55cef2ff4faf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_44e8a2f9-ddde-4024-9cde-9608d9378179_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_99d7bc3d-cea0-4d0b-955c-584780839707_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_28f8f816-860c-401b-bbd1-83c3a1ffde11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_23f5678d-4e9e-47d8-8656-fe77b3f81ce8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PR_ccb47911-bb6e-41b1-b8b7-0c69d6f08dfe_verboseLabel_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puerto Rico [Member]</link:label>
    <link:label id="lab_country_PR_label_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PUERTO RICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PR" xlink:to="lab_country_PR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_58f1cec8-1ba9-492e-ad89-80362e6955d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f17a68e2-8ce5-407f-8794-34988a44da44_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_faf0903a-558b-44ae-a8f6-f3f4a3041df7_terseLabel_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_label_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_documentation_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeNotionalAmountAmountTerminated" xlink:to="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_75c5e832-93fc-46fa-825a-679d769a0144_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_67e68a2a-6da6-4695-8c38-d3a19f91101b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_648bc3f6-ccee-484d-852a-068ac3b4b43f_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, number of annual installments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22daf918-fb91-4a04-9618-824a068cdfb8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5a33f8ed-1b21-4fa3-8be8-1b5eb096d128_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4cc911ea-775f-4fbc-94d8-f71d2f922161_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6ffc54c-8d01-44eb-a5fc-4a6b9b036040_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6e6a5ebe-d885-4e7c-85a8-ada490165da9_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale interest-bearing security investments by contractual maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_28179e3e-a517-46c7-b8f9-55b82f256f15_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of complaints stayed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Complaints Stayed By The Court</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Complaints Stayed By The Court</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:href="amgn-20201231.xsd#amgn_LossContingencyNumberOfComplaintsStayedByTheCourt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:to="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_b936955a-a1a4-4660-a606-4351768cc1f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of vesting of restricted stock units and stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_204195c7-57ae-42a7-a8f2-0ce3987c8771_terseLabel_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions used and the resulting weighted average grant date fair value of performance units</link:label>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_label_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]</link:label>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:to="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_2422fe22-a53f-4038-8569-87b480c3f1f3_terseLabel_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of trial</link:label>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_label_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Length of Trial</link:label>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_documentation_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Length of Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial" xlink:href="amgn-20201231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LitigationSettlementLengthofTrial" xlink:to="lab_amgn_LitigationSettlementLengthofTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_d44c1414-e22a-460e-8754-30eb2061915a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of interest rate and cross currency swaps</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5a7520c9-2a9f-4505-bd5f-92970b97b5df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized bond discounts, premiums and issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4bf1db66-7b3f-4629-844c-ae414179cb29_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfFourthQuarterEventsLineItems_26cbc305-605f-4ec0-908d-40ac6c682548_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfFourthQuarterEventsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Fourth Quarter Events [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectOfFourthQuarterEventsLineItems_label_en-US" xlink:label="lab_us-gaap_EffectOfFourthQuarterEventsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Fourth Quarter Events [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfFourthQuarterEventsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfFourthQuarterEventsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems" xlink:to="lab_us-gaap_EffectOfFourthQuarterEventsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_505d3686-580a-42c4-934d-23c1c6b5cd9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_49bc16ed-76db-4a5a-97b3-985ea1c9c744_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_8fb9cf3d-9cb7-4b74-b180-bf24d89e6959_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_315a2394-2b29-4235-b0b5-75846d51ef50_terseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and accrued liabilities</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:href="amgn-20201231.xsd#amgn_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_73a92c60-0cef-41b3-8a14-fad950a41902_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_69572651-d50d-4ac8-9279-01463a2790a4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5ee036fd-7dec-4e71-aef0-be543ba516df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9861e335-84aa-444d-a83a-e761373519e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_96114b36-86f1-4f67-89b8-0585a0c47dc0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e53b1e15-e09f-458d-9b19-1236e87728ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b79605fb-e580-49c1-a354-5305ed3a8662_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's share of profits (losses) of related party</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_2705e5b9-8f2f-430e-b4d2-dc27d903a328_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, At-Then Current Interest Rates [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, At-Then Current Interest Rates [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, At-Then Current Interest Rates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAtThenCurrentInterestRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:to="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5121c700-5818-4368-8f6f-b3bef405f98e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b4f68bd0-afc7-41f2-98d2-20d4ab4c7304_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Ratedifferenceinaninterestrateswaprelationship_75f6c87f-497e-4a48-9bc5-2b6f597d706c_terseLabel_en-US" xlink:label="lab_amgn_Ratedifferenceinaninterestrateswaprelationship" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate difference in an interest rate swap relationship</link:label>
    <link:label id="lab_amgn_Ratedifferenceinaninterestrateswaprelationship_label_en-US" xlink:label="lab_amgn_Ratedifferenceinaninterestrateswaprelationship" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate difference in an interest rate swap relationship</link:label>
    <link:label id="lab_amgn_Ratedifferenceinaninterestrateswaprelationship_documentation_en-US" xlink:label="lab_amgn_Ratedifferenceinaninterestrateswaprelationship" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate difference in an interest rate swap relationship</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Ratedifferenceinaninterestrateswaprelationship" xlink:href="amgn-20201231.xsd#amgn_Ratedifferenceinaninterestrateswaprelationship"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Ratedifferenceinaninterestrateswaprelationship" xlink:to="lab_amgn_Ratedifferenceinaninterestrateswaprelationship" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d5494bea-7cab-48aa-ada7-ce1d75521007_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1f55876b-5f39-486c-bb4d-b08d87f99381_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_2790be22-5aa6-4c3f-b18a-4adc1d7781ac_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2492314d-312f-4f50-b323-24901b46421b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_ae5322bc-6f70-4459-9521-0dc20a466b1e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired_f8ac2161-4310-4fa3-90c7-02fc85dc4d21_terseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Inventory acquired</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Inventory acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:to="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d4bf56c5-f732-4362-8132-8616c510fd18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Withholding taxes arising from shares withheld for share-based payments</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_fe739d34-e61e-4688-9938-6ba999c9832e_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_636d8218-aa9e-4952-9455-0e13c5af1ab6_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_9bc29179-6ab9-40ce-9e5e-18822bb3f09c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition from acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_1e9b8ee9-a423-4744-b367-3e80d7246108_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly financial data (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RestOfWorldMember_063c5af6-34d0-4c69-913f-4efddf5ab414_terseLabel_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_amgn_RestOfWorldMember_label_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_amgn_RestOfWorldMember_documentation_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember" xlink:href="amgn-20201231.xsd#amgn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RestOfWorldMember" xlink:to="lab_amgn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapThreeMember_37236a85-4c5d-4ab4-9b39-e31b1be52789_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Three [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapThreeMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Three [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapThreeMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapThreeMember" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapThreeMember" xlink:to="lab_amgn_InterestRateSwapThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ae9676da-9e63-4b19-8225-c401f85f2913_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful&#160;life&#160;(in&#160;years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_a615dd41-336e-4828-b7a7-2560707306ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_248fc963-aa25-4066-a332-a75e088923cd_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of challenges</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_label_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Challenges</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Challenges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberOfChallenges" xlink:to="lab_amgn_GainContingencyNumberOfChallenges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_0dbeb554-5e85-4334-b4aa-29396f72b298_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_de2ae824-87c2-421e-8ce1-6ca9d3bc6a91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AranespMember_b6ad23d3-6148-4d3e-a5e4-a1675775d0f7_terseLabel_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp&#174; (darbepoetin alfa) [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_label_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_documentation_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember" xlink:href="amgn-20201231.xsd#amgn_AranespMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AranespMember" xlink:to="lab_amgn_AranespMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberofCountriesProductsisMarketedandSold_83591502-6407-41d9-a8f1-8bc8bdbbf582_terseLabel_en-US" xlink:label="lab_amgn_NumberofCountriesProductsisMarketedandSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries product is marketed and sold</link:label>
    <link:label id="lab_amgn_NumberofCountriesProductsisMarketedandSold_label_en-US" xlink:label="lab_amgn_NumberofCountriesProductsisMarketedandSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries Products is Marketed and Sold</link:label>
    <link:label id="lab_amgn_NumberofCountriesProductsisMarketedandSold_documentation_en-US" xlink:label="lab_amgn_NumberofCountriesProductsisMarketedandSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries Product is Marketed and Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofCountriesProductsisMarketedandSold" xlink:href="amgn-20201231.xsd#amgn_NumberofCountriesProductsisMarketedandSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberofCountriesProductsisMarketedandSold" xlink:to="lab_amgn_NumberofCountriesProductsisMarketedandSold" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherNotesDue2097Member_6902eae9-1bf1-4cbb-8c77-e072eac87128_terseLabel_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes due 2097 [Member]</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_label_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_documentation_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member" xlink:href="amgn-20201231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherNotesDue2097Member" xlink:to="lab_amgn_OtherNotesDue2097Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22ef8a12-f073-4701-b403-d83ee9954fc0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d6f7889-95f9-477b-bb2c-7553819416f2_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18d93a48-a557-41f8-91f2-153651ba74f6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_9ab43cf9-3601-4a2b-a571-75c66cc58b69_verboseLabel_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of identifiable intangible assets</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_c65b06c3-ad5c-48e0-aef4-7ced52bde36d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2735534b-e514-4b2b-9a64-4635526d8903_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_8704cec2-8324-48d6-a6a1-9fc6d03de164_terseLabel_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Axis]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_label_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Axis]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_documentation_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssetsByDescriptionAxis" xlink:to="lab_amgn_AssetsByDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_f92184a7-28a3-4f5e-9c9f-28caad36eb60_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_253e5be4-1f10-40a2-9e96-8aed8b7bcdb4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7d24e02d-395b-43fb-80ae-8d87828da6ab_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_7aa25950-90d8-4aef-9aa0-8c4352dc17c3_terseLabel_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.375% notes due 2037 (6.375% 2037 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_label_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_documentation_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:href="amgn-20201231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:to="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_c255fbaf-9075-4c66-a563-144330f8da50_terseLabel_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future rental commitments for abandoned leases</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_label_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_documentation_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:href="amgn-20201231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:to="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CorporateDebtSecuritiesFinancialMember_ea072604-c70d-4808-ad47-537c2e03166a_verboseLabel_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities - Financial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesFinancialMember_label_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Financial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesFinancialMember_documentation_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities financial Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CorporateDebtSecuritiesFinancialMember" xlink:to="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e5a04623-ce25-4da2-a53a-e7806c6045c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_59d51208-af9c-4458-a89a-102c48f5ded3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_62f28003-9f23-4357-a9f6-c38a70cbd5cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_af0cfc6e-7321-4777-bd39-618f2cafee69_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Gain Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_91b0e061-54b4-4826-9091-f97a668ac62a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of derivatives included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_66320b81-fbb3-4e88-900f-cb5b40263961_terseLabel_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares added back for tax withholding on full value awards</link:label>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_label_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Added Back for Tax Withholding on Full Value Awards</link:label>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_documentation_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Added Back for Tax Withholding on Full Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:href="amgn-20201231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:to="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_30052b98-7ed1-49c4-ae6c-8b169bc5d298_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_8cf05eba-cdd4-4020-8ca9-286eb61420f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b52e16d6-d821-48c5-ba02-1af3fe276fca_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_f89dd84b-a466-474d-a70c-28b0cd8f8016_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_c030f7bc-b2fe-4f0d-93b4-fb1918f831ac_netLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap agreements [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_b0decec5-72c2-48ba-a719-24aa35a739fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to carrying value of intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3e65e17d-0550-4421-9722-29e4df8d2f68_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_2f6eb7b3-04d2-4ce0-a2f8-7fdc8264a2fb_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds [Member]</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4975b4c1-354a-4f82-bda3-216700cbd283_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b86b78be-c524-4876-a57a-6445ddc9b738_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_e83730c7-632f-4cb7-8872-0dcca84ee184_terseLabel_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.663% notes due 2051 (4.663% 2051 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_label_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_documentation_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:href="amgn-20201231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:to="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2cb56fde-5fff-4610-89da-c1b6b1ebdef2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a71f6ac4-cd95-4a8a-a5e3-238eae592cc4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ae8154a9-9edb-4f18-8d38-68cf03f8b07e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_40daec4a-353e-4e46-9eb9-820db93a41cb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_b295f90c-de52-4e3c-8f2d-98b0e646cc3b_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost recoveries</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherProductsMember_538137e9-8efe-41f5-bca6-43df942d48c9_terseLabel_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_label_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_documentation_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember" xlink:href="amgn-20201231.xsd#amgn_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherProductsMember" xlink:to="lab_amgn_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_26e21f32-920b-457d-9b87-1870b226fb27_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% 2022 euro Notes [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:href="amgn-20201231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:to="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A1.250SeniorNotesDue2022Member_ccd04f18-8f56-4b60-aeb4-2f92591cf624_terseLabel_en-US" xlink:label="lab_amgn_A1.250SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.250% Senior Notes Due 2022</link:label>
    <link:label id="lab_amgn_A1.250SeniorNotesDue2022Member_label_en-US" xlink:label="lab_amgn_A1.250SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.250% Senior Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_A1.250SeniorNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_A1.250SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.250% Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A1.250SeniorNotesDue2022Member" xlink:href="amgn-20201231.xsd#amgn_A1.250SeniorNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A1.250SeniorNotesDue2022Member" xlink:to="lab_amgn_A1.250SeniorNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProliaMember_1dae54f2-499d-4d35-a43c-fddf5baf13d2_terseLabel_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_label_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_documentation_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember" xlink:href="amgn-20201231.xsd#amgn_ProliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProliaMember" xlink:to="lab_amgn_ProliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e17fcee4-80e2-41df-a0e0-38f52a211caf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average exercise&#160;price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_7b7b54a1-40bf-4158-a111-066774d9037b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fb21ff1f-6727-4c49-9135-2e399a6a7cb4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_55183945-92b2-45c3-bf54-1e637af5317d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_52f0c446-df2d-461b-bb02-3d3d7a46667d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a2b13e2-4e06-4039-85c4-3bb23f8d570a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_b844b4cf-9d20-46ca-9132-b287003c9779_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_18bc3864-73c5-4259-a8f0-7230a83e14c1_terseLabel_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.41% 2023 Swiss franc Bonds [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:to="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_653bb300-c7fb-4679-b289-3e4d0dcd133f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_51b19200-7159-43e6-a2d2-f5c6e7d55969_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_309579b8-689c-4197-b1f2-1149f3c48292_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_e631ea8e-1a87-4bf2-bf0a-b601a175bd15_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% notes due 2020 (4.50% 2020 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Zero Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Zero Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:to="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_180d254f-c198-4855-afc4-e486e4d3cbb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_33b8a03e-f3c2-4983-9417-20c2befbcab3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_e6dcd55d-28fe-45a6-8320-9e00a97b49fc_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9fdbd552-3e73-4dbe-bc60-16d3267d1f3c_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_c10ffbf8-909e-45b7-8ed0-0c6e2fd4a39d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2f90579f-54e0-49c4-8943-cbaec05b95b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_3df7d25b-82b2-4ed6-bf4e-1ad8c2b7801e_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80b328e1-7334-44de-9d74-638b89985c57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dd480cb8-9d26-42bf-a7fc-eb3f981a72cc_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_db653d47-282a-4fb8-9ed1-5afe0e7e0343_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffe64d87-99e6-40d4-9969-ef7ca65dab54_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1b30d9e7-06d8-40df-bdcf-c7832c6a80c6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d597e5eb-36cc-4bf6-81f0-96447d8da119_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_103e61ef-6318-4ccf-9340-abe265968cc9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_24063270-a2f4-4596-8bb4-7e4a22d41257_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c7bbccfc-50eb-40f5-9faf-88b1bd10d187_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_8f5fd468-82a6-4c64-be9b-6def3f1ea68b_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e3fb2cc7-d696-460b-bb79-493ae43a1cdc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f4f8e40c-01cf-43eb-bb1a-183a5dffea47_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_1bdfbf91-d5a4-4849-a63a-a58d9eba84b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4e344a1d-2a76-4bf7-8360-a52f93ef0ea4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_4cadb3f5-d329-49d0-ba6e-2d6211858894_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_121cd65e-ef57-42f1-892b-b67750415ca6_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6b4953b-6372-4970-904e-1c620cc2b1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_b0e278e7-ae00-417a-85f2-b7031cfae925_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b73738db-3a86-4e7a-8eac-cb2de64028b5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_947334f7-7920-4ef0-85c4-48db7a06f024_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7fad992b-f900-46d5-8ea7-3e713908ef6e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for diluted EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_0792903a-541c-49ff-abf2-cb073b169fae_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_71c088af-f5c4-4869-98e5-c516fae032a3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3aa19872-3090-4c3d-92aa-715a439a0a8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c62422db-f03d-4e99-8aa4-2f52688bc6ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1bc5a009-7a94-4165-949d-728445e2f954_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_61cafdaf-9f76-435d-affa-799051de9772_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_99fffce8-aa1a-4ae8-810f-29ded5d2a648_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_79699e11-4922-49fd-b6cf-b180ee272e7a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f5000b3d-fec9-4e6a-8b21-806233ad170d_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_3d940aa9-f4be-4d61-bcfd-592b8ccfac56_terseLabel_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional term extension options</link:label>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_label_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number Of Renewal Options</link:label>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:href="amgn-20201231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:to="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_bd57f203-6ca0-4118-9da1-6e9b916ba65b_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d6bd9c5d-c4a1-4e5d-b308-399de7e62a46_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_37909af4-8179-4ae0-89ce-3e5d5e993eea_terseLabel_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns reserve</link:label>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_label_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Return Reserve Current</link:label>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_documentation_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent" xlink:href="amgn-20201231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedSalesReturnReserveCurrent" xlink:to="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_294de64c-2bcc-4af4-849f-8ee4d0d3cdc9_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_7d928d1b-7e47-4fe1-8393-c45d1ecc1a32_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae60f420-1eeb-46b6-9042-1b69d844a096_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_89ede25d-6b9a-4731-946b-02b697443d2a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6096f65b-2f03-436e-839f-d67ff220b508_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_40993660-6ed3-4fa1-af2f-f92e41bda8d9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_8d9d7aba-4fa0-488a-a5a5-8973233985a1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1b4850c2-430c-4a2c-b730-83acad913420_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_782a9a52-9170-43b7-b53d-889d5486401c_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6946cd69-dcc0-4592-b692-09d05b4cd268_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cb9d5e2d-151b-4195-bedc-d494e88ad6c5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_f180d67c-76c9-490f-8316-653bf6d773d4_terseLabel_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional period for extension of commitment term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_label_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Extension of Commitment Term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_documentation_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Extension of Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:href="amgn-20201231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:to="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_9f669864-e653-4fed-a6e0-fec8d5c9870d_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_label_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Combined Worldwide Gross Revenues From Major Customers</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_documentation_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:href="amgn-20201231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:to="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_08f5087e-652d-4822-a7c1-c3545a364f01_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2024</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_04c12dd1-ea1d-4c70-964d-859c668296ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_90f70f47-213b-423e-b45b-3709f8b03fa0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_f875a49e-ee4a-4f69-802d-7cd30626288e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging adjustments on discontinued hedging relationships</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_92012d7f-6cf4-4bc0-8368-dc0c437ad5d6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_14c8dbe2-d074-41c0-a645-867b7d9439c4_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ca816d9-6601-4fc3-ab18-4ba009250f3b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4770e409-30e2-4507-9d9d-51e4c475e069_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a262b3aa-36ef-4129-adf8-78f954f327d6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_f86f255d-6fd3-4617-bfaa-1d9cda17e614_terseLabel_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future lease payment</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_label_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_documentation_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:href="amgn-20201231.xsd#amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:to="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_cfb08ffd-89a5-443f-9102-8d9b4df9c29d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b24fa8b8-aa68-4ea7-8e46-70ff10a25938_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_53079599-a23f-408b-ac30-69b8671049bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_cef5908a-6ce8-4ed7-ad50-7dc914b831f6_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_fde1be33-2634-44bb-b57d-d1c324ced6c2_totalLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining U.S. repatriation tax commitments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:to="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_fa0e06d6-80fe-4cfb-a60a-90da8b0f0ded_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c621a563-0b11-47ed-8c93-401307de9873_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7554f700-fa32-4242-87a6-cf3582fe8f99_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a3608fde-c2a3-4c53-9d82-39b4f77bb9e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2ff96c76-f9b6-4445-81b3-d0f6cc3ac4b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b8496352-fd73-4c66-9bb4-f82bbf71697a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred to acquire K-A</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_82abe1d9-1705-4aaf-8893-23198de5c2be_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2b2283f3-ea16-4cdc-b153-67e8d0f703c2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f93bf3b8-7221-4707-9c70-5a52b9180079_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f2a5126c-6776-4f9e-8324-cc5da0123bd5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_d8b509ea-7ee9-4436-9f94-69333835c673_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest rate derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_12078985-045b-4f26-a4c6-cf91422b1548_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_eb5a37ab-98fa-41c1-a408-cfb95c1a7863_negatedTerseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Deferred Tax Liabilities</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" xlink:to="lab_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_cc4e4b73-28ab-46e7-8bdc-03be6f8102a0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_d6612886-b40c-4d25-ac6c-e1ffb2344390_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The NASDAQ Global Select Market</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_88ddd4a6-2d2f-4fa6-a10d-7d129f5442f2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0536ca95-1336-4b95-9add-7af66fe978b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_6f687d8e-2fb7-47a3-b583-a2e4a5fea673_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_740266fd-792e-492f-b711-f6c566dff8d0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_427ab4d4-8e67-48d5-a0e1-7c2f30e65a30_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_d4342078-2249-40ae-8a8f-223217e99aba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_13e0516e-3237-4ca9-847e-0a6be6198904_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86fe14cb-fc83-465f-b270-1c8d1ef58b6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RDTechnologyrightsMember_4a12677a-63ca-41b7-bb22-c265f1bc7e16_terseLabel_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_label_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_documentation_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember" xlink:href="amgn-20201231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RDTechnologyrightsMember" xlink:to="lab_amgn_RDTechnologyrightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e8fa2a0f-2ccb-46bb-9e35-1576b717eb1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e261b66f-a9b1-49cf-9476-8d3da5d06ed0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and Arrangements with multiple performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_b4c65a31-f375-4d7f-8793-99e0b5844db8_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a3ce6507-f1d2-4b3e-9e00-6b17db40cf22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_35308362-e9ed-4265-936c-8ca3ad63199c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6aa72474-154d-441d-918b-fbb05a5cee9d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fda3164f-6e0a-4296-90a1-2fb034a91bf0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c2eebbee-ab3b-4661-b02d-6d6f69951ecc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_da715dd6-590b-45d6-b5ce-300562a3985b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards available to reduce income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2cb887bd-5935-49f5-898c-014bb5019319_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a5501bf0-8dbc-46a7-8267-1c397b37258c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_433541bf-e438-4d8e-9db2-aba3fcbb1944_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_c7bab22d-e3c0-4935-9e82-ad22cdb666d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_9acdd949-0a57-4861-b9cd-2a5bae5f5d86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d62e9f4f-40bc-4954-9de4-382468cefce5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_a0f59bbe-01de-4bd8-ab06-24c2adb16e5f_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% notes due 2026 (2.60% 2026 notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_7f8fd92b-2e1e-41ef-afc8-86aa54bc4950_verboseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.600% notes due 2026 (2.60% 2026 notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_label_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:to="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b57181a3-9450-4066-80b8-0a685d8e1aaa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c05fe64a-1c94-45c5-85eb-35a1f000cd7b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_b79dc13e-d222-4641-a0cb-5b1468451b09_terseLabel_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:href="amgn-20201231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_22b1c551-a448-4929-b907-59a9dc694185_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2021</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtezlaMember_e835a939-2252-4773-a666-aca8f87d2dbe_terseLabel_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla</link:label>
    <link:label id="lab_amgn_OtezlaMember_4861d242-5e65-4397-b301-91ca2e8dfead_verboseLabel_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_label_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_documentation_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtezlaMember" xlink:to="lab_amgn_OtezlaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5698da79-d8c3-4351-93b2-65a3630fdaa5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_851bb25c-0462-4a48-800b-9c1085f0c97d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_a96b7b89-22a4-4c72-b16a-6554fe38423a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_ccdcfa52-83d8-41f1-b0ea-c16ecf486b54_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a893e5ba-f45f-4f47-b00e-3d8b4db185fd_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_91b4643d-b9e0-4a60-ac13-fd0e94305919_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) gains on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5cbfaeb3-94ee-482d-9735-7f925a787819_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage_1c43e033-55e2-4336-af9b-cdc06794fbee_terseLabel_en-US" xlink:label="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, royalty percentage</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage_label_en-US" xlink:label="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Royalty Income Percentage</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage_documentation_en-US" xlink:label="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Royalty Income Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementRoyaltyIncomePercentage" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementRoyaltyIncomePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CollaborativeArrangementRoyaltyIncomePercentage" xlink:to="lab_amgn_CollaborativeArrangementRoyaltyIncomePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_69cc64f7-d346-426c-9884-f493e0f8faab_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_98803847-e3cb-48c9-b2d9-a327177a5f4f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense attributed to Retirement and Savings Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_a49c475e-2d3f-48a7-81e5-4cd50ebf6bca_terseLabel_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% 2026 euro Notes [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_label_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:to="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d6c9d29b-a720-4e81-9182-b23883133195_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_4a46fc29-e22a-44f8-9d90-c2fb83ef404e_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments_9d19c684-f1dc-43e2-8278-aaa4be837bec_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments</link:label>
    <link:label id="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments_label_en-US" xlink:label="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of U.S. Repatriation Tax Commitments</link:label>
    <link:label id="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments_documentation_en-US" xlink:label="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfU.S.RepatriationTaxCommitments" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfU.S.RepatriationTaxCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfU.S.RepatriationTaxCommitments" xlink:to="lab_amgn_ScheduleOfU.S.RepatriationTaxCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d30ae595-c8d8-4e55-bddf-3a9e97225748_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d53c20b4-49f2-41c9-8c60-28d57fe3e4d0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Member]</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3123fb14-059c-4319-bce4-48d9794d8172_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_13b1d7ae-3ee8-4691-bd55-693524a579fd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_56f08843-75ef-449e-a54c-ad2e9f44d925_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7a71313a-66ac-48b9-b791-e50c368e9cbf_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0d3076d1-ac96-444c-bac0-703c018953c1_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_fd1df5ef-0f50-401a-b728-72bc9fda858b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f91575a6-52ab-42f3-bb7a-d6f3ba194f1a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f369521f-f38f-43a6-8ff0-18eae993bdef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_513b513b-77ac-4aa5-9bf6-4be1c354f801_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Hedged Items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_29bb1ecf-ec5e-4248-a874-055cf2a68363_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_0806a31e-3125-4c34-bb1f-8374713b1178_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ea09badb-6e0f-4d66-a33f-91c458fec23c_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_23896925-9a18-451e-8c6f-93231c9e5751_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars [Member]</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_188573e4-3b5b-46b9-8568-3cbcdc46e7bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e8ccec3d-cb23-46df-9b82-87e71d466a9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8beef185-05be-4523-8b20-54628f645373_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9ffadcdd-6d76-47db-851d-02d6d5a5cbbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs with no valuation allowance and no expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_6162d193-03b7-4153-a3b6-d6041db3af34_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dc7b193c-765f-45bf-b941-82ff1bc873ff_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ec2cafc0-2ef4-4db9-a00c-72c034fb28fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4b72071b-7285-4f34-bfc3-7885933d0e8c_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_633d0418-5782-4729-bdca-3723557af816_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_bd719c71-b725-4350-a276-4a2c235da4bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_51aec826-84b1-42bd-aa10-703c5d0a11c5_terseLabel_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after three years through five years</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_label_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_documentation_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:href="amgn-20201231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:to="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_76d9ed6c-809c-4117-a6f9-d283db52cc8a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_ba551bc8-76c1-426f-a4d6-6fb9396f62cb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_90a22689-3365-4af6-8b56-4e9a1edf4e05_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2dc96ec6-deb3-441a-9ccd-299858b6fa3b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_10e0241c-af8d-4258-9457-767bddca9664_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e7491a9d-89e8-48a7-874d-fd2206110117_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_403ee4c6-1c22-4572-9541-b123691eab80_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_385178ac-a7a1-4373-a9dd-096d447c9502_terseLabel_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payment</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_label_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone Payment</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_documentation_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:href="amgn-20201231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:to="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ba22a78a-fd2d-4c66-949f-177e3065114f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_c07a2428-9f25-4a3f-87db-dc24581c7908_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_688d55ee-58bc-47f0-b392-d085f8700882_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberofAffiliates_b60f22d0-f2cb-4a56-83eb-c41bd10fa534_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberofAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, number of affiliates</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofAffiliates_label_en-US" xlink:label="lab_amgn_GainContingencyNumberofAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Affiliates</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofAffiliates_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberofAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofAffiliates" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberofAffiliates" xlink:to="lab_amgn_GainContingencyNumberofAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_4c49de14-46c3-4693-939e-9f9e12a0ceb5_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total acquisition date fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5225c0bf-f6f4-4095-a43e-c8d104201509_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b645e13b-d272-4581-8ba6-3dab44a837dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values and the fixed contractual coupon rates of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8ea7ea10-2c5a-41b4-9d43-d279ec1b4214_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization charges associated with property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit_82b7bb56-901e-4ad6-834f-7c1e891380e4_negatedTerseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred credit</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Deferred Credit</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Deferred Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:to="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9fb1edd6-2607-4a26-8b9e-2552271bbf77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_b0aa2480-4d07-4a2c-b293-e56b9bf58bdc_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% notes due 2040 (3.15% 2040 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:to="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f919458b-bcf6-4fef-81c0-66316dff346f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_59dd899f-3a14-4643-a59b-a1bfa084cdb3_terseLabel_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% notes due 2021 (1.85% 2021 Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_label_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_documentation_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:href="amgn-20201231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:to="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_b4461278-4909-49c2-9336-b81310f754c6_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2022</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5702048b-f9b6-4628-a8b5-2f1ce58365fb_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_98251293-5b43-420f-aad5-29ae9d7ca50b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member_bac8be69-3b4b-48c9-85ac-7f9f93a55491_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2019 (2.20% 2019 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:to="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_945afd30-627a-4777-8379-c500a6dfd7e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0958b650-4442-40d9-9bf3-4bdc6192a9d9_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_894d75f9-d723-4e2b-a5eb-d5bb1ae8fac2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fb09b408-4046-4fd2-bdb3-3bdb81aeb42f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_5aa8508e-5076-4125-8fe7-61e0ac2a87d9_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b8c16b57-fbf0-4833-a967-f69e9dd6d6f2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_a5895e93-e7f1-452a-8f79-751b05a9c7d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f7c2c0d4-2036-42b6-a0b4-38d5498b2358_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_65db8884-a4bc-4a66-92ee-dee4bee11061_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c52fe60-7d92-40fe-9854-4c71ae72e5b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_61f1c324-104f-465f-ae9d-487e6b67fa7f_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product sales to major customer (as defined) as a percentage of total gross revenues</link:label>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_label_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Gross Revenues</link:label>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_documentation_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product sales to major customer (as defined) as a percentage of total gross revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues" xlink:href="amgn-20201231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfGrossRevenues" xlink:to="lab_amgn_PercentageOfGrossRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_45b4f5c4-2660-4a29-a62f-f1498073bc8d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeBasisSpreadOnVariableRate_6ece675b-3297-4482-a014-03159afeac10_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DerivativeBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:to="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ddac8dd8-a2d3-4a3c-859d-785824708e76_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ea0bbfad-02b6-4a5e-801c-833f3b9bd8ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_0ee9d313-d989-4b21-b80e-9f0318d933c9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed566b44-188a-4d40-8d31-098865a74182_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3e3ce15e-1e29-4ebe-800d-92240934c273_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6f7a7268-07ba-4b7a-826a-a2d7ad378616_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_da0fa93b-36a9-47de-8769-51a6bc3e911a_terseLabel_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through three years</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_label_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_documentation_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:href="amgn-20201231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:to="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_769d1d54-d07f-49f9-8c66-d27c39e94a76_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6f3edda2-01e0-4eba-85d4-bfa3d6230be1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f956c7a9-b7b1-4886-832a-04fbd485ad3e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember_41a45be8-4d24-4e9c-9a14-f14825637029_terseLabel_en-US" xlink:label="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KYPROLIS (carfilzomib) Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember_label_en-US" xlink:label="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KYPROLIS (carfilzomib) Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KYPROLIS (carfilzomib) Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KYPROLIScarfilzomibPatentLitigationMember" xlink:href="amgn-20201231.xsd#amgn_KYPROLIScarfilzomibPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KYPROLIScarfilzomibPatentLitigationMember" xlink:to="lab_amgn_KYPROLIScarfilzomibPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_210d988a-a335-41c0-81ce-813244abedb8_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other losses</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:href="amgn-20201231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_17c007ff-182e-4b75-b376-f195521974b3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in acquiree prior to acquisition (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_ad89f866-47de-48cc-a2d6-269b469c4109_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LaboratoryEquipment_e30700c0-269d-4542-a98a-ca4c6be917f4_terseLabel_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_amgn_LaboratoryEquipment_label_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_amgn_LaboratoryEquipment_documentation_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of laboratory equipment, gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LaboratoryEquipment" xlink:to="lab_amgn_LaboratoryEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f4f353bb-9dfb-459e-a5fe-38dbde9e6bdc_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b184f2fe-01af-4f74-80c5-6482d7c46adc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_53d8df32-6551-4e50-a115-061f77d6e391_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3a7237b7-8bc8-47ef-8460-0aa3c0c62378_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9554365f-4b16-4fab-852b-2804303bed32_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_ca16a751-a439-4498-b9f8-b91e543bf2d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_a0662609-f6bc-4a01-be2c-02568472409e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_aec60327-2e23-4e80-8fdf-a6be340ff1e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_7653d490-a27c-483b-88a7-7dd11b624296_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers (as defined) accounting for more than 10% of total revenue</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_label_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Customers Accounting for More Than Ten Percent of Revenue</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_documentation_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers (as defined) accounting for more than 10% of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:to="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_51b5d049-62f4-437f-b588-f40603b5cf13_verboseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair values of contingent consideration obligations</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_efeadbac-1c0c-4d41-8287-74916e01b6ba_netLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligation</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_label_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:to="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_17cc41ed-aafc-45f6-a01f-62fc0da4ff51_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_750fce4c-3604-4105-ba1d-303b40b80a6d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PerformanceUnitsMember_cdf8dd5e-ec36-4dcb-a4cc-895c09f12fb4_verboseLabel_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units [Member]</link:label>
    <link:label id="lab_amgn_PerformanceUnitsMember_label_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_amgn_PerformanceUnitsMember_documentation_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PerformanceUnitsMember" xlink:to="lab_amgn_PerformanceUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_756c057e-06ec-4c38-b6b7-7db029d93e53_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c9c3455-48bd-4075-85b2-a085acaf6cee_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a079c48e-0f47-4c1e-8651-f77cb33ce91b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_8d7241f0-2d2a-4896-8044-5c87e780ec30_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential-mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_78243d29-5568-4db2-bc57-2be1e707dd1d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_7b679b61-8ca3-4274-a0da-49f7f8247605_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe</link:label>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_label_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Amount Due from Customers Located Outside Domestic Location</link:label>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_documentation_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:href="amgn-20201231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:to="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainOnDerivative_d6a91de3-9795-4254-a746-a91ea3c58b67_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainOnDerivative_label_en-US" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9d14cc6e-4f80-4bcc-b5fd-547c26eb6dea_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c2a5f261-0d05-4ce5-9488-71e167321352_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_52316ca6-2ad4-454d-b5ca-0eae40b58623_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5d03e4ce-e2ce-427b-95cf-43caffd2f952_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3fedc5b9-e789-4673-a9af-905c786941e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3ebfb75c-0fa3-462c-8430-8626e7ff0525_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5db9d10e-828a-4712-9509-5f455032395a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cd3033cc-2a39-4a38-a82c-9b17cb7cbdb4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e40573bb-6fbc-4055-9d2f-af803fe18091_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a6022fc9-b156-4e7f-851c-89206175c2e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_69f1b93a-b309-4ff5-b88b-30a38fe22b18_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_40fccecc-774c-4ed5-ab25-5dabe4a58a1f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_40363387-f9c9-41ab-a0ff-100dd2fa515f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_adce6656-df5e-465d-857b-74e6f80925b9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_909d3a5b-8f99-4d8c-85a1-914825a0c224_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_72b24858-5e02-4019-b3e8-0713c86f2a89_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_a45c5564-1c56-40db-ad6e-cb23cd04b38c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherRevenuesMember_ef8f5015-d288-4d74-8695-86a86edb7dc4_terseLabel_en-US" xlink:label="lab_amgn_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Member]</link:label>
    <link:label id="lab_amgn_OtherRevenuesMember_label_en-US" xlink:label="lab_amgn_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_amgn_OtherRevenuesMember_documentation_en-US" xlink:label="lab_amgn_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherRevenuesMember" xlink:href="amgn-20201231.xsd#amgn_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherRevenuesMember" xlink:to="lab_amgn_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bb0f4280-1326-4e50-b4c1-76e5cb5d5e79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_3cf08d71-741b-412c-a340-33cb50188439_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_05d093c7-4788-404d-bb96-307afb5b0992_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs [Member]</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerOneMember_295e4147-12cc-4ccd-a573-9c179032484b_terseLabel_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_amgn_CustomerOneMember_label_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_amgn_CustomerOneMember_documentation_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember" xlink:href="amgn-20201231.xsd#amgn_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerOneMember" xlink:to="lab_amgn_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_fcc0e290-bf37-47ac-9111-9bc9a652e14d_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_label_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Combined Net Trade Receivables from Major Customers</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_documentation_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:href="amgn-20201231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:to="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_da922858-82f3-4af1-9f9b-86f3cee2f741_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Fourth Quarter Events [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Fourth Quarter Events [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable" xlink:to="lab_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_9a2ed98f-5d8c-4ae0-a634-149fa231c02b_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers (as defined) accounting for more than 10% of gross trade receivables</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_label_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_documentation_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers (as defined) accounting for more than 10% of gross trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:to="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_adaee3b6-3a57-4a09-b317-b81c4651f95e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_75cce86b-64f8-46c1-b647-6580e874d6eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0811603e-01a7-4439-a81f-0c46268517f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f7f70162-b33d-4cfd-9e2d-c676adc6e19c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ad9f01d2-b767-4c80-ae04-1e524d0f9753_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_3a4a3c08-c163-4ac9-bf4d-bc0c16e114a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_724fe386-2380-4b90-9f5f-fb47b960a833_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_6cb71a7d-e437-49ce-bd78-4fb86952129b_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_46ffc9a5-3c90-4cc2-b6a3-26f8d22cb16a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_a21e80d8-a5f6-452e-9318-491e80b5c637_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares by which the pool of available shares will be reduced for other types of awards granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Shares to be Reduced For Other Types Of Awards Granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for other types of awards granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:to="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_4ab6c942-3b03-4d7f-9746-a5fc609e5858_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0700cfb2-a2c5-4faf-a59f-274b8c7ae8d5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_000ce392-b799-44f7-8204-3831238cc660_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bb733d51-bfb0-4f06-957e-dc7cfea17dcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_dafbd129-d9e5-46eb-a063-6e51f477b9f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_55e60dc5-7a56-4974-ab6a-0f47d13b9e13_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_90581cb5-7682-4011-820b-53e1ab191afb_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising cost</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_91c45add-01a3-45e6-87bd-9d6075d7056a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_357dca42-ff5f-48cc-b176-cdb8bc572527_terseLabel_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_label_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_documentation_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:to="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_765386ee-3263-4cc3-8971-56d14ca7a809_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c17ef535-ba0c-4f47-be53-689ad26a14a1_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_8b0a4f95-2d93-4b7e-b95f-60bec1935e17_terseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contract [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_ea4ec4c3-c69d-4720-b07f-1fcdf945a5df_verboseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_label_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Swap Contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_documentation_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency swap contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CrossCurrencySwapContractsMember" xlink:to="lab_amgn_CrossCurrencySwapContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_bb54a30e-6ad6-4ef0-b4d1-b2cce071113d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_43101ccd-f998-416b-9503-d54006bfbca3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_43854f4d-b9ed-48c9-80e0-ef97754c25c1_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits filed</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_label_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Lawsuits Filed</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Lawsuits Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberofLawsuitsFiled" xlink:to="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_1d83cc34-d4b6-498a-bb1c-f0db31c1a3e1_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_71a4a3ee-e554-4b2a-8688-8a3c4385c7e6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_18259db4-c7d4-446b-8ad3-f42b613f8aeb_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_69ba9a75-30c4-496f-be3d-619680a227d4_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected total future rental income to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a96499b8-614f-4a87-a0b5-0132904ec203_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of amounts of income and expense line items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_756ed3bb-c59c-4ba9-a90f-cb18c58003a8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_2ded6376-ad20-4a90-9e4f-0bcb7ec271b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_aa123ea7-f237-44f1-b772-9bc013335cec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit settlements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_acf335f9-8217-4bcf-9f2e-bed0696cf34e_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of notional amounts and interest rates for cross-currency swaps</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:to="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b91f249e-c073-4f5f-b6a2-f88afab908ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_f90fd81d-25a6-469b-8fcb-17fa95aa355e_verboseLabel_en-US" xlink:label="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_label_en-US" xlink:label="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Seven Five Percent Euro Notes Due 2018 [Member]</link:label>
    <link:label id="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_documentation_en-US" xlink:label="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Three Seven Five Percent Euro Notes Due 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" xlink:href="amgn-20201231.xsd#amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" xlink:to="lab_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_e41c7a04-e5fb-4eb4-8b93-3850a882bd00_terseLabel_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.30% notes due 2031 (2.30% 2031 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_label_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_documentation_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:href="amgn-20201231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:to="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8f2d1d71-ad3a-481a-a712-e6a0f8cbd27a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ede1c3ce-6fb2-4c1d-85df-3d277cbf1210_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_0b2f7946-9784-4b7b-93de-ac69d78c135f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bad3157e-ae1f-4f4a-9a3f-5312a804b69f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation for basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a02e210f-1fbc-40a9-8d8c-1cfdacf4916f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_e4d4a371-35bf-479a-9dbd-cdc60f34d109_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under syndicated, unsecured, revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_4eb74e54-da98-4c25-872d-f78b375e051e_verboseLabel_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity under our stock repurchase program</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_label_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_documentation_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:to="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e9b66148-4ee4-4fd8-968c-4043849a0dd3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a652b171-52f9-4496-86f8-508d5fa5ebd8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CorporateDebtSecuritiesIndustrialMember_210a64f9-6a7e-4004-9699-6337a8eec447_verboseLabel_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities - Industrial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesIndustrialMember_label_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Industrial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesIndustrialMember_documentation_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities industrial Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:to="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c9033873-31d3-4e86-a63a-b359d54f3bf1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d8dc9a84-e957-445a-9766-93f13821a5db_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash&#160;flow hedges [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_265bccdb-ce69-46a4-bcce-e867a82822ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_bf4b4734-af24-4129-9798-df113967b1af_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_08dc2912-27b5-402b-9b03-5bf4ad3e6904_terseLabel_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_label_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_documentation_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:href="amgn-20201231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:to="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_34f6ed64-ab4f-4d20-8820-f9fbddeefa30_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_13e4fc9e-b9cc-4f0e-ad43-4d6f2277b7b8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_e7dbbb45-a704-41f9-a66e-5c8f1cfeff16_terseLabel_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_label_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_documentation_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:href="amgn-20201231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:to="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3654fb18-517e-46f2-9b8c-4076cb35b7ea_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Transactioncostsassetacquisition_4ec3643c-4bce-4bfd-9296-aee7c1727c50_terseLabel_en-US" xlink:label="lab_amgn_Transactioncostsassetacquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_amgn_Transactioncostsassetacquisition_label_en-US" xlink:label="lab_amgn_Transactioncostsassetacquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs, asset acquisition</link:label>
    <link:label id="lab_amgn_Transactioncostsassetacquisition_documentation_en-US" xlink:label="lab_amgn_Transactioncostsassetacquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs, asset acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition" xlink:href="amgn-20201231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Transactioncostsassetacquisition" xlink:to="lab_amgn_Transactioncostsassetacquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b905f001-33b5-4063-bba5-02ad42a258c1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b7b44af-775f-4ae2-8610-3682654f7285_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fa6e3d78-3c3f-406f-8db3-4a94345ee4fe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0309fafe-75d2-4f58-bbd5-54ed87d648d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e2b22299-7f33-4b03-8806-44e4e26c3a58_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_1b215944-77f5-476a-b401-a3022e39cea5_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5ea88cee-96f4-4fe9-aa33-f8df0848fffe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1ceb5667-4af7-4a16-ae32-509651d62eb3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_5a938012-07f8-4c9e-a995-3acb6f3d3bfe_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for each stock option granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Shares To Be Reduced For Each Stock Option Granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for each stock option granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:to="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CorporateDebtSecuritiesOtherMember_3a054e50-6b0c-4bbf-8d76-a5f4f33bf4b0_verboseLabel_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities - Other [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesOtherMember_label_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Other [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesOtherMember_documentation_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CorporateDebtSecuritiesOtherMember" xlink:to="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_838b1971-c81a-450d-ae7b-f4c55d76f64e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_2aa5ca02-10a1-4722-95a0-7702140dc3e2_terseLabel_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions</link:label>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:href="amgn-20201231.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:to="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_0c1c1ac3-f8bc-4b20-8317-83574cc2367d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_bd07e30e-43a7-4ed8-b7b6-93755e99e325_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1c8c1d85-83a3-4519-80b1-cd6d6747c4c8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization charges associated with finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_3fae51a5-93c8-4426-8d29-98ab2ef1ab9e_terseLabel_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</link:label>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_label_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</link:label>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_documentation_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:href="amgn-20201231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:to="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_d8f61edd-9458-4c2f-bce3-ad381f6767e7_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_59c8ce8c-82c9-44ce-9d38-9d3a7ac46152_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_64f74f6d-2d74-43f7-9914-4eb6bef4e48e_terseLabel_en-US" xlink:label="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_label_en-US" xlink:label="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_documentation_en-US" xlink:label="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:to="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6bbe7bbb-835f-4f58-8e0b-22261f5d1520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_57928ce4-03b6-4ffa-b5bc-9fd566ef8726_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f3fdf6e6-1919-4b00-8822-fa1ebc2c80b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_3848ba49-4577-47fb-a3f6-7c3cb01a5a74_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member_1d9d0780-f379-45b5-b798-27e503ba5024_terseLabel_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2021 and 2030 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member_label_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2021 and 2030 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member_documentation_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2021 and 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2021And2030Member" xlink:href="amgn-20201231.xsd#amgn_OperatingLossesThatExpireBetween2021And2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OperatingLossesThatExpireBetween2021And2030Member" xlink:to="lab_amgn_OperatingLossesThatExpireBetween2021And2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_d88fb290-bbed-4bd7-9f14-a7dd3008cc66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_6cacb0d9-820a-4c57-8c44-4bb31a8f3c76_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectOperatingCosts_4d2cec5b-899e-42f5-b81f-c1e42baf13ec_terseLabel_en-US" xlink:label="lab_us-gaap_DirectOperatingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost paid</link:label>
    <link:label id="lab_us-gaap_DirectOperatingCosts_label_en-US" xlink:label="lab_us-gaap_DirectOperatingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Operating Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectOperatingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectOperatingCosts" xlink:to="lab_us-gaap_DirectOperatingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cdf0088b-fb77-4a26-8148-a41ce1db1d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_c50ad130-93fc-4dc2-a7f7-888b8fbfeff3_terseLabel_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.10% notes due 2021 (4.10% 2021 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:to="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_78bee51e-bb3b-452d-b200-b808a306d566_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fb31164d-e40e-483c-88b0-046ec77f950a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_963f4d7b-1d70-40f2-8554-2fecc37ec323_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to deferred tax liability</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_label_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:to="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d4421696-3d05-4031-a01a-c452f1ac3970_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3e0eb5de-8a1d-4485-99c3-5869572dc413_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e3462c0c-8ac9-45a9-bbd1-744e73112606_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_200991f0-c6e5-47c9-999e-f2f3fdb4ef37_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact related to employee stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_label_en-US" xlink:label="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:to="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_7dc2cce0-5946-4035-9440-84f103c509eb_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapTwoMember" xlink:to="lab_amgn_InterestRateSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_61787ef2-7b91-4110-8367-9db63e53e800_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_0b27f97d-dbb6-4253-ba98-e357e0abd78b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_24b8ee54-06e2-4473-b845-2c53cf104ed8_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_395ac83d-bd90-4a12-8993-53818a3692a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_49c02d14-67a9-460f-a943-127bf31da923_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_ac2fb64f-783b-4ae5-aa78-74075189966f_terseLabel_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Domain]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_label_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Domain]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_documentation_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssetsByDescriptionDomain" xlink:to="lab_amgn_AssetsByDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_ab4f9cab-c637-41f1-91ef-6c5ac2c0e007_negatedTerseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Noncurrent Liabilities Other</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Noncurrent Liabilities Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:to="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_348059ad-8810-49a1-9eec-bca817564515_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other losses</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:href="amgn-20201231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_f060e341-46d6-42b2-b53c-c6a6c331e2ee_terseLabel_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated blended statutory rate</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_label_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_documentation_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:to="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31f8187a-3c48-4fea-a12f-5cd472777885_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b7fb4f52-fbcd-4a12-bc52-fa02b851e9dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_bee1e8ac-d560-4ca0-908a-a882f75ab6fc_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_0e5424de-20a7-4e8e-a09e-0f232fba3394_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends paid per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e751dcfb-34bd-4176-bbf5-bc10d32d059e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FixedEquipmentMember_b6db2541-8a0e-4c5d-ac54-24207d482964_verboseLabel_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment [Member]</link:label>
    <link:label id="lab_amgn_FixedEquipmentMember_label_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment [Member]</link:label>
    <link:label id="lab_amgn_FixedEquipmentMember_documentation_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember" xlink:href="amgn-20201231.xsd#amgn_FixedEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FixedEquipmentMember" xlink:to="lab_amgn_FixedEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_41a89540-0b3d-4c57-9f63-928dca650d93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member_7293842a-3e5b-46f5-8963-94af72761476_terseLabel_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2021 and 2035 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member_label_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2021 and 2035 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member_documentation_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2021 and 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2021And2035Member" xlink:href="amgn-20201231.xsd#amgn_OperatingLossesThatExpireBetween2021And2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OperatingLossesThatExpireBetween2021And2035Member" xlink:to="lab_amgn_OperatingLossesThatExpireBetween2021And2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_a80d6c81-6bb7-4ec1-a994-bb8307ab8215_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a4279649-e294-4b76-bb20-a66c5ff1e705_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly financial data (unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_81cd91c4-a9ba-488c-a97e-37007b21ae91_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_182b8297-64e6-40da-8f0d-00cc093e48e3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_ad5ae022-45f4-4227-93c4-488143f860c8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_f0c264df-52bf-46ac-ad39-9ed9d5f34ce7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f753341b-2758-4c25-8b86-3e7f300401a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_98103804-57da-4010-997a-f1ef49852f71_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_e5521d75-9935-4f44-beb5-8293ebfd9063_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_053623cb-98ae-41df-8665-c1a8b48025e6_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8f409ef3-5058-4183-a03e-be1362aecf25_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_1b212d93-fa89-460c-a615-c5a46b266d33_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_88a63127-8aaa-4283-99e2-83e94f9c5ec1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock_4085dc7c-a0af-4c6a-8658-dd3b003b7672_terseLabel_en-US" xlink:label="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate acquisition date consideration to acquire an entity</link:label>
    <link:label id="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock_label_en-US" xlink:label="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Cost Of Acquired Entity [Table Text Block]</link:label>
    <link:label id="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock_documentation_en-US" xlink:label="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the aggregate acquisition date consideration to acquire an entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" xlink:to="lab_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_6611b647-a442-45aa-bc94-999a0e293c9c_terseLabel_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial commitment term of each bank which is a party to the agreement</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_label_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Initial Commitment Term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_documentation_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Initial Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:href="amgn-20201231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:to="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_01403022-0e9e-44b6-bbf2-cf291326296e_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross-currency swap contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_be6fe192-7f11-4a90-b170-e8903b0783f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which the grants of equity instruments vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d73da058-e057-4f2b-b68f-3b90bca2d242_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_a258f358-961a-41e9-9633-e33ee291622d_terseLabel_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_4a24c258-1705-4c3e-88df-bcd76253f4a5_verboseLabel_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Euro Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_label_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Euro Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Euro Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:to="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e27de876-932d-45e0-9424-e2247a6f0d19_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EnbrelMember_862bb5be-384c-419d-9aae-842c9faae4bf_terseLabel_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel&#174; (etanercept) [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_label_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_documentation_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember" xlink:href="amgn-20201231.xsd#amgn_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EnbrelMember" xlink:to="lab_amgn_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_83047952-b66e-49f2-afc0-70782449b5b9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c11d1f6e-3750-4433-9232-6c8b19de49b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired, licensing rights</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_84a55f84-13d7-4cdb-9bf7-07468a797133_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrealized (losses) gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_51aeec32-f8c3-4eaf-8e15-10285b1f1b5f_terseLabel_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.15% notes due 2041 (5.15% 2041 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:href="amgn-20201231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:to="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_72c3fadf-cddd-4aab-81a6-f08b33d013e1_terseLabel_en-US" xlink:label="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired assets, weighted useful life</link:label>
    <link:label id="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Assets, Weighted Average Useful Life</link:label>
    <link:label id="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_documentation_en-US" xlink:label="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:href="amgn-20201231.xsd#amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:to="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralExpense_634bbe74-64ea-42f6-8a4e-4af57f9ce028_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralExpense" xlink:to="lab_us-gaap_OtherGeneralExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_76641f81-b8ba-4415-a6b0-02a5001352a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits, primarily federal R&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_6f1df05a-adab-4905-b218-6d3be468bb9f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_de8e12f6-651e-4dbf-82e6-8b44a921de33_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_52c60d9c-0f6a-4122-a824-1ec958247f97_terseLabel_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_label_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FloatingRateNotesDue2020Member" xlink:to="lab_amgn_FloatingRateNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e41f2d08-60a0-4096-90e3-495ff61dd282_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for stock repurchases under a board approved stock repurchase plan</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_59350244-1681-425a-8556-9e640137b6a0_terseLabel_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage-backed securities [Member]</link:label>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_d05d5a15-35f9-49c3-909a-2ddd05dd72ee_terseLabel_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales deductions</link:label>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_label_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Deductions Current</link:label>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_documentation_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent" xlink:href="amgn-20201231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedSalesDeductionsCurrent" xlink:to="lab_amgn_AccruedSalesDeductionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_733c0a9d-1c21-4291-b07e-9ae81b4438c6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-related rights [Member]</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_82766f6e-ba56-44e3-9ab6-df3b928e2295_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CollaborativeArrangementNetIncome_e4e788ad-c2ff-4e5b-937e-ba5d513b66df_terseLabel_en-US" xlink:label="lab_amgn_CollaborativeArrangementNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementNetIncome_label_en-US" xlink:label="lab_amgn_CollaborativeArrangementNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementNetIncome_documentation_en-US" xlink:label="lab_amgn_CollaborativeArrangementNetIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementNetIncome" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CollaborativeArrangementNetIncome" xlink:to="lab_amgn_CollaborativeArrangementNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cde2788b-6b29-43c1-a969-f607f3ad8ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_47a8534e-77c7-4053-9678-c7b20ccd53f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_bd85fdf9-9e4e-4e15-a098-7ef2794b0cb1_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_223b1cd5-ebd2-43f9-8b01-c41553a46933_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_221ca59b-5245-4645-825c-1d332e443d7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_e0a88560-02e9-4406-9b6e-e246fbd02ffc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b016c3ed-b1ac-4d4e-81ac-2a0a1387942d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_69bcd657-3bc7-4e1c-b25b-1307894b2e6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_73ad9730-4fa4-40df-8d96-a7c11d25474d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member_e31ec2dc-183e-47b6-9fe1-2d7746df0c89_terseLabel_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2035 [Member]</link:label>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member_label_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2035 [Member]</link:label>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member_documentation_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2035Member" xlink:href="amgn-20201231.xsd#amgn_ExpirationInTaxYearsBetween2023And2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ExpirationInTaxYearsBetween2023And2035Member" xlink:to="lab_amgn_ExpirationInTaxYearsBetween2023And2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_5a4d40ee-daa7-4975-9d39-a0296a1433e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Amgen&#8217;s investment in K-A</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_c4f17524-f752-4945-8705-f5a8e25265be_terseLabel_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.20% notes due 2027 (3.20% 2027 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_label_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_documentation_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:to="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_dea36698-f395-4831-96ef-52c60adbf263_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, additional authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BeiGeneMember_60206c79-394d-4788-aeb4-01d12712927e_terseLabel_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene</link:label>
    <link:label id="lab_amgn_BeiGeneMember_label_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:label id="lab_amgn_BeiGeneMember_documentation_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BeiGeneMember" xlink:to="lab_amgn_BeiGeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1491e0f0-a7da-4f1f-a2fa-ee93cbf5ba3b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_29f8d340-26a7-4e23-b37d-0013262cadac_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue by product and by geographic area</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_9c1a3010-9b61-4788-90cb-ad40179cf7d7_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2027 (2.20% 2027 notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:to="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_068e55b4-c87e-468d-8dbc-a8f429ddb93b_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_7d4cc573-7c13-4589-9eb4-943ee60c0de3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0dfc545c-1227-4de3-90be-5a5726c8cad5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dd00c914-0bdc-4825-ad23-893ed6e92260_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c1addbbb-4220-4818-8d23-992383bb0bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, pretax</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3f45fdc0-efdb-4604-9184-0313aace627e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_dcf7fe8b-52ca-4745-989c-f96c3ad7f3ff_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_972e17b6-a86e-4817-b05e-019c6cdfe235_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_1a7790d5-81f6-4bfb-be0c-9c8fc04cb675_negatedLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Accumulated Amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets accumulated amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:to="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d177bcc8-45fd-4c10-aba2-f5a8a9610c75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0800872f-be42-4c08-80f3-d6b24d2cd92d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_f56f3e08-0337-402a-ba3c-8de715e6f0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income before income tax, domestic and foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_388dfaa2-a839-4fc1-943b-a946a8d417ae_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_c12644fa-5b0f-4372-9f71-4e1eec101aeb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeulastaMember_694fd96b-ccbe-43ef-a978-3ec277f4db20_terseLabel_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta&#174; (pegfilgrastim) [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_label_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_documentation_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember" xlink:href="amgn-20201231.xsd#amgn_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeulastaMember" xlink:to="lab_amgn_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_21c3c539-cdc3-4382-a96f-2647e5c56347_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapDomain_9dfa0a97-fe1f-4f13-ae12-482810b613ea_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Domain]</link:label>
    <link:label id="lab_amgn_InterestRateSwapDomain_label_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Domain]</link:label>
    <link:label id="lab_amgn_InterestRateSwapDomain_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapDomain" xlink:to="lab_amgn_InterestRateSwapDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4dacfa81-095c-4ad2-8f70-41587adb2d53_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_da9d6063-fcfa-4a51-9edd-bfabc59e229c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9facccaf-050c-4c5c-8993-3382e4a2cf8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_151c7e0e-7ce7-4276-b8f1-157e7f34a872_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_658fb6e3-69f4-4199-9697-0bc627f62716_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_a93a80da-8d68-4145-8c17-2603dafb4b08_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership [Member]</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_86e668ee-9264-420c-91e3-896d0e494be2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1b9611b5-5b5b-404d-9ce5-d6d464028427_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c65a8134-323a-4e95-8921-65382d3a40ab_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_9368cfd0-fc22-4a88-998e-e8ac6a0e43a8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3b5e51d0-9a9a-46e2-baff-4bf196d31639_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other mortgage- and asset-backed securities [Member]</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8d08a4cf-8a44-420d-af7f-c941e352b989_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4d359727-da96-4f2d-9786-ec47d58b137d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US [Member]</link:label>
    <link:label id="lab_country_US_5a695d6a-60ad-4d70-ac36-5041b6ac3163_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US [Member]</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3848db85-6544-4c8a-ba03-69c54a91b3f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_dd147bc1-da0d-4d21-969a-5efcab9fc622_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6926aba4-1b3c-42d4-a96e-e81aa898f352_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_62ee9ace-9926-4170-bd1a-aeb01304ccd8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_c9f7689b-75fa-4b63-a1ec-a5cf6e32336d_terseLabel_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% notes due 2020 (2.125% 2020 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_label_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_documentation_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:to="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_217888c1-737c-453b-b2b4-aa3656b899a4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4e408d79-a7db-4d68-88ce-66833fa4a5f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a280e92e-4254-4f6d-a9de-7ed4f70b830f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_383acce4-3e6e-4935-bf1b-f7cfde60f2f2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual commitment fees for syndicated, unsecured, revolving credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_77ccb40b-529c-498c-9de6-2547a75388a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fbbeb1b6-1bb5-40f4-a4e5-26f7a9289f2e_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_c1fd1951-92f3-4706-966d-fc6b5c2a8760_terseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Finite-lived intangible assets acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" xlink:to="lab_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_e2c9a28d-3147-48c0-94eb-e6277a2faeb5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9862f288-329e-4d4e-af42-ef91d0246469_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cross-Currency Swaps [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_df373e5b-c182-4246-be5b-cd563e210e3d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_781874e2-c1bb-46f2-aa21-d3b327c9a2ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_d281d16f-6eb6-405c-9088-98f2008485d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss_cefd131d-478b-4859-a132-a07705bc1f3d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on remeasurement</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_bca22237-ce7d-410a-93b5-fab333dc8af7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_ff48fe06-8252-4d65-8169-982506eda973_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_196fa7ed-9c6b-4148-87dd-591f6294c74a_verboseLabel_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated cost (consideration transferred)</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_label_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_documentation_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:href="amgn-20201231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:to="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_cfa25f22-f274-494c-896c-68d108be6132_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_4a3273c2-a844-4e0d-8f2e-7d595d4d0c7a_terseLabel_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on uncertain tax positions</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:to="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_28196564-9a62-41f6-bf31-b1423b974eae_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions charged&#160;to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4caddf72-bfc3-4f56-9abf-7a2524305a9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5f2298d4-d647-4772-85a1-bbfa90fede1e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_c67fd2f8-a7d3-47ad-a9f9-ebabd81a19db_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_35656c12-7e70-4870-bca5-978a37d2ad72_verboseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_de54d848-3ccf-483f-83d0-5aff8d27f7f6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_698f523c-9644-4864-9e26-fa9422533d75_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_cb7e86bd-730a-451a-bae8-34c9da121ad9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_8fd0de09-6c3d-4985-acdd-51347cad76fd_terseLabel_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% notes due 2043 (5.375% 2043 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_label_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_documentation_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:href="amgn-20201231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:to="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c91a02dd-a829-4abd-89fd-121ab37315c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63f8fb72-4ad2-4f47-b56c-f91166744859_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7c809c34-9fe3-4939-a9e0-e43c2722f806_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_2f9dc5d4-319b-449c-b969-66ab5f5b4040_terseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_ddae9ba1-02f2-49f8-89e7-3bef90662285_verboseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% 2029 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_label_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_documentation_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:to="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_bd30b6dd-2831-469a-9f94-7ea0e2c043cd_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% notes due 2025 (3.125% 2025 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_label_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_documentation_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:to="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1f139c59-2aa4-4b3d-a84a-17d096124650_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_aa09ccea-2a74-4c90-a901-40914336de94_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired and liabilities assumed, net other assets and liabilities</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_label_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:to="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_ee257b53-5069-4b75-a60d-7e6b726ddd86_terseLabel_en-US" xlink:label="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold as a percentage of total revenues for determining a major customer for additional disclosures</link:label>
    <link:label id="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_label_en-US" xlink:label="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for Disclosure of Product Sales to Major Customers</link:label>
    <link:label id="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_documentation_en-US" xlink:label="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold as a percentage of total revenues for determining a major customer for additional disclosures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" xlink:href="amgn-20201231.xsd#amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" xlink:to="lab_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2266bd70-bbef-4cea-9f6f-bbb8de309481_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_dd02c27f-ad0e-4011-a7c2-6c23e2a2295b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_b91f2796-82c3-4bd7-a6ac-543cbb519e2b_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_e71a4581-6492-49b5-bb3d-c670e92cf447_verboseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_56a00284-589c-4399-b4e1-e47f00aff9ff_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2020 (2.20% 2020 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:to="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_84b344ef-f734-47c7-aae6-bc4ca0cc7e15_terseLabel_en-US" xlink:label="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate of sales deductions for prior period sales as a pct of total sales deductions (less than)</link:label>
    <link:label id="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_label_en-US" xlink:label="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Deductions On Prior Period Sales Due To Change In Estimate</link:label>
    <link:label id="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_documentation_en-US" xlink:label="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Deductions On Prior Period Sales Due To Change In Estimate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" xlink:href="amgn-20201231.xsd#amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" xlink:to="lab_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d0dd9e00-0e60-4e4f-b419-073f873df274_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_677818cb-d942-4ffb-9888-24c19d98bc95_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_13f3a451-18f5-4ae0-b3a9-2e5d886247e5_terseLabel_en-US" xlink:label="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Bayer [Member]</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_label_en-US" xlink:label="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Bayer HealthCare Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Bayer HealthCare Pharmaceuticals Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" xlink:to="lab_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0266996e-f2d0-4048-98a7-064da9c08b95_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred (benefit) provision:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_df2b2d54-f6ab-4a97-a9e0-dc9962f9ff16_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual tax benefits realized from tax deductions from option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_d5f804a2-5340-4394-96da-65a9575f12f8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Numerator):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6b79f781-6389-41fa-8e09-2d5f80b444b9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative assets, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_b556939d-ebdf-411f-ac92-b40c9ac32b24_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of lawsuits filed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits Filed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:href="amgn-20201231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:to="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5c218611-7b24-46d3-b82f-67c134e44c89_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_45622ac5-5b26-4405-8662-4a75efe11c5d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4dddb5de-e899-4bcf-a339-58e7ea3543a4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_bba8f639-2673-4a03-b0d5-4821864c77e2_verboseLabel_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/Other assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_label_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Noncurrent Assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_documentation_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:href="amgn-20201231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:to="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_45f9eef7-ee70-4f34-8023-be6f0e43b3ef_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rates</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_3f8455e3-a8b7-497d-87de-0f63aef066c8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_3de6cbca-a4d0-4dee-a786-b9278c804d1c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b8ea29c3-8fe7-4a6e-9de9-5a7d6842a149_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_c1fde358-249f-4ed4-ad0f-85c22bc3c384_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_61a1cf9f-cd1f-47ef-9357-4d90a79d1750_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_292ae153-8377-4263-ae5c-6a0636b16276_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_02a3908f-ed4d-4219-b55c-53e3ac341515_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2023 (2.25% 2023 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:to="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3fca80ad-5ae8-4b6e-a83b-3171d186e4e9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d612039e-4f51-4214-82ba-12d2c9ac5b5b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_af369f8c-139f-423b-86d0-ecf50085cd2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_56747dfa-6350-4ec1-bfa6-294c828213b9_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_20751395-2847-4309-875e-2ccd4915e647_terseLabel_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember" xlink:href="amgn-20201231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SensiparAntitrustClassActionsMember" xlink:to="lab_amgn_SensiparAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_4008213b-8ba1-4126-9250-519292e19191_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.65% notes due 2022 (2.65% 2022 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_label_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixFiveNotesDue2022Member" xlink:to="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member_5b8c1bb8-faf9-4e78-b5d0-55200946c841_terseLabel_en-US" xlink:label="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70% notes due 2019 (5.70% 2019 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member_label_en-US" xlink:label="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Zero Percent Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Zero Percent Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenZeroPercentNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:to="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NexavarMember_e922a38c-ec98-4f3c-bc87-ffd33f20d7c2_terseLabel_en-US" xlink:label="lab_amgn_NexavarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nexavar [Member]</link:label>
    <link:label id="lab_amgn_NexavarMember_label_en-US" xlink:label="lab_amgn_NexavarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nexavar [Member]</link:label>
    <link:label id="lab_amgn_NexavarMember_documentation_en-US" xlink:label="lab_amgn_NexavarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nexavar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NexavarMember" xlink:href="amgn-20201231.xsd#amgn_NexavarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NexavarMember" xlink:to="lab_amgn_NexavarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_66940499-b728-4384-ae1d-048a5cc58344_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8c9ed243-6e49-4400-b6ca-c1ff2f643d85_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_7d24ae57-6f92-441d-afd2-61d4030311c9_terseLabel_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_label_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_documentation_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:href="amgn-20201231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:to="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e3d4448b-4e56-41af-b4ac-1ba561a4dbf5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_51f4a567-5b45-492b-ad5b-3a228067df38_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2e59e35-d47a-4412-9b47-fb53fa5f6713_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_749367b3-febe-4e40-9852-c84cd344b8d3_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MarketingRelatedRightsMember_1693843b-1bfe-4e49-a4ee-27ee8d19f82d_terseLabel_en-US" xlink:label="lab_amgn_MarketingRelatedRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights</link:label>
    <link:label id="lab_amgn_MarketingRelatedRightsMember_label_en-US" xlink:label="lab_amgn_MarketingRelatedRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights [Member]</link:label>
    <link:label id="lab_amgn_MarketingRelatedRightsMember_documentation_en-US" xlink:label="lab_amgn_MarketingRelatedRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember" xlink:href="amgn-20201231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MarketingRelatedRightsMember" xlink:to="lab_amgn_MarketingRelatedRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c247ca7f-618e-4266-af6d-01e36252f74a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f4ac7b07-2955-4c2e-86f4-a92668f42b26_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_307ecd80-54b9-4e27-8760-ddc06604c94f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f421f08c-41a8-4bfa-aaf4-c5c5443c9d75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_e35bc58e-9963-4e80-b7f0-fcf9f36f34a8_verboseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_f63bb8c4-babb-4255-b54f-eec92aca81e8_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_a3044c42-46f2-40d7-9095-45c3f79629e8_terseLabel_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_label_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_documentation_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:href="amgn-20201231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:to="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2c7cc62a-77fb-4b0a-999c-40ac8eca3f83_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_9e408784-8862-4109-86b8-737d7a8c69d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_35015a3a-2c92-4e2d-a7ea-19a94f134e4c_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_701beccf-66c0-4229-bf9c-e121d8316bdb_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.563% notes due 2048 (4.563% 2048 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_label_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_documentation_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:to="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f2c6d7ee-f941-45de-a287-33b647af9b09_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3081375b-367a-48a1-af15-274c3c6a1073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e0ac526-dd66-4f6f-a89c-db6f873fd332_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of unit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_b4261669-0f8d-4554-9cc8-f03f72d62bf6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury bills [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fed4652a-871e-476e-8dac-1aa65f365dbb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_13dde6b1-fa89-4bb6-90e3-bbab165e8f16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_34d02b94-ec6d-43b3-a7d8-7f638ce0db7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_fab5a14f-ee64-43e9-bac5-3867cce38e66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_0a223429-c2aa-4f8a-83a9-1ed051aeef1a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8ad17c79-b89d-42be-9101-17def8fe312e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_88640141-7483-42c3-ae7a-9f57502fb0a8_terseLabel_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2031 (2.45% 2031 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_label_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_documentation_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:href="amgn-20201231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:to="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7a7c09f1-4878-4d38-a43c-efef866c9d3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_cdc0b08c-ebd8-42e2-9674-2c91dcc2a382_terseLabel_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of common stock available under the plan for future grants and/or issuances (in shares)</link:label>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_label_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances</link:label>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_documentation_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of common stock available under the plan for future grants and/or issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:href="amgn-20201231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:to="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_935ed48b-3c34-40cb-aacf-dfaac1a17799_terseLabel_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2040 (5.75% 2040 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:to="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cb15192e-4c69-47b1-947f-70bfe8b0e597_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_b9b050ac-cd59-45fe-8c1a-c1e1f6813b07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_6be8831f-85fd-4cc2-bc8d-cf4e123ad206_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_da3f6d86-166a-4ca4-a84b-c4246254e4ca_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c81ed45-52bf-4bc6-bdaa-b091afd966a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f269e8a6-e27a-4788-a76c-01b96cccd4ec_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyprolisMember_6207fa28-7966-41da-8df6-e31239eab743_terseLabel_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_label_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_documentation_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember" xlink:href="amgn-20201231.xsd#amgn_KyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyprolisMember" xlink:to="lab_amgn_KyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmnealPharmaceuticalsLLCMember_09f17cc8-14f2-4a44-bd0d-b0611d64d80a_terseLabel_en-US" xlink:label="lab_amgn_AmnealPharmaceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amneal Pharmaceuticals LLC</link:label>
    <link:label id="lab_amgn_AmnealPharmaceuticalsLLCMember_label_en-US" xlink:label="lab_amgn_AmnealPharmaceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:label id="lab_amgn_AmnealPharmaceuticalsLLCMember_documentation_en-US" xlink:label="lab_amgn_AmnealPharmaceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amneal Pharmaceuticals LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmnealPharmaceuticalsLLCMember" xlink:href="amgn-20201231.xsd#amgn_AmnealPharmaceuticalsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmnealPharmaceuticalsLLCMember" xlink:to="lab_amgn_AmnealPharmaceuticalsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5d824a2b-0da5-40a8-9247-38e717b4c06e_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues earned from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8ce7a91d-6af2-4c29-9bf3-83500d0259d1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3477af1d-b3f5-4d5e-a54c-8d425e34f5e0_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for expiration of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_34efd7e3-9768-4841-8b1e-b5a045ebdea5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_9185c8bf-e32d-4935-9029-a6ef0427dce7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_66d38b24-b574-4155-a81d-0e6d6c5a1c69_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_27bb3f60-816d-4a35-8178-90f128de724f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_b7b42c29-7c54-44f0-ad37-b4453e2834fe_terseLabel_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period without payment of make whole amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_label_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_documentation_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:href="amgn-20201231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:to="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated_f53abdd4-c149-42d4-9bde-a1c4948966af_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits consolidated</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated_label_en-US" xlink:label="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfLawsuitsConsolidated" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfLawsuitsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberOfLawsuitsConsolidated" xlink:to="lab_amgn_GainContingencyNumberOfLawsuitsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8109e637-4c1c-4523-8a05-cf12509095bf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f7527de4-73a9-41d5-9992-7d36c1394f2e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0263d7e7-701a-4c3f-9fbd-6af64fdee2f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b9e3df62-d3e5-482f-8d39-0366b9a26605_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_7afb1589-cc6f-4c4b-be1a-c4c4b0c4ab55_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit from product sales</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_aae19438-04a8-41bb-96a0-04a3ea95f925_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d827d8ee-ee89-428f-bdd9-ce763eead486_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_c626a168-639f-427d-8c1c-7f1db2e13267_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:href="amgn-20201231.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:to="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a543502c-e64c-4514-b158-6991a78b4620_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_d7e2b1ec-9594-4f99-a27f-ddc45052534d_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2024 (3.625% 2024 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9e77f769-a389-41df-a786-fe81e833eb2a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e806f027-3d13-4c79-9170-1f3ae0cdd032_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_896cca26-6803-4df0-a7b0-5b3c1a1b3261_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a8a65c60-9f85-4dbc-83c4-c1bfaea13a65_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b432d5ec-312b-4ef7-93bc-f43f08249641_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income for basic and diluted EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94be16f2-cd4f-4465-8818-e51d80fa290e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KirinAmgenInc.KAMember_e1bb61d4-75ea-48cd-8570-e1610b79bad0_terseLabel_en-US" xlink:label="lab_amgn_KirinAmgenInc.KAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kirin-Amgen, Inc. (K-A)</link:label>
    <link:label id="lab_amgn_KirinAmgenInc.KAMember_label_en-US" xlink:label="lab_amgn_KirinAmgenInc.KAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kirin-Amgen, Inc. (K-A) [Member]</link:label>
    <link:label id="lab_amgn_KirinAmgenInc.KAMember_documentation_en-US" xlink:label="lab_amgn_KirinAmgenInc.KAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kirin-Amgen, Inc. (K-A) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KirinAmgenInc.KAMember" xlink:to="lab_amgn_KirinAmgenInc.KAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_3f90c217-24d6-4849-b526-a97501520815_terseLabel_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of stock-based compensation expense recognized in the Consolidated Statements of Income</link:label>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_label_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Stock based Compensation Expense [Table Text Block]</link:label>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:href="amgn-20201231.xsd#amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:to="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_7be0f957-bd6e-4c2e-a6f8-be0d555025d1_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR [Member]</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_dc9e317e-b565-4c8d-b15a-b5cfd3a55a23_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_4e220cbe-997f-462b-b699-27769f135c22_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of time hedged in foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7fb7e1dd-4ff1-4f78-be7f-0b0719d9a835_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerThreeMember_50180e60-19a5-4051-bb5b-5926fc117a0f_terseLabel_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_amgn_CustomerThreeMember_label_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_amgn_CustomerThreeMember_documentation_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember" xlink:href="amgn-20201231.xsd#amgn_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerThreeMember" xlink:to="lab_amgn_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_8070f864-e2cb-49c6-b878-2abb28cdbb55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_434f6800-4b94-4b8c-938c-34dcf7cd0638_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments to income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_e7bde955-05d7-4086-993b-841c5175d490_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5b3579fe-6806-4301-9559-4fc5eb6fc1a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4aef7c06-ef0c-4f1b-ae8b-c5b9e1b1d2c3_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_39cdca57-01b1-4859-b244-4f20ac1e7dee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_4c1c3506-21ab-4555-99ac-18ddedfd2511_terseLabel_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_label_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_documentation_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:href="amgn-20201231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:to="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_8b95d705-2f70-4796-9e78-42ea59863cdf_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro [Member]</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_cd9f6ed7-a7d5-41b3-889c-9d7bb8483976_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases not yet commenced lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NonUsExcludingJapanMember_84a5a295-89cb-40ed-9467-248465ede17b_terseLabel_en-US" xlink:label="lab_amgn_NonUsExcludingJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonUs,ExcludingJapan [Member]</link:label>
    <link:label id="lab_amgn_NonUsExcludingJapanMember_label_en-US" xlink:label="lab_amgn_NonUsExcludingJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonUs,ExcludingJapan [Member]</link:label>
    <link:label id="lab_amgn_NonUsExcludingJapanMember_documentation_en-US" xlink:label="lab_amgn_NonUsExcludingJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonUs,ExcludingJapan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NonUsExcludingJapanMember" xlink:href="amgn-20201231.xsd#amgn_NonUsExcludingJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NonUsExcludingJapanMember" xlink:to="lab_amgn_NonUsExcludingJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointOneFivePercentNotesDue2018Member_5d058ee4-c330-449e-a661-aa208bfce5c3_terseLabel_en-US" xlink:label="lab_amgn_SixPointOneFivePercentNotesDue2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.15% notes due 2018 (6.15% 2018 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointOneFivePercentNotesDue2018Member_label_en-US" xlink:label="lab_amgn_SixPointOneFivePercentNotesDue2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Five Percent Notes Due 2018 [Member]</link:label>
    <link:label id="lab_amgn_SixPointOneFivePercentNotesDue2018Member_documentation_en-US" xlink:label="lab_amgn_SixPointOneFivePercentNotesDue2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point One Five Percent Notes Due 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointOneFivePercentNotesDue2018Member" xlink:href="amgn-20201231.xsd#amgn_SixPointOneFivePercentNotesDue2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointOneFivePercentNotesDue2018Member" xlink:to="lab_amgn_SixPointOneFivePercentNotesDue2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_03cb83b0-3e53-40ba-90de-808a0a13a76e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8b4b4b93-54b9-4b0b-b7f3-cdf9ee33f6de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_cf9052f7-c5a7-4c3b-9eef-5e977a1c1092_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_75908a75-e803-47b0-8ff5-9e3c6fff12a8_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties due</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1b722ef2-9471-4c8c-bef5-8aba3ec56c6b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_02010a94-0a6b-4dc9-93c1-78509a8c50cf_verboseLabel_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments liabilities fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:href="amgn-20201231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef7e86ea-0a8d-4874-8735-31d80eec0e02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b7241cb3-7e48-4f3a-912d-4f3e90fb7ccb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_60b4e0e6-b794-4b96-a643-72fbb976028b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7d3cc29b-ac13-4e39-8cfd-86e10a8affd5_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_47b71113-ebc4-4a0b-8e04-97c7eccc1af5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding&#8212; 578.3 shares in 2020 and 591.4 shares in 2019</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a56df657-8113-46f6-a57e-d54056d7e4b4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amounts</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_e6c5f740-c7dc-4f2f-9dcd-ed28003d8f41_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income (expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ccd022fc-bfb2-4af4-8a83-002afe880adf_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_142fe563-e540-445e-9fb1-18cb4b3da9f7_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market mutual funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fd9b6730-1d4a-4d8f-9258-968266b99a71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b9525ef9-36a1-4316-b8e4-9a7be1ebe7e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested or expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_d25c1e2f-4e50-41ed-a2fd-2989b2ac26d8_verboseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_3f4f9c54-3ca1-45a3-b32c-24ba8a164ffa_terseLabel_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment [Member]</link:label>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LaboratoryEquipmentMember" xlink:to="lab_amgn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_23fb0a30-77d6-45ce-8180-8ce2259cc8bd_terseLabel_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D technology rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_label_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Research And Development Technology Rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_documentation_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired research and development technology rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:href="amgn-20201231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:to="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_cc7544f0-92f9-453a-bc29-595573256a63_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0fe41f2d-595f-4ff2-aa7c-49c2bd6f90f8_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b0cc3c0d-d20d-4885-8d2a-040b8e9cfa86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_134bd0b7-b54a-413a-81f7-f1c274512e12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapAxis_d9180508-b351-4497-b872-db479aadb133_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAxis_label_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAxis_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapAxis" xlink:to="lab_amgn_InterestRateSwapAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e95f934f-2a59-4d27-a7d9-46faf6909133_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fa2f951-532d-4c4b-91d5-e61b6bbe254d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for basic EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_767a0e37-e3f2-49d2-bed4-264262694661_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_68b00b3f-f48d-4076-82b7-4de426e4041d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in fair value hedging relationships</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2016c0a8-506b-4c34-a2c2-f941785fdc62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CommonStockFairValue_0c5a2e5d-cd7f-4426-912a-5e8fce31cc5f_terseLabel_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of our common stock on grant date (in usd per share)</link:label>
    <link:label id="lab_amgn_CommonStockFairValue_label_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Fair Value</link:label>
    <link:label id="lab_amgn_CommonStockFairValue_documentation_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue" xlink:href="amgn-20201231.xsd#amgn_CommonStockFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CommonStockFairValue" xlink:to="lab_amgn_CommonStockFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_16fc50a3-0bd6-44d5-95b6-ea722aadbf1c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_cee5dff9-a3ac-4a00-a7a2-1fcc1e8b1469_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9bcb53ab-ddfa-444e-8612-49339a266f08_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_792de19f-1d0f-49d0-a978-613a786ce8eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_6077218c-1af1-4489-988c-d89e793d40cd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_c223a656-6159-4cc8-b885-28ff1d86557c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, continuous unrealized loss position, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_217b2260-d873-4401-ba78-89f7225d6365_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AbandonedLeasesMember_0fa7c9f0-1edc-4775-b9a4-acb4792bac67_terseLabel_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:label id="lab_amgn_AbandonedLeasesMember_label_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:label id="lab_amgn_AbandonedLeasesMember_documentation_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember" xlink:href="amgn-20201231.xsd#amgn_AbandonedLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AbandonedLeasesMember" xlink:to="lab_amgn_AbandonedLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bf27b850-6908-4638-bfe0-1faa4d96b767_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssembledWorkforceMember_6a9b54c0-3af8-4699-ad77-0e93f33b2c27_terseLabel_en-US" xlink:label="lab_amgn_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:label id="lab_amgn_AssembledWorkforceMember_label_en-US" xlink:label="lab_amgn_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:label id="lab_amgn_AssembledWorkforceMember_documentation_en-US" xlink:label="lab_amgn_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember" xlink:href="amgn-20201231.xsd#amgn_AssembledWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssembledWorkforceMember" xlink:to="lab_amgn_AssembledWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_900f50af-38ef-4cdd-b6cb-7ed97f5e0724_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_db4a8c7b-5297-4cd3-9b9b-4b8389c1d650_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_83cec330-b4a7-4934-8379-fad61fcafcd5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_25919198-968f-4229-92b8-186bc6e29026_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_810b6ca9-72a9-468c-99bf-b5e4ca30c4e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_85ccde6c-331e-4815-8a45-99d7e9525d7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities payable [Member]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesPayableMember" xlink:to="lab_us-gaap_DebtSecuritiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerTwoMember_e4e41dd0-b222-46a9-bb5a-88fc0ee863d2_terseLabel_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_amgn_CustomerTwoMember_label_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_amgn_CustomerTwoMember_documentation_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember" xlink:href="amgn-20201231.xsd#amgn_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerTwoMember" xlink:to="lab_amgn_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ed52de5-e057-47c0-9b0f-c381b67015f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d13a429-20cc-4950-9322-56e87cbaead1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b419c3d7-0e5c-49ab-86cc-b6de668efef5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b1f7bd01-6cb1-4b01-98ee-a783ca19ddc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate contractual maturities of long-term debt obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_94489ce0-3161-4cbd-8734-d815996cea3f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dbb53ea8-dc2b-4a2d-9c19-8de1313e94d4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9737b30e-5a5e-46bb-8224-ec95ec985d7a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_cab6c581-d101-4960-b1ac-b588e58b6d60_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_59f2df52-1a66-40ac-b6cb-6ee1eccc7c89_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash purchase price</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_40afa59e-4bfc-4d00-955d-7a5f6ad7a22c_netLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash paid to Kirin</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1ce069ea-25db-4611-8d3c-4cfcdc1c9014_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_c27e4647-7088-4b5b-aebc-9ee848a7d29d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_2a2dafac-9a50-4688-9c09-0813931fb861_terseLabel_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue payment term</link:label>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_label_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Payment Arrangement, Term</link:label>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_documentation_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Payment Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm" xlink:href="amgn-20201231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenuePaymentArrangementTerm" xlink:to="lab_amgn_RevenuePaymentArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_0807faad-3bf8-4ef6-a4e2-8c1bfa54ca4f_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued for each performance unit earned</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Shares Issued for Each Performance Unit Earned</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued for each performance unit earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:to="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fe4837d1-7e10-44dc-84f9-aa5237ffb6cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_35b6fec2-bd23-401c-83a0-8ff61a1537ed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_c8e5c667-f7e4-463a-b367-788b2db302f6_terseLabel_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper, maximum borrowing capacity</link:label>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_label_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Borrowing Capacity Under Commercial Paper</link:label>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_documentation_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Borrowing Capacity Under Commercial Paper Program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:href="amgn-20201231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:to="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_3c2ca726-4d36-4658-8906-619bb9bfed59_terseLabel_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest-bearing securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_label_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short Term Interest Bearing Securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_documentation_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest bearing securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:href="amgn-20201231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:to="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a9253fdb-1515-4886-a336-d46f311a57f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9272c981-9d1a-4378-a83f-13764c951b3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FixedEquipment_c5485f85-b767-4ca0-b32f-49f6c3b35346_terseLabel_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:label id="lab_amgn_FixedEquipment_label_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:label id="lab_amgn_FixedEquipment_documentation_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment" xlink:href="amgn-20201231.xsd#amgn_FixedEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FixedEquipment" xlink:to="lab_amgn_FixedEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4d634153-8cd6-4f0d-831a-e5afd00a4f9b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_8661b400-d615-4b2a-bfa9-e75fd612c772_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7fddce8-8b6e-4959-a5df-43dbb1620e1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_f00d1f56-8a72-4503-a415-ba7e7a49c45a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative costs</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_81e1412a-27a5-4712-a9e6-e556260312c1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_78dfa4c2-99fe-4ec3-aec8-d86c6f38c1b5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3c63fbf2-33eb-4e2d-9230-df3a2da2193e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant&#160;date fair&#160;value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_cb89c005-8184-43b0-8219-26864b6ace0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of units that vested during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_dcd5bdd3-11aa-4426-b6c9-70d129e1ed3a_negatedTerseLabel_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Tax Act, net impact on intercompany sales</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_label_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Impact On Intercompany Sales, Percent</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_documentation_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Impact On Intercompany Sales, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" xlink:to="lab_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2931d5b2-d2e2-40b7-a9d0-4627a9918c25_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_eba0ff40-f475-4daa-811f-e583d72473b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_073d3cc0-1be4-4959-97c4-6dac287bd273_verboseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/Other noncurrent liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Other Non Current Liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/other non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:href="amgn-20201231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:to="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_cdddca58-5225-4223-aca7-7aad13095072_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1d3c9e72-e61f-43fe-a151-1321235c0fb6_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ecccbde4-34f2-48c2-8a1d-f1cc3366981d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_95965406-5466-4427-8bad-4961d6e7d617_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options information [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_80ba3019-24e9-4013-a054-dcd2f140262e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), unexercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_9260caad-7884-40d5-a04b-523981c78ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of stock-based compensation expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcd19c78-561b-432b-a07a-9f23025df20c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_3009530e-e5e3-4a1f-a687-5901d95a8909_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2022 (3.625% 2022 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_72cf2e30-647a-4b68-997c-d7a89171fc3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_9352f14b-9ddd-4f4d-bed0-5db28e68912d_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_219e656a-0007-4165-94bc-d52946867ff1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_4f8e3247-4b7e-433c-abcc-51edd58fdbfc_verboseLabel_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_label_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earning Per Share [Abstract]</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_documentation_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earning per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:href="amgn-20201231.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:to="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_c25b4757-b8ce-4aaa-8721-0b32546896c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_78fb3cfd-3c25-40b1-9033-19a8da58e8fc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e8e29725-40ca-449b-bde0-3c8182414955_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2929b54d-ccb6-4939-b919-8456bac68659_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a80e90e4-521a-4496-9ff9-1cd6de10165e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_c8ccab7c-f575-46a1-8e89-be5956913d02_verboseLabel_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_label_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency and Cross Currency Swaps [Member]</link:label>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_documentation_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross currency swaps.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:href="amgn-20201231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:to="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_c6e28829-3b1f-4ade-8cf7-4daeb962c4a9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_791ee752-5929-454e-9ca3-11ad849589da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested or expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_26b11222-be15-46bb-8457-7151e2592117_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other recently adopted pronouncement and Other recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_dbe1dc02-3535-49ef-a688-eec2370e8a03_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>amgn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e0ca318f-3884-42e6-a64c-8779d462d73a,g:75807743-642d-4c80-8d38-07220e8d8bcd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20201231.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_959d6d07-ea66-40b9-920f-2cab8bdf599e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_959d6d07-ea66-40b9-920f-2cab8bdf599e" xlink:to="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:to="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_53a390ff-a435-4fc3-9721-a51397be1658" xlink:to="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a370f04e-4d65-4791-9f49-837adf038c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:to="loc_us-gaap_CommonStockMember_a370f04e-4d65-4791-9f49-837adf038c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A1.250SeniorNotesDue2022Member_bed0d9d2-bb7d-4379-878e-62e5345f09bb" xlink:href="amgn-20201231.xsd#amgn_A1.250SeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:to="loc_amgn_A1.250SeniorNotesDue2022Member_bed0d9d2-bb7d-4379-878e-62e5345f09bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_7da707b9-8fa1-4178-ac20-c447c4fe42f7" xlink:href="amgn-20201231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_251d435a-ca54-49a2-ac64-dd7d426fed34" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_7da707b9-8fa1-4178-ac20-c447c4fe42f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:to="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_1f1b6c82-805f-4b48-b048-b4f61a6b78e3" xlink:to="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_b06f0057-1282-4c44-b12b-5f24bfd4c74e" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:to="loc_exch_XNGS_b06f0057-1282-4c44-b12b-5f24bfd4c74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_aa7ea2dc-d206-43d2-9415-54c8117e5e33" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_XNYS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_21bd745e-07b8-43a2-af8c-2b6a4852ae7a" xlink:to="loc_exch_XNYS_aa7ea2dc-d206-43d2-9415-54c8117e5e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_2cde8740-593e-4b9c-911d-b3a0aff0ce39" xlink:to="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c68be916-580b-43cd-84c5-eaf96a2e423c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentType_c68be916-580b-43cd-84c5-eaf96a2e423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6e3c80db-9557-4a4c-8b2e-78af588f7688" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentAnnualReport_6e3c80db-9557-4a4c-8b2e-78af588f7688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6874bc64-572a-4c7e-8ae0-310fd5a63672" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentPeriodEndDate_6874bc64-572a-4c7e-8ae0-310fd5a63672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bb20a3b5-7aae-4ea4-aed9-9fd73fa91c58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentTransitionReport_bb20a3b5-7aae-4ea4-aed9-9fd73fa91c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ca3d82e4-3842-44f0-9fc0-3daa9ed82f38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityFileNumber_ca3d82e4-3842-44f0-9fc0-3daa9ed82f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bbd3543e-6345-418b-a9d0-65ab41265958" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityRegistrantName_bbd3543e-6345-418b-a9d0-65ab41265958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_037c3888-7196-421f-bd24-85784f9636e0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityIncorporationStateCountryCode_037c3888-7196-421f-bd24-85784f9636e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3acc66a6-c50b-45b0-8598-60a608993a8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityTaxIdentificationNumber_3acc66a6-c50b-45b0-8598-60a608993a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_73b57b2a-a511-4cf3-ad69-56214a3d09f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressAddressLine1_73b57b2a-a511-4cf3-ad69-56214a3d09f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_323586b2-9579-4964-a1e7-3c111b35ed21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressCityOrTown_323586b2-9579-4964-a1e7-3c111b35ed21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_35317354-b2b7-48fa-b5eb-794e312137ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressStateOrProvince_35317354-b2b7-48fa-b5eb-794e312137ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_89d98085-9e73-40ba-af78-437eef9abd61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityAddressPostalZipCode_89d98085-9e73-40ba-af78-437eef9abd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec47f718-e48c-4281-a60e-516d4b53af12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_CityAreaCode_ec47f718-e48c-4281-a60e-516d4b53af12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_12496e55-d068-4dbf-af93-921729d2677a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_LocalPhoneNumber_12496e55-d068-4dbf-af93-921729d2677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d996fa65-6ede-4277-aa90-4d1a37d38311" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_Security12bTitle_d996fa65-6ede-4277-aa90-4d1a37d38311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fd9b758a-4ea1-4e68-a125-be3e15b3a8e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_TradingSymbol_fd9b758a-4ea1-4e68-a125-be3e15b3a8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8f705f45-3295-4c8d-9ac7-32536090567d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_SecurityExchangeName_8f705f45-3295-4c8d-9ac7-32536090567d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9aba663e-2480-44bc-a51b-c316c3281708" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9aba663e-2480-44bc-a51b-c316c3281708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ac4974a1-f64a-4df2-8834-601f48bd7b02" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityVoluntaryFilers_ac4974a1-f64a-4df2-8834-601f48bd7b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0bc04c6f-7c87-40d5-9d7a-d4d08a545b14" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityCurrentReportingStatus_0bc04c6f-7c87-40d5-9d7a-d4d08a545b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e7d60b5a-4c81-4901-abdd-b96289f7b1de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityInteractiveDataCurrent_e7d60b5a-4c81-4901-abdd-b96289f7b1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eee5b9f1-26f5-4d38-96c6-08ecc998e015" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityFilerCategory_eee5b9f1-26f5-4d38-96c6-08ecc998e015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1b065504-0a34-4f6e-bfea-df82f6d6cdec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntitySmallBusiness_1b065504-0a34-4f6e-bfea-df82f6d6cdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c9b45a98-5e45-4ddb-a8bd-57adf8b50ce2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityEmergingGrowthCompany_c9b45a98-5e45-4ddb-a8bd-57adf8b50ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9fe32019-df76-499f-83fe-90bace5552a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9fe32019-df76-499f-83fe-90bace5552a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4bb0421e-4c9e-44e3-8e46-c8ddb762e23a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityShellCompany_4bb0421e-4c9e-44e3-8e46-c8ddb762e23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e85578ef-7c1d-4bb4-998b-16590db0c668" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityPublicFloat_e85578ef-7c1d-4bb4-998b-16590db0c668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_094434fe-fea7-48cc-bca4-c2e78990296c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_094434fe-fea7-48cc-bca4-c2e78990296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ab80ff66-7fb8-4926-a478-e985135c558e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ab80ff66-7fb8-4926-a478-e985135c558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1d32706c-9599-4580-a58c-03b6ca152086" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_EntityCentralIndexKey_1d32706c-9599-4580-a58c-03b6ca152086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5157d6c5-8e11-488a-8c9e-996bf8afd991" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_AmendmentFlag_5157d6c5-8e11-488a-8c9e-996bf8afd991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_80e91f33-aa34-4cf2-8cb5-b220a0064e66" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentFiscalYearFocus_80e91f33-aa34-4cf2-8cb5-b220a0064e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_29291f5b-b357-44cb-8151-ce524a053958" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_DocumentFiscalPeriodFocus_29291f5b-b357-44cb-8151-ce524a053958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a047e07b-6349-4c00-85e9-10de3a652250" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_63634280-6d6c-4fe1-9926-3caececec764" xlink:to="loc_dei_CurrentFiscalYearEndDate_a047e07b-6349-4c00-85e9-10de3a652250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_22e9eb4e-2726-412d-a049-7d015e06507e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22e9eb4e-2726-412d-a049-7d015e06507e" xlink:to="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:to="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e16937d0-4fe3-49df-b365-69f4b151cdb6" xlink:to="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d5a746ba-2914-462f-9056-4b517e25a14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:to="loc_us-gaap_ProductMember_d5a746ba-2914-462f-9056-4b517e25a14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6a6d9c16-e363-45b9-8c21-e187f9be10f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5eac7c3-be1f-4ede-91bc-30f1edd174ca" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6a6d9c16-e363-45b9-8c21-e187f9be10f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165b10b1-f2ad-4a11-a7cc-957e17244c24" xlink:to="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5f9b0195-cd81-417f-9e77-d6ffb022bcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5f9b0195-cd81-417f-9e77-d6ffb022bcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36596d40-6a65-4edc-9c42-165534b230f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36596d40-6a65-4edc-9c42-165534b230f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8d916f5e-ae7f-400c-a5be-320273be9fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_988e58bc-21bb-438b-a9de-9daf6b328c87" xlink:to="loc_us-gaap_Revenues_8d916f5e-ae7f-400c-a5be-320273be9fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3c6a8ff-fd6d-4ca0-a3cc-22306a15beed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3c6a8ff-fd6d-4ca0-a3cc-22306a15beed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_589ac90b-3a6a-4bc1-98e8-44e355bbf986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_589ac90b-3a6a-4bc1-98e8-44e355bbf986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_40f7a2e8-b8c3-4e25-8231-edb66a55dae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_40f7a2e8-b8c3-4e25-8231-edb66a55dae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_4899cb2b-029d-49b9-89b6-98b0633dbe3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_OtherGeneralExpense_4899cb2b-029d-49b9-89b6-98b0633dbe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8e917e78-abd5-4a44-9e5e-5cbcdbcd59a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d56c423-674a-4f0a-a8ad-ffa2475e1a05" xlink:to="loc_us-gaap_CostsAndExpenses_8e917e78-abd5-4a44-9e5e-5cbcdbcd59a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d21b7c32-ff72-494c-8d2a-698b0003c1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_d21b7c32-ff72-494c-8d2a-698b0003c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_55daeaff-ce57-4d92-aae5-79ffaecaaba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_InterestExpenseDebt_55daeaff-ce57-4d92-aae5-79ffaecaaba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed9fb0cb-f578-44a8-b9dd-2242dc084d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ed9fb0cb-f578-44a8-b9dd-2242dc084d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f790091d-c965-4634-910b-79e0de603f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f790091d-c965-4634-910b-79e0de603f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad5d8e93-39b6-457a-9bba-8e1d830d9546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad5d8e93-39b6-457a-9bba-8e1d830d9546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9c1db38-0615-4125-90cf-161c6deb665f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_NetIncomeLoss_a9c1db38-0615-4125-90cf-161c6deb665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fce6bb92-1404-4d49-adae-1a51a91a9d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:to="loc_us-gaap_EarningsPerShareBasic_fce6bb92-1404-4d49-adae-1a51a91a9d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_62f38dd8-4e19-460e-8c2f-02e051ffc0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1f69d4c2-3337-4da3-b089-8dc8bfcd6d65" xlink:to="loc_us-gaap_EarningsPerShareDiluted_62f38dd8-4e19-460e-8c2f-02e051ffc0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86185e27-a013-4387-b013-5ad5841260ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e1d72e1-a0ce-47e5-b9e2-0c69496f4323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e1d72e1-a0ce-47e5-b9e2-0c69496f4323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9dfd8f3-1139-49db-bf4f-c55a15fa0c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aafba76a-848c-4a4b-a2fa-3c5fcad7bc17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9dfd8f3-1139-49db-bf4f-c55a15fa0c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c0bfac5e-7c9b-479e-b2bb-eacbd31ccc24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58780db8-06a2-4bf2-9c57-cfb12d063072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c0bfac5e-7c9b-479e-b2bb-eacbd31ccc24" xlink:to="loc_us-gaap_NetIncomeLoss_58780db8-06a2-4bf2-9c57-cfb12d063072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c0bfac5e-7c9b-479e-b2bb-eacbd31ccc24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_be72b8ec-b545-4d76-9082-f16cde905e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_be72b8ec-b545-4d76-9082-f16cde905e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_65457851-5a74-4677-b40a-cd836f4fd339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_65457851-5a74-4677-b40a-cd836f4fd339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7ba12171-f694-4799-8eb7-38b2ee406140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7ba12171-f694-4799-8eb7-38b2ee406140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_d9a893fe-2063-481c-8370-b826372966b4" xlink:href="amgn-20201231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_d9a893fe-2063-481c-8370-b826372966b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fe9b7091-43a4-478b-be99-2260df90e067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3f09b53-0273-4886-84e5-a756b3024fa7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fe9b7091-43a4-478b-be99-2260df90e067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_022b8b26-c6ff-4cdd-821b-bfc726eacd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c0bfac5e-7c9b-479e-b2bb-eacbd31ccc24" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_022b8b26-c6ff-4cdd-821b-bfc726eacd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5efcf54b-a8d9-4666-bc38-a1cacb0fb961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5efcf54b-a8d9-4666-bc38-a1cacb0fb961" xlink:to="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3158c1e7-b7d9-4faf-bfa3-3c9f8c3d8909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3158c1e7-b7d9-4faf-bfa3-3c9f8c3d8909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d2c7d99a-2520-41d7-88e2-b6ca78de157a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d2c7d99a-2520-41d7-88e2-b6ca78de157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b50b678c-42bf-49f1-a360-ce9937ec5101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b50b678c-42bf-49f1-a360-ce9937ec5101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fefa4607-64ad-4220-a99a-ffc89bc15e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:to="loc_us-gaap_InventoryNet_fefa4607-64ad-4220-a99a-ffc89bc15e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b3f81602-b06e-4bbc-934d-fc3a92a65dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:to="loc_us-gaap_OtherAssetsCurrent_b3f81602-b06e-4bbc-934d-fc3a92a65dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cea99a96-a97b-4b23-9301-a685438e0421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7edbd72-fd86-4ace-97d6-1ba2f8a7e0cc" xlink:to="loc_us-gaap_AssetsCurrent_cea99a96-a97b-4b23-9301-a685438e0421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e5d1959-93b2-4289-958b-68b8eceda8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e5d1959-93b2-4289-958b-68b8eceda8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27345d19-60ec-4bca-960c-1ff15ab56d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27345d19-60ec-4bca-960c-1ff15ab56d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_abe836c6-0c61-44a5-a67a-62fcde5aacb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:to="loc_us-gaap_Goodwill_abe836c6-0c61-44a5-a67a-62fcde5aacb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3e8002bf-53f8-401f-be6a-a8fc096e6d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3e8002bf-53f8-401f-be6a-a8fc096e6d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69eb2222-3715-478c-ba93-42ae24bc9d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fdca339f-94d7-4fb1-93c1-bfacb947f0d7" xlink:to="loc_us-gaap_Assets_69eb2222-3715-478c-ba93-42ae24bc9d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5efcf54b-a8d9-4666-bc38-a1cacb0fb961" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_590afb0a-157f-45e9-9770-d82edeccd350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_590afb0a-157f-45e9-9770-d82edeccd350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ead8e617-0010-421a-803d-1e8bcd18b02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_590afb0a-157f-45e9-9770-d82edeccd350" xlink:to="loc_us-gaap_AccountsPayableCurrent_ead8e617-0010-421a-803d-1e8bcd18b02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ac10b435-724d-4b50-9f03-46f590edbfa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_590afb0a-157f-45e9-9770-d82edeccd350" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ac10b435-724d-4b50-9f03-46f590edbfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_58e857d4-c452-4cfe-ae31-439950de6021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_590afb0a-157f-45e9-9770-d82edeccd350" xlink:to="loc_us-gaap_LongTermDebtCurrent_58e857d4-c452-4cfe-ae31-439950de6021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_104959ce-dee3-42c1-be92-d0a55a2a8e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_590afb0a-157f-45e9-9770-d82edeccd350" xlink:to="loc_us-gaap_LiabilitiesCurrent_104959ce-dee3-42c1-be92-d0a55a2a8e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8c5a213a-1733-4f2f-8d8b-adca35fe73c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8c5a213a-1733-4f2f-8d8b-adca35fe73c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5aa2dcfe-15ac-4581-b7fd-b69475d95b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5aa2dcfe-15ac-4581-b7fd-b69475d95b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9d81d8de-1ad6-4c2e-84ec-83b1fe59ff97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9d81d8de-1ad6-4c2e-84ec-83b1fe59ff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_af5d40eb-a312-4e81-9390-4945e93814f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_CommitmentsAndContingencies_af5d40eb-a312-4e81-9390-4945e93814f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5a0e9b10-991a-41d3-93d2-4afa8265d9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5a0e9b10-991a-41d3-93d2-4afa8265d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a965939d-888a-4e10-b27a-42bc1cd92aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a965939d-888a-4e10-b27a-42bc1cd92aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_97e7fc99-76b4-4ae5-96a3-4046629a5127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_SharesOutstanding_97e7fc99-76b4-4ae5-96a3-4046629a5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6543324-c2e0-4ae3-8fd1-9138d84636d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6543324-c2e0-4ae3-8fd1-9138d84636d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_09d7605a-56c6-4825-a351-f61213db60bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_StockholdersEquityAbstract_09d7605a-56c6-4825-a351-f61213db60bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_2de1a1e9-3456-4e4f-9680-456293448d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09d7605a-56c6-4825-a351-f61213db60bd" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_2de1a1e9-3456-4e4f-9680-456293448d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90356ae2-aa3c-4ca2-9739-5beaa45a1486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09d7605a-56c6-4825-a351-f61213db60bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90356ae2-aa3c-4ca2-9739-5beaa45a1486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f5ec7f6-941b-47f5-86df-d6c6a111c1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09d7605a-56c6-4825-a351-f61213db60bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f5ec7f6-941b-47f5-86df-d6c6a111c1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad131778-883b-4548-885d-c68f9c3c7c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_09d7605a-56c6-4825-a351-f61213db60bd" xlink:to="loc_us-gaap_StockholdersEquity_ad131778-883b-4548-885d-c68f9c3c7c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23eedca5-11b2-401b-b6b2-9ea11d18ff4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d8c7e57a-04d9-4b95-b632-318a8f868e27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23eedca5-11b2-401b-b6b2-9ea11d18ff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4e031aae-f8f7-4a03-9852-2592ab0de62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14d9fde3-da9c-43ad-a472-933dc9b4798c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4e031aae-f8f7-4a03-9852-2592ab0de62e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14d9fde3-da9c-43ad-a472-933dc9b4798c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e010f716-be7e-42ef-a58a-ea15de0442e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4e031aae-f8f7-4a03-9852-2592ab0de62e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e010f716-be7e-42ef-a58a-ea15de0442e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c411b878-5ca2-4f08-9178-1759e646eb10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4e031aae-f8f7-4a03-9852-2592ab0de62e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c411b878-5ca2-4f08-9178-1759e646eb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb4b5c5d-0eb1-4d96-b675-27b02d3f2a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb4b5c5d-0eb1-4d96-b675-27b02d3f2a9f" xlink:to="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6971ca3e-200d-4c8c-9172-3ce3fc677482" xlink:to="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_59c00041-7ae9-4a93-90e1-6488006442af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_CommonStockMember_59c00041-7ae9-4a93-90e1-6488006442af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_579f5cb8-93a5-4bd7-a944-29e378e5ab02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_579f5cb8-93a5-4bd7-a944-29e378e5ab02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5de87f72-6792-4fa5-878d-d396c73dd5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_RetainedEarningsMember_5de87f72-6792-4fa5-878d-d396c73dd5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dd4bba00-154a-43eb-9d44-ab8fe38fe69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af195b8-08c0-4ebe-aaf2-253e420ce6b6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dd4bba00-154a-43eb-9d44-ab8fe38fe69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5230d4bf-a81d-4f2a-a5a3-586ebd999ce7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9d1c67ae-c2e5-4c3e-8c03-d14152f4cb10" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5230d4bf-a81d-4f2a-a5a3-586ebd999ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac7478fe-c5fa-4918-985a-b425a41b269a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5230d4bf-a81d-4f2a-a5a3-586ebd999ce7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ac7478fe-c5fa-4918-985a-b425a41b269a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f4dc3b3c-cc9d-4ba2-8764-7099155bd116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04cbb08f-1d2f-4e13-b0b0-1d54e2636b8e" xlink:to="loc_us-gaap_StatementLineItems_f4dc3b3c-cc9d-4ba2-8764-7099155bd116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f4dc3b3c-cc9d-4ba2-8764-7099155bd116" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4bb823a2-b437-4f89-9b6b-569e14c67903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4bb823a2-b437-4f89-9b6b-569e14c67903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b495d77-b429-4dfe-b300-c05f31912fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockholdersEquity_3b495d77-b429-4dfe-b300-c05f31912fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4ed0f28e-5c53-40e6-9170-f833ed62db0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_NetIncomeLoss_4ed0f28e-5c53-40e6-9170-f833ed62db0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_64c63667-4620-4b85-a671-5f74968c88a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_64c63667-4620-4b85-a671-5f74968c88a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_b98806ed-e27f-4de8-ad4a-3d96267c803a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_DividendsCommonStockCash_b98806ed-e27f-4de8-ad4a-3d96267c803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_315f879a-e9ef-4187-9e37-e2617cac33cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_315f879a-e9ef-4187-9e37-e2617cac33cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1904cfeb-f1b3-4ec1-9a53-87d73e4decdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1904cfeb-f1b3-4ec1-9a53-87d73e4decdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec5847b7-b68d-4937-9a45-bb7c35a9fb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec5847b7-b68d-4937-9a45-bb7c35a9fb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_384d3327-c824-4e89-be2f-37ff5d799f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_384d3327-c824-4e89-be2f-37ff5d799f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ef1b30f3-b338-4718-842c-b4c39a25297e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ef1b30f3-b338-4718-842c-b4c39a25297e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_7d97461a-bcd7-4a47-95d2-45c7f7839689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_7d97461a-bcd7-4a47-95d2-45c7f7839689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_592bb46a-cfd4-4439-9151-d98cd6c087dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_592bb46a-cfd4-4439-9151-d98cd6c087dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac484624-d61d-4277-8a90-187411357c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3380189a-1f3b-4e98-81f4-165e67624032" xlink:to="loc_us-gaap_StockholdersEquity_ac484624-d61d-4277-8a90-187411357c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_39eac1cb-1540-4474-bf64-7850534be590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c18b1bbd-cdee-4e8d-bbe1-f032f5716aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_39eac1cb-1540-4474-bf64-7850534be590" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c18b1bbd-cdee-4e8d-bbe1-f032f5716aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d6b356c2-2ad0-4080-b923-d5973b926bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_NetIncomeLoss_d6b356c2-2ad0-4080-b923-d5973b926bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d02556c7-6272-4f34-993b-c995b02a6eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d02556c7-6272-4f34-993b-c995b02a6eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fba40b5e-a9fa-4a49-b5b2-ce7e81c1cc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_ShareBasedCompensation_fba40b5e-a9fa-4a49-b5b2-ce7e81c1cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_388e0f45-e87f-4a7d-8bf5-82b51f0fc29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_388e0f45-e87f-4a7d-8bf5-82b51f0fc29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_10f98d6c-68bd-42cc-a433-282ca2e73d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_10f98d6c-68bd-42cc-a433-282ca2e73d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_75c27972-7697-46cb-8197-033570945cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_75c27972-7697-46cb-8197-033570945cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c4c1d1eb-2489-4bc0-8d04-1a47ec3fe03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c4c1d1eb-2489-4bc0-8d04-1a47ec3fe03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_74e9c57e-41e1-4221-a812-a2dcd4388eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_74e9c57e-41e1-4221-a812-a2dcd4388eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_de9310f0-98ba-4b66-83c7-6d58a9163d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_de9310f0-98ba-4b66-83c7-6d58a9163d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5156e765-c395-4b4c-a522-c398b600e159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5156e765-c395-4b4c-a522-c398b600e159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_4fc1b737-42bf-4f0f-a7ad-01c931f2ccdc" xlink:href="amgn-20201231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_4fc1b737-42bf-4f0f-a7ad-01c931f2ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ff2d1a89-237d-47f5-9a61-3620c2001db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf77e46-dbdb-441b-8949-cb01204846e5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ff2d1a89-237d-47f5-9a61-3620c2001db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0159d1ac-551b-4695-8a1d-b52ccc80402f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0338a0db-ae5c-431a-8494-7695ec9d4e23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0159d1ac-551b-4695-8a1d-b52ccc80402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a3061591-7180-46aa-8948-a41428694bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a3061591-7180-46aa-8948-a41428694bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1f6c43ac-0438-4a86-ba57-48d1aa14c8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1f6c43ac-0438-4a86-ba57-48d1aa14c8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_85c90ebe-0b5b-4dde-a6ca-0b635ff9a72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_85c90ebe-0b5b-4dde-a6ca-0b635ff9a72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c28072b4-71d8-4aaf-9489-ecc7622aefc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c28072b4-71d8-4aaf-9489-ecc7622aefc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c8c6e621-b394-4c80-ae6b-975241a1b827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c8c6e621-b394-4c80-ae6b-975241a1b827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_136604e3-b315-4b48-b244-aaff5ba163b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_136604e3-b315-4b48-b244-aaff5ba163b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06656d4f-7bb9-4bae-81a5-6c1ae74c9841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06656d4f-7bb9-4bae-81a5-6c1ae74c9841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e3f98eb-df12-401d-9ac7-bcde55158d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9de2265a-f001-4b45-a800-e85ea812f825" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e3f98eb-df12-401d-9ac7-bcde55158d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a846ddc2-3193-4ee8-996e-e934f6356923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a846ddc2-3193-4ee8-996e-e934f6356923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_69bcab1f-5024-40b4-8f56-b7fbcf6c37d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_69bcab1f-5024-40b4-8f56-b7fbcf6c37d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0c0c3c2d-c575-4a2b-b2d6-fa4efb30e81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0c0c3c2d-c575-4a2b-b2d6-fa4efb30e81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_5b966558-32ad-4b30-9723-4612fda9c5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_5b966558-32ad-4b30-9723-4612fda9c5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_168637ca-8de3-41a1-8320-eb26c5db181c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_168637ca-8de3-41a1-8320-eb26c5db181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_95babe97-0471-4c11-bf20-b41b8eef0db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_95babe97-0471-4c11-bf20-b41b8eef0db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8b118bb-574f-4179-8cec-ee8659a60ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48ca838c-9f7d-4c8e-be18-0a26c55ca061" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8b118bb-574f-4179-8cec-ee8659a60ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61dcf942-2ca1-47c7-b67f-2dc53e0d6631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61dcf942-2ca1-47c7-b67f-2dc53e0d6631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ac20cf7-69c8-46e5-9141-16934f41e4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ac20cf7-69c8-46e5-9141-16934f41e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64a2f859-8a98-491b-8d13-dbf5b68d5139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a68be286-3835-468c-aaa3-ad661968fb3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64a2f859-8a98-491b-8d13-dbf5b68d5139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="amgn-20201231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f89e8e2a-194e-42f6-be74-915403106091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8bd822c8-87c6-4e97-8b90-bd25773276ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f89e8e2a-194e-42f6-be74-915403106091" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8bd822c8-87c6-4e97-8b90-bd25773276ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="amgn-20201231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock_8b912044-ba89-49e5-9adf-d60d6160011a" xlink:href="amgn-20201231.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_amgn_NatureOfOperationsPolicyTextBlock_8b912044-ba89-49e5-9adf-d60d6160011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_59924161-8354-48c3-8bc7-ce2566c2bc64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_59924161-8354-48c3-8bc7-ce2566c2bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_74f83842-7b65-492c-846a-3bdaf1ebabdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_UseOfEstimates_74f83842-7b65-492c-846a-3bdaf1ebabdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2f58e7e0-c745-4624-92b4-d942f0402ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2f58e7e0-c745-4624-92b4-d942f0402ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0ee37af2-8fc5-47e2-ba30-8df1dadbce44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0ee37af2-8fc5-47e2-ba30-8df1dadbce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_626267a2-87e9-4307-b7f8-2da191933393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_626267a2-87e9-4307-b7f8-2da191933393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c94af639-ce6e-4d6f-9a0f-932352aa9f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c94af639-ce6e-4d6f-9a0f-932352aa9f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fa31ad60-c43f-4382-97e4-f22587f7966e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fa31ad60-c43f-4382-97e4-f22587f7966e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0f2621d3-b57f-44c6-b03a-672e37ddefdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0f2621d3-b57f-44c6-b03a-672e37ddefdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2ef55b55-7257-40a4-9c3c-293c223e8778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2ef55b55-7257-40a4-9c3c-293c223e8778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba74fb50-1335-4913-bdc1-fae923eb1d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba74fb50-1335-4913-bdc1-fae923eb1d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_a847edb2-2f21-4cd7-8fb9-b5d587dda1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_a847edb2-2f21-4cd7-8fb9-b5d587dda1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_4f058df9-88c7-4b28-aa68-b9afab2da47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_4f058df9-88c7-4b28-aa68-b9afab2da47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_75d27256-8701-43ab-8b22-143b57cd4ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_75d27256-8701-43ab-8b22-143b57cd4ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b1ba7070-02c4-4915-b64b-abc218213b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b1ba7070-02c4-4915-b64b-abc218213b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ed3f5ef2-c6ed-4f5d-b636-dae30f991675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ed3f5ef2-c6ed-4f5d-b636-dae30f991675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e42e9a4e-f246-4675-bfdb-2b3d236977fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e42e9a4e-f246-4675-bfdb-2b3d236977fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ad34d61c-c836-4d7c-97d1-d0f83568c50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ad34d61c-c836-4d7c-97d1-d0f83568c50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_cab3efb9-62f3-4a9c-81b5-c4a35de1130a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_cab3efb9-62f3-4a9c-81b5-c4a35de1130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fef909c7-2c37-4ad1-ae13-4730af711e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa093a6-3655-4d8c-b8ef-7f001b08f651" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fef909c7-2c37-4ad1-ae13-4730af711e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_713bd80d-11c6-44cb-b25b-aa1b2304f96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_713bd80d-11c6-44cb-b25b-aa1b2304f96f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:to="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e99d1ff4-5ee4-473c-a8a0-6e62c18f118b" xlink:to="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7df731dc-7aa0-443d-a7b3-4b7e933081a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:to="loc_srt_MinimumMember_7df731dc-7aa0-443d-a7b3-4b7e933081a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b80dcd7-e9a3-45b3-b3a5-f5f4e7bfe5e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8d53c040-05dd-4b3e-aca6-258faae5e321" xlink:to="loc_srt_MaximumMember_7b80dcd7-e9a3-45b3-b3a5-f5f4e7bfe5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_9a1fa110-23d6-497b-8b1f-b6cff20a3b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3ff20c82-651b-4fa5-8579-0f473b85dc08" xlink:to="loc_us-gaap_TypeOfAdoptionMember_9a1fa110-23d6-497b-8b1f-b6cff20a3b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_009b2164-5bc4-45e2-b3c7-140091a7f5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_9a1fa110-23d6-497b-8b1f-b6cff20a3b11" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_009b2164-5bc4-45e2-b3c7-140091a7f5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c597f9ae-43f3-408d-bedc-16064a9688fc" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_880ef71a-db84-40ee-90a0-9b971815912b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_880ef71a-db84-40ee-90a0-9b971815912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_a84a7838-ccc9-4e1b-9b06-2cf0a6ae74f1" xlink:href="amgn-20201231.xsd#amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate_a84a7838-ccc9-4e1b-9b06-2cf0a6ae74f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_a1fcbef6-ec07-46dd-9c0a-7b78e9f01ab0" xlink:href="amgn-20201231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_a1fcbef6-ec07-46dd-9c0a-7b78e9f01ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_8e1ab004-9178-4a60-9667-145dfdacd7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_AdvertisingExpense_8e1ab004-9178-4a60-9667-145dfdacd7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm_a2fa4b7f-edcc-49e5-8d3d-23e0f3f7c9a5" xlink:href="amgn-20201231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_amgn_RevenuePaymentArrangementTerm_a2fa4b7f-edcc-49e5-8d3d-23e0f3f7c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5895ad53-48f5-41ef-910c-3615ef5e15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_OperatingLeaseLiability_5895ad53-48f5-41ef-910c-3615ef5e15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_04647a3b-3fec-43c5-b7d8-58c05954539b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6001d63c-11b3-41ac-8e63-60fb08fad44d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_04647a3b-3fec-43c5-b7d8-58c05954539b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Acquisitions" xlink:type="simple" xlink:href="amgn-20201231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_55fc5e0a-43cf-4042-ad12-cf362fbff01a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3fb6e671-a57d-4bc8-a8c5-06dabd3a89eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_55fc5e0a-43cf-4042-ad12-cf362fbff01a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3fb6e671-a57d-4bc8-a8c5-06dabd3a89eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_93312b3b-8f4a-41f8-95b1-16ba4fdaf0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_01003831-b7f1-4aaf-9d66-596df5924524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_93312b3b-8f4a-41f8-95b1-16ba4fdaf0a9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_01003831-b7f1-4aaf-9d66-596df5924524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock_dc14f360-f5d4-4305-b521-36d46106ecb8" xlink:href="amgn-20201231.xsd#amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_93312b3b-8f4a-41f8-95b1-16ba4fdaf0a9" xlink:to="loc_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock_dc14f360-f5d4-4305-b521-36d46106ecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5e2a1319-932b-494e-9499-36ff3accd805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5e2a1319-932b-494e-9499-36ff3accd805" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionAxis_9ac1531b-5494-4268-8a3d-ef0fab11d266" xlink:to="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember_d6110ec2-ae65-4b6d-8067-6439fdd68497" xlink:href="amgn-20201231.xsd#amgn_AssembledWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:to="loc_amgn_AssembledWorkforceMember_d6110ec2-ae65-4b6d-8067-6439fdd68497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_7cfd05fa-b0d2-4e97-87f4-21994bfffc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionDomain_df741244-ca3c-4084-bdd9-9f937337f816" xlink:to="loc_us-gaap_InventoriesMember_7cfd05fa-b0d2-4e97-87f4-21994bfffc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22db6ddb-7ccb-4986-ae9f-05e7095ca360" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_88fa7d04-97ae-4907-a1a6-b724de785f82" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:to="loc_amgn_OtezlaMember_88fa7d04-97ae-4907-a1a6-b724de785f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember_ccac54d1-414c-4cf8-a823-118c58171680" xlink:href="amgn-20201231.xsd#amgn_NuevolutionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:to="loc_amgn_NuevolutionMember_ccac54d1-414c-4cf8-a823-118c58171680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember_4aac8d17-5e15-4b7c-92ed-9159f62b27ad" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f1b57cab-41f7-4558-a294-cf8aee7e046a" xlink:to="loc_amgn_KirinAmgenInc.KAMember_4aac8d17-5e15-4b7c-92ed-9159f62b27ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6019ea28-70c6-404f-88dd-d331dda9af49" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0da5c341-1aed-4c60-bc36-5d3a331e6bf4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6019ea28-70c6-404f-88dd-d331dda9af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember_f7cc8cfa-3a37-4062-9345-7f92384e2314" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6019ea28-70c6-404f-88dd-d331dda9af49" xlink:to="loc_amgn_KirinAmgenInc.KAMember_f7cc8cfa-3a37-4062-9345-7f92384e2314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dcd1f993-ff6f-4896-a9dd-106b4f476665" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_62763784-2df4-42ef-a4e7-c5f2fcd870e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_62763784-2df4-42ef-a4e7-c5f2fcd870e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_b86a05d5-9325-4f4c-84df-f3d285d60be3" xlink:href="amgn-20201231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_amgn_MarketingRelatedRightsMember_b86a05d5-9325-4f4c-84df-f3d285d60be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_2fbec864-43be-440c-8719-49d8949f2295" xlink:href="amgn-20201231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_amgn_RDTechnologyrightsMember_2fbec864-43be-440c-8719-49d8949f2295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5bb61160-f374-4fc0-89ce-2d36ceb10e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cec918a0-b0d0-40ad-9a4e-0e93e8ea9f05" xlink:to="loc_us-gaap_LicensingAgreementsMember_5bb61160-f374-4fc0-89ce-2d36ceb10e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_37a9e826-f05d-456e-a06c-1be76a648c8e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedMarkets_b71ff025-29bb-4c55-a9de-04c15e81101b" xlink:href="amgn-20201231.xsd#amgn_ApprovedMarkets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_ApprovedMarkets_b71ff025-29bb-4c55-a9de-04c15e81101b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05de375d-ea2a-4f76-a37a-d8c425370e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_05de375d-ea2a-4f76-a37a-d8c425370e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_cde3ccf6-2ad2-4f49-8f3a-5d735d7c4949" xlink:href="amgn-20201231.xsd#amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_cde3ccf6-2ad2-4f49-8f3a-5d735d7c4949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_819088ee-f536-46c1-8cca-caa526a39132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_819088ee-f536-46c1-8cca-caa526a39132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_ac69f1f5-2f2d-4536-896d-e917370f7031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_ac69f1f5-2f2d-4536-896d-e917370f7031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9323c861-75db-4c0c-83ce-b4a4ddeff5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9323c861-75db-4c0c-83ce-b4a4ddeff5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a80fd174-15b1-4168-97b9-990a1cdf1697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a80fd174-15b1-4168-97b9-990a1cdf1697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_2a52a68b-4703-4db9-8dad-28892999cdc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_2a52a68b-4703-4db9-8dad-28892999cdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss_82e748bc-4b2a-44d3-9f69-3af291d65cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss_82e748bc-4b2a-44d3-9f69-3af291d65cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_24431ee9-35cf-4372-b7f0-04a84dc7ef47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_24431ee9-35cf-4372-b7f0-04a84dc7ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_7738d7cf-aa9f-4684-bbac-e5d16dd50a3d" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_7738d7cf-aa9f-4684-bbac-e5d16dd50a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4132395-0d4b-4a3e-a74b-f3a1e233b2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4132395-0d4b-4a3e-a74b-f3a1e233b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a09539ea-c558-49a8-bcab-9c343870ab06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a09539ea-c558-49a8-bcab-9c343870ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_5eeba287-354f-4a55-acf2-59ac8fb616b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_5eeba287-354f-4a55-acf2-59ac8fb616b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_11efac7a-3f5b-4f8a-9a08-7ba95b186603" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_11efac7a-3f5b-4f8a-9a08-7ba95b186603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8002f569-376a-488a-870d-ad62b7820fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_Goodwill_8002f569-376a-488a-870d-ad62b7820fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2c9c6f7b-b1a8-43e9-b87f-d78357ae19fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_2c9c6f7b-b1a8-43e9-b87f-d78357ae19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_3da764de-091f-4035-b3da-210a6134073e" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_3da764de-091f-4035-b3da-210a6134073e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_e34234e7-00ae-45fa-aa37-d6166c55bb44" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_e34234e7-00ae-45fa-aa37-d6166c55bb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_b9547234-0f3a-4ef7-8c77-528122511324" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_147eedb1-0622-4cbd-9a4b-6e7d0507280f" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_b9547234-0f3a-4ef7-8c77-528122511324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsOtezlaDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsOtezlaDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsOtezlaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c68272a8-6e97-4663-aa76-9c8ed8ae183f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c68272a8-6e97-4663-aa76-9c8ed8ae183f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10aec0a3-4e6d-4caf-b0ce-64d5e5ded95b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_dd8848fd-dc75-4f43-8c90-54551ee3c4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_dd8848fd-dc75-4f43-8c90-54551ee3c4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_3b88b77a-d38a-4dbc-b3f3-8a07f35f6167" xlink:href="amgn-20201231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_651e12db-fc68-4112-b49f-4a190ac97375" xlink:to="loc_amgn_MarketingRelatedRightsMember_3b88b77a-d38a-4dbc-b3f3-8a07f35f6167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104415e5-1933-4d0c-b615-be4836c9d4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b3525730-b8eb-4cbc-abb0-64faef1d340f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104415e5-1933-4d0c-b615-be4836c9d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_5b65c153-3847-4b2c-937b-d4f5378ac940" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_104415e5-1933-4d0c-b615-be4836c9d4fb" xlink:to="loc_amgn_OtezlaMember_5b65c153-3847-4b2c-937b-d4f5378ac940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_50bd6e2e-81eb-4631-bc2e-bdc599e468bd" xlink:href="amgn-20201231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionAxis_f0828877-d987-47e9-86ab-32fd2cc3f9c3" xlink:to="loc_amgn_AssetsByDescriptionDomain_50bd6e2e-81eb-4631-bc2e-bdc599e468bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember_aec988de-741f-48e4-b7c2-bd7d33fd45fb" xlink:href="amgn-20201231.xsd#amgn_AssembledWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionDomain_50bd6e2e-81eb-4631-bc2e-bdc599e468bd" xlink:to="loc_amgn_AssembledWorkforceMember_aec988de-741f-48e4-b7c2-bd7d33fd45fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9af94f3-9096-4687-ad11-1928ed3ebfba" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6d012ae7-facf-4f24-8ac5-5ffc321871a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6d012ae7-facf-4f24-8ac5-5ffc321871a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition_54edf5a7-af25-415a-861d-d94b3bd14859" xlink:href="amgn-20201231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_Transactioncostsassetacquisition_54edf5a7-af25-415a-861d-d94b3bd14859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_460930ed-3e1d-4a08-999d-2b60350b57ff" xlink:href="amgn-20201231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_460930ed-3e1d-4a08-999d-2b60350b57ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_55c34802-76f9-4b1d-9c93-f29690c3923d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_55c34802-76f9-4b1d-9c93-f29690c3923d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_8bbccf44-a115-4a50-9c0c-89bf03f8efe6" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_55c34802-76f9-4b1d-9c93-f29690c3923d" xlink:to="loc_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired_8bbccf44-a115-4a50-9c0c-89bf03f8efe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_ee082c5a-b74a-43c9-bb42-a89f8ffb0dbb" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_ee082c5a-b74a-43c9-bb42-a89f8ffb0dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_764cb0c9-dc94-4bee-af26-237bbe265898" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities_764cb0c9-dc94-4bee-af26-237bbe265898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_fa48b97d-0a1c-449b-a087-1f5cb1c27bdb" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_fa48b97d-0a1c-449b-a087-1f5cb1c27bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_00217fc4-f23a-452d-8660-f6820db6971a" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_00217fc4-f23a-452d-8660-f6820db6971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_dea9e596-c22e-4488-a6d8-f65fff423244" xlink:href="amgn-20201231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_d56e3461-929e-449c-bb8d-ba4fecaba209" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_dea9e596-c22e-4488-a6d8-f65fff423244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_993db19c-f52c-4786-9959-a15ffca62a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_197f7c8b-353a-49a1-88d6-da1dfe738384" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_993db19c-f52c-4786-9959-a15ffca62a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_65c583dc-452f-44bd-9ec3-b7cbe04b16f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_65c583dc-452f-44bd-9ec3-b7cbe04b16f1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1edb71c7-e18e-4d4f-bc52-f00f0436e976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb056059-28b8-4e3e-a18a-049193e5f65d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1edb71c7-e18e-4d4f-bc52-f00f0436e976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_06a920b8-f431-4b78-91a4-590ff52c76dd" xlink:href="amgn-20201231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1edb71c7-e18e-4d4f-bc52-f00f0436e976" xlink:to="loc_amgn_RDTechnologyrightsMember_06a920b8-f431-4b78-91a4-590ff52c76dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_031e2392-5f94-4693-b70c-7712d3a8ac34" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember_99283526-f2ea-4175-ac36-59c1d236225e" xlink:href="amgn-20201231.xsd#amgn_NuevolutionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:to="loc_amgn_NuevolutionMember_99283526-f2ea-4175-ac36-59c1d236225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KirinAmgenInc.KAMember_eef8743b-ca25-47d9-994a-a47d285092b9" xlink:href="amgn-20201231.xsd#amgn_KirinAmgenInc.KAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30cf99e2-368e-4076-9e0b-675360e975f2" xlink:to="loc_amgn_KirinAmgenInc.KAMember_eef8743b-ca25-47d9-994a-a47d285092b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a479c6a5-cc65-422f-9ec7-4a9b4e4cf2bc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c67ab3cb-35c9-4ec4-99e6-b51593141ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c67ab3cb-35c9-4ec4-99e6-b51593141ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4bea891e-7cc2-48e8-bdd4-d1edf92ae33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4bea891e-7cc2-48e8-bdd4-d1edf92ae33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_52a05792-ebd7-4ed4-80fd-1a24b3e74b0c" xlink:href="amgn-20201231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_52a05792-ebd7-4ed4-80fd-1a24b3e74b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_13d76e1e-747e-43dc-bbc5-92c5d72a208d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_13d76e1e-747e-43dc-bbc5-92c5d72a208d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ac58e78-d16f-4247-b9b4-91b4d6785905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9ac58e78-d16f-4247-b9b4-91b4d6785905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2d2e3ac8-0bb6-476f-b5ac-bd334187c346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2d2e3ac8-0bb6-476f-b5ac-bd334187c346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_ea1691ee-a9d2-4587-b6e1-5908a3f3c793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e3fa8e9-e833-47a6-a2c0-69ef28bbff75" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_ea1691ee-a9d2-4587-b6e1-5908a3f3c793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Revenues" xlink:type="simple" xlink:href="amgn-20201231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04c7b5db-fb17-4387-9224-0c5965de015d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0155bd48-7f85-4357-820d-62cb09414f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_04c7b5db-fb17-4387-9224-0c5965de015d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0155bd48-7f85-4357-820d-62cb09414f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_189c5c5c-5910-490a-801c-3f2a55fbb552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ad6c0a26-8ed8-4a02-9cec-6cb0704b4f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_189c5c5c-5910-490a-801c-3f2a55fbb552" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ad6c0a26-8ed8-4a02-9cec-6cb0704b4f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_eb811d6e-c644-4697-95d9-43caa5ae0bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_189c5c5c-5910-490a-801c-3f2a55fbb552" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_eb811d6e-c644-4697-95d9-43caa5ae0bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0889409e-a656-43ba-84b8-a82a0bff8a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7cdf9feb-68fa-49cf-ae7f-eea76d36c3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0889409e-a656-43ba-84b8-a82a0bff8a21" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7cdf9feb-68fa-49cf-ae7f-eea76d36c3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0889409e-a656-43ba-84b8-a82a0bff8a21" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e7ca0748-f91f-41f1-8cb5-cee7271d760d" xlink:to="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_66fbfa2a-5fcd-4ce3-97c9-7acffc0b9051" xlink:href="amgn-20201231.xsd#amgn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:to="loc_amgn_CustomerOneMember_66fbfa2a-5fcd-4ce3-97c9-7acffc0b9051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_d07896d2-6e11-4053-9f91-4c6dd55bc2fb" xlink:href="amgn-20201231.xsd#amgn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:to="loc_amgn_CustomerTwoMember_d07896d2-6e11-4053-9f91-4c6dd55bc2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_1d53f557-8dcb-445e-9d62-13191dc1f26b" xlink:href="amgn-20201231.xsd#amgn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_11ba2635-8de1-49bd-a558-03a513ccf547" xlink:to="loc_amgn_CustomerThreeMember_1d53f557-8dcb-445e-9d62-13191dc1f26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_63263355-3551-4227-a5d1-34d1e136fd64" xlink:to="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:to="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_6c6d311a-87b0-4019-a229-e410ec99f257" xlink:href="amgn-20201231.xsd#amgn_EnbrelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_EnbrelMember_6c6d311a-87b0-4019-a229-e410ec99f257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_9303a672-3059-46fe-bb08-86c2930b0bce" xlink:href="amgn-20201231.xsd#amgn_ProliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_ProliaMember_9303a672-3059-46fe-bb08-86c2930b0bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_b2746457-03c6-4803-8369-b7c25677ffeb" xlink:href="amgn-20201231.xsd#amgn_NeulastaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_NeulastaMember_b2746457-03c6-4803-8369-b7c25677ffeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_57c1e4b1-ef0e-475c-b1b7-e0919fb6202f" xlink:href="amgn-20201231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_OtezlaMember_57c1e4b1-ef0e-475c-b1b7-e0919fb6202f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_7dd87efa-5827-4a5e-9c24-5cf238b4c332" xlink:href="amgn-20201231.xsd#amgn_XgevaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_XgevaMember_7dd87efa-5827-4a5e-9c24-5cf238b4c332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_4d5804f2-48ac-462e-81bf-f8a40c9d621f" xlink:href="amgn-20201231.xsd#amgn_AranespMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_AranespMember_4d5804f2-48ac-462e-81bf-f8a40c9d621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_fff3a940-8734-4136-b0fa-9bdb4324e6ec" xlink:href="amgn-20201231.xsd#amgn_KyprolisMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_KyprolisMember_fff3a940-8734-4136-b0fa-9bdb4324e6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_2b0273d6-9a94-43e4-a4c6-50e7b4fbca4f" xlink:href="amgn-20201231.xsd#amgn_RepathaevolocumabMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_RepathaevolocumabMember_2b0273d6-9a94-43e4-a4c6-50e7b4fbca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_7da03712-ab0a-4986-b769-ae20bd4c8772" xlink:href="amgn-20201231.xsd#amgn_OtherProductsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_57f05dbb-55b9-41f0-9b90-22ed45a8a545" xlink:to="loc_amgn_OtherProductsMember_7da03712-ab0a-4986-b769-ae20bd4c8772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e0de3948-5f46-4430-be09-1396fc684187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_188633ae-9c96-4141-bb10-ad0c693782e7" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e0de3948-5f46-4430-be09-1396fc684187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1039bb53-bf75-4737-aee3-1e9f6a089924" xlink:to="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6c0cef20-9075-4e7e-92f9-41aee08bec1a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:to="loc_country_US_6c0cef20-9075-4e7e-92f9-41aee08bec1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f0c86b04-5956-48ac-a64f-6cf2eb057cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e307744a-2956-408b-a804-a239f51b158b" xlink:to="loc_us-gaap_NonUsMember_f0c86b04-5956-48ac-a64f-6cf2eb057cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_1ca5d41f-2c8c-422c-8f17-84db343548df" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_f1366e1f-9e6b-4ed8-be30-a91681985ba6" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_f1366e1f-9e6b-4ed8-be30-a91681985ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_7cb3d92a-2755-45c8-a4cd-0451ca96f6b8" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_7cb3d92a-2755-45c8-a4cd-0451ca96f6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_92a696af-66c0-4668-9c39-4bedda40b51f" xlink:href="amgn-20201231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_92a696af-66c0-4668-9c39-4bedda40b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_fc5b3e6a-9d56-47a0-bf9d-fb8ce1d7140b" xlink:href="amgn-20201231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_fc5b3e6a-9d56-47a0-bf9d-fb8ce1d7140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd8523b9-4700-4e72-8ab7-fc6352d8f1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd8523b9-4700-4e72-8ab7-fc6352d8f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_0b467fce-7dc6-4075-a5db-f7ea282fd0d5" xlink:href="amgn-20201231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_504bab93-576a-4dd6-b659-674aa5388921" xlink:to="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_0b467fce-7dc6-4075-a5db-f7ea282fd0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_491a55d0-c090-487a-850f-5063e1e7dedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_491a55d0-c090-487a-850f-5063e1e7dedc" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:to="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52ed99a1-43a5-4484-b913-e164477a42f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_787b4774-6a38-4606-9687-a66f2562aa36" xlink:to="loc_srt_ProductsAndServicesDomain_52ed99a1-43a5-4484-b913-e164477a42f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_384d8a89-3283-406d-9e90-77f2cd00db69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52ed99a1-43a5-4484-b913-e164477a42f6" xlink:to="loc_us-gaap_ProductMember_384d8a89-3283-406d-9e90-77f2cd00db69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:to="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_62eadeb6-4dd6-44f3-a14a-fd7d41f2542b" xlink:to="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_c07e72a8-5f11-4a66-a015-ca277f22c3fa" xlink:href="amgn-20201231.xsd#amgn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:to="loc_amgn_CustomerOneMember_c07e72a8-5f11-4a66-a015-ca277f22c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_2996d45c-effe-4322-8187-603be3f36912" xlink:href="amgn-20201231.xsd#amgn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:to="loc_amgn_CustomerTwoMember_2996d45c-effe-4322-8187-603be3f36912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_59a4af3a-7912-43a1-a6f5-7b930a652d0c" xlink:href="amgn-20201231.xsd#amgn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6968b2eb-8836-4937-80d7-73f45e4f3b1e" xlink:to="loc_amgn_CustomerThreeMember_59a4af3a-7912-43a1-a6f5-7b930a652d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ee586c9e-dbd7-482e-b95f-fbb50665ba54" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_28a65cfe-8a67-4f53-93bc-96f04481115e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_28a65cfe-8a67-4f53-93bc-96f04481115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues_2b997e9d-3fd6-4bba-a1db-16fff6fa45b7" xlink:href="amgn-20201231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_PercentageOfGrossRevenues_2b997e9d-3fd6-4bba-a1db-16fff6fa45b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_77afc4ec-4434-4d13-aa59-ad6d7414f40d" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_77afc4ec-4434-4d13-aa59-ad6d7414f40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_ca762970-c771-412d-8e1c-db0ab708c809" xlink:href="amgn-20201231.xsd#amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers_ca762970-c771-412d-8e1c-db0ab708c809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_02e4ab7d-eccc-4d0c-8383-034a3247fb11" xlink:href="amgn-20201231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b7eaea70-5599-4c3d-a4bc-301caf097222" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_02e4ab7d-eccc-4d0c-8383-034a3247fb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="amgn-20201231.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dceb9c6-bec0-4e71-baaf-3dc641ce8cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70d8d432-1133-4477-b669-81eab9ba1a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dceb9c6-bec0-4e71-baaf-3dc641ce8cab" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70d8d432-1133-4477-b669-81eab9ba1a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dda6ee-8f58-48de-9043-5ccac7b55e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_7e7dc39d-b0a5-4a45-8071-5b7391b790f3" xlink:href="amgn-20201231.xsd#amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dda6ee-8f58-48de-9043-5ccac7b55e59" xlink:to="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_7e7dc39d-b0a5-4a45-8071-5b7391b790f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_dfc59641-5260-4018-b602-3e62bcd46ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dda6ee-8f58-48de-9043-5ccac7b55e59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_dfc59641-5260-4018-b602-3e62bcd46ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d987509b-c014-41db-a764-f972e686204c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dda6ee-8f58-48de-9043-5ccac7b55e59" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d987509b-c014-41db-a764-f972e686204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9e506810-1b97-4d92-b619-ae6a8cc0522a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dda6ee-8f58-48de-9043-5ccac7b55e59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9e506810-1b97-4d92-b619-ae6a8cc0522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_a13cb376-d586-45a0-b195-8e269f72f04a" xlink:href="amgn-20201231.xsd#amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07dda6ee-8f58-48de-9043-5ccac7b55e59" xlink:to="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_a13cb376-d586-45a0-b195-8e269f72f04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f66e1bc-9200-4127-8b04-dfdf10255e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f66e1bc-9200-4127-8b04-dfdf10255e21" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:to="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2571cef2-bef3-456c-9fdf-ebdd246cdd1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_87af8e33-0a9b-4c3a-b4dd-15b813ec9fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_87af8e33-0a9b-4c3a-b4dd-15b813ec9fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b6efaded-add8-4276-9a23-c8647ddf937a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b6efaded-add8-4276-9a23-c8647ddf937a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_2082f823-e2e6-4aa1-a102-2314f0c09400" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36765888-d554-4d73-b4bc-3055fc5ddcf8" xlink:to="loc_amgn_PerformanceUnitsMember_2082f823-e2e6-4aa1-a102-2314f0c09400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e33e89-c588-4e08-be6d-5930c98899cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_0abce899-c92a-4b83-bc5b-6f8363b1adfa" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_0abce899-c92a-4b83-bc5b-6f8363b1adfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_c389febb-0692-43e2-8c27-a49217a07f8b" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_c389febb-0692-43e2-8c27-a49217a07f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d2a802e7-327f-4236-b54f-c918d8f05bd9" xlink:href="amgn-20201231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d2a802e7-327f-4236-b54f-c918d8f05bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_f3873952-9848-401e-b009-2def0f187bce" xlink:href="amgn-20201231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_f3873952-9848-401e-b009-2def0f187bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2b601d50-f145-4113-bce2-1b4d9b931a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2b601d50-f145-4113-bce2-1b4d9b931a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe1bf2fd-f6ec-421a-ab6c-6dc9fd3e6232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe1bf2fd-f6ec-421a-ab6c-6dc9fd3e6232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_204d12b2-f03b-412f-a379-71a56828b0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_204d12b2-f03b-412f-a379-71a56828b0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2587fb26-6a51-4acb-a787-aa8f295eebc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2587fb26-6a51-4acb-a787-aa8f295eebc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_399eaf7e-6ffe-47af-8334-1fa72c1b26b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_399eaf7e-6ffe-47af-8334-1fa72c1b26b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5570d8b8-777d-4048-934c-fccc1d8b1014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5570d8b8-777d-4048-934c-fccc1d8b1014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e797be22-977a-424d-9c73-00f87e96b440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e797be22-977a-424d-9c73-00f87e96b440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f56025a3-9dce-40b1-8c4a-0bb73a9605a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f56025a3-9dce-40b1-8c4a-0bb73a9605a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c87c700e-8b2e-466d-9b1a-910baad7f08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c87c700e-8b2e-466d-9b1a-910baad7f08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_14800bf3-caa8-4b48-bf22-47d2acf52d58" xlink:href="amgn-20201231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_14800bf3-caa8-4b48-bf22-47d2acf52d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_008cd951-0d3e-4b78-ada4-174d12484add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_008cd951-0d3e-4b78-ada4-174d12484add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73b97b08-5fb9-453d-b976-7da5ff4e0a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73b97b08-5fb9-453d-b976-7da5ff4e0a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6be01a81-f3b2-4800-ad44-941a0a346c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6be01a81-f3b2-4800-ad44-941a0a346c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4835a08a-8aa5-41ad-afd4-c5c4046a7e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4835a08a-8aa5-41ad-afd4-c5c4046a7e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ddaa7f29-a0ee-45d1-82b6-869dda28c009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25d91085-ebf7-4866-958e-2ddce8ff0e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ddaa7f29-a0ee-45d1-82b6-869dda28c009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33a8bbe0-c04e-4b46-bf73-991e78bb1429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33a8bbe0-c04e-4b46-bf73-991e78bb1429" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:to="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1819a46e-6000-4ed8-a758-bb8bc36d7964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0677b7-9f2b-4131-b21b-16a0de863f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0677b7-9f2b-4131-b21b-16a0de863f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_17271fac-f118-464b-9bf7-8e914306787f" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:to="loc_amgn_PerformanceUnitsMember_17271fac-f118-464b-9bf7-8e914306787f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53473345-4dd6-44c2-8a88-0a3b8cd85174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6659b2af-238e-4588-8194-22359bcfdd7a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53473345-4dd6-44c2-8a88-0a3b8cd85174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c97892e8-568c-481c-9a58-ad83e0f7a089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca449d68-da63-4246-9595-4c4d5fe81976" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c97892e8-568c-481c-9a58-ad83e0f7a089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c97892e8-568c-481c-9a58-ad83e0f7a089" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_70414939-0dcc-44b8-9085-f098c3f08dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:to="loc_us-gaap_ShareBasedCompensation_70414939-0dcc-44b8-9085-f098c3f08dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_522eace6-1822-4028-8db3-5717c76fd39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_522eace6-1822-4028-8db3-5717c76fd39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_c7b0bd70-9f8f-4d5a-9c07-98c33d6723d7" xlink:href="amgn-20201231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7be507cc-ed5b-4562-83ab-9f09c3d94268" xlink:to="loc_amgn_StockBasedCompensationExpenseNetOfTax_c7b0bd70-9f8f-4d5a-9c07-98c33d6723d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df9a1716-62f1-4e9c-bcab-b238a9159566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df9a1716-62f1-4e9c-bcab-b238a9159566" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:to="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f602f95d-f265-4ec9-97dc-8092e825fe2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a495d144-4267-443d-8518-60582f8f59ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f602f95d-f265-4ec9-97dc-8092e825fe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_823212e6-b919-4d82-ae9c-0400e053c172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f602f95d-f265-4ec9-97dc-8092e825fe2e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_823212e6-b919-4d82-ae9c-0400e053c172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2175c560-8c62-4dec-98aa-9885d0ef4836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ac3dce8b-16e6-44c6-9b6f-c6a829c8af33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ac3dce8b-16e6-44c6-9b6f-c6a829c8af33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b515185e-096a-4bc6-9d37-2052402b35c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b515185e-096a-4bc6-9d37-2052402b35c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_312d2521-0c84-4617-a13b-a60aedbf395c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_312d2521-0c84-4617-a13b-a60aedbf395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_343359bb-dea7-4c87-a79e-347f4b36fda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_343359bb-dea7-4c87-a79e-347f4b36fda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_37abe796-7644-4da8-a0c9-bb735b203829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60015633-d245-4376-9f31-2bbf186acc3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_37abe796-7644-4da8-a0c9-bb735b203829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b05c58d-891b-41ed-896c-6fea37a90588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_190c4d43-a339-492b-846c-b2c7366fd51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_190c4d43-a339-492b-846c-b2c7366fd51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b290859-d079-45ff-b9d5-32d18601f7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b290859-d079-45ff-b9d5-32d18601f7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4b0472cb-0a0c-4b91-b207-5d5a1cb152b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4b0472cb-0a0c-4b91-b207-5d5a1cb152b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12c30f88-0116-483c-a8a5-61f865b4c709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12c30f88-0116-483c-a8a5-61f865b4c709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bca62222-0cc7-4f6e-a5c2-a0b070e6154d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_769cbb5f-67fe-4410-99a1-7e994133b4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bca62222-0cc7-4f6e-a5c2-a0b070e6154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02872b8c-24ab-4c53-be14-3aca4e256c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02872b8c-24ab-4c53-be14-3aca4e256c0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:to="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98a12d0-2c24-4b1d-89d8-c518439c5c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ec54c481-55e7-4a10-9da9-32dbb9647cca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98a12d0-2c24-4b1d-89d8-c518439c5c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a0c47649-4d65-4f41-9040-d148061e78be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98a12d0-2c24-4b1d-89d8-c518439c5c9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a0c47649-4d65-4f41-9040-d148061e78be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7727e0d1-fa6b-4e71-93c2-bd26e3cf78d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_1417b907-ab50-48ee-a83b-d061a3769750" xlink:href="amgn-20201231.xsd#amgn_CommonStockFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_amgn_CommonStockFairValue_1417b907-ab50-48ee-a83b-d061a3769750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81efa34a-0ca8-4851-bd9b-399a4a68d986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81efa34a-0ca8-4851-bd9b-399a4a68d986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e4c7c92a-17d4-422d-bd02-0e5c1b75c21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e4c7c92a-17d4-422d-bd02-0e5c1b75c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_907f4172-6944-4551-bed7-4f9ad2c80624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_907f4172-6944-4551-bed7-4f9ad2c80624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4727d44f-dd93-4e31-a6a1-4f4a38aced94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4727d44f-dd93-4e31-a6a1-4f4a38aced94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fefda351-69f4-420b-9d87-d59b8227fd27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19944f81-449c-4568-a65e-8db1dd1e648b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fefda351-69f4-420b-9d87-d59b8227fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33591ab6-b95a-4ad8-b676-73fdcc1499be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33591ab6-b95a-4ad8-b676-73fdcc1499be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:to="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd30ca8-ded8-47e7-95aa-c182908f608d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f1309c57-c663-4328-90c9-122594cf98fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd30ca8-ded8-47e7-95aa-c182908f608d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8bd225c-b349-4838-999c-0f0a7acf1e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffd30ca8-ded8-47e7-95aa-c182908f608d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8bd225c-b349-4838-999c-0f0a7acf1e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1faa6676-3f15-47f3-b684-19a085b75de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2abd9492-d0ac-49ae-99c8-a897746b4a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2abd9492-d0ac-49ae-99c8-a897746b4a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1b819552-4154-478c-a5af-1293deec3716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1b819552-4154-478c-a5af-1293deec3716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d6ec8e97-0a99-42fd-84b3-8ef3c18838ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d6ec8e97-0a99-42fd-84b3-8ef3c18838ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ae558ad8-25a5-498d-b452-265435310f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ae558ad8-25a5-498d-b452-265435310f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff1ce46f-6643-4093-b393-dc3222321362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a550e512-f7bd-4ecd-9bca-76a424db357d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff1ce46f-6643-4093-b393-dc3222321362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d2f12f9-2e24-44e5-aa4c-28fcdec8dc8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d2f12f9-2e24-44e5-aa4c-28fcdec8dc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3dac17d9-d62a-4960-b6e7-edfa46b08c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3dac17d9-d62a-4960-b6e7-edfa46b08c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f306901f-293c-4aa8-bafb-72a7b089b46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f306901f-293c-4aa8-bafb-72a7b089b46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8d36475-555d-417c-a507-8b6413e669c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8d36475-555d-417c-a507-8b6413e669c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee2684ee-3f2c-4f85-9310-8a534467a65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee2684ee-3f2c-4f85-9310-8a534467a65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_97b692d1-482f-4453-85f3-b6f0b0d603b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_97b692d1-482f-4453-85f3-b6f0b0d603b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4553b7f-2975-434a-a02a-d2dcb36e813a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcf71e4a-b7bf-4499-bda6-84b7d9ebb022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4553b7f-2975-434a-a02a-d2dcb36e813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b6ce52a7-8efd-458a-aaec-a88f0ad59924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b6ce52a7-8efd-458a-aaec-a88f0ad59924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30227a3f-982f-42f2-be9c-803f0a9f7ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30227a3f-982f-42f2-be9c-803f0a9f7ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7489d810-4295-409b-b63f-3c8aad54f451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eccb9021-653d-4fcb-aa3d-4115abbae538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eccb9021-653d-4fcb-aa3d-4115abbae538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d6b125be-f216-4c66-b082-f5341b818809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d6b125be-f216-4c66-b082-f5341b818809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f2021d9b-676a-4163-b661-082b589936f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f2021d9b-676a-4163-b661-082b589936f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6584f16f-ff8c-406e-a509-eaa42c2066c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6584f16f-ff8c-406e-a509-eaa42c2066c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c5b3bb38-b3c9-4c05-99b2-2a8dd400d70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c5b3bb38-b3c9-4c05-99b2-2a8dd400d70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15f1fa3a-5ae4-49f7-bede-87228dd293f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_320d4a9a-7c5e-482d-8dcc-97ca15f61eaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15f1fa3a-5ae4-49f7-bede-87228dd293f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf25175b-d513-445c-8ad7-918aad9cba2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bf25175b-d513-445c-8ad7-918aad9cba2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:to="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f62c7b-0f03-429f-bd47-69e8558c8474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6f65612f-2b1a-435a-9e04-971ed4668dec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f62c7b-0f03-429f-bd47-69e8558c8474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_06efd60f-8904-4808-98be-4f9307568cbe" xlink:href="amgn-20201231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f62c7b-0f03-429f-bd47-69e8558c8474" xlink:to="loc_amgn_PerformanceUnitsMember_06efd60f-8904-4808-98be-4f9307568cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f281a66b-c049-466c-9a3c-8e0c38c3860d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0db2528e-2317-4c52-8d94-18237e36bb65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f281a66b-c049-466c-9a3c-8e0c38c3860d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f281a66b-c049-466c-9a3c-8e0c38c3860d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_5cd96715-d30c-4ec9-bbdc-5ed85479f379" xlink:href="amgn-20201231.xsd#amgn_CommonStockFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_amgn_CommonStockFairValue_5cd96715-d30c-4ec9-bbdc-5ed85479f379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aa818743-cb65-44bc-8cd9-262d831249b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aa818743-cb65-44bc-8cd9-262d831249b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13ecacf6-3565-49e3-a81e-0e2a7dbb81c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13ecacf6-3565-49e3-a81e-0e2a7dbb81c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da724ab0-e7f9-4248-9cf8-7191c5b25748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ade8b8b3-c393-481c-9b49-353590c2b772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da724ab0-e7f9-4248-9cf8-7191c5b25748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Definedcontributionplan" xlink:type="simple" xlink:href="amgn-20201231.xsd#Definedcontributionplan"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Definedcontributionplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80ab45be-376b-48fc-9062-47bfa10e8045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0cf7d533-4720-4324-a3ec-fccba72669c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80ab45be-376b-48fc-9062-47bfa10e8045" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0cf7d533-4720-4324-a3ec-fccba72669c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DefinedcontributionplanDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dafe4048-b31d-4f46-abc6-fa5e96d1d96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_c099bf10-7d20-42fe-8e7f-13dfcd7c8a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dafe4048-b31d-4f46-abc6-fa5e96d1d96e" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_c099bf10-7d20-42fe-8e7f-13dfcd7c8a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Incometaxes" xlink:type="simple" xlink:href="amgn-20201231.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cdd1f2ce-5830-4376-8749-7fac2c781c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a6ac29ea-b30b-4b6c-8105-c8f08439c411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cdd1f2ce-5830-4376-8749-7fac2c781c8d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a6ac29ea-b30b-4b6c-8105-c8f08439c411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_adfed461-b936-492f-bbfc-86ebc287bb71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e7ae0986-fc93-4fa1-84e0-d2e186c5dd04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_adfed461-b936-492f-bbfc-86ebc287bb71" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e7ae0986-fc93-4fa1-84e0-d2e186c5dd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_23b69b4e-cc7c-423e-b791-f395c93259ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_adfed461-b936-492f-bbfc-86ebc287bb71" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_23b69b4e-cc7c-423e-b791-f395c93259ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9f444861-d315-4b61-a644-8b7715f560d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_adfed461-b936-492f-bbfc-86ebc287bb71" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9f444861-d315-4b61-a644-8b7715f560d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_11a3ad2a-a540-4f32-9f97-280ae9bf21bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_adfed461-b936-492f-bbfc-86ebc287bb71" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_11a3ad2a-a540-4f32-9f97-280ae9bf21bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8730634d-faa0-43b6-8f6e-338cba778f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_adfed461-b936-492f-bbfc-86ebc287bb71" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8730634d-faa0-43b6-8f6e-338cba778f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8e480767-f7f1-4be4-9caf-f54e00ecf3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8e480767-f7f1-4be4-9caf-f54e00ecf3bc" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d956eaf8-06d1-4fcb-9f2b-4c456600f32c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_aa5626e5-f47e-40a8-85f4-8e8dd1ec2e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:to="loc_us-gaap_DomesticCountryMember_aa5626e5-f47e-40a8-85f4-8e8dd1ec2e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0390c886-48d2-4c46-b6da-b57db846407a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1424881e-ed93-45a4-94ff-3effc6cac0d4" xlink:to="loc_us-gaap_ForeignCountryMember_0390c886-48d2-4c46-b6da-b57db846407a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_6b6f32ee-3f3a-4be5-a97a-682771383c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_a3de7bd9-c14b-4242-82df-7a1df50c4da1" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_6b6f32ee-3f3a-4be5-a97a-682771383c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fd414b69-abf8-43fe-8954-531256db6887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6b6f32ee-3f3a-4be5-a97a-682771383c9a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fd414b69-abf8-43fe-8954-531256db6887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6d3ec805-d3d3-4b94-b051-7cc7417064ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_275ff12d-d39e-40d0-b98b-f8e940fcf7d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6d3ec805-d3d3-4b94-b051-7cc7417064ce" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_275ff12d-d39e-40d0-b98b-f8e940fcf7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6e534155-c32f-4148-8780-03146dbb869e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_275ff12d-d39e-40d0-b98b-f8e940fcf7d4" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6e534155-c32f-4148-8780-03146dbb869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_22fb16f6-82df-4fd6-bff2-c884f9d32eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_275ff12d-d39e-40d0-b98b-f8e940fcf7d4" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_22fb16f6-82df-4fd6-bff2-c884f9d32eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e4646e94-7b37-4b94-97d0-d82aafabfee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_275ff12d-d39e-40d0-b98b-f8e940fcf7d4" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e4646e94-7b37-4b94-97d0-d82aafabfee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9d8fcfc4-bde9-4538-b2c5-fc3370438426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_275ff12d-d39e-40d0-b98b-f8e940fcf7d4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9d8fcfc4-bde9-4538-b2c5-fc3370438426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_08dccb50-f086-4f33-84fa-70932e26c3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6d3ec805-d3d3-4b94-b051-7cc7417064ce" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_08dccb50-f086-4f33-84fa-70932e26c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8700c03f-9486-47fb-ae61-d4b285cbe229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_08dccb50-f086-4f33-84fa-70932e26c3a7" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8700c03f-9486-47fb-ae61-d4b285cbe229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_66ae0db5-03ff-4a81-994f-e32e118761ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_08dccb50-f086-4f33-84fa-70932e26c3a7" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_66ae0db5-03ff-4a81-994f-e32e118761ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e222728d-bd3f-4d8d-800e-09af9bb93de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_08dccb50-f086-4f33-84fa-70932e26c3a7" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e222728d-bd3f-4d8d-800e-09af9bb93de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e0de450d-2c63-425b-bb8a-bbc10e0f7161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_08dccb50-f086-4f33-84fa-70932e26c3a7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e0de450d-2c63-425b-bb8a-bbc10e0f7161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e2126afc-e554-4098-a69f-a9eb03d01337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6d3ec805-d3d3-4b94-b051-7cc7417064ce" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e2126afc-e554-4098-a69f-a9eb03d01337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6554cded-2ed1-421f-9663-cc93d408724c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_19cbcc2b-a81b-4513-8beb-25d8acfac371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6554cded-2ed1-421f-9663-cc93d408724c" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_19cbcc2b-a81b-4513-8beb-25d8acfac371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_19cbcc2b-a81b-4513-8beb-25d8acfac371" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_561531b2-c56a-41af-aebb-087e164378a7" xlink:href="amgn-20201231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_561531b2-c56a-41af-aebb-087e164378a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9db67f9b-afad-42f9-9c5d-7e4015405bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9db67f9b-afad-42f9-9c5d-7e4015405bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_37082cb1-4ce6-4761-946a-97140f692136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_37082cb1-4ce6-4761-946a-97140f692136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_62272d07-4242-42d7-8789-015e203f08f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_62272d07-4242-42d7-8789-015e203f08f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2c4272c9-aef5-449f-a954-3d5b093518c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2c4272c9-aef5-449f-a954-3d5b093518c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4bda17c4-10ef-47c5-a12b-ecf339bdbeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4bda17c4-10ef-47c5-a12b-ecf339bdbeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5ed96a1f-85ea-4d22-b72b-351d6c94a763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5ed96a1f-85ea-4d22-b72b-351d6c94a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2305668b-2aa2-4a6a-8bfa-a8583fe44170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3666c437-d4a9-4e2f-a21b-8924acf214e1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2305668b-2aa2-4a6a-8bfa-a8583fe44170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_19cbcc2b-a81b-4513-8beb-25d8acfac371" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1b9fd7dc-7a71-4898-81ca-3c5347f9182f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1b9fd7dc-7a71-4898-81ca-3c5347f9182f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_7a2e52dd-8e4c-4050-b764-b12e018963ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_7a2e52dd-8e4c-4050-b764-b12e018963ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2e2fde5d-7fac-4f87-86df-4a283c83baed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2e2fde5d-7fac-4f87-86df-4a283c83baed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5d0ec677-8898-4794-bc34-0f0b86bfec10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5d0ec677-8898-4794-bc34-0f0b86bfec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_08a30a1e-a531-4464-a257-c4450be413dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_08a30a1e-a531-4464-a257-c4450be413dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cec6b85e-878a-4475-ab4e-4e910d5740ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_46cc52ac-8ddc-429b-a11a-928d0f00dea2" xlink:to="loc_us-gaap_DeferredTaxLiabilities_cec6b85e-878a-4475-ab4e-4e910d5740ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06d38bdb-5723-46d7-99eb-c36803baa39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06d38bdb-5723-46d7-99eb-c36803baa39d" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e71a1314-cc7f-4714-aa13-b4cf3aa4add3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4ab1b363-9c5b-4ad9-9cba-75369285ade1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:to="loc_us-gaap_DomesticCountryMember_4ab1b363-9c5b-4ad9-9cba-75369285ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_089e7c09-0903-4642-ad28-0a3bcc273231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_089e7c09-0903-4642-ad28-0a3bcc273231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_565ae4a7-fe59-4b55-a5c8-f26941603f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16f67e18-041d-4dfe-bfc1-e20bb86ddfc3" xlink:to="loc_us-gaap_ForeignCountryMember_565ae4a7-fe59-4b55-a5c8-f26941603f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:to="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_32082435-0f91-40f4-878c-5321d60bef8b" xlink:to="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2021And2035Member_02cb72d7-991b-4533-894e-49165489aaeb" xlink:href="amgn-20201231.xsd#amgn_OperatingLossesThatExpireBetween2021And2035Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2021And2035Member_02cb72d7-991b-4533-894e-49165489aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2021And2030Member_c8c2e6e7-298f-4fc5-840b-19b661dd04bf" xlink:href="amgn-20201231.xsd#amgn_OperatingLossesThatExpireBetween2021And2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2021And2030Member_c8c2e6e7-298f-4fc5-840b-19b661dd04bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2035Member_c9ca9261-5d71-4f54-bde6-cfc6fef787ef" xlink:href="amgn-20201231.xsd#amgn_ExpirationInTaxYearsBetween2023And2035Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_ecb42ca8-ab70-4dbe-b644-c92342bad475" xlink:to="loc_amgn_ExpirationInTaxYearsBetween2023And2035Member_c9ca9261-5d71-4f54-bde6-cfc6fef787ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dcea6516-d0fb-48fe-8f11-7557eb4b0087" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_134996dc-7560-4a30-9574-629a3077e4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_134996dc-7560-4a30-9574-629a3077e4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_61dec333-ba3e-4e51-aeee-f3c6f3349168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_61dec333-ba3e-4e51-aeee-f3c6f3349168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_835d532e-87f7-4d40-b654-0187813cc546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_OperatingLossCarryforwards_835d532e-87f7-4d40-b654-0187813cc546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_30972823-136b-4ae3-b7f3-1fffddca290b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_30972823-136b-4ae3-b7f3-1fffddca290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_750e3157-3ba2-4490-8dba-28be48cc2dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_750e3157-3ba2-4490-8dba-28be48cc2dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c8b724b1-fe58-4e5d-b3a7-e917d4d277cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c8b724b1-fe58-4e5d-b3a7-e917d4d277cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6950710c-c462-46a3-bffc-ac071fed33a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6950710c-c462-46a3-bffc-ac071fed33a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_53133ae5-1a72-4d13-b002-2a54aad67ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0889e13a-9e57-42cb-9bbb-7ff50716ee76" xlink:to="loc_us-gaap_IncomeTaxesPaid_53133ae5-1a72-4d13-b002-2a54aad67ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_406342b2-80fa-43d9-99f7-6d0d6f694321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_406342b2-80fa-43d9-99f7-6d0d6f694321" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e8f199e5-5362-4b6b-868c-64149e5d390c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e8f199e5-5362-4b6b-868c-64149e5d390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5360e876-de01-4efd-b57d-11f0db9e48c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5360e876-de01-4efd-b57d-11f0db9e48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a51f4972-9c8e-4b44-8336-ad77cacccd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a51f4972-9c8e-4b44-8336-ad77cacccd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a5e164b0-6f1f-4b51-a418-df212aad4cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a5e164b0-6f1f-4b51-a418-df212aad4cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_65a90f39-0181-4485-bbb9-c07467d06a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_65a90f39-0181-4485-bbb9-c07467d06a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5bb8bc99-e6cd-4169-b930-c91d40fa4c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5bb8bc99-e6cd-4169-b930-c91d40fa4c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_bb8990a1-9959-4781-b866-ae0874e2a540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5f9d45a-305f-4d3e-b7f9-c91b308ddc56" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_bb8990a1-9959-4781-b866-ae0874e2a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_18c55003-fd6d-46ce-ba6f-97d577e83c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_18c55003-fd6d-46ce-ba6f-97d577e83c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8089be5f-b2a6-4f82-be50-b0d13e9be72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8089be5f-b2a6-4f82-be50-b0d13e9be72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_4c6ca9ef-2697-46b7-a5a8-1fb344041b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_4c6ca9ef-2697-46b7-a5a8-1fb344041b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_4c656527-c502-41e2-8e89-547aac5521c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_4c656527-c502-41e2-8e89-547aac5521c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_7f34b2c7-4ac9-400d-a144-4c30b35f8005" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent_7f34b2c7-4ac9-400d-a144-4c30b35f8005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_9e305107-a0d8-4397-86c4-2367f84fa6ed" xlink:href="amgn-20201231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_9e305107-a0d8-4397-86c4-2367f84fa6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3a338968-601f-407e-87e1-873a3c40c25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3a338968-601f-407e-87e1-873a3c40c25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0252370a-b8d4-4da4-8cdf-a6fabba18f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0252370a-b8d4-4da4-8cdf-a6fabba18f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_aef5cea8-9e26-4380-8b33-f714ed97f197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_aef5cea8-9e26-4380-8b33-f714ed97f197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b875a9c6-fde4-4580-8ec0-ee9c55f652af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b74a9e6-9c25-4583-994d-ac1ed36bf126" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b875a9c6-fde4-4580-8ec0-ee9c55f652af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Earningspershare" xlink:type="simple" xlink:href="amgn-20201231.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89b7269f-3b9e-4316-9d5d-4576b3046133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d4cbf9e9-9729-4a32-b282-00a57bfc89dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89b7269f-3b9e-4316-9d5d-4576b3046133" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d4cbf9e9-9729-4a32-b282-00a57bfc89dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_74d12415-5c47-4517-bbf1-8cae4c80338f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1fa51eed-d6fe-447f-9d66-cfc68ea2fcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_74d12415-5c47-4517-bbf1-8cae4c80338f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1fa51eed-d6fe-447f-9d66-cfc68ea2fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#EarningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_71f69a64-08a3-4156-829b-b44d4c13ec52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract_f5473739-7217-4045-a5e2-f6ea6a273e0e" xlink:href="amgn-20201231.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71f69a64-08a3-4156-829b-b44d4c13ec52" xlink:to="loc_amgn_BasicAndDilutedEarningPerShareAbstract_f5473739-7217-4045-a5e2-f6ea6a273e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_dfd0c07e-6524-4957-97b9-5f1fefee453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_f5473739-7217-4045-a5e2-f6ea6a273e0e" xlink:to="loc_us-gaap_NetIncomeLossAbstract_dfd0c07e-6524-4957-97b9-5f1fefee453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0392bc9c-a046-4ad6-9e16-ea72186c3b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_dfd0c07e-6524-4957-97b9-5f1fefee453f" xlink:to="loc_us-gaap_NetIncomeLoss_0392bc9c-a046-4ad6-9e16-ea72186c3b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c3e8523e-9c14-435c-9bea-5f172b178ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_f5473739-7217-4045-a5e2-f6ea6a273e0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c3e8523e-9c14-435c-9bea-5f172b178ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_290ed39c-7ab5-4cb5-958e-f9949819043b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c3e8523e-9c14-435c-9bea-5f172b178ea6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_290ed39c-7ab5-4cb5-958e-f9949819043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0565816a-d035-46d2-9949-b6e00d562d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c3e8523e-9c14-435c-9bea-5f172b178ea6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0565816a-d035-46d2-9949-b6e00d562d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ae9e0f2-06a9-46a9-a384-9f195f472826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c3e8523e-9c14-435c-9bea-5f172b178ea6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ae9e0f2-06a9-46a9-a384-9f195f472826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f645a72e-49cf-4021-91c4-69f2a59b4c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_f5473739-7217-4045-a5e2-f6ea6a273e0e" xlink:to="loc_us-gaap_EarningsPerShareBasic_f645a72e-49cf-4021-91c4-69f2a59b4c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b182be9d-54f7-4267-b6f1-b7569c0b624e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_f5473739-7217-4045-a5e2-f6ea6a273e0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b182be9d-54f7-4267-b6f1-b7569c0b624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Collaborations" xlink:type="simple" xlink:href="amgn-20201231.xsd#Collaborations"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Collaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0217bcc-47f8-419f-b6b9-cda13fb6322e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_294f998b-2c83-4c9d-ab2c-a5fd5a8fc317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0217bcc-47f8-419f-b6b9-cda13fb6322e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_294f998b-2c83-4c9d-ab2c-a5fd5a8fc317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsNovartisAGDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1a624dc-7326-4a6f-aeda-6095e97d3917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1a624dc-7326-4a6f-aeda-6095e97d3917" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c738a416-d298-4289-ab8b-6e6bf40c2b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f986da10-6a5d-4afc-a07e-8c38b5bdcc0c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c738a416-d298-4289-ab8b-6e6bf40c2b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f2b1023e-e1da-4f23-b89d-33ec0864b4e5" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementwithNovartisPharmaAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c738a416-d298-4289-ab8b-6e6bf40c2b22" xlink:to="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f2b1023e-e1da-4f23-b89d-33ec0864b4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf0253ab-7fdc-468c-9818-487c8acc7b8f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_af99b493-aa08-48fa-8f83-e6f99e0fb923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_af99b493-aa08-48fa-8f83-e6f99e0fb923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_4d3ea7a9-80b6-4cd1-beeb-8484b9e6a451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f2312e8-df29-49e0-8316-692c12c86e73" xlink:to="loc_us-gaap_CostOfSalesMember_4d3ea7a9-80b6-4cd1-beeb-8484b9e6a451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22b07714-7e82-40f4-a0ce-caaff9e9bd24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c02b83ca-d4d1-40a0-94b5-b7acef601d7f" xlink:to="loc_srt_ProductsAndServicesDomain_22b07714-7e82-40f4-a0ce-caaff9e9bd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9aa7d0f6-e5e3-4ccf-b3bf-4c377cf31738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22b07714-7e82-40f4-a0ce-caaff9e9bd24" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9aa7d0f6-e5e3-4ccf-b3bf-4c377cf31738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2b4ce487-7828-4d49-9cd5-36af59328870" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_77169837-7eb0-4bf1-b7a0-19c6e91c23df" xlink:href="amgn-20201231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_77169837-7eb0-4bf1-b7a0-19c6e91c23df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_0b637e5b-04fd-4822-8d84-7e2aa1b9e3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectOperatingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_DirectOperatingCosts_0b637e5b-04fd-4822-8d84-7e2aa1b9e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_09372c16-19cb-4e02-9947-7843880171ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_09372c16-19cb-4e02-9947-7843880171ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_b47c9985-e9e5-4901-b9f7-f21af0b676a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_RoyaltyExpense_b47c9985-e9e5-4901-b9f7-f21af0b676a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f4ddad75-2c12-4208-b5a5-b827e258b4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f2bde64-e839-4330-8741-e421a9fe5dc6" xlink:to="loc_us-gaap_Revenues_f4ddad75-2c12-4208-b5a5-b827e258b4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsBayerHealthCarePharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40680347-3601-41ca-99fd-cce88744b155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40680347-3601-41ca-99fd-cce88744b155" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_def072b9-899f-4ebd-971a-3c508e8e4db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87c7292f-0a5e-4f43-94de-591add61f0a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_def072b9-899f-4ebd-971a-3c508e8e4db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_3510caff-3872-474b-bd40-10ed7bdfebca" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_def072b9-899f-4ebd-971a-3c508e8e4db7" xlink:to="loc_amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member_3510caff-3872-474b-bd40-10ed7bdfebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_56ab7f52-7dc0-4e67-8998-96c59ca6d9eb" xlink:to="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NexavarMember_57a4314a-5371-4420-a5b7-b4f050836f7e" xlink:href="amgn-20201231.xsd#amgn_NexavarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:to="loc_amgn_NexavarMember_57a4314a-5371-4420-a5b7-b4f050836f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_97c15cec-dcb5-43b9-a096-a5eebf8dec48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05cc00ec-ca3d-4111-9b13-eaf5911a0949" xlink:to="loc_us-gaap_RoyaltyMember_97c15cec-dcb5-43b9-a096-a5eebf8dec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca17b1f4-6ad3-482c-b3ac-28d717ca170d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5fb95dd1-a4cb-4990-a3ea-e536c7388c1a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca17b1f4-6ad3-482c-b3ac-28d717ca170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherRevenuesMember_8aa02890-2137-472a-96fb-60e1b604c5ae" xlink:href="amgn-20201231.xsd#amgn_OtherRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca17b1f4-6ad3-482c-b3ac-28d717ca170d" xlink:to="loc_amgn_OtherRevenuesMember_8aa02890-2137-472a-96fb-60e1b604c5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_be198243-dca9-479d-951d-ea87d4162bd2" xlink:to="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_216bc4d5-bec8-4061-ae3b-12acdd88718d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:to="loc_country_US_216bc4d5-bec8-4061-ae3b-12acdd88718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NonUsExcludingJapanMember_a28111fe-59ba-4551-9cc1-479432db09ef" xlink:href="amgn-20201231.xsd#amgn_NonUsExcludingJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8082c23b-a50d-492e-a26c-fb24eaa19254" xlink:to="loc_amgn_NonUsExcludingJapanMember_a28111fe-59ba-4551-9cc1-479432db09ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_446e5d79-b10b-43ca-84b5-c72bff24c106" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofCountriesProductsisMarketedandSold_5e69e012-67c1-4098-be09-97c482d4fad9" xlink:href="amgn-20201231.xsd#amgn_NumberofCountriesProductsisMarketedandSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_amgn_NumberofCountriesProductsisMarketedandSold_5e69e012-67c1-4098-be09-97c482d4fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementRoyaltyIncomePercentage_ca2b8f05-3f90-463d-9def-66162a9b929e" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementRoyaltyIncomePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_amgn_CollaborativeArrangementRoyaltyIncomePercentage_ca2b8f05-3f90-463d-9def-66162a9b929e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementNetIncome_ff1e5405-11ea-4488-9f04-e2f67df09a3e" xlink:href="amgn-20201231.xsd#amgn_CollaborativeArrangementNetIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_amgn_CollaborativeArrangementNetIncome_ff1e5405-11ea-4488-9f04-e2f67df09a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2f2f44f8-d415-43a1-9761-512ce1148249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d3ffceab-fb86-4512-80e8-59ca86e68805" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2f2f44f8-d415-43a1-9761-512ce1148249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#CollaborationsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd59dff8-c971-4343-949e-595993a276fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd59dff8-c971-4343-949e-595993a276fd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbaef52c-d2ad-4c2a-a8c5-e4c6e9bc9a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d055969-ec92-4dc4-8c50-6f4bdc8d8586" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbaef52c-d2ad-4c2a-a8c5-e4c6e9bc9a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_e5804253-da47-4bc3-afac-ff9bd02a4219" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbaef52c-d2ad-4c2a-a8c5-e4c6e9bc9a68" xlink:to="loc_amgn_BeiGeneMember_e5804253-da47-4bc3-afac-ff9bd02a4219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_658845d3-670a-4115-a3c3-61cb8470633f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5d5997f7-a9d6-4d8a-a25d-66d2a5f1b06f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_658845d3-670a-4115-a3c3-61cb8470633f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2be1f29a-a324-41de-ba7e-2896f2afa7fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_018e593c-a5fd-4097-a5bf-33eaf3796c91" xlink:to="loc_srt_ProductsAndServicesDomain_2be1f29a-a324-41de-ba7e-2896f2afa7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e293d1b-8d4a-4bdc-8ec8-ace44fbc30a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6d70f2af-10c5-4725-99c4-221e43c88f4a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e293d1b-8d4a-4bdc-8ec8-ace44fbc30a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85ca80f7-f816-4ff9-afd4-ee91093076db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e293d1b-8d4a-4bdc-8ec8-ace44fbc30a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85ca80f7-f816-4ff9-afd4-ee91093076db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_da4ab916-dc5c-47be-b201-1bd0c7bbed78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07bd719c-2fe7-417c-9ce1-39b70d236be2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_da4ab916-dc5c-47be-b201-1bd0c7bbed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_d3ef7f00-9531-4cca-9759-ae1c5d5407d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_da4ab916-dc5c-47be-b201-1bd0c7bbed78" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_d3ef7f00-9531-4cca-9759-ae1c5d5407d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34888e2-1815-41e5-9183-47dd1f791938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4225364e-e747-4b5f-9c06-71b5e3ba8b80" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34888e2-1815-41e5-9183-47dd1f791938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_059cc2d6-11e3-45cc-88bd-f39f2a517898" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34888e2-1815-41e5-9183-47dd1f791938" xlink:to="loc_amgn_BeiGeneMember_059cc2d6-11e3-45cc-88bd-f39f2a517898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8ede5a44-cc1c-45ae-8b5d-b46e275a6101" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b947b285-41d9-4503-9b29-7f4caa9da17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b947b285-41d9-4503-9b29-7f4caa9da17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_40d66528-b527-44d7-a3d2-fae8bfe5ab98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_40d66528-b527-44d7-a3d2-fae8bfe5ab98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RecoveryOfDirectCostsReceivable_ce5fb0b6-528e-4029-a85f-06f33058c2da" xlink:href="amgn-20201231.xsd#amgn_RecoveryOfDirectCostsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_amgn_RecoveryOfDirectCostsReceivable_ce5fb0b6-528e-4029-a85f-06f33058c2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d6254788-23ab-422a-ac83-d259030f2fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d6254788-23ab-422a-ac83-d259030f2fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_9204bc4a-7868-43f7-b029-5be544794477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6886c88e-d1c9-44a2-9b3e-bc0fab192cb4" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_9204bc4a-7868-43f7-b029-5be544794477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Investments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c3d5ee92-a3d5-423e-ac34-33383e80c8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5f990a87-b3a3-4715-8e58-7d860ff32b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c3d5ee92-a3d5-423e-ac34-33383e80c8c4" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5f990a87-b3a3-4715-8e58-7d860ff32b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10be8ceb-d96a-4705-83dc-6756782cf076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_65c5eca9-3a13-45a7-b6e8-2d8080ee917e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10be8ceb-d96a-4705-83dc-6756782cf076" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_65c5eca9-3a13-45a7-b6e8-2d8080ee917e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_651a908d-f34e-4f57-bfe7-60e509393e3e" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10be8ceb-d96a-4705-83dc-6756782cf076" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_651a908d-f34e-4f57-bfe7-60e509393e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2fae5f53-6211-4d9b-bf78-f5755c381a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10be8ceb-d96a-4705-83dc-6756782cf076" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2fae5f53-6211-4d9b-bf78-f5755c381a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_e82d13e8-78f0-4a1d-9890-a015bf1348e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_10be8ceb-d96a-4705-83dc-6756782cf076" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_e82d13e8-78f0-4a1d-9890-a015bf1348e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd1d2bde-2d53-4955-8404-113fa1d11fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd1d2bde-2d53-4955-8404-113fa1d11fe6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44006225-b1c6-4501-91bc-ee3a2f2f7fb4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d1f7e154-e982-46d0-bf08-c6840c87b90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d1f7e154-e982-46d0-bf08-c6840c87b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_60f599d2-a0a8-4605-b7fb-6c5c237fc7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_60f599d2-a0a8-4605-b7fb-6c5c237fc7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_5f13d6eb-9aac-4e95-bb20-4eaa089ab4d3" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_5f13d6eb-9aac-4e95-bb20-4eaa089ab4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_11ec3c7b-cb48-4d59-ab65-798dbb169502" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_11ec3c7b-cb48-4d59-ab65-798dbb169502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_ecd050f0-fe38-4c34-86b9-4590f8cafd3d" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_ecd050f0-fe38-4c34-86b9-4590f8cafd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5c5223d1-387a-464b-8997-2cd5d06d4263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5c5223d1-387a-464b-8997-2cd5d06d4263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f2c5cd19-95dd-4407-9b06-3a9fb32e465a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f2c5cd19-95dd-4407-9b06-3a9fb32e465a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_43afbbf8-f779-49ad-a82d-e0d54e7f456c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_us-gaap_MoneyMarketFundsMember_43afbbf8-f779-49ad-a82d-e0d54e7f456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_a4b1ec79-e567-4875-b6f0-f77bdb845a88" xlink:href="amgn-20201231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90afe074-11e5-41bc-87db-0448752bf828" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_a4b1ec79-e567-4875-b6f0-f77bdb845a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6c6a1a6-3077-41f3-80f8-4828e2b9d7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_73a56420-22bb-47c9-8d6e-d51f675855d6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6c6a1a6-3077-41f3-80f8-4828e2b9d7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6c6a1a6-3077-41f3-80f8-4828e2b9d7b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_febf10dc-790a-4766-a176-b2eb274ecef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_febf10dc-790a-4766-a176-b2eb274ecef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23c50fb4-8cd9-4b1b-9758-8e6e2f5a0ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23c50fb4-8cd9-4b1b-9758-8e6e2f5a0ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d17e9d7a-48d4-419c-87c0-b37f11558c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d17e9d7a-48d4-419c-87c0-b37f11558c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5160b5b1-fd17-4f34-8ce6-8a1af87ae0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0fcd32aa-bba3-4bfe-8ec9-b9e95b2534a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5160b5b1-fd17-4f34-8ce6-8a1af87ae0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9128364e-92ca-4c14-a6c3-fdde49973181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9128364e-92ca-4c14-a6c3-fdde49973181" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bd2987a-04f1-4893-856a-f985c85666c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b894d7f1-8c6f-405c-b3d7-0192f77898c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bd2987a-04f1-4893-856a-f985c85666c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_e8b2003a-23c9-4d43-8e60-630f0b10caea" xlink:href="amgn-20201231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bd2987a-04f1-4893-856a-f985c85666c2" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_e8b2003a-23c9-4d43-8e60-630f0b10caea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e40fa892-ff8f-4845-8bb0-64bd47b16177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c7cfb1f4-aac6-41de-8e26-b2a04c9d4b68" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e40fa892-ff8f-4845-8bb0-64bd47b16177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e40fa892-ff8f-4845-8bb0-64bd47b16177" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1e65d2ae-2f01-49df-aef6-1286b2f6f961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1e65d2ae-2f01-49df-aef6-1286b2f6f961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4352a495-0423-453d-89c5-215505c2b1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4352a495-0423-453d-89c5-215505c2b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6cd9c3cd-0b56-4e1c-8e9c-2ee5e3653bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0b4d4495-467f-4db6-a18e-8a89b7b17114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6cd9c3cd-0b56-4e1c-8e9c-2ee5e3653bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e06acbbc-e7e5-42ef-ae76-fed192ec88f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_fdefbd2b-0f04-406b-b3dd-d44863784d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e06acbbc-e7e5-42ef-ae76-fed192ec88f5" xlink:to="loc_us-gaap_Cash_fdefbd2b-0f04-406b-b3dd-d44863784d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b8580ef0-462e-4d80-b287-384d46b11eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e06acbbc-e7e5-42ef-ae76-fed192ec88f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b8580ef0-462e-4d80-b287-384d46b11eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_33e83711-3145-4fa7-bd6e-f868a562e7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e06acbbc-e7e5-42ef-ae76-fed192ec88f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_33e83711-3145-4fa7-bd6e-f868a562e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_89c5bfc0-6b25-44cb-9c5a-0f241ea1b621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_89c5bfc0-6b25-44cb-9c5a-0f241ea1b621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_c22c547b-b1d7-4334-b7cb-e97d8079c8b7" xlink:href="amgn-20201231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_c22c547b-b1d7-4334-b7cb-e97d8079c8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_43d454c7-1496-47aa-8a2f-123886a6a7df" xlink:href="amgn-20201231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_43d454c7-1496-47aa-8a2f-123886a6a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_5eb1693b-3cb9-4f92-8fda-624178b439d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_5eb1693b-3cb9-4f92-8fda-624178b439d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_a4907bc4-a3ca-4ac0-ae0d-029decf87027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_a4907bc4-a3ca-4ac0-ae0d-029decf87027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c3beef37-92ad-4f8d-864e-7cd06bdce531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bc0b35e-019e-4427-91cf-d7757058dad0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c3beef37-92ad-4f8d-864e-7cd06bdce531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1091a7-c14c-4772-91f4-70b57b8299c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c80f26cd-2c45-4312-935e-54c1db77bdaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1091a7-c14c-4772-91f4-70b57b8299c0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c80f26cd-2c45-4312-935e-54c1db77bdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_804586db-8552-439f-8df3-45efc67f6a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1091a7-c14c-4772-91f4-70b57b8299c0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_804586db-8552-439f-8df3-45efc67f6a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a19ba8e0-4e2a-4ea8-a6ac-af1e114a49c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1091a7-c14c-4772-91f4-70b57b8299c0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a19ba8e0-4e2a-4ea8-a6ac-af1e114a49c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa4f9766-b9ba-4ee3-8618-1bfe51b6b3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa4f9766-b9ba-4ee3-8618-1bfe51b6b3cf" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:to="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_028dc097-28e4-4e3b-9ac5-5cca6b558cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f327ce10-d715-480b-9705-9b45505f5ecf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_028dc097-28e4-4e3b-9ac5-5cca6b558cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_98a241d8-a77c-4473-bb47-8c83a2225f61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_028dc097-28e4-4e3b-9ac5-5cca6b558cde" xlink:to="loc_srt_PartnershipInterestMember_98a241d8-a77c-4473-bb47-8c83a2225f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce015675-db79-45a6-94fb-615c3d2ce934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_086f9e3f-61f3-45db-90cf-b05d4003b9d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce015675-db79-45a6-94fb-615c3d2ce934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_dc946008-74df-45e6-bf93-aaac70c305c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce015675-db79-45a6-94fb-615c3d2ce934" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_dc946008-74df-45e6-bf93-aaac70c305c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_f8ef1113-745f-4ab9-be11-49e1f41bd5e2" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_d333bf7a-4387-4c8d-877f-d60a6a3022ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:to="loc_us-gaap_AlternativeInvestment_d333bf7a-4387-4c8d-877f-d60a6a3022ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_ff259424-9111-47dd-a41c-c04b13b5ad40" xlink:href="amgn-20201231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_43cf2d3c-66d1-41fb-903d-deff80bcfc44" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_ff259424-9111-47dd-a41c-c04b13b5ad40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InvestmentsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ae2d4be8-6327-4abf-a54a-3a75c5f00ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ae2d4be8-6327-4abf-a54a-3a75c5f00ce0" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1e99871-7c0b-4ef9-9a5d-a67f6f04e731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2bde0bb-85cc-4ec3-a128-5dac1c198b30" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1e99871-7c0b-4ef9-9a5d-a67f6f04e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_5b3e0375-9279-4285-9380-b620314bd715" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1e99871-7c0b-4ef9-9a5d-a67f6f04e731" xlink:to="loc_amgn_BeiGeneMember_5b3e0375-9279-4285-9380-b620314bd715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:to="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2255c03e-b8e3-4628-861d-a18efce0a9bb" xlink:to="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d58123f-322c-4f85-9c52-f2ac00fb2298" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:to="loc_srt_MinimumMember_6d58123f-322c-4f85-9c52-f2ac00fb2298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab7d1f7f-9442-46c8-994f-e7fd45ad3890" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9688dfd0-84ad-458e-9ab1-525ce2cad1e0" xlink:to="loc_srt_MaximumMember_ab7d1f7f-9442-46c8-994f-e7fd45ad3890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b9360b7f-28bf-43e2-9eb7-d419fc2521d7" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef16c02c-03fc-479b-9143-919ea1a371ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef16c02c-03fc-479b-9143-919ea1a371ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b749749-11bc-4925-a375-79fca290ead3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b749749-11bc-4925-a375-79fca290ead3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_793e0d8d-09b2-4e45-8df0-669fff00e8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_793e0d8d-09b2-4e45-8df0-669fff00e8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_860d2d7a-ddbd-447e-a7d9-ab05d8ad57ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_860d2d7a-ddbd-447e-a7d9-ab05d8ad57ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c94dd54-4e15-405a-8e0d-f3e92dce194a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c94dd54-4e15-405a-8e0d-f3e92dce194a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_8f19655e-cd75-4e69-80ed-d82db554c2a0" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_8f19655e-cd75-4e69-80ed-d82db554c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_49b709ad-06ab-44e6-94ca-5a21c4314713" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_49b709ad-06ab-44e6-94ca-5a21c4314713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0de030a2-c9e9-46b0-8ebb-e23f9ac8076e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0de030a2-c9e9-46b0-8ebb-e23f9ac8076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_20e97515-3bc0-4ce2-9157-727c15163541" xlink:href="amgn-20201231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_20e97515-3bc0-4ce2-9157-727c15163541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e98ef61b-3e43-4b91-8e37-2ca96e8e6669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_3f468411-b0b8-478f-b3fe-5fa90fe57bee" xlink:to="loc_us-gaap_EquityMethodInvestments_e98ef61b-3e43-4b91-8e37-2ca96e8e6669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Inventories" xlink:type="simple" xlink:href="amgn-20201231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_45010ea0-ca2f-4ae3-a871-ab3678699d12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a21ed325-4ed9-4524-9c8b-07fb9216733f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_45010ea0-ca2f-4ae3-a871-ab3678699d12" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a21ed325-4ed9-4524-9c8b-07fb9216733f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bf5b2466-0a85-4311-a8b5-0b9e1cd188d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2566ed9e-5494-45fe-b6c9-7cf30eca70fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bf5b2466-0a85-4311-a8b5-0b9e1cd188d7" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2566ed9e-5494-45fe-b6c9-7cf30eca70fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b20d6bab-d986-472d-af58-6a4b0c4b016f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f78f8224-8d5a-4041-ac71-fa203d90a5b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b20d6bab-d986-472d-af58-6a4b0c4b016f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f78f8224-8d5a-4041-ac71-fa203d90a5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fe5d1560-ce03-496e-9542-a00ba549feea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b20d6bab-d986-472d-af58-6a4b0c4b016f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fe5d1560-ce03-496e-9542-a00ba549feea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1a385733-bf4f-4b0c-b651-e06ff470e612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b20d6bab-d986-472d-af58-6a4b0c4b016f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1a385733-bf4f-4b0c-b651-e06ff470e612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a07bb8ad-bb8e-48a8-b325-06b1ac529104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b20d6bab-d986-472d-af58-6a4b0c4b016f" xlink:to="loc_us-gaap_InventoryNet_a07bb8ad-bb8e-48a8-b325-06b1ac529104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="amgn-20201231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_336f56f8-3919-4329-8e79-631fab7a0d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_13ab130b-cedf-4d8f-8f51-c08f59c3cfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_336f56f8-3919-4329-8e79-631fab7a0d8a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_13ab130b-cedf-4d8f-8f51-c08f59c3cfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_13eb7bd5-bdc5-4ee5-8955-255ab2f67e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_df6ce209-92de-45c6-87ab-cf2af3162ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_13eb7bd5-bdc5-4ee5-8955-255ab2f67e08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_df6ce209-92de-45c6-87ab-cf2af3162ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_07a5d0ff-175d-488b-a551-386574d8a1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_13eb7bd5-bdc5-4ee5-8955-255ab2f67e08" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_07a5d0ff-175d-488b-a551-386574d8a1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c86e0933-e6bb-4c81-ba9a-7d5558e1806a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c86e0933-e6bb-4c81-ba9a-7d5558e1806a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_39eab571-604e-48d5-97a5-24ca4518e2df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a1f37396-9506-462d-a743-45f60e29c37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a1f37396-9506-462d-a743-45f60e29c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember_093853c5-385e-45a7-b01e-2d5abc68b9ba" xlink:href="amgn-20201231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_amgn_ManufacturingEquipmentMember_093853c5-385e-45a7-b01e-2d5abc68b9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember_af4984dd-42db-4faf-8609-a205db26ebba" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_amgn_LaboratoryEquipmentMember_af4984dd-42db-4faf-8609-a205db26ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember_4d72c92c-fae3-4f71-bb75-a52bcc56054f" xlink:href="amgn-20201231.xsd#amgn_FixedEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_amgn_FixedEquipmentMember_4d72c92c-fae3-4f71-bb75-a52bcc56054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_be21adf9-a1a6-4819-a1d6-649d24a0a86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_be21adf9-a1a6-4819-a1d6-649d24a0a86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_a3acbef9-9e74-45a7-8e8f-ab92400ced85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67b34ceb-001d-4dfc-8637-ec122d3ed6f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_a3acbef9-9e74-45a7-8e8f-ab92400ced85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:to="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_37115a26-2dea-4959-9c41-a0185c457d17" xlink:to="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b7e3a51-1bd7-4661-a07f-0c90ee72870d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:to="loc_srt_MinimumMember_9b7e3a51-1bd7-4661-a07f-0c90ee72870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a1c9a56-b9c5-4b76-a3e7-3f5b57acfd48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_073dc7d4-5066-469c-ab10-158ad4a32beb" xlink:to="loc_srt_MaximumMember_4a1c9a56-b9c5-4b76-a3e7-3f5b57acfd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41c6c8e7-bc11-4ba6-a09d-cb91f609a154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_14767723-5b4f-4d14-a837-5936e50f4ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_14767723-5b4f-4d14-a837-5936e50f4ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_edfacf05-0b87-4c0f-a826-c6768fdc3f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_Land_edfacf05-0b87-4c0f-a826-c6768fdc3f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_a8b3658b-b842-4de4-b788-cc9ea4570169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_a8b3658b-b842-4de4-b788-cc9ea4570169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_6d907f36-8ea4-4bef-8b97-d487c7b0a76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_6d907f36-8ea4-4bef-8b97-d487c7b0a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_b3979e00-e4d5-4916-a188-22e6ccd3e2db" xlink:href="amgn-20201231.xsd#amgn_LaboratoryEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_amgn_LaboratoryEquipment_b3979e00-e4d5-4916-a188-22e6ccd3e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_8fe80ede-f687-42f6-8b22-5ee264357024" xlink:href="amgn-20201231.xsd#amgn_FixedEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_amgn_FixedEquipment_8fe80ede-f687-42f6-8b22-5ee264357024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_be78e76c-3b3c-452c-b01a-a062046e4f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_be78e76c-3b3c-452c-b01a-a062046e4f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_61db1c81-e138-4ba3-91f6-570543f03ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_61db1c81-e138-4ba3-91f6-570543f03ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a0738437-08b8-4049-afe6-b7922ab1abc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_ConstructionInProgressGross_a0738437-08b8-4049-afe6-b7922ab1abc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_44f927fe-9f1f-4ba5-a65c-3e475d129e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_44f927fe-9f1f-4ba5-a65c-3e475d129e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a081d631-c803-4325-9c6a-a96765bb7ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a081d631-c803-4325-9c6a-a96765bb7ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_86707a22-4fcd-44ac-b735-6fc789f38be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_86707a22-4fcd-44ac-b735-6fc789f38be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c9eb0dbb-b27f-4e96-8d31-cde702878d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e378b35-347b-44a0-a2e6-d84a2659a494" xlink:to="loc_us-gaap_Depreciation_c9eb0dbb-b27f-4e96-8d31-cde702878d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f89d6017-1244-4018-ad69-94e5b3991997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f89d6017-1244-4018-ad69-94e5b3991997" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:to="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ddc619a8-3f4d-4641-8d73-3e416c142fed" xlink:to="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_cf761a2c-8ddb-42d0-8018-0c88f3a60259" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:to="loc_country_US_cf761a2c-8ddb-42d0-8018-0c88f3a60259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_7c3c4d11-4eb4-4cb6-b295-50694361a57f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:to="loc_country_PR_7c3c4d11-4eb4-4cb6-b295-50694361a57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember_7b024ac1-7583-4bd5-b68a-fdb026cfeb3f" xlink:href="amgn-20201231.xsd#amgn_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e341f5e0-181a-4088-b6ec-86ae6868e458" xlink:to="loc_amgn_RestOfWorldMember_7b024ac1-7583-4bd5-b68a-fdb026cfeb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ffffe148-b26b-4ad6-86ec-39863377f344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ecbd06f-36b6-441c-87b1-c27316c6ffce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ffffe148-b26b-4ad6-86ec-39863377f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca11ab24-9d22-4471-a9e7-00095a3f0a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ffffe148-b26b-4ad6-86ec-39863377f344" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ca11ab24-9d22-4471-a9e7-00095a3f0a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="simple" xlink:href="amgn-20201231.xsd#Goodwillandintangibleassets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c085e67-9242-4718-b030-9fa61563dd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a3a90d18-95a7-44d1-8b24-891f0629c195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c085e67-9242-4718-b030-9fa61563dd4f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a3a90d18-95a7-44d1-8b24-891f0629c195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d74e452-cdaa-4fdd-b1b3-205bd0f90846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_86e5d72c-cd18-4aeb-a8b8-a2e5858a3648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d74e452-cdaa-4fdd-b1b3-205bd0f90846" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_86e5d72c-cd18-4aeb-a8b8-a2e5858a3648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_029f3928-e178-4227-9808-ad3b0c4a29e8" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d74e452-cdaa-4fdd-b1b3-205bd0f90846" xlink:to="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_029f3928-e178-4227-9808-ad3b0c4a29e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4da7edcb-9c44-4919-91b5-7f19fffc63a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_40fce364-0ece-4941-975a-a1628a50b363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4da7edcb-9c44-4919-91b5-7f19fffc63a5" xlink:to="loc_us-gaap_GoodwillRollForward_40fce364-0ece-4941-975a-a1628a50b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3eeedefa-6358-4bf3-913d-c03e6f3d07d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40fce364-0ece-4941-975a-a1628a50b363" xlink:to="loc_us-gaap_Goodwill_3eeedefa-6358-4bf3-913d-c03e6f3d07d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_bc1be0df-529c-4a0b-a696-1fe2274ae203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40fce364-0ece-4941-975a-a1628a50b363" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_bc1be0df-529c-4a0b-a696-1fe2274ae203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f10c10c4-6538-431b-8d6d-1ba1907e1149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40fce364-0ece-4941-975a-a1628a50b363" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f10c10c4-6538-431b-8d6d-1ba1907e1149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a2ee3c8-f067-4442-a144-323fe78a3969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40fce364-0ece-4941-975a-a1628a50b363" xlink:to="loc_us-gaap_Goodwill_9a2ee3c8-f067-4442-a144-323fe78a3969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b86cf508-788a-4034-a4c7-db30e5d799ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b86cf508-788a-4034-a4c7-db30e5d799ac" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_665c7464-2bbe-40f1-b8ee-f2209b0706ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_27936118-01d9-4d1e-bec1-b8cf682b693c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_27936118-01d9-4d1e-bec1-b8cf682b693c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_63871ae6-b9c5-420b-9679-26e76bb502c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_us-gaap_LicensingAgreementsMember_63871ae6-b9c5-420b-9679-26e76bb502c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_094c4034-a3cc-4c40-8545-b579b5fc414f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_094c4034-a3cc-4c40-8545-b579b5fc414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_f46070e4-7178-4dc8-8319-6cde52618c74" xlink:href="amgn-20201231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7d40cd-7aad-4880-a4ce-eac107cc42d5" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_f46070e4-7178-4dc8-8319-6cde52618c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01e5b7e2-5f63-4d9e-a101-4e8eeb2bc61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5b24dfd4-087e-49dc-baf4-fe5a977f4532" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01e5b7e2-5f63-4d9e-a101-4e8eeb2bc61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_02eb1a83-422e-4aab-9587-beae7574c961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01e5b7e2-5f63-4d9e-a101-4e8eeb2bc61a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_02eb1a83-422e-4aab-9587-beae7574c961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8d6e439a-2a64-4731-b15e-445f1a5858a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b631fd9-e047-4146-8d49-30f25d63e31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b631fd9-e047-4146-8d49-30f25d63e31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc7214c7-5fc9-4e60-a835-4f389db0efdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc7214c7-5fc9-4e60-a835-4f389db0efdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bb63774-26bf-4030-b103-1a641b6615ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a1b1ab3e-6168-47de-afaa-ca07d35ef622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2bb63774-26bf-4030-b103-1a641b6615ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_72d6beb5-538a-4db3-8dff-799578dc55d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_72d6beb5-538a-4db3-8dff-799578dc55d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_11b9b9e6-2c05-4505-9932-15e73c4f9fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_72d6beb5-538a-4db3-8dff-799578dc55d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_11b9b9e6-2c05-4505-9932-15e73c4f9fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_98acdcf5-6598-4102-8786-118138cad4a8" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_98acdcf5-6598-4102-8786-118138cad4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_ca5376f6-1407-4069-abbc-c997953d1ee7" xlink:href="amgn-20201231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_ca5376f6-1407-4069-abbc-c997953d1ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d8d2dac-45a9-4e96-ba34-309872fb5503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0510ac17-6d58-469c-81e2-24ed847ff387" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6d8d2dac-45a9-4e96-ba34-309872fb5503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d49c91da-e233-42fa-a828-44bad3a33b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d49c91da-e233-42fa-a828-44bad3a33b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1ed92730-38f1-45ff-a764-4f1abadb2887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1ed92730-38f1-45ff-a764-4f1abadb2887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fd61863b-db50-4781-8f12-0bdf77b1c604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fd61863b-db50-4781-8f12-0bdf77b1c604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b89d3a1c-63f6-454d-be70-e124eaa3732e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b89d3a1c-63f6-454d-be70-e124eaa3732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_67f6665a-c6a7-40de-9745-c1f208832944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_67f6665a-c6a7-40de-9745-c1f208832944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e2f2cc0c-f298-47af-b8c9-f30d7da08f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3391cc1e-cf4a-498e-a44b-0dc542a28b86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e2f2cc0c-f298-47af-b8c9-f30d7da08f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Leases" xlink:type="simple" xlink:href="amgn-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0aec9760-7bf4-4b25-9ed9-75dd798a2590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8a5bddaa-0b85-4052-afeb-1d1504e19642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0aec9760-7bf4-4b25-9ed9-75dd798a2590" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8a5bddaa-0b85-4052-afeb-1d1504e19642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d6c5d5ad-7177-4c17-9c59-59094249352f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f4f9eb51-44a1-4907-b669-07384f63d5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6c5d5ad-7177-4c17-9c59-59094249352f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f4f9eb51-44a1-4907-b669-07384f63d5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a730be03-e428-435f-b8b1-3bd810b8f2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6c5d5ad-7177-4c17-9c59-59094249352f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a730be03-e428-435f-b8b1-3bd810b8f2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c9a079d4-b1a9-436d-8782-b51ed83740b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c9a079d4-b1a9-436d-8782-b51ed83740b5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:to="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1447df4f-e137-439c-bbbe-618fd63b158d" xlink:to="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca060fb9-9265-432d-8c9a-c0af3a6e0068" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:to="loc_srt_MinimumMember_ca060fb9-9265-432d-8c9a-c0af3a6e0068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_25b8a388-0a88-4177-93aa-34a01f31be30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1dcf0c2f-39f6-442a-9cf0-ff62fe07e211" xlink:to="loc_srt_MaximumMember_25b8a388-0a88-4177-93aa-34a01f31be30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f308c80b-ff8e-48e1-9671-7524415d4548" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_67804408-368a-48a3-b181-8aa2af989949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_67804408-368a-48a3-b181-8aa2af989949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6bfcd98d-a992-4cf7-a1c7-9e6dbedd1a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6bfcd98d-a992-4cf7-a1c7-9e6dbedd1a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_28186cb2-20e1-4a79-a1c2-fbc06f666a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_28186cb2-20e1-4a79-a1c2-fbc06f666a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_14854e15-d879-4c83-9c03-82e480230d9c" xlink:href="amgn-20201231.xsd#amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_14854e15-d879-4c83-9c03-82e480230d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0a197de8-ebb8-4a2e-bbbe-4785c046f3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0a197de8-ebb8-4a2e-bbbe-4785c046f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0186fa2-fae6-471f-812b-bd953b4d9b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0186fa2-fae6-471f-812b-bd953b4d9b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_88e02445-e46d-4df8-980f-a26c255dec37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0ccbf2c0-6146-4c2b-9620-f7647febfe5d" xlink:to="loc_us-gaap_LeaseAndRentalExpense_88e02445-e46d-4df8-980f-a26c255dec37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_697f714b-6220-423e-ac8b-2f040f246b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6de22c99-bb14-4599-acb4-3ce2e923312d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_697f714b-6220-423e-ac8b-2f040f246b18" xlink:to="loc_us-gaap_AssetsAbstract_6de22c99-bb14-4599-acb4-3ce2e923312d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5d476f8c-214b-4b1a-a1af-bc17a095a44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6de22c99-bb14-4599-acb4-3ce2e923312d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5d476f8c-214b-4b1a-a1af-bc17a095a44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8c4d3500-7d04-4b72-89b8-c9322a7e33b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6de22c99-bb14-4599-acb4-3ce2e923312d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8c4d3500-7d04-4b72-89b8-c9322a7e33b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_91c91be8-55dd-4ce0-9c3a-3b46e1470f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_697f714b-6220-423e-ac8b-2f040f246b18" xlink:to="loc_us-gaap_LiabilitiesAbstract_91c91be8-55dd-4ce0-9c3a-3b46e1470f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_22f1dd3c-5453-4a78-a25f-f6bc1f1b447a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_91c91be8-55dd-4ce0-9c3a-3b46e1470f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_22f1dd3c-5453-4a78-a25f-f6bc1f1b447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c6b6d5e6-96c0-4928-9800-c24322f075ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_91c91be8-55dd-4ce0-9c3a-3b46e1470f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c6b6d5e6-96c0-4928-9800-c24322f075ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e4524daa-4c45-4db1-a24d-a33b0c4642a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_91c91be8-55dd-4ce0-9c3a-3b46e1470f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e4524daa-4c45-4db1-a24d-a33b0c4642a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_af4d77cd-b2e2-40a4-81f4-fec27696773c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_91c91be8-55dd-4ce0-9c3a-3b46e1470f17" xlink:to="loc_us-gaap_OperatingLeaseLiability_af4d77cd-b2e2-40a4-81f4-fec27696773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b6cc6a6e-ad3c-4452-b884-dba76cc1ed63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3105d210-1742-4731-8eaa-a3dea1a893bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6cc6a6e-ad3c-4452-b884-dba76cc1ed63" xlink:to="loc_us-gaap_OperatingLeaseCost_3105d210-1742-4731-8eaa-a3dea1a893bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_a0190172-b16f-4187-b9fe-8082973e1ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6cc6a6e-ad3c-4452-b884-dba76cc1ed63" xlink:to="loc_us-gaap_SubleaseIncome_a0190172-b16f-4187-b9fe-8082973e1ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2ccded44-e737-4d44-8030-07ec9e575fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6cc6a6e-ad3c-4452-b884-dba76cc1ed63" xlink:to="loc_us-gaap_LeaseCost_2ccded44-e737-4d44-8030-07ec9e575fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_82764785-505c-4b95-9d13-88d3c7fd53fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82764785-505c-4b95-9d13-88d3c7fd53fb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1c73973-6ad1-406d-a7dc-133e180f96af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c7e18a03-8c9d-41d6-8de4-1eb195d3b165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1c73973-6ad1-406d-a7dc-133e180f96af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember_cebdb7af-1a4f-4a8d-bdc2-e3de86c23037" xlink:href="amgn-20201231.xsd#amgn_AbandonedLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1c73973-6ad1-406d-a7dc-133e180f96af" xlink:to="loc_amgn_AbandonedLeasesMember_cebdb7af-1a4f-4a8d-bdc2-e3de86c23037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4dcc8ab9-d25a-466b-9952-e2209f32388f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fad7b76d-0671-4814-b587-b4f417b71a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fad7b76d-0671-4814-b587-b4f417b71a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7a9b38c9-8a86-4fcd-9e5d-cf5ea6a61fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7a9b38c9-8a86-4fcd-9e5d-cf5ea6a61fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4bbc9c0d-7edc-4262-8770-4e3edb804cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4bbc9c0d-7edc-4262-8770-4e3edb804cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e8a60bd-300a-40fa-ae85-9d1e49756726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6e8a60bd-300a-40fa-ae85-9d1e49756726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a26e33c2-fcdc-4760-bf9c-0b0ae66cc963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a26e33c2-fcdc-4760-bf9c-0b0ae66cc963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4582d90a-c6a2-48e7-9786-1f8e9e2c1700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4582d90a-c6a2-48e7-9786-1f8e9e2c1700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e96c0f4-7dbd-4496-aad1-e40a7a49926e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e96c0f4-7dbd-4496-aad1-e40a7a49926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e747933-f079-405b-a85b-776587100c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e747933-f079-405b-a85b-776587100c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_88e03ecb-f2ce-4ecc-9b81-09c8b755ca55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_OperatingLeaseLiability_88e03ecb-f2ce-4ecc-9b81-09c8b755ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_fded7b46-6047-44bd-8f51-3351fa088976" xlink:href="amgn-20201231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_fded7b46-6047-44bd-8f51-3351fa088976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_220e5018-a4d7-4cd7-acfa-1613bf3bf387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a18bf814-f624-4088-a407-cdc6d0ae0414" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_220e5018-a4d7-4cd7-acfa-1613bf3bf387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#LeasesCashandNoncashInformationofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a94bfbb3-da80-443d-b4ec-d13099e663b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9234ed43-40ab-4a02-9514-1e52e739e7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a94bfbb3-da80-443d-b4ec-d13099e663b8" xlink:to="loc_us-gaap_OperatingLeasePayments_9234ed43-40ab-4a02-9514-1e52e739e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f8a2dde-12ff-4e56-acfc-1054a7f5846a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a94bfbb3-da80-443d-b4ec-d13099e663b8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f8a2dde-12ff-4e56-acfc-1054a7f5846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="simple" xlink:href="amgn-20201231.xsd#Othercurrentassetsandaccruedliabilities"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_012dcd88-c849-4145-9882-ef799c79472b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesDisclosureTextBlock_8ed68e65-6aa0-4183-960f-6f5e83a36a6f" xlink:href="amgn-20201231.xsd#amgn_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_012dcd88-c849-4145-9882-ef799c79472b" xlink:to="loc_amgn_AccruedLiabilitiesDisclosureTextBlock_8ed68e65-6aa0-4183-960f-6f5e83a36a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5e0f83b6-f6d0-4716-86ac-356b675094ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_039b2f1f-dd48-4b98-ba11-5f571ecf2ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e0f83b6-f6d0-4716-86ac-356b675094ec" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_039b2f1f-dd48-4b98-ba11-5f571ecf2ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1376647a-1aa4-477e-9096-9ced372bab91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e0f83b6-f6d0-4716-86ac-356b675094ec" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1376647a-1aa4-477e-9096-9ced372bab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_08589cc8-48d8-418e-a63d-716ae371d657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_04a4088d-4cde-414b-8995-e5154d6551fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_08589cc8-48d8-418e-a63d-716ae371d657" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_04a4088d-4cde-414b-8995-e5154d6551fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_9262e5ab-ee26-4825-a2ec-2341ef77f28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_08589cc8-48d8-418e-a63d-716ae371d657" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_9262e5ab-ee26-4825-a2ec-2341ef77f28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_aca706cc-81b4-4fbe-a2ae-1749ce501af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_08589cc8-48d8-418e-a63d-716ae371d657" xlink:to="loc_us-gaap_InterestReceivableCurrent_aca706cc-81b4-4fbe-a2ae-1749ce501af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_f75c384b-fcf5-46a2-be15-4534d72a2a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_08589cc8-48d8-418e-a63d-716ae371d657" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_f75c384b-fcf5-46a2-be15-4534d72a2a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a70f5aea-980b-4eea-8aa6-c327d8c6b0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_08589cc8-48d8-418e-a63d-716ae371d657" xlink:to="loc_us-gaap_OtherAssetsCurrent_a70f5aea-980b-4eea-8aa6-c327d8c6b0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent_c0085ab2-61b7-4ce2-8c5a-ad70ad4260ce" xlink:href="amgn-20201231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_amgn_AccruedSalesDeductionsCurrent_c0085ab2-61b7-4ce2-8c5a-ad70ad4260ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bcae7a7d-39d0-4e77-981a-e96ec07eb1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bcae7a7d-39d0-4e77-981a-e96ec07eb1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6e35d479-22dc-417a-9b5d-95d671275e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_us-gaap_DividendsPayableCurrent_6e35d479-22dc-417a-9b5d-95d671275e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_9ed553ee-16ea-4d13-8371-2c3089e570a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_9ed553ee-16ea-4d13-8371-2c3089e570a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent_f80e0a14-ba03-40fc-b761-f811952b5c47" xlink:href="amgn-20201231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_amgn_AccruedSalesReturnReserveCurrent_f80e0a14-ba03-40fc-b761-f811952b5c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2e8e6cde-ec8c-41fc-b78a-2676a4a59ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2e8e6cde-ec8c-41fc-b78a-2676a4a59ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0a25e743-c8c1-4c04-ac28-42f0e77ef19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d339ad82-2428-4045-b7d8-2815e7d230fb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0a25e743-c8c1-4c04-ac28-42f0e77ef19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Financingarrangements" xlink:type="simple" xlink:href="amgn-20201231.xsd#Financingarrangements"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Financingarrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2d3236ce-f574-4432-b59a-eab05fa5d123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0abd5ae4-9842-4a10-b22e-f9f7e82a5e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d3236ce-f574-4432-b59a-eab05fa5d123" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0abd5ae4-9842-4a10-b22e-f9f7e82a5e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d117ca40-947a-45ec-8dff-33e95d173375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c29ecd1e-f617-4a70-861b-b60b6161177e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d117ca40-947a-45ec-8dff-33e95d173375" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c29ecd1e-f617-4a70-861b-b60b6161177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_7198c2d9-c765-4053-925c-0c2747280e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d117ca40-947a-45ec-8dff-33e95d173375" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_7198c2d9-c765-4053-925c-0c2747280e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_5fcf8797-5a48-4959-b005-e882735e06db" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d117ca40-947a-45ec-8dff-33e95d173375" xlink:to="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_5fcf8797-5a48-4959-b005-e882735e06db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1630e2e7-8fc5-413d-bdd4-7316daeb6531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d117ca40-947a-45ec-8dff-33e95d173375" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1630e2e7-8fc5-413d-bdd4-7316daeb6531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fbcfe9c2-b5f2-4fe8-8665-da6a1373b434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fbcfe9c2-b5f2-4fe8-8665-da6a1373b434" xlink:to="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca4d0b16-5e2c-4a8a-a279-78cebbade161" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_744d2ad8-4eaf-44c4-a20f-6e561a167d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:to="loc_us-gaap_NotesPayableToBanksMember_744d2ad8-4eaf-44c4-a20f-6e561a167d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_5520e2c3-1898-43dc-ad67-624df70e4035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfb0307c-3631-4e00-8b5e-ec34e1d784cf" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_5520e2c3-1898-43dc-ad67-624df70e4035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d778eb6d-17c3-4410-875a-5e6fd0a6d209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_6ae3111e-bc8a-4f7d-9f56-9276889b77c9" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_6ae3111e-bc8a-4f7d-9f56-9276889b77c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_a264a1c0-3115-4d81-8e8f-82cd0fb528a5" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_a264a1c0-3115-4d81-8e8f-82cd0fb528a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_571380db-7692-447e-b6cb-518d858ba00e" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_571380db-7692-447e-b6cb-518d858ba00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_6622fdd7-b533-4c80-897a-2a3b49f46ff3" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_6622fdd7-b533-4c80-897a-2a3b49f46ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_d9c0b288-4370-4dcd-ac1d-c94a0cd9a577" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_d9c0b288-4370-4dcd-ac1d-c94a0cd9a577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b3e959d6-c8c8-47b2-aba5-242996da242e" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b3e959d6-c8c8-47b2-aba5-242996da242e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_49aadc88-c0a9-4d62-bbc4-55b5ca352651" xlink:href="amgn-20201231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_49aadc88-c0a9-4d62-bbc4-55b5ca352651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_b8cccb40-ca15-4a16-a57a-73e54460f5f5" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_b8cccb40-ca15-4a16-a57a-73e54460f5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_365f0df7-1dd6-4f46-bae0-03daa5b69ac1" xlink:href="amgn-20201231.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_365f0df7-1dd6-4f46-bae0-03daa5b69ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5d3a605c-9e2a-48cb-b762-0b60fd5ef2cd" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5d3a605c-9e2a-48cb-b762-0b60fd5ef2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member_52a28796-5f2b-414e-a304-63733430f9da" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSixFiveNotesDue2022Member_52a28796-5f2b-414e-a304-63733430f9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_0a9d1e07-aadd-4827-8106-765a1888fa9c" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_0a9d1e07-aadd-4827-8106-765a1888fa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_fb825b1e-c4c1-4709-8e3c-6920b8dd1284" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_fb825b1e-c4c1-4709-8e3c-6920b8dd1284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_1a9544fd-e06b-46b9-8f3a-f75ace4b3295" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_1a9544fd-e06b-46b9-8f3a-f75ace4b3295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_37879d66-3d08-416a-a4f7-bc77b30c9bf7" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_37879d66-3d08-416a-a4f7-bc77b30c9bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_d0adfbc5-f8e1-40c2-a98c-b72078c261fc" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_d0adfbc5-f8e1-40c2-a98c-b72078c261fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_2cf0ec25-afd2-4b64-be7f-904a6e6c4554" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_2cf0ec25-afd2-4b64-be7f-904a6e6c4554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_993683f9-8f05-4a8d-9fa8-13324f06af05" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_993683f9-8f05-4a8d-9fa8-13324f06af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_7d696b75-7b8d-49ce-9577-4759183691f9" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_7d696b75-7b8d-49ce-9577-4759183691f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_8413cf73-828b-4b4e-97f7-7037a970e631" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_8413cf73-828b-4b4e-97f7-7037a970e631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_6e7520cc-7861-4180-99aa-7f4b3d3a23f5" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_6e7520cc-7861-4180-99aa-7f4b3d3a23f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b830c557-f639-458f-8e62-2c504dad8182" xlink:href="amgn-20201231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b830c557-f639-458f-8e62-2c504dad8182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_f1aa36ed-ffb5-4cad-a9fd-66d306c952a0" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_f1aa36ed-ffb5-4cad-a9fd-66d306c952a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_e50ae0c5-5717-4334-a15f-50053c377ae7" xlink:href="amgn-20201231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_e50ae0c5-5717-4334-a15f-50053c377ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7b8053c-8403-4cbc-9e6f-ba976fc18039" xlink:href="amgn-20201231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7b8053c-8403-4cbc-9e6f-ba976fc18039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_a80e2d32-01ad-4892-b094-8a0883b800e4" xlink:href="amgn-20201231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_a80e2d32-01ad-4892-b094-8a0883b800e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_e2ab152a-0c0e-4d8a-b62d-0f37c22ef027" xlink:href="amgn-20201231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_e2ab152a-0c0e-4d8a-b62d-0f37c22ef027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_04b9f98d-23b8-46a2-bfb3-f546b52bbdf8" xlink:href="amgn-20201231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_04b9f98d-23b8-46a2-bfb3-f546b52bbdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_7cbc9b01-541a-4095-b1e2-0e663c1d6b3c" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_7cbc9b01-541a-4095-b1e2-0e663c1d6b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_80e34ce9-c70a-45b4-b8b7-5fc5757920b8" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_80e34ce9-c70a-45b4-b8b7-5fc5757920b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_b18d122a-a288-4b55-9479-484ae5eda19e" xlink:href="amgn-20201231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_b18d122a-a288-4b55-9479-484ae5eda19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_22accdc2-4f49-4eb0-a425-5a785d6e0894" xlink:href="amgn-20201231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_22accdc2-4f49-4eb0-a425-5a785d6e0894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_c1fac421-ff6e-4797-8734-85d41a5fab21" xlink:href="amgn-20201231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_c1fac421-ff6e-4797-8734-85d41a5fab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_f28de94d-64da-413d-8a8b-623d132e1b16" xlink:href="amgn-20201231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_f28de94d-64da-413d-8a8b-623d132e1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_1df2b531-3532-44a4-8270-6bda71be1ee9" xlink:href="amgn-20201231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_1df2b531-3532-44a4-8270-6bda71be1ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_60d40717-818a-4aba-98c4-4ff4f4235540" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_60d40717-818a-4aba-98c4-4ff4f4235540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_d114519a-c079-443e-b443-2de07947f031" xlink:href="amgn-20201231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_d114519a-c079-443e-b443-2de07947f031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_a909165e-303e-44d5-a468-41da440af8f4" xlink:href="amgn-20201231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_a909165e-303e-44d5-a468-41da440af8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_3c7578fc-0a93-476b-a8c8-06fe5178e48a" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_3c7578fc-0a93-476b-a8c8-06fe5178e48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_053b62de-973e-4d6c-a1ae-a5bc761f0318" xlink:href="amgn-20201231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3623d5e-3e12-496c-9da0-325c340e1527" xlink:to="loc_amgn_OtherNotesDue2097Member_053b62de-973e-4d6c-a1ae-a5bc761f0318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e1bcef9d-8a5a-4009-a278-bc35c80ea555" xlink:to="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4ff281a-1935-4460-b3bb-696893819d4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:to="loc_srt_MinimumMember_c4ff281a-1935-4460-b3bb-696893819d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b61a8812-cdc8-41d8-9906-1d7e2d4b2f49" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_15903922-d2e1-4d13-910e-aeacc7bcdce5" xlink:to="loc_srt_MaximumMember_b61a8812-cdc8-41d8-9906-1d7e2d4b2f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ebad9515-ca3a-431d-8986-7c3532bd4216" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_129505db-9fef-4334-a5a5-94f0b0bdc414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_129505db-9fef-4334-a5a5-94f0b0bdc414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8dd022d5-1f21-4d18-a2b2-b62544d8ebdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8dd022d5-1f21-4d18-a2b2-b62544d8ebdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7456ef78-a2be-4e30-8e78-6ca32d6b85d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7456ef78-a2be-4e30-8e78-6ca32d6b85d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_ee619333-0725-47b0-ae54-09fe5c5aed6d" xlink:href="amgn-20201231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_ee619333-0725-47b0-ae54-09fe5c5aed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_cdd8b4c6-067d-47f3-9e64-a52ad19e165f" xlink:href="amgn-20201231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_cdd8b4c6-067d-47f3-9e64-a52ad19e165f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a847e05b-a10e-4ad5-980d-d6c411c368fd" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_76bb419e-2ec0-4f00-a0d5-3ea9a0e69765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_76bb419e-2ec0-4f00-a0d5-3ea9a0e69765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d1a357e-1e42-4f17-9cd2-a7e3dbc3233b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d1a357e-1e42-4f17-9cd2-a7e3dbc3233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_591ac7bd-debf-41f5-b0dc-0ba80a8fbd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_591ac7bd-debf-41f5-b0dc-0ba80a8fbd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_cdeddad0-c5d7-4ffb-adf1-425a61a4eaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_OtherLongTermDebt_cdeddad0-c5d7-4ffb-adf1-425a61a4eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_29d94c3c-8c0f-43fe-986e-a77fe416f09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_LongTermDebt_29d94c3c-8c0f-43fe-986e-a77fe416f09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1705d3a8-13b7-482c-aba8-6931bde85fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_LongTermDebtCurrent_1705d3a8-13b7-482c-aba8-6931bde85fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0d11fa0f-2fd0-4427-9e8b-fd01906bf1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_ea9ed7d0-4edb-4dbe-827a-ccd05b0a6d20" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0d11fa0f-2fd0-4427-9e8b-fd01906bf1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d042c24-2ce0-465a-88ec-db2e7fb2ff76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d042c24-2ce0-465a-88ec-db2e7fb2ff76" xlink:to="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0a95b286-ab16-4455-a857-e3ae85f6ab2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c92c74de-69de-468f-86e6-4277337b0c64" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0a95b286-ab16-4455-a857-e3ae85f6ab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_25ec19bc-6451-49d9-90d2-c8d3b514535b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0a95b286-ab16-4455-a857-e3ae85f6ab2f" xlink:to="loc_us-gaap_NotesPayableToBanksMember_25ec19bc-6451-49d9-90d2-c8d3b514535b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:to="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_119e4a3a-c474-4a37-a7d6-123cd571b4f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_5a52850b-fb6d-4c15-81a9-531fd2dcf761" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_5a52850b-fb6d-4c15-81a9-531fd2dcf761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_8d6b2df0-3214-497d-a248-0277c41a1499" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_8d6b2df0-3214-497d-a248-0277c41a1499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_ab5b332d-05e4-4957-9d2a-e83afb9b4eb2" xlink:href="amgn-20201231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_ab5b332d-05e4-4957-9d2a-e83afb9b4eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_4722970d-53bc-4e02-9680-a2f0960f3b2d" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_4722970d-53bc-4e02-9680-a2f0960f3b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_5f04ed14-28ac-462f-9203-9c973e0792c1" xlink:href="amgn-20201231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_5f04ed14-28ac-462f-9203-9c973e0792c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_14d56945-7177-4483-bdaa-6abe5c82a9e2" xlink:href="amgn-20201231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7437af23-ef56-4f57-afee-005ada5e135d" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_14d56945-7177-4483-bdaa-6abe5c82a9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c50b09f2-f9fd-4edc-8ee6-7ca2b4084391" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d11811e7-c1c4-4d14-af61-0c04a316f986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d11811e7-c1c4-4d14-af61-0c04a316f986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e31dbfa4-9646-41b1-bab3-95b449d6b7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e31dbfa4-9646-41b1-bab3-95b449d6b7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_bde57b04-9a99-41e7-8630-ee660c3a2c17" xlink:href="amgn-20201231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bd83ae79-2bae-42f3-8b4d-cecae85f1a61" xlink:to="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_bde57b04-9a99-41e7-8630-ee660c3a2c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_405c01f4-e13a-4cc3-a57b-70ab92e4632c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_405c01f4-e13a-4cc3-a57b-70ab92e4632c" xlink:to="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9e13f41c-f267-41ae-9b6f-9f52af57918c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547cf410-e39c-4bfe-8c2f-5bc714926d47" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9e13f41c-f267-41ae-9b6f-9f52af57918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_f3d629a0-8ac3-4c37-a628-dddde7bdedb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9e13f41c-f267-41ae-9b6f-9f52af57918c" xlink:to="loc_us-gaap_NotesPayableToBanksMember_f3d629a0-8ac3-4c37-a628-dddde7bdedb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:to="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4483a9a6-f9af-4dbe-9349-b563bd907119" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_ff0b21db-634c-41e1-afff-82769dd48f5b" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_ff0b21db-634c-41e1-afff-82769dd48f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_7caf90cf-f427-42ea-98ca-7688ceea19fc" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenZeroPercentNotesDue2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_7caf90cf-f427-42ea-98ca-7688ceea19fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_d14e3ba7-d10f-4d6f-afe1-6cfda169f8a5" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_d14e3ba7-d10f-4d6f-afe1-6cfda169f8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroNotesDue2019Member_01f44286-da46-4eeb-83f9-152542a33fad" xlink:href="amgn-20201231.xsd#amgn_OnePointNineZeroNotesDue2019Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_OnePointNineZeroNotesDue2019Member_01f44286-da46-4eeb-83f9-152542a33fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2019Member_7470ff02-2ac3-433e-b81c-44d4a1608116" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2019Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FloatingRateNotesDue2019Member_7470ff02-2ac3-433e-b81c-44d4a1608116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointOneFivePercentNotesDue2018Member_1fff0c5e-7dc5-45a1-9b22-240b75a17cb1" xlink:href="amgn-20201231.xsd#amgn_SixPointOneFivePercentNotesDue2018Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_SixPointOneFivePercentNotesDue2018Member_1fff0c5e-7dc5-45a1-9b22-240b75a17cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_28d35a1a-8763-43c1-aca0-279c44541e50" xlink:href="amgn-20201231.xsd#amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member_28d35a1a-8763-43c1-aca0-279c44541e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_f0c3630f-ccc6-42e4-aefb-a2c81db881da" xlink:href="amgn-20201231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_f0c3630f-ccc6-42e4-aefb-a2c81db881da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_00f983fd-8f3a-43ff-aaa2-20bca9be7aa4" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_00f983fd-8f3a-43ff-aaa2-20bca9be7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_869ef4cb-e81d-4c54-8a83-9c1bbba340e9" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_869ef4cb-e81d-4c54-8a83-9c1bbba340e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_fd26c5d9-bbc3-48dc-bdb5-9b8c3ded9b55" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_fd26c5d9-bbc3-48dc-bdb5-9b8c3ded9b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_7b211aa8-4cb6-448c-9a8e-221c18eebf6d" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_7b211aa8-4cb6-448c-9a8e-221c18eebf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_a766336c-9352-4d96-ab4b-76ea23a009e2" xlink:href="amgn-20201231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_a766336c-9352-4d96-ab4b-76ea23a009e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3a8411ba-3bc2-4fd3-a916-9b8d5bd88381" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_3a8411ba-3bc2-4fd3-a916-9b8d5bd88381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_3ac3a31a-6f2c-41ea-8b4f-f050fea4cc51" xlink:href="amgn-20201231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2244aba8-1c7e-4ef9-b9ad-b8eb42c73f24" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_3ac3a31a-6f2c-41ea-8b4f-f050fea4cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cb3c6722-d080-4650-9d74-07cfb5910fae" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c95b9ab8-9cec-4c33-adff-0669a4df586b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c95b9ab8-9cec-4c33-adff-0669a4df586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8105ba25-0ea3-4781-9d0b-da4a1d383613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8105ba25-0ea3-4781-9d0b-da4a1d383613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_24f0bdfa-8cbe-4a1c-915c-f7e00d32dc50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc56e598-824a-431a-bb93-2813ffb6596b" xlink:to="loc_us-gaap_InterestExpenseDebt_24f0bdfa-8cbe-4a1c-915c-f7e00d32dc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eb598198-c8b6-487c-ac1e-469377335c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eb598198-c8b6-487c-ac1e-469377335c2b" xlink:to="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4925be2-8c02-47f3-9b87-e0d1e5b098ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_25cf9777-04b5-4cef-978a-233701bb7564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_25cf9777-04b5-4cef-978a-233701bb7564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_1682a4e8-43f3-4659-95df-588db8be8b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b294c0e1-a5c2-457e-8b98-59a47394fe73" xlink:to="loc_us-gaap_NotesPayableToBanksMember_1682a4e8-43f3-4659-95df-588db8be8b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_30b386da-d231-411a-8768-7994d189fb30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_f4d736cf-4e0b-4d4f-8409-ac6ff6afad7f" xlink:href="amgn-20201231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_f4d736cf-4e0b-4d4f-8409-ac6ff6afad7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e25309aa-6b59-42cf-aafa-6c455fa766e7" xlink:href="amgn-20201231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e25309aa-6b59-42cf-aafa-6c455fa766e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_3d3ac13c-a2fa-42b9-bc90-d2ed60ae850a" xlink:href="amgn-20201231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_3d3ac13c-a2fa-42b9-bc90-d2ed60ae850a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_c04dcda4-123e-4599-aeb1-73318f43413e" xlink:href="amgn-20201231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_c04dcda4-123e-4599-aeb1-73318f43413e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_62fac120-3072-4bab-a635-39a35235cd89" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_62fac120-3072-4bab-a635-39a35235cd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_cfafd3e1-ccb1-49d1-a996-783b78a34d0f" xlink:href="amgn-20201231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_cfafd3e1-ccb1-49d1-a996-783b78a34d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b35abaf3-9e3e-4826-819a-7052f4607256" xlink:href="amgn-20201231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b35abaf3-9e3e-4826-819a-7052f4607256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_a72bc91a-3678-4875-8368-4392d2ed3b34" xlink:href="amgn-20201231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_a72bc91a-3678-4875-8368-4392d2ed3b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_d1361ac4-1577-4a08-8932-2bc2c53d8869" xlink:href="amgn-20201231.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_d1361ac4-1577-4a08-8932-2bc2c53d8869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_7dfd8d76-81af-4ef6-9206-58677dbd750b" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_7dfd8d76-81af-4ef6-9206-58677dbd750b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_06215934-7184-4bef-b65b-9976bbfc9f7f" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_06215934-7184-4bef-b65b-9976bbfc9f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_0140a8f7-001e-4f0f-ad4e-c80e2f8a9015" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_0140a8f7-001e-4f0f-ad4e-c80e2f8a9015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_facf3224-7b39-4598-a6f3-386a978b42eb" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_facf3224-7b39-4598-a6f3-386a978b42eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_3d70cef5-ef43-4a91-b122-074de5454b13" xlink:href="amgn-20201231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_3d70cef5-ef43-4a91-b122-074de5454b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dde10b53-26bb-4b4d-84ea-ae002f938b46" xlink:href="amgn-20201231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dde10b53-26bb-4b4d-84ea-ae002f938b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_f2c2d23e-040d-4716-844e-4a686bd051ef" xlink:href="amgn-20201231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_f2c2d23e-040d-4716-844e-4a686bd051ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_00a3dd17-61d1-4977-80ae-83fb9ccc0dd8" xlink:href="amgn-20201231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_00a3dd17-61d1-4977-80ae-83fb9ccc0dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_ba0c622b-5ab9-49d1-8c6d-d9652b6273ea" xlink:href="amgn-20201231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_ba0c622b-5ab9-49d1-8c6d-d9652b6273ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ac381713-7544-4ca1-a88f-f2fd3f4fa2af" xlink:href="amgn-20201231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_ac381713-7544-4ca1-a88f-f2fd3f4fa2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b9538959-4af5-4fbe-8094-9109650fb081" xlink:href="amgn-20201231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b9538959-4af5-4fbe-8094-9109650fb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8f6b84b8-27ad-4b31-9c60-e57de1857b23" xlink:href="amgn-20201231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8f6b84b8-27ad-4b31-9c60-e57de1857b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_1e31a48e-6535-4d98-9d36-e04efc48c993" xlink:href="amgn-20201231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd8af0e8-5160-4927-8ab0-a6cff284e38d" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_1e31a48e-6535-4d98-9d36-e04efc48c993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e42f3456-bc3e-45a7-8c88-cbb95cc45129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bd09bc4e-2c61-416b-a638-3a40c82461bb" xlink:to="loc_us-gaap_VariableRateDomain_e42f3456-bc3e-45a7-8c88-cbb95cc45129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_cf6b57d4-7b34-4aea-9f64-af4449b11146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e42f3456-bc3e-45a7-8c88-cbb95cc45129" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_cf6b57d4-7b34-4aea-9f64-af4449b11146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapAxis_1d09ff48-0cfe-404e-ada1-e51ca053db4c" xlink:to="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember_7dfb10e3-bcbf-4a6f-9ff9-2f7a2abbe6c8" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:to="loc_amgn_InterestRateSwapOneMember_7dfb10e3-bcbf-4a6f-9ff9-2f7a2abbe6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_5ca429c1-4f72-4a64-91dd-71da35c00be9" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:to="loc_amgn_InterestRateSwapTwoMember_5ca429c1-4f72-4a64-91dd-71da35c00be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapThreeMember_56a663ca-3874-4a0f-985c-0e1732785ecb" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_2ee81878-6988-4c83-8f7b-861edff5b9e3" xlink:to="loc_amgn_InterestRateSwapThreeMember_56a663ca-3874-4a0f-985c-0e1732785ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_643eb017-f834-4c5b-865f-6d981ae6a632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ef38fc34-6e9a-4aa4-8eab-b5bd03ce659c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_643eb017-f834-4c5b-865f-6d981ae6a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8b869c97-3bbb-43f6-975f-f42cf0bb9df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_643eb017-f834-4c5b-865f-6d981ae6a632" xlink:to="loc_us-gaap_InterestRateSwapMember_8b869c97-3bbb-43f6-975f-f42cf0bb9df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_109efc7b-ac42-4a02-9c61-d66cb3d21af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_89674f38-ca2f-4dc1-adcc-2009b8fc7caa" xlink:to="loc_us-gaap_HedgingDesignationDomain_109efc7b-ac42-4a02-9c61-d66cb3d21af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7e1b3b2b-ed61-4cb9-8ed9-01fdfdd92e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_109efc7b-ac42-4a02-9c61-d66cb3d21af9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7e1b3b2b-ed61-4cb9-8ed9-01fdfdd92e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddee79e8-f78c-4f1e-8d5d-be6aa1792ed9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_672bed2b-847e-4d61-8fc5-6efcab2da394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_672bed2b-847e-4d61-8fc5-6efcab2da394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_2cf6f9e8-ef45-4e37-aee5-ade863230eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_2cf6f9e8-ef45-4e37-aee5-ade863230eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_adb66a7f-cd50-4a72-8a21-cfca41a3138a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DerivativeNotionalAmount_adb66a7f-cd50-4a72-8a21-cfca41a3138a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_0c228e2f-cff3-4e7d-b4a7-306049f068d3" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_0c228e2f-cff3-4e7d-b4a7-306049f068d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0d7456c-5dd1-4597-8025-a89ea76ab622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0d7456c-5dd1-4597-8025-a89ea76ab622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Ratedifferenceinaninterestrateswaprelationship_4e8a3fc7-ca51-4737-95c6-c33918eed3b8" xlink:href="amgn-20201231.xsd#amgn_Ratedifferenceinaninterestrateswaprelationship"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_amgn_Ratedifferenceinaninterestrateswaprelationship_4e8a3fc7-ca51-4737-95c6-c33918eed3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e1223600-7d4d-4dd6-a9f9-1ea1d58ed44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_e1223600-7d4d-4dd6-a9f9-1ea1d58ed44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32814185-8b84-4eb7-a41c-49e126670946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32814185-8b84-4eb7-a41c-49e126670946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_6b86dc45-fda8-4200-b10d-1fdf519e7f19" xlink:href="amgn-20201231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_6b86dc45-fda8-4200-b10d-1fdf519e7f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e21c1862-5ff9-49f0-99fb-b8e5ae4e6c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_47f20138-adfc-4ba1-9412-716b81278359" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e21c1862-5ff9-49f0-99fb-b8e5ae4e6c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_48ebfaed-9e2f-4274-8ef9-f695a3b165e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_48ebfaed-9e2f-4274-8ef9-f695a3b165e8" xlink:to="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68cc0c2f-10f5-436d-9739-80773b9d4b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1873d351-fae2-47ae-a135-0400e7171349" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68cc0c2f-10f5-436d-9739-80773b9d4b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8fcd5822-2ac4-4673-a6df-a0aa6045f84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68cc0c2f-10f5-436d-9739-80773b9d4b9e" xlink:to="loc_us-gaap_LineOfCreditMember_8fcd5822-2ac4-4673-a6df-a0aa6045f84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:to="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_77a03e09-be1d-4c99-9060-7e45d2596afb" xlink:to="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_4bf5494d-8055-4e7f-8556-39fcaf53a614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_4bf5494d-8055-4e7f-8556-39fcaf53a614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_da07869b-099f-474b-a11c-28f44c5ab463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_21307837-b51a-43d2-a3ec-03eeca7835cb" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_da07869b-099f-474b-a11c-28f44c5ab463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c32b6c-57cf-43e1-aa9c-06ffe65395ae" xlink:to="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6f15526d-0f06-4b35-8ede-28e2a9257fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6f15526d-0f06-4b35-8ede-28e2a9257fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_6e2c7495-cb48-442b-b726-3fa4a2b7ded3" xlink:href="amgn-20201231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_6e2c7495-cb48-442b-b726-3fa4a2b7ded3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_c45c685d-0dba-450e-9cdf-6f9f5010e7d7" xlink:href="amgn-20201231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_c45c685d-0dba-450e-9cdf-6f9f5010e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_99332b12-5bfd-4d04-bbc6-678053b11868" xlink:href="amgn-20201231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_99332b12-5bfd-4d04-bbc6-678053b11868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_1a40b349-7cd1-4c8e-9bc3-434592f83621" xlink:href="amgn-20201231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_1a40b349-7cd1-4c8e-9bc3-434592f83621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f9ec6555-09a5-4ba9-91ba-84933687405a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f9ec6555-09a5-4ba9-91ba-84933687405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a6e89d13-a83a-4843-9838-94fde715f03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a6e89d13-a83a-4843-9838-94fde715f03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_925986e7-83e3-4540-9d68-15861229d55a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_925986e7-83e3-4540-9d68-15861229d55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_7f224415-3aaa-4cb0-88a5-a0db04d82f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_afeacc57-2013-4923-9ec4-e8b3d71c2ca7" xlink:to="loc_us-gaap_LineOfCredit_7f224415-3aaa-4cb0-88a5-a0db04d82f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_352a96bf-bd53-483b-b014-b1154756a1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_352a96bf-bd53-483b-b014-b1154756a1dd" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_79e27856-28e8-4ccb-aae1-b24415923691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_79e27856-28e8-4ccb-aae1-b24415923691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b0ab0050-9fe1-401b-b705-6e88ccfa4382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b0ab0050-9fe1-401b-b705-6e88ccfa4382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_783c045f-5f0d-4fed-b9f2-d5048cf17e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_783c045f-5f0d-4fed-b9f2-d5048cf17e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d498c90e-754f-4c80-891f-30f27978f9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d498c90e-754f-4c80-891f-30f27978f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b91a5963-3e3a-4d29-ae85-694b71c56671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b91a5963-3e3a-4d29-ae85-694b71c56671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_05797d31-5d1f-4040-b38d-b95d8c56a3ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_05797d31-5d1f-4040-b38d-b95d8c56a3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_035e94ec-1a6d-4ad9-9c3f-cc371169fbdf" xlink:href="amgn-20201231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2c190c65-d11e-460a-a5b4-7269909d6909" xlink:to="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_035e94ec-1a6d-4ad9-9c3f-cc371169fbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FinancingarrangementsInterestCostsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c02f4c62-7be0-4da4-b0f0-12a9f005ab21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_052f0061-9897-4444-ae70-e3b49f3bbd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c02f4c62-7be0-4da4-b0f0-12a9f005ab21" xlink:to="loc_us-gaap_InterestPaid_052f0061-9897-4444-ae70-e3b49f3bbd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockholdersequity" xlink:type="simple" xlink:href="amgn-20201231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_813848cc-5fe6-4b61-9397-81e6770fc539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_12120974-828a-42e0-998d-37824b1859cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_813848cc-5fe6-4b61-9397-81e6770fc539" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_12120974-828a-42e0-998d-37824b1859cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ffa9f517-3032-4a95-8645-a22d01210f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock_b7916ed5-5f37-4ea8-81e1-b1ba69b76f77" xlink:href="amgn-20201231.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ffa9f517-3032-4a95-8645-a22d01210f8d" xlink:to="loc_amgn_StockRepurchaseProgramTableTextBlock_b7916ed5-5f37-4ea8-81e1-b1ba69b76f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_67199dc5-3d26-436f-9189-c4ff20b914bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ffa9f517-3032-4a95-8645-a22d01210f8d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_67199dc5-3d26-436f-9189-c4ff20b914bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_a7726081-c7de-43a4-88b4-12bb4b780eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ffa9f517-3032-4a95-8645-a22d01210f8d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_a7726081-c7de-43a4-88b4-12bb4b780eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityStockRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_727c4ef9-84b8-4aef-acb1-686d9e65189d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_633febca-0ca7-4332-bbb3-b491ffa782d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_727c4ef9-84b8-4aef-acb1-686d9e65189d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_633febca-0ca7-4332-bbb3-b491ffa782d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ccf3bc40-0fc1-4099-abac-e57fc4214a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_727c4ef9-84b8-4aef-acb1-686d9e65189d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ccf3bc40-0fc1-4099-abac-e57fc4214a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7ac97095-a835-4057-8f4e-243fc93ee467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_727c4ef9-84b8-4aef-acb1-686d9e65189d" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7ac97095-a835-4057-8f4e-243fc93ee467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_df1bd0f5-776c-41a3-a86c-ccb8bad44e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_727c4ef9-84b8-4aef-acb1-686d9e65189d" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_df1bd0f5-776c-41a3-a86c-ccb8bad44e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae023daf-1a72-4de0-ac32-5e5631ce1dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae023daf-1a72-4de0-ac32-5e5631ce1dc8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:to="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ca69937f-d3b9-4b0d-bc36-75f8bf88ac34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fa3a5212-fb54-4380-b85a-caf505a32e3a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ca69937f-d3b9-4b0d-bc36-75f8bf88ac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1259fc3f-690d-4b6d-bc49-ec0f09c2b4cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ca69937f-d3b9-4b0d-bc36-75f8bf88ac34" xlink:to="loc_srt_ScenarioForecastMember_1259fc3f-690d-4b6d-bc49-ec0f09c2b4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8073fa5e-d5c7-43d5-9d97-60a83ae58f7f" xlink:to="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_52665624-0591-4d24-a620-74b04d944629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_52665624-0591-4d24-a620-74b04d944629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_86308a94-f8ff-410f-80e5-85890a85c6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dde8719d-67f0-4be6-88c6-b9785f337392" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_86308a94-f8ff-410f-80e5-85890a85c6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a5ef04ea-bc93-4458-96f6-a6d998f24461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5ef04ea-bc93-4458-96f6-a6d998f24461" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8681696-c35b-45c1-b372-677a0fac15e5" xlink:to="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe96a858-281a-4f41-b003-87b4bb1fc625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe96a858-281a-4f41-b003-87b4bb1fc625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_ec572665-a4e8-4692-8f9c-6352d5197da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_ec572665-a4e8-4692-8f9c-6352d5197da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c4df6ddd-48b2-4d19-8229-5c0c22b4c480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c4df6ddd-48b2-4d19-8229-5c0c22b4c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_09a32e81-4419-453b-9202-9aa6456f0ee9" xlink:href="amgn-20201231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_09a32e81-4419-453b-9202-9aa6456f0ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d416f9d2-80f5-452c-928b-adea3111ff42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_133a1a04-af65-4976-9486-30cbacfc2ef7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d416f9d2-80f5-452c-928b-adea3111ff42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f18fb4bd-3a5c-4c72-88d6-c5b17fcfb8db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_140052ea-6763-474f-a430-25bbef8bad5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f18fb4bd-3a5c-4c72-88d6-c5b17fcfb8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7fba6a9d-7fc0-43c8-b552-fb8ca1b8318d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f18fb4bd-3a5c-4c72-88d6-c5b17fcfb8db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7fba6a9d-7fc0-43c8-b552-fb8ca1b8318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14a89e73-376c-4972-95ec-6e4a969e37ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ec9d4aa1-8652-48f8-8047-58a8e3530e38" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14a89e73-376c-4972-95ec-6e4a969e37ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14a89e73-376c-4972-95ec-6e4a969e37ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7979b9d9-21aa-4e0d-b6b7-b42c56c15b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_StockholdersEquity_7979b9d9-21aa-4e0d-b6b7-b42c56c15b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8105f1cd-00e9-49f3-888e-740b04bd84e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8105f1cd-00e9-49f3-888e-740b04bd84e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_bb667587-a2c8-41fd-8324-44b5216fdd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_bb667587-a2c8-41fd-8324-44b5216fdd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_9a3fdef0-464c-46a4-bd11-56517c530b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_9a3fdef0-464c-46a4-bd11-56517c530b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_d4338aff-47ee-46aa-9083-84b594952d17" xlink:href="amgn-20201231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_d4338aff-47ee-46aa-9083-84b594952d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_258eb415-aecf-404d-9c97-310434848405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_258eb415-aecf-404d-9c97-310434848405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_396ba300-59ee-430b-bdb7-eacff8f4b22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3d7def2-b993-46fd-9e9a-c293dd56a162" xlink:to="loc_us-gaap_StockholdersEquity_396ba300-59ee-430b-bdb7-eacff8f4b22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c97b1676-00a1-4158-8dc3-bcf5ac71d855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_e1f0aac8-dae3-4b3b-8732-1ba094c00d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c97b1676-00a1-4158-8dc3-bcf5ac71d855" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_e1f0aac8-dae3-4b3b-8732-1ba094c00d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_21fec155-c313-4a80-9722-53d083c96c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c97b1676-00a1-4158-8dc3-bcf5ac71d855" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_21fec155-c313-4a80-9722-53d083c96c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_6ca3851c-4ec5-404e-8793-d614437f6892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c97b1676-00a1-4158-8dc3-bcf5ac71d855" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_6ca3851c-4ec5-404e-8793-d614437f6892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_b06d28f7-9ba3-4988-9fb9-8fe6b1f707ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c97b1676-00a1-4158-8dc3-bcf5ac71d855" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax_b06d28f7-9ba3-4988-9fb9-8fe6b1f707ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2d433e3d-a0b0-462f-95b9-a578c4e82426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2d433e3d-a0b0-462f-95b9-a578c4e82426" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0699f699-1297-4448-b420-409815a083d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8144d5af-8012-4e2a-8dd3-46fe08a3b45e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0699f699-1297-4448-b420-409815a083d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_54338ad3-650c-46aa-b49d-c0d20f4bf998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0699f699-1297-4448-b420-409815a083d6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_54338ad3-650c-46aa-b49d-c0d20f4bf998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f0c6562-1fab-4b98-afbe-53be607764c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0956d98f-1a79-4899-b1a4-16eb8ab061f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0956d98f-1a79-4899-b1a4-16eb8ab061f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_f75eb8fa-d0b3-4590-8180-be410333277b" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_f75eb8fa-d0b3-4590-8180-be410333277b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_8ee41b7a-dc14-4214-b450-0e43ee926dc2" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf7377c7-a5d4-483b-b673-9fad70e8b59f" xlink:to="loc_amgn_ForwardInterestRateContractMember_8ee41b7a-dc14-4214-b450-0e43ee926dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9827bf66-c858-4416-9387-f581a4fa87ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2247dc76-0444-444a-822c-b372dc13b161" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9827bf66-c858-4416-9387-f581a4fa87ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_18242cd5-4dd5-46d7-96a2-5f64da4125f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9827bf66-c858-4416-9387-f581a4fa87ca" xlink:to="loc_us-gaap_CashFlowHedgingMember_18242cd5-4dd5-46d7-96a2-5f64da4125f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce6f3094-7633-49fd-abd1-6de0311dc8a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b1f15527-1ae6-42c8-b6f4-7e440ba66b7c" xlink:to="loc_srt_ProductsAndServicesDomain_ce6f3094-7633-49fd-abd1-6de0311dc8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0f8f1528-b72e-4688-a72e-eb7f5fb110da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ce6f3094-7633-49fd-abd1-6de0311dc8a1" xlink:to="loc_us-gaap_ProductMember_0f8f1528-b72e-4688-a72e-eb7f5fb110da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d93e214-b051-49b6-9eb7-5ee5ff192feb" xlink:to="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c7252605-c27f-4eb7-be6c-296274695336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c7252605-c27f-4eb7-be6c-296274695336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_162ecfe5-7db6-4f5b-a6d9-8538c17213c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0ac17e19-5536-4e04-ba3d-8f49dc1d5c5e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_162ecfe5-7db6-4f5b-a6d9-8538c17213c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4fc6252c-3103-4cd5-8d94-93db3080660f" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7d53c4f7-f060-46a2-8d66-5528a34cc5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7d53c4f7-f060-46a2-8d66-5528a34cc5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4952c378-9260-4b6b-ad7a-5129649847e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4952c378-9260-4b6b-ad7a-5129649847e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8e17fedd-f57b-4964-89ed-c5c3c32e8828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_InterestExpenseDebt_8e17fedd-f57b-4964-89ed-c5c3c32e8828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f992d7b2-68e0-4763-8747-cb8a4e3f745a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f992d7b2-68e0-4763-8747-cb8a4e3f745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1031d01c-a997-4fb3-bee6-58c9edd07d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1031d01c-a997-4fb3-bee6-58c9edd07d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f693644f-bf18-41a0-af78-e96c62ac6959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7efbce62-10ab-424c-8295-800467deb4c8" xlink:to="loc_us-gaap_NetIncomeLoss_f693644f-bf18-41a0-af78-e96c62ac6959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#StockholdersequityOtherDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4e97405e-d8ec-4061-969a-d36342b75a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4a45c825-b5d6-48d4-8619-22e885c2e85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e97405e-d8ec-4061-969a-d36342b75a37" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4a45c825-b5d6-48d4-8619-22e885c2e85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a1f48d48-6744-479a-8853-f1046822c866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e97405e-d8ec-4061-969a-d36342b75a37" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a1f48d48-6744-479a-8853-f1046822c866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f841db17-5c58-4152-a30b-39bc7ff8bde5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e97405e-d8ec-4061-969a-d36342b75a37" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f841db17-5c58-4152-a30b-39bc7ff8bde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_07ef8cc5-b1ab-4128-9b9e-109907edf8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e97405e-d8ec-4061-969a-d36342b75a37" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_07ef8cc5-b1ab-4128-9b9e-109907edf8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="simple" xlink:href="amgn-20201231.xsd#Fairvaluemeasurement"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_76fed5b5-3b73-4700-b8c6-ad0ec8ef9e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5c5bbe2c-ff48-4b22-b3bd-5977bd59a879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_76fed5b5-3b73-4700-b8c6-ad0ec8ef9e71" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5c5bbe2c-ff48-4b22-b3bd-5977bd59a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_138bbd9a-8747-410c-a779-4af81d7ede54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_60d85fd3-5dc6-4a84-b585-ca3748fdfbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_138bbd9a-8747-410c-a779-4af81d7ede54" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_60d85fd3-5dc6-4a84-b585-ca3748fdfbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7ad53e99-9f91-4178-b1c2-7346672d4580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7ad53e99-9f91-4178-b1c2-7346672d4580" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_10c46529-fd43-4a95-bfbf-56d67f32cac7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4978f21-9cb7-4ba1-b38b-328bf3f79d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4978f21-9cb7-4ba1-b38b-328bf3f79d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_226f3c64-9abc-4aef-a225-0441c426292e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_226f3c64-9abc-4aef-a225-0441c426292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2f212606-87cb-4cde-b20c-d1f88f7429f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ca24216-bfb5-4dae-9070-5053fc34d90d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2f212606-87cb-4cde-b20c-d1f88f7429f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_15f24ad3-1509-4e4b-8953-96e5ca7d9570" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b20bec62-e31c-46e1-ae0c-97bdcb17e69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b20bec62-e31c-46e1-ae0c-97bdcb17e69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_72dd3005-3d22-4a7e-9e74-f070ea435010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_72dd3005-3d22-4a7e-9e74-f070ea435010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_8cfabb71-9d43-4093-bc72-faa5a986f094" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_8cfabb71-9d43-4093-bc72-faa5a986f094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_226339f4-1ed8-4e8c-b162-bcbd7cf15247" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_226339f4-1ed8-4e8c-b162-bcbd7cf15247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_6002c581-457e-414d-804b-4e0bf2f8d0d5" xlink:href="amgn-20201231.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_6002c581-457e-414d-804b-4e0bf2f8d0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_d5c30c6e-34d5-441b-81fb-65bf02be799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_d5c30c6e-34d5-441b-81fb-65bf02be799d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_229377de-443a-43b5-9c28-d517039bb9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_229377de-443a-43b5-9c28-d517039bb9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_126f5c56-2ad7-4f55-bd48-122d1174f54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_126f5c56-2ad7-4f55-bd48-122d1174f54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_7cabaee8-97a1-41e7-a0ca-ff3202c8c9d4" xlink:href="amgn-20201231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6ddd4fa-1df5-4fcd-9ad9-b6d2b24d619c" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_7cabaee8-97a1-41e7-a0ca-ff3202c8c9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_78da90b6-8c9a-4aa5-8e65-1c342fbc25da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_10cacb78-ce32-4443-bf2e-1f2a50e3e48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:to="loc_us-gaap_ForeignExchangeContractMember_10cacb78-ce32-4443-bf2e-1f2a50e3e48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_96f459ac-871b-4662-b7d1-cc49e1816616" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_96f459ac-871b-4662-b7d1-cc49e1816616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_820a6906-effe-4f49-9dc1-e8821d35edff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa13c50e-3fc0-4959-baba-bad40eebb907" xlink:to="loc_us-gaap_InterestRateSwapMember_820a6906-effe-4f49-9dc1-e8821d35edff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83dc08eb-f00e-4ec1-ab3b-281cfab810dd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16c13bf-b304-44b9-89dd-7f0cbe9b0d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16c13bf-b304-44b9-89dd-7f0cbe9b0d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0b2ce186-c155-4d5e-bfa9-027824787381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0b2ce186-c155-4d5e-bfa9-027824787381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:href="amgn-20201231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_8db87b38-431c-49a9-b58c-64ee176f8f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_8db87b38-431c-49a9-b58c-64ee176f8f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_bd69f29c-14b1-42f1-93c0-fb6fdc64ab94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_87de3cc6-bc1e-43a0-ab45-db1c2716a53a" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_bd69f29c-14b1-42f1-93c0-fb6fdc64ab94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1e62135c-f9ac-4c9e-9ffc-e826f937b8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3904d52d-79bc-4341-9a83-0ff01dd900b4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1e62135c-f9ac-4c9e-9ffc-e826f937b8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_582e1e89-f983-409b-8ff0-a3e51a6cb5f7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:href="amgn-20201231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_77d8ebbd-562c-42aa-907a-ee27235fff46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_77d8ebbd-562c-42aa-907a-ee27235fff46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_12b59f37-a7e4-49a4-82a8-b8187b35889b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_9341a38f-af1b-40f7-b09d-fd4ab9bc2f69" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_12b59f37-a7e4-49a4-82a8-b8187b35889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6dbc2935-1380-4d9a-aaa3-34f343997148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6dbc2935-1380-4d9a-aaa3-34f343997148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_811fa216-738d-410e-81b9-e88215f19cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0430c5a9-f0d8-42bf-b2b9-693a2d793da2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_811fa216-738d-410e-81b9-e88215f19cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba6b9362-5498-46a2-9027-67c27c8c797b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba6b9362-5498-46a2-9027-67c27c8c797b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c85cba-cbcb-4f64-a926-eb96d4e2eebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40b0b622-3c3b-426c-9f89-9b0b4fae48d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c85cba-cbcb-4f64-a926-eb96d4e2eebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_3f89c960-f275-4332-a898-e3d8992ba03f" xlink:href="amgn-20201231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c85cba-cbcb-4f64-a926-eb96d4e2eebd" xlink:to="loc_amgn_BeiGeneMember_3f89c960-f275-4332-a898-e3d8992ba03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4e4f141f-2c92-4208-91da-b744f6a6cf18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e00696ae-e646-4d6e-8feb-750e25f04cb1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4e4f141f-2c92-4208-91da-b744f6a6cf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_7c38b022-bd36-4d4b-92d2-565e2f1561f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4e4f141f-2c92-4208-91da-b744f6a6cf18" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_7c38b022-bd36-4d4b-92d2-565e2f1561f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b3ee3d15-9f8a-4895-8418-3c52b0b70d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0c0c9568-21d8-4149-b549-9fd73afdb9cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b3ee3d15-9f8a-4895-8418-3c52b0b70d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6b40991-7ae8-4c28-bbce-414b7f43cdfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b3ee3d15-9f8a-4895-8418-3c52b0b70d6e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6b40991-7ae8-4c28-bbce-414b7f43cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6a4950ae-d140-497e-ace7-7c750ad9974a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_bbcaa7d7-36a5-4123-a18a-9b62e8cdbef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_bbcaa7d7-36a5-4123-a18a-9b62e8cdbef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1588eb75-d60f-4b6f-9efe-869300d90147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1588eb75-d60f-4b6f-9efe-869300d90147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_1f89c9d2-8579-43c0-bbf7-7e5d1d1476cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_1f89c9d2-8579-43c0-bbf7-7e5d1d1476cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d716c265-396f-4d39-94d9-ff5dfce19a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_LongTermDebt_d716c265-396f-4d39-94d9-ff5dfce19a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6df9f6dc-45ba-4b66-be0b-b04fab22b3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6df9f6dc-45ba-4b66-be0b-b04fab22b3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_35713cd1-1601-4fba-91b9-75b62efc7e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_58299a5f-0cb3-4714-abad-aa185b6f9794" xlink:to="loc_us-gaap_EquityMethodInvestments_35713cd1-1601-4fba-91b9-75b62efc7e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Derivativeinstruments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Derivativeinstruments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Derivativeinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dea3a7f4-6e7a-4b17-bb37-584df400e756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_430e54fe-0345-425c-b252-137280bda45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dea3a7f4-6e7a-4b17-bb37-584df400e756" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_430e54fe-0345-425c-b252-137280bda45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a69a659b-194f-4787-9460-cec748cab9ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_20320de9-1b91-4f7f-b083-02b11de8cb5c" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a69a659b-194f-4787-9460-cec748cab9ec" xlink:to="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_20320de9-1b91-4f7f-b083-02b11de8cb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_ac197662-a320-4285-9162-548ad2d3489e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a69a659b-194f-4787-9460-cec748cab9ec" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_ac197662-a320-4285-9162-548ad2d3489e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_62d51fc7-e9de-4136-a5bb-1d8b00738e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a69a659b-194f-4787-9460-cec748cab9ec" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_62d51fc7-e9de-4136-a5bb-1d8b00738e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_046c51a5-cfce-428a-9cb2-5000a04cdbb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a69a659b-194f-4787-9460-cec748cab9ec" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_046c51a5-cfce-428a-9cb2-5000a04cdbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_9bfbec31-1660-4a61-9e40-615b3f86a60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a69a659b-194f-4787-9460-cec748cab9ec" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_9bfbec31-1660-4a61-9e40-615b3f86a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c058ad3-5217-452c-bd98-c66473b17060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c058ad3-5217-452c-bd98-c66473b17060" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a8ba0d8-1b82-45d5-847c-58f899dfcb9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_431824cc-2147-4d29-aa7c-80565620037b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a8ba0d8-1b82-45d5-847c-58f899dfcb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_1ba64535-da34-4055-b2a6-cc2f11371ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1a8ba0d8-1b82-45d5-847c-58f899dfcb9b" xlink:to="loc_us-gaap_NotesPayableToBanksMember_1ba64535-da34-4055-b2a6-cc2f11371ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7d2a1e1-d019-4d43-9c89-a782dcbab918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_efcb2f6a-7102-4dd2-80de-b8c45b3aa6b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7d2a1e1-d019-4d43-9c89-a782dcbab918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_da66e5e9-4520-4725-a327-63bf46453ecb" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7d2a1e1-d019-4d43-9c89-a782dcbab918" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_da66e5e9-4520-4725-a327-63bf46453ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e2bb15bf-05f3-4086-a2ed-d8ac31dd6c5c" xlink:to="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_40de7323-726b-41b5-be13-302ec7121ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_40de7323-726b-41b5-be13-302ec7121ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f226973a-86b6-4f9c-81e4-b22c900f9864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a9317e5d-d70f-420d-8d98-f2eb6bdd86bc" xlink:to="loc_us-gaap_NondesignatedMember_f226973a-86b6-4f9c-81e4-b22c900f9864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1bf44161-8dd5-4d4e-85aa-846a96c62b5f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_db0f7810-7ca0-427f-9a2e-4fec645f9d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_us-gaap_ForwardContractsMember_db0f7810-7ca0-427f-9a2e-4fec645f9d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_3cbf0f85-2195-4856-b537-5fe1eab07fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_us-gaap_OptionMember_3cbf0f85-2195-4856-b537-5fe1eab07fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_a6306c02-468b-42e3-b336-610c35bb3cec" xlink:href="amgn-20201231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_a6306c02-468b-42e3-b336-610c35bb3cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_3ece5595-5d4c-4d06-973a-ed0388b34369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_us-gaap_InterestRateSwapMember_3ece5595-5d4c-4d06-973a-ed0388b34369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_c6c82309-d1a1-4da1-8250-7c78d9816926" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAtThenCurrentInterestRatesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ca402b-37f1-4555-abf5-bb20998d1d35" xlink:to="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_c6c82309-d1a1-4da1-8250-7c78d9816926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_681d2a65-dc60-4c8a-b038-3a4687d47d21" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapAxis_52d02d05-bed7-4edd-a683-e2062e25e51f" xlink:to="loc_amgn_InterestRateSwapDomain_681d2a65-dc60-4c8a-b038-3a4687d47d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_70452a64-9655-4046-8767-6d57de7001a6" xlink:href="amgn-20201231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_681d2a65-dc60-4c8a-b038-3a4687d47d21" xlink:to="loc_amgn_InterestRateSwapTwoMember_70452a64-9655-4046-8767-6d57de7001a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a60bd776-f05c-4663-81df-e8a00a7d7e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_056039a5-3d8b-4ded-9b78-4e467a978bd2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a60bd776-f05c-4663-81df-e8a00a7d7e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_60f8d77e-4505-42a0-8dc8-eb5029fa8769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60bd776-f05c-4663-81df-e8a00a7d7e7d" xlink:to="loc_us-gaap_InterestExpenseMember_60f8d77e-4505-42a0-8dc8-eb5029fa8769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7ccb6400-d8fa-4b4f-837f-c60fc40e0197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_25b8af99-f939-47b4-9032-40ca36106160" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7ccb6400-d8fa-4b4f-837f-c60fc40e0197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_3704f89c-697a-4c28-be9b-a063ca37beae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7ccb6400-d8fa-4b4f-837f-c60fc40e0197" xlink:to="loc_us-gaap_LongTermDebtMember_3704f89c-697a-4c28-be9b-a063ca37beae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0d68378b-57ed-43db-ac9d-969869c3ec7e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_efabe922-4d5e-440c-bb85-53b63bf9b37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_efabe922-4d5e-440c-bb85-53b63bf9b37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1807b58-2c79-4fdc-beb1-f7bf63721056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1807b58-2c79-4fdc-beb1-f7bf63721056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_f71440e6-6dee-41b1-9c59-9821a05606f3" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_f71440e6-6dee-41b1-9c59-9821a05606f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6976cf1a-9eb4-4a5b-9ede-b640a8ff55b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6976cf1a-9eb4-4a5b-9ede-b640a8ff55b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_eefb5416-9f1f-4b7a-8bd5-d401ad8bbac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_eefb5416-9f1f-4b7a-8bd5-d401ad8bbac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_28e44bc0-169f-431a-9663-10d5a3ac9e16" xlink:href="amgn-20201231.xsd#amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_28e44bc0-169f-431a-9663-10d5a3ac9e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_14ffd8f1-6efc-4a5d-a3e1-34b7cdd6d199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_14ffd8f1-6efc-4a5d-a3e1-34b7cdd6d199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e3be4ea4-5435-4706-aaec-399c9364a0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a300fff2-e9ce-44a4-a359-714950bfc6f7" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e3be4ea4-5435-4706-aaec-399c9364a0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4f1b52e7-f148-4ede-be97-eb1ad7e39feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4f1b52e7-f148-4ede-be97-eb1ad7e39feb" xlink:to="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9256fa86-c9ce-47f5-89c3-54984bdacbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bc7659ed-ec0b-47c5-a472-b2e34db21106" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9256fa86-c9ce-47f5-89c3-54984bdacbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_5d4ae16e-6e0e-4d8d-8ca7-acfd1f8d28b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9256fa86-c9ce-47f5-89c3-54984bdacbd0" xlink:to="loc_us-gaap_CashFlowHedgingMember_5d4ae16e-6e0e-4d8d-8ca7-acfd1f8d28b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_41819d06-b06b-4f32-95d3-874640a01988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ba7cbd77-9b2a-4145-bef0-dedf48b6b4c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_41819d06-b06b-4f32-95d3-874640a01988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_db85d4c7-5ea7-4772-be0f-1d0bde5b06fd" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41819d06-b06b-4f32-95d3-874640a01988" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_db85d4c7-5ea7-4772-be0f-1d0bde5b06fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_108e6710-753b-4bdc-93f6-65a0d6857ad0" xlink:to="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_26e0fc49-2000-4df5-9078-5afdf3c6d97b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_EUR_26e0fc49-2000-4df5-9078-5afdf3c6d97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_8ceb6f5f-36dc-4fcb-bd9f-42e296860c2f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_CHF_8ceb6f5f-36dc-4fcb-bd9f-42e296860c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_4046fc36-ac96-4d0b-a917-161c94b5688f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_GBP_4046fc36-ac96-4d0b-a917-161c94b5688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_d42e15fa-9e5b-46fb-8d09-c821bb540842" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_94ab1f4a-20d7-49ea-80a4-53c7b4652352" xlink:to="loc_currency_USD_d42e15fa-9e5b-46fb-8d09-c821bb540842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ddac7831-341c-4876-864a-ab987f6aca94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_8d3d189f-37e2-4534-b7c3-eb70b8fdf411" xlink:href="amgn-20201231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_8d3d189f-37e2-4534-b7c3-eb70b8fdf411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ac779fbd-5964-41c2-821d-dd7d1eafa99f" xlink:href="amgn-20201231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ac779fbd-5964-41c2-821d-dd7d1eafa99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_6ebe90b3-1a98-4b7e-ab52-98041f08045e" xlink:href="amgn-20201231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_6ebe90b3-1a98-4b7e-ab52-98041f08045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_83183661-00ef-456f-a78b-7dae300c5f27" xlink:href="amgn-20201231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_83183661-00ef-456f-a78b-7dae300c5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_db73a217-eab3-4fd5-80f5-81183a9b91c1" xlink:href="amgn-20201231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_db73a217-eab3-4fd5-80f5-81183a9b91c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_6f0715cd-5f43-438b-b452-8730a4e6d6f0" xlink:href="amgn-20201231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c99b8e4-8bf3-4c27-af7b-c730e48151d5" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_6f0715cd-5f43-438b-b452-8730a4e6d6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_174a4d4d-68d4-4078-acf4-07f543d6caeb" xlink:to="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_20fae692-800c-4d91-bdb3-d7f7a6ce4a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:to="loc_us-gaap_DerivativeNotionalAmount_20fae692-800c-4d91-bdb3-d7f7a6ce4a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_2a585601-2261-4a92-b1cb-7e616beb116c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bcc50943-d2b5-44ab-9836-e638db07eb78" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_2a585601-2261-4a92-b1cb-7e616beb116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ad97422-1afd-4ddb-8b8a-0949d56ac57e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ad97422-1afd-4ddb-8b8a-0949d56ac57e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_dfded723-7323-48b2-91de-7f4a62bc7369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_353f4f60-a2b3-456b-9c17-9ad8a848ff92" xlink:to="loc_us-gaap_HedgingRelationshipDomain_dfded723-7323-48b2-91de-7f4a62bc7369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1cf12b15-3c68-417e-8174-edf488aa93cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_dfded723-7323-48b2-91de-7f4a62bc7369" xlink:to="loc_us-gaap_CashFlowHedgingMember_1cf12b15-3c68-417e-8174-edf488aa93cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_67c2b7de-e3d4-491c-be05-dc0924f226b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d6ece120-e5ff-48be-a562-237f72fc4ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d6ece120-e5ff-48be-a562-237f72fc4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_a957a2bf-f1de-4d25-bbba-448a1dda3cca" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_a957a2bf-f1de-4d25-bbba-448a1dda3cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_50ce46dc-ff76-4852-bbbc-c067e213f9c2" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cbc32c71-9405-46e0-8d7e-796c45fb402c" xlink:to="loc_amgn_ForwardInterestRateContractMember_50ce46dc-ff76-4852-bbbc-c067e213f9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9768fd1d-3b69-43bc-8635-85ea68a6f4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7f285b37-1237-4657-93d6-4fe34ce01bda" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9768fd1d-3b69-43bc-8635-85ea68a6f4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_9a7235c8-1211-4f32-8dc6-937d3ede91eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9768fd1d-3b69-43bc-8635-85ea68a6f4a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_9a7235c8-1211-4f32-8dc6-937d3ede91eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_54e81837-111b-4c3d-8845-911f98d8757b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_54e81837-111b-4c3d-8845-911f98d8757b" xlink:to="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b339ca4d-994d-4327-910c-23c3badd98be" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_e0b44485-78f4-44fb-a75b-302d5bc1abf5" xlink:href="amgn-20201231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_e0b44485-78f4-44fb-a75b-302d5bc1abf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_2a61c8c2-8c7b-4d0e-bf9b-058e165d610a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d561e0e4-d6df-4f84-ae0b-72266ee995d8" xlink:to="loc_us-gaap_LongTermDebtMember_2a61c8c2-8c7b-4d0e-bf9b-058e165d610a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_244c70fc-2224-4d25-b0c3-685f1e605471" xlink:to="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_dfedaef4-b3fe-4b66-b9b5-9b4a9c586f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_dfedaef4-b3fe-4b66-b9b5-9b4a9c586f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_33ebaa0f-eb8b-449b-af27-89fdaa8d78ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_33ebaa0f-eb8b-449b-af27-89fdaa8d78ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_e1af43cf-bf48-4f98-82b7-8711fb710b40" xlink:href="amgn-20201231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_e1af43cf-bf48-4f98-82b7-8711fb710b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_8ecd1a9e-f1fe-45c6-910a-d143727b2e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b59f86aa-45d1-48a6-be86-96748f635b48" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_8ecd1a9e-f1fe-45c6-910a-d143727b2e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3857b2f0-b1ed-447c-9154-52162b0ab390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3857b2f0-b1ed-447c-9154-52162b0ab390" xlink:to="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_291ab721-825c-442a-98ab-3cbd4a31f240" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_05d464ce-84f2-4178-8511-8d853b48bc16" xlink:to="loc_srt_ProductsAndServicesDomain_291ab721-825c-442a-98ab-3cbd4a31f240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_85753043-ff38-4f01-bb1d-92ec0e4f689f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_291ab721-825c-442a-98ab-3cbd4a31f240" xlink:to="loc_us-gaap_ProductMember_85753043-ff38-4f01-bb1d-92ec0e4f689f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d09e0772-85f8-403a-b55c-7ef8c26fc104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_eb240656-a084-47cd-a858-45afe58faacb" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d09e0772-85f8-403a-b55c-7ef8c26fc104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b045c3-e54d-4ca8-98c5-d7442efdf3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d09e0772-85f8-403a-b55c-7ef8c26fc104" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b045c3-e54d-4ca8-98c5-d7442efdf3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21b6ea80-1346-4b86-8f62-9266cc3a4429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c2877098-d8c4-49f3-9900-fe3e1e4a12de" xlink:to="loc_us-gaap_EquityComponentDomain_21b6ea80-1346-4b86-8f62-9266cc3a4429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_110e580e-5ec5-4668-9b1b-67b8d1b21d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b6ea80-1346-4b86-8f62-9266cc3a4429" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_110e580e-5ec5-4668-9b1b-67b8d1b21d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1709e447-ebf0-42e0-b5b5-dc2387136cad" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5e49ca8d-21a7-4146-829e-5c5bb4290534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5e49ca8d-21a7-4146-829e-5c5bb4290534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_dd06870c-5d70-4dfc-babe-8ce749b11184" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_dd06870c-5d70-4dfc-babe-8ce749b11184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForwardInterestRateContractMember_32e55c39-469d-49d1-bee1-d7e810138f6a" xlink:href="amgn-20201231.xsd#amgn_ForwardInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_amgn_ForwardInterestRateContractMember_32e55c39-469d-49d1-bee1-d7e810138f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_af1f1bf5-f4a5-43ca-808e-da1f6e2f6e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b7c5e1e-93a6-4a43-9b1d-f6b4f2074a30" xlink:to="loc_us-gaap_InterestRateSwapMember_af1f1bf5-f4a5-43ca-808e-da1f6e2f6e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_8846975f-5274-4714-898f-ffcb20e767a7" xlink:to="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0f8c5396-6bda-4814-bd8e-523bd37fb479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0f8c5396-6bda-4814-bd8e-523bd37fb479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_85001156-b3d8-4e9d-8704-061ab9498e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_85001156-b3d8-4e9d-8704-061ab9498e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_dffdd79c-db7a-4523-8194-995a78f436b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_InterestExpenseDebt_dffdd79c-db7a-4523-8194-995a78f436b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bcf12f61-53ff-4363-a471-a612d219f94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bcf12f61-53ff-4363-a471-a612d219f94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_0d7fabe0-b926-4a78-a250-94e8dd32c688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bfd333f2-ea0e-47e6-b84d-cb9ca68b914c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_0d7fabe0-b926-4a78-a250-94e8dd32c688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bd6adf76-c497-4000-83cd-e3eb9f2084ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bd6adf76-c497-4000-83cd-e3eb9f2084ae" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_30a04b9b-be5b-4916-aa59-243b1af3357e" xlink:to="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5dba2127-449b-4d02-8dc6-d74901e1a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5dba2127-449b-4d02-8dc6-d74901e1a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_eb57eb0c-c781-4396-bef6-dfd160c0e39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0ad0ac5d-770b-436f-92aa-bc0f7a9da820" xlink:to="loc_us-gaap_NondesignatedMember_eb57eb0c-c781-4396-bef6-dfd160c0e39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9bf33905-2770-4114-9371-78a5cb699254" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_90165edd-50cc-4203-8c83-e73288859700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:to="loc_us-gaap_ForeignExchangeContractMember_90165edd-50cc-4203-8c83-e73288859700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_52e6cf80-269e-4a4a-934b-e5264966e6e0" xlink:href="amgn-20201231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_52e6cf80-269e-4a4a-934b-e5264966e6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b7b67c04-64d4-448d-9f9e-1b4fcf944d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_aa275bfb-7176-4d23-a441-74fb7b6e7ccc" xlink:to="loc_us-gaap_InterestRateSwapMember_b7b67c04-64d4-448d-9f9e-1b4fcf944d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e6d1f6d5-8d33-4021-9026-3dce3708b852" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_0166a078-c013-4c72-a961-c9165e5061dc" xlink:href="amgn-20201231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_0166a078-c013-4c72-a961-c9165e5061dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_7da7f5dc-e33a-48f5-a829-46e8d258ffe4" xlink:href="amgn-20201231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_7da7f5dc-e33a-48f5-a829-46e8d258ffe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_29c7e983-5c86-4c58-b569-44e353f6046c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_29c7e983-5c86-4c58-b569-44e353f6046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e2d28088-56db-4237-9654-4286c48a9f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5a6cf0b9-cbc4-4142-911c-b03860d27717" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e2d28088-56db-4237-9654-4286c48a9f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_507725c2-a530-464c-8981-f0bae7a243a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b4d92f40-626e-4bc2-9c7c-aafec6c1c33a" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_507725c2-a530-464c-8981-f0bae7a243a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:href="amgn-20201231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_507725c2-a530-464c-8981-f0bae7a243a5" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_800fb38e-0a19-4f74-8d38-26f40fb7fdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_800fb38e-0a19-4f74-8d38-26f40fb7fdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ee4634b9-9d72-4a0c-aab6-a4cbe9de3828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_800fb38e-0a19-4f74-8d38-26f40fb7fdec" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ee4634b9-9d72-4a0c-aab6-a4cbe9de3828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_8274a909-64d6-444f-971e-8395f3aec672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_9c694f0a-c36e-44d2-bbbd-1a886ffb4750" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_8274a909-64d6-444f-971e-8395f3aec672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a773f6f4-12c3-4229-b7e8-a9d7325f89a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_8274a909-64d6-444f-971e-8395f3aec672" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a773f6f4-12c3-4229-b7e8-a9d7325f89a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="amgn-20201231.xsd#Contingenciesandcommitments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616a6e88-0c6e-4ff2-acbc-d679ff317b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_58f91758-8f16-4adf-aa48-ff7eb68afbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616a6e88-0c6e-4ff2-acbc-d679ff317b37" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_58f91758-8f16-4adf-aa48-ff7eb68afbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2fccb11e-b64f-4509-aa1d-17b8bacd7291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfU.S.RepatriationTaxCommitments_371aa6e2-9e62-450b-8608-0b832b2ffac2" xlink:href="amgn-20201231.xsd#amgn_ScheduleOfU.S.RepatriationTaxCommitments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2fccb11e-b64f-4509-aa1d-17b8bacd7291" xlink:to="loc_amgn_ScheduleOfU.S.RepatriationTaxCommitments_371aa6e2-9e62-450b-8608-0b832b2ffac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c71c5c99-8435-4728-bd12-82673578ca7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c71c5c99-8435-4728-bd12-82673578ca7f" xlink:to="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_cdc9cdc9-70c8-4a55-b37c-b50a15b8dbb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4eb7ec8a-61f4-4092-bb39-96b984f3294c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_cdc9cdc9-70c8-4a55-b37c-b50a15b8dbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_eab05206-5298-4fd5-8036-019f6094c116" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_cdc9cdc9-70c8-4a55-b37c-b50a15b8dbb7" xlink:to="loc_srt_SubsidiariesMember_eab05206-5298-4fd5-8036-019f6094c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:to="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d45ffc38-706e-4f87-9de5-5d2653ee916c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_59a1ef7b-7546-43e6-a19f-9a4743d9904a" xlink:to="loc_srt_LitigationCaseTypeDomain_d45ffc38-706e-4f87-9de5-5d2653ee916c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KYPROLIScarfilzomibPatentLitigationMember_628177a9-f9f0-4ec9-b2dc-14c7bc07bdcc" xlink:href="amgn-20201231.xsd#amgn_KYPROLIScarfilzomibPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d45ffc38-706e-4f87-9de5-5d2653ee916c" xlink:to="loc_amgn_KYPROLIScarfilzomibPatentLitigationMember_628177a9-f9f0-4ec9-b2dc-14c7bc07bdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_cce6626b-04d7-449d-91d6-11ba6413108a" xlink:to="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_886751de-873e-4d16-ba77-a431d14db92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_886751de-873e-4d16-ba77-a431d14db92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfAssertedPatents_bb3a4e6e-b7e1-407a-95d6-c1e955c27d60" xlink:href="amgn-20201231.xsd#amgn_NumberOfAssertedPatents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_cc43c9d1-63b1-44d8-9632-31a346047bce" xlink:to="loc_amgn_NumberOfAssertedPatents_bb3a4e6e-b7e1-407a-95d6-c1e955c27d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01f38732-26ca-4433-b870-3cba93b097a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01f38732-26ca-4433-b870-3cba93b097a0" xlink:to="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:to="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ecfb8132-3f41-4a05-a13e-016ecfdfd2e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6f362153-32cb-4b40-8f74-ac359c295b62" xlink:to="loc_srt_LitigationCaseTypeDomain_ecfb8132-3f41-4a05-a13e-016ecfdfd2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember_8d88b9dd-1a48-49dd-a6bf-db68357dc45e" xlink:href="amgn-20201231.xsd#amgn_SandozIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ecfb8132-3f41-4a05-a13e-016ecfdfd2e7" xlink:to="loc_amgn_SandozIncMember_8d88b9dd-1a48-49dd-a6bf-db68357dc45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_07f5896e-f619-4bc0-ba7b-1fe2e1b12d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_459a394f-e8ae-4d2e-b63e-31ae784020d8" xlink:to="loc_us-gaap_GainContingenciesLineItems_07f5896e-f619-4bc0-ba7b-1fe2e1b12d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_ecb945b9-279a-4b3e-8b52-9439518f6c5d" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_07f5896e-f619-4bc0-ba7b-1fe2e1b12d25" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_ecb945b9-279a-4b3e-8b52-9439518f6c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76a5ce52-5ecf-4433-ae6a-8df8c958d4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76a5ce52-5ecf-4433-ae6a-8df8c958d4d3" xlink:to="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:to="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bfeee6bb-0460-496e-82af-7622a89cedff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5611bb38-8667-482f-87a2-2f89907f6b9e" xlink:to="loc_srt_LitigationCaseTypeDomain_bfeee6bb-0460-496e-82af-7622a89cedff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmnealPharmaceuticalsLLCMember_d58b281d-f4cd-4af9-a3b8-9fa9feee48b7" xlink:href="amgn-20201231.xsd#amgn_AmnealPharmaceuticalsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bfeee6bb-0460-496e-82af-7622a89cedff" xlink:to="loc_amgn_AmnealPharmaceuticalsLLCMember_d58b281d-f4cd-4af9-a3b8-9fa9feee48b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b9832a7c-2b4a-4f1d-8fd0-8da17ed53da0" xlink:to="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_05c423d7-4b66-4838-af97-bc9ccc95cb35" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_05c423d7-4b66-4838-af97-bc9ccc95cb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfLawsuitsConsolidated_ac46a36e-1865-42dc-9b9a-95490903350c" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfLawsuitsConsolidated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_1418b7e8-8d51-48d5-b9fd-256d3fae3484" xlink:to="loc_amgn_GainContingencyNumberOfLawsuitsConsolidated_ac46a36e-1865-42dc-9b9a-95490903350c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsImmunexandSandozLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd2a7b24-9e42-4e4f-9b0a-6d7cc0f9b14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd2a7b24-9e42-4e4f-9b0a-6d7cc0f9b14c" xlink:to="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:to="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2d3e2f93-03db-4ee5-a8aa-59a5701022dc" xlink:to="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSandozMember_be37ea8b-1f64-4b59-87a3-7bde6c2bce2f" xlink:href="amgn-20201231.xsd#amgn_ImmunexAndSandozMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:to="loc_amgn_ImmunexAndSandozMember_be37ea8b-1f64-4b59-87a3-7bde6c2bce2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSamsungBioepisCoMember_c0e9d24a-ec9c-4527-b95a-8329a18812f7" xlink:href="amgn-20201231.xsd#amgn_ImmunexAndSamsungBioepisCoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a15fb72f-e1de-47ef-9062-da4b0c3ce820" xlink:to="loc_amgn_ImmunexAndSamsungBioepisCoMember_c0e9d24a-ec9c-4527-b95a-8329a18812f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aa22ced0-682f-40b4-b006-51810662fd14" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofAffiliates_d2cdcc32-53f4-4acd-bc75-700f5bb6931e" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberofAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:to="loc_amgn_GainContingencyNumberofAffiliates_d2cdcc32-53f4-4acd-bc75-700f5bb6931e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7c57e8e9-5363-4b22-aae2-412167e59c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6afc05b1-ae4d-4681-ad7f-7d49b9140f02" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7c57e8e9-5363-4b22-aae2-412167e59c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71329531-81d7-4bd3-a601-a1dd48f1db33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71329531-81d7-4bd3-a601-a1dd48f1db33" xlink:to="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:to="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aac7fc0d-31a3-45ff-8d37-8b4c22e87138" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cdcbee85-04ba-4520-b40d-102a6c3b6daf" xlink:to="loc_srt_LitigationCaseTypeDomain_aac7fc0d-31a3-45ff-8d37-8b4c22e87138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_c0bd8407-afb3-4457-abf7-24d8a9704d17" xlink:href="amgn-20201231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aac7fc0d-31a3-45ff-8d37-8b4c22e87138" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_c0bd8407-afb3-4457-abf7-24d8a9704d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_39397088-25f2-43a0-bf2e-db0550cb25cc" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1f54155f-184b-4e42-994c-186920fd59a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1f54155f-184b-4e42-994c-186920fd59a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial_972ef52c-49fd-4a6e-b3ee-82d5c9b816b6" xlink:href="amgn-20201231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_amgn_LitigationSettlementLengthofTrial_972ef52c-49fd-4a6e-b3ee-82d5c9b816b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges_bb0edd5d-6ee6-4e07-afa8-71867a416a2f" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c3712718-cc21-4283-9024-424b4df869b4" xlink:to="loc_amgn_GainContingencyNumberOfChallenges_bb0edd5d-6ee6-4e07-afa8-71867a416a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a90724c5-7f05-463e-b221-664d92db0f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a90724c5-7f05-463e-b221-664d92db0f97" xlink:to="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:to="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_54cbf776-b158-44d9-95c0-bdc732dabb75" xlink:to="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisBreachOfContractActionMember_f08a5215-d78b-4ec3-ab3c-14f28f298001" xlink:href="amgn-20201231.xsd#amgn_NovartisBreachOfContractActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:to="loc_amgn_NovartisBreachOfContractActionMember_f08a5215-d78b-4ec3-ab3c-14f28f298001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_1c181a89-df83-4e9f-b038-262b06b92d0f" xlink:href="amgn-20201231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_1c181a89-df83-4e9f-b038-262b06b92d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_23ed992f-6119-4044-bb75-07f5a85579ec" xlink:href="amgn-20201231.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0aa46260-7fdf-4694-b139-19aba72ce224" xlink:to="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_23ed992f-6119-4044-bb75-07f5a85579ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_664f9f2c-be52-4bd3-a5b5-831fd65a5e47" xlink:to="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9ca05a76-caf7-4378-a54e-89191dc4a338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9ca05a76-caf7-4378-a54e-89191dc4a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfAgreementsBreached_9cf93d3f-44e7-4f82-9ebd-17336250d38e" xlink:href="amgn-20201231.xsd#amgn_GainContingencyNumberOfAgreementsBreached"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_amgn_GainContingencyNumberOfAgreementsBreached_9cf93d3f-44e7-4f82-9ebd-17336250d38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cea26143-3c74-4eb3-a89f-c258402deee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cea26143-3c74-4eb3-a89f-c258402deee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_28046b53-c825-4e51-8e57-0f47697644a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_28046b53-c825-4e51-8e57-0f47697644a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled_eb8c15a2-54d1-45d9-8e5f-78a454bdf922" xlink:href="amgn-20201231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_amgn_LossContingencyNumberOfLawsuitsFiled_eb8c15a2-54d1-45d9-8e5f-78a454bdf922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_09c4e1f4-414d-4284-b0d4-0317244db29e" xlink:href="amgn-20201231.xsd#amgn_LossContingencyNumberOfComplaintsStayedByTheCourt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_84d50471-1002-468c-9d0d-0a8928c2b82e" xlink:to="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_09c4e1f4-414d-4284-b0d4-0317244db29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_56750381-d041-4ce8-b4c2-750f8ecab0b2" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_56750381-d041-4ce8-b4c2-750f8ecab0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_c09db6e2-225f-45f5-8344-9012da083695" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_c09db6e2-225f-45f5-8344-9012da083695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_8c1fb16b-92d6-4783-83c6-311f1ad74d1a" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_8c1fb16b-92d6-4783-83c6-311f1ad74d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_f7f7530e-53bc-45c1-9cf7-b35d6e6909a4" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_f7f7530e-53bc-45c1-9cf7-b35d6e6909a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_f285506a-a25d-4bbf-8101-8b7a0b9af14a" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_f285506a-a25d-4bbf-8101-8b7a0b9af14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_dd355758-d3cc-40a0-a9ca-7acb7ce4f28e" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears_dd355758-d3cc-40a0-a9ca-7acb7ce4f28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_e508de91-448c-4b1c-a452-76bb27d554f8" xlink:href="amgn-20201231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4e43fd23-4c8f-4210-b4ec-173b102c2928" xlink:to="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_e508de91-448c-4b1c-a452-76bb27d554f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Quarterlyfinancialdataunaudited" xlink:type="simple" xlink:href="amgn-20201231.xsd#Quarterlyfinancialdataunaudited"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Quarterlyfinancialdataunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_af677338-4335-459a-b1ba-c0e561ba207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_feb749f0-a8cd-463c-bba9-6381161d81d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_af677338-4335-459a-b1ba-c0e561ba207c" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_feb749f0-a8cd-463c-bba9-6381161d81d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables" xlink:type="simple" xlink:href="amgn-20201231.xsd#QuarterlyfinancialdataunauditedTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_be7bc609-5015-4403-b575-5f460ca72f69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_40b2708d-641d-4942-99fe-e8e6f17882cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_be7bc609-5015-4403-b575-5f460ca72f69" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_40b2708d-641d-4942-99fe-e8e6f17882cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#QuarterlyfinancialdataunauditedDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8bdd1dcb-2154-47a5-addc-7a200288cce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8bdd1dcb-2154-47a5-addc-7a200288cce4" xlink:to="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:to="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06155f25-c3dc-484a-a238-956fa731e39a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e359c029-363e-474e-af5c-27abf06bb92a" xlink:to="loc_srt_ProductsAndServicesDomain_06155f25-c3dc-484a-a238-956fa731e39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8aa9ad11-f889-461d-8f18-9e161e5c4f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06155f25-c3dc-484a-a238-956fa731e39a" xlink:to="loc_us-gaap_ProductMember_8aa9ad11-f889-461d-8f18-9e161e5c4f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfFourthQuarterEventsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable_ea334402-54bc-4539-97b2-f671c9d68771" xlink:to="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3f36866f-069b-4356-9080-6e98af45eec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3f36866f-069b-4356-9080-6e98af45eec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e1205270-74c7-46ce-9909-7244872f65ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_GrossProfit_e1205270-74c7-46ce-9909-7244872f65ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e01bc67-bc56-4475-bf22-7c9ee1a68aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_NetIncomeLoss_0e01bc67-bc56-4475-bf22-7c9ee1a68aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfFourthQuarterEventsLineItems_8feda7e3-25a5-4785-8fe7-84fb8d5a620c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_16511a96-7d21-4dae-a9a4-c028fec62549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:to="loc_us-gaap_EarningsPerShareBasic_16511a96-7d21-4dae-a9a4-c028fec62549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7fdcea0c-e532-4867-8d8b-a1251590ce53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_02d108d5-4050-4842-a465-03e74d349d12" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7fdcea0c-e532-4867-8d8b-a1251590ce53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amgn-20201231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_67ba7fea-e7b1-4552-8a36-061b5796fd8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_974734f2-18fa-4c57-a1e1-ffb00d10e2ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_67ba7fea-e7b1-4552-8a36-061b5796fd8c" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_974734f2-18fa-4c57-a1e1-ffb00d10e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="amgn-20201231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_f8fd0daf-4c76-42bc-9cec-e6e616e4da1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_f8fd0daf-4c76-42bc-9cec-e6e616e4da1d" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3640df16-59f5-4087-8ea9-d85c84986800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_3640df16-59f5-4087-8ea9-d85c84986800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_6f5a3b40-f275-4ebc-b7cc-3c41fd78e5cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_6f5a3b40-f275-4ebc-b7cc-3c41fd78e5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7019c475-1f3a-4067-8fea-387e6442a0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7019c475-1f3a-4067-8fea-387e6442a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8d53ed6f-9368-4d9c-907f-ad1ad69daa18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8d53ed6f-9368-4d9c-907f-ad1ad69daa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_dc238dd7-55eb-45af-bacf-0ece88fc0b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_09a7690d-9ff0-4e51-8657-3b964fa1f654" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_dc238dd7-55eb-45af-bacf-0ece88fc0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>amgn-20201231_g1.jpg
<TEXT>
begin 644 amgn-20201231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;./FVE'%;7_!8G_@F#^S=_P5T^$=C^R]\1O'J^&OB#HMO<>(/ &OVL(FN-.
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MD>._V?OAC^P9\2OB+\2/BCXMU'6[GXGQ_P!BRVEYKL&J1M%<2W=WJ27BR)#
M(V8PYS))C<LC%NL_X*[_  N_X*T:M_P;_?L\:Y^T!\.M=;Q/\)/%<LWQCT2^
M>+4YI[6S>:'2=2O5B>5+F%8%C\XN7R\V^08#, #]R?A7^U5^R_\ '6.SE^"/
M[2'@+QBNHM,NGMX5\866HBY,(5IA']GE?>4#*6QG:&&<9%=[7XT?\$5_^"BW
M[!?_  57_;(\"_'>Y^&VC_!_]I[P5X/U/2_$&A:)IZ1Z=X\TF6!0[6T@96+V
M[QK,(I0\D49D4&5 9(OV7H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N"_:@\:>)OAU\ ?%'C
M;P=J7V/4].TWS;.Z\E)/+?>HSM<,IX)Z@UWM>7?MK?\ )JWC;_L#G_T8E>ID
M=.G6SK#0FDXNI!-/5-.2NFNJ9Y6>U*E'),54IMJ2IS::T::B[-/HT?"O_#PW
M]L+_ **__P"6_I__ ,CT?\/#?VPO^BO_ /EOZ?\ _(]>+45_7?\ JMPQ_P!
M-'_P5#_Y$_CO_6OBG_H/K?\ @V?_ ,D>T_\ #PW]L+_HK_\ Y;^G_P#R/1_P
M\-_;"_Z*_P#^6_I__P CUXM11_JMPQ_T T?_  5#_P"1#_6OBG_H/K?^#9__
M "1[3_P\-_;"_P"BO_\ EOZ?_P#(]'_#PW]L+_HK_P#Y;^G_ /R/7BU%'^JW
M#'_0#1_\%0_^1#_6OBG_ *#ZW_@V?_R1[3_P\-_;"_Z*_P#^6_I__P CT?\
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M_P#\CUXM11_JMPQ_T T?_!4/_D0_UKXI_P"@^M_X-G_\D>T_\/#?VPO^BO\
M_EOZ?_\ (]'_  \-_;"_Z*__ .6_I_\ \CUXM11_JMPQ_P! -'_P5#_Y$/\
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M@^M_X-G_ /)'M/\ P\-_;"_Z*_\ ^6_I_P#\CT?\/#?VPO\ HK__ );^G_\
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M %KXI_Z#ZW_@V?\ \D>T_P##PW]L+_HK_P#Y;^G_ /R/1_P\-_;"_P"BO_\
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M_P#\CUXM11_JMPQ_T T?_!4/_D0_UKXI_P"@^M_X-G_\D>T_\/#?VPO^BO\
M_EOZ?_\ (]'_  \-_;"_Z*__ .6_I_\ \CUXM11_JMPQ_P! -'_P5#_Y$/\
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M/_D0_P!:^*?^@^M_X-G_ /)'M/\ P\-_;"_Z*_\ ^6_I_P#\CT?\/#?VPO\
MHK__ );^G_\ R/7BU%'^JW#'_0#1_P#!4/\ Y$/]:^*?^@^M_P"#9_\ R1[3
M_P /#?VPO^BO_P#EOZ?_ /(]'_#PW]L+_HK_ /Y;^G__ "/7BU%'^JW#'_0#
M1_\ !4/_ )$/]:^*?^@^M_X-G_\ )'M/_#PW]L+_ **__P"6_I__ ,CT?\/#
M?VPO^BO_ /EOZ?\ _(]>+44?ZK<,?] -'_P5#_Y$/]:^*?\ H/K?^#9__)'M
M/_#PW]L+_HK_ /Y;^G__ "/1_P /#?VPO^BO_P#EOZ?_ /(]>+44?ZK<,?\
M0#1_\%0_^1#_ %KXI_Z#ZW_@V?\ \D>T_P##PW]L+_HK_P#Y;^G_ /R/1_P\
M-_;"_P"BO_\ EOZ?_P#(]>+44?ZK<,?] -'_ ,%0_P#D0_UKXI_Z#ZW_ (-G
M_P#)'M/_  \-_;"_Z*__ .6_I_\ \CT?\/#?VPO^BO\ _EOZ?_\ (]>+44?Z
MK<,?] -'_P %0_\ D0_UKXI_Z#ZW_@V?_P D>T_\/#?VPO\ HK__ );^G_\
MR/1_P\-_;"_Z*_\ ^6_I_P#\CUXM11_JMPQ_T T?_!4/_D0_UKXI_P"@^M_X
M-G_\D?LGX/O[O5/"6EZG?R^9/<Z=!+,^T#<[1J2<#@<D]*T:R/A__P B'HG_
M &"+;_T4M:]?QMB$HUYI=W^9_:>&;EAX-[V7Y!1116)L%%%% !1110 4444
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M !1110 4444 %%%% !7EW[:W_)JWC;_L#G_T8E>HUY=^VM_R:MXV_P"P.?\
MT8E>OP__ ,C["?\ 7VG_ .EH\?B'_D08O_KU4_\ 2&?E91117]JG\/A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!]=_\$C_^1\\8_P#8(MO_ $:U?=-?"W_!(_\ Y'SQC_V"+;_T:U?=-?RK
MXH_\EG7](?\ I"/ZS\*O^2)H>L__ $N04445^>GZ*%%%% !1110 4444 %%%
M% !1110 4444 ?(O_!7#_D0?!_\ V&+G_P!%+7PK7W5_P5P_Y$'P?_V&+G_T
M4M?"M?U7X7?\D90]9_\ I;/Y+\5?^2VQ'I#_ -(B%%%%?H)^=A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z2?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !7YN?\%,O^3J;_P#[ ]E_Z+K](Z_-S_@IE_R=3?\
M_8'LO_1=?J7A#_R54O\ KU+_ -*B?E/C%_R2<?\ K['_ -)D?/U%%%?TT?RZ
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '[&_#__ )$/1/\ L$6W_HI:UZR/A_\ \B'HG_8(MO\ T4M:]?PU
MB?\ >9^K_,_O'"_[M#T7Y!1116!N%%%% !1110 4444 %%%% !1110 4444
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MK\W/^"F7_)U-_P#]@>R_]%U^I>$/_)52_P"O4O\ TJ)^4^,7_))Q_P"OL?\
MTF1\_4445_31_+H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?L;\/_\ D0]$_P"P1;?^BEK7K(^'_P#R(>B?
M]@BV_P#12UKU_#6)_P!YGZO\S^\<+_NT/1?D%%%%8&X4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7EW[:W_)JWC;_L#G_T8E>HUY=^VM_R:MXV_P"P.?\ T8E>OP__ ,C["?\
M7VG_ .EH\?B'_D08O_KU4_\ 2&?E91117]JG\/A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]=_\$C_^1\\8
M_P#8(MO_ $:U?=-?"W_!(_\ Y'SQC_V"+;_T:U?=-?RKXH_\EG7](?\ I"/Z
MS\*O^2)H>L__ $N04445^>GZ*%%%% !1110 4444 %%%% !1110 4444 ?(O
M_!7#_D0?!_\ V&+G_P!%+7PK7W5_P5P_Y$'P?_V&+G_T4M?"M?U7X7?\D90]
M9_\ I;/Y+\5?^2VQ'I#_ -(B%%%%?H)^=A1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCS/*L0JV+<6YRG'W=E*%E**5E91NE&VEMMAU%%%?3GRP4444 %%%% !1110
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M^9U&UJVY.USZCHHHK[D^#"BBB@ HHHH **** "BBB@ K])/^"9W_ ":M8?\
M87O?_1E?FW7Z2?\ !,[_ )-6L/\ L+WO_HRORWQ>_P"25C_U]C_Z3(_5O!S_
M )*R7_7J7_I4#Z HHHK^93^H@HHHH **** "BBB@ HHHH **** "BBB@ K\W
M/^"F7_)U-_\ ]@>R_P#1=?I'7YN?\%,O^3J;_P#[ ]E_Z+K]2\(?^2JE_P!>
MI?\ I43\I\8O^23C_P!?8_\ I,CY^HHHK^FC^70HHHH **** "BBB@ HHHH
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MA_Y$&+_Z]5/_ $AGY64445_:I_#X4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?7?_!(__D?/&/\ V"+;_P!&
MM7W37PM_P2/_ .1\\8_]@BV_]&M7W37\J^*/_)9U_2'_ *0C^L_"K_DB:'K/
M_P!+D%%%%?GI^BA1110 4444 %%%% !1110 4444 %%%% 'R+_P5P_Y$'P?_
M -ABY_\ 12U\*U]U?\%</^1!\'_]ABY_]%+7PK7]5^%W_)&4/6?_ *6S^2_%
M7_DML1Z0_P#2(A1117Z"?G84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^DG_  3._P"35K#_ +"][_Z,K\VZ_23_
M ()G?\FK6'_87O?_ $97Y;XO?\DK'_K['_TF1^K>#G_)62_Z]2_]*@?0%%%%
M?S*?U$%%%% !1110 4444 %%%% !1110 4444 %?FY_P4R_Y.IO_ /L#V7_H
MNOTCK\W/^"F7_)U-_P#]@>R_]%U^I>$/_)52_P"O4O\ TJ)^4^,7_))Q_P"O
ML?\ TF1\_4445_31_+H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?L;\/_\ D0]$_P"P1;?^BEK7K(^'_P#R
M(>B?]@BV_P#12UKU_#6)_P!YGZO\S^\<+_NT/1?D%%%%8&X4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7EW[:W_)JWC;_L#G_T8E>HUY=^VM_R:MXV_P"P.?\ T8E>OP__ ,C[
M"?\ 7VG_ .EH\?B'_D08O_KU4_\ 2&?E91117]JG\/A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]=_\$C_^
M1\\8_P#8(MO_ $:U?=-?"W_!(_\ Y'SQC_V"+;_T:U?=-?RKXH_\EG7](?\
MI"/ZS\*O^2)H>L__ $N04445^>GZ*%%%% !1110 4444 %%%% !1110 4444
M ?(O_!7#_D0?!_\ V&+G_P!%+7PK7W5_P5P_Y$'P?_V&+G_T4M?"M?U7X7?\
MD90]9_\ I;/Y+\5?^2VQ'I#_ -(B%%%%?H)^=A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z2?\ !,[_ )-6L/\
ML+WO_HROS;K])/\ @F=_R:M8?]A>]_\ 1E?EOB]_R2L?^OL?_29'ZMX.?\E9
M+_KU+_TJ!] 4445_,I_404444 %%%% !1110 4444 %%%% !1110 5^;G_!3
M+_DZF_\ ^P/9?^BZ_2.OS<_X*9?\G4W_ /V![+_T77ZEX0_\E5+_ *]2_P#2
MHGY3XQ?\DG'_ *^Q_P#29'S]1117]-'\NA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^QOP__P"1#T3_ +!%
MM_Z*6M>LCX?_ /(AZ)_V"+;_ -%+6O7\-8G_ 'F?J_S/[QPO^[0]%^04445@
M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_*OBC_R6=?TA_P"D(_K/PJ_Y(FAZS_\ 2Y!1117YZ?HH4444 %%%% !1110
M4444 %%%% !1110!\B_\%</^1!\'_P#88N?_ $4M?"M?=7_!7#_D0?!__88N
M?_12U\*U_5?A=_R1E#UG_P"EL_DOQ5_Y+;$>D/\ TB(4445^@GYV%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?I)
M_P $SO\ DU:P_P"PO>_^C*_-NOTD_P""9W_)JUA_V%[W_P!&5^6^+W_)*Q_Z
M^Q_])D?JW@Y_R5DO^O4O_2H'T!1117\RG]1!1110 4444 %%%% !1110 444
M4 %%%% !7YN?\%,O^3J;_P#[ ]E_Z+K](Z_-S_@IE_R=3?\ _8'LO_1=?J7A
M#_R54O\ KU+_ -*B?E/C%_R2<?\ K['_ -)D?/U%%%?TT?RZ%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[&
M_#__ )$/1/\ L$6W_HI:UZR/A_\ \B'HG_8(MO\ T4M:]?PUB?\ >9^K_,_O
M'"_[M#T7Y!1116!N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y=^VM_R:MXV_[ Y_]&)7J->7
M?MK?\FK>-O\ L#G_ -&)7K\/_P#(^PG_ %]I_P#I:/'XA_Y$&+_Z]5/_ $AG
MY64445_:I_#X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?7?_!(__D?/&/\ V"+;_P!&M7W37PM_P2/_ .1\
M\8_]@BV_]&M7W37\J^*/_)9U_2'_ *0C^L_"K_DB:'K/_P!+D%%%%?GI^BA1
M110 4444 %%%% !1110 4444 %%%% 'R+_P5P_Y$'P?_ -ABY_\ 12U\*U]U
M?\%</^1!\'_]ABY_]%+7PK7]5^%W_)&4/6?_ *6S^2_%7_DML1Z0_P#2(A11
M17Z"?G84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%Y_\>H_XF(X*_P"@?$?^ 4__ ):'_$(>)?\ G[1_\"G_ /*SX,HK[S_X8O\
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M9_)?BK_R6V(](?\ I$0HHHK]!/SL**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_23_@F=_P FK6'_ &%[W_T97YMU
M^DG_  3._P"35K#_ +"][_Z,K\M\7O\ DE8_]?8_^DR/U;P<_P"2LE_UZE_Z
M5 ^@****_F4_J(**** "BBB@ HHHH **** "BBB@ HHHH *_-S_@IE_R=3?_
M /8'LO\ T77Z1U^;G_!3+_DZF_\ ^P/9?^BZ_4O"'_DJI?\ 7J7_ *5$_*?&
M+_DDX_\ 7V/_ *3(^?J***_IH_ET**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /V-^'__ "(>B?\ 8(MO_12U
MKUD?#_\ Y$/1/^P1;?\ HI:UZ_AK$_[S/U?YG]XX7_=H>B_(****P-PHHHH
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M."O^AGA__!U/_P"2#_5CB7_H"K?^"Y__ ")Y=17J/_#%_P"TM_T3;_RL6?\
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M]>."O^AGA_\ P=3_ /D@_P!6.)?^@*M_X+G_ /(GEU%>H_\ #%_[2W_1-O\
MRL6?_P >H_X8O_:6_P"B;?\ E8L__CU'^O'!7_0SP_\ X.I__)!_JQQ+_P!
M5;_P7/\ ^1/+J*]1_P"&+_VEO^B;?^5BS_\ CU'_  Q?^TM_T3;_ ,K%G_\
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M/4?\3$<%?] ^(_\  *?_ ,M#_B$/$O\ S]H_^!3_ /E9\&45]Y_\,7_LT_\
M1-O_ "L7G_QZC_AB_P#9I_Z)M_Y6+S_X]1_Q,1P5_P! ^(_\ I__ "T/^(0\
M2_\ /VC_ .!3_P#E9\&45]Y_\,7_ +-/_1-O_*Q>?_'J/^&+_P!FG_HFW_E8
MO/\ X]1_Q,1P5_T#XC_P"G_\M#_B$/$O_/VC_P"!3_\ E9\&45]Y_P##%_[-
M/_1-O_*Q>?\ QZC_ (8O_9I_Z)M_Y6+S_P"/4?\ $Q'!7_0/B/\ P"G_ /+0
M_P"(0\2_\_:/_@4__E9\&45]Y_\ #%_[-/\ T3;_ ,K%Y_\ 'J/^&+_V:?\
MHFW_ )6+S_X]1_Q,1P5_T#XC_P  I_\ RT/^(0\2_P#/VC_X%/\ ^5GP917W
MG_PQ?^S3_P!$V_\ *Q>?_'J/^&+_ -FG_HFW_E8O/_CU'_$Q'!7_ $#XC_P"
MG_\ +0_XA#Q+_P _:/\ X%/_ .5GTU\/_P#D0]$_[!%M_P"BEK7JMHMG;Z?H
MUI86<>R*"UCCB3).U54 #)Y/ JS7X?4J1JU'-;-W^\_I^A!TZ,8OHDOP"BBB
MH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB/XK"BBBO',0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KT/X=?\ (L1_]=7_ )UYY7H?PZ_Y%B/_ *ZO_.O>X<_Y
M&#_PO\T=&%_B?(W:***^Z/0"BBB@ HHHH **** "BBB@ HHHH **** "O//B
M+_R,\G_7)/Y5Z'7GGQ%_Y&>3_KDG\J\#B/\ Y%Z_Q+\F<V*_A_,PJ***^&.
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /6['_CRA_ZY+_*I:BL?^/*'_KDO\JEK]5I_ O0]=;!1115C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<E_F:[6OO\A_Y%D/5_FST<-_"04445[)N%%%% !1110 4444 %%%% !1110
M4444 <I\5/\ CRM/^NK?R%<57:_%3_CRM/\ KJW\A7%5^?Y]_P C.?HOR1YN
M(_BL****\<Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O0_AU_R+$?\ UU?^=>>5Z'\.O^18C_ZZO_.O>X<_Y&#_
M ,+_ #1T87^)\C=HHHK[H] **** "BBB@ HHHH **** "BBB@ HHHH *\\^(
MO_(SR?\ 7)/Y5Z'7GGQ%_P"1GD_ZY)_*O XC_P"1>O\ $OR9S8K^'\S"HHHK
MX8X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ];L?^/*'_KDO\JEJ*Q_X\H?^N2_RJ6OU6G\"]#UUL%%%%6,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K,\9?\BQ>?]<OZBM.LSQE_P BQ>?]<OZBN;&?[I4_
MPO\ (BI\#]#S*BBBOS \H**** "BBB@ HHHH **** "OR(_X/%O^3'?AA_V5
M=?\ TV7E?KO7Q1_P6$_X),?$'_@K+X+\-_"Z[_:ETKP'X;\-ZXVK06\7P[DU
M*[GN# T(WS'4X4VA7D.!$#\PYXY[LMJTJ&.A4J.R7K^AI2:C439]6? ;_DAO
M@S_L4]._])HZ_(?]DK_E;H^-G_8J77_IMTJOUN^"_@/XF_#CX+:1\.O&/Q"T
M;7=<T;1H+"'7K+PS+8V\IB@2-9'M6O)FR2I9@)@#G VXS7QI\(_^",7QN^%?
M_!4?Q)_P5$7]M3P[?Z[XJ6Z@U3PL_P (YH[06LL$4*Q1R?VR75D6"$[SG)4_
M+AL#3"5J-)5N:5N:+2WU=UY?F.#BN:[Z'OG[=/\ P3K^%G[<6M_#7XCZ[XAO
M?#OCCX0>,+?Q)X \46$*S?9;F.:"9H)X'($]O(]O 70,C9B7:Z_,&^;M>_9H
MMOV$]8\3?L[_ +(?CF]UC]I3]KKQC?:WXM\?W5LB?\(WIOG2RW^LK;H2+:VM
M!=RI:Q,[-)=74:[W"D+^BM>%?LH_LK>,/AI\3?B!^TW^T#XATS7OB;\0M4\F
M6\TKS&L]"\/VSN-.T>S:55;RT5C-*^U#+<32.1PN,J.)G"DXRE[JV7=WO]R>
MK7^9,9-*S/DK5/\ @I%X8_8G\9_$3_@GG^PQ^S[INKZ%^RI\%+CQ;XUU#Q#K
M4L']H?9EMYYK. PQ.6NI$N6GENI<@S>:"AY8_:G[$'[7/P\_;N_97\'?M6_"
MZSNK32/%NGO,+"](,UE<13/!<6[E>&,<T4B;APP4,."*^2?VG_\ @C3\3_$G
M[5'QQ_:1_9@^)WAW3X_VBOA#>^!_'6C^*C<QKI,MREM#)J=HT"/YY,-N0;:0
M1C?(["4 [!]7?L&_L?>"?V"/V2?!?[)OP_UBXU*P\):?)'+JEW&$DOKJ:>2X
MN;@J"=@>::1@F3L4JN3MS6N*>"EAXR@_?=K[]O>O_P!O;%3Y''3<]>HHHKS3
M(**** "BBB@ HHHH **** .K^%?_ !^W?_7)?YFNUKBOA7_Q^W?_ %R7^9KM
M:^_R'_D60]7^;/1PW\)!1117LFX4444 %%%% !1110 4444 %%%% !1110!R
MGQ4_X\K3_KJW\A7%5VOQ4_X\K3_KJW\A7%5^?Y]_R,Y^B_)'FXC^*PHHHKQS
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *]#^'7_ "+$?_75_P"=>>5Z'\.O^18C_P"NK_SKWN'/^1@_\+_-'1A?
MXGR-VBBBONCT HHHH **** "BBB@ HHHH **** "BBB@ KSSXB_\C/)_UR3^
M5>AUYY\1?^1GD_ZY)_*O XC_ .1>O\2_)G-BOX?S,*BBBOAC@"BBB@ HHHH
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M$.?+'V]_P2._8,D_X)P?L+>$_P!FG6=7M=1\0P-/J?BW4+'/D3:G<OOE6,D
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M_!/#Q+XY\<_&+]M;Q'\;M>\866G65EJWB;3)X)=)M+5[EVA1IKZZ9ED>X#$
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MYB0HHHH **** "BBB@ HHHH *]#^'7_(L1_]=7_G7GE>A_#K_D6(_P#KJ_\
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M]//P_P""?H117Y[T4?\ $!O^IC_Y1_\ NH?V%_T\_#_@GZ$45^>]%'_$!O\
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MHHH **** "BBB@ HHHH Y3XJ?\>5I_UU;^0KBJ[7XJ?\>5I_UU;^0KBJ_/\
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MI2_^3,O[*Q_\GXK_ #/H2BOGO_AN_P#ZI7_Y7/\ [11_PW?_ -4K_P#*Y_\
M:*/^(4\??] ?_E2E_P#)A_96/_D_%?YGT)17SW_PW?\ ]4K_ /*Y_P#:*/\
MAN__ *I7_P"5S_[11_Q"GC[_ * __*E+_P"3#^RL?_)^*_S/H2BOGO\ X;O_
M .J5_P#E<_\ M%'_  W?_P!4K_\ *Y_]HH_XA3Q]_P! ?_E2E_\ )A_96/\
MY/Q7^9]"45\]_P##=_\ U2O_ ,KG_P!HH_X;O_ZI7_Y7/_M%'_$*>/O^@/\
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M5_\ E<_^T4?\0IX^_P"@/_RI2_\ DP_LK'_R?BO\SZ$HKY[_ .&[_P#JE?\
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M1_BQ]4?F[1117]1'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /U4\#_ /(EZ/\
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M_I__ ,CT?\/#?VPO^BO_ /EOZ?\ _(]>+44?ZK<,?] -'_P5#_Y$/]:^*?\
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M^,WCL-I?@BYLO&G@;Q!\4->UJSGAU"9#8WRPZA=S)!.C:?=HKQ[6*2R9ZJ:
M/HNBORK_ &2/#.JZW_P<?_M*_ ;7?BW\1[[P-X'^'6@:MX4\'7OQ/UN73=.O
M+JUTR2:58&NRC9:24A6#*OF-M XQ^JE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7G/[7/_ ";=XN_[!?\ [42O
M1J\Y_:Y_Y-N\7?\ 8+_]J)7I9/\ \C?#_P#7R'_I2-*/\6/JC\W:***_J(^D
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#Z@_P""8G_(Z>*O^P7!_P"C&K[(KXW_ ."8G_(Z>*O^P7!_Z,:O
MLBOY]X^_Y*>KZ1_])1X6._WE_+\@HHHKXTY HHHH **** "BBB@ HHHH ***
M* "BBB@#Y\_X*!?$OQM\-?"OAV\\%:W]BDNM0F2=OLT4FY0@('[Q6QSZ5\N?
M\-4_'K_H>_\ REVO_P :KZ&_X*>?\B9X5_["EQ_Z+6OC>OVK@WAWA_,.'Z=?
M%82E4FW*\I4X2;M)I7;3>B/7PF'P]2@I2@F_-(]"_P"&J?CU_P!#W_Y2[7_X
MU1_PU3\>O^A[_P#*7:__ !JO/:*^I_U1X3_Z%]#_ ,%4_P#Y$Z?JF%_Y]Q^Y
M'H7_  U3\>O^A[_\I=K_ /&J/^&J?CU_T/?_ )2[7_XU7GM%'^J/"?\ T+Z'
M_@JG_P#(A]4PO_/N/W(]"_X:I^/7_0]_^4NU_P#C5'_#5/QZ_P"A[_\ *7:_
M_&J\]HH_U1X3_P"A?0_\%4__ )$/JF%_Y]Q^Y'H7_#5/QZ_Z'O\ \I=K_P#&
MJ/\ AJGX]?\ 0]_^4NU_^-5Y[11_JCPG_P!"^A_X*I__ "(?5,+_ ,^X_<CT
M+_AJGX]?]#W_ .4NU_\ C5'_  U3\>O^A[_\I=K_ /&J\]HH_P!4>$_^A?0_
M\%4__D0^J87_ )]Q^Y'H7_#5/QZ_Z'O_ ,I=K_\ &J/^&J?CU_T/?_E+M?\
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MX]?]#W_Y2[7_ .-4?\-4_'K_ *'O_P I=K_\:KSVBC_5'A/_ *%]#_P53_\
MD0^J87_GW'[D>A?\-4_'K_H>_P#REVO_ ,:H_P"&J?CU_P!#W_Y2[7_XU7GM
M%'^J/"?_ $+Z'_@JG_\ (A]4PO\ S[C]R/0O^&J?CU_T/?\ Y2[7_P"-4?\
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MR_.)W9?_ !_D>(T445^ZGM!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!^JG@?_D2]'_[!=O_ .BUK4K+\#_\
MB7H__8+M_P#T6M:E?RA7_CR]7^9\P]PHHHK(04444 %%%% !1110 4444 %?
MBW7[25\6_P##H+_JX;_RTO\ [KK]9\+^)LDX=^M_VA5Y.?V?+[LI7Y>>_P ,
M7:UUN?D7BIPOGO$GU/\ LZC[3V?M.;WHQMS<EOBDKWL]K[:GQ;17VE_PZ"_Z
MN&_\M+_[KH_X=!?]7#?^6E_]UU^L?\1,X(_Z"_\ RG5_^0/R+_B&''/_ $"?
M^5*7_P F?%M%?:7_  Z"_P"KAO\ RTO_ +KH_P"'07_5PW_EI?\ W71_Q$S@
MC_H+_P#*=7_Y /\ B&''/_0)_P"5*7_R9]I5^7'_  =,Z38:_P#!;]F'0M5A
M,EK>_M;^&(+F-9&0M&]M?*PW*05R">001V-?J/7AO[7_ /P3A_9"_;S?0S^U
M3X"UWQ)'X9U1-2T"VM?B%KFEP6-ZBE4NHXK"]@03J"P67;O7<<$9-?R<?UT<
MWXT_X)B_LC6?COP+\=M#T6X\.ZS\,/%*>(M/U>\\3:A<01QI!+%<)(EQ<F(*
MT,K_ #L#L(##N#G?M)>.?#GQ.^//[%'Q(\'74D^D>(/BWJ>HZ5<2P/$TMM/\
M//%,D3E' 9,HRG:P!&<$ \5N?$3_ ()7_LC?%WP;??#KXIW?Q>\1>']3A,.J
M:'K/[1_CBYM+V(]8YH7U@I*A[HX*GN*[7XM?L4?L\_&_QYX.^)7Q T/Q$VK?
M#^^-YX-?1O'^M:5!I4YMVMC)';V-Y##DP221'<ARDCJ>'8$ ^!_^"H/[,GQD
M_P""8G[4D_\ P7&_X)]^$9=1T]XA%^T_\*-.^2'Q+HX.9-8BC486ZA&9)) ,
M@CSB"IN?,]E_8 \?:%\5O^"%][\4?"PG&F>)?"GC[5=.%U&$E$%QJFL31[U!
M.UMKC(R<'O7W(]C:2V)TRXA$T#0^5)'<'S!(F,$-NSNR.N<Y[UY7I?[$'[-N
M@_LR-^QSX;\%WVC_  Y,5_"OAWP]XEU#2Q';WDT\L]LDUG/%,D)-S*HC#A54
MJH&%7 !^<W_! '_@G+^RI^U=_P $(_A>OQF\.^*+EO%-MXEAUC^ROB-K>GQR
M!?$&IP+MAM;R.%<)&F5";6(RP8LV=;_@W9^*GQ)^&?[2O[37_!+32_$-IXL^
M$O[/WBE+3X=^*K;2+6WEM$FN;E7L+J2UCC2YF_=DM*PWF2&<DD,JI]>?#;_@
MCM^PM\&_A='\$/A)H_Q2\,>#85F6#PKH/[17C>TT^%99&DE5+>+6%C17=W9P
MH 9G8MDL<^H?L_\ [%_[,'[*?P>F^ W[-GPBL/ _ABYF>>ZM?#-Q/:7%Q.P
M:>2[CD%Q),0JKYK2%]J@;L "@#\<_P!D']@7XA?MW?L\_P#!07P3\!_COXT\
M#?$(?M:^+QX;FT3QUJ-CI>I,DH<V%_9Q3K;3PW +1-(\;.H93EE0QM^A7_!"
MC]J7X%?'[]BNU^&WPW^!VA_";QE\+K^3PW\5?A-H^EI8#P]KD1*SR>0/F\N=
MT>59&W,6\Q&=WC<UZ[^R;_P3:_8^_8=\0^(_%'[,/@#7?#MWXOU1]2\3BY^(
M>NZE#J=Z^[=<S0WU[-&\QWMF3;N/&3P,.NO^";G['4O[5>I?MM:5\-=5T3XG
M:U:0VVN^)O"_CG6=)&JQ1*JHEW;65Y%;W0 1 ?-C?.Q<YVC !\#?#;X&_#'X
M\?\ !TG^TIX=^*6@3ZA9V?P*\/W-O%!JMS:%9?+TI<[K>2-CPQX)(YZ5]T_!
MK]F3]F+]@SXQ^(/$_P .KJ719/C7JNDZ?!X>N+^ZO9;W6+2WOG>6)YY9'P;-
M2[H,)&EE))_$<9<G_!(O]AL?'_7OVJ+#PM\0=/\ B+XGLTL_$'C#1_CIXOLK
MZ^ME$82W>2#54S$HABVQ_<7RUP!M%=7X!_X)[?LP_#OXS:?^T'INF^-]8\8:
M1I-WINC:UXT^+GB7Q"VFVUR$%PMM'JFH7$=NSA%!DC57QD;L$Y /BW]C7_E:
M6_; _P"R/^$__2+2:_1_QE\2O"7@35_#OA[7]0VZAXKUG^R]!L8P#+=W @EN
M9 H)'RQP032L>RQ'J2 ?GV^_X(X?L$7?Q]U[]J>U\'?$+3?B-XHA6'Q!XTT'
MX\^,=.U"^A5(T6%YK75HV,2K#$HC^X!&@ &T8Z[X2_\ !.']E#X,?'&T_:3\
M,>'_ !EJOCC3](N=+T[Q%XY^+/B3Q--9VMP8S,D*ZOJ%RD1?RD!9%#8!&<$@
M@'N=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %><_M<_\ )MWB[_L%_P#M1*]&KSG]KG_DV[Q=_P!@O_VHE>ED_P#R
M-\/_ -?(?^E(TH_Q8^J/S=HHHK^HCZ0**** "BBB@ HHHH **** "N+_ &C_
M (J3_ W]G_QK\8[73UNY_"_A:^U.WM7!VS2PP.Z(V.0I8 $]@2:[2L_Q;X5\
M/^.O"NI^"/%FF1WNE:QI\UCJ5G+G;/;RH8Y(SCG#*Q'XUE6C4E1E&F[2:=GV
M?1B=VM#\K]-\:?%GQU_P2=UW]O\ 7XT>)T^+&B^._MI\1P:Y.A2$WT%J;$0A
MO)%L(Y@_DA-F>W)![[]MW]O+XV^._P#@DG\./CY\/=7N_#FH>/=9@TKQ=K.C
M.T3VHB%W%<^4RG="LD]J<$'(0E,G=7$?MO?LD:Y^Q%^S=?\ [(/P(_:!USQ/
M;?&#QA;#PU\+)-!MI;W<DD<DLOVD'>8QY$"':B MM)X\S/W?^S3^R!X+^&?[
M$_A;]DOXJ^&M+\0V%EH2Q>(+"]MEFMI[J61KB? 8<@3R.5;@C"L,&OSG 8+-
ML36K8%2=-JA&,W>Z]KS.TKIO64=WI*S5UL>?3A5DW#;W;/U_X8\)_9:\<^._
M 7_!7+XM_LK^#M5OKCX<6?A&QU2#1IKF2:#1[O[)IQW1%RWE^:9Y2R@C>6#'
M.RO7/ NL:O\ M;?M)R_$C3M5N8OAC\+]0GL/#RVT[+%XF\0 &.YO#@XEMK0%
MH8^JM,97!/EK6+\;/"7ACX?ZW#^R;^R;HD6A>._BG'Y_BSQ5;N\][H^@P@0S
MZC-<2LTKR!3]FM5=L"1\K@1FO._B%\3?%O@[]O3X9?\ !,[X)Z[/X#^'^F>
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M8O\ P<WWVA:)X&_9,\2^(+RTM+6P_;$\)RW5_>2+'';P"*\>1G=L!$ 0,Q)
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MO?AW\8/A3=0#QAX&U#44O8I;.X4/;:E87:*@O+25&4[S'&Z%E5XT++N ._\
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M^VW (!]V>"_VSOV8?'OBJR\#:)\7K"WUG5'VZ/I6MP3:9<:FV"<6L=XD371
M!)$0? &3Q7I]?GUX%^*_B[]HG_@HG??L@^$/BY#^TC^SC>_#>ZD^)NJ:SI>F
M7MEX/\1PW"BWLXM4TZVABEN9%*NUHYDN("!,K1@ #ZJ_9#U_Q;'X=\6_!CQS
MXCO-;U'X8>-)O#:Z_J,QDN-2LFL[34;"29SS+.MEJ%K%+*>9)H9)#C?@ 'K=
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7G/[7/_ ";=XN_[!?\ [42O1J\Y_:Y_Y-N\7?\ 8+_]J)7I9/\
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MK'&_ 3X!?"O]F;X8:?\ "#X-^&$TK1-.W-'#YC2232,<O+([$L[L>2Q]@,
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MBB@ HHHH **** "BBB@ HHHH *^^O^"?/_)MUE_V%+O_ -#KX%K[Z_X)\_\
M)MUE_P!A2[_]#KX'Q'_Y)^/_ %\C^4CBS#^!\SVZBBBOPD\0**** "BBB@ H
MHHH **** "BBB@ HHHH *^!?^"@O_)R-]_V"[3_T77WU7P+_ ,%!?^3D;[_L
M%VG_ *+K[_PX_P"2@E_U[E^<3NR_^/\ (\1HHHK]U/:"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]5/ _\
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MLI2#)9ZA:I-$Y!R,HX(.#STJ?3]/L-)L8=,TNRAMK:WC$<%O;Q!$C0# 55'
M '  H _,G_@W5^/?P.L?@)^U'KM[\8?#$-E8?M8^-]<O;J77;=4@TR4V1BOF
M)? MWP=LOW&P0"2#7S3_ ,$^?V[_ !C^QI_P:CZ#\7?V?CI.K>)O#/BB]TOQ
M#.UJFI?\(C!>^);K=J-S9J26,<,JR1I( K,\;$,F0?W2IES;6U[;26=Y;I+#
M*A26*5 RNI&"I!X((XQ0!^+/QB_: _8H\._\%B/V$OVB_A3^T!XC^(7AM[;X
M@6VO_%35+C4M876[^?0%@M[6WE$9A>?SYPGV&QC589+E4\F-G"U]"?\ !6'X
M"?$+Q1^Q5\8O^">LGB/PKX1\-_%;Q5_;O@GXI^.]3N+/0=+-WK46L:AI]_<P
MV\P@N?MPN6@\[RHI8KR)$D:2!T/Z-0Z!H5M':0V^BVD:6'_'BB6R@6WRE?W8
M ^3@D<8X.*LS0Q7$303Q*Z.I5T=<A@>""#U% 'P/?7/A3]ES]MY?VMO@)\8_
MAY-:_&#2DB^,_P #_#?B:;5;W7-9@55M=9T""TMFDN+WRRT-QOB@AEC"2RO$
M4:4?5G[*OPZ\;^#O!NM>-_BO816?C#X@>)[CQ+XFTZ"X65-.DDBAMK6Q$BY6
M1K:PM;*V>1?EDD@>1<*X [3PC\-_AWX -PW@/P%HNB&[??=G2-+AMO.;KE_+
M4;CR>3ZUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7G/[7/_ ";=XN_[!?\ [42O1J\Y_:Y_Y-N\7?\
M8+_]J)7I9/\ \C?#_P#7R'_I2-*/\6/JC\W:***_J(^D"BBB@ HHHH ****
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M0K_QY>K_ #/F'N%%%%9""BBB@ HHHH **** "BBB@ K\EZ_6BOR7K]:\+?\
MF+_[A_\ MYZF6_;^7ZA1117ZT>H%%%% 'ZT5\I?MZ?\ !6CX5?\ !-KQCX/A
M_:H^"'CO2O OC/Q/#H-G\5;"/3[G1+"[D5G NPMW]JA C223_4$E(9"NXH0/
MJVOC[_@KC\ OA/\ M2WW[-_[/7QS\(P:[X3\6_'NZL-:TRXR!)$W@7Q:0RL.
M4D1@KHZX9'164@J#7\EGRY]6ZAXE+^$?^$K\&:=_PD*S6J7&G0Z9>0@7R. 5
M:.5W6,@J=P8L 1T/->9?L9_M;3?MD?#>?XJZ?\"/%?@O2H]:U/2K<>++C3S-
M<7.GW\]A=!4L[J?:JW%M,H9B-P7<N5*D_ W_  3<_: ^+?\ P2!_:SM/^"*/
M[=?C*YU3P)KKO+^RM\6=5.V/4K(O@:#<RGY5GC+*D:'&UR(U_=S6HKUSX:_M
M@0?L*?\ !'CQ#^T9'X?35]3L/BGXST[P[I,BRE+O5+_Q_JEE:(XB5I#&)IT=
MP@+F-'V@M@4 ??U%?G9\7?VEO^"B7P&^-7PC\7?!+Q!\4OCMX8\1>+;?1_C'
MX*UG]GB[T.+1+*?&_6-+N1IUM)#% 0?]'N9[MF#*#)]YQW'[*G[3/[2OB_\
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M0O\ [?7T-11_Q,!XN?\ 0R_\HX?_ .5!]7H]CYY_X8,_ZJK_ .4+_P"WT?\
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M !1110 4444 %??7_!/G_DVZR_["EW_Z'7P+7WU_P3Y_Y-NLO^PI=_\ H=?
M^(__ "3\?^OD?RD<68?P/F>W4445^$GB!1110 4444 %%%% !1110 4444 %
M%%% !7P+_P %!?\ DY&^_P"P7:?^BZ^^J^!?^"@O_)R-]_V"[3_T77W_ (<?
M\E!+_KW+\XG=E_\ '^1XC1117[J>T%%%% !1110 4444 %%%% 'R)_P50_X*
M,>"_V0?!]I\*M(\07D?C'Q6@5I=&CCENM$TUF*RWJH[*OG$!EA#$#>"YR(RK
M<M_P3(_;T^ ?QJU[2OV0_P!E7X#ZQX>\-^&O#EUJ.LWWB)X6>2-7CCS^Z=O-
MGFFG#O(YY"OA3G*_<E%>'/+<QGFOUKZPE#1<O)KR[M*3EIS/=I:Z+HC%TZCJ
M\W-IVM^I^3_[-?@RU_8@^#G[9?[-?Q7UB'0]5/A:<>$5U"<1/K=M-::C;VLM
MJ&.9M[20+\N2KR!3A@17US_P1P_9S\7?LW?L0Z/HGC_1IM-UKQ)JESKU_IMR
MA66V\Y8XXDD4\J_DPQ,5/*EBIP017T[?Z'HFJ75O?:GH]K<SVC[[2:>W5WA;
MCE"1E3P.1Z5:KGROAVEEN(A44[JG&48*UK*4W)WUU:^%;::]=)I8=4Y)WVO;
MYNYX)^UGXP\3?%'Q5IG[$OPDUF:RUCQ;9-=^.=<LWQ)X>\-AMDTBM_#<7)S;
MP]2,R2<>7FO O^"D7A>_\ _M!_LF_"[1M$-A\);'QY964^F0)_H"W45Q:):Q
M3@_*0(]^P/U'G'GFONNR\->'--UJ]\2:=H%E;ZCJ:Q#4;^&U1)KH1@K&)' W
M2; 2%W$[02!BD\2>%_#/C/1IO#GC#P[8:KI]P +BPU*T2>&4 Y&Y'!5N?45T
MX_*)XZC54IVE)QL^BC&2DH^DK>]WOV214Z3FG=GQ3_P1\G\<CXJ_M(:99FX_
MX5S:?%>\3P4C#_1HY?M=[]H6WQ\H7R_LA8+P"5QU-?<E4_#_ (=\/^$]'@\/
M>%M"L],T^U3;;6.GVJ0PPKG.%1 %49)X JY77E6!>6X"&'<N:U]?5MV7DKV7
MDBJ4/9P40HHHKT#0**** "BBB@ HHHH **** /U4\#_\B7H__8+M_P#T6M:E
M9?@?_D2]'_[!=O\ ^BUK4K^4*_\ 'EZO\SYA[A11160@HHHH **** "BBB@
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MBC'JR>/M?\1^)]4_:K\/>)UA%SIGB?[,R:AIZ6\*A%M#&JFV"AC+%,C%G9B
M ?HS17'_ +/.D>-?#_P!\#:#\299'\16/@_3+?7WFDWNUZEK&LY9OXCY@;)[
MUV% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6;XO_Y%J\_ZY?U%:59OB_\ Y%J\_P"N7]17DY]_R(\5_P!>Y_\
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MK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<;P1L88(V1&,,CQ1.GT110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI_Z+K[_PX_Y*"7_7N7YQ.[+_ ./\CQ&BBBOW4]H**** "BBB@ HHHH ****
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MCQ?L^_M/>&K_ ,,_ F5[EOLXO?#M[<1)=8/RJ;UWNI4(&98]0L<D[ !]M?\
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MBOXY/N0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ZGX7?\?MW_UR7^==G7&?"[_C]N_^N2_SKLZ_I_PT_P"2
M/H>L_P#TMGR.;?[]+Y?D%%%%?>GFA1110 4444 %%%% !1110 4444 %%%%
M'C7[8WP3_P"%U^']%T[_ (2;^S/L-Y+)O^Q>=OW(!C&]<=/>O O^&#/^JJ_^
M4+_[?7M7[=O[2'_#.7AC0-7_ .$-_MG^T[^:'R_[1^S^7M0-G/EOG.>G%?-/
M_#T/_JAW_ES?_<U?G'$7B1XH\.YK/ Y+BN3#Q2<8\E"5FTG+6<'+=O=^FA^L
M<*^'W$^?Y+#&X/#<].3E9\\%LVGI*:>Z['6?\,&?]55_\H7_ -OH_P"&#/\
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M -S4?\/0_P#JAW_ES?\ W-1_Q&3QQ_Z#O_*6&_\ E8?\0EXV_P"@+_RI3_\
MEAUG_#!G_55?_*%_]OH_X8,_ZJK_ .4+_P"WUR?_  ]#_P"J'?\ ES?_ '-1
M_P /0_\ JAW_ )<W_P!S4?\ $9/''_H._P#*6&_^5A_Q"7C;_H"_\J4__EAI
M^/OV*_$WACPI=ZSX.UJZ\2ZG$G^AZ-:6$%LT[DX&99[I411U8\D '"L<*?A+
M_@D;^T5\;/\ @H[^U;\9_@S\4/#VE> +;X810VT>C6<1O[A+L7D]O.LUQYB+
M(5,.,HJKQT/6OMK_ (>A_P#5#O\ RYO_ +FK\J_^"%O[6/\ PIO_ (*)?M7^
M._\ A ?[2_X2;Q)<2_9?[5\G[-G5[V3&[RFW_?QT7IFOH<L\6O%[$9-C:F(Q
M?[VFH.F^2@K-RLTTH<K5OYD_O/$S'P[XLP&9X3"U<-RRKRDHKGIOF<8\SU4W
M:RUU:1]5_M-^*_B'HO\ P5<^%G_!*SX._$&UTVY\9>%+WQ#XF\;W?AX3O811
MVM_-!;P0/-L9F:Q^=FSA9EVC*FM'_@BW\2-7_P""F_[*&K?%_P"(VNV7ACQ)
MX0\47&@^);>STPO:2O%!#.MU&S3?(K)-AE).&C8YVD5+^TYX@\$?'7]K3X??
MMX^ O!5SX,^+/PYTZ[TS2M>75$OK.^T^X@N86M[JU:&,R;!=W#1NDB%6E.[>
M-H7PWP9XE^&WP#^ 5A_P2!_9)\#ZW8Z5XAO#K_QY\;S>*%?4KG29BL=Q;>;'
M;(MO<WZ0K:IM!,5M'(VUFPYWAXM^)6(P2=/'2C7<8<S<*+46I3]I+EY.2SC[
M-125[Z:-OFVQ'A?QS@JJG6PGNRERQ7M*;NY644DIM[W;>R5Y-V3:^MOV+/A#
MX_\ VP-2\7_';2?B)#8?"1M5;2?A9,WA_P#TCQ)!;,R7.MDF;*6\LP:.W7/S
MQ1>:0/,6O>_^&#/^JJ_^4+_[?7P'J?\ P<HVWPQT#QP_P+_8LT=?AC\#+W2O
M#E]9+XI>">ZC>=K,"Q"6OE010F-557#;UV\IG ^NO ?_  5WT#XD>"-'^(7A
M7X+--IFNZ7!J&GROXDVLT,T:R(2/LW!VL,CL:\C,/%7QTPLW4CBG"$GHG##2
M:T3LVX/6S3:T6MDDE9<V4<$9[G%65'"45.<5S/WX*ZYYPNKS2<>>$HW5UIV:
M;]"_X8,_ZJK_ .4+_P"WT?\ #!G_ %57_P H7_V^N3_X>A_]4._\N;_[FH_X
M>A_]4._\N;_[FKSO^(R>./\ T'?^4L-_\K/>_P"(2\;?] 7_ )4I_P#RPZS_
M (8,_P"JJ_\ E"_^WT?\,&?]55_\H7_V^N3_ .'H?_5#O_+F_P#N:C_AZ'_U
M0[_RYO\ [FH_XC)XX_\ 0=_Y2PW_ ,K#_B$O&W_0%_Y4I_\ RPZS_A@S_JJO
M_E"_^WT?\,&?]55_\H7_ -OKD_\ AZ'_ -4._P#+F_\ N:C_ (>A_P#5#O\
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M_P#5#O\ RYO_ +FH_P"'H?\ U0[_ ,N;_P"YJ/[#S3_GW^,?\P_XA;QW_P!
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M\0>-[/P=I$^I:II'ARZLX9HK6&-I))W:ZFC B15);RQ))@_+&_./CK_@MO\
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M=\;3>%M7T*/7-/*>';Z/5;G3MMW-YGF.&:V=@UO!,IR!NP0QQ/%/_!;7Q/\
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M 4444 %%%% !1110 4444 %%%% !7P+_ ,%!?^3D;[_L%VG_ *+K[ZK\YO\
M@I+XW_L+]J._T_\ LSS<:39MO\_;UC]-IKZ3A;B/)N%\R>,S.K[.FXN-^64M
M6TTK14GT?2Q]-PGD&;\29H\)EU/VE11<K7C'1-)N\FEU76YYA17)_P#"T/\
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M'_Y,_P#V-'_$9/#?_H._\I5O_E8?\0E\0?\ H"_\J4O_ )8=917)_P#"T/\
MJ!_^3/\ ]C1_PM#_ *@?_DS_ /8T?\1D\-_^@[_RE6_^5A_Q"7Q!_P"@+_RI
M2_\ EAUE%<G_ ,+0_P"H'_Y,_P#V-'_"T/\ J!_^3/\ ]C1_Q&3PW_Z#O_*5
M;_Y6'_$)?$'_ * O_*E+_P"6'645R?\ PM#_ *@?_DS_ /8T?\+0_P"H'_Y,
M_P#V-'_$9/#?_H._\I5O_E8?\0E\0?\ H"_\J4O_ )8=917)_P#"T/\ J!_^
M3/\ ]C1_PM#_ *@?_DS_ /8T?\1D\-_^@[_RE6_^5A_Q"7Q!_P"@+_RI2_\
MEAUE%<G_ ,+0_P"H'_Y,_P#V-'_"T/\ J!_^3/\ ]C1_Q&3PW_Z#O_*5;_Y6
M'_$)?$'_ * O_*E+_P"6'645R?\ PM#_ *@?_DS_ /8T?\+0_P"H'_Y,_P#V
M-'_$9/#?_H._\I5O_E8?\0E\0?\ H"_\J4O_ )8=917)_P#"T/\ J!_^3/\
M]C1_PM#_ *@?_DS_ /8T?\1D\-_^@[_RE6_^5A_Q"7Q!_P"@+_RI2_\ EAUE
M%<G_ ,+0_P"H'_Y,_P#V-'_"T/\ J!_^3/\ ]C1_Q&3PW_Z#O_*5;_Y6'_$)
M?$'_ * O_*E+_P"6'[ >!_\ D2]'_P"P7;_^BUK4K)\ R>=X%T67&-VDVQQG
MIF):UJ_'*DXU*CG'9NY^*5(RA4<9;IA1114$!1110 4444 %%%% !1110 5\
MV_\ &O'_ #_:U?25?FW7GX_*<JS3E^NX>%7EO;GA&5KVO;F3M>RO;>R,JE"C
M6M[2*=NZ3/I+_C7C_G^UJ/\ C7C_ )_M:OFVBO/_ -4^%?\ H H_^"H?_(F7
MU+!_\^X_<O\ (^DO^->/^?[6H_XUX_Y_M:OFVBC_ %3X5_Z */\ X*A_\B'U
M+!_\^X_<O\C])***^7O^"A?_  5!\+_\$YM2\#P?$G]F[Q_XILOB)XPM?"WA
MC4O"$FEO'+J]RN8;:1;J]@>,OA\.5V_NVR1QGZ ZCZAHKP3]L3]NRT_8N^!^
MA_&/QW^S[XS\07NO^(;30]/\$>$9-/N]:N=0NI?+@MK>%KE%NI&&YRL+N52-
MW(PC$;_CS]I7XE_#_P#9HN_VA+_]COX@WVI:?9M>7WPXTF[TBXUV.W6,R.55
M;[[--(H!'E1SN['A YP" >N$ C!%4;;PSX;L[&'2[/P_8Q6UO.)K>WCM$6.*
M0-N#JH&%;=SD<YYKY]_X)D_\%+/AK_P5,^!4_P"T9\%_A=XH\/>&8]7GTR&3
MQ3/IXN)+F';YB&&TN9VBP'4CS-I(8$#!4F]I_P"W?J^M_MKZ[^Q-X=_9,^(-
M_J'AG1[+5M=\:V]UI']AV=E=R2I;.\IOA,LLGDRL+?RO-VH6V;<-0!]!45\9
MR_\ !8*XO?VV/%?_  3]\%?L"_%WQ'\2/!OAB+Q#K%CIFJ^&(;7^S9!!LGCG
MN]7A1\M<Q)L^^&)^7"DCO/V2?^"G_P !_P!M&Y\=^!?A/X2\6:5\2/AK>_9/
M&GPE\:V$&F:]ILA;:K,IF>WDB8@XECF>/I\PWKN /?QX/\)+XE/C-?"^G#6#
M!Y)U864?VDQ_W/-QNV^V<4SQ'X(\%^,8!:^+O"&EZK$'#B/4M/CG7<. V'4C
M(]:^./V?_P#@LY?_ +44/Q"O/@9_P3=^.?B&'X6>,+WPQXT6SO?"D<]MJEH?
M](MXH9];CDN&48(\L$.2 I)X'MW["'_!07]FO_@HQ\)+KXN?LX^(;^2+2M6E
MTKQ)X?U[3FLM4T*_CP7M;NW8DQN 0<@LIYPQ(8  \0_X+I_LP?M*_MB_LI:#
M\ OV7?@X?$.JP?$+0]?NKJYUZQT^SMK:PN#,\1:>42&1L*%"QE<$DL,8/UY\
M/=$T&UTMO$MA\+H_"M_JY\_5;&2VM$N?-R?]>]J\D<C<DY#O][KG->1?&'_@
MH#X#\%_M"I^Q[\%OA[KOQ1^*ZZ4NJ:QX3\*RVT4/AVP?'EW6JWMS)'!9(^1L
MCR\\F5*0LI#5D#_@HUI?PP^-_A;X ?MD_ _6_A)J?CV^-AX!\2:CJEIJ/A[7
MK_&1IR7]N^;>\8 E(;F*'S<8B:1OEH ^E" P*L 01R#6'X8^&7PV\$ZE=:SX
M-^'VAZ1>7QS>W6F:3#;R7!X^^R*"_0=<]*^>_P#@I+_P5!\'_P#!,GP[X7\:
M_%;]GCQYXJT3Q?XLM?#.CZAX,;3)2=5N8Y9(;=XKF\A==ZP28?!7*X)&1GZ*
M\$:]X@\3>'(-8\3^![WPY>2@F32=0NK>::'_ 'GMY)(R?]UC0!K45\P?\%(_
M^"G_ (0_X)E^'_"WC/XJ_L\>//%.B>,/%EIX8T?4?!KZ9)G5;F.62"W>.ZO(
M)%WK!+A\% 5P2,C/7_M'_MQ^%OV7_ 'A#5?B!\+O$EWXU^(/B)- \#?##1'M
M+G5M7U-][")7$XMHXTB1II9WE6**,99LX4@'N%%?+VK_ /!1?QS\+/BIX#^#
MW[2?[$_COP;?_$KQ3;Z#X3UZRU33=7T1[J0,[17%U;3^9;2K%')($DA D"$1
MNV'V^R?'+]HOP)\!X--LM;L=3UK7]=DDC\.^$O#UNDVHZHT>WS&19'CBAB3?
M&'N)Y(H(S)&'D4R(& .]HKQ&+]IGX^:?:GQ-XC_8TUJXT-3FY;PEXOTW5M2L
MTZEY;-7C$FU>3';2W$AQA$D) /J7PV^)/@;XO>";#XB_#?Q%#JNC:E&S6EY"
MK+RKLDD;HX#Q2(ZO&\;A7C=&1U5E( !N4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y1^W-_R:5XY_P"P-_[42O5Z\H_;F_Y-*\<_]@;_
M -J)7%F/_(OK?X)?DSZ#A/\ Y*G ?]?J7_I<3\EJ***_"#_2 **** "BBB@
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M\9?$[Q!::OXX\::L-4\6:AI\3):1.L206]E:*_S+;6\$:1KNP9'\V9E5YG
M/1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;F_P"3
M2O'/_8&_]J)7J]>4?MS?\FE>.?\ L#?^U$KBS'_D7UO\$OR9]!PG_P E3@/^
MOU+_ -+B?DM1117X0?Z0!1110 4444 %%%% !1110 5C_$37/"?AGX?Z[XD\
M>^7_ &%I^C75SK7FQ>8GV2.)GFW+_$-@;([]*V*R_''@[0OB'X+UCP!XHMVE
MTS7=+N-/U&)'*EX)HVCD4$="58C-73Y5-<VU];;F.)55X>:I).5G:^U[:7\K
M[^1^.OB?X(?$7PK\$=<_;"_9OTW4;3X.^)-=>SU'P=J.L2R32:=#=*J?;!"4
MWP-.KQ_*YDC4@%VW,]?H7HWPS^!G_!27]@_PG9W?AB7PUHMY:1SZ-;:051M$
MN[5I+4K#E=K(K++& 5^9&Z*<$9GAK]@GXL^$/V8]6_8TT3XVZ._@O4KF9;?5
MKOPY(VIVEE--YTMN )Q$[EBP$I QO)V= /?O@M\(O!WP%^%FB?"#P#;21:3H
M5D+>U\YPTDA+%GD<@ %W=F=B !EC@ <5]3FV<TJ].,J4_P!Y";<9*]^2VCE?
M>6R[V6OG^-<$\!XO+L55IXRC;#5\/&-:G/D:]OS-R5+E;Y:6LG965Y)K5>[X
M3XT^&NG?LM>-_$'[0]CJ+>,_C1\4&MO#WAB"2U%M TJPQHH2%68QP(D"3SR,
MY^6'@KG!IZ-\6&_9?^*/A3]ACX5:-!XF\>^)-.O?$GB_Q3K<[QQ3W;133RSR
M"-2[RS/"RJN0(T\H?,, >P^%O@MKUQ\?]9^/?Q,U6SOKB"U_LKP-I]KO:/1]
M.(5II#N S<SR#YV ^5(T0,1G/%?&W]D+Q/X@_:H\-?M@_"#Q!IT'B/1=%N=*
MU#2=:DECM;V*2&>..42Q*[1O&9R2-C!PBC*$$GAI8K#57[/$2O[N^RYE&T(Z
M6M&.W;FO?2Q]#B\GS7"0^M9;2Y/WR7*K.:HRJ)UZGO7O5J[W;<E324;3;1TG
M[%O[6?AC]LKX*Q?%?0-#ETJXAOI+#6-*EG$OV6Z14<JK@#>A21&#8'WL$9!K
MUJO'?V'?V2='_8S^!T7PKLM?.K7UUJ$FHZUJ7D^6LURZ(A"*22J*D:* 3DX+
M<;L#V*O,Q_U58RI]6_AW?+Z?/7[]3[#AQYR\BPSS:WUGD7M+6^*VNVE^]M+W
MMH%%%%<A[04444 %%%% !1110 4444 ?9'_!';_DH'C3_L#6W_HUJ^^*^!_^
M".W_ "4#QI_V!K;_ -&M7WQ7Z_PE_P B.GZR_-G\,>-O_)Q<5_AI_P#IN(44
M45]*?DP4444 %%%% !1110 4444 %%%% !1110!\<?\ !8G_ ))_X+_[#-S_
M .BEKX&K[Y_X+$_\D_\ !?\ V&;G_P!%+7P-7X_Q;_R/:GI'_P!)1_<_@C_R
M;K#?XJG_ *<D%%%%?-GZR%%%% !1110 4444 %%%% &7XN\*P>,M);1+S6M4
MLH)&_?MI&H/:2R+C[OG1D2(/=&5N.M9_PR^$'PR^#6BR>'_ACX,LM'MKB<SW
M9MD)ENI3UEFE8EYG/=W9F/K7245?M*BAR)Z=NASO"866)6(<$ZB5E*VJ3W2>
MZ3ZI;D&IV<FH:;<:?%?SVK3P/&MU;%1)"6!&]-P(W#.1D$9'(-8?PE^%7@_X
M*_#_ $_X;>!K66/3]/1L27,IDFN)78O)/*YY>61V9V8]68].E='124YJ#A?1
MZ_=_PY3P]"6(5=Q7.DTGU2;3:7JTK][+L>)^.?V ?V>?'WB7Q'KFIZ=JEK:>
M,K^TO?&6@Z=?B*QUNXMI&DBDF7:74[W9F\IX]Y.6W'FO9["PL=*L8=+TRSBM
M[:VB6*WMX4"I$B@!54#@    #IBI:*UJXG$5XJ-23:6U_1+\DEZ)+H<N#RK+
M<OJSJ8:C&$I[M)*^KE]W-*4K;<TI/=MLHHHK ] **** "BBB@ HHHH ****
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M&75^^G&^20K>QO!J%OYFPPN3$0-VY0'7!)_GX_V /NRBOSN_;K_X*-_MR?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'V1_P1V_Y*!XT_[ UM_Z-:OOBO@?_@CM_P E \:?]@:V_P#1K5]\5^O\)?\
M(CI^LOS9_#'C;_R<7%?X:?\ Z;B%%%%?2GY,%%%% !1110 4444 %%%% !11
M10 4444 ?''_  6)_P"2?^"_^PS<_P#HI:^!J^^?^"Q/_)/_  7_ -AFY_\
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MK_&OR9^X> '_ "7,_P#KS/\ ]*@?.U%%%?E)_: 4444 %%%% !1110 4444
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MH!YW^QM\3_BA\=_^")5W\)OVP_VY=3\'Q?"3]I1O &O^+4L;G4-3\>:/IUW
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MG(?_ (NC_A3?Q(_Z%S_R<A_^+KW6BC_73-/Y(?=+_P"2#_B:;Q!_Z!<+_P"
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M (NC_A3?Q(_Z%S_R<A_^+KW6BC_73-/Y(?=+_P"2#_B:;Q!_Z!<+_P" 5?\
MY>>%?\*;^)'_ $+G_DY#_P#%T?\ "F_B1_T+G_DY#_\ %U[K11_KIFG\D/NE
M_P#)!_Q--X@_] N%_P# *O\ \O/"O^%-_$C_ *%S_P G(?\ XNC_ (4W\2/^
MA<_\G(?_ (NO=:*/]=,T_DA]TO\ Y(/^)IO$'_H%PO\ X!5_^7GA7_"F_B1_
MT+G_ ).0_P#Q='_"F_B1_P!"Y_Y.0_\ Q=>ZT4?ZZ9I_)#[I?_)!_P 33>(/
M_0+A?_ *O_R\]!_X),^"/%'A/QWXPG\0:7]G2;2;98SYZ/DB5B?NL:^XZ^7?
M^"?_ /R-7B+_ +!\/_H9KZBK^F/#?'5LRX2HXBJDFW/;;2375L^*SGB[,N.<
MPEG&/A"-6I9-034?=2BK*4I/9:Z[A1117W1Y84444 %%%% !1110 4444 %%
M%% !1110!\^_\% /^15\._\ 80F_] %?+M?47_!0#_D5?#O_ &$)O_0!7R[7
M\C>+'_);XCTA_P"D1/B,Z_Y&,OE^2"BBBOS@\H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^R_V*_P#DA-I_V$+G
M_P!#KXTK[+_8K_Y(3:?]A"Y_]#K]9\&?^2NE_P!>I?\ I4#VLA_WY_X7^:/6
M:***_J<^R"BBB@ HHHH **** "BBB@ HHHH **** "OS(_X*C?\ )VNH?]@:
MR_\ 1=?IO7YD?\%1O^3M=0_[ UE_Z+KY'C3_ )$Z_P :_)G[AX ?\ES/_KS/
M_P!*@?.U%%%?E)_: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?M1\._^2?Z%_V!K7_T4M;%8_P[_P"2?Z%_
MV!K7_P!%+6Q7] 4?X4?1'^9&,_WNI_B?YA1116AS!1110 4444 %%%% !111
M0 5\H_\ #2OQK_Z'3_RG6W_QNOJZOA>OPOQIS?-LJ^H?4L1.ES>UOR3E&]O9
MVORM7M=VOM=GZ'P'@L'C/K'UBG&=N2W,D[7YKVNCNO\ AI7XU_\ 0Z?^4ZV_
M^-T?\-*_&O\ Z'3_ ,IUM_\ &ZX6BOPS_6[BO_H85_\ P;4_^2/T+^Q<F_Z!
MJ?\ X!'_ ".Z_P"&E?C7_P!#I_Y3K;_XW1_PTK\:_P#H=/\ RG6W_P ;KA:*
M/];N*_\ H85__!M3_P"2#^Q<F_Z!J?\ X!'_ "/NBBBO@3_@J3^VU\9I_P!M
MCX&?\$A_V4_'<_A#QE\:6N-7\;^.K&)&OO#OA6V2XDG-CY@9([NX6SO$CF93
MY1ARHW.K)_<Y_/1]]T5\Q?$7_@E=\"]5^'-SIGP7\;^/_ 7CRWLV;P_\3]+^
M(FKW&KVU\%^2XNI+BZ<:BA8#S(;D2)(I92!D$?-_[#W_  7GTW5/^"87Q!_:
M:_;7\.W*_$;X$>(+_P )_$?1?"NER2MJ^JVL;/%/#%$I%NDZH^]WVQ1-#.Q*
M1J, 'Z1ZWH]IX@T>YT._FNHX;N%HI7L;Z6UF52,$I+"RR1MZ,C!AV(KS+]F?
M]B#]F+]CHZRO[-GPXE\+P^(;^6_URTM_$%_/;WMY)L\R[DAGG>-KAO+0-/M\
MPA<%L<5^:_\ P6)_:J\*?MO?\&VGB;]I71_%6NVGC#3?!_@J_P!?AT>35]'L
MX;_4]0TJ.\@,3&**_@*3W"+N$R*#N4Y(8_?7@[_@IG^PA-\>]"_8MA_:4T)_
MB5?VYMK+P\L<Y2XN8(LS6J77E_9FN(]I#0"7S58%2H;B@#Z%HKSWXU_M2_!'
M]GVZM-*^)/B6_.IWUI+=V>@^'/#6H:WJ<MK$5$MR++38)[CR(RRAYO+\M"ZA
MF!(SQP_X*8_L"C]F1?VR)_VK_!T'PU:9X!XHNM3$4?VE#AK4Q.!,+D'@VY3S
M1D?)0![G17AWP1_X*4?L,_M(?&UOV<O@?^T;HGB+QJGA*#Q*^@644XD73)EB
M9)2SQJ@<">+=#N\V/?\ .BX./+/^"],>K:'_ ,$J_C#\5/!_C3Q+X<\2^$?"
M4FH>'M<\*^*+W2[FTN!/"=P>TEC+@A<%6R,$C')H ^Q**_&?]ICP1\3/V9/^
M" _PU_X*E?L[_MB?&#PM\6]"^%?@CQ5K-]K?Q<UK6]+\476HQZ>MU!>:=JEU
M<6C!Y+R1T6.),,%0 (=H^[_@=_P5A_9:U/X)?!+5_P!IKXW>$/ _Q%^+'PST
M[Q0_@NXU$B6T\S21J-S(Z'<UM;)&LKB6<HNU/O$T ?5-%>&_"S_@I5^PO\:O
MV?+O]JCX9_M'Z'J?@*R\0-H4^O>7/"#J@>-%L4AEC6:2X=IHA'$B,\IE3RPV
MY<[OP9_;9_9G^/7Q)U?X+_#[XA3Q>--"L4OM5\%^)_#NH:%K,-HYVK=?8=2@
M@N'@)('G*ACR0-V2,@'JM%>2?'?]K?\ 9J^&&M7_ ,'OB-XXUJ36GT!K_5=&
M\%:'J^IZEINFOO07L_\ 8\,L^GQ$JX2X<Q#<C;'RAQ\ ?\$$OVJO@%\ /V$_
MV@_CY\3/BS?O\/[3]J[Q<;;QK=#4-9C731!IRVUQ/=(LTGE&(1@3S-@Y7+98
M9 /U:HKQSXK_ +?_ .R+\#_A1X3^.OQ3^,$6D^"_'%O9S>&/%4FC7LEA>+=H
MDEJ#/' R0M*CJR+(49AG .TXZ_XS_M"_"#]G^PTZ\^*?BQK.?6;MK70M(L--
MN=0U+5KA4,C0V=C:1RW-VZHK.RPQN552Q  )H [2BOG^[_X*?_L7']GKQW^T
MMX?^*5QK&A_#::XM?&6DZ?X?O1K6F7L08FRGTR6%+NWG.T@)+&F,%B5568<9
M_P $_P#_ (*L_!/]K#]BFS_:M^(_BBW\+-;Z*=8\60W^F7=M::1!-=3+;PK<
M31+'=.%6./\ <LY=\ #+J" ?6=%>6?"W]L[]GKXP_%63X&^$/$VLVWC*/P_)
MKC^&/$W@O5M$OO[-2:*!KL0ZC:P,8O-GC0.!AF+ 9V/M]3H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KAOVEO^2$^)?^P?\ ^SK7<UPW[2W_
M "0GQ+_V#_\ V=:\;B/_ ))[&?\ 7JI_Z0SGQ7^ZU/\ "_R/A2BBBOX8/SL*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /H+_ ()__P#(U>(O^P?#_P"AFOJ*OEW_ ()__P#(U>(O^P?#_P"A
MFOJ*OZY\)_\ DB,/ZS_]+D?;9+_R+X^K_,****_1SU@HHHH **** "BBB@ H
MHHH **** "BBB@#Y]_X* ?\ (J^'?^PA-_Z *^7:^HO^"@'_ "*OAW_L(3?^
M@"OEVOY&\6/^2WQ'I#_TB)\1G7_(QE\OR04445^<'E!1110 4444 %%%% !1
M110 455UO6]%\-:/=>(?$>KVNGZ?90-/>WU[<+%#;Q*,L[NQ"HH )))  %<#
MX'_; _9?^)/B73_!_@CXZ>'-0U+5XWDT6UBU%5.J(GWVM2V!=*.YB+@5O2PN
M)K4Y3IP<HQW:3:775K8I0G)72/2**Y/XI?'7X0_!4:>OQ1\?Z?I$VKS/%I-G
M/(6N;YT7>XAA0&27:OS-M4[1R<"M7P%\0/ _Q3\(6/C_ .&WB[3M=T34X?-T
M_5=)O$G@G3)!*NA(.""".H((.""*4L/B(T56<&H/1.SL_1[=']P<LE'FMH:]
M%85A\3? 6J?$/4/A/IGBBUN/$6DZ;!?ZII4+%I+2WF9EB>7 PF\H^U20Q"D@
M8YK=J)TYTVE)-72>O9ZI^CZ"::W"BBBH$%%%% !1110 4444 %%%% !7V7^Q
M7_R0FT_["%S_ .AU\:5]E_L5_P#)";3_ +"%S_Z'7ZSX,_\ )72_Z]2_]*@>
MUD/^_/\ PO\ -'K-%%%?U.?9!1110 4444 %%%% !1110 4444 %%%% !7YD
M?\%1O^3M=0_[ UE_Z+K]-Z^-/VU/^2[7?_8/MO\ T"OSSQ-S3^R>'(U^3F_>
M15KVW4O)]CZO@[C_ /XAQFSS7ZM[>\73Y>?D^)IWYN6>W+M;KN?!5%?3E%?@
M'^O'_4/_ .3_ /VI^G_\39_]2;_RX_\ N!\QT5].44?Z\?\ 4/\ ^3__ &H?
M\39_]2;_ ,N/_N!\QT5].44?Z\?]0_\ Y/\ _:A_Q-G_ -2;_P N/_N!\QT5
M].44?Z\?]0__ )/_ /:A_P 39_\ 4F_\N/\ [@?,=%?3E%'^O'_4/_Y/_P#:
MA_Q-G_U)O_+C_P"X'S'17TY11_KQ_P!0_P#Y/_\ :A_Q-G_U)O\ RX_^X'S'
M17TY11_KQ_U#_P#D_P#]J'_$V?\ U)O_ "X_^X'S'17TY11_KQ_U#_\ D_\
M]J'_ !-G_P!2;_RX_P#N!\QT5].44?Z\?]0__D__ -J'_$V?_4F_\N/_ +@?
M,=%?3E%'^O'_ %#_ /D__P!J'_$V?_4F_P#+C_[@?,=%?3E%'^O'_4/_ .3_
M /VH?\39_P#4F_\ +C_[@?,=%?3E%'^O'_4/_P"3_P#VH?\ $V?_ %)O_+C_
M .X'S'17TY11_KQ_U#_^3_\ VH?\39_]2;_RX_\ N!\QT5].44?Z\?\ 4/\
M^3__ &H?\39_]2;_ ,N/_N!^AGP[_P"2?Z%_V!K7_P!%+6Q6?X2_Y%73/^P?
M#_Z *T*_KS#OFH0?DOR/PBI5]O4=2UN9W^_4****V("BBB@ HHHH **** "B
MBB@ KX7K[HKPO_ABW_JI7_E&_P#MU?CGBUPKG_$WU+^S:/M/9^TYO>A&W-[.
MWQ2C>_*]K[:GW/!><9;E/M_K<^7FY;:-WMS7V3[H\+HKW3_ABW_JI7_E&_\
MMU'_  Q;_P!5*_\ *-_]NK\<_P"(5<>_] ?_ )4I?_)GW/\ KCPY_P __P#R
M6?\ \B>%T5[I_P ,6_\ 52O_ "C?_;J/^&+?^JE?^4;_ .W4?\0JX]_Z _\
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M\6TN_$_BOQC;:.VDV/BWQ]XJN]:O[&P9E9[:W>Y=EMUD9$:0QJK3%$,C/L7
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M4445YQD%%%% !1110 4444 %%%% 'T%_P3__ .1J\1?]@^'_ -#-?45?+O\
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M_P""I_\ R(?4L9_S[E]S_P @HHHH_P!4^*O^@"M_X*G_ /(A]2QG_/N7W/\
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MN7W/_(****/]4^*O^@"M_P""I_\ R(?4L9_S[E]S_P CZ"_X)_\ _(U>(O\
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M^H_^!3_^5A_J_C/YH_>_\@HHHH_X@IQ5_P _J/\ X%/_ .5A_J_C/YH_>_\
M(****/\ B"G%7_/ZC_X%/_Y6'^K^,_FC][_R"BBBC_B"G%7_ #^H_P#@4_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^(O%/QFLWM[7X7/=C3/AQ%]EQ<:TD#LMSJ[.>1!++F.!!C,<7F$?O%KVF@
MHHHH **** "BBB@ HHHH **** "OLO\ 8K_Y(3:?]A"Y_P#0Z^-*^R_V*_\
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M4445^+_\04XJ_P"?U'_P*?\ \K/ _P!7\9_-'[W_ )!1111_Q!3BK_G]1_\
M I__ "L/]7\9_-'[W_D%%%%'_$%.*O\ G]1_\"G_ /*P_P!7\9_-'[W_ )!1
M111_Q!3BK_G]1_\  I__ "L/]7\9_-'[W_D%%%%'_$%.*O\ G]1_\"G_ /*P
M_P!7\9_-'[W_ )!1111_Q!3BK_G]1_\  I__ "L/]7\9_-'[W_D%%%%'_$%.
M*O\ G]1_\"G_ /*P_P!7\9_-'[W_ )!1111_Q!3BK_G]1_\  I__ "L/]7\9
M_-'[W_D%%%%'_$%.*O\ G]1_\"G_ /*P_P!7\9_-'[W_ )!1111_Q!3BK_G]
M1_\  I__ "L/]7\9_-'[W_D%%%%'_$%.*O\ G]1_\"G_ /*P_P!7\9_-'[W_
M )!1111_Q!3BK_G]1_\  I__ "L/]7\9_-'[W_D%%%%'_$%.*O\ G]1_\"G_
M /*P_P!7\9_-'[W_ )!1111_Q!3BK_G]1_\  I__ "L/]7\9_-'[W_D?HIX2
M_P"15TS_ +!\/_H K0K/\)?\BKIG_8/A_P#0!6A7].48.G1C![I)'UT5:*04
M445H4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5PW[2W_)"?$O_8/_ /9UKN:X3]IIBOP&\3,I
MY&G_ /LZUMAJ$\5B(48;R:2OM=NVIYF=9KA\BR;$YEB$W3H4YU)*-G)QA%R:
M2;2O9:7:5]VCX6HJM]HF_O\ Z4?:)O[_ .E?=_\ $-\\_P"?E/[Y?_('\I?\
M3K>%?_0'C?\ P70_^:2S15;[1-_?_2C[1-_?_2C_ (AOGG_/RG]\O_D _P")
MUO"O_H#QO_@NA_\ -)9HJM]HF_O_ *4?:)O[_P"E'_$-\\_Y^4_OE_\ (!_Q
M.MX5_P#0'C?_  70_P#FDLT56^T3?W_TH^T3?W_TH_XAOGG_ #\I_?+_ .0#
M_B=;PK_Z \;_ ."Z'_S26:*K?:)O[_Z4?:)O[_Z4?\0WSS_GY3^^7_R ?\3K
M>%?_ $!XW_P70_\ FDLT56^T3?W_ -*/M$W]_P#2C_B&^>?\_*?WR_\ D _X
MG6\*_P#H#QO_ (+H?_-)9HJM]HF_O_I1]HF_O_I1_P 0WSS_ )^4_OE_\@'_
M !.MX5_] >-_\%T/_FDAT/POX9\,O>R>&_#MAI[:E?/>ZBUC:)$;JY< //)M
M WR,%7+MEC@9/%5O&OP\\ ?$K2ET+XB^!M'U^Q242I9ZWID5U$KCHP256 89
M/.,U?^T3?W_TH^T3?W_TH_XAOGG_ #\I_?+_ .0#_B=;PK_Z \;_ ."Z'_S2
M26%A8Z790Z9IEE%;6UO$L<%O!&$2-%& JJ.%  P .!4M5OM$W]_]*/M$W]_]
M*/\ B&^>?\_*?WR_^0#_ (G6\*_^@/&_^"Z'_P TEFBJWVB;^_\ I1]HF_O_
M *4?\0WSS_GY3^^7_P @'_$ZWA7_ - >-_\ !=#_ .:2S15;[1-_?_2C[1-_
M?_2C_B&^>?\ /RG]\O\ Y /^)UO"O_H#QO\ X+H?_-)9HJM]HF_O_I1]HF_O
M_I1_Q#?//^?E/[Y?_(!_Q.MX5_\ 0'C?_!=#_P":2S15;[1-_?\ TH^T3?W_
M -*/^(;YY_S\I_?+_P"0#_B=;PK_ .@/&_\ @NA_\TEFBJWVB;^_^E'VB;^_
M^E'_ !#?//\ GY3^^7_R ?\ $ZWA7_T!XW_P70_^:3Z+_P""?_\ R-7B+_L'
MP_\ H9KZBKY8_P"">\COXK\1[FSC3X>W_30U]3U\AFV5XC)L=+"UFG*-MKVU
M5^J3_ _HOP]X[RCQ)X5HY_ED*D*-5S25114_<DX.ZC*<=T[6D].VP4445YI]
MJ%%%% !1110 4444 %%%% !1110 4444 ?/O_!0#_D5?#O\ V$)O_0!7R[7T
M[_P4*_Y%3PY_V$9O_1:U\K5]]D/ _P#;>61Q?UCDYF].2^S:WYE^1_(WBQ]*
MC_B&'&^(X>_L?ZQ[)0?M/K'L[\\(S^'V$[6O;XG>U]-BY15.BO8_XAC_ -1?
M_E/_ .W/SC_B>C_JGO\ R[_^]BY15.BC_B&/_47_ .4__MP_XGH_ZI[_ ,N_
M_O8N453HH_XAC_U%_P#E/_[</^)Z/^J>_P#+O_[V+E%4Z*/^(8_]1?\ Y3_^
MW#_B>C_JGO\ R[_^]BY15.BC_B&/_47_ .4__MP_XGH_ZI[_ ,N__O8N453H
MH_XAC_U%_P#E/_[</^)Z/^J>_P#+O_[V+E%4Z*/^(8_]1?\ Y3_^W#_B>C_J
MGO\ R[_^]BY15.BC_B&/_47_ .4__MP_XGH_ZI[_ ,N__O8N453HH_XAC_U%
M_P#E/_[</^)Z/^J>_P#+O_[V+E%4Z*/^(8_]1?\ Y3_^W#_B>C_JGO\ R[_^
M]BY15.BC_B&/_47_ .4__MP_XGH_ZI[_ ,N__O8N453HH_XAC_U%_P#E/_[<
M/^)Z/^J>_P#+O_[V+E%4Z*/^(8_]1?\ Y3_^W#_B>C_JGO\ R[_^]BY7V7^Q
M7_R0FT_["%S_ .AU\45]J?L1?\D$M/\ L(W/_H=>#Q%P9_8& 6)]OS^\HVY;
M;IZWYGV['ZSX,_27_P"(N<72R/\ LKZMRTI5>?V_M/AE!<O+[&GOS7OS:6VU
M/7****^'/ZG"BBB@ HHHH **** "BBB@ HHHH **** "OC3]M3_DNUW_ -@^
MV_\ 0*^RZ^-/VU/^2[7?_8/MO_0* /)J*** "BBB@ HHHH **** "BBB@ HH
MKEOC)\6?#OP5\ 7?COQ#;W%V8WCM]-TJQ0/=:I>RN([>SMT)&^:61E11D $Y
M)"@D '4T5^<'_!(;]H#X^?'G_@H+^TC>_'OQ SZCI4T.GKHEI?/+8:7]FO;B
MW\BV!P-BB/&_:&<Y9N6->&?&'X^?&_XA^&OVV_C5XV^).OZ1XL^$_C7P[I_P
MZ%IJL]N?#=N-<GMBMNJ,%4S11HKL!^\Y8YW4 ?LE17S(W[8'Q.\.?L*_##Q[
M>>&H]2^,'Q.\-Z59^%O#<D?EB^UNZM%D:>1 !Y5M$-]S,> D:%<@E:]@_9M^
M"\OP$^$.F?#[4_&%_P"(M74R7?B+Q'J<S//JFHS,9+FX.2=JM(S;4'"(%4<+
M0!W=%%% !1110 4444 %%%% !1110 4444 ?HIX2_P"15TS_ +!\/_H K0K/
M\)?\BKIG_8/A_P#0!6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PG[3G_ "03Q/\
M]@[_ -G6N[KA/VG/^2">)_\ L'?^SK7HY/\ \C;#_P".'_I2/C?$7_DWV<?]
M@N(_]-3/@JBBBOZ;/\,0HHHH **** "BBB@ HHHH ***RO'7CCPI\-/!FJ_$
M+QUK<.FZ-HEA+>ZI?W!PD$$:EW<XY. #P.3T&32E*,8N4G9(TI4JM>K&E2BY
M2DTDDKMMZ))+=M[(\Q_;A_;:^$W[!_P6E^,'Q1\Z[>:[2TT70K*11=:G<-R4
MCW< *@9V<\*%[DJ"G[3_ .V]\(/V2/V;K?\ :4^*\=\+"_2U32](L(UDN[VZ
MN(S)';QAF5=VU78DD +&QYX!_.#_ (+A7,/Q0_9=\-_M%^-];LCXEUWQ];P:
M#X8BU&*:3PSH7V*]>.W=$8[;F9Q'-<M_?\J'++;HQ^NOV^?V*_$/_!03]@OP
M3X6^#WB_3(?$'AXZ=K.A2W=QFTO7CM&ADMWD0-L)$A(;!P\84X!)'R,\XS/$
M8C&4\+%-PA%TUU;ES:OSM:T?1/6Y_1&'\-N!\HRGAO%Y[6E&&*Q5>GBZEVHQ
MC3]DE"+5URJ3DI54G>\I1;@HL]=^ _[;G@OXP?'_ ,8_LI>)/"E[X7^(G@FS
MMK[5-"N[F.XBN+.>*"59X)X\!PHN(5<%5*M(,;ADCJ?'?[0NC>%/CIX2_9XT
M+P[=:WXC\2V\^H7L-I*JIHNDPC:]_<L<[4:4I#&N,R.Q ("L1\NZ5\']>_9U
M_:^^+_\ P5J_:;M$\/:9=^%+32/#/@NTO([R_GD\BR@*L828VFFGMUBAC1F+
M&?YMN!77_"'XE^#/V6->C\4?M17]S?\ QX^-IDUF^\)^'K)[^[L-/M89)(M.
MA1!A+:S@20%V(\V83LI<G [*&8XM1]GB'ROG?O-)?N^:T+K^:?PI65]7:ZL?
M.9KP;P].O];RB#KP>'IKV5-N:>,=!3Q"C--MT<+=U:DN:2BW"FY<LG-?6U%<
MC\#?CK\*/VDOAGIWQ?\ @KXRMM=\/ZHK?9;ZW5E(93M>-T<!XW4C!1@"/3D5
MUU?04ZE.K!3@TT]4UJFO(_'L7A,5@,5/#8FG*G4@W&49)QE&2=FI)V::>C3U
M3"BBBK.<**** "BBB@ HHHH **** /HC_@GK_P C7XC_ .P=#_Z,:OJBOE?_
M ()Z_P#(U^(_^P=#_P"C&KZHK\#X[_Y*6KZ1_P#24?ZY?10_Y,A@/\=?_P!/
M3"BBBOCS^C@HHHH **** "BBB@ HHHH **** "BBB@#YX_X*%?\ (J>'/^PC
M-_Z+6OE:OJG_ (*%?\BIX<_[",W_ *+6OE:OWS@3_DFJ7K+_ -*9_D;]*_\
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M &5'_"OO^HO_ .2__P!E1_Q,9X-?]#3_ ,H8C_Y2'_$E7TF?^A#_ .76"_\
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M_P#+K!?_ #0<W172?\*^_P"HO_Y+_P#V5'_"OO\ J+_^2_\ ]E1_Q,9X-?\
M0T_\H8C_ .4A_P 25?29_P"A#_Y=8+_YH/9/^">O_(U^(_\ L'0_^C&KZHKY
MK_84\-_V%XFU^7[;YOF6$(QY>W'SGW-?2E?(YKQ/D?&&.EFF45?:T)V49<LH
MW<5RO2<8RT::U7IH?WUX$\"<5^&WAIA<@XCP_L,72E5<H<].=E.I*<?>IRG!
MWBT]).VSL] HHHKSC]@"BBB@ HHHH **** "BBB@ HHHH **** /"/VZ]!_M
MWPQH$?VKRO+OYCG9NSE![BOFK_A7W_47_P#)?_[*OJ7]LO\ Y%W1/^OV7_T
M5\_5^'\:^,OB3P?Q%5RO*,=[*A!1<8^RHRLY14GK.G*6K;>K]-#EJ_1E\$/$
MF?\ ;_$>4^WQ=724_;XF%U#W(^[3K0@K126D5?=W>IS?_"OO^HO_ .2__P!E
M1_PK[_J+_P#DO_\ 95TE%?*?\3&>,O\ T-/_ "AA_P#Y29_\25?1F_Z$/_EU
MC?\ YH.;_P"%??\ 47_\E_\ [*C_ (5]_P!1?_R7_P#LJZ2BC_B8SQE_Z&G_
M )0P_P#\I#_B2KZ,W_0A_P#+K&__ #0<W_PK[_J+_P#DO_\ 94?\*^_ZB_\
MY+__ &5=)11_Q,9XR_\ 0T_\H8?_ .4A_P 25?1F_P"A#_Y=8W_YH.;_ .%?
M?]1?_P E_P#[*C_A7W_47_\ )?\ ^RKI**/^)C/&7_H:?^4,/_\ *0_XDJ^C
M-_T(?_+K&_\ S0<W_P *^_ZB_P#Y+_\ V5'_  K[_J+_ /DO_P#95TE%'_$Q
MGC+_ -#3_P H8?\ ^4A_Q)5]&;_H0_\ EUC?_F@\)_:K_P"">/[//[:7@^Q\
M$_M!Z"^K6VEWANM+GMYYK:>TF*[69)(I%."O!4Y4X!QD BQ\)?V#?A%\']2L
M/$.EZMKVNZOI-B]EI.M>,=>O-7NM/MGP'BMWNIG%NK!5#>6%+A5#%@HQ[=17
M,_'_ ,67B/;O,%SZ:_5\-?3;7V/3IV/<C]%#P(AE$<JCEE18:/-:G]=Q_(N?
MX[1^LV2E]I+276YR>K_"^75=)NM,A\4W%D]S;O$EY9PJ)8"RD"1"^Y=RYR,@
MC(&0>E<W\#_V5/ ?[/7POTOX2?#BZFBTO2XVQ+=@RW%U,[F26XGD)S)-)(S2
M.YZLQZ#BO4**V?TB/&%U%4>9ZI6O[##[.U_^7/6R^X\R/T-_HX0P<L)')&J<
MI*3C]:QMG**DHM_[1JXJ4DNW,[;L^5/B/_P2 _98^)WB[Q7XDUAM9LK'Q_J5
MCJ'C[PUI5V(=.\0W5I(TL,UPF#(K;W9F\EXQ(22^XG-?0&F?"O3M%TVWT?1[
MF&UM+2!(;6VM[,)'#&H"JBJ#A5    X %=716-'Z0'BWAIRE2S%1<M[4,-W;
M_P"?/=M^K;W;/0S/Z)G@'G6'I4,?E4ZL*7PJ6,QS2]V,+ZXG?DA"%WKR0A&_
M+&*7-_\ "OO^HO\ ^2__ -E1_P *^_ZB_P#Y+_\ V5=)173_ ,3&>,O_ $-/
M_*&'_P#E)XW_ !)5]&;_ *$/_EUC?_F@YO\ X5]_U%__ "7_ /LJ/^%??]1?
M_P E_P#[*NDHH_XF,\9?^AI_Y0P__P I#_B2KZ,W_0A_\NL;_P#-!S?_  K[
M_J+_ /DO_P#94?\ "OO^HO\ ^2__ -E7244?\3&>,O\ T-/_ "AA_P#Y2'_$
ME7T9O^A#_P"76-_^:#F_^%??]1?_ ,E__LJ/^%??]1?_ ,E__LJZ2BC_ (F,
M\9?^AI_Y0P__ ,I#_B2KZ,W_ $(?_+K&_P#S0<W_ ,*^_P"HO_Y+_P#V5'_"
MOO\ J+_^2_\ ]E7244?\3&>,O_0T_P#*&'_^4A_Q)5]&;_H0_P#EUC?_ )H.
M;_X5]_U%_P#R7_\ LJ^N_P!CS2_['^"=K9>?YF+^X.[;CJ_IDU\T5]1?LK_\
MDAMO^OV?_P!"K[;@'Q;\0N-\\EEV=XWVU%0<^7V=*'O)Q2=X4XO9O2]M=C6C
M]'3P;\*Y?VSPME?U?$O]VY^WQ%3W):M<M6M..KC'7EOIH]6>C4445^RG2%%%
M% !1110 4444 %%%% !1110 4444 %?%W[;<TB?'F[56P/[/MNW^Q7VC7Q9^
MV[_R7N[_ .P=;?\ H%?:\!X7"XS.Y4Z].,X\C=I)-7O'6S/YC^EEG^>\.>%]
M/%Y3BJF&JO$TX\]*I*G+E<*K:YH-.S:5U>VB['DOVB;^_P#I1]HF_O\ Z4RB
MOV+^P<C_ .@6G_X!'_(_S;_XBSXJ?]#[&_\ A57_ /E@_P"T3?W_ -*/M$W]
M_P#2F44?V#D?_0+3_P# (_Y!_P 19\5/^A]C?_"JO_\ +!_VB;^_^E'VB;^_
M^E,HH_L'(_\ H%I_^ 1_R#_B+/BI_P!#[&_^%5?_ .6#_M$W]_\ 2C[1-_?_
M $IE%']@Y'_T"T__  "/^0?\19\5/^A]C?\ PJK_ /RP?]HF_O\ Z4?:)O[_
M .E,HH_L'(_^@6G_ . 1_P @_P"(L^*G_0^QO_A57_\ E@_[1-_?_2C[1-_?
M_2F5Y%^U?^V#X3_97T*V>3X=>+O&_B'4(99M,\(>!=#DU"_EACQYEQ(J<0P(
M64-(Y RV%#'(&-?*.'<-2=2KAJ2BNO)'_(]'*O$/QESS'PP6!SK'5*L]%%8J
MMZMMNHDDEJVVDEJVD>P?:)O[_P"E'VB;^_\ I7S9_P $_O\ @IO\$?\ @H/:
M:Y8> M UCP_X@\-^6VK>']<1/,$3DJLT;HQ$B;E*MD*RM@$8*DX/Q3_X*V?!
MCX>:[\3?[%\ Z[XA\/?!K4=-L/B1XATV6!5LKB]NFM4CMXG8-<F.5&63E I4
MXW5P^RX/>%CB52I<DKV?)'6R;?V;Z)-OM;4^H>.^D='/J^2RQ^8+$T>3G@\5
M67+[24(4_>=7E?M)3A&G9OG<DHWN?6/VB;^_^E'VB;^_^E<[I/Q0^'^M?#"V
M^,]AXKM#X6NM"368=;DDV0?8&A$XN"S8VIY9W$G&!UK&_9V^,[?M!_"G3_C!
M:^"=1T+3=;>6;0H-6P+BZL-Y%O=L@_U0F0"54.2$=<\G [EE'#KFH+#4KM77
MN1VTUV\T?*R\1?&2&%J8F>=8Y0IS4)-XJNK3?,U&SJ)WM&5TEI;6VAW?VB;^
M_P#I1]HF_O\ Z4RBMO[!R/\ Z!:?_@$?\C@_XBSXJ?\ 0^QO_A57_P#E@_[1
M-_?_ $H^T3?W_P!*911_8.1_] M/_P  C_D'_$6?%3_H?8W_ ,*J_P#\L'_:
M)O[_ .E'VB;^_P#I3**/[!R/_H%I_P#@$?\ (/\ B+/BI_T/L;_X55__ )8/
M^T3?W_TH^T3?W_TIE%']@Y'_ - M/_P"/^0?\19\5/\ H?8W_P *J_\ \L'_
M &B;^_\ I1]HF_O_ *4RBC^P<C_Z!:?_ (!'_(/^(L^*G_0^QO\ X55__E@_
M[1-_?_2C[1-_?_2F44?V#D?_ $"T_P#P"/\ D'_$6?%3_H?8W_PJK_\ RP_2
M#PE_R*FF?]@^'_T6*T*S_"/_ "*FF?\ 8.@_]%K6A7\V5DE5DEW9_MIETI3R
M^C*3NW&-W\D%%%%9G8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5R7QV_Y)%KW_7E_[,M=;7)?
M';_DD6O?]>7_ +,M>+Q'_P D]C/^O53_ -(9WY5_R-*'^./_ *4CY$HHHK^$
M3^B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ]H_8T_Y&'6_^O*+_P!#-?0%?/\ ^QI_R,.M_P#7E%_Z&:^@
M*_K[PD_Y(;#_ .*I_P"ER/Q'C3_DH:OI'_TE!1117Z4?*A1110 4444 %%%%
M !1110 4444 %%%% 'C'[9?_ "+NB?\ 7[+_ .@"OGZOH']LO_D7=$_Z_9?_
M $ 5\_5_('BU_P ESB/2G_Z1$_;N"_\ DGJ7K+_TIA1117YL?5!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U%^R
MO_R2&V_Z_9__ $*OEVOJ+]E?_DD-M_U^S_\ H5?KG@M_R5\_^O4__2H'Q?'G
M_(D7^-?DST:BBBOZL/QL**** "BBB@ HHHH **** "BBB@ HHHH *^+/VW?^
M2]W?_8.MO_0*^TZ^+/VW?^2]W?\ V#K;_P! K[SPZ_Y'\O\ !+\XG\F_3+_Y
M-)2_["J7_I%4\BHHHK]P/\L0HHHH **** "BBB@ HHHH *YOXE:KKW@KPIJW
MCGP!\+)/%?B&.Q1+;1[&[MK2XU (S%(3/.RHJJ9)"-QP-S8!+<])7SG\;/VA
M_P!M[X1_M16>A>&_V/G\=?"&\TJ+S-=\*:A#_;-I>$GS"T4]PB,@^4!-JY!W
M"4D&,<N,Q$,/2YI<VKM>,7)J_6R3T7=JW<]_AO*,3G.8.E0=)N$7-QJU8THU
M%!IN"E*=.\I=(QFI.SY7='R%_P $1OC+X,O_ -MCXY>%/BQ\']2\)_&'Q=K-
M]K5_#<R8M[6V%V9)M/2$HK1.DDX<LQ;S54'Y-GS]'\2/^"5G[2NA:=^TK\'?
MA3%H^JZ#\?\ Q)H^JZ)X@O=46!= $.IRWMU%=QD&1\"4I&81)NV@MM)('T1\
M"?V2-6U7]O+QE_P4(\>^"Y/"]SK?AFVT+PYX:NYX)+P1JD0GOKPV[R1+*WE)
M&B)(^(QER&.U?8?VEOB#\2_AQ\([_5O@Q\/+KQ/XNO9(M/\ #>F0P,T*7D[>
M6EQ=,.(K:+)ED<D#:A .6%?+8/)8/*'#&W_=RJ\K2M)PES)W5MY)OI?:VI^\
M<2>)^*CXB1Q7#'(GBZ6!]K3J3]I1IXB@Z52"A4<E:G0G3AKS\EE-2O'0^;-4
M^'^@>)]+\+?\$X-'\5A_AC\'/"NFW/QS\47,H@BO(K>!7MM'=\X03^6;JY&0
M$MU5-P\W%>N?"3_@H=^R?\5_$WAGP1X*\87-L/&*7@\!W>HZ+/9V?B!;.0PS
MBSDD4*Q1U*[&VLV/E#"LO6/V(+K3/V!?&O[+/A+Q>UUXK\9>'-3;7?%M_E7U
MG7;R-C/=W!'(624A,<[(@J#(4"OBOX/_ +$7[3_Q%NOV0?A7K/PAUKPG/\!=
M=U?4OB%K.I61@MHE_MB&Z@BMI\E+QIH[<8,)=5,Q+$ &KJU\SRVO!4J-^=1Z
M-VM.,5336W)!RE?J[RVNC# 97P-QOE>)J8_,7!8>I52?-&',Y8>O6GC)PDKS
M>(Q-.E1C!6<*;ITG>;A(_5RBBBOL#^;PHHHH **** "BBB@ HHHH **** /T
M@\(_\BIIG_8.@_\ 1:UH5G^$?^14TS_L'0?^BUK0K^6*W\:7JS_?++/^1;0_
MP1_])04445D=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7)?';_DD6O?]>7_LRUUM<E\=O^21
M:]_UY?\ LRUXO$?_ "3V,_Z]5/\ TAG?E7_(TH?XX_\ I2/D2BBBOX1/Z)"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#VC]C3_D8=;_Z\HO_ $,U] 5\_P#[&G_(PZW_ ->47_H9KZ K^OO"
M3_DAL/\ XJG_ *7(_$>-/^2AJ^D?_24%%%%?I1\J%%%% !1110 4444 %%%%
M !1110 4444 >,?ME_\ (NZ)_P!?LO\ Z *^?J^@?VR_^1=T3_K]E_\ 0!7S
M]7\@>+7_ "7.(]*?_I$3]NX+_P"2>I>LO_2F%%%%?FQ]4%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?47[*__)(;
M;_K]G_\ 0J^7:^HOV5_^20VW_7[/_P"A5^N>"W_)7S_Z]3_]*@?%\>?\B1?X
MU^3/1J***_JP_&PHHHH **** "BBB@ HHHH **** "BBB@ KY%_;#\(_VQ\;
M+J]_M#R]UA;C;Y6>B>N17UU7R]^U3_R5VX_Z\H/_ $&OB>/>,>(^",C68Y)7
M]C6<XPYN6$_=:DVK3C);I:VOIN95O#7@KQ5A_8W%.%^L89?O%#GJ4_?CHGS4
MIPEHI2TYK:ZK1'BG_"OO^HO_ .2__P!E1_PK[_J+_P#DO_\ 95TE%?C7_$QG
MC+_T-/\ RAA__E)S?\25?1F_Z$/_ )=8W_YH.;_X5]_U%_\ R7_^RH_X5]_U
M%_\ R7_^RKI**/\ B8SQE_Z&G_E##_\ RD/^)*OHS?\ 0A_\NL;_ /-!S?\
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M /RD/^)*OHS?]"'_ ,NL;_\ -!S?_"OO^HO_ .2__P!E1_PK[_J+_P#DO_\
M95TE%'_$QGC+_P!#3_RAA_\ Y2'_ !)5]&;_ *$/_EUC?_F@YO\ X5]_U%__
M "7_ /LJ/^%??]1?_P E_P#[*NDHH_XF,\9?^AI_Y0P__P I#_B2KZ,W_0A_
M\NL;_P#-!S?_  K[_J+_ /DO_P#94?\ "OO^HO\ ^2__ -E7244?\3&>,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?47[*__ "2&V_Z_9_\ T*OEVOJ+]E?_ ))#;?\ 7[/_ .A5^N>"W_)7S_Z]
M3_\ 2H'Q?'G_ ")%_C7Y,]&HHHK^K#\;"BBB@ HHHH **** "BBB@ HHHH *
M*** "OE[]JG_ )*[<?\ 7E!_Z#7U#7R]^U3_ ,E=N/\ KR@_]!K\C\:?^20C
M_P!?8?\ I,S[7@+_ )'<O\#_ #B><4445_*9^QA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]N>'/^1>L/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\6OA_<S7&A:]:_:M'NYX#&;JV+$1SA3R$D4"1<X;:ZY"G('S!_P3_3_AH/\
M;(_:$_;@O&$^G_\ "1Q?#GP),>0FFZ2!]KDB/\44]XY<'UC-=&4<09E@LMQE
M!PA"E2A-<O)%R]I4DXQ7,TY)QYG)6:TIV[WSQN6X7$8NA44G*<W%WYG;EBKM
MV3M9V2VWD?,7[4_Q=^*OQ?\ ^"B_[57PJ^)?C/6=,\/?"?\ 9DUG6/AQI5KJ
M4]M#8WR6=A.FKIY;*'N%DGDVR<E00@(V5]"_L&_MX^-=$_X)!>$/VK_VHGU'
M7/$8M;C3]-A"DZAXINA?RVFGP1+C=)<7!6)-V"6.Z4\$FOI7XO\ [)7[.'QY
MUY/%7Q9^$VF:MJ:Z5)I<NHL9(9[C3Y&W/93/"R-/;,>3!(6C)))7DUX)\)8?
M#W[4'Q;D_:9TSPS GP5^!L-WIWP8\/Z;:K':ZUJEM$\-WK,42@(880KV=G@%
M>)Y5VY6JJ9ME.<9-3H2P_+&C[-R>BUC!PY(-:WKR]Z5_AM*7O<MQ1P6,P./E
M452[J<]M]G)/FDNU-:+O=+2Y[%^QE\&/B3\+OAQ>>+?CQXD?5?B-XXU)M<\;
M2I<M);6-Q(H$>G6@)(2VM8@D* ?>*-(>7->OU^+<7_!6O]M#2/V*]'_X*57W
MQ1:[U"__ &C9?#-]\/DAA&D?V#_9ANA9)%Y>])%:-L7&_P WYUW%NE?M#;S?
M:($G\ITWH&V2+AER,X([&O$XJR'-,IQ"K8QQ;J2G'W=HRIV4HI65E&\5&VEM
MMCOR?,<)C:7LZ":Y5%Z[M2O9^KL[];CZ***^4/9"BBB@ HHHH **** "BBB@
M#VC]C3_D8=;_ .O*+_T,U] 5\_\ [&G_ ",.M_\ 7E%_Z&:^@*_K[PD_Y(;#
M_P"*I_Z7(_$>-/\ DH:OI'_TE!1117Z4?*A1110 4444 %%%% !1110 4444
M %%%% 'C'[9?_(NZ)_U^R_\ H KY^KZ!_;+_ .1=T3_K]E_] %?/U?R!XM?\
MESB/2G_Z1$_;N"_^2>I>LO\ TIA1117YL?5!1110 4444 %%%% !5'5_#/A[
MQ!>:=J&N:+;7<VD7IO-+DN(@YM;CRI(?-3/W7\N65-PYQ(P[FKU>/?MS^,OV
ML/!_[/6K?\,4_!X^+_B#J(^QZ.LFJV-I!I6]3NOI#>31+)Y8'RQC<6<IN&S<
M:Z<'0GBL5"C":BY.UY248J^EW)V27?R,J]2-&C*<DW;6R5V[=DMV?'/Q>_9J
ML?VU_P#@O/X<^)W@'2(X_#7P'T'3)?B#XEMTPESKL4T]U::>KCB695EMB_4H
MB.C$$(ID_P""E_PM_P""SK_M@77[1'["V@:/-X9TCPC;:+8VADTFZN;V$.;J
MY;R+]24+3.$(C8.ZVT?4@5Q/[*?@W_@OYX _X17]G[5OV8_!W@?P#>^)K9O'
M'BW2M:TR;5FMYKI'U&_DF_M.:6:[E0RLTH1I"S?+M(7;]7?&']I[_@HS\'OV
MOKGPOIG["\?Q ^"MU;6PTGQ%X+U>!=:@D,2&=IH[JY2-MLN]1'MB&S:WFL<K
M7ZGB,1C,OS2A##U,+B(4:#A&,ZD)Q<$US-^\H^TFVVH<S:BK*]DW\?2IT,3@
MZDJD:U*4ZBDW&,HM-IVMHWRQ25W;5ZZ7L><_\$CO^"F'B[]N"?QM^RY^T[\(
M8?!WQ0\'V3'7;.RL)+)+ZT+^1*S02$O;S1NZ*ZDD'S59=O*KX,G_  1$_:E'
M[*!_X)S/JFCGPI_PT!_PF?\ PLH:@FW^P_[-^R>1]DQYOV[/S;=ODYX\W'-?
M<GP _9>N%_;"\=?M[^-? I\+Z[XR\,:?X>TWP[-<PRW=O90;7EGO7MWDA-Q*
MZ0H$CDD5([6/]XQ<JG1_MH^(?CW)X T_X0_LU:-J$?BKQ[J7]D+XOAM&>U\)
M614M=:I,_"B2.(,((R09)WC !"M7DKB'ZEGLHY*H4H5?9SDF^:%.I&+;E&5]
MH.4NZ>R3T1VO+/K&7IX]RG*'-%-:2E%O1-=Y679^:U/%/B#\0/AG\=?B[?>.
MOB/XJM=(_9V_9FO1+J>J7\I^R^(?%=LH50< F:#3LJ H!,MY(J@.80*]G^ _
M[?'[-_[0_CFV^&/@OQ'J%CXBU'PM;>)M&T7Q#I$UC/J>C7 S#?VPD $L3#G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ KDOCM_R2+7O^O+_V9:ZVN2^.W_)(M>_Z\O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ?AS_D7K#_KRB_\ 0!5RO] ,+_NM/_"OR/YKK?Q9>K"BBBN@S"BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ KZB_97_P"20VW_ %^S_P#H5?+M?47[*_\
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MOX1/Z)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5D^.O!VE_$'PC?\ @O6[B[AM-1@,,\EC<M#,JD@Y1UY4\=16M10!X7_P[W^"
M?_0V^.__  LKG_&C_AWO\$_^AM\=_P#A97/^->Z44 >%_P##O?X)_P#0V^._
M_"RN?\:/^'>_P3_Z&WQW_P"%E<_XU[I10!X7_P .]_@G_P!#;X[_ /"RN?\
M&C_AWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\
M$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_
M .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C7
MNE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^->Z44
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MN?\ &C_AWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\
MAWO\$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&
MWQW_ .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65
MS_C7NE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^->
MZ44 >%_\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_^%E<_P"->Z44 >%_
M\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C7NE% 'A?\ P[W^"?\
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M -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C7NE% 'A?_  [W^"?_ $-OCO\
M\+*Y_P :/^'>_P $_P#H;?'?_A97/^->Z44 >%_\.]_@G_T-OCO_ ,+*Y_QH
M_P"'>_P3_P"AM\=_^%E<_P"->Z44 >%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/
M_H;?'?\ X65S_C7NE% 'A?\ P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\
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MCU&)FM[Q8P22$%S#,%!)(7 )- 'NM%%% !1110 4444 %%%% !1110 4444
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M58?V(?AM\&=-MOA5!IE[IW_"&:A--J%M+:W<LLUS%*UV\LDPDDGE8[V8_/Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>amgn-20201231_g2.jpg
<TEXT>
begin 644 amgn-20201231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB*J006W8&#GI7\]W_!OS^R7\!_VL_P#@C'^T7XO_ &F?!8\=2> HO$5C\/\
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M6D13>3+JO@[Q):ZG;))C.PRVTCJ&QSC.:_+G]K#X)?$[]E3_ (+RV'_!2?\
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M(O[3GP]T#QCJ 3[!X2UKQI8VNIW._E/+M995E?=VPISVK\"_^#6_2-+\/_\
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M\>_V+[3]O3PK;VUMXO\ @\\5OK$S85M2T&ZN4B,)/\3PW,R2H"<!9;@#)84
M?H;_ ,%&?BCX$^'?['GB/Q!KUGJ^LWFL1P:7X(T+PMXDN]-O]?UZ\<0:;8VM
MS92Q3(TMQ)&"Z. B!Y#\J,17_P"";7[&'B/]B;]F?0_AU\3?CCXR^(WCNYTZ
MWE\<^+O&'C+4=6-[J #,XMEO)G6V@1I&C18U3<B(TFY\M7YS?\&POQ:^,?\
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MKK/Q-UBRL/##3H)%LK6"RN80KQ*X5R24#J?+5% S^-?_  =+RZ[H_P#P7?\
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MH;A+V(R1L"C-"3C+N6 /OKX$_P#!>?\ 9_\ VGO^"NOB/]CCX4?%;PU'\+/
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M#1O_ $DU"@#F_P#@AI^QX/\ @H;_ ,$A_#'QO^,W[6_[1-A\2=>U#7+8^/\
M0/VA?%$%U:F"_N(('2V-^UH2B(@P8?FV\\DFO&?^#<S_ (+ _MQ:_P#\%%O$
MW_!+;]L;XPW_ ,4+"-];MO#_ (IUMO-U"PO]+>0R9N#^\FMY8X9>)2[*XCVL
M 6!\/_9@_P""AW_!57_@FM_P;U?#OXS_ ++/@CX=ZC\.=8\3^(-)O/%-SHE[
M<ZQX3N9=1G6.>5?M MW624NL<C1E$81HZL9%S]8?\&C/[%_[$NH_"'4_^"B'
M@WXI:OXW^-.I-<Z)XUAU](XF\*S22":6.*(,[2&X4(XNW8F1,JJQ$3(0#]C_
M (@?$;X>_";PE=^/OBIX\T;PSH5@@:^UKQ!JD-E:6RDX!DFF9409(')%9WP@
M^.OP0_:$\*_\)U\ _C)X5\<:)YQA_MGP?XAMM3M?,'5/-MG=-PR,C.>:_#O_
M (*G?MB^*?C-_P '._PA_9"\?>!/$7C?X=_!S4-.O;/X9>'4MI'UK6Y=(;5(
M[KR;R>"WFE5IK5!YL@"QP.%^9V5_</V>O@1^WYI'_!PYKO[8'P\_8=\;^ ?V
M??C!X>&F?%+3_%5QH\4<UQ'I3*EY-9VE]<(SF\AB_>+N<K<3DX\U\@'M_P 4
M/^"[OP,O/^"OOPP_X)N_!KXF^'IM&MY-;N/C'XRN;Z!;&TFM])O'MM)BN'.S
MS1<I&\SJ1M9(X0Q+2HOVSJ?[2O[.>B?9_P"V?C]X)M/M=JES:?:O%5G'YT+Y
MVRIND&Y#@X8<''6OYSOV9_V7_P!FG7_^#N[Q'^S7KO[/'@6]^','BKQ+%#X
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MT5^S[X9:T7Q)\=?!NGF_L8KVQ%]XGM(OM%M(,QSQ[I!OC<<JXRK#H37X(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3?L=?"V_^)GC&]T2TL9KJSU33=-AEOI-4BU&_OI7U"Z@"PEQ,(T4R2 &)",
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MOP3H.EZGI7B"_P!*U")[ZQMH8S-;R6%W<H566 2([['&4.T,"%]VHH ^)O\
M@X,_9\_::_:]_P""8?C;]D_]D_X%W_C?Q5XXO=)CCCMM:TRP@L(K35;.^>6:
M2_N[<89;8HHC$AW'D*/F&!_P;D?LN?M2?L2_\$ZM/_9;_:U^ >I>"/$V@>)-
M2N@USKVE:A;7\-U.TR-"^GWDY!4':PD"'/W=PY'WQ10!^2W[27_!!*X^*O\
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M_P $[/B1^R3^R]^S+X@\<>)?&^FV%MI][::_HMA8VI34()Y#,]_?02#;' V
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MJL%O=P7FE7OFF%Q*P*Q30A-LZAPC!]X4!-_[<T4 ?@5^WU_P34_X+2?M=?\
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MD#W*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_A//$%D'>W6P\2:>]YH<SR<Z?!;I!.\:<0A59#MV1AOZ!?@=_P3/^$7[/\
M_P %(-6_;S_9EL-&\.^&/B'\*[C2?&GAG0#Y%E?:O]OL;FSU6&"(>26DMUND
MD<;>1&P#&:5J /I'XE_%+X9_!?P5??$CXO\ Q"T3PMX>TR+S-1USQ%JD5E:6
MR^KRS,J+^)IWPT^)/@;XQ_#S0_BQ\,?$MOK/ASQ+I4&IZ%J]H3Y5[:31B2*9
M,@':R,&&0.#7X,_\'H/[-7A/P)X#^%7Q[M/'7C74M:\0>,-3LKZTUSQ?=WFG
M10^0LL:VUE(YM[/9RH\A(]RL=^]OFK]<?^"/LL4'_!)S]G"::141/@=X99W8
MX"@:7!DD]A0!Z!^T#^VQ^R?^ROJFFZ!^T%\>O#WAC4]7MY;C2](O;S=>W4$0
M)EG2WC#2F) #NEV[%[D5V/PM^*_PQ^.'@'3?BI\&_B#HWBGPUK$'G:7KV@:C
M'=VETF2"4EC)5L$$$9R""#@@BOPQ_P"#:/\ :8\3?M_?\%K_ -I_]M'XA32Z
MA>:OX0ECT"6[.XZ7I<FJP"ULHL_<1+>WB3 Z^62>6)-/_@UM_:GUKX7?\%0O
MVE_^"?7]J-!X%OM5U[Q!X9TIY,6^FWNGZJ+9UA7I&)+68%\<$6<?I0!^U/[0
M/[;'[)_[*^J:;H'[07QZ\/>&-3U>WEN-+TB]O-U[=01 F6=+>,-*8D .Z7;L
M7N178_"WXK_#'XX> =-^*GP;^(.C>*?#6L0>=I>O:!J,=W:729()26,E6P00
M1G(((.""*_#'_@VC_:8\3?M_?\%K_P!I_P#;1^(4TNH7FK^$)8] ENSN.EZ7
M)JL M;*+/W$2WMXDP.OEDGEB34_X-:/VHM>^&G_!4?\ :5_X)Z0ZA)'X(U#5
M]>U_POHY?]SIU]8:L+9UA3HGFVTPW8X/V./TH _?+5=4T[0],N=:UB]CMK2S
M@>>ZN9G"I%&BEF=B>@ !)/M7@.N?\%:O^"7GAC5[CP_XE_X*%?!K3[^SE,5W
M8WWQ&TZ&:!QU5T>8,I'H1FOH6OY:_P#@O-IFFS?\'/VGVLNGP-%=^,/A_P#:
MHVB!6;,&G*=XQ\V5 !SV&* /Z>OA_P#$?P%\5O#$'C7X:>,-.UW2+DL+?4M+
MNEF@E(.#M=20:VJ\1_;T_;[^"/\ P3C^#"_M!_M%Z5XE/A%+^.SO]6\/:.+T
M6$LK!8O.0.'578[0P!&[ )&5S\J?$+_@Z)_X)F^#/@!I'[27AC2/BIXT\.:C
M>&UU*3PCX":7^P)//DAC349KB:&WM9)#$SQPF4S/&5<1[74D _1FBOGF[_X*
M<_LP3?L$VW_!2?P7<^(/%7PLET<ZI<ZAX9T1KF[LK2-WCN))K8LKK]GDC=)@
M,F,HQ/RJS#$_X)U_\%<_V4/^"I*^)KS]DJU\6:AI_A$0KK>J:UH2V,$4\V3%
M OF2;WD94D;A2H"'<RDJ& /J&BO%OV8OVYOAG^U7XB\?>'?!/@/QEHI^&?B"
M?0O%]_XJT:.SM;;4X0K36L<PE=9V1&5V:,L@5E);YESX5XA_X+[?L7Z9X+\4
M?'+PIX$^)?BOX/>"/%4?A[Q?\;_"_ANVN/#6F7SO%&>7NDO;J)7FB#3VUK-$
M/,3#$.A8 ^WJ*\"_:N_X*9?LB?L??LOZ+^UQ\1_B$VJ^%/%<ME#X(7PI;_;[
MOQ//>)YEM#81JP$S21@N"650JDEA6/\ "+_@IY\-/B3^T?X=_9'\;_L]_%KX
M;?$+Q/HM]J^E:#\0?"UO DEC:JC23B[M+JXM9.75=D4KR(W$BID$@'TK17X<
M_MO_ /!?WQ?XY_X+1_"']C_P%\%/BGI?P^^&7CL7_C'0H? 6H#Q-XNO3I\S6
MWE:28UN_LJQS)/%&R!I0ZS%0$CK]"_VGO^"TG[+/[&O[/W@S]IK]I;X:?%GP
MAX6\<7TMAIC:[\/+BTO;2]1I\6MW9S,D]K(Z6\DJ!T >,!E)H ^NZ*_.CXR?
M\'/_ /P3?^$/PV\+_&:U\)_%WQ9X.\3/!"_B[PI\/FDTK2;N6,RBRNKNXFAA
M^UK&"[VT+RRH 0R@@@=#^TO_ ,''G_!.;]G3X8:1\9-%/Q!^)OAK4K.QN;_7
M/AAX.:^LM"6\C62VBU&ZN)(+>TN'1U/V5Y/M"Y&Z(;ER ?>U%><_LN?M7_ S
M]L?]G3P]^U3\!O&2:GX,\2Z>]W8ZC/&8&B$;O'-',KX,3Q21R(X/ 9#R1@GY
MEU__ (+]?L6:=X(\2_'?PKX&^)?BKX.>#/%,7A[Q9\</#/AFWG\-:=?.\<>
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M-Z/A#\'?VBOA%HGBC0M<T/7[>\AU&PC>6/=KNI*)89<;X9EX*2H0Z,H(((%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'Y>?\'>WC?XA>$/^"/.HZ9X'GN([+Q#\1-%
MTWQ2\#$?\2[]_< ,1_";FWM5/KD#OBOGE=+TBR_X,BOLC6\2PGP49]KXQYS>
M,_,W<]S(<CW(K]@OVNOV5/@[^VY^SCXK_9:^/>A/?^%O%^FFTU!() DT#AED
MAN(7((2:*5(Y48@@-&N01D'\]C_P0>_;-D_X)V+_ ,$?)OVXO!G_  HM=?\
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M_'OAVYO='U"XEEAF.IP-:3PRP7!E@1W0[UD9Y3E"Y-=Q_P $G?\ @DQ\+?\
M@ES\/O%']G^-+CQK\1?B)K)U?XC^/[ZP6U?5;G?(ZQ0P*S"WMT::5E3<[%I7
M8L<JJ@'Y#_\ !F+X4USX8_MU_M#_  J\963VFMZ)X1AL=2M'4YBGMM4,,R'T
M*OQ6-_P;;_#'7O%__!Q1\=?']G:R_P!G>$4\9W%]<@'8)+C64MXHB?[S;Y&
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MK_MO:!8:5X*N[7S_ !E;_""9[C4+2TR;2$6YUD+"ZEF\R3>XD 0!(\,6)/\
M@A9\;)/^",H_X(W?\-T>'QH(O@#XW'P>F%X=/&K?VM]F\C^VMGF?:?E\[=CR
M?D\O=^\H ^%OV*_B/\0O ?\ P9E?%S7? FHW$5_#>:SI<;VY(>.QO-7M;>[
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M0HS<I$EI<7"CJV'8LS'FOFC_ ((H_LM_M2_\%%O^#?\ U7]CWX8_'[X3>'?
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M_M]9LI)UCDN(?M,CM;2PF4/L1A$8U<!%8 G]$/\ @L9_P3/^)W_!3/X'>&_
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MH246-0H42+C YXP?S$N_^#<#]H"\_P""I@_X*R2_\%'?#?\ PG0\8)KHT/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEXN\*>/O#%AXV\"^)]/UK1M5M$NM+U?2;U+BVO('&Y)8I8R5D1@00RD@@\4
M:-%>/_'G]O[]B[]F'Q8O@/X]?M)^%?#6MG3CJ,VCWNHAKFVL@0#=SQ1AFM[?
M)QYT@6/@_-P:]/\ "/C#PE\0/"^G^-_ ?BC3M;T75;1+K2]7TF]CN;6\@<;D
MEBEC)21&!!#*2".E &C1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,H?VP_&WBGP?\6/V(?%^OW%YI7AA;/Q-X-MYY2XL8YY)(;Z%,_=C,OV:0(.
M\DK8RY)R_P#@R&O7TCP'^U%>>4#):7'A:0Q,<'*Q:P<'TY&*\[_X,A_AIK^H
M_M._&_XQ16SC2](\!Z?HTTQ7Y3<7E[YZ*#W(6QD)],CU% ']'5%%% 'EM_\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
M?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_
MZ#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?
M\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4
M?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!
M_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&
M/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF
M/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M^ ?^4@GC_P#[$32O_1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5X7X!_P"4@GC_ /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*_P#1C4 >
MZ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7X!_Y2">/_P#L
M1-*_]&-7NE>%^ ?^4@GC_P#[$32O_1C4 >Z4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[:)X1\/?%_PKI$^B^%8H7_L[1/$]L-16>[CM$ CCMI1/9.8XR"6CE "KL ^
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
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M'B#X;ZA>R6UOX@T2[TV>YA4%XDGA>)G4'@D!R1GTK;HH _+#QE_P36_X*W_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HI'=(D,DCA5499F. !ZU\8?MD_\
M!9/X._!":X^'O[/]O;^/?%^[R1-;2%M,LY<X :1#FX?./DB..H+J1BO*S?.L
MKR+"^WQM50CT[M]HK=OT.''YC@LLH^UQ,U%?B_)+=_(^KOBE\6_AI\$O!USX
M_P#BOXTL-!TBU'[V]U"8*"V"0B#[TCG!PB@L>P-?GK\<?^"JW[1?[6?C.3X
M?\$ZOASJT?VG*2^)#;*;Z6/.TR(&_=V,7/\ K9#NY!S&W%9_PL_X)V_MD?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=_ ']DCPS_PCWP;\%16UQ-&%U#6[S$M_?8[RS$ XSSL4*@/117Q7U[B;B[3
MIX3"O_EY)?O9K^Y'[*?23UZI]#YSZSG.?:89.A0?VVO?DO[J^RO-^J['Q_\
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M_&[X^_!']FKP!=?%3]H'XL^'_!GARR'^D:SXDU6*T@#8)"!I&&]S@[47+,>
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M#RA#96[O7JDF:8/A^"K+%8^?MJW=_#'_  QV7K\] HHHK[4^C"BBB@ HHHH
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M"VH_X0?2/^?F]_\  MJZC8V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDK66R6^[M=_+0U:***_3#[(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KPOP#_ ,I!/'__ &(FE?\ HQJ]TKPOP#_R
MD$\?_P#8B:5_Z,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **AU#4+#2+"?5=5OH;6UMH6EN;F
MXE"1Q1J,L[,<!5 !))X %?G7^V)_P5+^(WQT\:_\,I_\$[]-O]3U'496M+KQ
M9IL9\Z?LXLR<"*,#.ZZ;& "R[0!(?#SWB'+N'\,JF(;<I:0A'6<WVBOUV7W'
MFYGFN$RJBIU7=O2,5K*3[)'K_P#P4"_X*J^ /V6%N?A9\)DMO$_Q$<>4;-&+
MVND,> ;@J<O+Z0*=W=BHQN\:_9#_ ."7WQ2_:/\ ' _:O_X*):KJ-_=:C(MS
M:>$]1D*SW(ZH;H#'D0J,;;9 IQ@,$ *-Z[_P3]_X)1^"/V9VMOBY\;)+;Q1\
M0Y#YR2R#S;32'/)\G>,R39ZSL,@_<"\LWV'7S.#X?S+B/$QS#B!6@G>GAT[Q
MCV=3^>7ELOGRKQL/E6,S>LL5FJM%:QI?97G+^:7X?D0:7I6F:'IEOHNBZ=!9
MV=I"L-K:6L0CCAC485$50 J@   < "OBS_@K[_P5]\"_\$\_ K_#WX>S6>M_
M%C6[,MH^CNP>+1XF! O;L \#KY<7!D([*":^H/VG==^*_AC]GKQEXC^!M_X=
MM?%MAX?N;C0KKQ9<^3IT,Z(6WSN2%10 3EB$R!N(7)'\G_Q0\?>/OBE\0]9^
M(7Q2\67.N^(M6U"2XU?5KNZ$[W,Q/S-O4E2.,+M^4* %X K]TX.X>P^;5G5K
M-<E.WN]WTOVC^>QR<8\0U\EP\:&'C:<T[2Z12[>?Y;G]$'_!(+_@K[X%_P""
MAG@5/A[\0IK/1/BQHEF&UC1T8)%K$2@ WMH">1T\R+DQD]U(-?;5?R,_L]W'
MQOM?C?X7G_9L?65\>+K,/_"+?\(^&-V;LMA!&!USR"#\I4L&^7-?JROQV_X.
MF_ Z@:_\'3K.P88GP[H5QN]_]"=?4=/3V->CGW!]&CC.;#5J<(RUY9RY6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M">&;#1M'TNV6WT[2]+M$@M[6)>B1QH JJ/0"M*G6XIQE.I".!2HTH.ZBNO\
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M-*UB#[-J^F6]U'_SSN85=?R8&N1US]FK]G/Q.2?$OP!\$ZCN^]]N\*V<V?\
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M?+33M4Q#7NQ[JG_-+SV73=2/E*^:8S.:SPN5.T%I*KT7E#N_/;\&>3_L7_\
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU/\ 8IM5LX/M5OIT[':(H44'[5<Y.-HRBM@'>0R#'_8<_P""2^I3>)!^TO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$/E]I^;T]="MH^C:1X=TFVT'P_I5M8V-E D%G96<"Q101* JHB* %4
M"K-%%?+-MN[/JDDE9!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ7XCT:T\0Z)>+<65_:QW%G<(#B6)U#(PSS@J0?QH M44DDB1(TLKA54$LS'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPM[2NE?%WCG_ (+Q_M7_ +27B&;X<_\ !/C]DF]FN'.U=2O[&75;U5/23R(
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MU>X6QM8[1<DW.I7.=L46%)$ )S@D[]N5^;S_ (EPF2<M&,75Q%32%*.LI/\
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M0C3;5SF>0C*F\F)')VEPOE#];_V3OV-?V=_V)OAI%\+?V>/A];:/985M0OF
MDO=3F QYUS.1NE?KC.%7.%55P!VUOI7B^TMTM+35+"**) D44=GM5% P  .
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
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M_P :/L7C?_H-V7_@,?\ &M2#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QK0TV/48K4)JEQ'++N.7B3:,=N* +%%%% !1110 44
M44 %8GQ,\$6?Q-^''B#X;ZA>R6UOX@T2[TV>YA4%XDGA>)G4'@D!R1GTK;HH
M _+#QE_P36_X*W_ ;X)?!']F/X:?M.> OC!X/^&GQA\,ZCX7U?Q5X#N;+6=
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M)^-/"US>PZ#J*FX9=1TQ[:YBQM:[N'6VE4HK2$!P@5%]R_X)5?\ !+SX%_\
M!)W]F.']GCX-:A=ZQ=WM^VI>+/%FIPK'<ZUJ#(J&4HI(AB545(X02$4<L[L[
MM]+T4 %%%% !7A?@'_E()X__ .Q$TK_T8U>Z5X7X!_Y2">/_ /L1-*_]&-0!
M[I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M &(FE?\ HQJ]TKPOP#_RD$\?_P#8B:5_Z,:@#W2BBB@ HHHH **** "BBB@
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MY(^DHT*.&IJG2BHQ6R2L@HHHKH-0HHHH **** "BBB@ HHHH **** "BBB@
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M[2^O>,M6N9/.OM.\-@VT4LG<2W=QYDTX/]X+"WO7WQ^SA_P3[_8P_9)BB;X
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M\UQ.*Q.,KRK8B;G.6KE)MMOS;U844459@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !17E'[0?[=7[&O[*&JZ5H/[2?[3O@G
MP5?:U?P6FFV/B'Q#!;S2/*2$=D9MT<60<S.%C7^)A7H?@WQOX+^(WARV\8?#
MWQ?I>NZ1>)NL]5T;4([JVG7U26)F5A]#0!J45R/QN^/OP1_9J\ 77Q4_:!^+
M/A_P9X<LA_I&L^)-5BM( V"0@:1AO<X.U%RS'@ FNDT36=+\1Z-:>(=$O%N+
M*_M8[BSN$!Q+$ZAD89YP5(/XT 6J*\$_:"_X*D?\$[/V5/B(GPD_:(_;)\ >
M$_$[*C2Z%JFOQBYME< HTZ*2;<,""#)M!!R..:]J\)>+O"GC[PQ8>-O OB?3
M]:T;5;1+K2]7TF]2XMKR!QN26*6,E9$8$$,I((/% &C17C_QY_;^_8N_9A\6
M+X#^/7[2?A7PUK9TXZC-H][J(:YMK($ W<\489K>WR<>=(%CX/S<&O3_  CX
MP\)?$#POI_C?P'XHT[6]%U6T2ZTO5])O8[FUO('&Y)8I8R4D1@00RD@CI0!H
MT444 %>%^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\ _L1-*_\ 1C4 >Z44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44DDB1(TLK
MA54$LS'  ]37RO\ M1?\%>_V4OV=OM.@>&M;/CKQ'#E1I?AN=6MXG'::[YC4
M9R"$\QP1RHKSLRS;+,GP_ML;5C3CYO?T6[?DDV<F,Q^#R^E[3$S45Y_HMW\C
MZIKYU_:B_P""H?[*'[+OVC1=7\9#Q)XCARO_  CGAIEN)8W'\,TF1'!@XR&;
M> <A#7Q\WB[_ (*M?\%1F\GPG8O\/?AW>''VB-Y-/LIH3W,Q!N+W(X(C!B)'
M*K7T3^R[_P $8/V8?@;]G\1?%&!OB#K\6&,FLVX33X7_ -BT!(?_ +:F0'J
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MU$^#/V./V=-?\:ZK<2>39:CXA;[';R2'[IBMH?,GG!_NDPM_7S,:5_P<A?\
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MH^)_$FB>#?#>H>+_ !-?K::;I5C+>:A=.I(A@B0O(Y"@D@*I. ">* /Y?_\
M@E+_ ,%'?V;?&GA+P-^S3^T[I"Q?&;7?VQ?#?BWQ=\1?%L23?\)/IQG\N:.]
MO)OFC:!F(\J4B(K)E?F+K7[V?L;?\$TOAM^P[^V!\9?C1^SYIUAX>\ _%K2=
M!NO^$)TLM%:Z9KEK)J"WL]O;J!%##/%-:-M3^-)!A5V ?G;_ ,'$O_!#W]EG
M]I71_ O[6O[(>DZ=X8^)WQ:^)6B^'S>6EQY&A^('U42&.^N8DC8QREE1C-$
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
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MJY1VG?G^(2QY]*^\/@-^QY\&_P!F#2QI/[/_ ,)?!GA1/*$<MQI.@HES.O\
MTUG.99C[NS&KYN%<O^%3Q$O/W(?_ "7WD<O%F8[N&&CY>_/_ .1^[4_+K_A
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MOM&T;4)G\Y_2XOY_WTN1P0BH1CB0BOT)^"7[._P._9O\*KX*^!?PMT;PQIP
M\V+2[,(\Y P&FD.7F?'\4C,WO6W]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
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M (:?&'PSJ/A?5_%7@.YLM9T"PL9)/)^V-%J0BO;*V0JI5-D[*%"L  %^HO\
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MH **** "BN6^+7QM^$GP(\+OXR^,/Q"TOP]IR [9]1N0C3$#)6-!EY7_ -E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M**^B/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %>%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^
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MT;U=[=%IKU>QYF2\$4<LQL<35J\[CJDE97[O5_<=O1117ZR?=A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R/QE^/GP3_9W\)O
MXY^.GQ5T'PGI*9VWFNZG';K*P&=D88@R/Z(@+'/ K\Z?VIO^#F_X&>%K]_ O
M[%WPCU7XC:U-)Y%GK&JPR6.GM(3A3%#M^TW.3QL*PYR,,:]+ 9/F69RMAJ;D
MN^R7JWH>9F&<Y9E<;XFJHOMNWZ):_@?J(2 ,DX ZDU\H_M;_ /!:;_@G]^R
M;G1O%/Q@B\4^([;*MX7\$!-1N5<=4DD5A! P.,K)(K<\*:^!$_9G_P""^/\
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M)V.M?$?]L!;'Q;=RRS^(/LWA9M2MB[[2JI+)<P2.P;S"TC#Y]ZX5=I+MO?\
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M#TZ'B-XK8C6G]_L*:_%PL?GE_P 0Y7QS_P"C\?\ RW[K_P"2Z/\ B'*^.?\
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MIL=O]F^R?8]NW8[;MWVDYSC&P>M?T 5\G_\ !3__ ()@?\/(?^$'_P"+X?\
M"&?\(9_:?_,M?VC]L^U_9/\ IYA\O9]E_P!K=O[;>?.S;A? O+YK!4?WNEM7
MW5]W;:Y]1P3XP<10XGP[S_'OZI[_ #^Y%_8ER_!#F^/EV^>ES^>^BOU@_P"(
M8'_J^#_S&G_WRH_XA@?^KX/_ #&G_P!\J^+_ -5<_P#^?/\ Y-#_ .2/W[_B
M,_AK_P!!W_E*M_\ *S]8****_8S^#PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP
MOP#_ ,I!/'__ &(FE?\ HQJ]TKPOP#_RD$\?_P#8B:5_Z,:@#W2BBB@ HHHH
M **** "BBB@ HHHH **** "BL;QI\1OA[\-]._M?XA^.]&T&TP3]JUG4XK6/
MCK\TC**\ ^)W_!7?]@_X9F2W7XO-XANH\_Z)X8TV6ZW?24A83_W\KS<=G&4Y
M8KXNO"G_ (I)/[F[LX\3F&!P2O7JQCZM(^F**_.?QO\ \%\DUO4?^$>_9Z_9
MBU35;N<XM)=;O\2,?^O:V60M^$M8?_"Z_P#@N?\ M.#;X'^&$O@;3KC[TB:)
M!I8"'HP?46:;\8^3VXKY>IXA9%4FX8&-3$R[4J<G^+LOS/%EQ9EDY<N&4ZS[
M0@W^+LC],+J[M;&V>\O;F.&&-2TDLKA50#N2> *\=^)W_!0O]BOX0B1/&?[1
MGALSQ9#V>D79U"=6_NF.U$C*?J!7QK:_\$;/VSOCM<IJG[5_[87F!GWFW%[>
M:S(G^SB9HHT/;Y2P';/2O8OAC_P0P_8V\&>7<^.KOQ-XOG7!ECU#5?LMNQ]D
MME1P/8R&H_MGC?,/]SR^-%=)5I_G"'O(G^T>),5_N^$5-=ZDO_;8ZHY[XG_\
M%\OV;_#ADMOA;\+O$_B>=,[9KPQ:=;/Z88F23\XQ7G7_  \L_P""I/[2'[G]
MFK]E4:58S_ZC4X/#UQ=[,],W5R5MOS05]W_#']D;]F'X,^7)\,O@/X7TF>+[
ME]%I$;W/XSN&D/XM7HM'^K_%^/\ ]^S/D7\M&"C]TW[WX!_96?XK_><;RKM3
MBE_Y,]3\R_\ AA;_ (+$_M*CS/CU^TDWANQGYNM.G\3,H(/_ $[::OD,?8L*
M[3X:?\$ O@SI<B7OQ@^.'B+Q!-G=)#H]I%I\3-W#%_.=A[@J3[5^@%%:T?#W
MAM5%4Q49UY_S59RD_NNE^!=/A/)U/GK*567><G+_ "7X'@_PQ_X)E_L-?"<1
MR^'_ -GG1;^XCP?M7B$/J3LP_BQ<LZJ?]U0*]OTC1='\/Z?'I.@:3;6-K$,1
M6UG L4:#T"J !5FBOJ\'EN7Y?#EPM&--?W8J/Y)'NX?"83"1M0IQBO))?D%%
M%%=IT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%<I\8?CK\&?V??";^.?CA\4="\*:2F1]NU[4X[9)& SL3>09']%4%C
MG@54(3J248J[?1$SG"G%RF[)=6=702 ,DU^8'[4W_!S=^S[X.O9/!/[''PJU
M?XD:U+)Y%IJVHQ26&G-(3A3'&5-S<'/&S9%G(PU>*-^S]_P7W_X*V'[3\;_%
MD_PF^'NH??TF_P#,T6U>$]4%A%F[N>#D?:CM.1AQV^CH<,8Q4U5QLXT(=YO5
M^D=V_+0^:K\4X)U'1P,)8B?:"T7K+9+S5S] OVM/^"S7_!/_ /8_^TZ/XS^,
MT'B/Q#;95O"W@H+J-V''5)&5A# P[K+(C>QKX,\5?\%IO^"IO_!0S7[GX=?\
M$TOV7+SP]IAD,,NOP6:ZA=PYX!EO+A4LK/(.<,I8'[LG&:^F?V2?^#<K]A?]
MGX6OB#XQP7WQ5\00X9I?$2^1IB..Z6,;$,/]F9YA["OO/POX4\+^!]!MO"O@
MOPW8:/I=E'Y=GINEV:6]O G]U(XP%4>P K7ZYPYEG^[4G7FOM5-(_*"W7J9?
M4N),TUQ594(/[-/6?SF]G_A/R2^#/_!N/\=_C]XK3XQ?\%-/VM-7U75+DA[G
M1]$U)]0O67.1')?W098@.FR.-U /RN,5^BW[+?\ P3W_ &.?V,[%(?V>_@1H
MNC7RQ;)=?FA-UJ4P(PVZ[F+2X/)*!@G/"@<5[-7R?^W3_P %@?V7/V*H[OPD
MNJCQGXYA!5?">@W2G[-)Z7<^&2V]UPTG(/EX.:\7.>*<75H.6,K<E-?97NQ]
M$EO^+/I^&.!?KN.CA\IPKJUWU^*7JY/2*[NZ7<^I==U[0_"^C7/B+Q-K-IIV
MGV4+37E]?7"PPP1J,L[NY"JH'4D@"OSI_;+_ ."^'AG2-<;X)_L">#9/'WBN
M\G^R6_B$V,LMDLQ.T+:0(/,O9,]#\L><$>:#BO$]%^#/_!4;_@MIK5MXO^,?
MB%_AY\(WG6:QMVMI(+&2/.5>VM-PDOY .1-*P3EMKC[E?HI^QS_P3J_97_84
M\/[OA5X/CEUMH-NI>,=<*3:A<#'S#S" ((S_ ,\XPBG R&/-?$/&9IFZ_P!E
M7L:7\\E[S7]U=/5G[$LDX-X%][.IK&XU;8>F_P!U!_\ 3VIU:ZQCUT::=SX:
M_9\_X(Q?M/?MC>.HOVC_ /@J)\6=95[O;)'X62]5]1ECSN$4C+^ZL(>?]3$I
M8 D?NF%?II\&_@?\(_V>_ UM\-O@K\/M,\-Z):#]W8Z;;A [8 ,DC'+2R' R
M[EF;N35;Q/\ M ?"GPMNCN?%,5W,O_+#3AYQ)],K\H_$BN#U7]K/7-;N3IGP
MV^'\MQ,W^K:Y#2N?^V47_P 4:\6IQ-P1PS)Q>(4ZSWY;U*DGV?+>S\G9'DYU
MF?&W&O*J\/9X>'P4TO9T8+I:+M>W=\S\['M]?.7[4/Q-N=3\<6WAO0[UDBT*
M02&2-O\ EZX.?J@P/8[JB\?WW[1]QX8F\4^.-9FTG3PRJELLRP-*6/"!(_F/
M<_/V!]*\J9F9BS,22<DD]:_+/$CQ$Q.8X%990P]2@IVDW47+*44]+1U:3DKW
MOK;;4[N%>&*6%Q#Q=2K&HXW24=4GUUZM)VM;J?2NF?M7?#@>'K2[UF>Z^WM;
MJ;NUMK1CLDQ\P!;"D9Y'/0UEZI^V5X<BR-$\%WUP?X?M5PD7_H.^O/?V<CX*
MO?'8\/>-=!M;Q+^/99272;A',.0,'C##(Y[A?6OIG2_"WAC1,#1?#EA:;>GV
M:T2/'_?(%?6<)YGQUQGE*Q-''TJ*B^5VI<\TU;62D^6[5GIIKTV7C9SA.'LB
MQKI3PTYMZJ\[1L^UE>RV[Z'C/_#1GQJ\1_+X0^%GRMT<64\^/Q&T?F*/._;#
M\4?<B.GQ-U^6WAQ^>7KW6BOI?]2,TQ7^_9OB)^4'&DG\HIZ'D_ZP8.C_ +O@
M:2_Q)S?XV/"O^&??COXCY\6?%+:C=8SJ$\V/^ X"_D:N:9^QKHB$/KGCB[G)
MY86MJL7ZL7KVFBM*?AEP@I\]>E*M+O4J3D__ $I+\!2XMSOEY:<U!=HQBOTN
M><Z7^RQ\(M/P;G3;R]([W5ZPS_W[VUTFE_"/X8Z-@V'@33 PZ/+:+(P_%\FN
MBHKZ'!\+<-X"WU?!THONH1O]]K_B>77S?-<3_%KS?_;SM]U[$=M:6ME$(+.V
MCB0=$B0*/R%2445[L8QBK)61Y[;;NPHHHIB"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BO*/V@_VZOV-?V4-5TK0?VD_
MVG?!/@J^UJ_@M--L?$/B&"WFD>4D([(S;HXL@YF<+&O\3"O0_!OC?P7\1O#E
MMXP^'OB_2]=TB\3=9ZKHVH1W5M.OJDL3,K#Z&@#4HKD?C=\??@C^S5X NOBI
M^T#\6?#_ (,\.60_TC6?$FJQ6D ;!(0-(PWN<':BY9CP 372:)K.E^(]&M/$
M.B7BW%E?VL=Q9W" XEB=0R,,\X*D'\: +5%>/_'G]O[]B[]F'Q8O@/X]?M)^
M%?#6MG3CJ,VCWNHAKFVL@0#=SQ1AFM[?)QYT@6/@_-P:]/\ "/C#PE\0/"^G
M^-_ ?BC3M;T75;1+K2]7TF]CN;6\@<;DEBEC)21&!!#*2".E &C17C_QY_;^
M_8N_9A\6+X#^/7[2?A7PUK9TXZC-H][J(:YMK($ W<\489K>WR<>=(%CX/S<
M&O3_  CXP\)?$#POI_C?P'XHT[6]%U6T2ZTO5])O8[FUO('&Y)8I8R4D1@00
MRD@CI0!HT444 %>%^ ?^4@GC_P#[$32O_1C5[9J^KZ5H&E7.NZ[J=O96-G \
M]Y>7<RQQ01*"S.[L0%4 $DDX &:^%_AO_P %3_\ @FS>?\%#_&MK;_MV_"DK
M?^%M.T^PNV\<V2VUS=1R-OACG,GE.X/&%8Y/3- 'WA14=I=VE_:Q7]A<QSP3
MQK)#-"X9)$(R&4C@@@Y!%24 %%%5]4U;2M#L)-5UO4[>SM85W2W-U,L<:#U+
M,0!^-)M15V)M)798HKPOXG?\%+/V'/A-YD7B3]HC0[RXCX-KH#OJ3EO[O^BJ
MZJ?]XC'>OG;XF_\ !?SX'Z,TEI\(_@KXC\0S#*I/J]U#I\+'L5V^<Y'L54_2
MOG,?QAPQEEUB,7!-=$^9_=&[_ \C%<09+@_XM>-^R=W]RNS[]HK\S/\ AO;_
M (*^_M)_NOV?_P!F=O#MC/\ \>NI0^&7(P?6ZU!OL[?@HI/^'</_  57_:0_
M??M'_M3?V/8S_P#'QI<_B.>YVYZXM;0+;?DX[5XW^O,L9IEF K5^TN7D@_\
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MNGW16K\GL?.'BO\ X+:?\%/O^"@7B&Z^&O\ P3._97N]"L3)Y,GB!+)=1O(
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M^!EP-$GN<1_V[>V"W5RF<C$$!/EA^A5Y/,'8Q&O!?"__  2PTOX@>,YOB?\
M%#P3J?C'Q#>N&NO$GQ,U-KN63'0>2^$51V58@JC@ # K\YS#Q)P-6;P^249X
MNKWA"3BO5Z7_ "\S]!R3A#+Z;6)X@K^QI?R1MSR^<GRQ7G[TO[O4^??C+_P4
MQ_;U_P""F?B2[^$?[$_A"[\ >!FE,&H^(9;X6\[1GJ;J_P"$MLK\WD0$RD9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M%\K'NE5]3U?2M%MC>ZQJ=O:0KUEN9E11^+$"O"X/&'[5/Q(7;H6DR:9;2?\
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M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
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MJT:<[^LU:7W'Q?USA^M_%P3B^\*DU;_MUWB?+NG_ /!1WXIZ21_PG_[%VLS
M?ZQ_ _C33]1 ]2!?&P9ORS[=JV[#_@J?^S7!@?$'PM\2/")/#/K7PWU*>%#Z
M-/817$*_4OCWKV+5?@'\(=8R;GP/:QD][1GAQ^"$"N:U7]D3X;WF7TW4]4LV
M[*LZR(/P9<_K5+%^(N$_B8;#5X_W)U*<W_X'S1_ EX;ANMK3KUJ;_OQA./\
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MC?3?#VB6*YNM3U6Z6&)?106^\QZ!1EF/ !-?F?\ M,_\%P_C-^T1XU/[.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOT1^8=Q_P1PL/AJS2?!VZ^+7PZ9<E'^'GQ O$V'KE?WDV*K_ /"G_P#@I/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_
M /\ RD$\?_\ 8B:5_P"C&KW2O"_ /_*03Q__ -B)I7_HQJ /=**** "BBB@
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M_P!L?_@O=I,6OGX'?\$^/!,_CKQ5>S?9+;Q(^G2S6HF/&VSME'F7;]<,0J9
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M***[#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBXF;;R=K\;*_1O\ 8X_X)X?LP?L/>'Q9?!OP.DFM2P^7J/BS5ML^I7G3(,N
M(D.!^[C")P"03S7N(  P!@#H!17;@<EPV#J>VFW4JO><M7\NR]/O/G^(^/LV
MSS#+ 8>,<-@X_#1I>['_ +?>CF^[>E];)A1117L'PH4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!'!>!/_"7>@#WJBO!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
M"7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWH ]ZHKP7_
M (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>@#WJBO!?^%??\%#_P#H
MX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>@#WJBO!?^%??\%#_ /HX+P)_X2[T
M?\*^_P""A_\ T<%X$_\ "7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\
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M7@O_  K[_@H?_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N] 'O5%>"_P#"OO\
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MP)_X2[T >]45X+_PK[_@H?\ ]'!>!/\ PEWH_P"%??\ !0__ *."\"?^$N]
M'O5%>"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\ A+O0![U17@O_  K[
M_@H?_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N] 'O5%>"_P#"OO\ @H?_ -'!
M>!/_  EWH_X5]_P4/_Z."\"?^$N] 'O5%>"_\*^_X*'_ /1P7@3_ ,)=Z/\
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MC7W3_@W&_P"".GC'_@D]^S#K]Y\=KC3Y/BC\2=0MKSQ3;:9<">'2;2V1UM+
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M_P!FO]BO1]-NO%_CJ.#2;R34]82R2#2WD#WF'?AC)$AM]I[7#'C% 'Y:7?\
MP79_X.?O&-U+XN^%'_!)22;PMJLC7GAJ67X(>([EWT^4[[=FECNPDI,3(2Z@
M*W4  XK]??\ @F1\2_VSOC-^Q?X1^+/[?7@/2?"GQ+\0I<7FJ>%=)T.YT\:3
M;F9UMX98;F:619C$J2.&(VF3;M&WG^?GQA^T[_P=(?\ !#R_TWQY^TCKGC37
M? MO<1022>-M0A\6:!=)D*D$EY'+++9EONJ/-@D..,CBOZ _^"8/[?\ X"_X
M*:_L7>$OVN/ FA2:.VM1RVVNZ!-/YK:5J4#F.XM]X \Q0P#H^ 6CD1BJDE0
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M;5O$OPZT;6=:N(XQ%$;BXL(9YF"CA%WNQQT K\9O^#XO_DE?[.W_ &,'B/\
M]$:?7ZZ_L(Z+IGB3_@G9\&O#NMVBW%E?_!;P[;7<#$@21/I%NKJ2"",J2./6
M@#\5I_\ @XT_X.$?C)XHU[QA^Q__ ,$VH?&7PZEUV\'A'6])^!WB;5%GTX3N
M+9GN+:Y\N1S$%W,H4$Y( Z#ZI_X(-_\ !7/_ (*N_P#!13]L;XB? []M#X$^
M#O NA?#'PPDWBBPMO!.IZ5J]IJMS,BV=K*EY=N8=T2W4I#1[B(1C&<U^GOC_
M ,9_#?\ 9H^!FM?$'6X+;1?"'@#PI<:A=16<*QPV.G6-LTC+&@PJJD41 48
M  KX6_X-I_A=XIN_V+?%7[=OQ5L#'XU_::^)FL>.]8:0'?%9O<R16EN">L8"
MS31^BW0Q@<  _16BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *_*#_@J#_P5%_X+-OXM\867_!([]A]_$'PZ^&U[=6'BSXJ:
MKI27LFJZA:,R7L&F6;SQO<0V\J2P221QSEI89%79LRWZOURWQ5^)GPT_9T^$
M/B/XP_$/5+70_"WA+1[O5]:O-JI';V\2--*^. 6.&..K,<<DT ?FQ_P;G?\
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M*WU/_A./B/XDT1]5U"_O; I'<V>G6IFBA0I,YB+R^82(I9 H"A7]!_X-<?\
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MGCKQYXBL&OH/#-I);O=^3;VBR1B>[-K&9LR-Y:B6(;7+GR^-^$__  6F^/\
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MR7)BC:XD-]/(Q^15 MD4+PQ;X._X)5_%#PO_ ,$]/^"+_P"W+^PA^V1XDL/
MGQ0T.X\3"#P/K]]%;WVI2ZGX>@TZT-G&Y#7:33VZJDD6]2'1@=K@G^A>L;6_
MAW\/_$OB"Q\6^(_ NC:AJNEG.F:G>Z9%+<6G.?W4C*6CY_ND4 ?FK_P:K_\
M!/OXB_L%_P#!/+5_B3^T)X:F\->*?BEKPU^ZTO54\B?3=(@@$=FMRK8,3D&X
MG*M@JDZ!@K!@/S#_ .#IK]H7X'?$O_@M3\*_%_PY^*^@>(-)\)?#[PY9>(M2
MT/5(KN"QN(M=U*ZDB=X2P#K#/$Y7J XXK^G^B@#Y]_;*^%/PV_X*;_\ !/?X
MF? KX/\ Q5\/ZW8^/O!]YIVB>(]$U:*]L8[XQB6U=I8&9619A"S ')7ZBOQ]
M_P"#>G]H'P9_P3[_ &-OVO/V%/V[-3L_AAXT\'RW_B&;P_XSN([.>^AGTHV<
MHMED(^U8:TAV^7N$@NHBFX.#7] E8GB7X9_#CQIJUEKWC'X?Z)JU]IK;M.O=
M3TJ&>6U.<YC=U)0YY^4CF@#\A_\ @SG_ &!/C/\ LS?LR_$7]J'XT^$;_0&^
M+E]I<?A72M4@:&XDTNP2Y*WIC8!E2>2\<)N ++ ' V.K-^R=%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U_7]#\*:%>^*/
M$^L6NG:;IMI)=:CJ%[.L4-M!&I>261V(5$506+$@  DU;HH _FS_ &W_ /@Y
M^^ _Q2_X*+V/Q0O_ -DJ[^+_ ,*O@_?F3X/Z%>^-O[%LKC6U++)XDNK=K"Y-
MS*!A;1'V"W3=(5\V4^7^D?\ P1&_X+'?%?\ X+;?$3XH>)=>^ =E\/?ASX%\
M.V.E_P#".#7/[6?5]1U&2=GEEN6MH#MB@M-@C1%'^E,6+Y39^E-% 'X.?\$(
M_A=X:_X(>?\ !3+]IO\ 9;_;/\=Z3X$T;4?#-OJWP_\ %7BW48[*S\1:-97E
MP5GMYY2J32>3<H7B0LZM'*N/W;5T_P#P:,_L'?$[PSXJ^+O_  4Q^*G@V^T:
MR^(Y?2?AT-3LV@FU#39;PWEW>!& (A>2.T6-NCF*0C@*3^TOB_X?> OB#;06
M?CWP1I&N0VLPFM8M7TV*Y6&0='42*0K>XYK61$C01QJ%51A5 P * /Y\_P#@
M]?\ CY\%?'VG? GX4^ _BGH&N>(=#U7Q'<:[I.CZO#<SZ8A2PB3[0D;%H2SI
M(%#@$^5)_=-?L+_P2F^-WP@^-7_!/KX-WGPF^)FA^(1IGPI\.6NK1:1JD5Q)
M87":=#&\$Z(Q:&17CD0HX#!HV&,@U]$44 ?G=_P<K_%7QDO[#GA_]B;X0WFW
MQQ^TM\2-'^'^B1H3OCMIKA9;N8@?\LMJ1PR'LMUVZC[J^"OPE\(? 3X.^%/@
M=\/K+[-H7@[PY9:)HT& -EK:P)!$#COM09]ZT];\$^#/$NKZ;K_B/PCI>H7^
MC2M+I%[>V$<LUB[8W-"[*6B)VKDJ03M'I6I0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7\_'_!>7_@X?_9\\3?M7Z=^Q
MEHWPBF^+GP:^'NMBY^)NBZ=XP&D6GC/6[:0-#827*VUR9M.MI5W2QA0+B9%&
MX1Q R_T#T4 ?D7_P2#_X.&_BO_P5[_;>T#]FSX:_LH:?\*/!O@[PIJ/B+Q:T
M/BH:N]_:PQI96UFG^A6RVT8N+R"7Y06)MU4$)O5O'?"G[,D7_!*W_@ZBN?V@
M?C%>6_AOX2_'6'Q#J'A;QUJ]RMKI<>IW]NUW<V$UPY$44PNTE5(V8%EE@(^]
M@?NM6?XG\)^%?&^BR^'/&?AK3]7TZ?'GV&J627$,F#D;DD!4\^HH _#W_@E#
M^R!JO[8?_!Q?\<O^"J7A6R-]\(/!7B[7(/!WC%%W67B#5Y8#IQ^QR?=N8DB:
MYD,R$J"8,'YP1ZQ_P>'_ !U^"\?_  3/3X(?\+6\//XRN?B7I$L?A2+5X7U$
M11PW$CR-;JQD1%5D)=E"_O$&<NN?URTG2-*T#3(-%T+3+>RL[6(1VUI:0K'%
M"@X"JJ@!0/0#%6* /S9_X-4OC7\(/%7_  1N^%/P>\.?$[0;WQ9X9?Q$OB#P
MU;ZK$U_I_F>(+^X0RP!O,16BN8'#$8(E7GFOC[_@E;->?L"_\')/[2>E?\%"
M/$,'A77/B;I^N7/P]\9>+;I;6RUZUGUF"[B2UN9B(SYENJ;4#80VK0\,@2OW
MGK(\9?#[P%\1M-71OB%X(TC7K-'WI::SIL5U$K?W@LJL ??% 'X#_L=?L1^&
M?C/_ ,'5'BC]HW_@G]I5O)\#/AOXDEUCQ)XQ\/*#HD6I3Z-Y=W86<R?NY6DO
MKB93'&<*GFD#8BY_H/JIH7A_0?"VDPZ#X8T2TTZQMEVV]E86RPQ1+Z*B !1]
M!5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /QC_X.6/^"\7PR_9ROXO^"<WPPM+_ ,37VKF+_A=O_"-^)!IES9Z+( S:
M-#>>3/\ 9[FZC($L@C<Q0.5 WS!HO/O^"<W_  <MZY^UE\=?@E_P3,_8R_X)
M\:-\&=$U#Q/IU@+RR\;C5DT_0;)OME]!!;'3H%#R6MO.AF=F8>:\G+X8?N[1
M0!^''_!;/]D37OV6/^"[_P"SM_P5ON]-,/PLUGQIX:L/B7XH:/-OX=O;:X2T
M^TWCCB&![,P[9&X#6T@)!* Y/[2_[-=C_P %</\ @Z"\%?$#X!ZC9^*_A=\%
MM$\-WWQ$\;Z)<I=Z3'<6,TVHQZ>+F,F*6:9Y8(3&C%@#,3CRGQ^ZVI:9INLZ
M?-I.L:?!=VMS$T=Q;7,0DCE0C!5E8$,"."#Q53PIX.\(^!-&C\.>!_"NFZ-I
MT3%HK#2K&.WA0GDD)& H)^E 'QK_ ,'!OQY^"WPQ_P""4?QQ\%>/_BIX?TG6
M_$'P]N+30M$O]7ABO=0FG<11+! S"27+Y^Z#@(QZ*<?$7_!E9\<?A!IO[&_Q
M'^ ^J?$K0[7QC/\ %F74[3PU=:K#'>W5I+I=C&LL4#,))%W6TP)52!LK]N:*
M /#/VVOVV/V.?V4? TD/[3/BC3-1O+U,Z+\.[.R35=;\03CF.&RTQ0TMPY8
M!MH1207=%RP_/;_@E1_P2E_:*_:$_P""D'B3_@MW_P %%/A4/ >IWUT6^#_P
MANE7[3H5JMLMG:37<8 6!H+-%C2$JKF5GE9(BJJWZTZ=X+\':/KUYXITCPGI
MEKJ>HD'4-1MK"-)[H@ #S)% 9\!5'S$\ >E:= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?FW_P<2?\ !;KPU_P2\^!2
M?!WX2:Q'=_&GQY8,-!M+>9=_A_3F9HY-5DRK!7RKI;AE(:52Y5UA=6_22B@#
M^:[]D?\ X.BK#X(_ S1/V$OV!?\ @F=:^$=>U^\&FZ'XK\0?%=M:N+G7;]Q$
M=5OD_LN%KZY>=UD?=(H; 0;4"J/I[_@[^_X)W_%CXK_"3X:?MV_"'PU?>)KG
MX403Z9X^BM;?S+DZ6[QS0W[)&/\ 5PS)-YI4?*+H/@(CD?MG00&!5@"".0:
M/P2_X.#/"OA?_@M_^V9^R7^S5^P7X\TWQU+=:)JFJ^+-9\,W<=[;>&-'OYM.
MVWM])$S+;[8[:=O+<ARRH@!:1%/US_P7W_X+(^ /^"0G[+^D_LT?L_WD3?%C
MQ+H$=AX2TVVF7?X:T=%\@ZG)E6"N%1H[<,I#2J7*NL+HWZ.>$OAYX \ +=+X
M$\#:/H@OIO.O1I&F16WVB3GYW\M1O;D\G)YK8H _FN_9'_X.BK#X(_ S1/V$
MOV!?^"9UKX1U[7[P:;H?BOQ!\5VUJXN==OW$1U6^3^RX6OKEYW61]TBAL!!M
M0*H^GO\ @[^_X)W_ !8^*_PD^&G[=OPA\-7WB:Y^%$$^F>/HK6W\RY.EN\<T
M-^R1C_5PS)-YI4?*+H/@(CD?MG00&!5@"".0: /P2_X.#/"OA?\ X+?_ +9G
M[)?[-7[!?CS3?'4MUHFJ:KXLUGPS=QWMMX8T>_FT[;>WTD3,MOMCMIV\MR'+
M*B %I$4E?NKX2^'G@#P MTO@3P-H^B"^F\Z]&D:9%;?:).?G?RU&]N3R<GFB
M@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -GCQI\$;3PCX9\0:%J?B'X$>*%O)6;Q=I%AJ]SITSNK@*LW[@R;%^Z(I<Y
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MMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P_&OQ
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M<Q/T!"C80[K(CL ?7]%?GO\ &S_@KW^T_P#&;]JKQ=^Q5_P2)_9%TSXK:_\
M#FZ%G\2OB3XTU\Z=X7\.WV64V6Y,27<RLK*RQLK!HY JN%9EY3QE_P %9?\
M@IW_ ,$[O$?A_P 1_P#!7W]B[X?VOPHU_6X-*OOBY\$O$5S=6GAJ>=ML3WMG
M=EYC%GAI 4 P=OF.5C8 _3.BOF[_ (*.?MH>._V%?AAX2_:FTWPOI6O?"S3_
M !;9VOQ@G6*:2_TO0[QA;QZM9M$^UUM[B2%Y8VC<R1.Q4H5W'Z+T[4=/UC3X
M-6TF^ANK6ZA6:VN;>0/'+&P#*ZL.&4@@@C@@T 34444 %%%% !1110 4444
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M6S_9N_X)N>&%%QKGQE^/&G76HVR\M#X=TF.2ZU2ZQZ1*\+>^".M 'Z.T444
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MIU$DI22LI/J[=+]CX'$2HSKRE2CRQ;T5[V7:_4_)[X;_ !^_X)F_%C_@@_\
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MK]IGP_X6\/>+9?'C>/;E;>.XNKBR\[3H;)6$$5E&EPT<<:J/]6FXLI9&N?\
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M"*WQE\9>#/%.HZ1K%GX$M9;35=,OI+>Y@<W5J"R2QD,IP2,@YY-?!7_!5O\
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MZW9SJ5DM;O4;F;49('!Z/$;KRB.QC- 'UA1110 4444 %%%% !1110 4444
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MPH1%4 ]S_:<\5:]X%_9L^(7C?PJ[KJFC>!]6OM-:+[PN(K.62,CWW**^/O\
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M-9I<$BU!PH"B,MA57S-BJ@]$_8X_X)"_%+P-^U78?M\?\%$/VU=8^/\ \7-
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MR;%/%-<^#/"=O:ZO<6YS'/J,F9[V5/\ 9>ZEF8>S"@#VVBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *Y6?X(_":X^,]O^T3)X$L!XXMO#LF@Q^)HXRETVF/,LYM'92/,B\U
M1(%;(5LD8).>JHH **** "BBB@ HHHH Y7QY\$/A-\4/&'A3Q[\0_ =AK&K>
M!M3EU'PE=W\9D_LN\DA:%KB)2=HE\MV57(++N.T@DUU5%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex105image1a.jpg
<TEXT>
begin 644 ex105image1a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"L17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0?NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)I;F)E<F=E
M<BP@2W)Y<W1L90    'J'  '   (#   "'      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !; HD# 2(
M A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1
M @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152
MT? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0
M'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%
M! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D
M-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$
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M>M44 >2_\*F\5_\ 0]S?^ P_QH_X5-XK_P"A[F_\!A_C7K5% 'DO_"IO%?\
MT/<W_@,/\:/^%3>*_P#H>YO_  &'^->M44 >2_\ "IO%?_0]S?\ @,/\:/\
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M-_\ 2R*NOH Y?X=?\B@W_83U'_TNGKJ*Y?X=?\B@W_83U'_TNGKJ* "BBB@
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MWX1%_P"^<_E0!]24444 %%%% !1110 4444 %%%% !1110!R'Q+_ .19LO\
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MC!6@#Y@\-V6E2Z+?SVFL/?7D/@VZ>2+RB!!F,JT>?8UV]Q'C4? :HG_,B7(
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M)HUO0A(C4QKB3'X&N@\*V%A'J7@IM.NFO;>?Q==RF9D*[V6*,;L'UV@U[T?
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M:&;_ )Y-EWR?7/2@#WVBN<\(^+X?$_@&T\3/ ULDT#R2Q,#F,H2&'ORIK@?
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MA::WN?$UG%,J@_<82!NG3@T >3^+I;36/%/C"ZT[;)83^)-&A#*/E9@D@?\
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M^!?Q,T[X=SZU_:H+)?+#LQZH7S_Z%7M/_#-W@[_GD_\ WT:/^&;O!W_/)_\
MOHT >?\ CWXA_#KX@7%K=:E#)%=VPV"92P)3.=O%=1HGQ^\$^'=$M=)TFU:&
MTM8PD:#/ _*MC_AF[P=_SR?_ +Z-'_#-W@[_ )Y/_P!]&@#U31]2BUG0['4[
M;_4WENDZ?[KJ&'\ZN54TG3H='T:STVT&(+.!((QZ*JA1^@JW0 4444 %%%%
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M_OL5\S?V3:?W)/\ O\_^-']DVG]R3_O\_P#C0!],_:[;_GXB_P"^Q1]KMO\
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M]KMO^?B+_OL4T360F,HE@\PC:7W#)'IFOFC^R;3^Y)_W^?\ QH_LFT_N2?\
M?Y_\: /IG[7;?\_$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_ '^?_&C^R;3^Y)_W
M^?\ QH ^F?M=M_S\1?\ ?8H^UVW_ #\1?]]BOF;^R;3^Y)_W^?\ QH_LFT_N
M2?\ ?Y_\: /IG[7;?\_$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_ '^?_&C^R;3^
MY)_W^?\ QH ^F?M=M_S\1?\ ?8IKS64CHSR0,R'*DL"5/M7S1_9-I_<D_P"_
MS_XT?V3:?W)/^_S_ .- 'TS]KMO^?B+_ +[%'VNV_P"?B+_OL5\S?V3:?W)/
M^_S_ .-']DVG]R3_ +_/_C0!],_:[;_GXB_[[%'VNV_Y^(O^^Q7S-_9-I_<D
M_P"_S_XT?V3:?W)/^_S_ .- 'TS]KMO^?B+_ +[%'VNV_P"?B+_OL5\S?V3:
M?W)/^_S_ .-']DVG]R3_ +_/_C0!],_:[;_GXB_[[%'VNV_Y^(O^^Q7S-_9-
MI_<D_P"_S_XT?V3:?W)/^_S_ .- 'TS]KMO^?B+_ +[%'VNV_P"?B+_OL5\S
M?V3:?W)/^_S_ .-']DVG]R3_ +_/_C0!],_:[;_GXB_[[%'VNV_Y^(O^^Q7S
M-_9-I_<D_P"_S_XT?V3:?W)/^_S_ .- 'TS]KMO^?B+_ +[%'VNV_P"?B+_O
ML5\S?V3:?W)/^_S_ .-']DVG]R3_ +_/_C0!],_:[;_GXB_[[%-DN+26-HY)
MH61@0REP017S1_9-I_<D_P"_S_XT?V3:?W)/^_S_ .- 'TM#+96\*Q0201QJ
M,*JL !3_ +7;?\_$7_?8KYF_LFT_N2?]_G_QH_LFT_N2?]_G_P : /IG[7;?
M\_$7_?8H^UVW_/Q%_P!]BOF;^R;3^Y)_W^?_ !H_LFT_N2?]_G_QH ^F?M=M
M_P _$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_?Y_\:/[)M/[DG_?Y_\ &@#Z9^UV
MW_/Q%_WV*/M=M_S\1?\ ?8KYF_LFT_N2?]_G_P :/[)M/[DG_?Y_\: /IG[7
M;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_ !H ^F?M
M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^?_&@#Z9^
MUVW_ #\1?]]BC[7;?\_$7_?8KYF_LFT_N2?]_G_QH_LFT_N2?]_G_P : /IG
M[7;?\_$7_?8H^UVW_/Q%_P!]BOF;^R;3^Y)_W^?_ !H_LFT_N2?]_G_QH ^F
M?M=M_P _$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_?Y_\:/[)M/[DG_?Y_\ &@#Z
M9^UVW_/Q%_WV*/M=M_S\1?\ ?8KYF_LFT_N2?]_G_P :/[)M/[DG_?Y_\: /
MIG[7;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_ !H
M^F?M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^?_&@
M#Z9^UVW_ #\1?]]BC[7;?\_$7_?8KYF_LFT_N2?]_G_QH_LFT_N2?]_G_P :
M /IG[7;?\_$7_?8H^UVW_/Q%_P!]BOF;^R;3^Y)_W^?_ !H_LFT_N2?]_G_Q
MH ^F?M=M_P _$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_?Y_\:/[)M/[DG_?Y_\
M&@#Z9^UVW_/Q%_WV*/M=M_S\1?\ ?8KYF_LFT_N2?]_G_P :/[)M/[DG_?Y_
M\: /IG[7;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_
M !H ^F?M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^
M?_&@#VSXD7$,GANR6.:-F_MK3> X)_X_(J[.OF[1-&L7\2:5OB9ME] ZAI6(
,#"12#U]17TC0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex105image1b.jpg
<TEXT>
begin 644 ex105image1b.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"L17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0?NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)I;F)E<F=E
M<BP@2W)Y<W1L90    'J'  '   (#   "'      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !; HD# 2(
M A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1
M @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152
MT? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0
M'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%
M! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D
M-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$
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M>M44 >2_\*F\5_\ 0]S?^ P_QH_X5-XK_P"A[F_\!A_C7K5% 'DO_"IO%?\
MT/<W_@,/\:/^%3>*_P#H>YO_  &'^->M44 >2_\ "IO%?_0]S?\ @,/\:/\
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M-_\ 2R*NOH Y?X=?\B@W_83U'_TNGKJ*Y?X=?\B@W_83U'_TNGKJ* "BBB@
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MWX1%_P"^<_E0!]24444 %%%% !1110 4444 %%%% !1110!R'Q+_ .19LO\
ML-:;_P"ED5=?7(?$O_D6;+_L-:;_ .ED5=?0!R_PZ_Y%!O\ L)ZC_P"ET]=1
M7+_#K_D4&_[">H_^ET]=10 4444 %%%% !1110 4444 %%%% '-?$;5O[#^&
MOB#45.UX;"7RS_MLI5?U(KYHTOP]XN\#S> _$>NR?\2>VOX5MT&/W*3_ #/G
M'J,U]7:SHUCX@TB?3-5A$]I/@21DXW8(8?J!4&K^&M*UW1DTK4[59K.,H4CS
MC:5^[^5 'SEKFL647A'QO8N^+BU\<_:Y4V_=B,H ;\U-9'BN'1]1\8>,9K_6
MI+6*^N;6XM+81$_;(IE5E8?0$&OH^[^&WA:]DU=[C359M9*F].X_O"&W ^W/
M-.F^''A>?4M,OY=,1KC2XHXK5B3\JI]T$=\>] 'B?B2'RO"OQHCQDI=6"YQU
MP4J;7]3M;74OBOIL[;;J^T*PDMTV_?6.V.\_AN%>Y7/@W0[N#5HKBR5TUAT>
M]&3^]*XV_P JKW_@#PYJ>J2ZC>Z>LES-:?8Y'W$;HL8V_E0!X0?$=AX-UCQK
M%K>5;7/#-E]ARI/FL+41[1_P)OTJ;PE92V&K7EO<H1(OPV!8,.1GG'ZXKW'6
M?A_X;U^2P?5=-2=M/4);DDC:HZ#WZ5>F\,:3/JESJ$EHIN;JS-C*XXW0G^"@
M#RKX:RV(O_APDL^V]_X1JX6.';]Y6=#G/ML;\ZWOV@>?A'=8Y_TRU_\ 1RUV
M=CX0T73KS3[JTLECFTVV-K:L"?W<9ZK5O6M$L/$&FM8:M )[9F5RA.,E3D?J
M* //O&PS^T!\..,_N]1[?],17E_@YQ$O@=WC+HGB#6&9,=0(NE?2%WH>GWNM
M6.JW, >]T\.+:7/W-XPWYBJ%GX(T"P:R:UL%0V,\MQ!R?DDD&'/XB@#YY^%3
MVND_%SP^WA/4'FT_6A=?:K!D/^AJJL0N3[@?E7<?%/\ Y*Y!P?\ D4=2_P#1
M<E>DZ+X \.>']>N=8TK3D@O;G=YD@)/WCDX';FKVH^&=)U74EO[ZU66Y6VDM
M Y/_ "R<$,OXY- 'B7A*)7U[X+(Z95M(OPPQUS :Y/P;X<O[B'XA:=(C,?#>
MB7FE6HQ_?FEDX^N#^=?2MMX2T6SGTF:WLU1]'C>*R.3^Z5QM8?B*LV&@Z;IE
MYJ%U9VRQS:E()+IO^>C 8R: /EWPE!X>2TDO)]2DU<P^%Y&NK41LODJV$://
M^R3FJNAAM,TCQKHFC:FVJZ/-X9:]WF,CRWWIA>?0$U],Z)\/_#7AXWYTK38X
M?[04K<9.=X.>.>@YIFC?#KPQH&GZA9:9IJ10:BACN5))WJ01C)Z#DT >,:9?
MVFK:W]JLF\V(?#!XMVW^)'*,/S4BL/4[26[T/P;;VT9:1_ ]]M4#J?*8U]"Z
M9\/O#>CPB.PT]8U%D]A]XG]P[EV7\68FK5KX0T2SN=.GM[)5DTVV:UM3G.R,
MC!6@#Y@\-V6E2Z+?SVFL/?7D/@VZ>2+RB!!F,JT>?8UV]Q'C4? :HG_,B7(
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M)HUO0A(C4QKB3'X&N@\*V%A'J7@IM.NFO;>?Q==RF9D*[V6*,;L'UV@U[T?
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M:&;_ )Y-EWR?7/2@#WVBN<\(^+X?$_@&T\3/ ULDT#R2Q,#F,H2&'ORIK@?
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MA::WN?$UG%,J@_<82!NG3@T >3^+I;36/%/C"ZT[;)83^)-&A#*/E9@D@?\
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M^!?Q,T[X=SZU_:H+)?+#LQZH7S_Z%7M/_#-W@[_GD_\ WT:/^&;O!W_/)_\
MOHT >?\ CWXA_#KX@7%K=:E#)%=VPV"92P)3.=O%=1HGQ^\$^'=$M=)TFU:&
MTM8PD:#/ _*MC_AF[P=_SR?_ +Z-'_#-W@[_ )Y/_P!]&@#U31]2BUG0['4[
M;_4WENDZ?[KJ&'\ZN54TG3H='T:STVT&(+.!((QZ*JA1^@JW0 4444 %%%%
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M_OL5\S?V3:?W)/\ O\_^-']DVG]R3_O\_P#C0!],_:[;_GXB_P"^Q1]KMO\
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M]KMO^?B+_OL4T360F,HE@\PC:7W#)'IFOFC^R;3^Y)_W^?\ QH_LFT_N2?\
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MIG[7;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_ !H
M^F?M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^?_&@
M#Z9^UVW_ #\1?]]BC[7;?\_$7_?8KYF_LFT_N2?]_G_QH_LFT_N2?]_G_P :
M /IG[7;?\_$7_?8H^UVW_/Q%_P!]BOF;^R;3^Y)_W^?_ !H_LFT_N2?]_G_Q
MH ^F?M=M_P _$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_?Y_\:/[)M/[DG_?Y_\
M&@#Z9^UVW_/Q%_WV*/M=M_S\1?\ ?8KYF_LFT_N2?]_G_P :/[)M/[DG_?Y_
M\: /IG[7;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_
M !H ^F?M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^
M?_&@#VSXD7$,GANR6.:-F_MK3> X)_X_(J[.OF[1-&L7\2:5OB9ME] ZAI6(
,#"12#U]17TC0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex105image1c.jpg
<TEXT>
begin 644 ex105image1c.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"L17AI9@  34T *@    @ ! $[  (
M   3   (2H=I  0    !   (7IR=  $    F   0?NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)I;F)E<F=E
M<BP@2W)Y<W1L90    'J'  '   (#   "'      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !; HD# 2(
M A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1
M @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152
MT? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0
M'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%
M! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D
M-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$
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M>M44 >2_\*F\5_\ 0]S?^ P_QH_X5-XK_P"A[F_\!A_C7K5% 'DO_"IO%?\
MT/<W_@,/\:/^%3>*_P#H>YO_  &'^->M44 >2_\ "IO%?_0]S?\ @,/\:/\
MA4WBO_H>YO\ P&'^->M44 >2_P#"IO%?_0]S?^ P_P :/^%3>*_^A[F_\!A_
MC7K5% 'DO_"IO%?_ $/<W_@,/\:/^%3>*_\ H>YO_ 8?XUZU10!Y+_PJ;Q7_
M -#W-_X##_&C_A4WBO\ Z'N;_P !A_C7K5% 'DO_  J;Q7_T/<W_ (##_&C_
M (5-XK_Z'N;_ ,!A_C7K5% 'DO\ PJ;Q7_T/<W_@,/\ &C_A4WBO_H>YO_ 8
M?XUZU10!Y+_PJ;Q7_P!#W-_X##_&C_A4WBO_ *'N;_P&'^->M44 >2_\*F\5
M_P#0]S?^ P_QH_X5-XK_ .A[F_\  8?XUZU10!Y+_P *F\5_]#W-_P" P_QH
M_P"%3>*_^A[F_P# 8?XUZU10!Y+_ ,*F\5_]#W-_X##_ !H_X5-XK_Z'N;_P
M&'^->M44 >2_\*F\5_\ 0]S?^ P_QH_X5-XK_P"A[F_\!A_C7K5% 'DO_"IO
M%?\ T/<W_@,/\:/^%3>*_P#H>YO_  &'^->M44 >2_\ "IO%?_0]S?\ @,/\
M:/\ A4WBO_H>YO\ P&'^-;WQ+^*^D?#BUA%V/M-_.-T5JIP2O<Y[5>^'7Q#T
MSXB:"U_IW[N:%MEQ 3DQD\CZ\4 <G_PJ;Q7_ -#W-_X##_&C_A4WBO\ Z'N;
M_P !A_C7K5% 'DO_  J;Q7_T/<W_ (##_&C_ (5-XK_Z'N;_ ,!A_C7K5% '
MDO\ PJ;Q7_T/<W_@,/\ &C_A4WBO_H>YO_ 8?XUZU10!Y+_PJ;Q7_P!#W-_X
M##_&C_A4WBO_ *'N;_P&'^->M44 >2_\*F\5_P#0]S?^ P_QH_X5-XK_ .A[
MF_\  8?XUZU10!Y+_P *F\5_]#W-_P" P_QH_P"%3>*_^A[F_P# 8?XUZU10
M!XOJ?@SQ/X1;3=6F\827L2ZI90O 8 N]9+A$(SGT:O:*Y#XE_P#(LV7_ &&M
M-_\ 2R*NOH Y?X=?\B@W_83U'_TNGKJ*Y?X=?\B@W_83U'_TNGKJ* "BBB@
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MWX1%_P"^<_E0!]24444 %%%% !1110 4444 %%%% !1110!R'Q+_ .19LO\
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MC!6@#Y@\-V6E2Z+?SVFL/?7D/@VZ>2+RB!!F,JT>?8UV]Q'C4? :HG_,B7(
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M)HUO0A(C4QKB3'X&N@\*V%A'J7@IM.NFO;>?Q==RF9D*[V6*,;L'UV@U[T?
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M:&;_ )Y-EWR?7/2@#WVBN<\(^+X?$_@&T\3/ ULDT#R2Q,#F,H2&'ORIK@?
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MA::WN?$UG%,J@_<82!NG3@T >3^+I;36/%/C"ZT[;)83^)-&A#*/E9@D@?\
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M^!?Q,T[X=SZU_:H+)?+#LQZH7S_Z%7M/_#-W@[_GD_\ WT:/^&;O!W_/)_\
MOHT >?\ CWXA_#KX@7%K=:E#)%=VPV"92P)3.=O%=1HGQ^\$^'=$M=)TFU:&
MTM8PD:#/ _*MC_AF[P=_SR?_ +Z-'_#-W@[_ )Y/_P!]&@#U31]2BUG0['4[
M;_4WENDZ?[KJ&'\ZN54TG3H='T:STVT&(+.!((QZ*JA1^@JW0 4444 %%%%
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M_OL5\S?V3:?W)/\ O\_^-']DVG]R3_O\_P#C0!],_:[;_GXB_P"^Q1]KMO\
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M]KMO^?B+_OL4T360F,HE@\PC:7W#)'IFOFC^R;3^Y)_W^?\ QH_LFT_N2?\
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MIG[7;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_ !H
M^F?M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^?_&@
M#Z9^UVW_ #\1?]]BC[7;?\_$7_?8KYF_LFT_N2?]_G_QH_LFT_N2?]_G_P :
M /IG[7;?\_$7_?8H^UVW_/Q%_P!]BOF;^R;3^Y)_W^?_ !H_LFT_N2?]_G_Q
MH ^F?M=M_P _$7_?8H^UVW_/Q%_WV*^9O[)M/[DG_?Y_\:/[)M/[DG_?Y_\
M&@#Z9^UVW_/Q%_WV*/M=M_S\1?\ ?8KYF_LFT_N2?]_G_P :/[)M/[DG_?Y_
M\: /IG[7;?\ /Q%_WV*/M=M_S\1?]]BOF;^R;3^Y)_W^?_&C^R;3^Y)_W^?_
M !H ^F?M=M_S\1?]]BC[7;?\_$7_ 'V*^9O[)M/[DG_?Y_\ &C^R;3^Y)_W^
M?_&@#VSXD7$,GANR6.:-F_MK3> X)_X_(J[.OF[1-&L7\2:5OB9ME] ZAI6(
,#"12#U]17TC0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>amgn-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amgn-20201231.xsd" xlink:type="simple"/>
    <context id="ib3e09025131245718b40a342c9cd7808_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9617e3716fd343959fb610e4be443616_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff105cdfcde045cbb7f837fd8890833f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia1073bcf953749a699413c12f9ead93c_I20210203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-02-03</instant>
        </period>
    </context>
    <context id="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab0a9e21adce47979f7e38ab4025e6ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia25a2862d79c42ba91f97b4241baa3f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i62e077713b1f432fb30f0a3751b4bdf4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia802888bb7a6406592ff586c244944e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54b90fa0f4424779a6c9281cad32ba28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe76d84d24b74fe19c507ca3db178e07_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if9879d3c7b9a4deaaa7e74de73561d9c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iae5629c343b34f27808360cb92a2f04a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie781bbd2a4b948e48767b11ee16f2352_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6087f9de751b4b1a9a41839e6521a886_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ide99a054d6604b4c891c408659ba5c67_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i36d7388f79e144b99235c416c99550db_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i86190fe874cb49e198e5942201bb77cf_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i43beae92bfce49bc8cbb9c9c6cf4c99f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia658e307c35b4f75920a20f604851e24_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i606f729d14154f1bbee6cd17cade6bc7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i46b885f0f1534e088ba923195043b35c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idda2fa41bf7b4d32acb584d26141eb44_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i14141fd9eb484f7ba4154b56ad24b478_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i514f593334634486be45550fb53d0771_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie59aa49e96954ff0837acc1794975222_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2336bd3c48ac47339665832c8ac91be4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3cfd04cd281a41f9b3cf4f0a483ab314_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1f039062c98414ea66e3d16a12dea4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ff5e78fe2444f869a1054445d876292_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f92a1519afd4ee790c4f7f9669bc32b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib59b48b26e6d439d9a321fdb3fda477d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i127c87cb43eb488dbd0f2e72bc977df7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i180132b4355d4e00b34bceb464b6e2bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i298fcb4aef42470c9b276ca00abf854c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae63d786325d4ba28cd18ab21ff84b6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4afec46242043c98ea5b32c79a3dadc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42b0fccf031241ce995839be6adc2e18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e0600ada49541efa4f790040e4c766b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i500dae5a099d445bb1e35d1af32c7bce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4f66cb73cc34c1f99ee0486a92779e4_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i27362feb5854496997daf71cceac6d2c_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i5551c96cc50149c1880f899738b3a80d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8504707ad2dd45d19748815828f1e290_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="i77f9d1e3b77e4676870c5f350d1ef04a_I20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="i7e4762422d6345f488ba0c0ce5c4df0e_I20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="i33c2747ebad4402e9ac07aae03462e78_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="ibc8c902e15924dd683695464fe7097de_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">amgn:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="idc3c1c1c0a9b4e5eab8231f9ac287d8b_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="i8a2e62d8eeb048f38ca8736344e50d1d_D20190715-20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-15</startDate>
            <endDate>2019-07-15</endDate>
        </period>
    </context>
    <context id="ic20538b33ec0455ea0039c1984301d31_D20190715-20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-15</startDate>
            <endDate>2019-07-15</endDate>
        </period>
    </context>
    <context id="i36b9b3333490457493d595249f49eea6_I20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="i047674f49e494a17949b2b546351ed81_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ie94c75a285ca4a36b1982968d4172401_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4940f97696f6461f9e3e54bffb7828bf_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i5f9e4779ad6d4c519da3afeb8a9750dd_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:KirinAmgenInc.KAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i926aaf96c0584bbdad52c9ef18251ea8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6c90fddb2bc49aca05ba3690ecb0e12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb99da9fcc0c4198a6a265c212af7ab1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01555b26feb044308b7e206b9dccd0f5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic204c7f26f03488aab5ee3f10cb8e502_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib2bf2bacd2b2492bb28ef69a40f8ec26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i45f527e1b66d49af9406611b9596ff22_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i974741dcb1524051a7646fedb5f2c5ab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8afc5561327f469a8133f9d02a2cb093_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1b2d439e1e6f409bba4a3347af4696d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8ccac04c7f24f92b788839f717d6523_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d2728b90e4d4b7aa0313586de0029cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5483364e0744c68922713f01e91c7a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief15e22862ba4cf39454d38e1cbdcd80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0fa621683b24ffdac5458723dae9a1e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac24acf4d93f495ab9d6b3536f41e0ed_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i10cda4e685d04ba792d0adfb5f0a1437_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7459c244aa8e43f79da3a9ea0637ec62_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i480fcce9b28440b8b0224b6be301e101_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92377c788f944386a84ed9e862d6a789_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d93219c901f4d2993fd42b15214c20b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id01a0ca8cf65419c8aec6edf5d45bba2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieda0fe0d08b14312b1ce2f95d9af1d9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id66f6e020a4a4abd9de549021d7c3700_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85b462b363df4e43ac25594c6bc680ac_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i54b6d4d4a4f740d9bf97809cb4f715de_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8c93f72881be41c283567c566484b6ba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iba5aa16ed3e64d8187270f007bf3bef9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5b09f7a19b84d2bb41e108ff3322951_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i785509d5031b4d25817f65f949f65892_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8b3a114ec374c5c97599ab0369d2720_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i948008cca6de4273bad98a9766aaba9d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f37efa18d214f73a67190daafe053dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i954f15f923f241b18df02db5dbb43dc5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3b55b920060459e9114165eaf8c36bb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6bc6b87796b943d7934bab2b49c79114_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8e053e17a9c8401b9e7ebd23b33490dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id00a07432ae44f0e9d1fe5c284da0bf8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d0738e434f843b586e64e732d02c689_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76e04b7c055e466cad54c342d9bbc9ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6539a6cf160e487581559eeb0031769e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie608b9d0be364ba0ba1110fcb2c0fc98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb8758e51a2d4092bcb71092363b47a0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6e790b9674254ba09f653c813982f56e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i565f06fae6c54af084a236838566deec_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0b2f55bcc30a4cfca648fe698fc70f10_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae4de803606b49cf808e39411da4f3fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a8b822803f747429f4e453f30a1f8c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6ae041643bb42a9bd46624d883f023f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id8ac4fa9d33b4a7b953dcfb37f07cb31_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82550ed044ae48fcad2e75453e121d7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7283e03d6b247e5b00618781810a864_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifba12b5c33af41909da76cfd32eb41b6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic5881997bfdf454b806bb4e23f90b0f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if858ed80d6524471b48fe73e181c069b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i837af2fa08e640ef82a438132d76de4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1aade48bbe8e4569b0b5690c45eaa909_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c55591acd534a2bbf75ee8ff1c0fc2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b00f3f0c5064b28bcf5ecd0be53d820_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide8fccaf64c14f8eb120b3b7d5ba9bd0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c300e2b07004083841461728c0799c5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ieb9064c0fd8a47349673fd7361fe5c17_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8e4ed7c0dd1f403dbb6a02eae47b79e1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2a8c8a3331fe4b2cbcbfac819fa802e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc4a40aa83a243ddb4bd0747024f97c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f35c7cec9fe40ec8747a982642437ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4954236e263c4019bc3eeeca23e8ba96_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia70f8bc85eb544149a219b33c04fdc84_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic64ae6d964234f3e967e327673f9b5fb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24ee66a0043a4f228b82c153cef85490_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8cf63a10013548d8817d20a261bd0901_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3484149e2df04c2685210fde93380a2c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i14ed027ed29142ed9606f57e5869839d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d2835d9ca084e8fb4795aa78b07d43a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1186b599c8874028bb81519ce6bb2c59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9d438d374ae4f78b599ce6bf7a19bab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if72bee99f05d48eea6c4eb1bf4db9e82_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4092f5882c8142d39834b7722d6d303f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f466fc09cd44386b87d1c42d0cee056_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5caf3504dcd64ab2ac04090326aa57b2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id8b6988cfabf40cd958ae6cf44c7f9d3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic1b14be4183743e4b46f705ac6239e47_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedcb63d22b9249af85cc7ca7293e287d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i630a0351e5c24898bfb45b915cc63356_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b9811f73a8446e4b074fdb187aa7238_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i73b360a237fa4db9b2adfe8a31418cb1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i116be71a0f84428099ebff205742ed3c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i965bb3051c3c43e5a0bfa194108e71ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b9bc46f725a420caa5d9c001fe229ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67042c7baef94c1e889169924cf1d15d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i672733c420164f04985cc409f649c152_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i39bda5bc42554606892f0ef083ebb8ef_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6e4fc03ab19f4f3399d8c1f71e1a4ea5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3d5a2a803f5d48dcb8f85fdb926cdeee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34ebf38a5dda46d0af6058ec22408dd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf240dc750624161beefc465d5d2520f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02193c66855b4a3d9d3f81f4d4d0aa3e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb6193cdb49341959aaf15728de81f9e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9dcdd28acc6e4387a9bb47e6478a91ee_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14301973b9e04d95bee6bcdcae7c842d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i40c07a4b5b5b4cdd80a13653f61ff54b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic744474389a6477387cf4ff42d717bae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bd7acc9830e47eea1f588c56bdee6ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i271dc91e748b4ddea09ef131d4fd6b38_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i77d15f91e0634082b728d72dc4737601_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ad54f16489e40c38fdd8b424bd6f702_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b4eb4dc90c94e328e1dbe4584b6099a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i866165e293d6482ca7b4135f27841405_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97ce8a336da14fa284511392f12999d3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie818cfed00624ad480f081b1918b959a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ce4ceb699bb403ca25d48176261113a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i143d4186981e48d49d7be92adfcc173f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide4cd73575da4db0ba421cc3362a29bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id433645fbf594175aab48fd4faf64790_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5f742d812e548f1805b409e3b3b3abb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c9f45734b1443d9bf7b7850cb8ebccf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia2f8bbadab1f4527a14acd4c6c81cac8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5dfd09c3d064b5981a2ddae65d2710a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id8b0a52267d94c948c70743bd7a58fb1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9549cf1daa744587b04c3442d532545e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f91811a9c8c47ab955099101550454c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:ExpirationInTaxYearsBetween2023And2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b9c7cf9064143caa206e3b78960b8ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i316f6795382a4358b0d4048594444996_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2021And2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9455afa2b91e45d18c2d587bfa989d67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2021And2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9e22a47202d49c79c39aaafff5c59a5_I20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="id4c3de7ba47e48ddbb6721ed2b6093e0_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="if08caf3a57bd45d9a187961c49e97c9a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9eb1e8041bf4e8b93d86d4c965d1bcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7cb08466e4c94fc284de233b8b27d515_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64588391e1684a749dec8deb14c630d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i018453dd7c3743639ceacf5473e7c62d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6aa7777cdbf4d8ba13b5dcf14c0d732_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0041c53471f04a019348539dd1051757_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43d26623d3f34500a3be4c9287eaf130_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i147ff41e3aad46019e4652e564939eeb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5c99bb199b504bc5813a6070a2c0f7a2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5aae7473918a4b2fbd03dbe169ce9681_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26fb37cd13a747f1b39eabafba709ded_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:NonUsExcludingJapanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e670e37529947c6a6e43ad60cc1072e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ac446a3f5b049498d97d5cdc40e8884_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib720207eae304b4db4149e5ba761b733_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc295629ce08431a87b6af7ac665aa1c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6accd8c04bc64375b6db9a710bfd1a7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd4923b31ebb413985529cfbbf320c70_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NexavarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">amgn:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4abab397f36846d2963dacabb469a08b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia314c059b63d4452a382baae50386fbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1043550a1f84782876ef562e9149716_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2783b98e50e847a19205180e25cee168_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6cfcba5921d484abc0c737229312fef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25670902a03f4a9dbaa51f18d7ece454_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11aafa3aec9e4f27a262448b9328cb31_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe13998c78a94509a6a1caa4150f8b85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i211dbe0e1d8346459bff435cfdf00a61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if43ed126e7434f0eb4b8c08281ec7bae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i747e8d251292449b9dcf1d1f95265375_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7050eead3da44efb7f96c0d139c398b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i504ebb212b0e4de29bade641d2b4fb63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife9255d5d6fe481fad09edd63beb52e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78fbd934d2344ce09137ff8acd872830_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3acbfa95e2d42d59a15e70c74debd7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8005c102cf76487dae26362888d802fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f6cc35d1d07485d8a62dae2b89a8859_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bcbc99707a942a3b9412cca58536799_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if984bbfefa824630ad0be7898a756667_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic2cdef4357c64e9cb34661796f119661_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96d4a84d1d744c3196a3054655ba8dc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4746bb368e19427abd5d968255881278_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf2f91f1812e4b6985813bd5ad956751_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8de40ffd50114a4b85de7a66f9fe7476_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6f8655d04b041f4ad4b564443d75726_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i895c1063378b4068a891fd1e71fb3589_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d8a60c530804890ab62b6e0d832989f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e3dc8e131e74b639d5fa9747c30f69f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:FixedEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i396cde7c35a94e749b408f43a2826d8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4defc84603e845d1abe667bb41b2c371_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if71cd1836df64fa297d00f961c9878db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd99c6d5f7e14c2b9fb17834726169ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i380c4519a6324acb9471d6b0846ff47a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7412d430651b4c3aa09e75a732689d3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib25925681a284e8a8cc4bc5abf1a3047_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf95f14d878c44b7bd718c95c6943ab4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9275605c200a4299bbfa5428560e8a03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8ea8f1bac6a4be3807a3e1482036184_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iddb8f56cf7cb441696514975a5535ece_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38d4fa50eb91422a8dde19c58f864d75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd2f82635b7e4140849137d3c5812d24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i795833ab718e4229838a54da0009fbc2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05bcdb11924b427696274755e057121c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i058ba3d94d2c43168ff6130531a4ace6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8242170454444bd1ad4819726216ab26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie96ddc98bc504632bed269fd22978fdc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib87ff255d0fe407c8d140590358ce557_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:AbandonedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief37ee91742248e0885bab6c4ed8ddde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc37b0f57f9e459ab9249c3fd0808c48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i115359deafc44691979f165eb053cdfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18c11ed6245e4fa0a369c9f3aec56f9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib58dc479cd3d42319169a103d07a7574_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba619c4c18fc45ddb3aa9c5914a043e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic72dd6be73064790892c440bdd065b6e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81f0c45930bf446597ffdba0232d3d0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie507cdb44629455bb7c6aa2c3247d935_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a25ca8db8794930a6444001d3c53561_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7223a974c3e04bcba5c39ed1c654173e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic46c172c9e0a45198c8c6c17804b44f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i766f4994093f4740852f0817f605b8ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65782159d9f447c1a8360410b35c8b0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c3bbee60b53406ba6799bf10576c70a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d9ad1274914495687f1554666e681b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i321d29cee0af4ec499ff94a4d005e9d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i857fefc9adb94c98b9b9329678b7db36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d3ad6c912a4480fa33aa0d7eaac3019_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf1366b31913416482ed05d65527ce09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5601f95c84ff45209305a7ba1d0ed21f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2022e1a82ecc471c9bb13d27e09c51fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib86fea773d394279b54bf0ad27439680_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e302b2d804443b3b3a819a6e695f03a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ce43115364e4f88a797d0e9e1224e77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6eb195b8085e465b9c73e9a2403f0ca3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d2a2479b69b4482a8047db796a1bb33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d4292b26906463fba3b1c0f23beb71b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifcd6d09277ed4900bbac50776efa7a38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35327bb737e64d47a0eec71b3f1a920e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i955823ca905943e2bd3d94ca46061a7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35651b0d044d46cc9af068d473bf549b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie89c330f27314741941344d0b54c18ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf087f04fa3b433688c1f56ee1145222_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6894d534af44c5c9113bb8bb4838cfd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab8ddb0cf45940228df2b710f4b10a4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2a0aa4ebe0f4b39820910ec59611fc8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4cf58147d464ca393871d4bdabefa52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d9d8f452a50403f85e95d6a431bb569_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6de40b43c344b3680010e784e3163c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94fd52a87555424a9429b2446e6b20cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54a6377397b24b53a373e7137cbd06b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a255f173843436c994520d12b5046cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25a4a0e3fad546309834f83971cde048_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c9f0f7677c04b97bdc7ecf0cfe1bf34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8c556faa66a4640add9a389585dcb8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26bb56750156451db1cace7c4f21e6bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33bc0e6a798a4daa94404d7e959a5646_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e6f035a7cd84be5bea195a303cdeeb3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4bc950c75ba04c2f88fd9c7425c305e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86e8c0425a564da7849ac5fe7b5db51c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47bb60d0f1944a82bf76a4a9c8335c42_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic37ba0818a4249c3a031f0454e3aed09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e029c89be1a4c2aab1ec7352a2738da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1dcacc53791a4df7b253b539b0644b8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id84255d0cb47445195c3652626198334_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76cd436bd1f242d4bd92a582319d9cd9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98459dd3f7df4a9da1f0e4d9bfaf76c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie22a6012e30946cbaa82df3fa40dddb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96c28235c53c439eb0926746169e1187_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7539fdd6385f4c38b6c106d6250118b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88c4338c09d6451da39a441444432847_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ffc8374c7ee4daba236297c1ca19559_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia60bd30780674b5e8423eae04786b160_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ab35f913d01401c9cec4c3e1e26676e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85d6a61884124f82bfbd04c56c2051d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b51bd6ee36d4eaaa9fad68470af51f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id13b5ae91c924275a407d360294f8076_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d5ec697f57d429aa10a96bcc66005bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3741539a3da4406cb0892abdf6eb315d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i425c9514aedb4868a2ebec2a29ba5de7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1649580135964fee8432cd12950a049f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13ff7bfe32094c3b987aaaceb3014b9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39a772dcf3d84f278093296bdf9e1ce1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec571ed5581a4732ae9ee4817e228b10_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ec6c7c7b81b48d8a20694d3b57b6b70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d34c35332374923becedb1eee1b52cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60960cf4128a4427b534a20b852e2475_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e99d32a99b3493ba14074d4564ee157_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e69a6358c564547a5eca8d5fbe70622_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92b9a5668fbc41e6b4d63640b91febe6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie045a042bc9343f1a35b00097a53456a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9776aef7fdb48c8a1734dec44ec2dd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea83a41a94354282ac825a30792e7bd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if621495ed0e44e7f8c27f9d541876077_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8cfac5674c6443a598611b253a645a0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9165ad7e95445d9b3372c1c0f63c245_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3396b8f489aa45d9a88f6c5fbf1dcd70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec5d1ff18dbb4fe5bc76abb5d4d5b3c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafa733d1395a445ba18de686112112bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia054a1ac7a0c4c5a84daf3e02d258cd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2173cb44ec942b0b5e652729f5aedad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85b731805304467297b2b3b116999268_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6382073fcb1d4883b6219e6dc102e745_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ace2901bf0040e2a96399efee4d66aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9cea61b7422240dcbf72d21fa3477501_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ec3c2bdd29840c1b5cdb46000fb3552_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4925dc03736d47f9ae8d2a690a4103f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9936d965b2ba462d8b3888f904a7ae96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f84b1e89726471186203024e416a4a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7759f579c524eab8b6b4da9a496f1e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i368a178ea7354ca9b710ce74b30bcfce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie14c8cade2044c48a2677b8b57df8403_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibdb33bcf941a4a40b8e393ef62e8026d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ea19f674a134cfaa06e00ebe4983f41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d73c382070d4582bf5468d1be4dc656_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i517838d7aad1452d98142cd5be6f49a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib45e9dc787514755b7bc52c6e863a740_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3699b330b1b42a9bfd233ae168532eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01a00aa8b5524778b4c286af30fb3fd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49e8ff43661f4d5f912595d1b30d72ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb46aca57e78435db45dee35d03b5ff1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bcd5a1c6a104b778997f6496ca15582_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibef7ddaa81cf4000b87b570d84cd9ed9_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ib53845265cb94d07851b1fe0a47a9756_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i7cc614e1370249759a9ccfd03593d582_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ifa2bdf148e7042b9a29c5b3af1301bb6_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="icc9023f496d24d308cf4d1c092fc6f42_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i53985fa4c39e414b9da42cd3aab030a4_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i7e01b4d5cfb74268ae6c81e2e50ade30_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ia51aff5886bd45d0924ffffa26acaf1e_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i3994865e1ce04255bf33546e570e6feb_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i515b38364a38405fb4bcf56004a5d984_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ie8430beaafbd43bfacdaa980eb0137df_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="if188b1207e144488bc49e6f9af13f349_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2bc092c6728d4fd490eda91a340a32ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ea4835b2dc040188992a34180538c3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ced667ce35e445b84fea4f94ea73857_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4179a6ea77a3452ea924a970e6862138_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i725941cbca38484e85e015486a9604dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i963c8d3dfffb425ab800f22538a80972_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icfdeec3400fe43809c845700b9250d21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d664e75d7a74f7491af9306d427a5c5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i96e075bdda244694a4469e256df31166_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35730380319944e3910f345b948c0df9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i358bdc0bde924dd6a9e6f8e2d53a4fda_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idd6c0363be7c499eb126c69c7c63a409_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointOneFivePercentNotesDue2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie8daf767f6e14e758523360043a12636_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointOneFivePercentNotesDue2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic6268acd3d2a46dba0b2e730840ecee5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointThreeSevenFivePercentEuroNotesDue2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6ce07b37db1a4118b69a6f7fd3709440_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointThreeSevenFivePercentEuroNotesDue2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8fd749026d9457e843e73baf3eedd7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a91bd5c90e8492fa703ad1a89545d34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5c9cfe81f3e4917a0b8ebe47bd9a715_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb8f6352b8834211af6d0c68477f85f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if90978c11283437c9156f060d82208ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a7501d33a3a455691d18c20b0223337_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2eb21bbc622f4765b1b17b9e42cffcc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia90e46dcb35e465890654a17ea25721b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ce2131b83c543178a1ff35a8a9f7b29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbb51cf3560f44fd82a1ed3524aba9e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b4f018bc432431ba9e3ebae45b475b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7249a2eb8741476eac1bbed378060085_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e6a942464df49888f5da90fa7d3079f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8f92b19c4e34a72af65be5f26e24641_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib22110db36464336ba83d0caaaae87ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief290ad7941b442fab79e88967534cd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2335a1cb123c499e80a1aa39baa5fda5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7351dc6225e40e5b3d4da990aaafd0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic54306a521a5410e83f206562df048e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec5e5f1709434645a4f86bee8db7c5c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69d46bf88a054fb0abd4b6f021382f5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icda7d092fb704dcca96b59957bd2a0dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97abdf954cf14e22986f9fb69d4e08cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i959c8054e99b4ba4a601a0f7b2e68fb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if22d72d2f9754767b787702ea64e3553_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief48420564f04693bfa31f3606365235_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37f44fcba83d42e1a232fd794b15ec7d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86bd689abf77408fa7438dcaea1c9165_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i968c11eef2e44b85b73c09287db49afd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ee91c42bda54e20b6e7adf10ee4a30c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25258a7ecd234572bf5dbcbe63e9334c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9adb74cd7d004de18ef5c0ff3957a722_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd511439740c4be9a99104d33dcbf8bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i362b746ef24043558b07c52bd684d25b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6c809f8f67643efa3a6bb558412f991_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ddee0d2991140ffa22fd07e6d2467be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39652c0a62c5481095ff480fce17ca6c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibdd497f181c14d5ab36c9202a891b09d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70ba1158d5c74f23be9c43c581ee22e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i913aa3eb20c44b64967ed53a9ab6af9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09a160e4cefe420d887e332af50138c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib951b96e66134344b87919e6a15e9627_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1f832aa086b4bd39c60c6c87db97472_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3d59abe384541c89aa4311f241834bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i473af25953c84328a062db4c39eed37c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i65105b8f350547a9afe51cf16587594c_D20210308-20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-08</startDate>
            <endDate>2021-03-08</endDate>
        </period>
    </context>
    <context id="i60869bc47af9405383d397dfe67b7ce8_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i15cba6363e694ebfbb2115df9607f890_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iec98fde84dd7443daf65e4d48bd33cae_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if3e51d8ec78e482f981fd6bf9a9ca60c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i508432a61553416fbdccf7e432d4e8bd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id8870a99dcef48e5aa17b95e8de89a23_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i72a72f83ff6643498ddd2ad2b28672d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab14641cde404512b613907261773c1b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6c2cdd35e2524c0c8b0dca79a961b38d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88f71e0b4ef646179cff4ca0c5bb2784_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iff02eb33259b4098afad9b87c2f8f6f1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iab46e3e374ed4320a79dc7f501ca2a0f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id4ef7d0edff34c2eb74bbbcb8615f89d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iebe63279db194377849f0b40c57d4391_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i84262de6ad99499488051396e0055031_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieae7fdb0b6a64177be82f0c59a390de8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie382593a89bb40f88cbb7baae6848d85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i834e68b1d71c4cf88092899abf36f0bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id36dd4baf66a496999b27ea628bd7365_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59e1359200bb485e82a279c005e655f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a567dae4771464c8ac036044fce4ba5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38568b10d86a4316bf7376de6e8728d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i445ee927bb9f4ec6a1e136928e6720e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie06b327237f54c16b3d3e03f5d5e7398_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i946ba1f102a249339cc475cc38dbff62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe6d63071dc4400d8c5203ab02d542d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fe17c4200c54926b08b32de808d1607_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32e10debea2943bfa038e3e584b92196_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id48a4f1daf6e423eb316bae15e9e3e54_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i59f81c16e1ff44269b3e2017ea6eef9b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d4dd2242a604708a35885bb2742cbd6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9682afd0b98a49479f04e9a056ac6cf9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad9644e2219642dfb8b959deb45d2db9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb9f08921cf64e6b95d1f81c11c62ab9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i625fa9d4a306409181259806d10464fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6101c783a3084635bdf9cd570e9f1282_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac001eaacc55452bae4119e1a7b27c9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a3f5fa8487f48658b63af871c8fe2c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8b4a2b455184822b0f1116160cc18e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3b7da5c12534b3981691aba7cb821cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia986bf30e56b467ca51da380a21cfe6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5983e886096845e08a0cc96ad73632ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6edf08d2463042549609c2d138554631_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b1be9e0be7e44b886c4bba9044e55c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3220d9002c542069391fbf17f94d1ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91de10fa99174e29b365d56c9f6d3d48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33a9c55953194cd3a01eabe3994fd206_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89ce59970e704a549cf6e24fdbc6115d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i809345b5da314af5a55dfa6cc31e9467_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dbf334d697f42bcb8a2ab7042237c55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d7054c920374f98b6f1c0fb02b93de9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie386d2bd778d480f836e2fa1df624708_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66ddbd84bf09413aa009b1a257b36e6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f1609b78f64499fb1992720d032da1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib182df74839648c99a69305123764d98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4888dd7b32ab43db957c063fe6af1b4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cf4219cf3644d3396775ef8d389195a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c5e3f8152754918ab5eda6f40636b7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if30b3769d1f54f7aa9a0ad91a5b2b2a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab820ea663b142d683c134deffedff4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00f8425a23694b76902e702c9427cd89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i064fcfcd92604a3c88418ad109a62465_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9db18cb51ff42eaa1fdf223be2cef55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fb077631c2943a386f31198be2b482a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib52081e4ae094d09bfb8afeef0d34a19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic86eb7a229bd452995503e7a79b231f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i649ca6b917ff4847aefd1d96a215f411_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id401fea1268645f08278ada72856ed9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i272140d66a7c4798aed64a4683f7f5c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b21ba0b68054fb980abeb4ece605ae6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5e5faa80b5b4b10adeecf22f66b3581_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80d5adbe89e6449698d66ec80b68a414_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe8c6115d404415db720dd2a742d8eb4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ef1d913febf4a47abb4d2d49554d87e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24d55a7ee2cd4a33a48689caa2dcf916_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i286a3763387b42bc9a3cb41202817a79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadfd2fc877304237a30a42e164d32f71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie900b0b41bfb46fb953391112402fcb4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59e5d44ae1e344489c69734a0bc2cc50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib246c8ea900c4139925b4277352eb5e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51d01e59834f4139b4e0c85a155b259b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a87e19790014e689ae6a75f01a9d82e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesIndustrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0dd56a68a7ae47358902b75f24b8098e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i91c5c8997cac420db031456c5bd0c5a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id815d1f62e17488f819d1554819ccb75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:CorporateDebtSecuritiesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i515615df7d0649f19fcd37f592c7ece9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic879f5b36d054ed9a76eb771bfb892b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae474e4eb1174434902da312c3116aea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe3539b33168456ba7b264fa95739a21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b75e88402c841058a01fea422a2d5e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a943209d2bc469ca0bc93bd11d07f9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32090b1bcda448d0b03e44dc48a112e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4671a4128224590847baa4d91f4f23c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id243dd82ed464c5782fba60066763a4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6cb15475cbd6497f8125ba218618f3bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc2e56aa52234a9295f48ee3eb721a25_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifeeedafe9493400eaaf0bafdb1cc9eec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecf5136a442245e5983ef4b4dd9fe1a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79f07dda96ee49b7b10ec42bfd9ee318_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a356ae88a6f494eb208b656cfb3d39b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i05d3d663147d4671afc5b78a2cd03fd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03ffb83e4ee44f928713cdb0b9355245_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ae4c13d4f1a4e789c5111bdd1953619_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cc54bfdcf154b1c99478e3369c649f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80341c6920be4b8f83233fdbad6decc2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f39dc9f49db4cdb801668e25f02b78a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f0734c1cfd345e9b84e6222bec110fb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07aff99eff5e43eab44bd82f5c93ad1c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia87ed81df5cd4df18bf1c76cedc6ff15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3094f6fc9cc8496c8f65948eaea987c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide1f0bd164be4ab48c682b4349325400_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id78e562fe4a247969552202afc671b7d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0694e7fc221e482c91e8838576738184_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ba2d75207254328aa10efe32c1d7d92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idec4c95044a6412abcc5d68913628085_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id39bb9a5237948c1b1665fb28924169c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e7cab6ff6f34e259c4a6ca09c02afd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60cd5ec752de4c98b0157f82d6b72e5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7343472b32c748d99b7140235bb94b4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23f07f28ce2a46cbbc068409addaea19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89094b01572546878b2ff1d75b3818ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if028ba21936c4586893e5c30ab36bbac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05187f24dca245f89aba477135b8f57a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7db5b4699b5c43b1bcd765fc6632aa11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7d28914099a4db4a141ed2fbb2afc50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd8a2e81c4d541849a664d3e8219f829_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ca9160fcbd645a58623671457697045_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8781f9dbe8224717b48a58ba39d8e44a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84f84184b50a44f7b23e2915f0e16c7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie75450fb332b47589035297dd2cbfef4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7ab3fe75d88d4a25a823aa9d5bb0fa1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c26149bf9bc4af9b601bdee1ab9cef3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9313578881564713bd51c45434307224_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i99ae6fbb6ad64fb9b9ae8eee82d8664d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i471e2bff63624e0e81a47854f415cf1e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd7fa60265134785b2cab0462930cf52_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForwardInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5991882c8d74449db1e6b1214ea17429_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96f7642813ee4758a8d46ddcc6037f64_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic79e5b12752f45cf9a8cdcc982b21b92_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2961200acffa4d0c935574bdd8f22f7d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a30d28949ff465693152dab8f329ef6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic198d94557414ab3b4fc50e9ddb159f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:InterestRateSwapAtThenCurrentInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d904f96dd854c81b5c1105b3760f9e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fe46af694c14b4098014e42d59a4512_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i643b333982544519816452a792886641_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dbf0c2d81894f1f9732052b9877a70b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd4fc6eaae654eff9e476549ca95692a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if807e88d6a89408d9d6c6adb4b5eea3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c35c83ea16240faabb17b7cad3444a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9ec37ac4b3fa42bc95ed748f124e3eec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9833b553be6144e3aaf934620c21e9ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8ef5371ae064ef6b77eead6de300e3f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5b72e30920c84ae2a3d1e0e9a36c0610_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaa717f16dfa641f381206fe8143aa927_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iea320fbc2a944611a7e2a4627a50e4a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForeignCurrencyAndCrossCurrencySwapsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88cfe8096cf349ad9c97224ff1238178_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i182cce935cf94552ba35327c4614152f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4e8455f1edd4114b88fb3f5d1776535_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7516b524eadf4fe7bb058ffbd7cea637_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f64a6e311384121b9c8e278f3e7e78e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e546c55c6f64762bd48841a65da24d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i148fcee1a48b44a09d68649c316ae387_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34ee7f80e77b4cf38ef1e80f188af7ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b25825f647249218c055b6f57195f14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f76be3dfb864f1bba5b05a191f9d797_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a25b66b469d4c179aa132a6977ec4a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f104f0b1c7a4beb8c5cab4258107bee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5405ba26a454429daeaeb5a6346566fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcadd8bcd0564f47a4fcfdd5ac5f886a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e1df008b78a4d38ace56a2668c9f0bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7dde35b44684174afdf5dbfa0f9fd26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f16286ba82544188ba31ea248441fb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic27613a286f447649231bc7761e21a43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9926a2533e5347f6998a569828670148_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i824e358512984891ac64732ce456bf70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7232598b5dd4cbf8628dca2b745de71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadbc19c30e2d4747861f30ae61174fb5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife3a8d84d7a143f08a25619be5bb364b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0bfce81b8b324711af659a7858516c9b_D20161001-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:KYPROLIScarfilzomibPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i809cbf0f95194f08903685ccb680427e_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i3adccb2cee77458681e77740f4995ece_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:AmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ImmunexAndSandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-28</endDate>
        </period>
    </context>
    <context id="ifc0906f0e464443487073d2cfd195558_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ImmunexAndSamsungBioepisCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ia0e8f31ce26e4873a861d070ec4bab78_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="i0c1117b8cfa8440a9fe7743afd265be3_D20160201-20160228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-28</endDate>
        </period>
    </context>
    <context id="i9fad48569ed547d6bda68c928f79c3aa_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4ae1970a90b64a67af70b4ac4a36cab8_I20190520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2019-05-20</instant>
        </period>
    </context>
    <context id="i80dd2b5d6a6741578cd8c92ca187c67d_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ia4745ee7d51c48f38ab56aea1953d9eb_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i4c336ecb8a8a4d67a7a3bd87243f7b8d_D20190301-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="if453a7e1fbf04c769fde5a4f2ed3c28b_I20190604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-04</instant>
        </period>
    </context>
    <context id="i61225a3c72514f859602e544d725ab0e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2bf1db2cec2744fe9cf8a8abb012ff11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d59301d26594c2ba4ab4f364829aa82_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b74954f05984826a98fa8d1de70b8ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i43febb6cb9d3444caa73da4c92560180_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09079b5a58e246b5947144cbde795c44_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4254e372a9cd437fa13067b22cd6fc34_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8404b3b31ac149eca5db19a64dd46da4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>amgn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="market">
        <measure>amgn:market</measure>
    </unit>
    <unit id="customer">
        <measure>amgn:customer</measure>
    </unit>
    <unit id="country">
        <measure>amgn:country</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="renewal_option">
        <measure>amgn:renewal_option</measure>
    </unit>
    <unit id="patent">
        <measure>amgn:patent</measure>
    </unit>
    <unit id="lawsuit">
        <measure>amgn:lawsuit</measure>
    </unit>
    <unit id="affiliate">
        <measure>amgn:affiliate</measure>
    </unit>
    <unit id="claim">
        <measure>amgn:claim</measure>
    </unit>
    <unit id="agreement">
        <measure>amgn:agreement</measure>
    </unit>
    <unit id="plaintiffs">
        <measure>amgn:plaintiffs</measure>
    </unit>
    <unit id="complaints">
        <measure>amgn:complaints</measure>
    </unit>
    <unit id="installment">
        <measure>amgn:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8wLTEtMS0xLTA_0e5c16e2-32da-4a9d-9502-081dcba8e5ba">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8xLTEtMS0xLTA_2fdb560c-c334-478e-ab0c-833c1c6dbe77">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8yLTEtMS0xLTA_bf379578-320d-4432-b266-003f4dbe28f9">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl80L2ZyYWc6MTg3MWUxOTMzMzFkNGVkOTg0NDdlM2VmYTk5YTI3OWYvdGFibGU6ZTIwYTZiY2Q3NmIwNDkxYmFlODI4ZWJiZjA5YjQyMzYvdGFibGVyYW5nZTplMjBhNmJjZDc2YjA0OTFiYWU4MjhlYmJmMDliNDIzNl8zLTEtMS0xLTA_63a0bd8b-c45c-4f3a-8b70-b3458f939137">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc3_599ad375-b3ed-4c09-80ba-04236b1f3c5b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6M2FkNGU4OGQ5YTRlNDIwMGFjODlkMDQ1NzAwOWFhNDAvdGFibGVyYW5nZTozYWQ0ZTg4ZDlhNGU0MjAwYWM4OWQwNDU3MDA5YWE0MF8wLTAtMS0xLTA_f9c3428f-2c1e-4fbc-9ddf-48c53ea63430">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMjc_44b7b4c6-1972-4c8b-b53b-73ddf0dbff20">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMjc_2efa904a-d37c-4aae-984e-a69e944ec6fe">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODJlMjlhYmQ2NjZmNGExMzgyOTgzZTEyZjgxNWU2N2QvdGFibGVyYW5nZTo4MmUyOWFiZDY2NmY0YTEzODI5ODNlMTJmODE1ZTY3ZF8wLTAtMS0xLTA_f89f8c07-e2e3-45ee-993f-0be1536a4042">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcz_a8e79d6b-c7d5-4a3c-9610-92bbfd2c8c5c">001-37702</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcy_53248507-e48d-4f34-9db3-437ece765d7c">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8wLTAtMS0xLTA_1b95d869-34c1-4e0c-819e-f29da9d58fe5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8wLTItMS0xLTA_e9bdb400-cd65-4235-923e-32aa763eb81d">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8yLTAtMS0xLTA_02f1b579-22e5-4e2d-92d0-3443f9b1b0e9">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8yLTItMS0xLTA_f5176428-862b-4f93-9d90-4c5d63f5e220">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF8zLTAtMS0xLTA_0067850c-a8d0-4ba9-b607-a87062b7f582">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6MDgyNzJkNWNmNDA5NDY4YTk5OWRhYzRkOWY2YjBjYTAvdGFibGVyYW5nZTowODI3MmQ1Y2Y0MDk0NjhhOTk5ZGFjNGQ5ZjZiMGNhMF80LTAtMS0xLTA_ec0ced36-077e-40c7-a392-bded06708bc5">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc0_b7a3370a-d946-4d9d-b46d-bca4d0789dab">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDY3_432183bd-68c1-45fe-943a-c2d6f1e64893">447-1000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9617e3716fd343959fb610e4be443616_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8xLTAtMS0xLTA_8ba43c56-c40d-4d83-bcbb-bfda2fe7d6f8">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9617e3716fd343959fb610e4be443616_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8xLTEtMS0xLTA_6f8aa053-aa7a-47a2-b95d-2f2f4be4e33e">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9617e3716fd343959fb610e4be443616_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8xLTItMS0xLTA_734957be-40eb-444a-96b9-09c8e808567f">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8yLTAtMS0xLTA_eea90414-449b-4ae0-953c-27bccceacd9a">1.250% Senior Notes Due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8yLTEtMS0xLTA_36b0b6ba-e316-48bc-b11f-3b96c9acd63c">AMGN22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic2e091470ea64b65b2359590f8aa1968_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8yLTItMS0xLTA_3bd0e286-65bc-4da9-bd2a-5a69813b3cd3">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8zLTAtMS0xLTA_196071a1-f56a-404d-8dec-c5c62c18306c">2.00% Senior Notes Due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8zLTEtMS0xLTA_4763f4c2-0f52-4503-8f69-c418bb57e1e5">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifdfb609eb01d4647a535cc454cfdaf7d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ZDcyOTIyNWVhNjdmNGEyZGIyMDU4N2JjNjhhYTJkNzEvdGFibGVyYW5nZTpkNzI5MjI1ZWE2N2Y0YTJkYjIwNTg3YmM2OGFhMmQ3MV8zLTItMS0xLTA_f8252c91-2469-4a78-95f0-8b6cc16e5737">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc1_9a75b6b6-16e7-4887-98f2-ddc33507f5aa">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDY4_f2edc272-97fa-4174-8be9-5ed72df78bf9">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDY5_61bf328c-1702-4659-8b62-99666ca621e2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcw_0c82ff31-13d1-41ea-98d4-7e90de5c4dce">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODg0YmNiYTYzNTU4NGY5NzljNTBjODI5ZjM1MjAyNTgvdGFibGVyYW5nZTo4ODRiY2JhNjM1NTg0Zjk3OWM1MGM4MjlmMzUyMDI1OF8wLTAtMS0xLTA_75d8faf7-e013-4dd4-aee3-e873d46ad1ca">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODg0YmNiYTYzNTU4NGY5NzljNTBjODI5ZjM1MjAyNTgvdGFibGVyYW5nZTo4ODRiY2JhNjM1NTg0Zjk3OWM1MGM4MjlmMzUyMDI1OF8xLTMtMS0xLTA_7ed7db2c-d1cc-4a68-82b9-92a2d7eac2bc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGFibGU6ODg0YmNiYTYzNTU4NGY5NzljNTBjODI5ZjM1MjAyNTgvdGFibGVyYW5nZTo4ODRiY2JhNjM1NTg0Zjk3OWM1MGM4MjlmMzUyMDI1OF8xLTQtMS0xLTA_6b552458-afa3-4349-960a-35161cc6b786">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMDk5NTExNjMxMzA3_d9cf223d-40c4-4fe4-a9d2-b88ef5cd8546">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDcx_19d56f58-98b3-46b1-b600-7dffe85096c5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="iff105cdfcde045cbb7f837fd8890833f_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8xMDk5NTExNjMwODYx_c16dccb3-33d1-4349-8a2d-6fd0c0490555"
      unitRef="usd">138056968288</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia1073bcf953749a699413c12f9ead93c_I20210203"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8yNzY4_000f2731-bcce-4bd9-90bf-bc79528f8c95"
      unitRef="shares">577566383</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xL2ZyYWc6OGQ4ZGUzNDc3MWFhNDc5N2FjYTM3NjFlNjA1Mzc4YzQvdGV4dHJlZ2lvbjo4ZDhkZTM0NzcxYWE0Nzk3YWNhMzc2MWU2MDUzNzhjNF8zMDc2_580608e0-d662-4159-8ac6-98b8599e626a">&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specified portions of the registrant&#x2019;s Proxy Statement with respect to the 2021 Annual Meeting of Stockholders to be held May 18, 2021, are incorporated by reference into Part&#160;III of this annual report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzItMS0xLTEtMA_30a38ba8-aa57-4011-9dea-39c25284821d"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzItMy0xLTEtMA_a74a1eab-cc1a-4782-b95c-0aa8c0460d8d"
      unitRef="usd">22204000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzItNS0xLTEtMA_75bf9f38-70de-43dc-9436-da61457c189f"
      unitRef="usd">22533000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0a9e21adce47979f7e38ab4025e6ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMtMS0xLTEtMA_857b3be8-1f5e-499f-997f-73f6fded74ba"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia25a2862d79c42ba91f97b4241baa3f9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMtMy0xLTEtMA_59188e86-0672-4297-b6f7-2e7c6e797f24"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62e077713b1f432fb30f0a3751b4bdf4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMtNS0xLTEtMA_26e94618-5e77-4a5d-a63b-b431e93027e2"
      unitRef="usd">1214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzQtMS0xLTEtMA_142d85ab-168e-46cb-a8f2-f21be5880fc0"
      unitRef="usd">25424000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzQtMy0xLTEtMA_53e6f216-3fac-4762-b7ec-278c4f7d87c3"
      unitRef="usd">23362000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzQtNS0xLTEtMA_51c1d242-4bcc-49b9-ab13-c23e3d00072a"
      unitRef="usd">23747000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzctMS0xLTEtMA_b94d87f7-b4ac-43ca-8c76-6247c1874558"
      unitRef="usd">6159000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzctMy0xLTEtMA_48a6627b-b867-4f1d-880c-e94d1ba98982"
      unitRef="usd">4356000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzctNS0xLTEtMA_5bb27cd1-80c9-4529-8f7b-928f5f6dd2b4"
      unitRef="usd">4101000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzgtMS0xLTEtMA_b42fc5b4-a7ce-40d0-a4e7-cdb9cb9dea4a"
      unitRef="usd">4207000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzgtMy0xLTEtMA_238afe1a-99f5-46cc-b7f4-3f39d62a2692"
      unitRef="usd">4116000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzgtNS0xLTEtMA_fcd263f7-1bd1-4446-894e-fd66824324c5"
      unitRef="usd">3737000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzktMS0xLTEtMA_6b493609-6314-448d-8515-d5216dccdcbc"
      unitRef="usd">5730000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzktMy0xLTEtMA_1f2ee039-d810-4b83-b759-a3eb77cb48fc"
      unitRef="usd">5150000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzktNS0xLTEtMA_1e9aa7fd-455e-43ce-adee-079a93d15069"
      unitRef="usd">5332000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzExLTEtMS0xLTA_6ad0e4e3-2b31-4df7-a4ad-24fdfe8840bb"
      unitRef="usd">189000000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzExLTMtMS0xLTA_6aeed021-810d-4f27-bdfe-3e98634053a6"
      unitRef="usd">66000000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzExLTUtMS0xLTA_31a61443-c602-449d-bbec-bf3e574045a2"
      unitRef="usd">314000000</us-gaap:OtherGeneralExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzEyLTEtMS0xLTA_edefd3bd-baf5-46bd-8f01-09cb3e4e905a"
      unitRef="usd">16285000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzEyLTMtMS0xLTA_df077847-0720-4e64-a856-d0bfdd205341"
      unitRef="usd">13688000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzEyLTUtMS0xLTA_5a2703f3-0619-46c0-a547-4d51b31853f2"
      unitRef="usd">13484000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE0LTEtMS0xLTA_a2b7324a-c8ed-4934-b825-05e1584d6d82"
      unitRef="usd">9139000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE0LTMtMS0xLTA_4b51558f-e49f-4eaf-a506-6325661d9bf1"
      unitRef="usd">9674000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE0LTUtMS0xLTA_4d885f88-de66-4a37-ae04-cc64277200bc"
      unitRef="usd">10263000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE2LTEtMS0xLTA_26fd0b66-a390-4398-b357-7ace2d70ed16"
      unitRef="usd">1262000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE2LTMtMS0xLTA_02401e47-b2cd-420d-a8bc-9ad4ed4f0a5c"
      unitRef="usd">1289000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE2LTUtMS0xLTA_f4afa613-5647-4478-a8b3-cee096a4af2a"
      unitRef="usd">1392000000</us-gaap:InterestExpenseDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE3LTEtMS0xLTA_6484aae4-e468-48ac-806f-12115bac5b9f"
      unitRef="usd">256000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE3LTMtMS0xLTA_8cc447c8-7b5b-41ff-8edf-0b47c61e0a9b"
      unitRef="usd">753000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE3LTUtMS0xLTA_e244e3af-a3f9-49f3-b640-b0095bd5db55"
      unitRef="usd">674000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE5LTEtMS0xLTA_c21e7a00-b73c-47dc-b863-d6569ba7f69f"
      unitRef="usd">8133000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE5LTMtMS0xLTA_87f5ca2d-8a7a-4b1a-8ba9-c4249d9b5362"
      unitRef="usd">9138000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzE5LTUtMS0xLTA_60a5c629-b976-4917-bbcd-f0e37a20eea6"
      unitRef="usd">9545000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIxLTEtMS0xLTA_f5ad3b17-aaa9-41ad-91c4-c3ee19e141c3"
      unitRef="usd">869000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIxLTMtMS0xLTA_5236cf2a-335d-42fc-aa21-280f058b0a8b"
      unitRef="usd">1296000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIxLTUtMS0xLTA_1ec5d8bf-a7ff-419a-bb86-11b60ea19871"
      unitRef="usd">1151000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIzLTEtMS0xLTA_dac79fd7-cb52-4a5a-8439-851eef96f654"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIzLTMtMS0xLTA_aa407ebe-a5f1-4434-b400-56c8bbb2cf23"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzIzLTUtMS0xLTA_b98a1d23-7b64-4e1a-9d6b-6f4ca0d26bf5"
      unitRef="usd">8394000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI2LTEtMS0xLTA_1e5b00a7-9e37-4cea-9aaa-5587cb1f459d"
      unitRef="usdPerShare">12.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI2LTMtMS0xLTA_bf223a85-6910-4055-b66f-c34a2d573fab"
      unitRef="usdPerShare">12.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI2LTUtMS0xLTA_2121072b-dc6a-4d1e-863b-610f3805370f"
      unitRef="usdPerShare">12.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI3LTEtMS0xLTA_4b55a643-ae67-4fdf-9bd8-114472541310"
      unitRef="usdPerShare">12.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI3LTMtMS0xLTA_fec266c0-2adc-4230-8281-8ac4a8251de0"
      unitRef="usdPerShare">12.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzI3LTUtMS0xLTA_e91aca47-4c2d-4ace-b6c1-717530da4960"
      unitRef="usdPerShare">12.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMwLTEtMS0xLTA_917e16ab-684f-410f-b1c3-3da58ca1dddc"
      unitRef="shares">586000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMwLTMtMS0xLTA_a9b81ca9-1881-4d39-8c4d-464287925ca3"
      unitRef="shares">605000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMwLTUtMS0xLTA_a18a15f4-cbd0-40aa-b6d4-45d5da1d9c7c"
      unitRef="shares">661000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMxLTEtMS0xLTA_171c5b2b-6013-4d1a-a9ee-0a626105b2b4"
      unitRef="shares">590000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMxLTMtMS0xLTA_bd5e48d5-6402-48e6-a94c-ff7532690dad"
      unitRef="shares">609000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xNzgvZnJhZzozYzY4NDg0M2Y2MmY0ZGJjYjE1MjZhZGI1NWM4NDZlNC90YWJsZTo2OGUwZmY3MDFmYWY0MDc5YjFhOWRmNGIwNjcxYWIxNi90YWJsZXJhbmdlOjY4ZTBmZjcwMWZhZjQwNzliMWE5ZGY0YjA2NzFhYjE2XzMxLTUtMS0xLTA_2b03f26f-18a7-451f-8ee1-e749abe87a62"
      unitRef="shares">665000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzEtMS0xLTEtMA_c9bca7ee-1300-4928-b70f-82a351304365"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzEtMy0xLTEtMA_655fea8a-2575-4ccc-b0ee-8a2b01870b06"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzEtNS0xLTEtMA_b051651e-8507-4269-bab0-2f0f37b6a2b3"
      unitRef="usd">8394000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzMtMS0xLTEtMA_f86fc041-1e3a-4949-9cb6-e47cee67c881"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzMtMy0xLTEtMA_66c9b7fc-d5a2-47a5-b526-5d6d10f0638d"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzMtNS0xLTEtMA_fc4b49d4-d436-4d7c-abee-df949517edd3"
      unitRef="usd">-141000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzQtMS0xLTEtMA_d600f63c-1b71-4040-99b2-0448a396f029"
      unitRef="usd">-438000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzQtMy0xLTEtMA_5fa996d3-24dc-4287-90b2-2eae66694407"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzQtNS0xLTEtMA_db0c70e9-f278-42d6-b26a-91b7ec291bbe"
      unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzUtMS0xLTEtMA_7710a675-4438-4251-8b41-802003c4b33b"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzUtMy0xLTEtMA_562ad561-2c70-4071-a7c1-03c089c5198c"
      unitRef="usd">360000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzUtNS0xLTEtMA_e1557d6c-452d-49e8-a2f2-65a0f56a0312"
      unitRef="usd">-185000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzYtMS0xLTEtMA_a23c196c-a390-4a4c-a9d2-1764f29bf650"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzYtMy0xLTEtMA_795dc8f0-7da5-48a3-9c40-b2b9481b3ffd"
      unitRef="usd">-5000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzYtNS0xLTEtMA_e90e8934-45c2-4792-96e8-65f3ba95705e"
      unitRef="usd">-2000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzctMS0xLTEtMA_fea8cf72-d10d-494e-a710-88eabaf853c0"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzctMy0xLTEtMA_68e00212-75b2-44c5-9769-ef073cae4581"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzctNS0xLTEtMA_7a801f51-0eed-4aa7-a601-6ce92e366457"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzgtMS0xLTEtMA_b1830ecf-fe39-46d7-adc0-e0a654297d54"
      unitRef="usd">6807000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzgtMy0xLTEtMA_bfdb7c64-170b-4460-a9f0-6bdd60bd5102"
      unitRef="usd">8083000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODEvZnJhZzpiZTNhMjgxYjM5ZjU0OWE4YmM2ZGU5YjljMTI3OGZkOC90YWJsZToyYmE0NTk2YTk1NjQ0MGUwYTNhMDFmZTZiM2ZiYzQ4Ny90YWJsZXJhbmdlOjJiYTQ1OTZhOTU2NDQwZTBhM2EwMWZlNmIzZmJjNDg3XzgtNS0xLTEtMA_ee0685b8-4898-4a7f-826e-1bce6256ad47"
      unitRef="usd">8313000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMtMS0xLTEtMA_5f352e41-af4f-46be-9389-aaa9b920a502"
      unitRef="usd">6266000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMtMy0xLTEtMA_395ea0a1-c5ff-42b9-af29-22eba5256191"
      unitRef="usd">6037000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzQtMS0xLTEtMA_660391e1-768a-4d28-b358-a7425b2e7b8c"
      unitRef="usd">4381000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzQtMy0xLTEtMA_7907e893-d9a1-46e1-b94c-02c7f15d169e"
      unitRef="usd">2874000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzUtMS0xLTEtMA_78af5912-a89a-4189-b7f9-53035a78cdf6"
      unitRef="usd">4525000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzUtMy0xLTEtMA_5d1b3a85-75d6-4094-8dc3-8caf7c733092"
      unitRef="usd">4057000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzYtMS0xLTEtMA_8243cf85-190e-40d1-8561-b5861640f39b"
      unitRef="usd">3893000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzYtMy0xLTEtMA_8c9c132f-0805-462d-9baa-64780f482074"
      unitRef="usd">3584000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzctMS0xLTEtMA_411d35b9-bcd4-4d1a-970f-aee026177a36"
      unitRef="usd">2079000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzctMy0xLTEtMA_9b577e70-b0c9-4ea8-9538-c30b98e9ba56"
      unitRef="usd">1888000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzgtMS0xLTEtMA_9a52d2d0-5aee-4d1b-9525-591263528515"
      unitRef="usd">21144000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzgtMy0xLTEtMA_94a9edb1-4d82-4970-9716-a586c576fd79"
      unitRef="usd">18440000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEwLTEtMS0xLTA_4ca60e49-3fff-45d4-b060-b2aa365f4e81"
      unitRef="usd">4889000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEwLTMtMS0xLTA_59a70c46-d449-478a-8021-cc74d16f405b"
      unitRef="usd">4928000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzExLTEtMS0xLTA_b2ba520e-860f-41d2-92c1-bd42fc68a6cb"
      unitRef="usd">16587000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzExLTMtMS0xLTA_e6925b82-8dca-47d2-95cc-70cfa462989a"
      unitRef="usd">19413000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEyLTEtMS0xLTA_89e862e9-d92d-4550-a8af-940de771f91f"
      unitRef="usd">14689000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEyLTMtMS0xLTA_dd20a4bb-a598-4f81-9c4e-acd898f4335e"
      unitRef="usd">14703000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEzLTEtMS0xLTA_0933e518-364c-4841-8b02-6430d6fbe96b"
      unitRef="usd">5639000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzEzLTMtMS0xLTA_4141b67f-f28f-4dff-b27f-a8e011a6e05e"
      unitRef="usd">2223000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE0LTEtMS0xLTA_f010fa21-4424-4aff-82ed-495b94cddb93"
      unitRef="usd">62948000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE0LTMtMS0xLTA_9a6e5750-b2c9-40c5-a8b0-b5dd85733467"
      unitRef="usd">59707000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE4LTEtMS0xLTA_9aa03d42-694e-4ce2-80a0-ec767d751044"
      unitRef="usd">1421000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE4LTMtMS0xLTA_306319a6-c609-4880-838d-2384644a6501"
      unitRef="usd">1371000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE5LTEtMS0xLTA_f1d8416f-247c-4a50-adb3-964e87b15985"
      unitRef="usd">10141000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzE5LTMtMS0xLTA_465ef01d-e2bd-40d6-8c21-30d1dee120d3"
      unitRef="usd">8511000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIwLTEtMS0xLTA_d3d014c7-2bd5-4265-9404-aa0d76c57c90"
      unitRef="usd">91000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIwLTMtMS0xLTA_291973c4-fb6b-405c-b508-f6a73d6ef9fc"
      unitRef="usd">2953000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIxLTEtMS0xLTA_d7800381-d384-4b5a-b0fd-e4be2deec27d"
      unitRef="usd">11653000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIxLTMtMS0xLTA_6a1d2ecc-0c43-451b-8d45-a7783868ee3f"
      unitRef="usd">12835000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIzLTEtMS0xLTA_01a68903-92a9-435f-8952-e4c661ef8498"
      unitRef="usd">32895000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzIzLTMtMS0xLTA_bfd5e048-85b2-495d-a016-f160855f39dd"
      unitRef="usd">26950000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI1LTEtMS0xLTA_cf9c0553-8200-4287-87ac-bc29fb9b01ff"
      unitRef="usd">6968000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI1LTMtMS0xLTA_37d07d73-cc28-49d4-97bb-81ca94ef1c0e"
      unitRef="usd">8037000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI2LTEtMS0xLTA_4c71ffa5-02cc-46f5-828f-19e989558e98"
      unitRef="usd">2023000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI2LTMtMS0xLTA_7f1d3aba-aa4a-4f56-9114-4df117fe3a1a"
      unitRef="usd">2212000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI4LTEtMS0xLTA_6d6d1a63-7371-4c54-a089-094736ad29df"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzI4LTMtMS0xLTA_9d64c592-e914-4c4d-924f-383d54e4078b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMDk5NTExNjI3OTQ1_1ceb9758-585b-43d3-a811-63d30f307af7"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMDk5NTExNjI3OTQ1_b8311494-1efb-43f0-9c86-137c4a29dbf6"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg2OQ_2e9a1b7e-0773-40d0-8c2c-67290f3546e0"
      unitRef="shares">2750000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg2OQ_708c5b03-2ca5-4826-8349-26dac4e3d1e7"
      unitRef="shares">2750000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg3Ng_4ee0d94f-d698-4a59-9dea-304df3e69bc2"
      unitRef="shares">578300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjI1NWFlZDRkYTM0MGI4YmFkYzg1MjU3MWU0ZDZmNV8xMTU0NDg3MjA5MTg4Mw_a56d2ecb-980d-4b5c-ab6e-0780cfa58f19"
      unitRef="shares">591400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTEtMS0xLTA_59094a32-1603-42be-9786-967ec4a64672"
      unitRef="usd">31802000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMxLTMtMS0xLTA_ede11230-487c-439b-97df-51864b2f0a6b"
      unitRef="usd">31531000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMyLTEtMS0xLTA_d5805e63-bbaf-4089-8be7-919c1dce5729"
      unitRef="usd">-21408000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMyLTMtMS0xLTA_2259557f-dae1-4518-aa5e-b718efda905c"
      unitRef="usd">-21330000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMzLTEtMS0xLTA_04f99aca-024f-46c1-b37a-c818df03f07b"
      unitRef="usd">-985000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzMzLTMtMS0xLTA_2b5fbe89-a3f6-45f8-9ff7-165098ba1fbe"
      unitRef="usd">-528000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM0LTEtMS0xLTA_f0d5dcad-a9eb-45b6-bfd9-ddfa45868f33"
      unitRef="usd">9409000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM0LTMtMS0xLTA_6ff9ce17-fb3a-48e7-a726-9ba77835bab4"
      unitRef="usd">9673000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM1LTEtMS0xLTA_56e3174d-2af2-4b00-bd5a-f34dd3799873"
      unitRef="usd">62948000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xODQvZnJhZzpkNWM0ZmIyNmE3ZTM0Y2EyOWE0MzVhMTBhYzUzMjViOS90YWJsZTphZDVjNGVjOTU2MTQ0NDA1OWM3YzEwOGI1NmFmMzM5Zi90YWJsZXJhbmdlOmFkNWM0ZWM5NTYxNDQ0MDU5YzdjMTA4YjU2YWYzMzlmXzM1LTMtMS0xLTA_68c60252-0eeb-491b-8277-e33d4f32ae12"
      unitRef="usd">59707000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibe76d84d24b74fe19c507ca3db178e07_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtMS0xLTEtNjQ4MQ_e1481fbe-5717-4b29-9b29-005aeee36c23"
      unitRef="shares">722200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if9879d3c7b9a4deaaa7e74de73561d9c_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtMy0xLTEtNjQ4MQ_04099f2b-3982-4367-8ff3-dca43ec5b071"
      unitRef="usd">30992000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae5629c343b34f27808360cb92a2f04a_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtNS0xLTEtNjQ4MQ_1f867c28-37d3-454e-b047-33a0f541879e"
      unitRef="usd">-5072000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie781bbd2a4b948e48767b11ee16f2352_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtNy0xLTEtNjQ4MQ_6247ce47-12ec-4cdf-93b2-3b7f0f474eec"
      unitRef="usd">-679000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEtOS0xLTEtMA_3565705e-035a-4edd-b865-f85a58d41a71"
      unitRef="usd">25241000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide99a054d6604b4c891c408659ba5c67_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItNS0xLTEtNjQ4Mw_0f673ae9-cc03-448d-a50d-6105b4c0c724"
      unitRef="usd">38000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36d7388f79e144b99235c416c99550db_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItNy0xLTEtNjQ4Nw_0625e6db-ca89-4f89-88b5-92343383f564"
      unitRef="usd">-9000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86190fe874cb49e198e5942201bb77cf_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItOS0xLTEtNjQ4NQ_23a80439-0509-4ec8-a32e-d9898cb2d6d0"
      unitRef="usd">29000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzMtNS0xLTEtNjQ3OQ_d026f2dd-44a9-4888-bc75-81fa62b6ab05"
      unitRef="usd">8394000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzItOS0xLTEtMA_d3087363-950c-41ae-a1cc-4a0ce2b52bed"
      unitRef="usd">8394000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzQtNy0xLTEtNjQ3OQ_056baaf6-ad53-4b65-acb7-4d68fc49b994"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzMtOS0xLTEtMA_6326100f-b1ec-4032-9edc-3660d3ab22a4"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE3YTliMzkyODQzNTRiYTZiZDdkNzQ5MDFhYjg0OTU5XzEwOTk1MTE2Mjc4NDI_45d1a244-f07d-4370-a324-1a818588c94e"
      unitRef="usdPerShare">5.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzUtNS0xLTEtNjQ3OQ_fb1eb8ec-abd5-402c-827f-59fdb494c159"
      unitRef="usd">3482000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzQtOS0xLTEtMA_e211471d-f600-440e-99b9-b83fb407edd8"
      unitRef="usd">3482000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i43beae92bfce49bc8cbb9c9c6cf4c99f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzYtMS0xLTEtNjQ3OQ_673fe8de-cf48-445d-ac45-7a6f95fc8a1b"
      unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzYtMy0xLTEtNjQ3OQ_e6e27a41-82bb-409d-b931-f8a626a3c53d"
      unitRef="usd">56000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzUtOS0xLTEtMA_ae9af7cb-ae66-4d0d-9e77-c92425f7b89f"
      unitRef="usd">56000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzctMy0xLTEtNjQ3OQ_323d2f92-35c1-4bc8-bd96-0a5f67dd2c15"
      unitRef="usd">327000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzYtOS0xLTEtMA_97460920-4019-44bf-aed2-c2a6288bdf25"
      unitRef="usd">327000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i0446c2615e6a4985b2e4d83a59971891_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzgtMy0xLTEtNjQ3OQ_d640d52c-3d8f-494d-94f3-561f6e4e6db8"
      unitRef="usd">-129000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzctOS0xLTEtMA_07420b33-c889-4822-b044-e190f34d0802"
      unitRef="usd">-129000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i43beae92bfce49bc8cbb9c9c6cf4c99f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktMS0xLTEtNjQ3OQ_68f19653-316d-4689-bf62-6b72e147c266"
      unitRef="shares">94500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i3f4e40ce52384074af45968a2bb10727_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktNS0xLTEtNjQ3OQ_82a95602-6643-4a96-ac47-1d6181ccca79"
      unitRef="usd">17855000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzgtOS0xLTEtMA_403cebf8-397b-4702-8f9c-f60247b04eab"
      unitRef="usd">17855000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia658e307c35b4f75920a20f604851e24_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktMS0xLTEtMA_501d9572-f029-4f8c-993a-9f34afb90b83"
      unitRef="shares">629600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i606f729d14154f1bbee6cd17cade6bc7_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktMy0xLTEtMA_06408295-2bb2-4093-a813-a319d298cb5c"
      unitRef="usd">31246000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46b885f0f1534e088ba923195043b35c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktNS0xLTEtMA_d585b3e4-bc1c-4359-b7f4-2339742d6afb"
      unitRef="usd">-17977000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idda2fa41bf7b4d32acb584d26141eb44_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktNy0xLTEtMA_2b30c3f3-a3ad-4b4b-8b3f-c4f5dba5feb4"
      unitRef="usd">-769000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzktOS0xLTEtMA_f47c6267-0141-4247-9fd5-d51aa0324347"
      unitRef="usd">12500000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i514f593334634486be45550fb53d0771_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEyLTUtMS0xLTY0Nzc_48406c71-94b7-4fce-99ef-17658d05b993"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzExLTktMS0xLTA_8419f8ea-a9fb-41c8-b177-9ac188113ebe"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEzLTctMS0xLTY0Nzc_f33ebf18-3872-4007-a6f1-bc3449e1ae16"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEyLTktMS0xLTA_32b47ded-f456-4c93-bb60-763d924619c6"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MmFmZjY2OWUxZTk0NjhhYWM0YmY0OTExOTQyMjZlN18xMDk5NTExNjI3ODQy_7711c68f-346b-4b3b-871e-ca3cffaf45d6"
      unitRef="usdPerShare">5.95</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i514f593334634486be45550fb53d0771_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE0LTUtMS0xLTY0Nzc_c98d8731-6dae-46e5-89e9-1c6f895e5208"
      unitRef="usd">3555000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzEzLTktMS0xLTA_71a2fc27-9b8b-4a9d-bbc7-33c2ab3e23bd"
      unitRef="usd">3555000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2336bd3c48ac47339665832c8ac91be4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE1LTEtMS0xLTY0Nzc_93edf0ea-8026-4854-b7bc-34e3e3dc55d8"
      unitRef="shares">2000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE1LTMtMS0xLTY0Nzc_56644932-1549-4a36-8d50-e64105395489"
      unitRef="usd">97000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE0LTktMS0xLTA_877a00f7-151b-45f0-8b0c-bc892743c683"
      unitRef="usd">97000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE2LTMtMS0xLTY0Nzc_d51f48c9-b281-4336-a9ad-8dc6603063f4"
      unitRef="usd">323000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE1LTktMS0xLTA_1a2b6d6e-0185-4659-bd8e-6fe4f3fbbce4"
      unitRef="usd">323000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i2244e51660cd4949a7ec972eee7a424e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE3LTMtMS0xLTY0Nzc_bbb03c49-5659-4da9-b944-6e48dac05930"
      unitRef="usd">-135000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE2LTktMS0xLTA_b463ddae-3d79-40ad-aaca-91b97630eee1"
      unitRef="usd">-135000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2336bd3c48ac47339665832c8ac91be4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTEtMS0xLTY0Nzc_5344cbe7-a903-492f-851e-7756ea5a0c57"
      unitRef="shares">40200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i514f593334634486be45550fb53d0771_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTUtMS0xLTY0Nzc_2b36d974-8f7d-4f49-8925-f72ddf131996"
      unitRef="usd">7640000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE3LTktMS0xLTA_080258fd-805b-471b-a99d-c6f3640aad91"
      unitRef="usd">7640000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3cfd04cd281a41f9b3cf4f0a483ab314_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTEtMS0xLTA_8fbe2506-ffd2-45d6-b923-a360c28666ed"
      unitRef="shares">591400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if1f039062c98414ea66e3d16a12dea4d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTMtMS0xLTA_3f564b69-f769-4326-959f-6db710e063ef"
      unitRef="usd">31531000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ff5e78fe2444f869a1054445d876292_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTUtMS0xLTA_0f146c48-0c61-48c2-a0b7-f8a8ba6dc24c"
      unitRef="usd">-21330000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f92a1519afd4ee790c4f7f9669bc32b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTctMS0xLTA_c394391c-4ba7-4a15-9a0e-1aceee8d9dd9"
      unitRef="usd">-528000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE4LTktMS0xLTA_bee500b7-b604-4c87-922c-ca7c5106135f"
      unitRef="usd">9673000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib59b48b26e6d439d9a321fdb3fda477d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzE5LTUtMS0xLTA_9dc54155-238b-41ad-960d-14a4608f4c47"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i127c87cb43eb488dbd0f2e72bc977df7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIwLTktMS0xLTE2Njg2_e343a325-265d-40cb-9d16-11962485ce45"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIwLTUtMS0xLTA_e50ba7b8-750e-4052-a57a-be4280f1f10e"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIwLTktMS0xLTA_113aeaff-d50b-4b2d-b2d1-a84f4f6adf0c"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIxLTctMS0xLTA_32db2e38-a947-4ff1-8cdf-c0dd4d58e089"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIxLTktMS0xLTA_fa9b9b8d-2684-4b36-b13c-d85dd8c82842"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NTVlYzg5MDg3ZjE0NWVjYTM4M2NkYTE2NDE5MDBkMV8xMDk5NTExNjI3ODM3_c6d88d2a-20bc-4690-82e0-cdccb96aa77d"
      unitRef="usdPerShare">6.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIyLTUtMS0xLTA_04ca1623-2fa6-4f26-83e9-a575cca9a1e9"
      unitRef="usd">3843000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIyLTktMS0xLTA_fb6e1060-684a-4ad5-8545-2e11278d04ad"
      unitRef="usd">3843000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i180132b4355d4e00b34bceb464b6e2bd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIzLTEtMS0xLTA_4a419c42-54c7-4970-b0d2-2b3d8ce8ea79"
      unitRef="shares">2100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIzLTMtMS0xLTA_3ad5d2ca-c0e7-4f65-911b-59430a4a887d"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzIzLTktMS0xLTA_16a883c1-4c46-4928-af22-429495cccc07"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI0LTMtMS0xLTA_2b0e4b38-8939-4531-a114-17a83f09c8c1"
      unitRef="usd">349000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI0LTktMS0xLTA_b07911b5-ce7e-4a93-aa04-c0baa0687d1f"
      unitRef="usd">349000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="ia54da37c877e48e6aaa2ba6fab6415bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI1LTMtMS0xLTA_9d59fe83-c94f-4ce4-823c-26204f66b085"
      unitRef="usd">-169000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI1LTktMS0xLTA_9e99aa7e-de8a-4502-b583-9cfae46de324"
      unitRef="usd">-169000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i180132b4355d4e00b34bceb464b6e2bd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI2LTEtMS0xLTA_03f68c6d-7f7c-43e2-87b8-67d4f55e36e6"
      unitRef="shares">15200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ia0125701f9e7479ca5ffeea2fff66440_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI2LTUtMS0xLTA_40195be1-3b6a-4a9e-8c39-0ea1dabe6319"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI2LTktMS0xLTA_ceb8a551-1270-44b1-8013-4410fae58431"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i298fcb4aef42470c9b276ca00abf854c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTEtMS0xLTA_32f866e6-5475-43ec-a6cf-26b0aefc81e0"
      unitRef="shares">578300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iae63d786325d4ba28cd18ab21ff84b6c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTMtMS0xLTA_7cfb5d30-5ce6-445f-818f-74f79a74f06a"
      unitRef="usd">31802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4afec46242043c98ea5b32c79a3dadc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTUtMS0xLTA_635cba52-f89c-43ae-8324-6f7a692eede6"
      unitRef="usd">-21408000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42b0fccf031241ce995839be6adc2e18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTctMS0xLTA_59bfc40f-bc38-4224-81c2-3d5b2bb30fd3"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTAvZnJhZzoxZDZiNmIzN2I0MWU0YzE4YTVkZTQzYTczZjhiNDljNy90YWJsZTpmNjQ4Y2M2MDlkMzM0MGFjOTQxYzlmYTczYTg1MmUxZS90YWJsZXJhbmdlOmY2NDhjYzYwOWQzMzQwYWM5NDFjOWZhNzNhODUyZTFlXzI4LTktMS0xLTA_4e0e9ad5-ad43-4193-9b1a-0a56e27363c2"
      unitRef="usd">9409000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzItMS0xLTEtMA_d322fc4a-f167-4361-94b7-2caefe90e9cf"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzItMy0xLTEtMA_d3a4f672-0c82-48f6-b3c1-baa2610d749d"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzItNS0xLTEtMA_a8682b46-c994-4156-a877-8b84535f2a3d"
      unitRef="usd">8394000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMtMS0xLTEtMA_dc814103-a2d9-4e5f-bd4c-940228f14e64"
      unitRef="usd">3601000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMtMy0xLTEtMA_a859a671-9e9c-4128-bf6f-685ecbeee8b9"
      unitRef="usd">2206000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMtNS0xLTEtMA_30b778e5-b305-4ec9-aa3c-ff2b4ae31a55"
      unitRef="usd">1946000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQtMS0xLTEtMA_b95135a1-b806-4002-9145-50c6d9726264"
      unitRef="usd">330000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQtMy0xLTEtMA_c0462ad2-d22f-4e90-8bb9-39c367a47b20"
      unitRef="usd">308000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQtNS0xLTEtMA_0fc52057-ca6b-41eb-a759-77a2044d9f7f"
      unitRef="usd">311000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzUtMS0xLTEtMA_d02c94d6-751f-46f9-95b7-d82447df07e6"
      unitRef="usd">-287000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzUtMy0xLTEtMA_47667dfc-a1df-48b4-9eea-39d1b587cc21"
      unitRef="usd">-289000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzUtNS0xLTEtMA_fa160a1c-a089-4ca6-81e7-5ad1d1b07291"
      unitRef="usd">-363000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzYtMS0xLTEtMA_064d39d0-2bfc-41c6-896e-9d9e951c16fd"
      unitRef="usd">195000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzYtMy0xLTEtMA_784c06ca-78a3-4298-b498-538c99a39951"
      unitRef="usd">186000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzYtNS0xLTEtMA_f34e3274-744e-46f2-8922-8c5148faad02"
      unitRef="usd">-386000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzgtMS0xLTEtMA_43a8fa9f-8e77-4bce-b031-0a4441dc2d39"
      unitRef="usd">427000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzgtMy0xLTEtMA_40e58a91-7ab4-4141-908f-0fd7c020b723"
      unitRef="usd">504000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzgtNS0xLTEtMA_b58b12b8-c613-402b-a26e-3bbaae0873a8"
      unitRef="usd">378000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzktMS0xLTEtMA_a911ba54-8bf8-4054-8540-0f9004098799"
      unitRef="usd">215000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzktMy0xLTEtMA_809f808b-5d88-4dc7-b163-9eefd0c1c9a6"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzktNS0xLTEtMA_70a48afe-8c58-43b5-b8c7-6753c67b8f5b"
      unitRef="usd">3000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEwLTEtMS0xLTA_9b770e65-4e82-4097-b03f-1c3cf8293d3a"
      unitRef="usd">-129000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEwLTMtMS0xLTA_decaf1f1-d60f-4a19-8922-6fc369c41017"
      unitRef="usd">-10000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEwLTUtMS0xLTA_b366ef6e-4462-4221-b142-9663dab36339"
      unitRef="usd">-35000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzExLTEtMS0xLTA_2991ee3a-0fe0-427a-be12-e4977b26cfbe"
      unitRef="usd">45000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzExLTMtMS0xLTA_48e97326-dbaa-4263-8523-4c7075d54a7f"
      unitRef="usd">164000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzExLTUtMS0xLTA_1a9b2b36-3ead-4c86-ada3-82da61a8e95e"
      unitRef="usd">-143000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEyLTEtMS0xLTA_3e1f4cc9-da70-4ad4-ac2a-1adcf790844b"
      unitRef="usd">-249000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEyLTMtMS0xLTA_69c32e31-5541-4e6b-a39e-bde903d31a34"
      unitRef="usd">-585000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEyLTUtMS0xLTA_0a89cc63-3ccb-4b05-ae67-a381f175f456"
      unitRef="usd">-361000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEzLTEtMS0xLTA_5dc4e123-884a-4685-bba6-9c64f1802160"
      unitRef="usd">-482000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEzLTMtMS0xLTA_a670735b-b1f4-4d18-a98c-cc4636450e40"
      unitRef="usd">-146000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzEzLTUtMS0xLTA_92eec083-9cf5-4e9e-973d-1b4e5ece3a0f"
      unitRef="usd">258000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE0LTEtMS0xLTA_4f892d44-abc9-4113-aab0-e634d53803d9"
      unitRef="usd">983000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE0LTMtMS0xLTA_cdb97134-3988-435b-aaeb-d486d02b339b"
      unitRef="usd">396000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE0LTUtMS0xLTA_3adf4943-ec43-4daa-a1a6-be9ede8d455b"
      unitRef="usd">1214000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE1LTEtMS0xLTA_5935c32c-a14c-432f-8663-ec2371caabe5"
      unitRef="usd">10497000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE1LTMtMS0xLTA_1979fde2-919f-43db-a6bb-5246e79a2cca"
      unitRef="usd">9150000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE1LTUtMS0xLTA_c64d35d8-590f-41e8-9301-7a0e0c9b188c"
      unitRef="usd">11296000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE4LTEtMS0xLTA_134c2752-60c9-4def-a6cc-ea3c0f90cbcd"
      unitRef="usd">8477000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE4LTMtMS0xLTA_20d24e43-7d28-45c8-83e7-c96b05b41f07"
      unitRef="usd">9394000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE4LTUtMS0xLTA_a567c588-2133-423c-89c1-05a84f8176ac"
      unitRef="usd">18741000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE5LTEtMS0xLTA_e4c6ef26-3d0a-4b27-a472-1208b31936d0"
      unitRef="usd">2597000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE5LTMtMS0xLTA_84aedec5-13ff-495f-b03d-e5c4665bae86"
      unitRef="usd">8842000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzE5LTUtMS0xLTA_2d01faf3-9169-44fe-b1d0-be0620759321"
      unitRef="usd">28356000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIwLTEtMS0xLTA_33c078ab-1b02-4c6b-8116-4e030e4c8d38"
      unitRef="usd">4381000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIwLTMtMS0xLTA_788d735a-1472-4384-8faa-99e99eb88cba"
      unitRef="usd">20548000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIwLTUtMS0xLTA_39d63db7-8f47-4e0f-81f7-e075b835d286"
      unitRef="usd">5412000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIxLTEtMS0xLTA_f69287d2-bb49-4fe6-830b-3ff966bb7143"
      unitRef="usd">608000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIxLTMtMS0xLTA_ac0a618c-c474-41c1-9ad8-853fef610134"
      unitRef="usd">618000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIxLTUtMS0xLTA_c16e0583-b6c3-4850-9603-a2e2910beaf9"
      unitRef="usd">738000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTEtMS0xLTA_fee16d33-1cdb-46d7-9e58-6b1ccca4f000"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTMtMS0xLTA_bd564866-0b5f-4896-88a6-4863192c5a60"
      unitRef="usd">13617000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTUtMS0xLTA_95f2dc58-162d-45ae-981b-a834632c44b3"
      unitRef="usd">-195000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTEtMS0xLTEwNTE0_ea8ff11c-5464-4e82-bc0b-4446258a5d00"
      unitRef="usd">3219000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTMtMS0xLTEwNTE4_4568b41d-2abe-436d-b0ac-8342a19bdff9"
      unitRef="usd">24000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzIyLTUtMS0xLTEwNTIy_17c9930a-31b3-4e66-86fa-526668727ecb"
      unitRef="usd">40000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI1LTEtMS0xLTA_c6d46310-3ae9-4efd-a2c3-af11d5bb5eff"
      unitRef="usd">75000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI1LTMtMS0xLTA_743458a3-8cef-4ce3-9a8b-001e2a831f32"
      unitRef="usd">28000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI1LTUtMS0xLTA_98327575-5f98-43ad-b39b-2cd577f9e363"
      unitRef="usd">105000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTEtMS0xLTA_0e091706-55f0-4f0a-93aa-3508b12268f1"
      unitRef="usd">-5401000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTMtMS0xLTA_d8afd8d5-f366-451f-a08b-743864bdef89"
      unitRef="usd">5709000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTUtMS0xLTA_8080a23f-5d32-498c-938a-c1a2076f05b6"
      unitRef="usd">14339000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTEtMS0xLTE3MTg_3374bd14-7d9e-4131-aab6-d9a7ce0a9108"
      unitRef="usd">8914000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTMtMS0xLTE3MjE_566ffa2f-0f0c-4f96-9666-279166626f0d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI2LTUtMS0xLTE3MjQ_3f70ade8-779a-47e8-bf94-e96722a282a3"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI5LTEtMS0xLTA_22d644a3-2aff-40fd-abe3-21991530df87"
      unitRef="usd">6450000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI5LTMtMS0xLTA_8d189b14-af32-4752-b652-8378017435c5"
      unitRef="usd">4514000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzI5LTUtMS0xLTA_ad70c368-6748-4484-afac-db176c00d577"
      unitRef="usd">1121000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMwLTEtMS0xLTA_45402ba3-52e2-47ff-814e-54f85b99fef6"
      unitRef="usd">3486000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMwLTMtMS0xLTA_3ae55498-fcb2-445b-ae33-44b27eee56e1"
      unitRef="usd">7702000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMwLTUtMS0xLTA_4b197ef6-d7c8-4840-a88f-7aa73c9ac88e"
      unitRef="usd">17794000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMxLTEtMS0xLTA_50aa47d1-9713-48c8-aef6-99b639af5ae1"
      unitRef="usd">3755000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMxLTMtMS0xLTA_fbc6f534-cbaf-4f9a-9b65-109df322d67f"
      unitRef="usd">3509000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzMxLTUtMS0xLTA_cb5e7c34-03a7-4eae-8c99-548a11b1c063"
      unitRef="usd">3507000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM2LTEtMS0xLTA_31eabee8-41e8-4985-ba2d-80ec7fe1d979"
      unitRef="usd">-90000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM2LTMtMS0xLTA_18e00df1-3493-46e6-88ed-633524648a81"
      unitRef="usd">-42000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM2LTUtMS0xLTA_07f5112e-84ef-405c-b30c-71fd30ad4602"
      unitRef="usd">-68000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM3LTEtMS0xLTA_6d38f7f7-295d-4063-b876-743df66cd88e"
      unitRef="usd">-4867000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM3LTMtMS0xLTA_654bcad2-0a3e-45bc-be33-0fb69a3ddb6e"
      unitRef="usd">-15767000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM3LTUtMS0xLTA_f2f6c9f5-d1d3-441f-b781-30a4d619c05c"
      unitRef="usd">-22490000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM4LTEtMS0xLTA_cb8404c4-3f70-462d-9770-c7fc527b5ee9"
      unitRef="usd">229000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM4LTMtMS0xLTA_ca4e5e3a-1767-4cbc-aad0-80a19d3ff5d6"
      unitRef="usd">-908000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM4LTUtMS0xLTA_cd4ab9a4-9004-4c91-b30a-2eab2897d800"
      unitRef="usd">3145000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM5LTEtMS0xLTA_19cc9f86-d9be-411b-ab2e-916dc64db1f6"
      unitRef="usd">6037000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM5LTMtMS0xLTA_1124ae2f-cca3-4fb8-9bd1-15b57426f5ff"
      unitRef="usd">6945000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzM5LTUtMS0xLTA_0ca53325-e53c-4b8c-893b-4c33e2f5c018"
      unitRef="usd">3800000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQwLTEtMS0xLTA_5915a6cd-71e8-42e0-9674-bcd1437a66c0"
      unitRef="usd">6266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQwLTMtMS0xLTA_8072f08a-16ef-4e73-80f1-2fb8c9de9dcb"
      unitRef="usd">6037000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8xOTYvZnJhZzo2MjJhMzlmNjFmZWU0YTEyYmIxNDZkOWNhZWJkNzcxYS90YWJsZTo2NzQ1OWQzMzFkZGE0YzM4OTRlYmRiNDQ0MTA2NmY2OC90YWJsZXJhbmdlOjY3NDU5ZDMzMWRkYTRjMzg5NGViZGI0NDQxMDY2ZjY4XzQwLTUtMS0xLTA_3238df67-205a-4cb9-94b5-0bfebfa7f566"
      unitRef="usd">6945000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMjg0_cdb12497-49a0-4827-8c70-3324c911bdfd">Summary of significant accounting policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales and sales deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company&#x2019;s products, primarily in Europe, are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative (SG&amp;amp;A) expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with multiple-performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into arrangements for the research and development (R&amp;amp;D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#x2019; costs; and amortization of acquired technology used in R&amp;amp;D with alternative future uses. R&amp;amp;D expenses also include costs and cost recoveries associated with third-party R&amp;amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&amp;amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of new lease standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&amp;amp;D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#x2019;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets&#x2019; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of IPR&amp;amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&amp;amp;D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#x2019; earnings are translated into U.S. dollars using average exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees&#x2019; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets are now presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the former other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand on the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impact that both standards will have on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <amgn:NatureOfOperationsPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDQ0_7aef9cce-f839-4075-b9af-0a895f332605">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;</amgn:NatureOfOperationsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzI5MQ_edf2aedd-49a0-4858-8875-49340096c781"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzM1_a68299e2-1565-4d5b-92b9-49414da30298">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzEx_03a47182-6e1a-45f2-a103-9d522f1c780e">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDA1_8fd8a8d6-7b8f-4d08-8217-9e5c975c78ca">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales and sales deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company&#x2019;s products, primarily in Europe, are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative (SG&amp;amp;A) expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with multiple-performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into arrangements for the research and development (R&amp;amp;D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <amgn:SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyOTY_ff4302c1-6819-4002-bf38-df53bf0acaa6"
      unitRef="number">0.01</amgn:SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate>
    <amgn:SalesReturnProvisionsAsPercentageOfProductSales
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzI3MTU_8d398b29-874f-4fc7-9f40-a4e4bb26ed37"
      unitRef="number">0.01</amgn:SalesReturnProvisionsAsPercentageOfProductSales>
    <amgn:RevenuePaymentArrangementTerm
      contextRef="i3e0600ada49541efa4f790040e4c766b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzMwNDQ_bc222c0e-dd35-4902-b8e0-868c924c005d">P30D</amgn:RevenuePaymentArrangementTerm>
    <amgn:RevenuePaymentArrangementTerm
      contextRef="i500dae5a099d445bb1e35d1af32c7bce_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzMwNTA_083bafde-4a07-4ae5-8b87-24dd27cfaec5">P120D</amgn:RevenuePaymentArrangementTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDEw_0456f550-375d-44a1-832d-47e75bdb2ddb">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#x2019; costs; and amortization of acquired technology used in R&amp;amp;D with alternative future uses. R&amp;amp;D expenses also include costs and cost recoveries associated with third-party R&amp;amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDE3_8171b911-3ecc-4d74-8bf4-5a3fc8aa1932">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&amp;amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2Xzc3NjM_b45ee439-0659-47c5-9ab6-6b51b2a382e3"
      unitRef="usd">962000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2Xzc3Njc_d621b14d-9cb5-47a9-91f6-9d23e4f36219"
      unitRef="usd">789000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2Xzc3NzQ_d288abc1-c2e7-4229-a666-87c9b2b8a498"
      unitRef="usd">674000000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzI5_58cdcda5-e55c-493b-a061-b1bf63b14d41">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of new lease standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie4f66cb73cc34c1f99ee0486a92779e4_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzkzNDU_5747abcd-8f34-4817-b52b-a00ddc01aa86"
      unitRef="usd">510000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie4f66cb73cc34c1f99ee0486a92779e4_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzkzODE_09a5ff82-791a-4f30-94b9-567aa92d767d"
      unitRef="usd">439000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDM0_79aa46ec-1a0e-4f2f-822f-645d196f3112">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDA2_e3d96fec-3659-4020-b64e-722f3845e22a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzQ5_12ddfaa8-b6cf-402b-b05c-7b03445dfe6c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&amp;amp;D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#x2019;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDQw_f1cec887-0d18-4cdd-9544-7268efe41b4a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzUy_1aebae7b-84aa-4d53-bae2-8792b6232b9f">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDI5_7737c317-f660-4f2d-a28d-fc2c5f5b47cd">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDAy_d21244b3-0e6f-4b6b-a43e-e3fa7a98a94f">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDM3_b78fdbfc-9538-451a-b429-52d62854ca24">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets&#x2019; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzc1_c3a3eecd-3536-4dbb-b1a6-e55845dd6380">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of IPR&amp;amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&amp;amp;D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyNDQ2_8f207bc4-872d-473e-900f-9e7e8a1614ef">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzky_04ce12e6-28f5-4798-a917-fe6d22f84e46">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#x2019; earnings are translated into U.S. dollars using average exchange rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzU0OTc1NTgxODg3NDA_5326b4c8-15c9-4c58-9c3e-dd95a79f94f3">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees&#x2019; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDIvZnJhZzoxN2I0NjYwMTMzMDk0Y2NmOGNkMjUzNjdkNDkwMzY1Ni90ZXh0cmVnaW9uOjE3YjQ2NjAxMzMwOTRjY2Y4Y2QyNTM2N2Q0OTAzNjU2XzIyMzE3_0094860f-f666-4f6a-95e1-975e2ffeeb61">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets are now presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the former other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand on the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impact that both standards will have on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzcwODM_376ae1ec-f9fe-4d56-ae0e-19d2240e3606">Acquisitions &lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(apremilast)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 21, 2019, we acquired worldwide rights to Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene Corporation (Celgene). Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The operations of Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated cost (consideration transferred)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The developed-product-technology rights acquired relate to Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights will be amortized over a weighted-average period of 8.5 years by using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce will be amortized over a period of 5 years by using the straight-line method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#x2019;s effort are applied. Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate 2.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119&#160;million, a net deferred tax liability of $24&#160;million and a deferred credit of $96&#160;million. The tax effects of the acquisition are based on Amgen&#x2019;s estimated blended statutory tax rate of 20%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nuevolution AB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution&#x2019;s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kirin-Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin-Amgen, Inc. (K-A), from Kirin Holdings Company, Limited (Kirin), making K-A a wholly owned subsidiary of Amgen. Upon the acquisition, K-A&#x2019;s operations have been included in our consolidated financial statements commencing on the share acquisition date. The acquisition relieved Amgen of future royalty obligations to K-A. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the share acquisition date, we owned 50% of K-A and accounted for our interest in K-A by using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K-A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary means of consideration for this transaction was a payment of $780 million in cash. The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen&#x2019;s preacquisition investment consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash paid to Kirin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on settlement of preexisting relationship&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred to acquire K-A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Amgen&#x2019;s investment in K-A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this acquisition, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability-related-income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted-average period of four years by using the straight-line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K-A but not yet received, partially offset by payables representing R&amp;amp;D expenses incurred but not yet reimbursed by K-A. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma results of operations for this acquisition have not been presented because this acquisition was not material to our consolidated results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <amgn:ApprovedMarkets
      contextRef="i5551c96cc50149c1880f899738b3a80d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQ1Mw_285eee24-d767-49e7-b34f-233eb605609c"
      unitRef="market">50</amgn:ApprovedMarkets>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzcwOTg_8e669f9b-8d59-4c02-be43-9dda191fd3fc">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated cost (consideration transferred)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzEtMi0xLTEtMA_04a3ca79-66ec-4147-9286-59cc159b86e8"
      unitRef="usd">13400000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:Transactioncostsassetacquisition
      contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzItMi0xLTEtMA_7ff0c9d2-495c-4a63-8d38-ec6915c3705d"
      unitRef="usd">40000000</amgn:Transactioncostsassetacquisition>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzMtMi0xLTEtMA_424ea156-09ec-4742-9484-11fe9ef09ca1"
      unitRef="usd">13440000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <amgn:BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired
      contextRef="i77f9d1e3b77e4676870c5f350d1ef04a_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzYtMi0xLTEtMA_6754789b-1b2d-4134-849d-cb3c555d6ee1"
      unitRef="usd">13007000000</amgn:BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired>
    <amgn:BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired
      contextRef="i7e4762422d6345f488ba0c0ce5c4df0e_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzctMi0xLTEtMA_56a2b2e8-c7c7-48c8-bad4-730e8c575401"
      unitRef="usd">195000000</amgn:BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired>
    <amgn:BusinessacquiredassetacquisitionInventoryacquired
      contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzgtMi0xLTEtMA_71be2d16-05dd-4f70-b1c7-f3e7005e3fe6"
      unitRef="usd">367000000</amgn:BusinessacquiredassetacquisitionInventoryacquired>
    <amgn:BusinessacquiredassetacquisitionDeferredTaxLiabilities
      contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzktMi0xLTEtMA_7af0eb08-b2dd-4018-a650-af15e08bab3a"
      unitRef="usd">24000000</amgn:BusinessacquiredassetacquisitionDeferredTaxLiabilities>
    <amgn:BusinessacquiredassetacquisitionDeferredCredit
      contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzEwLTItMS0xLTA_4b7db508-72be-4b93-9884-b64de9dd67bf"
      unitRef="usd">96000000</amgn:BusinessacquiredassetacquisitionDeferredCredit>
    <amgn:BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther
      contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzExLTItMS0xLTA_9c8bb0ec-5cf4-45d3-b0e5-39dbb91d62d1"
      unitRef="usd">9000000</amgn:BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther>
    <amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet
      contextRef="i98b83cbd8e914dc5ad385a9b7b4a1f3d_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTowNjBjYmQyYmEzMmE0ZDcwOTE0OTJjM2Y1Y2VlYjAxZC90YWJsZXJhbmdlOjA2MGNiZDJiYTMyYTRkNzA5MTQ5MmMzZjVjZWViMDFkXzEyLTItMS0xLTA_4b200e22-1896-4dde-a343-50909082654f"
      unitRef="usd">13440000000</amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i33c2747ebad4402e9ac07aae03462e78_D20191121-20191121"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzE4NjQ_64f3b4a2-eeb9-44b3-ab2b-ba0e0c14cde9">P8Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ibc8c902e15924dd683695464fe7097de_D20191121-20191121"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzIyNTE_27c35a74-34c3-4601-8237-201f18f249cf">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <amgn:AcquiredFinitelivedAssetsWeightedAverageUsefulLife
      contextRef="idc3c1c1c0a9b4e5eab8231f9ac287d8b_D20191121-20191121"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzI2NjY_03c3eb0c-fde5-41c5-a2d9-43650169f514">P2Y6M</amgn:AcquiredFinitelivedAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzg1_7389b0a3-829a-4fb1-92b0-23821ed452d3"
      unitRef="usd">119000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities
      contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzU5_11351e9d-cd27-450d-adf6-eba6016c518d"
      unitRef="usd">24000000</amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities>
    <amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits
      contextRef="i8504707ad2dd45d19748815828f1e290_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzcy_b6a7de30-8ad9-44e5-b69e-dd48ab8f5d91"
      unitRef="usd">96000000</amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits>
    <amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzExNTQ0ODcyMTAwNzk5_9bb276d8-e545-44eb-b0a6-b7411c0891a9"
      unitRef="number">0.20</amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i8a2e62d8eeb048f38ca8736344e50d1d_D20190715-20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzI5MTU_703fc49a-58d9-499e-873a-4bead3bb816b"
      unitRef="usd">183000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ic20538b33ec0455ea0039c1984301d31_D20190715-20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzMzNTk_5a71ad74-28a8-4121-89b2-c6c932a4f891"
      unitRef="usd">150000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic20538b33ec0455ea0039c1984301d31_D20190715-20190715"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM0Njc_a04ac9f8-5c61-49ab-bee4-3dba2557af1e">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i36b9b3333490457493d595249f49eea6_I20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM0ODM_ec0dd8c2-e773-43fe-852a-0f95d3ca76cf"
      unitRef="usd">26000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i36b9b3333490457493d595249f49eea6_I20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM1NDQ_c2ce95ff-212b-45d8-8552-68792a24df45"
      unitRef="usd">22000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i36b9b3333490457493d595249f49eea6_I20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzM1NzI_bc69c03b-904d-4f16-bfbc-671045e56bf0"
      unitRef="usd">29000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQxOTc_5ba5132b-97bd-4424-b7f2-4efe96830bd1"
      unitRef="number">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie94c75a285ca4a36b1982968d4172401_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQ1ODg_7e16f83e-8ed9-4c7a-bd27-53da124d6765"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzQ4MDA_d5f3f185-76e5-422f-8a47-a53ca61d4c37"
      unitRef="number">0.50</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzUxMTk_987ea437-de91-47b1-b11a-770dd93cb5c1"
      unitRef="usd">80000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzUyOTI_14c77be0-f764-4e47-b9f7-6bbdf525597e"
      unitRef="usd">780000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:BusinessAcquisitionCostOfAcquiredEntityTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzcwNzg_04864e70-5c2c-4272-af01-cf4966e96003">The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen&#x2019;s preacquisition investment consisted of the following (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash paid to Kirin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on settlement of preexisting relationship&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred to acquire K-A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Amgen&#x2019;s investment in K-A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:BusinessAcquisitionCostOfAcquiredEntityTableTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ie94c75a285ca4a36b1982968d4172401_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzUzODA_f4dbce0c-6192-4d3e-9e57-aaa6a6568bd2"
      unitRef="number">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzEtMi0xLTEtMA_a2767a2c-2580-42af-9fdf-d86e6d444aeb"
      unitRef="usd">780000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzItMi0xLTEtMA_baff41fb-2113-4db8-9747-1c5b5e62f826"
      unitRef="usd">45000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzMtMi0xLTEtMA_9d8c49e3-5443-46ad-92a1-b180c58bb882"
      unitRef="usd">168000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzQtMi0xLTEtMA_f74c8195-4260-4602-9a02-acbc156c0603"
      unitRef="usd">657000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzYtMi0xLTEtMA_642b1659-3d87-4d1c-b07c-ff317f060f15"
      unitRef="usd">825000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90YWJsZTo3MTkwOTMxZGQ3NWQ0ZGI5YjQ0MDc0YTZlYTAxM2FlYi90YWJsZXJhbmdlOjcxOTA5MzFkZDc1ZDRkYjliNDQwNzRhNmVhMDEzYWViXzctMi0xLTEtMA_d4adb474-84c4-4e8b-a1ee-d093bf2cdc8d"
      unitRef="usd">1482000000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU3MTE_baff41fb-2113-4db8-9747-1c5b5e62f826"
      unitRef="usd">45000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU4Mjg_1e2aa4df-f4f0-4373-81f6-7da3a27e7978"
      unitRef="usd">977000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4940f97696f6461f9e3e54bffb7828bf_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU4NTI_66d6936e-49df-4c07-a47f-f2a5cf14b9dc"
      unitRef="usd">470000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU4ODQ_b1fc2636-408d-4f82-bc84-bc7f480b25d9"
      unitRef="usd">102000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU5MjA_6cff050c-264a-4b93-8b4c-01f0c86d8eec"
      unitRef="usd">131000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:Goodwill
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzU5Mzk_ba9bbaf1-e84c-4796-a6d4-d550a8976da3"
      unitRef="usd">6000000</us-gaap:Goodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5f9e4779ad6d4c519da3afeb8a9750dd_D20180101-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzY0NDg_b32eec5a-46e8-4bc5-af7b-78ade40f724e">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzY2MjU_3eda34a7-2e82-45e0-b5f4-b6ebf193a4a8"
      unitRef="usd">6000000</us-gaap:Goodwill>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i047674f49e494a17949b2b546351ed81_I20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDUvZnJhZzo2OTIyODM1MWRlMjI0MTVjYTNhMjUxZjJjNGNhYzU5Mi90ZXh0cmVnaW9uOjY5MjI4MzUxZGUyMjQxNWNhM2EyNTFmMmM0Y2FjNTkyXzY3MDA_048e332d-8e2f-406c-a8e0-ff8ea811c140"
      unitRef="usd">131000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE5NDg_ae02e1b9-1492-46fe-bd43-f8456b9fa80f">Revenues&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#x2019; locations, are presented below. The majority of rest-of-world (ROW) revenues relates to products sold in Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enbrel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(etanercept)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (denosumab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(pegfilgrastim)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (denosumab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(darbepoetin alfa)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(carfilzomib)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (evolocumab) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was acquired on November 21, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzMx_84255a21-02d1-4423-a0ed-bfe9314b05e2"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE5NDk_b2bb9102-c0a0-4e7f-b039-3b15aa7e039d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enbrel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(etanercept)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (denosumab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(pegfilgrastim)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (denosumab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(darbepoetin alfa)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(carfilzomib)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (evolocumab) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was acquired on November 21, 2019.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i926aaf96c0584bbdad52c9ef18251ea8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMi0xLTEtMA_6b4af797-1da7-4742-bff9-d95b943050e5"
      unitRef="usd">4855000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie6c90fddb2bc49aca05ba3690ecb0e12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItNC0xLTEtMA_d64ffba3-d91a-49fb-b4e9-6a24a6e19ada"
      unitRef="usd">141000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibb99da9fcc0c4198a6a265c212af7ab1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItNi0xLTEtMA_fe24e670-4ae6-42ad-9c77-ce2a2652c4a6"
      unitRef="usd">4996000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i01555b26feb044308b7e206b9dccd0f5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItOC0xLTEtODc4Mg_38a2b492-2c87-468f-90b5-6a0a89b405fc"
      unitRef="usd">5050000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic204c7f26f03488aab5ee3f10cb8e502_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTAtMS0xLTg3ODI_a692c165-c392-4a4d-8e85-6d611766a822"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib2bf2bacd2b2492bb28ef69a40f8ec26_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTItMS0xLTg3ODI_91a35ea0-c61f-4b2c-9619-a4dbf7ab5309"
      unitRef="usd">5226000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i45f527e1b66d49af9406611b9596ff22_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTQtMS0xLTg4ODE_f0a3c98b-25a9-4384-944b-624c8460673f"
      unitRef="usd">4807000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i974741dcb1524051a7646fedb5f2c5ab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTYtMS0xLTg4ODE_e9ec3e6e-d2e3-497d-a917-8706c8604689"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8afc5561327f469a8133f9d02a2cb093_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzItMTgtMS0xLTg5MTI_f57cacf9-6800-46c1-8988-c758ef506ef2"
      unitRef="usd">5014000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1b2d439e1e6f409bba4a3347af4696d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMi0xLTEtMTc2MA_847c73c6-a24d-4b50-9d31-79a0061fb36e"
      unitRef="usd">1830000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if8ccac04c7f24f92b788839f717d6523_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNC0xLTEtMTc2Mw_ee5d87d6-adb3-444c-a850-64182cc4363c"
      unitRef="usd">933000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4d2728b90e4d4b7aa0313586de0029cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNi0xLTEtMTc2Ng_800b4fe7-5104-41fc-a8aa-feea458f84ae"
      unitRef="usd">2763000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia5483364e0744c68922713f01e91c7a3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtOC0xLTEtODc4Nw_8fe178b8-e2f7-4030-82c1-2d7ed1168c34"
      unitRef="usd">1772000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ief15e22862ba4cf39454d38e1cbdcd80_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTAtMS0xLTg3ODc_3a229ed4-96f6-4384-8cc8-b31bcabb7c4b"
      unitRef="usd">900000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id0fa621683b24ffdac5458723dae9a1e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTItMS0xLTg3ODc_62b22a0e-039e-4d9d-97fa-45ee5cb19af1"
      unitRef="usd">2672000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iac24acf4d93f495ab9d6b3536f41e0ed_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTQtMS0xLTg4ODM_4e8c4d40-f1b1-4833-bdc2-37bebd87f4cd"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i10cda4e685d04ba792d0adfb5f0a1437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTYtMS0xLTg4ODM_b648a947-0854-4dd0-a9c9-40bb77c99968"
      unitRef="usd">791000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7459c244aa8e43f79da3a9ea0637ec62_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMTgtMS0xLTg5MTI_e21ca065-0d96-45d5-8278-188c433ba920"
      unitRef="usd">2291000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i480fcce9b28440b8b0224b6be301e101_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtMi0xLTEtMA_70e57a5d-c35a-40c5-8699-c18f6a819444"
      unitRef="usd">2001000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i92377c788f944386a84ed9e862d6a789_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNC0xLTEtMA_2a6ad296-5466-4511-b389-ca78af720c1d"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5d93219c901f4d2993fd42b15214c20b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzMtNi0xLTEtMA_54036485-1432-4eef-a501-9a17d3240bab"
      unitRef="usd">2293000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id01a0ca8cf65419c8aec6edf5d45bba2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtOC0xLTEtODc5Mg_76205860-2f0c-434c-a163-4dd096f79269"
      unitRef="usd">2814000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieda0fe0d08b14312b1ce2f95d9af1d9b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTAtMS0xLTg3OTI_217ef721-bc6d-495a-a4c8-9c500bede593"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id66f6e020a4a4abd9de549021d7c3700_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTItMS0xLTg3OTI_2537ecc1-4e24-4800-928b-bf8373519c18"
      unitRef="usd">3221000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i85b462b363df4e43ac25594c6bc680ac_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTQtMS0xLTg4ODU_e5bd7689-782c-4cf0-9c48-423a63f7bca8"
      unitRef="usd">3866000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i54b6d4d4a4f740d9bf97809cb4f715de_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTYtMS0xLTg4ODU_bcb4ecf1-3e4c-47bf-9bad-896e5cedc7ef"
      unitRef="usd">609000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8c93f72881be41c283567c566484b6ba_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMTgtMS0xLTg5MTI_c03e751a-8d49-42de-a7a4-af88738ee047"
      unitRef="usd">4475000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iba5aa16ed3e64d8187270f007bf3bef9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtMi0xLTEtMA_565c832d-0db5-4aa0-9eee-1efa3e26eb3a"
      unitRef="usd">1790000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia5b09f7a19b84d2bb41e108ff3322951_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtNC0xLTEtMA_45e6c812-0834-4034-b00e-c77630f082f1"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i785509d5031b4d25817f65f949f65892_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzQtNi0xLTEtMA_e51be870-f6cf-49af-b45a-3c1116b06d49"
      unitRef="usd">2195000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia8b3a114ec374c5c97599ab0369d2720_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtOC0xLTEtODgyMA_00dba7bd-e8d0-4a2d-9aa4-1c95804eb49f"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i948008cca6de4273bad98a9766aaba9d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTAtMS0xLTg4MjA_d24f3433-8ea0-4a9c-9885-01e838ab9e56"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1f37efa18d214f73a67190daafe053dc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTItMS0xLTg5MTA_41117f1d-2f4c-4d0e-adcd-1df8c9d1ea65"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i954f15f923f241b18df02db5dbb43dc5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTQtMS0xLTg4ODc_15acb080-bcb2-477d-8289-df292fd017ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia3b55b920060459e9114165eaf8c36bb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTYtMS0xLTg4ODc_1c11e1b7-6d04-47ac-944f-a0be7d39e020"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6bc6b87796b943d7934bab2b49c79114_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMTgtMS0xLTg5MTI_7842b71f-87a3-4ab3-af0a-af3c30de5843"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8e053e17a9c8401b9e7ebd23b33490dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtMi0xLTEtMA_74cf75c3-476d-4392-8b4d-b847dba61c16"
      unitRef="usd">1405000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id00a07432ae44f0e9d1fe5c284da0bf8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtNC0xLTEtMA_43bb71de-005d-4dc2-bc0f-d241d81ae814"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6d0738e434f843b586e64e732d02c689_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzUtNi0xLTEtMA_9b5c941e-9dd8-4589-902f-e20a3762d22b"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i76e04b7c055e466cad54c342d9bbc9ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtOC0xLTEtODgyMg_edd4165b-7c8d-4f76-9d70-476bfa1c98e2"
      unitRef="usd">1457000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6539a6cf160e487581559eeb0031769e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTAtMS0xLTg4MjI_fe14f9a1-ddf8-4b97-84ca-ce2fbfa52ab4"
      unitRef="usd">478000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie608b9d0be364ba0ba1110fcb2c0fc98_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTItMS0xLTg5MTA_2dbfc323-0106-4371-a81a-c0b1e2e83e6e"
      unitRef="usd">1935000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibb8758e51a2d4092bcb71092363b47a0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTQtMS0xLTg4ODk_1f5fe874-6aaa-4630-ab50-d336259e0016"
      unitRef="usd">1338000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e790b9674254ba09f653c813982f56e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTYtMS0xLTg4ODk_c76c34d6-ce53-41ec-80b0-51795732be18"
      unitRef="usd">448000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i565f06fae6c54af084a236838566deec_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMTgtMS0xLTg5MTI_1aace9de-2206-495c-9d6f-7decd1a8a827"
      unitRef="usd">1786000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0b2f55bcc30a4cfca648fe698fc70f10_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtMi0xLTEtMA_77485db9-4962-4fea-8ff3-064f4613ce39"
      unitRef="usd">629000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iae4de803606b49cf808e39411da4f3fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtNC0xLTEtMA_7d2ef952-5841-4df7-a8c7-58daab8965bc"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1a8b822803f747429f4e453f30a1f8c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzYtNi0xLTEtMA_ea37e1a2-3816-4d63-8b32-ddfa53107054"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia6ae041643bb42a9bd46624d883f023f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctOC0xLTEtODgyNA_92c96122-cb82-4c5b-8df7-2bbc73a9ec62"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id8ac4fa9d33b4a7b953dcfb37f07cb31_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTAtMS0xLTg4MjQ_8df07125-6a16-4139-b301-090cb4f15bf6"
      unitRef="usd">971000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i82550ed044ae48fcad2e75453e121d7d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTItMS0xLTg5MTA_39f409cb-0452-44e4-a009-a9f52b1fbc4d"
      unitRef="usd">1729000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia7283e03d6b247e5b00618781810a864_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTQtMS0xLTg4OTE_9c2c7536-f4a6-4099-bf72-e8bef3550cf1"
      unitRef="usd">942000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifba12b5c33af41909da76cfd32eb41b6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTYtMS0xLTg4OTE_9d507c19-7d15-4317-92c0-c822036271d9"
      unitRef="usd">935000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic5881997bfdf454b806bb4e23f90b0f9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMTgtMS0xLTg5MTI_c82504b2-be07-4a44-a1c6-4df5cfa50453"
      unitRef="usd">1877000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if858ed80d6524471b48fe73e181c069b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctMi0xLTEtMA_db01cf5d-2ab6-46e4-bc7b-c9704d805fb2"
      unitRef="usd">710000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i837af2fa08e640ef82a438132d76de4c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctNC0xLTEtMA_39d6fa4a-9654-4aab-9d2d-aba8b621f217"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1aade48bbe8e4569b0b5690c45eaa909_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzctNi0xLTEtMA_a9393415-f785-43eb-801f-168da567d9f1"
      unitRef="usd">1065000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4c55591acd534a2bbf75ee8ff1c0fc2c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtOC0xLTEtODgyNg_6d9c27d6-925b-4140-ba46-9dc0b7453df3"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4b00f3f0c5064b28bcf5ecd0be53d820_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTAtMS0xLTg4MjY_598fae20-06ad-4955-9f6a-3f3b450cace1"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ide8fccaf64c14f8eb120b3b7d5ba9bd0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTItMS0xLTg5MTA_eacfecb1-cba8-48d7-a365-f19fdb5d188f"
      unitRef="usd">1044000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7c300e2b07004083841461728c0799c5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTQtMS0xLTg4OTM_3093ff69-73b4-49db-8d72-c9750c2d6e1d"
      unitRef="usd">583000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieb9064c0fd8a47349673fd7361fe5c17_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTYtMS0xLTg4OTM_28f74902-8882-42d3-beca-5ac539e7398e"
      unitRef="usd">385000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8e4ed7c0dd1f403dbb6a02eae47b79e1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtMTgtMS0xLTg5MTI_724df929-c9c7-4dd6-a5d1-fe9baba595ea"
      unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2a8c8a3331fe4b2cbcbfac819fa802e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMi0xLTEtMTc4OQ_1cd6e150-9aeb-4add-beab-636a828d2316"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibc4a40aa83a243ddb4bd0747024f97c6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtNC0xLTEtMA_52a66559-0fc0-442b-bb8e-13d8f6c3e127"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7f35c7cec9fe40ec8747a982642437ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzgtNi0xLTEtMA_8b7e0cf7-562a-410e-ba41-060b879be01f"
      unitRef="usd">887000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4954236e263c4019bc3eeeca23e8ba96_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktOC0xLTEtODgyOA_d334309e-ee0e-432f-bdcb-8f7d28906a20"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia70f8bc85eb544149a219b33c04fdc84_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTAtMS0xLTg4Mjg_04df7a5e-7f9f-41b4-a79a-8287488c53a4"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic64ae6d964234f3e967e327673f9b5fb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTItMS0xLTg5MTA_86b9c308-e1d1-4bed-a403-3e41b4586846"
      unitRef="usd">661000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i24ee66a0043a4f228b82c153cef85490_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTQtMS0xLTg4OTU_0ec31984-a8b0-42e6-aaba-f4fa363ec7b3"
      unitRef="usd">358000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8cf63a10013548d8817d20a261bd0901_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTYtMS0xLTg4OTU_61613603-3a1f-4e5f-b4ff-410d9d2e63db"
      unitRef="usd">192000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3484149e2df04c2685210fde93380a2c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzktMTgtMS0xLTg5MTI_6f6a1d57-20a3-49b0-be82-5c41d7dec7f3"
      unitRef="usd">550000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i14ed027ed29142ed9606f57e5869839d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTItMS0xLTA_972650fb-a1af-4600-8fdd-c60c1134ee0e"
      unitRef="usd">4306000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9d2835d9ca084e8fb4795aa78b07d43a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTQtMS0xLTA_d47e2a15-240c-4135-8f0e-99448fa2846a"
      unitRef="usd">2268000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1186b599c8874028bb81519ce6bb2c59_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTYtMS0xLTA_7f7da72f-f4f7-45d9-b02c-53aed951312f"
      unitRef="usd">6574000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie9d438d374ae4f78b599ce6bf7a19bab_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTgtMS0xLTg4MzA_3d53bfce-f036-42c2-a91f-4f22e7a72259"
      unitRef="usd">3511000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if72bee99f05d48eea6c4eb1bf4db9e82_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTEwLTEtMS04ODMw_f7631152-70e2-4c50-bad7-14b6c7b9f0c0"
      unitRef="usd">2027000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4092f5882c8142d39834b7722d6d303f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTEyLTEtMS04OTEw_ed264d88-4361-46db-971a-54b670100354"
      unitRef="usd">5538000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0f466fc09cd44386b87d1c42d0cee056_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTE0LTEtMS04ODk3_223d4dcd-2117-41af-8e04-4a606c039349"
      unitRef="usd">4035000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5caf3504dcd64ab2ac04090326aa57b2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTE2LTEtMS04ODk3_d0a22e99-372c-41a4-9bdd-769078c57005"
      unitRef="usd">1537000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id8b6988cfabf40cd958ae6cf44c7f9d3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEwLTE4LTEtMS04OTEy_78d21d46-72f2-4c50-85e3-30a6e68a3a01"
      unitRef="usd">5572000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic1b14be4183743e4b46f705ac6239e47_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTItMS0xLTA_f71fead0-173e-4d59-a3d5-e7f671b3acfc"
      unitRef="usd">17985000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iedcb63d22b9249af85cc7ca7293e287d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTQtMS0xLTA_3c944f9b-6496-41df-ab36-dfadb1d0629f"
      unitRef="usd">6255000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTYtMS0xLTA_3bbb8010-d237-461a-923f-96633cc5c99c"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i630a0351e5c24898bfb45b915cc63356_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTgtMS0xLTg4MzI_eae5253a-e163-48cd-83c4-41e65022acdf"
      unitRef="usd">16531000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8b9811f73a8446e4b074fdb187aa7238_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTEwLTEtMS04ODM5_969baa3f-786f-47e3-b5a0-8b827096f46f"
      unitRef="usd">5673000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTEyLTEtMS04OTIy_f5229778-8db6-48bf-95ed-b6e28c59c081"
      unitRef="usd">22204000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i73b360a237fa4db9b2adfe8a31418cb1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTE0LTEtMS04OTE2_21f3fc76-678d-4320-a293-d908e3e1e9d1"
      unitRef="usd">17429000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i116be71a0f84428099ebff205742ed3c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTE2LTEtMS04OTIw_2283b9cc-26db-413e-b0f4-ba3d385db143"
      unitRef="usd">5104000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzExLTE4LTEtMS04OTI0_55314b70-8300-48b5-8d0d-53c9c658d937"
      unitRef="usd">22533000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i965bb3051c3c43e5a0bfa194108e71ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTItMS0xLTA_5ebd8c3b-3fe0-423b-a4af-5efcda9113c9"
      unitRef="usd">511000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3b9bc46f725a420caa5d9c001fe229ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTQtMS0xLTA_0b36c85c-ce57-46bd-a013-5c852fb68149"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iab0a9e21adce47979f7e38ab4025e6ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTYtMS0xLTA_1baeee2c-5490-4118-891b-abf735bf8e85"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i67042c7baef94c1e889169924cf1d15d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTgtMS0xLTg4Nzk_e685919d-ddfa-4754-b6f0-53584569ee5d"
      unitRef="usd">693000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i672733c420164f04985cc409f649c152_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTEwLTEtMS04ODc5_5c1ef18c-5085-4a6c-8622-23867a50e9e8"
      unitRef="usd">465000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia25a2862d79c42ba91f97b4241baa3f9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTEyLTEtMS04OTAx_699273a6-0b84-46a5-bf61-e121e121684c"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i39bda5bc42554606892f0ef083ebb8ef_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTE0LTEtMS04ODk5_38d2e292-01f0-431a-be0b-712e03794cd9"
      unitRef="usd">929000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6e4fc03ab19f4f3399d8c1f71e1a4ea5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTE2LTEtMS04ODk5_19853c60-a5a6-4d6a-b0f5-c6967c8236cd"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i62e077713b1f432fb30f0a3751b4bdf4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEyLTE4LTEtMS04OTI4_c8e359ef-4aef-4449-9dd7-f94426d662aa"
      unitRef="usd">1214000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3d5a2a803f5d48dcb8f85fdb926cdeee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTItMS0xLTA_221de37a-3b0c-4101-936c-0d216bf05f9b"
      unitRef="usd">18496000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i34ebf38a5dda46d0af6058ec22408dd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTQtMS0xLTA_0b64302c-aadb-405a-9c18-141307511788"
      unitRef="usd">6928000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTYtMS0xLTA_23d6d476-e2fa-435a-831c-646b58521d3c"
      unitRef="usd">25424000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iaf240dc750624161beefc465d5d2520f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTgtMS0xLTg5MzA_bdc1d80c-f393-4e4e-9057-ee98a1e7abd4"
      unitRef="usd">17224000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02193c66855b4a3d9d3f81f4d4d0aa3e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTEwLTEtMS04OTMy_4261c56a-d584-4bd1-be47-3f382d1afce6"
      unitRef="usd">6138000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTEyLTEtMS04OTM0_3dabb74f-f026-4220-97a7-eea730e20fa0"
      unitRef="usd">23362000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieb6193cdb49341959aaf15728de81f9e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTE0LTEtMS04OTMw_11c74a8c-269e-49a8-9f57-20fb8533ed9a"
      unitRef="usd">18358000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9dcdd28acc6e4387a9bb47e6478a91ee_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTE2LTEtMS04OTMy_700a0890-54a1-49d6-a1ec-7a8355cc4f7d"
      unitRef="usd">5389000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpiYmRhYTM0N2IwYWI0OTUzODlmMjQzYmM2OTNmMTAwZS90YWJsZXJhbmdlOmJiZGFhMzQ3YjBhYjQ5NTM4OWYyNDNiYzY5M2YxMDBlXzEzLTE4LTEtMS04OTM0_363abbc5-f9a4-4047-bb5d-83596bd0e160"
      unitRef="usd">23747000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzExNjk_3f1fc236-c30b-40a2-a6cf-9c27b211e047"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzExNjk_7cbff791-ae9b-40ac-9fa3-62514f083221"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzExNjk_9478b9f0-a240-4cce-b64e-2c7f7aa036fa"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzEzNTk_82d6e374-7d54-47ef-a08a-e268bec90188"
      unitRef="number">0.83</amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE5NTI_0efc3230-1c2d-4d98-a3db-caf33518797c">Certain information with respect to these customers was as follows (dollar amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzMtMS0xLTEtMA_35c5d3fa-4b83-4b9d-a5bc-657dc3690d9b"
      unitRef="usd">14743000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i14301973b9e04d95bee6bcdcae7c842d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzMtMy0xLTEtMA_ccbbce34-cbb1-457e-81ac-bae02be1b2f7"
      unitRef="usd">12301000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i40c07a4b5b5b4cdd80a13653f61ff54b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzMtNS0xLTEtMA_74b69678-8ab1-45c4-9288-a58c7736a8ce"
      unitRef="usd">12091000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzQtMS0xLTEtMA_393f9d86-f958-48a0-b1cd-b27c21e86eec"
      unitRef="number">0.34</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i14301973b9e04d95bee6bcdcae7c842d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzQtMy0xLTEtMA_77f105c8-ba2a-4629-aa29-15eb4ad90603"
      unitRef="number">0.33</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i40c07a4b5b5b4cdd80a13653f61ff54b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzQtNS0xLTEtMA_59f9fac8-c942-4803-a23a-c7e963d687ec"
      unitRef="number">0.33</amgn:PercentageOfGrossRevenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic744474389a6477387cf4ff42d717bae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzYtMS0xLTEtMA_acac64df-fdff-484b-8d4b-3418eb00ee30"
      unitRef="usd">13779000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4bd7acc9830e47eea1f588c56bdee6ed_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzYtMy0xLTEtMA_4b28034a-9630-44c5-a046-fe69fbdf9cd9"
      unitRef="usd">11795000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i271dc91e748b4ddea09ef131d4fd6b38_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzYtNS0xLTEtMA_efa924d7-b36c-4b1b-9625-13fcd6023c5e"
      unitRef="usd">11434000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="ic744474389a6477387cf4ff42d717bae_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzctMS0xLTEtMA_73b546a3-cec4-43d4-a110-a07a6ea084b3"
      unitRef="number">0.32</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i4bd7acc9830e47eea1f588c56bdee6ed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzctMy0xLTEtMA_4eb5bcf6-3c89-4448-962b-9edae2388e57"
      unitRef="number">0.31</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i271dc91e748b4ddea09ef131d4fd6b38_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzctNS0xLTEtMA_7e61cb3c-9c49-4b73-be39-cfd90d096595"
      unitRef="number">0.31</amgn:PercentageOfGrossRevenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i77d15f91e0634082b728d72dc4737601_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzktMS0xLTEtMA_8221e23c-1ef6-4d0b-ac10-4a7b5c87c47e"
      unitRef="usd">7332000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6ad54f16489e40c38fdd8b424bd6f702_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzktMy0xLTEtMA_1c583e5c-b996-468e-b611-3d973d6baff0"
      unitRef="usd">6538000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1b4eb4dc90c94e328e1dbe4584b6099a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzktNS0xLTEtMA_ebca5694-dda5-4dcd-ac0a-380b49451436"
      unitRef="usd">7475000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="i77d15f91e0634082b728d72dc4737601_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzEwLTEtMS0xLTA_9cba3d81-1da1-41de-b484-dc7bd6181669"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i6ad54f16489e40c38fdd8b424bd6f702_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzEwLTMtMS0xLTA_f2682b43-d8cb-4add-883f-96be805c751b"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i1b4eb4dc90c94e328e1dbe4584b6099a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90YWJsZTpkNGM5NjY0OWYxM2Q0YzFkOGRlMGVlZTIxNGFkMGE5ZS90YWJsZXJhbmdlOmQ0Yzk2NjQ5ZjEzZDRjMWQ4ZGUwZWVlMjE0YWQwYTllXzEwLTUtMS0xLTA_1f516b9f-cfe3-401e-a4f0-1108b884a31e"
      unitRef="number">0.20</amgn:PercentageOfGrossRevenues>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE1NTg_6b6c03ed-d6b0-4343-b71b-b97fe2eb218d"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE1NTg_9afc0d0c-bbef-4d42-a551-30ccbab4e2bb"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables>
    <amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE2MzM_12b38e55-0ef7-4333-ad65-7badbd38574f"
      unitRef="number">0.74</amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers>
    <amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE2NDA_6d72358d-ea84-437c-847d-4d72fbb1c2f5"
      unitRef="number">0.73</amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers>
    <amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE3MjE_fb7695ac-51cf-4d03-b2c0-4addc19cc4c0"
      unitRef="number">0.28</amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation>
    <amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMDgvZnJhZzowMTNlMGU2MTJkNGY0MTI1YjFiODk1MTExYzNlZGNjYi90ZXh0cmVnaW9uOjAxM2UwZTYxMmQ0ZjQxMjViMWI4OTUxMTFjM2VkY2NiXzE3Mjg_1a85100c-2d32-4474-bd2b-a1f3279a98aa"
      unitRef="number">0.27</amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0MjI_8c11c1f0-0d09-4c1d-94fa-0ffb3230c320">Stock-based compensation&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Amended and Restated 2009 Equity Incentive Plan (the Amended 2009 Plan) authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including RSUs and performance units (full-value awards). In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2020, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 23 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units and stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#x2019;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2020, 2019 and 2018, were $235.63, $182.12 and $179.18, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;grant&#160;date&lt;br/&gt;fair&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair values of RSUs that vested during the years ended December 31, 2020, 2019 and 2018, were $161 million, $160 million and $167 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black&#x2013;Scholes option valuation model to estimate the grant date fair value of stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (average of implied and historical volatility)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic values of options exercised during the years ended December 31, 2020, 2019 and 2018, were $98 million, $68 million and $53 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2020, 2019 and 2018, were $21 million, $15 million and $12 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, $345 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2020, 2019 and 2018, which are accounted for as equity awards, are based on (i) Amgen&#x2019;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#x2019;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of units granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, 1.8 million and 2.0 million performance units were outstanding with weighted-average grant date fair values per unit of $207.52 and $185.64 per unit, respectively. During the year ended December 31, 2020, 0.6 million performance units with a weighted-average grant date fair value per unit of $249.07 were granted, and 0.1 million performance units with a weighted-average grant date fair value per unit of $199.86 were forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair values of performance units paid during the years ended December 31, 2020, 2019 and 2018 were $230 million, $176 million and $133 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.&lt;/span&gt;&lt;/div&gt;As of December 31, 2020, $127 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQzMg_c7d55b04-b7c5-4d15-8dcf-84b373e95dbd"
      unitRef="shares">1</amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted>
    <amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQ3OA_cc17e3f2-954c-4e08-96c0-c85ce61af93f"
      unitRef="shares">1.9</amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted>
    <amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQ3OA_cc7c594f-7cb1-4c7a-9fd8-2f839140e6d3"
      unitRef="shares">1.9</amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted>
    <amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzEwNTU_b636fdb0-6625-4602-ae3f-7977d47767f4"
      unitRef="shares">1.9</amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards>
    <amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzEwNTU_dfcf0ca4-7dd8-4d01-8819-c0f57bbae1be"
      unitRef="shares">1.9</amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards>
    <amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzExNTE_1ab2df71-c000-4e65-8d33-2b9c0d877c87"
      unitRef="shares">23000000</amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances>
    <amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0Mjg_fb57f8ac-4571-43c7-820b-22f3b0bd0661">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzItMS0xLTEtMA_f29b5a20-338e-4bfa-aa24-ecc97d7e8b2a"
      unitRef="usd">178000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzItMy0xLTEtMA_62a70ee4-f6ba-46e7-9c55-2fbe88df82ee"
      unitRef="usd">168000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i97ce8a336da14fa284511392f12999d3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzItNS0xLTEtMA_eaa128d9-5367-475b-b4bf-401a04a3e0a3"
      unitRef="usd">165000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzMtMS0xLTEtMA_acbede0c-318f-4815-b58a-237a2728d678"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzMtMy0xLTEtMA_192a7282-b325-47f8-b5ce-ce15a6cfbd5e"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzMtNS0xLTEtMA_102adee4-f4b0-4a54-9dd9-6961a653c455"
      unitRef="usd">117000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzQtMS0xLTEtMA_fcdec163-e0ac-41b7-bdc3-86d08712eee5"
      unitRef="usd">34000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzQtMy0xLTEtMA_f66101b9-167d-41ee-af6f-f00a76189f70"
      unitRef="usd">35000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzQtNS0xLTEtMA_d2430de9-e10a-483a-85a1-19ac63549359"
      unitRef="usd">29000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzUtMS0xLTEtMA_f6008377-d32b-42d3-bae0-5fca67e77c5a"
      unitRef="usd">330000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzUtMy0xLTEtMA_4bc29d3c-d3db-4c57-8662-23f965a3a278"
      unitRef="usd">308000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzUtNS0xLTEtMA_5587d1c3-d736-405d-acfe-f769ef4be924"
      unitRef="usd">311000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzYtMS0xLTEtMA_8dfa379a-9ec8-4ca0-9bb7-23ae130b0fc9"
      unitRef="usd">72000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzYtMy0xLTEtMA_8c321bbf-4b2d-4205-8c0b-5147c699854b"
      unitRef="usd">67000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzYtNS0xLTEtMA_60cf9920-6305-4176-be17-57847574d85a"
      unitRef="usd">67000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzctMS0xLTEtMA_09d5f447-0d6d-4a43-bf71-02360e214624"
      unitRef="usd">258000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzctMy0xLTEtMA_cbf92909-e9ce-4919-9241-2598483b1827"
      unitRef="usd">241000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTpkOTNkYjdiZDFkODg0MGRkOWE4MTVlMWNlZDViYjJiNi90YWJsZXJhbmdlOmQ5M2RiN2JkMWQ4ODQwZGQ5YTgxNWUxY2VkNWJiMmI2XzctNS0xLTEtMA_efc3c875-71b7-430e-8918-63d69c5e13e1"
      unitRef="usd">244000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0MzA_5b926492-6437-43da-ba57-f408ebb480e5">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzI4MjE_c9c07145-7a82-4465-94fe-5685241afe96"
      unitRef="usdPerShare">235.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzI4MjU_6a8379c3-d074-47d5-8f24-70d62c297225"
      unitRef="usdPerShare">182.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i97ce8a336da14fa284511392f12999d3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzI4MzI_7599545b-c126-4aa8-8ea1-fc01e8526a60"
      unitRef="usdPerShare">179.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0MzE_8a50a70b-6d5e-46ab-a22e-6289a3d59682">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;grant&#160;date&lt;br/&gt;fair&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie818cfed00624ad480f081b1918b959a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzItMS0xLTEtMA_eecd7b63-031d-474f-9050-c075acfb87ab"
      unitRef="shares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie818cfed00624ad480f081b1918b959a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzItMy0xLTEtMA_1a717963-77ef-439a-b0a6-1fd8bc3888a8"
      unitRef="usdPerShare">174.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzMtMS0xLTEtMA_7a7e2960-80a5-4cfc-b494-9556af677e53"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzMtMy0xLTEtMA_9b33ce3a-af1b-4bcd-80f1-23a74190ce81"
      unitRef="usdPerShare">235.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzQtMS0xLTEtMA_2da24aed-a0e1-4e8b-9e56-29f32398ff2d"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzQtMy0xLTEtMA_349a6f88-b1b1-4ec8-9f9b-a022a81a89c3"
      unitRef="usdPerShare">167.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzUtMS0xLTEtMA_6283c7dc-e5fe-40f5-a600-241b1d26b640"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzUtMy0xLTEtMA_668c8a56-9dde-42c6-8d1b-d672c04f5a67"
      unitRef="usdPerShare">190.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4ce4ceb699bb403ca25d48176261113a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzYtMS0xLTEtMA_bc1ae1b4-d5b3-43eb-9096-1e1b5ca7aa1f"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4ce4ceb699bb403ca25d48176261113a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNDk4NmYxNzI3MGY0OWRjOTc4NTA5NThiMDFjYTIwYy90YWJsZXJhbmdlOmU0OTg2ZjE3MjcwZjQ5ZGM5Nzg1MDk1OGIwMWNhMjBjXzYtMy0xLTEtMA_d98443de-117c-4128-9373-74cd9366c647"
      unitRef="usdPerShare">198.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMwMjU_939d8785-6751-4f8e-a119-da12c1820c5e"
      unitRef="usd">161000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2cb4ba3aa8134d409a55b8847c0bc4f8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMwMjk_193c54ac-5fb0-4ee5-b257-b260e0b0b355"
      unitRef="usd">160000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i97ce8a336da14fa284511392f12999d3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMwMzY_5884b9cc-a2d0-40e9-a25f-ba7b1c3a8a47"
      unitRef="usd">167000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzMyNTg_06a3933a-a368-4ee4-a38d-449f7ebf03a8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzczOTY_c5829ab1-3e82-4950-8e0c-1d38ff3c5e06">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (average of implied and historical volatility)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <amgn:CommonStockFairValue
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzItMS0xLTEtMA_7d6d51b5-02e8-4447-bb97-b494dfca0038"
      unitRef="usdPerShare">236.36</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzItMy0xLTEtMA_9c4162cf-d67e-44d3-b69e-a1766fa58999"
      unitRef="usdPerShare">177.31</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzItNS0xLTEtMA_14f49736-e195-4696-bd8a-abd60d0386c0"
      unitRef="usdPerShare">177.46</amgn:CommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzMtMS0xLTEtMA_71cdefea-a76c-45c5-a8e3-93b5ccdf4135"
      unitRef="number">0.281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzMtMy0xLTEtMA_454e7647-218a-473d-a154-fc9aca36f69b"
      unitRef="number">0.235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzMtNS0xLTEtMA_28e24a51-b1a2-413b-98b0-3b01f49ea80f"
      unitRef="number">0.246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzQtMS0xLTEtMA_de0d8748-5fed-4891-8b28-6d5f77b5e7e3">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzQtMy0xLTEtMA_45764b29-33c2-4e3c-97af-d9264f9980bf">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzQtNS0xLTEtMA_ca7fd66b-0ba4-461a-ba60-9b75cac6e6d1">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzUtMS0xLTEtMA_5d279dfd-d65b-4257-8db1-84639a98218d"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzUtMy0xLTEtMA_894f3d9f-0cf0-4a9c-8096-4f1ee83fa90b"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzUtNS0xLTEtMA_cc38f96c-4fb3-4b7c-9efc-3b5e1947b96d"
      unitRef="number">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzYtMS0xLTEtMA_3ed191de-7476-44a6-afad-5ec24812f430"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzYtMy0xLTEtMA_5238fe85-12d9-41d9-9548-798957cf89d8"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzYtNS0xLTEtMA_24c503f0-904f-4d5a-8cb5-c2523036169e"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzctMS0xLTEtMA_a4262764-6fc1-4e6c-9471-63719eff3d6a"
      unitRef="usdPerShare">42.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzctMy0xLTEtMA_fd21a8c1-13d1-4522-a71a-947dd31ac009"
      unitRef="usdPerShare">30.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2YWY5MzlmYmZiZGQ0ZjRhYTcwYjYzODgwMTU5M2FhOC90YWJsZXJhbmdlOjZhZjkzOWZiZmJkZDRmNGFhNzBiNjM4ODAxNTkzYWE4XzctNS0xLTEtMA_e34273ff-1165-4f39-9ac7-221a76835aa2"
      unitRef="usdPerShare">34.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0Mzk_6e85d365-f719-4436-9077-f45f0b285e20">&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i143d4186981e48d49d7be92adfcc173f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzItMS0xLTEtMA_6a6f6ee4-5d76-4bdd-be79-895e6009c7fe"
      unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i143d4186981e48d49d7be92adfcc173f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzItMy0xLTEtMA_de643b7b-f44b-40fa-bb87-e25b792ade73"
      unitRef="usdPerShare">157.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzMtMS0xLTEtMA_53186532-6e35-4383-92fa-5412786cceeb"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzMtMy0xLTEtMA_3961b116-f6ca-4281-9673-27d355a0041a"
      unitRef="usdPerShare">236.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzQtMS0xLTEtMA_78c39f3a-fc3c-4324-97e1-153be7f1345a"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzQtMy0xLTEtMA_e405cc5e-5999-44eb-8dbf-bc84f7565ed3"
      unitRef="usdPerShare">117.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzUtMS0xLTEtMA_6b423e09-e4a0-4283-801b-ca3e1325eea5"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzUtMy0xLTEtMA_013cf294-55d9-4ef8-89ff-58eec44aaa88"
      unitRef="usdPerShare">178.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtMS0xLTEtMA_c61f2bb4-99f5-44ed-ad11-2776b9ec7354"
      unitRef="shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtMy0xLTEtMA_1b21d025-c031-405e-874f-9cf85b5eea29"
      unitRef="usdPerShare">179.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtNS0xLTEtMA_2cbdf055-2cc6-4ea3-bd25-3f5b9b7baad7">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzYtNy0xLTEtMA_0f2ab287-3fe9-4572-979a-4b92c8211a37"
      unitRef="usd">243000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctMS0xLTEtMA_2d9bb554-8300-4608-9a23-8325250897df"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctMy0xLTEtMA_13450a2f-98ed-4ece-9644-6740bd09f339"
      unitRef="usdPerShare">178.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctNS0xLTEtMA_270e5a46-6ac7-4ec8-8241-abfe10470701">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzctNy0xLTEtMA_c10c4928-1190-4488-bc35-ae28c022d3c7"
      unitRef="usd">239000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtMS0xLTEtMA_13df4308-3359-4276-9257-900138562ee1"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtMy0xLTEtMA_6ab98260-30ed-452c-9dfc-efaee8266ff9"
      unitRef="usdPerShare">150.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtNS0xLTEtMA_f3e2f0eb-3e80-41a9-a8da-08bddb720a75">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i6e76f04b38e440c88a6772d13ed3dcf6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTplNTlkNGNiZjMzMzk0Y2M1ODIwN2Y4MGQ0Mjg5ZjlmNS90YWJsZXJhbmdlOmU1OWQ0Y2JmMzMzOTRjYzU4MjA3ZjgwZDQyODlmOWY1XzgtNy0xLTEtMA_316ba1f9-f99f-4a06-b706-009a35760078"
      unitRef="usd">120000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM3MjU_38934783-1e68-4f26-a760-92bcdf198ec6"
      unitRef="usd">98000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM3Mjk_64568d85-654b-4b82-a1a6-989a604542bc"
      unitRef="usd">68000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM3MzY_9a066dd4-52b7-4c06-a95c-9653b4a93b5e"
      unitRef="usd">53000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM4NzI_6720a31e-c93e-4925-a29c-edb6c31113e0"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i7c2bc32c427f401fb2598adb1a00b5b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM4NzY_ef616026-0fab-4cce-936e-d5d1c5b2ab47"
      unitRef="usd">15000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ia9105313b92f42b98a063c9571663ac3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM4ODM_606c6864-8788-4c93-b3a6-d48e1935d0de"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzM5MTE_142e4c52-ce05-4a28-8ca2-016bcc551616"
      unitRef="usd">345000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQwOTM_245ae269-eefa-4fea-a3f9-f745e5c27d6f">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzQzODI_c8f6cb62-202c-437d-be16-b775bba92ae4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzYwNDczMTM5NjAyMTM_43d6d82c-65e7-4852-b28a-e481f37e6810"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzYwNDczMTM5NjAyMTM_8e0db10a-850f-4cde-b205-bb6e3c9f9281"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzYwNDczMTM5NjAyMTM_e17d2d85-6f8d-47e7-a563-0622bfe515f2"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzc0NDA_6f6d6d93-bc08-40bf-83d0-732e8db28ece">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of units granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock>
    <amgn:CommonStockFairValue
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzItMS0xLTEtMA_838f683f-7395-4e20-8d7a-3f58f72eee8b"
      unitRef="usdPerShare">236.36</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzItMy0xLTEtMA_87eb8fac-f74f-42dc-8d3c-c7117939b57e"
      unitRef="usdPerShare">177.31</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzItNS0xLTEtMA_47d013bd-358e-4637-9fe8-608b8cdab5d5"
      unitRef="usdPerShare">177.93</amgn:CommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzMtMS0xLTEtMA_bdf53e54-fec8-4b35-86bb-97e06a1334cc"
      unitRef="number">0.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzMtMy0xLTEtMA_1534af2c-c7ca-47fc-a5cd-b51ccb8cc2cd"
      unitRef="number">0.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzMtNS0xLTEtMA_3d17734e-7158-4563-ac41-c527329f94a0"
      unitRef="number">0.238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzQtMS0xLTEtMA_880009d6-5159-46a4-9442-11dcc40ffbb4"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzQtMy0xLTEtMA_72a79048-3d07-47a5-b65e-f7f6013b0550"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzQtNS0xLTEtMA_8d4c38dd-36c5-441e-9809-1344fd618f1e"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzUtMS0xLTEtMA_5534e5f4-a4f4-4f79-962d-ccc8c7aa0560"
      unitRef="usdPerShare">249.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzUtMy0xLTEtMA_43759ad0-91ad-4468-9eb6-1da746630b76"
      unitRef="usdPerShare">188.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90YWJsZTo2NWM1MWU5MThlY2Q0MmIwODFhMGU5YmQ2NTc4YjE3ZS90YWJsZXJhbmdlOjY1YzUxZTkxOGVjZDQyYjA4MWEwZTliZDY1NzhiMTdlXzUtNS0xLTEtMA_8463ac66-09c7-4e16-af1c-da3594122c76"
      unitRef="usdPerShare">189.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY2MTI_3163413e-25cb-4529-a6b5-ef63960d0708"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ide4cd73575da4db0ba421cc3362a29bb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY2MTk_5dff4c3f-c2bd-45e2-a030-62db54463830"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY3MDU_fa0a2615-3274-448b-9678-a233a0dade0b"
      unitRef="usdPerShare">207.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ide4cd73575da4db0ba421cc3362a29bb_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY3MTI_6b0bc18f-f87e-4e59-8f6e-2471a700a4d8"
      unitRef="usdPerShare">185.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY3NjU_0d9097b2-3c2b-4578-9e4d-69da0636794a"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY4MzU_e1fdc544-3f49-4ab4-9221-b04da86004e8"
      unitRef="usdPerShare">249.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY4NTY_de9e318b-faf7-4d4e-90c4-5c215eb97711"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzY5MjY_6fb0c21c-3e7b-499f-9176-6339a49a2589"
      unitRef="usdPerShare">199.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcwNDg_96eb67c8-da11-456c-a2fc-6937aa9eb6fe"
      unitRef="usd">230000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0a897aa729b34cbfa3442f1feb7300b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcwNTI_2c2ef15b-357b-4d41-9aee-b13e4b99d2be"
      unitRef="usd">176000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i04f87ca53f2a464d8a0216d10303faa7_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcwNTk_9555cb45-9e92-43c5-bac5-bf8d4e4640f0"
      unitRef="usd">133000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i3f4580c0aa0b46139e4f1ec02cdb5bd6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzcyMzY_20090935-97f3-4c9b-91fa-f4c58ada630c"
      unitRef="usd">127000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i866165e293d6482ca7b4135f27841405_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMTQvZnJhZzpkNGE0OTRhOGU4Y2Q0MWZiYTc1MjVmZTM2M2U3MDVkYS90ZXh0cmVnaW9uOmQ0YTQ5NGE4ZThjZDQxZmJhNzUyNWZlMzYzZTcwNWRhXzczODY_c511d648-344e-4dd8-8391-7f77da798d10">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzQzNQ_c4332333-4127-48fb-b4b3-6afc36962677">Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $231 million, $220 million and $173 million for the years ended December 31, 2020, 2019 and 2018, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzM3Mg_0fa742cf-9fa6-4e42-843c-b9adf1cbe4ae"
      unitRef="usd">231000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzM3Ng_6a1e8699-5010-49d1-9518-a42e23c57135"
      unitRef="usd">220000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjAvZnJhZzpiYTdjOTdlNWYzMWE0YzJmODI5OGEyZTExZTcxNTJiZC90ZXh0cmVnaW9uOmJhN2M5N2U1ZjMxYTRjMmY4Mjk4YTJlMTFlNzE1MmJkXzM4Mw_5ec3c4d6-05f8-43dc-ac52-408bd8faf282"
      unitRef="usd">173000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0MjA_fd53c7a7-2f14-4d77-8a36-128e884fc068">Income taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred (benefit) provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss (NOL) carryforwards. Significant components of our deferred tax assets and liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance increased in 2020, primarily driven by the Company&#x2019;s expectation that some state R&amp;amp;D credits will not be utilized and that certain foreign net operating losses will expire unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we had $20 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided no valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2035. We had $681 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $585 million of those state tax credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we had $143 million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6 million of those federal NOL carryforwards. The federal NOL carryforwards, for which no valuation allowance has been provided, expire between 2021 and 2035. We had $167 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for all of the state NOL carryforwards. We had $1.9 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $754 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $861 million has no expiry; and the remainder will expire between 2021 and 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the total gross amounts of UTBs were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the UTBs as of December 31, 2020, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2020, 2019 and 2018, we recognized $116 million, $198 million and $137 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2020 was primarily due to lower interest rates during 2020. As of December 31, 2020 and 2019, accrued interest and penalties associated with UTBs were $783 million and $667 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, Puerto Rico Excise Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act, net impact on intercompany sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, primarily federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Audit settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the years ended December 31, 2020, 2019 and 2018 differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#x2019;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company&#x2019;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid during the years ended December 31, 2020, 2019 and 2018, were $1.4 billion, $1.9 billion and $1.9 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. In 2017, we received a Revenue Agent Report (RAR) and a modified RAR from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and have been pursuing resolution with the IRS administrative appeals office. However, we have been unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a Notice of Deficiency, which we would expect to vigorously contest through the judicial process. In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office. The IRS audit for years 2016, 2017 and 2018 is expected to start in the near term. We are also currently under examinat&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ion by a number of other state and foreign tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0MjI_73bd484e-6d05-4738-979e-d31fabc4d009">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id433645fbf594175aab48fd4faf64790_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzItMS0xLTEtMA_f58bb6fa-0fd8-4593-840c-2934aeb59818"
      unitRef="usd">4087000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if5f742d812e548f1805b409e3b3b3abb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzItMy0xLTEtMA_5dd8b418-2a9f-4025-8414-8fe9e3fb0d4d"
      unitRef="usd">4371000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7c9f45734b1443d9bf7b7850cb8ebccf_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzItNS0xLTEtMA_8bfc8ee4-c7d5-45b5-9fbe-32eca3d0eb6f"
      unitRef="usd">4856000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia2f8bbadab1f4527a14acd4c6c81cac8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzMtMS0xLTEtMA_d8d40c9b-bdd5-40de-b2ed-d535742733a5"
      unitRef="usd">4046000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if5dfd09c3d064b5981a2ddae65d2710a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzMtMy0xLTEtMA_725d565e-d032-495c-bfea-d376049da3c7"
      unitRef="usd">4767000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id8b0a52267d94c948c70743bd7a58fb1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzMtNS0xLTEtMA_30f82d69-504d-4589-88e3-a0f7a86ebc78"
      unitRef="usd">4689000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzQtMS0xLTEtMA_846fefe3-fbd9-47c2-8372-6e86b359b511"
      unitRef="usd">8133000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzQtMy0xLTEtMA_93cee81c-e87f-41f6-b4d0-cfa1bb7b07f1"
      unitRef="usd">9138000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo2ZWI5NDA3MzQ0MTM0MTQyOWFkYTQ1NGNlOTM0ZjVkNS90YWJsZXJhbmdlOjZlYjk0MDczNDQxMzQxNDI5YWRhNDU0Y2U5MzRmNWQ1XzQtNS0xLTEtMA_f58739bc-5ddc-4ebb-839c-4b6b14346769"
      unitRef="usd">9545000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0NDc_0d1b3b47-597e-40b7-9f99-f6100fbad613">&lt;div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred (benefit) provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzMtMS0xLTEtMA_bc400aa7-47cb-46b1-968f-3ce299f1a667"
      unitRef="usd">921000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzMtMy0xLTEtMA_2f396b87-2566-4af7-94eb-300561eda192"
      unitRef="usd">1284000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzMtNS0xLTEtMA_91ea055b-4fac-4c31-9c6b-2fc2074a2beb"
      unitRef="usd">1270000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzQtMS0xLTEtMA_2e10adaa-b256-4edb-8491-77fbabb32f07"
      unitRef="usd">34000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzQtMy0xLTEtMA_7b8fd221-5e22-4892-99f8-8bc600735984"
      unitRef="usd">39000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzQtNS0xLTEtMA_d68d498e-8a4e-456a-a0df-860bacea3bdf"
      unitRef="usd">17000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzUtMS0xLTEtMA_2dab93be-4183-4e7f-8f86-0c7b15a2e530"
      unitRef="usd">277000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzUtMy0xLTEtMA_ab2abdb0-3423-4911-a009-56af3ed34ebb"
      unitRef="usd">277000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzUtNS0xLTEtMA_b906003c-01e8-4d06-82f0-917e1e9537ef"
      unitRef="usd">227000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzYtMS0xLTEtMA_3d7750bf-805d-4657-beb8-a71822849c9c"
      unitRef="usd">1232000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzYtMy0xLTEtMA_f0b2497b-c82c-4136-8777-120a7f2d612b"
      unitRef="usd">1600000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzYtNS0xLTEtMA_55441319-83bc-4db7-ac6d-797036403c0c"
      unitRef="usd">1514000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzgtMS0xLTEtMA_1114ac2e-c9c8-4a59-8150-765924c37230"
      unitRef="usd">-321000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzgtMy0xLTEtMA_effbffdc-4ea7-488f-9a41-1731f4de9170"
      unitRef="usd">-276000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzgtNS0xLTEtMA_ad0dae7f-ffc5-49da-a1b6-7e961f53157f"
      unitRef="usd">-317000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzktMS0xLTEtMA_84cd7836-700f-478f-ae78-bdce56d2bded"
      unitRef="usd">9000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzktMy0xLTEtMA_eb483f3b-e355-4a79-9c76-0a3710eb56d4"
      unitRef="usd">-22000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzktNS0xLTEtMA_90af050e-9f62-45e1-bdac-7eb4bb9478e3"
      unitRef="usd">-7000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEwLTEtMS0xLTA_266e4d51-5816-4094-b6b2-e4039bd78309"
      unitRef="usd">-51000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEwLTMtMS0xLTA_eeb580b9-b7bd-4b87-8ce6-170e2aaa5ff2"
      unitRef="usd">-6000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEwLTUtMS0xLTA_18bec500-272b-4c73-9dfb-d80c52b359fd"
      unitRef="usd">-39000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzExLTEtMS0xLTA_b9a93cd0-c465-4fd3-9ca5-751648e43e6f"
      unitRef="usd">-363000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzExLTMtMS0xLTA_af2e9c6d-51f3-4c97-827f-2f988906109c"
      unitRef="usd">-304000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzExLTUtMS0xLTA_f80ba00c-ea4d-450c-9391-075622f71f81"
      unitRef="usd">-363000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEyLTEtMS0xLTA_3f200725-4a35-4819-acd9-c8ea048af6b5"
      unitRef="usd">869000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEyLTMtMS0xLTA_10c1c742-77dc-4cdd-b09e-fea2313f4ec9"
      unitRef="usd">1296000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpjNDc2MDM4OTU3MGM0OTNhYTU1OTRhMTk3OWYyNThkZi90YWJsZXJhbmdlOmM0NzYwMzg5NTcwYzQ5M2FhNTU5NGExOTc5ZjI1OGRmXzEyLTUtMS0xLTA_8ee38904-fe53-4fb9-a19e-82d47e482259"
      unitRef="usd">1151000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0NTA_bdd9e146-b5e6-4d61-bcec-44c22edf5c45">Significant components of our deferred tax assets and liabilities were as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzMtMS0xLTEtMA_cd40ed15-4d48-47ae-a87f-14364c6297fd"
      unitRef="usd">794000000</amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzMtMy0xLTEtMA_785770d3-45d7-4337-8f56-658f7778b586"
      unitRef="usd">800000000</amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzQtMS0xLTEtMA_c4d8f0eb-e0a7-403c-bdc1-b4ad5d2771d9"
      unitRef="usd">561000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzQtMy0xLTEtMA_779b0a5a-4db5-4da1-a828-55ebbef11c5b"
      unitRef="usd">457000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzUtMS0xLTEtMA_70f8a415-25ab-4a7a-9589-e1603d828c1d"
      unitRef="usd">144000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzUtMy0xLTEtMA_a7917845-97f0-4149-9d2a-20a35902ed8a"
      unitRef="usd">170000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzYtMS0xLTEtMA_e97bcfba-560b-4be7-8d70-9e3685fb0fd0"
      unitRef="usd">92000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzYtMy0xLTEtMA_26b4c3f4-6cd0-4726-9823-a45115447bb3"
      unitRef="usd">91000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzgtMS0xLTEtMA_c5695dd6-e364-48a3-828d-8c1749df07a5"
      unitRef="usd">301000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzgtMy0xLTEtMA_e2169f8e-a738-4e68-a356-9b45631e1878"
      unitRef="usd">269000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzktMS0xLTEtMA_15035145-5da3-488a-a374-dc2ba30cfc95"
      unitRef="usd">1892000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzktMy0xLTEtMA_0b6bd57f-7f9e-419c-8115-37ad0ce93056"
      unitRef="usd">1787000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzEwLTEtMS0xLTA_6007c3e8-ab0d-4981-bfc8-c8cb7ee4ef21"
      unitRef="usd">571000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzEwLTMtMS0xLTA_8827a657-4f24-4641-b35a-515ba7f0f41e"
      unitRef="usd">517000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzExLTEtMS0xLTA_faa6f97e-f69f-4162-8f9f-fff40397bd12"
      unitRef="usd">1321000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzExLTMtMS0xLTA_b6966c22-2d16-4b37-9420-b94bd636923f"
      unitRef="usd">1270000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE0LTEtMS0xLTA_e20026ff-4137-4fdb-8eaf-da06b3f0fd10"
      unitRef="usd">903000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE0LTMtMS0xLTA_ee7fa2fd-8e93-46e7-9a26-f11de91f685b"
      unitRef="usd">1288000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE1LTEtMS0xLTA_6c4ce4b8-1e86-4676-8c3c-4cfeda74fe68"
      unitRef="usd">282000000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE1LTMtMS0xLTA_bd1d0f20-0870-4c91-b71d-e66b22696ff6"
      unitRef="usd">210000000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTEtMS0xLTExNTY4_5ccd5bc6-e6cb-4dde-883b-fac06aa7c3ff"
      unitRef="usd">148000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTMtMS0xLTExNTc3_fd814813-e4d7-41f8-8d0a-261a29e41d62"
      unitRef="usd">53000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTEtMS0xLTA_eed07070-3cb7-4780-a758-b29345043c0f"
      unitRef="usd">189000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE2LTMtMS0xLTA_9cbbb2e3-65df-4bf3-87a3-175d308cef53"
      unitRef="usd">233000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE3LTEtMS0xLTA_07f2478e-c6d5-49e8-9fb1-1ad5b7310eb4"
      unitRef="usd">1522000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE3LTMtMS0xLTA_48255c85-a4e7-4fd1-a2f6-4f1c9eecf7d0"
      unitRef="usd">1784000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE4LTEtMS0xLTA_467d90f3-abe3-4bfc-8e9e-23b8b98f4a7f"
      unitRef="usd">201000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTpkNTMxNzMzOTNjMDY0ODZmYjlhOTE2MmMzNzg5OWYzMS90YWJsZXJhbmdlOmQ1MzE3MzM5M2MwNjQ4NmZiOWE5MTYyYzM3ODk5ZjMxXzE4LTMtMS0xLTA_9df2b8ff-3388-4a2d-97a6-a989426d74c6"
      unitRef="usd">514000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i9549cf1daa744587b04c3442d532545e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1Xzk5NQ_31c719ef-8260-4f26-9e3a-16459da076c0"
      unitRef="usd">20000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i1f91811a9c8c47ab955099101550454c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzExMDA_583269c2-b425-4aa6-8d1b-5fcf0e62f565"
      unitRef="usd">0</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8b9c7cf9064143caa206e3b78960b8ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzEyNDE_c47c4685-8636-4036-bbb1-abbc989a344c"
      unitRef="usd">681000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i8b9c7cf9064143caa206e3b78960b8ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzEzNjg_5366953f-dc11-4c37-99e3-4a75c00c14df"
      unitRef="usd">585000000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9549cf1daa744587b04c3442d532545e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE1NDY_95e372b8-8092-4f69-a6e7-be952be6bb62"
      unitRef="usd">143000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i9549cf1daa744587b04c3442d532545e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE2NzA_1a70c9ec-ea6f-4cf0-b3cf-b2326bb12139"
      unitRef="usd">6000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i316f6795382a4358b0d4048594444996_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE3NTA_f6ed4f02-f501-4dff-b32d-2400712ed96a"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i8b9c7cf9064143caa206e3b78960b8ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE4Mjk_ed3eb888-aabb-4b82-981d-1d94a6655f51"
      unitRef="usd">167000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzE5OTM_71e1117e-fccc-48e5-8a23-8e965ebed854"
      unitRef="usd">1900000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzIxMTc_26c3a52c-b282-4d55-9374-1deb603326a7"
      unitRef="usd">754000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i9455afa2b91e45d18c2d587bfa989d67_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzIxODI_8be27d13-e472-4207-8ce8-39fd2db3950f"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i7b7b24f8429e4d2e963a09b18f1da8fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzIyMTU_014e8387-a4ef-41bc-a7d1-df47732ca552"
      unitRef="usd">861000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0MTQ_35b538af-c35a-4a8e-9110-4430b8f68c0e">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the total gross amounts of UTBs were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzItMS0xLTEtMA_6342d74d-5910-4c34-8ca1-d10ef96d60a2"
      unitRef="usd">3287000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzItMy0xLTEtMA_bdc66ab4-48c6-47e1-8169-3fa41ea38f4a"
      unitRef="usd">3061000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzItNS0xLTEtMA_f6a09f9e-eee2-4064-928c-c60b9963ca6f"
      unitRef="usd">2953000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzMtMS0xLTEtMA_4f67ccca-3787-4963-b8f0-1dce6ffb7f90"
      unitRef="usd">165000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzMtMy0xLTEtMA_c0aebaa9-7e52-475b-baff-a1d23d6afcd5"
      unitRef="usd">215000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzMtNS0xLTEtMA_cf4e6544-f5a4-4ba0-a4ea-4a73e1ab4f6d"
      unitRef="usd">173000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzQtMS0xLTEtMA_65120094-192d-4cd3-b912-6cc525158361"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzQtMy0xLTEtMA_26614834-4708-4c93-8f3f-ccda67263dc6"
      unitRef="usd">22000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzQtNS0xLTEtMA_dd0606b3-b6d0-4615-bba4-33f8adec526d"
      unitRef="usd">13000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzUtMS0xLTEtMA_c085d44a-ba75-4f40-9c1a-3f9953943df1"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzUtMy0xLTEtMA_84c5829d-59e4-4962-a0f0-089d23c3cc7e"
      unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzUtNS0xLTEtMA_14e00aaf-ec6e-4e91-9c8f-c22eff80064f"
      unitRef="usd">17000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzctMS0xLTEtMA_5357041e-f0f2-47af-8ca5-308fcd66c68f"
      unitRef="usd">68000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzctMy0xLTEtMA_1a576fd3-91cb-4dde-895f-0a4456bddee7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzctNS0xLTEtMA_d6e4c956-2ddb-4a8c-a4da-603469b05d0d"
      unitRef="usd">61000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzgtMS0xLTEtMA_ba5bd05a-7b0d-4572-a030-1ac861cb6636"
      unitRef="usd">3352000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzgtMy0xLTEtMA_3ad89e38-5352-41fa-82f9-d58462d7d3fb"
      unitRef="usd">3287000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZToyY2I3NzYzMmM4ZjA0ZDFkYWY0Mjc0NDAyNTU0MGZjMC90YWJsZXJhbmdlOjJjYjc3NjMyYzhmMDRkMWRhZjQyNzQ0MDI1NTQwZmMwXzgtNS0xLTEtMA_d6cea23c-debc-4258-b305-05c3cd101975"
      unitRef="usd">3061000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI2MTk_1e010e60-740e-430c-a25b-2ce9f1a54f79"
      unitRef="usd">116000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI2MjM_c3743df1-8f3a-4bfe-bb2f-7fe65248ab81"
      unitRef="usd">198000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI2MzA_f7a36964-9a84-4dc9-b280-27c9e1a208ac"
      unitRef="usd">137000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI4MjM_1cddc125-1152-40d5-ae52-13ab75f41192"
      unitRef="usd">783000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzI4MzA_ea1c1733-4aae-4bed-844c-75ee84c0845f"
      unitRef="usd">667000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzY0NTQ_54b5f846-494c-4b33-b396-f75b5e872b01">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, Puerto Rico Excise Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act, net impact on intercompany sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, primarily federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Audit settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzItMS0xLTEtMA_2857899a-b26c-4ec4-a97b-cf3f03099818"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzItMy0xLTEtMA_2467c386-9d9a-4f02-b6b4-848f9aa834b3"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzItNS0xLTEtMA_cefb9d1e-a306-40b2-b642-8304199c9697"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMS0xLTEtMA_a218b452-3163-4735-bd98-5901e6a80aee"
      unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMy0xLTEtMA_95052da1-5c50-426d-b2fd-d53a80901daa"
      unitRef="number">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtNS0xLTEtMA_2d5d712d-ebf0-4d6a-be07-8e71d01d0c5c"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMS0xLTEtMTIyNjc_c74c2c75-36ce-47ee-bcc8-f5aec0f365b0"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtMy0xLTEtMTIyNjk_02bda4b5-0312-4b90-a781-8a153322dfc9"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzQtNS0xLTEtMTIyNzE_8f936516-805c-4258-a80c-a74c565d94e3"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzYtMS0xLTEtMA_4c7964cf-46ff-42ff-86a2-9854ae52a4fb"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzYtMy0xLTEtMA_f28a16eb-0b7c-4dcc-8599-84a9aa75b40b"
      unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzYtNS0xLTEtMA_970056f6-1158-4275-9c26-9c7ee8e5a316"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzctMS0xLTEtMA_baec2865-878a-40a1-8a69-62f2b55b2ba5"
      unitRef="number">0</amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzctMy0xLTEtMA_da42633d-83ea-4fa7-9ec4-f7cb94df1bb1"
      unitRef="number">0</amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzctNS0xLTEtMA_80b6d45f-737a-4e79-b8de-d8370b2d5c03"
      unitRef="number">0.018</amgn:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzgtMS0xLTEtMA_8921384d-0c51-4099-a6ca-59adc8cd0fcf"
      unitRef="number">0.011</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzgtMy0xLTEtMA_da2766e6-0e24-42bf-a38d-3b350d543096"
      unitRef="number">0.016</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzgtNS0xLTEtMA_f8728d39-7490-4e69-9f8f-bdd165e8973e"
      unitRef="number">0.012</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzktMS0xLTEtMA_a93c32e0-45b6-430d-97ce-0de2cd7dffc6"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzktMy0xLTEtMA_0e9b5d9e-6b35-49f7-8af0-401ab29a431b"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzktNS0xLTEtMA_22e33993-d2e8-467e-baa8-16ad9216eb72"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTEtMS0xLTA_a59d0b3b-3cca-468f-9931-a3ffc029597d"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTMtMS0xLTA_ce514ac9-633d-402a-8ea7-29365a39fc4e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTUtMS0xLTA_d7d0f565-621f-407c-933a-8036708648c6"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTEtMS0xLTEyNDE4_ab83e438-d50f-4fba-ba95-cde54e3edbe0"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTMtMS0xLTEyNDIw_02782802-1ee5-4226-a786-4f62b50c6ceb"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzEwLTUtMS0xLTEyNDIy_7d0f48af-c306-4c67-a95d-0b873d88848f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzExLTEtMS0xLTE2ODkx_59a3d18d-938c-488a-969f-e88f51636f02"
      unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzExLTMtMS0xLTE2ODkz_835f52ef-e2e2-4208-864a-ff1a7b301004"
      unitRef="number">0.142</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90YWJsZTo3OGNjNDM2ZTQxOTM0Mjc1ODQ3NWI0Mzg0YjhjZGIxNy90YWJsZXJhbmdlOjc4Y2M0MzZlNDE5MzQyNzU4NDc1YjQzODRiOGNkYjE3XzExLTUtMS0xLTE2ODk1_8d971a5a-c8f3-4698-a3fc-fbdc03ba3b4b"
      unitRef="number">0.121</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzQzNzk_aae2423a-8de3-47ca-adf8-8c5ca0662455"
      unitRef="usd">1400000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzQzODM_9fc8429a-8ed3-4252-ae5c-01f00cf00720"
      unitRef="usd">1900000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjMvZnJhZzpkYTkzMmMwNTVmYjk0MGZhYTBiMzA0OWMzYTBlYmRmNS90ZXh0cmVnaW9uOmRhOTMyYzA1NWZiOTQwZmFhMGIzMDQ5YzNhMGViZGY1XzQzOTA_a07ba9f1-29c3-4a0c-be3e-3c5787bee98b"
      unitRef="usd">1900000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90ZXh0cmVnaW9uOjQ1ODIxNDk3ZDcxOTRhYTY5YWI2YmQzNmFkMmY5MmY5Xzc3Mw_146608ac-8d5c-4553-8f7a-0c2251c2d7be">Earnings per share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the three years ended December 31, 2020, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90ZXh0cmVnaW9uOjQ1ODIxNDk3ZDcxOTRhYTY5YWI2YmQzNmFkMmY5MmY5Xzc3MA_72a30a2f-7404-4914-bfd6-cc7017a2d295">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzMtMS0xLTEtMA_c9bca7ee-1300-4928-b70f-82a351304365"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzMtMy0xLTEtMA_655fea8a-2575-4ccc-b0ee-8a2b01870b06"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzMtNS0xLTEtMA_b051651e-8507-4269-bab0-2f0f37b6a2b3"
      unitRef="usd">8394000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzYtMS0xLTEtMA_917e16ab-684f-410f-b1c3-3da58ca1dddc"
      unitRef="shares">586000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzYtMy0xLTEtMA_a9b81ca9-1881-4d39-8c4d-464287925ca3"
      unitRef="shares">605000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzYtNS0xLTEtMA_a18a15f4-cbd0-40aa-b6d4-45d5da1d9c7c"
      unitRef="shares">661000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzctMS0xLTEtMA_0f193dc8-134f-4ccd-b427-af7e77c64368"
      unitRef="shares">4000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzctMy0xLTEtMA_2601530e-c474-4e4b-8ae4-f62294a4a6ee"
      unitRef="shares">4000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzctNS0xLTEtMA_3c13753e-1961-484d-957c-d873eacd46e5"
      unitRef="shares">4000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzgtMS0xLTEtMA_18e74bb5-4f09-41c8-a37e-e1f69e23e480"
      unitRef="shares">590000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzgtMy0xLTEtMA_7ddba103-c611-49db-9f0a-7aa8035d5c97"
      unitRef="shares">609000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzgtNS0xLTEtMA_2e0d790e-ecab-45ad-8954-679af6b9e558"
      unitRef="shares">665000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzEwLTEtMS0xLTA_aeb33b9f-78c0-4bb8-8608-65f331f73ebb"
      unitRef="usdPerShare">12.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzEwLTMtMS0xLTA_9c0920bc-56e8-49ea-bd19-8ad45c2b293b"
      unitRef="usdPerShare">12.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzEwLTUtMS0xLTA_485923b7-2a72-4773-bb0b-cd0f6f4642e8"
      unitRef="usdPerShare">12.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzExLTEtMS0xLTA_786e3d78-88e6-4f20-8096-f3ef5687d7e3"
      unitRef="usdPerShare">12.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzExLTMtMS0xLTA_3c44914a-df73-4965-a7a0-53768053f3ce"
      unitRef="usdPerShare">12.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjYvZnJhZzo0NTgyMTQ5N2Q3MTk0YWE2OWFiNmJkMzZhZDJmOTJmOS90YWJsZTphYWU2Y2ZhNmFhMjQ0N2Y2YWZlMjk2ZTkwNmI4Y2U2Ni90YWJsZXJhbmdlOmFhZTZjZmE2YWEyNDQ3ZjZhZmUyOTZlOTA2YjhjZTY2XzExLTUtMS0xLTA_2570656c-d38d-411c-9907-c39d51bdcbc2"
      unitRef="usdPerShare">12.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzEwOTk1MTE2NDIyNTY_103e1b2c-cc9a-460d-8009-7aa71236a7a2">Collaborations&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into collaborative arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized for these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2020, we acquired a 20.5% stake in BeiGene, Ltd. (BeiGene), for approximately $2.8&#160;billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene commenced selling XGEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and will commercialize KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and BLINCYTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global R&amp;amp;D costs by providing cash and development services up to $1.25&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, net costs recovered from BeiGene for oncology product candidates were $225&#160;million and were recorded as an offset to R&amp;amp;D expense in the Consolidated Statements of Income. Profit share payments and product sales between Amgen and BeiGene were not material for the year ended December 31, 2020. As of December 31, 2020, the amount owed from BeiGene for net costs recovered was $113&#160;million, which is included in Other current assets in the Consolidated Balance Sheets. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 9, Investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharma AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are in a collaboration with Novartis Pharma AG (Novartis) to jointly develop and commercialize Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(erenumab-aooe). In the United States, Amgen and Novartis jointly develop and collaborate on the commercialization of Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Amgen, as the principal, recognizes product sales of Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States, shares U.S. commercialization costs with Novartis and pays Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Novartis pays Amgen double-digit royalties on net sales of the product in the Novartis exclusive territories and funds a portion of global R&amp;amp;D expenses. In addition, Novartis will make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds are achieved with respect to Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. Amgen manufactures and supplies Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; worldwide. The migraine collaboration will continue for the commercial life of the product unless terminated in accordance with its terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in litigation with Novartis over our collaboration agreements for the development and commercialization of Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See Note 19, Contingencies and commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2020 and 2019, net costs recovered from Novartis for migraine products were $192 million and $187 million, respectively, and were recorded primarily in SG&amp;amp;A expense in the Consolidated Statements of Income. During the year ended December&#160;31, 2018, net costs paid to Novartis for migraine products were $44 million and were recorded primarily in SG&amp;amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2020, 2019, and 2018, royalties due to Novartis for Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $139&#160;million, $115 million and $43 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2020, 2019 and 2018, royalties due from Novartis for Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were not material. As a result of certain regulatory and commercial events, we received milestone payments from Novartis of $295 million during the year ended December 31, 2018, which was recorded in Other revenues in the Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bayer HealthCare LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are in a licensing arrangement with Bayer HealthCare LLC (Bayer) for Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is currently marketed and sold in more than 100 countries around the world for the treatment of unresectable liver cancer and advanced kidney cancer. In the United States, Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is also approved for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we amended the terms of our agreement with Bayer, which transferred all our operational responsibilities outside the United States to Bayer, including commercial and medical affairs activities. Prior to the amendment of the agreement, we shared equally in the profits outside the United States, excluding Japan. In lieu of this profit share, Bayer now pays us a royalty on sales of Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at a percentage rate in the low 30s. The rights to develop and market Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan are reserved to Bayer. In the United States, Bayer pays us a royalty on sales of Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at a percentage rate in the high 30s.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement with Bayer will terminate at the later of the date when patents expire that were issued in connection with product candidates discovered under the agreement or on the last day that we or Bayer market or sell products commercialized under the agreement anywhere in the world. Patents related to Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; began to expire in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the 2020 amendment to the collaboration agreement, royalties due from Bayer for Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $217&#160;million and net profits were not material for the year ended December 31, 2020. During the years ended December 31, 2019 and 2018, royalties due from Bayer for Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were $79 million and $91 million, respectively. During the years ended December 31, 2019 and 2018, Amgen recorded Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; net profits of $210 million and $164 million, respectively. Royalties and profit share due from Nexavar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were recorded in Other revenues in the Consolidated Statements of Income. Net R&amp;amp;D expenses related to the agreement were not material for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones, which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;amp;D costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzExNTQ0ODcyMTEzOTg1_109f394b-d8cf-4179-ac6d-9c1e1361cd32"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzExNTQ0ODcyMTEzOTcx_682f7e9b-794a-4fd0-af62-caaf6a103a78"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="id4c3de7ba47e48ddbb6721ed2b6093e0_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE2NDkyNjc0NTI1OTE_adbb65c3-bdc0-43fd-bc27-d6d65a74c662"
      unitRef="usd">1250000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="if08caf3a57bd45d9a187961c49e97c9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjUwMTE2_f27766ad-9822-4fc1-8774-fab3cdd4ff89"
      unitRef="usd">225000000</us-gaap:RecoveryOfDirectCosts>
    <amgn:RecoveryOfDirectCostsReceivable
      contextRef="ic9eb1e8041bf4e8b93d86d4c965d1bcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjUwNTI4_26e692f1-b004-4b1e-b4cb-f76ef7c9bf27"
      unitRef="usd">113000000</amgn:RecoveryOfDirectCostsReceivable>
    <amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment
      contextRef="i7cb08466e4c94fc284de233b8b27d515_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzIxNjg_60546b6f-66eb-4768-88dd-7f52a5206593"
      unitRef="usd">100000000</amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i64588391e1684a749dec8deb14c630d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzI3MzY_f1e509f1-e46b-41c2-8ed2-1edc80b3ca0a"
      unitRef="usd">192000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i018453dd7c3743639ceacf5473e7c62d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzExNTQ0ODcyMTEzOTY4_7900a9f6-eaaf-4b83-a38a-6df630389a8c"
      unitRef="usd">187000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="ia6aa7777cdbf4d8ba13b5dcf14c0d732_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzMxNTY_acbff8b0-07a7-4736-83bd-acba3428a4b7"
      unitRef="usd">44000000</us-gaap:DirectOperatingCosts>
    <us-gaap:RoyaltyExpense
      contextRef="i0041c53471f04a019348539dd1051757_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjQ2Mzg2_51b8a187-2df9-4c5c-a6bf-8f2a4c228652"
      unitRef="usd">139000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i43d26623d3f34500a3be4c9287eaf130_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzMzMzc_49ee7f0e-2ff7-4543-a282-53ef762633ef"
      unitRef="usd">115000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i147ff41e3aad46019e4652e564939eeb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzMzNDQ_af1b2b7f-b422-47a3-b66f-26348afca521"
      unitRef="usd">43000000</us-gaap:RoyaltyExpense>
    <us-gaap:Revenues
      contextRef="i5c99bb199b504bc5813a6070a2c0f7a2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzM2NTM_3804d79f-b5c0-44ae-bee9-a76c014a0f9d"
      unitRef="usd">295000000</us-gaap:Revenues>
    <amgn:NumberofCountriesProductsisMarketedandSold
      contextRef="i5aae7473918a4b2fbd03dbe169ce9681_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzQwNTY_692fcf5e-b8e3-4e74-9c29-93603dc4f763"
      unitRef="country">100</amgn:NumberofCountriesProductsisMarketedandSold>
    <amgn:CollaborativeArrangementRoyaltyIncomePercentage
      contextRef="i26fb37cd13a747f1b39eabafba709ded_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU0OTc1NTgxNjEyMzE_2adba96c-98c1-4a14-af18-23de958fa2c7"
      unitRef="number">0.30</amgn:CollaborativeArrangementRoyaltyIncomePercentage>
    <amgn:CollaborativeArrangementRoyaltyIncomePercentage
      contextRef="i6e670e37529947c6a6e43ad60cc1072e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU0OTc1NTgxNjEyMzk_aa0996bd-ec54-4548-bbfb-3da712e2ed32"
      unitRef="number">0.30</amgn:CollaborativeArrangementRoyaltyIncomePercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9ac446a3f5b049498d97d5cdc40e8884_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzI3NDg3NzkwOTE0Mzc_1aabf36d-f990-4005-9dae-e51848235739"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib720207eae304b4db4149e5ba761b733_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjQ5NjU3_c1d41023-db8f-4e0d-9c2a-ecc5d509d67c"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icc295629ce08431a87b6af7ac665aa1c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzE3MDQyNDMwMjQ5NjY1_991a82e4-4a48-4d48-a6d1-aadc5e893a51"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:CollaborativeArrangementNetIncome
      contextRef="i6accd8c04bc64375b6db9a710bfd1a7a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU5MjY_5b0f6bfb-a17d-4e4d-901a-bead5fa1155e"
      unitRef="usd">210000000</amgn:CollaborativeArrangementNetIncome>
    <amgn:CollaborativeArrangementNetIncome
      contextRef="icd4923b31ebb413985529cfbbf320c70_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMjkvZnJhZzowYjU0NDNlMzY5MmI0ZjU2ODA1MjhmNDUyMTQyNTU0NS90ZXh0cmVnaW9uOjBiNTQ0M2UzNjkyYjRmNTY4MDUyOGY0NTIxNDI1NTQ1XzU5MzM_44e42a1e-37a1-4785-8c5a-b7bfcb5b04de"
      unitRef="usd">164000000</amgn:CollaborativeArrangementNetIncome>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDI1Nzk_f45b17ac-98a5-4c3d-9602-f22e1f05b6da">Investments&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents in the above table excludes bank account cash of $802 million and $677 million as of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after three years through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2020, 2019 and 2018, realized gains on interest-bearing securities were $37 million, $92 million and $29 million, respectively, and realized losses on interest-bearing securities were $4 million, $36 million and $394 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review our available-for-sale investments for declines in fair value below our cost basis each quarter or whenever circumstances indicate that the cost basis of an asset may not be recoverable and assess whether the decline was due to credit-related factors or other factors. Our evaluation is based on a number of factors, including the extent to which the fair value is below our cost basis as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is impaired could change in the future based on new developments or changes in assumptions related to that particular security. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments in equity securities with readily determinable fair values of $477 million and $303 million as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. For the years ended December 31, 2020, 2019 and 2018, net unrealized gains on publicly traded securities were $174&#160;million, $112&#160;million and $24&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2020, 2019 and 2018, were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments of $203 million and $176 million in equity securities without readily determinable fair values as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. Gains and losses recognized on these securities, including adjustments to the carrying values of these securities, were not material for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Limited partnership investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held limited partnership investments of $496 million and $320 million as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2020, unfunded additional commitments to be made for these investments during the next several years were not material. For the years ended December 31, 2020, 2019 and 2018 net gains recognized from our limited partnership investments were $241&#160;million, $27 million and $91 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8&#160;billion, of which $2.6&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;amp;D. Our equity investment in BeiGene is included in Other assets in the Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $2.4&#160;billion. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Interest and other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we recognized an increase in the carrying value of our investment by purchasing additional shares to maintain our ownership interest for an aggregate cost of $569 million and recognized $34 million for the impact of other BeiGene ownership transactions. The carrying value of the investment during the year ended December 31, 2020, was reduced for our share of BeiGene&#x2019;s net losses of $229 million and amortization of the basis difference of $109 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the carrying value and fair value of our approximately 20.5% ownership interest in BeiGene totaled $2.9 billion and $4.9 billion, respectively. We believe that as of December 31, 2020, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzQyODA_49bf78c1-05dc-48db-9ab8-06e3ac9420cb">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4abab397f36846d2963dacabb469a08b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtMi0xLTEtMA_6eaf915b-9fea-4c73-9449-7fdaadfda096"
      unitRef="usd">129000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4abab397f36846d2963dacabb469a08b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtNC0xLTEtMA_d71bbab0-e172-42f5-b804-c0abde68ef0b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4abab397f36846d2963dacabb469a08b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtNi0xLTEtMA_20ad443d-3f7c-4e4a-981f-d840b682fb82"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4abab397f36846d2963dacabb469a08b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEtOC0xLTEtMA_9354d54f-5ade-4cbd-9ea2-12d03bb361a4"
      unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia314c059b63d4452a382baae50386fbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItMi0xLTEtMA_5ecbafdb-eef8-41ad-8e51-438ebec99e24"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia314c059b63d4452a382baae50386fbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItNC0xLTEtMA_1a47db3b-2fdf-42a9-baf2-470820d25cd7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia314c059b63d4452a382baae50386fbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItNi0xLTEtMA_02841f4c-c12b-4679-823c-3307258303d9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia314c059b63d4452a382baae50386fbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzItOC0xLTEtMA_ed6dc9b7-05a7-44fd-88e8-3be93b92701d"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctMi0xLTEtMA_796cfaa6-1feb-428b-a4f6-9506d9cd553f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctNC0xLTEtMA_3249e532-d20f-4faa-baa3-81c28ca78aae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctNi0xLTEtMA_28cc51d2-fc92-4cd9-8b41-1cdefddb3dcf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzctOC0xLTEtMA_a169a4f2-a12b-4c96-8f5d-ff6f7f781bf9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie1043550a1f84782876ef562e9149716_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtMi0xLTEtMA_feca299c-dab8-4ee6-b09e-7f5433035337"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie1043550a1f84782876ef562e9149716_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtNC0xLTEtMA_3e21ec6d-e933-4f59-88e5-73d9297f428e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie1043550a1f84782876ef562e9149716_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtNi0xLTEtMA_44dc9a40-0226-4477-b9d9-ab51b5e36296"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1043550a1f84782876ef562e9149716_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzgtOC0xLTEtMA_e4ca395e-8a39-40db-b356-80e0908bc036"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktMi0xLTEtMA_a3ba77bd-ff99-4fbb-b722-96bda46128a0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktNC0xLTEtMA_d3c8dd92-ea1b-4020-aae3-85d6cfcd86dc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktNi0xLTEtMA_b2806ee6-35ed-4993-b084-d2cc409b8eb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzktOC0xLTEtMA_6492bb18-d4a5-490c-a6c3-e2053dc201c7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTItMS0xLTA_3c9f5973-5574-4311-8173-f6e5409ed63f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTQtMS0xLTA_fa11aae1-2928-4544-96ec-0cc67ca54723"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTYtMS0xLTA_13c6649f-8799-4204-95fb-9bf7f799a976"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEwLTgtMS0xLTA_9b3ca34c-829e-47c1-a5cb-f5f0ff95c567"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2783b98e50e847a19205180e25cee168_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTItMS0xLTA_a4590dc5-4041-4e07-a49b-6e8358e10bee"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2783b98e50e847a19205180e25cee168_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTQtMS0xLTA_935ae129-3b6c-45ab-9239-1d210ca184ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2783b98e50e847a19205180e25cee168_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTYtMS0xLTA_3d2707f8-0e52-41f8-b56c-8f3a8e8e1c59"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2783b98e50e847a19205180e25cee168_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEyLTgtMS0xLTA_1377f42b-d587-4117-a26b-f6356c300627"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTItMS0xLTA_e8ba2d88-d01c-43f0-8374-517b5e8b66a1"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTQtMS0xLTA_9a024a3d-6447-4fbe-9393-8a5eb058b134"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTYtMS0xLTA_9fc4c460-f735-47a6-aa1e-93a9174f837b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzEzLTgtMS0xLTA_db480a34-4e79-4f42-91bb-e0257914327b"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTItMS0xLTA_bf22bff2-eda1-4686-a6f2-6a395eb01ecb"
      unitRef="usd">9844000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTQtMS0xLTA_b6922224-2a81-404c-b17a-c460558aa388"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTYtMS0xLTA_f29eb048-80d3-4eba-882f-da596e529f47"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo3ZGNhNjk3OGRiYzk0M2RhYjM3MDU5M2FlZjNlYTBjNS90YWJsZXJhbmdlOjdkY2E2OTc4ZGJjOTQzZGFiMzcwNTkzYWVmM2VhMGM1XzE0LTgtMS0xLTA_e2090d7c-7baa-404d-ae03-c819c9cbb927"
      unitRef="usd">9845000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtMi0xLTEtMA_724f3728-f9fa-45f0-bdb9-5da298fad395"
      unitRef="usd">359000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtNC0xLTEtMA_dc8821f6-b79e-4c25-a5f1-af7ee55593d8"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtNi0xLTEtMA_5da3c7cd-bd94-4197-bfaf-a405f78dd501"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEtOC0xLTEtMA_b719db84-f88e-474c-af54-f0d494abbf3a"
      unitRef="usd">360000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItMi0xLTEtMA_05346ff9-0165-464d-86a2-fc041e1b1079"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItNC0xLTEtMA_4d2d05d0-f701-4551-9755-12e780cfc82a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItNi0xLTEtMA_c892251d-a902-4c23-9ae5-a83df6c31d1a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzItOC0xLTEtMA_f56601cf-ccce-49f5-b491-30e31792c87f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctMi0xLTEtMA_359781f5-8dc4-4190-a593-52f246df1b75"
      unitRef="usd">1108000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctNC0xLTEtMA_e60c6cd9-348c-4ccb-a10f-a678cdb4984b"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctNi0xLTEtMA_86975278-6b13-4213-b3b8-9a88102a5881"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzctOC0xLTEtMA_a85aad6c-bc50-47f0-8b6e-e1cdf30b0c20"
      unitRef="usd">1121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtMi0xLTEtMA_d607bb10-2ae5-4bc0-8b66-27c4b10c35b3"
      unitRef="usd">824000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtNC0xLTEtMA_6314e3c6-90b3-480a-9387-06d7acb95572"
      unitRef="usd">10000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtNi0xLTEtMA_a1d7d406-20ab-4fb7-8568-8472bc45bc14"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzgtOC0xLTEtMA_676ec692-1a5e-4f88-9440-bcb94cfce034"
      unitRef="usd">834000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktMi0xLTEtMA_289354ef-be0e-4b7f-a363-8076138c6831"
      unitRef="usd">195000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktNC0xLTEtMA_c6d7db09-6fcf-4671-8cd7-9e7d045bcd89"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktNi0xLTEtMA_73b179d6-2d9f-44fc-8023-72422fdf5a99"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzktOC0xLTEtMA_238b057d-5c79-45bf-a03c-0d80caffdcbb"
      unitRef="usd">198000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTItMS0xLTA_1e5b369f-31ca-45ca-8b74-675187d5ffd0"
      unitRef="usd">181000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTQtMS0xLTA_0f95eff8-0358-41a8-ba4d-721bdd0fddb0"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTYtMS0xLTA_f4120b82-3abf-4ecc-b515-5286fa30d898"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEwLTgtMS0xLTA_33d248a3-8293-4ae0-a86f-fe3babccc92e"
      unitRef="usd">182000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTItMS0xLTA_59f5978c-9554-4b84-928c-038b2dd4374a"
      unitRef="usd">5250000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTQtMS0xLTA_97ef5bec-d089-4bdd-bdc5-2e33a12f1ed6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTYtMS0xLTA_be8c62bd-1bda-42c3-9561-90792bc92486"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEyLTgtMS0xLTA_8ba15bdd-8f5f-43e4-9aef-7095d1e93ca4"
      unitRef="usd">5250000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTItMS0xLTA_97a4ab37-4959-4b96-b5ad-40500afb98d1"
      unitRef="usd">289000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTQtMS0xLTA_ae7a68ab-5c9a-41c6-8a9f-4bfe068da41f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTYtMS0xLTA_12c04100-585a-4520-babe-13cac5d461c8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzEzLTgtMS0xLTA_aa30c7c0-0de6-40fb-9112-93c64225d773"
      unitRef="usd">289000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTItMS0xLTA_efd1d7b9-98fd-4ae2-96b8-fa8866691661"
      unitRef="usd">8206000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTQtMS0xLTA_e9e00410-9c0c-45d0-ac0f-64ede380ee08"
      unitRef="usd">28000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTYtMS0xLTA_d8221152-acd0-49cf-b693-6830164fa5d0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTozNjMzMDg2ZTExNWQ0NTVmODJiMDk3NmE1NGIzNDZkMC90YWJsZXJhbmdlOjM2MzMwODZlMTE1ZDQ1NWY4MmIwOTc2YTU0YjM0NmQwXzE2LTgtMS0xLTA_9809f383-87a0-419b-88bb-f0e040857546"
      unitRef="usd">8234000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzQyODg_0520f94f-b0dc-4f32-b1d1-fc9dbffeb6a3">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife9255d5d6fe481fad09edd63beb52e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzItMi0xLTEtMA_971c16cb-3aea-41d3-8593-742955dd32e1"
      unitRef="usd">5464000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i78fbd934d2344ce09137ff8acd872830_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzItNC0xLTEtMA_b8ba7a5d-471f-489c-b25d-39298d77047f"
      unitRef="usd">5360000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ife9255d5d6fe481fad09edd63beb52e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzMtMi0xLTEtMA_b89dceb6-4d8b-48ac-b851-9ea6194a90bc"
      unitRef="usd">4381000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i78fbd934d2344ce09137ff8acd872830_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzMtNC0xLTEtMA_a07b272c-10ad-4744-823d-3d984672de52"
      unitRef="usd">2874000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife9255d5d6fe481fad09edd63beb52e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzUtMi0xLTEtMA_b9a13638-f744-4b48-8bc8-8893a688061b"
      unitRef="usd">9845000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78fbd934d2344ce09137ff8acd872830_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo2NWFkOWQ4MzQ5Njc0NWYyYTNmMzY3ZDRkOGYzNjY4My90YWJsZXJhbmdlOjY1YWQ5ZDgzNDk2NzQ1ZjJhM2YzNjdkNGQ4ZjM2NjgzXzUtNC0xLTEtMA_c0007556-9201-43bb-833e-790926637041"
      unitRef="usd">8234000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:Cash
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzIxMTE_c32ce812-74ba-4f46-8da9-2fdd02b8fd7a"
      unitRef="usd">802000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzIxMDc_2d00e5a6-86e6-437d-bf63-5ea426f591f5"
      unitRef="usd">677000000</us-gaap:Cash>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzQzMDg_75959010-5c9f-4186-82b4-087010503cd0">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after three years through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzItMi0xLTEtMA_7ca73891-30e4-45cb-8953-4c83ac6e80cc"
      unitRef="usd">9795000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzItNC0xLTEtMA_8f7dd26d-60e3-4665-9b80-12ef6b404cf2"
      unitRef="usd">5629000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzMtMi0xLTEtMA_7ac70d62-646b-46d6-9cfc-335ee9f3a5ae"
      unitRef="usd">50000000</amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
    <amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzMtNC0xLTEtMA_2f8245bc-7a61-49f7-8e9b-90d26e42180d"
      unitRef="usd">2304000000</amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
    <amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzQtMi0xLTEtMA_00b857bf-b984-4305-8299-fad4c734576e"
      unitRef="usd">0</amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue>
    <amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzQtNC0xLTEtMA_9502c33e-d395-4677-beb9-8b25bd21252c"
      unitRef="usd">119000000</amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzctMi0xLTEtMA_947b01e5-161a-44d6-aafa-1d6b9cd6730a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzctNC0xLTEtMA_b483a49d-4e4c-463e-b5c0-ab819c002c71"
      unitRef="usd">182000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzgtMi0xLTEtMA_d14febe6-9f3d-4822-b8df-ee8d25d5e0bc"
      unitRef="usd">9845000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90YWJsZTo0NTgwYTYyMWFiYzU0OTYyYTU2YjBjMDgxYjczNmMyNC90YWJsZXJhbmdlOjQ1ODBhNjIxYWJjNTQ5NjJhNTZiMGMwODFiNzM2YzI0XzgtNC0xLTEtMA_d958f7d8-265d-4d31-984f-50a5bca1bec1"
      unitRef="usd">8234000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzgwMg_81b2fe58-6654-428b-b767-8261d6805dba"
      unitRef="usd">37000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzgwNg_be4da055-9c9d-4b85-a9f5-24c5a4155f2b"
      unitRef="usd">92000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzgxMw_060a1eb1-5dfa-4029-849d-4122ab0ae1b5"
      unitRef="usd">29000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzg4Nw_cb7f2863-2b12-46a5-8b29-bdd021956f3a"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzg5MQ_7594b226-9565-485b-938d-e13fc77a0c11"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzg5OA_b118e9d5-5a5b-45d2-bf84-0fb02939bb19"
      unitRef="usd">394000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMwMDg_48c1c8d4-c8da-4ab3-b753-655f2bd269f3"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMwMTU_5b1763e2-41bb-4427-8068-4501b0d3acc5"
      unitRef="usd">303000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDI1ODY_1509a25a-dd8b-4d44-9ee2-dbef2268e3cb"
      unitRef="usd">174000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzExNTQ0ODcyMTA2MzA4_fafc980d-bc3d-43e6-a841-4756062f4280"
      unitRef="usd">112000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzExNTQ0ODcyMTA2MzIy_e2726f50-a636-4e87-8fe3-10166d7c0cbd"
      unitRef="usd">-24000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMzMzI_cc8bd9ae-ee1a-4b72-bc90-df070096d475"
      unitRef="usd">203000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzMzMzk_928157e4-c6a0-4b10-8368-0893578ee7a3"
      unitRef="usd">176000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:AlternativeInvestment
      contextRef="ib3acbfa95e2d42d59a15e70c74debd7d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzM2ODk_c4827ecc-5995-4d36-b6ab-0f91d5cdeea0"
      unitRef="usd">496000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment
      contextRef="i8005c102cf76487dae26362888d802fc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzM2OTY_fc58dd98-a67f-4ca5-b1e7-d6b062eea26b"
      unitRef="usd">320000000</us-gaap:AlternativeInvestment>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i9f6cc35d1d07485d8a62dae2b89a8859_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDI2MTQ_9bed3911-537c-447e-bfa3-4c7f9193710c"
      unitRef="usd">241000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i1bcbc99707a942a3b9412cca58536799_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzY5OTc_c8bee449-a5e1-4477-afce-99e57e8df57b"
      unitRef="usd">27000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="if984bbfefa824630ad0be7898a756667_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2MzcwMDI_ff22c156-452d-4574-9237-756f18d1f92c"
      unitRef="usd">91000000</amgn:AlternativeInvestmentNetGainLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNTI_0df06163-a1b1-43ea-8c11-96c093fae20f"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwMDU_25e0c009-0b1c-487b-8d6f-64986050a2cd"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwMTk_db6f8ff0-cc69-443b-84ab-5ae90ed94353"
      unitRef="usd">2600000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="if9e22a47202d49c79c39aaafff5c59a5_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDMzNzM_6a196eaf-1b22-4ed7-ae20-a3b3d4f7b69d"
      unitRef="usd">2400000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic2cdef4357c64e9cb34661796f119661_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNTk_68a67454-7717-41a7-aa6d-a040eaf47a45">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i96d4a84d1d744c3196a3054655ba8dc9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNjI_0fd8ccf1-2684-4efa-bc14-7a921a0b5d8a">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <amgn:EquityMethodInvestmentChangeInCarryingValue
      contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIwNzg_779d02b5-f62d-42ae-b946-5886303d8626"
      unitRef="usd">569000000</amgn:EquityMethodInvestmentChangeInCarryingValue>
    <amgn:EquityMethodInvestmentChangeInCarryingValueOther
      contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIxNDY_e12795fd-0e6b-48e1-860a-12a09eebe764"
      unitRef="usd">34000000</amgn:EquityMethodInvestmentChangeInCarryingValueOther>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIyMzc_29230eb4-ce55-4223-846e-f17b77c39627"
      unitRef="usd">-229000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i5d4032e63050456abe6d8c0b2d245d2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIyNjc_69c12cf7-6791-4011-9078-5b5a1a8395f8"
      unitRef="usd">109000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIzMTg_663b8568-8a58-45f2-afa1-1ff4df6e234b"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIzMzM_9e3742be-41f4-497d-b72d-71b662bdded9"
      unitRef="usd">2900000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzIvZnJhZzo2M2QzZmVjZDYyODc0NTA1YTg0MTVlM2E2NTViYjFkMy90ZXh0cmVnaW9uOjYzZDNmZWNkNjI4NzQ1MDVhODQxNWUzYTY1NWJiMWQzXzEwOTk1MTE2NDIzNTI_0c312e8b-c30c-4cd7-a8d4-adb892e29821"
      unitRef="usd">4900000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90ZXh0cmVnaW9uOmE1ZmQzNDNlNTFkYzRiZjVhZjcyNzkxOGYxOTQwNWEyXzkw_3c588be0-187f-4e34-8db5-4ad16a3593b7">Inventories&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90ZXh0cmVnaW9uOmE1ZmQzNDNlNTFkYzRiZjVhZjcyNzkxOGYxOTQwNWEyXzg0_9319dd09-9ce3-4a47-a8c8-103925088573">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzItMS0xLTEtMA_bf8b2708-4153-4cd4-9495-43e4019c5be1"
      unitRef="usd">486000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzItMy0xLTEtMA_d763ee66-bc2e-48f9-a683-459a3c91b2c5"
      unitRef="usd">358000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzMtMS0xLTEtMA_dd018593-360b-4bab-b4e0-52e1b392c8ba"
      unitRef="usd">2437000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzMtMy0xLTEtMA_a460ac72-0674-435b-aef2-1f954f743068"
      unitRef="usd">2227000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzQtMS0xLTEtMA_20789795-d842-46eb-a5b1-7e1165625b65"
      unitRef="usd">970000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzQtMy0xLTEtMA_72e7c18a-5b83-45f7-9762-b8b752399dc6"
      unitRef="usd">999000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzUtMS0xLTEtMA_be91908f-d638-4a42-b12f-8a981282dda7"
      unitRef="usd">3893000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzUvZnJhZzphNWZkMzQzZTUxZGM0YmY1YWY3Mjc5MThmMTk0MDVhMi90YWJsZTo2MDcxNzI1M2NhYjU0OTVlOWFmYjQ3ZmJkMmYwNzlhZS90YWJsZXJhbmdlOjYwNzE3MjUzY2FiNTQ5NWU5YWZiNDdmYmQyZjA3OWFlXzUtMy0xLTEtMA_8562d545-f221-4e5d-8b71-853acfcda903"
      unitRef="usd">3584000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzQ2NQ_00269458-29bb-4f11-8a69-f53659be3eb5">Property, plant and equipment&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;life&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2020, 2019 and 2018, we recognized depreciation and amortization expense associated with our property, plant and equipment of $640 million, $635 million and $630 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Geographic information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzQ2MQ_92b8731f-21a2-43d6-aac5-37996d96bcce">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;life&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzItMy0xLTEtMA_e12b9d49-9700-47a7-98ee-f9e5d55f0806"
      unitRef="usd">259000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzItNS0xLTEtMA_299e06af-f5fa-40e8-8da9-888039f2b67e"
      unitRef="usd">263000000</us-gaap:Land>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4746bb368e19427abd5d968255881278_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjY2NzM3ZDgzZTQyMjQxZTg4MDI2OTg1NzVjN2U1ZmQ5XzEwOTk1MTE2Mjc3ODc_8130dd4b-b963-4784-920f-56ea5dc490f0">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icf2f91f1812e4b6985813bd5ad956751_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjY2NzM3ZDgzZTQyMjQxZTg4MDI2OTg1NzVjN2U1ZmQ5XzEwOTk1MTE2Mjc3OTI_ad40719e-960c-457a-8541-82f85e2cfd15">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtMy0xLTEtMA_7cc7daaf-c9c3-4f8b-a295-9473177d36d7"
      unitRef="usd">3857000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzMtNS0xLTEtMA_5b9eb619-eeb1-4eb4-ba73-973314da31e4"
      unitRef="usd">3757000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8de40ffd50114a4b85de7a66f9fe7476_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjVjNWQzNGU0ODA1YTQ5YzQ5NGEzODFhZDk4N2RlMDAzXzEwOTk1MTE2Mjc3ODU_97aa69a8-32e6-41e0-8b73-243dfcdf39e1">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if6f8655d04b041f4ad4b564443d75726_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjVjNWQzNGU0ODA1YTQ5YzQ5NGEzODFhZDk4N2RlMDAzXzEwOTk1MTE2Mjc3OTA_005b2b5c-10a2-4c95-b911-9803735c9bc5">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtMy0xLTEtMA_f6b64077-c05b-46b5-8286-629f453e86e2"
      unitRef="usd">2865000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzQtNS0xLTEtMA_4b1c6750-7064-4f49-b88e-d320770e39c8"
      unitRef="usd">2655000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i895c1063378b4068a891fd1e71fb3589_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjMxYjc4ZDBlYWFlMDRhYjQ4ZGUwNmY1Zjg0NjU3Y2M1XzEwOTk1MTE2Mjc3ODU_efe65445-522a-46cc-8dc2-18f76d0c07b9">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1d8a60c530804890ab62b6e0d832989f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjMxYjc4ZDBlYWFlMDRhYjQ4ZGUwNmY1Zjg0NjU3Y2M1XzEwOTk1MTE2Mjc3OTA_93715969-f691-4aa7-aea1-1e1006baeb28">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <amgn:LaboratoryEquipment
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtMy0xLTEtMA_f1c663a8-2c11-4b5a-9389-871ab5ecf222"
      unitRef="usd">1257000000</amgn:LaboratoryEquipment>
    <amgn:LaboratoryEquipment
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzUtNS0xLTEtMA_15bd5b1b-9d4f-4d98-b9f4-082fef1ada2d"
      unitRef="usd">1236000000</amgn:LaboratoryEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4e3dc8e131e74b639d5fa9747c30f69f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMS0xLTEtMTEwNDc_1b5b2d52-cfb1-46f8-9d38-a45398cbaeb5">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <amgn:FixedEquipment
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMy0xLTEtMTEwNDc_d4190f9d-a9eb-4928-98c9-33f76fb6cfe3"
      unitRef="usd">2406000000</amgn:FixedEquipment>
    <amgn:FixedEquipment
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtNS0xLTEtMTEwNDc_13489259-b0cc-4c2d-9e16-242d725c42e8"
      unitRef="usd">2338000000</amgn:FixedEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i396cde7c35a94e749b408f43a2826d8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMS0xLTEtMC90ZXh0cmVnaW9uOjRlZmRhODhiYjg5YzQxM2FhNTQzNjk5NzI3N2I1YWRhXzEwOTk1MTE2Mjc3ODQ_ace13850-4ca0-45e0-ad8f-782c4e369b44">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4defc84603e845d1abe667bb41b2c371_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMS0xLTEtMC90ZXh0cmVnaW9uOjRlZmRhODhiYjg5YzQxM2FhNTQzNjk5NzI3N2I1YWRhXzEwOTk1MTE2Mjc3ODg_3e9cba8a-706c-4af4-b633-8cc89bf7f954">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtMy0xLTEtMA_3ab18d62-7da7-4659-bcf7-8bfd5246ae31"
      unitRef="usd">1216000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzYtNS0xLTEtMA_396ca00a-5712-4172-a7ca-cbb55741f0dc"
      unitRef="usd">1154000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if71cd1836df64fa297d00f961c9878db_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctMS0xLTEtMC90ZXh0cmVnaW9uOjVkMjNkZWJmNTlmMjQwN2U5ODQ2YTdkYmRkM2ViMzNjXzEwOTk1MTE2Mjc3ODU_9cdf522b-6252-429a-88a6-68d9cf567950">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idd99c6d5f7e14c2b9fb17834726169ed_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctMS0xLTEtMC90ZXh0cmVnaW9uOjVkMjNkZWJmNTlmMjQwN2U5ODQ2YTdkYmRkM2ViMzNjXzEwOTk1MTE2Mjc3OTA_ebfc1a19-b414-4e42-8570-e02893253c58">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctMy0xLTEtMA_09d1b096-a744-4e36-a1d6-7b8e4f2745c8"
      unitRef="usd">1091000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzctNS0xLTEtMA_d69f7587-1589-45bb-b9b9-dc273390ad71"
      unitRef="usd">975000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzgtMy0xLTEtMA_b02beb37-a39d-4533-a159-68facef8dcea"
      unitRef="usd">915000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzgtNS0xLTEtMA_ebb8aeb8-be14-4125-a2a1-2e86bd929868"
      unitRef="usd">907000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzktMy0xLTEtMA_7ba602d3-4a23-4e71-9c08-1b048aa9d7c7"
      unitRef="usd">13866000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzktNS0xLTEtMA_fedeb1c6-cbbf-4c53-ae29-26b88be3b8e2"
      unitRef="usd">13285000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzEwLTMtMS0xLTA_6df3f1b2-b09e-4610-a4bf-3f175eeae19d"
      unitRef="usd">8977000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzEwLTUtMS0xLTA_87290a40-963f-4ed3-9d98-e99cd5b1d21c"
      unitRef="usd">8357000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzExLTMtMS0xLTA_527895ab-8970-4885-9c56-98faef83ad44"
      unitRef="usd">4889000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTplNDBkMDFkMjE0MzU0Njc3YmY0MWJjOTY3N2ExODcxZC90YWJsZXJhbmdlOmU0MGQwMWQyMTQzNTQ2NzdiZjQxYmM5Njc3YTE4NzFkXzExLTUtMS0xLTA_e070c6d1-ccdf-4143-b0b7-c12e2c085213"
      unitRef="usd">4928000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzI3Mg_f05c9a8e-5da4-4c3d-9bf3-0be1ae1eb182"
      unitRef="usd">640000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzI3Ng_db208f11-2e27-4f53-a9cb-8f1ee29b8725"
      unitRef="usd">635000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzI4Mw_2f0ada78-166a-4f20-a039-78c7d98d6f1e"
      unitRef="usd">630000000</us-gaap:Depreciation>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90ZXh0cmVnaW9uOmU5ZjY3MWFkNDgxNjRlZjdhMGFjZjY5ODM1NWVlYWMzXzQ2Mw_5dac49df-c84a-4eea-9da3-f68ced921a86">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i380c4519a6324acb9471d6b0846ff47a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzItMS0xLTEtMA_9333fee1-a9ff-4226-88d7-ce9e2b57a979"
      unitRef="usd">2473000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7412d430651b4c3aa09e75a732689d3e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzItMy0xLTEtMA_fa2993e4-0a4c-479d-b1fb-2663b4f3700c"
      unitRef="usd">2433000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib25925681a284e8a8cc4bc5abf1a3047_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzMtMS0xLTEtMA_64e8adb6-82b7-4846-82b3-5a36663383e6"
      unitRef="usd">1331000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icf95f14d878c44b7bd718c95c6943ab4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzMtMy0xLTEtMA_2814f5c6-f486-49e7-95bb-031c7c72c2ba"
      unitRef="usd">1402000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9275605c200a4299bbfa5428560e8a03_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzQtMS0xLTEtMA_f81c064a-bc21-4e2c-8e63-f91fcb78e375"
      unitRef="usd">1085000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8ea8f1bac6a4be3807a3e1482036184_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzQtMy0xLTEtMA_1865d1b6-2459-4b51-8752-3bcd8c108e1b"
      unitRef="usd">1093000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzUtMS0xLTEtMA_c828dc7f-c173-4956-99f4-23ebbd0ea675"
      unitRef="usd">4889000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yMzgvZnJhZzplOWY2NzFhZDQ4MTY0ZWY3YTBhY2Y2OTgzNTVlZWFjMy90YWJsZTo0YjNiOGE2YTk5MzA0YTY0YjFlODNlOTE4YWMwYWE5OC90YWJsZXJhbmdlOjRiM2I4YTZhOTkzMDRhNjRiMWU4M2U5MThhYzBhYTk4XzUtMy0xLTEtMA_cfbbef58-8d22-41c2-b7e4-c6ef10cdf9b3"
      unitRef="usd">4928000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5ODE_3f038e0b-fa0e-4a94-8565-ada6a1914b89">Goodwill and other intangible assets&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;amp;D technology rights pertains to technologies used in R&amp;amp;D that have alternative future uses. &lt;/span&gt;&lt;/div&gt;IPR&amp;amp;D consists of R&amp;amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;amp;D projects may vary from their estimated fair values. We review IPR&amp;amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.During the years ended December 31, 2020, 2019 and 2018, we recognized amortization associated with our finite-lived intangible assets of $2.8 billion, $1.4 billion and $1.3 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2021, 2022, 2023, 2024 and 2025, are $2.6 billion, $2.5 billion, $2.4 billion, $2.4 billion and $2.2 billion, respectively.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5ODI_c61404df-30eb-40f8-8562-f14316935dc2">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzItMS0xLTEtMA_888cbd69-e88a-4479-9eba-8b8d704610c8"
      unitRef="usd">14703000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzItMy0xLTEtMjI4MQ_a6dbed78-f7ac-4de7-b383-7d3a86af839b"
      unitRef="usd">14699000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzMtMS0xLTEtMA_d8a98352-0d00-4264-b2bb-c204c8352659"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzMtMy0xLTEtMjI4MQ_ab8fc5d9-aa96-42e4-955b-f2a261668a3a"
      unitRef="usd">26000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzQtMS0xLTEtMA_c40691b2-598f-4389-a7e1-4a58ad1fa9ca"
      unitRef="usd">-14000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzQtMy0xLTEtMjI4MQ_05bf43e1-8313-444f-be37-258948fb98bb"
      unitRef="usd">-22000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzUtMS0xLTEtMA_446e706a-2b5b-4c96-bf2f-7e2bc93f1b5d"
      unitRef="usd">14689000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo1MTMxYzhhN2Y0NDg0MjM1YmEwNTJlNDhlMDJhY2Y5MC90YWJsZXJhbmdlOjUxMzFjOGE3ZjQ0ODQyMzViYTA1MmU0OGUwMmFjZjkwXzUtMy0xLTEtMA_2944c92a-e832-4941-9788-e6429a4ff7c4"
      unitRef="usd">14703000000</us-gaap:Goodwill>
    <amgn:ScheduleOfIntangibleAssetsTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5ODk_2c3ab157-a0c7-4aa4-9945-a86b84b26d32">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iddb8f56cf7cb441696514975a5535ece_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtMS0xLTEtMA_8e9b5cd0-7f18-4d46-a8a2-068fa671cd54"
      unitRef="usd">25591000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iddb8f56cf7cb441696514975a5535ece_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtMy0xLTEtMA_8399619c-7c41-4589-aef0-456f68fe58c9"
      unitRef="usd">10564000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iddb8f56cf7cb441696514975a5535ece_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtNS0xLTEtMA_165507c2-42b3-4c28-9ab0-0c0ca3103906"
      unitRef="usd">15027000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i38d4fa50eb91422a8dde19c58f864d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtNy0xLTEtMA_ade9bd5b-441f-45fe-9495-798981973e1f"
      unitRef="usd">25575000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i38d4fa50eb91422a8dde19c58f864d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtOS0xLTEtMA_a20d09dc-af8f-4383-b33c-b0c8e3898f9f"
      unitRef="usd">8322000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i38d4fa50eb91422a8dde19c58f864d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzQtMTEtMS0xLTA_9696075c-c4f4-4cec-bdc4-86d4ec2545b4"
      unitRef="usd">17253000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibd2f82635b7e4140849137d3c5812d24_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtMS0xLTEtMA_ba4b1fa0-ef71-4b99-bfaa-c551e9823240"
      unitRef="usd">3743000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibd2f82635b7e4140849137d3c5812d24_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtMy0xLTEtMA_f030cb2f-2042-4221-a807-f516f6860e15"
      unitRef="usd">2791000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibd2f82635b7e4140849137d3c5812d24_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtNS0xLTEtMA_d57aab99-48e1-48a2-bb07-a9c3e7e3c886"
      unitRef="usd">952000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i795833ab718e4229838a54da0009fbc2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtNy0xLTEtMA_cabc147d-e282-4138-9c1f-a34f2b97a749"
      unitRef="usd">3761000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i795833ab718e4229838a54da0009fbc2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtOS0xLTEtMA_e9fc8a94-ce42-4ceb-9f54-131429accc3a"
      unitRef="usd">2398000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i795833ab718e4229838a54da0009fbc2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzUtMTEtMS0xLTA_0bcac85f-e38e-48c9-9b51-fa6ff7aa0689"
      unitRef="usd">1363000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtMS0xLTEtMA_55217b0c-593f-46c0-96b7-044f8d1feeb7"
      unitRef="usd">1367000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtMy0xLTEtMA_ea5ce533-8507-464a-bf8a-b82c59bc6d69"
      unitRef="usd">1041000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iba2dba40bf0848e8bf3deb9c026e20ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtNS0xLTEtMA_6b97c96c-ae43-4058-b045-84d53167e607"
      unitRef="usd">326000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i05bcdb11924b427696274755e057121c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtNy0xLTEtMA_397af5cc-7120-464c-bbad-250ae7a01108"
      unitRef="usd">1382000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i05bcdb11924b427696274755e057121c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtOS0xLTEtMA_c16dbf9b-0370-45d8-ab45-1102e31ca87a"
      unitRef="usd">965000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i05bcdb11924b427696274755e057121c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzYtMTEtMS0xLTA_a2daf894-61dd-4b85-8c95-f42c0117afc7"
      unitRef="usd">417000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i058ba3d94d2c43168ff6130531a4ace6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctMS0xLTEtMA_8f8ca67a-bbb9-40a4-a834-8b10688df69f"
      unitRef="usd">1317000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i058ba3d94d2c43168ff6130531a4ace6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctMy0xLTEtMA_1c0083a7-6029-45bb-9cc0-d7ded1c09c71"
      unitRef="usd">1065000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i058ba3d94d2c43168ff6130531a4ace6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctNS0xLTEtMA_99589602-0e9c-42b0-9ce7-1d5d6c604873"
      unitRef="usd">252000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctNy0xLTEtMA_fb4fb08a-ad7c-4d15-b07b-11b0527bb2dc"
      unitRef="usd">1273000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctOS0xLTEtMA_195f7e69-f0bd-4d1a-9678-c86f32aa96cf"
      unitRef="usd">947000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i70fd7a90aaab45f993dee5e04b1d19ec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzctMTEtMS0xLTA_e8ab9462-2c2d-4b9d-8fb6-edd48366d2da"
      unitRef="usd">326000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtMS0xLTEtMA_70c83c07-5c9a-4a8a-b5e7-eba2a719acd7"
      unitRef="usd">32018000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtMy0xLTEtMA_33107f05-df19-4055-abcf-7a1e8d36273e"
      unitRef="usd">15461000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtNS0xLTEtMA_09e8b6ea-ad1d-4765-b827-78619b255f6b"
      unitRef="usd">16557000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtNy0xLTEtMA_6b7e9222-ff07-4436-beb2-2c2f192454a1"
      unitRef="usd">31991000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtOS0xLTEtMA_5116ef06-0143-4e7b-bcef-f0a385e58219"
      unitRef="usd">12632000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzgtMTEtMS0xLTA_93b4f055-e37c-42b5-a46e-4d03be195eb0"
      unitRef="usd">19359000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8242170454444bd1ad4819726216ab26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTEtMS0xLTA_74a978ad-4d29-473c-aff6-8f55ff865a56"
      unitRef="usd">30000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8242170454444bd1ad4819726216ab26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTUtMS0xLTA_48dcb53a-0e81-4079-a94c-875d74221a94"
      unitRef="usd">30000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie96ddc98bc504632bed269fd22978fdc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTctMS0xLTA_978f3fac-187d-4d49-88a2-cdf400c1f6ea"
      unitRef="usd">54000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie96ddc98bc504632bed269fd22978fdc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzEwLTExLTEtMS0w_dba6d5d5-bcfb-4fd8-9d4b-d04dd57e2a56"
      unitRef="usd">54000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTEtMS0xLTA_ba9441a9-640a-48a4-9894-2b8929441ba2"
      unitRef="usd">32048000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTMtMS0xLTA_9b926c3d-56b9-4c32-a0b8-9a4c53f675d8"
      unitRef="usd">15461000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTUtMS0xLTA_1d70b6af-ae12-4842-b669-dbcc50a129df"
      unitRef="usd">16587000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTctMS0xLTA_12d75470-d864-4592-bac7-054df0778b0c"
      unitRef="usd">32045000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTktMS0xLTA_d3ad3777-44a5-4093-9fb7-3eace2c9e11a"
      unitRef="usd">12632000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90YWJsZTo3NzE5NWZkMjE3MmE0YzYwOGEzNDYxOTJiMDk4YzY1MS90YWJsZXJhbmdlOjc3MTk1ZmQyMTcyYTRjNjA4YTM0NjE5MmIwOThjNjUxXzExLTExLTEtMS0w_6b476728-cb18-4d91-a0dc-07f99363ff70"
      unitRef="usd">19413000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzE2NDkyNjc0NDQ2Njg_b69fab0e-c967-4c5d-a1e9-823937ab49a7"
      unitRef="usd">2800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI2NTY_a7960f43-ed69-4042-a1ab-491f4fbe4fcd"
      unitRef="usd">1400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI2NjM_57fe2c08-25c6-4922-83b4-bd15dac55aff"
      unitRef="usd">1300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5Mzk_60524bbe-9fc9-4a77-9a41-fad68877dbe4"
      unitRef="usd">2600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NDM_086a4b7c-504f-4607-b2e8-6baf055b0025"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NDc_7a38cc41-58b5-4ad1-b6c9-b898d2eee284"
      unitRef="usd">2400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NTE_73b35243-7042-4079-b0cb-6cd356fed15e"
      unitRef="usd">2400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDQvZnJhZzpiNThlMDMwZjhmMjU0ZjcwYWRhZGNkNzc5NzIyOTUxMS90ZXh0cmVnaW9uOmI1OGUwMzBmOGYyNTRmNzBhZGFkY2Q3Nzk3MjI5NTExXzI5NTg_1de716d4-4fad-4152-856a-ffa60f502e84"
      unitRef="usd">2200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzU0OTc1NTgxNDMxMDI_f1c92bf7-2548-4f79-a0d7-4ab27023ff28">Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. Certain required disclosures have been made on a prospective basis in accordance with the standard&#x2019;s guidance. See Note 1, Summary of significant accounting policies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain facilities and equipment related primarily to administrative, R&amp;amp;D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;amp;D and administrative space.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net lease costs were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020, were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes future rental commitments for abandoned leases of $133&#160;million. We expect to receive total future rental income of $107&#160;million related to noncancelable subleases for abandoned facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease terms and weighted-average discount rates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and noncash information related to our leases was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $339&#160;million. These leases will commence in 2021 with lease terms from 30 months to 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rental expense on operating leases under the prior lease guidance for the year ended December 31, 2018, was $166&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzY4Mw_4b14265e-347f-4cd6-acec-c46c888c6fa1">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzI2Nzk_bc245150-ff3e-4230-93d9-63638082cb2f">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net lease costs were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease terms and weighted-average discount rates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and noncash information related to our leases was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzItMi0xLTEtMA_a1bc1fc3-e055-4678-9f46-643c64238c55"
      unitRef="usd">408000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzMtNC0xLTEtNTkwMw_8ca2e572-12c7-4e94-bfbf-f93cebf8c6b9"
      unitRef="usd">469000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzQtMi0xLTEtMA_bd61e59a-6955-43a4-b6aa-9c908712d6d8"
      unitRef="usd">153000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtNC0xLTEtNTkwNw_904e9b8c-91df-4d39-b4da-7c0bc2e0005e"
      unitRef="usd">140000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMi0xLTEtMA_54d6da1c-3438-4b72-b7c2-6b88e36c8175"
      unitRef="usd">306000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtNC0xLTEtNTkxMQ_1c430393-2667-46f2-b0f9-6697c322ad5c"
      unitRef="usd">388000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMi0xLTEtMA_ef60759d-b4f3-455f-9429-a49a04eea184"
      unitRef="usd">459000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzctNC0xLTEtNjg2MA_a45cc84b-581d-4a60-a56e-dd7488f227e7"
      unitRef="usd">528000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzEtNC0xLTEtMA_1998a9c1-d564-4820-86e3-d891823d06a0"
      unitRef="usd">223000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzItNi0xLTEtNTk0Nw_9f8dca36-2221-4dc1-9b3b-618982fe6ead"
      unitRef="usd">204000000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzgtNC0xLTEtMA_428911db-56ef-4181-9512-e264bbdbf51e"
      unitRef="usd">34000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzktNi0xLTEtNTk1MQ_8613df51-9e1f-4ef8-b6b7-adfa1859fa3e"
      unitRef="usd">33000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzktNC0xLTEtMA_0b25ffe4-af88-4850-9034-ae45c7dc9b9f"
      unitRef="usd">189000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowOWU1M2MyNWU1ZDM0MTlhYmNkYTcwOWQxZDcyNzhjZC90YWJsZXJhbmdlOjA5ZTUzYzI1ZTVkMzQxOWFiY2RhNzA5ZDFkNzI3OGNkXzEwLTYtMS0xLTY4NjI_636a2b77-544e-47a8-bd4e-b3ceb68b8051"
      unitRef="usd">171000000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzI2ODA_2d7d22cb-214e-4adc-96e4-cdd00520ccc5">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020, were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Includes future rental commitments for abandoned leases of $133&#160;million. We expect to receive total future rental income of $107&#160;million related to noncancelable subleases for abandoned facilities.</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzEtMi0xLTEtMA_455f65ee-4188-4f63-979b-71776eae4fee"
      unitRef="usd">164000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzItMi0xLTEtMA_17bd5c1d-8dd9-4ef8-87fa-268a94eaa7d3"
      unitRef="usd">132000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzMtMi0xLTEtMA_7e84093e-3c10-408f-846d-088b88cd79f3"
      unitRef="usd">105000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzQtMi0xLTEtMA_a2d2bda4-086e-4313-b0e5-74527ed8f84f"
      unitRef="usd">36000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzUtMi0xLTEtMA_5bb124b4-1ffe-49dc-8d75-e3c15d27b677"
      unitRef="usd">15000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzYtMi0xLTEtMA_0820cc3d-00ac-4a17-8086-0ab9f94055f0"
      unitRef="usd">36000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzctMi0xLTEtMA_6dd90e65-f6cf-42e0-bae3-a0f411ba4c8f"
      unitRef="usd">488000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzgtMi0xLTEtMA_f9ddcef7-3fe3-4195-8fd7-7a4d4fcb6eee"
      unitRef="usd">29000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTpkOWVlYjgxODU0NTk0NWRkOTZhMDA3Y2VjNjIwYTQ3OS90YWJsZXJhbmdlOmQ5ZWViODE4NTQ1OTQ1ZGQ5NmEwMDdjZWM2MjBhNDc5XzktMi0xLTEtMA_c7e080af-20c1-4567-aa08-0bd668c8c8ea"
      unitRef="usd">459000000</us-gaap:OperatingLeaseLiability>
    <amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases
      contextRef="ib87ff255d0fe407c8d140590358ce557_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODI3_58b01215-7bc8-4050-aa2a-b2fa3de1a8d7"
      unitRef="usd">133000000</amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="ib87ff255d0fe407c8d140590358ce557_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODU1_4e679be8-2bbd-4f03-b4a5-bbb8a2516719"
      unitRef="usd">107000000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzItNC0xLTEtMTM2MzA_349d69b8-d220-465d-b1e0-fc798679605d">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzItNi0xLTEtMTcxODA_d4ee2c08-c2f9-472c-be18-4099069020cc">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzMtNC0xLTEtMTM2Mzg_0b24536d-7b03-4a75-affc-3d7fed18db2a"
      unitRef="number">0.031</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZToxNTg3ZjU1MjY5YTI0NTc5ODNkN2ZlYjFlNzBlNjQ0Ny90YWJsZXJhbmdlOjE1ODdmNTUyNjlhMjQ1Nzk4M2Q3ZmViMWU3MGU2NDQ3XzMtNi0xLTEtMTcxODA_7331aa51-c49e-487b-9b31-74f8194df7e2"
      unitRef="number">0.033</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzItNC0xLTEtMA_855b54be-898e-4639-af1c-bf7587041c3a"
      unitRef="usd">177000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzMtNS0xLTEtNTk4MA_49c07d82-9629-4d14-b35e-6f4c78faa5ca"
      unitRef="usd">148000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzYtNC0xLTEtMA_6a8ac0b9-5cd2-479d-967f-35dc403b0549"
      unitRef="usd">101000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTowZTVmZWY3YjdkZDI0ZmFmYTc2OGY2OGNkMTg2MGEyYy90YWJsZXJhbmdlOjBlNWZlZjdiN2RkMjRmYWZhNzY4ZjY4Y2QxODYwYTJjXzctNS0xLTEtNTk4NA_d9b52da9-d0d3-4e1d-9a08-a1a2310b99b9"
      unitRef="usd">163000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <amgn:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODQx_da9bb4cc-817d-4d47-89ec-6b2ba3628638"
      unitRef="usd">339000000</amgn:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="ief37ee91742248e0885bab6c4ed8ddde_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzExNTQ0ODcyMDk1ODI1_65a3ac21-b6a4-4b2d-8cd5-015ab886d8af">P30M</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="icc37b0f57f9e459ab9249c3fd0808c48_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzIxNTg_5b116af1-1264-49a1-be4c-60ea8e3c42f0">P15Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90ZXh0cmVnaW9uOmM5MDIzNTQxZGNmNjQyZTQ5MWE0M2EyNTc1ZWQ3MWUyXzU0OTc1NTgxNDMxMjg_a4e34f64-b182-4593-b46d-83366258d31e"
      unitRef="usd">166000000</us-gaap:LeaseAndRentalExpense>
    <amgn:AccruedLiabilitiesDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90ZXh0cmVnaW9uOmNmODYwY2EwMGNhNzQyZmI5NDQ3MjI2OWY2MmYyNTQ3XzIwMA_e5bcce46-0ccd-401b-8b53-8253c2900382">Other current assets and accrued liabilities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate partner receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90ZXh0cmVnaW9uOmNmODYwY2EwMGNhNzQyZmI5NDQ3MjI2OWY2MmYyNTQ3XzE5Nw_6fcf80a5-d1e6-4c4f-92b3-8724a5d19822">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate partner receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzItMS0xLTEtMA_8e66debd-1fb5-4d6e-a2fb-79b55a222097"
      unitRef="usd">1156000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzItMy0xLTEtMA_d0351954-12d4-43c7-9016-a1c8f064312e"
      unitRef="usd">939000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzMtMS0xLTEtMA_4883bd74-56cb-4959-8514-1fa09a3a36db"
      unitRef="usd">583000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzMtMy0xLTEtMA_d9e56e77-847b-4588-ac5c-beb88a3bb191"
      unitRef="usd">485000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzQtMS0xLTEtMA_6ed3ef23-713e-49f8-a57b-f84075eecce4"
      unitRef="usd">216000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzQtMy0xLTEtMA_fe49df6e-678c-41bd-8bac-249023704dd3"
      unitRef="usd">186000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzUtMS0xLTEtMA_5cd5db33-fac9-4219-8b0f-8569370ffed2"
      unitRef="usd">124000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzUtMy0xLTEtMA_124bed58-2897-487a-84cb-71f2bedfbdf7"
      unitRef="usd">278000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzYtMS0xLTEtMA_59c30597-5e9e-41b8-b821-6d8ae508177c"
      unitRef="usd">2079000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTpjNzE4NTk0ZGQ4Yjg0MTJhODRiYjVhM2YyODU4YmJiZi90YWJsZXJhbmdlOmM3MTg1OTRkZDhiODQxMmE4NGJiNWEzZjI4NThiYmJmXzYtMy0xLTEtMA_eedb587a-f12d-4cb5-8d5e-5d82979336af"
      unitRef="usd">1888000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90ZXh0cmVnaW9uOmNmODYwY2EwMGNhNzQyZmI5NDQ3MjI2OWY2MmYyNTQ3XzE5MA_72788861-c1aa-45c9-a1b3-d19e8670f1bb">&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <amgn:AccruedSalesDeductionsCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzItMS0xLTEtMA_c03b1b30-319d-4c2d-9394-cc1447937c02"
      unitRef="usd">4801000000</amgn:AccruedSalesDeductionsCurrent>
    <amgn:AccruedSalesDeductionsCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzItMy0xLTEtMA_73127b17-9ac5-43d4-9411-c6c2bbbdc1a4"
      unitRef="usd">3880000000</amgn:AccruedSalesDeductionsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzMtMS0xLTEtMA_5bffed93-86b0-453f-bada-1694bb9e3d1c"
      unitRef="usd">1098000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzMtMy0xLTEtMA_d6acdb83-811d-4dad-ab33-d7f03b92a925"
      unitRef="usd">981000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzQtMS0xLTEtMA_c512c8e2-adea-41d4-8157-e4a35bf4db35"
      unitRef="usd">1018000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzQtMy0xLTEtMA_d3fa81b9-70bf-41c5-ba4f-b4e619e0cf31"
      unitRef="usd">946000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzUtMS0xLTEtMA_1b5c997f-93a8-4e82-bd82-cc317e6158bc"
      unitRef="usd">828000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzUtMy0xLTEtMA_91cf4fb8-1f7c-4193-90c5-dd49d1eac2bc"
      unitRef="usd">557000000</us-gaap:AccruedIncomeTaxesCurrent>
    <amgn:AccruedSalesReturnReserveCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMS0xLTEtMTI2NTY_fe526579-8cd2-4fb4-878a-ab25e479eb6f"
      unitRef="usd">474000000</amgn:AccruedSalesReturnReserveCurrent>
    <amgn:AccruedSalesReturnReserveCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMy0xLTEtMTI2NjA_ef5f96b2-28c9-40bd-9481-d5bcf4bb8766"
      unitRef="usd">564000000</amgn:AccruedSalesReturnReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMS0xLTEtMA_db007d3d-eee1-4fee-9798-567a0755c199"
      unitRef="usd">1922000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzYtMy0xLTEtMA_f6549c70-9593-4ee2-a7df-f2e74bc07a56"
      unitRef="usd">1583000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzctMS0xLTEtMA_67fd943b-c28b-4343-bce4-f2d5d07b9d6a"
      unitRef="usd">10141000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTAvZnJhZzpjZjg2MGNhMDBjYTc0MmZiOTQ0NzIyNjlmNjJmMjU0Ny90YWJsZTo3ZWYzNGUzMTM5ZTE0MmFhOTJhNmQ5OGEzNWRmOGY1ZC90YWJsZXJhbmdlOjdlZjM0ZTMxMzllMTQyYWE5MmE2ZDk4YTM1ZGY4ZjVkXzctMy0xLTEtMA_ef08ea0c-718f-4102-9184-7415b3dfb530"
      unitRef="usd">8511000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNDU_b3b825e4-d3a9-486c-a85e-9ce35328eff9">Financing arrangements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% notes due 2020 (4.50% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.125% notes due 2020 (2.125% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Floating Rate Notes due 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2020 (2.20% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45% notes due 2020 (3.45% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10% notes due 2021 (4.10% 2021 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85% notes due 2021 (1.85% 2021 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021 (3.875% 2021 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% &#x20ac;1,250 million notes due 2022 (1.25% 2022 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70% notes due 2022 (2.70% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65% notes due 2022 (2.65% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2022 (3.625% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#x2014;except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097&#x2014;may be redeemed at any time at our option&#x2014;in whole or in part&#x2014;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we issued debt securities in the following offerings:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In February 2020, we issued $5.0&#160;billion of debt consisting of $500&#160;million of the 1.90% 2025 Notes, $750&#160;million of the 2.20% 2027 Notes, $1.25&#160;billion of the 2.45% 2030 Notes, $1.25&#160;billion of the 3.15% 2040 Notes and $1.25&#160;billion of the 3.375% 2050 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In May 2020, we issued $4.0&#160;billion of debt consisting of $1.0&#160;billion of the 2.20% 2027 Notes, $750&#160;million of the 3.15% 2040 Notes and $1.0&#160;billion of the 3.375% 2050 Notes, which represents a further issuance of, and which forms a single series with, each of the corresponding series of notes issued in February 2020, and $1.25&#160;billion of the 2.30% 2031 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not issue any debt or debt securities during the years ended December 31, 2019 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt repayments/redemptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We made debt repayments/redemptions during the years ended December 31, 2020, 2019 and 2018 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2020, we repaid/redeemed $6.5&#160;billion of debt, including the repayment at maturity of the $300&#160;million aggregate principal amount of the 4.50% 2020 Notes, the $750&#160;million aggregate principal amount of the 2.125% 2020 Notes, the $300&#160;million Floating Rate Notes due 2020 and the $700&#160;million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900&#160;million aggregate principal amount of the 3.45% 2020 Notes, the $1.0&#160;billion aggregate principal balance of the 4.10% 2021 Notes, the $750&#160;million aggregate principal balance of the 1.85% 2021 Notes and the $1.75&#160;billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2019, we repaid $4.5 billion of debt, including the $1.4 billion aggregate principal amount of the 2.20% 2019 Notes, the $1.0 billion aggregate principal amount of the 5.70% 2019 Notes, the &#x20ac;675 million aggregate principal amount ($864 million upon settlement of the related cross-currency swap) of the 2.125% 2019 euro Notes, the $700 million aggregate principal amount of the 1.90% 2019 Notes and the $550 million Floating Rate Notes due 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2018, we repaid $1.1 billion of debt, including the $500 million aggregate principal amount of the 6.15% 2018 Notes and the &#x20ac;550 million aggregate principal amount of the 4.375% 2018 Notes revalued at $621 million upon maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2&#160;billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45% 2020 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10% 2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% 2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2022 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% 2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% 2026 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% 2051 Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Excludes an additional 1.5% of interest for the difference between the coupon rate paid to noteholders and the fixed rate received under the interest rate swap contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt exchange&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940&#160;million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following principal amounts of each series of Old Notes were validly tendered and subsequently cancelled in connection with the Exchange Offer (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal amount exchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% 2037 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% 2038 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% 2039 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% 2040 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% 2041 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% 2042 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% 2043 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 1.25% 2022 euro Notes, 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shelf registration statement and other facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2020 and 2019, we had no amounts outstanding under our commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2020 and 2019, no amounts were outstanding under this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we filed a shelf registration statement with the U.S. Securities and Exchange Commission that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual maturities of debt obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December 31, 2020, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2020, 2019 and 2018, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2020, 2019 and 2018, were $1.2 billion, $1.3 billion and $1.5 billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNTQ_4a5d4f41-e9cb-4c65-b094-3c905876dc82">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% notes due 2020 (4.50% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.125% notes due 2020 (2.125% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Floating Rate Notes due 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2020 (2.20% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45% notes due 2020 (3.45% 2020 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10% notes due 2021 (4.10% 2021 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85% notes due 2021 (1.85% 2021 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021 (3.875% 2021 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% &#x20ac;1,250 million notes due 2022 (1.25% 2022 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70% notes due 2022 (2.70% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65% notes due 2022 (2.65% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2022 (3.625% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i115359deafc44691979f165eb053cdfc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmY5NzQ1ZjRhYmYzNjRkNjE5NWQ0MzZjMmRiZWIyNDA5XzEwOTk1MTE2Mjc4MjQ_65456f7d-5296-4241-bfb2-91fced90f1a8"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i18c11ed6245e4fa0a369c9f3aec56f9c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEtMy0xLTEtMA_2dfd21e7-4dcf-4a53-b463-a12e1c5d35b9"
      unitRef="usd">300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzItMC0xLTEtMC90ZXh0cmVnaW9uOjE2ZjRmYmQ5ZTQyZDQyNDk5M2FjN2ZkMzE4MzM2MGM3XzEwOTk1MTE2Mjc4Mjc_a3b100d2-3253-4893-9e55-c68f737fa6aa"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzItMS0xLTEtMA_69b8f4bc-2739-43be-ad3f-9bc3304426cc"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib58dc479cd3d42319169a103d07a7574_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzItMy0xLTEtMA_22c99999-11a9-4a63-aaf2-fc8f5508dec4"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iba619c4c18fc45ddb3aa9c5914a043e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMtMS0xLTEtMA_4cc643fe-2e24-42a3-9fad-3badbbb6c9d1"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic72dd6be73064790892c440bdd065b6e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMtMy0xLTEtMA_5bf1979f-dcc4-46b4-8038-9141e2ba0217"
      unitRef="usd">300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i81f0c45930bf446597ffdba0232d3d0a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzUtMC0xLTEtNzA1NC90ZXh0cmVnaW9uOjEwZjAwMWZiYzg0ODQ2ODViN2I4N2ZiNjkxZDYyYjQ5XzEwOTk1MTE2Mjc4MjQ_92e0dc40-3198-4720-acb6-e2a971e19e3b"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i81f0c45930bf446597ffdba0232d3d0a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQtMS0xLTEtMA_739db8de-1e27-4a3d-981a-32f146b3e329"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie507cdb44629455bb7c6aa2c3247d935_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQtMy0xLTEtMA_08768468-b132-40e2-9d02-b7e642ba54eb"
      unitRef="usd">700000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a25ca8db8794930a6444001d3c53561_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjFjNzNiODQyNGY4ZDQ4OTA5YzU2MDUzMjdiNjAxYmI0XzEwOTk1MTE2Mjc4MjQ_fadc2d72-758e-4299-bda7-56109c3f0245"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7223a974c3e04bcba5c39ed1c654173e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzUtMy0xLTEtMA_e68c8e69-793e-4bc5-af39-e69aa713ba9d"
      unitRef="usd">900000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic46c172c9e0a45198c8c6c17804b44f9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmNjMDE4NWFkYmIxYjQ5Y2E5YzllNGExYjExNjE2N2M1XzEwOTk1MTE2Mjc4MjQ_711e1339-2d17-4a37-9d82-3ed54b7309db"
      unitRef="number">0.0410</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i766f4994093f4740852f0817f605b8ad_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzYtMy0xLTEtMA_d8d6023f-c600-445a-9466-2cc8b806fe7d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjA4MThiZWQ3NjQzYjdhMDUxNDZjMTkyMjI3NjI2XzEwOTk1MTE2Mjc4MjQ_54efd4ac-8109-484b-b345-6e63a20952b2"
      unitRef="number">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzctMS0xLTEtMA_e8cae819-43d8-4c08-a2b4-dd7939ca77ac"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i65782159d9f447c1a8360410b35c8b0f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzctMy0xLTEtMA_a1b9fbec-5a1b-4f21-b56f-2a474b9bc40c"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c3bbee60b53406ba6799bf10576c70a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzgtMC0xLTEtMC90ZXh0cmVnaW9uOmQzZGRiMjE4ZDE5MzQyMjU4MmQyYTk2NGQ5NWUwYzhiXzEwOTk1MTE2Mjc4Mjc_436bfa1e-53ad-4957-a71e-7a64502ad2dd"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6d9ad1274914495687f1554666e681b7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzgtMy0xLTEtMA_2da38eb8-df7f-40a6-8214-ce088b38db23"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i321d29cee0af4ec499ff94a4d005e9d0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMC0xLTEtMC90ZXh0cmVnaW9uOjc5YTk3MjQ2MjU4ODRiMjhiOGYyNzRhODAwYzkyMWM3XzEwOTk1MTE2Mjc4NDQ_3754f242-f40a-4059-97d0-e24ff186194a"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i321d29cee0af4ec499ff94a4d005e9d0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMC0xLTEtMC90ZXh0cmVnaW9uOjc5YTk3MjQ2MjU4ODRiMjhiOGYyNzRhODAwYzkyMWM3XzEwOTk1MTE2Mjc4NjE_d311dac7-c103-49b8-9509-c30c81d8ff63"
      unitRef="eur">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i321d29cee0af4ec499ff94a4d005e9d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMS0xLTEtMA_9ddd38f1-6134-4976-b8b9-133a9e15a019"
      unitRef="usd">1527000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i857fefc9adb94c98b9b9329678b7db36_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzktMy0xLTEtMA_dc38473b-acbb-41e2-ba86-4cdfa6a27232"
      unitRef="usd">1402000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d3ad6c912a4480fa33aa0d7eaac3019_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNTY4YzkwNDQxNjk0MjhkYWU2Y2FhMjA5ZmI1ZWI0MF8xMDk5NTExNjI3ODI0_d472a9d9-15e2-4026-abb2-d5383b30a71b"
      unitRef="number">0.0270</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5d3ad6c912a4480fa33aa0d7eaac3019_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEwLTEtMS0xLTA_c27445ea-3fb7-4f6e-8e90-e34a671a9e86"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idf1366b31913416482ed05d65527ce09_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEwLTMtMS0xLTA_fb5a3d54-2569-481c-a8db-ea16f91d9b40"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5601f95c84ff45209305a7ba1d0ed21f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjpjZWU1MDRhNjIxMmQ0NDQ4OGRhM2I1ODQ3MDUyZGExY18xMDk5NTExNjI3ODI0_ae1e0062-ee4f-47ef-830b-912caf32ff84"
      unitRef="number">0.0265</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5601f95c84ff45209305a7ba1d0ed21f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzExLTEtMS0xLTA_cb963e46-41cb-4288-a043-1066ff207663"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2022e1a82ecc471c9bb13d27e09c51fe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzExLTMtMS0xLTA_1f6ae8e5-0e20-48d0-9f88-cf21fa9f12c3"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib86fea773d394279b54bf0ad27439680_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjoxNjFiNzYxNjQ5MTc0ZDk4ODZlYzIyOGZiOTIzZDJjMl8xMDk5NTExNjI3ODI3_30762426-da9b-4ced-be6d-22b5d4045fb4"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib86fea773d394279b54bf0ad27439680_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTEtMS0xLTA_e8ff762b-7a8e-446c-9f04-02c3181c3697"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9e302b2d804443b3b3a819a6e695f03a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEyLTMtMS0xLTA_eff4a654-096e-44d4-8006-67c3877069e4"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8ce43115364e4f88a797d0e9e1224e77_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4MDBmZTIwOWFjYjQ0NjhiYmVkMWRmNzUwMWRhZjgyZF8xMDk5NTExNjI3ODUx_183763bd-3c2c-48ea-bc4d-f5dd6ea86b85"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8ce43115364e4f88a797d0e9e1224e77_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4MDBmZTIwOWFjYjQ0NjhiYmVkMWRmNzUwMWRhZjgyZF8xMDk5NTExNjI3ODY4_61178b70-0be5-4ac6-9e02-02d245991148"
      unitRef="chf">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8ce43115364e4f88a797d0e9e1224e77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTEtMS0xLTA_13b6da9e-8056-41a0-9312-01534e7066fd"
      unitRef="usd">791000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6eb195b8085e465b9c73e9a2403f0ca3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzEzLTMtMS0xLTA_632782cd-574d-4678-ba00-82fa6934b2e7"
      unitRef="usd">725000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d2a2479b69b4482a8047db796a1bb33_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMTdmNDBmYThhZTg0MWQxOTVkNzkxMWI5ZjRhMTU5M18xMDk5NTExNjI3ODI0_3fd5db2f-0fb6-47af-99c0-60a0f65070f0"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2d2a2479b69b4482a8047db796a1bb33_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE0LTEtMS0xLTA_d9178226-5a56-49b5-900a-5c87c7ae6e88"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6d4292b26906463fba3b1c0f23beb71b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE0LTMtMS0xLTA_ed7c46d4-1229-4b5c-9a64-03b4efc00377"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifcd6d09277ed4900bbac50776efa7a38_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjphM2NlMTVkM2VjMzI0YjE3YmFlMWJiZTE5ZDQ1MmNmMF8xMDk5NTExNjI3ODI3_9617fae6-b38c-4fd6-876f-d5db02ac6b38"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifcd6d09277ed4900bbac50776efa7a38_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE1LTEtMS0xLTA_28b80a86-42d3-4958-ab31-a9b9d19864a8"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i35327bb737e64d47a0eec71b3f1a920e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE1LTMtMS0xLTA_f38e384e-f8d7-4399-8836-f4b9dd0283fd"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i955823ca905943e2bd3d94ca46061a7b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMDI0YjQ1YWZiN2I0ZTg1YTgwN2JlNzZjODY3NGZjZF8xMDk5NTExNjI3ODI0_baecb7b0-5dc5-45a5-8c22-22c7cf95f0dd"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i955823ca905943e2bd3d94ca46061a7b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE2LTEtMS0xLTA_bb237196-2e4d-4350-89bc-654b25e02fee"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjo4YTIxNjUyNzk1NDM0NTdiOGEwN2VmMjM5ZDRiZDJjMl8xMDk5NTExNjI3ODI3_df4a1c23-a02e-4508-8d22-fb28c966a812"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE3LTEtMS0xLTA_8938d7a7-5426-4c65-9358-a12ce1288c17"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i35651b0d044d46cc9af068d473bf549b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE3LTMtMS0xLTA_f6db8547-ed01-487d-9de6-e455555c2853"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NDg3NTgxMWJiNzU0YzBjODYwMDE4NDRiMTJjZTA5Ml8xMDk5NTExNjI3ODQy_84bc3165-a385-4b41-8c66-178af08ec400"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NDg3NTgxMWJiNzU0YzBjODYwMDE4NDRiMTJjZTA5Ml8xMDk5NTExNjI3ODU3_1a61c12c-5b87-4ea9-8e19-5e5b90d78162"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i01dae6f6ca8e40dd91f4f35cd84e2228_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTEtMS0xLTA_b79c0edc-0bb6-479b-8a2e-3a042262904d"
      unitRef="usd">916000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie89c330f27314741941344d0b54c18ab_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE4LTMtMS0xLTA_e934609f-6f4c-4bcb-b0d4-55293e9a84d3"
      unitRef="usd">841000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf087f04fa3b433688c1f56ee1145222_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZGYwOTMyY2Q3ZjY0OWYwYjllNDY5MTZkYzEwOGQwN18xMDk5NTExNjI3ODI0_3257039e-c8c8-4d3b-b318-2c981a9c5d19"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idf087f04fa3b433688c1f56ee1145222_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE5LTEtMS0xLTA_21f808b2-54f8-4df7-835b-10c7b5c23baa"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib6894d534af44c5c9113bb8bb4838cfd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzE5LTMtMS0xLTA_b58aa32a-42ac-44d2-96fc-222df3f61272"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZTYyYTc0ZTVkNjU0NzAyYTgwMTgzNGRlNzlmNmExOF8xMDk5NTExNjI3ODUy_23c9498a-b687-4707-b4b9-143d8ae40c5a"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZTYyYTc0ZTVkNjU0NzAyYTgwMTgzNGRlNzlmNmExOF8xMDk5NTExNjI3ODY3_4bff0223-2993-4c8f-b827-fd5f2e8b2e1f"
      unitRef="gbp">475000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTEtMS0xLTA_12997fa4-4337-419c-a436-99d31986df45"
      unitRef="usd">649000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib2a0aa4ebe0f4b39820910ec59611fc8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIwLTMtMS0xLTA_601c1fca-def0-4011-8621-b31aa65501e6"
      unitRef="usd">630000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie4cf58147d464ca393871d4bdabefa52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjphYzNkNmY4ZWE4ZDM0NjA5ODkzZDNiZTA4YmM0NjQzM18xMDk5NTExNjI3ODI0_63c91fbb-a86e-4671-85e0-a318419b9347"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie4cf58147d464ca393871d4bdabefa52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIxLTEtMS0xLTA_03e0f266-a3d6-4328-94b7-907b43b91a1a"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d9d8f452a50403f85e95d6a431bb569_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo5NzQ5MzU5ZDU5YmE0MTJmYWE4MjA1NzEyMTdkM2Y2YV8xMDk5NTExNjI3ODI0_4e712a56-7a48-4a08-a930-cd5ef0fcd281"
      unitRef="number">0.0320</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5d9d8f452a50403f85e95d6a431bb569_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIyLTEtMS0xLTA_adc05211-40bc-4c32-a867-89f9412cad69"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if6de40b43c344b3680010e784e3163c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIyLTMtMS0xLTA_f57b786b-7ee5-4ab4-9462-6d69147563d5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNWE0YmIzOGJiOGE0MTM4YmE4NDY3YmE1MWUwYWNkY18xMDk5NTExNjI3ODUy_9d75dd37-b128-47e3-98ec-6bba83cc2da2"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNWE0YmIzOGJiOGE0MTM4YmE4NDY3YmE1MWUwYWNkY18xMDk5NTExNjI3ODY3_8216452f-18d5-488f-a362-463039ba0011"
      unitRef="gbp">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTEtMS0xLTA_5765e651-445e-47c5-9b42-3acbd65184dc"
      unitRef="usd">957000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i54a6377397b24b53a373e7137cbd06b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzIzLTMtMS0xLTA_2bd90ec2-4bb8-4158-9314-952d6c37efdf"
      unitRef="usd">928000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a255f173843436c994520d12b5046cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjpiMzRhY2I4MzVhNTk0ZmVkOTdjZmFmMjMxOWM3NDc0NV8xMDk5NTExNjI3ODI0_2d17a557-ee3c-4b46-8406-1e51d14ded39"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5a255f173843436c994520d12b5046cb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI0LTEtMS0xLTA_6fda2ce8-2592-43b7-897b-96e3f5538949"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25a4a0e3fad546309834f83971cde048_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo4YzczZmVkNjdkZGM0MGY4YmNhNGMyMDBmYjkwMDc4OF8xMDk5NTExNjI3ODI0_231f83ab-ad05-4f9c-89d7-9fbbb7cdf6d2"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i25a4a0e3fad546309834f83971cde048_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTEtMS0xLTI3NzQ_d92d8c0f-0e1e-448f-a036-4fe4aa3a9932"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjpmM2MyNTBkOTNlOTE0ZWE5YWQxNzE0ZmU0ZmYxMGRhN18xMDk5NTExNjI3ODI3_b9a0dc12-3866-42e1-9d2d-1a56b619afb8"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTEtMS0xLTA_eaae123a-a71b-418f-a4da-2c8bd5b51a14"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8c9f0f7677c04b97bdc7ecf0cfe1bf34_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI1LTMtMS0xLTA_8684cd27-4f01-406f-bd25-6550834a0895"
      unitRef="usd">552000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if8c556faa66a4640add9a389585dcb8d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpiYThiNzg3YTVmZjg0MWU5OGNhZjBhMWRlNzFiZTRlZF8xMDk5NTExNjI3ODI0_778b6ade-2fc6-4026-9a1c-2f26df1a2588"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if8c556faa66a4640add9a389585dcb8d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTEtMS0xLTA_ee486e18-b538-4cef-a83c-7ed4148172df"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i26bb56750156451db1cace7c4f21e6bc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI2LTMtMS0xLTA_359b083c-73c4-45b7-b8dd-2d34b3e37348"
      unitRef="usd">291000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i33bc0e6a798a4daa94404d7e959a5646_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMjQ0YzJjMDUyMWQ0NzdhOTY4YTk3MDQ0MjQ5MDhjOF8xMDk5NTExNjI3ODI0_f55ea364-3c6b-4b7b-b4ec-6344deaed42a"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i33bc0e6a798a4daa94404d7e959a5646_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI3LTEtMS0xLTA_64b0e9a1-de87-46a3-b290-7fa4c4bfe254"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1e6f035a7cd84be5bea195a303cdeeb3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI3LTMtMS0xLTA_8d82179d-a5ad-4789-8791-a9d7d4b63118"
      unitRef="usd">466000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4bc950c75ba04c2f88fd9c7425c305e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo3ZTlkYzRlNjVjNDQ0ZDZiODQ3ZTYxZDkyMWRhNDY2M18xMDk5NTExNjI3ODI0_64d98708-de3f-4041-9e1f-cb0e6ba138b9"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4bc950c75ba04c2f88fd9c7425c305e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI4LTEtMS0xLTA_df605e4b-30ec-4297-bcf6-37966901b130"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86e8c0425a564da7849ac5fe7b5db51c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjozYWZiMTY0NWIxMjc0Y2VkODgwZmQxNmIwMTdkZTMzOF8xMDk5NTExNjI3ODI0_aa661097-3646-4b3e-be9e-85bad1c7da53"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i86e8c0425a564da7849ac5fe7b5db51c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI5LTEtMS0xLTA_2f208375-9e65-4353-ad24-e331e7895063"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i47bb60d0f1944a82bf76a4a9c8335c42_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzI5LTMtMS0xLTA_60944628-76a1-4d81-ac77-ff6394772ca2"
      unitRef="usd">412000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic37ba0818a4249c3a031f0454e3aed09_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo3N2U5ZjE0ZjljZDQ0YWYyOGVhZDU5NDNmNWViZjAyMl8xMDk5NTExNjI3ODI1_46605f1c-5568-4d65-84a8-28f30789f39a"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic37ba0818a4249c3a031f0454e3aed09_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTEtMS0xLTA_90fc2c31-f211-48ff-bd14-c01dbe616247"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0e029c89be1a4c2aab1ec7352a2738da_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMwLTMtMS0xLTA_b8259177-2eef-4cb0-83b7-987555a639b7"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1dcacc53791a4df7b253b539b0644b8f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxNzc3MDkxNmE5MmI0ZGZiOTljODM5ZjI3MDJlNmMzY18xMDk5NTExNjI3ODI0_3eb636f9-d211-4f68-a250-b336ebda9617"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1dcacc53791a4df7b253b539b0644b8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMxLTEtMS0xLTA_efdbd92b-b18a-4588-a1e0-daa1726988d7"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id84255d0cb47445195c3652626198334_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMxLTMtMS0xLTA_4c1f88e5-3ef5-4e01-9b8e-dbfc4d7b7916"
      unitRef="usd">974000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i76cd436bd1f242d4bd92a582319d9cd9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjYjk4MjMxODk5MTc0OTgzOTRlZWY1MzhmYzA1ZWQyOF8xMDk5NTExNjI3ODI0_cdc7c9a7-74f4-45fa-8cb6-beb90aebee09"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i76cd436bd1f242d4bd92a582319d9cd9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMyLTEtMS0xLTA_27c1270b-28d6-4ff9-a3df-fc5b95f8ee3e"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i98459dd3f7df4a9da1f0e4d9bfaf76c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMyLTMtMS0xLTA_1f93241a-bb42-4cc0-8cd5-51982ee66f1b"
      unitRef="usd">487000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie22a6012e30946cbaa82df3fa40dddb3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpmOGY2MDc1NjVjYWU0ZWNjODU5MzM5MjQzN2U3OTRlMl8xMDk5NTExNjI3ODI3_2cc5bf80-44ed-4860-9929-77e6c63cf80a"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie22a6012e30946cbaa82df3fa40dddb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMzLTEtMS0xLTA_74742292-54af-4347-9f19-c885cae312ff"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i96c28235c53c439eb0926746169e1187_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzMzLTMtMS0xLTA_eec8c5c3-0d2c-461b-991b-c636d28e4e58"
      unitRef="usd">261000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7539fdd6385f4c38b6c106d6250118b3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZTYxMDllNDFmZWI0Yzg2YTlhMTBjZDEyOTdlODU1OV8xMDk5NTExNjI3ODI0_873b1aa3-f549-476e-a5a8-a6fcde03b948"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7539fdd6385f4c38b6c106d6250118b3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM0LTEtMS0xLTA_368c6336-e163-490b-afd7-240c688fb842"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i88c4338c09d6451da39a441444432847_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM0LTMtMS0xLTA_8c4d4ed3-6922-4d24-a3b4-06074a93b143"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkMjc2NzA5Njc4MTA0MTFlOGE5MjI4MzBjOTRmNGIzZV8xMDk5NTExNjI3ODI3_52bde1d2-52f6-4f0b-b4dd-3f84907b4fef"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM1LTEtMS0xLTA_6111b8ab-7881-4e6e-9b0e-acd00215256a"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia60bd30780674b5e8423eae04786b160_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM1LTMtMS0xLTA_31a327bc-999b-46b9-9b15-9f0be163994d"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3ab35f913d01401c9cec4c3e1e26676e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM4LTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjplYzAxZTliZjliZjk0NDhhOTNhYmIwNjJhYTM4NzAwYV8xMDk5NTExNjI3ODI3_4102c8ef-4869-495f-9a3b-b4eb500c38e4"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3ab35f913d01401c9cec4c3e1e26676e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM2LTEtMS0xLTA_2dca6af1-e9d7-404a-8fac-79efca441ced"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NzhlNWNmZDk1NTQ0OTgzODViZmY3Njg2NjE0MjNiY18xMDk5NTExNjI3ODI3_8e8bfaf2-47cf-4f01-87be-a85af2628eba"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM3LTEtMS0xLTA_c22ebc81-79d7-45f3-bd06-7716b55df1ba"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5b51bd6ee36d4eaaa9fad68470af51f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM3LTMtMS0xLTA_9a0cdf40-b594-4062-874e-72f2da746834"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTAtMS0xLTcwNTQvdGV4dHJlZ2lvbjo3YWU0YzgwMmM5OWI0NGU3YWUyM2EzYzcxN2YwNjY0NV8xMDk5NTExNjI3ODI0_72fff9f3-656d-47cf-9910-84510a1baa41"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTEtMS0xLTI3NzE_ea002d59-67d9-430c-bc52-2f45490bbde9"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8d5ec697f57d429aa10a96bcc66005bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTMtMS0xLTI3Njg_250b7f09-8f98-4c92-b69b-2a07660a6462"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3741539a3da4406cb0892abdf6eb315d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM4LTEtMS0xLTA_42f684e9-55d2-4655-a50e-82d66e9c6c5f"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i425c9514aedb4868a2ebec2a29ba5de7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM4LTMtMS0xLTA_10a551d2-5f97-4cba-8d8f-c5efeba427ac"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM5LTEtMS0xLTA_c6518b2b-59a3-491c-a536-9749094d7c46"
      unitRef="usd">1188000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzM5LTMtMS0xLTA_6baed0f8-06e2-4ec5-b6c6-bc4cf9eb389c"
      unitRef="usd">868000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTEtMS0xLTA_00d9dddc-b595-4182-ab5e-fc8173043f38"
      unitRef="usd">566000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQwLTMtMS0xLTA_7cb6036b-9440-4dd1-8bc9-41da03935fb0"
      unitRef="usd">296000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:OtherLongTermDebt
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQ0LTEtMS0xLTI4MDY_e69357bc-32a1-4a87-a7e2-d5628e8f008b"
      unitRef="usd">5000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQ0LTMtMS0xLTI4MDk_9c174f09-f302-4736-8111-f4d0f4a12264"
      unitRef="usd">0</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQxLTEtMS0xLTA_22ed7c77-04de-4262-a684-7534d79fa28b"
      unitRef="usd">32986000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQxLTMtMS0xLTA_92f4cca9-5945-42eb-be41-95325a1aefad"
      unitRef="usd">29903000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQyLTEtMS0xLTA_bd0d6b93-685d-4e06-808e-9d6d15dc9c47"
      unitRef="usd">91000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQyLTMtMS0xLTA_df02a8ad-c424-4f6e-a74e-05e6c185b3a0"
      unitRef="usd">2953000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQzLTEtMS0xLTA_97af5160-fb3a-4ee1-a697-dfe39c786c70"
      unitRef="usd">32895000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTo0MzkzYTI4ZGJkMzU0OWM4OTMwNmI2OGIwOWZkZTk1MS90YWJsZXJhbmdlOjQzOTNhMjhkYmQzNTQ5Yzg5MzA2YjY4YjA5ZmRlOTUxXzQzLTMtMS0xLTA_aaadd993-44a9-4589-bc78-9a3f8844c529"
      unitRef="usd">26950000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIyNA_16132e2f-8ae5-4555-ae96-fc593724c904"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI0Ng_c5d5def9-7df8-4b1d-8b8c-748772d50642"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTEyMTgy_efcc420b-40ee-4465-938c-65d4544d4743"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8ffc8374c7ee4daba236297c1ca19559_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzMwMA_c075ddf0-7b02-43ab-841c-8fe76914fd32"
      unitRef="number">0.063</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzMwNw_b128e177-bfae-4f6d-bd6f-5f745265b8ac"
      unitRef="number">0.056</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTEyMTg5_38e03fda-0f48-4949-b810-4112c3fa62d4"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i1649580135964fee8432cd12950a049f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_01e7530d-8a38-47a1-9514-36acc092f99d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i13ff7bfe32094c3b987aaaceb3014b9f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_0bc64288-dfde-472c-8756-0dff2eb0d862"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i39a772dcf3d84f278093296bdf9e1ce1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_0c9ee806-cc6e-4f52-8d7b-02543a762150"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iec571ed5581a4732ae9ee4817e228b10_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_14127acb-b6e6-463b-9292-8f176fe095a0"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i1ec6c7c7b81b48d8a20694d3b57b6b70_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_17469e0d-d89b-4fdd-871e-21f1d4142ba7"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i1d34c35332374923becedb1eee1b52cb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_1a9171b3-1144-477a-a46e-48dfe2ee75ca"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i60960cf4128a4427b534a20b852e2475_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_25665fca-7762-467c-bf9b-0648ae4ce79d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i2e99d32a99b3493ba14074d4564ee157_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_2bf96af5-55d6-4f0e-b560-3e05d380652e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i0e69a6358c564547a5eca8d5fbe70622_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_364cb473-67be-4528-9afd-7720646fe64c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i92b9a5668fbc41e6b4d63640b91febe6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_38df0ddd-61cc-42f9-8873-789d6a4756b5"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ie045a042bc9343f1a35b00097a53456a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_44344ca5-63da-4457-bc5a-3e5df2af54f7"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="id9776aef7fdb48c8a1734dec44ec2dd2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_466be4de-f6dd-45d8-a3c0-945181057ff6"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iea83a41a94354282ac825a30792e7bd6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4a1d0b6d-6ed8-43af-b0ad-007194ccff62"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="if621495ed0e44e7f8c27f9d541876077_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4b049ee8-210f-4368-85b1-264ab322666b"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i8cfac5674c6443a598611b253a645a0e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4e3a62e8-508c-41d5-9060-48f8f1e9be5f"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ib9165ad7e95445d9b3372c1c0f63c245_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_4fef81e7-dc5a-4133-be99-996cdf725bb4"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i3396b8f489aa45d9a88f6c5fbf1dcd70_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_575f61f4-bc77-45f9-b549-63285aa47962"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iec5d1ff18dbb4fe5bc76abb5d4d5b3c0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_5781e02f-a24c-448f-bf20-d69f63917b51"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iafa733d1395a445ba18de686112112bb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_58eaf9b1-5ac5-492d-8d45-7897c2cc2e22"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ia054a1ac7a0c4c5a84daf3e02d258cd5_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_59563fb5-243a-48d2-bd36-1d34e3588f0e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ie2173cb44ec942b0b5e652729f5aedad_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_5b5598a5-dd39-4de5-bc49-c0cd4ae47277"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i85b731805304467297b2b3b116999268_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_5e3a409a-8b21-4dc4-a9a2-2c2438d9c74b"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i6382073fcb1d4883b6219e6dc102e745_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_651cd7ea-e5c1-4a1b-9933-a87d247459d5"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i9ace2901bf0040e2a96399efee4d66aa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_6e3d2bf1-7214-4773-8280-34aa37cbf3f6"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i9cea61b7422240dcbf72d21fa3477501_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_70096666-cda3-4822-90a4-d744ac05eee1"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i0ec3c2bdd29840c1b5cdb46000fb3552_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_74c94845-66eb-4033-91d3-1a9ed810f9ce"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i4925dc03736d47f9ae8d2a690a4103f8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_792fbd8f-8ead-44f8-bed9-e86b3d347bb8"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i9936d965b2ba462d8b3888f904a7ae96_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_81ec30ee-922f-4a0c-b0e4-7a90e6b897cb"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i1f84b1e89726471186203024e416a4a8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_8f0b4882-6f0c-4bcd-bdbe-a766da9e968d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ic7759f579c524eab8b6b4da9a496f1e7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_a43d0f65-529a-4c85-9900-d6430239566a"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i368a178ea7354ca9b710ce74b30bcfce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_a96fec0d-84ba-43d6-a63d-1dd84ea1d391"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ie14c8cade2044c48a2677b8b57df8403_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_c8f12a04-329d-488b-bfd7-9e2c97782fc3"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ibdb33bcf941a4a40b8e393ef62e8026d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_d39fc6c5-2b8b-4f18-9206-4fa36108c3fd"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i5ea19f674a134cfaa06e00ebe4983f41_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_da164d4f-9b21-4c4e-a8fe-f71ff388da0d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i2d73c382070d4582bf5468d1be4dc656_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_dbb2e023-bf87-4dd6-8d84-5f2dfa78ad5b"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i517838d7aad1452d98142cd5be6f49a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_ddf3357c-9860-4f13-aa36-c34b6ba4cded"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ib45e9dc787514755b7bc52c6e863a740_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_e97b6074-b2a6-4d19-aa39-a1cd83a2f521"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ia3699b330b1b42a9bfd233ae168532eb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_ecef5ab8-4018-47ff-9e2c-6c9a30eab0b0"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i01a00aa8b5524778b4c286af30fb3fd3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU1Mg_fdac08b0-42aa-475d-b86b-124ee0e05dfa"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i49e8ff43661f4d5f912595d1b30d72ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcwMQ_dfdc149c-ecb0-4bdf-a232-0bb01e2246ec"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount
      contextRef="ifb46aca57e78435db45dee35d03b5ff1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNzM_9d5f9f42-ea62-410b-ad05-b079e7a4c0f4">P1M</amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount>
    <amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount
      contextRef="i1bcd5a1c6a104b778997f6496ca15582_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNzk_ebfedb68-47ed-42d4-82df-2a875d50c4a4">P6M</amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibef7ddaa81cf4000b87b570d84cd9ed9_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MTgz_4965e4ea-4c65-4488-996c-be49d3b6f22d"
      unitRef="usd">5000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib53845265cb94d07851b1fe0a47a9756_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MTk3_0aa54cfd-0b52-4d9d-ac0f-a6e8166d578f"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib53845265cb94d07851b1fe0a47a9756_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjEx_dbd90532-81ec-467f-babc-8e3deb147032"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7cc614e1370249759a9ccfd03593d582_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjE4_94af0880-5190-417f-98e2-cbf6ca67dfa5"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7cc614e1370249759a9ccfd03593d582_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjMy_2cd7870f-9eae-432a-8ae9-0cc1136c542e"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifa2bdf148e7042b9a29c5b3af1301bb6_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjM5_f610e3a9-07df-46ac-8d36-76ef1afc6ea6"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifa2bdf148e7042b9a29c5b3af1301bb6_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjU0_6d908019-863b-4f2b-a741-50daf8a43cfa"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icc9023f496d24d308cf4d1c092fc6f42_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MjYx_5973817c-2173-415b-a798-a1bc41d92668"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icc9023f496d24d308cf4d1c092fc6f42_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mjc2_b38a1890-9ad8-41f8-b435-b76e87a059ed"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i53985fa4c39e414b9da42cd3aab030a4_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mjgz_37571075-c3b6-4785-bba2-cfd39d258653"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53985fa4c39e414b9da42cd3aab030a4_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mjk4_e0f9d141-2e18-427d-ab40-1321074fe7d1"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7e01b4d5cfb74268ae6c81e2e50ade30_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzA2_c237e030-442c-4475-959d-e13104889c01"
      unitRef="usd">4000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia51aff5886bd45d0924ffffa26acaf1e_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzIw_8d6ab9d8-b9f0-40e5-84d7-068e227e5141"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia51aff5886bd45d0924ffffa26acaf1e_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzM0_8b1a2760-8e01-4921-a90c-f00f956af1fa"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3994865e1ce04255bf33546e570e6feb_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzQx_014cc985-1933-4685-8f74-cb798c4de03b"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3994865e1ce04255bf33546e570e6feb_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzU1_b4e10809-3a16-48fb-96f9-f79363a58ff4"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i515b38364a38405fb4bcf56004a5d984_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1MzYy_3e031e00-c176-42f2-b1c0-fc2d35b97a1f"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i515b38364a38405fb4bcf56004a5d984_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mzc2_98a87bfb-25c5-4658-b95d-8573ebbd98a4"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie8430beaafbd43bfacdaa980eb0137df_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mzg0_d6e32fc1-6214-4d0f-a7a1-f97ddbbfc54c"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie8430beaafbd43bfacdaa980eb0137df_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1Mzk5_9e9c874d-b8f8-4587-b381-9be630b04cfe"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if188b1207e144488bc49e6f9af13f349_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MzAz_57c02b65-68e7-4857-90b1-6f3aa4ceb62c"
      unitRef="usd">6500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if621495ed0e44e7f8c27f9d541876077_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTEw_ffde69c4-6076-456b-b488-d3229fc94452"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i115359deafc44691979f165eb053cdfc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDM2_d110a717-9f5e-4e35-a8b0-a0ce92ebfc13"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iec571ed5581a4732ae9ee4817e228b10_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTM4_5038c1c4-be6e-42b0-97fc-56e6799c83cf"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ecb24ff0c574dc9b8e196b1970e33c8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDQz_8e96d998-7172-4cfe-8cf1-051e999de789"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id9776aef7fdb48c8a1734dec44ec2dd2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU0OTc1NTgxNjU4OTA_cd728289-f4e4-4ff6-bf93-d27c816b35a5"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie2173cb44ec942b0b5e652729f5aedad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTUy_698978aa-05c7-4455-a627-edd303557435"
      unitRef="usd">700000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i81f0c45930bf446597ffdba0232d3d0a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDUx_61644446-0cd2-4b9b-9067-0a847e8826df"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8cfac5674c6443a598611b253a645a0e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTY2_f92594e0-aa7e-4cca-9511-a24e4a38c6f4"
      unitRef="usd">900000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a25ca8db8794930a6444001d3c53561_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDU4_af7857b9-988e-47ae-97ca-5c3d52484f38"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia3699b330b1b42a9bfd233ae168532eb_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MDk1_947b9cb8-3e29-4505-b3db-16da0a8d4260"
      unitRef="usd">1000000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic46c172c9e0a45198c8c6c17804b44f9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDY1_531383a8-df94-40ae-8483-c3a67f9ec5a3"
      unitRef="number">0.0410</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i39a772dcf3d84f278093296bdf9e1ce1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MzE5_b76a28a0-3631-48f0-ae97-e04d6283c43f"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17fc6d727ef14b33a1f340c1f0b5fef4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDcy_8ed6242e-57e4-4bc3-bd3c-93aea6450287"
      unitRef="number">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i60960cf4128a4427b534a20b852e2475_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1MTk2_95139b2f-fe6c-4b57-ab21-3ea728af37f9"
      unitRef="usd">1750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c3bbee60b53406ba6799bf10576c70a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE0NDkz_adc43568-f361-488e-9a95-c0216beac67d"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="if188b1207e144488bc49e6f9af13f349_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY0ODkx_041457e9-f8f5-4a5c-b215-d0a922b72b3c"
      unitRef="usd">96000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2bc092c6728d4fd490eda91a340a32ae_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NTE2ODc_ea8471f9-6b1e-4e05-8f25-fc65b362ef09"
      unitRef="usd">4500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0ea4835b2dc040188992a34180538c3d_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIwODc_bf4bc8ca-91f7-44ab-8c53-b8009a417e2c"
      unitRef="usd">1400000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ced667ce35e445b84fea4f94ea73857_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxMjQ_4a0a264e-f47a-4395-ad75-3bf9ca5dc4ac"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4179a6ea77a3452ea924a970e6862138_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxNDM_6cc0ab0e-8fdf-48ca-a633-ab53473b3f0d"
      unitRef="usd">1000000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i725941cbca38484e85e015486a9604dd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxODA_2823c650-ca90-4a73-a9e1-5adbe675c2ee"
      unitRef="number">0.0570</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i963c8d3dfffb425ab800f22538a80972_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIxOTk_8aaf70b6-b900-4e94-be63-e5ac0a857319"
      unitRef="eur">675000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i963c8d3dfffb425ab800f22538a80972_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIyMzA_622320e8-bd40-4b5c-9f66-a829491cfdf4"
      unitRef="usd">864000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icfdeec3400fe43809c845700b9250d21_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIyOTI_ff18f7a8-5455-4cd7-8a13-6f4d6cf39247"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2d664e75d7a74f7491af9306d427a5c5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIzMTY_e23977af-03ed-487d-b2f1-52eac178cb80"
      unitRef="usd">700000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i96e075bdda244694a4469e256df31166_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIzNTM_fd56b8a8-ca1c-4160-a9f0-78b9b484d7d3"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i35730380319944e3910f345b948c0df9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzIzNzU_6b8a1022-a7a2-4167-8ec6-5bb4d273793f"
      unitRef="usd">550000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i358bdc0bde924dd6a9e6f8e2d53a4fda_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NTE2Nzg_0514a766-8754-4499-8db4-37794abeec6a"
      unitRef="usd">1100000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="idd6c0363be7c499eb126c69c7c63a409_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI0NTQ_cb123c06-eebe-4b96-9443-4abbe4be48f7"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie8daf767f6e14e758523360043a12636_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI0OTE_98c8868e-3c96-42ba-bfcf-98edd229cf9f"
      unitRef="number">0.0615</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic6268acd3d2a46dba0b2e730840ecee5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1MTM_4218a77c-3e3a-4708-be8b-adfe4903c4fe"
      unitRef="eur">550000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6ce07b37db1a4118b69a6f7fd3709440_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1NTA_f9d8605c-b62d-4b21-b88a-0364cff84290"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic6268acd3d2a46dba0b2e730840ecee5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1NzY_d1443e51-f241-4170-84db-9f923aad5346"
      unitRef="usd">621000000</us-gaap:RepaymentsOfLongTermDebt>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzI1Mjg4NzY3NDY1NjEy_c869c62f-c4dd-4430-9cd9-67a082a9c3c8"
      unitRef="usd">3650000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="id8fd749026d9457e843e73baf3eedd7a_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDA2_4c95d1b8-2d2b-4d01-9630-11b656386380"
      unitRef="usd">5200000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifcd6d09277ed4900bbac50776efa7a38_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDUx_d163a1c5-37c4-47c6-a715-5653a3aa47eb"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf087f04fa3b433688c1f56ee1145222_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDQ0_5a6651bd-85bb-4d68-8ce8-3ea3e80d155b"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85d6a61884124f82bfbd04c56c2051d5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDM2_b9f4ae95-e9b7-49b0-8ba9-10b33e5c82a0"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib86fea773d394279b54bf0ad27439680_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDIw_f173f4b2-5f8d-48a2-8409-7a01e6c4a08b"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9d96bb63d6154edbaeb3f2a417b4da61_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NDI4_12805f23-fb04-4667-81df-26b61a3339e2"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3a91bd5c90e8492fa703ad1a89545d34_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDE3ODg_f2183d8e-69b5-4b30-ba15-5241381278a9"
      unitRef="usd">576000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic5c9cfe81f3e4917a0b8ebe47bd9a715_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDE3OTQ_372825c4-562e-45dc-8d83-5eb2e957361f"
      unitRef="usd">5200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNDI_4286a225-e57d-4ce2-a1e2-b41cd84a622b">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45% 2020 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10% 2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% 2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2022 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% 2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% 2026 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% 2051 Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Excludes an additional 1.5% of interest for the difference between the coupon rate paid to noteholders and the fixed rate received under the interest rate swap contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb8f6352b8834211af6d0c68477f85f1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjk4M2JlYTdhZTFiMjRkY2JiOTYyYTVjMGJmZmU4NmIwXzEwOTk1MTE2Mjc4MDE_e8e0734f-ee38-4fbc-8bee-cf0aa10a0739"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibb8f6352b8834211af6d0c68477f85f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItMi0xLTEtMjk0Nw_94f3f447-9c70-4a20-bb49-e6d16cf838f6"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="if90978c11283437c9156f060d82208ee_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjllZDVkNDhhMmMxOTQyYjY5MTNhMzIxNDA1OGU0NmI3XzEwOTk1MTE2Mjc3OTY_42b62240-7da3-42be-aef9-f332a5750ef7"
      unitRef="number">0.011</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a7501d33a3a455691d18c20b0223337_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItNS0xLTEtMjk1NA_19dedace-9f26-4185-a3b0-584fa9092411"
      unitRef="usd">900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i2eb21bbc622f4765b1b17b9e42cffcc1_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzItNi0xLTEtMjkzNC90ZXh0cmVnaW9uOmM4Y2YyYTllM2EwYTRhYTJhYThhZjQ0ZTA2MTY2Mjk3XzEwOTk1MTE2Mjc3OTY_c4a5e660-4a2c-4ca6-a8a5-a62790b4198b"
      unitRef="number">0.011</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia90e46dcb35e465890654a17ea25721b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjBjOGQyYzkwYTE5MDQ0NGM4NWJkMTVlZWU0ZjljMmY2XzEwOTk1MTE2Mjc4MDE_c752f750-f1d9-40d0-bdc7-c2a2ac40cb9c"
      unitRef="number">0.0410</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia90e46dcb35e465890654a17ea25721b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtMi0xLTEtMjk0Nw_c4dcefbf-1195-4eab-80f2-a729fa94e039"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i9ce2131b83c543178a1ff35a8a9f7b29_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjU4OTI0YTI5Y2NlNTQxNThiN2U3OWQxODYwNjNmZDIzXzEwOTk1MTE2Mjc3OTY_630cb50b-391b-45e2-856e-84a252a1c3cd"
      unitRef="number">0.017</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibbb51cf3560f44fd82a1ed3524aba9e2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtNS0xLTEtMjk1NA_3817f383-75ef-4671-966d-653f88fee25a"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i8b4f018bc432431ba9e3ebae45b475b9_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzMtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjVmNmY3YzAxYzk3YTRjZDU4Y2M0NWM3ZTVjODc0NTZlXzEwOTk1MTE2Mjc3OTY_6d455556-5988-4340-9438-06a7b1f559d9"
      unitRef="number">0.017</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7249a2eb8741476eac1bbed378060085_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjMzMTcwYjc2NTQ4YjQyNTA4ZGJiYjgxNDM2MzBiOTkwXzEwOTk1MTE2Mjc4MDM_a9257be8-7791-460c-9a62-7086c97d86c2"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7249a2eb8741476eac1bbed378060085_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtMi0xLTEtMjk0Nw_3ccc6a74-6da9-4973-841d-0ddc66638c5e"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i6e6a942464df49888f5da90fa7d3079f_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjNlZmZhNmVhMmJkMzQzODE4YWZjY2EwOWYwYmFhOTM2XzEwOTk1MTE2Mjc3OTY_e4dadb8d-7933-4c68-91ca-639cfc45e036"
      unitRef="number">0.020</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic8f92b19c4e34a72af65be5f26e24641_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtNS0xLTEtMjk1NA_d18ae809-4cc8-4ec4-894e-9e6c30b5c7cd"
      unitRef="usd">1750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ib22110db36464336ba83d0caaaae87ce_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzQtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjc0OGIxNmFmMGFlMjQ4ZTU4NTIyYzUyMTgwMjExZTU3XzEwOTk1MTE2Mjc3OTY_60185a31-9d49-4498-aacd-eb3d8420a3d9"
      unitRef="number">0.020</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ief290ad7941b442fab79e88967534cd6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjhhZTllYjczZmJlZDQxZGQ4YTI0Y2Y3MzQwODhlYWNmXzEwOTk1MTE2Mjc4MDM_e27d160f-4ae4-4ad6-ba44-637ddf86c468"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ief290ad7941b442fab79e88967534cd6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtMi0xLTEtMjk0Nw_112e25cf-e26e-4c92-8600-2f9ce1aee61b"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i2335a1cb123c499e80a1aa39baa5fda5_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmQ3ZWZmOTMwOTViNTRjOGZiMDdjNmUyMGE2NDU1NzYxXzEwOTk1MTE2Mjc3OTY_4ee848f2-72eb-4584-9748-72d16147f770"
      unitRef="number">0.027</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id7351dc6225e40e5b3d4da990aaafd0d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtNS0xLTEtMjk1NA_f7203449-ca0e-44c5-8817-869da7c8160f"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ic54306a521a5410e83f206562df048e7_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzUtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjc0YjgyMjk0NzQ2ZTQxOTk5YTMwYWU5NjJhMjJkNTA3XzEwOTk1MTE2Mjc3OTY_a7639bec-830c-4ff6-a2f2-5d660a8277af"
      unitRef="number">0.016</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iec5e5f1709434645a4f86bee8db7c5c4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjc5OGYxMjE2ODYxYjQxZjdhNGQ1MWNiYmQzMDBhNWVjXzEwOTk1MTE2Mjc4MDM_4fd71c8d-18eb-415c-996b-4eff52aa7756"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iec5e5f1709434645a4f86bee8db7c5c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtMi0xLTEtMjk0Nw_e20e183d-4ba4-436b-a98b-755bc758bb06"
      unitRef="usd">1400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i69d46bf88a054fb0abd4b6f021382f5c_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmMwZjkyNjVjNWYyZjRjZmE5MDdiMGRkMjA1ODczMTYzXzEwOTk1MTE2Mjc3OTY_375b4c54-b6f1-441a-aaeb-40be92e168df"
      unitRef="number">0.032</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icda7d092fb704dcca96b59957bd2a0dd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtNS0xLTEtMjk1NA_b5322cf6-5d65-473a-a90a-52442d33c704"
      unitRef="usd">1400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i97abdf954cf14e22986f9fb69d4e08cf_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzYtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjE2NGVjZTQyMWFiZTQ4NGM5YWU4NWRkOTc2NDU4OTNmXzEwOTk1MTE2Mjc3OTY_6fd7351c-8b99-4c14-a7be-a06a9218fff9"
      unitRef="number">0.014</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i959c8054e99b4ba4a601a0f7b2e68fb9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjk1OTUyZmVmMWEyYjQ0MTlhNTE5ZmMwYWExMWMwYjU1XzEwOTk1MTE2Mjc4MDM_b7631846-ee5b-4ab1-820f-61b148a91bb2"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i959c8054e99b4ba4a601a0f7b2e68fb9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctMi0xLTEtMjk0Nw_d0ec4ec2-3a51-4d56-a25b-6ab5c0c83018"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="if22d72d2f9754767b787702ea64e3553_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctMy0xLTEtMjkzNC90ZXh0cmVnaW9uOjlhMGI2ODNlOWU3MTRhNTlhZWJkZDM4ZDUxNjUzMjkyXzEwOTk1MTE2Mjc3OTY_df83de48-26a1-4f87-8768-0d5b0c684d9b"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ief48420564f04693bfa31f3606365235_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctNS0xLTEtMjk1NA_370e2ef6-8f54-4220-acfa-e4412582d380"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i37f44fcba83d42e1a232fd794b15ec7d_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzctNi0xLTEtMjkzNC90ZXh0cmVnaW9uOjgyMDQzMmFiYWU5MTQ4ZDM4OGIyNDI0MDhkYTAxYWI1XzEwOTk1MTE2Mjc3OTY_d8d77e02-a044-43b4-a33e-cacd9aecc6d0"
      unitRef="number">0.009</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86bd689abf77408fa7438dcaea1c9165_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjg2NzhhYjNjMzBhMzQ2MWJhODJhZTBhZmViZjhiODIwXzEwOTk1MTE2Mjc4MDE_a58dd08d-e8cf-4fd7-a543-bcb9e9aef584"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i86bd689abf77408fa7438dcaea1c9165_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtMi0xLTEtMjk0Nw_d7d8985a-a507-4faa-8771-f058104072b8"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i968c11eef2e44b85b73c09287db49afd_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmRlNzQ1OWFmYWY5MTQ5ZjI4MTQwMjAwZDMzZDQzMDg5XzEwOTk1MTE2Mjc3OTY_daad87c8-a4a8-4610-903b-d79db8967da9"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5ee91c42bda54e20b6e7adf10ee4a30c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtNS0xLTEtMjk1NA_5948e3dd-eecb-4233-8a46-892f4b9f6ec1"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i25258a7ecd234572bf5dbcbe63e9334c_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzgtNi0xLTEtMjkzNC90ZXh0cmVnaW9uOmJiMDJhNjllN2UxNjRjM2I5ZjI0Nzg4MGQzMGRkMzJiXzEwOTk1MTE2Mjc3OTY_62ae08c5-79ac-40b1-a5af-3e2fd73a9ebd"
      unitRef="number">0.003</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9adb74cd7d004de18ef5c0ff3957a722_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktMC0xLTEtMjkzNC90ZXh0cmVnaW9uOjBmYmQwMWU3ZGYyZDRhNjY4Zjg4NTRlMzAzNTVlMTQwXzEwOTk1MTE2Mjc4MDk_6eac0cd8-3665-41ca-9f66-0d7b06212cb8"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9adb74cd7d004de18ef5c0ff3957a722_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktMi0xLTEtMjk0Nw_e1817719-02fa-4a85-b12c-e7cc8da8b518"
      unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="idd511439740c4be9a99104d33dcbf8bb_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktMy0xLTEtMjkzNC90ZXh0cmVnaW9uOmUyMjUyNGQwMjI5MjRkYmY4MTVhYjQ0MmRhZTU2YmM4XzEwOTk1MTE2Mjc3OTY_72704264-49b7-4aeb-9b0e-31ead82fbe97"
      unitRef="number">0.026</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i362b746ef24043558b07c52bd684d25b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktNS0xLTEtMjk1NA_6ec5507f-d2b7-4ca2-b357-3290577c5ba2"
      unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ib6c809f8f67643efa3a6bb558412f991_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzktNi0xLTEtMjkzNC90ZXh0cmVnaW9uOmQzNWMxNjkwY2JjNjRkZGNhNDRiZjUwMGI1OGNlMzg2XzEwOTk1MTE2Mjc3OTc_b8518fb6-7f75-45b5-9f41-1f27205a4f59"
      unitRef="number">0.000</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8ddee0d2991140ffa22fd07e6d2467be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzEwLTItMS0xLTc0MTU_aa7e1fdd-7b91-4a99-b285-fbd384d7d846"
      unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i39652c0a62c5481095ff480fce17ca6c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpiZjBiODViYjM5OGI0MDk4YjY0ODA2YTc5ZTQ3M2NmYS90YWJsZXJhbmdlOmJmMGI4NWJiMzk4YjQwOThiNjQ4MDZhNzllNDczY2ZhXzEwLTUtMS0xLTc0MTc_927ff75e-bfee-47f8-8de6-483d9da24ce0"
      unitRef="usd">9550000000</us-gaap:DerivativeNotionalAmount>
    <amgn:Ratedifferenceinaninterestrateswaprelationship
      contextRef="ibdd497f181c14d5ab36c9202a891b09d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDE5MDk_cbdcd2f1-88e7-41c5-a34e-9d68922d2050"
      unitRef="number">0.015</amgn:Ratedifferenceinaninterestrateswaprelationship>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIzNTM_c5e0e91c-dd8c-4ee4-b350-da685f400d22"
      unitRef="usd">940000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIzOTQ_b2684ae6-60e7-46e6-80ff-5a2109f24e20"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTE1NjA3_422386df-9355-49b4-81c8-b1574f031bb2">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following principal amounts of each series of Old Notes were validly tendered and subsequently cancelled in connection with the Exchange Offer (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal amount exchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% 2037 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% 2038 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% 2039 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% 2040 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% 2041 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% 2042 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% 2043 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8adffe9f09f4420c8fd2a34ac3a8daf1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzEtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOmE3ZGZiN2E4MDMzMTQwNTliYjFjNmQ3M2ZjOWY0N2FlXzE2NDkyNjc0NDE2OTE_6ede4705-6ee7-4019-8a7d-f013e3c43fcf"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i92b9a5668fbc41e6b4d63640b91febe6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzEtMS0xLTEtMzAwOA_cd9ce0c1-02f1-4851-9ea3-a273345039ee"
      unitRef="usd">74000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if8c556faa66a4640add9a389585dcb8d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzItMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjU5N2NlMzk3MWRmYzQ5NWU5MDNhMzJhMTc4Y2ViMDYxXzE2NDkyNjc0NDE2ODk_7d23008b-1e9a-414a-beab-9d0c6b7a3119"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i85b731805304467297b2b3b116999268_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzItMS0xLTEtMzAwOA_dec4f277-8079-41c3-af38-ab2b5d436be3"
      unitRef="usd">37000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i33bc0e6a798a4daa94404d7e959a5646_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzMtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjg1YTA0NDUwOGJlNzQ0MGVhZjg0MGNiNWU1MmMzNWRiXzE2NDkyNjc0NDE2ODk_92b588eb-bd6e-4847-9f93-3c84c172a576"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i6382073fcb1d4883b6219e6dc102e745_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzMtMS0xLTEtMzAwOA_9542d2c5-3926-4768-b878-975d3b379594"
      unitRef="usd">133000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86e8c0425a564da7849ac5fe7b5db51c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzQtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjgzMTUxOWE0MjI2MTRmODE4YTEyOWU2ZmUwODk1M2NmXzE2NDkyNjc0NDE2ODk_50b56909-6275-4c9e-96a6-57c5188a08c9"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ic7759f579c524eab8b6b4da9a496f1e7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzQtMS0xLTEtMzAwOA_4e0372ef-4f4c-496b-822a-9f81b08f8ff4"
      unitRef="usd">39000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1dcacc53791a4df7b253b539b0644b8f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzUtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOmViNWQ3ZTFhZmRkYzQxNjQ4YzExYmFiOTcyZGM4NGJmXzE2NDkyNjc0NDE2ODk_0935d900-995f-4fd6-a9c5-3ef67181771a"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i2d73c382070d4582bf5468d1be4dc656_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzUtMS0xLTEtMzAwOA_c3bb066e-a798-4934-b749-ee7acb0cce81"
      unitRef="usd">245000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i76cd436bd1f242d4bd92a582319d9cd9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzYtMC0xLTEtMzAwOC90ZXh0cmVnaW9uOmE5MTlkZjlmZjk5YzRjODBhZmNlMWMwZWVkZTJjM2NkXzE2NDkyNjc0NDE2ODk_2a816a8c-4872-4dae-beee-84b397f92956"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i1d34c35332374923becedb1eee1b52cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzYtMS0xLTEtMzAwOA_59fc5aad-ed58-43c7-9038-da5a9fee2403"
      unitRef="usd">72000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie22a6012e30946cbaa82df3fa40dddb3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzctMC0xLTEtMzAwOC90ZXh0cmVnaW9uOjViZDFlNWE3NTM4MjQ0NTg5M2JkMTM2NGZhMjU1NDdhXzE2NDkyNjc0NDE2OTE_929b7c7b-8124-4e72-9266-ee442f99a582"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i1ec6c7c7b81b48d8a20694d3b57b6b70_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTpkYjE0YjQwNWQ2NmE0OGFlYTIzNDNkMTcwNDE0ZTMyOS90YWJsZXJhbmdlOmRiMTRiNDA1ZDY2YTQ4YWVhMjM0M2QxNzA0MTRlMzI5XzctMS0xLTEtMzAwOA_1a1fa900-2584-4f65-abb3-d68a0c2a54f6"
      unitRef="usd">76000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0MTc_c1c02054-3265-47b5-b6b0-7a7ecec37db0"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0MzA_b64a0041-b58d-4e23-9101-2364ab97f061"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DebtExchangeAdditionalCashConsideration
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0NDk_29150a7e-635c-4958-90f9-b55bf82c6218"
      unitRef="usd">85000000</amgn:DebtExchangeAdditionalCashConsideration>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0Nzg_d09a7984-c544-4357-abc8-12b4250b3eec"
      unitRef="usd">264000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13b5ae91c924275a407d360294f8076_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM0ODY_baa5552c-5834-489f-882c-580f56af7373"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i70ba1158d5c74f23be9c43c581ee22e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzM4NDY_2c3784a6-ab2c-4821-96d3-ac3e8dce4476"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i913aa3eb20c44b64967ed53a9ab6af9a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzM4NjY_146d5252-b6e8-463e-93eb-6fa47fcdc137"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i09a160e4cefe420d887e332af50138c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzM4OTM_f3f48745-2d5e-4526-9a93-9dcc6085ab07"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iab8ddb0cf45940228df2b710f4b10a4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIwNzI_a73ca271-1cc9-4852-96fc-163cdf9686a5"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i94fd52a87555424a9429b2446e6b20cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDIwOTE_cf0955dc-c615-417e-8778-65cb6530f7c9"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:MaximumBorrowingCapacityUnderCommercialPaper
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzExNTQ0ODcyMTExODU0_f124ec69-d32a-44ff-8b49-0d09fd10097c"
      unitRef="usd">2500000000</amgn:MaximumBorrowingCapacityUnderCommercialPaper>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib951b96e66134344b87919e6a15e9627_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM2ODg_21c2fab9-f58a-428e-a8c4-7048dc99489d"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks
      contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM2OTU_333028f0-bf18-4d2e-912a-ef8fd484e16e"
      unitRef="usd">750000000</amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks>
    <amgn:LineOfCreditFacilityInitialCommitmentTerm
      contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzQ2NTI_e29c2701-525e-48e9-9446-6d995fd9a952">P5Y</amgn:LineOfCreditFacilityInitialCommitmentTerm>
    <amgn:LineofCreditFacilityNumberOfRenewalOptions
      contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzQ2OTI_531cc180-3a05-40ae-b85b-49dea9f8e05e"
      unitRef="renewal_option">2</amgn:LineofCreditFacilityNumberOfRenewalOptions>
    <amgn:LineOfCreditFacilityExtensionOfCommitmentTerm
      contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzU0OTc1NTgxNjI4OTQ_37ede041-faea-492a-ae46-6c5a7875ed82">P1Y</amgn:LineOfCreditFacilityExtensionOfCommitmentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7e1013f782884735b9d8c12b815092e6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM3MDE_676d6a69-5d52-4736-84d7-ef64df4d952a"
      unitRef="number">0.0009</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzEwOTk1MTE2NDM3MDg_36cc51b9-d5c6-4995-8e55-31a1511ad18e"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia1f832aa086b4bd39c60c6c87db97472_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUxNDc_58380fd6-383e-46eb-9732-b03c448e0c90"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyMzE_49365dbc-b984-42aa-a338-8a41815c7e9e">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i22940eb939ff4da3b16e5579ff8a4e38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUxNzg_d6f82f0b-91bb-4f25-bde6-e64766b5940c"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCredit
      contextRef="id3d59abe384541c89aa4311f241834bc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUzNjU_78e9ea71-c41a-4ffc-bc29-23f7733ddac0"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ib951b96e66134344b87919e6a15e9627_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzUzNjU_c36a3815-ac3e-48e3-85bc-4a615242d1e8"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyNDA_ac7f32b7-d4ef-4fd2-90b4-f40f8bc5494c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December 31, 2020, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzEtMi0xLTEtMA_66f6bb4d-0dfe-4537-9bb0-bfd1cde981f8"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzItMi0xLTEtMA_d01ff550-944a-461b-939c-4a5ddb32e774"
      unitRef="usd">4277000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzMtMi0xLTEtMA_c9e04941-fda4-4359-aeb4-f63beea9429c"
      unitRef="usd">1541000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzQtMi0xLTEtMA_ae5965b1-749f-499e-aabe-23ac30ac4a1c"
      unitRef="usd">1400000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzUtMi0xLTEtMA_f9759e98-b7c2-4427-9b7f-06673b2f730c"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzYtMi0xLTEtMA_94c27ebc-7b85-493f-9a13-2b551ad78bc3"
      unitRef="usd">24890000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90YWJsZTozYzM4NDVhYjQzMDM0YmFhODY2ODdiOTM3NDY0ZDc4MC90YWJsZXJhbmdlOjNjMzg0NWFiNDMwMzRiYWE4NjY4N2I5Mzc0NjRkNzgwXzctMi0xLTEtMA_a68823f8-75cd-442c-97b3-2aef8b81ad8c"
      unitRef="usd">33608000000</amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet>
    <us-gaap:InterestPaid
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcxODk_2a8cd629-49b7-4169-80ca-74be7f8b72d8"
      unitRef="usd">1200000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcxOTM_52474d66-3de1-4c8c-80ba-2eb46e236bb3"
      unitRef="usd">1300000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTMvZnJhZzo2MzE3YWI4YWIyNjU0MmFmOWEwNTgxY2I2OGEzYWE5Zi90ZXh0cmVnaW9uOjYzMTdhYjhhYjI2NTQyYWY5YTA1ODFjYjY4YTNhYTlmXzcyMDA_5152ca51-8ebf-4fab-9a86-91371036da5f"
      unitRef="usd">1500000000</us-gaap:InterestPaid>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwOTA_97df7707-f234-4815-8f64-f4cd31df24f7">Stockholders&#x2019; equity&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchase program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Total shares do not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0 billion. As of December 31, 2020, $3.0 billion remained available under our stock repurchase program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors declared quarterly dividends per share of $1.60, $1.45 and $1.32, which were paid in each of the four quarters of 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 16, 2020, the Board of Directors declared a quarterly cash dividend of $1.76 per share of common stock, which will be paid on March 8, 2021, to all stockholders of record as of the close of business on February 15, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative effect of change in accounting principle, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $14 million benefit and a $110 million benefit in 2020, a $28 million expense and a $46 million benefit in 2019 and a $21 million expense and a $55 million expense in 2018, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020, a $22 million expense and a $14 million benefit in 2019 and a $9 million benefit and a $3 million expense in 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2020 and 2019, no shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <amgn:StockRepurchaseProgramTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwNjU_74a714ed-481d-4c6c-8de1-5dd7b9e5e3e7">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Total shares do not add due to rounding.&lt;/span&gt;&lt;/div&gt;</amgn:StockRepurchaseProgramTableTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtMS0xLTEtMA_ef1d4119-6933-4902-ad67-3dee7c4283e0"
      unitRef="shares">4300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtMy0xLTEtMA_aae036ae-23aa-43c7-be8a-d6edc6df54af"
      unitRef="usd">933000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtNS0xLTEtMA_6ce4b802-9711-48a3-9f1b-afecccde4b2f"
      unitRef="shares">15900000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtNy0xLTEtMA_3a5eafcc-ec68-46e2-8a6b-d2768a8b80c7"
      unitRef="usd">3031000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtOS0xLTEtMA_2f63d56f-aa8a-4e3d-a131-db32edf77c4d"
      unitRef="shares">56400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzMtMTEtMS0xLTA_ed8d0b24-aa53-45b6-9ed0-d7d0aba05e34"
      unitRef="usd">10787000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtMS0xLTEtMA_cd3e8c4c-dfc1-4189-b63b-33bc4c530eff"
      unitRef="shares">2600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtMy0xLTEtMA_bcf3d03d-3012-45f0-b9f2-0f85fcc4fe64"
      unitRef="usd">591000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtNS0xLTEtMA_804365d4-a5e4-464d-92bf-abd94db8552d"
      unitRef="shares">13100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtNy0xLTEtMA_bd9f8305-0b86-4f3c-9d39-25be3d6a09e5"
      unitRef="usd">2349000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtOS0xLTEtMA_c255af36-cb0e-4f0c-a96c-c389b7a0eac6"
      unitRef="shares">18200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzQtMTEtMS0xLTA_1b12e195-2743-41a8-a804-b2e9d649e8ce"
      unitRef="usd">3190000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtMS0xLTEtMA_665330d5-a755-499a-8c7e-ecfc879bfed5"
      unitRef="shares">3000000.0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtMy0xLTEtMA_97c6b643-384d-4585-9617-3ab8bcd787a7"
      unitRef="usd">752000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtNS0xLTEtMA_290f713d-368e-46ae-8f72-f898cad2c2e6"
      unitRef="shares">6200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtNy0xLTEtMA_fc336c4d-ba83-44d2-90b2-3b385897437f"
      unitRef="usd">1170000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtOS0xLTEtMA_6c72c8b7-9de9-4882-afdc-f7fa830eb233"
      unitRef="shares">8700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzUtMTEtMS0xLTA_f456e659-d8c2-419c-8931-02795cea6806"
      unitRef="usd">1713000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtMS0xLTEtMA_3d9493f2-e1a1-488c-8df6-17db6d68ef42"
      unitRef="shares">5300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtMy0xLTEtMA_5f32f677-e3fd-4c1e-8642-32c7c3b1b3ad"
      unitRef="usd">1221000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtNS0xLTEtMA_3845575a-c763-4e56-b7e9-60dfa8d32cb6"
      unitRef="shares">5100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtNy0xLTEtMA_2076b042-50df-461c-9a50-8f26b102db09"
      unitRef="usd">1090000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtOS0xLTEtMA_77a5d3b5-b0f7-4785-9f8a-cb091169b7ba"
      unitRef="shares">11100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzYtMTEtMS0xLTA_37ce8e82-b120-4f94-a86a-a8d3cd3e46cf"
      unitRef="usd">2165000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctMS0xLTEtMA_92f55724-2522-443c-812e-88dc0739bb97"
      unitRef="shares">15200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctMy0xLTEtMA_a3d531c8-e8a2-498f-8b3f-c2c8726160be"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctNS0xLTEtMA_085eb9d3-363b-4fd3-bc30-55e1bf00134a"
      unitRef="shares">40200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctNy0xLTEtMA_c29b77a1-f553-4f08-82c1-005913741fa1"
      unitRef="usd">7640000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctOS0xLTEtMA_6134e881-af9b-43f5-9728-5669e89bc959"
      unitRef="shares">94500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTowZjcyZWU1OGFjNmE0Y2JiOTQ0YmU3YjA4MTkzM2Y3NC90YWJsZXJhbmdlOjBmNzJlZTU4YWM2YTRjYmI5NDRiZTdiMDgxOTMzZjc0XzctMTEtMS0xLTA_bdb19737-b3dd-450d-ad3c-d28ef3efb3fd"
      unitRef="usd">17855000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzM0MQ_fcc59ff2-7317-4095-b49d-d95d5e86b1e8"
      unitRef="usd">4000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzM2OQ_fc547d70-1394-4c54-bde8-ab7164c618da"
      unitRef="usd">3000000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_47d76540-c76c-4647-b366-933fb14602f3"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_8116adba-270f-4d7c-b768-ca1c46d300ed"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_beabf666-ce91-4e1d-9814-377717ec1d0f"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwMw_e7cf8fcf-6ed6-49eb-a031-9729b60d70f6"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_09aea56f-d27e-401a-b33e-1ba2b2e39964"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_3aa916ef-9c13-454b-8502-3f8693d2fa22"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_ac09a7b7-47e2-4823-8c6d-afc76a8e92b4"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUwNw_ad111ff8-23fc-4e20-91ef-374e686bd248"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ia9c65ae6d63b44c79cf329d652df2171_D20181001-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_13d86021-a73a-4330-b466-09edaca30078"
      unitRef="usdPerShare">1.32</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i32e26fc6c90545488746c1f62ac029c2_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_213b8f6a-2a3d-4832-8fc7-fc8068c16e02"
      unitRef="usdPerShare">1.32</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="icd4fbcf54fd84535a7ee75f90231795b_D20180701-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_cf7f7d0b-3551-45df-aac0-63e346f7b2f9"
      unitRef="usdPerShare">1.32</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i27362feb5854496997daf71cceac6d2c_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzUxNA_d0d211e0-8196-4939-8120-17150229afea"
      unitRef="usdPerShare">1.32</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i65105b8f350547a9afe51cf16587594c_D20210308-20210308"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5Xzk1Mw_60a179cd-8e4a-43a2-843d-5569c63c6cdd"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i60869bc47af9405383d397dfe67b7ce8_D20201216-20201216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5Xzk1Mw_bf2f6f99-32a8-4b6d-b80d-f104f8f7e486"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwODk_0a0ef37d-d11b-4470-aec4-792acaec9fab">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative effect of change in accounting principle, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i15cba6363e694ebfbb2115df9607f890_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctMS0xLTEtMA_f630aeae-3d62-4dfa-b4eb-217fcfef8b99"
      unitRef="usd">-529000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec98fde84dd7443daf65e4d48bd33cae_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctMy0xLTEtMA_a3cb7a4d-1c6a-4d6c-a6d8-f55bd27aecdb"
      unitRef="usd">-6000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3e51d8ec78e482f981fd6bf9a9ca60c_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctNS0xLTEtMA_3d2ebad6-130e-438c-bd04-d29130e80eb4"
      unitRef="usd">-144000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i508432a61553416fbdccf7e432d4e8bd_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctNy0xLTEtMA_3707aa6a-56d1-4f48-9881-04bd2d582bee"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie781bbd2a4b948e48767b11ee16f2352_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzctOS0xLTEtMA_72eca268-df05-4509-b66f-20bf5c1cf06d"
      unitRef="usd">-679000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8870a99dcef48e5aa17b95e8de89a23_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzgtNS0xLTEtMA_41324b14-3ea1-4161-b14c-82987bad271d"
      unitRef="usd">-9000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36d7388f79e144b99235c416c99550db_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzgtOS0xLTEtMA_85378a7c-696a-431d-83cb-d3da72d158fd"
      unitRef="usd">-9000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i72a72f83ff6643498ddd2ad2b28672d0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzktMS0xLTEtMA_9f24ff4a-91e0-4ab3-9673-d5c3a8f80ba8"
      unitRef="usd">-141000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzktOS0xLTEtMA_24092006-1059-4833-a5b2-b300aa22bc7a"
      unitRef="usd">-141000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="iab14641cde404512b613907261773c1b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEwLTMtMS0xLTA_23cc80a0-4c6b-414a-8b22-533f317f1807"
      unitRef="usd">61000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEwLTUtMS0xLTA_52057118-dac3-4420-9bc6-ddfe99a11319"
      unitRef="usd">-556000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEwLTktMS0xLTA_e27be00a-88c8-4766-9638-ea3849a441d2"
      unitRef="usd">-495000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="iab14641cde404512b613907261773c1b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzExLTMtMS0xLTA_abc76020-2b51-4571-9549-016debcefc35"
      unitRef="usd">-262000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzExLTUtMS0xLTA_55d82fd1-0073-4271-a650-4e6710f0c86f"
      unitRef="usd">-365000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzExLTktMS0xLTA_46932323-06d3-403f-a15c-e8828b65abea"
      unitRef="usd">-627000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i6c2cdd35e2524c0c8b0dca79a961b38d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEyLTctMS0xLTA_92e55796-ed7f-40d8-8207-2b5f1b449c98"
      unitRef="usd">-2000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEyLTktMS0xLTA_31a6e758-b7ee-4d20-9791-c6f1cb64b48c"
      unitRef="usd">-2000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i72a72f83ff6643498ddd2ad2b28672d0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTEtMS0xLTA_62d72744-f6f1-420b-8fa5-e2c9a4d4e7c1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="iab14641cde404512b613907261773c1b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTMtMS0xLTA_6e02680f-28a7-449e-afd3-5c712f5d5f63"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia8558341397549ec92f53ed2c49dfbef_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTUtMS0xLTA_c9f32ae0-8cf2-4c27-b677-c2eda1a81f04"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i05dc66e9c1c8492f80ee3915ad457332_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzEzLTktMS0xLTA_e4a1e739-11d0-41fa-b40c-2ee92ddd81ee"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i88f71e0b4ef646179cff4ca0c5bb2784_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTEtMS0xLTA_598c2038-c88b-4468-b24b-4894f2c584fa"
      unitRef="usd">-670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff02eb33259b4098afad9b87c2f8f6f1_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTMtMS0xLTA_06510dc1-47d8-4a78-aa6f-b773cf4a8ae9"
      unitRef="usd">241000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab46e3e374ed4320a79dc7f501ca2a0f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTUtMS0xLTA_94f1be24-3625-4abd-b0e4-b1c7a1bf739d"
      unitRef="usd">-338000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4ef7d0edff34c2eb74bbbcb8615f89d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTctMS0xLTA_b2bf0dcb-3931-43ab-8578-9df0cdcf0594"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idda2fa41bf7b4d32acb584d26141eb44_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE0LTktMS0xLTA_3581705a-f7b2-4a16-a92f-366f814e6880"
      unitRef="usd">-769000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iebe63279db194377849f0b40c57d4391_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE2LTEtMS0xLTA_fbe36a79-ee50-4236-9ced-e76ccba8aec7"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE2LTktMS0xLTA_9894d690-5139-490a-a92a-c48427f0d475"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i84262de6ad99499488051396e0055031_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTMtMS0xLTA_0ae9a5cf-8302-4cfa-b48a-daa0d23749fc"
      unitRef="usd">127000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTUtMS0xLTA_04e182ef-4e76-41ad-a469-c97e12e8330d"
      unitRef="usd">424000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTktMS0xLTA_92e0ea7a-1222-45dc-9550-256988834796"
      unitRef="usd">551000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i84262de6ad99499488051396e0055031_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTMtMS0xLTA_a37aa309-c104-4536-8070-e29e2d6b9f58"
      unitRef="usd">-211000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTUtMS0xLTA_17ce6cdd-26a3-4550-9e29-0cede3ecbfed"
      unitRef="usd">-56000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTktMS0xLTA_27b45fdc-21f5-46a6-b36a-796dc136d7ae"
      unitRef="usd">267000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ieae7fdb0b6a64177be82f0c59a390de8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTctMS0xLTA_617185d0-692c-403f-b709-8910c2e9d102"
      unitRef="usd">-5000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTktMS0xLTA_255f7e1b-ea85-42bb-b7c1-0ddf7648dcc5"
      unitRef="usd">-5000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="iebe63279db194377849f0b40c57d4391_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTEtMS0xLTA_9cdff90b-af11-42a2-9f66-899524a48edb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i84262de6ad99499488051396e0055031_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTMtMS0xLTA_adb5f04b-14d0-47d4-8f3b-60ad721e6cb8"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i9d5797717ebd45f4ae752bdea45a7d45_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTUtMS0xLTA_a0a03846-73cb-4f7b-9aad-610001b48045"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie59aa49e96954ff0837acc1794975222_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTktMS0xLTA_39ef9894-409a-4230-bbe0-a9366d9a1851"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="ie382593a89bb40f88cbb7baae6848d85_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTEtMS0xLTA_180b67f4-936c-4390-9bf8-675f1ccdec16"
      unitRef="usd">-718000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i834e68b1d71c4cf88092899abf36f0bb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTMtMS0xLTA_c74c8a99-742a-43cd-a774-f5ef62fd8999"
      unitRef="usd">175000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id36dd4baf66a496999b27ea628bd7365_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTUtMS0xLTA_10a1dd5d-72c7-4214-b416-8d43d4707766"
      unitRef="usd">22000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i59e1359200bb485e82a279c005e655f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTctMS0xLTA_ccb4e8e7-2e51-460f-936e-468a79294483"
      unitRef="usd">-7000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f92a1519afd4ee790c4f7f9669bc32b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTktMS0xLTA_106dca83-ccdd-42ae-a8c1-eddeed4cb1c8"
      unitRef="usd">-528000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3a567dae4771464c8ac036044fce4ba5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTEtMS0xLTMyNjM_d3d0b3fe-bdb2-4c61-972a-932c3aa3a878"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE3LTktMS0xLTY4MTE_0ed48055-d4f5-4e2b-8931-de5cb53a473a"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTMtMS0xLTMyMzk_3edd27c0-a359-436d-94a8-d486ee4ac3ba"
      unitRef="usd">-61000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTUtMS0xLTMyNDM_33f46ce7-39b1-4ef1-a2e6-10a4d5e8dafd"
      unitRef="usd">6000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE4LTktMS0xLTY4MTE_2b23ef9e-1bf7-49d7-b09a-5450cafbc19b"
      unitRef="usd">-55000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTMtMS0xLTMyMzk_07b66c5d-b2b6-481f-8b11-5227c35c093d"
      unitRef="usd">-501000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTUtMS0xLTMyNDM_701065f5-4968-4a06-b18b-73df6bd6e709"
      unitRef="usd">-33000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzE5LTktMS0xLTY4MTE_4fbbd70e-c04c-41c4-8a10-75f2c5a41aa1"
      unitRef="usd">534000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i38568b10d86a4316bf7376de6e8728d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTctMS0xLTMyNDc_170f3606-3c5e-4d52-beb1-a261bd660978"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIwLTktMS0xLTY4MTE_11ebb18a-7a96-4c04-aed4-7ecefd189310"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i3a567dae4771464c8ac036044fce4ba5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTEtMS0xLTMyNjM_bf4bc374-ff97-444e-9c0e-03f9759973ec"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i3f2ed733398b44bfaafcfe72e9855f76_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTMtMS0xLTMyMzk_2f6d94fe-7bfb-4f28-8512-62a1bf21a398"
      unitRef="usd">-124000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i23a016dc6bc84d2d936b12f98be36f7d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTUtMS0xLTMyNDM_09c1c967-f9dc-471f-b002-b08fc0177c8b"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ic5ecd58498bd452d9bd10e43f680bd75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIxLTktMS0xLTY4MTE_ad52d822-824b-46f9-bbc5-9f0caa333bc0"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i445ee927bb9f4ec6a1e136928e6720e2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTEtMS0xLTY4MTE_5f0d93d5-61ac-49d8-9050-699e06b2d7f0"
      unitRef="usd">-709000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie06b327237f54c16b3d3e03f5d5e7398_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTMtMS0xLTY4MTE_6ae83a95-fb04-4c88-8a98-665531e3d0d3"
      unitRef="usd">-263000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i946ba1f102a249339cc475cc38dbff62_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTUtMS0xLTY4MTE_611b510f-cde0-494e-a241-71aba541b0b2"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe6d63071dc4400d8c5203ab02d542d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTctMS0xLTY4MTE_40296766-8eb2-4438-95cf-5f070cf00ed3"
      unitRef="usd">-14000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42b0fccf031241ce995839be6adc2e18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZTpjNzZmMWJiNGZjZGU0NjY3YjBhNWQwNTYwNTRkOTMwYy90YWJsZXJhbmdlOmM3NmYxYmI0ZmNkZTQ2NjdiMGE1ZDA1NjA1NGQ5MzBjXzIyLTktMS0xLTY4MTE_7269f3aa-716c-4489-93a2-440b39bb14f3"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzEzODI_fff6dafc-832c-42e7-9c13-7ff340511160"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzEzOTk_64e5a7fe-aa22-443e-8c7c-960b3af0198c"
      unitRef="usd">110000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0MTk_0a4dc0b7-8c7b-4e71-9b53-c9181c363e1d"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0MzY_1117ecb2-10e4-4db6-bda0-319d19cee239"
      unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0NTk_42dc3578-79ba-4cef-87c7-0d2a29165292"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE0NzY_a24018be-e01d-428b-aa65-74d03b924d7f"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE2Njg_7367ff3c-1d1b-4a61-acc3-47aca174e1e2"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE2ODU_71c61662-fed2-47f6-8bc9-30701748f70b"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3MDU_01b889a5-3fd2-4abf-a0e0-59140be8dd49"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3MjI_1736be78-691f-4fdd-bfc4-39e120c141b5"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3NDU_4fb8c9b5-2349-45c4-aeff-c072e71d54d4"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE3NjM_0c5b1c4c-bab0-4ef3-b553-d080c918358e"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwNjY_fdedf5cb-17b4-432e-ad13-71d15969e90c">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7fe17c4200c54926b08b32de808d1607_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzMtMi0xLTEtMA_b08e2dfc-2aa5-44a4-9e44-bfa197ea8858"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i32e10debea2943bfa038e3e584b92196_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzMtNC0xLTEtMA_d7e6f985-1d36-4c02-8e4a-2c15851234de"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id48a4f1daf6e423eb316bae15e9e3e54_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzMtNi0xLTEtMA_1737d46a-f982-4d74-a6c1-73d99bb1842f"
      unitRef="usd">-21000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i59f81c16e1ff44269b3e2017ea6eef9b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzQtMi0xLTEtMA_d66e0adc-6790-4e77-8438-682c20744cd9"
      unitRef="usd">323000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8d4dd2242a604708a35885bb2742cbd6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzQtNC0xLTEtMA_3a0cebd5-9e44-4add-acd6-381d7f61f1ad"
      unitRef="usd">110000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9682afd0b98a49479f04e9a056ac6cf9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzQtNi0xLTEtMA_91bc8ddc-99a3-400d-803e-d1b8ba0a141b"
      unitRef="usd">-241000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzYtMi0xLTEtMA_532a65c0-9368-4b50-ada1-c630b977b28c"
      unitRef="usd">501000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzYtNC0xLTEtMA_aef0deb8-3bff-4be7-99fb-fda94f83db1f"
      unitRef="usd">211000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzYtNi0xLTEtMA_ec63ca96-196e-40cd-966d-6474bece6098"
      unitRef="usd">-262000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzctMi0xLTEtMA_33df52f2-ab5c-4042-85c0-e2afce6e935d"
      unitRef="usd">110000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzctNC0xLTEtMA_53ca61b8-6b85-424c-bdad-774911d09927"
      unitRef="usd">46000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzctNi0xLTEtMA_6c3ab326-0fbb-4099-8656-3710f5f15f05"
      unitRef="usd">-55000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzgtMi0xLTEtMA_1ccb62d4-8b54-4bbf-a0a8-c7eca9d76110"
      unitRef="usd">391000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81c572f22afd423abcd1f9ca88dfdc63_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzgtNC0xLTEtMA_8c1122e5-4c42-4cb9-ae13-b4e280c317cd"
      unitRef="usd">165000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i379e8c65221547f89124d57d27b5caa6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzgtNi0xLTEtMA_2fe7c69b-9625-4add-b084-858bda3d9f74"
      unitRef="usd">-207000000</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEwLTItMS0xLTA_367f155a-770c-42be-b58c-134efe41d294"
      unitRef="usd">33000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEwLTQtMS0xLTA_a56e6cb9-097f-4c6e-b343-4e077bb9f994"
      unitRef="usd">56000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEwLTYtMS0xLTA_39a2636a-048b-4157-92b1-1097213f2073"
      unitRef="usd">-365000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzExLTItMS0xLTA_1b6ad844-90ac-41bc-9e27-f01abc9e142b"
      unitRef="usd">7000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzExLTQtMS0xLTA_cc4e5fed-b4ff-4c45-825e-ea4e45cbbaeb"
      unitRef="usd">14000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzExLTYtMS0xLTA_adf6dc2e-1606-4f45-a0ee-f4215a91bb44"
      unitRef="usd">-3000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ibd04baf80af64b4382ffa1e453d26563_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEyLTItMS0xLTA_cae73f83-623d-4cd4-80d7-fb08ad2f77da"
      unitRef="usd">26000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i336ce579832a4b1991a1a696af5ed231_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEyLTQtMS0xLTA_33f959de-376a-469a-adea-38bdd10a2299"
      unitRef="usd">42000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa356dc858dc4d3f99b39f04c859de5d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90YWJsZToxMWU5ZmI4MTJkMzE0Y2VjOWY4ZDJjNDhkM2Y3NzIxNS90YWJsZXJhbmdlOjExZTlmYjgxMmQzMTRjZWM5ZjhkMmM0OGQzZjc3MjE1XzEyLTYtMS0xLTA_2b44f8af-942f-419c-9a10-8ceb5c68a5b4"
      unitRef="usd">-362000000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE5NDM_eaff4940-1724-4400-9045-d09de95c40a7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzE5NzM_e07f66b1-ee58-488b-acc2-6e56471c7ca8"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_06c4875f-8795-46be-8d24-1e957ffbe2a7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_7d7eeec5-18c7-4347-bdf7-f4349528ac18"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_9e956017-8907-441c-9076-b918ce8eb888"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNTkvZnJhZzozMDY2NGYxNWM5MzQ0NDUxYWJlYzEzOTZkNmFhYjQzOS90ZXh0cmVnaW9uOjMwNjY0ZjE1YzkzNDQ0NTFhYmVjMTM5NmQ2YWFiNDM5XzIwMDQ_add55591-e95e-497a-a474-c2dbcc56705f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5MzI_71ec76f4-4279-41b5-b29d-3c27284015ee">Fair value measurement&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations for which all significant inputs are observable either directly or indirectly&#x2014;other than Level 1 inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2019, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of our corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of our residential-mortgage-backed securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by Standard &amp;amp; Poor&#x2019;s Financial Services (S&amp;amp;P), Moody&#x2019;s Investors Service, Inc. (Moody&#x2019;s) or Fitch Ratings, Inc. (Fitch). We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2020 and 2019, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. During the year ended December 31, 2018, we discontinued the internal development of a program that resulted in an impairment of an IPR&amp;amp;D asset of $330 million, which was recognized in Other operating expenses in the Consolidated Statements of Income and included in Other items, net, in the Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of the fair values of other financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2020 and 2019, the aggregate fair values of our borrowings were $39.4 billion and $33.7 billion, respectively, and the carrying values were $33.0 billion and $29.9 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in BeiGene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2020, the fair value and carrying value were $4.9&#160;billion and $2.9&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5NDI_795b3065-3a5f-445d-b048-69d99f6dd289">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2019, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Industrial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential-mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad9644e2219642dfb8b959deb45d2db9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtMi0xLTEtMA_4cbd02cb-473e-4673-925f-a61a1b5b49f1"
      unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb9f08921cf64e6b95d1f81c11c62ab9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtNC0xLTEtMA_58e7c021-7e0d-4903-aaa1-039478066391"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i625fa9d4a306409181259806d10464fc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtNi0xLTEtMA_e3b7283e-27bd-4dbd-95e0-3ece08e88a1b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4abab397f36846d2963dacabb469a08b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzMtOC0xLTEtMA_211a3b75-701a-4bbe-9d81-ed6659d4df1c"
      unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6101c783a3084635bdf9cd570e9f1282_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtMi0xLTEtMA_de2f9586-d9f9-4e1d-a1f4-936cb838be7b"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac001eaacc55452bae4119e1a7b27c9e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtNC0xLTEtMA_308be263-bab0-4151-ba5e-3428d946117c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a3f5fa8487f48658b63af871c8fe2c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtNi0xLTEtMA_9d47fb6b-f568-49b9-80bd-f628a23b1dbc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia314c059b63d4452a382baae50386fbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzQtOC0xLTEtMA_ef7fa163-72f4-4d18-9329-5c29003c8e85"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8b4a2b455184822b0f1116160cc18e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktMi0xLTEtMA_0f455cd4-616e-45de-9a1b-b755fc77ec06"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia3b7da5c12534b3981691aba7cb821cf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktNC0xLTEtMA_aaf0c8dd-edfc-4f39-b634-5ad4fdc80772"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia986bf30e56b467ca51da380a21cfe6b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktNi0xLTEtMA_2a32d2c9-dd93-45cc-8787-c381fc283657"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib72cbc3a5a7b487a949da2b7bb7c9df6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzktOC0xLTEtMA_ed9a52cb-67e4-4393-a6a4-1df304055d5b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5983e886096845e08a0cc96ad73632ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTItMS0xLTA_978028d7-dec5-425e-b4f9-c19ae3473cd9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6edf08d2463042549609c2d138554631_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTQtMS0xLTA_98871ff8-a284-4543-bf77-2481888f8efc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b1be9e0be7e44b886c4bba9044e55c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTYtMS0xLTA_d8ede855-eede-4405-bc53-4e235eb17a92"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1043550a1f84782876ef562e9149716_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEwLTgtMS0xLTA_056f390f-5cc3-4ba2-9482-ae6e8194e022"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3220d9002c542069391fbf17f94d1ce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTItMS0xLTA_12d84b9f-f8e7-4af1-b8e3-cf363515a684"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91de10fa99174e29b365d56c9f6d3d48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTQtMS0xLTA_600fb2e9-107b-4d0a-a4b7-9e29acf11aee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33a9c55953194cd3a01eabe3994fd206_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTYtMS0xLTA_d061baeb-d4da-455f-8816-6da5d301be27"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib98c8f187b0e40dd9fb41d8d1b8bdfce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzExLTgtMS0xLTA_7a3a7a0a-884f-4ebb-a233-03d2761a812a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89ce59970e704a549cf6e24fdbc6115d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTItMS0xLTA_63b24324-c3bb-4067-af75-667f4f284be5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i809345b5da314af5a55dfa6cc31e9467_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTQtMS0xLTA_933b29e9-d69d-4158-aa2d-372899ceaff6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6dbf334d697f42bcb8a2ab7042237c55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTYtMS0xLTA_8cd77632-7bf3-4384-9a87-6423cf2cdf50"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfdeb4e4a1c6428ca021eaa1c6bcdb35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzEyLTgtMS0xLTA_03d8fa24-edba-4705-b172-67abf77b4a21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d7054c920374f98b6f1c0fb02b93de9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTItMS0xLTA_b43502c6-0144-45e6-a915-63b2be66bea5"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie386d2bd778d480f836e2fa1df624708_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTQtMS0xLTA_ba70c6c1-e1f7-4525-9f18-61f5a606850e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66ddbd84bf09413aa009b1a257b36e6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTYtMS0xLTA_a12e9f17-fc92-4091-bd7f-644ca2d24bad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2783b98e50e847a19205180e25cee168_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE0LTgtMS0xLTA_6826d0f4-43c8-499e-b1a5-6d5fa5e69405"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f1609b78f64499fb1992720d032da1d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTItMS0xLTA_5d13ddc6-17e1-43e3-9ebe-e10c80572801"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib182df74839648c99a69305123764d98_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTQtMS0xLTA_5b086809-161b-4957-be6d-4d6abc8de2e7"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4888dd7b32ab43db957c063fe6af1b4b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTYtMS0xLTA_33393dbb-52ab-4ca2-92ed-592f979870dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6cfcba5921d484abc0c737229312fef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE1LTgtMS0xLTA_6f84dfe7-c6e5-4baa-8173-85ee750bc37b"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTItMS0xLTA_49063eb2-8986-4918-9e7f-ad14fa052f73"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTQtMS0xLTA_41c15d72-2c42-4bfa-8c48-bc976cab2fc6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTYtMS0xLTA_c5a1c289-6883-4dfd-8fa9-4647bbbc5fab"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE2LTgtMS0xLTA_20371f02-28fb-44fb-a9d2-a9efc730b9ee"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="if30b3769d1f54f7aa9a0ad91a5b2b2a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTItMS0xLTA_0dc4f4b6-6640-40bf-afbd-818472d97887"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iab820ea663b142d683c134deffedff4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTQtMS0xLTA_56129b67-04b5-41fe-b783-dd5a33e0a6fa"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i00f8425a23694b76902e702c9427cd89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTYtMS0xLTA_351536a0-4d15-4d97-865a-3a2f34fddd30"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i064fcfcd92604a3c88418ad109a62465_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE4LTgtMS0xLTA_e80e1dca-2e4c-40c4-8f71-f61f95fce20e"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="if9db18cb51ff42eaa1fdf223be2cef55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTItMS0xLTA_b63aea2b-2a64-45d4-86e4-d36e6549abb2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i7fb077631c2943a386f31198be2b482a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTQtMS0xLTA_da07707e-89ba-43f8-b240-4a31348070d1"
      unitRef="usd">255000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib52081e4ae094d09bfb8afeef0d34a19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTYtMS0xLTA_5517c4b1-3156-4d79-81c9-727a25dc9104"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ic86eb7a229bd452995503e7a79b231f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzE5LTgtMS0xLTA_b0347c00-96ce-4180-832b-69be2d1300ae"
      unitRef="usd">255000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i649ca6b917ff4847aefd1d96a215f411_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTItMS0xLTA_8902cbe0-fa89-4a78-b0ce-d23c39c9e67d"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="id401fea1268645f08278ada72856ed9b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTQtMS0xLTA_9d362c15-f1af-4b8c-b1b2-ab0cee96bf41"
      unitRef="usd">66000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i272140d66a7c4798aed64a4683f7f5c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTYtMS0xLTA_c08afff4-3cdc-4f36-b25d-847aa370c4b4"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i1b21ba0b68054fb980abeb4ece605ae6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIwLTgtMS0xLTA_dfbf9f98-ffb7-47e3-9d8e-8551524e00d2"
      unitRef="usd">66000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIxLTItMS0xLTA_84966f7f-926f-4d4f-a2eb-89cd27522b1b"
      unitRef="usd">10320000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIxLTQtMS0xLTA_893d55e4-1fa3-4776-b907-0fc6e05a0f1a"
      unitRef="usd">351000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzIxLTgtMS0xLTA_5fd19e7d-97fc-427d-bcf9-5048a1c5e3fd"
      unitRef="usd">10671000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if30b3769d1f54f7aa9a0ad91a5b2b2a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTItMS0xLTA_1c39ec55-e6ed-4d2f-b613-dd90534f16dd"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iab820ea663b142d683c134deffedff4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTQtMS0xLTA_00671d6a-830e-4719-902a-217e45cde60d"
      unitRef="usd">237000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i00f8425a23694b76902e702c9427cd89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTYtMS0xLTA_40c10ce2-07aa-4ca3-9f96-635a6b57ccaf"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i064fcfcd92604a3c88418ad109a62465_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI0LTgtMS0xLTA_8339e216-f7e1-45ab-8e6b-ed754916ffb5"
      unitRef="usd">237000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if9db18cb51ff42eaa1fdf223be2cef55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTItMS0xLTA_daa651c3-1e2b-4f7e-a3cb-510df001d451"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i7fb077631c2943a386f31198be2b482a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTQtMS0xLTA_d878683f-60ce-4209-8c1e-8051974eebd5"
      unitRef="usd">318000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib52081e4ae094d09bfb8afeef0d34a19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTYtMS0xLTA_0d8d171e-4da5-4af5-b15f-3a60c3901bab"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ic86eb7a229bd452995503e7a79b231f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI1LTgtMS0xLTA_b4c1c214-8d42-49d4-81ff-449ac771a3f9"
      unitRef="usd">318000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i649ca6b917ff4847aefd1d96a215f411_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTItMS0xLTA_f95afd06-a7e9-464c-ae62-9e7326de8de1"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="id401fea1268645f08278ada72856ed9b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTQtMS0xLTA_45d33633-65eb-4c08-9529-4d9487439a64"
      unitRef="usd">15000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i272140d66a7c4798aed64a4683f7f5c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTYtMS0xLTA_49503af2-ef86-461a-82b0-6faca38cc451"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i1b21ba0b68054fb980abeb4ece605ae6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI2LTgtMS0xLTA_40a838d2-bafc-4f2b-914a-943249322960"
      unitRef="usd">15000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTItMS0xLTA_f3954ee2-4318-4cfb-a8ee-bf518c065b94"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTQtMS0xLTA_206647da-f937-408c-ae21-f702bdbc9e5d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTYtMS0xLTA_cb0f5a3d-e2e8-4a83-99cb-d616d0e9cf9f"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI3LTgtMS0xLTA_2080b09c-ef4a-424d-a58b-76dbbf8cc471"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5cf4219cf3644d3396775ef8d389195a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTItMS0xLTA_dcdbbbc7-921b-45dd-83ab-8f9f3c7f7ca8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7c5e3f8152754918ab5eda6f40636b7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTQtMS0xLTA_e2e7a946-a1c2-434e-a238-17b2b99c5226"
      unitRef="usd">570000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6660c8b16d1449c4ad9ea5542dc441a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTYtMS0xLTA_241d4aec-47f9-4110-8395-03ccc6eea928"
      unitRef="usd">33000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTowMTY1MTFhMjU4YmU0Yjg2OTkzMmJiOGYwMDJkNWQ0Yi90YWJsZXJhbmdlOjAxNjUxMWEyNThiZTRiODY5OTMyYmI4ZjAwMmQ1ZDRiXzI4LTgtMS0xLTA_530354df-e44f-4113-ade2-aa39121161da"
      unitRef="usd">603000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5e5faa80b5b4b10adeecf22f66b3581_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtMi0xLTEtMA_6fe150d5-ecc5-4a1b-9a51-3fe845b5ae1a"
      unitRef="usd">360000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80d5adbe89e6449698d66ec80b68a414_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtNC0xLTEtMA_0daa4859-6b38-4a7c-a580-e24bd54a10db"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe8c6115d404415db720dd2a742d8eb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtNi0xLTEtMA_b4ce1ea8-28fe-42b7-ab5e-f884503f1e86"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25670902a03f4a9dbaa51f18d7ece454_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzMtOC0xLTEtMA_953b4da7-88d3-44f2-8c1d-f74ada14e84b"
      unitRef="usd">360000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ef1d913febf4a47abb4d2d49554d87e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtMi0xLTEtMA_bbc7d724-b604-4774-9734-528ba9cef3c0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24d55a7ee2cd4a33a48689caa2dcf916_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtNC0xLTEtMA_02bf386c-a661-4a82-9a7a-f0c841d98d19"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i286a3763387b42bc9a3cb41202817a79_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtNi0xLTEtMA_364749c5-9b3c-4f9d-a1e6-53f5ae1ca499"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11aafa3aec9e4f27a262448b9328cb31_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzQtOC0xLTEtMA_c9cc67ad-4214-42b5-a8f8-0dca9fd8f2f4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadfd2fc877304237a30a42e164d32f71_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktMi0xLTEtMA_456f73ff-688f-4dc6-bfca-70dca4335d71"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie900b0b41bfb46fb953391112402fcb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktNC0xLTEtMA_cf969c49-be42-43c0-8cca-655233e49a37"
      unitRef="usd">1121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59e5d44ae1e344489c69734a0bc2cc50_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktNi0xLTEtMA_99a6f0c6-1ad4-4893-859b-568e098defcd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe13998c78a94509a6a1caa4150f8b85_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzktOC0xLTEtMA_d3105788-96b4-4659-b43a-aea04c717d20"
      unitRef="usd">1121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib246c8ea900c4139925b4277352eb5e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTItMS0xLTA_8ec6e294-2737-470b-b8c5-e21e9ef1c42a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51d01e59834f4139b4e0c85a155b259b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTQtMS0xLTA_e711aca4-eca0-4bdc-81cc-0e05551cbf7d"
      unitRef="usd">834000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a87e19790014e689ae6a75f01a9d82e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTYtMS0xLTA_14609b34-92d5-4125-a887-39b9d5022eb1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i211dbe0e1d8346459bff435cfdf00a61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEwLTgtMS0xLTA_49cb219a-d96c-4394-a2a1-531847e8587d"
      unitRef="usd">834000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0dd56a68a7ae47358902b75f24b8098e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTItMS0xLTA_5a7e6e7f-2c62-4d03-83c8-a03a39f36d25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91c5c8997cac420db031456c5bd0c5a1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTQtMS0xLTA_640ad4d2-87cc-4cca-9362-dd57aee7c947"
      unitRef="usd">198000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id815d1f62e17488f819d1554819ccb75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTYtMS0xLTA_7923f38d-eca5-40fd-b7e3-f1f154cac5f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if43ed126e7434f0eb4b8c08281ec7bae_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzExLTgtMS0xLTA_cffbc330-135b-44da-8c32-46a55763375e"
      unitRef="usd">198000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i515615df7d0649f19fcd37f592c7ece9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTItMS0xLTA_40dba74e-4a93-489b-8a2a-cc43d958d4a3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic879f5b36d054ed9a76eb771bfb892b0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTQtMS0xLTA_b24de2bb-be35-4d71-848e-a50bdaf3b6d7"
      unitRef="usd">182000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae474e4eb1174434902da312c3116aea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTYtMS0xLTA_31a15bfc-64fb-4346-aca1-1d75018a8105"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i747e8d251292449b9dcf1d1f95265375_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzEyLTgtMS0xLTA_868a1003-8718-4d52-9bb4-64196437574d"
      unitRef="usd">182000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe3539b33168456ba7b264fa95739a21_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTItMS0xLTA_eaf0be59-9a59-4e67-b16d-ff40abc27565"
      unitRef="usd">5250000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b75e88402c841058a01fea422a2d5e2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTQtMS0xLTA_cb5772c8-eff6-4888-b59f-5b1236c202e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a943209d2bc469ca0bc93bd11d07f9c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTYtMS0xLTA_e39e0813-1858-42dc-bed8-2644fe6844fc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7050eead3da44efb7f96c0d139c398b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE0LTgtMS0xLTA_38041550-b8f8-4a25-b621-fa659f66c637"
      unitRef="usd">5250000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32090b1bcda448d0b03e44dc48a112e1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTItMS0xLTA_c536e89e-fe2c-4012-a455-98eb542624b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4671a4128224590847baa4d91f4f23c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTQtMS0xLTA_4fb06021-1a66-44f1-89f6-f131d12bad40"
      unitRef="usd">289000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id243dd82ed464c5782fba60066763a4d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTYtMS0xLTA_7c16ec24-430c-40ba-bb0f-bef4c37456ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i504ebb212b0e4de29bade641d2b4fb63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE1LTgtMS0xLTA_e22d80ab-111b-4007-83e6-55c47430903c"
      unitRef="usd">289000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTItMS0xLTA_bb5e55c8-aa64-4928-bc98-1fc588459075"
      unitRef="usd">303000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTQtMS0xLTA_30bfb084-a2f3-4ad1-a5b8-7c2c381f31b1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTYtMS0xLTA_9ee76e3d-7eb0-4ffd-a9ba-66bd8e84a71e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE2LTgtMS0xLTA_459572d0-5322-4cef-83cf-bd800c5a7e63"
      unitRef="usd">303000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ifc2e56aa52234a9295f48ee3eb721a25_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTItMS0xLTA_f280c919-f24c-419b-b8f7-d09eea006d75"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ifeeedafe9493400eaaf0bafdb1cc9eec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTQtMS0xLTA_15167f66-5b14-4b2e-941b-180939fd264f"
      unitRef="usd">224000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iecf5136a442245e5983ef4b4dd9fe1a0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTYtMS0xLTA_507c11ba-8147-4454-af23-7f261d811417"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i79f07dda96ee49b7b10ec42bfd9ee318_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE4LTgtMS0xLTA_b416c72b-76a8-4c71-93f2-aa71ac099596"
      unitRef="usd">224000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6a356ae88a6f494eb208b656cfb3d39b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTItMS0xLTA_1c433dab-5836-4205-a2b9-3b3dde7b5373"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i05d3d663147d4671afc5b78a2cd03fd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTQtMS0xLTA_37daedc8-0c02-48b8-9717-acab73d6a7c2"
      unitRef="usd">66000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i03ffb83e4ee44f928713cdb0b9355245_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTYtMS0xLTA_b3a9bd34-327b-45a6-b100-0aad9b12fd14"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8ae4c13d4f1a4e789c5111bdd1953619_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzE5LTgtMS0xLTA_27fcda8a-645d-4074-8379-8d7bd8ed551c"
      unitRef="usd">66000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i4cc54bfdcf154b1c99478e3369c649f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTItMS0xLTA_8aec4785-2f76-4f69-9194-4771bc4e3052"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i80341c6920be4b8f83233fdbad6decc2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTQtMS0xLTA_a3ba7b48-39b7-40c2-86c5-3fc22f3bfd7c"
      unitRef="usd">259000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i5f39dc9f49db4cdb801668e25f02b78a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTYtMS0xLTA_8d0c7a8e-1b18-4db6-bfab-0634487e71a2"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i3f0734c1cfd345e9b84e6222bec110fb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIwLTgtMS0xLTA_c709dc6e-e555-4d40-bd25-2561f71727ba"
      unitRef="usd">259000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTItMS0xLTA_277244ea-1ed8-41b3-bc16-6354602ae503"
      unitRef="usd">5913000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTQtMS0xLTA_7c773315-f5f6-4f0b-93e2-40ae3cbcb122"
      unitRef="usd">3173000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTYtMS0xLTA_79e83b80-bc78-4f2b-9580-038c2885dee4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzIxLTgtMS0xLTA_6b9a7864-2e31-4de3-be6f-bc6140d56385"
      unitRef="usd">9086000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ifc2e56aa52234a9295f48ee3eb721a25_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTItMS0xLTA_042a609d-6f20-4f0d-97e1-ad4d16e6f743"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ifeeedafe9493400eaaf0bafdb1cc9eec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTQtMS0xLTA_f3969826-6244-4f80-9691-e4c909986133"
      unitRef="usd">31000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iecf5136a442245e5983ef4b4dd9fe1a0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTYtMS0xLTA_d138ed4d-9251-4d70-a1ab-abdcdd0b8d48"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i79f07dda96ee49b7b10ec42bfd9ee318_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI0LTgtMS0xLTA_bed59344-001c-474d-85cd-020333c54c7a"
      unitRef="usd">31000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6a356ae88a6f494eb208b656cfb3d39b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTItMS0xLTA_7fba42d8-c7c3-42f5-a74a-e7595e363964"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i05d3d663147d4671afc5b78a2cd03fd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTQtMS0xLTA_ae3384d9-8636-4f9b-bed1-4ff24ef46986"
      unitRef="usd">315000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i03ffb83e4ee44f928713cdb0b9355245_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTYtMS0xLTA_b76a8c5a-1a0f-4164-8e5f-1d1b6154b597"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i8ae4c13d4f1a4e789c5111bdd1953619_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI1LTgtMS0xLTA_64717076-2515-41ab-b4d0-5293b217d6d6"
      unitRef="usd">315000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i4cc54bfdcf154b1c99478e3369c649f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTItMS0xLTA_371cf34c-f824-48c5-9b68-0502e62a41ff"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i80341c6920be4b8f83233fdbad6decc2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTQtMS0xLTA_d18482b1-bc4c-49c1-a636-5186bb67fe6d"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i5f39dc9f49db4cdb801668e25f02b78a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTYtMS0xLTA_fedb437e-4f10-4421-8e95-7f12dd3180e5"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i3f0734c1cfd345e9b84e6222bec110fb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI2LTgtMS0xLTA_be55f7a7-9584-45e5-ae97-7d3c1079ed18"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTItMS0xLTA_e4ea1eb0-1d57-4690-ab01-b002638423ec"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTQtMS0xLTA_896d210f-9111-40e8-8e87-bcccc72e9cf3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTYtMS0xLTA_d0f8aab4-46fd-443d-9525-e2618ae6adb9"
      unitRef="usd">61000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI3LTgtMS0xLTA_1123027c-fe99-4e28-892f-605e8cf09e86"
      unitRef="usd">61000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6cb15475cbd6497f8125ba218618f3bb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTItMS0xLTA_65f09c0d-de33-4b0d-9f8b-8fe881327e74"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6a6b5f1a7e604a64a6e9d0a0ba849d59_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTQtMS0xLTA_e3980901-4c48-44ff-9abd-50992a3e6eb3"
      unitRef="usd">346000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic5c86b3a9d1f461e91c4f1f62c2deaf0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTYtMS0xLTA_0ebd78d6-a405-4739-bc1d-6fd98cf9bbea"
      unitRef="usd">61000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90YWJsZTozMWQzZmZlYTM4NGM0YzRlOTc0NGFhYjZlZDYyOGM0Yi90YWJsZXJhbmdlOjMxZDNmZmVhMzg0YzRjNGU5NzQ0YWFiNmVkNjI4YzRiXzI4LTgtMS0xLTA_a2609855-08d7-4782-8395-2a3fdb3db8f9"
      unitRef="usd">407000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzM3MDA_a94c3c41-d296-436f-ac6a-e5fb81858de8">P3Y</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i07aff99eff5e43eab44bd82f5c93ad1c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzgzMjY_c7ee7619-2a5b-481a-9850-88271f6355f6"
      unitRef="usd">330000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg4NTU_a911dbef-ad80-4898-9a56-fbefdf530aba"
      unitRef="usd">39400000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg4NjI_992831fc-11fd-495f-b031-04622ab3a8a4"
      unitRef="usd">33700000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LongTermDebt
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5MDk_86449209-f400-4bf3-9ce9-892038b82643"
      unitRef="usd">33000000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4Xzg5MTY_5446e7e5-4e89-4d9c-92cb-3cc616bc2659"
      unitRef="usd">29900000000</us-gaap:LongTermDebt>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzExNTQ0ODcyMTA1MTE3_16a7d50c-a481-4198-b8bf-d1eb228bf835"
      unitRef="usd">4900000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestments
      contextRef="i8b7a2eccdd2a4651a37e5247253abcf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjUvZnJhZzo1Y2RiYjE5YmU3ZDQ0N2RmOGE3YjM2MmMyNjg3YTI1OC90ZXh0cmVnaW9uOjVjZGJiMTliZTdkNDQ3ZGY4YTdiMzYyYzI2ODdhMjU4XzExNTQ0ODcyMTA1MTMx_0e59b253-8b3a-4681-9875-c5ec7057660c"
      unitRef="usd">2900000000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1ODY_25d3f3b9-7669-407a-9f0f-d3a48ccd1d2a">Derivative instruments&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, 2019 and 2018, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.1 billion, $5.0 billion and $4.5 billion, respectively. As of December 31, 2018 we had outstanding foreign currency option contracts with aggregate notional amounts of $21 million, and no such outstanding contracts as of December 31, 2020 and 2019. We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The notional amounts and interest rates of our cross-currency swaps as of December 31, 2020, were as follows (notional amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% 2022 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2020, and amounts expected to be recognized during the subsequent 12 months are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses and gains recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2020 and 2019, we had interest rate swap contracts with aggregate notional amounts of $5.9 billion and $9.6 billion, respectively, that hedge certain portions of our long-term debt issuances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps with an aggregate notional value of $3.7&#160;billion were terminated during the year ended December 31, 2020, in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $40&#160;million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $5.2&#160;billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $576&#160;million from the counterparties that was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount will be recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2&#160;billion principal amount of notes. See Note 15, Financing arrangements, for information on our interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of December 31, 2020. Long-term debt includes $525 million and $136 million of carrying value with discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020. Long-term debt includes $425 million and $36 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impact of hedging transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2020, we expected to reclassify $136 million of net losses on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2020, 2019 and 2018, the total notional amounts of these foreign currency forward contracts were $1.0 billion, $1.2 billion and $737 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2020, 2019 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Our derivative contracts that were in liability positions as of December 31, 2020, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our, or the surviving entity&#x2019;s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia87ed81df5cd4df18bf1c76cedc6ff15_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE1NjA_c7773042-a295-4a99-bee6-33f6ca16fcee"
      unitRef="usd">5100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3094f6fc9cc8496c8f65948eaea987c1_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE1NjQ_1d740c8d-6bd2-4a39-aa7b-bbc6b914ba4f"
      unitRef="usd">5000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ide1f0bd164be4ab48c682b4349325400_I20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE1NzE_2c871fc7-d9ce-4540-8bbb-91e96f9f328a"
      unitRef="usd">4500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id78e562fe4a247969552202afc671b7d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzE3MTc_71e881b8-1de9-4b59-a707-e1ca093ce3e1"
      unitRef="usd">21000000</us-gaap:DerivativeNotionalAmount>
    <amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1ODc_b7db4ce8-7a2a-4602-a6c3-82a573c42de9">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2020, were as follows (notional amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% 2022 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0694e7fc221e482c91e8838576738184_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtMi0xLTEtMA_f83fb9c0-bbe2-41b4-99fb-a6d7348bf634"
      unitRef="eur">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i8ba2d75207254328aa10efe32c1d7d92_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtNC0xLTEtMA_1141092d-cde1-4c9b-a37f-9e22c2eae20e"
      unitRef="number">0.013</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0694e7fc221e482c91e8838576738184_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtNi0xLTEtMA_35501b57-78ac-4333-bd7f-b18a48cfddeb"
      unitRef="usd">1388000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="idec4c95044a6412abcc5d68913628085_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzMtOC0xLTEtMA_75e637bd-bc8b-4096-bc9c-2ad2dd714fec"
      unitRef="number">0.032</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id39bb9a5237948c1b1665fb28924169c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtMi0xLTEtMA_369ef6c2-1c05-412c-a326-fe9a7119abd6"
      unitRef="chf">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i6e7cab6ff6f34e259c4a6ca09c02afd1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtNC0xLTEtMA_b103370f-28c0-411e-a314-5ca4e5f05829"
      unitRef="number">0.004</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id39bb9a5237948c1b1665fb28924169c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtNi0xLTEtMA_de9488fb-dd47-4ad8-b4f7-0f0b245d8eef"
      unitRef="usd">704000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i60cd5ec752de4c98b0157f82d6b72e5a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzQtOC0xLTEtMA_c6df3f55-b0d7-40b4-bef5-5e21fbfa1986"
      unitRef="number">0.034</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7343472b32c748d99b7140235bb94b4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtMi0xLTEtMA_4973afb6-83d2-4f46-846b-42fb5466960e"
      unitRef="eur">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i23f07f28ce2a46cbbc068409addaea19_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtNC0xLTEtMA_cbfb9120-09a1-435d-ae39-3e685adcda86"
      unitRef="number">0.020</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7343472b32c748d99b7140235bb94b4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtNi0xLTEtMA_6a907216-14fd-4ba5-aa2b-57d7d5b68e9e"
      unitRef="usd">833000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i89094b01572546878b2ff1d75b3818ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzUtOC0xLTEtMA_d749b8a8-06f4-4fc3-84fd-99c0affacb4c"
      unitRef="number">0.039</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if028ba21936c4586893e5c30ab36bbac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtMi0xLTEtMA_b0dbcf32-5a06-408c-95f4-2b0ad1555f27"
      unitRef="gbp">475000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i05187f24dca245f89aba477135b8f57a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtNC0xLTEtMA_ca022368-a691-4819-980b-03d6a91585ce"
      unitRef="number">0.055</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if028ba21936c4586893e5c30ab36bbac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtNi0xLTEtMA_e9aff562-aab6-44f7-af71-1ecd6620f472"
      unitRef="usd">747000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i7db5b4699b5c43b1bcd765fc6632aa11_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzYtOC0xLTEtMA_718f2ef0-f866-40cf-827e-e06ecb933b8c"
      unitRef="number">0.060</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie7d28914099a4db4a141ed2fbb2afc50_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctMi0xLTEtMA_908c8425-29e2-4fcd-a127-57e62b575e3b"
      unitRef="gbp">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ifd8a2e81c4d541849a664d3e8219f829_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctNC0xLTEtMA_89bd4ca0-ae4d-42df-b3c1-b1503f58925b"
      unitRef="number">0.040</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie7d28914099a4db4a141ed2fbb2afc50_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctNi0xLTEtMA_48b09cee-c113-4db1-8016-cc4e9bcf5432"
      unitRef="usd">1111000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i3ca9160fcbd645a58623671457697045_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo5MzQ2Y2ZlYzMxYTc0N2FkODZjZDQ4NGI4N2FhNDY2Mi90YWJsZXJhbmdlOjkzNDZjZmVjMzFhNzQ3YWQ4NmNkNDg0Yjg3YWE0NjYyXzctOC0xLTEtMA_a0d41086-863e-45f5-a1fc-82a9206d9426"
      unitRef="number">0.045</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icfdeec3400fe43809c845700b9250d21_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzM2OTE_37f37449-5545-4f93-ab20-c6661ffcb1d9"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1OTM_dde088f8-bed6-4037-8118-d9f815a07be6">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses and gains recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i8781f9dbe8224717b48a58ba39d8e44a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzItNC0xLTEtMA_c0aec4e7-88ef-4067-ab32-2f8e0fafcef8"
      unitRef="usd">-251000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i84f84184b50a44f7b23e2915f0e16c7b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzItNi0xLTEtMA_b89154c8-2a18-4dad-9489-f0bb1e835bf3"
      unitRef="usd">148000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="ie75450fb332b47589035297dd2cbfef4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzItOC0xLTEtMA_3a8eabf2-82b1-4595-a472-722d7804313e"
      unitRef="usd">348000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i7ab3fe75d88d4a25a823aa9d5bb0fa1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzMtNC0xLTEtMA_f839a78b-82ac-4b69-ab4a-405b2103ecd2"
      unitRef="usd">190000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i2c26149bf9bc4af9b601bdee1ab9cef3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzMtNi0xLTEtMA_eed5aad3-14e1-41be-a407-8999f647db78"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i9313578881564713bd51c45434307224_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzMtOC0xLTEtMA_58b61f46-a1b3-436d-a693-40271fd087af"
      unitRef="usd">-287000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i99ae6fbb6ad64fb9b9ae8eee82d8664d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzQtNC0xLTEtMA_6062c4b5-8ee3-40af-ab48-47d8c5b8b6cd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i471e2bff63624e0e81a47854f415cf1e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzQtNi0xLTEtMA_ae7f8091-44e3-44ff-8096-7f7e8381f120"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="ibd7fa60265134785b2cab0462930cf52_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzQtOC0xLTEtMA_559ec0bb-113a-449c-a09f-a8ed30142b01"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i5991882c8d74449db1e6b1214ea17429_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzUtNC0xLTEtMA_9ca899be-2083-483f-8746-d1fdd16ccbfd"
      unitRef="usd">-61000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i96f7642813ee4758a8d46ddcc6037f64_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzUtNi0xLTEtMA_8f31774a-1cab-4ad7-925a-f4e4365b13b2"
      unitRef="usd">127000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="ic79e5b12752f45cf9a8cdcc982b21b92_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTo2MjBmY2Y5MTMyNWY0NzVkYWZlZmE2Y2M2M2M3MjI1ZC90YWJsZXJhbmdlOjYyMGZjZjkxMzI1ZjQ3NWRhZmVmYTZjYzYzYzcyMjVkXzUtOC0xLTEtMA_014e6596-3df2-4bac-9d39-e3aee27d4c43"
      unitRef="usd">61000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzUxNDA_010249fa-56a9-4393-a5f1-87935e5730ac"
      unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2961200acffa4d0c935574bdd8f22f7d_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzUxNDc_3f7c1940-4627-488d-b9f5-174812bb8fbb"
      unitRef="usd">9600000000</us-gaap:DerivativeNotionalAmount>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODMw_c0d5bf97-c6e9-421d-9eef-cfbc9f07d613"
      unitRef="usd">3700000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="i1a30d28949ff465693152dab8f329ef6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODU4_aa157320-0cc2-47fb-979c-44d9ce541928"
      unitRef="usd">40000000</us-gaap:DerivativeGainOnDerivative>
    <amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities
      contextRef="i086d5cbe0a3a4ef2b5d1c4f8b8fcb235_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODQ0_cd9dda8d-6583-4754-94b0-058679fba84c"
      unitRef="usd">5200000000</amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3a91bd5c90e8492fa703ad1a89545d34_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0ODcx_fe175605-8eb8-40fc-a40e-2e199973528b"
      unitRef="usd">576000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ic198d94557414ab3b4fc50e9ddb159f9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzExNTQ0ODcyMTA0OTMw_cfbcc177-670c-45a2-ad2b-a9d11184a9b4"
      unitRef="usd">5200000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1NTQ_e0608925-4596-44f8-acf8-4f3fe5d00a23">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of December 31, 2020. Long-term debt includes $525 million and $136 million of carrying value with discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020. Long-term debt includes $425 million and $36 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtMi0xLTEtMA_56553694-0349-4a5b-82f1-a65dde3e053a"
      unitRef="usd">89000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i9fe46af694c14b4098014e42d59a4512_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtNC0xLTEtMA_23cd7bf0-cabb-4025-8e6a-f610b27fa81e"
      unitRef="usd">903000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtNi0xLTEtMA_b60b8347-aed6-46a1-81af-4c4fbe5e777d"
      unitRef="usd">89000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i9fe46af694c14b4098014e42d59a4512_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzMtOC0xLTEtMA_a055de6b-be1d-4d81-81ca-c4294947da17"
      unitRef="usd">4000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i643b333982544519816452a792886641_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtMi0xLTEtMA_1ac43b67-ffc4-4ef0-a2f0-bec0579cc5d2"
      unitRef="usd">6258000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtNC0xLTEtMA_8a05c3ca-ab6c-4f43-931f-37dd2737dd32"
      unitRef="usd">8814000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i643b333982544519816452a792886641_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtNi0xLTEtMA_24f42496-ecfc-4892-85d1-932b6093931c"
      unitRef="usd">477000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpmZTJiZWE4ODhjZjk0NTRlYTFlYmNjNTZmYjhlYTQ4Yy90YWJsZXJhbmdlOmZlMmJlYTg4OGNmOTQ1NGVhMWViY2M1NmZiOGVhNDhjXzQtOC0xLTEtMA_5fce96c0-82c6-4734-b541-49f1bfd002b0"
      unitRef="usd">292000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODI4MzE_bfd5eba0-1c07-43a1-bda3-a25ba6834cb9"
      unitRef="usd">89000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i643b333982544519816452a792886641_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODI5NDI_1ffe25ff-79ff-43bc-be03-3a914f837050"
      unitRef="usd">525000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODI5NTA_0b3d2b2b-9501-4661-b192-095c62d2f56d"
      unitRef="usd">136000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i0d904f96dd854c81b5c1105b3760f9e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODMzNzE_c020263d-8b53-4614-bb9d-ed20d473bd6e"
      unitRef="usd">89000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i643b333982544519816452a792886641_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODM0ODU_39186d06-ae0c-47ba-b626-6a09bf415398"
      unitRef="usd">425000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i6dbf0c2d81894f1f9732052b9877a70b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzI3NDg3NzkwODM0OTM_3df48559-6195-4a27-909a-77f96b11083a"
      unitRef="usd">36000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1NTU_df3ca58e-b3d5-4941-b7e3-58a15b9c1e9c">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest and other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5f96d44ea3d1414ebc9440282259c660_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzItMi0xLTEtMzM4Mg_03da4bf8-5744-4e04-9413-5e96584f8345"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzItNC0xLTEtMzM4NQ_7156e0b9-caf6-4147-8da3-fb002331c7e3"
      unitRef="usd">256000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzItNi0xLTEtMzM4OQ_7a7806ad-7aa9-464a-870c-0efe212603f0"
      unitRef="usd">1262000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifd4fc6eaae654eff9e476549ca95692a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzUtMi0xLTEtMzM5Mw_d45e962c-fe32-4be7-b6ae-7ec44005ecc7"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if807e88d6a89408d9d6c6adb4b5eea3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzYtNC0xLTEtMzM5Ng_e123fb2c-7e9b-4305-9533-bc7ec596efa5"
      unitRef="usd">323000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzgtNi0xLTEtMzQwNA_b17406d7-f156-4776-a301-2674776b00ab"
      unitRef="usd">315000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpkZTVjMGEyMjY1YzY0NWVhYTAzMjY1NzRiMmM2Mzk3MS90YWJsZXJhbmdlOmRlNWMwYTIyNjVjNjQ1ZWFhMDMyNjU3NGIyYzYzOTcxXzktNi0xLTEtMzQwNA_396f807b-1e45-45ed-96f5-7a9642b92fbd"
      unitRef="usd">-204000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib6b920743a284b8ca1561e3ff12c2cb7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzItMi0xLTEtMzQwNg_59d46d29-f4ce-4d38-ac1c-3c335dab88de"
      unitRef="usd">22204000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzItNC0xLTEtMzQxMA_d7a49d2b-b814-45e5-88ce-65c0aeb69403"
      unitRef="usd">753000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzItNi0xLTEtMzQxMw_25568d28-5e54-492f-9628-b22b39482971"
      unitRef="usd">1289000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1c35c83ea16240faabb17b7cad3444a1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzUtMi0xLTEtMzQxNg_dc0149bf-9dff-4d1a-8b76-d7fc96e19317"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9ec37ac4b3fa42bc95ed748f124e3eec_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzYtNC0xLTEtMzQxOA_59f2a08d-4e09-4d0d-a706-9883eac67cc0"
      unitRef="usd">110000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i9833b553be6144e3aaf934620c21e9ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzgtNi0xLTEtMzQyNg_97f5ffa3-1af1-41e3-a1b4-bee616d4e05b"
      unitRef="usd">-349000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i9833b553be6144e3aaf934620c21e9ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozZGUyZDU3ZTQ4MjA0YjU5YTNhY2ExOThiYjY0NzU2OC90YWJsZXJhbmdlOjNkZTJkNTdlNDgyMDRiNTlhM2FjYTE5OGJiNjQ3NTY4XzktNi0xLTEtMzQyNg_8922e702-26d0-4267-8802-187336feb9ff"
      unitRef="usd">352000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic61510fd52d042d198fcc7200d6192fb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzItMi0xLTEtMzQyOA_734a7d1a-f3a7-4819-8f79-a8e993204f61"
      unitRef="usd">22533000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzItNC0xLTEtMzQzMg_245ad335-0159-4322-97e3-8f072f278941"
      unitRef="usd">674000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzItNi0xLTEtMzQzNg_88b024e2-e8e7-441a-a883-ddf6c7a9dfbe"
      unitRef="usd">1392000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if8ef5371ae064ef6b77eead6de300e3f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzUtMi0xLTEtMzQzOQ_85c55444-3009-48cf-bef6-cbfbfac1be19"
      unitRef="usd">-21000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5b72e30920c84ae2a3d1e0e9a36c0610_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzYtNC0xLTEtMzQ0Mg_9add617e-91d1-4869-94e3-3e57e7acc4ae"
      unitRef="usd">-241000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="iaa717f16dfa641f381206fe8143aa927_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzktNi0xLTEtMzQ1NQ_bf9c551b-1d52-411c-ba93-b67f8a7ed9a7"
      unitRef="usd">65000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="iaa717f16dfa641f381206fe8143aa927_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTpjOGMxYTkxMjM4NjA0MmY1YjY4NTQ5NTAxMTk2MjYwNC90YWJsZXJhbmdlOmM4YzFhOTEyMzg2MDQyZjViNjg1NDk1MDExOTYyNjA0XzEwLTYtMS0xLTM0NTU_1546449b-f638-4166-91d4-f87ae3da736a"
      unitRef="usd">-42000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="iea320fbc2a944611a7e2a4627a50e4a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzczNDU_8b17d18f-2f1b-4d36-8861-01b436203a2f"
      unitRef="usd">-136000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i88cfe8096cf349ad9c97224ff1238178_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzc4OTY_b0c51cac-5789-42a2-a9d4-36477b3a5efb"
      unitRef="usd">1000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i182cce935cf94552ba35327c4614152f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzc5MDA_061414dd-ebf7-43e2-83de-e1491968a3a7"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie4e8455f1edd4114b88fb3f5d1776535_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzc5MDc_341ca9bb-b1e3-445c-ae56-86d1e0846bd0"
      unitRef="usd">737000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90ZXh0cmVnaW9uOmU1YTIyMGRlYWJkOTQwYTc5YjMxMGJhYWZkYjJmZjgwXzk1ODQ_79873b91-802c-42d1-8d33-87af1e887f41">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i7516b524eadf4fe7bb058ffbd7cea637_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzMtNC0xLTEtMA_04c7ff1b-e71d-488e-b588-526d00ab4f3b"
      unitRef="usd">28000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6f64a6e311384121b9c8e278f3e7e78e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzMtOC0xLTEtMA_7c1013b0-35e0-4dc2-86b3-9377859ebbf1"
      unitRef="usd">237000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8e546c55c6f64762bd48841a65da24d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzQtNC0xLTEtMA_da0b6a09-cca9-43ac-8dfa-9eae81e5ac3c"
      unitRef="usd">255000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i148fcee1a48b44a09d68649c316ae387_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzQtOC0xLTEtMA_e1cdb7fa-524e-4029-9ead-95ef74e6f60c"
      unitRef="usd">318000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i34ee7f80e77b4cf38ef1e80f188af7ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzUtNC0xLTEtMA_f38d0e98-bc20-49fe-9607-af976ef6eb1d"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7b25825f647249218c055b6f57195f14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzUtOC0xLTEtMA_bc645742-3d2b-430a-9312-9fe7b5b14bcb"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i9f76be3dfb864f1bba5b05a191f9d797_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzYtNC0xLTEtMA_17bd00e1-2fb0-43b2-8356-95807c63db39"
      unitRef="usd">349000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9f76be3dfb864f1bba5b05a191f9d797_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzYtOC0xLTEtMA_5cf50790-f98d-4414-b99d-c820ee5cbe32"
      unitRef="usd">570000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8a25b66b469d4c179aa132a6977ec4a5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzgtNC0xLTEtMA_90e2ecc4-d8f3-49f7-a72f-5ab407990e59"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3f104f0b1c7a4beb8c5cab4258107bee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzgtOC0xLTEtMA_6f367a0c-32c6-49e8-b0d0-523faa32d032"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5405ba26a454429daeaeb5a6346566fb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzktNC0xLTEtMA_365e4833-3310-4706-99b4-ffbe99a33404"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5405ba26a454429daeaeb5a6346566fb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzktOC0xLTEtMA_bab232ad-8505-4017-b951-f103fba473d5"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzEwLTQtMS0xLTA_9ff7ce46-27b6-46cb-8a7d-a76a729e8363"
      unitRef="usd">349000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzEwLTgtMS0xLTA_6638d09f-861c-4728-8655-e3f370fcb644"
      unitRef="usd">570000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="idcadd8bcd0564f47a4fcfdd5ac5f886a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE1LTQtMS0xLTA_7eff8c67-9f7a-46f4-8489-6f3285afe5de"
      unitRef="usd">223000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0e1df008b78a4d38ace56a2668c9f0bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE1LTgtMS0xLTA_79cecba2-f1a3-426e-a131-7ff8991163d1"
      unitRef="usd">31000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie7dde35b44684174afdf5dbfa0f9fd26_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE2LTQtMS0xLTA_2db85b42-9f3c-4ef4-b6bf-5b0eb8aabd27"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5f16286ba82544188ba31ea248441fb8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE2LTgtMS0xLTA_99a408aa-5a29-43fe-aaec-e250b73acb01"
      unitRef="usd">315000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic27613a286f447649231bc7761e21a43_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE3LTQtMS0xLTA_712c181f-a11b-428b-8d17-3d45c9eace44"
      unitRef="usd">259000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9926a2533e5347f6998a569828670148_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE3LTgtMS0xLTA_ef1ce455-fe0d-4b98-a164-cc7713f49754"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i824e358512984891ac64732ce456bf70_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE4LTQtMS0xLTA_077acb9b-efbf-4934-9b28-f77e45c72221"
      unitRef="usd">548000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i824e358512984891ac64732ce456bf70_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzE4LTgtMS0xLTA_2d004d36-8b8d-4766-869c-72853a2174a2"
      unitRef="usd">346000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id7232598b5dd4cbf8628dca2b745de71_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIwLTQtMS0xLTA_c5a52c8f-813b-47e4-9468-689e61045b53"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iadbc19c30e2d4747861f30ae61174fb5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIwLTgtMS0xLTA_eaa05fbd-7232-4853-a22e-62ede58996e1"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ife3a8d84d7a143f08a25619be5bb364b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIxLTQtMS0xLTA_0d965fd3-3e81-41e2-b7a8-564ed5c5b08f"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ife3a8d84d7a143f08a25619be5bb364b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIxLTgtMS0xLTA_cb5b9117-efb5-4470-a767-cbe867ea3b13"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIyLTQtMS0xLTA_0256da1c-02b6-4272-9226-e91ee656cf0f"
      unitRef="usd">549000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNjgvZnJhZzplNWEyMjBkZWFiZDk0MGE3OWIzMTBiYWFmZGIyZmY4MC90YWJsZTozNDEyNDNlN2U2OTY0ZThiYTZmZjY2NWNhMjE5YWU2ZS90YWJsZXJhbmdlOjM0MTI0M2U3ZTY5NjRlOGJhNmZmNjY1Y2EyMTlhZTZlXzIyLTgtMS0xLTA_c16439d9-cbc1-493c-a3de-5cddf03aff62"
      unitRef="usd">346000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzYzNzAw_0eaadfd2-c61c-49f6-9a2c-be7c6f77cee0">Contingencies and commitments &lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our business may be affected by litigation and government investigations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain recent developments concerning our legal proceedings and other matters are discussed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Abbreviated New Drug Application (ANDA) Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Onyx Therapeutics, Inc. v. Cipla Limited, et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between October 2016 and April 2018, Onyx Therapeutics, Inc. (Onyx Therapeutics, a wholly-owned subsidiary of Amgen), filed separate lawsuits in the U.S. District Court for the District of Delaware (the Delaware District Court) against: (1) Cipla Limited and Cipla USA, Inc. (collectively, Cipla); (2) Sagent Pharmaceuticals, Inc. (Sagent); (3) Breckenridge Pharmaceutical, Inc. (Breckenridge); and (4) Fresenius Kabi, USA LLC, Fresenius Kabi USA, Inc., Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited; (5) Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.; (6) MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN); (7) Dr. Reddy&#x2019;s Laboratories, Ltd. and Dr. Reddy&#x2019;s Laboratories, Inc. (collectively, DRL); (8) Qilu Pharma, Inc. and Qilu Pharmaceutical Co. Ltd. (collectively, Qilu); (9) Apotex Inc. and Apotex Corp. (Apotex); (10) InnoPharma, Inc. (InnoPharma); and (11) Aurobindo Pharma USA, Inc., each for infringement of one or more of our following patents, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) for KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: U.S. Patent Nos. 7,232,818 (the &#x2019;818 Patent), 7,417,042 (the &#x2019;042 Patent), 7,491,704 (the &#x2019;704 Patent), 7,737,112 (the &#x2019;112 Patent), 8,129,346 (the &#x2019;346 Patent), 8,207,125 (the &#x2019;125 Patent), 8,207,126 (the &#x2019;126 Patent), 8,207,127 (the &#x2019;127 Patent) and 8,207,297 (the &#x2019;297 Patent). Each of these lawsuits was based on each defendant&#x2019;s submission of an ANDA seeking U.S. Food and Drug Administration (FDA) approval to market a generic version of KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In each lawsuit, Onyx Therapeutics sought an order of the Delaware District Court making any FDA approval of the respective defendant&#x2019;s ANDA effective no earlier than the expiration of the applicable patents. The Delaware District Court consolidated these lawsuits for purposes of discovery into a single case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Onyx Therapeutics, Inc. v. Cipla Limited, et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, by stipulation with Onyx Therapeutics, Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited were dismissed from the lawsuit, leaving Fresenius Kabi, USA LLC and Fresenius Kabi USA, Inc. (collectively, Fresenius) as the remaining Fresenius defendants. In September 2017 and February 2018, respectively, by joint stipulation with Onyx Therapeutics, Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. were each dismissed from the lawsuit, and in February 2018, Qilu was dismissed from the lawsuit by joint stipulation between Onyx Therapeutics and Qilu. Between April and July of 2018, the Delaware District Court entered orders on stipulations between Onyx Therapeutics and each of Apotex, DRL, Sagent, Fresenius, Breckenridge, Aurobindo Pharma USA, Inc., Cipla and InnoPharma, respectively, that each defendant infringes the &#x2019;042, &#x2019;112, &#x2019;125, &#x2019;126 and &#x2019;127 Patents. Onyx Therapeutics provided those defendants, either through a stipulated order or other agreement, a covenant that it would not assert patent infringement of the &#x2019;818,&#x2019;704,&#x2019;346 and &#x2019;297 Patents against certain of the respective defendants&#x2019; ANDA applications and products. In June 2018, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and MSN that MSN infringes the &#x2019;112 Patent. In December 2018, Apotex, DRL, Fresenius, InnoPharma, Sagent, Breckenridge, Aurobindo Pharma USA, Inc. and Cipla amended their responses to the complaints to add the defense of unclean hands and to seek declarations of unenforceability of the asserted patents based on allegations of inequitable conduct. In January 2019, MSN amended its responses to the complaints to add the defense of unclean hands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2019, Onyx Therapeutics filed a separate lawsuit in the Delaware District Court against Breckenridge for infringement of the &#x2019;042, &#x2019;112 and &#x2019;125 Patents in connection with its ANDA that seeks approval to market generic versions of KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On March 4, 2019, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and Breckenridge, providing that Breckenridge infringes the asserted claims of the &#x2019;042, &#x2019;112 and &#x2019;125 Patents, and consolidated this lawsuit against Breckenridge into the existing consolidated case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Onyx Therapeutics, Inc. v. Cipla Limited, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for all purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 6, 2019, the Delaware District Court commenced trial in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Onyx Therapeutics, Inc. v. Cipla Limited, et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. consolidated case. During trial, the Delaware District Court signed consent judgments filed by Onyx Therapeutics and each of Aurobindo Pharma USA, Inc., InnoPharma, Sagent, Apotex, Fresenius, DRL and Breckenridge, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties&#x2019; claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the &#x2019;042, &#x2019;112 and &#x2019;125 Patents by the manufacture, use, sale, offer to sell or importation into the United States of the applicable defendant&#x2019;s carfilzomib product unless specifically authorized pursuant to the applicable confidential settlement agreement. During trial, the Delaware District Court also entered a consent judgment between Onyx Therapeutics and MSN, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties&#x2019; claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the &#x2019;112 Patent by the manufacture, use, sale, offer to sell or importation into the United States of MSN&#x2019;s carfilzomib product unless specifically authorized pursuant to the confidential settlement agreement. On May 16, 2019, trial concluded between Onyx Therapeutics and the lone remaining defendant, Cipla. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 8, 2020, consistent with its May 4, 2020 decision and order, the Delaware District Court entered final judgment in favor of Onyx Therapeutics and against Cipla on infringement, validity and enforceability of claims 23 and 24 of the &#x2019;042 Patent, claim 1 of the &#x2019;125 Patent and claim 31 of the &#x2019;112 Patent. The Delaware District Court entered judgment in favor of Cipla and against Onyx Therapeutics on Cipla&#x2019;s counterclaim for invalidity of claim 32 of the &#x2019;112 Patent and ordered that the effective date of any final approval by the FDA of Cipla&#x2019;s ANDA must be after expiration of the three asserted patents (the &#x2019;042, &#x2019;125 and &#x2019;112 Patents) and any regulatory exclusivity to which Onyx Therapeutics may become entitled. The final judgment includes an injunction prohibiting Cipla from making, using, offering to sell, selling or importing into the United States Cipla&#x2019;s carfilzomib product during the term of the three asserted patents. On May 29, 2020, Cipla filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). The Federal Circuit Court has set the hearing date on Cipla&#x2019;s appeal for March 5, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Sandoz Inc., et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC; Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited; Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc.; Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc., each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#x2019;940 Patent), 7,208,516 (the &#x2019;516 Patent), 7,427,638 (the &#x2019;638 Patent), 7,659,302 (the &#x2019;302 Patent), 7,893,101 (the &#x2019;101 Patent), 8,455,536 (the &#x2019;536 Patent), 8,802,717 (the &#x2019;717 Patent), 9,018,243 (the &#x2019;243 Patent) and 9,872,854 (the &#x2019;854 Patent), which are listed in the Orange Book for Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Each of the defendants is seeking to market a generic version of Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before expiration of the asserted patents. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene Corp. v. Sandoz Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#x2019;s ANDA effective no earlier than the expiration of the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz Inc., Actavis, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 9,724,330 (the &#x2019;330 Patent), which is listed in the Orange Book for Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN Laboratories Private Limited, Pharmascience, Prinston, Sandoz Inc., Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 10,092,541 (the &#x2019;541 Patent), which is listed in the Orange Book for Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN Laboratories Private Limited and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243 and &#x2019;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus Pharmaceuticals (USA) Inc. in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#x2019;283 Patent) and 8,629,173 (the &#x2019;173 Patent), which are not listed in the Orange Book for Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene Corp. v. Sandoz Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz Inc., Shilpa, Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Amgen&#x2019;s acquisition of the patents-in-suit and the new drug application for Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;717, &#x2019;243, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101, &#x2019;854 and &#x2019;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz Inc. with respect to the &#x2019;717, &#x2019;516 and &#x2019;854 Patents, leaving the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330, &#x2019;638, &#x2019;101 and &#x2019;541 Patents asserted by Amgen against Sandoz Inc. in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330, &#x2019;638, &#x2019;101 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#x2019; apremilast product during the term of the &#x2019;638 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal Pharmaceuticals LLC, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal Pharmaceuticals LLC&#x2019;s apremilast product during the term of the &#x2019;101, &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101 and &#x2019;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#x2019; apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;717, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trial in the consolidated action against the remaining defendants is scheduled to commence on June 14, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(cinacalcet) ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2016, Amgen filed 14 separate lawsuits in the Delaware District Court for infringement of our U.S. Patent No. 9,375,405 (the &#x2019;405 Patent) against a number of manufacturers of purported generic versions of our Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product. In February 2017, the Delaware District Court consolidated these 14 lawsuits into a single case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Aurobindo Pharma Ltd. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2017, Amgen filed an additional lawsuit in the Delaware District Court for infringement of the &#x2019;405 Patent which was consolidated into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Aurobindo Pharma Ltd. et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. in August 2017. The &#x2019;405 Patent is entitled &#x201c;Rapid Dissolution Formulation of a Calcium Receptor-Active Compound&#x201d; and expires in 2026. All defendants responding to the complaint denied infringement and sought judgment that the &#x2019;405 Patent is invalid and/or not infringed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between September and November of 2017, Amgen filed, and the Delaware District Court signed, stipulated dismissals of the lawsuit against Micro Labs Ltd. and Micro Labs USA, Inc., and the lawsuit against Apotex, as well as consent judgments filed by Amgen and each of (1) Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, Sun); (2) Ajanta Pharma Limited and Ajanta Pharma USA, Inc.; (3) Hetero USA Inc., Hetero Labs Ltd. and Hetero Labs Ltd. Unit V; and (4) Breckenridge. Each consent judgment stipulated to an entry of judgment of infringement and validity of the &#x2019;405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the respective defendant&#x2019;s cinacalcet product during the term of the &#x2019;405 Patent, unless specifically authorized pursuant to the confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Delaware District Court commenced trial on the infringement claims and defenses in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Aurobindo Pharma Ltd. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consolidated lawsuit against the defendants that remained in the lawsuit, collectively consisting of (1) Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson); (2) Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); (3) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus); and (4) Piramal Healthcare UK Limited (Piramal). Just prior to trial, the Delaware District Court signed consent judgments filed by Amgen and each of Cipla, and Strides Pharma Global Pte Limited and Strides Pharma, Inc. (collectively, Strides), and a consent judgment filed by Amgen and Aurobindo. In each consent judgment, the parties stipulated to an entry of judgment of infringement and validity of the &#x2019;405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the applicable defendant&#x2019;s cinacalcet product during the term of the &#x2019;405 Patent, unless specifically authorized pursuant to the applicable confidential settlement agreement. Just prior to trial, the Delaware District Court also entered orders dismissing each of DRL and Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan), on stipulations between Amgen and such parties, respectively, subject to the terms of confidential settlement agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Delaware District Court issued a trial order finding on the infringement claims and defenses in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Aurobindo Pharma Ltd. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consolidated lawsuit that Zydus infringes the &#x2019;405 Patent and that Amneal, Piramal and Watson do not infringe the &#x2019;405 Patent. In August 2018, the Delaware District Court issued an order dismissing, without prejudice, the invalidity counterclaims of Amneal, Piramal and Watson and entered judgment of noninfringement of the &#x2019;405 Patent in favor of Amneal, Piramal and Watson. In September 2018, Amgen filed a notice of appeal to the Federal Circuit Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Delaware District Court dismissed, without prejudice, the invalidity counterclaims of Zydus and entered judgment of infringement of the &#x2019;405 Patent by Zydus in favor of Amgen, including an order that the effective date of the FDA approval of Zydus&#x2019; generic version of Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shall be no earlier than the expiry date of our &#x2019;405 Patent. Also in October 2018, Zydus filed a notice of appeal to the Federal Circuit Court, and the Federal Circuit Court consolidated the appeals of Zydus and Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the FDA approved Watson&#x2019;s generic version of Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Watson&#x2019;s parent company, Teva Pharmaceutical Industries Ltd. (Teva), began selling its product at-risk notwithstanding that the appeals were pending at the Federal Circuit Court. On January 2, 2019, Amgen, Watson and Teva entered into a settlement agreement in which Teva agreed to stop selling its generic product until the mid-year 2021 (or earlier under certain circumstances) and to pay Amgen an undisclosed amount. On January 9, 2019, Watson and Amgen filed a motion asking the Delaware District Court to vacate its final judgment of noninfringement as to Watson and to enter a proposed consent judgment of infringement and validity of the &#x2019;405 Patent and an injunction prohibiting the making, having made, using, selling, offering to sell, or distributing Watson&#x2019;s cinacalcet product in the United States or importing Watson&#x2019;s cinacalcet product into the United States, consistent with the confidential settlement agreement. On January 11, 2019, the Federal Circuit Court stayed the pending appeal by Amgen of the judgment of noninfringement as to Watson in order for the Delaware District Court to rule on the motion of Watson and Amgen. On March 26, 2019, the Delaware District Court denied the joint motion for indicative ruling of Watson and Amgen. On April 10, 2019, Amgen filed an appeal to the Federal Circuit Court and the Federal Circuit Court lifted the stay of Amgen&#x2019;s appeal of the judgment of noninfringement as to Watson and consolidated it with Amgen&#x2019;s appeal of the Delaware District Court&#x2019;s denial of the joint motion for indicative ruling. On September 13, 2019, the Federal Circuit Court denied Amgen&#x2019;s motion and lifted the stay of the briefing schedule which had been stayed pending disposition of Amgen&#x2019;s motion to vacate. On July 9, 2020, the Federal Circuit Court granted a motion filed by Amgen and Watson to dismiss Amgen&#x2019;s appeals of the Delaware District Court&#x2019;s judgment of noninfringement as to Watson and denial of the joint motion for indicative ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 19, 2019, Amgen filed an emergency motion for an injunction pending appeal, seeking an order from the Delaware District Court enjoining defendant Piramal from making, using, selling, offering for sale or importing its generic cinacalcet product. Amgen&#x2019;s motion follows an announcement that Slate Run Pharmaceuticals LLC (Slate Run), in partnership with Piramal, had begun selling Piramal&#x2019;s generic cinacalcet product at-risk notwithstanding the appeals pending at the Federal Circuit Court. On April 15, 2019, the Delaware District Court signed an order enjoining Piramal and Slate Run from selling their generic cinacalcet product until certain events occur related to a decision by the Federal Circuit Court on the parties&#x2019; appeal. The order has no effect on the product that Piramal and Slate Run had already sold to third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 7, 2020, the Federal Circuit Court issued an opinion affirming the judgment of noninfringement with respect to Piramal, affirming the judgment of infringement with respect to Zydus and vacating and remanding to the Delaware District Court for further consideration the judgment of noninfringement with respect to Amneal. On April 22, 2020, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court. On September 8, 2020, the Delaware District Court entered judgment of validity and infringement of the &#x2019;405 Patent in the lawsuit filed against Amneal and, except to the extent specifically authorized in a confidential settlement agreement, enjoined Amneal from infringing the &#x2019;405 Patent by making, using, selling, offering to sell or importing Amneal&#x2019;s cinacalcet product during the term of the patent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A hearing before the Delaware District Court on the request of Piramal to recover damages for being enjoined during the pendency of Amgen&#x2019;s appeal has been rescheduled for March 24, 2021. On October 14, 2020, the Delaware District Court issued an order permitting Slate Run, Piramal&#x2019;s business partner, to intervene in the pending action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ENBREL Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immunex Corporation, et al. v. Sandoz Inc., et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (collectively, Sandoz). This lawsuit stems from Sandoz&#x2019;s submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#x2019;s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182 (the &#x2019;182 Patent), 8,163,522 (the &#x2019;522 Patent), 7,915,225 (the &#x2019;225 Patent), 8,119,605 (the &#x2019;605 Patent) and 8,722,631 (the &#x2019;631 Patent). By their complaint, Amgen and Roche seek an injunction to prohibit Sandoz from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. All Sandoz defendants responded by denying infringement and/or asserting that the patents at issue are invalid. In August 2016, and subject to the terms of a confidential stipulation, the New Jersey District Court entered a preliminary injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz&#x2019;s etanercept product. Sandoz&#x2019;s Erelzi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a biosimilar to ENBREL, was approved by the FDA in August 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the New Jersey District Court entered an order that the making, using, offering to sell or selling in the United States or the importation into the United States by Sandoz of Sandoz&#x2019;s biosimilar etanercept product infringes the &#x2019;182 and &#x2019;522 Patents and held a bench trial, focusing on Sandoz&#x2019;s challenges to the validity of these patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2019, the New Jersey District Court issued its decision upholding the validity of the &#x2019;182 and &#x2019;522 Patents. On October 8, 2019, by stipulation of Amgen and Sandoz, the New Jersey District Court entered final judgment and a permanent injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz&#x2019;s etanercept product, and, on the same day, Sandoz appealed the final judgment to the Federal Circuit Court. Following a motion by Sandoz, the Federal Circuit Court ordered an expedited briefing schedule for the appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2020, the Federal Circuit Court heard oral argument on the appeal. On July 1, 2020, the Federal Circuit Court affirmed the judgment of the New Jersey District Court upholding the validity of the &#x2019;182 and &#x2019;522 Patents. On September 29, 2020, the Federal Circuit Court denied the petition for rehearing of Sandoz filed on July 31, 2020. On January 29, 2021, Sandoz filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#x2019;s affirmance of the validity of the &#x2019;182 and &#x2019;522 Patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Roche, filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis&#x2019; submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#x2019;s ENBREL. Amgen and Roche have asserted infringement of five patents: the &#x2019;182, &#x2019;522, &#x2019;225, &#x2019;605 and &#x2019;631 Patents. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis&#x2019; etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court&#x2019;s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repatha&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Sanofi, et al. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2014, Amgen initiated a series of lawsuits that were consolidated by the Delaware District Court in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#x2019;165 Patent); 8,859,741 (the &#x2019;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#x2019;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#x2019;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#x2019;s infringement of Amgen&#x2019;s patents is willful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; infringe certain of Amgen&#x2019;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#x2019;s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#x2019;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#x2019;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron&#x2019;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#x2019;s conclusion that the judgment affirming the validity of Amgen&#x2019;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#x2019;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#x2019;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#x2019;s claim of willful infringement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2019, a jury of the Delaware District Court unanimously upheld the validity of claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent. The jury also found that claims 7 and 15 of the &#x2019;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse judgment as a matter of law or for a new trial with respect to claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent, and Amgen filed a motion for a permanent injunction. On June 6, 13 and 21, 2019, the Delaware District Court held evidentiary hearings on Amgen&#x2019;s motion for a permanent injunction against PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron&#x2019;s request for a new trial and their request to reverse the jury verdict that the &#x2019;165 Patent and the &#x2019;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court. On December 9, 2020, the Federal Circuit Court heard oral argument on the appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Disputes in the International Region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in the United Kingdom, Germany, France, the Netherlands, Italy, Spain and Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#x2019;s patent, and each of Eli Lilly and Company, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#x2019;s patent. In November 2018, the EPO confirmed the validity of Amgen&#x2019;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, but ruled that broader claims encompassing PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were invalid. As a result of the TBA&#x2019;s decision, national litigations regarding PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe are in the process of being resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#x2019;s appeals making final the Japanese High Court&#x2019;s decisions that PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; infringes Amgen&#x2019;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#x2019;s Japanese patents that were previously held infringed by PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and valid over challenges filed by Sanofi K.K. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NEUPOGEN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (filgrastim)/Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Pfizer Inc. et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Pfizer Inc. and Hospira Inc. (collectively, Pfizer). This lawsuit stems from Pfizer&#x2019;s submission of an application for FDA licensure of a filgrastim product as biosimilar to Amgen&#x2019;s NEUPOGEN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Amgen has asserted infringement of U.S. Patent No. 9,643,997 (the &#x2019;997 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#x2019;997 Patent. In July 2018, the FDA approved Pfizer&#x2019;s NIVESTYM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a biosimilar to NEUPOGEN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was subsequently launched in October 2018. In August 2018, Pfizer answered the complaint and counterclaimed seeking a declaration that Pfizer does not infringe Amgen&#x2019;s &#x2019;997 Patent and that the patent is invalid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 22, 2019, Amgen filed an amended complaint against Pfizer in the Delaware District Court narrowing the patent claims at issue in the infringement dispute and adding a request for damages. On April 11, 2019, Pfizer answered Amgen&#x2019;s amended complaint including counterclaims seeking declaratory judgments of noninfringement and invalidity. On February 18, 2020, the Delaware District Court entered an amended scheduling order moving the trial on the infringement of our &#x2019;997 Patent to May 17, 2021, to enable Amgen to seek additional discovery into Pfizer&#x2019;s invalidity defenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2020, Amgen filed a separate lawsuit in the Delaware District Court against Pfizer for infringement of U.S. Patent No. 10,577,392 (the &#x2019;392 Patent) and seeks, among other remedies, damages and injunctive relief to prohibit Pfizer from infringing the &#x2019;392 Patent by the manufacture, import and sale of Pfizer&#x2019;s NIVESTYM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On January 7, 2021, the Delaware District Court granted Pfizer&#x2019;s request to stay the patent infringement lawsuit on the &#x2019;392 Patent until the co-pending patent infringement lawsuit on the &#x2019;997 Patent is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Hospira Inc. et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Pfizer. This lawsuit stems from Pfizer&#x2019;s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen&#x2019;s Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the &#x2019;707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#x2019;707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the &#x2019;707 Patent. In June 2020, the FDA approved Pfizer&#x2019;s NYVEPRIA&#x2122;, a biosimilar to Amgen&#x2019;s Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Trial and Appeal Board (PTAB) Challenge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lupin PTAB Challenge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2020, Lupin Limited (Lupin) filed a petition to institute inter parties review (IPR) proceeding at the U.S. Patent and Trademark Office (USPTO) of U.S. Patent No. 9,856,287 (the &#x2019;287 Patent) challenging claims of the &#x2019;287 Patent as unpatentable. Amgen&#x2019; s preliminary response is due on April 14, 2021 and the PTAB will then have no more than three months to decide whether to institute a proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Apotex PTAB Challenge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, the PTAB of the USPTO granted Apotex&#x2019;s petition to institute IPR proceeding of U.S. Patent No. 8,952,138 (the &#x2019;138 Patent), challenging claims of the &#x2019;138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the &#x2019;138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2019, the PTAB issued a decision denying Apotex&#x2019;s request for rehearing on the PTAB&#x2019;s finding and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;sua sponte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; amending the final decision with a finding that the one remaining claim in Amgen&#x2019;s &#x2019;138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court&#x2019;s decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arthrex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inc. v. Smith &amp;amp; Nephew, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., 941 F.3d 1320 (Fed. Cir. 2019). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the &#x2019;138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the &#x2019;138 Patent, for proceedings consistent with its decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arthrex Inc. v. Smith &amp;amp; Nephew, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 941 F.3d 1320 (Fed. Cir. 2019), requesting that such remanded cases be held pending the U.S. Supreme Court&#x2019;s disposition of the petition for writ of certiorari in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States v. Arthrex, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government&#x2019;s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Breach of Contract Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharma AG v. Amgen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis Pharma AG (Novartis) seeking a declaratory judgment that Novartis materially breached two collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; due to Novartis&#x2019; affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and entrant in the calcitonin gene-related peptide (CGRP)-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis&#x2019; complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis&#x2019; first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Amgen&#x2019;s second amended counterclaims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2020, the New York Southern District Court entered an order granting Novartis&#x2019; motion for judgment on the pleadings that Novartis did not breach the 2017 Agreement, and denying Amgen&#x2019;s motions for judgment on the pleadings seeking dismissal of Novartis&#x2019; amended complaint that Novartis did not breach the 2015 Agreement or the 2017 Agreement, and Novartis timely cured any breach. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the June 9, 2020 order, which was denied on September 14, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.46pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Antitrust Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. Two of those actions were brought in the Delaware District Court, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (February 21, 2019) (Local 1500) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cesar Castillo, Inc. v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and alleges that the plaintiffs have overpaid for Sensipar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a result of Amgen&#x2019;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson and Teva of the parties&#x2019; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#x2019; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cipla Ltd. v. Amgen Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consolidated and designated as a MDL in the Delaware District Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#x2019; consolidated class action complaint and the indirect purchaser end payor plaintiffs&#x2019; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#x2019;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the Delaware District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#x2019;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#x2019; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#x2019;s recommendation in part and denied it in part, denying Amgen&#x2019;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#x2019;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#x2019; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#x2019;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Biosimilar Antitrust Class Actions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From March to May 2019, twelve purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). The cases are captioned: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 18, 2019) (Local 1500); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (March 20, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mayor and City Council of Baltimore v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 22, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pipe&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trades Services MN Welfare Fund v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 29, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;St. Paul Electrical Workers&#x2019; Health Plan v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 29, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C and 137R v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(April 1, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(April 9, 2019) (Law Enforcement); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(April 16, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sheet Metal Workers&#x2019; Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 19, 2019) (Sheet Metal Workers&#x2019;); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Locals 302 &amp;amp; 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 25, 2019) (Construction Industry); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Louisiana Health Service &amp;amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 30, 2019) (Louisiana Health); and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (May 10, 2019) (Cleveland Bakers) (collectively, Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Antitrust Class Actions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of the Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and biosimilars of Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including by creating an allegedly unlawful so-called patent thicket around Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In the Local 1500, Sheet Metal Workers&#x2019; and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; biosimilars, including Bioepis, Mylan, Sandoz, Inc., Fresenius Kabi USA, LLC, Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, whereby Amgen and the other defendants that have developed Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(adalimumab), its Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; biosimilar in that market for five months, beginning in January 2023. In each of the Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney&#x2019;s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. Defendants&#x2019; responses to the first six complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the twelve purported class action cases for pre-trial purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz, Inc. and Fresenius Kabi USA LLC. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs&#x2019; allegations to state any claim for relief under the law. On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support of the motion to dismiss. On June 8, 2020, the Illinois Northern District Court issued an order granting the motion by the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the Federal Trade Commission and one on behalf of 20 states, each filed on October 13, 2020. On December 21, 2020, the defendants-appellees filed their opposition brief. Defendants-appellees amicus briefs, including one by the Department of Justice, were filed on December 28, 2020. The plaintiffs-appellants&#x2019; reply brief was filed on February 1, 2021, and oral argument has been scheduled for February 25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments &#x2013; U.S. repatriation tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining U.S. repatriation tax commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i0bfce81b8b324711af659a7858516c9b_D20161001-20180430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA2NjE_1ca2e2f9-851f-4e4c-9cf4-fd5c7b2bf7d8"
      unitRef="patent">1</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <amgn:NumberOfAssertedPatents
      contextRef="i809cbf0f95194f08903685ccb680427e_D20200508-20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA2NzA_4501b17e-76cb-4077-9da0-a3e71d96d1f6"
      unitRef="patent">3</amgn:NumberOfAssertedPatents>
    <amgn:NumberOfAssertedPatents
      contextRef="i809cbf0f95194f08903685ccb680427e_D20200508-20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA2ODE_ca53ec2c-24aa-445b-abb3-31e6b7c37720"
      unitRef="patent">3</amgn:NumberOfAssertedPatents>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="i3adccb2cee77458681e77740f4995ece_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MDM_7b2ea974-5685-47a0-a727-e1f8ac1f327a"
      unitRef="lawsuit">19</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="i3adccb2cee77458681e77740f4995ece_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MDc_fdb4e76d-6922-49e4-8498-1a4292dae07d"
      unitRef="lawsuit">19</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MTE_0985cb67-8b25-43ab-9202-10b101e3f6e4"
      unitRef="lawsuit">14</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:GainContingencyNumberOfLawsuitsConsolidated
      contextRef="icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MTU_11072fa2-a741-47eb-9369-b7efbfbd4e01"
      unitRef="lawsuit">14</amgn:GainContingencyNumberOfLawsuitsConsolidated>
    <amgn:GainContingencyNumberofAffiliates
      contextRef="ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3MTg_d2c45417-bb81-48e5-be7e-40fc537b0f3c"
      unitRef="affiliate">2</amgn:GainContingencyNumberofAffiliates>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Mjc_08a1d007-671d-4e56-94c1-28cbb9b2e6ba"
      unitRef="patent">5</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <amgn:GainContingencyNumberofAffiliates
      contextRef="ifc0906f0e464443487073d2cfd195558_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Mzc_6a417990-3198-47f6-a12b-616c23e7699c"
      unitRef="affiliate">2</amgn:GainContingencyNumberofAffiliates>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ia0e8f31ce26e4873a861d070ec4bab78_D20141001-20141031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3NDY_6d35106d-85eb-4564-8adb-a1461bc09567"
      unitRef="patent">7</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <amgn:LitigationSettlementLengthofTrial
      contextRef="i0c1117b8cfa8440a9fe7743afd265be3_D20160201-20160228"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4Nzc_04c63e19-a648-4880-a260-73c48f5a8326">P5D</amgn:LitigationSettlementLengthofTrial>
    <amgn:GainContingencyNumberOfChallenges
      contextRef="i9fad48569ed547d6bda68c928f79c3aa_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Njg_3811a437-25dc-45fa-89ee-29fc2ff42ce6"
      unitRef="patent">2</amgn:GainContingencyNumberOfChallenges>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4ae1970a90b64a67af70b4ac4a36cab8_I20190520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3Nzc_1f1d8129-8312-4a56-a23e-4c66e925af7d"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4ae1970a90b64a67af70b4ac4a36cab8_I20190520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3ODY_01c40759-6555-4ab2-b839-a40a32818315"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <amgn:GainContingencyNumberOfAgreementsBreached
      contextRef="i80dd2b5d6a6741578cd8c92ca187c67d_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA3OTU_da3e6954-e56e-4f2a-9ce6-b0cbbf9037e6"
      unitRef="agreement">2</amgn:GainContingencyNumberOfAgreementsBreached>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MDQ_4b8da9a9-6c10-445d-b83c-221cc32c0b98"
      unitRef="plaintiffs">4</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MTQ_be183ce9-7569-4c2a-bdd9-fdbcd6109897"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MjQ_ebce46ac-b927-420e-b5a3-959f13f20a5d"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="ib670230b76714e3f955e6ed2b4fdc9dc_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4MzQ_c7091d83-6eb0-48f2-99d2-d91f3112bb75"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia4745ee7d51c48f38ab56aea1953d9eb_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4NDQ_3320d680-a887-4ec3-a858-6538407ebf07"
      unitRef="claim">12</us-gaap:LossContingencyPendingClaimsNumber>
    <amgn:LossContingencyNumberOfComplaintsStayedByTheCourt
      contextRef="i4c336ecb8a8a4d67a7a3bd87243f7b8d_D20190301-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4NTY_3179ccca-01ba-4e38-903c-59b9cd45cc19"
      unitRef="complaints">6</amgn:LossContingencyNumberOfComplaintsStayedByTheCourt>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if453a7e1fbf04c769fde5a4f2ed3c28b_I20190604"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzU0OTc1NTkwODA4NjU_013eabd5-86fc-4602-a595-bc362a4b8a3e"
      unitRef="claim">12</us-gaap:LossContingencyPendingClaimsNumber>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzYzNDI5_5c40b67e-855f-4242-989d-7d128071e288"
      unitRef="installment">8</amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments>
    <amgn:ScheduleOfU.S.RepatriationTaxCommitments
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90ZXh0cmVnaW9uOjRkODAwYmE0NTczNjQ4NjlhNDQ4YzFjMDkzMDdkODlkXzYzNjk4_8e7193e3-246f-4399-a1d6-d2d1697bec4c">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2020 (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining U.S. repatriation tax commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ScheduleOfU.S.RepatriationTaxCommitments>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzEtMS0xLTEtMA_2a8a1fd3-024f-49af-91fc-4dfb19f09a05"
      unitRef="usd">587000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzItMS0xLTEtMA_c75709f3-853c-49d6-ab47-7bca9496df0a"
      unitRef="usd">587000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzMtMS0xLTEtMA_6c0829ad-2c19-4aac-9527-c552fe5293c2"
      unitRef="usd">1100000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzQtMS0xLTEtMA_6538e12e-50f9-4922-b4d0-f9efb1ef7181"
      unitRef="usd">1467000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzUtMS0xLTEtMA_bce56fc8-d88e-4773-b3a7-a34c6c248f87"
      unitRef="usd">1834000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears>
    <amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzEvZnJhZzo0ZDgwMGJhNDU3MzY0ODY5YTQ0OGMxYzA5MzA3ZDg5ZC90YWJsZTpjNzQ5ODE5Mzg1NTY0NjFlYjlhY2I4N2QwZjQzYzBhZS90YWJsZXJhbmdlOmM3NDk4MTkzODU1NjQ2MWViOWFjYjg3ZDBmNDNjMGFlXzctMS0xLTEtMA_a1c47f9d-8a3b-40c4-80e7-adea4f9ebdcf"
      unitRef="usd">5575000000</amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90ZXh0cmVnaW9uOmU5YjFkODE4ZGI3NDRiNDQ5YWZmOWU5ZDlkZWI4ODU5XzUxNQ_8b00981e-fbe2-48e7-9bb8-c0c259649d79">Quarterly financial data (unaudited)&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s unaudited financial data on a quarterly basis. The sum of the quarterly earnings per-share amounts may not equal the amount reported for the full year because per-share amounts are computed independently for each quarter and for the full year based on respective weighted-average shares outstanding and dilutive securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly financial data is summarized as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Quarters ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit from product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019 Quarters ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit from product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90ZXh0cmVnaW9uOmU5YjFkODE4ZGI3NDRiNDQ5YWZmOWU5ZDlkZWI4ODU5XzUxMQ_e390c6b4-640e-4204-ad57-e22f70c1ef09">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly financial data is summarized as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Quarters ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit from product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019 Quarters ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit from product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i61225a3c72514f859602e544d725ab0e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItMS0xLTEtMA_6438aa53-46ed-4c35-93a0-55d13a530553"
      unitRef="usd">6334000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2bf1db2cec2744fe9cf8a8abb012ff11_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItMy0xLTEtMA_12646a33-2042-447f-8eb8-cc30533ea8f9"
      unitRef="usd">6104000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4d59301d26594c2ba4ab4f364829aa82_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItNS0xLTEtMA_5075f5f6-de07-4155-9fec-4d8d12ef399e"
      unitRef="usd">5908000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9b74954f05984826a98fa8d1de70b8ad_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzItNy0xLTEtMA_d36d3fda-841c-4d0b-ba44-d424dfc3fcb3"
      unitRef="usd">5894000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtMS0xLTEtMA_40402f54-9d01-4bae-a588-e6b404b15c15"
      unitRef="usd">4737000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtMy0xLTEtMA_3cfc9277-2241-4152-a86b-9c946a7d3779"
      unitRef="usd">4543000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtNS0xLTEtMA_989ae5e1-764b-423b-9dc5-567a9756327a"
      unitRef="usd">4420000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzMtNy0xLTEtMA_97956d9c-fea3-4fe9-91e6-1e49644d4696"
      unitRef="usd">4381000000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtMS0xLTEtMA_668d08b5-458e-4db8-be15-40a8126f39c4"
      unitRef="usd">1615000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtMy0xLTEtMA_1d966ab5-e4aa-4ad5-81c3-1dff76472758"
      unitRef="usd">2021000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtNS0xLTEtMA_dd9584da-7822-411e-8b1d-719b8ab3842a"
      unitRef="usd">1803000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzQtNy0xLTEtMA_d51f9793-079f-47a2-8133-068bd6f25b90"
      unitRef="usd">1825000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtMS0xLTEtMA_efa7a47a-784d-43c9-83f5-626b798691d9"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtMy0xLTEtMA_02462aa5-6ba9-4e5b-83a2-b341de99d765"
      unitRef="usdPerShare">3.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtNS0xLTEtMA_03146820-52dc-4b1b-b908-08f160f849cf"
      unitRef="usdPerShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzYtNy0xLTEtMA_fcfbcbdb-bdb0-4743-b042-9c9285fba1d7"
      unitRef="usdPerShare">3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i98fd075b8f9149569c46402ade7585a6_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctMS0xLTEtMA_58057737-883f-4661-b18d-3399f8435f4d"
      unitRef="usdPerShare">2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41aa666e2c2741e8be4ee2dae2d19c02_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctMy0xLTEtMA_85a72d08-c557-4b14-991f-e5ced98940c4"
      unitRef="usdPerShare">3.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i473af25953c84328a062db4c39eed37c_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctNS0xLTEtMA_96ada069-10a3-48e7-a583-c67c26d91418"
      unitRef="usdPerShare">3.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibc3a4daaedfb42449ef91e63e4ae3764_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzctNy0xLTEtMA_7c3e570a-1c95-4561-bdcb-aff4c1ec3c90"
      unitRef="usdPerShare">3.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i43febb6cb9d3444caa73da4c92560180_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTEtMS0xLTA_289674fa-413c-474f-ae4d-0caec570a6a6"
      unitRef="usd">5881000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i09079b5a58e246b5947144cbde795c44_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTMtMS0xLTA_0485b718-1983-4c64-aa10-48675248c96c"
      unitRef="usd">5463000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4254e372a9cd437fa13067b22cd6fc34_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTUtMS0xLTA_e55b6017-657c-46c0-92ae-5302b31aafff"
      unitRef="usd">5574000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8404b3b31ac149eca5db19a64dd46da4_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEwLTctMS0xLTA_77458eff-05c0-4490-9d7a-311ff8ddd4b5"
      unitRef="usd">5286000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTEtMS0xLTA_dad0e978-ad6a-46b6-894d-622f701ac14d"
      unitRef="usd">4628000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTMtMS0xLTA_b53737ea-a1a9-442d-a781-cb153dc1a399"
      unitRef="usd">4427000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTUtMS0xLTA_1de88344-eb14-40ef-b720-c0f551899451"
      unitRef="usd">4562000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzExLTctMS0xLTA_b4b0ff7b-b299-4548-a5d9-b45b61bdb5d9"
      unitRef="usd">4231000000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTEtMS0xLTA_f5b0b0a2-0820-4ca3-b716-dff57c1df4e2"
      unitRef="usd">1703000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTMtMS0xLTA_0b61acbb-4399-4b14-a059-6f1ca360a238"
      unitRef="usd">1968000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTUtMS0xLTA_b6580c5d-4982-4d5d-9369-3021126c3c33"
      unitRef="usd">2179000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzEyLTctMS0xLTA_2e788e98-5a0e-4f42-8df7-68b93584fc31"
      unitRef="usd">1992000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTEtMS0xLTA_501a6ed4-cbd1-4754-a74f-d89915adcc74"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTMtMS0xLTA_55a0f887-6d79-4346-9436-247db435575a"
      unitRef="usdPerShare">3.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTUtMS0xLTA_394551b7-bccf-4461-9444-29a1fa08b441"
      unitRef="usdPerShare">3.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE0LTctMS0xLTA_b452044e-a61d-4cae-98c2-3b4179c34e92"
      unitRef="usdPerShare">3.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5844693a1fc343cbac54c68bebbffd0a_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTEtMS0xLTA_d86e150b-baae-4b2c-8349-59e6aabe4473"
      unitRef="usdPerShare">2.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i04f99a7535ab4b43837eeaa0eaf00108_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTMtMS0xLTA_d1440379-0d6d-412a-b53f-ba193fe42aa2"
      unitRef="usdPerShare">3.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i25c0467bbeff4470b81b1e3d3da21efc_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTUtMS0xLTA_76b941ca-9d48-46b7-8024-04ee0b786f92"
      unitRef="usdPerShare">3.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i105716ab4b8d48f3bffe50fd7325d2dd_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNzcvZnJhZzplOWIxZDgxOGRiNzQ0YjQ0OWFmZjllOWQ5ZGViODg1OS90YWJsZTozMjM3NmI2ZjhjOWU0ODljYTY2ZWZhMjM4ODFmYjRkNy90YWJsZXJhbmdlOjMyMzc2YjZmOGM5ZTQ4OWNhNjZlZmEyMzg4MWZiNGQ3XzE1LTctMS0xLTA_739d3031-616c-4ac9-b4c5-5fc45d63f0d3"
      unitRef="usdPerShare">3.18</us-gaap:EarningsPerShareDiluted>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90ZXh0cmVnaW9uOmZkY2Y2YzQwZjc2MTRkNDI4YjEzZDFhZGI0NThhYTgzXzEwOA_723e6f73-7d40-4858-99e3-a3203f19c174">&lt;div style="margin-bottom:8pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AMGEN INC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ended December 31, 2020, 2019 and 2018 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at beginning&lt;br/&gt;of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;br/&gt;charged&#160;to&lt;br/&gt;costs and&lt;br/&gt;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at end&lt;br/&gt;of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtMi0xLTEtMA_2538b951-020e-4e90-9bd4-716d964a14b8"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtNC0xLTEtMA_4211f53e-9f1d-4005-ad75-bb98dbcd6c95"
      unitRef="usd">8000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtNi0xLTEtMA_4ff29030-3d61-4a14-a69c-e114d084f114"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib3e09025131245718b40a342c9cd7808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtOC0xLTEtMA_fa9d829f-1132-4122-b934-3b8a1a0c608a"
      unitRef="usd">2000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia802888bb7a6406592ff586c244944e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzEtMTAtMS0xLTA_4339edc7-98d4-4dca-abac-995903bfeb62"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItMi0xLTEtMA_ca141574-58ea-4032-bea5-33789a741969"
      unitRef="usd">48000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItNC0xLTEtMA_8979f2cf-1224-40ae-98a9-9433a6482ede"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItNi0xLTEtMA_aa47352a-c21c-46e5-9b66-271ff5544cb5"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItOC0xLTEtMA_7db377c7-05e3-49c3-b0e8-ad9b2d35cc57"
      unitRef="usd">22000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i54b90fa0f4424779a6c9281cad32ba28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzItMTAtMS0xLTA_32f5feb7-51e6-48b5-9290-7384bcaa7e17"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6087f9de751b4b1a9a41839e6521a886_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtMi0xLTEtMA_34abded9-c571-482a-9f6d-e6ca08b5b865"
      unitRef="usd">51000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtNC0xLTEtMA_3ee78cd9-0b19-42a7-b9b6-55dce513ed59"
      unitRef="usd">1000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtNi0xLTEtMA_43cf0171-0b51-4493-a658-fd38110b4459"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i94156bcd847d48e9b2be20239739f9dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtOC0xLTEtMA_24928c09-2386-432d-a76a-a895181b3a7d"
      unitRef="usd">4000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i14141fd9eb484f7ba4154b56ad24b478_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yODYvZnJhZzpmZGNmNmM0MGY3NjE0ZDQyOGIxM2QxYWRiNDU4YWE4My90YWJsZTo2YzAxMWQxZDc5MTQ0NmY1YmZhYmMyODgzZjM3ZjRkMS90YWJsZXJhbmdlOjZjMDExZDFkNzkxNDQ2ZjViZmFiYzI4ODNmMzdmNGQxXzMtMTAtMS0xLTA_77d84198-f25b-484e-9a93-f185d8cf5d67"
      unitRef="usd">48000000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600063432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 03, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,056,968,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,566,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s Proxy Statement with respect to the 2021 Annual Meeting of Stockholders to be held May 18, 2021, are incorporated by reference into Part&#160;III of this annual report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | The NASDAQ Global Select Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member', window );">1.250% Senior Notes Due 2022 | New York Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes Due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">2.00% Senior Notes Due 2026 | New York Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.00% Senior Notes Due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601763176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">25,424<span></span>
</td>
<td class="nump">23,362<span></span>
</td>
<td class="nump">23,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">4,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">4,207<span></span>
</td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,730<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
<td class="nump">5,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,285<span></span>
</td>
<td class="nump">13,688<span></span>
</td>
<td class="nump">13,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">9,139<span></span>
</td>
<td class="nump">9,674<span></span>
</td>
<td class="nump">10,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">8,133<span></span>
</td>
<td class="nump">9,138<span></span>
</td>
<td class="nump">9,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
<td class="nump">$ 12.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 12.88<span></span>
</td>
<td class="nump">$ 12.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in the calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">$ 22,204<span></span>
</td>
<td class="nump">$ 22,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Other revenues</a></td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 1,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606104680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income, net of reclassification adjustments and taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Gains (losses) on foreign currency translation</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">(Losses) gains on cash flow hedges</a></td>
<td class="num">(438)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">(Losses) gains on available-for-sale securities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent', window );">Other losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income, net of taxes</a></td>
<td class="num">(457)<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 6,807<span></span>
</td>
<td class="nump">$ 8,083<span></span>
</td>
<td class="nump">$ 8,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606761176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,266<span></span>
</td>
<td class="nump">$ 6,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">4,381<span></span>
</td>
<td class="nump">2,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">4,525<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,893<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,079<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">21,144<span></span>
</td>
<td class="nump">18,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,889<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">16,587<span></span>
</td>
<td class="nump">19,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">14,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,639<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">62,948<span></span>
</td>
<td class="nump">59,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">10,141<span></span>
</td>
<td class="nump">8,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">2,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,653<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">32,895<span></span>
</td>
<td class="nump">26,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Long-term tax liabilities</a></td>
<td class="nump">6,968<span></span>
</td>
<td class="nump">8,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">2,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies and commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">2,750.0<span></span>
</td>
<td class="nump">2,750.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">578.3<span></span>
</td>
<td class="nump">591.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding&#8212; 578.3 shares in 2020 and 591.4 shares in 2019</a></td>
<td class="nump">$ 31,802<span></span>
</td>
<td class="nump">$ 31,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(21,408)<span></span>
</td>
<td class="num">(21,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(985)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">9,409<span></span>
</td>
<td class="nump">9,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 62,948<span></span>
</td>
<td class="nump">$ 59,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603062280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock and additional paid-in capital, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid-in capital, shares authorized</a></td>
<td class="nump">2,750.0<span></span>
</td>
<td class="nump">2,750.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid-in capital, shares outstanding</a></td>
<td class="nump">578.3<span></span>
</td>
<td class="nump">591.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599658888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div></th>
<th class="th"><div>Number of shares of common stock</div></th>
<th class="th"><div>Common stock and additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th">
<div>Accumulated deficit [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
<th class="th"><div>Accumulated other comprehensive loss [Member]</div></th>
<th class="th">
<div>Accumulated other comprehensive loss [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 25,241<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,992<span></span>
</td>
<td class="num">$ (5,072)<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="num">$ (679)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">8,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(3,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(17,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,246<span></span>
</td>
<td class="num">(17,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">7,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(3,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (7,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">591.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 9,673<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,531<span></span>
</td>
<td class="num">(21,330)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(3,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (3,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 9,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,802<span></span>
</td>
<td class="num">$ (21,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599462056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603154136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and other</a></td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(287)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(427)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Accrued income taxes, net</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(585)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability', window );">Long-term tax liabilities</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">10,497<span></span>
</td>
<td class="nump">9,150<span></span>
</td>
<td class="nump">11,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(8,477)<span></span>
</td>
<td class="num">(9,394)<span></span>
</td>
<td class="num">(18,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">28,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">4,381<span></span>
</td>
<td class="nump">20,548<span></span>
</td>
<td class="nump">5,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(608)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,617)<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="num">(3,219)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(5,401)<span></span>
</td>
<td class="nump">5,709<span></span>
</td>
<td class="nump">14,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of debt</a></td>
<td class="nump">8,914<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(6,450)<span></span>
</td>
<td class="num">(4,514)<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(3,486)<span></span>
</td>
<td class="num">(7,702)<span></span>
</td>
<td class="num">(17,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(3,755)<span></span>
</td>
<td class="num">(3,509)<span></span>
</td>
<td class="num">(3,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,867)<span></span>
</td>
<td class="num">(15,767)<span></span>
</td>
<td class="num">(22,490)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">229<span></span>
</td>
<td class="num">(908)<span></span>
</td>
<td class="nump">3,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">6,945<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 6,266<span></span>
</td>
<td class="nump">$ 6,037<span></span>
</td>
<td class="nump">$ 6,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Noncurrent Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IncreaseDecreaseInNoncurrentTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594752024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative (SG&amp;A) expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the research and development (R&amp;D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of new lease standard</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&amp;D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&amp;D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars using average exchange rates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets are now presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the former other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand on the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impact that both standards will have on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594441704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business combinations</a></td>
<td class="text">Acquisitions <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(apremilast)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2019, we acquired worldwide rights to Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene Corporation (Celgene). Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The operations of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated cost (consideration transferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed-product-technology rights acquired relate to Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights will be amortized over a weighted-average period of 8.5 years by using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce will be amortized over a period of 5 years by using the straight-line method. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#8217;s effort are applied. Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate 2.5 years. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119&#160;million, a net deferred tax liability of $24&#160;million and a deferred credit of $96&#160;million. The tax effects of the acquisition are based on Amgen&#8217;s estimated blended statutory tax rate of 20%. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuevolution AB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution&#8217;s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kirin-Amgen, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin-Amgen, Inc. (K-A), from Kirin Holdings Company, Limited (Kirin), making K-A a wholly owned subsidiary of Amgen. Upon the acquisition, K-A&#8217;s operations have been included in our consolidated financial statements commencing on the share acquisition date. The acquisition relieved Amgen of future royalty obligations to K-A. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the share acquisition date, we owned 50% of K-A and accounted for our interest in K-A by using the equity method of accounting.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K-A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary means of consideration for this transaction was a payment of $780 million in cash. The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen&#8217;s preacquisition investment consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash paid to Kirin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on settlement of preexisting relationship</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred to acquire K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Amgen&#8217;s investment in K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability-related-income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted-average period of four years by using the straight-line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K-A but not yet received, partially offset by payables representing R&amp;D expenses incurred but not yet reimbursed by K-A. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results of operations for this acquisition have not been presented because this acquisition was not material to our consolidated results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594730408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of rest-of-world (ROW) revenues relates to products sold in Europe. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(etanercept)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(pegfilgrastim)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(darbepoetin alfa)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(carfilzomib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,747&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was acquired on November 21, 2019.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594755592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text">Stock-based compensation<div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated 2009 Equity Incentive Plan (the Amended 2009 Plan) authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including RSUs and performance units (full-value awards). In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2020, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 23 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units and stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#8217;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2020, 2019 and 2018, were $235.63, $182.12 and $179.18, respectively. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair values of RSUs that vested during the years ended December 31, 2020, 2019 and 2018, were $161 million, $160 million and $167 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black&#8211;Scholes option valuation model to estimate the grant date fair value of stock options. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.37&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised during the years ended December 31, 2020, 2019 and 2018, were $98 million, $68 million and $53 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2020, 2019 and 2018, were $21 million, $15 million and $12 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $345 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2020, 2019 and 2018, which are accounted for as equity awards, are based on (i) Amgen&#8217;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#8217;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, 1.8 million and 2.0 million performance units were outstanding with weighted-average grant date fair values per unit of $207.52 and $185.64 per unit, respectively. During the year ended December 31, 2020, 0.6 million performance units with a weighted-average grant date fair value per unit of $249.07 were granted, and 0.1 million performance units with a weighted-average grant date fair value per unit of $199.86 were forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair values of performance units paid during the years ended December 31, 2020, 2019 and 2018 were $230 million, $176 million and $133 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.</span></div>As of December 31, 2020, $127 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594429592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined contribution plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined contribution plan</a></td>
<td class="text">Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $231 million, $220 million and $173 million for the years ended December 31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594803992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) provision:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss (NOL) carryforwards. Significant components of our deferred tax assets and liabilities were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,784)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased in 2020, primarily driven by the Company&#8217;s expectation that some state R&amp;D credits will not be utilized and that certain foreign net operating losses will expire unused.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had $20 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided no valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2035. We had $681 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $585 million of those state tax credit carryforwards.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had $143 million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6 million of those federal NOL carryforwards. The federal NOL carryforwards, for which no valuation allowance has been provided, expire between 2021 and 2035. We had $167 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for all of the state NOL carryforwards. We had $1.9 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $754 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $861 million has no expiry; and the remainder will expire between 2021 and 2030.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the UTBs as of December 31, 2020, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2020, 2019 and 2018, we recognized $116 million, $198 million and $137 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2020 was primarily due to lower interest rates during 2020. As of December 31, 2020 and 2019, accrued interest and penalties associated with UTBs were $783 million and $667 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico Excise Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act, net impact on intercompany sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the years ended December 31, 2020, 2019 and 2018 differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#8217;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid during the years ended December 31, 2020, 2019 and 2018, were $1.4 billion, $1.9 billion and $1.9 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. In 2017, we received a Revenue Agent Report (RAR) and a modified RAR from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and have been pursuing resolution with the IRS administrative appeals office. However, we have been unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a Notice of Deficiency, which we would expect to vigorously contest through the judicial process. In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office. The IRS audit for years 2016, 2017 and 2018 is expected to start in the near term. We are also currently under examinat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion by a number of other state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596003976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three years ended December 31, 2020, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596031384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">Collaborations<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized for these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% stake in BeiGene, Ltd. (BeiGene), for approximately $2.8&#160;billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene commenced selling XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will commercialize KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global R&amp;D costs by providing cash and development services up to $1.25&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, net costs recovered from BeiGene for oncology product candidates were $225&#160;million and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. Profit share payments and product sales between Amgen and BeiGene were not material for the year ended December 31, 2020. As of December 31, 2020, the amount owed from BeiGene for net costs recovered was $113&#160;million, which is included in Other current assets in the Consolidated Balance Sheets. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 9, Investments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis Pharma AG (Novartis) to jointly develop and commercialize Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(erenumab-aooe). In the United States, Amgen and Novartis jointly develop and collaborate on the commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen, as the principal, recognizes product sales of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, shares U.S. commercialization costs with Novartis and pays Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Novartis pays Amgen double-digit royalties on net sales of the product in the Novartis exclusive territories and funds a portion of global R&amp;D expenses. In addition, Novartis will make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds are achieved with respect to Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Amgen manufactures and supplies Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> worldwide. The migraine collaboration will continue for the commercial life of the product unless terminated in accordance with its terms.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in litigation with Novartis over our collaboration agreements for the development and commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 19, Contingencies and commitments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, net costs recovered from Novartis for migraine products were $192 million and $187 million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the year ended December&#160;31, 2018, net costs paid to Novartis for migraine products were $44 million and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2020, 2019, and 2018, royalties due to Novartis for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $139&#160;million, $115 million and $43 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2020, 2019 and 2018, royalties due from Novartis for Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were not material. As a result of certain regulatory and commercial events, we received milestone payments from Novartis of $295 million during the year ended December 31, 2018, which was recorded in Other revenues in the Consolidated Statements of Income. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer HealthCare LLC</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a licensing arrangement with Bayer HealthCare LLC (Bayer) for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently marketed and sold in more than 100 countries around the world for the treatment of unresectable liver cancer and advanced kidney cancer. In the United States, Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we amended the terms of our agreement with Bayer, which transferred all our operational responsibilities outside the United States to Bayer, including commercial and medical affairs activities. Prior to the amendment of the agreement, we shared equally in the profits outside the United States, excluding Japan. In lieu of this profit share, Bayer now pays us a royalty on sales of Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at a percentage rate in the low 30s. The rights to develop and market Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan are reserved to Bayer. In the United States, Bayer pays us a royalty on sales of Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at a percentage rate in the high 30s.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with Bayer will terminate at the later of the date when patents expire that were issued in connection with product candidates discovered under the agreement or on the last day that we or Bayer market or sell products commercialized under the agreement anywhere in the world. Patents related to Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> began to expire in 2020.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2020 amendment to the collaboration agreement, royalties due from Bayer for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $217&#160;million and net profits were not material for the year ended December 31, 2020. During the years ended December 31, 2019 and 2018, royalties due from Bayer for Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were $79 million and $91 million, respectively. During the years ended December 31, 2019 and 2018, Amgen recorded Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net profits of $210 million and $164 million, respectively. Royalties and profit share due from Nexavar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were recorded in Other revenues in the Consolidated Statements of Income. Net R&amp;D expenses related to the agreement were not material for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones, which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595988024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $802 million and $677 million as of December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual maturities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through three years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after three years through five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2020, 2019 and 2018, realized gains on interest-bearing securities were $37 million, $92 million and $29 million, respectively, and realized losses on interest-bearing securities were $4 million, $36 million and $394 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review our available-for-sale investments for declines in fair value below our cost basis each quarter or whenever circumstances indicate that the cost basis of an asset may not be recoverable and assess whether the decline was due to credit-related factors or other factors. Our evaluation is based on a number of factors, including the extent to which the fair value is below our cost basis as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is impaired could change in the future based on new developments or changes in assumptions related to that particular security. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values of $477 million and $303 million as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. For the years ended December 31, 2020, 2019 and 2018, net unrealized gains on publicly traded securities were $174&#160;million, $112&#160;million and $24&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2020, 2019 and 2018, were not material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $203 million and $176 million in equity securities without readily determinable fair values as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. Gains and losses recognized on these securities, including adjustments to the carrying values of these securities, were not material for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnership investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $496 million and $320 million as of December 31, 2020 and 2019, respectively, which are included in Other assets in the Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2020, unfunded additional commitments to be made for these investments during the next several years were not material. For the years ended December 31, 2020, 2019 and 2018 net gains recognized from our limited partnership investments were $241&#160;million, $27 million and $91 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8&#160;billion, of which $2.6&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other assets in the Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $2.4&#160;billion. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Interest and other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recognized an increase in the carrying value of our investment by purchasing additional shares to maintain our ownership interest for an aggregate cost of $569 million and recognized $34 million for the impact of other BeiGene ownership transactions. The carrying value of the investment during the year ended December 31, 2020, was reduced for our share of BeiGene&#8217;s net losses of $229 million and amortization of the basis difference of $109 million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the carrying value and fair value of our approximately 20.5% ownership interest in BeiGene totaled $2.9 billion and $4.9 billion, respectively. We believe that as of December 31, 2020, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808699314376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594776664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020, 2019 and 2018, we recognized depreciation and amortization expense associated with our property, plant and equipment of $640 million, $635 million and $630 million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595766808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text">Goodwill and other intangible assets<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition from acquisitions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,632)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses. </span></div>IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.During the years ended December 31, 2020, 2019 and 2018, we recognized amortization associated with our finite-lived intangible assets of $2.8 billion, $1.4 billion and $1.3 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2021, 2022, 2023, 2024 and 2025, are $2.6 billion, $2.5 billion, $2.4 billion, $2.4 billion and $2.2 billion, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594776664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. Certain required disclosures have been made on a prospective basis in accordance with the standard&#8217;s guidance. See Note 1, Summary of significant accounting policies. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and equipment related primarily to administrative, R&amp;D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;D and administrative space.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020, were as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes future rental commitments for abandoned leases of $133&#160;million. We expect to receive total future rental income of $107&#160;million related to noncancelable subleases for abandoned facilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $339&#160;million. These leases will commence in 2021 with lease terms from 30 months to 15 years. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental expense on operating leases under the prior lease guidance for the year ended December 31, 2018, was $166&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595766808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AccruedLiabilitiesDisclosureTextBlock', window );">Other current assets and accrued liabilities</a></td>
<td class="text">Other current assets and accrued liabilities<div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599829464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing arrangements</a></td>
<td class="text">Financing arrangements<div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% notes due 2020 (4.50% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.125% notes due 2020 (2.125% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating Rate Notes due 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2020 (2.20% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45% notes due 2020 (3.45% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10% notes due 2021 (4.10% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85% notes due 2021 (1.85% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% notes due 2021 (3.875% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% &#8364;1,250 million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#8212;except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097&#8212;may be redeemed at any time at our option&#8212;in whole or in part&#8212;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt issuances</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we issued debt securities in the following offerings:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In February 2020, we issued $5.0&#160;billion of debt consisting of $500&#160;million of the 1.90% 2025 Notes, $750&#160;million of the 2.20% 2027 Notes, $1.25&#160;billion of the 2.45% 2030 Notes, $1.25&#160;billion of the 3.15% 2040 Notes and $1.25&#160;billion of the 3.375% 2050 Notes.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In May 2020, we issued $4.0&#160;billion of debt consisting of $1.0&#160;billion of the 2.20% 2027 Notes, $750&#160;million of the 3.15% 2040 Notes and $1.0&#160;billion of the 3.375% 2050 Notes, which represents a further issuance of, and which forms a single series with, each of the corresponding series of notes issued in February 2020, and $1.25&#160;billion of the 2.30% 2031 Notes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any debt or debt securities during the years ended December 31, 2019 and 2018. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt repayments/redemptions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made debt repayments/redemptions during the years ended December 31, 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we repaid/redeemed $6.5&#160;billion of debt, including the repayment at maturity of the $300&#160;million aggregate principal amount of the 4.50% 2020 Notes, the $750&#160;million aggregate principal amount of the 2.125% 2020 Notes, the $300&#160;million Floating Rate Notes due 2020 and the $700&#160;million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900&#160;million aggregate principal amount of the 3.45% 2020 Notes, the $1.0&#160;billion aggregate principal balance of the 4.10% 2021 Notes, the $750&#160;million aggregate principal balance of the 1.85% 2021 Notes and the $1.75&#160;billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2019, we repaid $4.5 billion of debt, including the $1.4 billion aggregate principal amount of the 2.20% 2019 Notes, the $1.0 billion aggregate principal amount of the 5.70% 2019 Notes, the &#8364;675 million aggregate principal amount ($864 million upon settlement of the related cross-currency swap) of the 2.125% 2019 euro Notes, the $700 million aggregate principal amount of the 1.90% 2019 Notes and the $550 million Floating Rate Notes due 2019.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2018, we repaid $1.1 billion of debt, including the $500 million aggregate principal amount of the 6.15% 2018 Notes and the &#8364;550 million aggregate principal amount of the 4.375% 2018 Notes revalued at $621 million upon maturity. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2&#160;billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45% 2020 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10% 2021 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% 2021 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2022 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2024 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% 2025 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% 2026 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% 2051 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Excludes an additional 1.5% of interest for the difference between the coupon rate paid to noteholders and the fixed rate received under the interest rate swap contracts.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt exchange</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940&#160;million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently cancelled in connection with the Exchange Offer (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% 2038 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% 2039 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% 2040 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% 2041 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% 2042 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% 2043 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 1.25% 2022 euro Notes, 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement and other facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2020 and 2019, we had no amounts outstanding under our commercial paper program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2020 and 2019, no amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the U.S. Securities and Exchange Commission that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual maturities of debt obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2020, are as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2020, 2019 and 2018, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2020, 2019 and 2018, were $1.2 billion, $1.3 billion and $1.5 billion, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596478344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text">Stockholders&#8217; equity<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,855&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Total shares do not add due to rounding.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0 billion. As of December 31, 2020, $3.0 billion remained available under our stock repurchase program. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors declared quarterly dividends per share of $1.60, $1.45 and $1.32, which were paid in each of the four quarters of 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 16, 2020, the Board of Directors declared a quarterly cash dividend of $1.76 per share of common stock, which will be paid on March 8, 2021, to all stockholders of record as of the close of business on February 15, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of change in accounting principle, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $14 million benefit and a $110 million benefit in 2020, a $28 million expense and a $46 million benefit in 2019 and a $21 million expense and a $55 million expense in 2018, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020, a $22 million expense and a $14 million benefit in 2019 and a $9 million benefit and a $3 million expense in 2018, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2020 and 2019, no shares of preferred stock were issued or outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594479288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text">Fair value measurement<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2019, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of our corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of our residential-mortgage-backed securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A&#8211; or equivalent by Standard &amp; Poor&#8217;s Financial Services (S&amp;P), Moody&#8217;s Investors Service, Inc. (Moody&#8217;s) or Fitch Ratings, Inc. (Fitch). We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. During the year ended December 31, 2018, we discontinued the internal development of a program that resulted in an impairment of an IPR&amp;D asset of $330 million, which was recognized in Other operating expenses in the Consolidated Statements of Income and included in Other items, net, in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2020 and 2019, the aggregate fair values of our borrowings were $39.4 billion and $33.7 billion, respectively, and the carrying values were $33.0 billion and $29.9 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2020, the fair value and carrying value were $4.9&#160;billion and $2.9&#160;billion, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595837496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments</a></td>
<td class="text">Derivative instruments<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, 2019 and 2018, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.1 billion, $5.0 billion and $4.5 billion, respectively. As of December 31, 2018 we had outstanding foreign currency option contracts with aggregate notional amounts of $21 million, and no such outstanding contracts as of December 31, 2020 and 2019. We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The notional amounts and interest rates of our cross-currency swaps as of December 31, 2020, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% 2022 euro Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2020, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and gains recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized (losses) gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2020 and 2019, we had interest rate swap contracts with aggregate notional amounts of $5.9 billion and $9.6 billion, respectively, that hedge certain portions of our long-term debt issuances.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps with an aggregate notional value of $3.7&#160;billion were terminated during the year ended December 31, 2020, in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $40&#160;million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $5.2&#160;billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $576&#160;million from the counterparties that was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount will be recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2&#160;billion principal amount of notes. See Note 15, Financing arrangements, for information on our interest rate swaps.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of December 31, 2020. Long-term debt includes $525 million and $136 million of carrying value with discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020. Long-term debt includes $425 million and $36 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income (expense), net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2020, we expected to reclassify $136 million of net losses on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2020, 2019 and 2018, the total notional amounts of these foreign currency forward contracts were $1.0 billion, $1.2 billion and $737 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2020, 2019 and 2018. </span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Our derivative contracts that were in liability positions as of December 31, 2020, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our, or the surviving entity&#8217;s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594429592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text">Contingencies and commitments <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated New Drug Application (ANDA) Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 2016 and April 2018, Onyx Therapeutics, Inc. (Onyx Therapeutics, a wholly-owned subsidiary of Amgen), filed separate lawsuits in the U.S. District Court for the District of Delaware (the Delaware District Court) against: (1) Cipla Limited and Cipla USA, Inc. (collectively, Cipla); (2) Sagent Pharmaceuticals, Inc. (Sagent); (3) Breckenridge Pharmaceutical, Inc. (Breckenridge); and (4) Fresenius Kabi, USA LLC, Fresenius Kabi USA, Inc., Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited; (5) Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.; (6) MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN); (7) Dr. Reddy&#8217;s Laboratories, Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL); (8) Qilu Pharma, Inc. and Qilu Pharmaceutical Co. Ltd. (collectively, Qilu); (9) Apotex Inc. and Apotex Corp. (Apotex); (10) InnoPharma, Inc. (InnoPharma); and (11) Aurobindo Pharma USA, Inc., each for infringement of one or more of our following patents, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) for KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: U.S. Patent Nos. 7,232,818 (the &#8217;818 Patent), 7,417,042 (the &#8217;042 Patent), 7,491,704 (the &#8217;704 Patent), 7,737,112 (the &#8217;112 Patent), 8,129,346 (the &#8217;346 Patent), 8,207,125 (the &#8217;125 Patent), 8,207,126 (the &#8217;126 Patent), 8,207,127 (the &#8217;127 Patent) and 8,207,297 (the &#8217;297 Patent). Each of these lawsuits was based on each defendant&#8217;s submission of an ANDA seeking U.S. Food and Drug Administration (FDA) approval to market a generic version of KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In each lawsuit, Onyx Therapeutics sought an order of the Delaware District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents. The Delaware District Court consolidated these lawsuits for purposes of discovery into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, by stipulation with Onyx Therapeutics, Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited were dismissed from the lawsuit, leaving Fresenius Kabi, USA LLC and Fresenius Kabi USA, Inc. (collectively, Fresenius) as the remaining Fresenius defendants. In September 2017 and February 2018, respectively, by joint stipulation with Onyx Therapeutics, Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. were each dismissed from the lawsuit, and in February 2018, Qilu was dismissed from the lawsuit by joint stipulation between Onyx Therapeutics and Qilu. Between April and July of 2018, the Delaware District Court entered orders on stipulations between Onyx Therapeutics and each of Apotex, DRL, Sagent, Fresenius, Breckenridge, Aurobindo Pharma USA, Inc., Cipla and InnoPharma, respectively, that each defendant infringes the &#8217;042, &#8217;112, &#8217;125, &#8217;126 and &#8217;127 Patents. Onyx Therapeutics provided those defendants, either through a stipulated order or other agreement, a covenant that it would not assert patent infringement of the &#8217;818,&#8217;704,&#8217;346 and &#8217;297 Patents against certain of the respective defendants&#8217; ANDA applications and products. In June 2018, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and MSN that MSN infringes the &#8217;112 Patent. In December 2018, Apotex, DRL, Fresenius, InnoPharma, Sagent, Breckenridge, Aurobindo Pharma USA, Inc. and Cipla amended their responses to the complaints to add the defense of unclean hands and to seek declarations of unenforceability of the asserted patents based on allegations of inequitable conduct. In January 2019, MSN amended its responses to the complaints to add the defense of unclean hands.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2019, Onyx Therapeutics filed a separate lawsuit in the Delaware District Court against Breckenridge for infringement of the &#8217;042, &#8217;112 and &#8217;125 Patents in connection with its ANDA that seeks approval to market generic versions of KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On March 4, 2019, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and Breckenridge, providing that Breckenridge infringes the asserted claims of the &#8217;042, &#8217;112 and &#8217;125 Patents, and consolidated this lawsuit against Breckenridge into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for all purposes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2019, the Delaware District Court commenced trial in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onyx Therapeutics, Inc. v. Cipla Limited, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. consolidated case. During trial, the Delaware District Court signed consent judgments filed by Onyx Therapeutics and each of Aurobindo Pharma USA, Inc., InnoPharma, Sagent, Apotex, Fresenius, DRL and Breckenridge, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties&#8217; claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the &#8217;042, &#8217;112 and &#8217;125 Patents by the manufacture, use, sale, offer to sell or importation into the United States of the applicable defendant&#8217;s carfilzomib product unless specifically authorized pursuant to the applicable confidential settlement agreement. During trial, the Delaware District Court also entered a consent judgment between Onyx Therapeutics and MSN, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties&#8217; claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the &#8217;112 Patent by the manufacture, use, sale, offer to sell or importation into the United States of MSN&#8217;s carfilzomib product unless specifically authorized pursuant to the confidential settlement agreement. On May 16, 2019, trial concluded between Onyx Therapeutics and the lone remaining defendant, Cipla. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020, consistent with its May 4, 2020 decision and order, the Delaware District Court entered final judgment in favor of Onyx Therapeutics and against Cipla on infringement, validity and enforceability of claims 23 and 24 of the &#8217;042 Patent, claim 1 of the &#8217;125 Patent and claim 31 of the &#8217;112 Patent. The Delaware District Court entered judgment in favor of Cipla and against Onyx Therapeutics on Cipla&#8217;s counterclaim for invalidity of claim 32 of the &#8217;112 Patent and ordered that the effective date of any final approval by the FDA of Cipla&#8217;s ANDA must be after expiration of the three asserted patents (the &#8217;042, &#8217;125 and &#8217;112 Patents) and any regulatory exclusivity to which Onyx Therapeutics may become entitled. The final judgment includes an injunction prohibiting Cipla from making, using, offering to sell, selling or importing into the United States Cipla&#8217;s carfilzomib product during the term of the three asserted patents. On May 29, 2020, Cipla filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). The Federal Circuit Court has set the hearing date on Cipla&#8217;s appeal for March 5, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC; Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited; Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc.; Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc., each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#8217;940 Patent), 7,208,516 (the &#8217;516 Patent), 7,427,638 (the &#8217;638 Patent), 7,659,302 (the &#8217;302 Patent), 7,893,101 (the &#8217;101 Patent), 8,455,536 (the &#8217;536 Patent), 8,802,717 (the &#8217;717 Patent), 9,018,243 (the &#8217;243 Patent) and 9,872,854 (the &#8217;854 Patent), which are listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of the defendants is seeking to market a generic version of Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before expiration of the asserted patents. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz Inc., Actavis, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 9,724,330 (the &#8217;330 Patent), which is listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN Laboratories Private Limited, Pharmascience, Prinston, Sandoz Inc., Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 10,092,541 (the &#8217;541 Patent), which is listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN Laboratories Private Limited and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#8217;940, &#8217;302, &#8217;536, &#8217;243 and &#8217;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus Pharmaceuticals (USA) Inc. in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#8217;283 Patent) and 8,629,173 (the &#8217;173 Patent), which are not listed in the Orange Book for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz Inc., Shilpa, Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Amgen&#8217;s acquisition of the patents-in-suit and the new drug application for Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;854 and &#8217;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz Inc. with respect to the &#8217;717, &#8217;516 and &#8217;854 Patents, leaving the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents asserted by Amgen against Sandoz Inc. in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#8217;s apremilast product during the term of the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#8217; apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal Pharmaceuticals LLC, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal Pharmaceuticals LLC&#8217;s apremilast product during the term of the &#8217;101, &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#8217;s apremilast product during the term of the &#8217;638, &#8217;101 and &#8217;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#8217; apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;536, &#8217;717, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial in the consolidated action against the remaining defendants is scheduled to commence on June 14, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(cinacalcet) ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2016, Amgen filed 14 separate lawsuits in the Delaware District Court for infringement of our U.S. Patent No. 9,375,405 (the &#8217;405 Patent) against a number of manufacturers of purported generic versions of our Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. In February 2017, the Delaware District Court consolidated these 14 lawsuits into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2017, Amgen filed an additional lawsuit in the Delaware District Court for infringement of the &#8217;405 Patent which was consolidated into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. in August 2017. The &#8217;405 Patent is entitled &#8220;Rapid Dissolution Formulation of a Calcium Receptor-Active Compound&#8221; and expires in 2026. All defendants responding to the complaint denied infringement and sought judgment that the &#8217;405 Patent is invalid and/or not infringed.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between September and November of 2017, Amgen filed, and the Delaware District Court signed, stipulated dismissals of the lawsuit against Micro Labs Ltd. and Micro Labs USA, Inc., and the lawsuit against Apotex, as well as consent judgments filed by Amgen and each of (1) Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, Sun); (2) Ajanta Pharma Limited and Ajanta Pharma USA, Inc.; (3) Hetero USA Inc., Hetero Labs Ltd. and Hetero Labs Ltd. Unit V; and (4) Breckenridge. Each consent judgment stipulated to an entry of judgment of infringement and validity of the &#8217;405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the respective defendant&#8217;s cinacalcet product during the term of the &#8217;405 Patent, unless specifically authorized pursuant to the confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Delaware District Court commenced trial on the infringement claims and defenses in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated lawsuit against the defendants that remained in the lawsuit, collectively consisting of (1) Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson); (2) Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); (3) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus); and (4) Piramal Healthcare UK Limited (Piramal). Just prior to trial, the Delaware District Court signed consent judgments filed by Amgen and each of Cipla, and Strides Pharma Global Pte Limited and Strides Pharma, Inc. (collectively, Strides), and a consent judgment filed by Amgen and Aurobindo. In each consent judgment, the parties stipulated to an entry of judgment of infringement and validity of the &#8217;405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the applicable defendant&#8217;s cinacalcet product during the term of the &#8217;405 Patent, unless specifically authorized pursuant to the applicable confidential settlement agreement. Just prior to trial, the Delaware District Court also entered orders dismissing each of DRL and Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan), on stipulations between Amgen and such parties, respectively, subject to the terms of confidential settlement agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Delaware District Court issued a trial order finding on the infringement claims and defenses in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Aurobindo Pharma Ltd. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated lawsuit that Zydus infringes the &#8217;405 Patent and that Amneal, Piramal and Watson do not infringe the &#8217;405 Patent. In August 2018, the Delaware District Court issued an order dismissing, without prejudice, the invalidity counterclaims of Amneal, Piramal and Watson and entered judgment of noninfringement of the &#8217;405 Patent in favor of Amneal, Piramal and Watson. In September 2018, Amgen filed a notice of appeal to the Federal Circuit Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Delaware District Court dismissed, without prejudice, the invalidity counterclaims of Zydus and entered judgment of infringement of the &#8217;405 Patent by Zydus in favor of Amgen, including an order that the effective date of the FDA approval of Zydus&#8217; generic version of Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be no earlier than the expiry date of our &#8217;405 Patent. Also in October 2018, Zydus filed a notice of appeal to the Federal Circuit Court, and the Federal Circuit Court consolidated the appeals of Zydus and Amgen.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the FDA approved Watson&#8217;s generic version of Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Watson&#8217;s parent company, Teva Pharmaceutical Industries Ltd. (Teva), began selling its product at-risk notwithstanding that the appeals were pending at the Federal Circuit Court. On January 2, 2019, Amgen, Watson and Teva entered into a settlement agreement in which Teva agreed to stop selling its generic product until the mid-year 2021 (or earlier under certain circumstances) and to pay Amgen an undisclosed amount. On January 9, 2019, Watson and Amgen filed a motion asking the Delaware District Court to vacate its final judgment of noninfringement as to Watson and to enter a proposed consent judgment of infringement and validity of the &#8217;405 Patent and an injunction prohibiting the making, having made, using, selling, offering to sell, or distributing Watson&#8217;s cinacalcet product in the United States or importing Watson&#8217;s cinacalcet product into the United States, consistent with the confidential settlement agreement. On January 11, 2019, the Federal Circuit Court stayed the pending appeal by Amgen of the judgment of noninfringement as to Watson in order for the Delaware District Court to rule on the motion of Watson and Amgen. On March 26, 2019, the Delaware District Court denied the joint motion for indicative ruling of Watson and Amgen. On April 10, 2019, Amgen filed an appeal to the Federal Circuit Court and the Federal Circuit Court lifted the stay of Amgen&#8217;s appeal of the judgment of noninfringement as to Watson and consolidated it with Amgen&#8217;s appeal of the Delaware District Court&#8217;s denial of the joint motion for indicative ruling. On September 13, 2019, the Federal Circuit Court denied Amgen&#8217;s motion and lifted the stay of the briefing schedule which had been stayed pending disposition of Amgen&#8217;s motion to vacate. On July 9, 2020, the Federal Circuit Court granted a motion filed by Amgen and Watson to dismiss Amgen&#8217;s appeals of the Delaware District Court&#8217;s judgment of noninfringement as to Watson and denial of the joint motion for indicative ruling.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2019, Amgen filed an emergency motion for an injunction pending appeal, seeking an order from the Delaware District Court enjoining defendant Piramal from making, using, selling, offering for sale or importing its generic cinacalcet product. Amgen&#8217;s motion follows an announcement that Slate Run Pharmaceuticals LLC (Slate Run), in partnership with Piramal, had begun selling Piramal&#8217;s generic cinacalcet product at-risk notwithstanding the appeals pending at the Federal Circuit Court. On April 15, 2019, the Delaware District Court signed an order enjoining Piramal and Slate Run from selling their generic cinacalcet product until certain events occur related to a decision by the Federal Circuit Court on the parties&#8217; appeal. The order has no effect on the product that Piramal and Slate Run had already sold to third parties. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2020, the Federal Circuit Court issued an opinion affirming the judgment of noninfringement with respect to Piramal, affirming the judgment of infringement with respect to Zydus and vacating and remanding to the Delaware District Court for further consideration the judgment of noninfringement with respect to Amneal. On April 22, 2020, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court. On September 8, 2020, the Delaware District Court entered judgment of validity and infringement of the &#8217;405 Patent in the lawsuit filed against Amneal and, except to the extent specifically authorized in a confidential settlement agreement, enjoined Amneal from infringing the &#8217;405 Patent by making, using, selling, offering to sell or importing Amneal&#8217;s cinacalcet product during the term of the patent. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A hearing before the Delaware District Court on the request of Piramal to recover damages for being enjoined during the pendency of Amgen&#8217;s appeal has been rescheduled for March 24, 2021. On October 14, 2020, the Delaware District Court issued an order permitting Slate Run, Piramal&#8217;s business partner, to intervene in the pending action. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunex Corporation, et al. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (collectively, Sandoz). This lawsuit stems from Sandoz&#8217;s submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#8217;s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182 (the &#8217;182 Patent), 8,163,522 (the &#8217;522 Patent), 7,915,225 (the &#8217;225 Patent), 8,119,605 (the &#8217;605 Patent) and 8,722,631 (the &#8217;631 Patent). By their complaint, Amgen and Roche seek an injunction to prohibit Sandoz from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. All Sandoz defendants responded by denying infringement and/or asserting that the patents at issue are invalid. In August 2016, and subject to the terms of a confidential stipulation, the New Jersey District Court entered a preliminary injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz&#8217;s etanercept product. Sandoz&#8217;s Erelzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to ENBREL, was approved by the FDA in August 2016.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the New Jersey District Court entered an order that the making, using, offering to sell or selling in the United States or the importation into the United States by Sandoz of Sandoz&#8217;s biosimilar etanercept product infringes the &#8217;182 and &#8217;522 Patents and held a bench trial, focusing on Sandoz&#8217;s challenges to the validity of these patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2019, the New Jersey District Court issued its decision upholding the validity of the &#8217;182 and &#8217;522 Patents. On October 8, 2019, by stipulation of Amgen and Sandoz, the New Jersey District Court entered final judgment and a permanent injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz&#8217;s etanercept product, and, on the same day, Sandoz appealed the final judgment to the Federal Circuit Court. Following a motion by Sandoz, the Federal Circuit Court ordered an expedited briefing schedule for the appeal.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2020, the Federal Circuit Court heard oral argument on the appeal. On July 1, 2020, the Federal Circuit Court affirmed the judgment of the New Jersey District Court upholding the validity of the &#8217;182 and &#8217;522 Patents. On September 29, 2020, the Federal Circuit Court denied the petition for rehearing of Sandoz filed on July 31, 2020. On January 29, 2021, Sandoz filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s affirmance of the validity of the &#8217;182 and &#8217;522 Patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Roche, filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis&#8217; submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#8217;s ENBREL. Amgen and Roche have asserted infringement of five patents: the &#8217;182, &#8217;522, &#8217;225, &#8217;605 and &#8217;631 Patents. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis&#8217; etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court&#8217;s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Amgen initiated a series of lawsuits that were consolidated by the Delaware District Court in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#8217;165 Patent); 8,859,741 (the &#8217;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#8217;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#8217;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#8217;s infringement of Amgen&#8217;s patents is willful.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringe certain of Amgen&#8217;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#8217;s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#8217;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#8217;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron&#8217;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s conclusion that the judgment affirming the validity of Amgen&#8217;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#8217;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#8217;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#8217;s claim of willful infringement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, a jury of the Delaware District Court unanimously upheld the validity of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. The jury also found that claims 7 and 15 of the &#8217;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse judgment as a matter of law or for a new trial with respect to claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent, and Amgen filed a motion for a permanent injunction. On June 6, 13 and 21, 2019, the Delaware District Court held evidentiary hearings on Amgen&#8217;s motion for a permanent injunction against PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron&#8217;s request for a new trial and their request to reverse the jury verdict that the &#8217;165 Patent and the &#8217;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court. On December 9, 2020, the Federal Circuit Court heard oral argument on the appeal.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in the United Kingdom, Germany, France, the Netherlands, Italy, Spain and Japan. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#8217;s patent, and each of Eli Lilly and Company, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#8217;s patent. In November 2018, the EPO confirmed the validity of Amgen&#8217;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but ruled that broader claims encompassing PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were invalid. As a result of the TBA&#8217;s decision, national litigations regarding PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe are in the process of being resolved. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#8217;s appeals making final the Japanese High Court&#8217;s decisions that PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes Amgen&#8217;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#8217;s Japanese patents that were previously held infringed by PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and valid over challenges filed by Sanofi K.K. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (filgrastim)/Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Pfizer Inc. et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Pfizer Inc. and Hospira Inc. (collectively, Pfizer). This lawsuit stems from Pfizer&#8217;s submission of an application for FDA licensure of a filgrastim product as biosimilar to Amgen&#8217;s NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen has asserted infringement of U.S. Patent No. 9,643,997 (the &#8217;997 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#8217;997 Patent. In July 2018, the FDA approved Pfizer&#8217;s NIVESTYM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar to NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was subsequently launched in October 2018. In August 2018, Pfizer answered the complaint and counterclaimed seeking a declaration that Pfizer does not infringe Amgen&#8217;s &#8217;997 Patent and that the patent is invalid. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, Amgen filed an amended complaint against Pfizer in the Delaware District Court narrowing the patent claims at issue in the infringement dispute and adding a request for damages. On April 11, 2019, Pfizer answered Amgen&#8217;s amended complaint including counterclaims seeking declaratory judgments of noninfringement and invalidity. On February 18, 2020, the Delaware District Court entered an amended scheduling order moving the trial on the infringement of our &#8217;997 Patent to May 17, 2021, to enable Amgen to seek additional discovery into Pfizer&#8217;s invalidity defenses. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, Amgen filed a separate lawsuit in the Delaware District Court against Pfizer for infringement of U.S. Patent No. 10,577,392 (the &#8217;392 Patent) and seeks, among other remedies, damages and injunctive relief to prohibit Pfizer from infringing the &#8217;392 Patent by the manufacture, import and sale of Pfizer&#8217;s NIVESTYM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On January 7, 2021, the Delaware District Court granted Pfizer&#8217;s request to stay the patent infringement lawsuit on the &#8217;392 Patent until the co-pending patent infringement lawsuit on the &#8217;997 Patent is resolved.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Hospira Inc. et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Pfizer. This lawsuit stems from Pfizer&#8217;s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen&#8217;s Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the &#8217;707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#8217;707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the &#8217;707 Patent. In June 2020, the FDA approved Pfizer&#8217;s NYVEPRIA&#8482;, a biosimilar to Amgen&#8217;s Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Trial and Appeal Board (PTAB) Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lupin PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, Lupin Limited (Lupin) filed a petition to institute inter parties review (IPR) proceeding at the U.S. Patent and Trademark Office (USPTO) of U.S. Patent No. 9,856,287 (the &#8217;287 Patent) challenging claims of the &#8217;287 Patent as unpatentable. Amgen&#8217; s preliminary response is due on April 14, 2021 and the PTAB will then have no more than three months to decide whether to institute a proceeding.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Apotex PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the PTAB of the USPTO granted Apotex&#8217;s petition to institute IPR proceeding of U.S. Patent No. 8,952,138 (the &#8217;138 Patent), challenging claims of the &#8217;138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the &#8217;138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2019, the PTAB issued a decision denying Apotex&#8217;s request for rehearing on the PTAB&#8217;s finding and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">sua sponte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amending the final decision with a finding that the one remaining claim in Amgen&#8217;s &#8217;138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court&#8217;s decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc. v. Smith &amp; Nephew, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., 941 F.3d 1320 (Fed. Cir. 2019). </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the &#8217;138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the &#8217;138 Patent, for proceedings consistent with its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex Inc. v. Smith &amp; Nephew, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 941 F.3d 1320 (Fed. Cir. 2019), requesting that such remanded cases be held pending the U.S. Supreme Court&#8217;s disposition of the petition for writ of certiorari in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Arthrex, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government&#8217;s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breach of Contract Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG v. Amgen Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis Pharma AG (Novartis) seeking a declaratory judgment that Novartis materially breached two collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to Novartis&#8217; affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and entrant in the calcitonin gene-related peptide (CGRP)-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis&#8217; complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis&#8217; first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Amgen&#8217;s second amended counterclaims. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, the New York Southern District Court entered an order granting Novartis&#8217; motion for judgment on the pleadings that Novartis did not breach the 2017 Agreement, and denying Amgen&#8217;s motions for judgment on the pleadings seeking dismissal of Novartis&#8217; amended complaint that Novartis did not breach the 2015 Agreement or the 2017 Agreement, and Novartis timely cured any breach. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the June 9, 2020 order, which was denied on September 14, 2020. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.46pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Class Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. Two of those actions were brought in the Delaware District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 21, 2019) (Local 1500) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cesar Castillo, Inc. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and alleges that the plaintiffs have overpaid for Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of Amgen&#8217;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson and Teva of the parties&#8217; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#8217; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla Ltd. v. Amgen Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated and designated as a MDL in the Delaware District Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#8217; consolidated class action complaint and the indirect purchaser end payor plaintiffs&#8217; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#8217;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Delaware District Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#8217;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#8217; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#8217;s recommendation in part and denied it in part, denying Amgen&#8217;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#8217;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#8217; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#8217;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Biosimilar Antitrust Class Actions </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March to May 2019, twelve purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). The cases are captioned: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 18, 2019) (Local 1500); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 20, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mayor and City Council of Baltimore v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 22, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pipe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trades Services MN Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">St. Paul Electrical Workers&#8217; Health Plan v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C and 137R v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 1, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 9, 2019) (Law Enforcement); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 16, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sheet Metal Workers&#8217; Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 19, 2019) (Sheet Metal Workers&#8217;); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Locals 302 &amp; 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 25, 2019) (Construction Industry); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Louisiana Health Service &amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 30, 2019) (Louisiana Health); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (May 10, 2019) (Cleveland Bakers) (collectively, Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and biosimilars of Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including by creating an allegedly unlawful so-called patent thicket around Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the Local 1500, Sheet Metal Workers&#8217; and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilars, including Bioepis, Mylan, Sandoz, Inc., Fresenius Kabi USA, LLC, Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whereby Amgen and the other defendants that have developed Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(adalimumab), its Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biosimilar in that market for five months, beginning in January 2023. In each of the Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney&#8217;s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Defendants&#8217; responses to the first six complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the twelve purported class action cases for pre-trial purposes. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz, Inc. and Fresenius Kabi USA LLC. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs&#8217; allegations to state any claim for relief under the law. On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support of the motion to dismiss. On June 8, 2020, the Illinois Northern District Court issued an order granting the motion by the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the Federal Trade Commission and one on behalf of 20 states, each filed on October 13, 2020. On December 21, 2020, the defendants-appellees filed their opposition brief. Defendants-appellees amicus briefs, including one by the Department of Justice, were filed on December 28, 2020. The plaintiffs-appellants&#8217; reply brief was filed on February 1, 2021, and oral argument has been scheduled for February 25, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments &#8211; U.S. repatriation tax</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2020 (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595793864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly financial data (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly financial data (unaudited)</a></td>
<td class="text">Quarterly financial data (unaudited)<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s unaudited financial data on a quarterly basis. The sum of the quarterly earnings per-share amounts may not equal the amount reported for the full year because per-share amounts are computed independently for each quarter and for the full year based on respective weighted-average shares outstanding and dilutive securities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly financial data is summarized as follows (in millions, except per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Quarters ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit from product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 Quarters ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit from product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602587064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at beginning<br/>of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>charged&#160;to<br/>costs and<br/>expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end<br/>of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600617096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NatureOfOperationsPolicyTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues and Arrangements with multiple performance obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative (SG&amp;A) expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the research and development (R&amp;D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, general and administrative costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of new lease standard</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div>We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&amp;D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Interest-bearing securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&amp;D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars using average exchange rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity method investments</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Other recently adopted pronouncement and Other recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets are now presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the former other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand on the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impact that both standards will have on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808605920184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated cost (consideration transferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock', window );">Aggregate acquisition date consideration to acquire an entity</a></td>
<td class="text">The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen&#8217;s preacquisition investment consisted of the following (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash paid to Kirin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on settlement of preexisting relationship</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred to acquire K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Amgen&#8217;s investment in K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate acquisition date consideration to acquire an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601141880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue by product and by geographic area</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(etanercept)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(pegfilgrastim)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(darbepoetin alfa)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(carfilzomib)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,747&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was acquired on November 21, 2019.</span></div>(2)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenues earned from major customers</a></td>
<td class="text">Certain information with respect to these customers was as follows (dollar amounts in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595917160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock', window );">Components of stock-based compensation expense recognized in the Consolidated Statements of Income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSUs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.37&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock', window );">Weighted average assumptions used and the resulting weighted average grant date fair value of performance units</a></td>
<td class="text">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601763352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income before income tax, domestic and foreign</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) provision:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,784)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico Excise Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act, net impact on intercompany sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595788648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation for basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596150408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock', window );">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair values of available-for-sale interest-bearing security investments by contractual maturity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual maturities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through three years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after three years through five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594739688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599865128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Property, plant and equipment by geographic information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594452440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition from acquisitions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of identifiable intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,632)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596104648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary information, components of lease costs, cash and noncash information on leases and other lease information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_020e365c-0c24-462f-a58e-45732bd5286e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzUtMC0xLTEtMTc3MTk_85176805-ec7e-4393-a056-23747195e988">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_5b6bc1e8-b8aa-40fc-a434-17e9612b1d61"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY4ZDA3NDBiNDNkMTQ4YTViYTY3ZTRkZDViMzhjZTQ2L3NlYzpmOGQwNzQwYjQzZDE0OGE1YmE2N2U0ZGQ1YjM4Y2U0Nl8yNDcvZnJhZzpjOTAyMzU0MWRjZjY0MmU0OTFhNDNhMjU3NWVkNzFlMi90YWJsZTo4NzhkZjhkOGVjYzY0ZTI2YWExYWU4MjcwYmJkY2Y3Yy90YWJsZXJhbmdlOjg3OGRmOGQ4ZWNjNjRlMjZhYTFhZTgyNzBiYmRjZjdjXzYtMC0xLTEtMTc3MjE_b1b11a20-6382-449e-b05b-cc5eabdc478c">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020, were as follows (in millions): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div>(1)&#160;&#160;&#160;&#160;Includes future rental commitments for abandoned leases of $133&#160;million. We expect to receive total future rental income of $107&#160;million related to noncancelable subleases for abandoned facilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595847832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603030184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Carrying values and the fixed contractual coupon rates of long-term borrowings</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% notes due 2020 (4.50% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.125% notes due 2020 (2.125% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating Rate Notes due 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2020 (2.20% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45% notes due 2020 (3.45% 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10% notes due 2021 (4.10% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85% notes due 2021 (1.85% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% notes due 2021 (3.875% 2021 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% &#8364;1,250 million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of interest rate derivatives</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45% 2020 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10% 2021 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% 2021 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2022 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2024 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% 2025 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% 2026 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% 2051 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Excludes an additional 1.5% of interest for the difference between the coupon rate paid to noteholders and the fixed rate received under the interest rate swap contracts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock', window );">Schedule of Long-term Debt Instruments Exchanged</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently cancelled in connection with the Exchange Offer (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% 2038 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% 2039 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% 2040 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% 2041 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% 2042 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% 2043 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate contractual maturities of long-term debt obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2020, are as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Long-term Debt Instruments Exchanged [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808715119992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_StockRepurchaseProgramTableTextBlock', window );">Summary of activity under our stock repurchase program</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,855&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Total shares do not add due to rounding.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of accumulated other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of change in accounting principle, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassifications out of accumulated other comprehensive income</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockRepurchaseProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockRepurchaseProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595998824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2019, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential-mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601849784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock', window );">Schedule of notional amounts and interest rates for cross-currency swaps</a></td>
<td class="text">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2020, were as follows (notional amounts in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% 2022 euro Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses and gains recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized (losses) gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives in fair value hedging relationships</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of December 31, 2020. Long-term debt includes $525 million and $136 million of carrying value with discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020. Long-term debt includes $425 million and $36 million of hedging adjustments on discontinued hedging relationships as of December 31, 2020, and December 31, 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Summary of amounts of income and expense line items</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest and other income (expense), net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div>(1)&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair values of derivatives included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595803800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfU.S.RepatriationTaxCommitments', window );">U.S. repatriation tax commitments</a></td>
<td class="text">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2020 (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfU.S.RepatriationTaxCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfU.S.RepatriationTaxCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600952968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly financial data (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly financial data (unaudited)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly financial data is summarized as follows (in millions, except per-share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Quarters ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit from product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 Quarters ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit from product sales</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601161544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate', window );">Change in estimate of sales deductions for prior period sales as a pct of total sales deductions (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_SalesReturnProvisionsAsPercentageOfProductSales', window );">Sales return provisions as a percentage of gross product sales (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, Right-of-use asset</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenuePaymentArrangementTerm', window );">Revenue payment term</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenuePaymentArrangementTerm', window );">Revenue payment term</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenuePaymentArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Payment Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenuePaymentArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Deductions On Prior Period Sales Due To Change In Estimate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_SalesReturnProvisionsAsPercentageOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Return Provisions As Percentage Of Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_SalesReturnProvisionsAsPercentageOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808693618808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>market</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
<td class="nump">$ 14,703<span></span>
</td>
<td class="nump">$ 14,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate', window );">Estimated blended statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_KirinAmgenInc.KAMember', window );">Kirin-Amgen, Inc. (K-A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ApprovedMarkets', window );">Approved markets | market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Adjustments to carrying value of intangible assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities', window );">Adjustments to deferred tax liability</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits', window );">Adjustments to deferred credit</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember', window );">Nuevolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Fair value of liabilities assumed, deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Fair value of assets acquired and liabilities assumed, net other assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember', window );">Nuevolution | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember', window );">Kirin-Amgen, Inc. (K-A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Ownership interest in acquiree prior to acquisition (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss', window );">Net gain on remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Estimated fair values of contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Fair value of assets acquired, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Fair value of liabilities assumed, deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Fair value of assets acquired and liabilities assumed, net other assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember', window );">Kirin-Amgen, Inc. (K-A) | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Fair value of assets acquired, licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember', window );">Assembled Workforce [Member] | Otezla | Marketing-Related Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AssetsByDescriptionAxis=us-gaap_InventoriesMember', window );">Inventories [Member] | Otezla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife', window );">Acquired assets, weighted useful life</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Assets, Weighted Average Useful Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ApprovedMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Approved Markets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ApprovedMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of net gain (loss) recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_KirinAmgenInc.KAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_KirinAmgenInc.KAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AssetsByDescriptionAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AssetsByDescriptionAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600513672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Otezla (Details) - Otezla<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 21, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash purchase price</a></td>
<td class="nump">$ 13,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Transactioncostsassetacquisition', window );">Transaction costs</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Businessassetacquisitionconsiderationtransferred', window );">Accumulated cost (consideration transferred)</a></td>
<td class="nump">13,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionInventoryacquired', window );">Inventory</a></td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities', window );">Deferred tax liability, net</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionDeferredCredit', window );">Deferred credit</a></td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther', window );">Other liabilities, net</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet', window );">Total assets acquired, net</a></td>
<td class="nump">13,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired', window );">Business acquired asset acquisition, Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 13,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember', window );">Marketing-Related Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired', window );">Business acquired asset acquisition, Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember', window );">Marketing-Related Rights | Assembled Workforce [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionDeferredCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Deferred Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionDeferredCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Deferred Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Finite-lived intangible assets acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionInventoryacquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Inventory acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionInventoryacquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Noncurrent Liabilities Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Businessassetacquisitionconsiderationtransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business asset acquisition, consideration transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Businessassetacquisitionconsiderationtransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Transactioncostsassetacquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs, asset acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Transactioncostsassetacquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808609281816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Aggregate Consideration Paid (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember', window );">Nuevolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred to acquire K-A</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember', window );">Kirin-Amgen, Inc. (K-A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid to Kirin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Fair value of contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss', window );">Loss on settlement of preexisting relationship</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred to acquire K-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of Amgen&#8217;s investment in K-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total acquisition date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember', window );">R &amp; D Technology rights | Nuevolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_KirinAmgenInc.KAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603982328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue', window );">Number of major customers (as defined) accounting for more than 10% of total revenue | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables', window );">Major customers (as defined) accounting for more than 10% of gross trade receivables | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers', window );">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers', window );">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation', window );">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,496<span></span>
</td>
<td class="nump">$ 17,224<span></span>
</td>
<td class="nump">18,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
<td class="nump">6,138<span></span>
</td>
<td class="nump">5,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 6,334<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 5,908<span></span>
</td>
<td class="nump">$ 5,894<span></span>
</td>
<td class="nump">$ 5,881<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="nump">$ 5,574<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
<td class="nump">22,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">17,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">5,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,996<span></span>
</td>
<td class="nump">5,226<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,855<span></span>
</td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">4,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="nump">2,814<span></span>
</td>
<td class="nump">3,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,935<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,574<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">5,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">3,511<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,268<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerOneMember', window );">AmerisourceBergen Corporation [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,743<span></span>
</td>
<td class="nump">12,301<span></span>
</td>
<td class="nump">12,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember', window );">McKesson Corporation [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,779<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember', window );">Cardinal Health, Inc. [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
<td class="nump">$ 6,538<span></span>
</td>
<td class="nump">$ 7,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Major customers (as defined) accounting for more than 10% of gross trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers (as defined) accounting for more than 10% of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_ProliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_ProliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_XgevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_XgevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_AranespMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_AranespMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_KyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_KyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602970920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Customer Concentration, Product Sales (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue', window );">Number of major customers (as defined) accounting for more than 10% of total revenue | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables', window );">Major customers (as defined) accounting for more than 10% of gross trade receivables | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 6,334<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 5,908<span></span>
</td>
<td class="nump">$ 5,894<span></span>
</td>
<td class="nump">$ 5,881<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="nump">$ 5,574<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">$ 22,204<span></span>
</td>
<td class="nump">$ 22,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | AmerisourceBergen Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,743<span></span>
</td>
<td class="nump">$ 12,301<span></span>
</td>
<td class="nump">$ 12,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,779<span></span>
</td>
<td class="nump">$ 11,795<span></span>
</td>
<td class="nump">$ 11,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Cardinal Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
<td class="nump">$ 6,538<span></span>
</td>
<td class="nump">$ 7,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Major customers (as defined) accounting for more than 10% of gross trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers (as defined) accounting for more than 10% of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfGrossRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross product sales to major customer (as defined) as a percentage of total gross revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfGrossRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600786920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Textual) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted', window );">Amount by which the pool of available shares will be reduced for each stock option granted</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances', window );">The amount of common stock available under the plan for future grants and/or issuances (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of vesting of restricted stock units and stock options</a></td>
<td class="text">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to nonvested awards</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period over which the grants of equity instruments vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned', window );">Number of common shares issued for each performance unit earned</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted', window );">The number of shares by which the pool of available shares will be reduced for other types of awards granted</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards', window );">Number of shares added back for tax withholding on full value awards</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 235.63<span></span>
</td>
<td class="nump">$ 182.12<span></span>
</td>
<td class="nump">$ 179.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of units that vested during the year</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 198.11<span></span>
</td>
<td class="nump">$ 174.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units, forfeited (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in usd per share)</a></td>
<td class="nump">$ 190.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of stock options from date of grant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the year</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Actual tax benefits realized from tax deductions from option exercises</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember', window );">Performance units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted', window );">The number of shares by which the pool of available shares will be reduced for other types of awards granted</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards', window );">Number of shares added back for tax withholding on full value awards</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 249.07<span></span>
</td>
<td class="nump">$ 188.40<span></span>
</td>
<td class="nump">$ 189.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of units that vested during the year</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to nonvested awards</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 207.52<span></span>
</td>
<td class="nump">$ 185.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units, forfeited (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in usd per share)</a></td>
<td class="nump">$ 199.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock available under the plan for future grants and/or issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued for each performance unit earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the pool of available shares will be reduced for each stock option granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the pool of available shares will be reduced for other types of awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Added Back for Tax Withholding on Full Value Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603149992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Components of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit from stock-based compensation expense</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_StockBasedCompensationExpenseNetOfTax', window );">Total stock-based compensation expense, net of tax</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember', window );">Performance units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total stock-based compensation expense, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603384760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Summary of RSUs) (Details) - RSUs [Member] - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance nonvested at beginning of period (in shares)</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance nonvested at end of period (in shares)</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant&#160;date fair&#160;value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance nonvested at beginning of period (in usd per share)</a></td>
<td class="nump">$ 174.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">235.63<span></span>
</td>
<td class="nump">$ 182.12<span></span>
</td>
<td class="nump">$ 179.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">167.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">190.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance nonvested at end of period (in usd per share)</a></td>
<td class="nump">$ 198.11<span></span>
</td>
<td class="nump">$ 174.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808593448296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CommonStockFairValue', window );">Closing price of our common stock on grant date (in usd per share)</a></td>
<td class="nump">$ 236.36<span></span>
</td>
<td class="nump">$ 177.31<span></span>
</td>
<td class="nump">$ 177.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">28.10%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">$ 42.34<span></span>
</td>
<td class="nump">$ 30.47<span></span>
</td>
<td class="nump">$ 34.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600639864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Summary of Stock Options) (Details) - Stock options [Member]<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance unexercised at beginning of period (in shares) | shares</a></td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/forfeited (in shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance unexercised at end of period (in shares) | shares</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest (in shares) | shares</a></td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise&#160;price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance unexercised at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 157.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">236.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">117.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">178.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance unexercised at end of period (in shares) | $ / shares</a></td>
<td class="nump">179.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested or expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">178.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 150.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock options information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years), unexercised</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (years), vested or expected to vest</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (years), exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, unexercised | $</a></td>
<td class="nump">$ 243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested or expected to vest | $</a></td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599459320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Weighted-average Assumptions) (Details) - Performance units [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CommonStockFairValue', window );">Closing price of our common stock on grant date (in usd per share)</a></td>
<td class="nump">$ 236.36<span></span>
</td>
<td class="nump">$ 177.31<span></span>
</td>
<td class="nump">$ 177.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">27.50%<span></span>
</td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">23.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of unit (in usd per share)</a></td>
<td class="nump">$ 249.07<span></span>
</td>
<td class="nump">$ 188.40<span></span>
</td>
<td class="nump">$ 189.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595841208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined contribution plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense attributed to Retirement and Savings Plan</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602352504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Income Before Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 8,133<span></span>
</td>
<td class="nump">$ 9,138<span></span>
</td>
<td class="nump">$ 9,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">4,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="nump">$ 4,767<span></span>
</td>
<td class="nump">$ 4,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602606184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Provision for Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 1,284<span></span>
</td>
<td class="nump">$ 1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred (benefit) provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit</a></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
<td class="nump">$ 1,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808598605400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes (Components of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards', window );">NOL and credit carryforwards</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses capitalized for tax</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangible assets</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(1,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Debt</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Deferred Tax Liabilities, Property, Plant and Equipment</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(1,522)<span></span>
</td>
<td class="num">(1,784)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred income taxes, net</a></td>
<td class="num">$ (201)<span></span>
</td>
<td class="num">$ (514)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602539416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Textual) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to unrecognized tax benefits recognized in income tax provision</a></td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="nump">$ 198,000,000<span></span>
</td>
<td class="nump">$ 137,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties associated with unrecognized tax benefits</a></td>
<td class="nump">783,000,000<span></span>
</td>
<td class="nump">667,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">143,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Operating Losses That Expire Between 2021 and 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expiration in tax years between 2023 and 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">681,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">585,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">167,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">754,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs with no valuation allowance and no expiration</a></td>
<td class="nump">861,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member] | Operating Losses That Expire Between 2021 and 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2021And2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2021And2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_ExpirationInTaxYearsBetween2023And2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_ExpirationInTaxYearsBetween2023And2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2021And2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2021And2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600090456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 3,287<span></span>
</td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 2,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior years</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(68)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 3,287<span></span>
</td>
<td class="nump">$ 3,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601394712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Foreign-derived intangible income</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Credits, Puerto Rico Excise Tax</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent', window );">2017 Tax Act, net impact on intercompany sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent', window );">Interest on uncertain tax positions</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Credits, primarily federal R&amp;D</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Audit settlements</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Impact On Intercompany Sales, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602001176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Income (Numerator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="nump">$ 2,021<span></span>
</td>
<td class="nump">$ 1,803<span></span>
</td>
<td class="nump">$ 1,825<span></span>
</td>
<td class="nump">$ 1,703<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 2,179<span></span>
</td>
<td class="nump">$ 1,992<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares (Denominator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares for basic EPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares for diluted EPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (in usd per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
<td class="nump">$ 12.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (in usd per share)</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 3.57<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 12.88<span></span>
</td>
<td class="nump">$ 12.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601087656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Novartis AG (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember', window );">Collaborative Arrangement with Novartis AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment', window );">Potential future milestone payment</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember', window );">Collaborative Arrangement with Novartis AG [Member] | Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember', window );">Collaborative Arrangement with Novartis AG [Member] | Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Cost paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember', window );">Collaborative Arrangement with Novartis AG [Member] | Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties due</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Future Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601994936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 18,496<span></span>
</td>
<td class="nump">17,224<span></span>
</td>
<td class="nump">18,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member', window );">Collaborative Arrangement with Bayer [Member] | Nexavar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberofCountriesProductsisMarketedandSold', window );">Number of countries product is marketed and sold | country</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member', window );">Collaborative Arrangement with Bayer [Member] | Nexavar [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CollaborativeArrangementRoyaltyIncomePercentage', window );">Collaboration, royalty percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member', window );">Collaborative Arrangement with Bayer [Member] | Nexavar [Member] | NonUs,ExcludingJapan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CollaborativeArrangementRoyaltyIncomePercentage', window );">Collaboration, royalty percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member', window );">Collaborative Arrangement with Bayer [Member] | Nexavar [Member] | Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CollaborativeArrangementNetIncome', window );">Collaboration profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member', window );">Collaborative Arrangement with Bayer [Member] | Royalty [Member] | Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CollaborativeArrangementNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Net Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CollaborativeArrangementNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CollaborativeArrangementRoyaltyIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Royalty Income Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CollaborativeArrangementRoyaltyIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberofCountriesProductsisMarketedandSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Countries Product is Marketed and Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberofCountriesProductsisMarketedandSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NexavarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NexavarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amgn_NonUsExcludingJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amgn_NonUsExcludingJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=amgn_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=amgn_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601736904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - BeiGene (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | Other current assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RecoveryOfDirectCostsReceivable', window );">Recovery Of Direct Costs, Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RecoveryOfDirectCostsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery Of Direct Costs, Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RecoveryOfDirectCostsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601979608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 9,844,000,000<span></span>
</td>
<td class="nump">$ 8,206,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">9,845,000,000<span></span>
</td>
<td class="nump">8,234,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">129,000,000<span></span>
</td>
<td class="nump">359,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">4,948,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">4,948,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesFinancialMember', window );">Corporate debt securities - Financial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,108,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,121,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesIndustrialMember', window );">Corporate debt securities - Industrial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">824,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">834,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesOtherMember', window );">Corporate debt securities - Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">195,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">198,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">181,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">4,765,000,000<span></span>
</td>
<td class="nump">5,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">4,765,000,000<span></span>
</td>
<td class="nump">5,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">289,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 289,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesFinancialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesFinancialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesIndustrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesIndustrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601064088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Values by Classification (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets locations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 4,381<span></span>
</td>
<td class="nump">$ 2,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">9,845<span></span>
</td>
<td class="nump">8,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember', window );">Available-for-sale investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets locations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">5,464<span></span>
</td>
<td class="nump">5,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">4,381<span></span>
</td>
<td class="nump">2,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">$ 9,845<span></span>
</td>
<td class="nump">$ 8,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594587720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Available-for-sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Total realized gains</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Total realized losses</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601843512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Values by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 9,795<span></span>
</td>
<td class="nump">$ 5,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue', window );">Maturing after one year through three years</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue', window );">Maturing after three years through five years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Residential-mortgage-backed securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">$ 9,845<span></span>
</td>
<td class="nump">$ 8,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603091736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 477<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity Securities, FV-NI, Unrealized Gain (Loss)</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808609254424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Limited Partnership Investments (Details) - Limited Partnership [Member] - Fair Value Measured at Net Asset Value Per Share [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Investments</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AlternativeInvestmentNetGainLoss', window );">Alternative Investment, Net Gain (Loss)</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AlternativeInvestmentNetGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Net Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AlternativeInvestmentNetGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL6742756-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 35<br> -Paragraph 54B<br> -URI http://asc.fasb.org/extlink&amp;oid=117332851&amp;loc=SL7495116-110257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808607015016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - BeiGene (Details) - BeiGene - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValue', window );">Equity method investment, change in carrying value</a></td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValueOther', window );">Equity Method Investment, Change In Carrying Value, Other</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Company's share of profits (losses) of related party</a></td>
<td class="num">(229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Approximate carrying value of the company's equity method investment</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, change in carrying value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Change In Carrying Value, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606101656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 3,893<span></span>
</td>
<td class="nump">$ 3,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602272504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Schedule) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements</a></td>
<td class="nump">3,857<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing equipment</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LaboratoryEquipment', window );">Laboratory equipment</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FixedEquipment', window );">Fixed equipment</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">2,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized software</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Other</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">13,866<span></span>
</td>
<td class="nump">13,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(8,977)<span></span>
</td>
<td class="num">(8,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,889<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization charges associated with property, plant and equipment</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember', window );">Manufacturing equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember', window );">Manufacturing equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember', window );">Fixed equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FixedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FixedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of laboratory equipment, gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600948584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment (Geographic Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 4,889<span></span>
</td>
<td class="nump">$ 4,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,473<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PR', window );">Puerto Rico [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=amgn_RestOfWorldMember', window );">ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 1,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amgn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amgn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606037560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Goodwill Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 14,703<span></span>
</td>
<td class="nump">$ 14,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Addition from acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 14,689<span></span>
</td>
<td class="nump">$ 14,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603006184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Identifiable Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">$ 32,018<span></span>
</td>
<td class="nump">$ 31,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(15,461)<span></span>
</td>
<td class="num">(12,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">16,557<span></span>
</td>
<td class="nump">19,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsGross', window );">Identifiable intangible assets</a></td>
<td class="nump">32,048<span></span>
</td>
<td class="nump">32,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(15,461)<span></span>
</td>
<td class="num">(12,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, net</a></td>
<td class="nump">16,587<span></span>
</td>
<td class="nump">19,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">25,591<span></span>
</td>
<td class="nump">25,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(10,564)<span></span>
</td>
<td class="num">(8,322)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">15,027<span></span>
</td>
<td class="nump">17,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">3,743<span></span>
</td>
<td class="nump">3,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(2,791)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing-related rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">1,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember', window );">R&amp;D technology rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,065)<span></span>
</td>
<td class="num">(947)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601115944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization charges associated with finite-lived intangible assets</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Total estimated amortization of finite-lived intangible assets for 2021</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Total estimated amortization of finite-lived intangible assets for 2022</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Total estimated amortization of finite-lived intangible assets for 2023</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Total estimated amortization of finite-lived intangible assets for 2024</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Total estimated amortization of finite-lived intangible assets for 2025</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603316728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount', window );">Total undiscounted future lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease rent expense</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Leases not yet commenced lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Leases not yet commenced lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603031912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other assets</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595927976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total net lease costs</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601096824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember', window );">Abandoned Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases', window );">Future rental commitments for abandoned leases</a></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Expected total future rental income to be received</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596001096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash and Noncash Information of Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606114584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets and accrued liabilities - Schedule of Other Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Corporate partner receivables</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Tax receivables</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 2,079<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602700584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AccruedSalesDeductionsCurrent', window );">Sales deductions</a></td>
<td class="nump">$ 4,801<span></span>
</td>
<td class="nump">$ 3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AccruedSalesReturnReserveCurrent', window );">Sales returns reserve</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 10,141<span></span>
</td>
<td class="nump">$ 8,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedSalesDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedSalesDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedSalesReturnReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedSalesReturnReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808587171992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized bond discounts, premiums and issuance costs, net</a></td>
<td class="num">$ (1,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other Long-term Debt</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">32,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 32,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Floating Rate Notes Due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2027 (2.20% 2027 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2031 (2.45% 2031 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Three Point Three Seven Five Percent Notes Due 2050 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.77% notes due 2053 (2.77% 2053 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Other notes due 2097 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember', window );">Debt securities payable [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount', window );">Redemption period without payment of make whole amount</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember', window );">Debt securities payable [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount', window );">Redemption period without payment of make whole amount</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Period without Payment of Make Whole Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFiveNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFiveNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601988648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements (Debt Issuances) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_MaximumBorrowingCapacityUnderCommercialPaper', window );">Commercial paper, maximum borrowing capacity</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2027 (2.20% 2027 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2031 (2.45% 2031 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Three Point Three Seven Five Percent Notes Due 2050 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_MaximumBorrowingCapacityUnderCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Borrowing Capacity Under Commercial Paper Program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_MaximumBorrowingCapacityUnderCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602140184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Debt Repayments) (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 6,450<span></span>
</td>
<td class="nump">$ 4,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Make-whole payments recognized in interest expense</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Make-whole payments recognized in interest expense</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.70% notes due 2019 (5.70% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">&#8364; 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Floating Rate Notes Due 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.15% notes due 2018 (6.15% 2018 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.15%<span></span>
</td>
<td class="nump">6.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">&#8364; 550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Floating Rate Notes Due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenZeroPercentNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenZeroPercentNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointOneFivePercentNotesDue2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointOneFivePercentNotesDue2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808607368120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">$ 10,497<span></span>
</td>
<td class="nump">$ 9,150<span></span>
</td>
<td class="nump">$ 11,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember', window );">Interest Rate Swap, Two [Member] | Interest rate swap contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapThreeMember', window );">Interest Rate Swap, Three [Member] | Interest rate swap contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember', window );">4.663% notes due 2051 (4.663% 2051 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Ratedifferenceinaninterestrateswaprelationship', window );">Rate difference in an interest rate swap relationship</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.77% notes due 2053 (2.77% 2053 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtExchangeAdditionalCashConsideration', window );">Debt exchange additional cash consideration</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtExchangeAdditionalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt exchange additional cash consideration paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtExchangeAdditionalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Ratedifferenceinaninterestrateswaprelationship">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate difference in an interest rate swap relationship</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Ratedifferenceinaninterestrateswaprelationship</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603057272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Shelf Registration Statements and Other Facilities) (Details) - Line of credit [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks', window );">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LineOfCreditFacilityInitialCommitmentTerm', window );">Initial commitment term of each bank which is a party to the agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LineofCreditFacilityNumberOfRenewalOptions', window );">Number of additional term extension options | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm', window );">Additional period for extension of commitment term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Annual commitment fees for syndicated, unsecured, revolving credit agreement</a></td>
<td class="nump">0.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under syndicated, unsecured, revolving credit facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Extension of Commitment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineOfCreditFacilityExtensionOfCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineOfCreditFacilityInitialCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Initial Commitment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineOfCreditFacilityInitialCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineofCreditFacilityNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineofCreditFacilityNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808725947160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements (Contractual Maturities of Long-term Debt) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">4,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">24,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet', window );">Total</a></td>
<td class="nump">$ 33,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595971016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Interest Costs) (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid, net of interest rate and cross currency swaps</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602269576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Stock Repurchase Program) (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchases, Shares</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchases</a></td>
<td class="nump">$ 1,221,000,000<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="nump">$ 591,000,000<span></span>
</td>
<td class="nump">$ 933,000,000<span></span>
</td>
<td class="nump">$ 1,090,000,000<span></span>
</td>
<td class="nump">$ 1,170,000,000<span></span>
</td>
<td class="nump">$ 2,349,000,000<span></span>
</td>
<td class="nump">$ 3,031,000,000<span></span>
</td>
<td class="nump">$ 2,165,000,000<span></span>
</td>
<td class="nump">$ 1,713,000,000<span></span>
</td>
<td class="nump">$ 3,190,000,000<span></span>
</td>
<td class="nump">$ 10,787,000,000<span></span>
</td>
<td class="nump">$ 3,497,000,000<span></span>
</td>
<td class="nump">$ 7,640,000,000<span></span>
</td>
<td class="nump">$ 17,855,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, additional authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available for stock repurchases under a board approved stock repurchase plan</a></td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603100712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Dividends) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Dec. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid per share (in usd per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599912392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Components of AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">$ 9,673<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 25,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">9,409<span></span>
</td>
<td class="nump">9,673<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(718)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(709)<span></span>
</td>
<td class="num">(718)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized (losses) gains</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(263)<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized (losses) gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-for-sale securities [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax', window );">Other losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="num">(679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized (losses) gains</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="num">(534)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax', window );">Other losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">$ (985)<span></span>
</td>
<td class="num">$ (528)<span></span>
</td>
<td class="num">(769)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Adjustment, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603150280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax', window );">Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax', window );">Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="num">$ (55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808596497656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,133<span></span>
</td>
<td class="nump">9,138<span></span>
</td>
<td class="nump">9,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="num">(1,296)<span></span>
</td>
<td class="num">(1,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="nump">$ 2,021<span></span>
</td>
<td class="nump">$ 1,803<span></span>
</td>
<td class="nump">$ 1,825<span></span>
</td>
<td class="nump">$ 1,703<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 2,179<span></span>
</td>
<td class="nump">$ 1,992<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="nump">7,842<span></span>
</td>
<td class="nump">8,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,334<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 5,908<span></span>
</td>
<td class="nump">$ 5,894<span></span>
</td>
<td class="nump">$ 5,881<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="nump">$ 5,574<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
<td class="nump">22,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Foreign currency contract [Member] | Product sales [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Foreign currency contract [Member] | Cash flow hedge [Member] | Product sales [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cross-currency swap contract [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808601422072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity (Other) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808598460648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">$ 9,845<span></span>
</td>
<td class="nump">$ 8,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">10,671<span></span>
</td>
<td class="nump">9,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember', window );">Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">4,948<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesFinancialMember', window );">Corporate debt securities - Financial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesIndustrialMember', window );">Corporate debt securities - Industrial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesOtherMember', window );">Corporate debt securities - Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">4,765<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">10,320<span></span>
</td>
<td class="nump">5,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">4,948<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Financial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Industrial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Residential mortgage-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">4,765<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Financial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Industrial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Residential mortgage-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Financial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Industrial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Residential mortgage-backed securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeAssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeAssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments liabilities fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesFinancialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesFinancialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesIndustrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesIndustrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_CorporateDebtSecuritiesOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602580792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Length of time hedged in foreign currency contracts</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Aggregate fair value of long-term debt, including current portion</a></td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of long-term debt, including current portion</a></td>
<td class="nump">32,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other operating income (expense) [Member] | IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Approximate carrying value of the company's equity method investment</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808599653416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">$ 10,497<span></span>
</td>
<td class="nump">$ 9,150<span></span>
</td>
<td class="nump">$ 11,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">6,258<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember', window );">Foreign currency and cross currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</a></td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_InterestRateSwapAtThenCurrentInterestRatesMember', window );">Interest Rate Swap, At-Then Current Interest Rates [Member] | Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency forward contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency option contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities', window );">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap [Member] | Interest Rate Swap, Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign currency forward contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Two Point One Two Five Percent Euro Notes Due 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_InterestRateSwapAtThenCurrentInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_InterestRateSwapAtThenCurrentInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808693645384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member]<br> &#8364; in Millions, &#163; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">1.25% 2022 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,388<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Euro Member Countries, Euro [Member] | 1.25% 2022 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Euro Member Countries, Euro [Member] | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Switzerland, Francs [Member] | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United Kingdom, Pounds [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United Kingdom, Pounds [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars [Member] | 1.25% 2022 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars [Member] | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars [Member] | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808600651240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Total unrealized (losses) gains</a></td>
<td class="num">$ (61)<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Total unrealized (losses) gains</a></td>
<td class="num">(251)<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Total unrealized (losses) gains</a></td>
<td class="nump">190<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Forward interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Total unrealized (losses) gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558989&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606537672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">6,258<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hedged Liability, Discontinued Fair Value Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_HedgedLiabilityDiscontinuedFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808725937944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Summary of Income and Expense Line Items) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Gains (losses) on fair value hedging relationships, Hedged Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 6,334<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 5,908<span></span>
</td>
<td class="nump">$ 5,894<span></span>
</td>
<td class="nump">$ 5,881<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="nump">$ 5,574<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
<td class="nump">22,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602399192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Fair Value of Derivatives) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign currency contracts [Member] | Other current assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808595893288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details) - patent<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">19 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfAssertedPatents', window );">Number of asserted patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Onyx Therapeutics, Inc [Member] | KYPROLIS (carfilzomib) Patent Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfAssertedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Asserted Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfAssertedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_KYPROLIScarfilzomibPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_KYPROLIScarfilzomibPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594727912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Sandoz Patent Litigation) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>lawsuit</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_SandozIncMember', window );">Sandoz Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberofLawsuitsFiled', window );">Number of lawsuits filed</a></td>
<td class="nump">19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SandozIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SandozIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808605947080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Amneal Pharmaceuticals LLC Litigation) (Details) - Amneal Pharmaceuticals LLC<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>lawsuit</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberofLawsuitsFiled', window );">Number of lawsuits filed</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberOfLawsuitsConsolidated', window );">Number of lawsuits consolidated</a></td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberOfLawsuitsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Lawsuits Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberOfLawsuitsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_AmnealPharmaceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_AmnealPharmaceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808605896056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Immunex and Sandoz Litigation) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>affiliate</div>
</th>
<th class="th">
<div>Feb. 28, 2016 </div>
<div>patent </div>
<div>affiliate</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_ImmunexAndSandozMember', window );">Immunex/Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberofAffiliates', window );">Gain contingency, number of affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_ImmunexAndSamsungBioepisCoMember', window );">Immunex/Samsung Bioepis Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberofAffiliates', window );">Gain contingency, number of affiliates</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Affiliates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_ImmunexAndSandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_ImmunexAndSandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_ImmunexAndSamsungBioepisCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_ImmunexAndSamsungBioepisCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808603176712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Repatha Patent Litigation) (Details) - Sanofi/Regeneron Patent Litigation - patent<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2016</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LitigationSettlementLengthofTrial', window );">Length of trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberOfChallenges', window );">Number of challenges</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberOfChallenges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Challenges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberOfChallenges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LitigationSettlementLengthofTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Length of Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LitigationSettlementLengthofTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808606815512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>agreement</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>complaints</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>claim </div>
<div>lawsuit </div>
<div>plaintiffs</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 04, 2019 </div>
<div>claim</div>
</th>
<th class="th">
<div>May 20, 2019 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_NovartisBreachOfContractActionMember', window );">Novartis Breach Of Contract Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberOfAgreementsBreached', window );">Agreements breached | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember', window );">Sensipar Antitrust Class Actions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, number of lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LossContingencyNumberOfLawsuitsFiled', window );">Loss contingency, number of lawsuits filed | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_HumiraBiosimilarAntitrustClassActionsMember', window );">Humira Biosimilar Antitrust Class Actions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt', window );">Number of complaints stayed | complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberOfAgreementsBreached">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Agreements Breached</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberOfAgreementsBreached</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Complaints Stayed By The Court</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfComplaintsStayedByTheCourt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_NovartisBreachOfContractActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_NovartisBreachOfContractActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_HumiraBiosimilarAntitrustClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_HumiraBiosimilarAntitrustClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594455512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments', window );">U.S. repatriation tax commitments, number of annual installments | installment</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths', window );">U.S. repatriation tax commitments, 2021</a></td>
<td class="nump">$ 587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears', window );">U.S. repatriation tax commitments, 2022</a></td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears', window );">U.S. repatriation tax commitments, 2023</a></td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears', window );">U.S. repatriation tax commitments, 2024</a></td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears', window );">U.S. repatriation tax commitments, 2025</a></td>
<td class="nump">1,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1', window );">Total remaining U.S. repatriation tax commitments</a></td>
<td class="nump">$ 5,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808602273928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly financial data (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfFourthQuarterEventsLineItems', window );"><strong>Effect of Fourth Quarter Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
<td class="nump">$ 23,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit from product sales</a></td>
<td class="nump">$ 4,737<span></span>
</td>
<td class="nump">$ 4,543<span></span>
</td>
<td class="nump">$ 4,420<span></span>
</td>
<td class="nump">$ 4,381<span></span>
</td>
<td class="nump">$ 4,628<span></span>
</td>
<td class="nump">$ 4,427<span></span>
</td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="nump">$ 4,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="nump">$ 2,021<span></span>
</td>
<td class="nump">$ 1,803<span></span>
</td>
<td class="nump">$ 1,825<span></span>
</td>
<td class="nump">$ 1,703<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 2,179<span></span>
</td>
<td class="nump">$ 1,992<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
<td class="nump">$ 8,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
<td class="nump">$ 12.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 3.57<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 12.88<span></span>
</td>
<td class="nump">$ 12.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfFourthQuarterEventsLineItems', window );"><strong>Effect of Fourth Quarter Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 6,334<span></span>
</td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 5,908<span></span>
</td>
<td class="nump">$ 5,894<span></span>
</td>
<td class="nump">$ 5,881<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="nump">$ 5,574<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">$ 22,204<span></span>
</td>
<td class="nump">$ 22,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfFourthQuarterEventsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfFourthQuarterEventsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139808594667304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Allowance for doubtful accounts [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions charged&#160;to costs and expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Other additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>142
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  :FTA2'-T6>3@'  #A'P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+59V6[C-A1];K^"<!?, .-8FY>T20#'R]2=B>/:GA9IT0=:HFTADNB25)P
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MV %_HBU];HC ZKM9WG% QC1ED_)C[/"\9P$\30, 4.Z@C1IX;L5HEGKLX<
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M)T023;8"&OA&%#F3]:^_) 3'U[IW5L]3'0'IN8R<X;(V/G6SC#YV-,]YPVK
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MYC$8D.W];/NBQ%9?<3X(I42I'S>, O1& +ZOA5 O+\VM:7=+OOH/4$L#!!0
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M!8$\8P:!\H"8T[/#[KB8GU+I,9."^04D!LBSB2_7=$(PG!4N;@/AB-ED!U(
MG86<QH7\\U!+;E8->M/PZ>FMI3DY%./&Q@=KR1Z-[0YH.?7UEWCG,0#(S+2K
MB "*XC2@B'36<AK7\G6(#F(:W?.'=ACLE)K$\<P9'*B^5.<)]:830%7NR<X&
M0-$R"4WE+/LT+OM1DMS>.T3HY=XU2$[<T[XUA/(&80.A*F\.5V<W@CV7#^/-
MJD+CV=ETMW;Z]71[^W&\LW1^_X0_;*8[V+F:Z4KX"Y-F9A7J^-94F;PO3)?D
M=,LZO6BQ'^\=[X76HA\?=YPU7%J ^7\KA/[Y8ALXW77?_!]02P,$%     @
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MY6PJ,L.=(DSP"$5#!MI'C+G&*BM@Z=N=JW<0@LK>':SLMK;"J:UM5E4'KX7
MJ>L!"/,56"+BI<'::\+/"LOT.!_..%3US@Q;?%Y_(-U!:F0*E.A)NG-4W8=Q
M9>\!&@9'F*/R <\:+!0.!F-;R).#)09-A3$ !W,[360)!9>UQW^JN#=@/E.S
M^H96+,]P0C4,!6L-[1',H>S&$XBSEL:;@7;X!73!B-N=)4K:KO&D=7.]0,S
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M32-0=OF3WMZTEE#?1 MZH9[WV =,T:#Z5-_8$L#+OR "NT,"4@\;8Q#5)_%
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M:0$^7QGCTP,=T/WPZ,6_ 5!+ P04    "  :FTA2"<>W7M0'  #U$0  &0
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MZ$( WZ^MI:,1"(8_B,4?4$L#!!0    ( !J;2%+9B7A XPT  -0H   9
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;-5:6V_C-A;^*T0VLW  U['D^]R
MS TML.T,DFF+Q6(?:(FVV9$E5Z3BI+]^OW-(2O(UT^GNPS[$BF7R\%R^<Y5>
M;HORBUDI9<7#.LO-JXN5M9OGU]<F6:FU-+UBHW+\LBC*M;3X6BZOS:94,N5-
MZ^PZ[O?'UVNI\XO7+_G>I_+URZ*RF<[5IU*8:KV6Y>,;E17;5Q?11;AQJY<K
M2S>N7[_<R*6Z4_;GS:<2WZYK*JE>J]SH(A>E6KRZN(F>OQG2>E[PBU9;T_I?
MD"3SHOA"7WY(7UWTB2&5J<02!8G+O7JKLHP(@8W?/<V+^DC:V/X_4/_ LD.6
MN33J;9']JE.[>G4QO1"I6L@JL[?%]GOEY1D1O:3(#'^*K5L[&%R(I#*V6/O-
MX&"M<W>5#UX/K0W3_HD-L=\0,]_N(.;RG;3R]<NRV(J25H,:_<.B\FXPIW,R
MRITM\:O&/OOZASPIUDI8^:#,RVL+BG3_.O&[W[C=\8G=42Q^+'*[,N)]GJIT
ME\ U6*GYB0,_;^*S%-^II"<&45?$_;A_AMZ@EF_ ] ;GY?LL'\0[;9*L,%6I
MQ+]NYL:60,2_SQPQK(\8\A'#;U3AU^\6_LM<P=N4T.V?\"6KH&-A5THLB@S>
MI/.EZ.@<L,@R(-Q</1?_5+(T0I$Q!%2IUG-5UNK$1S2CCZEX!\+&ZD1<BF&W
M/YWP=3")^#H=C04@#T#G].MPC,_)>(+/\70F/A=69H&W8YQ>BFDW&@QPG>$Z
MY>MH.!*?P?BF+.XU.S3V_2\%?%N5I<IM<^!S\4&EJ@3KX"<F0:-N/!VZZZ0O
M[JRT2@R&8C 3T:26/YY,W%\\\9(G^Y2)P"#&Y[C?Q^<H&H*SA<*J5'3F*E<+
M;:^.,=(9Q-&5Z,23,3X'T>3*,S'#O1BW<".PT1G12EXWN_*,I.$0?P9^&P]H
M17]XY?]W"\\H';8:SYP.9F.^1J.H87]G+<(EQ5*V#^X(M5C0UV(AK%IOBA(Q
M7:0:-Z&>!.OGRFZ5RGE](LORD<PIUT656T.[I#$*_\D\%9F6<YUIJ[&->%SH
M7.:)!N^E F5+.S=5N2F,<AN(9B!5&7"Z*UF]N,O?$L@"_3 36+B59=J0:41A
MKG(D0J2\4O*AB!=&='[Z^(^KW=T]<0>SZ(5.)*" 8S=%KKQ<154VMB'J)P3=
M0E'XS6/=["/]!+J/V,8?\%R 3S[EJ+R78C(CN$^!TILD*2O04 ]([J33T3@2
MP]%$O \W$KG1P([^P^N6CHF&0[@&N4J1?/F.<F'*HF.'Y!0[B\4L$A^A57#=
MCT0\GNUC]8!K0&XZ(^^9( K](K/*D9*D$V!  ?H3POZ(_.,G&.<L*7B4]^=C
M>FII_SET\'NEW0(K\Z6>9RK0Z<SZY$@4(*97H#2';\53<LDXZL,I]0.VA;71
M<$KL88,3O!--9[1R,#APU..LT$$C=GA2PO#,+L(SX?,2Y/M0RB6I!1N.J UP
M*WVXY9A:P)/2"NIL>\X9L&*#S/U"[)%6:"/6%.LS_45ECW0O%WEA:>5<@;H'
MBX,%L9(S+6/6%"UQ%!Q24PG&$,W54O(710R"X:Y/ .1UE)I0<"GF<%%92MG@
M39*)O#9R>(<Q%')8-#X\+$U)4NL,ZB3M<?*Y/X(ND,-NPVIF+^M":3B\U) Q
M+<%A+N:/K+6W@+K,'__^MVD<35X8=I[$.H*L(4.,&0[AMW^7Z\V+=]X3X>OP
M:]865%59[53E(A V)JJTJ)_)T3C:'\8@Y4G@3&!65#D%O9ZX80T=1(HN8HM8
MR51<(FKXD,*J](GG=$R\ESIC-3> \4H->W=2 DFPDO<MH.7%435S"%DA(C_)
M@S/5DYQZ180< ZD'S$W<'XQZXE<O_G@:M>5WMOD6Z=W.)V27)T6_'$U';4:<
M*LZS\Q76C8:#8^:E-/#?MNL9V<:'DIWD9->Z!S]WF>)VI9/5*22M)%46,'E@
MK7L$"]$1+$2H8 ^P\*=4]1=!@&].0^K4X2UF>S,Q;UG6!X8_9UF_Z=LM.QD-
MC]CV%"\]JE9]]5XOH;AE3QJSL>'E=-RX*MD8.]BNCR_J2JU4-&4 ='9BX3&S
M]QW.2I44*".1:^E<$[1O.;\N2ZKM6JGPY\]OGBS*OK;]>*.6.L\I>L]EQJ)>
MB@'*B0E?^V/J/^+N;#00-RD\G[FK,R<7L)PLZ7:I,H"%4SA7TK[]> 0G(AJ/
M1!R-4)7].4)(<3#5(PLS0&\CHH&X=5F35H:"K]E+Z;NUIS,84;E"=1FW+<K:
M3*VY .Z,40YQCHQ?X N6O,_3?44,1O&!0NXJ].2HIE'U(_6VG(7M(D_%0KU@
M,Z,8_X-PM"VJ#)CVK0F*&U?:4Z5!$B&EJIYX5Y7$$1%G-9ZP)P?:>C^8,BQG
M6N=K;4RE/,*)V ^W=QRU)5@R56:9 %"+ J.B^HKX<=(D25&25K+''II^"] 9
MR^!%,2TSK@I;YG)[7)_M>F0<3L1.=W8'0IY$;=?!UGE.-/4\!XTB%$5U@(>;
M1K-I[::TY3(:3)J?(<8F:*M+!M/'9;.KLJB63FGMKJT61^>^Y,I-D>F4%<'-
M\3IT66Y4XOP\5:Z(HVWUB;ZW\:7'>4N++?#5JOLJ#J<( *IL")9<D:9.K;3K
M9(8.RIQUR=+<:9U0!"KD GTNB<<H:F+0Y60ZV-7T>'Q"T\>#7;O]#@F7\DYE
M"ZJ:O3,(N=EDVL'LS$R'&#CN3?L1\^MCY(?33,51KR^>[5W"+ 3D*;(BU Q[
M"#[/Z#KRU\%5L_ [D >G.PV>%ZK3]SN;ZY"N;UVYWA6?*KAX(6YU4J G3K1Q
M(\1.W)OQ^K@W]E<^&?),>,%-8EV+IM$K4 3R@$Q<[R",S*#-$!Z?M?[K1+TI
MD:JC ;96>8@TN]$XZD58&?7&_!FW&6] '&P>6A$<P#+BVO<R\X$W%96>IAW"
M_8H6<WVG6>YPG8!!==#<SM+WAPB)L)0X'3*K4<S<$V0/T61VW/5K8Y8?.XE%
M6:Q/X)T9.?!P9Z6Z,/@-OFU2S5D0N]?ZP<4PQ@P=%N8EO=/9*@SC0/V$PS"7
MBWTPNXQA&AGVVTW?$)+] 8@60!%D!#!3:A8T),U<US'3U V\19BT/+O GL!"
M6VI6_\\]I+'V%*TG/D*4DPQP:C+5_#>>#A:\%4H#EDCN92D)5"'DNZ(\%"ND
MO>Y3XB*N46GBTMX=M"4W%*#V3I7'SFT?.W1B'&B>Z,C,%&UBM0J@-^GKZM29
M#PH&H$?/7-1U"]O:;RL&^/(C2T"'HPC1+%Q0=@7H3GB PI,5)3(@->&CED7A
M9Y5&E?>:!CN,$,+66N;5 OAU&0G!0>T9QB<&S_7P&4&@!4BOFGWOFG ;0B4*
MS7Z"/[;X9_3L'IX4IAD3M6>'G)'O81+23LN%^!?>1;T81\7MRF>K4/F@'""[
M.PNA#DA=A\$J/S[KW>4SN%1KLM(TV]XIB/02+ENR'[?JGB<KK(;?UI&:GV-0
MB9[VPM,<MWHC=1J*AV^IR:@D0 0/76%WMT=TI5AS8[] ^)@# J4;X/FI7Z:6
MB''D+&[LKK.=6JQ4,*US=1MP'L)J.V)TT=BA,ZB,6^(ZV_8"A][]$=?."N>8
M1PXGZP"D5N=4?JL'N<9_*0_D"(<5.M+2L<]L4GNZ1[@]ID^UV504#M<26"S)
M9JYT/Z!U7V3W9"A?X)=0%9?KKGW4:WZ2 :G\?!0:3>ONR<&P,JSH-MYX VJD
MI.E&CZ06H@GJ0:E$8%>;<Y5(3]VE/6:4HL@&:FMUNC1EEEM#4%A6F6QL ?]2
M]Z00\E]#..4")E3^BHLFB880?HL\>;.D?O.6'\2(SNW-[943!6@" U0[XEZ3
MM[B H?09]M^YP"4Z:(^N]O([SG5@#ZU[%)/+4:G#(:TQGDQ_JXQU!0I[;I/,
M7;P(#7*C8M>U%@M2?JB& PZ]$]3P#S#?29MA\' VR'.T!+3DLE2JZ06=%*3(
M%N/L"3)+=LS!XQ@WTJI*4Y'@<-XBJUB&=G,)6H">ID?7;I"^V2AD+C $):$7
M^AX-RST5:#P@#%2KO)D/R635)B[=T[P39($2E769QRV!U.I$;UC3I/^M<F,8
MCQC@X:?"^JSU#B50HE6>(+F[:1ZMYM;<3<V)FWN]+.#<!A9$AK?*--G:%6.
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MXE.[]']FBY-*M!:EZQA%G$X$;C_3'PF#-K(Y#!I=:* I0?9!$SH19G# I'$
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M5):![BLIS7YC%1S^;>;_ E!+ P04    "  :FTA29HR:++($   I"P  &0
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MS;Y*"Q$-N]2533R=;(Z/,!0-I#M?W<;BZHZ1?(I\%&.8V9T@<<#M8_CH L"
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M,S8^S[Q],/@F<&M?S,%'LM#ZP2^NJVF4>$$HL70>@=/PB!<HI0<B&;\ZS.A
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M,%W3'PB--Z#SI=9NO_ $AW_:[#=02P,$%     @ &IM(4GLE5#$M$P  8SL
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MA"]Y$M^V9>^ERLM:=8U@__5FJ]H&K.*_SR!/'?*4D*?_L1C_'3SL<P>V5S=
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MP259C.5G28_#Q",]B1 JH463:!YJ&29^J$B 8S-,7PQ<NEJS+(L!PK?'9(T
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MM!EX&4;N[SH7"#$]*\-Y$XPV/V088R29Z>^-D9BFTG+0V3F#ZOIRO4S=1"I
ME&C;4MA$2/M!29++FUJI&UTZY8],W?/3BXDS S5]IRKX=_S3[OR6K]Y2L^PY
MD2':^.I<C]09A=%WU9G]$,5+L_U&:X]BHXSLA^)B:O=HAZX15-!2IGZY!+<;
M*:Q/_CX-BS;2CX)B%ASK(*$R N\LA*)RZ @Y)*RVDP^BN*')2/'.B%2/:+F
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M#=$\/F.?*>FLS9=8N$\T(TO@F4:.=T)B@OT$5;]'%=.6^T;?<3/%F?^_:_!
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MR8&(U4R62?'>+/^A*GLFQ"\RB>/_8NEIP_&!B$I7F+0:# U2G?E?^;7R0VO
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M "O@9&UB]> AB+,0-ZXA!WRQXRKL-=_(+3+88X&26E\47^L=W_;R:36AFVK
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MEB@DNX#'+9@Y:$K#^!AUA?MRMXLT1@W8,+/EL$L"G"]D/_7O^I!@Q#%7)J/
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M8X!@K3+^O_BB\>!],#ON^6"L/Q@3W#P00?E25.+YLR*_C0IL#;WA'S15^AJ
M4QD2Y:HJX*V"[ZKGEWE6J>Q:9@LERTAD2;3(UVM5 =ZK\ME1!4-@PZ.%[NX%
M=S?NZ6XTCMY!CZLR>I4E,@D[. +8+(!C ^"+\=8>7\K%8309Q='X>'R\I;^)
MG?"$^IOT3MA.CZ8;(N"E*A=I7M:%C/[[8EY6!7#-_VP9]<2.>D*CGCP6FO]
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MNR@5MV6MV XAL_U\>'6(7F%5("]> LXK4@3XSOX,W;T$@WB+F-ZG-^8I_/+
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M'7M,9]<@O?;>M@-.+3478* U[-^R Z\#K^2FDFOM0$UY/#DO#.[ AW*LA(,
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M^[(CKS3.1K@'T\\09U ME':K!AI.Z.U&/M%3\U<4EOUZH,W: %MXC;^T(_4
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MJ'!/6N#B:8SAG8K O"M[;LNV[4B-<$V^5'ZDQBN).3$Z J"M^+I4+*B@8A"
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M\'Z9@P'3#SC ;5Y\)O">_R]02P,$%     @ &IM(4C^/ES/) P  Z@@  !D
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MDN&=!)6G*9/O?>1BW74\9[/PD"R6VBRXO<Z*+7"">KJZDS1S*Y8X23%3B<A
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M'CLZTLP;N!3WY(;1B;4E158G2)H\<,^3?="92ZXE0EZFB3N]EW21T]:@\,7
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MU0%<BR3/6VPY/*0>@SC8V8U(]E'A##B#]Z3NLY!3SQ+_>?G!KRE[96\0QTH
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MKO'%C+2HP],=)E95_KG<*$N/KQ\6]+6#VAG0_E8I>YBX!.WWT^H_4$L#!!0
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M0IRBD'3I]==F@_:8A8"**H6!A"FK)+&L(ORSHH12R1E_\MWWC^?/WIT]G%S
M$94(:595D&5! E LJ3)@)UE6DA!!+LJ<SBR*[A9W4,J.],)H#[JH9JH.*.<5
MBA609%Y2(4NJ"A:LP[I X2)J613TZL/5]>5O+V^V8&-E4:BOIJT16<%2RF30
M37-)N13(,0V2$"3+C+)24@4/UWJA_/RNVOK6-&;<9R<DBLA+*DL4%Q3@L,ES
ME!A1,1R !#DN_1R,7-\KAYIG:1Y.!M!Y(@NX320+9YOR ER1H1Q)&I.065P!
M!WJ";BZG4TUHBASE+9(J^$PX,N$BX0(I #9C,,P+'#X\I2+H"=1')@P"UB38
MU@=F-Q<T!!$L6,)*03F((_(0! L5AFW(C24<5.J#V1J"_64BXG7(DPK5 /$E
MW(EX+T Y$7=8%G>R),MY;Q.J%*Y'5E;]3B$*^OO>'P4V?D-/6J&%J/&G96UQ
MW]&]WIC;_LKS=3\XW-,AY;9#RA]K6F@M'?S$UMRJ?XQ=_^IIZQYJA?M1+[3U
M>(A0W?7/E=!\8YNW(#S> >0-X4B<OG/2IWNO:4XP0;M3K5EV(-/W/=3M;**Q
M6<:F> ;HVIDE>MNYMC/=X6?'+HR-(1W1<VN<^P_70M_#\61APL%@UD]2M*-'
MX1?$1TK,HN66&)G )HBV'EZ/7VGGS(]Y QF*P H6FI'L)R("[O3&@R.V&2Z4
MG=0=U%YHU?AY0B^[\>$N=P6Z$(\LE9&E16R,NWVQ IMQ0&$?/<2XX;U73QN*
M'-YVCL;AW/H'T'9U^WP\ZU]-=^K]V_.ULK.Z<]3H*4S3PP(TL_U[KA>\6<0W
MU,AXT"9.YW@":QL4L#\UQF^$X&#[J#[]%U!+ P04    "  :FTA2;NN@B5(%
M  !^$   &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6S-6%UOVS84_2L7
M1@HDP"KKTY*#Q$"2MEL?B@5)VF(8]D!+US812?1(VD[VZW<O)2MI'2M&UX<]
MA"(E\MP/GGMHYFRC]+U9(%IXJ,K:G \6UBY/AT.3+[ 2QE-+K.G+3.E*6!KJ
M^= L-8K"+:K*8>C[HV$E9#V8G+EWUWIRIE:VE#5>:S"KJA+Z\1)+M3D?!(/M
MBQLY7UA^,9R<+<4<;]%^7EYK&@T[E$)66!NI:M X.Q]<!*>7&<]W$[Y(W)AG
M?>!(IDK=\^!C<3[PV2$L,;>,(.BQQBLL2P8B-_YN,0>=25[XO+]%_^!BIUBF
MPN"5*K_*PB[.!]D "IR)56EOU.8W;.-)&"]7I7$M;-JY_@#RE;&J:A>3!Y6L
MFZ=X:/-PR(*P71 ZOQM#SLMWPHK)F58;T#R;T+CC0G6KR3E9\Z;<6DU?):VS
MDUNK\ONW'%<!N:IHKXUPZ3J^$],2S<G9T)(9GCS,6\C+!C+< QF$\$G5=F'@
M?5U@\2W D/SKG RW3EZ&O8CO,/<@"GZ!T _]'KRH"SIR>-&^H!="8QOTM7@D
MCEFXT%K4<W3]/R^FQFHBS%\]QN+.6.R,Q7N,75%654VP!M0,S+Y\XP/WD8B>
MJWDM_Z'OL@:[0+A2M5&E+(2E=[>6'M46[6--&/C2%O7ZQ)5^:I8BQ_,!E;)!
MO<;!Y(YLS51)92KK.5C>?BX[KA_C',G_2R1JI5^/!(YI9B7+DG#,R2G\@4(;
M0*81$ FPFJ+NB$!-,.8F@YO;SP:.($@S;D=-F\ U:B=;=8ZPJB59"FARX"?T
M3,%1']22G380Q1 E$([A3EE1OAK=+T")L^(!HLB'R,_(JP#N:#S%&F?2PDRK
MZO4<':?A"1R/TK8YU'9-:DU)8_M'$"8<;Q@'KHVAA[-)Q]FDE[.WC42S#4[M
M2P3K!3B<8,UA0"0Q1)+FC&GD?BYTP=.8-^Q#0X:]7/CLMO>K$V$LWHHU:CI3
MX%*4;O=K5:_1,.V$H]MW ,2CR L<@V)OG,*OI 4\.7 OPRCQ1A%\:0". \\_
M<01+O3 ".AMF*-T'WPO=A['O!<FAILGWR//=LLPC#O7LWJC;O5'O[NUD01A*
M<\OS%;-*U(6K:-H:.KTXS9OOU\PY!<"E"C,A-:Q%N<*N[K=E\Q(S>IW;SXP=
M#W:\;O6P,>T<:LA2J0++'X[)[ 35S".#&]3L1DM:<[@>797*L =++7.7-&8Q
ME7)%WK:FZN?>,,=&7C1R#$R]*&@[\0C>4\WG[,Q:E11N*>TC'&\#(F19+4O9
M;NE"$CB9) UYFGT"(1$+WI )+^%'[(WHT>&6<M;H[B,'=P*)EW5_-]+<OYUI
M1,J]I608"YK]];V8D=HV>PY7R+4L*$/P*+$L'+??N.+BF6-J/^QG4Y?X(XA#
MCQ3YB*35BU-^DM=^7W&D77&DATK;JTSN1?K)&O>-,Z^(W>]MNKI"?]:[F,\9
MV#YIWZK&!]2Y-#WJ%WONS$Q2S_>?J9__Q,SW'0;IW-CI7)!Z8Y]W7FHLAK-=
M(4PS7GFP'Q19[*5NX9B1J1#<D=9)K]+N"'0\LPI85GN0DJT+Z18I&F_#</NR
M;VG0+$U\+_.I#-P@["5?UI$O.TB9X0>4&5Y5YN7W/W=>XG2O@S]!G9?BD>Y^
M8&2U*G^:/.]$]O^1Z#&Q\TF9P[31V'"KN*R-^U4T=*H8N7:THXW?1LJ5,/9\
M5Q]9YL7N-T,V]L*7?S,,G]T)*]1S=_,U%.&JMLWUL'O;7:XOFCOET_3F9OY)
MZ+FD;2YQ1DM]+Z7??KJY[38#JY;NACE5ENZKKKM 4:#F"?1]II3=#MA ]R^'
MR;]02P,$%     @ &IM(4BK-//M:!@  8Q$  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&ULK5AK;^.V$OTKA&^VL '7UON1)@&2S2ZZP&T;9-,617$_
MT#+M$"N++DFMD_[Z>X9ZQ$EL-2WZP:)$#6?.S)P9BC[;*?W%W MAV<.FK,SY
MZ-[:[>E\;HI[L>%FIK:BPIN5TAMN\:C7<[/5@B_=HDTY#SPOF6^XK$879V[N
M1E^<J=J6LA(WFIEZL^'Z\4J4:G<^\D?=Q*U<WUN:F%^<;?E:?!;VY^V-QM.\
MU[*4&U$9J2JFQ>I\=.F?7F4D[P1^D6)G]NX9>;)0Z@L]?%J>CSP")$I16-+
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M1NVK7@#*CRQ_,+)R8V(E#0T=M\UIRJ.R"O1]+:79'ZR#YG]C^A=02P,$%
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M%,434'&%KEG?K^4_=/VI_PGL)(BG, G#J;U$KR*FL_PY]!%FDI&9Y,/,\)(
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M6='W"2JK0/*-E.:PL0'&+Y[EOU!+ P04    "  :FTA2OMIZ.GP$  !&"P
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M OFE+>TW&-Z(VTJ:T?'4H@H2G&9KN/,.CN^!8QS>J\86!MXVN<SO TS1MMY
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M5S&3 "'8XQB1%U&Y)', 'UDB>EH#I-,.K(2'<D4C=MP#7203GUA/1TW##K2
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MH"TN@.=SSE5U@P+J?P4X^0=02P,$%     @ &IM(4I_^F(R# @  @@4  !D
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M1L<S'^Q][J>@U_Z<98B/KOA.KF:KL]R-/\&\F9_2JUEQ(JMAB@/BG.DUQ\\
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M]&24S&AZC&Y2B(^C-R<C6U3T2L^]@T5%OVRC;U5_3\6$I@H60\2G:,D52V>
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ME'T!QU=2FK>&O2977SGSOP!02P,$%     @ &IM(4@Y'(5-K P  8@H  !D
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M$E(Z@$E@B9(##I8[]Q>E^[#!_1^%[ (;OH:PQ\YKS!?MYI^X[D*?>?/H5_.
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M !1#S%G!KL%8J&<_2#O^9%C H^B*U#]JE9:F8_!E]9:&4_I8OIB_L*38I0L
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M^<DO5T1^FC %D.^?*!7;&^6@.E$?_@M02P,$%     @ &IM(4K+"IB$+!P
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ME&:BAO5V;49#Q)5,=9;5^GGYV!XZW"'D?GL0-;-K7P['I(U),\4\<L-16W>
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M#5\B,F5_85?;^@XD6Z5%7H/)@YP7U9,]UW$X  3],X"@!@27 L(:$%X*B&I
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MII;$5II"R\DG9<N*%FOR34/*-,(5+V"K4BA15D7RKJU(JG<.[3M-QWN:!>'
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M(,P+^OF2<_72, ZJSSSS_P%02P,$%     @ &IM(4ILGBN$B P  %PD  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULC5;;;N(P$/T5*]J56FG)E1):
M 5);MMI]J%2UVO9AU0>3#&"1V%G;@?;O=^R$%&A(>0%?YHSGS!Q[,MH(N5)+
M $W>\HRKL;/4NKCR/)4L(:?*%05PW)D+F5.-4[GP5"&!IA:49U[H^P,OIXP[
MDY%=>Y"3D2AUQC@\2*+*/*?R_08RL1D[@;-=>&2+I38+WF14T 4\@?Y3/$B<
M>8V7E.7 %1.<2)B/G>O@:AH;>VOPS&"C=L;$,)D)L3*3W^G8\4U D$&BC0>*
M?VNXA2PSCC",?[5/ISG2 '?'6^]WECMRF5$%MR)[8:E>CIVA0U*8TS+3CV+S
M"VH^%\9?(C)E?\FFMO4=DI1*B[P&8P0YX]4_?:OSL ,(!D< 80T(#P'](X"H
M!D2G OHUH&\S4U&Q>9A232<C*39$&FOT9@8VF1:-]!DW97_2$G<9XO3D28MD
MU3.92TDB<E23HK8@9R\V99#VZ!HD*H!<*]1&83;5.3F;@J8LPU&//("T^N,)
MD)(SK<C?>\AG(%]Q\QOQB%I2"6KD:0S8'.LE=7 W57#AD>""D-P+KI>*_.0I
MI/L./&3:T VW=&_"3H]32%P2!3](Z(=^2T"W)\.#RQ;X]'3XL(--U!0OLOZB
M(_X^E8A^E(A0GN*]5*A_QA=D<VBZD)1KDE(-9$Z9)&N:E8"5NYXI+?$VOG;$
MUV_BZ]OX^D?BN\V$,H<7DJ$TQ)R(4AJ5Y:@O981'<+ 3R!GCI%0I*4!6FCEO
MTTQU9FS/-*_:>A)& S<:C+SU;B4_FP5Q[$;!OMFTW>PR:LSVF%\TS"\ZF3^+
M#*]1QO1[&X-N;!B[%_[W-G%^@0O=H!4W_0(7N<-#W![I04-ZT.GHD:E5;RX!
M".,:4'N:2"QK6P:Z'?ENV)Z ;ECH1NW\OX(-.NG'#?VXT\]=<XV,U,U#>**@
MX\^"[E^Z?GP@Z,]FP7#H]@_TW&9UZ8;!@9Z]G9:1@US8UJOP<I9<5\]IL]IT
M]VO;U [6;[#K5TWZPTWUR7!/Y8+A0Y3!'%WZ;HPRE%4;KB9:%+8QS83&-F>'
M2_QR 6D,<'\NA-Y.S '-M]#D/U!+ P04    "  :FTA2P"ELSU\"  "^!0
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MGPO'5VII_9?M.M_+*&#EQJ)N>C!%T C5_?E+?P\C0'QY!)#T@.0U8'($D/:
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MLAREL%*2WEVD+(FBRBP>)-^:NFO!I:KB3'.C*G,0&J#Z5YS+PX,>H*KUQ_\
M4$L#!!0    ( !J;2%(PRB1"QP,  ' -   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;)6786_:/!#'OXH5[44GC29V" D5('6P1\^D;JO6;<]K$PZP
MZL3,,87NT^\<TD 3)\_V!ISD[OSSW_'=97)0^K'8 AARS&1>3+VM,;L;WR_2
M+62\N%8[R/')6NF,&[S4&[_8:>"KTBF3/@N"D9]QD7NS27GO7L\F:F^DR.%>
MDV*?95P_OP>I#E./>B\WOHK-UM@;_FRRXQMX /-]=Z_QRJ^CK$0&>2%43C2L
MI]XMO9G3V#J4%C\$'(J+,;%+62KU:"\^KJ9>8(E 0FIL"(Y_3S '*6TDY/A9
M!?7J.:WCY?@E^C_EXG$Q2U[ 7,G_Q,ILIU[BD16L^5Z:K^KP+U0+BFR\5,FB
M_"6'RC;P2+HOC,HJ9R3(1'[ZY\=*B L'.NQP8)4#^U.'L'((RX6>R,IE+;CA
MLXE6!Z*M-4:S@U*;TAM7(W*[C0]&XU.!?F;V,4]5!L3P(Q3D:JZRG<HA-P51
M:[* -6@-*_*-'\EM40#>YOF*W F^%%(8 <5;<K4 PX7$T8!\?UB0JS=OR1LB
M<O))2(D;54Q\@YQV-C^MF-Z?F%@'TP+2:Q+2=X0%+'"XS__8G8Y?N_NH3BT1
MJR5B9;RP,UXE@ZBU(KQ4XZ8G>EA'#\OHPX[HG[_<E:*F.(,P).5:/^/I/'"]
M<DIWBA:5T>P9?9K%X^'$?[K4IVV3!$%M\PIS6&,.>S%OTU3O40,X8@(IP(EV
MBC"ZF#8:T09:VV88Q6ZTJ$:+>M$^5$BHW4X8+L4OY$0)[4:Y,*,6 ATV%738
MQ!T*CFK,42_F@U'IX\"F'-QL/&?(S&TF<R&.6M./68/084+=@'$-&/<"?C%;
MT"Z:N#55&#3WM6W#1F,W3U+S)+T\WQ1NIDW)':?/A9JT]RUI2><PBI..EW!<
MPXY[87]PN>>GPB2Q-/(\!1??N#7U((J;6KJ,: <?#<Z)/NA/--@3_)V85<!7
M0H6L2>NR8EV'A5[4)?K765>>"T]?ZJ7GS$[9_V2UGWMQFL3P?".6$OKT8.V-
M&0=A4P^'%65)TB'(N4[0_D*Q@*5Q4H7M^5C2?.>=5K1KE\Y5@?:7A5<MPD5?
M\([<:VPUM7G&D>2Y*6O<!U1[ASV@>QWMTC"@PZ2Y#H=5%'8LXUQ!:'\)Z4Q]
MM%T(!IA1FE .*Q9V49T+!NVO&-T)\.(@.*G;Q6% (]9Z)UQF<3+LX#[7$=I?
M2#JY[7N1@WOWXU;/,F"M*N.RBF@3V+]HA^VWR">N-R(OB(0UN@77,?KK4WM_
MNC!J5W;(2V6PWRZ'6_PD FT-\/E:*?-R89ON^B-K]AM02P,$%     @ &IM(
M4I3S\49[!   &10  !D   !X;"]W;W)K<VAE971S+W-H965T-C0N>&ULM5A;
M3^,X%/XK5K4/(,V2V&G3%I5*0&>T2+"#!F;G830/;G+:6I/87=N],-H?O[83
MDI:FGC)#$:*-<R[?N?@[QH.5D-_5#$"C=9YQ==&::3T_#P*5S""GZDS,@9LW
M$R%SJLVCG 9J+H&F3BG/ A*&<9!3QEO#@5N[E\.!6.B,<;B72"WRG,JG*\C$
MZJ*%6\\+G]ATINU",!S,Z10>0'^>WTOS%%164I8#5TQP)&%RT;K$YZ,HM I.
MXA\&*[7Q'=E0QD)\MP\WZ44KM(@@@T1;$]1\+.$:LLQ:,CC^+8VV*I]6<?/[
ML_4/+G@3S)@JN!;9%Y;JV46KUT(I3.@BTY_$ZB\H ^I8>XG(E/N+5J5LV$+)
M0FF1E\H&0<YX\4G792(V%'"\1X&4"N2E0F>/0E0J1(<JM$N%MLM,$8K+PXAJ
M.AQ(L4+22AMK]HM+IM,VX3-NZ_Z@I7G+C)X>WO!$Y( T78-")X^PU@N:G:*3
M$6C*,G6*_D2?'T;HY(_30:"-/ZL5)*7MJ\(VV6,;$W0GN)XI])ZGD&X;" S0
M"BUY1GM%O!9'D)RA"+]#)"1A Z#K@]5QOT%]=+AZSQ--5.4^<O:B/?8>Z1I=
M2TB91M=4RB>SBU=4INCKK1%$-QIR]<WCIEVY:3LW[;TEUB!!:41YB@Q?T$PS
M4VP)&=60(BW0@DM(Q)2S'_;9H!H#APG35JA:9]S\/C<+FDNQ9';S-[5%@:?C
M\%CB60XQCD/W,PB6F_5JD.SWFB1'#9)1]X7D5GHZ57HZWO1<)HE<N/@:TT25
M$@ESF5HQ/=N?JZ9$%)[C#=#=7M28B%W)./:&%U?AQ3^I_L8&GU.6-N&,=[SC
M=A@V HT;*M8L.CI(="NH;A54UQO4!TA!T@Q]O8-\#-*W2WJ5R=XQ-V._<M/W
M(K=NDL)-LN'&]-G2\"T=9V WI!%8)+"QWZ"QO?H[92/>].*PG@JA%^;?'V_?
M %_I9+NO7O;_-L*-N85?A_ =6M)L08O31&;.,Y0GT(@*[^XU+R928R*O:DOT
M'_HX-RN:\2FZ%4J9+?@XHQJ]7\^9!'0%>@7 [33#CG9(&'4.:6I<CQA\U!F#
MZR&#_5/F-^K1WJG'ODK4G([]I-Y0"9?S HX999:YGX!*9?B[*D+TNB+4%(SC
MHQ:AID7LY\5][')X+;H'UZ(F5MSS@GK09GH>E-":1''_F DE-0\2/P^^*5V3
M73J,>]A'/:2F0^*GP]^N/-EEQ4ZOXP57\R+Q\^+;3)/2R=8T\9^12$V3)/+S
MA9#F/T1^2)>2FA))^ZA=6K,=\;/=&^5W]PSZL_,:J2F0^(^AOSX>R.[AM-MI
M>U'5?$G\?&E0J>)8ST43'C</S"NH9D<CPEW2[,7^?5V3)_&3Y\O&_)4C17A0
M6]?D2XY*OE%-OM$K#Z$']TQIN.,98\'&G4D.<NKNGA1*Q(+KXD*B6JWNMR[=
MK<Z+]2M\/BINJ6HSQ:79'953QA7*8&),AF==@T<6]U#%@Q9S=S,S%EJ+W'V=
M 34G%RM@WD^$T,\/UD%U&SC\'U!+ P04    "  :FTA2S=YDHFT#  ","@
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M$DZE_46'ZMMIX*&DE(KG-5C/(">L^L?'VH@S0#CI $0U(/H9,.X C&K Z%K
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MQE:KXA1'/62;GY%E6 9@T*2=OL9[23=NTJ?M].6!MM)G[?27D+<:/^_LNQD
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M+N*C'B<P.R,)?4[B*(Y:"%V>#*>#%OCD='C_2#1)HT?B_24/Z[$"<JXUDPO
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MVAG@^[G"(ZP>N 6:F]'X-U!+ P04    "  :FTA26L ET=L#  "S$   &0
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MS02:/\9 (Y#6P+R?"Z&W"WM ]7^*\3=02P,$%     @ &IM(4B2GF7$A P
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MT-A4V&&,?1](<P/NSX70ZXGI+*I.<O0'4$L#!!0    ( !J;2%*EU?RW;04
M *P@   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;*V:76_B1A2&_\H(
M]6)7:F+/AXE9$:3=1&GW(FJ4-.U%U0L#$[!B>^C,.&SVUW=L' _&P[$1WHN
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M,(6OVN+@^#N7\J2M]"I#M%&6UP^W2F^)\?R/,7%O1]ZI'[;+BQIYT?^U7EN
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MV3J[0$&ZM,IR8M72F\=,6;0B/\SQ[P+: 7!_KI3=3-P!]?^J_P]02P,$%
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M^M9![1;0^UA13R\'SD#U]33_"U!+ P04    "  :FTA2KB0DEUP"   G!@
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M-E=%"*K_/; K%L=%)(WCYS;HH!ZS<-R]?H[^L4Q>)W-/,W8EXG]YI%87@W
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MLYS.G*=V?RQ1.(IP$W4@TFM$>J,BK^)XE^X2JG07M$*I^#^T^!QM,JM*04O
M&?:] '=TVL(@(& 7ZC="_5&AO]JM_!%E3-G$^CT5./#]L*/5$A41/[)+#1JI
MP:BU;C*-G?]LK[ 9)1QMR,$7W!O!UI*P-UEM,Z]K,WN4;V_)M!$[/9G-IL?9
MS!8V;+.H$1K]CZX.NBVRN6W:=9LE*O(PL2O&KB&^.Z[Y[OX'FFY_7* _;UGZ
MR.1?(_;"K84$OZ&-L0$QAG'YWQW'NMA WZ=NI]^6&-\;Z+:A.A['^H(]Z;W2
M5NO\C<6;3"1B_8S*W5(^U@X#9.R]T<*$#4OQ.$R/7YIPGY#@^U'W8[2'A0/4
MP(:D.#@9-^I2AT1P_<#K:K7$30D,@ ,;'N-Q(+]VA<)]TF+?A2XT;&$A^$/4
M,$3&XTC^A<?%YEV_?OE=\QIZXNB-S L&=S".N^/-6Q<Z8$3HD4Z#K5'!P+X*
M##X!G\RZ=:D#2T+8^\JL822:#DAM;87'"?Q:YT*?JY$/7;']($R" =N"P2^,
MX_>6RJ],Z1=_)EG5W,J^QZQ]8" ,;P5A,!"&4T$8+-M4$G1!88V:#F -#(+A
M= @&*X*]GH\M85$PL%B  3"<%L!@V^H&7:W]( ^' U(-?&$<OB\;-F6V$*^P
ML<$QO!6.B<$Q.16.21^TF."NC6U1$ YP@Q@<D]/AF%@XB]V606NEEK#(&_ &
M,30FIZ5Q7:Y],  ]&EN"VEZOI#JM8Z?BS$^S=LVS'"5LI;/<\U"GR^H8K;I1
M8EN>1#T*I41:7FX873)9!.C?5T*HEYOB<*LYS)S_"U!+ P04    "  :FTA2
MIXJM[>$"  !G"0  &0   'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6R]5DMS
MVC 0_BL:3P_)3(/Q@U<&F('01P[I9)*F/71Z$/:"-9$E*BTA[:^O)!L'4H5R
MX@*2O-_N]VE76@TW4CWJ @#)<\F%'@4%XNHR#'560$EU2ZY F"\+J4J*9JJ6
MH5XIH+D#E3R,V^UN6%(F@O'0K=VJ\5"ND3,!MXKH=5E2]7L*7&Y&011L%^[8
MLD"[$(Z'*[J$>\"'U:TRL[#QDK,2A&92$ 6+43")+F<#:^\,OC'8Z)TQL4KF
M4C[:R74^"MJ6$'#(T'J@YN\)KH!SZ\C0^%7[#)J0%K@[WGK_Z+0;+7.JX4KR
M[RS'8A3T Y+#@JXYWLG-9ZCU=*R_3'+M?LFFMFT')%MKE&4--@Q*)JI_^ESO
MPPX@ZKX!B&M _!J0O@%(:D!R+""M :G;F4J*VX<913H>*KDAREH;;W;@-M.A
MC7PF;-KO49FOS.!P_$G*?,,X)U3D1&(!BC"!5"S9G .A6@-J<D&^4*6HS1 Y
MFP%2QO6Y67VXGY&S=^?DG<&0J?%B,JF'(1I>UGN8U1RF%8?X#0Y13&ZDP$*3
M#R*'?-]!: 0UJN*MJFE\T.,,LA9)HO<D;L=M#Z&KH^'1P .?'0_O'U"3-#E*
MG+_DF!Q=OV1G4F5GQG3&I5XK(#\F<XW*G*6?!\*F3=C4A4W?"#LII4+VA[KS
MF154+4';BI 9HPBY*50LR(()AG#!36GD_U:.KQ:JH%%5D/96>AK'+;--3[OY
M\1A%K73?:.8U2AJC/=&=1G3GH.BO$BDGH)&53B3=W02Y^(]>8NYA6W.13W@5
MN+^GN^MGVVW8=D_ -O:Q[7K8=OQL>PW;W@G8)CZV/0_;U,^VW[#MGX!MZF/;
M/Y[MH&$[. ';CH_MP'=@XU=TPYT65(*Y*FPKUR23:X'5O=VL-J^%B6N2K]:G
MYA51-?T7-]43Y,;<0$QHPF%A7+9;/7.@5-76JPG*E6MT<XFF;;IA85Y"H*R!
M^;Z0$K<3&Z!Y6XW_ E!+ P04    "  :FTA28++]0F$#  !Z"P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970X-"YX;6RU5E%OVS@,_BN$L0$MT-66G:1ID018
MFSO<@.6N:-?M8;@'U6828Y;ED^2F_?>C9,=).T?K#MA+(LGZ^'TD)8J3C53?
M]!K1P*,H2CT-UL94%V&HTS4*KD]EA25]64HEN*&I6H6Z4L@S!Q)%&$?1*!0\
M+X/9Q*U=J]E$UJ;(2[Q6H&LAN'JZQ$)NI@$+M@LW^6IM[$(XFU1\A;=H[JIK
M1;.PLY+E DN=RQ(4+J?!>W8Q9T,+<#L^Y[C1>V.PKMQ+^<U./F33(+**L,#4
M6!.<_A[P"HO"6B(=_[5&@X[3 O?'6^M_.N?)F7NN\4H67_+,K*?!.( ,E[PN
MS(W<_(6M0TY@*@OM?F'3[!TF :2U-E*T8%(@\K+YYX]M(/8 ;'0 $+> ^ 4@
M'AX )"T@>0DX)&G0 @8N,HTK+@YS;OALHN0&E-U-UNS !=.AR?V\M'F_-8J^
MYH0SLX](0=/P#O[F2G&; SB:H^%YH8]I]>YV#D=OCN$-Y"4L\J*@7.E):(C9
MXL.T9;EL6.(#+"R&A2S-6L,?98;9<P,A2>YTQUO=E['7XAS34TC8"<01&_<(
MNGHU/(YZX//7LY][O$FZ+"3.7G(P"UHCGH#+Q@G,4:<JK]S%^/J1]L('@T+_
MZV$:=$P#QS0XP'2#)6YX 0:5Z N;'WT&3\B5]N@8=CJ&7DM?W(7$[!U_0$4%
MAFJ(K5)YN8+"!L$)A",Z=8[QN$^KGR%ID# &T1P].H09?^H[O7._I4%KB366
M8-1CYUD01ET01K\6A"S7J:Q+ W05L<]EO[WDE$5O^_S[&2QY"7OFSEGGSIG7
MSB=IZ&35Y=8+S&!9FUIAF]**/]&+8?K\:@P/G6'[5#W,DH0NUD./FG&G9OP*
M-<^8^W)_-?Z!>C >]U.?=]3G7NI_*K2UM#O+BK@!'^FMUGU9O3S_00(;C?HE
ML&A7V".OB 7=)E$+^+I <8_*5SS8WFO!?G.A8O&.*_8ZT#Y-I31T_PRD4E .
M4SI4NP+1E\^?6$VBMA[X-.[J-DO\0>:/KP[RKD2SP>\.\JX,,W]M^[]!]EME
MP\,/1;C7K A4*]?T:7 5H^E;NM6NL7SOVJEPM[WI2A=<K?)2D]8E0:/3,U*E
MFD:OF1A9N=;G7AIJI-QP3<TQ*KN!OB^E--N))>C:[=EW4$L#!!0    ( !J;
M2%)9D*?!W (  "<)   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;+56
MT6[:,!3]%2OJ0RO1)B2$ @(D"JLVJ=U06;>':0\F7,"J8S/[4MJ_G^V$%&A(
MJZE[@=B^Y_C<>Z[C=#=2/>@E )*GE O=\Y:(JX[OZV0)*=47<@7"K,RE2BF:
MH5KX>J6 SAPHY7X8!$T_I4QX_:Z;&ZM^5ZZ1,P%C1?0Z3:EZO@(N-SVO[FTG
M[MABB7;"[W=7= $3P/O56)F17[#,6 I",RF(@GG/&]0[P[:-=P$_&&STSC.Q
MF4RE?+"#+[.>%UA!P"%!RT#-WR,,@7-+9&3\R3F]8DL+W'W>LE^[W$TN4ZIA
M*/E/-L-ESVMY9 9SNN9X)S>?(<\GMGR)Y-K]DDT>&W@D66N4:0XV"E(FLG_Z
ME-=A!Q"'1P!A#@C?"XAR0.02S92YM$84:;^KY(8H&VW8[(.KC4.;;)BP+DY0
MF55F<-B_ 5,#3<[))+.1R#G)YTY'@)1Q?696[R<C<GIR1DX($^26<6XLT%T?
MC0++XR?Y;E?9;N&1W4:07)"H7B-A$ 8E\.&[X?7V/MPW>1?)AT7RH>.+CO -
MM ;4G0JFJ&"*'%/C"-,W7((BU/&5E25#QPYM#]9COQ&TNO[C;NXE,<UV$;,G
MJU'(:E3+6H&BR,0B\[1&;AB=,L[PN4:&:Z5 8(U,D"*8@XG6^VLFJ$@8Y60L
M-7,G[=>G)[3'=LK!X#7^+DNP6L=:GR\H774&22+7 O68/E-#-Q S,Z/6,-OJ
M8J!S767=\9\WV2MQ7)0XKNRA'=*J1FH6=,W*)'*IA+_0EI6[^:I7ZG%TT$\E
M,8V@O)\N"W67_]Q/7Z5(/K2EJJ5LW78G;\>$%QEE'?2QG'LU;!4U;+WC52$*
MRK>L;KVR,0J:!U:7Q+1:Y5:W"YGM2IG?)1K'N+7Y+87MUR^NN'V@\'5,'!XJ
M]'>N,?L)<4O5@@EM1,P-*KBX-'"57<O9 .7*W6Q3B>:>=(]+\R4#R@:8];F4
MN!W8R[+X-NK_!5!+ P04    "  :FTA2G>E4IG,"   X!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970X-BYX;6R-5=]OVC 0_E>LJ ^MM#:_("U5B%1@TR:M
M&BKK]C#MP20'L>K8F6V@^^]W=D)&64![27SG^[[[[F)?TIU4+[H$,.2UXD*/
MO=*8^M[W=5Y"1?6-K$'@SDJJBAHTU=K7M0):.%#%_2@($K^B3'A9ZGQSE:5R
M8S@3,%=$;ZJ*JM\3X'(W]D)O[WABZ])8AY^E-5W# LQS/5=H^1U+P2H0FDE!
M%*S&WD-X/TULO OXQF"G#];$5K*4\L4:GXJQ%UA!P"$WEH'B:PM3X-P2H8Q?
M+:?7I;3 P_6>_8.K'6M94@U3R;^SPI1C[\XC!:SHAILGN?L(;3U#RY=+KMV3
M[)K89.21?*.-K%HP*JB8:-[TM>W# 2!,3@"B%A = P8G '$+B%VAC3)7UHP:
MFJ5*[HBRT<AF%ZXW#HW5,&&_XL(HW&6(,]EGP!YH<DVFLJJE &$TD2OBW.C3
M:%[.P%#&]15&/2]FY/+BBEP0)L@CXQP_A4Y]@THLGY^W62=-UNA$UC BCU*8
M4I/WHH#B+8&/)71U1/LZ)M%9QAGD-R0.WY$HB((>0=/_AH>C,W+BKJVQXXO/
MM_7'PU(;A4?UYQG.0<<Y<)R#$YQ?:E#4,+'NZW<#'3JHO;G;+(KBU-\>MJ G
M)AAT,6\T#3M-P[.:%ILE=T>%B5Q6T*>L(4@.LE['@R-E?3%QO[*D4Y:<5?95
M&LJ)P#G8",SM6>[3E_S3E?!N=*2O)^8V/-+G'US""M3:S2:->3?"-.>X\W;C
M[\'=^B/_!,=B,\7^TC0S]9&J-1,:*UHA97!SBXI4,Z<:P\C:7?6E-#@XW++$
MT0[*!N#^2DJS-VR"[F>1_0%02P,$%     @ &IM(4@)QGVHG P  $ H  !D
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MP7[ 72ZQ90-E%^#]A93F?6";@J8)'/\%4$L#!!0    ( !J;2%(/.7/XB0(
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MK]:?8/#C!9:*&_\EZR$V"DC9&:O$ $8%@LG^3U^&/&P!XO,#@&0 )+N R0%
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MX0ODTR%@<H&*O9OT^*B";A1?(,<. 3.Y12$Q(&PY>'Y15*U'[X)LZ8()C+G
MA %4AA(I'9B5;G0IW;ZC3BU=8"ZE$\B 1! >'$= 6D2$(T@+^80(F#U_0T8=
M @Z5OT$_?XN$:@NX;X4Y*W3%T%6 I(MP^="5RJC9F]^4RNR);#-^TH.L/ 3,
MD[TARPX!,V1O1)_-N.CO7AXPY@(3!E QOD-"=_3N)%2$([@#^9.(V0U*!'(H
M$8>R*!$:CY*ZVEHE#XU/2:>9$BEV0)SX(H'7F/,]5E?!XNVV.H0*</]VD6WR
M]7+3W&XJL7A[-S]_A[+VJ"G)%7(U$?/8F@CD:R)F,#:A^O0&'?Z8P)@+3!A
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MU1/(=$80IBX3R+3_93T8?O(:X6^'3_QRGG>J+O#4/+G;.I$GP<:?]9[EVWF
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MDQ;N%)=Z0-8O0%B_L+D#B0?A]\+C#G.?WM!W+;C F M,&,#N4")#&B ,:8Z
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MD;Z( &;(2VM>%+21MK2L]I!6*$#:VK+^#%22]6)9&2@=Z\"R+EC9LD[KZL]
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M("[6Q_7SSP7=!@MZX \5'3-%;U9KEE2'*[AC1,$=KN#.O!9!2JHB9)N3*=I
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M+<$["!,S4BEX"&%B0"H5,>5^6T!@! 7& . @E8),*NR2^J3]$A731](&P;9
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MTYP*ZJ[PD,Z8T1FW=-8:4Q'\8;!G9B*H8/&"%1XO,#K/QVSR,DUG&#"" F,
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M*T7VE?IE;0<O:A=@]]=*T=9P"<91GOT#4$L#!!0    ( !J;2%+HE"5G/ 0
M +$1   9    >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;*58:V^C.!3]*U:T
MTK92)V">H4HCM4W?31HUFMT/J_W@!">@ F:,T\SLKU_SW  7Q.SD0P/..8=[
M[KUV;:9'QC\2CU*!OH=!E%R-/"'B2T5)MAX-23)F,8WD+SO&0R+D+=\K2<PI
M<3-2&"B:JEI*2/QH-)MF8RL^F[*#"/R(KCA*#F%(^(\;&K#CU0B/RH%W?^^)
M=$"936.RIVLJOL8K+N^42L7U0QHE/HL0I[NKT36^7-DI/@/\X=-C<G*-4B<;
MQC[2FR?W:J2F =& ;D6J0.37)[VE09 *R3"^%9JCZI$I\?2Z5+_/O$LO&Y+0
M6Q;\Z;O"NQI-1LBE.W((Q#L[/M+"CYGJ;5F09'_1L<"J([0])(*%!5E&$/I1
M_DV^%WDX(6"[@Z 5!*U),#H(>D'0AQ*,@F ,)9@%P1SJP2H(5I-@=A#L@F /
M)4P*PF0HP2D(SE "5LO*J8,I5;%;U>ZDE.7&K7I;792RX+A5\:YZX++DN%7S
M3DI9=-RJ>F=@9=EQ5G<EGR39#)L30693SHZ(IWBIEUYDTS3CRXGE1^F"LA9<
M_NI+GIBM!=M^>"QP*4]^1_3;P1<_T%DVBMYI?.!;3\Y7M.)LSTEXCL[F5! _
M2,[1%_1U/4=GOYVCQ".<)LB/T,(/ KE.)%-%R-C2)RC;(HZ;/ ZM(PX=+5@D
MO 3=12YU ?ZRGX^U'@%%)J7*C%9FYD;K59S3[1CI^ )IJJ8" =WVT]<TEG2U
MDS[OIS\?HE[Z73]]07AO\/>#O6,'H#\,]@[2'P=[!^E/@[V#].?AWB< _66X
M=XC^.MP[1%\,]P[1E[_6\V^_UC:K_YWYV@S6J[5-S_3T#KV[?#7[ZWJ3""ZW
M+G_W:!J5II%I&GWKI=Q)E2MC<H'6V?('+7FYU"232G=VGS-SK$^5S]-5),=8
M)Y@&8MY6T<96'7/7QAC-)]U#T> ZYJ&-L<9:'?/8QF"]*?0$@,RQ4P<] R#<
M5'II@R9CRZE]ZHQ70';2=+$ LF&-C3IH";IH*+T!N5>;H%4;Y!ACLP+5>M&L
M>M'\N5Z$>C"7,$\M:!I6LT^C%=M0V]0@Y+R--!U0\ZZ-='0=0MX#@:J."D$?
M "BV0>AC&ZKIA@-!G]I07=5!5\^ *K9,"/H"Q&IC, .O0  8SL "2I8]L2'L
M$I U'!#Z!G2 98 1K"!?$[.9@UI?6U5?6S_5URC.=Y\7B+BNGQY$28#(07B,
M^_]0%Y&0'2(![7*L5I"EFY;U0=":';NR8_?:N<["0^13[IO))J!HQ^2)OCEW
MT4'N6SDB:,,(EYYB:?I3FFL"41R0")KH-M"^L-?E(&CN53DY6H24[[/#?X*V
MJ:7\/W$U6KU?N,Z.68WQ&WRYP,#X$E^N\M<'_\GG+S/D7F;O1PD*Z$X^2AW;
M,F">OR#(;P2+LX/-A@EY4,HN/4ID%E. _'W'F"AOT@=4;VEF_P)02P,$%
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ML'<0$RD1GZ&\8J&?%_H[.E4TD;]:K'=KZ]W<NK?).D\2?8N2QO8.BJKRIV]
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MHI,7I^@%BC-T'2>)2F%Q-I#*H=+L8-IT?E5W3CHZQP1=BTPN"_0FF_%9V\!
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M#WTS48 $[!1 DR= 2@(X2T3K!''KQ(=,C5L2_\MGZ"011<'5FF"AEIA@Q1!
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M9/ML0!&IHD\7 R.7KG/-I*$^Z!X3NMJ@L@!Z/Y?2/ WL!ZK+TO@74$L#!!0
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M@5#8P' T3A&-TQC-'_)^8AL#-!HXE1[%)C;V_1I607*#QON@"\"2K2DYO81
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MNIILW_QO#T2\S-Z^/L1"Q&'V<<'<*4M2@/Q^%L?BZ2"]0/'[B\%_4$L#!!0
M   ( !J;2%)43V$L6@(  $H&   :    >&PO=V]R:W-H965T<R]S:&5E=#$P
M,RYX;6R=55UOVC 4_2M6-&D@=3@)'UNK$*F%3>O#-%2T[6':@TDNQ,*)4_N&
MM/OULYV040U*NSP0?]QS[CDW]B6JI=KJ# #)0RX*/?4RQ/**4IUDD#,]D"44
M9F<M5<[03-6&ZE(!2QTH%S3T_0G-&2^\.')K"Q5'LD+!"U@HHJL\9^KQ!H2L
MIU[@[1?N^"9#NT#CJ&0;6 )^*Q?*S&C'DO(<"LUE012LI]YU<#6;V'@7\)U#
MK0_&Q#I92;FUD]MTZOE6$ A(T#(P\]K!#(2P1$;&?<OI=2DM\'"\9__DO!LO
M*Z9A)L4/GF(V]3YX)(4UJP3>R?HSM'[&EB^10KM?4C>QX] C2:51YBW8*,AY
MT;S90UN' T P.@$(6T#X4L"P!0R=T4:9LS5GR.)(R9HH&VW8[,#5QJ&-&U[8
MK[A$97:YP6&\1)EL,RE24/HM@?N*XR/I?<4,5)_TYH","]TG[\@;0HG.F (=
M432)+9PF;9*;)DEX(LD<D@$9!A<D]$/_"'SV8GAP^11.C=W.<]AY#AW?\ 3?
MQ\;ES^N51F7.T:]G.(<=Y]!QCDYP+LSI Z4@)=I6M"T5815F4O'?9KW'BW:U
M?ZR"#?W$T=NKMXO'OGLBNCNB:]3I&KU&UP4IF2([)BIP@BJ=DA)4(^RHKH;^
M\D"7/S"J@N.RQIVL\>MDM?7B6E?G:S7^IU9_J]0<J.<BG@B>=((G_R78-$:-
MK$AYL3FG>G)6]7,1C6IZ<--ME_W"U(87F@A8&XP_>&^,JZ9S-1.4I;O\*XFF
ME;AA9IH]*!M@]M=2XGYB^TGW]Q'_ 5!+ P04    "  :FTA2- JZTR8,   N
M9@  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&ULO9UM;]LX$L>_"A'L
MBQ:XU!H]JT@#;-,KKL 6UVNW>R\.]T*VF42H+&4E.=D ]^%/DA\X%JDA+;%Y
MT]K)B!G.2#^/./S+5T]E]:.^Y[QA?VWRHGYW<=\T#V\7BWIUSS=I_:9\X$7[
MF]NRVJ1-^[:Z6]0/%4_7_4&;?.$Z3KC8I%EQ<7W5_^Q+=7U5;IL\*_B7BM7;
MS2:MGM_SO'QZ=P$7AQ]\S>[NF^X'B^NKA_2.?^/-]X<O5?MN<1QEG6UX46=E
MP2I^^^[B5WA[ W'2'=&;_)'QIQJ]9MU<EF7YHWOS:?WNPNE<XCE?-=T8:?O?
M([_A>=X-U3KRYW[4B^,?[0[$KP^C?^QGW\YFF=;\ILS_G:V;^W<7\05;\]MT
MFS=?RZ=_\/V,@FZ\59G7_;_L:6_K7+#5MF[*S?[@UH--5NS^3__:1P(= /[(
M >[^ -?T &]_@-=/=.=9/ZT/:9->7U7E$ZLZZW:T[D4?F_[H=C99T>7Q6U.U
MO\W:XYKKCVE6L<<TWW*VX6F]K7B;I(9=LE?];_[H?U/>LH]9D1:K+,W9KW7-
MFYJEQ9K]EJ7++,^:C->L3<E7OMI655;<L?=IG=6OV:L/O$FSO'UUR;Y_^\!>
M_?*:_<*R@GW.\KQ-8GVU:-HY=)XL5GM_W^_\=4?\_<!7;Y@'?V.NXSJ*PV^,
M#X?D]/!%&[EC^-QC^-Q^/&]DO%TPWA(C><>1O'XD?V2D3T7#*UXWETN>]C&L
MNVCVL55%:3=8T _67:N/UTGL!U>+1QP+V2AV/?]H=.*G?_33)_W\^Y_;K'G6
M>+<;(D1_V(^B@7.RC>=X:M^"HV\!F8T/O,H>TXX+9$K"XW A.=7?RZ8]W],^
MQ:I9AM(,P DC&,Q3MDJ<.%1/-#IZ%MF8:'P<+B8G>E,637O*=1?^JKTJLS6O
MTAZRY3+/[OJ7R@#$<@J]P>QEDQ#4<T^.SB8&6<D%>E2>)?*?=8:NR3:^$ZE]
M T?@U"&]:S];VD^.@G4DY,7JN0MH4[4?5C7[SV>^6?+JOT3" &$;;)P!($ &
M[GF.=X!?565=7QY_5#^E#V)"2GB[4E#=>!!WE8T[0B40^ 3/2D $YX &G:6
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M35,^]%_OL2R;IMST+^]YNN959]#^_K9L;V#V;[IO##E^1<SU_P%02P,$%
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M!9\)907P^5PBOOF-=5#\6V+X'U!+ P04    "  :FTA2/>:><5X%   8(0
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MR&3",R(@&EIG[FG@^AI@+'XGD,O:,]&I/'+^I!<7X=!R=$3 8*HT!<6_)4R
M,<V$<?PM2:W*IP;6GU?LWTWRF,PCE3#A[$\2JGAH]2P20D073-WP_">4";4U
MWY0S:7Y)7MHZ%IDNI.)I"<8(TB0K_NES68@:P.V\ O!*@+<-:+T"\$N _UY
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M!(WSQP"(#RP#R-^7E(KM2S9 =6,Y_0]02P,$%     @ &IM(4J5ER#5B!
M 1D  !H   !X;"]W;W)K<VAE971S+W-H965T,3$Q+GAM;,596X_:.A#^*U;4
MAZW4W<0VX5(!TI95=2J=55?=TYZ'H_-@@@&K24QM ZW4'U\[R<:!7#8I&_4%
MXF1F&,\W\\TX3(]<?)5;2A7X'H6QG#E;I79O75<&6QH1><-W--9/UEQ$1.FE
MV+AR)RA9)4I1Z"+/&[H18;$SGR;W'L1\RO<J9#%]$$#NHXB('^]HR(\S!SI/
M-SZQS5:9&^Y\NB,;^DC5Y]V#T"LWM[)B$8TEXS$0=#US;N';!9X8A43B"Z-'
M6;@&9BM+SK^:Q8?5S/&,1S2D@3(FB/XZT 4-0V-)^_$M,^KDOVD4B]=/UM\G
MF]>;61))%SS\EZW4=N:,';"B:[(/U2=^_(MF&_*-O8"',OD$QTS6<T"PEXI'
MF;+V(&)Q^DV^9X$H*,!!C0+*%%!;!9PIX&2CJ6?)MNZ((O.IX$<@C+2V9BZ2
MV"3:>C<L-C ^*J&?,JVGYG=4L ,QH00LEDKL-41*@FMP]9XP ;Z0<$\!7P,K
M)U^#JSNJ" OUU37X_'@'KEZ]!J^T/KAG8:C!D5-7:=_,+[A!YL>[U ]4ZT=P
M S!\ Y"'O KU16MU.#E5=W5$\K"@/"PHL8=K[-U*295L,(1S0S@Q-*@Q] ]7
M)-1YE4>9));?@+4)[\&$MRI8J5$_,6HJ\3#' [VO0S$B91F_('/B[2#W=M"X
M[;\96;*0*4:;]N[GUOQN>P^M^><"D%H>%C<W\LX"4);!@V%U (:YR\-&EPMI
MKAV7;!,315<:-+"EJPV+-R=5\M\]C994_-\0JU'^PZ/+$FZ<&QKWD7#CBEB>
M)UQ9QA^,J^,]R;V=O$#"0<^RF==;RF6FFW.N0J@VZ6"!A&$/:0=^ MW*=*.*
M=:<0@L;!#Q#P6 G=&T^D/JHM%9F,RA+"36^FBS:9#"UWP@O)$UKVA+W09V:U
MB!(:GR-9(8-P#9*60.'@3R)Y&P1BK^T5TCH#,N;Q$\"%AZV M7P._9>H5DNV
ML)EM+ZK681D^/#K'N"R$80W$EJGAJ!^(%X)+>9T#+(]DUV>]VHX!QQ?6JZ5S
M..FE7B=E,'W_',RRT+"&>9%M&*BY8?0/9A\EBVQG0? %2A85YF+46\EFID^K
M\9R6*X7\&IAM'T'-?>2W8?X0*RJH5$!HA;Y+%MDV@YH']6=+%EE21QVG]'8E
MB\K3=Z$:,RS+,LBO.:(@VS50'S-Z!RQ[J5C;7E#S2:!EQ5IV1QT/!%TJMCSR
MPW-:KI#Q:B"V;00UMY$BQ#%7+W,4P[8I8._"T[_E7]P\V?_N^1\V!#4[_I=%
M:D8;;-D=-T_N[7(/%UY^=!S?.^0>+L_GI1 TB9RZ;)D5MQ_@NZ7>1<>Q5@EL
M.1TW#^K/)[!E6]QQ1F^9P.7)NX1>6:0N@2UYXO:S>4_H572'5N!9PL;-XWC+
M(K1DBCO.Y%V*<%)ZR5B"L4DD==DMO)\V?P[<$Z%QD""D:ZWCW8RTLDC?MZ<+
MQ7?)*^LE5XI'R>66$KT%(Z"?KSE73POS%CS_UV/^"U!+ P04    "  :FTA2
M2'4Y#&\"  #A!0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&ULM53;
M;MLP#/T5PD\MT-6.G:9%X1A(4VP+UDO0[H*AZ(-BT[9073Q)29IA'S])<8VT
M38*][,42)9Y#\M!4NI3J2=>(!IXY$WH8U,8TYV&H\QHYT<>R06%O2JDX,=94
M5:@;A:3P(,[".(H&(2=4!%GJSZ8J2^7<,"IPJD#/.2=J=8%,+H=!+W@YN*-5
M;=Q!F*4-J? >S;=FJJP5=BP%Y2@TE0(4EL-@U#L?#YR_=_A.<:DW]N JF4GY
MY(Q),0PBEQ RS(UC('99X!@9<T0VC5\M9]"%=,#-_0O[1U^[K65&-(XE^T$+
M4P^#LP *+,F<F3NY_(QM/2>.+Y=,^R\L6]\H@'RNC>0MV&; J5BOY+G580/0
M2W8 XA80OP7T=P"2%I#X0M>9^;(NB2%9JN02E/.V;&[CM?%H6PT5KHOW1ME;
M:G$F&TMAJ*A0Y!0U$%% +CFGQC;*:#CX\G-Z=WLUN8?1S>4(IL388[BBAE;$
M=>$0#B[1$,KT(7R QE^GH;%Y.?8P;W.X6.<0[\CAFJP@.CN".(JC+>CQ?O2H
M4<>01 [>.WL-#ZT8G2)QITCL^9(=?)_LKP^O97FXLCXP,<CUXYX(21<A\1'Z
M.R+<S/D,%<@2B-:H#!:M='J;=FNN@>=R,[G(DC1<; G?[\+W]X:_%:MG^%JC
M(@W.#<WU$4Q$#@_7Z-)ZA#_0=?T@)ZJD[+?D=';XOOT=9H\H)UU6)_])]D$7
M8?"/LK=J V$,*RS8"J@HE0M<;/O_!N\ZT'O3@7!C -WC=TU4184&AJ7%1,>G
MMG:U?E#6AI&-G\F9-';"_;:V;S JYV#O2RG-B^'&O'O5L[]02P,$%     @
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M,6!] -U7QN#.\ 3C3RO_"U!+ P04    "  :FTA2)ZT*2SP"   A!0  &@
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M J1A2A(-^30Z[YTM)NZ\/_"%P=ILC8F+9*G4@YM<9=.HZPP!AY5U#!0_C[
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M:A2CKHT/](7,WUPNR/D"#&4<1V>$"7++.$<_G?H&\6P1/Z]1;BJ4L =E ?F
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MWNF9$23S%II/M%AD364JM&E1V3 Q7QTH+< \GPFAUQ.;H/R.Z?T#4$L#!!0
M   ( !J;2%(C'@CLD@(  %8/   -    >&PO<W1Y;&5S+GAM;-67W6[:,!3'
M7\5RIZF5IH; @+(FD;9*2).VJ1)<[*XRB0.6_)$Y#H->[E5VNZ?8H^Q)9L<F
M"90@UHL5;K#/.?;O_&,[YB3(U9KBR0)C!5:,\CR$"Z6R=YZ7QPO,4'XM,LQU
M)!62(:5-.??R3&*4Y&82HUZWTQEX#!$.HX 7;,Q4#F)1<!7"F\H%;/,Q":$_
M> N!Q=V)!(?PX?+UMT*HVU? MA=O+BXZ#U>WN_[+,G %O;W0_A'0ZTX[5\?:
MT(-MM!NN29N9;1.'QVDZK*I=U\U1^ /L-O!H/_C/CU\M6U1'#F[2L+,?/!G+
M%G =.0SV]X-__VSA5H$&UG.G-PI2P>M#W(/6H?,BAL$2T1#>(4IFDIA9*6*$
MKJV[:QRQH$("I=\>+<0WGOS1AGUKF1?+<1CA0I:Y;0;[.W/#=P(;RP@DE%8"
MN] ZHB!#2F')Q]HH!Y?.)R'@^M-UIA7.)5K[W3ZL)Y2-3C(3,L&R2N/#C2L*
M*$Z-'$GF"],JD7DFJ)1@NI,0-!<<E1HV,UQ'8V-,Z<3<.E_3+?8J;>QH>5!X
MU=6"7-=BK&'X39IE-[']9W%!1I9"?2CTX_#2-B<%WTN<DE5IK])*0!O=;Z>C
M+*/K]Y3,.</VX8].& 5H,P\LA"2/.ILY*K%V8 G!$DM%XJ;GNT39%*_4YCBM
MTG;-W3/4_'_7>8XYEH@V1>NS?\JK_&S%[F_Z)327U\JNXKTB>\/3U^A*DU,7
M.3@'D6>PW;W1Z6MTI>.IBSR'E1R^V,W^+R+]DQ3IN7*M41-N5825%YC*.X1?
M3(5/ZZ1@5A"J"'?6@B0)YD\*0XU7:*8_<K?X>GR"4U10-:V"(:S[GW%""C:J
M1MV;A7"CZOXG\WC^H$Q8?TE'?P%02P,$%     @ &IM(4I>*NQS     $P(
M  L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2
M!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4
M+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(
M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/I
MKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  :FTA2_<7@
M3%4(  "Q3@  #P   'AL+W=O<FMB;V]K+GAM;,6<47/:/!:&_XJ&FTUG-AMC
M,,:=IC,TI"TSV31?TG8O=X01H*F164FF37_]RB9)I6"_NS<'KA(,F =AG4?'
M.M*[GZ7^,2_+'^S7IE#FLK>V=OOVXL+D:['AYA_E5BCWS++4&V[=0[VZ,%LM
M^,*LA;";XB*.HM'%ADO5>__N^5QW^L)_4%J16UDJ=[ ^\%V*G^;/\_5#MI-&
MSF4A[>-EK_F_$#VVD4INY&^QN.Q%/6;6Y<_/I9:_2V5Y\9#KLB@N>_W]$]^%
MMC(_./Q00W[E<],<L7Q^SQW(96\4N1,NI3:V>45S?NX8=\*]>/^HLN5'65BA
MI]R*3[JLME*MZM.X;W'A?8VF'9[_[AOQK?Y_FK%<+F4NIF5>;82R^W;4HJ@!
ME5G+K>DQQ3?BLG=5[H1F6[X2]9=RGS);[+^@=61><^FWTCVA9XN&D9)'F;*0
M"_?I"_900]1O,*Q<LIG*2P\R!I#QR2"ORLW6@QP R,$1(3_P@JM<L.:*-![@
M$  .3P;(SNZX!YD R.1D/_6#+7,/<@0@1R>$_'?L0:8 ,CU=I^%F[4&. >28
M%O*AVFRX?JRAC%PIZ=[&E77A.R\K9:4'F0'(C!9RDO^G<I_9'/>C=H3"=D3+
M="]V0E4BX($:(?9(W3E_G,^Y<1=;[F*R4*9YD<^'#-(G5LA4+*5JV)35<E[5
M+V!;%P-]0&2//K$^:MMNA!O6_ I_5"2,/K$QKKE6;J!DV-:-6<R:ZV#0@BS1
M)]=$4?!YJ?E!IT1:Z!-[8:9VPM@FS/I(2 )]8@O42,JZD79X5:&0WR>.^2Z'
M<->3??Q[T_]<L%<+)ER$W=;O\R%1R.\3Q_Q/9;GX*8NBH9,N25&KFH!Q8\(!
M78PL$!-;X$:X@!O0( ?$Q [X8M<N3N25UJ+^69N6:MK/Z5Q7?NR(83)!K(*/
M4KFAKXMKC&OM?E?QNL/&R ,QL0<:D:[+8B&T^5O3+^RCSX9\$!/[X".7FNUX
M40FV<5=>I<6K+ALC)\3$3I@*+7>\SOM=AS565P>_*W)#3)\S6'?-"7?EB7VO
M<+[?R -;Q,@6,;$M_JJXMD(7CVRY[R2\8"Z!X.RL4KQ:^)C((#%UUG#U^7KZ
M[>::S6;LG'V?W'R;?)U]N663VRG[Z]O$QT0.B8D= I.;($T<((D,B"7BIS>N
M.<^^<O?YYHV/AZPR(+;*<Z;3"H8\,B#V2%?*\P3J8\+;4D=,+%K;$!EE</0,
MHQ41:65 K!5O4-_1.Y!6!D=(.9[&]ZULR"8#8IO @3X[\S&130;$-@F&^F4S
MAO4'_#XFLLF V";[L7[[)3A$_A@2^P,.^P/-#9%'AL0>:1_VM[8FLLKP&%9Y
M-?YOA41.&1([I3T1>+DV?4PXX4%LE_:,H!43&69(/^?1G1JP<Q\3J69(K!J8
M'(3]'%EG2&P=/.H>^)C(.D-BZ[P:==_60:FY4L^FPG)_YF.(K#,\XMR'P_QB
MQ>^"/S$604!*D(.2X^8PD]5*BY5C8?4LF/03UP0Y*#E6+G/X@[]J3*2@A%A!
M'N559:S+'G3=CKE[5XWL8R())<>X4]:>?XE?MO(QD8028@EU8]:U"WZ%10+G
MW8DEU(W9!%0?$TDH(990)^;^"1\322BAEA!JS<"5"9)00GTCK1/S7T*N_!J!
M!$DH(990Y^3M/G;Z12%(0B-B"85W6IX>?1#N7*(NIO(QD81&Q!(*,5V27B.X
M!G4G>XV)+#0BME"(V<1*]5S XBX('Q-9:'3<VVNU>7CQYD7J/B:RT(C80B'F
MO7!=*9>%W/?V,FA-9*$1^<TV@!G$S1&L_R*V4-MMRY91W @I:$1>_^672-0C
MSG+G$CAIV.23H_4QD8)&Q HZP/S 'UVC?A:\L.NK(+8C!8V(%72(*>0GH5K2
MM10I*"57D'^S^L&=<5$5HBT:I4A!*;F"?,SF;M+W^FZ28?-'=E7XF$A!*;F"
M?,S)SC5A?=_HW)WLW/  $RDH)5<0:DT_PTB1@E)R!?F8U_L[FP\BK[3+VX,J
MEA0I*#WJ?,^-W,BZ@/;.A4XE=% WFR(%I<>K-3N(1J&%4EB$?+SZLW8XY)[T
ME)5H81TW<D]*[!Z,Z=_1'"/WC(G= ^?1@M8<(_>,B=V#,8/61.X9$[L'8PY]
M3.2>,;%[7F8E\?W,,1+/F%@\+XS>U,#3L9K5QT3B&1.+YP4SS'6;PZ'&QT@\
M8V+QO&#^D]LG=?_!O/%'PF,DGC&Q>/ZT)C?KIA/=NERR_G^FW E]3+C^A5A!
M>/(\B$9(06-B!6%,/QIE2$$9L8*ZYOCOM'2'_86"&5)0=J)2A*F86S;S1\(9
M4E!VDD+I)\Q[?_H\0PK*J(L1.C!GR@H=Y!49LE!&73S=@?FP%L62W?N8R$(9
ML86Z,.LB!<W]N\,9LE!&;"'XHP>#S0Q9*#O&/-!!-4]SU/6@(" A"V7'F <Z
MP)S*G5P(M0BZ$%R'25U0W8KY,ESR,/L17IQ)[*%VT$GNWEBYEP>@<-5F=(QE
MFP>@]R(OG./E,@"%RS>CDY3%-<.2-^'=['X$EW%&)RN-:YX)0.':SN@DBWE>
M,KD %"[UC$ZRKJ<=%*[^C(B=U%UN>*5+$RX=AVM"(V(K=8->+Y<B#T#A2M&(
MV$O=H)_%(MQ")8*K12/R"H4NT-?5,WV\;0#UO@'=H ?AZ7_L)T"_,0THBCT+
M0*&9J'<6@*#!2+2/-QB@WF$ @PX"4&@FZFT',.@P (5FHM^% ($F 2@T$_7&
M!!AT%(!",U%O5X!!TP 4FHEZ$P-<#!]V)F@FZHT,X%K9,#S!K0SZ^[T,+IJ7
MF_?O%ON:O%OW(<8=SWF1WVE6_]F?:YC4WWM9%<65._9%W91\\;SCVO-N<>__
M"U!+ P04    "  :FTA2;/*&>TP#  !K1@  &@   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QSS=M)3AM1&$7AK2 O@'I]$P&C3)A&;, R12/<R5518/>Q
M8 #W5P:9H#HCJVSQ?$<?J*AS]6O<KN?GPWYZ>CY.%Z^[[7ZZ7CW-\_'',$R;
MIW&WGBX/QW%__N3A<-JMY_/EZ7$XKC<OZ\=Q",Z5X?3UC-7-U=<S+^[>CN/_
MG'AX>'C>C#\/F]^[<3__X^#AS^'T,CV-X[RZN%N?'L?Y>C6\;C_?GH;W%W]Y
M/GEU<7M_O3K=WOO5L/2@((/"\H.B#(K+#THR*"T_*,N@O/R@(H/*\H.J#*K+
M#VHRJ"T_J,N@OOP@[U1&!YADL 9H[95K#_#:*]@>(+97LCW ;*]H>X#:7MGV
M +>]PNT!<GNEVP/L]HJW!^@=5.\ T#NHW@&@=S!_; /T#JIW .@=5.\ T#NH
MW@&@=U"] T#OH'H'@-Y!]0X O8/J'0!Z1]4[ O2.JG<$Z!U5[PC0.YJ;)0"]
MH^H= 7I'U3L"](ZJ=P3H'57O"- [JMX1H'=4O2- [Z1Z)X#>2?5. +V3ZIT
M>B?5.P'T3N9F-T#OI'HG@-Y)]4X O9/JG0!Z)]4[ ?1.JG<"Z)U5[PS0.ZO>
M&:!W5KTS0.^L>F> WEGUS@"]L_EG)4#OK'IG@-Y9]<X O;/JG0%Z9]4[ _0N
MJG<!Z%U4[P+0NZC>!:!W4;T+0.^B>A> WD7U+@"]BWG8!*!W4;T+0.^B>A>
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M<',O87!P+GAM;%!+ 0(4 Q0    ( !J;2%+\N#Y;[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  :FTA2DEH75W\#   ]"P  &
M    @($ %0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M&IM(4N4'^Q#2!0  ,1<  !@              ("!M1@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !J;2%(0O@IW? (  %@&   8
M          " @;T>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  :FTA2%XI\DL4&  !<(P  &               @(%O(0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &IM(4D_-V<1- @  W 4
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !J;2%+WD[P?M0P  !,H   9
M      " @4)H  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ &IM(4A,HLS>Y @  + 8  !D              ("!+G4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  :FTA2V8EX0.,-  #4*
M&0              @($>>   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( !J;2%+$.+8)N ,  *,(   9              " @3B&  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ &IM(4NNOV43K
M#   %B8  !D              ("!)XH  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  :FTA2)&D1?]$+  !.)   &0
M@(%)EP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !J;
M2%)%^CVI7P(  !0%   9              " @5&C  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ &IM(4M@JI;_M P  YP@  !D
M         ("!YZ4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  :FTA29HR:++($   I"P  &0              @($+J@  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !J;2%*;Q\C+] 8  + 0
M   9              " @?2N  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ &IM(4I' ()8$ P  WP8  !D              ("!'[8
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  :FTA2>R54
M,2T3  !C.P  &0              @(%:N0  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( !J;2%*)WUA;P0<  #P5   9
M  " @;[,  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M&IM(4C6HEG,7"P  \"<  !D              ("!MM0  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  :FTA2>"D9XUX/  #[/   &0
M            @($$X   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( !J;2%+3GTKT/B$  ">*   9              " @9GO  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ &IM(4C^/ES/) P
MZ@@  !D              ("!#A$! 'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  :FTA2<#X48\("   G!@  &0              @($.
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !J;2%)!
M64<W+B$   =L   9              " @0<8 0!X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ &IM(4B8K.,?Z P  2PD  !D
M     ("!;#D! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M"  :FTA2E4":6"X%  !@"P  &0              @(&=/0$ >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !J;2%)NZZ")4@4  'X0   9
M              " @0)# 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!
M A0#%     @ &IM(4BK-//M:!@  8Q$  !D              ("!BT@! 'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  :FTA25:B]H]H"
M  !#!@  &0              @($<3P$ >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;%!+ 0(4 Q0    ( !J;2%*3G'"OT00  !T/   9              "
M@2U2 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ &IM(
M4JA*@OQD @  $04  !D              ("!-5<! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  :FTA2"5I;,,(#  "M"   &0
M        @('060$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( !J;2%([\[P0[ ,  /T(   9              " @<E= 0!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ &IM(4K[:>CI\!   1@L
M !D              ("![&$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  :FTA2VC)H6#,#  !8!P  &0              @(&?9@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !J;2%)8=X:G
M^P<  ) 6   9              " @0EJ 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ &IM(4O6^LZ&?!0  ,P\  !D
M ("!.W(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  :
MFTA2?["8'WP$  !&#@  &0              @($1> $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !J;2%+)P0,(D <  !8@   9
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M970T.2YX;6Q02P$"% ,4    "  :FTA2E*I@3-T#  #Q#   &0
M    @(&\E0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M !J;2%(.1R%3:P,  &(*   9              " @="9 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ &IM(4A&Y]LC%"P  KU   !D
M             ("!<IT! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    "  :FTA2%9\.<^\$  !=%P  &0              @(%NJ0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !J;2%*RPJ8A"P<
M &<?   9              " @92N 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ &IM(4O:N4NY' P  Z P  !D              ("!
MUK4! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  :FTA2
MS+B?W&0#  !^"P  &0              @(%4N0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( !J;2%*\!U'"<0,  %T+   9
M      " @>^\ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ &IM(4M*W*7-M!   \A$  !D              ("!E\ ! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  :FTA2FR>*X2(#   7"0
M&0              @($[Q0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( !J;2%+ *6S/7P(  +X%   9              " @93( 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ &IM(4O$ ?M?!
M @  T @  !D              ("!*LL! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    "  :FTA2FL:O?DP#  #W"P  &0
M@($BS@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !J;
M2%(PRB1"QP,  ' -   9              " @:71 0!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ &IM(4I3S\49[!   &10  !D
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M=#8X+GAM;%!+ 0(4 Q0    ( !J;2%):P"71VP,  +,0   9
M  " @23J 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @
M&IM(4B2GF7$A P  50H  !D              ("!-NX! 'AL+W=O<FMS:&5E
M=',O<VAE970W,"YX;6Q02P$"% ,4    "  :FTA2I=7\MVT%  "L(   &0
M            @(&.\0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4
M Q0    ( !J;2%+1IQ!9K@(    (   9              " @3+W 0!X;"]W
M;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ &IM(4FQ"%#R= @
M"0<  !D              ("!%_H! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6Q02P$"% ,4    "  :FTA22!6<P, "  !J!P  &0              @('K
M_ $ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( !J;2%(O
M865#MP(  #<'   9              " @>+_ 0!X;"]W;W)K<VAE971S+W-H
M965T-S4N>&UL4$L! A0#%     @ &IM(4@120)F? @  NP8  !D
M     ("!T (" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4
M"  :FTA2AII);NX#  !)#0  &0              @(&F!0( >&PO=V]R:W-H
M965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !J;2%*N)"277 (  "<&   9
M              " @<L) @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L!
M A0#%     @ &IM(4HXEZFQF!0  VAT  !D              ("!7@P" 'AL
M+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  :FTA2]^> L9P"
M  #R"   &0              @('[$0( >&PO=V]R:W-H965T<R]S:&5E=#@P
M+GAM;%!+ 0(4 Q0    ( !J;2%(KXY9WJP(  !0'   9              "
M@<X4 @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ &IM(
M4CP;( 1E!   V!0  !D              ("!L!<" 'AL+W=O<FMS:&5E=',O
M<VAE970X,BYX;6Q02P$"% ,4    "  :FTA2IXJM[>$"  !G"0  &0
M        @(%,' ( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0
M   ( !J;2%)@LOU"80,  'H+   9              " @60? @!X;"]W;W)K
M<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ &IM(4EF0I\'< @  )PD
M !D              ("!_"(" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q0
M2P$"% ,4    "  :FTA2G>E4IG,"   X!@  &0              @($/)@(
M>&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( !J;2%("<9]J
M)P,  ! *   9              " @;DH @!X;"]W;W)K<VAE971S+W-H965T
M.#<N>&UL4$L! A0#%     @ &IM(4@\Y<_B) @  " 8  !D
M ("!%RP" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4    "  :
MFTA28OR5)9T"   .!P  &0              @('7+@( >&PO=V]R:W-H965T
M<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( !J;2%(/RO_DXP(  & (   9
M          " @:LQ @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#
M%     @ &IM(4G\NU+S<%   3<$  !D              ("!Q30" 'AL+W=O
M<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    "  :FTA2^:XD,3D$  !_
M%0  &0              @('820( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM
M;%!+ 0(4 Q0    ( !J;2%(+C4)%?P8  $0H   9              " @4A.
M @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ &IM(4NB?
MJ?QQ#@  8'X  !D              ("!_E0" 'AL+W=O<FMS:&5E=',O<VAE
M970Y-"YX;6Q02P$"% ,4    "  :FTA2/+GBWC4$  "+#0  &0
M    @(&F8P( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    (
M !J;2%+HCC6B9 (  ($&   9              " @1)H @!X;"]W;W)K<VAE
M971S+W-H965T.38N>&UL4$L! A0#%     @ &IM(4AWQ8BUJ @  U@4  !D
M             ("!K6H" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"
M% ,4    "  :FTA2Z)0E9SP$  "Q$0  &0              @(%.;0( >&PO
M=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( !J;2%(')%M:1 ,
M /8.   9              " @<%Q @!X;"]W;W)K<VAE971S+W-H965T.3DN
M>&UL4$L! A0#%     @ &IM(4M\JP<)Z!@  LB,  !H              ("!
M/'4" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%     @ &IM(
M4NB0ICDE P  . D  !H              ("![GL" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#$N>&UL4$L! A0#%     @ &IM(4CT>04M)!@  BR$  !H
M         ("!2W\" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#
M%     @ &IM(4E1/82Q: @  2@8  !H              ("!S(4" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @ &IM(4C0*NM,F#
M+F8  !H              ("!7H@" 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N
M>&UL4$L! A0#%     @ &IM(4E[@BXS) P  K@L  !H              ("!
MO)0" 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%     @ &IM(
M4B!V7:E?!0  HA@  !H              ("!O9@" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#8N>&UL4$L! A0#%     @ &IM(4CWFGG%>!0  &"$  !H
M         ("!5)X" 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#
M%     @ &IM(4CNH]78P P   0L  !H              ("!ZJ," 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%     @ &IM(4C9\:/ [ P
M?@P  !H              ("!4J<" 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN
M>&UL4$L! A0#%     @ &IM(4E4^5]/O!   O10  !H              ("!
MQ:H" 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%     @ &IM(
M4J5ER#5B!    1D  !H              ("![*\" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3$N>&UL4$L! A0#%     @ &IM(4DAU.0QO @  X04  !H
M         ("!AK0" 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#
M%     @ &IM(4IJ$.4LK @  P 0  !H              ("!+;<" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%     @ &IM(4B>M"DL\ @
M(04  !H              ("!D+D" 'AL+W=O<FMS:&5E=',O<VAE970Q,30N
M>&UL4$L! A0#%     @ &IM(4E5']0^I @  2@<  !H              ("!
M!+P" 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#%     @ &IM(
M4LD]T+27 @  H 8  !H              ("!Y;X" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,38N>&UL4$L! A0#%     @ &IM(4NF"OL>- P  \ P  !H
M         ("!M,$" 'AL+W=O<FMS:&5E=',O<VAE970Q,3<N>&UL4$L! A0#
M%     @ &IM(4@&=MKZ8 @  LP<  !H              ("!><4" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3@N>&UL4$L! A0#%     @ &IM(4AK= ,*W!
M%Q0  !H              ("!2<@" 'AL+W=O<FMS:&5E=',O<VAE970Q,3DN
M>&UL4$L! A0#%     @ &IM(4DTS)6T1 P  TP@  !H              ("!
M.,T" 'AL+W=O<FMS:&5E=',O<VAE970Q,C N>&UL4$L! A0#%     @ &IM(
M4B,>".R2 @  5@\   T              ( !@= " 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  :FTA2EXJ[',     3 @  "P              @ $^TP(
M7W)E;',O+G)E;'-02P$"% ,4    "  :FTA2_<7@3%4(  "Q3@  #P
M        @ $GU ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &IM(4FSR
MAGM, P  :T8  !H              ( !J=P" 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ &IM(4H/_L%J7 @  BT,  !,
M     ( !+> " %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     (  @ !,(P
&]>("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>700</ContextCount>
  <ElementCount>602</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>180</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>20</UnitCount>
  <MyReports>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010002 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020003 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210041002 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210091003 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210131004 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210211005 - Disclosure - Defined contribution plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Definedcontributionplan</Role>
      <ShortName>Defined contribution plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210231006 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210311007 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210341008 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Collaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210381009 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210471010 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210501011 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210541012 - Disclosure - Goodwill and intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Goodwillandintangibleassets</Role>
      <ShortName>Goodwill and intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210591013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210661014 - Disclosure - Other current assets and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities</Role>
      <ShortName>Other current assets and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210701015 - Disclosure - Financing arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Financingarrangements</Role>
      <ShortName>Financing arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210791016 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210871017 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Fairvaluemeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210911018 - Disclosure - Derivative instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Derivativeinstruments</Role>
      <ShortName>Derivative instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210991019 - Disclosure - Contingencies and commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Contingenciesandcommitments</Role>
      <ShortName>Contingencies and commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>211081020 - Disclosure - Quarterly financial data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Quarterlyfinancialdataunaudited</Role>
      <ShortName>Quarterly financial data (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211111021 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>220022001 - Disclosure - Summary of significant accounting policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - Acquisitions - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Acquisitions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230103002 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Revenues</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230143003 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockbasedcompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230243004 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Incometaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230323005 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Earningspershare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230393006 - Disclosure - Investments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsTables</Role>
      <ShortName>Investments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Investments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230483007 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Inventories</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230513008 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Propertyplantandequipment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230553009 - Disclosure - Goodwill and other intangible assets - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</Role>
      <ShortName>Goodwill and other intangible assets - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230603010 - Disclosure - Leases - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesTables</Role>
      <ShortName>Leases - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230673011 - Disclosure - Other current assets and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables</Role>
      <ShortName>Other current assets and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230713012 - Disclosure - Financing arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsTables</Role>
      <ShortName>Financing arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Financingarrangements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230803013 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockholdersequity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230883014 - Disclosure - Fair value measurement - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementTables</Role>
      <ShortName>Fair value measurement - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Fairvaluemeasurement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230923015 - Disclosure - Derivative instruments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsTables</Role>
      <ShortName>Derivative instruments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Derivativeinstruments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>231003016 - Disclosure - Contingencies and commitments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsTables</Role>
      <ShortName>Contingencies and commitments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Contingenciesandcommitments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>231093017 - Disclosure - Quarterly financial data (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables</Role>
      <ShortName>Quarterly financial data (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Quarterlyfinancialdataunaudited</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240034001 - Disclosure - Summary of significant accounting policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Acquisitions - Otezla (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsOtezlaDetails</Role>
      <ShortName>Acquisitions - Otezla (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240084004 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails</Role>
      <ShortName>Acquisitions - Aggregate Consideration Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240114005 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240124006 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails</Role>
      <ShortName>Revenues - Customer Concentration, Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240154007 - Disclosure - Stock-based compensation (Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationTextualDetails</Role>
      <ShortName>Stock-based compensation (Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240164008 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240174009 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails</Role>
      <ShortName>Stock-based compensation (Summary of RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240184010 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails</Role>
      <ShortName>Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240194011 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails</Role>
      <ShortName>Stock-based compensation (Summary of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240204012 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Stock-based compensation (Weighted-average Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240224013 - Disclosure - Defined contribution plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DefinedcontributionplanDetails</Role>
      <ShortName>Defined contribution plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Definedcontributionplan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240254014 - Disclosure - Income taxes (Income Before Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Income Before Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240264015 - Disclosure - Income taxes (Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240274016 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240284017 - Disclosure - Income taxes (Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesTextualDetails</Role>
      <ShortName>Income taxes (Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240294018 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails</Role>
      <ShortName>Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240304019 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240334020 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/EarningspershareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240354021 - Disclosure - Collaborations - Novartis AG (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsNovartisAGDetails</Role>
      <ShortName>Collaborations - Novartis AG (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240364022 - Disclosure - Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails</Role>
      <ShortName>Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240374023 - Disclosure - Collaborations - BeiGene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsBeiGeneDetails</Role>
      <ShortName>Collaborations - BeiGene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240404024 - Disclosure - Investments - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsScheduleDetails</Role>
      <ShortName>Investments - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240414025 - Disclosure - Investments - Fair Values by Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails</Role>
      <ShortName>Investments - Fair Values by Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240424026 - Disclosure - Investments - Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsAvailableforsaleDetails</Role>
      <ShortName>Investments - Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240434027 - Disclosure - Investments - Fair Values by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails</Role>
      <ShortName>Investments - Fair Values by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240444028 - Disclosure - Investments - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails</Role>
      <ShortName>Investments - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240454029 - Disclosure - Investments - Limited Partnership Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails</Role>
      <ShortName>Investments - Limited Partnership Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240464030 - Disclosure - Investments - BeiGene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsBeiGeneDetails</Role>
      <ShortName>Investments - BeiGene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240494031 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InventoriesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240524032 - Disclosure - Property, plant and equipment (Schedule) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails</Role>
      <ShortName>Property, plant and equipment (Schedule) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/PropertyplantandequipmentTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240534033 - Disclosure - Property, plant and equipment (Geographic Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails</Role>
      <ShortName>Property, plant and equipment (Geographic Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/PropertyplantandequipmentTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240564034 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails</Role>
      <ShortName>Goodwill and other intangible assets - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240574035 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240584036 - Disclosure - Goodwill and other intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails</Role>
      <ShortName>Goodwill and other intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240614037 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240624038 - Disclosure - Leases - Summary of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesSummaryofLeasesDetails</Role>
      <ShortName>Leases - Summary of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240634039 - Disclosure - Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails</Role>
      <ShortName>Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240654041 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails</Role>
      <ShortName>Leases - Cash and Noncash Information of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240684042 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails</Role>
      <ShortName>Other current assets and accrued liabilities - Schedule of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240694043 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240724044 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails</Role>
      <ShortName>Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240734045 - Disclosure - Financing arrangements (Debt Issuances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails</Role>
      <ShortName>Financing arrangements (Debt Issuances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240744046 - Disclosure - Financing arrangements (Debt Repayments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails</Role>
      <ShortName>Financing arrangements (Debt Repayments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240754047 - Disclosure - Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails</Role>
      <ShortName>Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240764048 - Disclosure - Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails</Role>
      <ShortName>Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240774049 - Disclosure - Financing arrangements (Contractual Maturities of Long-term Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Financing arrangements (Contractual Maturities of Long-term Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240784050 - Disclosure - Financing arrangements (Interest Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails</Role>
      <ShortName>Financing arrangements (Interest Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240814051 - Disclosure - Stockholders' equity (Stock Repurchase Program) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails</Role>
      <ShortName>Stockholders' equity (Stock Repurchase Program) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240824052 - Disclosure - Stockholders' equity (Dividends) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityDividendsDetails</Role>
      <ShortName>Stockholders' equity (Dividends) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240834053 - Disclosure - Stockholders' equity (Components of AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails</Role>
      <ShortName>Stockholders' equity (Components of AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240844054 - Disclosure - Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails</Role>
      <ShortName>Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240854055 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails</Role>
      <ShortName>Stockholders' equity (Reclassifications out of AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240864056 - Disclosure - Stockholders' equity (Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityOtherDetails</Role>
      <ShortName>Stockholders' equity (Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240894057 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FairvaluemeasurementTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240904058 - Disclosure - Fair value measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails</Role>
      <ShortName>Fair value measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240934059 - Disclosure - Derivative instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails</Role>
      <ShortName>Derivative instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240944060 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails</Role>
      <ShortName>Derivative instruments - (Cross-currency Swaps) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240954061 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails</Role>
      <ShortName>Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240964062 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails</Role>
      <ShortName>Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240974063 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails</Role>
      <ShortName>Derivative instruments - (Summary of Income and Expense Line Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240984064 - Disclosure - Derivative instruments - (Fair Value of Derivatives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails</Role>
      <ShortName>Derivative instruments - (Fair Value of Derivatives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>241014065 - Disclosure - Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>241024066 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Sandoz Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>241034067 - Disclosure - Contingencies and commitments (Amneal Pharmaceuticals LLC Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Amneal Pharmaceuticals LLC Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>241044068 - Disclosure - Contingencies and commitments (Immunex and Sandoz Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Immunex and Sandoz Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>241054069 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Repatha Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>241064070 - Disclosure - Contingencies and commitments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails</Role>
      <ShortName>Contingencies and commitments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>241074071 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails</Role>
      <ShortName>Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>241104072 - Disclosure - Quarterly financial data (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails</Role>
      <ShortName>Quarterly financial data (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="amgn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>241124073 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</ParentRole>
      <Position>120</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="amgn-20201231.htm">amgn-20201231.htm</File>
    <File>amgn-20201231.xsd</File>
    <File>amgn-20201231_cal.xml</File>
    <File>amgn-20201231_def.xml</File>
    <File>amgn-20201231_lab.xml</File>
    <File>amgn-20201231_pre.xml</File>
    <File>amgn-ex104_20201231xq4.htm</File>
    <File>amgn-ex1050_20201231xq4.htm</File>
    <File>amgn-ex105_20201231xq4.htm</File>
    <File>amgn-ex107_20201231xq4.htm</File>
    <File>amgn-ex108_20201231xq4.htm</File>
    <File>amgn-ex21_20201231xq4.htm</File>
    <File>amgn-ex31_20201231xq4.htm</File>
    <File>amgn-ex32_20201231xq4.htm</File>
    <File>amgn-ex433_20201231xq4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amgn-20201231_g1.jpg</File>
    <File>amgn-20201231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/exch/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>147
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amgn-20201231.htm": {
   "axisCustom": 2,
   "axisStandard": 35,
   "contextCount": 700,
   "dts": {
    "calculationLink": {
     "local": [
      "amgn-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amgn-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 930,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 8
   },
   "keyCustom": 96,
   "keyStandard": 506,
   "memberCustom": 107,
   "memberStandard": 69,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover page",
     "role": "http://www.amgen.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i27362feb5854496997daf71cceac6d2c_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210041002 - Disclosure - Acquisitions",
     "role": "http://www.amgen.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i27362feb5854496997daf71cceac6d2c_D20180101-20180331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i54b90fa0f4424779a6c9281cad32ba28_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834053 - Disclosure - Stockholders' equity (Components of AOCI) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
     "shortName": "Stockholders' equity (Components of AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i15cba6363e694ebfbb2115df9607f890_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844054 - Disclosure - Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails",
     "shortName": "Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854055 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
     "shortName": "Stockholders' equity (Reclassifications out of AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "id20ee98d9c9644089c1afeefbd09e9a8_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864056 - Disclosure - Stockholders' equity (Other) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityOtherDetails",
     "shortName": "Stockholders' equity (Other) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894057 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240904058 - Disclosure - Fair value measurement - Narrative (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
     "shortName": "Fair value measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240934059 - Disclosure - Derivative instruments - Narrative (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
     "shortName": "Derivative instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "iea320fbc2a944611a7e2a4627a50e4a8_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i0694e7fc221e482c91e8838576738184_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944060 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
     "shortName": "Derivative instruments - (Cross-currency Swaps) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i0694e7fc221e482c91e8838576738184_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i5991882c8d74449db1e6b1214ea17429_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954061 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
     "shortName": "Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i5991882c8d74449db1e6b1214ea17429_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964062 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
     "shortName": "Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i0d904f96dd854c81b5c1105b3760f9e4_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210091003 - Disclosure - Revenues",
     "role": "http://www.amgen.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240974063 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
     "shortName": "Derivative instruments - (Summary of Income and Expense Line Items) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia3bf50be410a40a4ad50594f2ce4b938_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984064 - Disclosure - Derivative instruments - (Fair Value of Derivatives) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
     "shortName": "Derivative instruments - (Fair Value of Derivatives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i809cbf0f95194f08903685ccb680427e_D20200508-20200508",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfAssertedPatents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014065 - Disclosure - Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails",
     "shortName": "Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i809cbf0f95194f08903685ccb680427e_D20200508-20200508",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfAssertedPatents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i3adccb2cee77458681e77740f4995ece_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024066 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails",
     "shortName": "Contingencies and commitments (Sandoz Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i3adccb2cee77458681e77740f4995ece_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034067 - Disclosure - Contingencies and commitments (Amneal Pharmaceuticals LLC Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails",
     "shortName": "Contingencies and commitments (Amneal Pharmaceuticals LLC Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "icc1181f5cad9413a9756eebeefeb4cd1_D20160901-20160930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "affiliate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044068 - Disclosure - Contingencies and commitments (Immunex and Sandoz Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
     "shortName": "Contingencies and commitments (Immunex and Sandoz Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ice6f585f7e2e4f1ab9e63c18ec932f9a_D20160201-20160228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "affiliate",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia0e8f31ce26e4873a861d070ec4bab78_D20141001-20141031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054069 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
     "shortName": "Contingencies and commitments (Repatha Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia0e8f31ce26e4873a861d070ec4bab78_D20141001-20141031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i4ae1970a90b64a67af70b4ac4a36cab8_I20190520",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064070 - Disclosure - Contingencies and commitments (Additional Information) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
     "shortName": "Contingencies and commitments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i4ae1970a90b64a67af70b4ac4a36cab8_I20190520",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241074071 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails",
     "shortName": "Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241104072 - Disclosure - Quarterly financial data (unaudited) (Details)",
     "role": "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails",
     "shortName": "Quarterly financial data (unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i98fd075b8f9149569c46402ade7585a6_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210131004 - Disclosure - Stock-based compensation",
     "role": "http://www.amgen.com/role/Stockbasedcompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i54b90fa0f4424779a6c9281cad32ba28_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241124073 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "role": "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i6087f9de751b4b1a9a41839e6521a886_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210211005 - Disclosure - Defined contribution plan",
     "role": "http://www.amgen.com/role/Definedcontributionplan",
     "shortName": "Defined contribution plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210231006 - Disclosure - Income taxes",
     "role": "http://www.amgen.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210311007 - Disclosure - Earnings per share",
     "role": "http://www.amgen.com/role/Earningspershare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210341008 - Disclosure - Collaborations",
     "role": "http://www.amgen.com/role/Collaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210381009 - Disclosure - Investments",
     "role": "http://www.amgen.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210471010 - Disclosure - Inventories",
     "role": "http://www.amgen.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210501011 - Disclosure - Property, plant and equipment",
     "role": "http://www.amgen.com/role/Propertyplantandequipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010002 - Statement - Consolidated Statements of Income",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210541012 - Disclosure - Goodwill and intangible assets",
     "role": "http://www.amgen.com/role/Goodwillandintangibleassets",
     "shortName": "Goodwill and intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210591013 - Disclosure - Leases",
     "role": "http://www.amgen.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210661014 - Disclosure - Other current assets and accrued liabilities",
     "role": "http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities",
     "shortName": "Other current assets and accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210701015 - Disclosure - Financing arrangements",
     "role": "http://www.amgen.com/role/Financingarrangements",
     "shortName": "Financing arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210791016 - Disclosure - Stockholders' equity",
     "role": "http://www.amgen.com/role/Stockholdersequity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210871017 - Disclosure - Fair value measurement",
     "role": "http://www.amgen.com/role/Fairvaluemeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210911018 - Disclosure - Derivative instruments",
     "role": "http://www.amgen.com/role/Derivativeinstruments",
     "shortName": "Derivative instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210991019 - Disclosure - Contingencies and commitments",
     "role": "http://www.amgen.com/role/Contingenciesandcommitments",
     "shortName": "Contingencies and commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211081020 - Disclosure - Quarterly financial data (unaudited)",
     "role": "http://www.amgen.com/role/Quarterlyfinancialdataunaudited",
     "shortName": "Quarterly financial data (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211111021 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "role": "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ifd0f1f299f5147a48d5e18854d8ae4af_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020003 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220022001 - Disclosure - Summary of significant accounting policies - (Policies)",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - Acquisitions - (Tables)",
     "role": "http://www.amgen.com/role/AcquisitionsTables",
     "shortName": "Acquisitions - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230103002 - Disclosure - Revenues (Tables)",
     "role": "http://www.amgen.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230143003 - Disclosure - Stock-based compensation (Tables)",
     "role": "http://www.amgen.com/role/StockbasedcompensationTables",
     "shortName": "Stock-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230243004 - Disclosure - Income taxes (Tables)",
     "role": "http://www.amgen.com/role/IncometaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230323005 - Disclosure - Earnings per share (Tables)",
     "role": "http://www.amgen.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230393006 - Disclosure - Investments - (Tables)",
     "role": "http://www.amgen.com/role/InvestmentsTables",
     "shortName": "Investments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230483007 - Disclosure - Inventories (Tables)",
     "role": "http://www.amgen.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230513008 - Disclosure - Property, plant and equipment (Tables)",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230553009 - Disclosure - Goodwill and other intangible assets - (Tables)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables",
     "shortName": "Goodwill and other intangible assets - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030004 - Statement - Consolidated Balance Sheets",
     "role": "http://www.amgen.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230603010 - Disclosure - Leases - (Tables)",
     "role": "http://www.amgen.com/role/LeasesTables",
     "shortName": "Leases - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230673011 - Disclosure - Other current assets and accrued liabilities (Tables)",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables",
     "shortName": "Other current assets and accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230713012 - Disclosure - Financing arrangements (Tables)",
     "role": "http://www.amgen.com/role/FinancingarrangementsTables",
     "shortName": "Financing arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230803013 - Disclosure - Stockholders' equity (Tables)",
     "role": "http://www.amgen.com/role/StockholdersequityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230883014 - Disclosure - Fair value measurement - (Tables)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementTables",
     "shortName": "Fair value measurement - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230923015 - Disclosure - Derivative instruments - (Tables)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsTables",
     "shortName": "Derivative instruments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfU.S.RepatriationTaxCommitments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231003016 - Disclosure - Contingencies and commitments - (Tables)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsTables",
     "shortName": "Contingencies and commitments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfU.S.RepatriationTaxCommitments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231093017 - Disclosure - Quarterly financial data (unaudited) (Tables)",
     "role": "http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables",
     "shortName": "Quarterly financial data (unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "amgn:NatureOfOperationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240034001 - Disclosure - Summary of significant accounting policies - Narrative (Details)",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
     "shortName": "Summary of significant accounting policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i8504707ad2dd45d19748815828f1e290_D20191121-20191121",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Acquisitions - Otezla (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
     "shortName": "Acquisitions - Otezla (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i8504707ad2dd45d19748815828f1e290_D20191121-20191121",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:Transactioncostsassetacquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i8a2e62d8eeb048f38ca8736344e50d1d_D20190715-20190715",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084004 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
     "shortName": "Acquisitions - Aggregate Consideration Paid (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "if25bf3da4131474dbf032ec98b354ae1_D20180101-20180331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "amgn:NatureOfOperationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114005 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.amgen.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124006 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)",
     "role": "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
     "shortName": "Revenues - Customer Concentration, Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ic289e4896d8242f8a43d7b143dc356ec_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:PercentageOfGrossRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154007 - Disclosure - Stock-based compensation (Textual) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
     "shortName": "Stock-based compensation (Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164008 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based compensation (Components of Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ie818cfed00624ad480f081b1918b959a_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174009 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
     "shortName": "Stock-based compensation (Summary of RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i2925c208b623496e998dbde8a0fc11e1_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184010 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
     "shortName": "Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ic860ea2811fe43c7b4a1b731b90c8ed6_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i143d4186981e48d49d7be92adfcc173f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194011 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
     "shortName": "Stock-based compensation (Summary of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i143d4186981e48d49d7be92adfcc173f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i866165e293d6482ca7b4135f27841405_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240204012 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails",
     "shortName": "Stock-based compensation (Weighted-average Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i866165e293d6482ca7b4135f27841405_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ibe76d84d24b74fe19c507ca3db178e07_I20171231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ibe76d84d24b74fe19c507ca3db178e07_I20171231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224013 - Disclosure - Defined contribution plan (Details)",
     "role": "http://www.amgen.com/role/DefinedcontributionplanDetails",
     "shortName": "Defined contribution plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254014 - Disclosure - Income taxes (Income Before Income Taxes) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
     "shortName": "Income taxes (Income Before Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "id433645fbf594175aab48fd4faf64790_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264015 - Disclosure - Income taxes (Provision for Income Taxes) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income taxes (Provision for Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274016 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284017 - Disclosure - Income taxes (Textual) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesTextualDetails",
     "shortName": "Income taxes (Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i54b90fa0f4424779a6c9281cad32ba28_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294018 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails",
     "shortName": "Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i6087f9de751b4b1a9a41839e6521a886_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304019 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails",
     "shortName": "Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i98fd075b8f9149569c46402ade7585a6_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334020 - Disclosure - Earnings per share (Details)",
     "role": "http://www.amgen.com/role/EarningspershareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354021 - Disclosure - Collaborations - Novartis AG (Details)",
     "role": "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
     "shortName": "Collaborations - Novartis AG (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i7cb08466e4c94fc284de233b8b27d515_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364022 - Disclosure - Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details)",
     "role": "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
     "shortName": "Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i5aae7473918a4b2fbd03dbe169ce9681_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amgn:NumberofCountriesProductsisMarketedandSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i60869bc47af9405383d397dfe67b7ce8_D20201216-20201216",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "if9e22a47202d49c79c39aaafff5c59a5_I20200102",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374023 - Disclosure - Collaborations - BeiGene (Details)",
     "role": "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
     "shortName": "Collaborations - BeiGene (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "id4c3de7ba47e48ddbb6721ed2b6093e0_D20200102-20200102",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404024 - Disclosure - Investments - Schedule (Details)",
     "role": "http://www.amgen.com/role/InvestmentsScheduleDetails",
     "shortName": "Investments - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414025 - Disclosure - Investments - Fair Values by Classification (Details)",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
     "shortName": "Investments - Fair Values by Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ife9255d5d6fe481fad09edd63beb52e7_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424026 - Disclosure - Investments - Available-for-sale (Details)",
     "role": "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails",
     "shortName": "Investments - Available-for-sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434027 - Disclosure - Investments - Fair Values by Contractual Maturity (Details)",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails",
     "shortName": "Investments - Fair Values by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444028 - Disclosure - Investments - Equity Securities (Details)",
     "role": "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails",
     "shortName": "Investments - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3acbfa95e2d42d59a15e70c74debd7d_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AlternativeInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454029 - Disclosure - Investments - Limited Partnership Investments (Details)",
     "role": "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails",
     "shortName": "Investments - Limited Partnership Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3acbfa95e2d42d59a15e70c74debd7d_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AlternativeInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i8b7a2eccdd2a4651a37e5247253abcf9_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464030 - Disclosure - Investments - BeiGene (Details)",
     "role": "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
     "shortName": "Investments - BeiGene (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "if9e22a47202d49c79c39aaafff5c59a5_I20200102",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494031 - Disclosure - Inventories (Details)",
     "role": "http://www.amgen.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524032 - Disclosure - Property, plant and equipment (Schedule) (Details)",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
     "shortName": "Property, plant and equipment (Schedule) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534033 - Disclosure - Property, plant and equipment (Geographic Information) (Details)",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
     "shortName": "Property, plant and equipment (Geographic Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i380c4519a6324acb9471d6b0846ff47a_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i54b90fa0f4424779a6c9281cad32ba28_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564034 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails",
     "shortName": "Goodwill and other intangible assets - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574035 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
     "shortName": "Goodwill and other intangible assets - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584036 - Disclosure - Goodwill and other intangible assets - Narrative (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails",
     "shortName": "Goodwill and other intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614037 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.amgen.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624038 - Disclosure - Leases - Summary of Leases (Details)",
     "role": "http://www.amgen.com/role/LeasesSummaryofLeasesDetails",
     "shortName": "Leases - Summary of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634039 - Disclosure - Leases - Components of Lease Costs (Details)",
     "role": "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails",
     "shortName": "Leases - Components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654041 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)",
     "role": "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails",
     "shortName": "Leases - Cash and Noncash Information of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684042 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails",
     "shortName": "Other current assets and accrued liabilities - Schedule of Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedSalesDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694043 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails",
     "shortName": "Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedSalesDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724044 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
     "shortName": "Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:MaximumBorrowingCapacityUnderCommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734045 - Disclosure - Financing arrangements (Debt Issuances) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
     "shortName": "Financing arrangements (Debt Issuances) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:MaximumBorrowingCapacityUnderCommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744046 - Disclosure - Financing arrangements (Debt Repayments) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
     "shortName": "Financing arrangements (Debt Repayments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "if188b1207e144488bc49e6f9af13f349_D20200101-20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754047 - Disclosure - Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
     "shortName": "Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ic5c9cfe81f3e4917a0b8ebe47bd9a715_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib951b96e66134344b87919e6a15e9627_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764048 - Disclosure - Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails",
     "shortName": "Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib951b96e66134344b87919e6a15e9627_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774049 - Disclosure - Financing arrangements (Contractual Maturities of Long-term Debt) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails",
     "shortName": "Financing arrangements (Contractual Maturities of Long-term Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ia802888bb7a6406592ff586c244944e8_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784050 - Disclosure - Financing arrangements (Interest Costs) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails",
     "shortName": "Financing arrangements (Interest Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "ib3e09025131245718b40a342c9cd7808_D20200101-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i98fd075b8f9149569c46402ade7585a6_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814051 - Disclosure - Stockholders' equity (Stock Repurchase Program) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails",
     "shortName": "Stockholders' equity (Stock Repurchase Program) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i98fd075b8f9149569c46402ade7585a6_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i60869bc47af9405383d397dfe67b7ce8_D20201216-20201216",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824052 - Disclosure - Stockholders' equity (Dividends) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityDividendsDetails",
     "shortName": "Stockholders' equity (Dividends) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20201231.htm",
      "contextRef": "i98fd075b8f9149569c46402ade7585a6_D20201001-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 180,
   "tag": {
    "amgn_A1.250SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.250% Senior Notes Due 2022 [Member]",
        "label": "1.250% Senior Notes Due 2022 [Member]",
        "terseLabel": "1.250% Senior Notes Due 2022"
       }
      }
     },
     "localname": "A1.250SeniorNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AbandonedLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abandoned Leases [Member]",
        "label": "Abandoned Leases [Member]",
        "terseLabel": "Abandoned Leases [Member]"
       }
      }
     },
     "localname": "AbandonedLeasesMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Other current assets and accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities/other non-current liabilities.",
        "label": "Accrued Liabilities Other Non Current Liabilities [Member]",
        "verboseLabel": "Accrued liabilities/Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedSalesDeductionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.",
        "label": "Accrued Sales Deductions Current",
        "terseLabel": "Sales deductions"
       }
      }
     },
     "localname": "AccruedSalesDeductionsCurrent",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AccruedSalesReturnReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.",
        "label": "Accrued Sales Return Reserve Current",
        "terseLabel": "Sales returns reserve"
       }
      }
     },
     "localname": "AccruedSalesReturnReserveCurrent",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "label": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Assets, Weighted Average Useful Life",
        "label": "Acquired Finite-lived Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired assets, weighted useful life"
       }
      }
     },
     "localname": "AcquiredFinitelivedAssetsWeightedAverageUsefulLife",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired research and development technology rights.",
        "label": "Acquired Research And Development Technology Rights [Member]",
        "terseLabel": "R&amp;D technology rights [Member]"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AlternativeInvestmentNetGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Net Gain (Loss)",
        "label": "Alternative Investment, Net Gain (Loss)",
        "terseLabel": "Alternative Investment, Net Gain (Loss)"
       }
      }
     },
     "localname": "AlternativeInvestmentNetGainLoss",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AmnealPharmaceuticalsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amneal Pharmaceuticals LLC",
        "label": "Amneal Pharmaceuticals LLC [Member]",
        "terseLabel": "Amneal Pharmaceuticals LLC"
       }
      }
     },
     "localname": "AmnealPharmaceuticalsLLCMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.",
        "label": "Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks",
        "terseLabel": "Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks"
       }
      }
     },
     "localname": "AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of common stock available under the plan for future grants and/or issuances.",
        "label": "Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances",
        "terseLabel": "The amount of common stock available under the plan for future grants and/or issuances (in shares)"
       }
      }
     },
     "localname": "AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_ApprovedMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Approved Markets",
        "label": "Approved Markets",
        "terseLabel": "Approved markets"
       }
      }
     },
     "localname": "ApprovedMarkets",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_AranespMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aranesp.",
        "label": "Aranesp [Member]",
        "terseLabel": "Aranesp\u00ae (darbepoetin alfa) [Member]"
       }
      }
     },
     "localname": "AranespMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assembled Workforce [Member]",
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled Workforce [Member]"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AssetsByDescriptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets by description.",
        "label": "Assets By Description [Axis]",
        "terseLabel": "Assets By Description [Axis]"
       }
      }
     },
     "localname": "AssetsByDescriptionAxis",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_AssetsByDescriptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets by description.",
        "label": "Assets By Description [Domain]",
        "terseLabel": "Assets By Description [Domain]"
       }
      }
     },
     "localname": "AssetsByDescriptionDomain",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value",
        "label": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value",
        "terseLabel": "Maturing after one year through three years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value",
        "label": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value",
        "terseLabel": "Maturing after three years through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AvailableForSalesInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sales investments.",
        "label": "Available For Sales Investments [Member]",
        "verboseLabel": "Available-for-sale investments [Member]"
       }
      }
     },
     "localname": "AvailableForSalesInvestmentsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BasicAndDilutedEarningPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earning per share.",
        "label": "Basic And Diluted Earning Per Share [Abstract]",
        "verboseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningPerShareAbstract",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_BeiGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BeiGene [Member]",
        "label": "BeiGene [Member]",
        "terseLabel": "BeiGene"
       }
      }
     },
     "localname": "BeiGeneMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BusinessAcquisitionCostOfAcquiredEntityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the aggregate acquisition date consideration to acquire an entity.",
        "label": "Business Acquisition Cost Of Acquired Entity [Table Text Block]",
        "terseLabel": "Aggregate acquisition date consideration to acquire an entity"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "label": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "netLabel": "Fair value of contingent consideration obligation",
        "verboseLabel": "Estimated fair values of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits",
        "terseLabel": "Adjustments to deferred credit"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities",
        "terseLabel": "Adjustments to deferred tax liability"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "terseLabel": "Fair value of assets acquired and liabilities assumed, net other assets and liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "label": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "totalLabel": "Total assets acquired, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionDeferredCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails": {
       "order": 4.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Deferred Credit",
        "label": "Business acquired asset acquisition, Deferred Credit",
        "negatedTerseLabel": "Deferred credit"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionDeferredCredit",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionDeferredTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails": {
       "order": 3.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Deferred Tax Liabilities",
        "label": "Business acquired asset acquisition, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liability, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionDeferredTaxLiabilities",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails": {
       "order": 1.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Finite-lived intangible assets acquired",
        "label": "Business acquired asset acquisition, Finite-lived intangible assets acquired",
        "terseLabel": "Business acquired asset acquisition, Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionFinitelivedintangibleassetsacquired",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionInventoryacquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails": {
       "order": 2.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Inventory acquired",
        "label": "Business acquired asset acquisition, Inventory acquired",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionInventoryacquired",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails": {
       "order": 5.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Noncurrent Liabilities Other",
        "label": "Business acquired asset acquisition, Noncurrent Liabilities Other",
        "negatedTerseLabel": "Other liabilities, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_Businessassetacquisitionconsiderationtransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business asset acquisition, consideration transferred",
        "label": "Business asset acquisition, consideration transferred",
        "verboseLabel": "Accumulated cost (consideration transferred)"
       }
      }
     },
     "localname": "Businessassetacquisitionconsiderationtransferred",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_CollaborativeArrangementNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Net Income",
        "label": "Collaborative Arrangement, Net Income",
        "terseLabel": "Collaboration profit"
       }
      }
     },
     "localname": "CollaborativeArrangementNetIncome",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_CollaborativeArrangementRoyaltyIncomePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Royalty Income Percentage",
        "label": "Collaborative Arrangement Royalty Income Percentage",
        "terseLabel": "Collaboration, royalty percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyIncomePercentage",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Bayer HealthCare Pharmaceuticals Inc. [Member]",
        "label": "Collaborative Arrangements with Bayer HealthCare Pharmaceuticals Inc. [Member]",
        "terseLabel": "Collaborative Arrangement with Bayer [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CollaborativeArrangementwithNovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Novartis Pharma AG [Member]",
        "label": "Collaborative Arrangement with Novartis Pharma AG [Member]",
        "terseLabel": "Collaborative Arrangement with Novartis AG [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementwithNovartisPharmaAGMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CommonStockFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.",
        "label": "Common Stock Fair Value",
        "terseLabel": "Closing price of our common stock on grant date (in usd per share)"
       }
      }
     },
     "localname": "CommonStockFairValue",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.",
        "label": "Components of Stock based Compensation Expense [Table Text Block]",
        "terseLabel": "Components of stock-based compensation expense recognized in the Consolidated Statements of Income"
       }
      }
     },
     "localname": "ComponentsOfStockBasedCompensationExpenseTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_CorporateDebtSecuritiesFinancialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities financial Member.",
        "label": "Corporate Debt Securities Financial [Member]",
        "verboseLabel": "Corporate debt securities - Financial [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesFinancialMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CorporateDebtSecuritiesIndustrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities industrial Member.",
        "label": "Corporate Debt Securities Industrial [Member]",
        "verboseLabel": "Corporate debt securities - Industrial [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesIndustrialMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CorporateDebtSecuritiesOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities other.",
        "label": "Corporate Debt Securities Other [Member]",
        "verboseLabel": "Corporate debt securities - Other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesOtherMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CrossCurrencySwapContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross currency swap contracts.",
        "label": "Cross Currency Swap Contracts [Member]",
        "terseLabel": "Cross-currency swap contract [Member]",
        "verboseLabel": "Cross-currency swap contracts [Member]"
       }
      }
     },
     "localname": "CrossCurrencySwapContractsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "AmerisourceBergen Corporation [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three.",
        "label": "Customer Three [Member]",
        "terseLabel": "Cardinal Health, Inc. [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "McKesson Corporation [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DebtExchangeAdditionalCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt exchange additional cash consideration paid",
        "label": "Debt exchange additional cash consideration",
        "terseLabel": "Debt exchange additional cash consideration"
       }
      }
     },
     "localname": "DebtExchangeAdditionalCashConsideration",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "label": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "terseLabel": "Redemption period without payment of make whole amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.",
        "label": "Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards",
        "terseLabel": "NOL and credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DerivativeAssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative assets.",
        "label": "Derivative Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeAssetsFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial instruments liabilities fair value disclosure.",
        "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]",
        "verboseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeNotionalAmountAmountTerminated": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Notional Amount, Amount Terminated",
        "label": "Derivative, Notional Amount, Amount Terminated",
        "terseLabel": "Derivative, Notional Amount, Amount Terminated"
       }
      }
     },
     "localname": "DerivativeNotionalAmountAmountTerminated",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities",
        "label": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities",
        "terseLabel": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities"
       }
      }
     },
     "localname": "DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate",
        "label": "Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate",
        "terseLabel": "Estimated blended statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "terseLabel": "Interest on uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Impact On Intercompany Sales, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Impact On Intercompany Sales, Percent",
        "negatedTerseLabel": "2017 Tax Act, net impact on intercompany sales"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ImpactOnIntercompanySalesPercent",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ENBREL.",
        "label": "ENBREL [Member]",
        "terseLabel": "Enbrel\u00ae (etanercept) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "label": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, change in carrying value",
        "label": "Equity method investment, change in carrying value",
        "terseLabel": "Equity method investment, change in carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValue",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValueOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Change In Carrying Value, Other",
        "label": "Equity Method Investment, Change In Carrying Value, Other",
        "terseLabel": "Equity Method Investment, Change In Carrying Value, Other"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValueOther",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ExpirationInTaxYearsBetween2023And2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration in tax years between 2023 and 2035",
        "label": "Expiration in tax years between 2023 and 2035 [Member]",
        "terseLabel": "Expiration in tax years between 2023 and 2035 [Member]"
       }
      }
     },
     "localname": "ExpirationInTaxYearsBetween2023And2035Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.",
        "label": "Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Consolidated Balance Sheets locations"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.",
        "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.",
        "label": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "terseLabel": "5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]",
        "verboseLabel": "5.50% 2026 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointOneFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Five Percent Notes Due 2041 [Member]",
        "label": "Five Point One Five Percent Notes Due 2041 [Member]",
        "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointOneFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSevenFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "label": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointSevenFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSevenZeroPercentNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Zero Percent Notes Due 2019 [Member]",
        "label": "Five Point Seven Zero Percent Notes Due 2019 [Member]",
        "terseLabel": "5.70% notes due 2019 (5.70% 2019 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointSevenZeroPercentNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSixFivePercentNotesDue2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "label": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointSixFivePercentNotesDue2042Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointThreeSevenFivePercentNotesDue2043Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FixedEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed equipment",
        "label": "Fixed equipment",
        "terseLabel": "Fixed equipment"
       }
      }
     },
     "localname": "FixedEquipment",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_FixedEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed equipment",
        "label": "Fixed equipment [Member]",
        "verboseLabel": "Fixed equipment [Member]"
       }
      }
     },
     "localname": "FixedEquipmentMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FloatingRateNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes Due 2019 [Member]",
        "label": "Floating Rate Notes Due 2019 [Member]",
        "terseLabel": "Floating Rate Notes Due 2019 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FloatingRateNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes Due 2020 [Member]",
        "label": "Floating Rate Notes Due 2020 [Member]",
        "terseLabel": "Floating Rate Notes Due 2020 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForeignCurrencyAndCrossCurrencySwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency and cross currency swaps.",
        "label": "Foreign Currency and Cross Currency Swaps [Member]",
        "verboseLabel": "Foreign currency and cross currency swap contracts [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyAndCrossCurrencySwapsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForwardInterestRateContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward Interest Rate Contract [Member]",
        "label": "Forward Interest Rate Contract [Member]",
        "terseLabel": "Forward interest rate contract [Member]",
        "verboseLabel": "Forward interest rate contracts [Member]"
       }
      }
     },
     "localname": "ForwardInterestRateContractMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPercentPoundSterlingNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "label": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "terseLabel": "4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]",
        "verboseLabel": "4.00% 2029 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FourPercentPoundSterlingNotesDue2029Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveZeroPercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Zero Percent Notes Due 2020 [Member]",
        "label": "Four Point Five Zero Percent Notes Due 2020 [Member]",
        "terseLabel": "4.50% notes due 2020 (4.50% 2020 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointFiveZeroPercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointNineFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "label": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "verboseLabel": "4.95% notes due 2041 (4.95% 2041 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointNineFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointOneZeroPercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "label": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "terseLabel": "4.10% notes due 2021 (4.10% 2021 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointOneZeroPercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointThreeSevenFivePercentEuroNotesDue2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Three Seven Five Percent Euro Notes Due 2018 [Member]",
        "label": "Four Point Three Seven Five Percent Euro Notes Due 2018 [Member]",
        "verboseLabel": "4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes) [Member]"
       }
      }
     },
     "localname": "FourPointThreeSevenFivePercentEuroNotesDue2018Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_GainContingencyNumberOfAgreementsBreached": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Agreements Breached",
        "label": "Gain Contingency, Number Of Agreements Breached",
        "terseLabel": "Agreements breached"
       }
      }
     },
     "localname": "GainContingencyNumberOfAgreementsBreached",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberOfChallenges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Challenges",
        "label": "Gain Contingency, Number Of Challenges",
        "terseLabel": "Number of challenges"
       }
      }
     },
     "localname": "GainContingencyNumberOfChallenges",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberOfLawsuitsConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Lawsuits Consolidated",
        "label": "Gain Contingency, Number Of Lawsuits Consolidated",
        "terseLabel": "Number of lawsuits consolidated"
       }
      }
     },
     "localname": "GainContingencyNumberOfLawsuitsConsolidated",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberofAffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Affiliates",
        "label": "Gain Contingency, Number of Affiliates",
        "terseLabel": "Gain contingency, number of affiliates"
       }
      }
     },
     "localname": "GainContingencyNumberofAffiliates",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberofLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Lawsuits Filed",
        "label": "Gain Contingency, Number of Lawsuits Filed",
        "terseLabel": "Number of lawsuits filed"
       }
      }
     },
     "localname": "GainContingencyNumberofLawsuitsFiled",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_HedgedLiabilityDiscontinuedFairValueHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Liability, Discontinued Fair Value Hedge",
        "label": "Hedged Liability, Discontinued Fair Value Hedge",
        "terseLabel": "Carrying value with discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedge",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_HumiraBiosimilarAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humira Biosimilar Antitrust Class Actions [Member]",
        "label": "Humira Biosimilar Antitrust Class Actions [Member]",
        "terseLabel": "Humira Biosimilar Antitrust Class Actions"
       }
      }
     },
     "localname": "HumiraBiosimilarAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets accumulated amortization.",
        "label": "Identifiable Intangible Assets Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_IdentifiableIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets gross.",
        "label": "Identifiable Intangible Assets Gross",
        "totalLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsGross",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ImmunexAndSamsungBioepisCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunex And Samsung Bioepis Co.",
        "label": "Immunex And Samsung Bioepis Co. [Member]",
        "terseLabel": "Immunex/Samsung Bioepis Co."
       }
      }
     },
     "localname": "ImmunexAndSamsungBioepisCoMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ImmunexAndSandozMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunex And Sandoz",
        "label": "Immunex And Sandoz [Member]",
        "terseLabel": "Immunex/Sandoz"
       }
      }
     },
     "localname": "ImmunexAndSandozMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_IncreaseDecreaseInNoncurrentTaxLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Noncurrent Tax Liability",
        "label": "Increase (Decrease) In Noncurrent Tax Liability",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentTaxLiability",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_InterestRateSwapAtThenCurrentInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, At-Then Current Interest Rates [Member]",
        "label": "Interest Rate Swap, At-Then Current Interest Rates [Member]",
        "terseLabel": "Interest Rate Swap, At-Then Current Interest Rates [Member]"
       }
      }
     },
     "localname": "InterestRateSwapAtThenCurrentInterestRatesMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap [Axis]",
        "label": "Interest Rate Swap [Axis]",
        "terseLabel": "Interest Rate Swap [Axis]"
       }
      }
     },
     "localname": "InterestRateSwapAxis",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_InterestRateSwapDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap",
        "label": "Interest Rate Swap [Domain]",
        "terseLabel": "Interest Rate Swap [Domain]"
       }
      }
     },
     "localname": "InterestRateSwapDomain",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, One [Member]",
        "label": "Interest Rate Swap, One [Member]",
        "terseLabel": "Interest Rate Swap, One [Member]"
       }
      }
     },
     "localname": "InterestRateSwapOneMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, Three [Member]",
        "label": "Interest Rate Swap, Three [Member]",
        "terseLabel": "Interest Rate Swap, Three [Member]"
       }
      }
     },
     "localname": "InterestRateSwapThreeMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, Two [Member]",
        "label": "Interest Rate Swap, Two [Member]",
        "terseLabel": "Interest Rate Swap, Two [Member]"
       }
      }
     },
     "localname": "InterestRateSwapTwoMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KYPROLIScarfilzomibPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KYPROLIS (carfilzomib) Patent Litigation [Member]",
        "label": "KYPROLIS (carfilzomib) Patent Litigation [Member]",
        "terseLabel": "KYPROLIS (carfilzomib) Patent Litigation [Member]"
       }
      }
     },
     "localname": "KYPROLIScarfilzomibPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KirinAmgenInc.KAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kirin-Amgen, Inc. (K-A) [Member]",
        "label": "Kirin-Amgen, Inc. (K-A) [Member]",
        "terseLabel": "Kirin-Amgen, Inc. (K-A)"
       }
      }
     },
     "localname": "KirinAmgenInc.KAMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyprolis [Member]",
        "label": "Kyprolis [Member]",
        "terseLabel": "Kyprolis [Member]"
       }
      }
     },
     "localname": "KyprolisMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LaboratoryEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of laboratory equipment, gross.",
        "label": "Laboratory Equipment",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipment",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount",
        "terseLabel": "Total undiscounted future lease payment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases",
        "terseLabel": "Future rental commitments for abandoned leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LineOfCreditFacilityExtensionOfCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Extension of Commitment Term",
        "label": "Line of Credit Facility, Extension of Commitment Term",
        "terseLabel": "Additional period for extension of commitment term"
       }
      }
     },
     "localname": "LineOfCreditFacilityExtensionOfCommitmentTerm",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LineOfCreditFacilityInitialCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Initial Commitment Term",
        "label": "Line of Credit Facility, Initial Commitment Term",
        "terseLabel": "Initial commitment term of each bank which is a party to the agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityInitialCommitmentTerm",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LineofCreditFacilityNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number Of Renewal Options",
        "label": "Line of Credit Facility, Number Of Renewal Options",
        "terseLabel": "Number of additional term extension options"
       }
      }
     },
     "localname": "LineofCreditFacilityNumberOfRenewalOptions",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LitigationSettlementLengthofTrial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Length of Trial",
        "label": "Litigation Settlement, Length of Trial",
        "terseLabel": "Length of trial"
       }
      }
     },
     "localname": "LitigationSettlementLengthofTrial",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Current Maturities [Member]",
        "label": "Long-Term Debt, Current Maturities [Member]",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.",
        "label": "Long Term Debt Maturities Repayments Of Principal Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LossContingencyNumberOfComplaintsStayedByTheCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Complaints Stayed By The Court",
        "label": "Loss Contingency, Number Of Complaints Stayed By The Court",
        "terseLabel": "Number of complaints stayed"
       }
      }
     },
     "localname": "LossContingencyNumberOfComplaintsStayedByTheCourt",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LossContingencyNumberOfLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Lawsuits Filed",
        "label": "Loss Contingency, Number of Lawsuits Filed",
        "terseLabel": "Loss contingency, number of lawsuits filed"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsFiled",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing equipment.",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_MarketingRelatedRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-Related Rights [Member]",
        "label": "Marketing-Related Rights [Member]",
        "terseLabel": "Marketing-Related Rights"
       }
      }
     },
     "localname": "MarketingRelatedRightsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_MaximumBorrowingCapacityUnderCommercialPaper": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Borrowing Capacity Under Commercial Paper Program.",
        "label": "Maximum Borrowing Capacity Under Commercial Paper",
        "terseLabel": "Commercial paper, maximum borrowing capacity"
       }
      }
     },
     "localname": "MaximumBorrowingCapacityUnderCommercialPaper",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\".",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta\u00ae (pegfilgrastim) [Member]"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NexavarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nexavar [Member]",
        "label": "Nexavar [Member]",
        "terseLabel": "Nexavar [Member]"
       }
      }
     },
     "localname": "NexavarMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NonUsExcludingJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonUs,ExcludingJapan",
        "label": "NonUs,ExcludingJapan [Member]",
        "terseLabel": "NonUs,ExcludingJapan [Member]"
       }
      }
     },
     "localname": "NonUsExcludingJapanMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NovartisBreachOfContractActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Breach Of Contract Action [Member]",
        "label": "Novartis Breach Of Contract Action [Member]",
        "terseLabel": "Novartis Breach Of Contract Action"
       }
      }
     },
     "localname": "NovartisBreachOfContractActionMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NuevolutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuevolution [Member]",
        "label": "Nuevolution [Member]",
        "terseLabel": "Nuevolution"
       }
      }
     },
     "localname": "NuevolutionMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NumberOfAssertedPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Asserted Patents",
        "label": "Number Of Asserted Patents",
        "terseLabel": "Number of asserted patents"
       }
      }
     },
     "localname": "NumberOfAssertedPatents",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued for each performance unit earned.",
        "label": "Number of Common Shares Issued for Each Performance Unit Earned",
        "terseLabel": "Number of common shares issued for each performance unit earned"
       }
      }
     },
     "localname": "NumberOfCommonSharesIssuedForEachPerformanceUnitEarned",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the pool of available shares will be reduced for each stock option granted.",
        "label": "Number Of Common Shares To Be Reduced For Each Stock Option Granted",
        "terseLabel": "Amount by which the pool of available shares will be reduced for each stock option granted"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the pool of available shares will be reduced for other types of awards granted.",
        "label": "Number of Common Shares to be Reduced For Other Types Of Awards Granted",
        "terseLabel": "The number of shares by which the pool of available shares will be reduced for other types of awards granted"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major customers (as defined) accounting for more than 10% of gross trade receivables.",
        "label": "Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables",
        "terseLabel": "Major customers (as defined) accounting for more than 10% of gross trade receivables"
       }
      }
     },
     "localname": "NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers (as defined) accounting for more than 10% of total revenue.",
        "label": "Number of Customers Accounting for More Than Ten Percent of Revenue",
        "terseLabel": "Number of major customers (as defined) accounting for more than 10% of total revenue"
       }
      }
     },
     "localname": "NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberofCountriesProductsisMarketedandSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Countries Product is Marketed and Sold",
        "label": "Number of Countries Products is Marketed and Sold",
        "terseLabel": "Number of countries product is marketed and sold"
       }
      }
     },
     "localname": "NumberofCountriesProductsisMarketedandSold",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares Added Back for Tax Withholding on Full Value Awards",
        "label": "Number of Shares Added Back for Tax Withholding on Full Value Awards",
        "terseLabel": "Number of shares added back for tax withholding on full value awards"
       }
      }
     },
     "localname": "NumberofSharesAddedBackforTaxWithholdingonFullValueAwards",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "label": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "terseLabel": "1.85% notes due 2021 (1.85% 2021 Notes) [Member]"
       }
      }
     },
     "localname": "OnePointEightFivePercentNotesDueTwoZeroTwoOneMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointNineZeroNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Nine Zero Notes Due 2019 [Member]",
        "label": "One Point Nine Zero Notes Due 2019 [Member]",
        "terseLabel": "1.90% notes due 2019 (1.90% 2019 Notes) [Member]"
       }
      }
     },
     "localname": "OnePointNineZeroNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]",
        "label": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]",
        "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes) [Member]"
       }
      }
     },
     "localname": "OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "label": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "terseLabel": "1.25% 2022 euro Notes [Member]"
       }
      }
     },
     "localname": "OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]",
        "label": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]",
        "terseLabel": "1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]"
       }
      }
     },
     "localname": "OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OperatingLossesThatExpireBetween2021And2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Losses That Expire Between 2021 and 2030",
        "label": "Operating Losses That Expire Between 2021 and 2030 [Member]",
        "terseLabel": "Operating Losses That Expire Between 2021 and 2030 [Member]"
       }
      }
     },
     "localname": "OperatingLossesThatExpireBetween2021And2030Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OperatingLossesThatExpireBetween2021And2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Losses That Expire Between 2021 and 2035",
        "label": "Operating Losses That Expire Between 2021 and 2035 [Member]",
        "terseLabel": "Operating Losses That Expire Between 2021 and 2035 [Member]"
       }
      }
     },
     "localname": "OperatingLossesThatExpireBetween2021And2035Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtezlaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otezla [Member]",
        "label": "Otezla [Member]",
        "terseLabel": "Otezla",
        "verboseLabel": "Otezla [Member]"
       }
      }
     },
     "localname": "OtezlaMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "label": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "terseLabel": "Other losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherCurrentNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current assets/other non-current assets.",
        "label": "Other Current Noncurrent Assets [Member]",
        "verboseLabel": "Other current assets/Other assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentNoncurrentAssetsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherNotesDue2097Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Notes Due 2097 [Member]",
        "label": "Other Notes Due 2097 [Member]",
        "terseLabel": "Other notes due 2097 [Member]"
       }
      }
     },
     "localname": "OtherNotesDue2097Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other products [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues [Member]"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherShortTermInterestBearingSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term interest bearing securities.",
        "label": "Other Short Term Interest Bearing Securities [Member]",
        "terseLabel": "Other short-term interest-bearing securities [Member]"
       }
      }
     },
     "localname": "OtherShortTermInterestBearingSecuritiesMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.",
        "label": "Percentage of Combined Net Trade Receivables from Major Customers",
        "terseLabel": "Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables"
       }
      }
     },
     "localname": "PercentageOfCombinedNetTradeReceivablesFromMajorCustomers",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.",
        "label": "Percentage Of Combined Worldwide Gross Revenues From Major Customers",
        "terseLabel": "Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis"
       }
      }
     },
     "localname": "PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfGrossRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross product sales to major customer (as defined) as a percentage of total gross revenues.",
        "label": "Percentage of Gross Revenues",
        "terseLabel": "Gross product sales to major customer (as defined) as a percentage of total gross revenues"
       }
      }
     },
     "localname": "PercentageOfGrossRevenues",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.",
        "label": "Percentage of Net Amount Due from Customers Located Outside Domestic Location",
        "terseLabel": "Percentage of net trade receivables due from customers located outside the United States, primarily in Europe"
       }
      }
     },
     "localname": "PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "label": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "terseLabel": "Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event"
       }
      }
     },
     "localname": "PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PerformanceUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Units.",
        "label": "Performance Units [Member]",
        "verboseLabel": "Performance units [Member]"
       }
      }
     },
     "localname": "PerformanceUnitsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ProliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prolia.",
        "label": "Prolia [Member]",
        "terseLabel": "Prolia\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "ProliaMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RDTechnologyrightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R &amp; D Technology rights [Member]",
        "label": "R &amp; D Technology rights [Member]",
        "terseLabel": "R &amp; D Technology rights"
       }
      }
     },
     "localname": "RDTechnologyrightsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_Ratedifferenceinaninterestrateswaprelationship": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate difference in an interest rate swap relationship",
        "label": "Rate difference in an interest rate swap relationship",
        "terseLabel": "Rate difference in an interest rate swap relationship"
       }
      }
     },
     "localname": "Ratedifferenceinaninterestrateswaprelationship",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_RecoveryOfDirectCostsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery Of Direct Costs, Receivable",
        "label": "Recovery Of Direct Costs, Receivable",
        "terseLabel": "Recovery Of Direct Costs, Receivable"
       }
      }
     },
     "localname": "RecoveryOfDirectCostsReceivable",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RepathaevolocumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatha (evolocumab) [Member]",
        "label": "Repatha (evolocumab) [Member]",
        "terseLabel": "Repatha (evolocumab) [Member]"
       }
      }
     },
     "localname": "RepathaevolocumabMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World [Member]",
        "label": "Rest Of World [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RevenuePaymentArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Payment Arrangement, Term",
        "label": "Revenue Payment Arrangement, Term",
        "terseLabel": "Revenue payment term"
       }
      }
     },
     "localname": "RevenuePaymentArrangementTerm",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Future Milestone Payment",
        "label": "Revenue Recognition, Milestone Method, Potential Future Milestone Payment",
        "terseLabel": "Potential future milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Deductions On Prior Period Sales Due To Change In Estimate",
        "label": "Sales Deductions On Prior Period Sales Due To Change In Estimate",
        "terseLabel": "Change in estimate of sales deductions for prior period sales as a pct of total sales deductions (less than)"
       }
      }
     },
     "localname": "SalesDeductionsOnPriorPeriodSalesDueToChangeInEstimate",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_SalesReturnProvisionsAsPercentageOfProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Return Provisions As Percentage Of Product Sales",
        "label": "Sales Return Provisions As Percentage Of Product Sales",
        "terseLabel": "Sales return provisions as a percentage of gross product sales (less than)"
       }
      }
     },
     "localname": "SalesReturnProvisionsAsPercentageOfProductSales",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_SandozIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sandoz Inc.",
        "label": "Sandoz Inc. [Member]",
        "terseLabel": "Sandoz Inc."
       }
      }
     },
     "localname": "SandozIncMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SanofiRegeneronPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi/Regeneron Patent Litigation [Member]",
        "label": "Sanofi/Regeneron Patent Litigation [Member]",
        "terseLabel": "Sanofi/Regeneron Patent Litigation"
       }
      }
     },
     "localname": "SanofiRegeneronPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.",
        "label": "Schedule Of Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of identifiable intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Long-term Debt Instruments Exchanged [Table]",
        "label": "Schedule of Long-term Debt Instruments Exchanged [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments Exchanged"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps",
        "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]",
        "terseLabel": "Schedule of notional amounts and interest rates for cross-currency swaps"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfU.S.RepatriationTaxCommitments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]",
        "label": "Schedule Of U.S. Repatriation Tax Commitments",
        "terseLabel": "U.S. repatriation tax commitments"
       }
      }
     },
     "localname": "ScheduleOfU.S.RepatriationTaxCommitments",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SensiparAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensipar Antitrust Class Actions [Member]",
        "label": "Sensipar Antitrust Class Actions [Member]",
        "terseLabel": "Sensipar Antitrust Class Actions"
       }
      }
     },
     "localname": "SensiparAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]",
        "terseLabel": "Weighted average assumptions used and the resulting weighted average grant date fair value of performance units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SixPointFourZeroPercentNotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "label": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointFourZeroPercentNotesDue2039Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointNineZeroPercentNotesDue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointNineZeroPercentNotesDue2038Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointOneFivePercentNotesDue2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point One Five Percent Notes Due 2018 [Member]",
        "label": "Six Point One Five Percent Notes Due 2018 [Member]",
        "terseLabel": "6.15% notes due 2018 (6.15% 2018 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointOneFivePercentNotesDue2018Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentNotesDue2037Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_StockBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total stock-based compensation expense, net of tax.",
        "label": "Stock Based Compensation Expense Net of Tax",
        "totalLabel": "Total stock-based compensation expense, net of tax"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseNetOfTax",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_StockRepurchaseProgramTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program [Table Text Block]",
        "label": "Stock Repurchase Program [Table Text Block]",
        "verboseLabel": "Summary of activity under our stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramTableTextBlock",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total",
        "label": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
        "totalLabel": "Total remaining U.S. repatriation tax commitments"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments",
        "terseLabel": "U.S. repatriation tax commitments, number of annual installments"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Five Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Five Years",
        "terseLabel": "U.S. repatriation tax commitments, 2025"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFiveYears",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years",
        "terseLabel": "U.S. repatriation tax commitments, 2024"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years",
        "terseLabel": "U.S. repatriation tax commitments, 2023"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years",
        "terseLabel": "U.S. repatriation tax commitments, 2022"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months",
        "terseLabel": "U.S. repatriation tax commitments, 2021"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ThreePointEightSevenFivePercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "label": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "terseLabel": "3.875% notes due 2021 (3.875% 2021 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointFourFivePercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "label": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "terseLabel": "3.45% notes due 2020 (3.45% 2020 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointFourFivePercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Five Percent Notes Due 2040 [Member]",
        "label": "Three Point One Five Percent Notes Due 2040 [Member]",
        "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointOneFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "label": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "terseLabel": "3.625% notes due 2022 (3.625% 2022 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2024Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "terseLabel": "Three Point Three Seven Five Percent Notes Due 2050 [Member]"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointTwoZeroNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Two Zero Notes Due 2027 [Member]",
        "label": "Three Point Two Zero Notes Due 2027 [Member]",
        "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointTwoZeroNotesDue2027Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThresholdForDisclosureOfProductSalesToMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold as a percentage of total revenues for determining a major customer for additional disclosures.",
        "label": "Threshold for Disclosure of Product Sales to Major Customers",
        "terseLabel": "Threshold as a percentage of total revenues for determining a major customer for additional disclosures"
       }
      }
     },
     "localname": "ThresholdForDisclosureOfProductSalesToMajorCustomers",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_Transactioncostsassetacquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs, asset acquisition",
        "label": "Transaction costs, asset acquisition",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "Transactioncostsassetacquisition",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "label": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "terseLabel": "2.00% 2026 euro Notes [Member]"
       }
      }
     },
     "localname": "TwoPercentEuroNotesDueTwoThousandTwentySixMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointFourFivePercentNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "label": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "terseLabel": "2.45% notes due 2031 (2.45% 2031 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointFourFivePercentNotesDue2030Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]",
        "label": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]",
        "terseLabel": "2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes) [Member]",
        "verboseLabel": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]"
       }
      }
     },
     "localname": "TwoPointOneTwoFivePercentEuroNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]",
        "label": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]",
        "terseLabel": "2.125% notes due 2020 (2.125% 2020 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Seven Percent Notes Due Two Zero Five Three",
        "label": "Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]",
        "terseLabel": "2.77% notes due 2053 (2.77% 2053 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]",
        "label": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixFiveNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Five Notes Due 2022 [Member]",
        "label": "Two Point Six Five Notes Due 2022 [Member]",
        "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSixFiveNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "terseLabel": "2.60% notes due 2026 (2.60% 2026 notes) [Member]",
        "verboseLabel": "2.600% notes due 2026 (2.60% 2026 notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointThreeZeroPercentNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Three Zero Percent Notes Due 2031",
        "label": "Two Point Three Zero Percent Notes Due 2031 [Member]",
        "terseLabel": "2.30% notes due 2031 (2.30% 2031 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointThreeZeroPercentNotesDue2031Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "label": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "terseLabel": "2.25% notes due 2023 (2.25% 2023 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Notes Due 2020 [Member]",
        "label": "Two Point Two Zero Notes Due 2020 [Member]",
        "terseLabel": "2.20% notes due 2020 (2.20% 2020 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoZeroNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroPercentNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Notes Due 2019 [Member]",
        "label": "Two Point Two Zero Percent Notes Due 2019 [Member]",
        "terseLabel": "2.20% notes due 2019 (2.20% 2019 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "terseLabel": "2.20% notes due 2027 (2.20% 2027 notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_XgevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XGEVA.",
        "label": "XGEVA [Member]",
        "terseLabel": "XGEVA\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "XgevaMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "label": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "terseLabel": "0.41% 2023 Swiss franc Bonds [Member]"
       }
      }
     },
     "localname": "ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.amgen.com/20201231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PUERTO RICO",
        "verboseLabel": "Puerto Rico [Member]"
       }
      }
     },
     "localname": "PR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US [Member]",
        "verboseLabel": "US [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "verboseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Switzerland, Francs [Member]"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "United Kingdom, Pounds [Member]"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "United States of America, Dollars [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XNGS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "terseLabel": "The NASDAQ Global Select Market"
       }
      }
     },
     "localname": "XNGS",
     "nsuri": "http://xbrl.sec.gov/exch/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "New York Stock Exchange"
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r510",
      "r511",
      "r515",
      "r516",
      "r740",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r510",
      "r511",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r61",
      "r128",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r145",
      "r153",
      "r251",
      "r423",
      "r424",
      "r425",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r145",
      "r153",
      "r251",
      "r423",
      "r424",
      "r425",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r145",
      "r153",
      "r251",
      "r423",
      "r424",
      "r425",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "verboseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment, including named security. Excludes consolidated entity.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r214",
      "r351",
      "r355",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r378",
      "r381",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r689",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r378",
      "r381",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r689",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r214",
      "r351",
      "r355",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A general or limited ownership interest in a partnership or unincorporated joint venture.",
        "label": "Partnership Interest [Member]",
        "terseLabel": "Limited Partnership [Member]"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r210",
      "r351",
      "r353",
      "r640",
      "r688",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r210",
      "r351",
      "r353",
      "r640",
      "r688",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r357",
      "r378",
      "r381",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r689",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r357",
      "r378",
      "r381",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r689",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r379",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment, including named security. Excludes consolidated entity.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r351",
      "r354",
      "r691",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r351",
      "r354",
      "r691",
      "r724",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r752",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r302",
      "r379",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r367",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity owned or controlled by another entity.",
        "label": "Subsidiaries [Member]",
        "terseLabel": "Onyx Therapeutics, Inc [Member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r18",
      "r650",
      "r672"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r294"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r72",
      "r81",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Cash\u00a0flow hedges [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Available-for-sale securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r69",
      "r71",
      "r72",
      "r674",
      "r701",
      "r705"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r68",
      "r72",
      "r73",
      "r142",
      "r143",
      "r144",
      "r514",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss [Member]",
        "verboseLabel": "AOCI [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r63",
      "r72",
      "r73",
      "r514",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average period of amortization"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net",
        "terseLabel": "Tax impact related to employee stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r642",
      "r643",
      "r644",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r383",
      "r385",
      "r428",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising cost"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestment": {
     "auth_ref": [
      "r556",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.",
        "label": "Alternative Investment",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AlternativeInvestment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r114",
      "r276",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization charges associated with finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r231",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Other mortgage- and asset-backed securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r199",
      "r203",
      "r208",
      "r247",
      "r510",
      "r515",
      "r570",
      "r648",
      "r671"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r59",
      "r126",
      "r247",
      "r510",
      "r515",
      "r570"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r222",
      "r259"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Available-for-sale securities, continuous unrealized loss position, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r226",
      "r229",
      "r666"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Maturing after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r226",
      "r228",
      "r665"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value",
        "terseLabel": "Residential-mortgage-backed securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r218",
      "r223",
      "r259",
      "r654"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair values",
        "totalLabel": "Total available-for-sale investments",
        "verboseLabel": "Interest-bearing securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r220",
      "r259"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r387",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r525",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r9",
      "r293"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r377",
      "r380",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r497",
      "r498",
      "r500"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred",
        "totalLabel": "Total consideration transferred to acquire K-A"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "auth_ref": [
      "r485",
      "r500"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "totalLabel": "Total acquisition date fair value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r496",
      "r499",
      "r502"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "terseLabel": "Adjustments to carrying value of intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Fair value of assets acquired, cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "verboseLabel": "Fair value of liabilities assumed, deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Intangible assets:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r490",
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Fair value of assets acquired, licensing rights"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r486"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Fair value of Amgen\u2019s investment in K-A"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Ownership interest in acquiree prior to acquisition (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of net gain (loss) recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net",
        "terseLabel": "Net gain on remeasurement"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss",
        "negatedTerseLabel": "Loss on settlement of preexisting relationship"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r122",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r38",
      "r706",
      "r707"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r38",
      "r116"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r117",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r110",
      "r116",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r110",
      "r571"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedge [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Hedged Items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r124",
      "r126",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r179",
      "r180",
      "r181",
      "r247",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r504",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Collaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r301",
      "r655",
      "r678"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Contingenciesandcommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r313",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends paid per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "terseLabel": "Common stock and additional paid-in capital [Member]"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Number of shares of common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock and additional paid-in capital, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock and additional paid-in capital, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r26",
      "r332"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding\u2014 578.3 shares in 2020 and 591.4 shares in 2019"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r86",
      "r659",
      "r682"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r90",
      "r640"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r465",
      "r474"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r465"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r465",
      "r474",
      "r476"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r465",
      "r474"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt Conversion, Converted Instrument, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Financing arrangements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Financingarrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r649",
      "r652",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r316",
      "r652",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r581",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Aggregate principal amount of notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r50",
      "r319",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate on note"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r129",
      "r326",
      "r329",
      "r330",
      "r331",
      "r580",
      "r581",
      "r583",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r580",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r317",
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized bond discounts, premiums and issuance costs, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Total realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Total realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial obligations in a security form.",
        "label": "Debt Securities Payable [Member]",
        "terseLabel": "Debt securities payable [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r466",
      "r474"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r466",
      "r474"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r127",
      "r466",
      "r474",
      "r475",
      "r476"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred (benefit) provision:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r20",
      "r21",
      "r455",
      "r651",
      "r669"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r466",
      "r474"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "NOLs with no valuation allowance and no expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Expenses capitalized for tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r439",
      "r458"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedTerseLabel": "Debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Deferred Tax Liabilities, Property, Plant and Equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense attributed to Retirement and Savings Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DefinedcontributionplanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r114",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization charges associated with property, plant and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r114",
      "r196"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.",
        "label": "Derivative, Basis Spread on Variable Rate",
        "terseLabel": "Derivative, effective interest rate"
       }
      }
     },
     "localname": "DerivativeBasisSpreadOnVariableRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r60",
      "r62",
      "r529",
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Total derivative assets, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r60",
      "r62",
      "r529",
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Total derivative liabilities, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Interest rates"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative",
        "terseLabel": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r526",
      "r530",
      "r535",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Derivativeinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r523",
      "r526",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r523",
      "r526",
      "r535",
      "r540",
      "r541",
      "r548",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments Gain Loss [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r518",
      "r520",
      "r521",
      "r523",
      "r524",
      "r532",
      "r535",
      "r545",
      "r547",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]",
        "verboseLabel": "Schedule of Cross-Currency Swaps [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r132",
      "r518",
      "r520",
      "r523",
      "r524",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DirectOperatingCosts": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate direct operating costs incurred during the reporting period.",
        "label": "Direct Operating Costs",
        "terseLabel": "Cost paid"
       }
      }
     },
     "localname": "DirectOperatingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue by product and by geographic area"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Stockbasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r48"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic [Member]",
        "verboseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:",
        "verboseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r87",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r159",
      "r161",
      "r165",
      "r166",
      "r167",
      "r171",
      "r172",
      "r660",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)",
        "verboseLabel": "Basic EPS (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r87",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r161",
      "r165",
      "r166",
      "r167",
      "r171",
      "r172",
      "r660",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in usd per share)",
        "verboseLabel": "Diluted EPS (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Earningspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfFourthQuarterEventsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Effect of Fourth Quarter Events [Line Items]",
        "terseLabel": "Effect of Fourth Quarter Events [Line Items]"
       }
      }
     },
     "localname": "EffectOfFourthQuarterEventsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "negatedTerseLabel": "Foreign-derived intangible income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "negatedTerseLabel": "Credits, Puerto Rico Excise Tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Credits, primarily federal R&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r441",
      "r477"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "negatedTerseLabel": "Audit settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to nonvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": 2.0,
       "parentTag": "amgn_StockBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Tax benefit from stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Actual tax benefits realized from tax deductions from option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147",
      "r156",
      "r158",
      "r178",
      "r251",
      "r325",
      "r332",
      "r423",
      "r424",
      "r425",
      "r470",
      "r471",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity Method Investment, Aggregate Cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Equity Method Investment, Quoted Market Value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r39",
      "r200",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Approximate carrying value of the company's equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r39",
      "r109",
      "r122",
      "r244",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r241",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r557",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r373",
      "r558",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Fairvaluemeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r358",
      "r360",
      "r365",
      "r373",
      "r558",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r358",
      "r360",
      "r365",
      "r373",
      "r558",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r373",
      "r558",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs (Level 3) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r360",
      "r556",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r373",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r525",
      "r532",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r277",
      "r281",
      "r285",
      "r289",
      "r641",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r285",
      "r645"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "amgn_IdentifiableIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross carrying amounts"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r277",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r285",
      "r641"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "verboseLabel": "Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Foreign currency and cross-currency swap contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Foreign currency and cross-currency swap contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r358",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency contracts [Member]",
        "verboseLabel": "Foreign currency contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "verboseLabel": "Foreign currency forward contracts [Member]"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAmnealPharmaceuticalsLLCLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsKYPROLISANDAPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r269",
      "r270",
      "r647"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Addition from acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Goodwillandintangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r273",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r89",
      "r126",
      "r199",
      "r202",
      "r204",
      "r207",
      "r209",
      "r247",
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit from product sales"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Hedging adjustments on discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying amounts of hedged liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Fair value adjustments",
        "verboseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r523",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r114",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "IPR&amp;D impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r130",
      "r199",
      "r202",
      "r204",
      "r207",
      "r209"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r83",
      "r114",
      "r197",
      "r242",
      "r656",
      "r679"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Company's share of profits (losses) of related party"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r442",
      "r453",
      "r460",
      "r472",
      "r478",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r157",
      "r158",
      "r198",
      "r440",
      "r473",
      "r479",
      "r686"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r122",
      "r437",
      "r438",
      "r453",
      "r454",
      "r459",
      "r467",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r111",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Accrued income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r280",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "amgn_IdentifiableIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r280",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r275",
      "r283"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r97",
      "r320"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense, net",
        "terseLabel": "Interest expense, net",
        "verboseLabel": "Make-whole payments recognized in interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense [Member]"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid, net of interest rate and cross currency swaps"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Asset at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Liability at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "netLabel": "Interest rate swap agreements [Member]",
        "terseLabel": "Interest rate swap contracts [Member]",
        "verboseLabel": "Interest rate swap [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Tax receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventories [Member]"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r266"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r56"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r57",
      "r122",
      "r174",
      "r264",
      "r265",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r34",
      "r266"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r33",
      "r266"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r244",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Interest-bearing securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale interest-bearing security investments by contractual maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r646",
      "r667",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r8",
      "r41"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r599",
      "r601"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total net lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary information, components of lease costs, cash and noncash information on leases and other lease information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Leases not yet commenced lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Expected total future rental income to be received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r126",
      "r247",
      "r570",
      "r653",
      "r676"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r126",
      "r247",
      "r511",
      "r515",
      "r516",
      "r570"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r19",
      "r652",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under syndicated, unsecured, revolving credit facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Annual commitment fees for syndicated, unsecured, revolving credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Property, plant and equipment by geographic information"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r318",
      "r652",
      "r673"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Carrying value of long-term debt, including current portion",
        "totalLabel": "Total carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, by Current and Noncurrent [Abstract]",
        "verboseLabel": "Carrying values of long-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtByCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current portion",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r134",
      "r314"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 6.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r134",
      "r314"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r134",
      "r314"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 5.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r134",
      "r314"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 4.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r134",
      "r314"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r134",
      "r314"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Total long-term debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r51",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r9",
      "r293"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing-related rights [Member]"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Maturities of Long-term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Length of time hedged in foreign currency contracts"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market mutual funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Allowance for doubtful accounts [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r110",
      "r112",
      "r115"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r74",
      "r77",
      "r84",
      "r115",
      "r126",
      "r146",
      "r151",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158",
      "r164",
      "r199",
      "r202",
      "r204",
      "r207",
      "r209",
      "r247",
      "r570",
      "r657",
      "r680"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income for basic and diluted EPS"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/EarningspershareDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Income (Numerator):"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r171",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r642",
      "r643",
      "r644",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Other recently adopted pronouncement and Other recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net",
        "verboseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Aggregate fair value of long-term debt, including current portion"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes payable [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes [Member]"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "verboseLabel": "Number of business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Unrealized (losses) gains"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r199",
      "r202",
      "r204",
      "r207",
      "r209"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r593",
      "r601"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r588",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, Right-of-use asset",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r598",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r597",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards available to reduce income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "NOL carryforwards, valuation allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Options Held [Member]",
        "verboseLabel": "Foreign currency option contracts [Member]"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r48"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "totalLabel": "Total other current assets",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r508",
      "r509",
      "r513"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "(Losses) gains on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r508",
      "r509",
      "r513"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Gains (losses) on foreign currency translation",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "(Losses) gains on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r75",
      "r78",
      "r81",
      "r85",
      "r325",
      "r572",
      "r577",
      "r578",
      "r658",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r75",
      "r78",
      "r508",
      "r509",
      "r513"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive (loss) income, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of reclassification adjustments and taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r70",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "terseLabel": "Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax",
        "terseLabel": "Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r508",
      "r509",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r64",
      "r69",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax",
        "verboseLabel": "Total unrealized (losses) gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": {
     "auth_ref": [
      "r64",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax",
        "terseLabel": "Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r66",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r525",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Other General Expense",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r19",
      "r652",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Other Long-term Debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other operating income (expense) [Member]"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r268"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Gross, Current",
        "terseLabel": "Corporate partner receivables"
       }
      }
     },
     "localname": "OtherReceivablesGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r100",
      "r103",
      "r133"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Withholding taxes arising from shares withheld for share-based payments"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r101",
      "r501"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "netLabel": "Total cash paid to Kirin",
        "terseLabel": "Cash paid",
        "verboseLabel": "Cash purchase price"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Payments to Acquire Equity Method Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r357",
      "r359",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined contribution plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Definedcontributionplan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "verboseLabel": "Net proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r98",
      "r99",
      "r219"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "verboseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r105",
      "r108",
      "r133"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r98",
      "r99",
      "r219"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other [Member]",
        "verboseLabel": "Other revenues [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]",
        "verboseLabel": "Product sales [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r297",
      "r728",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Propertyplantandequipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r293"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r295",
      "r677"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r122",
      "r295",
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful\u00a0life\u00a0(in\u00a0years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly financial data (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Quarterlyfinancialdataunaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Reclassification adjustments to income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "verboseLabel": "Reclassification out of AOCI [Member]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassifications out of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.",
        "label": "Recovery of Direct Costs",
        "terseLabel": "Cost recoveries"
       }
      }
     },
     "localname": "RecoveryOfDirectCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r434",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r122",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResidentialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r221",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by residential real estate mortgage loans.",
        "label": "Residential Mortgage Backed Securities [Member]",
        "terseLabel": "Residential mortgage-backed securities [Member]"
       }
      }
     },
     "localname": "ResidentialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r332",
      "r426",
      "r675",
      "r700",
      "r705"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147",
      "r156",
      "r158",
      "r251",
      "r423",
      "r424",
      "r425",
      "r470",
      "r471",
      "r696",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r194",
      "r195",
      "r201",
      "r205",
      "r206",
      "r210",
      "r211",
      "r214",
      "r350",
      "r351",
      "r640"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r194",
      "r195",
      "r201",
      "r205",
      "r206",
      "r210",
      "r211",
      "r214",
      "r350",
      "r351",
      "r640"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Product sales",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues and Arrangements with multiple performance obligations"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r82",
      "r126",
      "r194",
      "r195",
      "r201",
      "r205",
      "r206",
      "r210",
      "r211",
      "r214",
      "r247",
      "r570",
      "r661"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r596",
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalties due"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r72",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r227",
      "r230",
      "r233",
      "r234",
      "r235",
      "r237",
      "r663",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/AcquisitionsOtezlaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r51",
      "r129",
      "r326",
      "r329",
      "r330",
      "r331",
      "r580",
      "r581",
      "r583",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "verboseLabel": "Carrying values and the fixed contractual coupon rates of long-term borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Fair values of derivatives included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Summary of amounts of income and expense line items"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Computation for basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfFourthQuarterEventsTable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about transactions recognized in the fourth quarter, including, but not limited to, disposals of components of an entity, unusual or infrequently occurring items, or both, effect from changes in accounting estimates and effect of year-end adjustments.",
        "label": "Effect of Fourth Quarter Events [Table]",
        "terseLabel": "Effect of Fourth Quarter Events [Table]"
       }
      }
     },
     "localname": "ScheduleOfEffectOfFourthQuarterEventsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation between the federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Derivatives in fair value hedging relationships"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r277",
      "r284",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of income before income tax, domestic and foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of interest rate derivatives"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Net Investment Income [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r95",
      "r97",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]",
        "terseLabel": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Aggregate contractual maturities of long-term debt obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Quarterly financial data (unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/QuarterlyfinancialdataunauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r387",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r392",
      "r404",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r54",
      "r124",
      "r179",
      "r180",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Revenues earned from major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, general and administrative costs"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "amgn_StockBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Total stock-based compensation expense, pretax",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Components of stock-based compensation expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period over which the grants of equity instruments vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Description of vesting of restricted stock units and stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, forfeited (in usd per share)",
        "verboseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Units granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "netLabel": "Weighted average grant date fair value, granted (in usd per share)",
        "terseLabel": "Granted (in usd per share)",
        "verboseLabel": "Fair value of unit (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance nonvested at end of period (in shares)",
        "periodStartLabel": "Balance nonvested at beginning of period (in shares)",
        "terseLabel": "Units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance nonvested at end of period (in usd per share)",
        "periodStartLabel": "Balance nonvested at beginning of period (in usd per share)",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant\u00a0date fair\u00a0value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of units that vested during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock options information [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, unexercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r394",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance unexercised at end of period (in shares)",
        "periodStartLabel": "Balance unexercised at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance unexercised at end of period (in shares)",
        "periodStartLabel": "Balance unexercised at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average exercise\u00a0price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested or expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r384",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r122",
      "r387",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period of stock options from date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r410",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), unexercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "terseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r124",
      "r126",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r179",
      "r180",
      "r181",
      "r247",
      "r325",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r55",
      "r142",
      "r143",
      "r144",
      "r147",
      "r156",
      "r158",
      "r178",
      "r251",
      "r325",
      "r332",
      "r423",
      "r424",
      "r425",
      "r470",
      "r471",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r178",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r332",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r332",
      "r386",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, additional authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchases of common stock, Shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchases, Shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchases"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r126",
      "r217",
      "r247",
      "r570"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r594",
      "r601"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r444",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards available to reduce income taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "terseLabel": "Tax credit carryforwards, valuation allowance"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r642",
      "r643",
      "r644",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBayerHealthCarePharmaceuticalsIncDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. Treasury bills [Member]"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r358",
      "r373",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "U.S. Treasury notes [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r436",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties associated with unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties related to unrecognized tax benefits recognized in income tax provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Reductions for expiration of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r135",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions charged\u00a0to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "terseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "verboseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r160",
      "r167"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares for diluted EPS",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares (Denominator):",
        "verboseLabel": "Shares used in the calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r159",
      "r167"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares for basic EPS",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 20
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1570-108306"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=SL65897772-128472"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r742": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r743": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r744": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r745": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r746": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r747": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r748": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r749": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r750": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r751": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r752": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r753": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r754": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r755": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r756": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>148
<FILENAME>0000318154-21-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-21-000010-xbrl.zip
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MB)XHY5VF_V=-_/RQ9%"9""]Z%@5GXHA-/9,II-'Z64L%C3['*;1=VO'B0M:
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MH$7&YH6HY[0< N;=M)S*[(<9B.YBPC)2TD@3*?J6,+IH D9IM]]O>NQ8H>T
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M<QD:<$(Z5&NYT.)^VICT2>0-*. 4/?'**4&U]F!80A-N';<D@ED<>5?"$5=
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M-1\M"H'B*"897+2"<F>U5  >(($7(4XJ#2IB)\+#%S43WMI)#USWS;$;G+@
MXU$GN.[P]>OU![>(Q-Y1EN6E/RK+"\UV"3U-!V^\7;<OOOYN[0Z@$OKEI(&!
M2/G :5 \4 /!<I:LFP*$S0#"V(.;V;D"9/OD9-R#3VN].-'SAP<&NSLP6(O]
MH,F_3JH#*K!*!(020G!A--$\LI BM5)*,ZVX)J85UVK'MZ[*\&0X[AV][/3A
MM#-<[S^P-&UF,W<MM38OXN,(F,1I *8 18GQDJ*1: )!>.?U1)IBQI[Q1?5B
MI6_YVW[J[,$1]&#0[WTG<[ZO2,7=N6QYZ5QJT1#TPE1[$Y(S0A!G4^92W.7U
M"-(#K[N1?5J1/HG-M<E%8:2R$*704?GH\OHH9I*V@3LW9<5\QHIYHZ7?QY7Y
MW;DR_V$MO>!7H>LZ)[=SJ_*K[^95P@&U&E6=^+S;7[NDB1<NB%R.S\T6=A#)
M'MP5?V]2"0-1=N''?C"IY(X&4):^^PI=G7W]W<-J2(S,RZAP2 65VH28M2XX
M:G10.M:=ZK3['Q'JG>'+ ;APO)MFJ>6U\ A:]UATYS+WB*J5QS$-OY)_O/C^
MNX'BE2:,$Z^5I@)X0B(,"A [(L5@XZQ^-ZLK4/;S5:=NL);;.A@/1Y.SG$J8
M/$)9Z;LZW#G28J&%!-!1TB"0(!OGI7+@,,3AT<)T9P.1-?.SOXU/.@.' <VP
M<]+I/IH\KVUS0(M_[VF$T#^9:.M75/GR^^]WI8%S!<$;E]>CHRO5COMH-!,\
M(:F>V7P^4^4& C^DTG<E7/8Z7NZ3MQ"2.PTT^41$T,JF"-*)Q"#RP,QT,I H
M(AIY?B^)PTA'W%.ER]NZW:_3N"L7?+=2*\J8=#QH)JE(1EJ,>D$*$?$#Y\ET
M>F>:Y:CFCK6*5!O/^]3NF-*8XQ%&S"<:\ZQ08%J(!#:D;)^]1U&E1.ET>DY/
MY5?5B85JR(_H.\OO'I,)UYUJE"@2FA-05@3FG7!(C;D2AEGG#)O*3\SD5]%9
MO8K([XYA4[YT3A-[UFMAI4A$YL6A3#EKDC.11M $F5*\<2Y<5?-/%9'?W8^
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M ;@/+9>P@\]=]\R=#U=^N38.)YU>Z\:XWQRRR<"\^)<?_')3IC<E>.(&1_C
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M<9ZD50&X'.IW.D?]];!NJ=X)3L)?02RDC4_IBLF?AOR06P&3<P+47@(H0,'
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ML0EJ2'UY33+0/$ GDN[H 39JNQK!/:+[,HV"$-N)4KO'IL9!OD#IE5A.,E:
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MX4F^"^;6U)D+G %;9SW7#R ?TYQUK<-10MP1_MV?-()G^#5F_8QU/J2PF"P
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M<0'@#,V=DFM88Z<W&7VM) -&$M&4I&PSXY/EX,55XI"8$O-(G[*[27F^)\<
M081:S',86Z/;] 7;B";R_)G(:C<XFMTIGL)F;CIP:/,W)L:@T^ OV].C$X0
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M5TF3'HD"Q4Z6*JC9XR&]TB(-JJY_BAD^M0E>N[QK@PN[C6@IV"9 &9<*IQI
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MC6#Z1UQ'&OO>:;Y+[P[EHNHV_W7PM]DTR_JUK^^?>3ZC70+OCED.IYABZN%
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M2FX8DTRD@-;F>.-7SC<6FX&6'B\N4HA.*=EKXP2Y;Y]1-$7RVVD/KM8FI4X
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M0-$P8UZ[&_1F'J3J ,PBB-F@Q2+^E.J>.CPBLB,U!B27,U0N$U0F0>6V ^A
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M7-BAMB*9,H/2Z$^P\_YH[))+T$!C&<!,G"+-ARJ1?#5A>]:74#<LPSW7\Y/
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M)I9W+6RP[IHOU2GNT]E)Y$H!#264"@A"3!KKF;I\+ZNE/VN*_KJ)09^'NO%
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MV\Y+S*I]S6&G9HK?9B3 7OHT?*:?T5EE+K*RK>F6=EU&V\F9P<FDUETO.<S
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M%'Z=DQ-3-U<8,T&!G/:G8<MD.#%3&XB A+1#/JSY*<,Y38TILL=DI1S2C*'
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M/]U^E _V++C;AJ!?8P'N8M80\/)]?H)J]:9,3K.F_906#V]*[UX%_O0V'7S
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MN<MATIY7Y279%V-F1?7TB!M_'+W^Y70S^668C%LQ;:46\N;ZLC"E>_+&I4'
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M4N:CVAHHPW(KM#_"*.XGSB)?A/O1?F]/S46:#USYCQ13CC-X+4)?L&G=@K$
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MO-.)R'0?<N;(NCCBO>2$[FG+;TXFSF;HZVN+C:6Z/^>4\PU'?[4 67E]:4-
MO?AUQ1[2UK;"1=Z99$Z"M#G'NKQ5Y$W_G9>=6_HINL%RB+UN6VGQ07(V)*FF
M/[;>YPQQCK9[Y\MPUW>^6CZZSN9?V/#TO8LRA?G6*!';)/_@4_ ?GS'ANA/P
M!_VO:PJY;#;6Z=,H??ILG3[]&O-XZ'3HVVTZ@OA@M,'^SYH52IL11+1P.[[+
MZFCW4_$P@'#!V;5LE\4<ULI;Q@30]G1SA-?<DPG%_.&SKPAM?$#(,G?HF_">
M)\60J4^]56Q]O!<: ;G!'7L+8;3GJZWP>.1A!/: 5HS?_E1?TT)[7E7<(N$
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M[]D=-I^.IVOWB9RX'Y:1Q'J_8=8.<B7!/D=NA7MA.3),;EQMB>?3\Q3MAH0
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M@<#Q,+L]I?"L-O;V/F47W(C.G(QT2U8M](@7I&1D"K&YH]G[)5#+]6GTW?>
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MJ$Z<IDC"6;,MKR)TCV,DK"5-KQ23H:E^0;:7A-9))QA)NC LM?5J;P%()#B
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M&#7IJFPRN#\,#O6<]-;#>2_4FA8S[E$5J5)E#< K+=?R)-(_.2*AK4(YRV1
MF6[1;?I8.6A%>$4[M9+W P8#_*YX %"QN5#CYJ*' X29)WOQ4#A3<.R6B6PJ
M(14514A[G)DE60Q'+A-E2Y#(8R@60OI6^W=R56:+7(<<80/4S>/J2S-0!G1?
MO:1OL\A!0\ND4^#+ I!H[##2Q(V)+,],Y""5M5+)"^>IL8_7"HXH<]>I0CAZ
MV]\,BNNG<"ZVG*4=-(D/S\*I$_N9$92P-'LU !BV=4#"1?J!NW. ULL39:E
M<T]ZQA$*?3#SZ7LV%3%VO/5[=?<NIRQ\*$E.(+-23:K[Q6X)W-$N&:T2R$JN
M(%*1/6XUHF;X3U$:(';Q%F)Y!9I</>^AM#O&&,E4SZ/5C]E]L@+[%@_H[@99
M_/@PUJ@;CHJFCK)M07R$81[" BW>"NOW3KAR,4=C)0#7>P _[U-US%D%+3"S
M^Y?IR:C8)0J>'"9 PKY#]C,;Z6(VH06<(V)<QQT&I5YR5I*;]F<&U,U!6<VT
M9@$K ,2HGG=2W\BOIEL=0YF6!1JL6W>+K;,N.U!P '69V3RO4TCC5+<,E'"K
MNT!$(JT4!I;F2^@)H2%)DS$EM5,WPW)DQ!) P87&;MP;M#/)SS/G&$U:D'VG
MT? 4,OXAST713.>TK3S/7 =P'W2XXG(@JQO]('W+SY1+9$>E%N<RFZ'L^<\&
M(=?=#!]K-\-OO.A7@_N9$)PW9.OH:CHJR<:TZ$1\3-Z%LQYA.=IFAER9H$=S
MRMX%\FVM4EX[YC\;;O#Q]*7UA$V5CA!5)+,/YH4/0@5Z,N*%CSY7VDP$J(47
M6(Z"IF*@I*;%S9 4*WWG2^>"!+V>P4MY"@<&H"VMN6_5#5(RV+ E7R_&4OWD
MTVO>QXY:6UT:-X-7\@5J,=20;0]Z L<0V,UGR@6A4++)>YYO7R+BH$/L%67U
M1_'T"[7..(+%NYY#W^R5L_8>SB5>$$6T8J,Q]!<V\>L\G<'CHW/ N6B])6\3
MW,)_V.'1\T?B%F?2QN!9T-C(9D]+]I1U.;PA.1\M8#\='LVRLA X.:<@#K3=
M5!HSP6%:T,YFSW+"(N)291#I@".6WDG3O!-Z<R#R2*QLEM>N.82!X>AA=03+
M3;0S7+KPDS28@H"%E)HBC];S5NP)LW.H9R GBZ^=7:,K@*[86Z,KOL8\'EK6
M\2 K$YAS3AMW<\Y08X4TJ'6H0=Z&EY-RRM1Z9>!,.0=1-HFK^G300WL[N8=W
M <-0J;^)%E>G0\FQ2*'UT"=;>#]J*G]!N\F1GODC[PKTDZ<H=$ZK;6#J2]N\
M*]HUA1##3"_]$203419RDKB7ZZ08V!$47'';X<J%/EGJ*KZDX_6R=)2),LN6
MV5I[^; E20?"7#Q)]WBU\SD"X9NW!MY,",((L6;=UB_1:>$:/?;IK)'HS)DA
M1]."R\7KB@?LQ8+%8%4 +Q(*:[:RJK5?<>QX)I%]A LY51..-&3^M=&P(_S(
ML3]Z_EC7+J;U&&B.[D41/2V7P;+I2UE"->?3_&E[++%396,?:+2VY':.!P=P
M\3)*OKI'N'0K0'X#97YQ$KH,-![T,XW"]_!SIV6E^7%D$NR93G?B^B!W>1/W
MD]*7[8D%- 1H%^ A:?,':T5^@' J^SN(]\'[!.I4)LVQ<98#5_?A%_(F01V?
MUJE6M4J+H):7 60@CGXM9P<@22;MGG$W&(M,1ZJ_$Z/Q!=.6GVDA;2B>/NFS
MK'(-RP/H0L!6VJW!MOJJDU/A6W4C6R.39RB4B$'URVOX([JBQ^+9]'-LA?/)
MLD95NM5\E!V+96/<19SU6SA%>GK$">=_SHE%EO95=W/'C_7LOXHT_VDZ>8D+
MY;>1L@H;ENK9L*D-RP/XG@OPSE(;V/X)ZM5T;%@^2JT><RP,0JJ@L?*BA$DN
MQ;:!,:R))<$K2&2_%Y9NH/9VSDH0DAK$?/FYK"" K _G=6D2I)>$!P]>(3SQ
M0]6JF<Z5AWX4HXB#G#^YI7"5\V5=NQ-;$SUV+GLA[WW/1LQZ\9%N%>DEDJY=
MGSK$D?KG.KEQ+G1/Z@UZ'9FQ:5#Z*324^+8":EE&L$#GS/"CU- &AY5K\B)I
MHCQ+7><Q5\<O" 9;:4VJ'OL"$4SN Z& ?JPO2LPU^H55Q>R9:$7";)B^L<C
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M(BW;)8IPL#4KT12ZO0]*ED%MV[2Z7E_H+>1+>J[]]K0#E'L'=;8(ZCF(SL3
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M!='WW1/R"Y"6Y$ENO7,B*(IVLUM34+(5?;_<0%5EL6"A@&H,I.A?_W*/N1-
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M6:>#_M85E+JE+_G_>&.[/1X_W3=#"V>1'*_8 QMQZ)>+L>E3Q\U?G!O\I82
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MOL]U&PJ=MS;H2Y8A[)"E7\]$&G6X1*0AV$L%+<KL:;<;T->UJ[S12 N[L[F
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MRYQ0#;>YJ%P3J0C#B:8D"MI@[W>G]H%BL'%A2<<'9S\\_OF+=[H-QCJ@0TA
MO ?[H79VEFE:DVEQZN-@)+8!'6Y)K"O%6TR1P]&. KZMA\54.67OS ]]Z>?[
M!JG8@!YX(#5>04H*S(C6S.&?"QM(,U%R $A$L>LU4!>W6:YZ!S4XBC $,! .
MH'$/5SZVQU-\.I%YPZTN!!"X[0TX<E@Q"00?8VDA6'0F=$*4HH%>RLUZ-!F:
MA>^%A_0IOS1W&P)*FGGM5BS1K9$!"FTJE9@W%TN(' R76"^@#.]OSW<8=D33
ML_E#&AU3)I8').IMKOI%I%,V>)PY5?KL\YKUORI\I?S<SLX/&=AQ?(>9 :F/
MD^RE73,P6@0TX3F  (;5Q,?F7<0/*01#L(V/U."T)N%MH0)!&M>Z.A/Z<7!N
M'"ITT?39<Y5KEHT;6SLF*2Y 5=:4Q(?S>WO32>I1B%Y3"^R!0]3?'54A(60M
M2&C6LG;3&4A)C^%I'X%V0B3))PCT.Z2]CD-!>5-I:Z:P!G+ET@@6P8-L'#F.
MV2-6&Q;<W<K?P9^G%D&'"W&8H@KT><@W4V_8WL^BU!".QCF\'_S8LB:5OP(^
M,Y4W6]"3RRE,7^EXGN6XUN=-\@8) O9[V>;#LJQ.Z*4 6^Y_]?CAPY^3!\_>
M[!_N?>,#?VV\I2^MLX6C-B' C[14U"954SP(2K0IX$Z5E(\++Y$F:!2]>YE*
MP87=S=1B',&K\5>HP'\!9V!!&JZ(,T9#H5;->$LICHYZ0[@9SS;,;F3P ]!K
M511LEWM0?("#N=/=Y+<-TB;"/UA3EN3=BW@H+.P7R/\1Y=)B_=K;%&H?P$05
M [CIBK@A9:!DP=%%<D@M@E.$I_*"6%N8^%E>@0N5Q!HLA##40"BUK A0NR=#
MQ9L9+FK6,7(05BWG20"28K8!&4:[%<+74FOXDQ._R% O&>W/3(X [@AT_JJC
M9X,Y1DAO%\OPR_$6K/$WX%B 2N%X=[]=F;^C\P_7OU!V_GCD31]L$F5R,'\\
M7[E%5RA<9?LV8+U@RLYL?0-$T]*I$%O!;?9H!@J[X2%M^6C1L3 Q7A/'Q$XF
M+#/MBL4\(V,#M%.TJ!IT_@6&2ZVZ("B )/T [N5!-K:)UW<XJ'5^D8PLQ_P6
M1^"[R4L_)I3BI ^*BHBW!4+"X3DL)GK?"#L6Z*R;5H#"0EN4!AQRW+O2J[ !
MICJ6.M>&'LC[!=H!Z/,(Z&4+RI(P29/9,B A7K6N!JZ+WI7G>$)VC6R4^,LA
M.RNKIN=(G2KHZ+C+:O\:CG%':+#T^;#L-'-&7[#"PWZ-#6]^HP3B0B(]1>#2
M?4EXJ-9/0+;\(VM]6/L^^P@PZ;UY/YMM2;40:_9\S_SXE^?[>Y?;H#V;/?!$
MZ-C62I-U<MEL>"<GK[6+$B ^.P#Q,; ?[\1E@J(YR5O1H>6ZW/97%BAA58N1
MPWM%K5GBLH(0H:D6JE/_(O_@@!LVY10%.1$GZ.>@OS%2(/BD\3KG>7LQ54IC
MRUHQ=O]CN<N'+UBB$"9[ + 8[XS\UQ98N@'.@=L#SN.1]%0:/]2CQS1!T8S0
M9.G$A$E!_VJXIQ7Q/QP!\FP10T2-$RJ6;IY^K/),L0G(S'-0*;4EC7KLC!M,
M).?*8OPC:L%375G=7U5M0#M>%'1R6DXZ\85L) ;Q$0DMX>,@L4O-FC+T)V=T
MCN0->3+P007IQ#'$\]"'/)*>H3"-W2V,53 "8A9T+8O1N%,O/N$ON[JU3I5M
M]4.3B:3=H=9.89!M$S)/&CPS!>I15H;$7<7]"A%.1"9'7TJC9$,T>2M7H.D:
MS*"E<.<AZ,I0??2.8L&Y.:HUT?/*53'Y :!5R/1LCY3"5U)RY82T$AZ)2J 8
MY%.Q/.("7SLB,L? +0(C9(@(*V)M)7JM* 7:4#LX_!Z*]+1G3(+19!["ID*5
MSION.+LGA^E^"%G)!C-\10U'.5(81DOM%C>'RWDCR9J])CH(Z,9I9/L10L7^
M#F;SBS-^7&?K[!<EF*P]-&&]U&$AIM)\;3]'>&-TYGVIF_#6(^>O?2(X?650
M0MH2)6"@T9A;+"3[CWSPY^0ST?H/$V]3-3FJ)C^:JLDW4YEY;U.%2Q*J"[$?
M92=,(BY">\7G+O[8]#==_CK1F7A?C/^G#"Q01G,2F )=335?U&UST$$Q.5!!
MQ3IN&7%T;9\SXS5RV#\(N"B!EC?8/D$%8]34V@7]2HTQ:@/4,IY7S'@85\>)
MUM)$*5E$#S(2)""4WM^E<"1%BBZ8><YM+XPH/Q,GA$8 IC3!E*LF/N8PHG'4
MM)N\'AS<"#4.:+N%(O &\T[ *DSS1TEN,]HL\;)V)N.'FFFS&MSS12]S'F'7
M(I^BJ%0+M#H=*9KO)N\D0L1/\'*A"-L002D-V092N40P.-+_#/FE<N$'4CV_
M43>"01*BVT.S[EU\F,#0]:T7A3AZVSYA-:^,E ="I3X:\%ZSL[1,Z[*Y+_;F
MD(SHP6]I/%Z0&"&6'LY*F$$F;BHN+F&0P6 3;;#"H>:\NT;*1=;XQP0]7\!T
M!*[F(?D>@$&UAM]LNB@N]3ZK5K:4N('K8"%3;GI;F@R"^89!M@>_F29$Q2GO
M9V6VR#,N[*#>(>U.6,94(L@H\,*"@";=A8:7!"/T$3?8;[;VSX2MHB):IJ(B
MB2@$P87^TU5M1I1%G5\R&2!K5<\8NP[RMAO>)>1$H0?302/0@LCP^CD 5D2(
MWIR$=.T=L6J%>$=N4MM@%0IMB"/-J&4$>#8O;':ME4Q;.*3\8R2VMA$$_8"1
M2V!Z'3F0 I_A8,Y474LS1+FL8TH(0-NO=Y!90Z1O"73_ Z4&:8;;.(#,@F;:
M(@3\S.$6, 0T6]XA;\P)><^L1<\_T#2;F@:$"U-2EVJ!D.N-IN$DS]!<;#+R
M1;+9#.IV:&Y Y ZY;L^)98V@T)%VX*H$K/QA%"+%W]HS$IO/;#_!.TP#U]$Q
MBSL@(U*N*F2EY(CUV_>M7UC5GTJX\7^R^F->W56EOEL%!#U8YL5QG?FEO]YI
MRL6?P%H\DIB$>7MU\-N;U[\>O+JKXWR;P\PTMX]^ %[PDB3(6)L!]NW**I\8
MLO@H$3.6GXD2QZ^<WXG>PYLFZ#H3=# M[FO+??IC_N#5LZ.#%\*P/I0)"R#E
MGBY4 (AI,ZBIG6Q9ZC$WTB]5M[6:,FV*3YE8/R-E=<I'KUN,'O']$/[<XM8T
M'9\P'01Q<4RO30X5T:<_BK(\AWZK42X%-L8TY)\PY!2C]+-8\,]P2@_J$D7F
M3=OJ)@M$4>/V7FD0'J.NVW2V77L!*!>(3.KY-C#&]9Z+VVT"^\X =,M0@VUS
MBM^A$W?7KY'>CVWH-U:'']:XHQK\UCPEE."%;IKRHP"DT>Y3R:5J>RKIH,UH
M?!!T0 Q147MK497'KMX!])8R@2$3D*J&5W6[K(J\"B".</+O#YO.>QW8EW @
MKM8'$54'4>8U+ZE?>NY"&;D/Y='2:(3#5V@O:U_@HHG:IZE)S5%S,<UX*$UR
M,T$6T:#*<UX91["UU'$[ (.OE/5N:NO\4IU*G/;A!)5T+%"RBS/!<>6A5W!9
M.Q> M?,ZQPW(C0LAV&X&P#BQRGF]/;UK6B[5V,>(KZR QK>SF"57]Q?,M_0<
M<;6E_Q@@4"+-+YPGB)OB38L22M2<2B+;&^6&]* YG>T8X=;/9Q,'[0#%!@.
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MIO(=H;4/^I<;B7:18 L*XTRI!,D:(*T%-<8U+8K QF;NZP]=$@RL4$C5;T)
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MH'\2D^$H2:5 1_HN]: KZYB/9PG03Q#93;5ACF= X!CHV(PLH YG$$+@5J*
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MA/=CW\GN]V.T@QP4_KM9@SV/H>,6YX(YZ!](>J#T'GJ1^+W0-90@$G\^SB!
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MDUVH NB#V#:>Q](L' ^,GQ'SS:4/:=93(U%%#!KQ/'VSC72B7?54XQ39&S7
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M/CG5=N$3;$7PHF/D?[7HM]3UEEPP #BUXN]:G1'MV=0>0$.C#/2J+!Z.76.
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M %9@Y^21=Y/#I:3ZN.*XK?JY'+S:6,6;B]Y4R]1G-TB;$<Q,V(BCD@MCD)H
MD4D#ZH0HTY#Y[1QT#>&I1Z UOV")!Y0E@<P#_E>06#G(*I+>??BQ ,"*:@RG
MTP?'_;-#VM9'W\-%P_4LH24#O<$(E%-/YR> O?R,!*[,T+9Y\!O3Z8>J'FH2
M!-PUT+U(,*2'/<ZAW]I%49T2:L? #M \(>DSL\_Z:^QMZKR N7[2G^L-3#&Q
M44;S[1V-9):U\Q5E,7Z'0V.6?YPF_QJ3WYOXMZ=Y^Z>KC2)$( >:U]Z+Q"EU
M5.>@Y<!8_;!PUJY%E0G$;)8DZB"V#R&%:$6YM $4<_[<0OL1[+4X"EG90WML
ML:XH>]KF9!_9B!9P<,E?*?.X.FN ++@D["D*/-#=7.-?;N:$VHWJ.0*):M!I
M!J#J !XTH?LNO=)>#\0F& Q Y+57\C)B*$\/UGQN\$#D+TPJ/*:T'9XJ,- $
M.C^A3EL(^RCQ^Z/[FZDLJKTL,Y:"X'1RB&=_T@*S%3,\>FL(W+]^Y1 0'"C9
MNKSPKH!_%G02&*^(HN1*,-,;2+]=Q9YNN46[ G9+O0=:[>59?&W4W1T=<*QZ
M]H92-C'M(L"[(=R7'3,44_C@E$*-U0:V+ #OK)%<";"[^8?84DA+\4,T!QM0
M"U;Y7_<QQU3<H"5:Y@/;W6&9Y0(154=P^%@H>&TVY!;H\@VX8:(%B1-0NN,*
MCD)%N+)C!@S/"$F+GKFGQ(O2.>!Y@S,.SZ=#M&U'U6I_L;L*V$%9N(MA?B#)
M0K2Z6*7FF4V-EO6$ZK&HGL=W!]7S-9\;$1!X+*\@T/O:[RO@\EA7);(L<@)?
M/K;9A0LD/8,R-YT#X.E ,TUSK7-J< :AY1P_(]"YKM?P&D+KR#'R)6XV9-L[
M_RA$A^4DKPH.U8ZY=XCX-,_0D$#0"X?0O*IKDG</9*(4'Y*&SRGQ"R>%:UM)
M X!ETP9<,(@- 'E)7ORD^N#8'X(N*)/J\?^Q\MX\VJJ.@80]IICQW@LT;CT-
M6#RWR)#1A-<?7&NE:8B5C8894P^2 KC<>)\_P-223BD1OY.@$:M%N2\ ;:.)
M_KJ$:,!%8ZC1*%9_(-[(JE,S8.HIJ.O*;\(QMVKW5BG<\,#DQC4]'O'\%GD#
M\OU,D<\D:22MX?W ==ZV3,H?^2C@"Z:TX/UYB^?C&(R?%?T6.>PE[*"@O<=L
MJ"&N,*W*Q@ZULMDBL%$#FC/L/EW>*EW)4O2\8.OQCF5\@SU#'G+HZ4#+05YG
M?KG=12[^N:Z\GSY>?ME)EA?DO$!2@CT6'VCGD8/"+NN53.H%6YQ\R#JD\:).
M#W6_/LL+0Z''\-&:%G=K#I4GV'^S:VXNISC(&%K_]L+LX9YVB8*%/'4F$=$3
M1(6,W]H4C8;M1#ZX434W?YZL(5L4I9W($<37>U%U>7/BG5N7)O\"48;YA]!
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M' )P<C=Y2V2QD/[A5OT*)=GGCB0"LJ4+?,C:O!^5XIENUO[-,"7WB&YE%0"
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MU0_._K:#D]W61[JMK(VJM+:^.>B4DU=P5.[E6P>K;(R-BT_7[%E69PE6JW$
M1,Q)>I8=]BQ9O,L7[P<"I^Q9%CB\5%_H$\M\[0[+ 4^Q,[;[6=-F9XPY8R,Z
MM5G.'7-V+OQ$!;U^KGOUS$M50S(KM;;6_BEK#K*"><.JX=B?9I+U*X\])ZF*
MG[1*Q(*YNHD&_33IA9L,2468X\!.*^:O=#G$QM]9'[.D&5EHO$CZH2UFR]"Q
M':':O>@V!51E-WQIPD*$N\3:P:J.$4PYJ8ZJ2\#!H3<7-K6"7*F<>V=E29.#
M4"](_\/QJ#"KIUOU;%A?]O5,NE0L,^UHAHW#0V 0J;LQ8JEG;&ZVLKQD@B^/
MI5;K!O1D2EW5/T8UB5H$#BP,WF^, P=H2)V(<_R5[0B5</4D=J$9!0+;UF1%
MB3]&\C\N-VO9KUF+ZK9*Y:>OL(T)UMI2O>D_?#V_OF2J[D/5?Y]?_>ORZ@M3
M;Y^6&"CXGR7VDV:9WJM]N.J$N5F/ZEX) ;8NHAYIU-T8U*X^P.D\\R26IW9=
MAWIZ8L.EC3V_S)5WI /@3^>"&@AH54VUJ*E#;=:<&,]8W9HXW\E8M5V>98T\
MMW4W4[6KL7GX2I<=?-.&Z=\ZKKO:H5K--FN@JP?(M6M=F95NR$*M$;,U))1H
M;-KPN[;IA/[O]<$DZ9UJ9J0ZNDZ< !:0=**8.2&V8535P(.L"0W^$IN]A=':
M\9T\J+L7Z+Y3R WP.5AANC$N5AO7EA%^&\:!4-VY5&L:.U>!77=XLOVSA5BF
M^>!H$5%!_JQ-E1]\2ULDC55CFY&K^D#DNL1-=!L*;4XMC1%PU\2)[FY2S8VK
M7#^PI ?9:CNMS9T \QVY"O<")*62[Q(!K( ]&&&L.=K1J8F>-&70_?_HAZIY
M4)BTV7)5=Y,QJ-6EFH(CIIZ?M/](&Q_HGIOKO=RP%YAJ%R'LP,>VD3A//XC
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M!A4KTUHI4\9GL")E1?K\BK1XDE9E%"DYHS]% EZ:%(&!_R03GXM@ZGC)_ 9
M#_T)3:BURK-_QF'D3):'WX86]3,SWLR$-Y6&XQGRNRW#T/ G!FY1EK[U%,M3
M'SG>6'K1JU8+:^R4M.)W<10'4CG5N%8_SA#?QJWCNL98+J0W1HHL1! 9OF=$
M,VE,A!WY06B,G=".PU#2#_"+C\ I-XZ\-8U/^/-+T[B,Y-RP&L8O<0BO#T/=
M+>J#"+[)"%C/--XZ810XHQCK#QD"7G8M76E',*CZ$?SQ2<])/_S&GR_@87S
MQ#>OONN\87QVPF_&.S5)D\84WM) 7L=GA+M] ; KSHTSCO,A!Y@,/!4:(^GZ
MMPWCTDM',HV)'QC"<&$)Z_2CN?9?&R'LO#,!Z?$B.%;4Q&E:H92'HE(1_CTD
M<]*(KYP(Q,/>@5TOKG[Y?/&^Z%HJ*GLJKJ66I"5PM#2FTI\&8C%S;".04]SK
M6PD2*D+@-!?8+S1>C.$/ 5PWA], Q!08%V;G(H>^?+4[;6#5I++3 T8=$S8.
MO@CEJ^2/UR B"U<L7SD>K8$>VA =?'WKC*/9J^&PT>U9?_LA#4_JX=6W5@-7
MOGZVJ>_:_4:KU=WZ=;-A;?WNOF&M9J/7Z>\U[/W?==L=GBQ/]KDFV]UM0@_<
M!#SHM=[]Z097P@9E*8/#F,R#->79WV@Q_R%! X)A J?>6VG+^4@&1MLRC5:S
MU=S!ESM6LBC[]80)L)TOK.$)DX7Y8CM?#%;(<O20)&5PJEC#2N?>1Z*43CE"
M5?L 5,<<%$XK+$J"&L7I'\?6U=O>%YW"0?SGW-93B_"S>JRY>NR:S<*E1ED]
MUD8]5O#D8Q7)*K)6*A(LR&;1C@B'4I%'CX;:ZM.]$9X8BZUR?9RYV5:'"_M7
M?(M>M)I<N8E98S.PML?26^TM>F$5J!# TGM*K-$J; 0R*NH1J*BUA!A./.7$
MTX)>VW!8]+BM3-XI)_ _4^S_9,YJ3N!G/?I$%P2M%NO1H]:CY70#8UW*NO3D
M=&G3JBVHM"@6JM( A9DTQM(.I @)$K4"54#<"R;;&K<B-,:!<R,]A"^X_JT,
MC-AS@/1RKH W8\.3B*)QX1538Q$XMC0)3>0(UUT:_F02PO?P\$3<^ %A$FS*
M5PR-R#<D4&4N$-ZB7CR6B'$A/(X@8!*\.?*#9<-X Y\Y803_-&Z=:(9O@DDN
M8/'^.#23Z<]@OC:LW?%B&!->X/JPO#EA:(QP)@*I $/1S,&7V4@7>F@D88D(
MX$'&@T=APL((DMDD^"'@RUMX=P S1D 0?A3,9 PK@%V;+I,7P7CX<!B[A!MZ
M\_'KY=LS:]@PWBFZ6J9Q*PWY?2'M*)DYS%5A0&A4F!XLV[&!DE$D P^'4=17
M=-+SF3A!&!E_Q4!N^"KI[HYCA?$HE'_%2"[]-:PWIJ\("#5?")LF-Y*>G,"&
M+ES@0;TS"+L*XT!X-JQ/WB"#@4RDV"3'TVQC^V<+L:2%>"',"M:->88X:4<B
M>N76#[[!^T":I[-D;X$#P@TPJW6RW/AN/)>;&2S9.6*A9+L+HZ J+)@IA3<+
MIC4DP01:P-)@!CD1W4?*A+?RPAWE^8XRV'4#^HU^Q;< F/,<5NX2J4T2F'=O
MSPVQ6 3^#5!1(&K0!\J-'#]T8 (B,$!*0A00$"FU8TK1 $.#TD%%YKLW4D,M
M28NYP/Q3H7:!-!J^)KKU20L)SX'EA%)^PUV +=2:!7[C!#B9LW0R=^<09I-H
M&-<I#O&KOCR^\D%[X;K>D.1,I6?CRW"V\.JY$\U1=LU$5:#BQ9.4^.>=XX%6
M %8PKB/X@'Z)NCF9,2UDMZG!DI:T0N)03"FGUY$"T:MU)@G]/!]X,K81M3N)
M7:0B@C%S)#0-D R)0B!%X#HR:!BJQ7%&31Q'N*$/['HC77^A^-M?^.&#5-S*
MV9IM.BT54(:Q2*6]2E3QZP3R0W"@W(-:%IK9(V($9(ZC[8_<2<$O23IZG55R
MY/\["S( P52>C4"I?#L3$YCL*^'>BF7XPT^KF@'4PAH-UY>O%OGS/T8!/+KA
MQ556]#3B[@C83P$(6IK0\:1SZN%"]YC4!I9&^_JL3>.M6\MP@N  /_P,%GZ_
M\]HXEB.9KF,.LSO/M1?/,N\=Z5<" /HN8(DAT17%PO)D>;(,B69(-$-?&1+-
M?'&DD.B4%JE'=^B;AW+-]V8]S7>BW$-P<N6,,R3HI"!!ECEH,VKR:%&3CZM7
MR:A)1DVRBK3,?K]5/3EB%?E$VSNHWMZRCF0=63,=V6U6U8P\$+*<7>.C<HWS
M;4M7/.,C!P<."]>X9VAOQ;/<&=U[2MPQ+'P0LP ?VEIB"6;VV$ZS_K#$VC@E
M7"2MW<R=X>_!XNR7DBF6 ^X?ASV]U[T.0[Q.'N+5,ON]VK:[8KCL,]X.G8P9
MPG!9UJ5/I$M[C[Q"8EU:<5UJ[5E8E94I*U-6IL64::NP@UP997I,M0?>.F$0
M+Q3T50%B$2YNW#C@M(;KZ'G"H&H$/?P4IC]W;$-,)JH_IBY$,(X#Q'-2T0+$
M[KN1I \(5.O,\4\8*P6F!]*6SHW^@1,8(0PJ/ \;@X[]4*-A$Y!S,L[8$5,/
M'&O53#6,I+_P _HWH:9OT^$;QA==7T"Z,E# >7A$3Q7+#83^))(>EBC(@?WA
MY;D" QJ;C0O)EJG+ = ,&(^V-QX-:PP$L%6V0F0OI0A"75%"HYX31LO7;,CM
MT_IV()8Y*42 0XR2$@NJE,3*B,<"BERK4S!U_5'IL:\G0ZR60=%[:Z_,X(>[
M%%]A]JHP>U4 A+M20>0^]JH1(]&(N\/LKV3LBC Z(J!]?;9J!YS]H;;GB(7\
M8$C['K<:KRR@FB?+DV5</>/J&3_-N'KF"\;5/U-4O6QS_<C@ XRL/W5(5,ML
M-A]W37545_K'!AM]T1IROW:&C+)^W%\_#A[90H#U8X6W]T6KS_J1]2/KQ[V3
ML\U![W'MJAA2SUYQM;SB4P75MX9%L[\9DWMP>V7 _;*9-3;66RBS7S9OT4[2
MVVZS]#)K;*)9KSED-'T%T/3'8DHSGIYA2_O"EAA/?]08T'WNA$[&"F'\)RO2
M)PJ,MEJUQ7^R(GWR8 PK4E:DK$CWB6N9G7ZWKHKTF(#T")(<2P62#',HR;)=
MYF."X2+*5@$F$3^5(281TZTPW@C&S_6/QH[3,G(4ZG]#.W4:,0^TK/UV50#Q
MYGBV&X^I-_N/PT$"9#-(F1B3P)]GS<6G/BS'P];E*#'X\<0)PLCX*Q8!=B&'
MW<3]KA'^]5X"_2Z-F;C)P-3C%0;5%/@-V!&^H:;NJO#$11SX"[E>C&-+FW1F
MX/WWQS1N9XX]H[(@,Z%0_;? OBOU)&@'A3$76-8$%+P8(_DS!>0I,6@8O^L>
M]UCA K^($-6]:==4D0JQ6 0@#N-4$N(H#J0J>B&,L1/:<1CJ\B6^-_5)B<$D
M0'9<H/94J"(N1'*L9D+%,T*EXM;?'9J@!Z7Q":3,N/RJK_>O_$@:UM TWM!J
MI]*S'<V!P*9S)T(YA2=U60[X%5D$]+9WCB?@YT .XEOZ98VDED;<';7^,9+_
M<1FS7C7UJNXH#K,YQZC^2N@-SXCUBD*5>;(\64:L,V*=D<F,6&>^8,3Z,X6O
MRS76CR$S_TY^/F/7&7ND6QX/J]K.\ZEOT'<88^<U]?6:*G_!_M^,3&3ML+=V
M:!?-J&;=4 .=</73.6L%U@K[&Y4Y0[)RFN%D$,OL%3V35W2JV.5.LVB.6(71
MCP4E_LCM^=,&!A:V8H^'KRN_-_O:HJ?-T?N98 QW?0ZXZW'880QV96C!?F!7
M:UA;:$$)4:03,CH9OL0ZYHDZ[@Y8PSR%B56]K2TW%,VZY>1URU,$LVL$CM2?
MT(1:&S/U2TK+_V]#)7YACKC\;LN0<$JX1S5"B)2%!^DWUE/+BD ..HU6Q1&>
MV/I2V'_%#G96]CWCRK]1>7$MG2]I$@!I*CWLW@R_^;'5:!DCC2G$KWX$&R(%
M&6:XVPPZBF EU59X2ZINBBLU$5Z'8"T@H+O,]QN^E0F,J]Y[72J\)/(U?&2E
MU7;2N1F5 O7X3F&D&P"AR9)QK# >A?*O& %P^NO0&"N,WAH@&)AGXD3&PH5%
MVZ2+0A/&#^- >+:$06]P14"V*&&JM-VM[9\MQ)(VWZ-FY*%"KJ;MRV_]X!N\
M#\Z0Z<P ]HJ!>T:$_SL2Y78?_C #'N9QAXS VA^ 6B8L4T^ETZ+(ZP8B)K@0
MPHSD'M2<W,P>$2.81!QM?^1.GG9)W-WKKH5)<_^=!5E@>BK/1J 1OIV)"4SV
ME7!OQ3+\X:=5N0:A7J/A^O+5(G_^QRB 1S>\^&$M44U$[/_^>O'U_+DEOM"<
M&!";W&(<9&^.41N7@(>]BU]AA&Q%H9$\69XL(V09(<M(2$;(,E\P0O:9;C%*
MM=Z/(16<&SHSP"4'BBV>"E]7X-LI-BSM<+]2QO^Q>GR$>NP6[9/&ZK$VZK&"
MD&]6D:PB:Z8BV^W'Y:PR0)J=X@HYQ2>+B1YVC@<[>IQ;5+35'C>%/27NZ!3&
MCK  'WB+RNFYS0)<#^[H=$H48(:Y5R-!C%'N57;7CQ\E9IF#X>/B8D>$03W6
M3J3<B/1YHYJL1UF/FL,V5PLY:CVZ9]B;=2GK4M:E!4OW#WIUU:5[-76N!%HJ
MU\$Y!R1G^-3CX%-I]V:$^F<]FQ74.]=[>;V_+8%9/WZ]?'MF#0V8/OS*L8^E
M8@3R6HHQ/Q)>JTRG<&P0#LRT"!Q@"GA5CNMF\,@JV]6(HVC$W3&YYX'P9+A@
M5&[59)^"K@?:G2,^6+A/+:-P>;(\64;A9@J34;B,MF04+O,%HW"?-B)7LK5^
M9"G'C,,]=11%KU5!+!+#S)XHW\+J,PR7,6:L'?=.F^Y6%6'&VO$)LM&:K!U9
M.[)VW!O%WFE55#N>#/Z6W>&G<8>-4P7?#H^I<>MQ;M&+]NYF"N/V3HDSAGV+
MA;?:6U1.:0,6X'IP1W&D!@-OGP-X>R1F-$-O&>:P'\RAV^/VKT<-&7LQ9.CM
M\X8S68^R'C7[C[Q.9SU:=3TZ8#W*>I3UZ#/KT4'_<=6OZP:[K2I":C,2ER%3
MSX3%!5KC(X2.\B1PIW1=;.^["!Q;4J?9>@(FF<G*8[)[0+BKW;EM?[Z0$2T8
M&\#G$>&Z!?AO\)$<JQ;&][0OKA?[,9_MSV<38<-H><:9!/[<$(;K>],SX"M4
M7A?7YXVZ2W.ID'KAAOYV4H\<6!>\500&+")I#'_QZ>.O%U=U)7>9U&X8[]3A
M;)G&K33D]X4$_1C-1*35ZJWCNK 1V ,^EMCM79_:QEC],YSY071&IW5>#');
M5R/522/N7NK@WW]\^OSQ_>4UUSJHV"FG[KD.M3W'J!=*;D*N.8KK'U04^,Z3
MY<ER_0.N?\ X=ZY_P'S!]0^>Z6JD; O^:! ?7 "!06P$\;6:%06Q,<27^^S6
M/YV#%63-%62O6Q3#P@JR-@K2JB""FS4D:\A::<CNH&A_7*Z#P&YQ-=WBDRV$
MT.Z6",5DM.Q38Y@81WU*G-$>%@WBL/ >VM/@0@C,'=L%>,"%$*I0".%8[&BN
MA,#(L_V09\T>-\\]:@3OGA'/DS%$&,7+NO2I=&GG<5='K$LKKDNY$3GK4M:E
MATADJ6]]KF.KA["A6W397O,1P*I6"B)LPJK#S/*4WUP=82)N_(#@43:E3A/R
MRO%@B,@/EJ:Q$$ 'X<+ _F02PA";^I_7")U996:E(0\"T:QIOW/C2/CL=Y"]
M0!K2FXJII%H1+FSE5!!(_=:)9D9TZQ/\67@.O):@U/@$R*CKPF.$CH8M%@Y!
MU_TX $&-) (GB1M@T,AG)?L8)8O*,:5[*.4WI#D0%3CM&ZC!J?1@8-NP13!Q
MW/_X<V<$7.R/8SL*&\KPN):@/&$OW"7!XF?B!K<\D@%M>80;[$T<Y$90L/"*
M*'+E'/YEB&D@Z:]0,8,?H2!D[#"6-]+U%SBA^Z9AZC4 VP"#1#"!,'T_O#K$
M5_T9CZ?J3=+[TW<\6N3,#V7N=50UP?$F@7,?XYE&&(_^)."_;\!+YB'^0+W]
MH66F!)/&)SAOC,NO.K?BRH^D80U-XXV/Q0-@M3;."-<%\YL[T5R]&E\);X)?
MD35& O#.\03\'-Y)U5?4BPQ4\>_>GH.8+/R Y 3WV%'4F0;"H\_@M\2L!BBI
M"8SC&F(!9+V!/^!5YZ-1(&\<>@NRV]L@GAKGBP6H;1+AT'AQ?O7V/'Q)2NZ^
M+8+!71@$#VO#BPFLH\O*:-(_\+Q:#ZX7GTOG2(3'3:1I/#P+!Y;N@S!Z:BY(
MRG^*R)Z=_2Z^@R09Y["K2'/A+?$EN$X"5&]DV9&,;J54Y6_(>KBO\(V6N4Z+
M+G(V:(L$)TH8TMR#6M,WLT?$"/8^CK8_<@>W59+V[_76[EQR_YT%V3W75)X!
MGXEO9V("DWTEW%NQ#'_X:?7<@T-OC8;KRU>+_/D?HP >W?#B*I^BA2RB'W[^
M#!H7Y/EX[+0CL7?43>F!=N<HK9%R*VFDZI(+:52Q@@)/EB?+A32XD 873.!"
M&LP77$CCF6[42K;?'YOH6%;,6R.&%%:(JV><.O2QTZU@B04&AS]1IB2#PTO/
M_6$-67,-V>[WJB=%K"&?"/E?O:UE!<D*LEX*LONXU$:NGL&^< 5\X5.MF]%I
M%15?AMX?VDHIISA"?2R1TV:/5IG8>]ZBG91L.3J6);@>[&$-BT;JN'K&<U3/
MJ+D=S<4S&*3X*#3PH+9-FQGNO5.H9D\X_\F8(8SW9E7Z-$77>T7KY;$JK94J
M;>W9=815*:M25J6%HI^%PY^54:7'6CHCS)4C8!S5DY7.0%"K*D* (*K[:@_<
M5PGC3F4-#<N5NI*$1B?SONV_;W>+EX \I-5/D+J!#&,W4O!I+PJ2%O*ZJ EL
M@3-'=+0T/L@QK#+04/.WB%]W",(,2BR\!ZI<+^7Q#EA<&&,GM.,P1)@@HO6]
MJ8]$R16;R%6+8/;<F]@F%HAX[M(%]6%,&G%WU/9'*F^1%".HSS)W7]2AX;N]
MC<1A_&Y%@9L\69XLXW<9O\LX3<;O,E\P?O>9PGI7"_3UZIYJ40;E#(;O,O8B
MR2NL((*)P6GE=%QC<!J#TUA!KBO(QUT>LH*L\.9:%=Q;UI"L(>NE(=L,WV57
MN.ZN\*FB=]N%NUTR]N_05DK1^C&,_3LE]FA;+,$5WR*KS1+,[+$="M O6D.Q
MWNC=<JC\5=J1,W*^U]5,KD21F^TW1D<.UVEWRFD;SH@J[D5\F'C=D7-'N[ ;
MQ0)<DW \2_!)L$=K4(Z&/ZU8,IO)7 MR_[N@7HF>+ <;GN60Y5C4*;$'5W.M
M_!;Q=1!SQST"W"SGLN&T@LD?OIY?7];51*Y$PL7)1I)[W2,*1#U.MJNW.?_-
M<9GB'D5K3Z !,_0!4@-_.F>6WC>.P^%&-J0J;TB=:JS1*GPC7^%(Q>-$NWJ;
MLY\===J>>SEQ'6;G9[2B3INA][.B.!Q5G-*?1!"*D7/#AA1'I/8X>)I[%H&H
MH@-_G%O$J5','O?0;.\2YRS!A]JB03GYXRS!]6"/=K-$?,')1!O93N: X_XV
MF%7TGJO"$9KCW*)V.>FG]3ED3YL]"M?RJK  'UN(E6\,]E!W1=MQ<FRU.)$O
M/GW\]>**+4:.K.X1EQF6"%ECQWN7+7K1MEYR3(998Y.YV-NSG3E+[\&DU^JP
M]#)K; S7F,V2;LU.*Z;Z[_.K?UU>?>$DSA(MY/JZL)W^$54OY)@,QV0LZX@
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M+AJS?D)\ CMJ.RE;!G$R9.J$5)+59954<97THD!70]9&K(UJK(W:);4I.M%
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M:;8:[>9^'6\?ZJ/;?O(^NKUNH]_;;=@=^^AN< :KU^SRC>*^Y0GW^WQ+$K?
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M34>;?[];S03GG 6'%3UL>"G8$G,9Y90X5M_6D69-]/P$:,]TT21ELZL-6YF
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M22)%RW2<+1+=Z[&U"*%!]9,_VLZRSW=H]PJ,OVF9O4YW=3E!%[37]/8D>K-
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M*IICC-?,IP!%4EW*C;/OC1LI!(A0?-;GZ8ZC$UI:T7,1 #G7"KXZL[B608:
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M,/]@BU,Z_ %L4D09E>C>Q0O%GK2"3"&+ADA^LY2Y+#ZF%DPDI4Y67"5@H3#
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M^.>FD6=5'C9LQ\Y@&,+!M8M( '6#F+R6H['L'91O>AE2#)RTC.=ZB&=*J-B
M]\8;^^WRPUU,5F5)C,,5J3-C"F5(*.AWG:UTLD\X0ZEINA2%YP=3D<5$5:(!
M).D,\DOE3NT^CI.EVI9,P9W#R<:JM4A1*GAS%?MH;B\I/\IY8#^SRP)[] .;
M5.$6Q5ELX\P?RFV;AW(VM!$@^B0BN7:>@&H?Q>I)%Z:3TK8X>.Z!EU4.J2Z+
M4G)6U8QD)P66#_[0Q5:OR.J)$!<C#,PU, &[]F*! 7&@7/@;C]% T3_;1&,P
M3B(*\/V//TS)"VE3"=:#3_+R"$8?S*E,D@SS+:2^YP6C-/ .9W7EB\(U:83,
M5;9T);(L:_)+5)6ZGSW_.F9S*E(5X'I.:$_!+\K).OAB"L (*!]QD796RLE3
M""O&HZLW65EM(*MWR3MV QL%#_#R1=9Z35\B3.>\]@ET#]&2%L5AX.[PBHKV
M0NV>5MW3=EW+&U425A6.K.I)[SX<0*KSQUY'_MB'O<H?.[W\]>C<.#[Y='K^
M=7!Y?'KRZ,RQM6.\ULJWKWT$V4DT4^S SQ88]T0@<YJK1<+7)2#G;'!^:1P?
M'S]N.W-3?^K..9H%:!; ":#-O6(!'X_/CPXO3\\O3./H_XX.OUT>_W9DG'[Z
M='QX=,YYQ8>GYV>GYX/+(^/SZ6]'YU@$XO%U'PKA?RN5U]DJLA\K6:_L$$+K
M>18!5ZRLDRNI(]L\H.^01D!CSFP,/SN^//HJZ$E$+QU]@7, %@R;;Z2'(G.Z
MSN+H[I[C2<C*).LS4C2#J*7SU?=GPGN2"]]C3^@H&*M>TXNC0YDC#.LT/)#-
MRV--*%ZI\'J*<"INBR@7*55\V <.-5:C2TCQ1\/@!(;!V ],P! %D"LB#!_>
MW\'9V=')Q^/_$T7N[/>#KY^/3D"J.6P8'TX'YQ_S._KYV_''HR_')T<7!H@]
MZ1?&/[\-OAP#V9,<Q)1_]-O@RS?Q-UKN6%P"2>D2[H9XF;+5N$V@S[GC1#T?
MNW@^Y4=:MJ7XLP%Y=-*X-=.8T &IID41T29#7PI/*/8HM'V*9/+'T&P9$,@M
M+[QSO37Z:59IQ)FC-$4T4Z5^4YF*/6='>3HG+C(E P SD(:C%]5*T^# LC<O
MY+.6V3%7E1$Z.Y1G>!AY9+0[ @@8;K)$:&W*0[A&?HWIG5R6R7SAAT$4+Z8R
M)VJ4AR@YF[6Q6Z!?4_DRNWXE7RJN"_$M6DJ%@78L)B5<Q3 +M >KCN0 ]M"-
MC=$\E&UE+B/C1P";2=E00[$!OM@ ::B]@5,%))F.J8L:YK_S;;CUK^"?/@;5
MW=[>-ER,6FT P#2,-Y<X7OJ]YU$X4,!5<\E?Y8GNHV(J5*$!RY=3AZOO6=R?
M6D4B=\/5"90,?$5A06E-5O1D!]@[J_$6'>'\2_Q= D,GH_MB[081%<)N)4[7
MS-"BW6BV<5BJ0=<[^(?B@<'8$>15Q'7QX.%(C%LW($,_(J7+OIPD=:\L[+MI
M!&3"-Q%G@3_,TA@ =2^B_ Y@=D^:H@9X]>.)2N6&U*"^5H.T&L0<UMHK-2C3
M?0Y/OX(\>?%T<]B.JSG2B2V\YI+#H9?/#Y.T#-!C!,GRS5Y#:,Q-(I. .4U\
M3?DV64G /53?B#NB)#Y_Q/(XT93^?9@3QU<=,'M*Q.U6;(5V1*F.*&<C>9*M
MK*1VG?(D-1M]'6S4WBLV>@' ?GY\^2_C]/>3H_.+7X_/T/AR>'1^.3@^,3X<
MG1Q].J82LOP]65F^#DX&GZD,+?UY?O0% /.C<7%Y>OB/7T^_?,Q,+JNPXU5O
M_0JUHMMU4=:5S(%!%NV%^NQQDLPIXN8;J31'&-Z,ZL41IV_EF,S9&*:P+U6S
M+JE"&9;\HZ!2ADF?@T%!8Y(=(E0-JS(CDMHVQ*&,3DU /<ZZ.*-T(1O4&*(C
MW3VEEG!B*>N2&*%%R048K46]TJYC-YREWRLM:G*R"R8G4'B5"+"KROA[D]6;
MDP7<4":+AP$':HFNMF;V[0\1X2XGE' P*;>OH 1!7- \Q.BV-^<7WY*WJ-O>
M8J4O86$@NN(?8#B9[\:R$J',W?.PQP?JW5E+D81#!ZGTA=B"MZMJKIT*_]TS
M,<%VQWH,$VP#W3<?QP67?]=V6AOGK:"E]3O]79FLW6@U=V:RK8:S6:FEB:S]
MIY7D@#5^6B(R\,4JW@V^A)N&\]Y*8L,;]^T:4M#>K?[J5:]^^'91KMN8C+_-
ME:' 96 ]Y.LHOG_%)WPR)V$&Y \EA5;DYPHA"J66G#PSGV79@-,L;87BO)-7
MO)>_TQ^^=^!B2[IK10KDUI!Z[]:DP]B?R#34'VXP=F4E )%0$4@%B^7X:AG^
MC7\G)?3<Z)2#Q1XN6.9\$F)_I+40;S$<?CCT05]X+T1A,C!/9P85_S#D+M8"
M)U=H9EEACJ_<9RK[_H.-NEQ61VSWO2&"3'Y9@<0K]W0-VG_:N3SE!7J2E9-<
M^RZ)U)+'7A=%F15#'.#O4?&RMV(=H>LSF+#?'&'_W!=E(NUFLR\-0\?4J!+]
M.2BDR NST:EV,//YP;F6N"KPM \<>KJXZV[BXP @-%IO"];T=:BK<.:5%&JO
M1S=-HX1Z.#/MA=%V*7'TS5Z_:7:;-EN@BVBYYDVA-3=77_$F#^K)A[,-3KCT
M;'Y^RFFL<0K;6)O5[3?ZNT]T>XX.MF-:S9[9[G:V=U*/%8A? 1.W^GUK;YBX
M_10FOJJ8N>R:EM#-CES3MMFWG#5O:/DM>58L?=V')$)]]#'I8]HLOUO":RV;
M>%:MI=Q2SG8TF8ZC>U_4'C?.YO'P!L/35=ZFY;AG)FHM;NMCTL>T>$PMT^D[
M9L=JO1ZE:!OA@Y?1#).BI(E_FHM8VY) L[*794=(&<U_'2#E]N/DG76<3KLB
ML^[;$3_*TJ;/=V?.U^Z:[:9M6OUF3<_XI;UP]79:4R[K<_FM5Y7+]!B;&:,N
MMNG^%NW22+UG<83]V2]NN+L@Q;IAW(Q4XRFJ_1CMP:&W@Z9I1YNF=]:<IH])
M']/>'%.G:3;;_9VW36];E%O![# /-V!XV*"9;-^TEB>9.FNCENH#U@?\6@_X
M4;SHI<[W%=G'Q^-:F<9%^JX#!^=%<TR@D#NQ;Q=@,[;S#>S7EF7N+1-&[0(:
M5@_;W?P&U?O&;, 5L?O716/J \Z,CFW:K4<JN=NGDG4*PQ5JRE!AN)Q=ESL&
M/E1\Y<!R2AH+OH1-U=Y$SLX+TQG-6=WD=J-/W6&PBLR:N5*&3P9NK&XZFH?7
MU#F:*L8<9*V*HW@R'[MD#J<N5Y,@+2X39CFH7&8FGW5:2#>EFMKP4JR!5](4
ME]MYXKM,T99]*GO%<7D7-&CXPX!=443)!LV2NHU&H9BYB96ZQSX/<7[QS5RH
M ,-]Y!:*O2B#68V^6!%VY$W7R<L8IHFOV!(-?D.%8KB-]0Q+8R_L"NT#;DI6
M/D=-:Q85;7 ;L!S@-4PM;=(J^YT]<#I+ICE<F.:ZIP8'0XZ_M"DL;2W5?,V>
MI*&,=%[JB32H(J ?#O&+M&8[U=-)N#=A$!J#:1R,@5(MV\132]0VLVKMGN$P
MGOOEM7JX3R[VC7/O:4XPK"Q_A,T/Q59B<TW1VI *!.%GM-0QM1^GEV.](203
MY?/%N62U@91J0J(C*-T[N;UQ6AI 3(%K"?E\:HL#YZLM90>@%"[*-^@=<K>Z
MY$;V9\=.S,$H\/-;>!UA-7?1Z@YWCZNN!['LW1Q0]]W8]P_NX3VY9T4OOO<%
M"JJ>?$ITQ@P+-,_4GV8%E"?N73"93Y01>12E>^/5XJ*I8+7R9M@@P+@_RRKR
MU9,"B@ 2HT9H5I\F@06I5NY8W5Z9OVVID-B@JBI8_M1*T&<!V]+&KV^"MT;+
M[-J6Z33;BY!66L"KI&@#-QLU;A\N^? SB]GOX<WP:L>TVQW3Z3>K7ZU4!U/?
M3#=9J35F]?MFI]M96O#KK>AJ&L"KR_C[UEMY&A;FRIC-9G=[X@?,0IR%TI53
MW?F2.U9R*96CZ3MFU^DM/QE&RX?H)[F);D.U/L756R/(RN67428RAQP#Q2IS
M><96O!\K,%71K'="U?M7*,:AP'S5)69A30I?>9$@E=.X,;.?S"<^SRQ]#Z(C
M0W%N38]!S <+YZG[F=^\A-"%+AGLHA=1/-$U<IZ\Q(,PB^>#?7F5'4UY0@H#
MHI\&MZ*EXO(E'$>RRD5VF&Y"DJ>.Q2W!9N'#&VQ1[S6,KX)QY7^6#<6#\VSQ
M-,8SWDK!I7+GP%V:"8A%)<RU.=C&&=CN*VAV#14T><5OX(ZS*D4WR%6['K-@
MO%SQ(&8JA#:^,'+DE&U33F4USTS\V6SL2WG1PX+B,<QD@6>:5J?Y "YKVEL2
M<%4?VO.-]6/=TH99Q2> !-U\^:**CE= ;G^?@_)E,V193-=E<YCB?0"D@SUD
MON:G$Q)R_6&ATSM('TG@!3 &_&8<#5T!D'+RMS<1-5D)L#W-+.4492^'.X0]
M<>ZQ PIV.4_;RX-R] <H]4"5^-NK*)RS:IJX8^RI+)C55.;W5<PT5W=7W,!H
M"H<!5^0[, *ADXF_6)*YPLG Q8Z] UP$O"N&Z^%3-Q6XX,,XN,JZ296L2=?7
MS]77;VVFOG[OI[_5L+Y^;]O5O.^-T]L01+V;8)J__WA7%ON2<3\)4=;Z@Q_Z
M\#$UJ*)!]J6!UV*KCS1*/E)W2];WOLHV@K^G;9IDO3D>VPJDO)!]UD60V@,N
M]LND'F)KUL!?M]?'=GL(MZV?'IR3[EWQ.GI7.'O5NT+>4&I @3T_X>9>Y%I2
M7)X/3BX&AUF#T+1YZ/')QR/L0GKTU-ZXK[B'>DF;)X'R+&4!/@/Z)SE#R@PT
MO\0=9D5NTZY5N*0I>O:$M?MQ#:'6(XD'6CY)%F\<Y^:V6_#?TO"OX9_AO[57
M\']V?GQR>'P&<MG@\/#TV\GE\<EGX]/1$=_WBZ/SWT#$6ZD%D0;W5<"=#/*R
M^?<4E'&?6CNC\=J/?X#.@]6ST8K'>(T8F6$Z^@FN ]#M\=OI_&H<#&4O7?*1
M/[(QX>#;Q^/+0H/O8^6EY]E+S_BE _6ENFG?PT:%]D:,"NUN78T*I1V,MF%F
M.!N<7QK'OST.0'(S?Z+(T&EJD4&+#"PRM/=*9#CZOU^//QQ?7IC&IV,4]-&H
M<W$)LC\U,[PX_/7HX[<O:\D,,)/A 2PW!IWFEV0^@5MR_WZQ2]K2"-)V2^Z9
M] <YUG/X@U:HDU'. ]ZX;[/FT7684G[_++OAM'"[D//?H;_B4Q"Z(1D94ZZ^
MJL6U4W?!+-](\1#47XR/)J&I;-D<FL<>4\^X 5$H"']YKKU82P1^5A;2;78?
MPT)Z5J/;>H;><YU&L]W9 @]YF>X]5=FE9=D!ZZVI?CV)SD!F)2KGN(5G[(3V
M$FRR_.1$3_-H9*RD2R$.?0KBR2K9C1OL@,3[\SB5:31ZMNWC:7O^$#595/4X
MP)J")OZ?6RHW^'<WP54P>[_U"1HWH'3_[T]_6D%)Z+9_^MNG@__WSMVW15FT
MIL5:0N)R%VP!S/LVUI9MG<I5.P,G.1E%D4P(7X;1A$-&.1^&8TLH0-_  /U$
M1G]P<+[!J3\R<)19C&.9_ \,$WPN=47CS):N9&\?<086U=I1G.$DU6;)O<FI
ML/W%X,%:(A"&L<7^C1\F&+RC\4CCT?*KV[/V$(]P4>T=Q:,=D7L^N&-*=;BX
M\7V1SCM:Q(TL\P1S'S1V[!EVM/81.V!1G1W%CCV39:@1CRA.+>+R94V$)TLT
MAA9F]@^0^LT]!"1<5%<#4AT Z=!-;HQ/X^@VT2J51J'*"]O91Q2"1?5V%(7J
MJU*=1#.?$HD?]'MKD-@SD.CO(TC HOK+0&+%6.5BB-%"'OHNA!C9NQYB9%P,
M;WQO/O;W--9(+H^*S01C+NJ >=LLT\&G@S#$ZG R?B T/D7Q!.39@W^L$7*D
M@X)T4) ."JJ=Z'5\W#!^<\=SD1(2>L8_LZ(1(A)HI0+G&PP!*FNZI:6REQ-@
M[-X>JFZTJ$[S&<0RN^[\?C >&]'LQ@?55(HR%#\<38(9967Y0W>>H/'&OZ<O
M1*-$$*AP0TSZ.\;*21@E&,7J ]GG@9):QGE?')PLS$!#5;4;I6)6HEB68GP1
MUWZ+_5FT:NYMIUHL7E*<J7Z2LK,+DO(1W_Q'RL(I=#^3*-BRVH]+,>HX[4=)
M@LN^LQO-YN-&72JVMAO]SC82E[8IB0FJ8S'S)%HG>VD-V]I."*4?J8 6%0!=
M1R#=?(CV-J15NV%M]NA?*G+]P>+*6FA=)M_=S&;37]Z]N[V];< T&]?1CW>#
M>'@3_/"3=[YW[<;O0*YPWSE6SVJWWL%L+:OO6';;ZMMVK^<TWWG=7K=GMSW_
MSK8:-[,)%IQ._)EQ)LO?#:YCG^00TV 193"_AC,S[#87+#6IJEV(PM+L%BNG
M<TG"XW#8$"7!QO WUL_C9'=81D.5-;=Q6XPWGZ0]!QLF\)F2E0OM-[V#?Z M
M1ZZSHQ1FS>7L<W)9+G6_4=:5]^7='Z_04V(W[!?C?1KC=@7CNDW+Z;_S.NUV
MW^X!QEE-"7+85(6,V" T&98L^OD0]IT.9Q%6[[6Z>PY^Q85J]*LY^CD:_?87
M_9*UX*_)_[2)Z*SN.]=V7 EW863/(G?JEJ&@K5%0HB"Z\-(&$]0X)Q^E)3HX
M "ZBT\^_BN=8.1H;':4![1HLZPN6+0V6&BRKP+(U]F<S;$0C4.^'PV#YA3Y>
M1,.3Z =C@FVM!H<4^XDU[&%?0D!FC^WZ5$?T%^,R]MV9;.(@ZVF?Q9$W'\Y@
M#&R)$@'64#N<,!0%XJAY!+TFK4_O#O^8!UQ]#4<ZG?G_';M_^9/5;;W7V*NQ
M=VO8V];8N[_8NRE3I,V0>QS'_H^(?*W&9[CFU&+QD7;(#W&0S*+QP==[K,)_
M >!X=26;>M1<&M4&R1U$.F?3'AF-=%N?X*.1KM5J.\VVY2#H-4'(G%R'L+H;
MQ_HWW&3'<:R[/X1A,NWPC*)?, JP Y*L')-JS_A!!F_;!Z]!DG6F_NK"5AB,
M44[C[8.RWC]36>\/0'B4L%G<XW&$K.<@_GUU[PU'_*FQK][8IYTQ&OOR4EZG
MU>E8W=X[K]6QFRT0\AS5%5/L;__A?NS>)C7$N=+99EHH"Z.=AW!/2'39<VQ)
M[>PSKE4&D;YDF?G2^L6UJ3W?J:X]7Z<J\CIV<6]B%[<G([2T?J1EA+P1_J#?
M/2"RZS5F=W#:Q"JQ_3KU6!TJ"I%4&=0FK"8:U8T?[GCN&S\W4/(HM&ZM@0#Q
M9%W(ZO>[4A>R6N+O/18:]@+H7DX9D@D=M5F\O,+'E%PRCU/K[=_=D"5?HF&[
ML?QN7!PXHAZW,(!D2<B<F0L?I?XAM 7#F-:Z]T+?B!>[$3I:2;/^G'F@V6NV
MFBW'>N?Y=RWA<$\][0@@H&O#\=!;36,PG49!R%YRO.2#X="?SJC>I%>FD(-
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M3Y/65UW#[6#2P^'[N>_T[Y9INL3"TB<I5UULWO -U9GIS9$YIF*$S:+9ZA]
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MAO@N#4GH#WI%L[Y<\U,%-7^X4:_+;8ITM3VS24/&RIPT%R=]F=;HN:&*<*@
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MC[BZJL];WSM,N%VL2P5?57-&1#'ZNN)4C=4=F-6=NZ@[,PU<D&<&0BV \D0
M:GU4=[36@#$IK$&!,N4VMA#>I&LX.S7SSYKSSP-=-9E_'HE_)FX9$S F6C+
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MVI27<1]>Q6WX*^U",CK3+[=3(NC[*XZ'1%Z1HC(;S<]&[Z;M$L<A#)Q8@(Q
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M^W 9B2<SSER,,].?3V)*;(B,@Q3TD7$< C+U!C9QOU#<O$"4V=@B]6CC5,B
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M!$@,(:!8"B"%ML!8K()1!J(0C=C(HKQ*?8]S4&P%=:",Z$=$]%2&KG!0.$&
MM5A&Q<A1H(0Q(.VFHCX@"WU*K(%D406?%0J655?-*/N+=<9G/.?G5D33*#9F
MRC6>:>B^-(1G9Z*(J#IH!B"V%E >6%0Q9 !(>2458](G[PJNPTHU+LK.E=53
M+#* %PC@B1XA G)$&PVTIAK0P#A0"*6IUP$A$3S12!>=QQ"N$(!S "L'L*92
MF.,[XHWZCHV\4(RCL]UVNSE($Y-NU[KN0?R/H]%\[S?_Z#1;_[LQZ%WXJ[3W
M<O(DVQTW\Z29[>["=C,UUMQQAS0G0!"! +6, @VE E!10;AV6+F08'.%Z"K3
MP^)Q)'(^@(]\ *<:-3D>3YW"P*LD9"UU0&$: )'$,>HI%-+<>@"SU,M2;R+U
M#@==^^6TVW*^UQ_U+TIC6 >7N7W/0L)4KOEU=.'AYT%Z<P3<5$E7L^,B-?X!
M5'&33Z/]M-O=]*WQ.!3*3[K7Q!JZ53O731=OL6;U>7.@6W_6_O4S$?+6]PY/
M=<\OQ+C;:[RZ291T.\6Y?:M[![W#@1YX]X]N7?C)5P]M.9B%RQV$RWX2*B/A
M\M6]_H>ZO_YN?<*MK^;L_,O^6?R>CZ]:GW;>?SF.][W_>H\>Q^L?_SA!^V<?
MR/['^-P[G]J-?^3W_9TO\?MVOS?.]LC!T3OT&5EOE& 2,,D,H,01H"5"@,>?
M8"!0Z"!^KI'<<ISNY^S+QVFUCY.1!*&XP0#YD(Y3@$!9R0$BPE(=]6X3^,86
MW(Q<>;TN[]HO(K'U:E_33M?.?52(TE[_6;OU,!:O]Q?C=&9S^*RF3FAQ'/O;
M%X/3;B^2N\M.JZ<ZF4?QN7=.R/[9-ML_.L$'[SYCKS0RP@,H!$E%ZC 5J5O
M!8Z"CS#*/?P)U=UXNN[I$<VG:^U.EX#2,@,)P%8S0"7F0!*J .9.6^J)0UXD
M#ZM@D?WN0'WE<:OI\6;_6>M>#/J#J/I%%;6P!/#RN/ 71_)@<F?Y3%;C3)+&
MR6?J/72*!N!X&D^FF0+*>0T(I"X0SY6Q>&.+";EY/6PW.H#1K$B'HC YEL6-
M^;2MVFFC^]\^:\93"94!2D*7RB8MT(8G<2O3@%PF U*I.SG:I#\_;4B-/1O1
M.,\97D^223&%NOY>9SA&>GOL<WBKFVZO\[)T.&04SHW"2;""*:BH)A@@'K4'
MBHT'2D2327'AH\W$:=1/-[8(JL<]KU".5\[:7+WDBHSI1\7TU*1XYU'<*1CM
M@-30D*@H%(4+@"')J<$!ZC2D,6*:D2JU)WIFG54OVA>MY$N,< I-VWQN-;&_
M+47AZ,?GC#_-P5+O?4HF]VY7]SIQ2?M3.[53;E3FIOFX:6;&O&,2,L\),$8'
M0%->A#1> (641<YZ)G!4TS&JQY>N<=/O.8]S'>!\?UTCP[D2<)YJIX:98DP$
MX+1'J7&)!%HS#XQ T@>G%62V@#,AU]V.3P+GY]1V=5K+Z!9%([;;/N_Y4]_I
M-[_Z6JO;?VZEJ4M6.ZZU?Q[M1Y%I_G)Z-Z))U&W[-W%+&GYP$([T]\Q,\S'3
M;$L.&I325@.84M\HMP@8(C2P$DD7( E01"-(R>O]..Y.2]FA46'T+D#+R.A=
M+GJG] K#@O'1.- D\*A7! E4" (@SJ"21J/XZL86PP^Q$2KJNEB%_JS]6]-"
M<YO6JH94IE-Y=XN]R@PU'T-=F?#NF(O"!&CE360HPX$)3@'G@J9QZV0@).H7
M=0K5JG1LS%U:URSBDB&_ ,A/=6D-05F/! B&:$"E%T +S($R19]69K2A"?)<
MK$QCYK5OR57J*U,-,HI4HKOK+[]:B.$.E:MZTS3TAS'<ZD\<7> "K0WU+[<I
M_W;'94'P4$$PT^F,<4^0H Y@'3"@!D)@'-,@$.H<$4I)$74_CNN*+JK5V>)@
M5/$AS)E0,Z%649?.A+IP0IW2K*7E$#,,H$_&M$KS#[ 0P!/B:"!8>Y12Q55=
MP$5UFGMZ0BUT[W\/TCCQ4:[Q5#5P6_=.FIW1_<F(F.%OBAO"LZQF?01#;_DX
MQ46-N/<U;5-D47<NXZ+4.MV![V_.9E%//=GPPQ27T=/S8=/&/WJ^I0?-K_[/
M;TTW.!V1P-0'AVL!)Q_1)F[+Q>#VCU1EC5X!?B6K?.K/=+\%903IH*#04.(0
ME3H:E%SXJ%(P0Z3UE']&::;@\%.GXQX-Y_K$ ]/S^@O0(3[C'[KU35_V-_X]
M>Z#BV;FR]%=7K5R;K?\QO?C1&V[WI\=S^4LM;ESJ[?W7NXW:7N/E[2>PNC?_
M\J!Q>/!F;V?[:'>G=G@4_]K?;1P=U@Y>Q7\=O/S/7P=O=G;?'XYLUMUW'_:.
MCE?P.8^][O5KON.\J^UXZ]O&]VH$U8MJGWI1A5$8ZO$'65O!Y_MMKU.+EVVE
M9K3UFO]N?102YU&<%)4F-:<'^O<[/A8O.Z\D,3$APD(TQ8=IZ?.^_V/TPY^C
MKNO-3G%+Q8=N\,4,@:_4)D4L87_H 1I>?D@+FP4M7)&GY6L4;2HI;WT9;J);
M7_O99>4F0;=_\F=7_?EKC+"%WRN"FU#P%;E9M4GH"BVL7)E3H#85(7>ZZB\\
MK7-TL_F)[[7DO.58<?)71%BH%8V+1.V%1M$-I:9>%MO-_,H6I2'%KPK7[!UZ
M"ZWK@KV\LA1)#!;_FG3<*?XY[+HS7+^R:N89+]M4<DZQ/+\JJGA^*U(D@!8_
MS22!%K_Y+66"_EYK%DE,SWC-BFC1S/,OJ</;DSK:7NB6[MAHQ/=KW7!5'4<B
MI_3<P2=Y8P\"XP5WDCI,C:#!(V49%%839Y"0'HK"+2G6I0?!T?;0[]C]_FGG
M4[/1WOO1P'LPU>T?_]A-W_4E7OO'\9']\>GL--Y#ZZQQ.?8[MAMG\7[P/M[?
M:7W9_Y'J_U^='1R]^W[\H]5.GSD^.D'[[0_?/QU>]3L>X\;.Z=GQC^-O!Q_?
M_=A/]YM\D#OQ\Q\_G39^-$X/=CY<?CIZU?KOCU$09W>0OF__W6>/J$S9A( )
M)  U6 &5_H"0:>\]X1:3C2V!\>:B>E-7)E+SBSR>Q\5VY5CP[H&8N9]_13GM
M>IPE*"F4(U88I:GS6FOA1?Q!$,:14_860EN7G*558;C+&8:#%"H5L %$20PH
MX0+($ AP5E/B4]LH@3:V"*PKE2DN4]PZ4MQ<55^><:PLH<00&K"04!(.K5%8
MXP"IOIWCYJ].S63W8+)KS*IS*$@NTK0R(AP!E%$/#*0"$*)A8!1%^94*1^I0
M7.>ZN>M1,\UEFJO2@\]#<UY(9(S#FAI%I:=2<&$0\A[Q@ G#=Z"YS&6+YK)9
MQ8UC*JR/Y(6PMX!:%X B!@-B1("!"NJ]W=CBXGJ!26:RS&0KS61S$!F'4@05
M;5"&##5(1\L42:(\9QAI*7FV2:M ;0=#-6U_^S-AG G(/("$:4"]<\!(SD"0
M3#/I*-+)'L6LCNF#VY.M61W-^$M796Q(&8%*O4;B-G@[2 $&>ZH[)V6WU90V
M>%$,>ZJ=]YH=VSQO^7Z]UO'%&P?Z^]1 V^?4C'788#OWU\S;E+=IF<J$\TII
MR*CC'%)#K53(4ABEDS*:67Y;Q(YGC6'!&L/>K&/GVV<8N"#:*V!M:E1,I0.:
M00<X@BQN%+0"TXTMLJAZJXS.*CHM"'>"2!F$\HA2HQ0FS%+$K5(L'@:3G19/
M@-,IIT4CXI1CYKDSP&JI  VIP:<T#,2MHH1($AA/1?+5Z-N3$;I@^2DY4C!X
M*:@U-()42<\4Q1&5Q@AA0Y:?2\/EP93\;+S[C(F6D!(%((,1E]Y*H GVP"FI
MI#78<0>CU?W@9C45[:IUMU:=3PJS1K1Z?Y&!N9Z]@^]G1N46SWF;\C8]2%J3
MD*:!6\\PD10*J@-EBDN-C4%08/%Y)]7?00012#\\R(<>V6W2(S,+\[F$^?ZT
M,4P.WGUV$/. G8MVL(["7$H)C!4,2!0TQX9K ]G&EJP3=7W85<9OM?&;:78E
MMFD.FE44,6ZLDU0X*KTRV'@,,5&"J*"<RS1;#9K=FXY2.@*E()P Q: %%&D/
M-++Q)QT%)C8L[J&K'L7F..2-8#VX9?A!#C7F&%;>IKQ->9N>US;-$W."S%G.
MO;+(2JIPD-![HA#3CC)!"+Z#]G9+\&FUIDBLA KW;CH<E2QE&#5OK0,'VC$"
MJ.$,:&L$H([+8*DR2M&HQEU/-,OQJ+5 [P)LKXS>Y?FYI@PP3C"/^QV 02G[
M'1(,E'<6$,ZA(]I@K"N$W&7WB5@1PVNG^;49[\'U$Z9:NI<&T75J9;N?6MG?
MYK=__0S.;WVO:'FP6%CO-5[]I,?"^*9'7[XSO/<QG&&&\YV$\?[+(9Q?*OCI
MOZ?0MO_IZ(_JXJ"]2XZ/6G$-OEP>[+S[T3AZ']?F4_/3COL2UX#M[[PZ/3X[
M@0='']A_4]_9HR]H_V@7[Y]9VMC9^TR90QI3"@(4#E B8 IF4X"T1))):15-
M57Z;-R20IRY\M:);Q^\/L/=7UV^9W<MYF_(V/4GRXA*CK6,1-B767NK^:59(
MYY)@'ZX&7D-41HV,^J@VCD6E%-O4J#P IH(S5%&+F-K8(G4J%U!>GF&<V39O
MT],9_IEMEVTO3)G_'B-$!7(@< @!I= #I8P"1I)@HOCTSLE*,6T.O=Z(V;U^
M_Z+H+IDJ/Z?M_F;R W0ZOD3RM^;@M#8X];67Y1R)88?[_G L6TU_TSU7.^]U
M3WJZ_3PCM?/UGJ3$>.T5-L%ZJHR5UAAEE>4V4*M4^!7_76M"6;!:VDWO=BYZ
M<>W>QL?HNK(A9?'G"]WW+NV?[_1UNL7,?W/QW_%T;\JD;7)!@I?.@[AG,G(@
M<T!;RH#0/"@6K-3(;&RAS2HE[><0QH*SQR"EW&*.F.>:*LD,]M1)HIE2 DF%
M[J#(W G(_^C6A<\X7@R.9X.0GGLL-$715C0F6HW* :,( D%JCKDFEA&WL<5X
MAO&*P3BG>^1MRMNTFBG562@NV94Z9=Q'PT0'80W0GG- '71 >2& 59AB%H21
M*E1,(#ZS8M0"#\"D0U_D38].?<U_3S_G$M7L(*[@-CVE6;7MSB[Z@[;O#/I'
MW>WQL*:WNNGV.B_+ 4V%)#%7)<G[Y./J-P?^T/>^-JTO1<][;[LGG>(JA13*
M\F8N>6.O&F$$$X>#PH PBP U5@+C% =0L\"%<]@BMK%%\(,'#&?49W+.VY2W
M:46WZ2FML"Q#*R5#CZ=M-B4HAPI#0"%2@%(3HO7F,+!8<RRE<0%73G[FF.S-
M8P[U]UJS?1ZWI];SQ83(VJ!;\^WS5O?2^S(^>Q?;[SE%7[,/<26V::[*OH>;
M@+?4!DWDV*UBK"P6BDC<+1ICO^IUVS?[&1M^D,767&+KY*KIYSB%CF$+B),!
M4$4=4#00P#@*W-/4KE)N;*$;FM_E*L#*(CT3<MZFO$TKFEJ;Y68%Y::=-O>@
MH!@:0H"5J8^SQ#@-TJ/ IP:_A#HH(:Z0S'QFX;GW_ORB9T_CF>]?3:Q]9I&Y
MVXEKB6FQD^UPVQWWW@^:O9NR9#,?S<5'7Z[EP\J %&<$$,0=H#P2DPD< VX$
M]HB*:,SQC2U%-UDU2@*RPSG'!=9FFZI:ZGHW L[N__OP[Y7J5XFU8AQ&PN64
M *H53_4( B#'XR9::[5042<4=<DR Z\0M#,#K\0V5;7\-3/PXWFRIRQR"HGU
M)D@0-]$ *B(/RZ!L*I#%5$3CW&M3+?9==OCU*4#Y0K>*\E9=&.([WOJV\;T:
M0?5: M:]K/'A,CQLF'7U^&L^2UUS)CV!PA)F:!!,8:@QC(>=2H8\IL4HJ3L8
MZ%,U^:45?G QZ ]T)ZU>IJ-[&N21CAA$3C&!08"X&/1F@5)$ Q5(U/>-@D:2
MC2V.U>:BTO@K,Z1^@:&"9X/QFP:W\R"P<BBJ*C0@8[SGUB%AM?-1=1&W #P/
M;E\NXB\G(0%.H<2*@6C&XU3&2H"6*/Y!D'(X39%C=F,K2CY,,^2?#^3G,4LH
M-U*R  -BA'HHI=$J EPQ2(DAS-Z.^7'$,(-_^?Z?- ^%26:(I\!89 $E3 $C
M @681'.$8L>CS"^L#R6N9X#.'1+,N%\OW#NG<= 4F2 ,=03K*"LD=9A'X>\-
MO4V9SX.;'Q/<$\F.#8&6A"3*M0/44 .D(0%8&I@SFH6X1QM;@B\@V)^177UD
MSP'LB%^*@E/Q@,AHI1N=E'G#N'8X'B,ALQ)?!:A/>1$#%99C+@",&P<HIB):
M[(X!QY#6D&!*J$AY/74&X:HH\;_P,[IF_[RE+].3^)^S1'[GX[_SF65JY:G>
M.:B8MREOT_)4,H:BUJX((9032B4WGC+&8#",."A$6=:D1J%?E<?-/I%:MGOY
MYNC#,*)R#!L_[.>H0D-N!0**IA%EP::>QSX )#B3#C*C%(EF6%W2ZSV/,X"K
M#>#,LRNQ37/P;' PH("5"I%QA:;2,8^D9-1)[:D.F6<KPK.17T>1Z^W/DB(5
MI-= JV  1:D-$!+1"-8V;AY"Q!M?/8Y=4"9-B4%^L]5TM3E!I7!YTP3OTJRZ
M98;W\RC;R]65>9OR-N5M>E;;-(>.YIG2FBJON&(T!"B)T-8BH:@2#&-\!QTM
M3_U];/WLQYLC.V,'!Q*UL( D(%*D1",H@.8! 6,)C9N)M$=\8PO?,-TS0W=M
MH+L \RI#=PDNK(EI1;"APGD' F4<4*L(,(9#(#AQ"E..E*T<;//<[J7.[7X@
MJ//<[F4)Y.T1JK^ZU_]0]]??K4^X]=6<=>%^^U7[T]DQ/O@8O^?H"VR<G9[&
M:\'C]C$\.-J-S_CN<O_L4ZN!Y/?]G2^L$7_7.-LC!SOO+C\+@9#E,@!"N0'4
M$ .D0!Y836P(J4S8\32X6UVO8,J#N[,#.6]3WJ;E)Z\N,Z":1\DN1H3!J[%5
MJZ23@B# G?: <L^ 5%Z!*(Z"5,PS#(MYLJPJQ;,9QYENUV:;YJ';9<95,]TN
MS&*8^ $$TCA8+( RTJ0V,0X88P4@Q&)MB,?$N$I1;6X3GT=W5ZCS 2:$&T<L
ME:F[$B&*<R8)MO&?"D7E\U<$F$=W+Y\ 45%>,:5O*N)=@%X#"3$'-(HO8(2Q
M@%!//'&6,1?U3;RYJ"*+',-X<C!?5V4PIM0SQ#FTCBJJM/!6">R]CWH-IG[N
M&$8>4[H$(._/ )EQ3JDB&"!&5=1F" =1(X7 <XH@(XI1J3:VU(/'WF0<KX3I
MF+<I;U/>IFI%]K-47(([=2J%6@@-81!1(J)HW[, @330 F.EPH(2RU/GKTI)
MQ&=6=)JG=V<G\>IMTU,:5GGR:+4$#KYJACF& I56 8,E I1$,TPK[:(M9N,I
M()"30-/X45*AJIT,^\S.>9OR-E54B"[<#LM"M%I"%$U;;4ACPQWW "+) .6I
M@:.3'O#@:2#!&.LK)T!S8#;/[\YNQ.?D1IPG46@!1F">0UI%N46N&G_&&$@L
M58 EL46=CK)+40JXCTJ+MI I C>V$'E(/E&&>F;DO$UYFU9TFY:<89L%9Q4%
M)YXV^ SEQ*5B!^)$%)I0.Z"UU4 AHP0G,.I)J$)"\YF%Z/($[WM.\'Z<[-@\
MP?M1"(E>38MEA%)KO !:00*HP@&D<6Y ",:]9AI:)C:V*-R\WGTM5V%5%L(Y
M-K 2VU35HM<\0/8Q"7BV#A8;PIT2%,@@'*"!*B 59B ([%Q !"G%4_]+3J]7
M)F0&KBRT,P.OQ#95M0XV,_!C.K,G-CF4$#,9')"0I1G>R$1%6,6#S0.)C*NU
M4ZA2[)M'>*L\PON^A:S$1@ZCUF&)-$5!F?@+&F"D,J(-0>74OSM8Z'F$]Z-8
MY-N?93 >,\A!" Z#U'P+&(73&$ .+9:<<^\VMIA"FW159H'E\7]+32%# 1(%
M.;9*4D2]CB>&.,0UPLYKZFY!>![_MV3([T^:= ;&J>$J&GSQ#THP!XJI +@S
M D$/.?&A&.+-R*+Z=&;,5Q_S\Q@F* 3FA0P>4TJ#Y$HCR.*/S$G!L<*W@SX/
M\7Y2#U"T/P*BW%()H.4(4&DQT- ($*261G-G,;4;6QC5"7F( 9*!OY; 5T%A
MC1A2.CCJO5#0TB""XEP92["Y _ SNA>.;CM&MR6*$H4LH$8+0.-6 :6A!TA;
M[[UTRCD5U7DL,[2? [3GB?90HV#0,- T$5HHS:V*5KO5+L):8YGU^&I@?2J[
MQWL&D^@V'%) K11 86R!U<(R!#DB+.KQJL[%@PLZE@7YW(O_1AB_O&A?M/0@
M33SS1<I<D2]TJCLG\3N:G9JV-B[*(-Y^[;S7[-CF><OW;YF*EANFYY!8WJ:\
M38]K)QBF#)4&<\]=5$B=T@2CX P)3D?MXB=>P6PG/)+NP*:] ,I91A%C )/4
MH!=I!Q2'#B"J*8<R4$O%QE;.P%LA>&8678EMFLO-BD74ZJVAQ$<VE<XX&+ 7
MV%@5.32(S*++9M&];Q,++#['V0G^[ DE4;I%*N7, 0JM <HA#A!2'%/)K*>L
M,E2ZR"G2*U!BT8@64#DC.D^%SB5[>9OR-CVV&U5#A)F *"@OJ%!6LQ"\US@^
M>>HB#5/*)H;#E,THO1_B3XWL-IE?F@7YW()\8@YY!HT61@+!H(\RG&&@F=#
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M6$_ MT3 3:=TF>:YL;DAE.8)=@&.04VG">%YGFH!WZ;H'D]7#6J/(U9LLU6
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M.I,R@P.\M5U<IZ=T;VC<8.*]-6&_)][;(MY6$@--*>CD*6'*6$*520D73!(
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M\GI7RFBC;(R-T,'.[^-&G3F#_-GA;>W3M@.I-4K!N$RB%CA7#'E.+)3LE8#
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M,047SUR XX5>U ?I@/P$%[B4$$S(BHM,1J)MKLZ9N3BKKV1YUA8US6>ED9S
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M 26(Q>I(QL'6<Y[*2^8")!8<V!30D)=H:CK3/61"M(SRV45XXARY!24Q4PS
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MC(:PJD1:P9"B;19Y$%EFI[+)U6![U5;/%ACF(50KG;5 F8![&6*P@OY7&17
M(F_U&.8-YM/I4!^V1=$E.PO,("(#HSC#H#E+2AE)KAGGXT5RI9HU7V"8FVP]
M#]Y8D+I:\WI*4$4GE'>R:-,**,TFEK?.83E:$Q4D0XZX5@Q$CLSQP)D6UFNK
M9,BUYB% 0_("(UD;7;@IF$W4@(4[0#+63CEM3,JY53R<.Y"?SWL2B#'[E)F4
MU2_W.C*?3&&6QB@)=.BD[8ITN%FJ>/@\"BB]&.)!'AW.:][3TXK')1R&?#C(
M1_V#'NX5;-6<'L%:\$#NG0XQ*HX02T0#KF3C78F6%\%;<L0LFH2I'"<+3J?@
MR1 8R:!D9+50#^,&"ABA8E9^:=7(=NYT@4&,&5)V7!EN:F9[<=S1L(,0":&H
M<A-UJ0;BQP;Q5(:333(7KR73#@2#5"Q#%RW],R$&YPT1]-*J;X?'%QG$Y+H'
M)R7!N%BP('VM5Z]5(<,LZHFTEN$T9_B>*MB$RF:!DBDG*&1+1C$7E*S;IZB5
MX)9KJ"&;-NU0^0(C' UF#L+4A%:0Z$,"8R0DYU3A4I66^S!S,([GTIC67VQ[
M&;T14K)(9,T@ZL!<M=<RA&@5^AR-7%JUN@%Y@8&<'$8HZ)-2 = &7XN[E*!L
MX38&)1J09Q#(YY.8WFS7DAY62,T,5J,LE&=!T8AQSZMLB-"A&'*Z[9WEH1J2
M9Q?)3FK-<^( %$.[$I$B,:NAG@BL2G W*;W6G.Z9 OGY)"9%4525 6(<*+P&
MBJ@8<NX9^J)E$"5$2-UF25L@6V28HY5.9:Z2"1)LUH%S(YQUP@F.SMRD#$3#
M\N-C>2I3:?/5MH\R6JT,*X!DL+DG@UVL9-F%7!3Q>*QES3W(AN3%17()*&30
M42DL0);9)[0FEJ1D#B"":4B>221OG4=RTA0H"<]L$IJ!$I917,U9=%)R9:05
MR=?U[E:^?(&1'+5SPGL;2BJ@(3AN0H L5?$\\+&.4,M3FB>07Q!ZH]B*0Y L
M9&X9()#K+6)=_BXZ%J3/M.J.]=H['_AKU9EN"=/_WOK7;QO_\_KWEJCT/8E*
M$8>EO_=EL-]O)9H>Q>=SVN7D>#): E@1:HJ259F,0N3&M_2&F30'9]N?*7 1
MBTY,8B#^-QE8B#:PZ"T'&E==0MTS$7<6E6MIZ;,+8J<L%EF0NVR Y^(D@G)"
MR62K[$5L()Y!$$_E**F:9(Z S!L-51LR,)]D8AC0!2-%D<(NK2K=#H,N,(@%
M(F'5A9!=!DVFEP?ZR2/HC.AYJ\(T;_@^,]+HE5<@-"O6U369'!@%WX4)XQ)J
M8Y.OJZMBF9N&\ 5&.$2MM1<8DU: ,H1B=<ZN%%&K.L@F83-[,-XYGZ.TLVV2
MC](FP[S4@8$ S@)"K;<4>;"@52IJ:97,> /R @,Y<%Y4X5%S T&Z0!%8CK5<
M"XV_:^J0,PGD\SE*6]O:NX)9<L8-IGK64S-?##)55 #-(\8LJJA<BYP7&,F)
MS&^,6 Q$ <7E("0/*MBD0\TAO@F2F],]4R _GZ.4,98<@V"10FD&+EF&RI C
M+GRIDF/"N=)YWM ,]@+#W$;%>9:!6\Z!.^7(<3/"2A>Y]?Y&DG,-RX^/Y>D<
MI;5MQ;TJQ7AFR4"3P4[U>("5=:F;S+5,)HNTM*J=:DA>7"3GX,GGIG@Y.02K
MP!NK2K+*=+H#PC8DSR22M\XA6;IBP7/)G*L'?612+.2(3&/4RF>KO,OD>KNV
M&K; 2'89<K*1IR0*<)5",,AEQ@PV6)]%0_),(OF"4)R$5+ST9(2C99"284A>
M-2O9!PRHO<ZXM.KO?O:VE4NZ)1)_RX=XM(OSFH7TM#)Q^2]Z5.QTXGJM4M+#
MVP*)+CI42I$7!T'&$$/!Z"A(1T<VP;0$AIFS!1_.LI V(VR\V1:Q1F":,X\Y
M,*#Y2DX=!F:402==HC$S2ZN@VV&P!09RB(# $9U""2JE "%Q"Y9+*-[&!N39
M _+.=":2EFB,UI[Q$CD#D(&%X#(3*KEB8CVZ:PG$LI5@6& 0VZ)TM#%'3]:8
MY^@(P.B=-$"8MAD;B&<1Q&?I1B[8S&.Q3!N)# 3/-4=!,&YX<-:'S$596G5N
MELZ&-!#?=XZ"UR"5R=*H"%SX0.2=<T2IL@OH3<M1F#D0?SB7;+3Q8CLI!8K[
MS'(F#(.2A844 W/%)ND\-RCYTJJR=RY&W8 \NT!&RXL+T>D<-(  CY+0K%3D
M4%)TT( \@T ^GVRTL\UKX5'4F=GB"YGD  RM1T:!L07GHE8(2ZOR[CL>#<FS
MB^1H +-)GOQH!45E;VQ6TM8=3!_TN)1P0_+,(?E\1I$SP4?%'<LB"08A)X;
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MAEPHINF/Y(H:)^KYN7O8,FDHGET48^#HLQ288@;KK2\V*X<!N-39Q%:B;NX
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MU'0:B=^@KZJD># XHN<>4;B'>RL7Y-POQ:934>FMPM"KQ.+KO;IY6%SB%G@
ME00XU &-S9"2)@L?,YAMV<G#7Q<7GXG$/WC,>TGCJHMYX<$U2U_V1W%O,#H>
MCGV'PWPPZ@;DM[Q7I]7/@]'1Z/=='.:?<)33O_#S/@W!:&;T2S??3/!>UZ?H
MNYN_[6[\^@=]_H:OO7U'SXF"L+O_;G--$J;5VDO"[>\7\%[7IS;?:+H>WFU2
M6UZ^^?1N_Y^[ZU_^^+S^]MW>VI>M+^\VX\?UM[_M_OM+Y&OO7V^[*$04A;-Z
MVH%!%(EY*,AX*:'JFD8E^47]4N=\#CYH#Q)!JA0@.EX2^9<NJ9SU1?W2WX^H
M?UFHW5[=A].1^;KNZ)7:HM]^]/FF6FL@%YZETQET2DYX%4J4G/QB@;E"YFM@
MF>UUI,IR+_;'$H^5KWXC6]8Q*"'%]U[][W%ER=>=?"]Q<N]?>]3$'RJ%GES4
M?:_^^6\]/#[:)5K],M''[H]&QQUK'@UZ>?]P;_ YYXXI7^Q7J;;Z-!JXDT]Z
M^QU[=E\84*-^&N P=;S:)^(_&@RKG#$A[_0+- OV![6_:&+T#H^']6&=C.W.
M$"LKT]=RU_S)K,&/=$/B__Y)DDWOM]__H'^/;S XK!-D'*T>YF&W4%';7ET.
M\E WZ8T/!X.]>M=),_ O[.]U&K3'U!%C0>]+G4*=0'8K'<?J['Z^WJ$9WW,&
M5ERZ3NTH;K0Y^(D"IJ[MOPR&KRCF[T"XT?74K[63<YJ=)99'Y[XW7]9VMJ--
M6@=.#HZ--<-(:.82N;KUK+95V6N*D9=6:99?7D[IAOQ,2'YZ&HZG\ 21MYXV
MSAAA=)9>)0-.1K0!A-)%6@<"N+[)M+G5U-B@J3_<_'Q8I;Y?="AKL^.-VJB*
M.L)F523S&B*#S.NI7PI_HM,Q&X'%J_*5A=@K1U=ZJ<GVN&"D F^R]X[F6'84
M]Y 9SM]*_&FC>X^C2Y@G1X?96-5'HD7F2W),%J<\ 2V;I)96Q<KEZGK7D,'8
M; YJ?_>.:H=7:S,V6R>,<-%\76VO>C]0?++'_L(]BI#&-_C;"EGQ'MG=/,0]
MN@O=^.#SR6-'Q^']1 .>3%9WP2D%?<VXY4^'9)Q[U.B0R1QW;%9ROVLG!3K[
M_8-Q,$;&NC9NCWZOFO,4G'4W/'403HWJ.#J[W*K1,3'DI"<J:V)*W>H1,6;_
M8*Q<?^9]I(FE/AC?C.;Z>)V)_HG=@S^/H[UAWA_\E5/7,76KLX[$\M?>=_FD
M9?4E=O->JDT[Q,_=L-'+]O>/]WO5?3HF=^5S[P@_]0:!_#X<NQ;UJI/XMEYY
M:8QN^VKCMZ+.FP'[,"AC[GA1F_\3M9[Z9!,_U>SFW<%>G:_4/GKA/^O[CFGD
M&?/'JX_KFW]L!Z-,28$S4VM&@>&2(9D+9KVU"2CLL 5FPCRTP;W]X*82"X\(
MS%+$6)<^!7,4.;+(B[8A8!8AW\XZ7+M.OGP-/1\.!W_UT\2LE..C8Z*727!$
M9N/O4R%:=]_CP\X '-)EG_IUI6KOMI[G]ZV[7XQ3KCY"T4W'\7KLJ;=27>87
M)V'8'Y6XZWN3S_)+][*=GS)Z<9 VAJ]/7G1VCE,\_KS\M+[Y:EM@D*E801.1
M<_))38U8E&(R^,B3LS8ZN[0J+^_QD(7;VZMSX/HP?*4WO4PS,6IC@UJ_>AKJ
M3R_@] YIR,:F;[^N\G96\B!_I,E79R?=9_(\^F\>_C790C[:)<M'0?_A8)17
M+JWY/, *83?]ZI(@Q7(TJ39*]Z;=,N#T0N&K3_77O%DGY/->%MS9+D';XC!6
M*5'RCU6TS$D>F)1%!1X2)S_DXC+?'*^DU26B,JA;!=4Y[[+.:,Z6/?+V1AU!
MQ]/9TSF\URQH5J>Z3J&ZW3'8.>B<OOY!AY^?R8L<[/43GFYG[)_<[?5!YW__
M0-^<P'3TMQ\O;P-<V;.FZ[)Q@T]R @=# FW-!]S#PU'^\>27?Z3^B/#Z^<?^
M0=<!W447,P"/!H?_^-A/1[LU*6^%CY-1)^>9)O>??+S2?70A'W'\F?8KTEW_
M,5\1UW[VM=L*L6*$_Z[;?OTSK5ICC90WNNT-RX]>FZ\M]'6E2J<9HBY9Y^'C
MI*>Z;^U?=2#8REB3ISHO;=J)NTW9I-O4U!F#N*:SUO3=CCIZ)R\Y5QU7C?%-
M3@#<Y(6?6<<)WSKN^SK./44U,^JZ)TJ=KZN)MSTA<./Q7K2""+=^_]D^-G&;
M8O9W6U^JU1+.IUR<I5-,QU%S'Z:?G!/:V%S_L/4^]=^]_.7#QLL=OO;K;Q\V
MWKZ"M<T_]];>KN_5]FV]_V=_O7_IG)!>D[_UU^4_/]3S01LOWWRDMNFMS9U/
MZV__^+0E__RP_O:?_;7]U_+?7UY/UY4JT@>-DC.E7&80"E:]46 Y1F^3S2Y(
MK,<)[URDY;8HF'&!C<9FSX_-8H" "M$)!0FX1ZWK23H;>8A0W V*534V>P@V
M.RLZ921:GC.P8D)53\Z6^:@UDR5DYU)Q,M=U=-/8K+'9,V<S;R,Y8DJ9A (*
M2@=:".5E$=)[G]0-*EDU-GL -INN2(4HI$N>:64L ZL#(PM4ZF%NY( J<ZPY
M(^:^],T>G,UN)R4TN^'OOR[FT#PST:#+;'+'-)'&)@_")FOG)5Y#3IE'IH2K
M$J]"LZ =,JDLREH0S%A7Y<=NZ1L]G)?S3)4]+H.+H_,6T5*HKB!2B*X R$Z7
M'*SB/)@6>#P1N*:JW7J*/*23+*B:G66+(W#%S&(6&DTL(77:?OR6IKJ!Z^'!
M19&[C:A5D0BF%BKA4I@DN.*J$.B:'_PTX)KR@P67F+JH'FJ)$M3 ?"*WV'@C
MT&@50>MJN6Y9\VR&RJ_.KJO[^_2!IU9D]3H6B<[P3$&T(*M<DY<"H"#K+(+G
MT>5DFO_[%"SRYMQ.1Z3^%D8Q"ILC QH>%E)4S)G$G14RU].<JS,EO=MJ%]ZW
M0$Z4(2H90=H"7)0@M7>8@D#RHW7SI)\,IF>>=#&&NC]X)DPM)B-R9EA,885S
MM$8X7RPGF-[7FE>#Z0S"%#U%2DJHX&4!&0BBW*CHM17&*(QM;?J)8#KEDR<)
MBJ?L618<&3B%S&D43'B,1FGP2ONE57GYP,H""MD_G7>^V96<^59V^'+O<)B/
M\---W/<[;03.->G<L8!"(YT'(9T_SKGPAG.GK&6U2!<#F13-^LR9+K%6)[(V
M:B3?0-VVJ/'3[.+?Q@]XOK"\8TGA!LN'@N647GV(TB<5"9:)8!FUI:#:2"95
M\4:C0EEWEA2_;=9-@^7LPM*#T";$5$M^@LL^R)#)+"IOE2\^I>:B/PTLIUQT
MK9U-(BJ6K#(,N*Z"9B6S8HW/!4+V$JK4_"VUYI\Z2V3^U]0W\5,OY(-<^D?C
M*I+?<N"?V;K[#T_IM;^:G#O_/0__ZL=\-2W1"/XT'L"Q.N.E,]V-MV[%6UOG
MI*Y3064],I^C(W<".?,A6'(G, O% R_1+ZW:RSK7?VN+?XL Z7OW^!NDGP;2
M9Q&"BTJ*4%-7@TP4N'/-7.2!U0&.QGL:W+"T:BYOX#=(+P2D[SU::)!^$DA/
M11>&Q^*]Y,PH0C,(:UC(PC)M:9"U);*N:W&S NEGO/9?:^)7T>3+Z__G [I)
M@1=%KU^KUN_ETZ#NN9P.NK]^F&WF?HKPJBN)]=4R6.OY:*/,E(;]7)!RG Z=
MN$^Z %C&DR$_"ZN86RW?1J;6\"P%F+KD(_7WK<3> S(>9ZFV$5LCML<*,ANQ
M/1RQG060,10O/?<L^Y@9>.&9ET!CH[T#IX)PLA:BA.];RV[$UHAM48CMWD+M
M1FP/1FS39[Q+5-%9S6Q-2 ?%,W->.(JJD_&1;)+*HA+;;=/2GYS8SNMIGRJ7
M3:LO?;5\ZY2^MI!7EG-]."QV=_RQ3_%U/]Z@F&N50:(7JH56Q\(L8UV%JK8P
MNO+XS#<UT[Y9O%:N/%WMVE?4K'Z=2V<Z31.IB+W/$]V]W$E#'!P<X]ZXB'A=
M@3B1H%CNBC)'FCS8K^L4.1Y7N2BVE__*>V<WO2"VM#PN]MRI-%!CN]ZMNA>G
MLA=3C4AY+"@QUE&JEYS<]?_]'R>%_<>H-\(]''ZNC4OYDBY&UY*5WL^3)M(?
M<:<KGSO^YG!0\FA$C:*I?Z'1M4D5$E,]0:]]4DC]^)"XN]; SO24[GY5=ZJ[
MMOYKI;=^*XDK(NS!MSK\-N*!DU$&.5[Y.AR,.IF+'X=5T(Z><5:H]S_.%U^>
M3%Q^=@D&8I3CH^LON530\8DF\R]LJG;CN(NF?NX.SSRRG<S",.,'AH6:^R/N
M?<3/HZ6_GP<RH?A"+U[L@.NE%[^B0O=-5;D+*G1)*5=D-@A%0K 03+$@978<
M/ 01[EH[^RGIIXK054Q=I-<3D$V$##J2P5B%9(:GPC(GG=3[JZJP'NS48MDG
M1!3[PWB\/SH:2QS@B%BD=!32'PNH3$K/TU.'8X''"=!P9YC'M;6G]78ZJ*>,
M1[O+O=0?8>CO]8\^GRG==$-;R>#@((]]NH[>L!=W\6 G3SX[&@[VQDRW6VM\
M'Q'TS]-&I9R/NP,BBWQT^B:C\:;(B6X#S5RZ]G^/)Q>/'EP8\^K=F!?#87VS
MVH2?/E_2Q>R$0+H??XZ'YK<ZY*,Y=2CO5 W_RXMM';PTX"4SH*I7F) %U)85
MX"Z' ([7LXJGFD[G50G/[&"=Y74FT>!79=K]L0+MB=91IG&OVDN[_>%8/*Z0
MG:ES\." R'XXPF%_K-Q0OSV>Z[6:_,I%/VYBV&,<'F>:ZQ5\=+,ZX?ZBJ*##
MQ5@VM\HVG-G'0_S<59'OGXE$'-"?/^Y.Y!XG<D8T,>N,K[]VXA![GT_EK+K7
MJU^M-Y[H/TRN(JO8/^Q7FSH_3M>]>)WW^+I/+I!P-N=Z!?O#WEC^JOI[!YT%
MZ*;U1"YACSP/FA>'P_Y8(NR2Z.=DUI_=<[ER_+>F;B\=#SN%!FK<\-1JD*_8
M'Z2QT.?X+7)B2)BI5'MEJT?UFFZ$3CWA$\VTLR?T/E]3\WTBW%,7(D]THMWR
M6)?L_WYM:>!?>=@1[?V6Y97WQO=CQ=C7!S21CSO3-)8/) LXU@T=BP>.7A_\
MJ^OPMY.N?C'NZ>[#E]3/OU W=VI2SUA'ZC6LO7^U34::6P&:67153-WH*JZ<
MF39.2Q!8LC=5KT>OF,N:/<O?-YGN5A6U3:89G4Q_;!MTROJ:/\XM,+!),PHJ
M@%F>C(S26REKV14G5\3E7,R.I[YG/MVQ+F6;3[,YG[Z\WK;:>PTZL"BD84",
MP5Q&P4KD(A,_&32\EAKW*U?4H%L^$<,DUW3O,X4PCR#C=3J%XFY.QWMYHUP]
MF<X\L6ZY_(_JAXWCF=I<FD1-X>O+JVV'FJ/E@9FD,P.#@:&4F1GI/*JDO7%R
MP16^1L?[]!:=YGW_8"QB6%EQF'=HLM2O#<9K&Z.G5^/R?L5R^SUB7):O. _W
M+QE%T9<R#Z)OI1ZFL?91]*W\_,I;71?I-(FK;W1>9V&Z%>0?^@?C?<!3(;^F
MX/0='?KV0A#?]6T7H(][MT;SW=]J1#_^4Q?6/R_5IY]PK]L>(U>KKH14U=:K
M-(:_HB)V@Y,0S^9,]96BR-D)%TM.G!L)F,#QPIT(%#>[X+7'*HI\13::?KRH
M9_UD\,=JWXN2^[&W_O(#K.]O?5K_\EJM_;K%-][^]GYC,\+ZY@N]OKG;7WOY
MR_NMS=<?MSY?S/WX@YZU(]^]?Z76WL>/[]Z_T>]^7=/K7W;$VLL/8N/7UQ_7
MWJ[OKKW_Z?T%[:6<*00)1C&N1*( &PKS7',6N=482W 6P]*J6KEM4EM3*UF,
M[+;GK%9RS>K0]_'C(RX*G=+CXJ\'/3IS3I5;1RNL)^:T-A<&RB,+' T3);D0
ME7,.JY:!A15_RZ+0\R*.,A='U'X=;W$],W64*QV[NTIA/J*'=WY=NSEXMZ*I
M<Y(K%FV6WG#F.&H&L406P /S6ALLALA+5P&GVSIX3W;N8'%\J\7VDMH&?R.C
M"1F=^4P^*!6S0H9%! 8A)J*E(FI9'0O"\TB^];6Y ?,BI#$7;M&?78#0BGHM
MB+\T'L[F+WT719V3Z) )*:JOR_ \"P;9!>:S-DSZHJ3RKA29JK]TN;[O/-<)
MNC/8Y\;KNMDKSC:/+;0[=I[*FCMV[UQWYH[13$!3G&-!A,IUT3%??"#JDQ*=
M0.=C)^YK5^0MW;%62.EVB/YE,"RYO[#K5(OK>)T.7/.]OHN/SFDK&.E4M"FR
MK$MFP(MF:#AG$HB?DC3! %]:Y2LW+[O:EJG:,M6"^$43ICDFNFQ.T;V3T)E3
M9(R+#BGB\RD1"<EHF$LBL&2LC!R*1F/)*?)\13R!DG)+\+HR0_/[$KP>JGC1
M'#'CE?X7Q$S_'XSW(0!7$:5.X(0UT@@A5)?A\+1N5\L NPO?G2MU'Z+ + *P
MI(-BH')@GGO#R/@%'=$BBE(SP&XK:/7PV&MK9FW-["%]P^^CP9;HM1 $>>80
M)N\ %/F"0M@JVBT=\\HJ9B$FKXR)!CJ'T*W<6L;HP5?)'K3XV8R==#OJBI%?
M4_K@I.+!T2X>]2:.Y0-6/;CG!2UR:\9']>A>GXY^/#C>3X.CR>=/M3+?U7Z_
M3##SZH%]_]'2M8_UI+I7/CGK-#-6"P;%989">)90R"B<Y%'GNI9^F2)ZDW-3
MWZA]<+\U#]J4FO4I]6%;>!4U8&2Z!,X@9\V"U)9^&)YYX$'I6OS 7/;,3Z;4
MMRL@W&_E@S:K9GQ6?=G:UD02P<?(4"::53Q[^DT7%M &$14Z[-R9*U13SHCJ
M7!V$A:UN]?L#%4Y]<D\I?\K#V!_ELU)5YZNW]4>]43ZJ"V_?7]?JM&#@N$[A
M0;=.TSUJ7&CMI/04/:OT/]5EOJ.Q<W8XZ!]T%>..Z+57>AWB1U5*ID].U]>J
M;$1'M$B4)43)H*(-@")8)8+GT>5DKG2RIMB*>C3^2#[A_V?O6YO:2)*U_XJ"
M]YP3NQ$NINX7SP81'F-/>.,(QC8>+_Y"U!6$A<31Q1A^_9O5+2$)"8R0 $GT
M3BS6K;OKDOG4DUE9F9D+SL0J]VNL<E-8E=M=_'BX/?C20.=R[^#X"$O+#,N!
MGTSJO)1Q>*4#XMPD%5W"K#@L@Z?R^I7$O*A0FL6IX/4@1(7T;->^QEH?Q#A_
M\T<3C*DBM2[Y_;,_:3<SZ2^3<F83H,QR<=8.L9GS\^4D:F?Y7KV[<KQ-:,7S
MYWL9EZL"FX;+W;!_;[K=_EGYV4M/]W*U?W!XY(6FQCJ"6,RIR(S 2$?L$0E,
MIP3D*F*Y8>E>IE(!VI%,9%VY3B5[BVZ,<+O;;Q:)!N^;7'!J%1DB?&$MPUI2
M9J)9C;PR6K"'Y)61?)L;NO14+68;2-DCI)4QZF%7;E!;S>W?+C,##A'KFP)G
MEM]KL:0BJ?C?RTSC<N?6=)7_YJZ!NR-I2S5P=PZ<?HXD0,^ZG??V/D;IB*D\
M7GJ+]=S8?91L2(3-OU6U)EO!#_(MS-@3+@I:O2W$M+#@-FV#MDT/OQZ*^E7S
M[/#L6P/NC;^=?CJ!:^#9AU?[N\<7]8,OHD[?G^R_O;%!>_KMY-OI]ZM]> ;8
M=="/3V=[?[X'^P[Z">W;WWWS<^_@^]7AUW?\1@XC%600Q F$:=2(Y]JCSAE5
MG',/R5N,F<ZG2N4VDU-.S?LL.57RH"IYT)* 1'GJ/*.>4Y4X)LGEZI$V. )2
MZH23]TU57@')TH!D['BZYT12GW*L;P0@"0PY:?)&KI(R6:&-,3FEC]IF53ZT
M"M(J2"L@S1J"!2/,&9HX=0!G6#)OA")2,NOOG2V_@K1E0=I8;4_"$S>*212)
M$8A+(Y$+VB+K@L0!B)'TN(0T/LV-5A32%O5'K0, Y?*V15VE'^U<^# 7;JO]
M8^B!!W.W<7;>;,2R9M9) RS>3F[YV*]O3\)\E\DW8Z36_81#:W!"8)GV'%M:
M+,LUR(WMW0WG_N_KR?QD>R,41+2"P7O X&06-.)#3!%P3TF/N/ "61T9,LP)
M[T/BA DP$?7B>6YG8\TTSJT<XOSW@RSA^[KZ*]!9V/:K0&<M0&=D3G+!HY)<
M(4J <7'% EB2@J/DC?66R22-RWZI[3G/D3X<=%9/@RK4>6S46= \JU!G'5!G
MS.*C.E)N!4&PKE $Q,8AHQU&S,&2PTVT&B= ';Z]L+VW*:CS$O9+K^W)9B/%
MVC\:K3*R\EZE>N[5_^'>W[J@Y_J$$-^%FP>Q<T8JC+P'1DXD>0P1!ZVX1B+%
M@+@V!&E'=2X+F)1R(JK(MG;$MIXZ,OD(NX4O6^4>9!15*K<F*C=N#($IY*A!
MC'F@)9%Y9)1-*!@J>3)&8Y<JE7L2E7N015"IW'JHW)@EX*U*04J'L+,<<4DL
M<E9B9)P2WGH992"_5KF7L-ORJ=']CE(GQEHC1W?&;J_6F1$U6/D5UF4+)4_H
M>YC/#X/IK+P*\V/)1&I.$:@R(044I'"(YV/H&D@:TEPR8XVF1(><FI-7^R>5
M)_,E[I]4B+,4Q!D9#-KPQ())"/N$$;?&(YWSTO%$8M0L68/S[LG3(<[JJ4\%
M.2]Z\Z2"G&5 SKC!Y)E.)@>(I)P*TRF/3$P>,2<B,5PY(T.&'%U!S@O<.0F-
M'XT06Z%VV8C-EU8Z:X-LP^&$[@[FLX+-^6%S(H,PBP'8=HA(<07\C%N);+(!
MB>@IAS4Q<8:7F4'XI=B&]W5B5XBSXK9AA3A+09R1;2@H$+6H!2(T&,0)_#&"
M:Z2,!F[NDS9!9\19D7R\%>1L(N2LM&U80<XR(&<\K(Y[@5G"R&">$ _"(NV=
M0)X"&&$FB30QVX:F@IR7LV_X_O9T@</T9XOX!-;TK.Q#/8A5_I#'+S/VHFO>
M/]7"X<>M8\NII$IR))//15:E1X8K@B13Q #2LR#MU@ZGVVQZ)^,Q_/LO (#F
MZN+&8<VR4HQ46+,F6#.RBU.@Q&J &<("8(V@%%E%; :<$!BQ'F,#=C'>YM/9
MW9]E"Z,"M@K8GCS12 5LZP%L8]9W9+":L900(5(@GIA!QGJ%*."=DIH):RD
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MST/RGZM##(IWE()@7EF%:"(<#%"ED+9,(D)UU)HGCZ6^R=*I2(S&X%F \=<
M81@03=#(E"?:8G^3I7^XIGNQ>S<QGTEO?_VXR>9QIK64E%IO+&>):*\Y!AN;
M68<5#>SZ[.=CB=EG?Q)#OQGW4]GS/R( 11P)'_P#>N;!CGP/GX/BK59=\6>1
MQ ]'BCF85QZ1#%@@KIA&1IF( B/).D!JC*?LO_6UY 8ZX0K1&#.(X GPIMG/
M2TE>6LHJX]GB^0>8,8.%I_O/U_>O,CZ.]Z;H[R,5#]>"/:AXN-H&=7N,>MQ,
MFD>IQTVKQJK[U22OBH=7Q<.KXN%5\?#5'KAG*1[^K,E/AA2T*@Q>E9S\A=\J
M<,8D%\FEG,Y$"6L=URGP9)/DRN!E.J]+4OR_[6[W?:=]]K:TZF!(]\]CI\S+
M<<.4BMUZH]7N% %39:I;,*HF[U+&4]5C[Z0-W^3-ZB*J:H6\7P\SMX8I;[Y]
M_2#VH'WUJX^X?E"'_W^\W/_Z'N[UD>S]N=<$,PQ_._W[^]Y4RIMOS>(9N_YJ
M;_?C3[C^Y][N!W'X]=/)WNX7#.T3]2MXUM>/Y$89\B2T<S)9A%/(A5(,0V!A
M>T0-XS8Z83316SO\%=8+9S:L2O96^+G>^)E$4IP&36@4 )Q$8^$X-I$Y^,\Z
MM\R]GPH_5Q@_1VD210C:<:(1M28ACJE .6(+Z91/9"6' P\9/YFJ2IY7^/G"
M\5-YD[A0C#O".0O&)>64%M@['9WW:9G[IA5^KBY^CJ=<=,GK&#GR*@C@GTX@
MDUQ$C$9O6<#Y.%+&3RV658]A4^JK/ZO2#S:[JOKJMT&=I0D,*QNL(P!Y5%G"
MK0_<2Z^)MWZI<6(5U*TJU$W47P\Z@&5M''(A0QT.$3D: PJ""3 K%&-6%*8V
M7QCJ5B^A=H4,(R,RI("-A\5-\L+!8FD(-DH1J"+85D;D"T&&\2IX(HA<]BY@
M1A$WPB.7HD6!*8FY"99YE9%!R0TL+U(AP[5[7CML!:52!<.]X=HKK#AS05FA
MDR.5>?0RD&&\CCE.F@:9@YMYSA:J#=(Z,F1Q4E9+L)I5X9Z7VJP0,BQIV[5X
MMBKS7*]L\;CBF.0PZ&M&"-@#S=-!S!>#40CM?H[Q&G:E\ILM;8 V9N5XRE-)
MU<JQJBO'9#%W+E-,L%0D%PSBRE.DF:)(1BT=$\:)G!%.OYJ5/V,AQ]H2%',]
M=BXJB*X@>C7/#580O<(0/3+[#0-UT<2CJ%5"G"2)' \8^62)<\IAE0"B#4#T
M=#F)"J(KB*X@>KD0_93'>BN(7EV(WIL(CX3)=QZ)$#SBT;F<TP=>.>D(9UPJ
M:3)$"RXV!J(GRPE>IZ4;/^CY5&<N<V*/=JO(G)BN->%=F;QCD*3GQ9^WW-OU
M1S@0QQQ72)A<<P,[A0"Q#$H20# Y&R1A\YVWG#QHN-J)!HN"D)WVCT9W.BG-
M\L]@/MZA2X75@PY=RFU-U*,<#=2/<X[Q?@<.-[FQ@MVOL=6AR^K0977HLCIT
MN=H#]RR'+I]OR^]MO].!:1AQCM?W$9R%XE'O(U'S^E"J1MYW!5FG_>CW$<;
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MH6I.Z'AZM^&+T[+'XM:5EBU+RT:LVCIJ77 8 0J"EAE"8'W&!L%"G5@,+,>
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M$8E: M8HB;1GN6A2BL$JGJ+,@9MZ.A+J_DA3'1Q;885]A+W(2F&7KK!CGK]
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MGD,,?3ABP@FF;4(^EZKA5D=D",&(<P8&=I+:8UC&(\#S>=:53C]NK;,[_J!
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M^^D;W5@#Y:QVX5;-B(,/!W,V ,8*$.<#Q,/Q;3?NE9'<)\1E@C\4_FAI*3+
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M!2W)4@ :  I0U$C)(P/"DN<-$+S;G4S1"V+C3VRWT#=?#-AQNQVZA09!(W_
MAP,YSQH"'>@GT$*0PM9QK0MB>T.\MFNYB<.QY_^=!7E,K083?!,CU';M*\RK
M][# ]*Y19:S]A0Y,/MRWN[UK7?'VO-&#.;LJY:[1^@%3E4=G# B*;XJKH&5%
M9N+:Q4DL!Z83FX6NG7?:67I+.8/5*FS7W@^5;  MX[KVZF8[A\#0:%V+;O[8
MEV=:RN;F6Q\#\'0*-.I$WSYN#1N>QQC:\*/1'>KWZ*GC[1U[9",_S?<[\(AE
M2CG?5L\GYA_&.WUN@3.$<M+G76Q>U2XB#/=_W<J ^]VP7"<CTI/[.$"Q0[LW
M^/XF-;YFQ+'[%_3RFO^:-:6_W_YS@OW9WRW[U?3WSSZ= /6]/+QZ0_:^?FOL
M'WR\^';V_J3^YX>K^NY'<7BU!Z__;GS[\Y#\Y^KCU=[5]R-K(^4T!\&%".Q5
M>8ML2&!U>^$MEA(F1,P^-UUSC6837KR::ZX7],Y4<_W N=[?K1^9Y#6G)L=/
M!Y9KO%%DH_ (DX2QA_\KBO-<3]<U&LYUH>7S3/>"EFTUW0^=[GP<!RMG38*1
M-1ZFVV*/7&01,2^45BY&H]W=T_TJKZ[G)9-H7MY8Z_)%OG0I%$1T8O4;K"V<
M%FO:[\/TDJ^+51_N]OM%(_1.ALZ2L0L'ZR4>76(=L()^[_9+QM;53&YCYYF6
MT/>(LAM#-/;WI#-LS[D]CLB!J?$=V03-?6V;%_:RN_7;)'\ \G!C%&\.0-G-
MG7^Y#EPZX\$W)JC4 NEXPIRQX+GD5D7MK0HLL,@=<<S%K37FZOLMX,! F;/Y
M XPS4[MF/ 93-=L\O4:FU8WK4O0#]@C<MK38>D.B/[2.QPV_5[4?8!FW^]WR
M)]EPGK2'2_H^3*DZRW8<F(DS'I[I*;!TF"C0,B":,#0M8%KNLB3B_=Y)NU,V
MOV@FT.";-_X,#VNDAL\F76ATS_O9JCVS0,8[F;1>-'HG,^[UH]W\D2E>H]OM
MQVQB']M.&'*^7N,LO\R]LF>%D0 C&K*E5SRSY.'];C'0XX2[N*#9;/N!=3K;
M0Y#O"7<?#FJ^P>1HNNCMX.ZE]Z)H:-;N<QBVT;WSE4U[T<U0==QOVM%< -3$
M'_^?O3=O:B/)^H6_BL+QW!O=$223^^)^PA%NT^[K?EO0MO%X\#]$KB 0$J/%
M&#[]>S)+2[&:18" ZHDQ(%5E966>\SM+GB4O2#9@8(T^]+)^JK)^FDV ""@$
M,VU]BF"XC&/K+1@((_@+;.=1ZY=/;S_]6KT*4!-,H /7PF=S]T.I<Y:](-/[
M/U>66^N7#Y\^_WK&30//K=1D,E63:;8Y,L05FVZ^>78>0E29+G.?3&4P%0?"
M;JPM<5X%&"QUYNG%==Z[U(WX4$P)6SDZBF!%39ECPIDSGISRWBF73%ZGT<],
M[V+# KW;G4&<4OENG"QMWMW::A;VM%U_BD9V[??LDH+)@7TYS*[Q+/&RN,D+
M.QL0MA3& G[H#$>#(K]:]O P@HH"$X*=BZNM_]<_ D(8%.J:CSKN96=EWC.
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MF,V)]!B/9C(+!!]0?SRW=*U?_O@'S$P0DS/1F.5#-7P,"'![8'=B78\I0'T
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M)EOCNKH+E]=<5Z"VJ."80S2%A#BU!@'7Y\X@6%,<J/!!+<QD:_B\X?/&-?.
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M6 X.&R233XA+19#V02$35<#9< C:O'K3A!8TO-SX!IX2A]>*[3%'E D2T6"
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MXNO."-#%7\WM1 "WYPZ#L'(7Q$ ^>13;C5E-J($5;&D\^[J5P ![.L <@!@
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MJJ+W2)A<VB. RNZD=0@G0X+P(48+YAPW"PSPT!@+3S#U24FN5;"1@J605<H
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MR3:1<:2# PO-!B(M$X8Y56$Z$',,;S,B8^T8!SLNIP)P:ZR10AC-B4U><4)
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MO@);LJVCRL&#FW-(K$:"5SGI/<VO"@= Y5\=V&6HD[=9IFBPS_X-_,X.X#\
M.SN=WMF@\B]XXDBN!__^\DQ9EL4D%1K7C;92:'DP61U[/(A?KG[Y-;0&,,"+
M+ZVCXI6+BQYPHXPHO3$K6K#,ZD=^G-'M1X1_I2#\=U33X=\479&&/OIGO$(>
M_=M3MR5D13+UHML^_3?!WFBPYEFW_8FO[*6U0*8J./J9:5X/F2VNW\D\YYW>
M,WOM[ENI!]_J2E$;OAUH:[=>\-.LWIAM? (STGPO;>8$TWKAYSAH/]#$$3.)
M&$R]TM$L#/<[H$+!^?W7B3V)]]),WC:F>^[FXJ7NG<_DO6$:>RZ(L9)1;KTS
M7)$@'=9<IL25+3WAS_'>]'"C76O!_6FC?BBJEVL8Q@6??>MLK=<Z6_4-#HK*
M66-W0VS=]=ZT?[2J=!/>9:^Y53^\S)W_:OFSW1U>I3NB6F\V&Y?P[/HA!Y7\
MIBQ1;OK'6(J1(&M20IQ2B;0."OEH(G5"6:-,T4Q!L44)9']?/W>)<Y\'YQ0G
M-'"&I2".>V8M-E$)JQB5V@062R_UG.'<6$=&2XUAD2-LN4=<F8 <20Y1*9GC
MB0'[\P7.L87!N7=*V)FI</YY"H/I57ZT?.]1]>5C1L=/XJFDPE A-;%4\ZBM
M]IX[+ZQ+Q#+,54F_Y@F6JN/T2^;U"@Y(%W4*<2#,^3>&A&42D(EI%F6N-\?8
MJ^O-E?DM\RO!/AF1" ]::<^Y4RXHHKT17AK.K.,EL9@S";XA%E03GF"A4.):
M(@Z$$)E<C0XSXI57U%-GLP1S3.=(@C^#%>O'UNZ+.,.GJ'!IJ!(2"T\Q$&*@
MQLXE*SC5\"&<2)B5G&&>$&=[G#,D33R6W"+G*4$\4H]TE PE0Y)W2D>F1%&C
M=FJU!^;(*E-*\$WZ4;0Z$7A[:;F+3&-E621<4\PDT25GF#<)ON$,1$L1B,O-
M+X5!W F"M!(4L1R;Y@G6D;AAE>EI&2/FR-XP0:KK3$6QWCNQG6>$O$Q*W\K\
MJ/>;H \$]F6NZ>* _<XX7?.:ZN!50IXH!@IBSC(UB2/*HG,!1RLS79M*JNG4
M!6C&!J(22DLH+5--/SN4WO!FGYR+<.XA'6CN N@I<BIRY&5,!/N0C)M6ING<
M0.G4,TU_DD):[,FD U8<.\X"*)16.#BD(@]!.*9]Y'*?YO((,TV_>"QJKXAK
M)W2E\L;9%-][O7#6ZG1 O#>/3NS100M6:)A9L=X:^$YO<-J?FVR*VOKVE:RW
M:O5FI[I>/=MK-[O5-GRW[<]R6^J][[7#VJ7/K:HOMNH[Y]6_[F93;)*M[SMG
MU<O?X-F-BUK]1[<&<KKW_=MA@VZSVN4AJ[8W1:V^<?[?RTVQM;ZQSQ)F.F('
MJXPCXM9PI(44R 8K+8 L=]H,X1GV;@QK&5R!(!%*F.7&.\YM<$%Y1W5441E/
M-;Z;?G&U$(5JULM]=2JMZP49Y2 \W0?MP4S=GP_C]K"9%H(YJ9.'D\418K%W
MUE@6C932BQ?DB<Q/ZM)HAM\S6>DOWXSAM!.WTM73/[<L;>Y[23CF(2&&HT,<
M)YUEB:)$."/2,!$\G6YJ$EV97692O1DKO@E2#+=L'14YY=[V^Q<YP=QVX:0^
M&>2$[H,KX3^+_3B-'*/[T>AOE'4$O'4%#[GKI&E'4JP(HJ>?R2-6L'[\SR]/
M.]+T97?]Z6"?E\WTS,251ST-"Y[-4WEA(L\G2_,H\V,6*C]F=E4P?XMP8ASE
M<\A9T.]]+!-DRL#QV=N<KFCRW-B77LJ31_8E4JU7SQN7S6:--G!M_0!7V]7\
MK+-:_?=.;3W?[_=LGQ+5>_8EN,_EMS:,C>VUM_'6^O9%]3*_UQJI=G=PP;N[
MN0+ X=F=9!BMM7=!&A2UMHAS99")SB+M=% X%QXONO_R9847)DJ\S(8I0>UM
M0(UP^%\*("%<\Z2<Y01P3D@;*'=<#4'M=45T2E![*:A=&<W;F[RZO6]E<#$H
MC9*R'O$0%7),,Z0"LUK:I)EQ!;!),^5ZMS-+?UG$ NMK,.1"ZE*_UZU8__].
M6\,RC(_W^J,/OO#'BW:;<C6^R]CO!3MH/FK5SW/?CV%8TO!/>+U>*$%H(A"Z
ME><2M#6:"8IPP!AQ*CERU#GD*>8^_T$*,]8]>Q($>CN2-$$,ZL<6OBF42"S%
M[.W$[,Y9[W3R(AADK9$@:I$C(X1#B5HJB93:,KNT2B=L2SE'22<+<91_/>WW
MXY&_J)STX2Z=43';D/TL.1#D.0?Z1XIKGZ37TQ2.^@&\,/SV&.Q\Z_5A<$=7
M:U2_6:+OMG7TQSPUQUP,$+J5G^(YEB:W:Q-&)\29!BA2D2!NA;:!)&M\SHCC
MKVC@5.:ES+'\3H$ME/+[[O)[FT1@X1)G(+2:$88XYPFYR!2B0ANNDS/:.2 1
M]U-:9R+#TRU-.#O2L'$4GN%7*H.>IST/\XV]\Y4F4IID7X2PMU)".)=186D1
M=:"8<0]ZFDLT(16I\R;WNA5A:(Z=."=DYO'*DYE22DPK,:WTG2\NIHW508$#
M!A;&HJ@917#<$&24UBA*3HWE*2G/7^@[GSFF/2,'8U%CN[<>"YA_^U!OVX7Y
MN(GSOIM%,5?M*&83]'VX3SVSC@B%+/8*<6LY,H8+9+5TFCLJ 00_4#^*1W9C
MWG*#UB#7I.ZE(A9\&.:=E:47!7KKMVPF(21Y250W(ROJ#9I)F!6N7G;7G_62
MX.58R[%^^K$^+P_CU3'W]V+'1TBVX.'CKTU26/QN(T1\R*R =TBG^* S-UD^
MQ<<1A(^8'?.]WQL,BD3[J^3%XC]&"8QEPM$+IG3-^]/N:2<W_KV:R^OFP.6$
MOF!"[^I<PUDM]*X'ZYN5*8.E;)>RO1@3.I%L?_C,S6^MW-=LU)STGI'IRW-V
MV*NR'9ZS]5X<=U0.LASDIQCD)RM#NQ[_B9W><0SHN-\+I_X$G43?/(*G'UQ4
M"M_5\SLT/K>7QMQ-PL2%#S^F*SP$IY.0/JE<DXI((P7A1@DK!!/1QRF$]PS/
MR*)-_%V'7$%X/XJ+G-4N-T1M=^^PVMY@U>X&;EPVSN!YE[7UQOE6_?=6=?V0
MPV?D^IIK%[EGU?HAV>MN7U3K_J)1_]&NM=?@W:JXUMX0U>[FV5:]"9_MG-\)
MC-;1..$#1BH1C7C@$EEM*<)2)RL5\4'PI54JEH7Y@-U^2E1:)%2:).![MK T
MIC2NC>F+)5!-"E0WL3R:&2.)\4AY3A 7.8,C)@R_R018%87V9FF5X&4A7Y/%
M46)4B5&?@CG-4]GG18&CV@UO(E((K#Q%/+=&Y)YJ9*S#"'OL+2.8&9R;)(IE
M3%7)FTI,6A!,8CKP9 6.SA!.J=4A1#ATA4Y:\J#$% *;2VUNVJAT0Y)L '4N
MY/P-3A)0HQ21X48@9;31Q"@621IJ<^K5?=A*5"I1Z;VTN=G"4JG-30>HMF[H
MDZ4X8!,\LFF8C\^08\PCA[V.#, J&0 JO<Q>E<Y;0E0)49^".)7*W ML2QF)
M"D1:VS>@?&,E//(\<=#F(B!1\!QI&7CT5'#A<J*86J;BU456YZ]C]J*X'?]H
M^7@TR DV#_L8/WB]DTG*%06:-)5,Y%94A&/-#6$J,, C0@/EI5-NWO#H5BZ^
ML]R19#&*21'$G3'()6N1%X)$HRFC'"^MLF7%YZD7;UFU:.I5QV8JQJ7:,R7!
MOK'/),RP=S0ABGDV'5."K,8*)4&R%TOB2,32*EU6#SC;RTID<RO3[R+2I3+P
MAC(ZYMD)0EF;CURN<X' ' SC',BH-9Y%%9G76BZM&G'?,%$>O1]&3)41FC'K
M%-$18-IHIJW@P<( 37*>EGZ0.93AL::\UGG"54"1ZMR4EVED/$G(,IZH,\HJ
M;@H"+5\=U%9*\1P3Z-F*<4F@IR/88WZ#:)+7N66OCYE ^^B028(CPD@NZ>2]
M+PJ)+S-SO]MV2:#G5J871J1+;OT"_7?,T(Z=MUZ+A"+3$<BU-\@X06!7R92
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ME+IT+<PA %R,I:FH:"BE**6<&,:91"ZZPA"2<CRGX): .D"6S=1ZE94 ,/\
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MR4;Z@+F=93KLATJ'O6ZJ]>Z9C%>JP-7<3'40,E.ZGX[B@2YM>781*ZZ^.V6
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M(9&=KXWZ:OO!W"W$\Y.%'GK%^58(9]EZ^>$0TX4/*[WJ,;I7_[N[M]M@C7:
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MH!)B$I@73$A2$M69B][.$\[7;^W:92VWBK^HY42Z]6UX_AK<:X=6UW<NJ^T
M1'7MO-'=Q ^1U&2#IT%1I(2.B%-CD M6(5AW;#Q+F'(!"N<*?X[O-7]MRA%G
M"WC*O2JNK+2:S1PD[Y,112D#G8U[%C%W'DXWSTP,Q$O!B6*EU6PFB#B6*BRU
MUU$:I P#$'->()N80?"1M8HP9TU86C6EU6RNY.Q!,N*Y]$11;R*V7! #"^OS
M)QH$C_-D2C(R<]%K/!'^7FM7US=X;?<;W&?S/%O&&G0#[M7IU+YOP']OG-?:
M^=VKY"$RH@B)A('@TD *[5^!4J$I8C$([A3#)K@<_DY^:C$C.?R=#"UFY#-;
MS%Y&1DK+R+R Y -D1,K$C>'8L,05QUK0A#5126+AM U3J&=2\I1I@N58+R$=
M)*8L(2\Q1IP+BPR7$E'OM=-8IJA"T>VK-)O,E1 ^G*BGDI>@.:N8"'>,69(8
MQYXD[$2*B9=,9>;"YY]@*C#.]AJOUINMO=UM5H/[-MJA65W?.:^M[[6K]<.+
M:GL3/M^D#S$5P6,*W'JD"<Z5.KA#CG&!9)3,4FP$=10D>47_U&P"3"5_;5I,
MY5/HXR\3O=*W-PL!O/'M1>UMU"0'JP>-N,<:6>HX"@'4=N.M4G9Z$>NE.6U^
MQ5<*!6LL3#")<^6)U4QB3K!C G@03J4Y;1:">D-3+7$FN>B1@-\03Y0@)V1"
MU(*^X8SS@+53B5@OS6EO'H3FF7,Q2C@8X824N>B=,2X1+)3TJ@Q"FP/1.WB"
MI,([?O_1JK8W8)XVX/IM(*4[O-K=OFC4#VGM^[:H[>Z<-2Z;K8<2*SF3+ED2
MD6 V(&Z$0E;!?^:*T@)3&V@(V;>GU7-8:O&]TJ!6&M068IDFH2/!V$"HXH9P
M$!*I52)"<"E!F=/$J=*@-F=P.5X<PC(=G48AJ80XMA*!='+D(];:,1T<9=F@
M]KFSZQ:$JS!* C7PJM@F'CTW)B7#+0\8BV@"+KG*S(7O\(DX)"^ D[!J>YMF
MCK*UGGE+L[7UO7%1N_S1W%I? YYR>%'=O5\$HK:^O<^4 $6#4Y1 BD&2A4%&
M!8QBKDQ M"2P$[)![<$:$' F,\E_?72[Q=,I[K47@OXWZV,)^/.SY]H;^X$1
M$JQ7R!/,@!_#.6($-L@S[#4).B59G![T@=/CJB[L;9I,LS%W5'Z$5F#;]4J+
M[K,XV,ODL>1@,Q/)&[.N"2$PG0B2A'&0(B61T\X@PI@UD0@+Y+GH949?W1V]
M-.K.KP1KH5),'E0I9[@WL .<8=1(I9T*CLE2BYHS"1X+2_!,<\5<3D]T*"<:
M(V>U1-R'7'R+*LJR,W.9XU=W%"TMOF]>2B\P&Z0'2;.<:YPLP+#%045K@=>0
M,H!R]L*W<?9'?6UTA*[]$[[_S</_]WMGCW;^<>WC;JT.W[_\_]G[TN8FDV3=
MOZ(@SD3,B4LQM61M/?<20;=IKCM&\M!CFB-_461596%YY=JFC?WK;Y9D8V/D
M1<+&:GB9P6VTO%OED_ED5B[;Q^P5?1QL;<O),=^^T4/]*Q^_'6=5;;Q=E?U?
MP\?^RK8=K+>DRE6SMK(J1P6\QEC8^EIJ95G:"4Q)BV)-,,E(]&I2<^QOS:#4
MK>;8RS,J^P,'?.?II+<0]KJ-S0?&VLMSK(VR]@"64)B:O(#J2 2*4I !=%XQ
M7PWNR7.[5.EW7;S_GE%:JC+.I=8ISX!R$#05:8NS[*%DDK%+/W@4E/8_H;0F
MBZ98$-JZEERGVABLD@2A<C6J$A/(94-I%].?S4:=5#7:'*!6L%I&(RWZA*I(
M*EK5CHT^/O9.+MAHYNMY?961;FV\?:/Z*[]O,LO\V-]]+0>MQOC5[YM]O:K6
M5EZ;_LJ;DXU6WJ-F,%(D15(Z+8B@"O!413 R"5:P&:O1M09HC-3=FH,P8:3.
MWA<C_2&B,HOAKXO*/!(4/WY&5E-TAL )4&TLGPY!M!Z;0DGG:M72N^GVQ#T8
MPBZPNKP0;MJ.%#)+S1F\RC$E98KVS%2S5?6&XO,.PH\#X0LFJZI#"F2%)"V9
MR18I8F4<Y\JZ%V-E&[B$$.XBJS.Y; JN$GIOBHF@?4P64I7(4 037>CR4Y8
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MG8"..FD7I0-G:D*35)95FT3)J]2QT4=!Z:7P?/$9>)4$._%10+)91'0@I$E
M-4MI_-)MHG7A^9ELM.;BBHS:>RK JC;Q@V 6XAU5]&A"QT8?'WOJAD*\S;X>
M[/29??;U'UO]TU4YW.+[V/UUI__VM_'&.E_ORFO5WQWLSBC$,Z/HE*]L544R
M(0NHQ8G@716-HTJ-V?'K=TP7@<OI(M E/M_)TBV&OBYK\O& >$%5=6N&/RE
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MI-A:'JG;MNM!MI9':K);#_=0#_%#1%X6PU^77_A(9O"S4:&E.EXB2,)(]N!
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M*J]=#*$P/+SN!C]_QR@M ;2U1>8$'L"J:+-Q5COM5 RFJ[I^))1>L%'(JH9
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MM?/@E(ND5/ ='WT4E/8O]>K*(=MLA"PZ"UZ8Q&:,?[ )<T4' K*M"Y#[ZBY
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M$2[8TN;:LALD XE87%&VY)C!/WD>ORQ5[#(CO@M<?F.>T$%V4<A>T(52I<:
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M 9P)6GI3<U(%0C#):17)E:RD)M^Y@4LE ,XJ]LP(!=G<VN>KQ!X@^X(8?-'
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M#.P[9R?0*RNLLP9;=TQ/::+,KNM0!9>WO^=;_5)E\%5"19/ &!="5M4Z(J7
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M.YVP=,*RF+#<HC43YNUW!_SLBCB[ZIR)6?<_%WU,-^K:3P[M-_0EIJ[T?!M
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M54V4!D4#348)KJ1R2BN%:;221R8$*RZ>.3+D_3VE#^!:='.]T=K\MLWJ6U]
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M1)9V.O/GLOV?N'CV:>,RSS-O'-8OWQ_4+S_3^K<_#S;7X;FVWA_L'G^%=1[
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MYX!7PT8QPR8QM]"J*KGW<!*9(D9'<;/L_D5K!S=*I?.^6.^SH@Q GGN2Y!>
ML-UI[;@3*DC.>[!<06W^9#=K9[FU28AP@0S_*;=(\EF0^$[OM _*H=GS_?IO
MV^MU?#.CX8@_K[9\N39YRZ^ ?4$X=S+@;\.;N6/,90SK@^<M;#MDV\O]O8!-
MC@5QY 4'RR%WLK?.:T2HXU1@QV+T //R=G'7%=\.Z6@B&16I_V+(87-]9\]9
M*X2@'@G-@!RT24CKZE><A+1),<4>HNF"S@GJ8,8;P*-NU=>I\WW0TBLKBP-@
M[]WHH].^TAB[,<-8[C31JPV/#Q34D]CNQ67XTNER;C21+Y=%<BX1K.BN.MVJ
M^4F^PT8;]-\XH4U8)KIF^ZS"L6O"8H#%G/:[K=]NXW?5+N)_7V\(,A O>/05
MZV!99Z=W?V4!)B14(N<C8O+&%HW]?= =-8?8C\AUHSU"-L%RW]G6N;WH+?WK
MNK@%67MC%V]NP-U&_57/G/$#ZG-E]"1G&*0D$N."!1NH23(I(XGW":?I^[,L
M3&^W/[J=7@_YLVYNHG=1-;GKO1)U!I3_JIJWTNEB )VF<];-?-SIG0%$P*L@
MU^$+8",,'_^JTUN_)6"S=W1+L%SU?4O5Y5J=]CZJ4&70]2VV.T"&U>?A4S?N
MT,PJS3E8NQ6JY$_ *OSM(QCK,YC-X8&->X5;5^_6(FAI@V9R^=7L];K>NG!@
MJ/>!;8(%#U=M5P\R908 =I80L,Z$5SSER*3QG'FA28R4QB(L9RLLZ[P! I)Z
MIC2W,A?]Y= [)<C(P)#U+.K@(^>Y<(BLT,F1"$IK\:S;&6K64\YS)<Q:%AW%
MGG.PSXU4,0AFC74@FHTM!S[K S_<V2-<!D$%14Y&C;AD$1DX R23Y2KYX E3
M>2(,)Y,/G-7^/@?MII:Z8(#5WG?:8>IS!Q6=2!RY!VN.4QRT5I$Q:I/ A&E?
M&'W6Y[ZY5=]++'&MN$ TB(BXH!(9:Q@RP7N)M; .5Q/T)@R7J,Y=/H'1K=,A
M..P3%X8#9NB0J%,$)^X(MOR.J8WEP&?1(!+6N;%G%?.6*H) MS2YXPD%E$\>
M$<E\2$9J:44..$_H;3\X_),<-@-M*W9;V0H:N<*GA'R> 'VL5F"5<<JMX=0X
MRG/+RBP&"B7\2DK(J0=@6A@A@D=>DCQ"6T6DE=)("N^D8#BI7#S%[X0!,YD2
M4K=S7 $$8$/U@=[H$YE*QF1&%6397OE[I19R;\-N7QW-&NA].FOMP'[/)GAL
M UWDR$VE#>>(4';DI5;GO*^/P]4^=G)0JN]?RQ39C?NV\B".A79NJ[W+M5Z,
MU=/4B%ZNC>9LP+6N.I!.X95=&&OL[X/82GD3FE4S^;PCO:%7H3J;?C0L6=]L
M@:5_,ZOD2:8:KPSF.=EJ:]4QKT<?,Q#5&%D>M>>NJ,GF<.(Q $43K)<3>U+%
M(SO[77O<#R+:W&&T5SNK*+;RZ-3.3O+/TWB(K<94:^V<LI)C*0P%DU]+#Z!G
M.(_Z'L1[6'"G;G\TC\^.WW>ZW:H?ZA_V!([R]&([MS;]X^H!_\K/=X6%YNU!
MX7C3W!^;Z]MX+Q'*HY<&!5 ^$><I(>VX03A@DP+!V*CL*YXP.*#F!KYB(+"S
M=B\":%7Q[AO4E-T!&2RS+7S>Z1[E!OW>GC2KL8(Q!@"K.XBT8LP\+&A K=F5
M.&IO.]8>OC]9(-_@+EJ>921IKOQ<M=<?[ B0?SL,^O9FP5])@[P+T["F,X(X
M ZJ')(RS7%&G3&[G8(F(1E(U@^#-O^$I-M,?0!W-W-@^(^S%70S[EIESW'%/
M-]?W]RCQ-%EG$( E\";5$5GM.5*8Z^"-X=J$G_!F[P)8Q&?*6!XQZ3*0R_=.
MZWL5.JR.I6;WN[&2ALLY2\4? -37['?;;%5]F7-\<C^V8Q?XRG>Z)YW^ ) S
M^*F7>TL/HI>MYG_/FB&GJN0LL]YIIQ(4]_)EY87+[S9/^UZST920N]=8.[9P
MBZR4P#NVEV<[7#Q"*JE(P-9.2H-LXHH)9X+VA#I-!#;T0;TK'R:=^@F1[R^^
MY9V=+*/^OCJG[>$I?1D^?Y]SUH9/7[<7[^/&\-&W3SKMS;/NE]RTNW>Z=IH#
MHMV8'WTSO;?MHUZ)C XY:FM[CS$&FDC"R"6B$0\T(D- [L6D4^":1R)SU\L)
M)N HHV$8!1V1XR"AP>7M7JE]R%W7\\]]!2HS$A!]%[ABD%@U^N*!K<8O-8%&
MFQ5K#?G@*IYVWZR!1]'O&,6"#/+OPED7I'+HQ?8UDIV$V1O]9?YQM<H\GN#-
M$=5G>']C+U+CJ8*=%31[DG0T"#19B63(5<K!6"/HTFK*IM-%!/ON9AYL!CZ@
MC.J8!V@&Y]J7YQEM^VAV)YB!=1C/;6NO<]+/69HEKMU4NRLR 7"[BTPZ-\BD
M4?D\-M.7_AHWJR6.8 B_08K9!(H1C'A/-$;,8H$XSJ5]6CC$38C6)!VQ .@Y
M/>_<AI[;X]D6 @\^9(+M59+FC6/"-M[<\B1?LW&XP?,T&J9BB#G3,MD(JIL!
M&6-CQ@<OK-)*Q)"K6SJ@WF=XN(D.-5"1FIW0^[FP66NWSZY+CA2S*ZH:<I5%
MS]7W<O;&E+'(I^$(?X@=,"*<CS$6?^4MK875US_L226#M&"CBR H@J.0*,_"
M!JU%\I!X %EC<[@*WVYG\[^']'+6/LN*\F#2VO#5@<,K*^SYW4'(NN]^/!WJ
MW=EAUMY?J7WJ6P Y!Q&LS_/.62L/5<MIX]W]?LQ]-$/0MB^N3'57:;QC$P"!
M+H<W7G[ G9=S-OQOS7_6_KWQ?O-+[:1UUIN2DBDU'$=GF$FP798Y4/.$4/";
MMCRRGW7GI?<[WM_;7K/W]PGHXV&S_=5VF]EFREYX4LAX1,;[>TQZGYT-* @O
M 1.-0!J. 3%BB2#$!J)! DX*N7;R;"$@@$RR5=%$K\+!W];Z+PV-W"J!=3_3
M3Z5^9\H:MSQ;L>\NRL;K<NVW]_TOYQ2V=O:P '*&RL)-E>N^;^).3VN6),VH
MM5A+QUU@QDOLI=<J.*.XH@_1O@JU32V!?S36_9[03./<((AI%O,,.(>,8A0Y
MS#P')1U[@S-03@SQ92+[XY_W:EB/PI'[#G,]@K7>/.F;Z^.'69WRFSM%?P'W
MV>.&21&<1R[G,'/@)609TPCVF(#NX54TL:\['</A'/3%PFT5ZMG%1&'=Q[)N
MSEF72=.$@6&) Z,H48%<'CT?)5=2NIPSX2<*A[X+<:3GYA.US78ONQB_-WO5
M6-E^IF]_Z&PUW3AFPSMG$PYTH=Z9]['7 PBH1DWGSX'1!=I,K_K\2:?7:V9'
MZ,D!R!34.3O-:''6'GA(^RH47&8L*MN-P_G)U14?$N28IN2"!6&L YKD@A.O
MC;6<D=PUB&C&7=7_E9A'6O:3]/4W;+YO7\*U]Y0&U+&*(,\)&'0I 3QY:A %
M TDQ%H+U>*JZ_,<%7LH1/OX(/9.6@0"I\CJSSXXA+4#,<"N)R/VV2-1+J^W;
M#I@)'IF!:5,5T]X.15XS<5Y+%=M&N_8QNNZ9[5Z,<@A2LU6-]^[=EV!QY<6H
M,E[^SN&-*LFBPKZKPKC*%=#+@'UWYD&[=P*LD)KYGJ,YIU757._JLK]72G^U
M@HX_^AT$P;!B;O#"N>UV;?XN7/CDK.LSJ-^\R/*UBRS?O$C&_Q"KNI .[$</
M;.!\XZI'PO7KCE\F?^O6:D;W'/_2("-G\ML95N"MJN#OYB)6:MLC&KSO6);S
M#@\= 6-WN1[VRQN?Q\ .O=35_/;LI,[)3J= 7Y5,S?_V3[G*+(*7W$C*YL/J
M9\]7GX,[#B\Z\(+?2SSQQTD3'BLG_8^3'WLM;/7'];J'45%G1:3[@\*G@593
M Q0:?*+R^GV/[4S(54'VT$N\7%WGGNAIL^U;9R&?=.WVM8;QWWZ7@CCDOV.X
M>;4 8/4K%H2SS4'\D><G7Z1K^V4>S4YEH@^L]MY9%<[RXW5=[5BMI7,<ET>7
MN"H'NU+?^F18?:YV:G]DU@2B[\9</)+?OOK&H"CTQJO9\95=I' 1V+QNIO.J
M^4+?;=4;R_Z"MZM$NB907@]LP?&U?GB_L;6>W0V=OB?BVIM7M6P?AC>M)B_;
M7+62^O1?<6JV]5R_?J4JO[UQ,"NU;X/V#-6XY>.35K/BO(JQ,J_:$WC)5ZQY
M=?2C@#G@PC62L9,5SI>8OO?'  [S.0[:80QF6E>HW7' VM6Q]YYC4/M0N1K-
M:J]?K>GZW/8W/J/=7S36U_:L5XE1IU#@53_V0)'!CJ/$<=+."VZX?UUCV>W^
M?LZW/1W)\=N$F_G9#5-! "C.XMCL]0PS$W(V<PC']@93WWN+-F[=F!4MV*.F
MK8L5SNY^^[YIZ_>_)QB=_0QWLB*9GN4,][G.0G[86/;Z> ^BWLW68F]H/GT_
ME:LWDV'TT\S$7>A!V8!.Y $T\=/6<S>)I<P;+_/&9U))<#-5\S)V.P%4_5ON
MLC'=;:33?;FJZ=Y,?PTKO3?:#5C4UGEL?8_U'(9X^8F6_7Z7G<N=JBSZZT&^
M5WV]CG>./QYLKN_0S?70W-RJP[IW\.ZZY_4_;O2[/&P<UB_W<>/;1WBN^GG]
M\DL3KITK;GF#;HCZI<>-PR]'C<O]\VHB>7/0[W)M3\HDG>,!X9!R8293R#B7
MTS0#\2$:39)>6OT__TM30G]_)2/)7QC"TUE(?3KQZ5]?T]W9P-3]51738-5.
MM-VM\TZ!J*D@:F,<H@(F<(8"YSQ?B[@D#AEF<O1 Y'[E-"K%EU;Y,IW01NE>
M@'I!3>8!*^<'0.Q7J)BE3_A"0]9!-\8"6E.!5GT<M+R)&(Z/H!1LU0G0(!NS
M[TTR%V/5>2!G52R+"9U.%G8ZU$L"+5ZTII<-01\[9]V"0%,AT.=Q!+)1&"D<
M08J;E)-^([+61429]0Q;SRVI$(A/:+91U*89() H:M.;PZSF]Z(U38=9V^.8
ME8P2)AJ-G/(4<4ZS-THEA*54S-&D&.YK3=-B5M&:'L!\U9B*JAEMT9U>*@ZM
MY>,K4/0H*-H9AR+#/571>:2<%GFX;T+&$H:H$X+8H+3SN7<W7];FY>I/U;U5
MOZ_TXL)2Y]2VYACE'.1O,-BNT#G+Z1O#9RYAT)EM4!$'#VQI,X4L:,27/YWC
M>26 OV9 2ZTI2QHIX4-61CTRRH$$L#%IIT$(:%!&&5N66,\V,CH#AOJU@P3O
MSA <O)(7:!8HCW5CE"C=.WT]XP#&'ZI*4APD7U>]20$%SJIRA_C#QY/380E>
MU>WF-!?>'8R2OYN#4KW^;+N<+'[:/>MC7;/=[QD6>[UJ2D@_2]WG:HCQKP\Z
M"^;10"NU&RL;>V_0(&/0G*?6[[LS(>,R5]$-*_3T\G!V7FY !E=NVM;8/?*4
MJ^5!;OVPSRJ 9"?_W#P^ 8:L*A^&'Z_*R_.5[^WXNEP+9]WAU1ZQUJDZ 3XF
M(WI,=N@I3(GAKOT%F_:&6_[Y'YMYRIK5/DAJ0+UW"G$B#=+86Z2XBPHP7M&@
MJ_$#=[;YFV[27@HXD42-28)P9;D.(A*M!0_:1FY3/FAB!@=]NXJT'/2C#GJK
MOB<H5SQ(B5B(!'&O/1RTLXA&QV6D3#K'\D&SN_LY9OZ>YJP-)T(Z'S17(7<I
M<]3%'$LWBIED0JC.6@_/6I>SGDD3@_6U/4$$]580I*/+50_6@>&N)3*$*8*9
M#%:D?-9W]^[,73ISK55_"DT9>/73@5?J[H%7><$5&28=L.+8<18(UU8X*U7D
M(0C'M(]<[E%AEN8X)FLAM-J[,N"KC29RY=X>*;,HK,J%L8-IH1_^>Y9["G9.
M8^YLVJI&3"U.1=71$%O &MRAC4\[/QK?ZF#-?<:-]>T?8 '"-3]<;F[M'C7
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M7G2;.<#%> $)*"]1:X)L,J#;L"20450C(:6)VCAOA%E:-7SEMH>\Z#9%MUE
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M*OD <^Y:H--7N]\/<%\!5+/5JKD!1G4&>%;3%8"0Y9RI!/C2_\I!IQ4&H@:
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MDBE]C5^'K*+C#N'D(I-@]*,8<TD\91(9'P.*2GKOLOO(JZ55_A3SLL272QI
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M#EM+ I:OQ"87;LR@BKBP\B*R\NRCH(65G[^M8-^4(B0Z1[1%RAJ).!A4R,;
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M>XMS!L:T\ F!D:VP3QC'K#"2IU0(%6@LT%B@\8:?D3J<// 7(Z",^&B,T,P
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M-O9#R\)Y/AKOC\:E;%;$F7_EY+6;/,^Z/J,[S]AHX,UV'#,OEYL.:ZSM.NV
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MEG*/Q@<';Z@UU?CH)(U];;O^92N&2CH3'A0G$*D@1@1#'!5.V"Q4Y+(N3#P
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M4G1=..HNG+77,AD#E)?BFU0:1UE.#CAW/,K$JY?7422OHC7!2ZUQ^ @:<XJ
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M:V@TC/.\KW7;W$CV=$//6' ],1KS?)H?<.)1UQJ*R[-QL]38HKHEJ:W!KWF
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MB(4\-X"2<X=7-"U?*AK,Z%UO.!J,8_>]NF1(+?G<;WX0^Q3HLT<@*6[?YNT
M'QV_.24B$$&IRABC+*-!D4P;G&>6<XX"B&GD5,R10'B1X?\K;74MT;%HBYEZ
M]?;<3._*I:W;4H>VH1^-NM[MM1Y)7\-WJ:=QSQ<4G_K/QH70(!-BV\W4BW(X
M'*>&D_U0:T:;&JEFJ8MMT>+S"UQ@K1XF#!I[(4];T%:=E6?ZY,WV,DY5Z&+K
MRJ*/;IS#9SWH:-/I=D97\8I)Q\W8@3(UURWZO$[:%NO+RR[(W-B0+C4_.AYX
M/1P/KHJG&3_ZXGUQY0A6<*Y+[D(WSI(BTJ5UTDA=+CO#M"J1#GY9TMKSAO>M
M]XZN=1Y=TE6T778%M?VS7FHDNF%?T'BWONB#+BINKK<&]5\O?6^X<4?0Y4US
M:SV,RP4J:";V12W;%\Z^Q3S1+5^R@O'<.D(\]E!,KUP^+KZ>'17M4,W,&M:&
M&X[-T/_O.#:51;AU 1MT7C1B[?5'43H 3^GN7 O3^^D#6BF#:2O0*6*<*H?A
MF]1>]:AW%'NZONI?7 [\.>QBNBANSZ] @TT_T..#4^=\+F60F?$NGCH2D4F$
M9.94D(CI7!C/Y_M[[JX4/YYM-UQ*HL@.1>?A)1(DMGV.H,=-R Q^FM#9#7)I
ML5OI7'/2M70C3^MU3RU$12YNTT*4D#U%R;WTCKS=J-=-%LL]B6[7DO+'3U;M
M\7Q7%G;7YKI>9]8?V#_T?BY%;#=[<9X :ADN@2V/M"_G%+D,9X![4AX1>B4L
M'57%>>?RCMLIWL^ECZ>_8,2=36/&6RT<4LW"W6[AY)W$M]UE$T48Y(&\L?,M
MJJ=N@>\Y6;XSLGNP!S3MBYYV^Z+G&QRK2R%14,YXB3$52!@J-9-&$^6DIU0O
M];/,GJ]'ZQ;^FG>_K/*KO)\8U]'?%[TL1[T:S-D?=(:PSL5IPV_P?=_][,'"
M]L?ZZV,YB,=P_<4)/F$'QP=7AW^?Y(??_OIT\O>'[@=XW@D^B/]'#CZ^0Q]>
MS9_NG5P=_/+AXX>/G[X>?(/?/_Y.#O_^X_S#Q5\7)\<?/IY\B_]G83Y_??K/
MMW<S&6VY]I9ZD4GI0T9S+C)M",YPD#X/.E@?)&@8MG@,_V*;^J T\K"1A_<8
M921ID#&>TK!<QT0H@XG'"K&0>\2M,%$<(E6*P\4CR<4@Z$8*;H$4K"7@2]A,
M:F6&-9(9==IEBDJ5A=P8Y"5A)I!G+Q%]:EW?&E'8B,*%@$M&61X,(=A0P:3*
M"<-*.(>M"3[0) IE)0IE(PIW0136PKV(EEZ;@#.)#<HH4RS35.!,8!Q/6"E!
MQ#][279'%-ZMU_?AW!JO%B-F-O)L/)"+%R]=Z5T/95U2"A/,I@#"T4GIJ,9,
M2TRT5HX9 W84<FM8S(U<W"ZY.--Y/4BBM) FQKW:C!JNP%"F&DQF9C#*B;<N
M1JRK#3-W[@_L/6[.W,29A2WFB"H3E+%4P[\\1\9YC[11U@>RAO76.+.VET=K
M%4N\8UH[DB'J ;L@XP&[Y"*32JG J7!&1&?6^KZLACOOGSL5($HFI)2(P18A
M8AQ#EC)**,D!=*YC4#3<N;7<6;,LF#0<Q>88&AF24<)=+*,&?^58H.!R*70
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M_UKN:QCT+](BZ93*$7<]#E'<5*20 L7TX*>]UGX:?:X,'\[;,&0KEIRR<;.
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MZW3?AE._4&^B(>L[6MXR[ \2X\,>Q/T!85"(!)?DQA 8;@!#7L'38-GW80K
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MZ* ]XP)H7VNA%:(HCEVW]V;W/IW$SH*+B4%7$-P4J;5K>*M=0TWM.CR*CUN
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MQ3/NY>,^KWZ&*P^T[?J^&ZZXLOHY7=D#@.YFEN5Y^67\^89,H'^6-PYCW02
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M?YRG@22_(,?OF;'/LBO2R-S977Q]*1?,8L:!>V((>/YM?7;^>*&XH> R*B\
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M;?+YF4]0;\M"K@C=FNE]Y/>O&YI?[0S:C86-G3\H\??!?/5S3JW-27HKB8.
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MEC.WY<D7(0LX7-%T3_['#<.,3_N]E_[X.N_WG(TX*CH?'%@8R]#=";(8G&1
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M.;<;1WK@ZYF>JN%LX$GJ-U>L"S++C9O6UX.S7TLQNUG3X5LZ3,NDI][^P;8
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MNM>*CR9D$ *^JM&@* 4^4:9@4;>=A-P ]VJ85]^U3P=C>P8LSOOGSKSIY\3
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M,QXK1G FTDP($B>Q2%B"=?J@9]UN/(-TV\D<(C6>9W,X''_S.IOGW)[.3T&
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MKC]B\0?P$2[RS^E*?Z2C=-LL[?P5XE3\\YEPFS-/(GOW9IS-* ]=&A1/#8+
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MC'>W1F<\&(W@3 C"N5[_HE#3N*HY3Y4=G_ R6TV>4$'F Z%%PK13PX*?>[4
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MD.7?&?<<6?!TJ:#QY:&153)SB0<.L9F2>)XP^ZPC9V43==.I$.YHY!%@(-D
MEXN9!Q=VXF#"/#PBYG;CQ;3_3TPQ6UH[8H9O)[=P[*(T?PB%DH!F3G>H(</D
M.(,73(X)IV7Q=?T(M".VJ7H+C.M1N%+!%B^/#]*C8WQ=_.9RUQ_@4Z?HD_W;
MH+F#=:6-=R/>(;,K(6IWL[2FPEW_ 282K-8X)XE0^:(HON=X;\0IUI"-9@VD
M/T9J*U\\"PZXL2>A\S]1$OH0AMQ]B4)L7,@>".H;)1;E5K2,3Y#BRRB8_E?]
M'95B:>/=4(TIA=.&CH^J+KE-%>1U(2EPK8CUC0V/X$IK;NQ+FWED'P9_5;Z!
M<[!_<*@:'JA$Q/A*6#I<2(16=6'CG<ARK;OO15-U_@2 TI%#E8+Q[E:XQ&<^
M>&R4&7]"=)2#ZW_<EF)DV<!QA%P:<38MJ!"UG/#7Q7%SQ<&?]SH"S*^->:DA
M;\NF[D[B[/A(9Q&W)R"&H!MC3J:J:3R5*F^"HCQ5Y3_2 /"P)P#^)7VE'IO%
M,0JI-50EH4P[6L8%'9P:V<A]I"!:0 K[\0NL^9L^TO<I5"H;[V3\##*L8TXG
MF%XLM>FB(5]\A\$<0?SX/#[!.H)U_8"1UB!A"U>%I^2J4#OSU\YG8R5WGJKW
M^=/PDT@PR7.3>!;FT_#.I3*!31 4RP$P"H_3-%8QOB(R8Q#^4@B>?H MSAE"
MRSW4[BH[;[<F9WP@_K1M_PZFV],;]5[I-SC+33;@(%)NT:8>1Z#O'*]#ES3^
M]Z;@<U:X\-=GTU GL*GFWUBW=S[_/G'M2?6+B\.Y[^#K1]1Y]@/TJL3#R"OS
M7K&@P"=[.?D;F9_3=%#B//,1?Z3_BD!@#4(T%'"*[;\?G1/_ATSC:*Q5FPJ6
M</0Y)R*0:CJ#D\#R9>U\GA=)LDV+..#EC&39#5!$5PLG8.5D^G]F&S9ACX:.
MN#:>NETO@MF62+X'C"4@\IA.U=JFP]ZD1\Q<R_U" 4?T6VQ_7JTDMK&'TN5X
MBNK$4DJ/=;<B9?PPDYKC8T?#@8-^*<3^ <@!<-_=<(*68)AGS+^./"]>U"+]
M@,2!L15%TSZ,N;\3AB.W>O95BX1Q] <>'+1]$KLLIZYN<,W$2^=MTRO>\HH;
MN^0KGH?2>4IJ@]V3;/9*^1R3O'%JA^AZ&N3/VS6\>2&IMZ']7?\KGXK'I(]G
MO EGH\*#0\UO\!PII^94)F1<+MZQ5\)#-SB'>X4]N1^ET?X#6Z[A5*MKO(NY
M>Y/0+3Y-2'CU/@,)D"2&Q%QX<+@]V.\?2<X]^H2,=_Z6^6/T.,5HPB0GS3=\
M1T,AUEBIJO$._IFF*5S5FV,H*[1F4W536>J;)=6GQH.0&A2,S\7E/3(/W\4U
ME"^>P0C.E'"+ @A9-)[D2&8;;OUQ=(TL-O2XDUL_BA*HD)/GZMT6,2J.]M.)
MN@0WX7CRVWS&X2PE$=;+I8ROA0J7C8(<N_&%&BT^+8KT=[E@+ C+3,/2TB'N
M8YEO[,4/S6I.EO\:T["YB<$-$PL$;V3&\6$75%9.W%G]?4F3C&'/^(6M0I(_
M'8I>H:^!QN:C2='X E0)T4[ML/?^,R#,0Z LK.Z)=]0ZHL!561B>/+@CI-M
MZBQ&/ QB6_ I:XCY4JR_J4<US$S*EC*3IA':C]2G;\2+$ZTT1)-HD#"> "+S
MF5[RE;:+<(5X1H^%O]SY6IG0QNX;U^X[=>2ZPN5B&WJ.+#F9R#(T-%0P+LU3
M!V$\TB]X=2_E#Y4H[;7)&.]X32KA-)],4=.HFXZXFH9QR:2RJZ9/(CKG'O4=
MZ@Q#N/FA]OZQZ=G%-5 VO$W?,?\9KVM>A(:UOY,9D>HH:RL8G]J__?[P>'][
M,[0)'[G>'VSJONBYF&H0,-[9NLB<1S8G'NJS<$8FPHB,]2-\:ND8GK%99$>-
ME32WEDOWIU:DC ,_Z'TZ."HGKY4DY)#5,MZMW-@CKGWUQA[92STM"!GO?$V2
MPBSC>ZL4AZ7:QKN9N3C4/K4G>X5)G8#QSFIIEL6D373+V+&/T%[+>&SHM:/\
M'I7P%H.#R$4I$:0T1EN;DO%I))KXB$(L4DIFO%S4> >RM'1IRH]<.0RS]ALZ
M^DV(_T3]9#'?C[[B TI/G#@T=R:1>8VM@;[QBTKM9;)\(,%_6MY,FXD9GRZ+
MIJ1'ZM#8#?A!- '?4&11F+@0L]$W\H-^GS"/QL[AC>K$%:B:?SLHS2:/>O'J
M)Y8EF@H- L;G0&4:'?P/M/9W&F+$%EI0\,51-Q"+G3J2"; *R4U5,:>02KRC
M^B=J,T.9C/'YD3TX'LNN6L$F.J/X=KD.*>,#4$BZ(S\D5A?^J&N\<-[6UHW+
MCOU598VC<!=A;%&DX-A7+FB\\?CTRA0:X'QG'%WL;4F00GUYXUU1R]$B49!H
M$C'>Z318X@+W* XWEB3+7N &WPC_04/Q9N:0>;*$T6HDC!^.$Q^^]%W5@>^4
MWEF57(]T*!B']]=HZG)R[K+ G<(5GP\P 32'*XYP#8\]@B7]U2)AO,/+QL+R
MRU%-IL6->35*N+@TQZ/+XH T*!CO;FX8N!_=T20C+S3RFK-I=B&_92(D]SX*
MT8 /4 %PKBT^;7(!60OM=:<8U#-6B$-7*2[VZAU_I6E2CN;<-O+:&QN8G+F)
M+J9M1F_NA7=<03"7);&V+^HZF&R"?VIZ(T$Y4'T1DX7-J!/8*/DAU'*I^E))
M*BS5V!3+9)SR7N/H*:]H'*A$=RYR.#_2,.(^YI[BKS11G=>;**05-U6]\C%.
MS[$[WY_M:IUQW5A?N3\QTB<S?FU"V%&A,9NZ$!()F^;MR'U$,/2C(3JXL99Y
ME7IQ)XE7FU!N>,X;G"07MA8\<2KFP%^-J.$=[ %#7F1O&"P6,KXQY3$%U8:-
M0CR!/!-'2V+&!T$T-6XW#^>83R1N]_#-#6"B@9 X9[Y3_2":/+O<NJ@;'Z;%
M%!O5#B2R^$D=$G]>AW_>@_X&<!>:DE_^\K]02P,$%     @ &IM(4G";'LHO
M.@  97@" !4   !A;6=N+3(P,C Q,C,Q7V-A;"YX;6SM?=MV6SF2Y7M_14[V
MZZ 2]TNMKIZEM--9GG':;MO9-?W$A4O XA1%>@Y)V:ZOGP!)W46)Y &HHYQ:
M7>V41 G8$;$!1 "!P+_]CV]GDQ_.H9N/9].__,C^1'_\ :9QEL;3SW_Y\?=/
MKXC]\7_\^[_\R[_]-T+^]\\?WOSP<A:79S!=_/"B [^ ],/7\>+TA[\EF/_]
MA]S-SG[XVZS[^_C<$_+OJS]Z,?ORO1M_/EW\P"EGMS_M_@PT>L%L)L):220'
M3;R6D5AC7)*:)R/\?__\9Z,L-48*HB5/1$9+B4W"$FHXIV"3#3&M&IV,IW__
M<_DG^#G\@,)-YZMO__+CZ6+QY<\__?3UZ]<_?0O=Y$^S[O-/G%+QT\5O_[CY
M]6]W?O^K6/TV<\[]M/KT\E?GX_M^$9ME/_WOW]Y\C*=PYLEX.E_X:2P=S,=_
MGJ]^^&86_6*E\T=Q_;#U-\IWY.+72/D189P(]J=O\_3CO__+#S^LU='-)O !
M\@_EO[]_>'VC2W_V&:9_BK.SG\JG/[V8(1>^^,\%Z^IO%]^_P%]^G(_/ODPN
M?W;:0?[+C_B74^R34\;7/?[KU1__=-5Y]).XG*QD?8/?;YHHG1V  [XM8)H@
M7>]@+^FF\]EDG IQ/R[PW\+D^2R_1L:?'2CR@RU6T,/NB"^54SJ]Z'8RBS=^
M:5)X-^LN_G+B TQ6/QTMY^2S]U]&;V&Q;OW-;#X?>4I=ILP3T-X1*:DFEEK\
M5N7,;-"),7]321MA5DS-?AY6=-TT_E-1WD\P6<PO?K)2)Z%LP]I_O1?%6H^'
MBW35TBN<HE"GB_%TB3/<NR_0K2PR_QGRK(/U[WWRWV#^VW@ZZ\:+[Z^G"^A@
MOCB9IINM_/)_E_CQ;[ XG>$GY_@K*].,K%$:BL)\<)Q(#XG@_T>20/C 1- Q
MA!8*.Z*,-\UQC=@G7?QAUB7H<"7Y\8>O4.;]S:*R%MAW\0[C;TYIF]_X:;X\
M.UNU2<9(^HN_+RM,+;8N9L^#)&N2HU[JC ($_LNW+S"=P\\PA3Q>C"Q-W'.M
M2):@B-21$J=3(-$[Q;,0.D1HQ]@[>'9A%[]B%WE6].JG_<I4. [7#3.&.BJ)
MB@8]/&8Y<1D%%,EHXSV$2.D?:D+<WQP;2-//U[@6!!6<)49 *$$D>I3$&9PG
MA.0A!>TI5ZR%VN[!,J3Y?JC,O3W<^YJTXE!?2[V9=EY"6(S 2YN5,20SFC'H
M4CB/:4$)N-5$)I,#V69(WL$RJ-G^N9"KKTVKD>OM;#J[2?0-I)$,V5"C.*%
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MJHXR)SX \CF<LC:?%6L9L1W-UO=!?X/%Z2RMU;'Z?&1R!$L#13C9E9(5#J-
M##DQ^HM:*6.I;3/U[0CP.1S -J=7#>.UH]9OOOL[K%X0O3:Y:F>B3%JB-^ 5
MD39[@G%-( SU;H-@U+&F5Q8>1/<<#F6;DZJWV>H]/8#BWZII^0%E[\9Q 6E3
M\_+F#Z[]YGOHQF54W-[XVI3J^>5;//73S_#!+^"7G"%B)$29DJ5*CW*EEID/
MEJ!K&DB"F#EWU&76YC6#HXIYQ)1]K[2/DB8B@BZ%Y[,FC@I-LC Y&Z4R=4W6
MD$-3]I_X3?'ALOV>'/D6''B*W>2D'8>L+'*(^Z(&33QED0B?N **Z)L];7_0
M;O(3OTS^[#G:EP.M.7KO-;"(RWO.DAA/5Z]#.>+!XY RN"@S81)W3<*]0TM_
M/&WZ_O/G:%\.M*O=];'8H/L^R_/QY^DXCZ.?+OPZ6P;A?IE-QJLWF&[@V*W$
MSXXM]Z[S<X@$/4LB[=;E^^;*>W]D)=XOT5&4^=9WQ1,YQQ&\\.-)0Z7>Z>E(
MRGU8PIY*7D6"FU<*#U'=C;_OK9#M:"J*^:D$O+V%W;125>3[D%44O,90>;"]
MJLHX&NW?+> ?$U]))S<;JZJ0!W#VK%&WRDR[V,#VFUUK7]*J_57_ZS3KRT^G
MUU]@PM]=GD&:0CEDC@'G,$4$+P5MK57$::#$\0@@C98QT<<46A%/K[S)QR"@
M]X8.Z@0YBA[C KW%,8Y??P/7B!H)TF5#="Q57U,*) !J1F@JDJ0RN?@HP6J!
M&<(>R%-Q[486YK$-6R>-]S'4E\\U7&+4(ADC7";&15H>CP7$:#G)CE$M373)
MB"KDN]/U$+8RG@75^AGM.,2ZN(=\+4%Y%:@&PX24ED#V#H$*@3I1@60?>,I.
M>G%[0^U =MW?_R"2<9X%QRK8[[A$6]]O'QF0B@GARRM3.,5&G8C+'HA3*@EG
MN,MJM^L(^_4[B&)YSXI8!]CK.(2ZNEQQ33.KE-R1R")KCTIAQG BA<)I-I7R
M:Q%,CM)1+505<FW',(C$F6=!M$IV;+==>CU0._G\N8//?@&ETO@XK4[*9M/R
M3DRE(//Q#JH&GGO*4ZE@^@4E7LS.PGBZZO)&_Y\Z/YVOIQ\VLL'%I#A#^XOR
MCQ?$2TZ)4B):3ATUOLGY\SX@&^8-_MJ5"F;6>,^E4R25E$;)A"56X'IN CJ.
MFFO0H4F=L,> #2'L;,ZJ/1($][=6W<7RFNRO_+A;/1D[RZB&LNN,F&\HY*3K
MRC'8.J=V\^A54>OU"6($L<3".A,.I;*,S!Q#%G0LHTB,12X4NWTK^9&UM#K$
M(<2C1^/@@*Q=[1#]'G$^+N#+-6#K%,G7TP5T,%^4&]BK<8<K^!GX^;);2;4J
M]0@@$I>LY+0Q3R3X\C)BMD2GY"DX98(YUFIQJ R#"'Z//JD^%0E:LGB;IJXR
M$;:(]%>8I/?=>-9]FEUKCHT2-\!DD8F5IYI-4"1@F$]0YRY+J[Q^<E_H4-F.
MJ'XV,AQC5B. 4 JEJA7EQ N#T44PB3-03K6YCG:X3_EL7*NC<'N'R:..\0>P
MQEVN[&SD&=?"8A2L:::DZ(38'-&O3-[@/$M=;O,^<@WPS]1+&PJ=VY*EW>;)
M!SB'Z?*PG(S+O^V]Y7$_BIZ)!A>-'IYT<JN%:F(V2#:Y:+I&HLG6MJHIH&F"
MR44G+Y;SQ>RL/-@ZC>AY;K;.NEE:QD6YC#JOH**=^ZBFNL.DZIL/6)[M":6*
M=KQ>3OR0?+_[6^J?S[<#PB9*.'QV>;"]1@II,/-LZ0A;7?I)G\S07=IMI:8'
MT#=15RE./YM>>T@VW"Y9OZDD75VA>_?<2.7]-% C"V_5ZYVG C:]7C[O#4YH
MYV-).T*/3?(@RAL"G)2R031882&;QRRQ>W>-GJ4HEQR4SD"L84 D5998Q1()
M+ DN.!C'58M Y?!G*8Z2&U>? 3L^1[&//:J%O+_@I#'[#O 1NO-Q>5S]/F@H
M\,\PA3Q>E'(?]ZAEI%-D$K0A((S#0"IJ8CU*D63FJ934!-GD0F\=^(-X'?9(
MY'L"@S>\)'7O*G)YK>/#Q]_[^/=[M-YH/7Q<DB:.R"-@5A^_^[(ZC*JOWOW[
M;J7\GEIH8YKC&.$IU/VTBOW;:G*'Y,^A\Y_AI"15-=+NXUTU4O&>,O;4\TM<
M/Z8%P'31C<.R]/-EX@_:,-C65&\][82QC1YZT.J1%EMII05)UO79%Z4^^R&:
MN/[GO<7>BJ6>C(=O%-UMI*:\#;:$KK6^_O)GR+,.KA7D[S$"=F^\II;VD:.>
M]E8U"^8E$6C65=?>(XW7U-X^<E3*8;WL9A.V;(*:4<I*."D<\;Q$+\PQ$F(T
M1 F:C- L<-=DZV,+GM[5N]:IV5NE99P9 4"\BI;($$I6.)/XK8K91:X\:_(J
MU\.PAK#A4Y,GMP/MBD9I]_CH+5 !+.7EO1WCR_,[W#KB M5$6B-D<#X!-'E
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MA E"FLA#:)(&]1"H6L'&S59_G<W2U_%D@G/LZ\L*;6M;W/Y^Y V'1"TGP@I
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M>2EAG*56S-.G4,]CL)^E2[(/$_=;*ZI:N<Z-B%T!G^0%=(CWTVDW6WX^Q?_
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M"M,Y+M?KM+TWL_G\$W:\]).JNCVLZP::KZ"#ZG;Y ''BY_-Q'L>5@//9<M&
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M/$/MB3?I!2-# ID1-NMH%!31XC[M]CM/'M>M!;@$R9VNSVIL>O#;A]'P^B)
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M& :OAQD__P=^Z8FLI./$;C A,&V(>S ^,:ZB32",Y-ZVVQ_NOOSD@=]=I$M
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M3EKU3XEGS-<=3ZZIJN-E:_-6ZP+YMH5(\\YGELF_34[E;')'XWN6D7,.FM%
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M/MX%N)L<3KL@L]*'[KZV_&&XIVDA[B:OVE\]Z/JENL;+&*,B/>%:6UO[?;E
M.XY71>L(N$%Q:)>UNS4#^N?!Z(^=:]*7/[2S;@#+R;Y?HVYCL2A0ABRUC-*#
ML-HD! M* IC5/0"6,;"!M-]=75["^,NH3/H7PWXAW(932&ET59OL7WRD5Z8^
M;B7R-9^\J]RW8>">\).)2600B3P^30X[E."S#]FE N@A]S9GI3D"OW6.Q&_[
M160Y0_>0X0XBQVRL@J*5MQ$=><0IA)B"-"C71&89:\T1^A7&\\EXK^H-T:!#
MI!Z\:3^(/<[@_0T-R #0UN7ZGQ*UM]PFS9'L \%#46LB]^"=NU9(_O'BZSM^
M&X^&]-<TWTK?C%]^@.$%OA[>_D1_F/J$VR]?$QLLYR);E9B89:D+2,RC5<SR
M4N\#(&O=26;.SI3O7%RZZ"+Z=4[8NWFJQ*3G/<?B!+ <O:YUC\@"!\Y"#$YX
M88*0G8S064G1_F\0]ZM7#\I0FT#3,,A5-[;>.QC@Y!76SE1U1,^;(7$]&B^2
M.V<_N\+WHVOA_#29]B_)K.F!U^"\\BRE%.K-6B1JN64R%4[6$#I=Q%/;Z [O
M_U9T9U\0-;P\N"'Y+4ZOQG5N\:=^O6V9O*@-_A-)#"[P35FT0YM]L@>BI(C%
M,DR\EM7FS$+BP%QT'D/A@@R,]=5I_1=_>WK4$2A=!,OR)QQ/B<KAQ?7$.X_U
MG;P.^ZH3[\#2'EGKL(4VN61(V6%'92OW2?E6%*<1& UC8C-5?HN?<'B%O\&7
M*H 79'T2^[.X#XXO>[4%NXZN,,PI,1W0,)]59E(A+ZJX%.Y/'UVQFSSZFF]%
M!1H+O(.&"%\MJE]JZ<(O?8C]04U<-S[4;NS$J"]UBAB6.B4P,66%P6*0_NPD
M/6\%/=^*PK2$I<L1U3.RWM8A#&_*[Q-\,9G@M,>UU0Y49*H@J;)*AD67/3,^
M<1.,-BIT.ZQZ&57?MN;L E$GTQ^W$\T\)2&9X$H )+I+;3_D,XNT:S)AN=40
MK/>ED\2>G:C>5XG*@1WTO0%[Z *8&D9\6_F9M[ /(8M2-#.(FFE'T@,/G%FT
M,@E?A/#K;'EK16Z_OO50&4)[!'FTJ[ ;A_1G1"QBPNN0T3HUZ-;[]Y__LR4"
M]S'<07P=HNG)FDI<D\!-KG5\"ADDL$P:VO( #2HI3@;%1W)RVH*XB=0:@_<W
MDM3EU>6"$)>+4X*V$0?$@M;D.8&KQU=T&)3B7D"S;*L[;]YO7LS6LA^U$%S#
MB_,9(?#Y-B'1\UPKU#' ;'Q#[80 AA53-+I8B*%UJC[60_#VFT\0P:T%UT$]
MQJV^03^/QH_8!K--1Y4B>?*262/BHGK N,!XH0TH>I,3]]U</VY Y;=C6'4/
M8@>WVN_I<S>Y>HM5L Y-7=87+R/J,.7%'6(YZ@B(#K:EI;0%$ 6$X$RJ;)D.
M+C(?16'1IDHUJ"C6,?*.6#F>J#4^L&YL(O\NCJJOS+ZKK5Y@G">_?ZR)AI+3
M)BD71'(>HA26[.*8R"ZFTY/.TU2#,O03LH:*R9THR5K4[?\:<W<@'Y:,-49A
M#QG7+]*\QV&-]VZ3[W;GW^^:Q;::F'NY:<*%&)/SB1:K1J&#E2ZA\V09QD!?
M]%:1M:5D9H;(SO)9/*6EE)81=G^.4U%U4^/.!:^EUUXCB.23)BU,6L7>XR1N
M*;$6N92//J^E%#?+B]12Z1"MQ)*T$QH<.!TP!Z&%C%SU'GWR;AO]CU>3_A G
MDUNON+G?%MHAYB@8MU(RG6*N?4@CL^@R-]Q)W\VXB,>(VBF2_^+CQ_'H$^:_
MP?B?.)WTHA.E<&F8I-5/#!K#(&1D7"=AT-.V+>)3.K7LP?L_>YKA>"<0OXN\
M.FB0,6-NC/GG*D[\A19!?CVDD_&B3WO,+%PWN3?G_O<)EJO!+_V"/6XR*F<R
M0Y! )IJS#)0#ENO&993CJ#MI>[ +T6>@1WO'KG5VX5W"!Y7PI\A-1&U*Q3()
MM7MDT8'YHH"9[!3]3CK<5[55V\K&[SX#C=F'U#NX:[F6P\O19>P/9WV0:X%6
M/\^R"T;#]V,83@J.B2G1\R)P[Q%9,8J\ IL$\RD!2P!&6E!!=#/E;Q,BST"5
M.L>F@YE-MS3^_@9YO2A$#Y(-110ZB(O,Y/,1H3Y8VA^#<+0=%L=5)Y[W.L2=
MD=XTQZ*#?,0ES-].LO[[J-X?$/4XQLD-V;V@I$K>"D;':C7E>&)>)611@\X$
M6C'0Z0ZT&;EGI%-[P*N#/,9Y+???</IA1$OA$\ZO1M_\,<3QY$/_XPT'/2#>
MZVQZ)@P)2 OK67 QL! XB)2+L&&=^/*6;2K7H/",=*D;5#I(8UQR +^;XL=;
M IFS<JWW-7@W4WR\Q8.D\Q>L)^VG+97I3.3[#)E)[X.L+2QRVI?1M#'Q9Z1T
M>\>R@\E.V_/P%B\1)E?C6?#GKP3$F_%LTJ>7Z+2/B>E8752=%0O%!J:@R""R
M->29')=RKN#D65,;H=S!9*9%14P=.S4G])I#G/QU7.F36BN!2 01)4PK)UET
MA?1&@]<Y.2RZD\/W*<+.2*F:8M!P\M'LVF2)QO\,_?%LO,FHD,];C4NB_H[W
M>ZO :G+=T+8*]';8H>><\K7["0,(Q)7UFL4(B:')PN9L.*A[30Y6W&EU1N(9
MZ-@18=C%X*0EG"UFW_T/.=B9:.^7/CQPL5\,\W4]5Q\G]+.K2\RUR1']H&[@
MGV PZVP0M2 G*1A6.YTQ75O!@Z._%04"I5*T9>_+/FS(UAFH]1'BW\7XII;L
MW5PW37K @U$!@25C/-,!/(L)(@M):>4=A\CW95JVX.=9H9LBOD23NXAE;,W7
M*YQ?K+^'S[=^V#.($:1W9"5I.HN@AI)3D<P$2+Y$*VPTQZ[4RUE[UN^N]&")
MJN_6V6%+_F 9?[.F[O//W>9/""R0'#!53,T,]4#BYYZY",%$X:WE:EN[N3&M
M9Z"XQXCJ$JW=.>CSU]$H_]$?#'J><UE,O8%P%ICV1 B=#YE!MC(Z+WG)NHMM
M])J ,]"9G62Z!-R=8RU+]/=K"Z4ZA;F,QI>S[[ZNLH;!39KP;(S$QP%.\29]
M_;9=(5-(MKC(HB"30BL,+'I76'9>&0<H0EFG;7:+0[<-1V>D?L>!^A)]WCKX
MLVHSWH&M%4:$RN"LKHF(09 1P95AD;['I.!@A=+<J2=S@_=&[1GH['$BNT1W
MMPX4=<CA2_K=GTYZJ&K>-SK&>2U%K.WR 92K@X^M)<<O1JT/J+0+,I^UM366
M2]1TZ\#0C+7Y9(:O4Z1H!;V%*5:3=YAH'<VXNF[4F7\<S$H/:K_X*WKFE_K1
M7@Q&.V* \9HPJ;$XYI-SS$@OI#1"*+F>*NY,RKFHVWXQ6:)26\>1KN7R+GW
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M92_C1+< ^F24N&0UFS>5,7M:XNA8,  L"2\#]\5R?Y@&;$>CO!LU83T^W=T
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MH&*3!0&6*>ZJ6UP4\[SX6CV/UJT8LHM-W(->* \.C=\YQ*LX7U8K&/&2LI(
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MSC[7V+*- Y@;0:R[F!:AR*:-+  DILD!)Z]<UH:V -P'B'HS>G-G _DNX[U
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M7M"XB$U\XU/>M5U?3/^&BX_3?#OZ'U]7O@N]0XF^APL<D0%K$Y>)<55J6]%
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M!S@#B99E6N2D-0%T:)*O^C2T0P]I=XYP-_91.TN+D6(FZMIW1&@&7CEF KU
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MV1JFZ=T)Y-I@R>G(_-D!]:4Q:@B--2A#^KA01C+2*^"<9M+61EM<<18%5TR
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MDBC:])7>!N9426 '*WC+"G&0H%O4N]O M,XAZH"J98+7=EBGR>DZ7&U/\.
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M+;AP!)<UQ5%H0N#6"\PC)(!/@LYF.-WW%^U)T]F@\D)'%. 2$^054ZSMH[.
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MZA24\(F<R%+[>(*IV;^<P?(<I$Z,Q8[C/[<^XLP4NI_H6K^A#^]]M0G&R!1
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M3%G0+CB4=)R@;.*P]@$YUMWYJ+FC9EHZ]CW[O6'?WC']NI907MXU96<<-]Y
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MWT?43>@V5KA>3_Y9SN6YNY"X$$$[;4A+0A@.*A#(R%,$B^0-5%IV;IHTG^W
M=$Z&<)C FY9PWX3MW*J@LLI@7*Y,,-91V%X4,%LT!?$F!6P\5N-(7(-#:[J_
M.$^%_:]_DF@93<1DC?:8 1.+%$TD#4%9LF:!4N4H. 448_4A/0WW^!FX/0SD
M8!;+WHIJU_?\$-9J]EL'8".TQ#]&=CJM14.K=W.+]$"Z&=5XO-"F!&<@+>E@
MZ?4!BOXD:.6=BCFDF)OD^4<VFCUZC8YF,WU4TL!6'G)6$\#;O(#.*B W" 89
M@<HN@TO!UETW\^*R<+%)6]I&-$=KF3Y46[.A1=TTS-G0=Q>#3?4:%'P4H<[^
MK&5YA=&NG(MRT425FFP7I]TUW<8GV4OH38@!=U3>=\'VL[5Y/U7VZ5O=1P]C
MMS8K[KBO#36151Z0(@5XG24XJ^I8*<:]:YP.? ZMS<U,I(_XARY\?M1T][CC
MUM6&*PL:Z:A3MGI1R KPS&)&39#+6D':EOKGIYYT8IU+O90R:R71 =V(Q?SJ
MXJ[;<MFJSQP:6WNIM:05QIS RV+ Z%"+7;0-G2(,^MP';SS]:?UM7W_P<W8+
M#A+B@%V)JWNBBQ>7E[=X)KBZ>>R":?O1OU@)?('I__HT^^O_7CWK1LNK/ZUK
M>1>B<<_[PW0T:R3@ 3?NG=B\"I$7%4@_M2O'8P#'ZL BF6Q41@NI-W0V/!NE
M;SG V^N\CUQ;Z/K7/S]<" H\2U*>,#!& 2B%M+YN6SJ47&0RV6\:67.H;NG)
MXYW-P^E@7:E]!3C@T7N'X=5_O;YP":,INH T9)2JI @QUXF( H4WSK D-O";
M':I$>O(Y*+&O %N\B?]Z^?ZB-K.5)$VM 3:5C"!"\-P"-SQY%;5QKH$2Z<GG
MH,2^ APP=7*'X<^/OUQDLABN2YVEK.F,,"6"R\Q#<H+'J!5SJL%124\^!R7V
M%6 #+NH-)/\YAV2=K -#.>T-SAIPAE88HG>VF)"";\0K>WIC5H9(?AXDX"9L
MCEN8_;O@^J%GH?127-?Q%_M(?<Q9*"QY'QTJ<+'2:R=A(10;(5G)4#FN>6[$
MV7C:LU":&$,?81][%HK+,G-'3J.T6,>.2071)@D8+8N.@@'%NS%T/-]9*+W4
M=<@LE#ZR'C#H6F(EC$NL?_Q-^+YMP4JK^./S['H1IOGF[]U36-!K8GV)&;0W
M='KR)(!\FPPYV\PQE.!]-Q*G X&<@]V,J8NA]Y?_'^<W1O]Z-K_Z5E=R _WC
MWY/%XO4\3-/+V31O7@#9Q5UG,4;T+$K@P3M0T2)MN5J =TSQPNAW_61?Q(!X
MSL&JCJ"9 >/1NPVUPYOP<?+/:D>5W$EC.#"&A7944^H$JP@V!Y2,)5V$[7QZ
M]7GR.1A,4VD/33RYW"67UDU?+$W]!OK[V?4T?[S".?VK3_=GKC!W=XQ6!L$M
M8"";5J6.566U HK36H*/GJ=N_LV> ,[!4,:0_=!,E*]GU_,G8*[<,E.8Y3K1
M<5H4P91DT5'1CN=(+D&AR?07NIE(YV>>A56TD?!6SLG&+9N_EH+I:FGI\_KI
ML_+G=([A<O(?S*LZVZ&;./L\LTE;Y]Z+7FOT-(C<>^6B2T()PZ-T*<3L4I(I
M<ZTW-WKV>7K#SI<W=PU"WAH*P\B3EM%XLM.8P!E)&Y;&8%PP184F9'C=X!W,
MV7_U&>>O9E^^SO%SS9C4IU4&F,="?S>]1[1X,9\LZBRFZ]H&3B_\9)9?8IG-
M\8_PSX4/5DB=''#!^4UQD,O)@)<V2\SH>9NNL@9K.6;9U6!6^6B6P)%U/E+U
M=R.J(UN$TU%:6BG]IHRVM,A<YX2A5 D9C[EQYW3K)8[?CMG,U$_4+IYY\Z?4
MLJAB& 11?7AM(OA$+KT/V06G7"E^_"/QA)L_3\OVANDK[6,#H[8&=@'VLZ]T
M4/5V[A'<1S>C&D\N%+_8.O.U#GZEV$6 YQG!TB%C1*3XMPV7Z%GTE;:QF3XJ
M&:VOE*?"1>0:9#(.%+<(CEL%RV87%X*7J<D8UI/O*^VEK4Y]I7U$/79?J;%)
M1$O+0UG+ASQ/M5FE3@E@7J@Z1[A->_%I]Y4^.W=G+WV.W;+:!=O/EM7]5-FG
M'W$?/8S=LIIBDB)9#EY5CFZ#E:.;-D[K35*Z1,5$8UZOY]"RVLQ$^HB_!6_O
MS?#(7_])G\/TTQW U06<P82<U(>ZE'I"(P1M!-!66JPHB3;0)D7 .U&=6'MK
M+P4^GLT[D/2'+O=ZLO<V>&W)=R]0JLNFLJBC"&, I5S@.0>9TEIJ\SRZF?=1
M]_ 2';HJZW9(]$/^P35CU(RLK;8)E6)-G2,L*KH$B1F+@LOBD^BD[R<?=2X*
M'U:F6UW(QM?:U1?'_(#;.4SSJ^LOUY?+OWA#6WI[QSKT[?8>CVYRR7VH"-;N
MNEU.7GC.%,^B#MQQW&C&F+5%VX0Z;K[KW@-$ [9C[8LS@?8DG3D9;##D!3D#
MWECEBI$ZJN?"=OR]/+_=L9@OOW^1"^: 14&4A?;B:&BA/FKP406?M#-%-AD>
MM1/5B=#=]K"!39F[883>('NS$]S]J_;;-,TQ+/ 7O/GOA9080V %,-816JI2
MR1=AP?F20Z"SPK4A_]\3[YE;T4"*&MK!6L/\RV11KVDGTVO,:V\!\E"43 5B
M40Y4\0X<A9[@+.<E6L[(X^CD:'5^Y/.UB(:B;9"RZPQTAPT[3)D'CQ0DU#U2
MU[(9S@)DKJ05-@K<1%PQ^&:S#_;G:V;'4F"33N_OFYJ%4LFRDD (H6Z#3I8D
M&*<+1\.TLKRM1W=\5O<#+.(0<9Y*8<_N45!12I^"RN"]JM/ZZ+PD>Z4%RB1C
MR-F[V,2[.?$IB7NHN]<HPSYB?Y;CW+HL\.<HPX%'&?:RJM'GNNUC$L_2]K,V
M'!DJR"87\D.=@H L@A7"&$3O=6Z21GFF-G_0*,/3-OD^EC!T2/IP--[-O<35
M[^'J>GZ[S&6&FK HI9P&ZPH=<*I0R&QU!,E$UC'Q$(ON%(QV>-@YCB[LI=]9
M0^4TR)=M&*TH@N')53J!9.LT>884:OL(3#OD1F=#D4Z+C>W'F(.YCS$-I*RM
M>T_CVZ>/UU^^A/FW6;FI_@K3?#M@_BY\&_K2J?L3F]PU[;G@M2LFZP-ZJ9R@
MTTT976J:4W N$U-,"ETV7S%U?W:#FZ62I91% (8Z$<0B!>&.#NP4Z?0V+GJN
M&E<A#7:S] '_PNDUOJ8=8G7?^]^3J\^OKA=7)-4Y"??R.M-.\&*Q0/J5:TL<
M*RYIZ0V8F ,HQQ7$[!"TD#%+6Z*R36K)]\!Z(FF\'O:ROA>V5E"#L_;M;#K[
MBG,2PO33S=MY^VI>.,T8YYJ6+[,#A3Z#LTP!,W3^>^4=^B8)O*V(GK]]#"/L
M!I'IJI3D%DX]RR]R*3E;GR#'.LV:[!$<]XK"'1VJ7RA-;+)S;,#R_#5_J( ;
M7!J]6E8&_C;=U'!]<Q]1E_W;]/L+"'X1:RM$,1RTK,6#TL@ZN(T#.7TB"^Z+
M5TWRMGOB??ZV,X:B&EP([8+]'=3E9GCG*_(+EFVACV,0O3"@0J7#%9H!P74Y
M2Y%,FU%'^P(^;PL;3%5-J(:_OS5Q3AEO=2'GR2J2 ?E2SKL"I:0H&%IC@VWK
MZQ__SO$ ,SA$G,>^<ZS31=[/9_DZ7;V;?\3Y7Y.$RS0MTUD9E1"<(JDH3B;J
M-.?@LM,R*A<3[S(CNM,(I4T 3N5&L9<R9P,*=4!W]0&>Q8MIOD6TRF)U =7C
MXJ^/QA^C&7^>TN&*>JSU@:0\F@D(3^&2%81&Z 1*B0#>A0@RQ:R"Y$6LE[@]
M&]7OF*HTDN;["+=!C'H+;,7XJ:V63$G:OV2MN"/=Q,@S>(&)H2K&K;,^#W/4
M?X=B/,]O0,W,AA)K@VS4!TSU6F)2)C<]V.^NK]Z5%RG=5+UAWD8:MK1XC+1,
MHPT$YNH)ES($IVD5.A34KH20FE0P'@+Z.7L'HRNM01)D7^RW+UX7]"UKC0Z#
M?YQ"HO',92 [/4#7#8[! U>1F4=6Y]DZ70@[DP&BID/#8G%)F)(X:])X?8J6
M^D3YSW,UU#XJ/B$#714/N,B4KK-'="VK2L&1+Y,T9$M^#=89D-BDTN,PV./G
M ,<TDH'L<P\--_ Q[XA^?OV?ZUH'0SAGTYK.7+ZW23AKF7>07:IT'$6"]XQ!
M08D<5> B-[G=V(GJ'+S$X<3>X*YB#=.J0;\#J);>W494QW':!M3>K)7H&YQE
MF\$)'@T&QX!+94!%9\ 5(RA(-B8E&6@;:W(S/J(]/.$:C6T.?23>P P>G&VK
MB[&W>/60*1#?AV4E[2U;(&?DXS$$C:DR>Q@ZX2*/8&QTF4?!,V]B(#UQCN^T
M#*#=V7BJ&9O(D=-+@TI9P%A8G97-R">+E0I,2&>Y-"DTX88X;2+'PUV/P83>
M] I[ T-0%VP_V1;W4V4?*KU]]# VVZ*--FDZ7L'+4$LQE*P;6X9BHBJ"615D
MEZNO9V CA[ M-C.1/N(?G6U1H_(49F<0/%A0G$Y9)SR=@4G'2(<KT_*'9UOL
MI<!>;(M]I#\ZVV+.S#C+$NALZ87()4&DSP"7T"H2 .=NS33.@VUQ'W4/+]'Q
MV1:E0*V3].3Z^DRQ6>80$3EDBXXS+LGQ[L:N^=S8%O=6^+ R;7"'^1!9-<@5
MZV?AA<>BH:A D8Y, 1QSY'P'7@P*^K]N,A]G,YPSL(8!Y;TUA=FXZ_&NF'=6
M'LQ4&[K3<?=3FG0W]EC8>D<C)^7P++.T00F+47FNM&;>U+YG$39W-.Y^WE!N
M_N)!Z^^JP%?76QN=! 0MZ7@Q*M5 F$-A,: -0LG0>-K#!E2''5JKCUN\*R]G
M5Y^_$^B"_*J:W'FQ>%Q__F*:W\ZN=O^=FYX[I.V;=H%<>V\R?;&874YR_2<O
MPV68)OSX&9$^+RZ6^\2%3\:KP@(D:1"4RDOZW P\.&=*;<G3'>?NGMK2CKD-
M'VK-WY_*IR;97D;3-+-8NTNO[N3S%J_N(#K&2I1T)K' R5LI5H'+TH$P1=%/
M;,G8N!=Z*[;Q#/,<S&=K9F(8W3?-7=VA>U?6<%\@*B-5]."S%>2541 50C00
M5(KH,THG&K- ;P=WS)US(*UNM9J!5-+4;!ZS\GXG!T$NNV<>C*HCF,AU V_)
MO7?2ZR(#)F,;#P/=B>_G[C;([C:<#32=F[7Q=;K#?A&LE87>3^ B25!">(@6
M'01ZQ2J'BO/A&+O<'<#C]K,.IN%^N]U^ZFE)$KAX\-8^?*G>;)A/]S##<3?E
M;O4:T]^]N4.-*GM!YP(845_"2&ZW3[9NZ(5$EWB2LDEI9;LEC=]I.U00<V+J
M/G;[[DH<C]=R,]25!49.2(2(.M8A:>2 !.V!1!MY*%)JVVP2PF,XQZJ).!5;
MV3PU]Q"=-=A''Z-:C7_N@&N$T=R/@!VGH&((Y3UI#P=(?DS+8"&SD'0&:UFL
MA"GD7H@0("96+!W_P8DF)13C6L03Y1-C&D0?@3<)+G?$.:O+^QR#X,+>3'51
MF0D*L).IS0J><>1!N49C#)[$=K2)VP<J\I%C/JP6VI#DY3N4*X[<2!8?68)D
MR=53E<$O8B%()7/#$D/IF[@D&["<B2$<*N6FZ:<-M60^TK;GF09A:Z$'YPJ\
MM!RL"SI%X[W03:JJ3K%<]T1=T\'TUS1?M*$^H0NVGY6_^ZFR3UGG/GH8N_(W
M!&%U+!$LK\->LZ@\?XHPJA)M-&A3^CEGO9V)]!'_Z)6_Y!T9C3F#9BF!$DR"
M2TX"6BF<<]I;UB2D>4Z5O[T4V*ORMX_T1Z_\U0)-*HZ!,!YK"5R@%T)%0"V,
M\L:@P6Y%+L^L\G<?=0\OT88DSFMUB751-C%5+TWJ, ^7P1?"QZ,JJ7BELFM"
MBODLZD />?<'D'<#MW*3TWW#2&(R+R;K6B @03'!P3-A0.:$TC(779MZX&V
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MYC:44F:#271 W[ZBN0^V7X7%S4P<[0/'8B-877F^)1H(! 1\4%;)[#U373S
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MAHR160@E."!9&!L4-Z&C1_ODH\Y"W<,*M 'E\>8$C/32V\J^*W01H&1@$(M
MR)%IS5(4NLWDMA--6!ZRX1\NX!--6*:<(J+3P%0,U7VG)2B6@2+W8)*,)H=&
M91RGE[#LI<[="<L^8ATK9=4%TP^5L.REI"ZYJWTD/%K",B1;$H&I_(]0B23J
M5!@++JHD!#K+99?6XQ/4>K^$Y>!*[R/8!IUFLS+Y0%''%.>SZ19.C\1B=FKI
MDD1"J#1]%8L%H;(+M..IO#XF:7O_V=./.Y6,5Q^US)K*],B]:CDO/SM<4E@Z
MFW]IV9ZVZU$M.](Z+W$MX14D68&R,O!EO3Z%9=RD[!RF4NCKG=,2=C[T,'?^
M39T$NKGMP*FLF;*<]BLFZJU[ I_)REEP7K@DHA--F-^W0SHT=OG^D[^])_W0
MEZ\NP^3+XC9WXE-@.E@#*= KIJ1U$+2B8-ISSW-2078ZNPY<]"9HXX>W ]G&
M>H SL!9&:E-[\6F.R_!H\7*.(7W&3"B+EUF6.FW(5HXL 1XCG>]62B,TR](=
M4.*WZ9'/W@8:2KA!<=::I:Z OB=3I6^60BX>!F&XDB"3I? >Z8"FU1=(0E>^
MD(S8B53AT.WB,;)G;REM=- @(;8.$/^^V<J6#;>W^YEP3)FH)20G-$'4'!R2
M'\>*LL9;HU08Q4PV8#M;0SE4#X]-9>\)Q#>)_,V&O,8E%EWB.@C0Y-53*)%]
M!5C NJ"TBKEX(3H=*5V>]NQ5WT:NCQ6O6BC^U8Q"H+J)+3Y>A6^87W[[XS.^
MFEU3I,E\4KBD1N>UWE6X6LZ8%3#)K5 J1['>VMK/"K8_^JQ-8B")/[8//>P9
M<M?5:XPJOH@$$34)(&8ZV734X"0OV>B@48UP;(S="3_*^;"7C$_T8D6K%(NE
M:"ER[>KX'0]>5WK#G*P4.<1HNY"9/K.+E2'T^40G? ^YCM8)WP'3#W6STDM)
MG3KA]Y#P6-IG(2@C# -;,@7%QM,QQ:4'[D,,5B04HDL)V@EJO6<G_-!*[R/8
MH6]6WL[^"O.KR6W6H[HITZMY2%<OTH-+@,)<T()KR-;5FJY$VUJ4E2R]"%>$
M=XSQ3BYAEZ>=R+U*+Z7,6DITZ!SCQVKV7\/\19V7,[]>7%&HNEC<P%M-O.&)
M.TY^#>3B).'S93D@&X01D9GH16;="J<Z/.RY*WQH>0[]BO_7]9?)/+R<S!:3
M+Y/+W3B%Q.R]*&!XY:EFBH1 VQE4_NK@M+8>NU&?]7CH<]=_*_EN31>.<IWZ
MY\=EI?M\LI35'^&?!V5$;6Y5NSRQX>5J[P6O#]E.,B!/(00=5!+!J^ LENPP
M)L[RSCO6GDOOH>'_=4V'$<XOOY&P CTY7.9P%:ZGX3I/*NW@'BI\ZB,/U5$O
MR&M*R$SD8FJ7C\\J*NV$X>2F&>50>%+$10_PPTEY&1SN];IT^^#&$M\$?[VC
MIG;!*YXMTU+)R!S+J9YM,F061,Y/R?WQ0H:3_@&[5<=/;BS_+KM/*L[ZB()'
M(Y5US#/AE0\N,>FM,_(I!0Q3T/%K*9BNWI77-:_Y^?:1O_[U?7VR*YB#10E"
M!PT$5@-]RX)3);JL@Q'K]*K#)!:[@#LTE_H!Z?.N\36Y'"N__[\G5Y]?D3<P
M^X+SWZ;I\KH6'-19X_2+[/Z?"UFD<<848,93+""U 4\O$!CT+A2E$1-O(8\]
ML(Z?H1_<HM8SLZTUUH(-:#Y;+-[/9V5R=8%<,"TL>:TJ6?):$X+WS$.].'!6
M%*.Q2UU[_YZX>PQG:!3[2KA!&<A;O"(;)%.L*><+AHS'9"IG-AF=4A0ZQ"($
MV.01>3 NM&F!_ [%&2I\?RDW*.KX-<RGM.,LWN/\X^<PQQ=QL=R7+LBYY:PR
M,"NF&2BG!%#,2M&C_#_=7<EJPS 0O?=?!-IE70INTL40$DJ:0D]AM$&@$$A(
MO[]2DT*WM$XBJ:47@WVPW\P;2V/F><8K[AC7CA1I8[</T#\,A"R^SZC>V(?K
M M8+.R=2$ ):(N72KUX./ (-'%E,H\564L%UC8!X0?,+T9"%K!\BX'!/%]@%
M/H(:+AXWJ8F^"LYZP!9YP6@T-*Y9C6L, D(%24,QX_4: ;##\T]#X!AO%]@7
MIDF6NGGTD_#-,K@M1'M@C'.<)$<F=2MA&FEE* I2$:N=;)0J\DW1'V(M04?Q
M':,0*W]![A$S8+>)%JVF?O6TL-ORIT^3RC#5B*7IA%SQN!(&81%58 *6QF@*
M/4*K5QGX*P"_)?DHQ?,RH[\S2P%V>-:I*](6T?IU%EH/4+F5('O1U)>"G$[4
M9]8S>;E:"&"9VKQ0@2QS-FVP@("R!FDA RA&/-.YUX%:U'^C!ZG$_"'.+9!N
M[H"]SBN$F.HZ0E!H&HVX?)GO0B(83R3QPO(@3(EDXAV*NE7B3,PL<[FUPJ^U
MT\'-Y7 VNNRZ^W8T:^^ZR;@=#V]G[:B[>NC&U^U@,)F-[Z;'U%%ZW_O42LIQ
M1GR<<2!B,L@%QQX"Q[(Q!F.'I4R=!'T\FQ]C3@$F3BAL'?J(6KST*749)2PH
M80QE-KU_C72">(*E"-8X)7O3\\:XW6N4#@;6_OSL&5!+ P04    "  :FTA2
M?^+$P,!) 0##] $ %    &%M9VXM,C R,#$R,S%?9S$N:G!G[+T)5!/;MC9:
M"((T@O2*2%10$$2V J((1$5 1$1 04"(B$@/=@A(2"E(WPG2**A16I4FTBM=
MI.^E!PDB"8CTDH"$@B255^QS[WW_V?OL-\X][[U[__L/BS%KI$;(JKGF^N8W
MOU6K4F%_9I.!+6?T#?4!C@T<P!7D#V#_  1/7/.ZZ@@X LC&P1X&=($-'.O;
M^G[#^L;%N;[?R,7%R<6]D9O[=^/AW808#S?W)OY-O'SK&_)*@)]/8/U@O9&_
M?73#1D[.C7P\W#Q\_^F-_1$0WL1U=J,O)\=N8(,P!Z<P![L>0"$^;OS=/0[@
MWS:.#9Q<&[EY$#?XD7\HV8*XS\F).+T1\1AY-P!Y'^ 2WBBRZ^ );E%3>Y[=
M-\4./8A[M4GV9$&-N%DW54[UZJU 7CX)R:W;I/;LE5?8IZBF?ECCR%%-W5-Z
M^@:G#<^87[AH87G)RMKAFN-U)V<7U]MWO._Z^/K="WH8'!(:%AX1_S@A,2GY
MR=.4M/2,S*SLUV_>%A85EY26O?]07EM7W]#8U-S2VM/;US\P^'F(1!D;_S;Q
M?7)J>H:VN/1SF;X"K:ZM]XL#X.3X]^T?]DL8Z=>&]3'@6>\7QP:?]7\0YMJX
MZR"WR E3'ON;HKL//=@D=C+N54$-KZRJ&57\ZJUN/@DY-<H>VGK7?N_9/]>Q
MP'^I9__1L?^[7R1 @),#&3Q.80 -L)AI$0K +_MEO^Q?-DY:.LRWRKB,O0X5
ML(&-BZQ4-#FI<VS>YC1DY',[PTU&K:NX;=7#LL&LX^:M[_REX8E9)9?F3;7B
M[TKX&7&OWBV#-^DQKC#O4)N8$D[T'#80:#.K<[B?>8):5ZLY&+8<"UBYDA+*
MLFMI5K,W2)D)(JU&F1]":))M^R_:;21Q^"BOF,R/LP&N9$B7X0)W@?Q$]X#M
MC<DO-D%$:NC%TG(J(7(N5V21/\?7234O>CFG,"!MM-UE$Z_<N>H[3\"42I5+
M+'SU!K"&1V<[\R*KZ Y/7_5^N'NT6#+:KM> X5%XXN98K,B,I9FQ6\9G4N/I
MDB+1YM[3KT:8[\,/#._6 V;9 #D-AZ8MS \SSCL3J09L8*BSH3SF<69F578X
MZ$*4FO+Q$" )A:R$EG;;/]UTT&YF_\L;NGO>.Y&FYGA&=&2ZU+QXIR1T)*C?
MG^_(PF=9-;C9NVQ9W16BMBFLNN8XYS0F:52,Z&K" ]9\  M60BS'\N^S 4G0
M!4_:WB@Z4ZT0IRY>++.3)M"H4F*LW!+=?ECB!5:B*\V@6:E$%!M5/<DXP@9J
M[#'U:*KYJ 18(PNZQH9(.07#>Z?6W#5C@[T7!&86O[K([ G^"1&^11S4,NW@
MZJZ1+=VJ^;[LR0^SM_D<*^*W1T7A ]A]D"QE7V4 #3_F$UHI^\KFO5&T6X-4
MGU1 QME[W"D^%\QNW."=M]T,HM'%34T+(O!7(M5'H\YKR&;L ]P%W:8F-^AW
MUKT0(VZ?@_M=THW>F-REOE-8K.J[XBG[A!)\._BET @AB W(5'/CNJJEO+8Q
M-T"=%+2T\[1*PEI9$%//X\VPTOBQLZ6?I@2/.:E#O6R QQFL,:\^C-TR@)."
M&\'"A2:K2@V/,5T?/YJL*36I?%??70.U\PU7EHZ/V5P\^O3;^8O/W+GF!;9_
M KUB2?RV"-3N(+'YC..FH3_:L\(SL.=C:U.\ZJ.%C#<HV5[?K.]@KQ9??U^I
M^8'#\TM1JP7<G>U#2UZ0EC]YM!852BS3J!D!/Z+YF!JO1J&*NA4?>']5]\]C
M_BXE.>FX"*<*WR[U]@K?T5W7F[:]%!I ?=: ></'B$-M,!\'C9/>#2DSO%IR
MF9MI7^.IOOX4P6BU04W;O.;?=CT[.VA6WR'VZ!QGXX.6IWV)'(D5>$@!/V=#
M2Z4/L%[!/)!Y':98J!X,Q0MI'64#O()Y-)D%2F=D_D^7Y1LYV4V.V5H#GS*V
MR?EAY$1D0P(RK8*$,F$)ICQD13WV,0G-C^/#JE'90!#S8.8J<>B%-+4TFAMO
M[_+]S)+AA,W'<&G_B7C#[:[1[7--<H]M-P+@H5'J[:8(&#E5C0;1PX23*<UZ
MA'87BH&W4>$":N'PI3[W'SJ:OO&LS"J/,S#WXX#^GU$?8C:%]._"71Z7FUP^
M1D<0&VCJBR0!R(_3AILP)0;S'%E04=T+%6HI80RU^2OS%DTP+QM*-G)CZ+ZN
MT=(8C)]7\NQI/;PE5_::XZX:3&LGI W"9@;47K@Y(!M^H6X-/ZX6!5N4J)VL
M2#IF;9<"AXX\\S)D3C6H-?=EC*/K%X1\#4Z6W4B6&HQ0?ZW&./WDYV:U'Z\S
MR&11TELL"EJFJM*#J;V^G63)1I 7&C<PQ&;W5Z+&E#S.#6&VD1Q+?8[?'#Y*
MJ,60',97PD$O#'0LE5(VET>[S :<L4<AH[%T)THG'R::#KH6=V?V95?X7A+S
MLYOY34.X_4;MA]K>?QUB (L;^=@'Y&->.%%<+5Z\>CNN&2V@Y90QBKU(&ZW?
MS-UT.?Q[S&GLOE>=X(81VZ^>JPY)I[?U* QS\:A**RH\_H'G8YZ"P/$J;A-Q
M7]DFZ\-%F;4_'KM:6V2+-Y0?NF]U-J[@_/&=CTR "/@&D4Q9"$1M_(F"CDR2
MG8+5T ]U) M[F"YL8%, &XBZ,VR\@70LX.[,4GW9&Y^;?E(O;=XXG9>P?*1Z
M&A X3>@S@91#F2(+#2@)D/Q4*G8.\9IK>J!:DLE%_6FG%&M'&WBZH]AN6]>R
M\<&=CR[OJ2^]L7IS\]A7)R?C?.4$5>#E%B$"<QOC%ES/!H3AW4(/T4)H=Y7@
ME)5(*5TI"*,'!66-N.YINLA0,R_^L%7+8QXCB(1EX.L>Z $5#_/&XXXQ=T ?
MQC$;(<()6NE3#X<<2*/1<LV\6%)@6LTL+[>Y:!_'Z:^\9B\#CW9.F#"EE6@Y
M%+!>:"B(;DPC?JS249J__3$EX'M0#O8FU2185+>KTBAG:'@ZC3PM$ASB'^;Q
M(RVQQWG,YH[+Z? VKPNL[4C2/&4:Y$)U\.89)(,BL0;80>N8G #R;!LC>79_
M3_V.+^,?KLO37@IE(65AA!".%M8Y@'@L!?,Q]:""\7FW!IF=?;G>(7W>H\*N
M179?;<4&EC=UM6BU?YHP%=8?N_$6(/.MJ=#+(*-73'MHXQ@H."OUB9C5)A@<
M</CY:\BK07)-KS_O8^DCN1SUA&[#1+DMO+([;[A-$*##&/C\;:HL7+,V"N.7
MI1CHL4YF/%$4_$ST9P-I,O?1S[R@PYH+XZ%,L4%Z")1.+:(7LXH1,&^V,>F"
M44W@JXY,YAW:YBBZAH>?M-T]-8TKQS8Z!#_2=(K/JC*'>1%$;+1B51 =T9#R
MCQ)DF.-9Z6AGXA:F(Y6+#6Q9!GE=[@U&_8"'<RZU<3S-4]G8>]WRP.[H/>$C
M<3Y%"F9$C0XBU44_E6'K.EHBU%"!^LQHP O=L?4T":$IPZ]H0J>JB(%;C7^>
ML-Z:=V"7\DZL]#&/G3)*RTTP;QP;X)Z%).DJK#QO J2 GM=@Z-HQ':#NW!GK
MD'2)D@,/4QQ#GOMC>[979-PWE#4\QNMX?")1V/%*05!) N>"FQ!)E"R1,W:!
M>CV95E>SHEF?K$_2WCM:7TJXU;OA1-@IN:^8G='O/QF< 8-Q.DQ>VF"]AQMY
M)5!'W=?(BN83,BXTIL+O8B=;\KZO.%-.P2W5^=NAC[P['?MNN:VV(8GZFJE#
M0T6@R?.=@I D!1V.JM4L"\/:D#\+A=WQ=3!*Y=1Y[OSXJUZBHJ?([A]1'YDS
M#R?%U[Q?(JC8C79 0[NEF%BDE1Q<VZ)OXV2]%+HFX*Z_"A\46<^]5LL3L;'J
M46B<3J^LL?JSHX?:&3XM,3GO.'\(1:)+->8BJ:(-$M6;H&F&.?,(U:X$^W9
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M]*HHM,!R&\.O"2'G#7)B RTRO6Q :#/K'7&*P 8FB-EL8%$;1:6.#O/#$6P
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M%7C4!NXV[=0F1"]@C[HF:Y94^CO&[%.Q^#RJ</YPQ<=3#Q* O+V4^VGOV<!
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M2=9]4%?Z\$-@\Z;1@WT4XU=VN@^VH'^;C/$O)!6_=GAEEEYH1WR5N3?=]'"
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MY#_ER8@_)=%*#F(/S*NN'<>,M1MN ^7@I@?*_Z.M<CS[_Y@J[Y+_F$7'5U?
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M',2 (@?Q:)Z#R(:U7GP[U&&/9O#YL:![\*_IJM"Y5I82$B1&<! :$V>5QLG
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MH&$9S&^ U5__,)WA8*?9!">RN)A*F 0[9$"1I,J<80R@J J^BEIA/YA%+SG
MQ"T,N7#!&/K<NAC^$]87R%&_*)@6EZ=\^U=VO:]E_<;&6NEH,#P #3^,@UBR
M[4G'*UI!NI\Q8[C:];UF37_9 HZ)]&$9841A6?.:/$4E+\ <9*Z<[5(#R3<?
M\9W&#XCX'V4353_MQR3"JFFK0Y[/QU6QB%>J*0R%[QQ$42;+U&7VZ.>)AA\_
M$H"WI,#CI-*,^F*K 0Q]0G7M Q8L)K/R"< =,;:]-F2+8?=B<O%UYX8):["A
M6GSPJ]P+JL"CW3 $G"#^76OA[/2#8)FW'=84.8\XB%98N97#W#/L)+Z[%O\+
M_N7GG3\5@(#%Z)5&]!+OW\6HRX#%JA=,QLY-'I: PQ';'W:J^\HAVR&H!]KU
M8$PKYFDQUA.7J[U_TVW>T1V&3IC,92H9]G-0*(QYBEU!T4.7F-XKH0@:4I/-
MM)0W#/321#^F5SL%1%BHI$74,#<*91X4=?C4ZU4MK@6^PCOLID2AAY^3"[6(
MT2 _8U"OXZ:N3BZHQCCK%VG:/:]KDFE_<K?;Q@)[N7"OVU?YOK5P$#K<[^_5
M?CA**4Z,QAUEZ(RTSY@Q9*M[+YJ^]0NA#65D3EH)5C$T2[M 7<:YF*.&7'&*
M+7??;W39R%U_$W=Z_1A$J(DBAI,,HD_3DBGU\SO]\.8/:[-= ]IGD2.1+XW[
M"-9CH<L/8M_,1?.ET#YA(C$%AC.+#')CRG8@GL&MQQ!RIPC,1XV'8 P84$GZ
MR?3SG@-]S5*?HT;51JOE8J2:;L<>2Y&ZCP"0$%\(ZQ#NVCI6!G^/@TWI11XF
M!N],-.L:VB,VBZ:GG5_=PU")WGZM9V^4@>C4SA=R3[<^T*7QO21J].,O"R!=
M,2+DX= 5LC#NH(*$2SAN_\BLU7DQLX?/3GIE>P@9?CZI8^?QY,DKZ>45V;X!
MXZMW6A^?_J:)NA3S ZEVYGGUMD\ZA<?&C\X[6J5#=<BBFW!=M&>\J>1-%%?8
M-\Y9P0B+.TYST#/>.3ADHELT*-?C77_HE,F7;-GM(I>R[X?:(X*]\=4(_/ K
M<F'&+$PE-LH"CF3Q"AU:9 +#I"S\2@^ZL%+6(P!W>Q-C<\:&V4<]"T>L>"6<
M3WE>/50=>=B'//R3&$$4#!:'.LG%O:!@ES%C6T8D2A!J']IO;!H6?*"T4]GS
M5[%1_DV+&96W)=&:'U^N7"O.U7ZQYU6LWH&,7N(V\G TY7U9-3FT ]P!&*6!
M%^F-(5=L$@3X)M#%5E&SFH"EC821A3*M1U33RO?NK=>;7:[V'_2>0A9Q$#,8
MEEIP"Y[G';"-=1BW]ST=_4CENO]<'D[#ZWAZ?=T,PFWT4_1)+[FZ Z2D3K&!
MUS>K-MQ#[X:I&[)/C"8V^Y.E"W?729P0'3E"CM+=QM@2W%.I*BWY\C2C)\TI
M?>I<;-AA,:;7^=*NVEO\ISMU;TR)G[>YT$!Y@Z&?(@PD#J^?)9C?2RVKQ=\?
M0-9@Q7$JY+A:O$BPD.N:K;6 @$>,8%'SJ,#+UN2.7S:2WJ*+.Y.'M+6FR858
M4,B#B6*'X?1H:.'@+RA$+T['E\8V6U85BB0^#IA+WYX1P"JS;]NV/--1T1AX
MW>0305QWZ[%IB/<C2\J893&%*>V)I_=:=* 4/"R?#GI4RM/)T3[)<NX%I[,S
M$^_V6,78_43LY%ITPLW8C[M6\511ME5N!M4!!ASN1E!GBA20_MHTTZ8?Y*.S
MVRHNN)<=#G5>6$K_.NTOZU0KS2N;$K]B6DWJCV->98>@U(&0NO53$M,[K@&]
MV9/'<-+2'\CEGQ-6K(O+*GT3%%)LD)O;C,NWRKDYRQ'KO!(50$%5IB02N3P_
MD%I;0]EQ!TX[E0I%QN@=?K6&L"YC*4U/.^]\6.8OTVVNKOA(N8!=O]"+\!3I
M!G@@WEF6&J@#M&5 WP)NOAP)<FJ0,(CS?3<QT!N%4O%+K%-^-VC_4(S?4SHK
MT][PYM>=)V.UK!H,9H2>"D3BG3"KMG9,6($7HJEH]MY.CR5\ T:P8M^P"::V
M4KIW>5MY6,0R<>;SY@:UK66^&WAO7N/C11Z\=5(S-_"@898,DHB%'1'Y7I_2
M^#.0F5%"]ZU3UJ9I1^RQQIT<,>$9:7]R9_;4FLB9CBO^>3ZN?74Y6\_*LNX9
MW.,J=LH'X-2[D<I^AMJ*\RIFOP75J1R$N'OED:ZER&35\PRQZ."#0%Q=E\W
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MQ!DS%FM<ZD4'[B;<6(J2@,;TBPM<[KKE[Y1U_M(IL-\X]FRN4ME-Z[)Z#-T
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M+_QH\"?U5+Y_IFE?D;0PUQF7\*K];D*YRN/ZKLRI16^W 4K6*IJE!1SJ9<H
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MSMA/!!*"/I?*V;_@N4X_6U[65<^.([<$)LV4H(A0W+#R+6H(I8^/F!K6[ L
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M<G\3>-8$$@K@A^SMD&.S8#AT0TO(+/3HK_@P(/"E>0-(;DDK<6(*8AGY0RR
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M)O:YE(R*(\X:1&:+1>QF_Q8RJ1MWV&&?/?\R.'\&AA?3/3[&M$,BC0B<&W6
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M6/\K?[Z;M[)[#@8KDJ;5=3F/N$3M/GC5(G3/OSDL%C $F07(F\E(7#D1&:'
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M,S1.Y[G9"O;Q'<I]^Q.2[RW)6?Q-3;,U.KA10<Y#2_U:PD2VS#X$ H)!#]D
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M8U@ )];%.,32MQD1%*A<-H ^DR<O;C7GX[#_.<EO5((CNC=*Z/J.E9\V/N@
MUQ.W5QWT"ZP=1!R3B@T]DOQ5;NL?CW3)/_HV0O[8+SZ?Y\ Z>.)/NE)$F(_A
MJ=/9'J"%VH20O]P<T!2$:35_Z&H:E"A%^HA:%VGIV_3(,I^9+OA;CT\ZC!$
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M]OIDSW8;W\FRMD(IO#89#0V_?$Y9CQ._QR;U^I?KRBA#VF.J.>U"/M2FBOU
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M$93Y?!-P&U)\<X,8P>#E"%3T,KS(S6OD/UNI-&6%D3.@7?DJIB7;)KR@M<]
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MJ?VM]>2D@029^;ZCEGWRI?>^"LX;4WW'B/7L=B^D>3-*[A@F:CE%N9;,"3M
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ML[VR&B<SR]]YHMI\WZ6$0^8[KTQZ-\?NQ$M"/62*,7"'7-S(X$/17&']'K3
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MZ'JU"6%)VNU%*T*;]"0[1BM2 Y)F.&B/[#4?WWG<,T.:7P=_Q"(S&76%')%
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M0JO YWDJZ=]3_K1J*CH=+X;3;?V"E[#1 6([G2]+3ALD5AZ)N@!_WLPM#_M
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MET\,4!L?G!EI4SM/:3$6M)#!HUMP_C.KYI]^W(AIYR.W=H!P[(_]T;QG;8)
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ML EC/7 &7K,":6^0@CBEA>Q3(TAXO<2)P7,L1.K;@-1BQWJE,#\G7YMI#<X
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MWV:51DS#J;8F=O7F=JUBGUHMQ_S:&>NE;O6]:H^0QO=9SX2H#06N2@P4)#^
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MX:/K>V^ ABNK2HL;9\EF[!SM>S_./RV7D$KR.GG[D9:7YFG956V/$:A7SQ$
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MS#XOZRV:<!GWX/FD+)Z[;5D0BF/N_T"_P'JY _$;  S?DH6;B1,:9,E82J*
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M&D:!08!?YUS@#A4QYP[K2:=:N05>YTV,.]=Q3/W@D< ICBU_B8VR%0%0[ T
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MRJ\5M .IRA5-CJZ%4Y_G'/7%341<[)S$]NU H,Z_60^8]<>851RS.*HYX0#
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M(1\7[S9^.31;WC"\XK_:I/A44,KP@&F$S"C8BR*[%UX-NA:6;%Z!$FSG#D2
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M:HZPM$J=/ARP!?6'Y\T;DBVC*/IV9N4RR;(>N\P<[X-@$]E#N K<\@K#@VD
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MN2BXK<UM\BOV1MW3=.-_@M*^+GESKG?^?QXH&!N0AJ#QN6+XW3,SI-EJ&&>
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MZZ]%'FKY,;>N69PC<SVQ[3&NK'\$^^^I<1+DW:2LY^'H'0B[S49C!W+6(+0
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MV$-,%)!2BD$"E2"CWVL<;;"AV%ST-W<>"1(.9\S7?TF+-TG U=0_:Y*&W(!
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ML+9X%&#S=.XZ-W2,5%Q$#&[(9W0C[']KQ\JO(M-(]^I<!X0$@A\A/TSO0.Q
MJ6B,^,;_?WU7\G]'?^7GOX Z:=MM,$Z,)K6$F&2FB*YH/3.H>25H)*_8^:.M
MPK+NM,,FOZX5:8^OU_'+$2^G4X=KWUCW9IX_&O\\)_68QE>X+V$RF?Z0E5PE
MAJ/9MW?_^?@M8XAI\&XEB[WV+6:=R_L<O.'I^SLGE6A(A=TT)*I]63Q4WL09
MR[$K%5!?^^WMC]]AL<2+NB[G&P4FFUKW*RQY9K\^H?YBVHE84<@4"=?("<1X
ML^J83O!XC&7(T2_9K:V70O(V$"?JOZ@^ZMGL+N;K$#CW#B\@TOYBBM+PZ>4)
MJVM^5G9IPVH/3>>9&:5%O^.^K"H>+?KIL7_!S])V\2(<7K7[]7J?%Z5VMWP-
M_T;)%!I!MHMC\P W%UZ4>8EU262_"W&*?\HY8Y7TJ>.8<,:]9 +R%KN#2+V
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MXX;ONY5'H\*5:&6G&V?IB3!"-JZ\>M6GH-.'8,K+!+D%)LZ,!Q%[;PL9=:E
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M5WFPB0<U-G?KSQMR-([ \E D[X6GC3SN/Y _\-6.>>QM\*AJ"WH=573=PJ_
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MN+Y#=T&_GPX-4W_.!($I?J_Q)R72]$RI5MO"JRP4?&@'V0'GX&DL)<<P0;9
MXL?V"-^A.77[P,=3GF\]?[D"]U.&=@1WL@0K>25ZEOHFK!OL=C+F:>HT7N[.
M=@G9MIEI8=!,> [M=>!'CP7I#3RN'CO&8$6ZF4X,R1*^IPZA-?B:,HSS&,>#
M6 Y-CPG*8X6OGM&K3-"O"4:X8DGQ:O']AKHW3C$B/3V2QP^:J1A2]G]!A>&/
M%3>>Z2NR-Q1M5\N:U/T4RC51VL+/^-$!'@H>_78O,"3B<] +;D'[02LYGR=R
MG8Y6 920T(7IF^0%M,?,QWLG7[1^N?RS+ZD@K1_5,S@+ TZRKVI3S1D=*%(E
M;.8=0P35HL$$<<A0(!0EFLDG++2?@EH#:S-T7=)<\%"EAKCU64U-^N'<&&H<
MCLU(H<6 Q[!:!!_ZVW/;".=$;CQ-E/<67$CQN77+233E@M?;='2=2+.=ADR%
MU>]@_)]CW*LZ1_XZ=/E/QR?O*,B1>CY24?/.- R()\;JBND/WE697A8>>)Z@
MMK9NJ+E/W^@HZ,#+LW]3[[[N],VX4W,R]^,CG?445_<_2S(D< )BE'F6AZW
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M%G?V7>63&3DK=0>.7!2"ZH.%MROV\T[9U$*C-]8K$U/N38;#UU_X7J:?,**
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M]:CL%$11U=LA)-CF9,F>*[41OQ=;L^39].+A\(H9P]IE ,+9ULS+LEM[_A*
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MR)!JX 8HJR=+EG;V7[IB/ -192;>HN8%J4 \Z:!Y1BY],[KV5M6J=9K@=7^
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M]B^#3H?=X$/",=JD;CJ?/.4B^:5I'G,4S!&/FA5.KDC6V_KRR^TC:]5Y$BD
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M6^G&IL0)#_+$M*^O18!/GH5P4-Z#V^>>7'PGV);G>O)HD2B [<E#2XNS[ZY
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MHPR6 ALSI<PN\09DGJ19-1NNRZN-+>G#?_P>_U;JC+6;^BJ^^ONFX.^WK9]
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MY[B@2\1S+'^D; @R"NY,@O':A&*;MS<JWCG!<7X?7;@@_V#L[ST.UF0,H>_
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MI!26"TVAU<8K/,=6B B=QT;MO1UR?E9&\5ECO.E5 ;C&/_;D/:M3$,Q'2'$
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M$A,38^;_/&L%6GYJL;BL?J6/P,)&91YY)@2ZUV!F7?.UZ%Q4^UVZCUUZQOR
M<2?:O]/#'X=.@%);T%1O Y8(FBU'3V'T0YH@^XF^9^+RW?5,XDB0!G9&7MSJ
M8?;8EV+.8,CF8C_ D#L0+1"^+EP);;,%=Y*14F 0=KJ\+T/!6%&3+!FH*AUR
M:>KP8/#PG*CHNAHCZU(&Q#G2/5;;W X?#]"#+00XW"?_/KWJ]8+I5J&&<A/L
M!P4GB.B![L:[9.SA'$:]1.[7T20I'/EDR/,RJ\ECAO(Y(4'O%G%)179[V%%?
M=*T_?=ZPPVMI(QBMS^>=LT]<-O%O^;^>GM/"T\"FM_SUFIJG#6$06?],ZQ.
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M[SXLS<<.U^6W9R@W"9V-H#CT_[S86B^44=!]1-X6K#YBX2Q^0@QCP$[#3TY
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M:4GTW>#0>V/$8 ^9)=_I5!'9_T991>.E[H4#6TKB 2]GK+:RSSP=F<NWF.'
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M?Y:%?XU;2Y.+,[BA-TFX5H%ZZ?IJS&%$O&S\I!>29D92[ KY2IN?>?/+[Z@
M@:_WH7G6T-BN%83"1D8+QFL;LJO_SZ<A[!A6OAJTY?CO5M8K^/W/D4&^A+I'
M _!W/,_B3.2NNCD+ M.$UUQM,@2F$B=F!P%><!*^]243]>=C#G;H0.9&'+/W
M=K55-BD[_87Y990G_J3=5$E+O+QJE/7<S%O:Q"2TD2C0..D;JK>CHKQWR<(M
M\<V[>;\?MA=TQ<2NPR<3\-L0_DCZ"S!^%;VS\7D;R7S?C+;W*#!D>Q?_4HPF
MN7+@DXMR2M//NS-X3]6 #P@&0&:DA7V[B5'M*IZW[O:L@F\%P=W-@)%(%/$N
M*Q&83,$7\RP9W$CBC*B>]_;6@RQN=$JK'7'+*7/T!K[<W/0B- #G#)0H?JM%
M,BYB%*AM<S]I)R8N$U?;S9!G\:#0)H*V,.F]#;F%#V>?>>M;KX#1/^1^1%AQ
MM)HA\#(?=+5V)^.&<61DV(/.@"S3O*_$U;XK*7=[&)'/VOL/;)Y@GJ=H"/7[
M-T].G4=4ODAY5<#>LX"/_[95O1_)^_-W@J:5?^5PEI@DQY"11@OEFGN-Z 4T
MZQ>_8MY0>\A+\9>PB]T$;3R@HN/"WE)'L850I#"*;Q?%5_A,O(>"C=/D!;ZM
MH+M1^(RA*@^2TYN,$7YE!?,G@V*,8ONFW SJE5U(FVU(WOXT]\* -P,?TJ@Y
MGM=9!V)*G (OC[!N--U4:[AYF(?9NS&]D/)C%2[ _JPG6*2(B"A?[+ID7B!]
M[OS^K2DE;,VS8-CS^H-HB<9)H$F#[*5M[12O=#B3Z5C2OE;P1B[F&,G6X43N
MT3<QD)U5A*<('P!4&6J #H][$<(0I>5UQ!;< 45)3.?QCMX[;MVJ<O-=S3MQ
M8\TO@W9?E!5;NEDB*$2^=*G@A%#V8*]7LF^O^2H@[YM(1C='%Q,MFXX/)%TO
M>VH=Y"U)T%CM9QA1 EM1S_\<]]P?2!.AM$?_GH#>3E1,*4!:5MLXHPQVU:_)
M/#:TQ4%$4&^V(64]3 GHE,:R\)0%0_-/Z20]\87JQ"QLUSYTB?>QSL 3OSV4
MO6W$'O-P]_A]VW?)*'K@RU\[^IS);N1$T<D\K%H9N,CIC1=,R$>;-CVK'3M]
M/I%+;")N=*F\6+:SY-K94U\%PB"OXK7S?S?3;[%B 7?B,'^C?L,$A"UM.U>D
M11@A/-E,2OK%,Y'VH/-S\$M>4M7A"S&*@$?*+*+9_)G$ /.>D^G2ULJ/K94/
M5 TNKTB_KWZ=2P:<8-<'C">NVRV5C:FEY33A2Q280LZ,%JS"-N39)D>@P^#C
MH"GHOHFO*H48N'B!W%QOP#;$K':LGAP&R70]-!*]>KP5&PL:-;)%J-#G2\R#
MD[Y[;6YOF>/W1+1?[E/>MT?YV_WKT7^*_UI%BRU.GOHJ8R]HISKP:[Q@BS@/
M@[:D.N+]K Y?_WIB7!6\4??C_(,HJT@S>'Z(/=^Q])J>Y/_P"XW_-2Y1[GP%
M5E+ADT/M!$$\+_,VB'J/SD V#OL6>!3W3(LPKR9RMTTL'^<.'FHBE@4RI3(8
M9\%Q#XP1XS3SXJ >S/-F[6>UQ0IO(Z2 X#G')85(/&4-)GT33?ANIQBZ/V%Z
M\TEYL">2B*KS#)'7;Y,V:SY=;Q^1H,ZLK(5]/$AA+^)?,HB3M1-4,]5X.BYB
MG+]X&U*8S"H*!U8B&0&6VY 'ZANM#V%+'%;#(X'MUM-(AN]E]VY#!-=Q8:37
MOBHAAM_MK_8U"_)Z1W"Z)J].2$]_XG1-FR!ITW>P7@*>H!L03=QYW]OH2L)=
M]1$;L^STG&+&Y5VN-[2>.7<N[ T"AC73>!P$#Y<SRW6G5Q]F+ %#YL(46."+
MDM;]=8LWB8$(:YY?)IO$.&W@*?Z@WEY,,'62YMX(1!R 1:BM[F9$2UR+ 8[A
MR2^/RY_9AK@]DNVMKF:6@IQHOIO.- !M*;*TT_2=K+QR,^CUBJ/+2NJ+'<HJ
M+BL5VHR3T"*K%X*[477WZ!/4JQS6I@1EBGRAZ(K0^T$>>%2MI@\%L=QUH?^P
M6S?$S/RK#G=LS\K5GYK[V]4 '^>3P;=$C^YB?M_( #V)0MN0%T$)L_GXYZ=/
M!(R0$I!C5K\O.2VQ+(Q9]]/KU5C)'"]1C2_"M?>4SLLHTJ)[FKL\'11MT6VJ
M8L4^#%^ALL,ATZKQ\Z@;<\DSX13'$WL?-B>W%KYW"9",&Z1_(;M%N.KN=S01
MT&TDN/-'-[G<[+K@:=K!]@I8T^,_2V:NA"TRE-JA6M?FOR8COR_#KY.4KVM4
MASS/DHC-_=&L!=R['0K]W-]O?3%C?WOBI;E5$;] (]4/3''0HL!U @TUWU5=
M7JMG@HAZ:.:O15AZ2_VP#9'_['E&H7+XUP;7-@38"6C])BDVM-U-$G!96:;>
M_\E8-4#4R6U#1'K?O[T%^I*'DE=G'G"B:R@Z@W[P>WF-1@FN]>3H"'&\;$"M
M-4%J<<WES\5P*!C+B:T^X/$IV"E'%_I#,"2WYF?9%C8MT;]JX[[Q#SPH%M)G
M@"ZBKH11XV<[IZWWJOSVNA[))&F?H,D@Q&0<7(\/.GZPB")>Q-X<!1JEE?0.
ME)I0'RQ2AIJS'5X!87@AN,C-Q036SQ^< 5 YG'HR<QO"*\=+[63S^4XQ;@JS
MQO M2'Z2UZWSK,&X:7WLH5O$J\=+FD5IKW/"'9&6 9_5?Y3$J'%H1+5[@MLV
M!$5&"F]41\SR8T[;@U5W9#F@U$T+L:5O-/,<S[ "&KWUI*),0J@:%/4/5#/V
MVX?9XY_692S:^>)7\%D^'AP1;'I&< T_0J=0S'V5UC71P*"G'C?MJP0C[,/(
M1_.)QW=#\E>\K<FH9F]?A6O4,XE+P9\K/'';D)!C/.N%7I:L1+;0@NT9DN5
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M33V@/'SI+9#S7AO6(C(_=9WX&#F6T+&C^W/PYK@G;B4"3_^3>% *LYL:_?5
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MR*&:QUH*Q]Z%MF%O/A'<LW%B#8@D0LJAD3*'(JVK:!,_)BL?&7C?4ILXJ?#
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MNIY_OBG3 IEA;60H(1'9,&19-'"4MR!+G#*48>4^H]&. C5,#?K4\2"2(Q-
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M6PWSYHZW3+E<&6>)65N#@=IYU$!!:HCZ"\J7T8%*&SLSS?KQ00\2?X=V^8=
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M.B4T0KP,N'G+TN=94?7',0 5NLQ/P[?").O%0=-&.]^(>D%T:$N%$."EI;6
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MSY/?S>?6IX0C%\:OJ\:XO?F\)S;&<?CZ/0.L.'MB@NJ( L].T8T&E! >N!=
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M&>?H\BX35<$8CCI3Z7=)>NW>A,RIGL&;;S-PV<H=;:YU'Z2ZSF0*% 0/S7:
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M0RZV9@>0:NB[UJTV5HO2I !KYE]#Y-:Y-H$FJC+R2]=RO$>!\SR)+XWCFI-
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M>\OK-_4*'Q"69S>Z4RVV[UF9A\1#>1K0)TK-8B3&MT^6&P9&P)Q/<O3.*B*
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M.6JPJ!B.UA\N[L9-EC'SM"P>GX^J^"5SO)F#G>EGZW!XL,'*DN!< :B"9YW
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M@)L\WF3E3^P5:X8*C \Q(Z5..NVTXWH=.']=V3/6"34BA.>OQX1W[HRLQ*H
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MFSDFI66]&PN=R=DSP60?[9=GO'QDSGN\2"^0WQ>SH]B<20%U/4>[34'-WWC
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M@N11EXG5;3#[CX(2Q+?;X+2P4P !&Y<@4B<=U*3PY4NY\X)B/",?(6TORU>
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MAZA76]-BVG$M37L<]NQ,AUN[!+POQ$,Q7VSXQE)M0<8\A'Z"(R6>A-H>0AE
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ML]O97S[]]6HF8LR%2"7$+%$F:D(P)&&*E3;F16F*DI0A8B,=5B-.30!\$M_
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M(U,7WC>55Y6MW":O7^B.B/.%CBXU QLQ;M94S:]4E4HLKWP)WDMS24,2* S
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ML2F0GVF)K&YZ5^AF;8N[Q5RW:%5_B>PF?]M62UP=CY'YRI!\GYM<8&U$5K.
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M6ML'>'0'W793'Q#*P;?[+GE/FHEGRGS:Q._9<I\,$=/-?MK$Z*S\IZV!SLB
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M=+@HM5![=P+6@A_2A1M<[VZNBME]4Q-J/BO?*CU?J'46FI%;S*HTM%:9:JO
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MQB$BC-DFXCD4*I9YEB5Q%.4^JYS#8L8V%31:@BTUO2H1G '5;>UP.50]LW@
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M@Y*KJ=J?K#=I@)^*F?JX5(_EA$0\38B*89ZF""(D%:0R1Q"GA!,SZIG(G%H
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M+V9 29O30'1;UN:(K(%+VYRV>+^\S9GKPWCW[:J85IVA9K+]\>/CTV+^O=Y
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M$\L)$DSR5&=0IHE=:\D(<H853"1.XIADA%"O(-?=QX_-8ZBU W^V^GGNZ;S
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M8U%$8<ZH<3]CG$&*J(1Y0A#*5*)IAD+J28WL/1B^'M6'?Z[WP&U"'-NPCB?
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M82C"0F(*I1"&+S*:0(ZIG<AEE'$D9()#-B\[57*DVYE;:G<2+!\X@FXD-?R
MO')@_A5H;0-KVX#]E,&6=>"',0_4]H$M WN/ZK\,]P%R 0(5'$,&P678.N8=
M7"@DL-79<S.%?%65CS.[_[8TTW@Y$=QX=RJ1,,YB#E%,,\B5%% BBI19_$LL
M_#J?'1$TMD5^K>O:IUEK"VIU/?NB'4/W_.%T5YCU3):A</DW43N#Q:4]U8X]
M?M@6:V>,W.NX=N[ZP"(!MR^R4=^WR>[F'^:/C\72\I'U02<Z)I'$N8 YMH5$
M:*3-BCO&$&<IUUCF>2J15YT 9]%C(X[K38& .KVR.AO9*A.@@5@;4-40\,QH
M=Q^4T^S2+]1]KSV/Y;&_WP9ZHSZXZQ-HS^H!O0#^V@4$@H#WKR'@C=W9,@+N
M3QRVDH"WI7O%!/R?$#!/?%'FS3*OW;VJGLJ-7/GW^6(J?Q12_;:8E\:/_:YF
M*U5:-_9W]I_SQ<VJ7,X?#1=/J,:8$HR@,A.%S:^0D&$5V7)41&:"$L?Z4Q=K
M,K999&.+_9Q^M%: >VL&6#1V &D[*)KE:;7Z?+06 =&:!-XP>X&V,/P"[)F)
MG7@J5 !G9>%32>6B07:8AH8:NIYGI:U1NZU(L$9[;0FH3 &M+< : RIKP-J<
MH4;%8\X::G0&FL*&^+:ZRN'M OJ3,^!% H:;$+O 86=^[.2! =/E'?MYLUK:
M:L#_>\[+:[&<:S,D>14Q]S152]6<D9HUW-V"F=G:?@OFI@_SA?F7U>.JRB4W
MOZGB?O:>+6RMFK*JREE6BXZVJ/#SQ]D'\\78L)!R$A&=12179CF62(A(DD"6
MBQB*-$,92S'2D5/,QJM9,+;I^8]?O_UJF.*)+1=%'9"P9#^WUG7EE8V&0QY<
M_BKOA</,//;1[GE&M_O^UGY@   6 5NTV$X;%H0KL($!;'"X ALDJH,#8SW8
M @,T:( 6CBNP!<BZM/RS?3RPH%11?3Z.P:N\3!X.Q=A?JH$<D7^&E\O/77G-
M@3WIYKR*8L.Y1Z^)^XY;]:J*!"81U,+J'73Q;*N<?YC.?_R;DO?J-U;,JC2&
M^5OU58DI*\M"%TJ^6RV,8I_5SV6<_#Z?+1^,CX5$G$@90\5BXV.)/((4(PE)
M1@7&)*&8,[_ LVX4&U^LVO5C':NIVA#VY1QP9=RIC1GUHNOZ]N:CS368 ]6\
M"6#^O>KSI<#,F CB!#Q61E:M BO:$PU:582HL'X\7/^I_,&>/ ,J.GHYW"(I
MAA_PGKVG=BYJ+:K;0EB;0&44L%8U^6/-6[!M&ZB- Y^;L:[MZS"UH5.\.\UU
MZ$:S89,?.D5S+QNBVZ>'-DQ;%-^-4_A=K>>A#ZQ8V&!G]5DMU_'X--)YI%$.
MDSCE$"6I@AQE'*9Y1#7A4:J99Q"RH^3QD;U+HZR+L':CUA[PZYD[-QIO.^U6
MZ2H-0EV!>AX%G^=+<*MUJ9;@^MY\">42W,RGUH]:&(>_GR[67F!VVX;,3?3
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M)$M@$A&"$66*]#TSBA]Q.J;A>PW]#&:D?TD8$>61UP<E%JBD!DHZH 4%E>!
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MI[^8^DUD=^M='&V1/V6ENI"LV@"PYS_$S\WW'V+U)'[/UYO[<AD$U&<8J[4
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MC#/KU:EEIW/C >-.%JW<@.P%;R*965]TAU65[0A8K%8#X#J%A_[5('58IP:
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M)"N07J#GJ$C/"8SVDFIN=JF1%=SMA0772MHSXZ7]AFL4KAQ_$&9!H/WS)F;
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M2,HRA0EA-),)3ZB=J7*6%'.CH+9.%7T /[Y7[+M9T-UN-BM3I:;;V6I*AM;
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M+F"21U%.44Q$Z93#]F0O<V,X(Z0V4(R8X$\M*#"2.GHH3V-J1UQG(Q68F'Q
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M%+2S0#O02YXGG.B('A&E.<0244BS0L*$EA%E!'&$K;80K'N<&_<WYYG6>_G
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M[O399CM6&NC+B8KV/0:<]8^. 5=&5C?V&0+6CG)&@BLPSPP>F%;R:J-(2;P
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MF5Q]>X$=8R^&01TFA=&@"LP(?73V^Q#CE0&Q@F& #=3]/290WQZSP' 'DU"
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M"Y<9DY#<5&OC]= ! 9]4S_62HR+F<29A)F@&<90R6$:Z$$0A%1H%+E(>N]6
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M__IO<1;];;<Q?JCF*+EH1'?<]?(;)+NU1G#H \^>)X_UOWB4?P'VH[4 C9)
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M!'*JU&?;\=@4Y*O0PUI-JR: 0'TGEN9F[OU")\UK-G5J_>O5;*$^>C_3V8?
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MQ.X(QB:D7_^5/#[]_1U8KM&"A8'K5RG78T@LA+9OHGO?OFW@@PX_4 : +0O
MQ@3P=5CVG>H4]SL*@]4I;D=CT8V&WEK@6Z/QXKL02O<O8?!,?6*/AH>L3^QO
M]UY]X@L:\MND5BMHH=Z4Y5?!1/5-WPML?'H=155D",D(EHDLU5R2$DA94L*L
MS+(B3;*<Y%8%K,[V-+8YXX[\4%^>#J1C:/AQ/NVV5X.PU+/@=QC!!N05:&&&
MVXL\RT3(O<+CG0VZEW?6YOV]MO,/^,G"OPM^7\WNOXJIF:[JA^JIS8$428%B
MF7"M Q*JY7<""2D81"5+*,]E&4FG',]'>QJ;++1 P392SUQ3Q]FU$XD@G/4L
M$GYT.:O$62I"JL3QS@95B;,V[ZO$^0<\X[&[='CU5J;1-T2]!TS</@BQ_#1O
M$A.\>=Y\H"M,K!-6O7ENH;T3=74_,Y]M,GW0B+&411SR)-*Y[G &,4\(C%!$
ML2B9)-BI_GI_4,>F4YO,HC78LA6TQ@)C+>C,!6^>MSZU+AK>9-)3?^N^QEM6
M^R5^Z?%=L1/-<;P!/:OND<&_.C+Z5_J4^NCP!T\@T_\0!(U_[P_ML#'SO;/^
M(LZ^_Q[])BP=!RK$^H;2)T&4'+?I79]_(TN=[>+9=+1)MQ>GB/*(%I!F.N(V
M5NM@',L"RI@E!<KB1,1.65<],(QMBFE1ZC0M<PFFVH+M[,AN$X//F-@I?L],
M]WVT9=!?;5U_- 9<K=.(/U^!SHA>4R1>0&-(.?:!,:C.7L#3OH!>TI3'6=-Z
M%X$LQ>UW\M1$P90QCK((0YIFL2Y@KQ00%PGD%!4E(9S&J7T!^T,]C$W5-MM:
M.L9.HW0*BCG.I,41T*7\#+;C%Y@:A_.92RD:Z/S%G2JW0Y93-)P\1#GXX'"'
M)*=P[QR"G/R@G]OW3Z$/3 2__J8$]5Y\7NF#DQMIHA#KK;C"-Z2NV$24F2Q3
M)&%"LA(BGA20%+S4^7*(S,NHU,+G=%/3J7^7=WJ8&$$#R[\&NQO[I22)+-6,
MDZ4ZHSA#%)8QSZ#(8YI3*I(,684P],[]$%-2!QZ2!GV7;DW.%X":47G_Y;;/
MT;!SM'OCN.=IK<,-6N"@0:X7-0WVW0!\ S^<7^W%6DB/V@W H+ZT%S?[7K1?
M(WY3S#M!EYN:,;K%^O9I(0B_F?T'653:5=<36CPI\H)$(BV@2&4"4<D32 5'
M,,E1DB=YB?+<*3^2;<=CDS:#%-0&*IC/P+<6+%!+'L=JJM;<VZE9'XSV+&0:
M\E:IL4:J:G"[9K<#;KS2<!+F2E5(];+N>U#A<F5D7[.<G_>\F\H>!%]-Q8U<
M[]6V.ZY;A:]NU5K)7-BIU<>ZPEA?Q$)Y'X]Z*_=ZQC>_GC>E[KN=W;T-NQS3
M***IA!+ITE51D4.<T$)YUT+)GD 1BIV\NH'QCTT\M\_UE%N^58WNH3VO6VR=
M]3INR [];MBI\HA'O&=Q[RS7;NE6V<CN9';+_"NP(<!\>EW'<(L#$P^Z]9>6
MAJO-D7"?F\D_:1B#WBL=V(1A;Y/^G/%Y<8?T)\$8.-/#VKCKNEX]-M=?OU;U
MGQ\60FSO@TV2*,Y91##,(EWNF*4(DH0E4)8H+G F.<N=#B%[1SRV&5-CA%*!
MU)D;F@U:]X5&_^-L.1>.:?3ZGOTNS[6P-6ENV7T%M.5 FPYV-NU'D$[!=9Q&
MD3;!&O1?(SV"ZQ@$2X/@W+''B>]658)U=Y.(9201&8>,%Q(BM3#393T)S 26
M3*0Q8YFT/O$]U,/8)H6W4^45*!?Z:5$QXUZKE@';+K2B?KA?Z(J47)_FZ2.0
M5<TWQ50L3T*.4VYQ-'PID3WK\W;IDBVEO908AX/A2PD:Z&#X[D$ YOC"K>HF
M&Y#ZQE>/^A=+U<C6W[<6_FUCII5V&F1;NA/JCM\ILD\>/Q]\<+CCYU.X=XZ?
M3W[0L^X5J1\^3.??VQ5,EQ XERR+2 HCJN]J(Y[!,J,Y%*1($AU?(V/FXM(?
M[&5TBJM  JE0FHTJX9D!^#"A=K[SQ33UK:>:(0UPO<$3/OWO20Z"EG8ZV-&P
M-9Q.V?JB6-/)#WO&',_K6L<VJ_;$C%6B;BXM,*$\+2E+2%+"='V[")*")#"6
MC,4"TQCEI5-8\<%NQO;]URC!#DR_VR1'2+63@,NIZED#/%ARC^H]24+0P-W#
M/0T;FWO2VA?AMZ<_[:8#7%23]ZJMY?,_Q73ZC]G\^^Q6D'H^$_RC6N"IB:ND
MC&8IH9!S290G@ 3$>:R# ]*T)$F>R\CJ2NW9GL:F!@U8H-'"/S5<T.$%#6 [
M43C/\&E=",I;S]+@3YFU0EC3L1&)NE.)6K#7]_-O?U-M- *A?MC7A?/M#R(-
MUF9VZF#_@)^C\%5\$[.5^* 0=G>A_EDM']ZNU)KN42PV!Z9%F7 1EQ+&/)(Z
MA$BY#F6!81ZGI, Y$UA0%]?!MN.QR4>+V_%XVYIF.V>B#_)ZUI 6,M#?A<V5
MS^\*->A@*W^CC]-?5[)"NB'6?0_JF+@RLN^J.#_OITTZL=WR^3>Q?)CSCS.=
MU5SOF-U\GZFO^4/U]$6H5W.V)/=BDD=%D<28P9A(?6T(E[#$ZC\Y+D51IAQ%
MS"G2Q[KGL:G3&J+>+FXQNBF5/>EV4M4+E7W[.P8S:$"##>HKL.'WRWE^G97*
MF:N04F7?^:!:Y<S)OEBY-^!9;>D;J:9ZR?9AOK@E4W$K6'M?N5G5K>:K^O?9
M0I"I+GNO5WM=>,AZRW<O1HTE24KR+%<^EKX3Q!B&5.<D2;"4,<=YEA5.F[7!
M$8Y-_=8&0CE?P%J9".JUC5> K:T$J[698*KW/9[6 6F;TPW'BDS!A]].7W_J
MH/:LPP?&\W9K/#<&@HV%P.QC;0(,M^(P^@PQ[&T8@E9N"@YRV!).?7'\HI93
M;QUY+M+UE:(;^7O=U V]H4M2Z0V V?L?[$%'=BB<1^[M3Y*XH$F21\H7+E+E
M&JNW@JH%.\2E+)(DXWF:.Y5EN@#+V*:+KS>_MT6)P;PU0P>VB]80<^&QR3,R
MI]/JO@EM=USW7S!REEL!PXQ'W[L#V@HXEU#9T50W!C=;0_)^>TCV<I-L4I,$
MW#*XG-2@NP@7P!EV8^%RWE[L-01HTB<3/B4SKG=939-=9N](DH*5,H*QX RB
MHL@@+0F"A.G\) DE+"_L4]T?ZF)L&KD&V7S9_)*H'^3RM+R%8:AO_[0W<EQ2
MR%]*TE YXIW)<DP$?XJ'TYG>#SXY8"KW4\AW<[6?_*1_H-CUC.M_Z:T2M?35
MEUN^S*<5>]XL1JE,"HJS".9EA"'*4PRI%$H()2&(ESDM[)3/J=>QB:$)DQ(;
MN.X!9.>)MO/Z@M/7LU(:YO0=0//#%N0KT( &?[3_[F5U[D17Z%BT\QT/'IMF
MS<6A6#7[AWW\+N7D/:JE,__G?/&G\O:9:&?$G)0T0RR"*9%:@,H2$EX4,!)E
M*M.4)BQQ<+V.]#(VP5GC!&N@7C[&,5)M?+  5/7MAO7,DHLS%H"MH?PQ']8<
M7;(S;)SVRHX]/*!C=@;_KF]V[L.^M7*^J7=AOGC>=Q3**))91"1,L9 0,<XA
MS1F%A>!E(3,1%0ER*Y5SN*.Q:6*'TSGG[U$F[5RN$/ST+(1KB,-X5><8"5LK
MYTA? Y?*.6WQRTHY9S[OJPEL_BCNR ]=K'I6BS=B)F2UG'"*"&8%A5E2%EH2
M4EC2DD)$<8I+%O,\B]R22![IR>6='R9=Y)?%_%M5ZRO:>HNX,K#!DOQP%XG#
MU.*4"9:F$504%SI(&D&<%B64A.>Q9$0RGDV6\R69#D;LIK?^:+W3?8"GGLE-
MLC)6_\.PS+&:RI*DA&5",8QQ3EDNDC)*\LG,%%_G=RXSFC_'9</QBT[_NF^P
M[2QW\7O9^R1GF-$%\UJ,X%6+\OC-:(^Y[20/8:>VPUT-/+.=M/?EQ';ZXY<F
MB-L$:C4]?15/\X7.JODX7\V6]9OGM^IK>:\FUN8*%HXCY?N2$A8)T3F3,8-E
M226DF4",I!%#(O++].8&9(R^<H,>M%\;KXMOWN-BISE#L#V Y^U&] 5)S/Q8
MZB<;F2.6GY16S(^QX_G!/-OSS_*[B4#Z0IYUF^W6%,X8XR)G,$UC 1&.,X@)
MRI3Z\4*469+QPNE6SHF^QJ9M)OWL)KP3/#5@/6_WGR+93L4"4=>S4!G6-C#!
M%UO6O-+TGN$C=&;>8]T-GHSWC-V'\N^>>\0GWU)W'^?[O'V3!1(HYERM8I,D
M47Z2<I8HS0C$6+)(")RGW"JCW^'FQZ80O[%_B+I6"ZJW\X72YS;/J/O!P$L>
M+<Y-+F*G[]/8[L*= A>&$)?,29<0,]#9R)J@Y?=YL"1&Q^P^G<'HQ5,#IB\Z
MAG@W=]'13_G'H^R=+W]5SM:B8LK!:L^?=W^Q]<D)%CQ+N,B@B+("HH)%L*21
MA"S%,<V+*,YD.GD2BVK.;Y=DL;1SBR["Y/)^[R,;("*#[06U +($5-Q7LYD.
ML9U+\"R(94Z$,$-8\C@E*"G5MX'I$N^9&L)435=9+G#!*!&$Q^T0OI_Q40Y@
MA^LG#9]0O_\) V?G)P\V%'U/H@K9U8%XI@UVL!ZD_=^]MX@A\PIRNIC8T,%/
M_H &#XJZF+M#P5*7-^HWBWY9S)44+9^_J'=VJ?K1+3]IS^E%8">*2Y9R'4B5
M:;4E%.)<Z2[-N<AS+*20F=N9H6W7HSQ$-,BOP)/&;KZZHD-_!69BZ2:GUH-@
MIYQ]$-NS2&X8_;)F]/V&T2&B%%Q9"ZF UGT/*G:NC.SKFO/SEYX&;4I_W\A/
M\]G]G5@\ZCV3O0O3-)8%Y6H4<D9CB*CZJ<1"0%+@E)&XY)PY53ES!3"V_8_K
M^_N%.;\V-]]UEI85F8+'W3KJRAJHP#P"KG<&O2\Z.@^6Z]%0^"'H6?JV*^CL
MUJ[_M.;<[,8.4_G&C;]^#HLL,?RD0R(WAHX?#CFVX^G?-;G[Z[OY-5/RNQ"_
MD<6?8JF[V.PD3TJ="HF)2 U)KA2140YQD2+(<9R59<X$26476&/IW-GTZQ%A
MT[=GIQIZ,+?.U/?O<0UYZ_S(T;.SHM_2K0M&Z4 ^78M7YXAO$8,-Y*W#I8 ^
MG M%01TXJXZ']=Y<N'CANCD][!N=RH6L9M52?*J^Z9O:2_7V5*H'<X&[_HW\
MUWSQ=DKJ^K-ZR=[-'TDUFW!*LU00##E+*$0DX;!D<0DQ%W$:IZ)$W#&8W1G#
MV+RWC0EPJFT &R.:# GU%3!V &,(T): /QI;' ^_?4;,3MMZ'H>>E:Z?(?"(
M1?0F,6R<HCN,@6,8O7EZ&=_HWY1[INY/ZA68?GF8S]IRX9.R2 N:1@)F)!,0
MY91"G"0("E9FZO]QQ@MBFYQ[O_&QZ9S!!PQ T""T3\#]@KC3JG0I'3W+C0,3
M3GFUCYE\02KM%TT.ECW[F#';";./?B;06NO-JJYF0BE!_>MB7M<31FC.,AQ#
M'BN:4)E'D,:$09IA+#),<YX[A1^?ZW!L7V%SIO5$*G[A(FJ?UZR4"9=9 F.2
MYQ!%FE)]Q3$7(A:,L8+ATO%L(B"SPYQ)--RVR]>FAE=@EA6ODF2EFF>H9!#Q
M*()EEG%8D$SF1,TT2<(F,V$9*A&$X?7>0-]1$,W])M:]OWI)^X]J4<T"4^RY
M$7#!R_D3]@ V:*^ P=OC^O\(,[TN_??[_+FK_B,,G%WP'WO.-S9]47TC2^4C
M;Y7(OI[QMI;5-5-_,GL*[ZI:UR%<+<0UK<U9Q"1F(LI+06"2<;7FS^-8+?=3
MI4!,,LYB5D:QTYK_ BQCFU WIH M6\SI:5>@;6,.V-@#_N@L<@Y_]Q]'.W$;
M:'1ZUKT^!\8CPOYB2L-&X/O#&3A"_V+>7D;P7]ZDFP+7B^7D[>IQ-36]OI=2
ML.47$WQX(Z_YW%1P;K?J6%((E*,"%A'&RLO+*"2",E@*@1$F!4]*J^H8]EV.
M34\WJ$$#^PHTP/5Q4 ?=<?/480!.*V0_M/8LA($8M=8\=Y).2)MJ;$O6U'_M
M2YI#;X,HE[OUG4!Y/.EQTZ@M"-05E-^4F]=GWY.$)%PM,97@D"S2M[,Q+%E4
MP@C':9G&DN+<*B[G?%=CTYVNZ-53@Q;HH ^'>S:G:3VM*F')ZEE-.IY:H& +
MZ16X"TF:PT6E8.0-=&G)GT2WBTQ6O)R\U'2ZA>$N.%E9LG/9R>X)#P5M-JIO
M9%L)_H&H-\,4>.0?YHOWA#THT9;SQ2-15OT^JY;OR6(F^"3"42$)X3"E.BNF
MD#DD2"00LYA*DB%&D+265C\,8]/<Q@KMAC!C!ZB-(: REICD.D+9H@ND=<:
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M4A"UW"[4XH:4(H<BR_(DCU*UX':JE^32^=@$LPO[9:O%PER9>Q&]#E8F_)>
M^GG&*Z:W*:_4[TR$E_YQ(;[-I]_,$X8!0.X70MB?"W@-H9VR]C4P/>NIAFU2
M"#1\=LAUSOUC,=KAI-.'LY""Z=3_H#+IP\R^.'JUX2>)YK;@G7KV^D=53PK,
M)4$L@64IU9)8,.4N"H8AQSG+9:KSIF0NFK?3^MA$S8 #&AWX0^-S7-3N,F<G
M-=Y\]*PE]E0X*\5!DT-*P6X'@W[7#]JV_V4^_*&!$TSHP]3E\U;V37.N<?=
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MA=[NU.:M9J9\LXE>M;A-\A,&V])%',L0]NU9!BS%N[%Y*WM</:Y+12[#,XI
M8BO ?XUX81?N0Y?<M>OT@LF)GL=&CV#;.I_;NT+T53R22@<+Z%T.C71%IKHJ
M4#+!$25II*_>(%'J6KXI)%&&(&<\D3&*DCQQO^([K UCF\A>7.-==,C-)FL+
M'4PK*< K4V[C%YU+95V-WF.2&_BE<9CZQOLJ_(4FQ"TF#ES!7;,!MN@PM? "
MSY,_9RR#SYX#FS'\G/ISQNG@3/N3H 1='*Y7=TD>,:*6<P76EU8CGJFI$E&8
M)6F)8U9@*:V*F]IU-[9936.<S\R%0+TGKQ=KK6JQ;74336:WT&NV((NN<:^:
MUN*_^8:8U MF3_&]/:VAUD##+V+&M KQ6T8$7 ><6J/4QQ8IFV1$,_Y%O6F?
MU;OW;J[5<D(9CTLE4C#+8PI1FE"E7@6!I4S2*,FX3"(6=&_* ^38-&\[;U:#
M,/0.E,](!MIXZGE\>E9.EZ$)ORMT 7>#;@;YX!R#^@9AVGGKYY*^/.*@[]2K
M(+[,J]GRMOIQ]WW^H?HFVFM=G^=+4;];"37N21O@F491F:61@"+[?]5=2V_;
M.!"^]U?PLD 7,!=Z41+W4*!)V\4"6S2+]+:'@"^UQAI15I;;YM\O25FR'=<Q
MAZ94]9*'$I$S'^GA<,B93Z4X8W&%65X6F- HEI2PDD9.WB>\Z[E9Y?2W/"&_
MH'LC*)(;A8RHZ.7VL?W%*O&KS]5;V* \;XK'A7ID VOE1E9PI"5'6G1D9.\S
M6CN,T9L>_]&Q!MQP'@WSB2XW!\<>=L79"[YG;S?#6ISN8K.7I@=WFOU:^#&'
MUV^["+.AJW@24=G^1=TT2Z'NBD14B4HCG&=Z@Y#QO,24%@++0J\R<1%7(I53
M'F,[RCVW=>KH'*"/\!NF;:$6_>]&+YL\N%E+]*":+HD0F$,XU=R8YM1[A!'_
MB<+]>]I_)]S?(X L!/,Y"@>.V9P.Q5U%G]?6*.QXA#XHAW;OMR1^$,LK5=6-
MJ::Q8NNUO1IK^^\>?V3?7K=ML^2;UDCRL;YA)M'HCJ;$'&]S3*64.*LRB;F2
M$2:2)Z7*]3*7@)8X3SGFMF092GFV,H3RZ.6J7J_-)NJ3WN8";ZKZCHK;XC(!
MUB,O%A^N_UP@;H5%1TH,?]%Z+-"^)JBM4:=+.*M_(9@AK;BO*)-:Y0OQ>FIE
M+VW.M]A'K?W,]M'$LMK7]SLN]N]QW28Q53G)&8ZBJ,!9G!-,,ZYW R2A65[F
M156!B)(@G<_-/O:R+]##RJ8CW4ND>OFA13\ 8^!F&,="=F1KN /U9@!U$'T\
M_N!+4 M;+030_\2E0^#('-<1\6C#(YBNW="ET.V_6:XV[5 ;Z48UUDD=[@]D
M5:G2)--VC!<*9VDJ,.-"8!(K*4E925X)0"$1MUXAG[5ILBN-2[_IHICF-@<W
M:MC/G>P40:HO[37$(P!Q7<>Q< B>A\=W9%MF!;:%(K<B]T723.BVV_R#K\9
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M_2\79V$ZGPC-,]$>( 5-.Z\/ D(R"G*V60E3,$LU!& >DC(.4GK6\:)7@;<
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M!&510_0H@"7CE3=%23'(8=E.5(Z[:0X+F3WQN;OV6@;GI<U_V'&.W(2279'
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MB?=[DWP3=N8U*6%^.B7OZT)$Q,1U6]+:0O>/Z6PV$5:JRA<8AJEV(@W@#4O
M2^$Z1&VR'.32HPMQ+;C%O>"J=TTT@:]KRNE73IID:ET7KYV5-)E6&\"(DC+J
M0 (:I$AO)YP,[ _W@I.])-H$%F[Y9;\MYNERXY7H&*M1GB8?#13C!2*:VF.R
M).8-FCQ,#?%6:EIPA7M!R>&R;@(R%QQ,C,<HZ'\@;>T!4P\&8O"2-MB @JR@
MSVZ06.GB]2TXOCU>5>PDS09<W3?3$*>SBPS">?ZP7J3?/RUF)/3513.RFV#
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M%%$]I/'49[Y;+NH2R#]_^SM%,Z_G;VE+#G4PTDE:T^+8]%*\;OU)+D9@.4)
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M'"S'!NXWKOH?3G%U56V22F:Z!(@LB\L1D+8H$-Q[%4LI20\R*N,!)>-$40,
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MF)X:P."MU77?D%\M0#X)R?C""SD;153OE1ASWI =]]R2V2Z6R4&:8G<A;MQ
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M?$)_MF@;24>V2-SYI.G_M)]P!LJS ([Q!+*(H'6)4>M!\C6.9)%>3E?ALK2
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M1QD-;9-ORR_S]73][1_3C+>FLM^2Y2^TFI?S,+N2X^KG;^^6BWR>UJN3>?Z
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MDXG,F&,2G#1^,T-7&VM+P6Y1QMWGCENUU9..#Q#5V%I^N\;_F85K 22.*G+
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M8PAU*T'=0T]N(/( I)\80K:%N28SS)MPLYMEO+8:@'X ,G:)P%-E.O75^+:
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MWT@EYS8CQ5HPT]-4QKVP=8JIC/LHN@.P/S_3SR(SUD8+OHC:-B,Y1,'K;NS
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MCR*_RZ1H"(R.H-TCYOI<U*>#WP?:M_C<*NU?<?6N$-N39".+V3(2IBL4:NL
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M C*Y$+)61>F^1A2\NJJ88^*%$P.@ [][[.W+NZO5<A5F>3J[N-]_%;1FJ+F
M8F.N2U4R^)@"6!.44#E*;?OJQ'N6G<X]_L"@'/A^;@"$O"X[V4SX$R%FK[R
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ME$;6^DVRK)!K)6<,9%G24"2H0V[4T7!.(^+W4?1.(^+WD?J RXJ/V!)V?ZS
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M+9?!QU(R;H8Z'H#F8VFS@QCA^^D"*7"ZGN0TNZC)UW)":9:TJ",P53(EZ4*
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MS_=F(6"^7R=R[2_NBX,'SUQ]]%)UYYPF<=32(\-0,R^]Q!VG2K6F=-R;PL8
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MEJ%IG)ANIVW\L>]-D3:04OI"&O$Q"<S&Z$(&^B>"<L%!K#DH,Y&'I(7GK,E
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MN^KTB6$:#$TGCP[ ]3L2,Y=Y_?TNGZXI,<F3&R -.-HXF0&Y@ N^S@5Q-MK
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M(%0J20%SM@9:4X2 14')&KVU16G9Y,H=N<]>*EZ:^K\M9=<_-!\_ZSSK8+,
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M^0G7ZYJ0?5W]L$=,Z?$/.CP\-&"#$T5Z?L[A\C;UZ08X(DDA3<Q0M%4U_UU
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MA#?)'G=92B9R3@F):5$G6]-CR31*A8,2&@U'E1&;1!X?[&1>K_I(,#N,_QT
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M#\4?)N87<+,'SSM SN;A_AU^K\?HX^HG7/[C8M>21N?(?8A@E.:@R)L$SY*
MZ)(,FBLM=9- ^I,[Z@L_^XA[U8+W'8#H1Y6\.5F<^ZQJYG!45@%]90%M,D!V
M;DS:\J#NCP!J8>,,OJV.E*-X^&UU(*N[ \N=TD2KI,4B).2BZ2@5.D58<@;&
M-";4F4M]A)3\VPWU9.:,%_2SN-F3ZW,G7NTS)U*C%HX.')1@Z+!%KL%Q]* E
M+TFD2+[$L!X8S09U'@=!^XK\T#F=8_@_-[[V&5?DD@DBE5I!S>E0>IL A7+
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MW%QS>?WE+"H=C=.D$E(@>TFS##ZF J;XHAEGV28[".B#E^SIII\ E&U8W0.
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M.\6?EQ;+3^@./("^24BVU\A-H"@GAO_", O-1A(\)<M4#*P35I[]U+@O?W7
M,JQ\&[BQ=EWKB^U#YOFO,JYN,OWZ*:V;J!:7D^^K"Y\QH6,HKTT8V93HQI59
M86$U_!,9YY[6Z;DXC-QQD=B6NSZP<AN \ XV-L?<&J9]5@I"F?(I!%4H-J,A
M2X.W?79&ARK/S'LI:L79J@>'60W=- "RN_,[D:'M_J/RH%2.I(CE7RIJL,HQ
MD%F)Z 1E,E?)J^VD9EQP#:3IA]LWCA;[R).0/LYG\3HL/\P_I_F/25CGO3W-
M5$JF,?Q("GV$,D='90$Z"4&\4\KKT $VG:8=[2)@W,*5T]^'@RBB#2 MSJ9Q
MP\%BN],MJ<P)BD K7LIM<@3G(P45$^&T[!5U77RQ/FAZ3,5X0[*.5^QCE!PI
MY0;NJPTCVWQ'-B@/AD+0K/0O&@.N_"IYG67VE))8Q1&Z1\7H$#E6J[.A1-S$
MH\O3BQU4M#RM@E<B*0K&XZ6-K(!,2>9,+<NIRHJQXQ>L5&M1'B^.&TY5#5BF
MW>. B0M4)VI!2J[*0"-DQ_$()@N+04:4H4Y)T8O;N-)+VYTVKO01?0/XZ;M?
M(6@\=HI("$QG9*],R4HJ +.*::&LY+Q*54^--1@GWL'2"QE'KL'HHZ:V4-AM
MNP)5+(6<).B(1U9DZ5<KWL!(;E#*C/)0>P/0<&LP3KR.92 <#J^H!H"XOS^C
MJW_R[F84ID[9HT?,@)+RC,]$ ,,L.BJ$"*5C\B*<I$SL"![&G0723IGOJ6#0
MQ GXD:;7J;0C;=_B_G.RO'R%_"-;<^3NZKJTG9XM%@G_6;7?Z2AY$%E#)JKT
M"3B&HE8*#0PSCHL0I*MBC0^@M:TJR)/AZA&^ZRKYB(DWPPQ'?3^;SKZG.0IY
M^G4MN-<_OZ,<T2Q8M E<&["LL.%565^B'4B*OI&P1N@D:F!U+T5M53^.A<AA
M%-: _=P6,VS(_R/YY85)5.<4(V2I43!(-AB;(@09>"A;G RKX@GLH*6MQ_NQ
MT':LDMJ9Z'7;6KPUYI/I-9ZA#^O#=#/@=.L9_4R+/R?3V1SC@JT0SJ;Q_D]9
MAPU_IN7E[(YCO[C(UK*H/0-E$I[$LI;%:*$A>.-$XED+627O?4(>VWK+&^]X
MM FJ)LS[AN6-Z3A/TY0GRPN,,6@D-("SI4$E>PX^)?2.3$ C$HF.NDH)UQYZ
MVLKMCXOCXY35CJE_GY:W1^HB*\N5$!E\IF4RM2/@,GI)R2J,>UU05E9IY+E'
M15OY@=%\UX,5\T+F=:S$-^AHCGL_L<84COTDUQFX(9+5@L@$T:0 @B@*5ED'
MD2LNF-?2<5WC. X[<./C%H0K@7Z^Q&.X.+O&*WM>DKP7P@D9#)/@950@3$07
M65$+K'C',N"_.VW+/*#PX2FR6GCK.0@'CTL@!I-^ Y[2?6X^NOF'^>HM-OZ'
MN[I.']-\Q>"%H[FP8D#I4@^K45;(#8=,T?"6REBCJCPH=B.OA?>;"M@:1!O-
M86Q]8MXN%M=X6K(1-'JJ0892)TLE U>F*G/K@\[9^)BJY*3WD]34[+ZA[=0!
M4F\4/^@[+I9N6M+?%P3=0A."+/V,Z!529L!ZF]!)M!;_+.(?5KG5GZ&KJ5%Y
M0R/I4/DWZ4N_<9/YCV)AOR6WN)ZO"I$.\:!W_ISC_>;GR1O(6RX?6MTT?TP6
MX6I6OK6X09!6.47I)7"ORZ9G0L";H,!%DH))V:8ZN9.GB#JZ=WW'SRX#WL_Q
M+_WS JVC]XD%R'C=0AGN#Y[["-)J[:.TSN@JP?N35(WK1P^&D$>]ZX-I8L!"
MX]HV9E4"<5"L_L1/JV-O=I%Z"JM#N?$^%@>WI)L%)0&<+O,+7#8TXN629)6'
MX)I6YW.X3/&ZS+B_^4IYPE_5ZK^;.#^Y6HT'_W,M_?AA^JF,#"^SE,_=8K)>
M,GU[-A2)1N;(048\:\(9@:&GD1#P1A<FQ^Q]E\:J_E7K0W+1L%7K@\!'1>RC
M:?H%6<$;T<SRF\G43</$7:VEY.Y):?9 .D>D.FN04<?N#BJ<D[B)+DJ>K 6;
M;9G)K0V&!8&!YD(IS:*0AKPT@]WW\.)?>#^;SA^?Y0O#8R F><B$I#('GX(K
MNTR8H2$[;RB)57*S@W'0L*'N@[R][N=)-=Q ;N6&\?-?-[_\MTF:(U&7O]ZE
M'^EJU8&#MYY0DEG(492=)!:#_>PS2!65SIP%5R?%THV\1D!Y6NSL0_!PBFP)
MGG_>7HF+Q_QM>B9$<$PPJ@I+95""2V"))B")Y#EP$2VI:UV[4-D(6 >$R3XD
M#JZSE@#Y=OK]>KE828QNAZ8)JTUF%&SP&"EX1\%C\ "<&9]YUC;2NO![3%,C
M8!L>"?LP=Z1:FNA2W\4,VS##F,H\* '6^8 ',V5PC,DRIX@&P12SK$K/\!,T
MC?OZ.B[&#E%+LQCC6V;PL#!%%!@=?.G)2N 9"1!I-B9KP6RN\BC[!$WCOLJ.
MB[%#U-(&QK8)B]O1:VOG0F8FRJQV*HE%-U=X,%9RL"K)X'2T4M=)$>RFIQ'[
M-6[T,("J&O#.OLS==(%?OIUZ4^KA\P[N%F4RZF+W'VW.<50Q1I$=T)CQ'.<0
MT;I'"UY%YIF(BMHJB?4AF1C9_QL"5;-&5-P O/_Z_&6^L@B_;I?(;BX'O E\
M"HI!XF7!IDIX^!->#E;[&#S52=DJ?N%^DL:%WG@PF57161,7^BTOYY.KJT?\
M:!8C)T0"CXRA$ZS1\4E:X'VD27*"2T*KW.M/DS7N]=X@#H_6W=@#WU_-YM]G
M<[=<=83><G(CN.U4\N+U>(UQ_RJ'16Q9#*L99.>DLT9E8A^4#NS;$-#I>^.&
M**/CK)9F&EA%L9NIM]-XC8*[Y8HQQ;G- FB*!KT:$\!3M.X^^*A#&90H]#%X
M>_C!<>M+FP;<4;II%G&K;JD-0XH0%J2A("2::D%%!$/0CQ:)^,RRB23*8\!V
MYUOC=JDVC;-#-=*$-_<I+281A5-.R6R^_.J^IG,7_IGB(^<@RL!)4 FX*+/'
M!<5XC68/2OI,F$_:VBH/&YTI'+?#=72(UM5H X'O*C>VAQ7&+-<ZXI$3W('@
M7H(-S$"45!-NO;>I2I7V$S1U@J/^[>$XE-8: ."?LVGZ]:>;_S,MWUQ/X\W<
M1*:R#%(!<[&,*) 2?.G+HXQ%2C7^AJ@R,7HW.9U@9WY[V V@J_%=P)5G\?D2
MK?B7-/^VG==RGEQ)^C^.WH/S+B4#5KM2^I8T.!(<Y,P10<$$#+0Z>8.]/ML)
M;_:WQ5ME/35@]9[<?ZI-=)9X!4@U6G ,W<$D)8$&+ECV@<DZ^Q6.WE%<_YEX
MU*>\P936% !W+#1TKHPE1OGP' @(*_&XXO'"?T5!4D(7@E2I27VA^XI[J;[/
MON(^>F@ 4T]OR:5HCH/7!D+BK"Q^XX#1>P*:F4,>>1*FBE5[J?N*>RF_U[[B
M/IH8_47BN7VZ5F4AK0M@-(;:0I74HXX40A V44.5HJJ3@_:"MQ4? I7AI=M$
MZNWN+MW"T/9=A!&G+%&0<L9K/PL+9=8_E*FF-'*98LXUC,]N<AK>97R,U1E
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M_I&F:5/\S5$(P2H"F6D)@G,&SJ ]3SP::YEWA.?GW*;'/[8]#!RAK]D@PFO
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M^MLW-_\UR^MW3#>-KW]^3]/%K>"'?IOK_L5*3W('LMS 2QPW$G&6"7B:(M[
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M[%N:OYV&J^M8JMD6BX3_Q#(JAV03)+<*E(\.A$&1^8B'03+N(]?9"UTEA70
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M2?QM4OO$1>*"C* U\<5MSV"9<^ #R=K9Z RK4@.RCZ FEM$=I>QG\7. Y!M
MT):!%,\6CQSL;<5!](Y1IM=3=$0DFY'O40M+:*).F$KSI)^EK35<'0*"1X\E
MPVJDB53C^QEZ\EN^MB,S/9XO3P($;2@*R981*1F9R)$J$DCBMLHMN8.6<5/4
M56!TK,2;L$U/E.U9CP;:$@E,E]H62D5904%!&R>#5]8R6:4@[>ABV?J#2]OR
MM ;38E.(W%%.X1S3TF</FI;U5I&55*E 7D3VVJND0_B?Q9@'JKY/W6T?/32
MJ:>K/?$Z5S+%")*$ ((1#B88#DES9HR15I,JCOQ+K;OMI?Q>=;=]--%\W:UD
M285L"#!E4RG]<GCXA(<DF1)6J:12MRF2+[CN]A"H#"_=)MSS/=5\10PZ$ %*
ME-W%PD2P&3FB7N20K1#15!E?=D0EY3@UN<=8G0%DW\ MMLO/7,^!4)%F%24&
MJ)R#((R")4P!CR%Q38PW=:IQ]Q$T+HH:]=$'T5ZC*-P<4>G0)!-O(?C2 $T%
M*^N\ GC"C2(1G5!:Q9;M)VE<+VH8E7? T0'R']M]6L_@6&]Z>3^;AO6O2K7H
MS16/SJ!R1!L(A**4@F;@K*(0;/$2)5$TADX.U//?:@\GAZAT5D^^X[<NG84P
MO[ZW.'/%(O*VX?+>+ID5@SHZG64,D- N@S!9@C.LM-XD$YDT.:=NG6_]OSVN
M3UX#4)7EWX2/?O?0W#LJ#*_Y9#$2E<&@\QFD 2_+KF"1N.19$:&JY)WV$32N
MAS4PO :5?@,>TN.3LGT;8)$98@Q(%3V(LD+=*HEB8D8%89S-O J*]A$T;OEM
M)10-(OT&4'0G>+FS+FU;"2K+;#2)\8>3G$"9OUM:Q2B@U%S2C@GN9 TH/4G5
MN'AJ-.X;3H]CN^RW OZ0SV?+RWO%I4\\J)=ZN?>SY=-_9]TPEN+;Z:ORJCI=
MI(B_6,RN)K'\3^[J<7%386>#LB(3!X$7O8C(P'L?@3IC5"[]9+);BK4YUEI)
M_Q^-V=EO Z F/-1;D:T\I!N)OD_+&Z8,(=ESDX XBDY2UJ+D&0PPA28L>YUC
MJOQ(NI>V<6#].X!O[ZTR# X: _<-/Q_R TXO4A**"_0-;=0,A"/E&O8*G @^
MV9BX897WF.XGKA6K/1 F]F)N(/4TY64_7G]X3VY,"V>)+4]%&((*D<%JFL!P
M*S-WZ 7J*D\L'>D;)]WT6]O5X?#P$FSK#;<73FN>T1H 98%C<,PL>)T,.#S0
MG,ELK!O#OMX0V(J-'1 ?_>SL8:IJLC/SU6KG(OY6F*2%FT;\@V^3Y>KDWZ>[
M6POF4S_N^%[+SL0.U%3YZO;GHZF\]_4=S6:**J>2,4!",7HY8W@6?("HM,V9
M4^UYE;?77E0>W7K>Y6-?4/[G^+_ZYX4TV5(M#9A,2^=RS.B+" ,YZ^25<=DG
M/II,;L@<UZ#50]FC!O1ZRAOPACV1>5OE%8<V<IL?6M74[2)\%(/'<@B>XI7J
M%5ZN0N)=ZQQ%+T][XUW Z*/.#*:3&+R59_TY7*9X?867_U__Z_/_^I2^N^5\
MLLE*_[Q#Q@77U.&Q9&"38D44'HPB>$B]X<RSG%U@S\&JUQ=?DLGJ@Y-[V<HJ
MXG]I;MC_\U\?/WUX]_;SV?L_SCYBR%6>^9>3K^O'NL.'91SYQ:H6KC?+HYB_
MH&F0P5HP@DL0FAGPD3(P3&DNM0E.5UDS>5)_KTRHN?>)]7-<"$DIICP0$5?]
MF1$LQ3"+4N^4H)P24V7(Q6YR7I(Q[(.:A_[; ,H8>:_OW=31:V2D% >LZC%%
MPK@Y& >*8C0MB"T9(V[!*F^-R)S93A-I.ZWUW4?$N# :0KFS@27=(%HV]2DA
M!EO^#S0)!F,3*0$#GP!>$D>E-]'[+L'VP7@9>P_T,.I]!B\'R'IDQ'R^]HM)
MG+CYG:(CYXED1(%DMJPJ+C7?A"O4L<V*H#3H< OE'W^^+80<HM#98-(=&1NW
M/N0KMUBO;Y76T92U!RW+#B^>%#@D'*P36O!H+1%=W)A.V'C\^7$KE >^;XZ4
M;E/8N-/S%H7,.7"#1V65;C,:;$P29&1*\I0L[51V? !"QFYO'T*I>_%QH(3'
MKK_;!J;!S?/DZK]GWR;^87RZL8N*&:JULY!MV;>5T-AZ%@-0$;0/1/OX<$S"
MGH10YT^V@I)#53NK+N<&BAT>&=UW-S5](0@>RC(:Q3TM;^8&?3;.T$ X+A01
MR$Z504'[21JWQ6' ^VE@Z3>'HU_KP[$XN[I*7U.\^O5VFN?EC^)?WV?3]]>K
MDV*,TI+&!$9S/(R1*O!.:W""TTA%]);Y^OCJ0FIC<?B!('D2>X-K;.R;<4WR
MAUQ*T.88<6SXN\#8TXF$UA^C4A09T0ZLQ.,::+)2!J:CZE8?ON<#C?G0QV%E
M,$F^M#>.S_B?L_\^S>O&T]^J^J[1@\U17C0(S1QM#0.F@D/,<@[>: (\>&>Y
M)U:[*F.86GC1$!C8<"LR)..*L67EN1+-+I[7I(U PF.5HKN7_Z+1!S4=7S3Z
M**.IS,$J1%:9*T8E!\Z"!^$% 5/*O%W@T@9FI5==*I5K9I5._8K12Z%/9Y7Z
M2+<I;-P)C%/(WM#B#61!2XF^!$=1'(0J_*.843Z#O5Z\B*Q2+Z5VR2KUD?#8
MOO/:+7@[#9N<AHG&>!M+N;PP94%M!*=\ANB5X5+'(.2S#M"N']R*Q@]5TVP@
MF347O]\+'(C.TECT\[,J_4$^D!+U>: YL41]64A5I:_\R#S0J=\I#KE1!I;^
MV';C04IA'3C.\COW]^)ZLER\F5REB"?,6R&]!:8M>F<>162\9& %MY*:K(*,
MG8Q)EZ\UYGL<J-9931F_M-#\[-LTN:N/EV[^S85TO9P$=[5X]^Y5[3"]^W>K
MANP'LC]*^*Z5DR$A[B3>G>M S"7EP,1L@I4FBCA>LT7E\-U;PYG3 9@7> 0S
MC>A 1O0BHZ,Z1<ECG=3%RP_?^Z"F8_C>1QE-A6CK%VY%J??<@%%*@S L@]&.
M <O&6KQ(E.^TL>-W"M][*?29HI >TFT*&W>B%I]32LJ7-TA%,-A O\(PET$K
MQIRQ(<7<I?+[]PG?>RFU2_C>1\)CN^'[7(1-9!JE\<S@B<DB1 QQLP7'O0&;
MG2U<"O.P4G7?",PGO],*'@Y5XJR.1-N.]:F@9M4O;J*D>&ZB!&]S!"95Y-DE
M+DR5]3XO+-8_Y/H96/IC&YE.<2B103!>RF*\4L@0&F0\'!I\L"&@+Q<\EYU,
MS8N.]7NIM7>LWT?&38+FPPU#=RO$+UP0RI5I+=0H":+4T%EO2XV!L,02SB7I
M5K#8XZ.-&9M:$!I XB\M:_3VV[?K:?J)O[E.U-?.%CW_O:I9HI[LCI(=\A&O
M4,\$V"08B%3FX7CB0$4= LG6TTX==FUGA]8#K!_,2BB+:QAZFP14B4P$\0(\
M*3TKU%"B%,N15G&S=E+SDG)#?3"S>Y;X,:IH*OQ?Q;DL\L2RY4!X&6"=4AFG
M[QQ(ZZ0FE##V<!_&[Y,:&D"?3V>&^@BW*6C<79%%9?8:)9%*W:[0"0\,40RB
M$YX$'E*WC>2_3V:HEU*[9(;Z2'AL_WOC%IQMW8+MTK/$=7*FO#XJ@7&$M"5;
MQD'[F%1@/J#$.KG:NW]^*_H_5&FS8278$@B^+:ZG7\\GL_1]@K' AIE DHU,
M.$@80H*0#(-)*QT8SJRCQE"6NR4(G_O2..%6?6 <+=4&DH0/;]?;6%2Y'(CT
M%%P2$80R^*NH,^@H,%RD@F129>[M7HK&C=J'<T.&%?W89F9/\NHLY\G5Q"W3
MXB*R$$/@#"0ODR%<B."#EJ )R=)[93GM5E;X[*?:<E0/U&>'S."!PFW W!S0
MC::#U,DDBQPJCG<N8^!<PJB0,JITDC:H*N--*_4/GLQ '0>_$RGLI>475[,
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MXCQZ:_*/</J_D<^_0U=5BA@BG<#WQ*6:^M'7M_QK![^[\^.MG?S&WN)CS,3
M0"&$!RK,'P6$%VV@!9? ?0N1+,Y5"%:V85-53J%!!YY 8-_1?(6S'E4@9JH9
MW7UOU:#L(>MZCN$<&J^EO%].8O@$C>*^'633NNH/$T;[#/X'764D)=&D'IAB
M0@-'H)*C%8/F+[T&OR':"N:<#4!MSZTSWW%)E4PPZN?91]#AQT"\.1#4F/4
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MQ&W8UO:H>*4^;)]M1R\MFBC:FO<\)^S6>0V^F9)&>*?T-9B2/JYB?H7OI^3
M3Y9B5#O7?O@2E_KNAG7N"=]PS9<A<4K)2[CYW=U!@GQ(;@32 4;1RG+S'NWZ
M*QRN+F&-VFC#X &.0@1ZY&J;D>9(V:)- ;(22M=O=L#MH,_Z&\E+@^F:@D'E
M(+=K7#7$2FFP9?HM;[#/_V1PLX$=$EIOT/(\A/1>]+BD@3I%1^I>-QE(IJN>
MC!S.'HU6EA;L&3F2:T7+6.0URV-!DL#^TW(UKUKSM:]N. #A+>42B_(LP7RJ
M]Z^N!;Y<]*R9%EO+SX'!L;MS6/K&)ADYO*:*:M>:73T:?@L,?$DAO*[\=LO@
M5W-OQ)*];; 094' XLTX-[-)8.^[<&S845P["#@\F/"FHIY&?,0Q<,<GA$W0
MI74\HL8(PB8<5S3'7B\%:X7TJ\=2W;O$;EE0I!E6;C=-37'Z8$% G$LW8V]/
MN"YVWJZHP<>$HWG%KM=$%:IUKF=G+OMT9,BP_4)=<B_K .$Z;;0*(C #(;<^
M3XOA\&NK4@^>@M:V^#N*9;@8>='J.B9U\>@VMD/IC8:5K]A3CMJ=N_=BE#5L
M3=Z:!H4@X<U9+CYG:4[3J[>ZD$G"1 8V3UU2@FPRS[-QN*BTULO 22="H=:H
M4NM1V=N0.(#V2B,$/-?D+;#QM. #'?^<9K[8![X1PC'6H*?0T1= ZU*S.O'4
M>WI4^#PMDB0>XR=5'T(F/@]KD+-@;K;1/4\Z-"-/W,)[5^_*I)UWP@K?1FN#
MKH38-I"N:SQT_08\:\8?5\BQXPU0?RZB\W$TRM7=QE/&;*;SJJMIZ=5AJ+3%
M1,7L:04Z";@KR+%J6)%^FH&:C$VXBD7H/F@N.F=\B-ASH0G7FMB1Z;K4282$
MV 0,\XR*G?M#+.W B%51L\]J,+UH?2*:33&I9Y\NINA[YU#?6U>'^@JQE=7A
M*T^WGS;=6BKN:XE/,S-W3;)#50(N=!=V'\;!26(U)$F0<B&%Z8%^T4Q %&1O
M9\5WJ3'N19KZ+1/N"=[Y/'0T*81N $PA<!3M[EX]KRAQY^]6VY;^O 'A?'?$
MW@H1Z/[VTUW<BDYP=L/Y^7E+81D%)35+<5Z]49G-+.4GD9<K"&Y1HK>\1D83
M9]3"LF6?=10D#<F$I/UJ+=[ R>D=.-FKE4=V6__]#>\W'$9"6Y<7O07[U)TF
M\K"'^-^#MZ^/3J+CD\-%1+9L\S[WN_N^Z2_F_UKZ?P_;UOG?*'J)=SUHH$*I
MHL"I1P\[MF#'1'=ZD9F<LL%?:L.U&UW;>VO4["\V:G"V\?#_?1<;\WC0?_JH
M;Y\^-H]V[?ZSG<=F=X\^V]W;'?7_]6CGNUNWA+[ZAK9N2%<?EJ4@Q._?'YV\
M//ZG!R&^]B*N719SBTN'!;Y\>7Q^_.[DX$UT?G3Z]BPZ.'D9';X[X4_/HG>O
MHO-?CE9_&6_AF(Y>TNQ/C\[.#\Z/7J[!I%7-B?9V=IY%1__]X?C\#_S@Z.3\
M^+>CZ/V;@Y/>M7+:;W<=0#5^_RG(^^[4'4/TZO3=V^C\^.U1=/Z._O>.7J77
MIP<GYWAASL[?'?X:O7N/-VCE9[WQX@^X[Q].SD__V/PL\;LRR:"'TE5W8&;4
M@0MU,8YJ59AEK(5NM802C(4XG'FQKUV5K"0VM0)M71D1-JC#+3.-J=7&AW]K
M]XTOWMA\A3N7=HF5=5[^4AH\KY\X-U\IKNP,0OXAQF,F3XO69RL00#U\0?@3
M[3[,YK+'"K;FQ!KMD(S!VUHC TZ'JWU/3AX$A\ORC](<MK.A3!)3*UD"'1*T
M_GKV*B4#_<7U^EXKE)!%M<Y2!R?)L:ZC81WOSG>5T];0BQKCA.MPF=ZU(D$7
MI:T':"4\Q+<<EA'$D#K7VHI9,Y<)%[6L+>X:W(@;,H23=^?'KXX/#^X3)S!)
MD7EV &+(M427F+ZDD+CJ4TW!"')",3634C=<*U0MINMS;70[X+$\@"J)"6&O
M4IASWQ3LQ.  :7T^O4@:Q6NB(L]-T9\D9.$[X6E;V&Z)2&TGJ=DKXJ,.R@P[
MS^_M[.U0[TELN$?-5ZG*"RZ9]+?\Q#>,YS7*V6.=S.$W!P7SM"HI>_7[C,D$
MXR0H>2Q\^0 J!;DE- 7Z4?UT--&$X]8$N,"-(ZG/<+!UX3%* BQ[TP<VZ*2[
MI$QQ8*I"4R+]L)K.6I5#2EZXG' )<JT39@TO1(+>&@-OAKZIS$'&\!Y_7!8V
M<5T>.%]KO67I=468?1%:O0XJ0!H<VY1Z,+8QXPFM,^#G>LX55G\7L120]UIB
MQN7D8VLX<4-18!^NNJ0+:$C(C\?TC=1.R><QTG4OY :%M1]K&;U8P6(+A4<?
M,I8"7<J)  <B/-:%"6#<:FW*FC(X6!.6KL0P;%)O.FBB 2SF/U8P&KR28=R@
M0?D)7RQ;Z_),PTB*$]W;0JN>G8Q73444%T5*PBA8_9T.L(;?3)D;5+X?PG?T
M6C>O);CUJ/MAIUG52[@D6J]K(^NN7IT:EJ^&N%]+6FQ\YO6Z.Z[1W9UK76/O
MK]M:Q5K*6V!W-_9XOGD3G;P[V:*BE7]\.#T^>WE\N/:JVH/-NGBQ;VTYR2@.
M<R0J16"/W([JW EZI3#WA:O<.#ZF+A(!CM5JW:6UMNJ6'U$;.* CS:@HC72^
M!<6GUDQ/X)C4+'>Z[*R.74Q%IA5I!B/$&"#O7C$A_/N)'7QL ]A0:E;N=*9F
M!@WK%Q/0?J0X3'YK!/. C?&7#+O#Z9VYY9;;++U#C"_@D+T:8KO?!\IXGG>M
MK3_W&=(T7Q ^P_E6=HF*QID#MS."$&2Q'K.%^<-#:8MQ_M&(%'MG9/EZR+ZE
MANSRVV&SVEB/(M!NJ"&X()5.^P$6,6T^9\"%T\;2%7C@K,P&'^^"B;! *)A/
MT>]@8$^R!%71%662107W3S*)E4_^MG&XJ=3BW-0WQ?];U<-::,^%1:?>YKJ4
M$V3PR\& @;;P\N#YOG,E6E36H#8%;K&F5@;\+2>4+S67ZLVYU1C0F@FT2485
MH]]1,AUP@"V:#,+2,."7XV]4?Q+[+@Z"X^D;SX)U#OR!G)[NEXHFB$@R(_%J
MX!L1>45GP[:A3L45;[(YA 68DL>"_AT@\.-& 1#)MJU+?PEZH='CVE *]VND
MN#?WE_%HV:H,*DC)I@IF0GGW\D@ W:Q68 W^;:V9SSUWHW:O\I@O8'2>&[+_
M3P-I3"3PUN0?;1D=]-%Y]L9<%K>8# P:'U5.M9T L2RCE&74E(J FJ>\&D.K
M06?,#1?S(LL^1@? +4!M6+221S>#TKN-;>SV03O]+=!Z4/624 ZAEZ0A&ZDY
M5Z*P!JZ)U.BPX)U[2CA+/\\^VMRE]\O7Y.QRZ"=:0AE /#(ZGN""N=+0GOI5
M>^QL52P&@H<>Q@670HT<)Y<>7O![6>W&5SZ4A2RH^YCL]O@VJ02T;_%[;Y*?
MD7<+GOOH):7#V=26+Q4)<^Z#09,!6\#Y&[T+4=&R!1B%[V_H'E0@%(]#& JH
M$+E"TOW5M;J(/C>W!4W\#0GC)L?@4$C=CE*,]TG<CUG+&2"B1Y(X_%]7.,X1
M7JQW9311ZA<GT(CT0584MB@H+Z*YU.W08*"G'0"<OER+4C;B30J7)EFA6](>
MCRY$.@_+,\,K)&&R:&0)64E[8 'U!SYC+/UQJ#66#PSK+?18@(/$0!:X88@H
MJX^6\6P&$].G_ PP2H56I:ETXM/@;F*\O)ISYS.XMSX&AFYXKFWT[-R%3(2%
MLP\\@'E!N"I$@R& 6<5ZCGT 0O>G-FH-I86*)C4XTVAA[X(+#0)BX  -V?\A
M)(_!0J1Z+6FT:<$W1+@AUA=Z?)O&JYI2K!:%F%GS,8#W=-">@NHIB%M:PLF5
MTVNMORW58UXQO/"MZB:WYR3[[N<#X"TE:3D';'/UR!XXM;,LIZCI<<!O;EV#
M"_2 D<LE870@1I"35#,%C3:XNE"/$\,279:ROEIM\S7T!8[A(F0=6%K=L5QF
M6,7$@\01-PEBS)S'TP4#X%K=P&7!U0T+-TK/0?D2PH@=<@\KWY\* 0\$Z9?G
MM<DA3-:5"%L.%">3?G3;H&XS#8/+[F[7U.70?.1]$_ 3,=)[O,W$3Q\B7AT1
MKU4L=EX9AU#04<2!>:&;P>&A!9Z/9@1<Z)22>+J)U90<:J]?&S<V>EO\!>,J
M38[CXY58?&$UWJ[<2%#WC&- 5 3,:&V"+*-SO;%L;R+%];Z,1+\+,9#/B:$>
M?3A]]_[HX"0Z.GQW\N[M\6%T<'IT$&V((GIT="!**.JF(#3\#SZ<'+\[\0]^
M<,_5HK$]? [3ZW\]/GG]\MU;BE:>_7Y\_C]'IV_@W^N\[0_1VL6+?6E*@RT^
M+\Q@CH",\<!NA]5UMQN3B(NE\=I_=D<AOGSZZZIA&-R0HM]SMT+*CU1A]<K$
M.1Q\A@ PR,3Y[!%+\2+.JB*9>XA$#F1JEM.D@AFB,*"T111#A+^8EJ03J>6=
M\G"<E%U(!F.26 EGH#^2TM<T[]IE-*H4&")A>GR:45;KTT* VV: "J[K*;XL
M,?4XP$#&G_]9@:VI *:"OE4TG"_=.Q2"I/I13!_!4FD:XC<"31P=)'5\U4#\
M43J8JNK7V5EV%V"P%/MMFYC"N$4)[T&\B$DN'=#^]OV31\_-=&S3;1#)ZP/+
M<4.2?M5H*A5/)4S)[3(%0(E#;9Q7F9JQGBQGKBYNW$F&&=I)JA?5J=(==D@+
M-$)*C;4FF E@AL,<$8.)RFUB9Q/,TTNK:1\)@0]0GNGAL&3-]..\)#!P:DX2
MHX*%&A5)=/$2S66,:*.CVT+IJSO"4@[-3MS$\'Q1D"WDE$E*;'2YJ6Z&W.JK
M%W&TGII4]*)_9_V(0H<T(\R8C(!'8T<LF:*TX8)]S["UEJ^;H-P-^$02.;$C
M?(\4YB#ZQU"U9IX#HZ"=EKZG+HNAP(P :H:L%=XP3*&=.$+^0)45L,6%)G&@
M?EW.6PW-/ Y)H[>AQ@.P1QAW("1/*/[SPF)\ $MF^%^TE6"1*@"A:OLC<X'X
ML:)XU4A(=;!EE1IK?D'):E 4 S:/EO-ZV/2W-L\Q3/UFGH((>8$F_]^^WP>!
M?I[#<N%LMWO1J[,7O:#1)#)G%@VYQ>Z2E$V2^GS@T"$;N$F HQ?U0/Z&\-ID
M+AU1"0.-D! WV4JY-HNY(C7?(Q_VU$]. A&O"W&;FF!L[Q05$@60AMXLS/)I
MSTE*X8XW8HY7(>0%4-/D4.9V3?6C)<.OP3"++CO7'Q-[>H K%H,<RZ?& D39
MAEVD@[B<B-M(+JDSA#OZC[6 O(>6G#*4N+3JZOE2H_#T-99UGUP+26!539,'
MR^Q&>;2W:8R%1N'BA$;@%@?YF#B-69K,TY%_J!T3Y%8W:A[D%K=+.CFQT!03
M:M"  ;4M$O@R>$^"LP29YBN2*!T*DRI0S8NG4SM$AQLP_SH/T1(;\HM[1]R(
M/'/8OJLH.I;">DLS00G':L3_1U;BA C6324U( IT:@].Z0ZG]!*PF@>G=&Y]
MOC"G'E^-F.MZNOO,NBEQ'B)S1]<@-JW@:Z=B4 SMA4VR&86@;H:LMG*\]@V8
M=#FF>T4''F:1>BG=/LN-;I*:^\_CX_N7F<O94 Z-? %6?B_LIA6 B2L(/DF6
M1OM;BCMP\GK-5L!LV)K+8',!!+L($+.T2^_5"--A_P??94FZ<6.B/C"\HMF6
M6\90>8S9(TCE6*7H]/A>1\/NGD@\Z=+-J?J8B8-C\QBNC4HP4+MC$)C*9N @
M=*D%4EY:F,S$>1=J]CAL81+;BGN1ER)'4RQ8H&[>U/A;@MILZ"46_7EHX?<+
MBJC[_M^V'&QS_Y989AZT$V=7FG0=C]!ZGJ:QYNQHLV\=:ZV32!Z2@#M6>>8Q
M!Y#EAZDBT>U'/4Z"KN3"(U(QZ5M-D"DN.ZM R1R@WX(22,D?)3FLVK6+_&8N
M\354TM>:NI>>\I$N]S!C[(M520D2L?Y>PRMAR5?-3*IR6$%A75I0K3T\Z7J2
M"8!L%[B@.]0PY6<!; .K<"U\D)HQ=TF!"H=& .KD+]KI-QYAQTJ=+<M:]?D@
M?&E'N@ WT=+><K7F*EY$N26ZF=53"!"& *2HIJYV94/!-(_:RPJRI4+REV:?
MSM+DWW'[KGJPIM%>W#FX-$_!QX[(KQ78?2[PM #\XMO3X%TO,EV:,QFU<@<7
MI W>;D'><0!_D08W1*$H?*EH1Z*;QJWJ@#(A@0I;(-I$%PB#YKRT TO!I?W=
MB!#;Y]:XB+&?0Z.RR_56$6T-OP;UM\KO!,#+C1VS'\[.3P_>'-\GQ^R#WK@2
MO&*9R&=XK=%(/@JJO"G)D)HYLU"CCED8#9U[W!N4F14V)$IBP_8A#]4N39-R
MC2IOM,D48U0'2:EI""<7+A2RV67:R :4$I,I]3(*&A329,))WE7.PW7CJT-Z
M9U4?4[[)(?7C_L'6H;HWCE,"1,#9'E",DR+K!T DN\^>/8TV#LO))B<IV*+N
MXU^$4QEZ\FL@97G8];79F=FUG0:I5-?][QQE++5X5H-#B3;CN8!79SIL$=7*
MXL(K.2.M4JAE8,./K27EYN##R]V='JR&&-XHD^[7FL9"%I.+5Q><&@;S> BV
M= 1;'CT$6Y;LDR=B*DY!/&9**W$FKDMZ,0,/!$C/4HAO%"=6X/(X(TNT:.[V
MP91)>2T,[!>U7IA>9,F%[V6N1,V6@4810^N@\<:[R@FOU,X?=/-U7/<7->Y7
MP '8(1-#B>CJ9<**O>[XT"P-2^)DI%KZ1:T]H>Y'Z*12&U]G<:+R$K/PUAQ0
M>EV5I@-?U]WIZG3JLP?@O1ISE\O'%42(-"FMV8QF)J:8 >G9/(RB]H#.#<\R
M'GMNE:Q:.EM(4O&H(W4&J9WR==L$ZR1>*#0CD''5U&&Q,9R1PBR9?IZ9832U
M4L;)6B!6PR%D=3R**?T>5H%7B,7O-+L(6G;W36(44)E0U'7D*>:;]G7?89@I
M+'""L+3&M3M/##PS-'/]FQZA+L+>4,7/=Q^#+A \YV/Y_A>,ZHKYCW&?E=SI
MJJ%SO(53J^"LT^CL>.L5@3_PGY76*2.9P7>_V7R&/=TG)7U_FS=H\SZJ."^.
MWKP^_O!VG5?^H.)T.WY<.H;W?ZP"N@$Z_&OX]&1\7&!R2BUOS,DISM@)5^%*
MM%I?$8XWNEW%K((_G^P@/W6,F+U_6$-3-WW"#%*W=\QKG^P(3^9BY_HHRR8S
M9:YN_"2Z1KAZ'M3IP\'C=A7HA0EY!I/U,>Q)@EC'%>!/E^_'"4 \12Y_@:^&
M)%1F(>&TC@NE7Y!#%1Q*AWNV'OZD4) X9V=YS-AZG8/=Y7OIC0P.'=_4&EF5
MBMO0)(E>V&1<=]$MB3A2AA40-T;[8W;]FA*TNGY5*JS]TBSNQ2%$#T! @ D+
MWAWT$5DQO<ENCV^51_>N, @V61]G==B#K!0AO(N'8M%O-[%G>"HP>5,3:V^#
M0*TG^JFF2X^6<EOC'&NQ$'H""4P.E35EOD:N]#& Q*D#PM1?(03HW^39,7=C
M\VG/^)J:K1O._!"H'EMTH&F(M;KO,UBG]^WIV\-20XU(.2B?CMT,?ZOEEK0<
M+!^5?D\,T.%:6(3(-=$EVB"T^X*4X^&_@*/0KI+''/>1#)9+- M-44L'@/]'
M[3HR:8,#OXY+JG-$T3+*"%N6A>6E[5.5EXB/1=O5BRXO+[?3?G^[K\FV]/QJ
M7<=?X0;$MASPT<*;&"[CT/V-'94&^=^^W]O??PX2^*:0F5]6OQJ8KR,\[W-4
MX_%#5..SS,K3@_\Y?K/.6MQ#M>'BQ1XVX)O>F,M;MBQ?S#OMB%9=1^0ZKTE!
MAT@T*18.<!!>Y.8_L>:>%(HV4,M$K8.&$YPK@3%0JS25^_4*8S^Q-I+=0B>L
MUA4&C2N&#CFOY8&]LU1WPHW/8/6OT2*X]1X(-;RAA_JJ&]5748F0OXMAEA:&
MJFU1$J6#<*'M[7%E3BN;1YT;[4XJW"U1H@HX'@X>=$:E5S)N)MUI#QXDN"2%
M&*\I8S++J +A' [*^"7M/LV_R?=GV'2Y2FQ/ 8'#A=2*O-H5&]*D;Q1_<L83
M813GY %";!,K_X:7RE@7PCH:\].*JUH1E91^KC,]/GA_;QRGO%51'7B-?*-$
M(.1L&@_(!PF4S+)W<6I*4?6QGH4->*P@P7N0F-QYO 6LE>H^&&&K&4;D5[C>
M'F*[.R.5OQ7V8<9CS(<O@^O*)G;K+?#V,"L>:Z)=8KS&&S^<_6]0^C'IC%W'
M/!1W4FD_0_]?TG (\7] ;EJ_6@T^\IZ@ZO%G9?(2&4E/61&%#H-0(NDEW Z&
MYB>_H"ZVS24Q]G<SPJDXZ;40)>/I(6<G!X6 IQ3LY20&GF0F]7_#!Z,X!362
MYA1DZ.D3%YL1^;KU@XM- 7,*9(3[#D;#R<%LXBS\/@2B6:YHN9'\Q*AR'0$/
MT=0MVJ\EEGY!2Q& K/#%0B6P;5@^A:A6@?\>&+NHH^K^B5-2ZRKTW2O*E5=#
M0=$P1;-5@/]:+Q.G:8=H9Z5W\+1R E"DX-DR1:$;EG:<A9/0-WO\.'K.(04,
MZKL]]'U\]38I0!EB!Y4EF0F*.NL:H_+$*6&@O>B.B]6ZN705ASQAPM6 /?#7
MIK-&3ME&>'_N)4;LBP]O7A\\)+:MY;K7LXR5)!W7G[+D#WH5:N6J,F?B-+VV
M4&_@E+%,=!Q&190#(A5FQ+6K))"(>0$OU-Q7I\K3Q'Q&4?<\#0\2=F$\JO)L
M9I'QI!Z^P3:%>9A@Q%_U0-T95%,&ZT0$(3+F!SJ=P X(DYLV.#^]$(X*8F#F
MTH0R#I49-3,W6_NQUDK^'2K5_&.!3NN46<J[1ET!L\.1=G'FA7<HO:B2L6FG
M708EFXPL2VE[:!%3$7,]6O?@ZN]P]3]Y</4OWB?1_X+X(%%9$$F7)QX"ZC<,
MJ(N166:P)%!1IYI>*CT1_"U&\1+L-W7G79C)*C+()Z J5C=B]8#M!P8I6J5;
M\,_M #J*S006?MC\N#^/WAJ0SV#-MA)\/"*U5)@XUL2Y13XEJ;NR7.P29XW<
M50FU3!,_/#@Y>/G%]/!54;:7!<-N0T-HR[LU(A_8SA",:B0P8K<..!?YU@J_
M;;S8W-AMMWFF,K>IJ[7%MMW(D=AA5-SM4 CNAZ!YKR9V2UFG*F+DUI'6[98\
M<8=$QK&;HH$5E%!P!P>24 )^A2'2 74]T'Z-2HF*P4=8=]'!:(2^LM)R^VW\
M!>C;-AV#3D>$^5*0XILMGQL_9]=?W.A/3166(',QAK1\;Z,-%H+DN'*6K$$T
M!8)8H,+U8 3JR#VQM%;XG@#X,,E7$J^XBAU>#V1/>%Y5FIC+496$GD\<&-76
MP03_"N:BK4%Q$F%/4'QC'FPU[RR-3^J*1:.D8VW.!"7<)]B]S5[0ZB+ ,P]3
M/'&%Z#=M%?'S$ )SJWL"LZ'.=525Y':0*,.9^'@R!BB=8,;%,;V[Z1_DY$&>
M"":,ES;5-B0X7OW\@N6Y+G0!;=3 '1E'<*_Q*G9'1DF6CFU(>[JK#<S(YJ!1
MG6 (MY'#>A*0#/NH]"A1H86/R+5<"64G*%PA15[,E  A"1U.G2?TK#=.0[\*
M'Y%K$[$M:?UTO/[ VJ!BLRHO*I,V,9HE(W[AAJNM#&P <4+<5JF3N>NJU;B!
M<W37FMI_$@B(/J=TR!;)I@('&YJR:ZW.>L=Q@,"D?$L;0CBH>MBMK9R&T# L
M(^T#=9)+0CQ:F,8:%'_QFC2-LWYKZ'JX&U#T".>/IH+TU3&%6J 7WYYD,(),
M9QL;U*!+P36BT!3:<48 G7B./KTEV$GZ =!B@6 K<2&@G_83/AMC0P2AFX),
MA#BM@CT08C7DWJBP$TA]XYN<@M8LO$E"_C=B"6'1'8V,O0RF8&(M?'^?>[5<
M><;M\VVD&M!1CD!^A34?$G-CRWG1%/[2N9)HN@,ZU0)%N!O<6/) "'=0JUOB
ML#@A##S]=V7[=G!7=,]%"-7IN#(<!L V)2M3,G).66S<8*65E1>KY([1I3&C
MADB7<>% ?.#+ Z]<!)XHU!+5H4Z,$>]3H:B_B @E%<5 -45$WD8*82-Z\1@X
M1AJ)8YV0DH=>4G&?&"<XZ5Z3BJA]7]Q?VE$&"ZUR<YE&U0P9UU$Z3F %:^W9
MN*'M+R3']M\I;=M(R6]O[]%S8,H1T:>-/I2@3Q></&^_OEO^AI[#-ZBS"*W"
M*6=I:N*B(&7B(B,2C<<\=UR2U@!(K,:B3CM.X!?1$%LV@WZ)\A!M!0KEP(X\
MW?TV%_)&RUZ*AJ*7;Y4F'/0:^?'I<[ U#/:>QV9[N/$E.CP#UF! 8$2V)'X@
M!U:AJO)O,)(&L4&U!;&E^*M!5?(_$$P<CE_^B%"Z((*8?HN'?6'SLH(W]O#;
M)-9OF#_P7:"?A1_P?>@A]<R$?.CF!(2RUHSCKK02[4KM_8QNHO<YM/9TG4)K
M*W>#%@>24>U "[;6.B]L51G\[?H(-3J%"@QG512*M0U&2I][RR4(K)?8"T.H
MGCZ(0UX0_)9+NU.;8$N\;&2I+1$H7.RFVFS!CFD[N7I6A_1=Q16-JKP,.J+7
ME]1K>$5PJM=L QAMU!HX,LC]C+IE:!]*=G#DFP$P*1=8ZO9<T:I/(_1QKD7N
M1=B\??$AU1?%'K(L'[(C,-QV?/BCM3-2E;5Q9)S8M183#XE<ZX0>K.7UOH,L
M)E9V(4F5DSRKQA-_/\(/AF"1CU-RH'"Y.%KO6##= >2J#A^?V:75$_ ^J: *
M2J"BTGQ$U1W;?X=YHX<F-4-3FX4TA8X%U2)JM+YPGKC28R#CVJ5?QD.F0R/3
M@>N]BZ'Y,WJ=9'T0 V?4>113"#[:\L[B*ZU;"MJ9RQ+1S/,9YC'FY;R=*]_S
MR,FH%Y#PU,H '\HY<UV7#<C]=(ON&J:H#43,40XY-5]T7SFGG O:C6UJ<\J!
M:]4;N.PXE(*(F#*-SG=W]Q]'&[KU B']&VZ)MJ<^PXQ[3H>L9=D,T&,JNH>^
MW:E'Q<+=<8DVAS[-7,!,T)$?U(9A:@U!*U1:!:"[V%H9O7?W>;!X&#.-99+Z
MK4S?OYB^=7!UZ#CCR2%#M0-388XL:SJ+EQ,7[ES"G8")_X[82P''4Z;>$_V&
MWNYG+ $W,\1;:(?\=1]S>C=6.@1^</AB!>+<+F_"E?"BFQ3F!EHTW$0#ZNU<
MVNM0SI>(KA@!]9&OUHL(]=180A)A$F(3=U^F6DH,<L1UZD?T_$(IQEUFKE&>
M6KW&/?'"PM2HZ[W HP YFPM"? GJGFG^DIP<#'M79<#2)*]?'CHOW\GE+PYR
M!+5VE"C!L2FJ288+H_CR[I*]M]DL\2((E 9JTT9JZP0[3VW@4]^&EWXQ?_'[
MT\-5FFK ;TGUH*"MF.]??:97S.LN!R/7M36Y$,;B*N2'SN37ZDR^2GVF[\J=
M6I@1?)LW"T^V#J=3[Z0XQ<H]9VV0;18=M/S!:L]I*6-/;PZE;)5T Q0PSB<@
MMZ(Q'M ^N 3SI4EGC4S&^L6O^;O<D(%I)PE>7QW![C.%,9B)6.)_JPGC6HG2
M 9BRY"2Y[B7^%&T\V7R(KG5%UWY<I^C:MZ8ZPKXH?-[NLKQ1?_D5W0$$::JW
M?:@WG?/20VF;F!ER R%2?64-;V/Y^^Z"J%IL#2T7]BP8! E5PG\U98PT"X_<
M5&A#"8_9U(!Q8\E!6ER0Q.K2>$/U;O'&3TT^ANL@+()6*Q^5V8S_7IE-;D&*
MD#NNGUW8Q5F22,/-'GJ2/-F,P 2Y=I*$NN"'LJ\STTKE!^7@<Z#I;AU X31L
M%GWKZ/F\J92"S<AE#&)(*E&87P^$W=4BSR]EL563VYG!!BNE[; 8'!?5N%O@
M<03%'W.]R?"HV1(UX$-\!;DT&O'^8&&AAA=>7[BX/:V*E3F&S+0^4T[@MJY\
M@=/#*XHX:@A0ZF6[6ILK>C*"]O0QA;.S1@/_QU4%A;&31D6(:\[$Z1H#3I%L
MG*#6#5R]T\+^'(R%HML@]+,L2.?O4/;[EK)7&TT POR$Q@G4UDJ[*3^6:F*9
MIUQ\X Q%AHIU$0$SIS[N[&?6H7P;(!@&.R$ JQBBXH^@[S4<#AURR,;Y4C+&
M492:WNN4Y#W4G\CSI0_;9]O1$$2RR4FBL#1P+>3K"W:6+:9^Y-8WG:BMG>+@
MB]^R!+\,5-]J!O07/%['*-=UP:[ZTY@U5B@ 6Y++S+YY&>!ZLZWO0:]VY+%V
MX4VSH%$3SWY0Y6Q.<3),A=-W.TG9BSEESA',>",-B28_PMB\)P3^B2.#D+@:
MQ[28*+R^H$2M *]]1%^CR@D=9914Q MHCG'Q$1XI+ZU-PSHRWU&DB+P&J(NA
MN H=# -9VK:;)+>Z+C[T)L$AN%7@&J%1ZZW2'6+D)G"RLGZ25PWM[E9PU__H
MPL)-I8@R/**TR=L<%5.\$#Y"AJR.+CI'NL_,(+J.,> U>BP%(=YC"I1:>K!@
MQCH)D/N%5RH.'1,^WB5+D<8V3^Z\Q:UL$Z0A)Q$X+ZR)* 2S<9U?>P%5$_?@
MD!:M$/L51X:KCQHKWZZGM'4B#KN4M!I?"U?;<)RX"YH*SR14W!B+&(:\,DEK
M,24'[D*DYNMRTSM@CMPX2O?NS;NW+^X5*-I="]1=4135AXN+V70'G@?>/HK"
M@IJVOP@HO:(GLR2GL"F70G/F +6,!)LCXO+Q"!_OD(#8??9L)]IP7^_]Z O_
MDVS:QS0C/O;#;&@W>SX7D:4O%T/W;6I'<8F%(E3RB2*'2\$(9 VX;RJU@Q*
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MBS.](^PWKA+C:AWD54U=<91+8R?YM>:QT&-98@GML9BA+UH#PA:]6RX%QD-
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MO=3[U"F\'+;8"CG;P"06V[D3>PL RQ0Y+P@<AE,A_LY^)E#<FP&^D?.[2^M
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MK%+W5FW/<Y?45;B4%(6&D=S41MTL)9=S)RNZ_"Z1RT&<G1AIR7(J7TH:N6Z
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M[ML!=S<.6&/I'S-8)$?JSU@/"$'[$NE55]<P-$DKSHT[U3\'2X*>DVPRVWU
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MT1[FUS3!3)5%WG2PL@"91S%'XQ<),LEGX,4Q85"Y T9JBWK$]58;[3C_ ;0
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M6MAF(AZQU_5S[^S]R?GI)D_ KKEBR<.&7TP_!29$5BT5]:T]%5OP@N[14F'
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M*J-),8XGGF)%#@F(=P*3"V8AJ#LM/I41'-2?J$H3TL0A"5X6Y=V-N 8_B%B
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MEY&5QUA-"QT2@WC%79XR*;L AE% *T]:RLJ[DO(\;'M=!E?1A5Z9_FVAT78
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M^Z.#X]>PN2^.SMZ=!Z>O@]]//YP%;\X&)Q?X5^?4G >#LZ/@]>F'D\/@^"3
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M7<#]X,83?&IC4+!/8UBF:S2 R-V!NYYF<+AF5SF< _Y,SNM0@154UAB%G\(
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M'AP=C(*#JRB[),EV '<O\G1-,YG-6H([5+;@00^U^0T;B^('^)M*L'0.;)@
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MR^G>CL(#+.@Q&".5EV-:&L[E4(_@]>P*+5X]43%"+7I_SG^/!,#>]OY/RP7
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M._=?+G(P @AZARTQ@S)O/@-_1T:TN,(.T;RUI#W]U K$\,\%+Y>#B9&(74]
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M\K;&=J JEBI?#!42#@'+'RRK2^ASR[6& 1? V04# H,0U ^1,Y6AGQ200<)
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M_C3Q?Q\[!=*9LT%TL7)HONY XNC8OL\WX)X/V:V4.,)L ',J',+NIP#\_FY
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MRJGMPO ^IF"<%,R3QQ3,^@92![86LS.V9^QDR\IX,Q%CZ%#LD-%D@IG3**'
M.AG4-H#967!&UPK]CB:^ 0L<_F0*WT)IB;0T]BHM76D<3L6:]&UORSIC,[EF
M5P!6$OB)&@#)C$":J2@:%GD4!Q,EU6=L%6+9%_*<)N.$@,OPJBA\V8";Y-<2
M.D7!/(S22+-P$O6NOC/%<(=Z:> V$WC!*Z0SC(P7#;YP%<21:1-/EU"73TI.
M4S$\?K[[%*Q)YSH+H["_8#\=,5#)D(W>2=]8*=[!JM6PUEEP?KSUFJK_^<]:
MEUWB3H3O/JIB.H9[7E7T_2K/VN9]=?Z6F<BOCMZ^.?[P;IW?_-%$7A $,L8P
MT_&MJ]7L&LW!*Y5>^J&!)?D.@D1$GZDB(.%P4U2!]AC6E:9=;4>5+&G\XOR%
M+>BE N0%CW8XKGLFGE=/&K3<--EDM<]:UY:@EVY1O"U4U]]N8N/03%B\)E&B
MJ7<=ZX&V3SU9NK2$7DP*A'UC*3?N+UG42GI1XRDRM2D.D8!?+N\_0O:??9(-
MW7!3CUQ7G]%C/&_,'?D!;'IDD$9+%8NIWN?PGC8(I9_NUH(P /[*$B!TS*;[
M6UT/0Z^#]3W2BX +W@W#LEO7'\S0U*'9%QX!2QX" D6WU.1Y)+MHA@9J5'JY
M2&RMB6S2DI90\.NDHD(4-*_&>9T90K>9&A*@7,RD1=,5!K/9;#L;#K>'&DQ)
MU_?K./X*)R!1U8B7%I[$)<T'YF]D^Q\5?_W+WO[^RQB$U4I#^J-H>I]#Y4NM
MI;/!_QR_7><7?\34+W[9@P;]QMMHI>19(#1?S3VLN)@J+9BX12X)/MS/ZSIU
MD:^*Z-\)Y14,J9LAG!70D<\F2[Q]5)Q)72.TFL$R0 HHCMUA=>">%L8>R(EE
M^"E!3"RSC1]WT/T.A$M%*[3;Q"+N[49ME'S@G)QP-PGXE^[_Q8NR<A""1VGP
M6 !RQP(0JF*PIYN":9\8K(5)03B%M % 6]$$APP%-SEP.4,Z04B]?V+3;0*;
MT$C<39]GI^$4/8R)LNC$66("J7DNQ>W*F,B3*1,T[Z=[4ZZ-;F,[/LKWY]AV
MKDY5J D"W5?P"E#:Z&!I?S)./AN[GU@<"Z)_0-2EDG_#0^5>UR*(&N/3Y2!>
MA8=TUEKGS=BG^,A#SL \?<S K&$&)G"3MK8E$ B6?)*,DI1!&6Q7+89CE/5P
MDE02"P"Q&Z%<2J/"5*L)*QZAMYE-I9GXX$<80G\) QA_E[\5<1Y=7B*NMW+$
M)WOKK:? TUUT+UQH ;XZ0_+A_/_"WD+8#&==^%;</J%]#?U'3#;B-A_!%+AO
MJ],E/"=H5OZKCHH*!7NH50,E.YSD![%^< \(&I_\@IJU-5^)24B;.1G-[.LE
M59@]"74LQ3JDZ+OD>"FITC2/,OLW?#!.,O 0:$P.QDA?<;T9$/&0_N!Z4X@[
M'&UMOH.[X>!@-$GN?N^6SR\WH\V=[, (4(G\5BA1R_9C2<5>TZL(&8K[8-DE
M,&UP'X4,)@KF6,B40-&*JZ$C24E&10TU%AYH1A/K8H#1%Y5-OF_[M3Y,7 ;J
M,MM4-E;42G2BBL>UY1V% 5V:<3869']S\)#S?33>&:8AS1S:CG7Z-&DR&F0\
MJ"KR #4AI&D!Q@.G%&?[I3L.5NODTE&,><!ER532]MC0/''OD;;8<,_/O2W*
M6!IX^?#VS6#-H5Q?%=*T<M;=3C5G]!O!#U%\($@2J9APY*6-'[RJT\NH#3MR
MJE&86(P "AB+H.HE/Q<@!]R))7-?0:>S*%_QF'RY8_)%K(@JAU<"&331B ?A
MH[5K@O+.F6_8"2@4'7#%JS<GP5.1;P8+H0GWL&(?E#I8&FAN;,$_70()EO^L
M/^*:" W>104,8']7\F]=M'("ES4;C"D&;+%!=^F3*!RC9AZDC#T8G P.OYJ$
M[8L[NRR"O0I!OXA-:"VV#TRGRS PEH(:.C(K+C/1#?O0F&_&$PFP/S$U(&#<
MDMI@-Z#\)M%&CW#IZ9.;.=FVOBTIV]+I@SE;81<.;ZKVGFP_>X$3T>_N(/XI
MX#S_B"A+E3D1?>@=PBP\$R4=D@6%6"D_IBQL#)@W<%]"F;BK9A$BNIY@,!ZC
M!U<I[@2)OP"33V67T:5FTC\4MLH;;L N:=)HEDC5+F#B8:RY:Z;M% <;K,/)
MH9)'8;0WIVX/4A#FW(':0UXI>EOXGEB$HHH8\:CRA^K#X/%P3(ECHL[2:#:N
M4]<CQQMC@&YTA7\Y8]%=EG 0;GLE?*+T+J+)YKFE^Y.5I= R[GBWR&8%$DIZ
M;88.W:[##DCA>=N[G3JZ-]-M?(>0K78])3 8ZFA!]S 3:/='PBS&8)RE"95;
M2KQD=]->R/ 8'L>LP'A.IIF0\7[^\CEO9[I0.%O#XZ=B9IN]QJ/82P[2/+M4
M[N;3D]J@O6K>-/#W"W%/<?1?\A8NE7-(N=$6QQ.WRDDI(:H)="@@&$V(U(H(
M2S21-%UK':2A\Q4OD6&J9:-65M<NF--?1,SV:5U@7]W*AZ]QQXG%\ZW=-9 %
MV!C>S)0.?=Q*I+7[JWZ6TLHA)Y%EAF1.08S%4;7H5>V-8(,)#MIKV$JK4^1;
M!=U#9VNX!!AV)[G%/%H":CDH:GXIIQ6\<VCH>)@34#XR=G4F*Y[U,%EQ&YMJ
M1184TA?1=D89U;&-O9PB[N TAUTH6QJ.PTE>86S$$"IKI.%E3DQU* PL+,,Y
MC_0#$&@ELMXDI;#?J<]X;8(4M2)\2O*2DZQV#I)(O(CB-#45\7O'MZEMZ."(
M?A/ QQVTBEL 0?=%;EEL"[WPZ4-F'+]13+1%1".I3=)@#(:0D9(VF\ AHT5#
M^%/+2L;-GW(0UBFR0"%,BA2=6V9=ZGD+9BBKJ/?1G/;O*0$/=-_MWN#,FV<0
M%]BAQ<0!LY/)E[_8?JKWMN[O!;^HR"H4S4R%3A%C9CV'-'04=YS3YM;@7^)+
MIB,W9N,E;*<B#J(LBJ/0,P&E="JR>IIM?[0X!!:E*[E@^M<:T+ \0-'-/2L@
M&)2B<PV 2=S" G=^_[M60S6Z+RBD103"V64=<<(=Z<Q[U 5'&2+V%L8QT4Y)
M@C'F*;6;F"6E0_OAG#$G,X G(182F3(4,5]JADWDBY.B0]@T94 V&.6,D5OV
M$LY7QESOPF,;6QN<Z>2-2T#JAGQ?30]O_M+$\T@N7D2S+*BG>"B/LLL47F"M
M#^0=0[*RXUA%G-&TC?7NV]M[\A)LA8"V)XC(*H'98>"[^O9)KSMF<MZB-R9;
M%58YS[(H*4N2O]<Y[=#DDL>.KZ3Q^U*KJC <<9G"+X(8FU2"YXP* X,@^/4&
MS,A/N]_G/-[IM9<2;NC#UZ<!.UK^^4\O-^'08]=9[&2$$U]A(LH1#1'HBT"1
M/A[)@M6H-?^H8S"I([2ED8Z&OQK5%?\#B7MA^>6/ )4+D@[I;W&QKU51U?#$
M$+]-$_T-RP?!\=9&8&C["<]#B+MG*MN'3HZS4=9:<-R75FW=N.;OUJVM-VXP
M1G50SV$TR&OIXC:><OXF_^"GEZV^7TC-!99W79::%!6<M2'W/$F1_"E5UZA]
MW6PN-\F%;YD(-E,IMFK)Q]C*C%*_'/#=;)$IZ38G%HQG^4\I3C7F#O3=KQ0V
M HPXU%NVIPDVO'9,3&$\)?)\W56*G8)B4\](FDL7.3T]-[20T8"+I-"$N*7;
M.7?Q(ODOQ8Y&7L0<4G>G'2_^I-243#/=!BI)U5K+I3Y!IGLCCY=1BJ\<C41!
M=],/#J%S700HU561UY=7]GRX'\3@ 5YF%$CBVF+T%K&ZMJ-Z20>^3##?^!_P
M/*F <JN8JN@3VHK8S]-%!K(C[XU"6CPFPC,2-(C-35#;*>_ =Q<V]$>H4P/J
MQ,7!91S]*WB3YD-0 ^?4$0NQ1)]4M7EOD3[K!BD\-R0\&EP,9PM.=#5OPZ%#
M.17Y5$J5T#P@':HAX#8P)F?D\6 T#@8%'S=9QF1YMD6B" &9([$""$2-AEQ@
MOC(Q,H,/N%29*@CQV0+<&RPH&@D!!8<O=G?WGP8;>F,* ^Q'? 7=B_,<(>=H
M*C=0B",,K(MIII]NK,=RX=XQ0,0#B[,67A!,&3K%:@A!))J"6L/@VWM,.L3)
MFS[F#3ORAC_U,&_8&_?(G V=%[''!W9EEL@VU]_* ;!;E[XU'&48">7MC1:+
M&D7885I<B<4'(BG-R7;/$FS]WY [SC$IM-44B@-!3[<C%G!(%..<JIB_'F*=
MR'?J__JE,:J#5SU 9AF0HB3!F'8&Q@9N*FBZ"/S'>3 C?#.AJL4V3+!3,QHN
M?EVL7C4V04FTH6 ?<=M-*@S&;&KBR\\@GR'-.^\8TW&8B_@G2BN"4&J486BF
M+PHC6:)KXM]Q: %H_'P+][9K[0M^*9KZEV7].-?@O1\X4\@=#3H_[<B8/DXV
M4IE]E7NU<K.KO-GRJ(/AW#;X,3$=E4]3:_> '4^-L<B5O,(^2AMXU8K;;]]5
M(+\_.^C34*V(I@QBK!C7TL86=K?/7*UN^089ZUNU%U^1B_NQ@X9FM?WMX/"]
MV.V"DBP$AMC*A;A=N1 *2*'PH9RB;A?!LBVZD2JG&.Y0!!\-JMJIXI!-/J8=
MWA@.67Y9D_"GNPF'2V-BH2=(=)(J1F=I")F+-(89F$Q4C*-.$>P)3CM-&#E@
MG>/EMP?A.!7!B4]:P."X#8NQ__(_O\E^^&G[^:V*&UK^7Y5/?]YZLHW;"5."
M6!TI9PF-9Q:)3U:ZA7NA?Y>'HC'$>N;6ZZWTT-_EN#>.MYS/EO9WBPE 088N
MNY<.->OCCYFS HO]*?YLBP,8-8X?FD-FZ+F<9F_""E1/,9%IL7N^3*6<T>)F
MU(9CLOTDEX,H'XT05HY*$Z-"1-\S+1 0P37"VGY:/(Q!*OU:$/8?:H_&\5H1
M2^?*E!(]Y67O%GIS2<-TIZYCPG27!1*.Y(GCZL-BE<GG8./9)K-7E)3>HTEA
M7TA \5&I"=%-80#+4 ?ARY DKJ-M6H6VH>-F@R#CAEJ9EMJP8564GD9]W)/F
M6$MR1=W'"(L$=3XT9HL=+/ :<P6WS.?ZZ]V13S)+7U(2HFU3HCZCSD)VM?0&
M=/:YWSZH41#BO(96\-)51 !SJ9N<I_'*\%S>5??)3B++2QYKKL&22&4Q<:SE
M&APJ+OAWR'%'C/K2_"SZ"&"Q%NQY1JJKLF-.-J10JHD9:,TO9<D9>UY'C7=P
M9F_CAA;PD>F-8CI!V<IUW9G 9!Q:)W02517^!-E2,"X'!W23<0\Y_V26E'@U
MQN-PE*UCV31P:/KEKLV,([5Z(&-+"G*\'*CZK(I14C*H.,G&:4T=Q(D [2J?
MA=PN C'N4A.G9ZQD20VK_6$JA+OMB738CG2RA92=U\+!E'GA[T-F/J&M8H4=
M4I6?VE80H</L/%;<>0*VY20A' >1XQ '1!%;IDZW.*)3DW)77--\^*L'I(;4
MXL X2=,*]4X"RY]&HT\O?1?J*0@J^01M08JQ2W#[Z0[5 "_RP?#R9]_%_WJV
M_?1/6+?[].OO;=W>+E?QC0S%G2^,-;R/8*,7T?0J$/?/^%^=5>QXREV"5I#"
M,RK_H;P<A_Q%? XLK"DGU9/!.UR![8!]7RH&#X:<*6!; \[L)*=GDR-EJ5?]
MGJ DCJ9FV,;5$RLTEK,FU%]DE!)$VA\AUAJ#L"^2\E.P\9^;]C:YB"\C.*Q2
M"11QOHZ,@\CC7'R8'W(B[OEC(NX&*[!96_#]K#PXR&SR9[G3!(E.<U&0\M)]
M;CO,%_&V&/,'"@T/+D)C@^"0?4E0\V0 N8%C^BU?Z-ID77JSH+C14%4S);$?
MQW&B4CIF:1USZ;Q3G[T(FU2:ADI"&@@O9 R$.JV2";MJ,4HK;,YA.6IE(B=8
MV(OE=88X#>^V)!.6=X]\@\>G4Y<\&H,FI8:P[$09!BKPB(:(QYK3DC1,E<T;
M_>+&JC._6SE%.CR<=+W,=E[PPC0O2VO>":%M78@\;MP5W(4:3P86Q7MCQ2_O
MLA5\H\S;#O":]\(E7( SMR?X%9]@P4FMOBUN1X2FL:W=2,;"^,<RPOA&YQS=
M-L4]3&AP9[;3!QK<WT]6PB.3M$NB&-0D/4 NWVH]XK[FGCLH<YV Z&JK:F^0
MBJ$7L6!6B*6!KL6\NH6:1M@.L+K1]VPH")\*?5E\D%M%ZULM:$.PN#\B/(%2
MLXU: F=R>$K:,4#P6T--N2=OZ4;V_'?E(GEE6$9L&,0>E,A8^ZW9UH<;*5^'
M6(_82:6"_V/"A"XLLT'<8MK8<BF(1'ZZ8L9F_"(%=,3%\)\B#D\&K<<(JBLO
M^#6IW!*\RFM5F,5T0U2-66Y'>N7'?G!'-H43I@9/@!0VPVCTK6QK2[@-F,TH
M*(T-8U@<ZLS><E&TW]WL>!>]8]XWIH<JN77U<A9\V#[?#N(\!2.0-B ?)3 5
MT/6:!_X+V[B9R57;)II>R\TE3UG"< V66#V%/>9<[C?$TN\%LVI7H[D!A()9
MBF\EG&G4\2U&Z\^!']Q?;'<3B:5J&M9F)JG<KJ!2KT);P.Z-<?!CQ/;;C< _
M,=O W5R-95J\*2P I%F)U-GFQ502>=O)#;<F$^18[D(R\%:E'B()A@1CC@=+
M-4)4,1S,[8YSRTW\[>$(_8-^G;X]???J2\B*'V%<WYD#80A2$XN9&AUU>L!)
M$OB(LL<>.C<'<%RK<H!"/,5^RC@SN,1/=\C5W7WQ8B?8,%_O/;<4A6D^&6*9
M V^+@SQ6C("Q+94T[=M096KLD+>@A</4$$C$ H(RS\2,[#44&NSBJ)CW  UM
M A;2!8#AT 41NM$2S)MM!-C*)2L<2>B*2&#3\R#C3EA-ICKI_Q W4Y)ROV8+
M M#0HUH(/=SN:"GM#;W^MF$"9>SIOF,L*7FL#ND,2K]X#$HOGB>[J:ZCD<Z%
M(COP)*-ZT/".!_4 7FI8)%\)#+:*&9E&<S L4^Y#"&<M)S\PR<JZ(#N4+$]R
MMJ1"RPUFLBE,YW5+RVV.L]*Q-<!K%/ V_5_:!'N2D=[8W7^Q3_?=V]G=66MS
M]OM6M3^6ISNE 0V 6E,Y%4C>R)Q3#AQ$VR/\;4'4B0SXQXJ"(L)-VM\>XV<\
MZCPX 1^2"#AB%7R,8#@(H0N.)LA&H5;:RGA3._*%I8Z5E4*'618G'X^UR4&>
M/)=<H(,K*\3\G03X)$\ZL81"ND?%D(V7JJB9(9O35Y\$41T%IHYC3#S+[K*Z
M#[H']OP7M'];+:#_V+;9Q$0(-WK"$ XI%.DPH\W FSJKQ+DJW2Y/$LR,IJAU
M$ )K6+'=_FX].]DPIA&F2I&6ZDQ-__J7O:<[+W'_1BL]S'0,,P2R89HXU%0U
MIKM9L^)*Q"K' !WR:&_JJ4V$;G9F;^5T& L;G.*4CJ8V8:;O#$=-J6Z<&B.1
M-XG5\99)YQJ5 #@NEK)'PH1@^VBX9C7'_'24I$[',0JSY\Y@.,--SW);WC4W
M9F1H:H,-=:U N5#+/_1D<KH[W9F(?>#GDTWRR$"P.6'3A*E$W9R%;C_8;L/&
MA<J-9/<>535C4ITS+1MT#CYO8UNTO;UM^'+S/HB\!6X1Q9J%/GZLB>J=IKZP
MXI<$YV:]HI4 S))$G],$%C,V6:'F?M\T3 5>5L7AFK$FAM[C)J@KV(J>29[5
MTV;PH<2\1KFI#YN<,];J?EYAE!="_VF0U91.1"E 9P$W_)03F*TU0-'0MQ60
M1H0CY"]\LO\R(^[*"#91OEK9O\Y^V9>F&<Y.P3=;G&5X="T?@'5Z -JU\KNI
M-JN+&":1%YQQ[[)F-F[;;W;3M!_6C_7;-U+3':?KHXZH^@W[L"YT%A42M>_(
M(QJ</ND]?E33>AL7TL)5?JTQ!P(/4E11XB/M% :.#%S!-D1H9C8Y,UO9E^RL
M*;@/ELF=1<[_'!W\$IP=O?_PZNWQP3I/P/<56/UY[W5MPCX(#OZM" HE%&0=
M4@Y9W<>";*"+?>'4;UJB@Y->T1(YW$%.$:^O#1!R1'A1E9'PI$B6UB\&]3.F
M_NI7A-\N*>S%"%/K6+<[I N@Q4*[]\*GPH'U*QB>SUZ\I&?GC%;A*A'I>!]R
MW_:NYW%&0#_5]DL7=[7U3-O/OOE4[DU&3=3M;C-;,S&,="-BRK*5C8@PSQ'_
MI $X)Z^^FAKIFZXX/#IY-SC[]3$/VI$'W=WI42)T)9OJ6\"2UDK7'D89]BTY
M)Y+)4R*9# :CE=<<D.!64X-;%(J$A?4#1 <GY;^(K;"<X8;)D\-/G( E4">_
MNHF>E +DM97-/JX1A[%XMB[8(:%&A!6KA'%T#?)(ZB-IY 3=L89"\^[-VW++
M)6D8S&!'@E-S>/X?458CT&0W!!6Q^Z(MP-?A0"TW:-?J)-V5Y[@_/224BYEU
M_/21*J@&Q^79%\=;#@+&S =^WX+K1%AV/Z)Q\FLP@SVL$-C U3"V)U]S_P;!
M+_D,<P!\S&$IL64PAHYE.(0-EDG&R"?-L2W2%TO/U LGA49Q2X,E,1XI'8 I
M-.]FU-"O>2_320"S'Y(7L;9G*:C'W,:MHS%R8_(0$J(5?HCN^=&;W]]?K/-[
M?PTAMA+_=)TG?5U# L?<OD\GMZ32ABR,H\OYM)(JC$RDA='VKDG3J'XT]W(J
M=TSQE /2(<&%S=OP.0]1TKP^/GD+UO@ZO_EC!/ KV%*KE0"$$=<MX77(1:P6
M'*E7D=2D53*F T5_Z%VU)>.:1--4(:<YLCDY-?EH'8VN%'@-W("I4%LZP1N[
M1@LY&]DX*2:VY"V?9:HHKY*I$UBS?%(NH$\/$9O+@TF#295- <+KM+*FE-\V
M\G"<4,'M/%!%D7-=8&[)D\SH)]$G3D&#?%1EB0:AW)42+U2-7>29A+#02)O#
MV)C?T$SU-)IR1&UB.+/:J)7D81* OSX;G!P<K?.+WU%""NDU[#ZP%1CX5*[S
MZ]^M?>YJ)>&K>2-N0]1(?-RU +J*KEDH1ER0+\71>1[[14Z6<(H#-#-5* \5
MCU=+V]H@E7G05=<TB$"S46KB/!"@IL6FD+?!4-:\#?4=C\>]Z7I[I&.$6&J7
M2EEY5)E*C#"XQIZJLNW4OZ49;EIC6U74DD6"]5*\X>"C5)P+9$$ ?1W@2_*[
M2_M4HO^KL^1?M=-.->6IDA:Z,$L?\:$\,'@F<ACB#E327=?I\8J_UKUZ*6]%
M$*:Z7!(R>-"YBMT>Y2KNKWAX]"_ZYU^\1H*&*P=:A>H1FZ4Y8"NTI1D4J0PX
M"C[+0?<-K %LV6GP%HZ-3[6M2,M05,SW3/_2M+3X*^KJ1)EUD[#6C>@IK&$8
M^G7>FG# ]*S<<R=T*S20V/O/GKS<I<SV=M=;(G6*&P#&PE<O9HLOT1$ SC,'
MVCZ,RL2#EMG+I@J;#6 !;DIT%$X;-G0<$(F^B3>C</8)-D)_]C+8?['[+(0I
MOF2J6A/.X7"OXW3A*T5)6A<N0\:(D&>@HRXOT<F"-Z'T/-+)J"Q*'ZJ3\N;H
M[-W@Y/=U?O/'F'&_MMNZ"?ECX=.Z%>(I!>>)0AU1@%W9F,[6;[^MF:VP<[ K
MV49("!9'!8DWAT=)DW8YR39W*"3?.:X#AG(S*:8)) V'I;2Q'"P<'O(I59A=
M1%^.L5F>]N@J%FIJCJ<,BF(,U*9V">LL33XA[E9=HXMC*I/D;GP3G(W=G?^P
MI!L^-Q4W^X1/)]0+-!]]NJ]2N=>IE8,B+\LM)C6W14H)(:&ES$WO!4+FM;N_
M4@L,;GR&Z_P&7#$X/J]5K'I;U8A'O43S9M55C,<9FF]T&MVY;^:RW$BQM;(,
MT1CX8BEULJB;%/Z:(U>+#L-H>'@3FZ'PX8BHTHL^B<"#%D3C4Q@8MG62\TW;
MH-&FA#]+7+)@>4W"+#A@HM@\ H5?W A*2\],JI*"Q\F@>K:K!FF*E%+P>1F\
M4VE,@\0NY%(EL=K-!OLLTVVZ2K3$$42""]*O2;1'4RN*E8K'F1HB16&P,9O-
MMH=F;-NQ8D(!5+'7X(%P22Q,< [[720@?B^Q4QTRI1RT7ZE2XN88SPWYD*VP
MM<DM6VAX-P1:S_3@4N_D[.CH0:50'IV31^>DF>%VC_RXD;7NJMPSF62O%#PI
MV7?(9YE;HDR0O>@3_&Z:(G^I1KNP1\2!'">R<E\%S2^G)V^"7^&_UGG;?PM(
M_1J]_DVG?L+==0S'-YD2NR^%>N)]-"?]>HJ,%M@&U6]<OHK3[^*4.SI,.CS.
M3M]6OOS%]E-M@>M"K3OTI+34YT)O*<E?>BKWEQ2^"HY;<.^O2!C)Q92G.+=N
MZD,<S696B3;DJ_OU#SI'M[=..;KO??C//;^W-V=:#H/U=RTE#_H$DLHFNK (
M^_J55,IJM3I'"JCXA0)N!#!SB.:DQ4&2&=2;U]:@NV>I7/(&X2/!(=53-CK/
MVL!E7@EAF<^,AH"S2O<Y!"&%# "-R**A\*>P!(]@B^,"8'0@(S\!TEJ#6>M@
MX$--"-_QO<^/#CZ<@3ER=![\-C@[.3YYXU%9]R,BX9[C"]&F%*>C+>L2 %*!
M'#,)*CR)UXF:Z19X<\UUD1=SA^0+3N4O2,+U*_R7SYQA&GJ.HEHK?E9QMD*(
MCJ2%@T9<(QWG]1"4\A"SRL2..C96@!VWWWC>>!;<W'TZ1?3GYU#'#=&PD(HA
M'EP^E**E6.&EBEIUY&-%T%,LLXZON4_9A==:I=V)>I'$ZB+;=HD3Q45RXJ*<
MO3&3B;P=_$R4KR9$0RQFV/M(389.L]=7>51P%%)J&HG'Y.*6L^1!ZK1#-J(,
M.S9_8$03T_QB<U<8?926C=TRQ<8O!<](J^6IO ;U>\)%-)63SNQ\'\:#.YV=
M96X8;!=:]OI;Q_?N?-H=EO);;3GA]M)1.^?[%*M(Y,0V#GK[7&@IPI=K%N-*
M.FKRT9:E%\X;G1 T]H+ 1U2$K("TP5O[6[,FZVW.D7=+@-KHRV?)E?DA:ZV4
MOS1@\.'DS>!LK7$3-]6FVLH*"H\5\RT+^S<-81_BVA\?''W-VJ>^V%TGR)XC
M&JF-VU^CM>MU9GV@F7XU XQ+-@N"^7@$0IYS2-C1$Q2#[>=$TM>B.0SW#5MB
M/@OMC9@.']B"W6/!Y$JDCQ[ZI!EU1HT^&WY1IEFXL4V?6(-HA]2IM(OD(BFM
MDM 0+-G_(TJV=F^I9?W<?7HX-L'UK&'+-FZ89Z]9SANW) EGZ.):HTL[.NA1
MF_G&>+;O;=?4I?+QY/!+>E_UY[T?JJ.^GC+5=<4;;4?]>DVG5RB:L!2MMH@7
M"E'GV0UR$B7(,3AXD6Z'V862,>%N? 1QR<Q4FE(<SVUYV6I/>L.C)6 7H5M8
MCL @1VP?S%D>DW2&.0TVA+HRG8?Z\CQ3P17<J1!$#4W=/-C8?;ZSB4B=DK$S
M!@/4F)8%0*!06EC0(S)8$[SEB^X[TNOIM]X,&SV!&V\0M?E+6YU1'>DNXIOB
MD38183E.9^CB@'I*JHH[QF!+1K)R5,_Y %\?GQVL]E@)(:#9IH3\GY%C0+U,
MF>/%8X>Q;3<?TS1=:9K]QS3-XHG2#+Y2GN[T(<>S0&UXBQSD!&/]O(;(FOJC
MF0W!/\\4C ?$@K&PM?CVFA9KDL8%#\%X:F5 %,92Q-ZH\PY&L=)C=KJW7O*Z
MH6E^[Z!\T;5;?GV32VGELF:W2$/; !RBN<KK"JNIS'[;-(Q6;5#-G;964G9"
M  W]=</[\ATO8F40YTMW*F*W\;[NT*5^RME7C>.L@:?RH" _C9:^>!1/N#4H
M_,MD9BC>WB-*P*1\;/6[E)(4DVPV_3;W'3[ZCX4JD-6J6_4:G$7+K;)]^! *
MF3&%F&8BU)UI05W #R-LV Z?U!GR#6)F!*EU,*&71LGD04K1B\';W]<ZS/4H
M1+]0B)ISN.H*SILD1(NY>&-WDX5]!X4QV$Y3@X_@T+HG;87FU$GV@_Q]\3+8
MV&O?4\ >C6RP92)ACR7!6',%!FG%?:;'-5)N>7$L!ZE!V=]\S _%;S?VG0<+
M 0^&J&V6[DYO<S^"UMU[Y;4(<\ZR$T>2BGF/C.N"XE'+6*Z%.,DC]Z>8VF=<
MVZ3B9G@P[2HT% ZVM7 HH1)="U=JKK5.?>X#>H]YN?W/NC_T/PT^MC[Y9^//
MYM<?VQ\<V]W&),15%+PODNL(M"'F#4><,1G KCNJBWRJD @<=FP^24;! ":N
MY\&VHZ-!+V)MY$';*81M"O/?\ZG[T(N9^T==)&6<C*1M.AYP$+R_PCF+\PFS
M4,.)_#>,FBFB&S)OG27>8[IJ[0-3Q[AX7A.WV54>:BH)2HPX3!+CI$2.3>:1
M((J%VX2G#/L0QZDV=:?8:!Y<@H]4,*! <^GHVE4<V;P5-+-<%:7I]IIK6Z85
MX8)A?#@Y/C@E/I\P./LM.!]=@3N5JDV#5Z/NL_*.MBY<;HV/Q[ :Y8XPV,4J
M.$JY^#L9(U;"8<5 _&TM2-.RNV:V9+^/J([0-*-06^<R!)'T!69/DA[+%*YN
M/5YKYMG+U'><Y)F:!VE$GYIF%_<:0F7/X&LS-P.>FXOH\XK[G!!Q 'KPTN?6
M0&4<-'(KD(M'X?L,NGL^5SICV-3*HFBB9B$JA98K_#R%_T%AHND96K.<$#<D
MSJI(DZ'RX4J/N<.NW.&3Q]SAXHER$&Y"=G(2E7'TK^!-F@^1;H.H0X)WO _A
MDD/P]PD,O;]K6MY9#YVTD6$H(0\0A8'SE W01(9ZSRFZ,N -E_DIKPM; L5J
M6W/=$17J=<(8?^P%C9K*%G-$HPIUJ495H+(G/78M$4R/5 JY8TY8$>HJS+@F
MT'E48-&([LYN^J^[J?N6 L/;P.U'-8/.4>TB#6#S,K?)>YRKDD*ITNT],IUL
MJBN8(!R]7\^R!"3HYJJX;.6FT=Y71;K,^_K'X/W@9)W?^]%Y67OGQ0"PNIM.
MBR3[1S2-,K3&&ZT!@EB!A$A+;7RY8L4QONCGB %!FBHKN\O*8QBUQMM-#:RE
M7QP!T?0C(P*/,05=!FJB;;I8#CN,MCU]^=1T" 6Y=L[(8R%PY?D -P21WJ!W
MX+O=IUR&(QQ]7R 'B7H0U Y%*BT35Q,+@(I,E6[W._V;^8*UXCDTB')YB\;2
M6-XP\B5M=)3E^CT]CLO$[Z^G9T>/4.<U?.^O*GY7Z\HN S6YQ,V.R:3133WC
MRE/;EZM594CM_2M,5]2 @85=9-?:%F>I& :J&FT;]2)W<76=Y/:0Q372 I;!
M5Y0,(D6D[YTX[(GI' :3Z@;;_G6:F+7#T&8R[CG?8POAVS%&^,0MB7S/8448
MM,4%0/(0 Z'\3OMB0=SE(:JVMT>O!B>GC[[%&K[W<GH-6XK^-IKU2(]=:$"6
MB2(X5 8D#<D2)YE3+*J^!PGX5H'L!FDTK8NR1N(8D#+XIB?Y=K#[;#?8V-O9
MW14BVX-HBMM#XD(T(S +IW+O%OLWJE3N54V4MYHW0L&R4M6@X8G 47GP\M!E
MN^;:H6 P!F60K#NKS9>*E^.+7SX,3AX+!=?QO>]1\$)8<I &GZPF;4?]D0\#
MG2\ .ZNLHB%R]C)S#YYEI)+1!/AQCCVVJ3H[!Y,)D4%<I\W>LOUP%($ @,D!
M8\AIQ<@V(<P8)TYIXF"R*)4I45HL(KA.8OQZXS7-!%44<(,4$&ROSV"B=EL]
M+MU@RF-6I2NK\O0QJ[)XHISXVUO86:!-D^C1:?2?'VH\A:7<POY&U C)-K./
M.MQPMXL3@]<9-P''GO([$HO3=]&^WM&'LV#W*<4=FR+$)F7E-^RF/43[XMW1
M/X\/3M?YQ1]AZ7>"I7L(6J^@9Z5>30.;#F.DDG2!'@>(Y:9=NP"H?CM\>AMM
M;NJ;;DOJ=TLD.OWG)HCY'1XL:9 _";X&\5M:[#7GUDTSXI%I1LP$T O+J$*_
M)XD%:B-@)551 8^(#?,"/=J:A5]8@_7=#=X[#)'%:T),CC_O/YM6*QJS*=9H
M__?O%%KT^UM93J3.2 +I98F4$Y?U]E>/[DVC&'?Z5JK&8@O>,+E;JYS=O86S
M>^&>Y_GRJ8X*81YE#VDPN00;Z#@;;3-><P;.5>I2EB.]+W6(_/K3W^.=O/^E
M.QE$T#4X5UD%\_;0-^R3A9/H[#I"^8/K:X)LI6%+;?)\$=&F@GV)/;>21C-5
MRSZK5;9#F.G3UC88U>ZM\?4V&L*[8TBU:8;AI+_/P5Z=4W^KU=<&NIO#L\1P
MS9=:8M:J ,LKO\S@H6R1V#T6ZG#+95)6)/A  ";8:APN.\V47'I H8[@L$BP
M+.SB*J]+G*?3Z%,9!@>PH+ 'T:]^L;N_!R[=A^WS[0'<&_&V3.G:W*_D%,:3
M)$-:5H^=SS&^HNI&B4VF7%?/RPZ>Y2Q0%,F>:%I ,JBNDFDP5-5,28M*O*5S
M!LL$\WF:A-H9"=I4SDA<#8'$R,AQ;1H(&]V#LR&C0.>XE">]4Y^341[@I&$C
M]X/MC]L]KYBB<6_QN/M0.P4V^*NH9(BGQEA>YK!(-YR$EKEO2NTM[UJ$HA5W
M/M-(+3/5&#BJ+6K;:Z1L;;%&9L6=3^8EDYM1<0@^TK!7VCWL> 6.0#=O(!U/
MK"TC]S>$,),\-FRIS58K- 7@?R09?\UM4%K4Y<*GAS_ J'#A>K*+W!=Z=?L:
M]T')+$:U:*^P@]'O!EN)6F; KD7X ?5.K[,$8<S(M$H;Q+-#X9@RWP;6M!OQ
MQ26O5&V-)R)T)5O!G%+<UEW'O:4U#H;=)RKS# 5\'KQRDM7J1K'LU'SI&F+\
M (P8B\> >]S?I<=RH109#!EW7ZCAW ":C&21(RX+(7-2E"H5%"E[^3#U9E&&
MA5;\Q-411)<11F#=9=76(*)15%9&^AYQ-(DN5>G =83(\=KL&_?\>[*0Q5_3
M.@P-6,9L,+9$,(A;I[Q+&52/K9W1,H57<&T/W[@-89'RT2=,85%NB2T1_!<,
MG/H[%,@\'R%+(HISYI3''=Q*&9D)HKE&"4[5 TN\C@>=0'JV3@FDWDF NX;U
MSZ=1AM;!!9P5Z:)P#^1@MY]UII!!891,$I41IC,-3JN\N(SX@]XX5@-$E()?
M%17!J(Y2\"A T+DC!4O^#T3)!")Y+ ,*V&LPQ1B)XW=5P;] 0UZA[AXEPP2$
M?)U1P!O\(WQ_%IWF&A"_44QWGB3E!,&$05DS@#^)HQBI=__ZE[W]GUZB1,?"
MJ,DPP0_V7V;XH\&H5D6,,QN<3D?XS1/X)G2^DKCU'-1YCK8I^'13N4$,\A4>
M$*L)?+#W]&5)PT+-46!#CF".U_-7^(!(GC6BVJX8#)04_L/=L< 0R+$_-%@X
MLLZD2>:M);]A.&#(#\J$IF+1O*:*)P1^#S8LG*5Q@B9W0/*?OT*K=D*K-!?;
M7_Y,<24(N(&32V^2YC!J'@&:N_#7G U6>2,VYV$M8_@*5@=N<:Y&9JHQ"A^[
MLZWXECA8T'CZURJP@7?4384,""YCJI2''0];'!X_KZVA:2==T>9GKTLA>?,E
M'C(8!YC'QD.9*SAZ:+RH$9; QQ@QAU5\Z+''Q<'R(W-JRR6SSG*J))NQD',Q
M1>8<:X3&W-(^8DRTJF2SL\LRHE9:CS'SVVUO9:/F2?30M^ZMPN:X>]&O0+<"
M]V;&FU5"D"B-2U=H$/]A5C<G_SI*T6NBR#FH"D3!X5^H\08C40T'^:0F%3$!
MXQ_UX43%"89B]>I]CTW>%\L.%>-;-0\HM([4+ECCB(K.SBQ<]#Y/644CF'![
MI;"&X&:C#P9L%KMI +;,$\_00/7ONKHC$I=PS+.HE'![$9$)E8]@.?]-_X:K
M_W3,'=NS8=.\O:<[+[$YG[OO995LX-U=&B/[R7*Y4?[/^4X4>_=6N'4ZLMS1
MR%WZ&O^)KK:]32I["!L+*9GGN3>?L2+3.KIQM%J(VAGA!6H_%&F#.&IOYL#\
M**> I0)Y4N#-UCQLS]9NCV+WAQA@BMB-23%^@[TD\^+F(V9W+=K<FMTHQ] I
M+-\XNH;UPNNF=0R'FZQ%?%(A)V'Y'@]QZQH#GGJ$7,J.,%:EOT/AF6:?Z&"K
M[M'NS'H88%]"-I$R&H32NL7U/.04P+_F'(1MOF1.LLJWOQ8\S@HX'?7O./LY
MSHE$_?VO^<P[)SDIQ"^LL44,^*0YZ<=RHOZ ,?,Z+O>K8CIA((10L-[?2'#3
MFT5L&CG7MQ5<G +0AR.22+^^UDD*S#W[FD2Q(S!QAZ0Y^^=>'H#(Q3 "'>%3
MC;?$<4QZJ-XQA=F'Z,ER+B J;O$2F;?]*&B"AX7;[ERR)!8EE5#4 V\8\83=
MWYU!.8*):THXP0S<'6BXVL714Q4YL8?<K!=>GQ?))3R%5%NLX&9Q1'.?8WN^
MKOU@5T5G"[Q;1_COW9=T<J>J^*,FJ4,1CJ;F=%?8!(0ZY(O(!4>&Q2+Z2RMG
M4%[QN+$J3B'27!^>S]1?B>IL@WG#NXP:'BB&J)H;*^0HFHFI>>&TR'4<(LP[
MD"D#EA+^$2<PTR!PE4Y(D$M@4Q'T >4G%(EQG9! (\69'%D71RG!4XO+I%B\
MT1]T;N*GQ]S$8UG?0Z@;MEVS72(X@:,VBGC]%NL.>DLW;T*&>S8#SN1+ 8[K
M]]>]J6PQ('DS<&_S2VPVQ7GBV/TEN'78+T)7_,!/I/&$'FM..*=8>HRG<X0&
ML*NTS3SW,8-!0B>3W.9SMQVZ=:)%,%L(O\\=3*/3Y-L\T>WV[3R=J51MIWJB
M%XECA 8QYPA5/F%%]%"-(NDZSG"5SW!'?+2'&S.SK8NB6\@>O9[>8X5;0@:-
M&B2/ZQ'/'.:)>-#2LFE"P^;))57.B\9P"^^VG4CQ&SJ]PQ0AT>45WUM^55)_
M1M#*<(,IZ'E3G^+\T$Z;5\Q -$RZS--2SXJ.U- W+BXG;2T^--6B)UST5<0N
MAX;J*-#06]79E<**",<Z--M'H%=\=KA=HYX%"V<:$D,OUK/2_%>8E(6+BOMA
M>=XU-WUR=/'+T1FVE%IK+?"H_;Y4^WW3MTXFH$W2ZK]^4)]W=YXF"$C:C;;_
MF%[^$)3%J/-CSP)^_M/T\\M)!-9RMB7F[5-X]6MLB KR1YY'C^:OQ<9[MO=D
M^OF'>[>D2P_RZ=EO@]_7>2\_GN&O0$S1EZ9P)WDQ T/4XZ67'LEN7WN7C]OA
MY\*VJ18"G8 MBPA&A+UZ+2CM0Y#Y#-STSCIU^)SZV:B8X@=1A@(1B<],AVUD
M-=,<&O]_>]?:VS:29?\*@1D,+*R<M9,XCPFP@-M6TNY.;(_L=';WRX(22S8G
M%*DA*3N:7[_W655\2';224396@RV8ULBZWGKUKWGGA.[P52W\Q+>>5BI75#B
M3/_#V+L2R95'Y/[L2JQ"?+N@.2 4N'WYIJCVZ=?LUMP@0ESHU/33< 4HT%F)
M#"L*Q(SC)5)_&*=ZWW,1:]H2'[03'Y KV)@F);CFV>!;2G/B>-UPMHX*@_UE
MH 0GP[>[^_L'K_M2G$M%(5CL2Q7$NK*\F7^P%FSP16H&CC LF26=-%=P2V4]
MD:3?,N'U&YRO*>#I[!KMJ2^CC L";EJIE'#K)0<E1_PZIIP5YUT]4QUZC4P:
MLQ): $.7>*:R\BY95JX'1Z)M+E$!K,-$P@\"Z\O%QY>BAN\C3=F<-?/@*6#3
MXH(O:^5UGLVOKBNF#,TN[Q+664>2WFGXV8CENG(&\WLO[T<=(GVU22'2[KC(
MYV>/3#IYZR)WC_D82XV+:^]H44I>/46\F%M#I[U'H2X-Y9*G;$7?N?#&$2OQ
M$5&T1(@QSDMZTAGKRHG"QM45E@J57AVYTM)3U!<:391L<<JAM1IMD^/U/7]_
M&KST*.;AO%&:Y[Y'U,[16.2:IU+:?\T1%9$GPK"@0>JG>]#Z*%QXS"94%)EB
MX3(ST\LW>6BP^R-#(T"UH;[F%KSQ)HP3 D9)V>BM&<%!8(OFEPS1P^6)WQSW
MS"41&CNH3B1N/1MV:YSCXO-CXSJN;@ O$JQR,Q*5+V#9)?(!*=)S)-82#B<.
M(Z6QWAF3WX7:JG#+>_;B^1LF/R,%'MP?\F,LW-@MOAC6@Q;9."8=&[N'1W-H
MBRD*JA6\P<)*JA05UNHP+7L]82>BG5!@^II(CYQ\KSBC^M16!];K:<'UU.D5
M\HC#>%"Y(:(#XHRVX 3KI'<.>D3)77#%M+=#K4P>Z0ZYSNK#;TUNR+^$9I\;
MV'J2K%J(P!V^;@*;%OFV:YS>MK5C6;F^*_Q0[U.K_9OAY<=WA^^_=]>K =C]
M=LQX9YR>[\,I][/-\!%B7YCW><BL:;XAQHTW !L$=J\#NCE2WNPX%AJ%SI2N
MII)@1XTFQD"Z$8#EO9J3-@$8"LN6UM>Z^2R+/#(WYD 1 K,0T\:>36RE'?#)
M;^L$(DT)^ =F)&@Y7<.QQ,B[* S>(Y8L_/&N[U>& \_!ND]-G&%EO(/9F[FL
MJ$S7F < +LTTF"6&D:F5/DJ= 78TH .[" /^3A+WI<@1HV\!_N*&SPFL<33@
M .(OX7F8BX9_PV>#C.DPL 20UQ4^??\-0MP.WFB5H*$RP9 @[[B\H,'XST-\
MSGIK71^JP[KJ_!N>?=B2LV]FO[_]BK+>X_!(%6S$@2^<!T\P)6/%8OG2*Q<4
M_ZIY1JP7Y.B>Y^8&X>*"M-+NPB,_D!3S>R?%K%=;^*[<;>7"C,P;-\C)09<=
M])[;<F*.]SDR% M%T W?:*P'7PM(9RK>!@9S1@'B8X3]&.PK_$U_" ;@A-^@
M3@_'OINW+AKX..Q;LJ6:K)O0&-';Y+,J;504@LIRA[]W)^/[#/*ISO(X]"KV
M0[FRS1*)FE#WLGD^MFX)BXBO$+@+A8K$DP&*#)=.F#N5ZHKY:!J+<%^U4;(:
M*OU\J&[)2MO]\>+B^YON1YTE>/W(LP1KN3=NQ$9L.5*';;&3]5TQ6XX%.$##
MDNTZ!:.K!]9R;K(M J*&@*#1LV=WG\]Y'<T>8F^*+"/96CS.8K!F*4T PJ/+
MZZR0\><0:6'YQV;S'.RE\5G3<Q.G-W!1HKLV>1P2_N>)C*EFQJX[E8#M2WZ!
MO2@,8\*A7<8$-T8N%5@/<>G@VRZ\JV',L2:]U>D@>CK5-/PW(N#1FT!79 X>
M!5Z+#R>E9-OYM1C-<&^U//;V*Y3(6.@R5<Z_''D!I&F9<,.K&*,;%2J&#$O;
M7,$NM8"A^5UI,]*9A+?%PTA*+*NA)+PXN'%)L/^R'SS=PXKWE8M'JP(X;%PG
MB*NL6'\Z/<43BE[%%"#'S$+N*B6P,C_WLD(\+^+8NW77T-LD414;:/<\<=%G
M]L54,I%'#M5E1HP9.(GS,LL7@OZ@R)9XC,MW45)D+H#^D%?)_;2H5[CME/9$
MHS-6FLKL#A.E7(,A):#<,JHC?.Y!8[Q<1Y0*2Z19B7F<>8X&>KTS#DJ%A 9F
MJDJT[C%RWU?%I$IN#9='-@6NSD?OR;+@/$;/.Y:9G,Q+6MA&F1T1M+X0O4I\
MQ%+)2GMV8K42LLFKVF\K@(W@JV2?4=@]=K4X7BV;?6B#Q58>Z55^>;5G5+%$
MWY;2IW&<C^>)'0[;T,::[^A^6)H#Q_@R!HAX !6=H<(@M0$?(<5$ NLE=[Y2
M;81#]Q2-6GAE@EG*ZVMDKL-DH@L+%Q/\D:CR6ZS/1@VIJI 3%AC/!'7>"D-L
MMHN[QIA+Q+D,+K3N&I\X&,@K2395D0H/UU8O55?HP%6R(<\4<^#3<EO#W!%H
MXXZYIO (FD2XTZBJ284QO<ETWG<!03%;5G67+K1LSN>I1_%N*9B=X7JPJ^8X
M+,/@'.M.X:YVFI7,!KKNLFP'-'-<V<4<W#'!6#LQKC\::ES?**C5N?E:;B[K
MLFK8<T\Z 6_K6E%!'^#J!C".'L#A'&,-12%>Q;DZZK0<=G \.TVI)1WI I$6
MBT7(A5!*TF$'O>5P!%N?Y1,F=M!Z@:MFK>5%575PW\B%8N"4=@YQ;;GU+%PE
M/_N.ZN/5&DM-A+_-"R$ < VLM@H>C;>F* ]OK4L\E@_0-1@\Q;'H+WAJ!,YK
M-K[/O-'6MDO9X\><>GFZ]\A3+P^RI%7=^^7 8[!_,*SV'H#5?1)TIDLSFJD8
ME:-,L+/?"Z;P1F2HH"@A*1>-DTROWA3RT51U9,!P)A@3Y5%H:":#)6UI'08"
MZTV43#1%&UBYV4N@2RFL1O0K,/]&<-./:% \; )N$V/V;)R3ZWJW&9BV&M1>
M!0C=#[@*<,2R*K_!I2#85__2N:0(I9:02WUUC4,;JN2\B$-2^)@(=&5EDSE,
M.-EE#SROZ.R*"+B/XQ"@!*XND\)O<&%$?$K#(:_'K8W!:O15>L=Y$A? NF<F
M#[&Q''D/B]5143KX^>\;?:"OUI.&^^ON49;G<\H,!.\QDB9AK^X@I$X\=B M
M=7(418A\\I)J(18$8.BED!K98I;-"RE!B@Q&3$D'[3I.HMRD?4W P0JZCD<4
MF*(U)!;5=SNI6*K%FN&J] %*!$>6=I(1M$'/OH7YV!"!C?]@07ZJ/_6K^V8L
M+G*CFFM9J*&W H9T[]R&MI6"S?"R,H_9R$N65=6G.%HZ1:<;+F4/EK]\I3[/
MR>F[P_.SX6"3^[Y%NRSO[-!;_O"_"P0\X#Z_%-2F7 O7''SR2BN\6WI;%'HV
MSS'=4E9Y\?PKN*9')DHL !;I BQ/.,N(G2UF<T$XR/A+L/.BM\ON*'B%F#(H
M,+@IWL<[DG@[#HFV-DVP^HP\0\:'YL)4IS0!?MO0TT43C.\T7\Q4,MAL[<Z1
MX.6_3TY."(M"8;;]X&(^BO2GG>>]8,=+BQ<2>'OZ:J^G;?.2A#BA;^?E'$?J
M$#R0G:/K</8$/OT:\0-[+X)!]*37<;KVB[>'78@K$<&,-Y',L+>$K:^B]=GW
M:!R]%':3T0]ZNM&>69="+9VQLRL(Y];KA.)]B94J*^KH6&9NT!]K6*[.1Z'_
M,4=!D 4VG@/H'; ;SL8K!:=:[)?/=O9[.Y.>M_OIPLO<2%SP'Q/XBA_ABA#
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MF0A%7@/UFT:J1C<&RYN&RNJZH(^WH1A)U09#Z,B)AS<;YE=I,A31B6WQDJC
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MRX:M)AZ>\QQ<%QJ?8%F'__I_\G\/I>>G<U*NLY#AU7B-C>T<!5.[OTW_D$*
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M%SV,\GU/.^".O$#4>H'OH![WE!0H"#1(CP5WF*\7F Q0DX.[RDHNT"5J3<B
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M6Z]^ATO_\>3B[/?MKY#7WUNY.)0"PE#-* D5,\(YRZ3"$)'I!AKIL>MJ$Q.
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M*!"S5TB5(#U&56FP6YWKL@TZOSC"X,I]J3QYP:L]C.R>L>?50PK=35799C6
MI; K6"_\$GI7UFZ^W<;^FVF[T;.G31 Y5=.E1TV)AM1&G@J_D=[DD$OI)8NW
MRI:P>+ #]>+Z^BN$'MV;G&>%FX=DIFB-7E,SDOR9'\(E0%AJ5&*QYNI#!NMT
M/B+S=K]DA%/G)PXNH6,W_=^:LAE:#I8!26\#+H^WL,T^"D!PC:H/[;Z@#CBH
M$6 PIC$E[R/I2=>HP*JB%CW$!I4(42V!!(T]OTNJ5T%U:YQ5J86"N]8C2C47
MM6G1=@V"Z^OKW70TVAV9/$=ZOE_7\Q>X$;$N0SY:>!,70A_:O[%[0)C__6\'
MCQZ]C.+5MKG&7CGWV9.]5'LZ&_[/\;MU7O@F_7WQ8@\;8!WOU/6*_0*OYHVT
M[INSN5WVD:1QUZ.R7BGEJUS])Z80@(6#L["UDCA4QZ0EQ#^JYZ2.%$;D8.4@
M^?P6Y&QWYC'=OA_]Q&:94O*(P\NI^RO,#P6AQ0B^V_@P[BU!GW#?"MB*MZCL
MKCR%H :*L*G;^)-U&U14X&X[.=X^<^H5QO/@5M*E 4E&&S[@S&P;RI9[8V)[
MU&<HLNTML.&-^.C,_?::6]'+&'*+;IG#.I"RZ4),M)0A0:5;O2"(^H-R>74[
M4^.3?'^.K>^J1 \,U*"_A%JM2#OC5_JMC.,OUB8@/,B<$"4PDU++O^&E,M:5
M,*/&_$QU1JW@0KIX;0(8WRZ \>2!!S VOJWU"MQXOBK7@P@82S:-PSCA? K6
MLQ9G4A35:!J7XB< MJN0+R4JM\5C@J]'&=D,R-(,DO K;)L <1%86YB_%7:N
M+B\Q2[?TV"=;\JVWP-O]7%UXT*7KFFC*Q_/_#7<*,UXX0L-#<5.&]C/T?Z*F
M$6)Z"%O@K]:$5GA/4,W\=Z7R$AG[P(@&"HQX@1("#N'.$C0_^04UAFLNB>%,
MF_$;@Q%<"\ P(!/*6/*#2'FXM$(A49ID*G5_PP?C. 5Y37/RTH/,$U>"DDN
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M_+[.*]^XM/M%;NNF%QP+_M:M,L,2,.G( :,";*C$#=7J394-$A;V1?4Y6X@
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MLE%@G,:@Z12E&B':+(/0X%U&]!,#6!YEV+*9BH@S4%HPRX;+B=E:=1^&"A@
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M\V@_B):DPNO0U@R15BS,YY&).:P()D5I%!^^TT";[;@-R#"8E7P.2TW,8/E
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M;7_.S.R&2ZU(_-/@;T]RVXMVO]_-=[__;9!%4_C/=3E._N/_ %!+ P04
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MAH$ YJLDU_??'3Y_!0R660$VSO0L*&!MZ-GX[_ )@*:+LQL""6P' 6*C!2B
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M.QT0U+B=KO=9_O:E#[=MU?6G,PA?W,T@W!GI> '_3(M9\N;_ 5!+ P04
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M 0O<A45 D[N(+V!7]3E4I&,EQQP3:4I'Q?<$7412GF1233F,3F+E8R=] &H
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M&_RD)#KX:?3,<6 BPGQ%N8904J)I!+EB? D7$567X#CEK+'(-I(M$PTMOQ7
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MD[IU4K=.'L;[@U]K*3^+K_S8+Q\=_ -02P,$%     @ &IM(4O+0NF6.80
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M0QK]%38NBQ/JW>4Y'CS7#<9!/W-PCY[X ]8J9\D&%&4B:U\NY/C-OVC98Y-
MDJA:&X)CVJGT'"@$W:CD=9IPJ6O!FX/>E+J,\A(K"VI3"EGIO]JL<H'IWPM*
MX;C$DOW:1_=PH!ZG:T$]NI<[QY@I1JS*1*=MI;T<* I.I)H<[\!M.87Z30M7
MYL",H\MEW>B9+>NW/UC$ 7CT!7Y1-W#49N37H]-R>7A^:&_SKK W[E%Y&5!Z
MHNNZY(R_7(1+36_=C_D@K)Q94P706VXL1C?1O5H#W>/1]_> )&*2E%5*>3\6
M\H//K2R)<W_AP?;]IU[1ZDKR&3*&*J/8Y0;UG8_$:>W\F$"@6L]H[K:0S#'
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M64;[C!M@C<ZY0D^.&Q!1.R6H)(261=3.EJE-2_(T>Q+]!:51<BJ= :Q=&;.
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M\(30(:EW7V_<^X%4'XA4?U$?],$?!!AS3ETRMX=N6013-RN@Q[WC?;9+B7Q
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M22(U 90U*+$LER]+'(_#6569:)WVE7P;K?+**6QWTJZ'KE-*HXH/7G=>[E5
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MZI>9'^U<[/RD5^T-4PI'ZZ&.%GKVIF6>>G67;_YJM^F044V])(<;H,94(TD
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MU*G!I77(-"R54&'UM4G2(EG+'.2<GC*J!@9<6674)*P[G7)1MGGJFJ@3<?F
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M3-<+E^=D- %S%T8<2O)<$8ZC#5&,4? 3)!EZMJ,2++:JCM!DN^U,;(U*?N>
M\M:0WM-;2<_X&+,"&7NC2"I/LG$#:ILB4#;],<F(Z4KW5@2O5CEP9]1AC7L
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MAW9(U;U7%I/63!0'#_N&)F$Z]DGS99Y0@<>BRC/3TL/Z2*@?*+N?NW#P-O[
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M,)9EP.0RN/;/-IVP#QY3/!-,'Z?^B-T>][.RT+Q8]EGE"&G!%37*"L3]T_C
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M/^/?EXWD&!LZNX'/?WT<^^Q^'/O[49DNX9]I,\O_]?\#4$L! A0#%     @
M&IM(4O>.'W/O'08 (]I# !$              ( !     &%M9VXM,C R,#$R
M,S$N:'1M4$L! A0#%     @ &IM(4CG4Z LH)@  >K4! !$
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M2P$"% ,4    "  :FTA2>NU_R73[ 0"UD0( %               @ 'WM@@
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M,3(S,7AQ-"YH=&U02P$"% ,4    "  :FTA2@GV@S'2/   ][P, &@
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M,7AQ-"YH=&U02P$"% ,4    "  :FTA2\M"Z98YA  !>B0, &@
M    @ &0T0\ 86UG;BUE>#0S,U\R,#(P,3(S,7AQ-"YH=&U02P4&     !$
,$0"4!   5C,0

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
